<SEC-DOCUMENT>0001493152-21-025555.txt : 20211015
<SEC-HEADER>0001493152-21-025555.hdr.sgml : 20211015
<ACCEPTANCE-DATETIME>20211015161615
ACCESSION NUMBER:		0001493152-21-025555
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		31
FILED AS OF DATE:		20211015
DATE AS OF CHANGE:		20211015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Hillstream BioPharma Inc.
		CENTRAL INDEX KEY:			0001861657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				842642541
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-259821
		FILM NUMBER:		211326249

	BUSINESS ADDRESS:	
		STREET 1:		1200 ROUTE 22 EAST
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		302-743-2995

	MAIL ADDRESS:	
		STREET 1:		245 MAIN STREET
		STREET 2:		SUITE 204
		CITY:			CHESTER
		STATE:			NJ
		ZIP:			07930
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>forms-1a.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>As filed with the Securities and Exchange Commission
on October 15, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Statement No. 333-259821 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
</FONT></B><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">WASHINGTON, D.C. 20549</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
No. 1</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
S-1</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Exact name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>84-2642541</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</FONT></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</FONT></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary
                                            Standard Industrial</FONT></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
    Code Number)</FONT></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</FONT></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1200
Route 22 East, Suite 2000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bridgewater,
NJ 08807</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(908)
955-3140</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address,
including zip code and telephone number, including area code of registrant&rsquo;s principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Randy
Milby<BR>
Chief Executive Officer<BR>
Hillstream BioPharma, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1200
Route 22 East, Suite 2000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bridgewater,
NJ 08807</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(908)
955-3140</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
address, including zip code, and telephone number, including area code, of agent for service)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Copies
to:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jeffrey
    J. Fessler, Esq.<BR>
    Nazia J. Khan, Esq.<BR>
    Sheppard, Mullin, Richter &amp; Hampton LLP<BR>
    30 Rockefeller Plaza<BR>
    New York, NY 10112-0015<BR>
    Tel.: (212) 653-8700</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rob
    Condon, Esq.<BR>
    Dentons US LLP<BR>
    1221 Avenue of the Americas <BR>
    New York, NY 10020-1089<BR>
    Tel.: (212) 768-6700</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public:<BR>
As soon as practicable after the date this registration statement becomes effective.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933 check the following box: &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer &#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company &#9746;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company &#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CALCULATION
OF REGISTRATION FEE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title
    of Each Class of Securities to be Registered</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed
    <BR>
    Maximum Aggregate <BR>
    Offering Price<SUP>1</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
                                            of Registration</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fee<SUP>2</SUP></B></FONT></P>

</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock, par value $0.0001
    per share</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; width: 16%"><P STYLE="margin: 0">18,975,000</P><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD><TD STYLE="text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; width: 16%">2,070.17<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to be issued to the
    representative of the underwriters <SUP>(3)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock underlying warrants
    to be issued to the representative of the underwriters <SUP>(4)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,185,937</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right">129.39<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>20,160,937</B></FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><B>2,199.56</B><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
    solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933,
    as amended. Includes shares of common stock that the underwriters have the option to purchase to cover over-allotments, if any.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calculated
    pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price of the securities registered hereunder
    to be sold by the registrant.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    registration fee required pursuant to Rule 457(g).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have agreed to issue to the representative of the underwriters warrants to purchase shares of common stock representing up to 5%
    of the common stock issued in the offering. The representative&rsquo;s warrants are exercisable at a per share exercise price equal
    to 125% of the public offering price per share of the common stock offered hereby. As estimated solely for the purpose of calculating
    the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the representative&rsquo;s
    warrants is $1,185,937, which is equal to 125% of $948,750 (5% of $18,975,000).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> * </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> Previously paid. </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date
as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: red"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #D2232A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>The
                                            information contained in this preliminary prospectus is not complete and may be changed.
                                            These securities may not be sold until the registration statement filed with the Securities
                                            and Exchange Commission is effective. This preliminary prospectus is not an offer to sell
                                            these securities and it is not soliciting an offer to buy these securities in any state where
                                            the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #D2232A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PRELIMINARY
                                            PROSPECTUS</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>SUBJECT
    TO COMPLETION</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>DATED
    OCTOBER 15, 2021</B></FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>3,000,000
</B></FONT><FONT STYLE="font: 14pt Times New Roman, Times, Serif"><B>Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="logo_001.jpg" ALT="" STYLE="height: 63px; width: 130px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Hillstream
BioPharma, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is a firm commitment initial public offering of shares of common stock of Hillstream BioPharma, Inc. Prior to this offering, there has
been no public market for our common stock. We anticipate that the initial public offering price will be between $5.00 and $6.00
per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have applied to list our shares on The Nasdaq Capital Market under the symbol &ldquo;HILS.&rdquo; Upon completion of this offering,
we believe that we will satisfy the listing requirements and expect that our common stock will be listed on The Nasdaq Capital Market.
Such listing, however, is not guaranteed. If the application is not approved for listing on The Nasdaq Capital Market, we will not proceed
with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have
elected to comply with certain reduced public company reporting requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Investing
in our common stock involves a high degree of risks. See &ldquo;Risk Factors&rdquo; beginning on page 10.</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
                                            Share</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initial public offering price</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriting discounts and commissions</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to us (before
    expenses)<SUP>1</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    discounts and commissions do not include a non-accountable expense allowance equal to 1.0% of the initial public offering price payable
    to the underwriters. The registration statement, of which this prospectus is a part, also registers for sale warrants to purchase
    shares of common stock to be issued to the representative of the underwriters. We have agreed to issue the warrants to the representative
    of the underwriters as a portion of the underwriting compensation payable to the underwriters in connection with this offering. We
    refer you to &ldquo;Underwriting&rdquo; beginning on page 105 of this prospectus for additional information regarding underwriting
    compensation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted the underwriters a 45-day option to purchase up to 450,000 additional shares of common stock solely to cover over-allotments,
if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters expect to deliver the shares to purchasers on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>ThinkEquity</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="drsa_001.jpg" ALT="" STYLE="height: 273px; width: 670px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to submit an investigational new
drug application to the U.S. Food and Drug Administration for HSB-1216 in 2022, for HSB-888 in the first half of 2023, for HSB-510
in 2023 and for HSB-114 in 2024; however, no assurance can be provided that our investigational new drug applications will be
accepted by the U.S. Food and Drug Administration based on our anticipated timeline, if at all.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: justify; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="drsa_03.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE
OF CONTENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_001">PROSPECTUS
    SUMMARY</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_002">RISK
    FACTORS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#g_001">INFORMATION
    REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#g_002">INDUSTRY
    AND MARKET DATA</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#g_003">USE
    OF PROCEEDS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#g_004">DIVIDEND
    POLICY</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#g_005">CAPITALIZATION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">49</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#o_003">DILUTION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#g_006">MANAGEMENT&rsquo;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">52</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#hj_001">BUSINESS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">60</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_001">MANAGEMENT</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">87</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_002">EXECUTIVE
    AND DIRECTOR COMPENSATION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: -10pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">91</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_003">CERTAIN
    RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: -10pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_004">PRINCIPAL
    STOCKHOLDERS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">97</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_005">DESCRIPTION
    OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_006">SHARES
    ELIGIBLE FOR FUTURE SALE</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_007">MATERIAL
    U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR COMMON STOCK</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_008">UNDERWRITING</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_009">LEGAL
    MATTERS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_010">EXPERTS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#aR_011">WHERE
    YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: -10pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_007">INDEX
    TO FINANCIAL STATEMENTS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those
contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take
no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give to you. The
information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this
prospectus or any sale of our common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
should rely only on the information contained in this prospectus. No dealer, salesperson or other person is authorized to give information
that is not contained in this prospectus. This prospectus is not an offer to sell nor is it seeking an offer to buy these securities
in any jurisdiction where the offer or sale is not permitted. The information in this prospectus is accurate only as of the date of this
prospectus, regardless of the time of delivery of this prospectus or of any sale of these securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All
trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience,
the trademarks and trade names in this prospectus are referred to without the &reg; and <SUP>TM</SUP> symbols, but such references should
not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights
thereto.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_001"></A>PROSPECTUS
SUMMARY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary highlights selected information contained elsewhere in this prospectus and is qualified in its entirety by the more
detailed information and financial statements included elsewhere in this prospectus. It does not contain all the information that may
be important to you and your investment decision. You should carefully read this entire prospectus, including the matters set forth under
&ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo;
and our financial statements and related notes included elsewhere in this prospectus. In this prospectus, unless context requires otherwise,
references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo;  &ldquo;Hillstream BioPharma,&rdquo; or &ldquo;the Company&rdquo;
refer to Hillstream BioPharma, Inc. and its subsidiary.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Hillstream
BioPharma is a pre-clinical biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer
mechanism resulting in iron mediated cell death (&ldquo;IMCD&rdquo;) for treatment resistant cancers. Our most advanced product candidate
is HSB-1216, an IMCD inducer, targeting a variety of solid tumors. In a clinical pilot study conducted in Germany by the University of
Heidelberg, the active drug in HSB-1216 was found to reduce tumor burden in treatment resistant cancers, including triple negative breast
cancer (&ldquo;TNBC&rdquo;) and epithelial carcinomas. Our goal is to submit an investigational new drug application (&ldquo;IND&rdquo;)
to the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) in 2022 and start a clinical study with HSB-1216 in 2022; however,
no assurance can be provided that our IND will be accepted by the FDA in 2022, if at all. If our IND is accepted by the FDA, our HSB-1216
clinical study will focus on expanding upon the clinical pilot study conducted in Germany. If we are able to start our clinical study
with HSB-1216 in 2022, we anticipate that initial data from such trial will be released either the end of 2022 or early 2023. We use
Quatramer&trade;, our proprietary tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment (&ldquo;TME&rdquo;)
with an extended duration of action and minimal off-target toxicity. In addition, Trident Artificial Intelligence (&ldquo;TAI&rdquo;
or &ldquo;Trident&rdquo;), our artificial intelligence precision medicine platform, is used to identify biomarkers in our clinical programs
to target specific patient segments.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
discovery of regulated cell death processes, such as apoptosis and autophagy, has enabled novel target discovery for drug development.
Ferroptosis, a form of IMCD, is an emerging regulated cell death process which decreases intracellular iron, or the Labile Iron Pool
(&ldquo;LIP&rdquo;). Cancer cells increase the LIP leading to unregulated cell growth and metabolism. Decreasing the LIP, induces iron-led
reactive oxygen species (&ldquo;ROS&rdquo;) production and lipid peroxidation, two key hallmarks of ferroptosis/IMCD. HSB-1216 binds
iron in the cytoplasm of cancer cells and decreases the LIP, thereby inducing ferroptosis/IMCD, leading to regulated cell death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Quatramer
is a tumor targeting platform which allows us to leverage and exploit key tumor targets and novel emerging pathways such as IMCD to facilitate
the delivery of potent drugs directly to the TME, while sparing healthy tissue. By efficiently extending the circulation half-life, as
well as targeting delivery to the tumor site, Quatramer traps drugs into the TME. This emerging orthogonal anti-cancer approach utilizes
a fundamental recognized mechanism of iron mediated tumor growth and metabolism. We are building a portfolio of long-acting, potent anti-cancer
drug candidates using our Quatramer platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Trident
uses an artificial intelligence precision medicine platform to identify novel biomarkers. Trident integrates diverse public datasets,
including The Cancer Genome Atlas (&ldquo;TCGA&rdquo;) to identify novel gene signatures to stratify patients prospectively in clinical
trials. Quatramer tumor targeting also allows us to segment patients by exploiting Trident&rsquo;s findings by (i) synthetic lethal sensitivities
with novel combinations, (ii) pursue undruggable targets such as <I>c-myc</I> and (iii) target tumors with a high degree of cell plasticity
indicative of recurrent/drug resistant phenotype.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our
Lead Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
most advanced product candidate, HSB-1216, is a IMCD inducer of a variety of solid tumors. Our second product candidate, HSB-888, is
a dual Quatramer loaded IMCD inducer coupled with our ultra-low dose, next generation anthracycline analogue for solid tumors.
HSB-888 has demonstrated highly synergistic tumor killing capacity in a TNBC cell line.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HSB-1216
is for multiple, therapy resistant or high unmet need solid tumors. HSB-1216 exploits a key feature of certain tumors that rely on an
excessive LIP within the cell to modify the dysregulated iron microenvironment of cancer. In our Phase 1 study we intend to test
HSB-1216 in a variety of solid tumors. Although we have received orphan drug designation (&ldquo;ODD&rdquo;) in small cell lung cancer
for HSB-1216&rsquo;s active drug, we may pursue ODD in multiple indications. HSB-1216 has the potential to be used in cancer patients
who have failed standard-of-care therapies in solid tumors. HSB-1216 is being advanced to alleviate these devastating consequences due
to a lack of therapies. We anticipate submitting an IND to the FDA in 2022 and anticipate initial data in either the
end of 2022 or early 2023; however, no assurance can be provided that our IND will be accepted by the FDA in 2022, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Iron
is a central player in cancer progression and metastasis which is dysregulated in tumors. Certain cancer cells rely on an increased LIP
which fosters tumor growth, metastasis and relapse. HSB-1216 decreases the LIP in tumors and causes cell death by reducing the cancer
cell&rsquo;s access to iron. HSB-1216 is a novel and potent inducer of a powerful mechanism involving IMCD. Areas of interest for the
development of HSB-1216 are as a treatment of solid tumors, including TNBC, uveal melanoma, glioblastoma multiforme, head and neck
squamous cell carcinoma and other treatment resistant cancers with high unmet need. HSB-1216 uses the Quatramer tumor targeting platform
for both chemotherapy resistant tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
a clinical pilot study in Germany, the active drug in HSB-1216 was studied in seven patients with positive results in heavily pre-treated
and therapy resistant cancers. By design, HSB-1216 circulates systemically after an intravenous injection and concentrates in the TME
of solid tumor masses. The localization of HSB-1216 has been demonstrated in multiple <I>in vivo</I> models with pharmacodynamics signals
showing significant decreases in tumor size after multiple weekly injections. Based on findings from acceptable daily intake thresholds
in Europe, the compound was therapeutically used in a &ldquo;first-in-man&rdquo; pilot clinical trial in Germany with a cohort of patients
with metastatic breast, ovarian and head and neck cancers in which tumor and metastatic regression were observed clinically in four patients
with metastatic breast cancer, one patient with metastatic ovarian cancer, and two patients with squamous cell carcinoma (one of the
head and neck and the other of the vulva). Two of these cases are described in the literature showing promising results inducing cancer
regression of heavily pre-treated and therapy-resistant tumor types. These data may define HSB-1216 to be an optimized dosing profile
to have novel effects as a clinically significant anticancer agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HSB-888
is our second product candidate and is a dual-loaded IMCD inducer coupled with our ultra-low dose, safer, next generation anthracycline
analogue, which is in IND-enabling studies and we intend to develop such product candidate in the clinic in 2023 for multiple
sarcomas. The FDA has granted one of the active drugs of HSB-888, a next generation anthracycline, a Rare Pediatric Disease designation
and ODD for pediatric osteosarcoma. This component of HSB-888 has more rapid cellular uptake with data showing lower cardiotoxicity and
greater antitumor effect in a variety of tumors including osteosarcoma, breast cancer, lymphoma and acute myeloid leukemia. A more rapid
uptake into tumor cells causes targeted incorporation into the cell&rsquo;s DNA and causes cell cycle arrest. HSB-888 has the potential
to exploit IMCD as well as synergistic tumor cell killing at lower doses of anthracyclines and may be effective against multiple rare
solid tumors with high unmet needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our
Other Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HSB-510
is a novel highly targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6,
which is also known to downregulate <I>c-myc</I>, a highly pursued and yet undruggable cancer drug target. The Quatramer platform achieves
optimal tumor targeting and bioavailability of the highly potent targeted small molecule. HSB-510&rsquo;s active drug, in co-development
via a Cooperative Research and Development Agreement with the National Center for Advancing Translational Sciences, part of the National
Institutes of Health (&ldquo;NIH&rdquo;), induced necrosis in several mutant and <I>FLT3</I>-resistant acute myeloid leukemia (&ldquo;AML&rdquo;)
cell lines and primary blasts from AML patients, while showing no cytotoxicity against several normal cells. The <I>FLT-3</I> gene is
associated with high risk of relapse and poor clinical outcomes upon treatment with conventional chemotherapy in AML patients. Target
specific engagement of PI3K-delta and HDAC6 was further demonstrated using the cellular thermal shift assay. HSB-510 also showed ideal
pharmacokinetic properties in mice via intraperitoneal administration which provides a means to examine the biological effects of inhibiting
these two enzymes with a single molecule, either <I>in vitro</I> or <I>in vivo</I>. We intend to submit an IND to the FDA
for HSB-510 in 2023; however, no assurance can be provided that our IND will be accepted by the FDA in 2023, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HSB-114
is a novel immunotherapeutic agent which uses our proprietary Quatramer technology to deliver tumor necrosis factor-alpha (&ldquo;TNF-alpha&rdquo;
or &ldquo;TNF-&alpha;&rdquo;) gene into cancer cells. Previous immunotherapeutic strategies used adenovector technology requiring replication
deficient gene deletions and complex manufacturing controls in order to deliver the TNF-alpha gene, but posed a theoretical risk of systemic
toxicity and adjacent tissue damage due to overflow of TNF-alpha in blood from the tumor, resulting in some dose-limiting toxicities.
We believe our novel non-viral immunotherapeutic TNF-alpha gene therapy, HSB-114, builds on the previous clinical development program
with improved scalability and tunability to treat metastatic soft tissue sarcomas. We intend to submit an IND to the FDA
for HSB-510 in 2024; however, no assurance can be provided that our IND will be accepted by the FDA in 2024, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our
Platform Technologies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Quatramer
Technology</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
key aspect of oncology treatment is that effective anticancer agents do not penetrate the tumor bed in order to kill cancer cells due
to the limitation of the microenvironment of the tumor. The TME is protected by multiple layers of collagen, proteoglycans, hyaluronans
and laminin layers shielding the tumor from the deployment of traditional treatments, including chemotherapy (novel small molecule and
immunotherapies). Parts of the tumor create an environment to survive despite reduced nutrient sources whereby hypoxic regions of the
tumor continue to thrive by incorporating a shift in metabolism, including iron dysregulation. Subsequently, any drug reaching the tumor
is effluxed out of the cell by transporter pumps upregulated by the cancer cells rendering any drug reaching the tumor ineffective. The
TME continues to thrive by the inability of immune cells normally designed to infiltrate and kill the tumor made ineffective by reducing
their ability to activate their killing effect of the cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
proprietary Quatramer technology overcomes the limitations that have hampered development of nanoscale and liposome derived products
as cancer therapeutics. Limitations include, but are not limited to, drug efflux, toxicity, eluding phagocytosis, physiological barrier
penetrance and immune responses. Our Quatramer technology incorporates a therapeutic payload and is designed to be tunable while having
a prolonged circulation within the blood, allowing a targeting of diseased tissue or cells, while providing a controlled and timely release
of the therapeutic payload.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
also plan to develop other Quatramer based compounds with therapeutic cargoes from our product pipeline, which include DNA-based contents
which hijack the tumor&rsquo;s genetic code and kill the tumor from within by generating an array of cancer killing cytokines, such as
TNF-alpha and potentially interleukin-2 (&ldquo;IL-2&rdquo;). The platform&rsquo;s tunability stems from the fact that the system can
be modified and adjusted to deliver single or multiple ratios of payloads in order to optimize synergistic mechanisms of action in lower
doses in order to eradicate rare cancers and treatment resistant tumors with minimal or no treatment options.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Characteristics
of our Quatramer technology:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prolonged
    circulation</B>: the stealth nature of Quatramer allows for a prolonged circulation time resulting in accumulation at the site of
    disease prior to being cleared.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Targeted</B>:
    the size, shape and surface of Quatramer allows it to escape via gaps in the blood vessels in the TME allowing for release of the
    payload directly into cancerous cells.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Blocks
    drug efflux</B>: Quatramer composition offers reversal of p-glycoprotein mediated drug resistance in cells via generation of poloxamers
    (breakdown products comprised of small co-polymers).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tunability</B>:
    Quatramer physicochemical characterization allows for optimizing size, shape and surface chemistry based on payload characteristics
    to render enhanced permeation and retention into the TME.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ease
    of manufacturing</B>: large scale production efficiency and analysis for uniform chemistry, manufacturing and control capability
    at lower costs.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Established
    </B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>regulatory path</B>: chemical compositions listed in the
    FDA Inactive Ingredients Database with known profile.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payload
    versatility and flexibility</B>: combined with the tunability of Quatramer, the technology allows for a variety of delivery payloads
    including peptides, small molecules, nucleic acids and antibodies with the added flexibility of dual-loaded payload therapeutics.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biodegradable</B>:
    Quatramers ultimately breakdown into known metabolites such as lactic acid and ethanol.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Trident
Artificial Intelligence</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Trident
uses an artificial intelligence precision medicine platform to identify novel biomarkers. Trident integrates diverse public datasets,
including TCGA to identify novel gene signatures to stratify patients prospectively in clinical trials. Quatramer tumor targeting also
allows us to segment patients by exploiting Trident&rsquo;s findings by (i) synthetic lethal sensitivities with novel combinations, (ii)
pursue undruggable targets such as <I>c-myc</I> and (iii) target tumors with a high degree of cell plasticity indicative of recurrent/drug
resistant phenotype.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Trident platform:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
    the ability to create a Ferroptomics Atlas which integrates diverse multi-omics datasets including not only genomics, epigenetics
    and transcriptomics but also emerging proteomics data which enable identification of dynamical re-wiring of intra-tumoral signaling
    circuitry designed to target IMCD;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
    the ability to identify biomarkers that potentially differentiate between progression of cancer plasticity and correlate it to degree
    of sensitivity to a synthetically lethal target that is induced with standard-of-care treatment and development of resistance; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
    designed to classify and select patients that are most likely to respond to treatment.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to disrupt the biotechnology landscape by developing novel therapeutics by leveraging both our targeted-delivery Quatramer platform-based
therapeutics and our Trident platform and to address significant unmet medical needs, with a focus on treatments for cancer. We believe
that our technology has the potential to generate differentiated products to treat multiple unmet needs, including rare and treatment
resistant tumors. We are prioritizing our efforts based on our assessments and expertise of clinical development and regulatory strategy,
unmet medical needs and market forces.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical components of our business strategy to achieve our goals include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Developing
    drug candidate, HSB-1216, in solid tumors.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
from a clinical pilot study in Germany led us to progress HSB-1216 into IND-enabling studies with the goal of submitting an IND to
the FDA in 2022.</FONT></P>

<P STYLE="margin: 0pt 0 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Developing
    our combination drug candidate, HSB-888, for pediatric sarcomas.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888
is in IND-enabling trials with the goal of potentially submitting an IND to the FDA the first half of in 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leveraging
    our Trident Artificial Intelligence Platform.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAI
is a computational intelligence platform that identifies synthetic lethal sensitivities associated with degree of cell plasticity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Developing
    and commercializing Quatramer in collaboration with leading pharmaceutical companies.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our internal development programs, we actively seek opportunities to collaborate with recognized biopharmaceutical companies
to develop Quatramer incorporating therapeutic payloads from their proprietary product portfolios.</FONT></P>

<P STYLE="margin: 0pt 0 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leveraging
    our novel platform to develop a pipeline of high value Quatramer leads.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tunability of our technology allows us to efficiently expand our pipeline of Quatramer, both on our own and in collaboration with others,
through various combinations of targeted DNA encoded for anti-tumor cytokines and therapeutic payloads, which enables us to move into
other areas of oncology, including immuno-oncology whereby we could potentially increase the effectiveness of ICIs.</FONT></P>

<P STYLE="margin: 0pt 0 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Commercializing
    proprietary Quatramer based products, including HSB-1216, directly in the United States and with collaborators outside the United
    States.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
own </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">HSB-1216 and our other proprietary pipeline and expect to maintain
similar rights with respect to other proprietary Quatramer we develop.</FONT></P>

<P STYLE="margin: 0pt 0 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Continuing
    to extend and protect our product technology and Quatramer through our intellectual property portfolio.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to protect our novel platform through U.S. and international patents as well as know-how and trade secrets relating to the design
and manufacturing of our technology.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Team</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Our
Chief Executive Officer and directors have</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">
extensive scientific, drug development, and commercialization experience across pertinent disciplines including oncology; small molecule,
peptide and antibody drug manufacturing and quality; clinical drug development, and commercialization. Our Chief Executive Officer
and directors have held various research, clinical development, artificial intelligence, strategy, corporate development and operational
positions at large biopharmaceutical companies</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">, <FONT STYLE="background-color: white">public
biotechnology companies, and universities having worked at companies such as DuPont Merck Pharmaceuticals, Amgen Inc., Exelixis,
Inc., Salix Pharmaceuticals, Inc., Global Cancer Research Institute, Sanofi and UCLA School of Medicine.
Our Chief Executive Officer and directors have been involved in the discovery, development, manufacturing and commercialization
of multiple marketed products across various therapeutic areas, including, but not limited to, Cabometyx<SUP>&reg; </SUP>(cabozantinib),
Remicade<SUP>&reg;</SUP> (infliximab) and Clolar<SUP>&reg; </SUP>(clofarabine).</FONT></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Associated with Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
ability to execute on our business strategy is subject to a number of risks, which are discussed more fully in the section titled &ldquo;Risk
Factors.&rdquo; Investors should carefully consider these risks before making an investment in our common stock. These risks include,
among others, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
    have a limited operating history, and we have not initiated, conducted or completed any clinical trials, and have no products approved
    for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and viability.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have incurred significant
    losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient revenue to achieve
    and maintain profitability.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Even
    if this offering is successful, we will require substantial additional capital to finance our operations in the future. If we are
    unable to raise such capital when needed, or on acceptable terms, we may be forced to curtail, delay or discontinue one or more of
    development programs or future commercialization efforts.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt">We
    may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization
    of HSB-1216 or any of our other product candidates in development.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our independent registered
    public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability
    to obtain future financing.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are substantially dependent
    on the success of our product candidates. If we are unable to complete development of, obtain approval for and commercialize our
    product candidates in a timely manner, our business may be harmed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any delays in the commencement
    or completion, or termination or suspension, of our ongoing, planned or future clinical trials could result in increased costs to
    us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The outcome of pre-clinical
    testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical
    trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we experience delays
    or difficulties in enrolling patients in our ongoing or planned clinical trials, our receipt of necessary regulatory approval could
    be delayed or prevented.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be required to perform
    additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory
    approval. If our candidates prove to be ineffective, unsafe or commercially unviable, our entire technology platform and pipeline
    would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of
    operations and prospects.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse side effects or
    other safety risks associated with our drug candidates could delay or preclude approval, cause us to suspend or discontinue clinical
    trials or abandon further development, limit the commercial profile of an approved label, or result in significant negative consequences
    following marketing approval, if any.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our products may never
    achieve market acceptance.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face significant competition,
    and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less
    expensive than the products we develop, our commercial opportunities will be negatively impacted.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on third parties
    to manufacture our product candidates and conduct our pre-clinical studies and clinical trials. If these third parties do not successfully
    perform their contractual and regulatory duties or meet expected deadlines, we may not be able to obtain regulatory approval for
    or commercialize our drug candidates and our business could be substantially harmed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we are successful
    in completing all pre-clinical studies and clinical trials, we may not be successful in commercializing one or more of our drug candidates.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The development and commercialization
    of pharmaceutical products are subject to extensive regulation, and we may not obtain regulatory approvals for our drug candidates
    on a timely basis, or at all.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our inability to protect
    our intellectual property and proprietary rights may have a material adverse effect on our business.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business may be adversely
    affected by the ongoing coronavirus pandemic.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may encounter difficulties
    in managing our growth, which could adversely affect our operations.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our employees, independent
    contractors, consultants, commercial partners, collaborators and vendors may engage in misconduct or other improper activities, including
    noncompliance with regulatory standards and requirements.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There has been no prior
    public market for our common stock, the stock price of our common stock may be volatile or may decline regardless of our operating
    performance and you may not be able to resell your shares at or above the initial public offering price.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our principal stockholders
    and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder
    approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Corporate History</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hillstream
BioPharma Inc. (&ldquo;HBI&rdquo;) was incorporated on March 28, 2017, as a Delaware C-corporation. On July 16, 2019, Hillstream BioPharma
Holdings, Inc. (&ldquo;Holdco&rdquo;) was formed as a Delaware C-corporation. On July 24, 2019, Holdco entered into a Contribution and
Exchange Agreement with Nanoproteagen LLC (&ldquo;Nanoproteagen&rdquo;) whereby the members of Nanoproteagen exchanged 100% of their
membership interests in Nanoproteagen for shares of Holdco common stock. Also on July 24, 2019, the stockholders of HBI exchanged 100%
of their shares of common stock for shares of common stock of Holdco. HBI and Nanoproteagen became wholly-owned subsidiaries of Holdco.
On August 7, 2019, pursuant to a certificate of amendment, Holdco&rsquo;s name was changed to Hillstream BioPharma, Inc. and HBI&rsquo;s
name was changed to HB Pharma Corp. On November 12, 2020, Hillstream BioPharma, Inc. entered into a Share Exchange Agreement with Farrington
Therapeutics LLC (&ldquo;Farrington&rdquo;), whereby the members of Farrington exchanged their membership interest in Farrington for
shares of common stock of Hillstream BioPharma, Inc., and Farrington became a wholly-owned subsidiary of Hillstream BioPharma, Inc. The
estimated fair value of the common stock issued in exchange for 100% of the members&rsquo; interest in Nanoproteagan and Farrington was
$185,000 ($0.0792 per share) and $289,200 ($3.8174 per share), respectively.&nbsp; Management estimated the fair value
per share with the assistance of an independent third-party valuation firm. The fair value per share was based upon the cost approach
prior to September 2020 and comparative companies thereafter, as the Company has not had a priced equity round to date. At June 30,
2020, Hillstream BioPharma, Inc. has two wholly-owned subsidiaries: HB Pharma Corp. and Farrington.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807 and our telephone number is (908) 955-3140.
Our website address is www.hillstreambio.com. The information contained on our website is not incorporated by reference into this prospectus,
and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or
in deciding whether to purchase our common shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a company with less than $1.07 billion in revenues during our last fiscal year, we qualify as an emerging growth company as defined in
the Jumpstart Our Business Startups Act (&ldquo;JOBS Act&rdquo;) enacted in 2012. As an emerging growth company, we expect to take advantage
of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    permitted to present only two years of audited financial statements, in addition to any required unaudited interim financial statements,
    with correspondingly reduced &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
    disclosure in this prospectus;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (&ldquo;Sarbanes-Oxley
    Act&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions
    from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
    payments not previously approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may use these provisions until the last day of our fiscal year following the fifth anniversary of the completion of this offering. However,
if certain events occur prior to the end of such five-year period, including if we become a &ldquo;large accelerated filer,&rdquo; our
annual gross revenues exceed $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will
cease to be an emerging growth company prior to the end of such five-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
OFFERING</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock offered by us</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,000,000
    </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock to be outstanding immediately after this offering</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,277,221
    </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">shares (10,727,221 shares if the underwriters exercise their
    option in full). The number of shares of common stock outstanding immediately after this offering assumes the issuance of 919,907
    shares of common stock issuable upon the conversion of outstanding convertible notes in the aggregate amount of $3,820,995, including
    interest accrued thereon, assuming an initial public offering price of $5.50 per share, the midpoint of the range set forth on the
    cover page of this prospectus.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    to purchase additional shares</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    underwriters have an option for a period of 45 days to purchase up to an additional 450,000 shares of our common stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    estimate that the net proceeds from this offering will be approximately $14,447,500, or approximately $16,914,250 if
    the underwriters exercise their over-allotment option in full, at an assumed initial public offering price of $5.50 per share,
    the midpoint of the range set forth on the cover page of this prospectus, after deducting the underwriting discounts and commissions
    and estimated offering expenses payable by us. We intend to use the net proceeds from this offering to advance our product candidate
    HSB-1216 through pre-clinical activities, completion of Phase 1 studies and manufacturing, to advance our product candidate HSB-888
    through pre-clinical activities and IND submission, as well as for general corporate and working capital purposes. We may also use
    a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products; however, we have no current
    commitments or obligations to do so. See &ldquo;Use of Proceeds&rdquo; for a more complete description of the intended use of proceeds
    from this offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lock-up
    agreements</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities
    for a period of 12 months from the date of this prospectus, and all of our stockholders have agreed with the underwriters not to
    sell, transfer or dispose of any shares or similar securities for a period of 6 months from the date of this prospectus. For additional
    information regarding our arrangement with the underwriters, please see &ldquo;Underwriting.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    factors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    &ldquo;Risk Factors&rdquo; on page 10 and other information included in this prospectus for a discussion of factors to consider carefully
    before deciding to invest in shares of our common stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed
    Nasdaq Capital Market symbol</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;HILS&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock to be outstanding after this offering is based on 6,357,314 shares of our common stock outstanding
as of September 17, 2021, and excludes as of that date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">1,480,998
    </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">shares of common stock reserved for future
    issuance under our 2019 stock incentive plan;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">903,468
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">shares of common stock issuable upon exercise of outstanding
    options with a weighted average exercise price of $4.269;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">150,000
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">shares of common stock issuable
    upon exercise of warrants to be issued to the representative of the underwriters as part of this offering at an exercise price of
    $6.875 (assuming an initial public offering price of $5.50 per share (the midpoint of the price range set forth on
    the cover page of this prospectus)).</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Except
as otherwise indicated herein, all information in this prospectus assumes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">a
     1-for-26.4 reverse stock split of our common stock effected on September 16, 2021 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursuant
    to which (i) every 26.4 shares of outstanding common stock was decreased to one share of common stock, (ii) the number of
    shares of common stock for which each outstanding option to purchase common stock is exercisable was proportionally decreased on
    a 1-for 26.4 basis and (iii) the exercise price of each outstanding option to purchase common stock was proportionally increased
    on a 1-for 26.4 basis (the &ldquo;Reverse Stock Split&rdquo;). No fractional shares were issued as a result of the
    Reverse Stock Split. Any fractional shares resulting from the Reverse Stock Split were rounded
down to the nearest whole share; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">no
    exercise by the underwriters of their option to purchase an additional 450,000 shares of common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Financial Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following tables set forth our consolidated financial data as of the dates and for the periods indicated. We have derived the summary
consolidated statements of operations data for the years ended December 31, 2020 and 2019 from our audited consolidated financial statements
included elsewhere in this prospectus. We have derived the summary consolidated statements of operations data for the six months
ended June 30, 2021 and 2020 and our balance sheet data as of June 30, 2021 from our unaudited interim consolidated financial
statements included elsewhere in this prospectus. The unaudited interim consolidated financial statements have been prepared on the same
basis as the audited consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal, recurring
nature that are necessary for a fair presentation of the unaudited interim consolidated financial statements. Our historical results
are not necessarily indicative of the results that may be expected in the future, and the results in the six months ended June
30, 2021 are not necessarily indicative of results to be expected for the full year or any other period. The following summary financial
data should be read with &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and
our consolidated financial statements and related notes and other information included elsewhere in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Operations Data:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: center; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Six
                                            </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Months Ended June
                                            30,</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(unaudited)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Consolidated Statements of Operations Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left; padding-left: 10pt">Research and development</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">847,272</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">368,732</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,570,675</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">291,714</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Acquired in-process research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">289,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">429,403</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">671,879</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">625,807</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">994,636</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">161,324</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total operating expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,808,351</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,423,942</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,565,311</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">453,038</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other Expense:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest Expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">246,534</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,074</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">337,090</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79,132</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Change in redemption value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">362,486</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,458</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">903,744</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">175,222</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">609,020</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">101,532</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,240,834</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">254,354</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,417,371</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,525,474</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,806,145</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(707,392</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per common share &ndash; basic and diluted<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.38</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.41</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.60</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.11</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average common shares outstanding &ndash; basic and diluted<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,347,144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,753,886</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,357,314</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,281,557</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: center; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    Note 2 to our consolidated financial statements appearing elsewhere in this prospectus for an explanation of the method used to calculate
    the basic and diluted net loss per share attributable to common stockholders and the number of shares used in the computation of
    the per share amounts.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Balance
Sheet Data:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30,</B></FONT><FONT STYLE="font-size: 10pt"><B>
    2021 (unaudited)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Actual</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As Adjusted<SUP>(1)(2)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 64%"><FONT STYLE="font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-size: 10pt">29,271</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-size: 10pt">14,811,771</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Working Capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(4,935,557</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13,430,623</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Total assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">283,126</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14,816,824</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Accumulated deficit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(8,510,752</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(8,510,752</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Total stockholders&rsquo; equity (deficit)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(6,295,581</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13,430,623</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On an as adjusted basis
    to give further effect to (i) our issuance and sale of 3,000,000 shares of common stock in this offering at an assumed initial
    public offering price of $5.50 per share, the midpoint of the price range listed on the cover page of this prospectus, after
    deducting the underwriting discounts and commissions and estimated offering expenses payable by us and (ii) the conversion of $3,820,995
    of principal amount and accrued interest of outstanding convertible notes into an aggregate of 919,097 shares of common
    stock upon the closing of this offering based upon an assumed initial public offering price of $5.50 per share, which is the
    midpoint of the price range listed on the cover page of this prospectus. As adjusted balance sheet data is illustrative only and
    will change based on the actual initial public offering price and other terms of this offering determined at pricing.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each $1.00 increase (decrease)
    in the assumed initial public offering price of $5.50 per share, the midpoint of the price range listed on the cover page
    of this prospectus, would increase (decrease) the as adjusted amount of each of cash, working capital, total assets and total stockholders&rsquo;
    equity (deficit) by approximately $2.8 million, assuming that the number of shares offered by us, as set forth on the cover
    page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses
    payable by us. Similarly, each increase (decrease) of 100,000 shares in the number of shares offered by us at the assumed initial
    public offering price of $5.50 per share, the midpoint of the price range listed on the cover page of this prospectus, would
    increase (decrease) the as adjusted amount of each of cash, working capital, total assets and total stockholders&rsquo; equity (deficit)
    by approximately $0.5 million. These unaudited adjustments are based upon available information and certain assumptions we believe
    are reasonable under the circumstances.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="o_002"></A>RISK
FACTORS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with
all other information in this prospectus, including our financial statements and related notes and the &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations&rdquo; section of this prospectus before investing in our common stock.
Any of the risk factors we describe below could adversely affect our business, financial condition, results of operations or prospects.
The market price of our common stock could decline if one or more of these risks or uncertainties actually occur, causing you to lose
all or part of your investment in our common stock. Additional risks that we currently do not know about or that we currently believe
to be immaterial may also impair our business, financial condition, operating results and prospects.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Our Financial Position and Need for Additional Capital</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects.
We commenced operations in 2017, have no products approved for commercial sale and have not generated any revenue. Drug development is
a highly uncertain undertaking and involves a substantial degree of risk. Since our inception, we have spent the first three years developing
and refining our Quatramer technology, and since 2019, we have focused our efforts on advancing the development of our product candidates,
HSB-1216, HSB-888 and HSB-510.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Quatramer technology is new and unproven. We have not yet commenced human clinical trials for any of our product candidates, nor have
we demonstrated an ability to initiate or successfully complete any large-scale or pivotal clinical trials, obtain marketing approvals,
manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities
necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict our likelihood
of success and viability than it could be if we had a longer operating history.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan on submitting an IND to the FDA for HSB-1216 in  2022; however, no assurance can be provided that
our IND will be accepted by the FDA in 2022, if at all. Our other programs are in pre-clinical discovery and research stages. As
a result, we expect that it will take several years, if ever, before we have a commercialized product and generate revenue from product
sales. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates, we expect that
we will continue to incur substantial research and development and other expenses in order to discover, develop and market additional
potential products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are leveraging our Trident platform in an attempt to identify synthetic lethal sensitivities associated with degree of cell plasticity
using biomarkers that can be translated for patient selection and stratification for the development of oncology drugs. While we believe
that applying our Trident platform is a precision oncology approach that identifies the mechanism of action, potential combination drug
usage and potentially responsive patient population, our approach is both innovative and in the early stages of development and therefore,
the cost and time needed to develop such platform difficult to predict, and our efforts may not result in the successful discovery and
development of biomarkers. We may also be incorrect about the effects of the biomarkers on our drug candidates on the diseases of our
defined patient populations, which may limit the utility of our approach or the perception of the utility of our approach. Furthermore,
our estimates of our defined patient populations available for study and treatment may be lower than expected, which could adversely
affect our ability to conduct clinical trials and may also adversely affect the size of any market for medicines we may successfully
commercialize. Our approach may not result in time savings, higher success rates or reduced costs as we expect it to, and if not, we
may not attract collaborators or develop new drugs as quickly or cost effectively as expected and therefore we may not be able to commercialize
our approach as originally expected.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Trident Artificial Intelligence platform may fail to help us discover and develop appropriate biomarkers for our potential drug candidates
which would limit our commercialization prospects and cause our losses to continue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
biomarker discovery or drug development that we are conducting using our Trident platform may not be successful in identifying biomarkers
that have commercial value for our products or therapeutic utility. Our Trident platform may initially show promise in identifying potential
biomarkers for our drug candidates, yet fail to stratify patients for clinical development or commercialization for a number of reasons,
including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">research
    programs to identify new biomarkers will require substantial technical, financial and human resources, and we may be unsuccessful
    in our efforts to identify biomarkers. If we are unable to identify suitable biomarkers for pre-clinical and clinical development,
    our ability to stratify patients could be compromised, which could result in significant harm to our financial position and adversely
    impact our stock price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-indent: -13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">biomarkers
    identified through our Trident platform may not demonstrate correlation to efficacy, safety or tolerability;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data available for our Trident platform that seeks to correlate genomic or biomarker signatures with certain cancers may be influenced
    by the race of the patient which may limit the efficacy of our drug candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    regulatory pathway for the biomarkers may be too complex, expensive or otherwise difficult to &nbsp;navigate successfully; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitors
    may develop alternative approaches that render our potential biomarkers non-competitive or less attractive.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development
of, and seek regulatory approvals for, our product candidates, and begin to commercialize approved drugs, if any. Typically, it takes
many years to develop a new drug from the time it is discovered to when it is available for treating patients. We may encounter unforeseen
expenses, difficulties, complications, delays and other unknown factors that may increase our expenses and adversely affect our ability
to generate revenue. The size of our future net losses will depend, in part, on our ability to manage these aspects of our business.
&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient
revenue to achieve and maintain profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have never been profitable and have incurred significant
losses in each year since inception. For the years ended December 31, 2020 and 2019 and the six months ended June 30, 2021,
we reported a net loss of $2.4 million, $1.5 million and $3.8 million, respectively. As of December 31, 2020 and June 30,
2021, we had an accumulated deficit of $4.7 million and $8.5 million, respectively. To date, we have funded our operations primarily
with proceeds from the issuances of our convertible promissory notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur
may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a
good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our
expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse
effect on our working capital, our ability to achieve and maintain profitability and the performance of our stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
ability to generate revenue and achieve profitability depends significantly on our ability to achieve several milestones relating to
the discovery, development and commercialization of our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial condition and operating results have varied significantly in the past and are expected to continue to fluctuate significantly
due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations
include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    our current research and development programs, including conducting laboratory, pre-clinical studies for product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate
    clinical trials for product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of our clinical trials through all phases of clinical development;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in the commencement, enrollment and timing of clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to secure and maintain collaborations, licensing or other arrangements for the future development and/or commercialization
    of our product candidates, as well as the terms of those arrangements;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain, as well as the timeliness of obtaining, additional funding to develop our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of clinical trials or marketing applications for product candidates that may compete with our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    from existing products or new products that may receive marketing approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    side effects of our product candidates that could delay or prevent approval or cause an approved drug to be taken off the market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delays in regulatory review and approval of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to identify and develop additional product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of patients or healthcare providers to obtain coverage or sufficient reimbursement for our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability, and the ability of third parties such as Clinical Research Organizations (&ldquo;CROs&rdquo;) to adhere to clinical study
    and other regulatory requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of third-party manufacturers to manufacture our product candidates and key ingredients needed to conduct clinical trials
    and, if approved, successfully commercialize our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs to us, and our ability as well as the ability of any third-party collaborators, to obtain, maintain and protect our intellectual
    property rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to and outcomes of potential intellectual property litigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to adequately support future growth;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain key personnel to manage our business effectively; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to build our finance infrastructure and, to the extent required, improve our accounting systems and controls.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
new products and services is a speculative and risky endeavor. Products or services that initially show promise may fail to achieve the
desired results or may not achieve acceptable levels of analytical accuracy or clinical utility. We may need to alter our products in
development and repeat clinical studies before we identify a potentially successful product or service. Product development is expensive,
may take years to complete and can have uncertain outcomes. Failure can occur at any stage of the development. If, after development,
a product or service appears successful, we may, depending on the nature of the product or service, still need to obtain FDA and other
regulatory clearances, authorizations or approvals before we can market it. The FDA&rsquo;s clearance, authorization or approval pathways
are likely to involve significant time, as well as additional research, development and clinical study expenditures. The FDA may not
clear, authorize or approve any future product or service we develop. Even if we develop a product or service that receives regulatory
clearance, authorization or approval, we would need to commit substantial resources to commercialize, sell and market it before it could
be profitable, and the product or service may never be commercially successful. Additionally, development of any product or service may
be disrupted or made less viable by the development of competing products or services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
potential products and services may fail any stage of development or commercialization and if we determine that any of our current or
future products or services are unlikely to succeed, we may abandon them without any return on our investment. If we are unsuccessful
in developing additional products or services, our potential for growth may be impaired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
cases where we are successful in obtaining regulatory approval to market one or more of our drug candidates, our revenue will be dependent,
in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the
ability to obtain coverage and reimbursement, and whether we own the commercial rights for that territory. If the number of our addressable
patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the treatment
population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of
such products, even if approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our research and development expenses to continue to be significant in connection with our continued investment in our ongoing
and planned clinical trials for our current product candidates and any future product candidates we may develop. Furthermore, if we obtain
regulatory approval for our product candidates, we expect to incur increased sales and marketing expenses. In addition, once we are a
public company, we will incur additional costs associated with operating as a public company. As a result, we expect to continue to incur
significant and increasing operating losses and negative cash flows for the foreseeable future. These losses have had and will continue
to have a material adverse effect on our stockholders&rsquo; equity, financial position, cash flows and working capital.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if this offering is successful, we will require substantial additional funding. If we are unable to raise capital on favorable terms
when needed, we could be forced to curtail, delay or discontinue our research or drug development programs or any future commercialization
efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently advancing our product candidates, HSB-1216 and HSB-888, through pre-clinical stage development. Developing cancer drugs
is expensive and we expect our research and development expenses to increase substantially in connection with our ongoing activities,
particularly as we advance our product candidates in clinical studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020 and June 30, 2021, we had cash of $191,852 and $29,271, respectively. We estimate that the net proceeds
from this offering will be approximately $14.4 million, assuming an initial public offering price of $5.50 per share, the
midpoint of the price range set forth on the cover of this prospectus, after deducting underwriting discounts and commissions and estimated
offering expenses payable by us. We expect that the net proceeds from this offering and our existing cash will be sufficient to fund
our current operations through at least 12 months from the date of this prospectus. However, our operating plan may change as a result
of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity
or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic
alliances and licensing arrangements or a combination of these approaches. In any event, we will require additional capital to obtain
regulatory approval for, and to commercialize, our product candidates. Raising funds may present challenges including, but not limited
to, as a result of the novel Coronavirus (&ldquo;COVID-19&rdquo;). Even if we believe we have sufficient funds for our current or future
operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to
develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient
amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights
of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may
cause the market price of our shares to decline. The sale of additional equity or convertible securities may dilute our stockholders.
The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive
covenants, such as limitations on our ability to make certain dividends, incur additional debt, limitations on our ability to acquire,
sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our
business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than
otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or product candidates or otherwise
agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our
research or development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise
capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which
may hinder our ability to obtain future financing.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements as of December 31, 2020 have been prepared under the assumption that we will continue as a going concern for the
next twelve months. Our independent registered public accounting firm included in its opinion for the year ended December 31, 2020 an
explanatory paragraph referring to our recurring losses from operations and expressing substantial doubt in our ability to continue as
a going concern without additional capital becoming available. Our ability to continue as a going concern is dependent upon our ability
to obtain additional equity or debt financing, obtain government grants, reduce expenditures and to generate significant revenue. Our
financial statements as of December 31, 2020 did not include any adjustments that might result from the outcome of this uncertainty.
The reaction of investors to the inclusion of a going concern statement by our auditors, and our potential inability to continue as a
going concern, in future years could materially adversely affect our share price and our ability to raise new capital or enter into strategic
alliances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to the Discovery and Development of Our Product Candidates</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are substantially dependent on the success of our product candidates, HSB-1216 and HSB-888, which are currently in pre-clinical trials.
If we are unable to complete development of, obtain approval for and commercialize HSB-1216 or HSB-888 for one or more indications in
a timely manner, our business may be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success is dependent on our ability to timely and successfully complete clinical trials, obtain marketing approval for and successfully
commercialize HSB-1216 and HSB-888, our product candidates which are in the pre-clinical stages of development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no products approved for sale. The success of our business, including our ability to finance our company and generate any revenue
in the future, will primarily depend on the successful development, regulatory approval and commercialization of HSB-1216 and HSB-888
as well as other product candidates, which may never occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may also become dependent on other product candidates that we may develop or acquire; however, no product candidates based
on our Quatramer technology have been tested in humans and given our early stage of development, it may be many years, if at all, before
we may be able to demonstrate the safety and efficacy of our product candidates to warrant approval for commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical and commercial success of our current and any future product candidates will depend on a number of factors, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to raise any additional required capital on acceptable terms, or at all;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to complete IND-enabling studies and successfully submit an IND to the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">timely
    completion of our pre-clinical studies and clinical trials, which may be slower or cost more than we currently anticipate and will
    depend substantially upon the performance of third-party contractors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    by the FDA or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to
    support approval of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the
    FDA and similar foreign regulatory authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to consistently manufacture our product candidates on a timely basis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability, and the ability of any third parties with whom we contract, to remain in good standing with regulatory agencies and develop,
    validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices (&ldquo;cGMPs&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable
    risk-benefit profile of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future
    approved products, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual
    obligations and with all regulatory requirements applicable to our current and future product candidates or approved products, if
    any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully develop a commercial strategy and thereafter commercialize our product candidates in the United States and
    internationally, if approved for marketing, sale and distribution in such countries and territories, whether alone or in collaboration
    with others;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of coverage and adequate reimbursement from managed care plans, private insurers, government payors (such as Medicare
    and Medicaid) and other third-party payors for any of our product candidates that may be approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    convenience of our treatment or dosing regimen;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    by physicians, payors and patients of the benefits, safety and efficacy of our product candidates, if approved, including relative
    to alternative and competing treatments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of physicians, operators of hospitals and clinics and patients to utilize or adopt our cancer therapeutics approach;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    demand for our current or future product candidates, if approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and enforce intellectual property rights in and to our product candidates; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals
or commercialize our current or future product candidates. Even if regulatory approvals are obtained, we may never be able to successfully
commercialize our product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through
the sale of our product candidates to continue our business or achieve profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Quatramer approach is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes
us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory
approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are using our Quatramer technology to develop product candidates to treat cancer. Our foundational science and product development approach
are based on our ability to target specified cells or tissues and converge a therapeutic payload at the site of disease to boost efficacy
while abating adverse effects on healthy tissue. We believe that this approach may offer an improved therapeutic effect by driving an
intense, focused attack selectively upon a patient&rsquo;s tumor. However, this approach to treating cancer is novel and the clinical
research that results in a product candidate has had limited testing in humans. We are currently in the process of validating different
tumor-specific therapeutic product candidates. We may spend substantial funds attempting to develop these products with the Quatramer
approach and never succeed in developing a marketable therapeutic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
such, we cannot assure you that even if we are able to develop product candidates to treat cancer, such therapies would safely and effectively
treat cancers. We may spend substantial funds attempting to develop this approach and never succeed in developing a marketable therapeutic.
We are unable to predict when or if our drug candidates will prove effective or safe in humans or if we will obtain marketing approval.
Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate, we must complete pre-clinical development
and then conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. Clinical testing
is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the outcome. A failure of one
or more clinical trials can occur at any stage of testing. The outcome of pre-clinical testing and early clinical trials may not be predictive
of the success of later clinical trials, and interim or preliminary results of a clinical trial do not necessarily predict final results.
In particular, the small number of patients in our early clinical trials may make the results of these trials less predictive of the
outcome of later clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to obtain
marketing approval or commercialize our drug candidates, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
    or institutional review boards (&ldquo;IRBs&rdquo;)/ethics committees (&ldquo;ECs&rdquo;) may not authorize us or our investigators
    to commence a clinical trial or conduct a clinical trial at a prospective trial site;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols
    with prospective trial sites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trials for our drug candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to
    conduct additional clinical trials, delay clinical trials or abandon product development programs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of patients required for clinical trials for our drug candidates may be larger than we anticipate, enrollment in these clinical
    trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or
    the duration of these clinical trials may be longer than we anticipate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    for clinical trial participants from investigational and approved therapies may make it more difficult to enroll patients in our
    clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or third-party collaborators may fail to obtain the clearance or approval of companion diagnostic tests, if required, on a timely
    basis, or at all;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    third-party contractors may fail to meet their contractual obligations to us in a timely manner, or at all, or may fail to comply
    with regulatory requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may have to suspend or terminate clinical trials for our drug candidates for various reasons, including a finding that the participants
    are being exposed to unacceptable health risks;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    drug candidates may have undesirable or unexpected side effects or other unexpected characteristics, causing us or our investigators,
    regulators or IRBs/ECs to suspend or terminate the trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of clinical trials for our drug candidates may be greater than we anticipate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    supply or quality of our drug candidates or other materials necessary to conduct clinical trials for our drug candidates may be insufficient
    or inadequate and result in delays or suspension of our clinical trials; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or a diagnostic development partner may fail to receive regulatory approval of a companion diagnostic for use with a marketed product.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product development costs will increase if we experience delays in pre-clinical studies or clinical trials or in obtaining marketing
approvals. We do not know whether any of our planned pre-clinical studies or clinical trials will begin on a timely basis or at all,
will need to be restructured or will be completed on schedule, or at all. For example, the FDA may place a partial or full clinical hold
on any of our clinical trials for a variety of reasons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
pre-clinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our
drug candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize
our drug candidates and may harm our business and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
delays in the commencement or completion, or termination or suspension, of our ongoing, planned or future clinical trials could result
in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
we can initiate clinical trials of a drug candidate in any indication, we must submit the results of pre-clinical studies to the FDA
along with other information, including information about the drug candidate&rsquo;s chemistry, manufacturing and controls and our proposed
clinical trial protocol, as part of an IND or similar regulatory filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining marketing approval from the FDA for the sale of our product candidate in any indication, we must conduct extensive clinical
studies to demonstrate safety and efficacy. Clinical testing is expensive, time consuming and uncertain as to outcome. In addition, we
expect to rely in part on pre-clinical, clinical and quality data generated by our CROs and other third parties for regulatory submissions
for our drug candidates. While we have or will have agreements governing these third parties&rsquo; services, we have limited influence
over their actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions
in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed and we may
need to conduct additional studies or collect additional data independently. In either case, our development costs would increase. We
still need to receive FDA clearance of our IND for HSB-1216 and HSB-888 before we can begin clinical trials and would require the same
acceptance by the FDA prior to initiating any clinical trials in the United States for any of our other drug candidates. The FDA may
require us to conduct additional pre-clinical studies for any drug candidate before it allows us to initiate clinical trials under any
IND, which may lead to additional delays and increase the costs of our pre-clinical development programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delays in the commencement or completion of our ongoing, planned or future clinical trials could significantly affect our product development
costs. We do not know whether our planned trials will begin on time or at all, or be completed on schedule, if at all. The commencement
and completion of clinical trials can be delayed for a number of reasons, including delays related to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA disagreeing as to the design or implementation of our clinical trials or with our recommended dose for any of our pipeline programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    FDA authorization to commence a trial or reaching a consensus with the FDA on trial design;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failing
    to obtain regulatory clearance or approval of companion diagnostics we may use to identify patients for enrollment in our clinical
    trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation
    and may vary significantly among different CROs and trial sites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    approval from one or more IRBs/ECs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IRBs/ECs
    refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects,
    or withdrawing their approval of the trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    to clinical trial protocol;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    sites deviating from trial protocol or dropping out of a trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failing
    to manufacture or obtain sufficient quantities of drug candidate or, if applicable, combination therapies for use in clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    failing to enroll or remain enrolled in our trials at the rates we expect, or failing to return for post-treatment follow-ups;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    choosing an alternative treatment, or participating in competing clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of adequate funding to continue clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    experiencing severe or unexpected drug-related adverse effects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
    of serious adverse events in trials of the same class of agents conducted by other companies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting
    or being required to use clinical end points that require prolonged periods of clinical observation or analysis of the resulting
    data;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    facility manufacturing our drug candidates or any of their components being ordered by the FDA to temporarily or permanently shut
    down due to violations of cGMP regulations or other applicable requirements, or infections or cross-contaminations of drug candidates
    in the manufacturing process;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    changes to our manufacturing process that may be necessary or desired;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials
    on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices (&ldquo;GCPs&rdquo;) or other
    regulatory requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">us,
    or our third-party contractors not performing data collection or analysis in a timely or accurate manner or improperly disclosing
    data prematurely or otherwise in violation of a clinical trial protocol; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations
    of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all
    of the data produced by such contractors in support of our marketing applications.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs/ECs of the institutions in which such trials
are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA. Such authorities may impose such a suspension or
termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or
our clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical
hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a pharmaceutical, changes in governmental
regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory
requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require
us to resubmit our clinical trial protocols to IRBs/ECs for reexamination, which may impact the costs, timing or successful completion
of a clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our scientific advisors or consultants who receive compensation from us are investigators for our clinical trial. Under certain circumstances,
we may be required to report some of these relationships to the FDA. Although we believe our existing relationships are within the FDA&rsquo;s
guidelines, the FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest
or otherwise affected interpretation of the study. The FDA may therefore question the integrity of the data generated at the applicable
clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection,
of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our product candidates. If we
experience delays in the completion of, or termination of, any clinical trial of our drug candidates, the commercial prospects of such
drug candidate will be harmed, and our ability to generate product revenues will be delayed. Moreover, any delays in completing our clinical
trials will increase our costs, slow down our development and approval process and jeopardize our ability to commence product sales and
generate revenues which may harm our business, financial condition, results of operations and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results
of our clinical trials may not satisfy the requirements of the FDA, European Medicines Agency (&ldquo;EMA&rdquo;) or other comparable
foreign regulatory authorities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe
and effective for use in a diverse population before we can seek marketing approvals for their commercial sale. Success in pre-clinical
studies and early-stage clinical trials does not mean that future clinical trials will be successful. Product candidates in later-stage
clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA, EMA and other comparable foreign
regulatory authorities despite having progressed through pre-clinical studies and early-stage clinical trials. Regulatory authorities
may also limit the scope of later-stage trials until we have demonstrated satisfactory safety, which could delay regulatory approval,
limit the size of the patient population to which we may market our product candidates, or prevent regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product
candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences
in and adherence to the dose and dosing regimen and other trial protocols and the rate of dropout among clinical trial participants.
Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using
other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product
candidates. As a result, assessments of efficacy can vary widely for a particular patient and from patient to patient and site to site
within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain
approval to market any of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interim,
topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes
available, and are subject to audit and verification procedures that could result in material changes in the final data.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials, such as the interim data from our
Phase 1 clinical trial of HSB-1216 or HSB-888. These interim updates are based on a preliminary analysis of then-available data,
and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related
to the particular study or trial. For example, we may report tumor responses in certain patients that are unconfirmed at the time and
which do not ultimately result in confirmed responses to treatment after follow-up evaluations. We also make assumptions, estimations,
calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully
evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions
or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject
to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously
published. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report interim
analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the
risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available.
Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure
of interim data by us or by our competitors in the future could result in volatility in the price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a
more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate
information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with
respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If
the preliminary or topline data that we report differs from late, final or actual results, or if others, including regulatory authorities,
disagree with the conclusions reached, our ability to obtain approval for, and commercialize, HSB-1216 or HSB-888 or any other product
candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we experience delays or difficulties in enrolling patients in our ongoing or planned clinical trials, our receipt of necessary regulatory
approval could be delayed or prevented.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to initiate or continue our ongoing or planned clinical trials for our product candidates if we are unable to identify
and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA. Patient enrollment is a significant
factor in the timing of clinical trials. Our ability to enroll eligible patients may be limited or may result in slower enrollment than
we anticipate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
enrollment may be affected if our competitors have ongoing clinical trials for programs that are under development for the same indications
as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of
our competitors&rsquo; programs. Patient enrollment for our current or any future clinical trials may be affected by other factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">size
    and nature of the patient population;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">severity
    of the disease under investigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    and efficacy of approved drugs for the disease under investigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    eligibility criteria for the trial in question as defined in the protocol;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived
    risks and benefits of the product candidate under study;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&rsquo;
    and patients&rsquo; perceptions as to the potential advantages of the product candidate being studied in relation to other available
    therapies, including any new products that may be approved or other product candidates being investigated for the indications we
    are investigating;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&rsquo;
    willingness to screen their patients for biomarkers to indicate which patients may be eligible for enrollment in our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    referral practices of physicians;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to monitor patients adequately during and after treatment;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">proximity
    and availability of clinical trial sites for prospective patients; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer
    patients and will not survive the full terms of the clinical trials.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon
one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product
candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are
able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining participation in our clinical
trials through the treatment and any follow-up periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
no regulatory authority has granted approval for a cancer therapeutic based on a Quatramer approach. We may never receive approval to
market and commercialize any product candidate. Even if we obtain regulatory approval, the approval may be for targets, disease indications,
lines of therapy or patient populations that are not as broad as we intended or desired or may require labeling that includes significant
use or distribution restrictions or safety warnings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not previously submitted a new drug application (&ldquo;NDA&rdquo;) to the FDA or similar regulatory approval filings to comparable
foreign authorities, for any product candidate, and we cannot be certain that our product candidates will be successful in clinical trials
or receive regulatory approval. Further, any future product candidates may not receive regulatory approval even if they are successful
in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.
Even if we successfully obtain regulatory approvals to market a product candidate, our revenue will be dependent, in part, upon the size
of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets or patient subsets
that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if
approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to seek regulatory approval to commercialize our product candidates both in the United States and in selected foreign countries.
While the scope of regulatory approval generally is similar in other countries, in order to obtain separate regulatory approval in other
countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy. Other countries
also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and distribution
of our product candidates, and we may be required to expend significant resources to obtain regulatory approval and to comply with ongoing
regulations in these jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements
to maintain regulatory approval. If our candidates prove to be ineffective, unsafe or commercially unviable, our entire technology platform
and pipeline would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results
of operations and prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HSB-1216,
HSB-888 and HSB-1218 are novel technologies, making it difficult to predict the time, cost and potential success of these product candidates.
We have not yet been able to assess the safety and efficacy of any product candidates in humans. Our success depends on our ability to
develop and commercialize product candidates using our novel Quatramer technology. The novel nature of our technology makes it difficult
to accurately predict the developmental challenges we may face for product candidates as they proceed through research, pre-clinical
or greenhouse studies and clinical or field trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been a limited number of clinical trials of products created with induced ferroptosis and reverse epithelial-mesenchymal transition
(&ldquo;EMT&rdquo;), none of which has utilized our Quatramer technology, and no therapeutic product candidates created with induced
ferroptosis and reverse EMT technology have received marketing approval in the United States or Europe. Because our therapeutic research
programs are all in research or pre-clinical stages, we have not yet been able to assess the safety or efficacy of any product candidates
in humans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our product candidates do not achieve projected development milestones or commercialization in the announced or expected timeframes,
the further development or commercialization of such product candidates may be delayed, and our business may be harmed. Current or future
product candidates may not meet safety and efficacy requirements for continued development or ultimate approval in humans and may cause
significant adverse events or toxicities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Adverse
side effects or other safety risks associated with our drug candidates could delay or preclude approval, cause us to suspend or discontinue
clinical trials or abandon further development, limit the commercial profile of an approved label, or result in significant negative
consequences following marketing approval, if any.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
of our planned clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics.
Undesirable side effects caused by our drug candidates could result in the delay, suspension or termination of clinical trials by us
or the FDA for a number of reasons. Additionally, due to the high mortality rates of the cancers for which we are initially pursuing
development and the pretreated nature of many patients in our planned clinical trials of HSB-1216, a material percentage of patients
in these clinical trials may die during a trial, which could impact development of HSB-1216. If we elect or are required to delay, suspend
or terminate any clinical trial, the commercial prospects of our drug candidates will be harmed and our ability to generate product revenues
from this drug candidate will be delayed or eliminated. Serious adverse events observed in clinical trials could hinder or prevent market
acceptance of our drug candidates. Any of these occurrences may harm our business, prospects, financial condition and results of operations
significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
if our drug candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we
may elect to abandon or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other
characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations
for our drug candidates, if approved. We may also be required to modify our study plans based on findings in our clinical trials. Many
drugs that initially showed promise in early stage testing have later been found to cause side effects that prevented further development.
In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that as we test our drug candidates in larger, longer and more extensive clinical trials, including with different dosing
regimens, or as the use of our drug candidates becomes more widespread following any regulatory approval, illnesses, injuries, discomforts
and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous
trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings
may harm our business, financial condition, results of operations and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if any of our drug candidates receive marketing approval, and we or others later identify undesirable side effects caused by
treatment with such drug, a number of potentially significant negative consequences could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw approval of the drug;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to recall a product or change the way the drug is administered to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require additional warnings on the label, such as a &ldquo;black box&rdquo; warning or a contraindication, or issue
    safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information
    about the product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to implement a Risk Evaluation and Mitigation Strategy (&ldquo;REMS&rdquo;) or create a medication guide outlining
    the risks of such side effects for distribution to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    restrictions may be imposed on the marketing or promotion of the particular product or the manufacturing processes for the product
    or any component thereof;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    drug could become less competitive; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of our drug candidates, if approved, and could significantly
harm our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
sometimes estimate, or may in the future estimate, the timing of the accomplishment of various scientific, clinical, manufacturing, regulatory
and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific
studies or clinical trials, the submission of regulatory filings, the receipt of marketing approval or the realization of other commercialization
objectives.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
achievement of milestones such as the timing of the accomplishment of various scientific, clinical, manufacturing, regulatory and other
product development objectives may be outside of our control. All of these milestones are based on a variety of assumptions, including
assumptions regarding capital resources, constraints and priorities, progress of and results from development activities and the receipt
of key regulatory approvals or actions, any of which may cause the timing of achievement of the milestones to vary considerably from
our estimates. If we or our collaborators fail to achieve announced milestones in the expected timeframes, the commercialization of our
product candidates may be delayed, our credibility may be undermined, our business and results of operations may be harmed, and the price
of our common stock may decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
a product liability claim is successfully brought against us for uninsured liabilities, or such claim exceeds our insurance coverage,
we could be forced to pay substantial damage awards that could materially harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of any of our existing or future product candidates in clinical trials and the sale of any approved pharmaceutical products may expose
us to significant product liability claims. We currently do not have product liability insurance coverage but we intend to obtain such
insurance. Such insurance coverage may not protect us against any or all of the product liability claims that may be brought against
us in the future. We may not be able to acquire or maintain adequate product liability insurance coverage at a commercially reasonable
cost or in sufficient amounts or scope to protect us against potential losses. In the event a product liability claim is brought against
us, we may be required to pay legal and other expenses to defend the claim, as well as uncovered damage awards resulting from a claim
brought successfully against us. In the event our product candidate is approved for sale by the FDA or other regulatory agency and commercialized,
we may need to substantially increase the amount of our product liability coverage. Defending any product liability claim or claims could
require us to expend significant financial and managerial resources, which could have an adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
current and future products may never achieve significant commercial market acceptance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on the market&rsquo;s confidence that we can provide therapeutic products that improve clinical outcomes, lower healthcare
costs and enable better biopharmaceutical development. Failure of our products, or those jointly developed with our collaborators, to
perform as expected could significantly impair our operating results and our reputation. We believe patients, clinicians, academic institutions
and biopharmaceutical companies are likely to be particularly sensitive to defects, errors, inaccuracies, delays and toxicities in or
associated with our products. Furthermore, inadequate performance of these products may result in lower confidence in our immune medicine
platform in general.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not succeed in achieving significant commercial market acceptance for our current or future products due to a number of factors,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to demonstrate the clinical utility of our Quatramer platform and related products and their potential advantages over existing
    drug products to academic institutions, biopharmaceutical companies and the medical community;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability, and that of our collaborators, to secure and maintain FDA and other regulatory clearance, authorization or approval for
    our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    agreement by third-party payors to reimburse our products, the scope and extent of which will affect patients&rsquo; willingness
    or ability to pay for our products and will likely heavily influence physicians&rsquo; decisions to recommend our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate of adoption of our Quatramer platform and related products by academic institutions, clinicians, key opinion leaders, advocacy
    groups and biopharmaceutical companies; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of our investments in product innovation and commercial growth.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our customers and collaborators may decide to decrease or discontinue their use of our products due to changes in their research and
development plans, failures in their clinical trials, financial constraints, the regulatory environment, negative publicity about our
products, competing products or the reimbursement landscape, all of which are circumstances outside of our control. We may not be successful
in addressing these or other factors that might affect the market acceptance of our products and Quatramer technology. Failure to achieve
widespread market acceptance of our Quatramer platform and related products would materially harm our business, financial condition and
results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business may be adversely affected by the coronavirus pandemic.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outbreak of COVID-19 evolved into a global pandemic as COVID-19 spread to many regions of the world. The extent to which COVID-19 impacts
our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including
new information that may emerge concerning COVID-19, including variants such as the delta variant, and the actions to contain
COVID-19 or treat its impact, among others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the continuing spread of</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> COVID-19, our business operations
could be delayed or interrupted. For instance, our research and development may be affected as a result of delays in the distribution
of clinical trial materials, study monitoring and data analysis. Furthermore, if COVID-19 continues to spread, some participants
and clinical investigators may not be able to comply with clinical trial protocols. For example, any ongoing or future quarantines
or other travel limitations (whether voluntary or required) may impede participant movement, affect sponsor access to study sites, or
interrupt healthcare services, and we may be unable to conduct our research activities, including our clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
continuing infections</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> and deaths related to the pandemic may disrupt
the United States&rsquo; healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources away from,
or materially delay FDA review and/or approval of our product candidates. It is unknown how long these disruptions could continue,
were they to occur. Any elongation or de-prioritization of clinical trials or delay in regulatory review resulting from such disruptions
could materially affect the development and study of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a shelter-in-place order or other mandated local travel restrictions, our employees conducting research and development
or manufacturing activities may not be able to access their laboratory or manufacturing space, and our core activities may be significantly
limited or curtailed, possibly for an extended period of time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
spread of COVID-19, which has caused a broad impact globally, including restrictions on travel and quarantine policies put into place
by businesses and governments, may have a material economic effect on our business. While the potential economic impact brought by and
the duration of the pandemic may be difficult to assess or predict, it has already caused, and may result in further, disruption
of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession,
depression or other sustained adverse market event resulting from the continued spread of COVID-19 could materially and adversely
affect our business and the value of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ultimate impact of the COVID-19 pandemic, or any other health epidemic, is highly uncertain and subject to change. We do not yet
know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or
the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor
the situation closely.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications
that may be more profitable or for which there is a greater likelihood of success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and managerial resources, we focus on research programs and drug candidates that we identify for specific indications.
As a result, we may forego or delay pursuit of opportunities with other drug candidates or for other indications that later prove to
have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products
or profitable market opportunities. Our spending on current and future research and development programs and drug candidates for specific
indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market
for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty
arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to
such drug candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be successful in our efforts to design additional potential drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key element of our strategy is to apply our knowledge and our understanding of the structure, biology and activity of ferroptosis to
develop drug candidates. The therapeutic design and development activities that we are conducting may not be successful in developing
drug candidates that are useful in treating cancer or other diseases. Our research programs may initially show promise in identifying
potential drug candidates, yet fail to yield drug candidates for clinical development for a number of reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    research methodology used may not be successful in identifying potential drug candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    drug candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are
    unlikely to be drugs that will obtain marketing approval or achieve market acceptance; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    drug candidates may not be effective in treating their targeted diseases.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
programs to identify and design new drug candidates require substantial technical, financial and human resources. We may choose to focus
our efforts and resources on a potential drug candidate that ultimately proves to be unsuccessful. If we are unable to identify and design
suitable drug candidates for pre-clinical and clinical development, we will not be able to obtain revenues from the sale of products
in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are
more effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis
on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product
candidates and processes competitive with ours. Any product candidates that we successfully develop and commercialize will compete with
existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently
under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop
product candidates. In addition, our products may need to compete with drugs physicians use off-label to treat the indications for which
we seek approval. This may make it difficult for us to replace existing therapies with our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, there is intense competition in the field of oncology. We have competitors both in the United States and internationally,
including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging
and start-up companies, universities and other research institutions. We also compete with these organizations to recruit management,
scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business
plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and
in-licensing new product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective,
have fewer side effects, are more convenient, have a broader label, are marketed more effectively, are more widely reimbursed or are
less expensive than any products that we may develop. Our competitors also may obtain marketing approval from the FDA, EMA or other comparable
foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors
establishing a strong market position before we are able to enter the market. Even if the product candidates we develop achieve marketing
approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced
competitiveness. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete,
less competitive or not economical. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our
products we develop may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to healthcare laws and regulations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our product candidates, if approved, or any other future product candidate will be subject to healthcare regulation and enforcement
by the federal government and the states and foreign governments in which we might conduct our business. The healthcare laws and regulations
that may affect our ability to operate include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Anti-Kickback Statute makes it illegal for any person or entity to knowingly and willfully, directly or indirectly, solicit,
    receive, offer, or pay any remuneration that is in exchange for or to induce the referral of business, including the purchase, order,
    lease of any good, facility, item or service for which payment may be made under a federal healthcare program, such as Medicare or
    Medicaid. The term &ldquo;remuneration&rdquo; has been broadly interpreted to include anything of value.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    false claims and false statement laws, including the federal civil False Claims Act and the Civil Monetary Penalties Law (&ldquo;CMPL&rdquo;),
    prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, for payment to, or
    approval by, federal programs, including Medicare and Medicaid, claims for items or services, including drugs, that are false or
    fraudulent.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
    Insurance Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;) created additional federal criminal statutes that prohibit
    among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program,
    including private third-party payors or making any false, fictitious or fraudulent statement in connection with the delivery of or
    payment for healthcare benefits, items or services.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and their implementing regulations,
    impose obligations on certain types of individuals and entities regarding the electronic exchange of information in common healthcare
    transactions, as well as standards relating to the privacy and security of individually identifiable health information.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which
    payment is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program, with specific exceptions, to report
    annually to the Centers for Medicare &amp; Medicaid Services information related to payments or other transfers of value made to
    physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
many states have similar laws and regulations, such as anti-kickback and false claims laws that may be broader in scope and may apply
regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Additionally, we may be subject
to state laws that require pharmaceutical companies to comply with the federal government&rsquo;s and/or pharmaceutical industry&rsquo;s
voluntary compliance guidelines, state laws that require drug manufacturers to report information related to payments and other transfers
of value to physicians and other healthcare providers or marketing expenditures, as well as state and foreign laws governing the privacy
and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws and regulations applicable to our business are complex, changing and often subject to varying interpretations. As a result, we may
not be able to adhere to all applicable laws and regulations. Any violation or alleged violation of any of these laws or regulations
by us could have a material adverse effect on our business, financial condition, cash flows and results of operations. We may be a party
to various lawsuits, demands, claims, <I>qui tam</I> suits, government investigations and audits, of which any could result in, among
other things, substantial financial penalties or awards against us, reputational harm, termination of relationships or contracts related
to our business, mandated refunds, substantial payments made by us, required changes to our business practices, exclusion from future
participation in Medicare and other healthcare programs and possible criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found in violation of applicable laws or regulations, we could suffer severe consequences that would have a material adverse effect
on our business, results of operations, financial condition, cash flows, reputation and stock price, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or termination of our participation in federal healthcare programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
    or civil liability, fines, damages or monetary penalties for violations of healthcare fraud and abuse laws, including the federal
    False Claims Act, CMPL, and Anti-Kickback Statute;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enforcement
    actions by governmental agencies or claims for monetary damages by patients under federal or state patient privacy laws, including
    HIPAA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">repayment
    of amounts received in violation of law or applicable payment program requirements, and related monetary penalties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandated
    changes to our practices or procedures that materially increase operating expenses;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of corporate integrity agreements that could subject us to ongoing audits and reporting requirements as well as increased scrutiny
    of our business practices;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    of various relationships or contracts related to our business; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">harm
    to our reputation which could negatively affect our business relationships, decrease our ability to attract or retain patients and
    physicians, decrease access to new business opportunities and impact our ability to obtain financing, among other things.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Responding
to lawsuits and other proceedings as well as defending ourselves in such matters will continue to require management&rsquo;s attention
and cause us to incur significant legal expense. It is also possible that criminal proceedings may be initiated against us or individuals
in our business in connection with investigations by the federal government.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are unable to effectively adapt to
changes in the healthcare industry, including changes to laws and regulations regarding or affecting the U.S. healthcare reform, our
business may be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Federal, state and local legislative bodies frequently
pass legislation and promulgate regulations relating to healthcare reform or that affect the healthcare industry. We anticipate that
there will continue to be increased government oversight and regulation of the healthcare industry in the future. We cannot predict the
ultimate content, timing or effect of any new healthcare legislation or regulations, nor is it possible at this time to estimate the
impact of potential new legislation or regulations on our business. It is possible that future legislation enacted by Congress or state
legislatures, or regulations promulgated by regulatory authorities at the federal or state level, could adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and if we are
found to have improperly promoted off-label uses of our drugs or drug candidates, if approved, we may become subject to significant liability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to have improperly promoted off-label uses of our drugs or drug candidates, we may become subject to significant liability.
 The FDA and other regulatory agencies strictly regulate the promotional claims
that may be made about prescription drug products, such as our drug candidates. In particular, a drug may not be promoted for uses that
are not approved by the FDA or such other regulatory agencies as reflected in the drug&rsquo;s approved labeling. If we receive marketing
approval for our drug candidates for our proposed indications, physicians may nevertheless use our drugs for their patients in a manner
that is inconsistent with the approved label. However, if we are found to have promoted our drugs for any off-label uses, the federal
government could levy civil, criminal and/or administrative penalties, and seek fines against us. The FDA or other regulatory authorities
could also request that we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us
under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of our drug
candidates, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to obtain or maintain Fast Track designation or accelerated approval for our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a drug is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet
medical need for this condition, a drug sponsor may apply for FDA Fast Track designation. If we seek Fast Track designation for a drug
candidate, we may not receive it from the FDA. However, even if we receive Fast Track designation, Fast Track designation does not ensure
that we will receive marketing approval or that approval will be granted within any particular time frame. We may not experience a faster
development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition,
the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development
program. Fast Track designation alone does not guarantee qualification for the FDA&rsquo;s priority review procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to obtain or maintain orphan drug designation or exclusivity for our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as &ldquo;orphan
drugs.&rdquo; Under the Orphan Drug Act, the FDA may designate a drug candidate as an orphan drug if it is intended to treat a rare disease
or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or if the disease
or condition affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing
and making a drug product available in the United States for the type of disease or condition will be recovered from sales of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
drug designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax
advantages and user-fee waivers. Additionally, if a product that has orphan designation subsequently receives the first FDA approval
for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity. This means that the
FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except
in certain circumstances, including proving clinical superiority (i.e., another product is safer, more effective or makes a major contribution
to patient care) to the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication
for which the orphan product has exclusivity, or obtain approval for the same product but for a different indication than that for which
the orphan product has exclusivity. In addition, exclusive marketing rights in the United States may be limited if we seek approval for
an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation
was materially defective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
Breakthrough Therapy designation by the FDA for our drug candidates may not lead to a faster development or regulatory review or approval
process, and it does not increase the likelihood that our drug candidates will receive marketing approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation
as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our drug candidates meets the criteria
for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive
Breakthrough Therapy designation, the receipt of such designation for a drug candidate may not result in a faster development process,
review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval
by the FDA. In addition, even if one or more of our drug candidates qualify as breakthrough therapies, the FDA may later decide that
the drugs no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.
We may seek a breakthrough therapy designation for some of our drug candidates. A breakthrough therapy is defined as a drug that is intended,
alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical
evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant
endpoints, such as substantial treatment effects observed early in clinical development. For drugs and biologics that have been designated
as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient
path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough
therapies by the FDA are also eligible for accelerated approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Reliance on Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely on third parties to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully perform their
contractual and regulatory duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our
drug candidates and our business could be substantially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have the ability to independently conduct all aspects of our pre-clinical testing or clinical trials. As a result, we have relied
upon and plan to continue to rely upon third-party medical institutions, clinical investigators, contract laboratories and other third
party CROs to monitor and manage data for our ongoing pre-clinical and clinical programs. We rely on these parties for the execution
of our pre-clinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible
for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards,
and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with current
GCPs, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic
Area and comparable foreign regulatory authorities for all of our drugs in clinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities enforce these current GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we
or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and
the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our
marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine
that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced
under cGMPs. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory
approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or
to do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under
our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical
and pre-clinical or clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected
deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure
to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated
and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result, our results
of operations and the commercial prospects for our drug candidates would be harmed, our costs could increase and our ability to generate
revenues could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for
whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. If the
third parties conducting our pre-clinical studies or our clinical trials do not perform their contractual duties or obligations, experience
work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy
of the clinical data they obtain is compromised due to their failure to adhere to our clinical trial protocols or to GCPs, or for any
other reason, we may need to enter into new arrangements with alternative third parties. Switching or adding additional CROs involves
additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work.
As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully
manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future
or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Manufacturing
pharmaceutical products is complex and subject to product loss for a variety of reasons. We contract with third parties for the manufacture
of our drug candidates for pre-clinical testing and clinical trials and expect to continue to do so for commercialization. This reliance
on third parties increases the risk that we will not have sufficient quantities of our drug candidates or products or such quantities
at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any manufacturing facilities. We produce very small quantities of small molecules for evaluation in our research programs
in our laboratory. We rely, and expect to continue to rely, on third parties for the manufacture of our drug candidates for pre-clinical
and clinical testing, as well as for commercial manufacture if any of our drug candidates obtain marketing approval. This reliance on
third parties increases the risk that we will not have sufficient quantities of our drug candidates or products or such quantities at
an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to establish any agreements with third-party manufacturers or to do so on favorable terms. Even if we are able to establish
agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reliance
    on the third party for regulatory, compliance and quality assurance;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operations
    of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including
    the bankruptcy of the manufacturer or supplier or the issuance of an FDA Form 483 notice or warning letter;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible breach of the manufacturing agreement by the third party;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible misappropriation of our proprietary information, including our trade secrets and know how;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">carrier
    disruptions or increased costs that are beyond our control; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to deliver our drugs under specified storage conditions and in a timely manner.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have only limited supply arrangements in place with respect to our drug candidates, and these arrangements do not extend to commercial
supply. We acquire many key materials on a purchase order basis. As a result, we do not have long-term committed arrangements with respect
to our drug candidates and other materials. If we obtain marketing approval for any of our drug candidates, we will need to establish
an agreement for commercial manufacture with a third party; however, no assurance can be provided that we will be able to enter into
a commercial manufacture agreement on reasonable terms, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
manufacturers may not be able to comply with cGMPs or similar regulatory requirements outside of the United States. Our failure, or the
failure of our third-party manufacturers and suppliers, to comply with applicable regulations could result in sanctions being imposed
on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation,
seizures or recalls of drug candidates or products, operating restrictions and criminal prosecutions, any of which could significantly
and adversely affect supplies of our products. In addition, our third-party manufacturers and suppliers are subject to numerous environmental,
health and safety laws and regulations, including those governing the handling, use, storage, treatment and disposal of waste products,
and failure to comply with such laws and regulations could result in significant costs associated with civil or criminal fines and penalties
for such third parties. Based on the severity of regulatory actions that may be brought against these third parties in the future, our
clinical or commercial supply of drug and packaging and other services could be interrupted or limited, which could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug candidates and any products that we may develop may compete with other drug candidates and products for access to manufacturing
facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers
that operate under cGMPs and that may be capable of manufacturing our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we prepare for later-stage clinical trials and potential commercialization, we will need to take steps to increase the scale of production
of our drug candidates. Even minor deviations from normal manufacturing processes could result in reduced production yields, product
defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our drug candidates or in the manufacturing
facilities in which our drug candidates are made, such manufacturing facilities may need to be closed for an extended period of time
to investigate and remedy the contamination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do
not currently have arrangements in place for redundant supply or a second source for bulk drug substance. If our current contract manufacturers
for pre-clinical and clinical testing cannot perform as agreed, we may be required to replace such manufacturers. Although we believe
that there are several potential alternative manufacturers who could manufacture our drug candidates, we may incur added costs and delays
in identifying and qualifying any such replacement manufacturer or be able to reach agreement with any alternative manufacturer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and anticipated future dependence upon others for the manufacture of our drug candidates or products may adversely affect our
future profit margins and our ability to commercialize any products that obtain marketing approval on a timely and competitive basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
failure to find third party collaborators to assist or share in the costs of drug development could materially harm our business, financial
condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy for the development and commercialization of our proprietary drug candidates may include the execution of collaborative arrangements
with third parties. Existing and future collaborators have significant discretion in determining the efforts and resources they apply
and may not perform their obligations as expected. Potential third-party collaborators include biopharmaceutical, pharmaceutical and
biotechnology companies, academic institutions and other entities. Third-party collaborators may assist us in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">funding
    research, pre-clinical development, clinical trials and manufacturing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeking
    and obtaining regulatory approvals; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    commercializing any future drug candidates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to establish further collaboration agreements, we may be required to undertake drug development and commercialization
at our own expense. Such an undertaking may limit the number of drug candidates that we will be able to develop, significantly increase
our capital requirements and place additional strain on our internal resources. Our failure to enter into additional collaborations could
materially harm our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our dependence on licensing, collaboration and other agreements with third parties may subject us to a number of risks. These
agreements may not be on terms that prove favorable to us and may require us to relinquish certain rights in our drug candidates. To
the extent we agree to work exclusively with one collaborator in a given area, our opportunities to collaborate with other entities could
be curtailed. Lengthy negotiations with potential new collaborators may lead to delays in the research, development or commercialization
of drug candidates. The decision by our collaborators to pursue alternative technologies or the failure of our collaborators to develop
or commercialize successfully any drug candidate to which they have obtained rights from us could materially harm our business, financial
condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Commercialization of Our Drug Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we are successful in completing all pre-clinical studies and clinical trials, we may not be successful in commercializing one or more
of our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we complete the necessary pre-clinical studies and clinical trials, the marketing approval process is expensive, time-consuming and
uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our drug candidates. If we are not
able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our drug candidates,
and our ability to generate revenue will be materially impaired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug candidates and the activities associated with their development and commercialization, including their design, testing, manufacture,
safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import are subject
to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and similar regulatory authorities
outside of the United States. Failure to obtain marketing approval for a drug candidate will prevent us from commercializing the drug
candidate. We have not submitted an application for or received marketing approval for any of our drug candidates in the United States
or in any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party
clinical research organizations or other third-party consultants or vendors to assist us in this process. Securing marketing approval
requires the submission of extensive pre-clinical and clinical data and supporting information to regulatory authorities for each therapeutic
indication to establish the drug candidate&rsquo;s safety and efficacy. Securing marketing approval also requires the submission of information
about the drug manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our drug candidates
may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other
characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. New cancer drugs frequently are
indicated only for patient populations that have not responded to an existing therapy or have relapsed. If any of our drug candidates
receives marketing approval, the accompanying label may limit the approved use of our drug in this way, which could limit sales of the
drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years, if approval is obtained
at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the drug candidates
involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or
regulations, or changes in regulatory review for each submitted drug application, may cause delays in the approval or rejection of an
application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may
decide that our data is insufficient for approval and require additional pre-clinical, clinical or other studies. In addition, varying
interpretations of the data obtained from pre-clinical studies and clinical trials could delay, limit or prevent marketing approval of
a drug candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments
that render the approved drug not commercially viable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to develop satisfactory sales and marketing capabilities, we may not succeed in commercializing our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no experience in marketing and selling drug products. We have not entered into arrangements for the sale and marketing of any of
our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are risks involved with establishing our own sales and marketing capabilities. For example, recruiting and training a sales force is
expensive and time-consuming and could delay any product launch. If the commercial launch of a drug candidate for which we recruit a
sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily
incurred these commercialization expenses. These efforts are expected to be costly, and our investment would be lost if we cannot retain
or reposition our sales and marketing personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek to collaborate with a third party to market our drugs or may seek to market and sell our drugs by ourselves. If we seek to collaborate
with a third party, we cannot be sure that a collaborative agreement can be reached on terms acceptable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be sure that we will be able to acquire, or establish third party relationships to provide, any or all of these marketing and
sales capabilities. The establishment of a direct sales force or a contract sales force or a combination direct and contract sales force
to market our drugs will be expensive and time-consuming and could delay any drug launch. Further, we can give no assurances that we
may be able to maintain a direct and/or contract sales force for any period of time or that our sales efforts will be sufficient to generate
or to grow our revenues or that our sales efforts will ever lead to profits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
development and commercialization of pharmaceutical products are subject to extensive regulation, and we may not obtain regulatory approvals
for our drug candidates on a timely basis, or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval or other marketing authorizations by the FDA is unpredictable, and it typically takes many years following
the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities.
In addition, approval policies, regulations, and the type and amount of clinical data necessary to gain approval may change during the
course of a product candidate&rsquo;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval
for any product candidate, and it is possible that we may never obtain regulatory approval for any product candidates we may seek to
develop in the future. Neither we nor any current or future collaborator is permitted to market any drug product candidates in the United
States until we receive regulatory approval from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to obtaining approval to commercialize any drug product candidate in the United States, we must demonstrate with substantial evidence
from well-controlled clinical trials, and to the satisfaction of the FDA, that such product candidates are safe, pure and effective for
their intended uses. Results from pre-clinical studies and clinical trials can be interpreted in different ways. Even if we believe the
pre-clinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA.
The FDA may also require us to conduct additional pre-clinical studies or clinical trials for our product candidates either prior to
or after approval, or it may object to elements of our clinical development programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates could fail to receive regulatory approval for many reasons, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may disagree with the design or implementation of our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for its proposed indication;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of clinical trials may not meet the level of statistical significance required by the FDA for approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate that a product candidate&rsquo;s clinical and other benefits outweigh its safety risks;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical
    and commercial supplies; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the large number of products in development, only a small percentage successfully complete the FDA approval processes and are commercialized.
The lengthy approval and marketing authorization process as well as the unpredictability of future clinical trial results may result
in our failing to obtain regulatory approval and marketing authorization to market our product candidates, which would significantly
harm our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have invested a significant portion of our time and financial resources in the development of our pre-clinical product candidates. Our
business is dependent on our ability to successfully complete pre-clinical and clinical development, obtain regulatory approval for,
and, if approved, successfully commercialize HSB-1216, HSB-888, HSB-1218 and any future product candidates in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we eventually complete clinical testing and receive approval for HSB-1216, HSB-888, HSB-1218 and any future product candidates, the
FDA, may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including
post-marketing clinical trials. The FDA, also may approve or authorize for marketing a product candidate for a more limited indication
or patient population than we originally request, and the FDA may not approve or authorize the labeling that we believe is necessary
or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable
regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would materially
adversely impact our business and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA may change their policies, issue additional regulations or revise existing regulations, or take other actions, which
may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose
additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability
to maintain any marketing authorizations we may have obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to obtain marketing approval in foreign jurisdictions would prevent our drug candidates from being marketed abroad.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market and sell our drugs in the European Union and many other foreign jurisdictions, we or our potential third-party collaborators
must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies
among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required
to obtain FDA marketing approval. The regulatory approval process outside of the United States generally includes all of the risks associated
with obtaining FDA approval. In addition, in many countries outside of the United States, it is required that the drug be approved for
reimbursement before the drug can be approved for sale in that country. We or our potential third-party collaborators may not obtain
approvals from regulatory authorities outside of the United States on a timely basis, if at all. Approval by the FDA does not ensure
approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside of the United
States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, a failure or delay
in obtaining regulatory approval in one country may have a negative effect on the regulatory process in other countries. We may not be
able to file for marketing approvals and may not receive necessary approvals to commercialize our drugs in any market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
drug candidate that we obtain marketing approval for could be subject to post-marketing restrictions or withdrawal from the market and
we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems
with our drugs, when and if any of them are approved.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While it is possible that one or more of our drug
candidates may require a companion diagnostic to select the patients who will likely respond to a cancer therapy involving one of our
drug candidates as a condition of approval, it is too early in our drug candidates development to identify which drug candidate,
if any, would require a companion diagnostic. According to FDA guidance, if the FDA determines that a companion diagnostic device
is essential to the safe and effective use of a novel therapeutic drug or indication, the FDA generally will not approve the therapeutic
drug or new therapeutic drug indication if the companion diagnostic is not also approved or cleared for that indication. Under the Federal
Food, Drug, and Cosmetic Act, (&ldquo;FDCA&rdquo;) companion diagnostics are regulated as medical devices, and the FDA has generally
required companion diagnostics intended to select the patients who will respond to cancer treatment to obtain Premarket Approval (&ldquo;PMA&rdquo;)
for the diagnostic. The PMA process, including the gathering of clinical and pre-clinical data and the submission to and review by
the FDA, involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of
the device&rsquo;s safety and effectiveness and information about the device and its components regarding, among other things, device
design, manufacturing and labeling. A PMA is not guaranteed and may take considerable time, and the FDA may ultimately respond to a PMA
submission with a &ldquo;not approvable&rdquo; determination based on deficiencies in the application and require additional clinical
trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. As a result, if we
are required by the FDA to obtain approval of a companion diagnostic for a therapeutic drug candidate, and we do not obtain or there
are delays in obtaining FDA approval of a diagnostic device, we may not be able to commercialize the drug candidate on a timely basis
or at all and our ability to generate revenue will be materially impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
drug candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling,
advertising and promotional activities for such drug, will be subject to continual requirements of and review by the FDA and other regulatory
authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing
requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records
and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a drug
candidate is granted, the approval may be subject to limitations on the indicated uses for which the drug may be marketed or to the conditions
of approval, including the requirement to implement a REMS. New cancer drugs frequently are indicated only for patient populations that
have not responded to an existing therapy or have relapsed. If any of our drug candidates receives marketing approval, the accompanying
label may limit the approved use of our drug in this way, which could limit sales of the drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy
of the drug, including the adoption and implementation of REMS. The FDA and other agencies, including the Department of Justice (&ldquo;DOJ&rdquo;),
closely regulate and monitor the post-approval marketing and promotion of drugs to ensure they are marketed and distributed only
for the approved indications and in accordance with the provisions of the approved labeling. The FDA and DOJ impose stringent restrictions
on manufacturers&rsquo; communications regarding off-label use, and if we do not market our drugs for their approved indications, we
may be subject to enforcement action for off-label marketing. Violations of the FDCA and other statutes, including the False Claims Act,
relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations
of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. In addition, later discovery of previously
unknown adverse events or other problems with our drugs, manufacturers or manufacturing processes, or failure to comply with regulatory
requirements, may have various consequences, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on such drugs, manufacturers or manufacturing processes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    and warnings on the labeling or marketing of a drug;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on drug distribution or use;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to conduct post-marketing studies or clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters or untitled letters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of the drugs from the market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to approve pending applications or supplements to approved applications that we submit;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall
    of drugs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    restitution or disgorgement of profits or revenues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of marketing approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage
    to relationships with any potential collaborators;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    press coverage and damage to our reputation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to permit the import or export of our drugs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">drug
    seizure;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation
    involving patients using our drugs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Healthcare
Reform in the United States.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, there have been, and continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare
system that could affect the future results of pharmaceutical manufactures&rsquo; operations. In particular, there have been and continue
to be a number of initiatives at the federal and state levels that seek to reduce healthcare costs. On the federal level, the
Affordable Care Act (&ldquo;ACA&rdquo;) was enacted in March 2010, and included measures to significantly change the way healthcare
is financed by both governmental and private insurers. Among the provisions of the ACA that have been of greatest importance to
the pharmaceutical and biotechnology industry are the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned
    among these entities according to their market share in certain government healthcare programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementation
    of the federal physician payment transparency requirements, sometimes referred to as the &ldquo;Physician Payments Sunshine Act&rdquo;;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    licensure framework for follow-on biologic products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">creation
    of</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> Patient-Centered Outcomes Research Institute to oversee, identify
    priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
    of a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services to test innovative payment and service delivery
    models to lower Medicare and Medicaid spending, potentially including prescription drug spending;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the
    average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs
    at 100% of the Average Manufacturer Price;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">adoption
    of</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> methodology by which rebates owed by manufacturers under the
    Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, that are inhaled,
    infused, instilled, implanted or injected;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extension
    of manufacturers&rsquo; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed
    care organizations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
    of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals
    and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby
    potentially increasing manufacturers&rsquo; Medicaid rebate liability;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">creation
    of a</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> Medicare Part D coverage gap discount program, in which
    manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries
    during their coverage gap period, as a condition for the manufacturer&rsquo;s outpatient drugs to be covered under Medicare Part
    D; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
    of the entities eligible for discounts under the Public Health program.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">There </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">have
been legal and political challenges to certain aspects of the ACA. The Trump Administration signed executive orders and other
directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA; however, the Biden Administration
has affirmed support for the law, entered its own executive orders to enforce and strengthen it, and committed to examining and,
where appropriate, reversing contrary Trump Administration policies. Congress has considered legislation that would repeal or
repeal and replace all or part of the ACA. While Congress has not passed repeal legislation, the Tax Cuts and Jobs Act of 2017
includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain
individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the
&ldquo;individual mandate&rdquo;. Congress may consider other legislation to repeal or replace elements of the ACA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">of the volatility surrounding the implementation and enforcement
of the ACA since its passage, and at this time, the full effect that the ACA would have on a pharmaceutical manufacturer remains
unclear. This uncertainty is heightened by President Biden&rsquo;s January 28, 2021 Executive Order on Strengthening Medicaid and the
Affordable Care Act which indicates that the incoming Biden Administration may significantly modify the ACA and potentially revoke any
changes implemented by the Trump Administration. It is also possible that President Biden will further reform the ACA and other federal
programs in manner that may impact our operations. The Biden Administration has indicated that a goal of its administration is to expand
and support Medicaid and the ACA and to make high-quality healthcare accessible and affordable. The potential increase in patients covered
by government funded insurance may impact our pricing. Further, it is possible that the Biden Administration may further increase scrutiny
of drug pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Additionally,
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">in</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
<FONT STYLE="background-color: white">December </FONT>2019, a federal appeals court held <FONT STYLE="background-color: white">that
the individual mandate</FONT> portion of the ACA <FONT STYLE="background-color: white">was unconstitutional and </FONT>left open
the question <FONT STYLE="background-color: white">whether the remaining provisions of the ACA </FONT>would be valid without the
individual mandate. However, on appeal, the <FONT STYLE="background-color: white">Supreme Court </FONT>ruled in June 2021 that
the parties challenging the law lacked standing, leaving the ACA in place. <FONT STYLE="background-color: white">It is unclear how
any other potential litigation challenging the ACA and the healthcare reform measures of the Biden administration
will impact the ACA. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation
or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care
reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health
care products and services. </FONT></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Moreover,
prescription drug pricing has been a recent focus of federal policymaking. The Trump Administration issued a series of executive orders
and rules related to prescription drug pricing, including executive orders in July and September 2020 focused on reducing drug prices
and rules in November 2020 establishing a &lsquo;Most Favored Nation&rsquo; rule tying Medicare Part B drug pricing to prices in other
countries, as well as a rule effectively banning rebates from Medicare Part D. The Biden Administration,</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">
including his nominee for Secretary of DHHS, has indicated that lowering prescription drug prices is a priority for the Biden Administration
as well, but we do not yet know whether the Biden Administration will retain the measures adopted by the Trump Administration,
what other steps the Biden Administration may take, or whether such steps will be successful.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
there is uncertainty surrounding the applicability of the biosimilars provisions under the ACA. The FDA has issued several guidance documents,
but no implementing regulations, on biosimilars. A number of biosimilar applications have been approved over the past few years. The
regulations that are ultimately promulgated and their implementation are likely to have considerable impact on the way pharmaceutical
manufacturers conduct their business and may require changes to current strategies. A biosimilar is a biological product that is highly
similar to an approved drug notwithstanding minor differences in clinically inactive components, and for which there are no clinically
meaningful differences between the biological product and the approved drug in terms of the safety, purity, and potency of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
states have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and
biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access,
and marketing cost disclosure and transparency measures, and to encourage importation from other countries and bulk purchasing. Legally
mandated price controls on payment amounts by third-party payors or other restrictions could harm a pharmaceutical manufacturer&rsquo;s
business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals
are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription
drug and other healthcare programs. This could reduce ultimate demand for certain products or put pressure product pricing, which could
negatively affect a pharmaceutical manufacturer&rsquo;s business, results of operations, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, given recent federal and state government initiatives directed at lowering the total cost of healthcare, Congress and state
legislatures will likely continue to focus on healthcare reform, the cost of prescription drugs and biologics and the reform of the Medicare
and Medicaid programs. While no one cannot predict the full outcome of any such legislation, it may result in decreased reimbursement
for drugs and biologics, which may further exacerbate industry-wide pressure to reduce prescription drug prices. This could harm a pharmaceutical
manufacturer&rsquo;s ability to generate revenue. Increases in importation or re-importation of pharmaceutical products from foreign
countries into the United States could put competitive pressure on a pharmaceutical manufacturer&rsquo;s ability to profitably price
products, which, in turn, could adversely affect business, results of operations, financial condition and prospects. A pharmaceutical
manufacturer might elect not to seek approval for or market products in foreign jurisdictions in order to minimize the risk of re-importation,
which could also reduce the revenue generated from product sales. It is also possible that other legislative proposals having similar
effects will be adopted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
regulatory authorities&rsquo; assessment of the data and results required to demonstrate safety and efficacy can change over time and
can be affected by many factors, such as the emergence of new information, including on other products, changing policies and agency
funding, staffing and leadership. We cannot be sure whether future changes to the regulatory environment will be favorable or unfavorable
to our business prospects. For example, average review times at the FDA for marketing approval applications can be affected by a variety
of factors, including budget and funding levels and statutory, regulatory and policy changes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous foreign, federal, state and local environmental, health and safety laws and regulations, including those governing
laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve
the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste
products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination
or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held
liable for any resulting damages, and any liability could exceed our resources, including any available insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our leasing and operation of real property may subject us to liability pursuant to certain of these laws or regulations. Under
existing U.S. environmental laws and regulations, current or previous owners or operators of real property and entities that disposed
or arranged for the disposal of hazardous substances may be held strictly, jointly and severally liable for the cost of investigating
or remediating contamination caused by hazardous substance releases, even if they did not know of and were not responsible for the releases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could incur significant costs and liabilities which may adversely affect our financial condition and operating results for failure to
comply with such laws and regulations, including, among other things, civil or criminal fines and penalties, property damage and personal
injury claims, costs associated with upgrades to our facilities or changes to our operating procedures, or injunctions limiting or altering
our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&rsquo; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal
of biological, hazardous or radioactive materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.
These current or future laws and regulations, which are becoming increasingly more stringent, may impair our research, development or
production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we do not obtain patent term extension for any drug candidates we may develop, our business may be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, depending upon the timing, duration, and specifics of any FDA marketing approval of a drug candidate, the patent term
of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration
as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration
Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent.
The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent term extension cannot
extend the remaining term of a patent beyond a total of 14 years from the date of drug approval, and only one patent applicable to an
approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing
it may be extended. Similar provisions are available in Europe and other non-United States jurisdictions to extend the term of a patent
that covers an approved drug. While, in the future, if and when our drug candidates receive FDA approval, we expect to apply for patent
term extensions on patents covering those drug candidates, there is no guarantee that the applicable authorities will agree with our
assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted an
extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to
apply within applicable deadlines, failing to apply prior to expiration of the relevant patents, or otherwise failing to satisfy applicable
requirements. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors
may obtain approval of competing drugs following the expiration of our patent rights, and our business, financial condition, results
of operations, and prospects could be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability
to protect our drugs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining
and enforcing patents in the pharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming
and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase
the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Recent
patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act)
signed into law in September 2011, could increase those uncertainties and costs. The Leahy-Smith Act includes a number of significant
changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide
more efficient and cost-effective avenues for competitors to challenge the validity of patents. For example, the Leahy-Smith Act allows
third-party submission of prior art to the United States Patent and Trademark Office (&ldquo;USPTO&rdquo;) during patent prosecution
and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review,
inter parties review, and derivation proceedings. In addition, the Leahy-Smith Act has transformed the U.S. patent system from a &ldquo;first-to-invent&rdquo;
system to a &ldquo;first-to-file&rdquo; system in which, assuming that other requirements for patentability are met, the first inventor
to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent
the claimed invention. The first-to-file provisions, however, only became effective on March 16, 2013. Accordingly, it is not yet clear
what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation
could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the
prosecution of our or our collaboration partners&rsquo; patent applications and the enforcement or defense of our or our collaboration
partners&rsquo; issued patents, all of which could harm our business, results of operations, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly
uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened
the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and
enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws
and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and
our ability to protect, defend and enforce our patent rights in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
or our future licensors may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which
could be expensive, time-consuming and unsuccessful.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
and other third parties may infringe, misappropriate or otherwise violate our or our future licensors&rsquo; issued patents or other
intellectual property. As a result, we or our licensors may need to file infringement, misappropriation or other intellectual property
related claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke such parties
to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property. In addition,
in a patent infringement proceeding, such parties could counterclaim that the patents we or our licensors have asserted are invalid or
unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace.
Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty,
obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution
of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute
such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include
re-examination, post-grant review, inter parties review, interference proceedings, derivation proceedings, and equivalent proceedings
in foreign jurisdictions (e.g., opposition proceedings).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
adverse result in any such proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted
narrowly, and could put any of our owned or in-licensed patent applications at risk of not yielding an issued patent. A court may also
refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned or in-licensed patents
do not cover such technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual property
litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this
type of litigation. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products
and have a material adverse impact on our business, financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third
parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property
rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our drug
candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property
and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical
and biotechnology industries. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual
property rights with respect to our technology and drug candidates, including interference proceedings, post grant review, inter parties
review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European
Patent Office.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability
of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive
and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting
these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as our drug candidates
near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement
claims against us based on existing patents or patents that may be granted in the future, regardless of merit. We may not be aware of
all such intellectual property rights potentially relating to our technology and drug candidates and their uses. Thus, we do not know
with certainty that our technology and drug candidates, or our development and commercialization thereof, do not and will not infringe,
misappropriate or otherwise violate any third party&rsquo;s intellectual property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we believe that third party intellectual property claims are without merit, there is no assurance that a court would find in our favor
on questions of misappropriation, infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold these
third-party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize any
technology or drug candidate covered by the asserted third-party patents. In order to successfully challenge the validity of any such
U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present
clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction
would invalidate the claims of any such U.S. patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to infringe, misappropriate or otherwise violate a third party&rsquo;s intellectual property rights, we could be required
to obtain a license from such third party to continue developing, manufacturing and marketing our technology and drug candidates. However,
we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license,
it could be non-exclusive; thereby giving our competitors and other third parties access to the same technologies licensed to us and
could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing,
manufacturing and commercializing the infringing technology or drug. In addition, we could be found liable for significant monetary damages,
including treble damages and attorneys&rsquo; fees, if we are found to have willfully infringed a patent or other intellectual property
right and could be forced to indemnify our collaborators or others. A finding of infringement could prevent us from commercializing our
drug candidates or force us to cease some of our business operations, which could materially harm our business. In addition, we may be
forced to redesign our drug candidates, seek new regulatory approvals and indemnify third parties pursuant to contractual agreements.
Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse
effect on our business, financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intellectual
property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract
our personnel from their normal responsibilities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant
expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public
announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors
perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or
proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future
sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings
adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because
of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual
property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings
could compromise our ability to compete in the marketplace.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with our obligations in our future intellectual property licenses and funding arrangements with third parties, we could
lose rights that are important to our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may be party to license and funding agreements that impose diligence, development and commercialization timelines, milestone payment,
royalty, insurance and other obligations on us. If we fail to comply with such obligations, our counterparties may have the right to
terminate our agreements or require us to grant them certain rights. Such an occurrence could materially adversely affect the value of
any drug candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights
under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose
our rights under these agreements, including our rights to important intellectual property or technology, which would have a material
adverse effect on our business, financial condition, results of operations, and prospects.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
these and other license agreements may not provide exclusive rights to use the licensed intellectual property and technology in all relevant
fields of use and in all territories in which we may wish to develop or commercialize our technology and drugs in the future. As a result,
we may not be able to prevent competitors from developing and commercializing competitive products and technology in fields of use and
territories not included in such agreements. In addition, we may not have the right to control the preparation, filing, prosecution,
maintenance, enforcement, and defense of patents and patent applications covering the technology that we may license from third parties.
Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, and defended
in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce, and defend such
patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right
to develop and commercialize any of our drugs that are the subject of such licensed rights could be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to obtain additional licenses from others to advance our research or allow commercialization of our drug candidates. It is possible
that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all, or such licenses may be non-exclusive.
The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies
may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These
established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development
and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license
rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make
an appropriate return on our investment or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights
we have, we may be required to expend significant time and resources to redesign our technology, drug candidates, or the methods for
manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis.
If we are unable to do so, we may be unable to develop or commercialize the affected technology and drug candidates, which could harm
our business, financial condition, results of operations, and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disputes
may arise regarding intellectual property subject to a licensing agreement, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of rights granted under the license agreement and other interpretation related issues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing
    agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sublicensing of patent and other rights under our collaborative development relationships;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    diligence obligations under the license agreement and what activities satisfy those diligence obligations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors
    and us and our partners; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    priority of invention of patented technology.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any agreements under which we license intellectual property or technology from third parties may be complex, and certain provisions
in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may
arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what
we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect
on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we
have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be
unable to successfully develop and commercialize the affected technology and drug candidates, which could have a material adverse effect
on our business, financial conditions, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
future licensors may rely on third-party consultants or collaborators or on funds from third parties such that our licensors are not
the sole and exclusive owners of the patents and patent applications we in-licensed. If other third parties have ownership rights to
our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products
and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations,
and prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
spite of our best efforts, our future licensors might conclude that we have materially breached our license agreements and might therefore
terminate our license agreements, thereby removing our ability to develop and commercialize drug candidates and technology covered by
such agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity,
competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to ours. This could
have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to protect our intellectual property and proprietary rights throughout the world.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting, and defending patents on drug candidates in all countries throughout the world would be prohibitively expensive, and the
laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be
able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing
products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to
territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products
may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them
from competing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets,
and other intellectual property protection, particularly those relating to pharmaceutical products, which could make it difficult for
us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary
rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or
interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against
us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.
Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition,
many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent
owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to
grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and
our business, financial condition, results of operations, and prospects may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Managing Our Business and Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may encounter difficulties in managing our growth, which could adversely affect our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 17, 2021, we had 1 full-time employee and 1 part-time employee. As our clinical development and commercialization
plans and strategies develop, and as we transition into operating as a public company, we will need to expand our managerial, clinical,
regulatory, sales, marketing, financial, development, manufacturing and legal capabilities or contract with third parties to provide
these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic
collaborators, suppliers and other third parties. Our future growth would impose significant added responsibilities on members of management,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    recruiting, integrating, maintaining and motivating additional employees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    our development and commercialization efforts effectively, including the clinical and FDA review process for our product candidates,
    while complying with our contractual obligations to contractors and other third parties; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">improving
    our operational, financial and management controls, reporting systems and procedures.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively
manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities
in order to devote a substantial amount of time to managing these growth activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors
and consultants to provide certain services, including contract manufacturers and companies focused on research and development and discovery
activities. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available
to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage
our outsourced activities or if the quality, accuracy or quantity of the services provided is compromised for any reason, our clinical
trials may be extended, delayed or terminated, and we may not be able to obtain, or may be substantially delayed in obtaining, regulatory
approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing
consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors,
we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly,
may not achieve our research, development and commercialization goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may acquire additional technology and complementary businesses in the future. Acquisitions involve many risks, any of which could materially
harm our business, including the diversion of management&rsquo;s attention from core business concerns, failure to effectively exploit
acquired technologies, failure to successfully integrate the acquired business or realize expected synergies or the loss of key employees
from either our business or the acquired businesses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which
could result in a material disruption of our product development programs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to
damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While
we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause
interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due
to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial
data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover
or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications,
or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed
and the further development and commercialization of our product candidates could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of
information maintained in the information systems and networks of our company and our vendors, including personal information of our
employees and study subjects, and company and vendor confidential data. In addition, outside parties may attempt to penetrate our systems
or those of our vendors or fraudulently induce our personnel or the personnel of our vendors to disclose sensitive information in order
to gain access to our data and/or systems. We may experience threats to our data and systems, including malicious codes and viruses,
phishing and other cyberattack. The number and complexity of these threats continue to increase over time. If a material breach of, or
accidental or intentional loss of data from, our information technology systems or those of our vendors occurs, the market perception
of the effectiveness of our security measures could be harmed and our reputation and credibility could be damaged. We could be required
to expend significant amounts of money and other resources to repair or replace information systems or networks. In addition, we could
be subject to regulatory actions and/or claims made by individuals and groups in private litigation involving privacy issues related
to data collection and use practices and other data privacy laws and regulations, including claims for misuse or inappropriate disclosure
of data, as well as unfair or deceptive practices. Although we develop and maintain systems and controls designed to prevent these events
from occurring, and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and
processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become
increasingly sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely. As
we outsource more of our information systems to vendors, engage in more electronic transactions with payors and patients, and rely more
on cloud-based information systems, the related security risks will increase and we will need to expend additional resources to protect
our technology and information systems. In addition, there can be no assurance that our internal information technology systems or those
of our third-party contractors, or our consultants&rsquo; efforts to implement adequate security and control measures, will be sufficient
to protect us against breakdowns, service disruption, data deterioration or loss in the event of a system malfunction, or prevent data
from being stolen or corrupted in the event of a cyberattack, security breach, industrial espionage attacks or insider threat attacks
which could result in financial, legal, business or reputational harm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by earthquakes
or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster,
including earthquakes, outbreak of disease or other natural disasters.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication
failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing
facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business,
particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to
these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations.
Earthquakes or other natural disasters could further disrupt our operations, and have a material and adverse effect on our business,
financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented
us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities
or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult
or, in certain cases, impossible, for us to continue our business for a substantial period of time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event.
We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, could
have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that
we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you
that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities
of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for
a short period of time, any or all of our research and development programs may be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Unfavorable
global economic conditions could adversely affect our business, financial condition or results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Portions
of our future clinical trials may be conducted outside of the United States and unfavorable economic conditions resulting in the weakening
of the U.S. dollar would make those clinical trials more costly to operate. Furthermore, the most recent global financial crisis caused
extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, including due to the impact
of the COVID-19 pandemic, could result in a variety of risks to our business, including a reduced ability to raise additional capital
when needed on acceptable terms, if at all. A weak or declining economy or international trade disputes could also strain our suppliers,
some of which are located outside of the United States, possibly resulting in supply disruption. Any of the foregoing could harm our
business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely
impact our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
increasing use of social media platforms presents new risks and challenges.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social
media is increasingly being used to communicate about our clinical development programs and the diseases our therapeutics are being developed
to treat, and we intend to utilize appropriate social media in connection with our commercialization efforts following approval of our
product candidates, if any. Social media practices in the biopharmaceutical industry continue to evolve and regulations and regulatory
guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations
applicable to our business, resulting in potential regulatory actions against us, along with the potential for litigation related to
off-label marketing or other prohibited activities. For example, patients may use social media channels to comment on their experience
in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that trial enrollment
may be adversely impacted, we fail to monitor and comply with applicable adverse event reporting obligations or that we may not be able
to defend our business or the public&rsquo;s legitimate interests in the face of the political and market pressures generated by social
media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive
information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur
or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to
our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
estimates of market opportunity and forecasts of market growth included in this prospectus may prove to be inaccurate, and even if the
markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
opportunity estimates and growth forecasts included in this prospectus are subject to significant uncertainty and are based on assumptions
and estimates which may not prove to be accurate. The estimates and forecasts included in this prospectus relating to size and expected
growth of our target market may prove to be inaccurate. Even if the markets in which we compete meet the size estimates and growth forecasts
included in this prospectus, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including
our success in implementing our business strategy, which is subject to many risks and uncertainties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
employees, independent contractors, consultants, commercial partners, collaborators and vendors may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial
partners, collaborators and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails
to comply with the laws of the FDA and other similar foreign regulatory bodies, provide true, complete and accurate information to the
FDA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud
and abuse laws in the United States and similar foreign fraudulent misconduct laws, or report financial information or data accurately
or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those
products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance
with such laws will also increase. These laws may impact, among other things, our current activities with principal investigators and
research patients, as well as proposed and future sales, marketing and education programs. In connection with this offering, we will
adopt a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by our employees, independent
contractors, consultants, commercial partners and vendors, and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or
lawsuits stemming from a failure to comply with these laws or regulations. If any actions are instituted against us and we are not successful
in defending ourselves or asserting our rights, those actions could result in the imposition of civil, criminal and administrative penalties,
damages, monetary fines, imprisonment, disgorgement, possible exclusion from participation in government healthcare programs, additional
reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations
of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and the curtailment
of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil
or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and any potential collaborators may be subject to federal, state and foreign data protection laws and regulations (i.e., laws and regulations
that address privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health
information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection
laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related
and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health
information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy
and security requirements under  HIPAA, as amended by HITECH. Depending on the facts and circumstances, we could be subject to criminal
penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity
in a manner that is not authorized or permitted by HIPAA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
data protection laws, including Regulation 2016/679, known as the General Data Protection Regulation (&ldquo;GDPR&rdquo;) may also apply
to health-related and other personal information obtained outside of the United States. The GDPR went into effect on May 25, 2018. The
GDPR introduced new data protection requirements in the European Union, as well as potential fines for noncompliant companies of up to
the greater of &euro;20 million or 4% of annual global revenue. The regulation imposes numerous new requirements for the collection,
use and disclosure of personal information, including more stringent requirements relating to consent and the information that must be
shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals
of personal data breaches, extensive new internal privacy governance obligations and obligations to honor expanded rights of individuals
in relation to their personal information (e.g., the right to access, correct and delete their data). In addition, the GDPR includes
restrictions on cross-border data transfer. The GDPR will increase our responsibility and liability in relation to personal data that
we process, and we may be required to put in place additional mechanisms to ensure compliance with the new EU data protection rules.
Further, the United Kingdom&rsquo;s vote in favor of exiting the EU, often referred to as Brexit, has created uncertainty with regard
to data protection regulation in the United Kingdom. In particular, it is unclear whether the United Kingdom will enact data protection
legislation equivalent to the GDPR and how data transfers to and from the United Kingdom will be regulated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts,
restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure
to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could
include civil, criminal, and administrative penalties), private litigation and/or adverse publicity and could negatively affect our operating
results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the
providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we
have violated individuals&rsquo; privacy rights, failed to comply with data protection laws, or breached our contractual obligations,
even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm
our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in U.S. tax law could adversely affect our financial condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative
process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive
application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes
are likely to continue to occur in the future. Future changes in U.S. tax laws could have a material adverse effect on our business,
cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisors regarding the
implications of potential changes in U.S. tax laws on an investment in our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Common Stock and this Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
has been no prior public market for our common stock, the stock price of our common stock may be volatile or may decline regardless of
our operating performance and you may not be able to resell your shares at or above the initial public offering price.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering there has been no public market for shares of our common stock. You may not be able to sell your shares quickly or at
the market price if trading in shares of our common stock is not active. The initial public offering price for our common stock will
be determined through negotiations with the underwriters, and the negotiated price may not be indicative of the market price of the common
stock after the offering. An active or liquid market in our common stock may not develop upon the completion of this offering or, if
it does develop, it may not be sustainable. As a result of these and other factors, you may be unable to resell your shares of our common
stock at or above the initial public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter
into strategic collaborations or acquire companies or products by using our shares of common stock as consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
price of our stock may be volatile, and you could lose all or part of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading price of our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in
response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed
in this &ldquo;Risk Factors&rdquo; section and elsewhere in this prospectus, these factors include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commencement, enrollment or results of clinical trials and pre-clinical studies of our drug candidates or those of our competitors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delay in identifying and advancing a clinical candidate for our other development programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delay in our regulatory filings for our drug candidates and any adverse development or perceived adverse development with respect
    to the applicable regulatory authority&rsquo;s review of such filings, including without limitation the FDA&rsquo;s issuance of a
    &ldquo;refusal to file&rdquo; letter or a request for additional information;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    results or delays in future clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    regulatory decisions, including failure to receive regulatory approval of for our drug candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in laws or regulations applicable to our drug candidates, including but not limited to clinical trial requirements for approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    developments concerning our manufacturers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            inability to establish collaborations, if needed;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            failure to commercialize our product candidates, if approved;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
                                            or departures of key scientific or management personnel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
                                            serious safety concerns related to the use of our drug candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction
                                            of new products offered by us or our competitors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                            of significant acquisitions, strategic partnerships, joint ventures or capital commitments
                                            by us or our competitors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to effectively manage our growth;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
                                            or anticipated variations in quarterly operating results;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            cash position;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            failure to meet the estimates and projections of the investment community or that we may
                                            otherwise provide to the public;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication
                                            of research reports about us or our industry, or product candidates in particular, or positive
                                            or negative recommendations or withdrawal of research coverage by securities analysts;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the market valuations of similar companies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the structure of the healthcare payment systems;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overall
                                            performance of the equity markets;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
                                            of our common stock by us or our stockholders in the future;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
                                            volume of our common stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in accounting practices;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ineffectiveness
                                            of our internal controls;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
                                            or other developments relating to proprietary rights, including patents, litigation matters
                                            and our ability to obtain patent protection for our technologies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            lawsuits, including patent or stockholder litigation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                            political and economic conditions; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                            events or factors, many of which are beyond our control.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and
volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, including as
a result of the COVID-19 pandemic. Broad market and industry factors may negatively affect the market price of our common stock, regardless
of our actual operating performance. If the market price of our common stock after this offering does not exceed the initial public offering
price, you may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class
action litigation has often been instituted against companies following periods of volatility in the market price of a company&rsquo;s
securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&rsquo;s attention
and resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have broad discretion in the use of the net proceeds from this offering and may not use them effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion in the application of the net proceeds to us from this offering and could spend the proceeds in
ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these
funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our
common stock to decline and delay the development of our drug candidates. Pending their use, we may invest the net proceeds from this
offering in a manner that does not produce income or that loses value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate
declaring or paying any cash dividends for the foreseeable future. Furthermore, future debt or other financing arrangements may contain
terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will
therefore be limited to the appreciation of their stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters
subject to stockholder approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
following the completion of this offering, our executive officers, directors and their affiliates will beneficially hold, in the aggregate,
approximately 41.48% of our outstanding voting stock. These stockholders, acting together, would be able to significantly influence
all matters requiring stockholder approval. For example, these stockholders would be able to significantly influence elections of directors,
amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may
prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as
one of our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial public offering price will be substantially higher than the as adjusted net tangible book value per share of our common stock
after this offering. Investors purchasing common stock in this offering will pay a price per share that substantially exceeds the as
adjusted net tangible book value per share after this offering. As a result, investors purchasing common stock in this offering will
incur immediate dilution of $4.19 per share, based on an assumed initial public offering price of $5.50 per share, the
midpoint of the price range set forth on the cover page of this prospectus and the sale of shares of common stock in the Company, representing
the difference between our as adjusted net tangible book value per share after giving effect to this offering and the assumed initial
public offering price. Further, investors purchasing common stock in this offering will contribute approximately 83.6% of the total
amount invested by stockholders since our inception, but will own only approximately 29.2% of the shares of common stock outstanding
after this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
dilution is due to our investors who purchased shares prior to this offering having paid substantially less when they purchased their
shares than the price offered to the public in this offering. To the extent outstanding options are exercised, there will be further
dilution to new investors. As a result of the dilution to investors purchasing shares in this offering, investors may receive significantly
less than the purchase price paid in this offering, if anything, in the event of our liquidation. For a further description of the dilution
that you will experience immediately after this offering, see the section entitled &ldquo;Dilution&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies
will make our common stock less attractive to investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take
advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth
companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act,
reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements and
exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden
parachute payments not previously approved. We could be an emerging growth company for up to five years following the year in which we
complete this offering, although circumstances could cause us to lose that status earlier. We will remain an emerging growth company
until the earlier of (i) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b)
in which we have total annual gross revenue of at least $1.07 billion or (c) in which we are deemed to be a large accelerated filer,
which requires the market value of our common stock that is held by non-affiliates to exceed $700.0 million as of the prior June 30th
and (ii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may choose to take advantage of some, but not all, of the available exemptions. We cannot predict whether investors will find our common
stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a
result, there may be a less active trading market for our common stock and our stock price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards
apply to private companies, which may make our financial statements less comparable to companies that comply with new or revised accounting
pronouncements as of public company effective dates. We have chosen to take advantage of the extended transition periods available to
emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise
apply to private companies provided under the JOBS Act. As a result, our financial statements may not be comparable to those of companies
that comply with public company effective dates for complying with new or revised accounting standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financial
reporting obligations of being a public company in the U.S. are expensive and time-consuming, and our management will be required to
devote substantial time to compliance matters.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a publicly traded company we will incur significant additional legal, accounting and other expenses that we did not incur as a privately
company. The obligations of being a public company in the U.S. require significant expenditures and will place significant demands on
our management and other personnel, including costs resulting from public company reporting obligations under the Exchange Act and the
rules and regulations regarding corporate governance practices, including those under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street
Reform and Consumer Protection Act, and the listing requirements of the stock exchange on which our securities are listed. These rules
require the establishment and maintenance of effective disclosure and financial controls and procedures, internal control over financial
reporting and changes in corporate governance practices, among many other complex rules that are often difficult to implement, monitor
and maintain compliance with. Moreover, despite recent reforms made possible by the JOBS Act, the reporting requirements, rules, and
regulations will make some activities more time-consuming and costly, particularly after we are no longer an &ldquo;emerging growth company.&rdquo;
In addition, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer
liability insurance. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with
all of these requirements and to keep pace with new regulations, otherwise we may fall out of compliance and risk becoming subject to
litigation or being delisted, among other potential problems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Failure
</I></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>to maintain effective internal controls could cause
our investors to lose confidence in us and adversely affect the market price of our common stock. If our internal controls are not effective,
we may not be able to accurately report our financial results or prevent fraud.</I></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Effective
internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner. In connection
with the preparation of our financial statements for the years ended December 31, 2020 and 2019, our independent registered public accounting
firm identified a material weakness. A material weakness is a significant deficiency, or a combination of significant deficiencies, in
internal control over financial reporting such that it is reasonably possible that a material misstatement of the annual or interim financial
statements will not be prevented or detected on a timely basis. The material weakness that has been identified by our independent registered
public accounting firm relates to the design and implementation of a control to review the completeness and accuracy of contracts with
financial reporting implications. In addition, the terms and conditions related to these contracts were not communicated to the financial
reporting function for analysis and reporting implications in a timely manner. &nbsp;While we intend to take steps to remediate the material
weakness in our internal control over financial reporting by formalizing certain accounting policies and internal control documentation
and adding staff members with requisite experience to oversee the review of contracts, we may not be successful in remediating such weaknesses
in a timely manner, if at all, which may undermine our ability to provide accurate, timely and reliable reports on our financial and
operating results. Furthermore, if we remediate our current material weakness but identify new material weaknesses in our internal control
over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and the
market price of our common stock may be negatively affected. As a result of such failures, we could also become subject to investigations
by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities, and become subject to litigation
from investors and stockholders, which could harm our reputation, financial condition or divert financial and management resources from
our core business.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Substantial
amounts of our outstanding shares may be sold into the market when lock-up or market standoff periods end. If there are substantial sales
of shares of our common stock, the price of our common stock could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our outstanding shares of common stock held by our directors, executive officers and our stockholders are subject to contractual lock-up
restrictions on resale as more fully described in the section titled &ldquo;Underwriting&rdquo; in this prospectus. If these stockholders
sell, or indicate an intent to sell, substantial amounts of our common stock in the public market after the expiration of the applicable
lock-up period, the trading price of our common stock could decline significantly and could decline below the public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price
and trading volume could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about
us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities
or industry analysts commence coverage of our company, the trading price for our stock would likely be negatively impacted. In the event
securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades our stock or publishes inaccurate
or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company
or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume
to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Certificate of Incorporation, as amended (&ldquo;Certificate of Incorporation&rdquo;) provides that the Court of Chancery of the State
of Delaware will be the sole and exclusive forum for substantially all disputes between the Company and its stockholders, which could
limit stockholders&rsquo; ability to obtain a favorable judicial forum for disputes with the Company or its directors, officers or employees.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation provides that unless we consent in writing to the selection of an alternative forum, the State of Delaware
is the sole and exclusive forum for: (i) any derivative action or proceeding brought on behalf of us, (ii) any action asserting a claim
of breach of a fiduciary duty owed by any director, officer or other employee of our Company to us or our stockholders, (iii) any action
asserting a claim arising pursuant to any provision of the Delaware General Corporation
Law (the &ldquo;DGCL&rdquo;) or our Certificate of Incorporation or Bylaws, or (iv) any action governed by the internal affairs doctrine.
This exclusive forum provision would not apply to suits brought to enforce any liability or duty created by the Securities Act or the
Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based
upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any
duty or liability created by the Exchange Act or the rules and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability
created by the Securities Act or the rules and regulations thereunder. However, our Certificate of Incorporation contains a federal forum
provision which provides that unless we consent in writing to the selection of an alternative forum, the federal district courts of the
United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the
Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
choice of forum provisions may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for disputes
with us or our directors, officers or other employees and may result in increased costs to our stockholders, which may discourage
such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find our choice of forum
provisions contained in our Certificate of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs
associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
could be subject to securities class action litigation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, securities class action litigation has often been brought against a company following a decline in the market price of its
securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility
in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&rsquo;s attention and
resources, which could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
is no guarantee that our common stock will be listed on Nasdaq.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have applied to have our shares of common stock listed on The Nasdaq Capital Market. Upon completion of this offering, we believe
that we will satisfy the listing requirements and expect that our common stock will be listed on The Nasdaq Capital Market. Such
listing, however, is not guaranteed. If the application is not approved for listing on The Nasdaq Capital Market, we will not
proceed with this offering. Even if such listing is approved, there can be no assurance any broker will be interested in trading our
common stock. Therefore, it may be difficult to sell any shares you purchase in this offering if you desire or need to sell them.
Our lead underwriter, ThinkEquity, is not obligated to make a market in our common stock, and even after making a market, can
discontinue market making at any time without notice. Neither we nor the underwriters can provide any assurance that an active and
liquid trading market in our common stock will develop or, if developed, that the market will continue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_001"></A>INFORMATION
REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these forward-looking
statements. All statements other than statements of historical facts contained in this prospectus are forward-looking statements. The
forward-looking statements in this prospectus are only predictions. We have based these forward-looking statements largely on our current
expectations and projections about future events and financial trends that we believe may affect our business, financial condition and
results of operations. In some cases, you can identify these forward-looking statements by terms such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;depends,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expects,&rdquo; &ldquo;intend,&rdquo;
&ldquo;may,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo;
&ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; or the negative of those terms or other similar expressions, although not
all forward-looking statements contain those words. We have based these forward-looking statements on our current expectations and projections
about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term
business operations and objectives, and financial needs. These forward-looking statements include, but are not limited to, statements
concerning the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    projected financial position and estimated cash burn rate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates regarding expenses, future revenues and capital requirements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to continue as a going concern;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    need to raise substantial additional capital to fund our operation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success, cost and timing of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    dependence on third parties in the conduct of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain the necessary regulatory approvals to market and commercialize our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ultimate impact of the current COVID-19 pandemic, or any other health epidemic, on our business, our clinical trials, our research
    programs, healthcare systems or the global economy as a whole;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential that results of pre-clinical and clinical trials indicate our current product candidates or any future product candidates
    we may seek to develop are unsafe or ineffective;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of market research conducted by us or others;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain intellectual property protection for our current and future product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce
    or protect our intellectual property rights;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility that a third party may claim we or our third-party licensors have infringed, misappropriated or otherwise violated their
    intellectual property rights and that we may incur substantial costs and be required to devote substantial time defending against
    claims against us;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third-party suppliers and manufacturers;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competing therapies and products that are or become available;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to expand our organization to accommodate potential growth and our ability to retain and attract key personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential for us to incur substantial costs resulting from product liability lawsuits against us and the potential for these product
    liability lawsuits to cause us to limit our commercialization of our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    acceptance of our product candidates, the size and growth of the potential markets for our current product candidates and any future
    product candidates we may seek to develop, and our ability to serve those markets; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    successful development of our commercialization capabilities, including sales and marketing capabilities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &ldquo;Risk
Factors.&rdquo; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is
not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which
any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements
we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus
may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected
in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events
and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither
we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation
to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual
results or to changes in our expectations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration
statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and
events and circumstances may be materially different from what we expect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_002"></A>INDUSTRY
AND MARKET DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain
of the market data and other statistical information contained in this prospectus, such as the size, growth and share of the industries
and the market segments we operate in, are based on information from independent industry organizations and other third-party sources,
industry publications, surveys and forecasts. Some market data and statistical information contained in this prospectus are also based
on management&rsquo;s estimates and calculations, which are derived from our review and interpretation of the independent sources, our
internal market and brand research and our knowledge of the industries we operate in. While we believe such information is reliable,
we have not independently verified any third-party information, and our internal data has not been verified by any independent source.
Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties, and actual
events or circumstances may differ materially from events and circumstances that are assumed in this information. Notwithstanding the
foregoing, we are liable for the disclosure set forth in this prospectus. </FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_003"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the net proceeds from our issuance and sale of 3,000,000 shares of our common stock in this offering will be approximately
$14.4 million, or approximately $16.9 million if the underwriters exercise their over-allotment option in full, based on
an assumed initial public offering price of $5.50 per share, the midpoint of the price range listed on the cover page of this
prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds from this offering as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
                                            $1.5 million for pre-clinical activities and manufacturing related to our product
                                            candidate, HSB-1216;</FONT></TD></TR></TABLE>

<P STYLE="margin: 0 0 0 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
                                            $10.0 million for clinical trials related to or our product candidate, HSB-1216
                                            through Phase 1 studies; and</FONT></TD></TR></TABLE>

<P STYLE="margin: 0 0 0 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
                                            $1.4 million for pre-clinical activities related to our product candidate,
                                            HSB-888 which will take us through our IND submission.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
additional capital that we raise pursuant to this offering will be used for general corporate and working capital purposes. We may also
use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products, however, we have no current
commitments or obligations to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
$1.00 increase or decrease in the assumed initial public offering price of $5.50 per share, the midpoint of the price range listed
on the cover page of this prospectus, would increase or decrease the net proceeds from this offering by approximately $2.8 million,
assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 100,000 shares in the
number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the net proceeds from this
offering by $0.5 million, assuming no change in the assumed initial public offering price per share and after deducting underwriting
discounts and commissions and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
expected use of the net proceeds from this offering and our existing cash represents our intentions based upon our current plans, financial
condition and business conditions. Predicting the cost necessary to develop product candidates can be difficult and the amounts and timing
of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development and commercialization
efforts, the status of and results from clinical trials, any collaborations that we may enter into with third parties for our product
candidates and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds
from this offering and our existing cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we expect to from time to time evaluate the acquisition of, investment in or in-license of complementary
products, technologies or businesses, and we could use a portion of the net proceeds from this offering for such activities. We currently
do not have any agreements, arrangements or commitments with respect to any potential acquisition, investment or license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments,
including short-term, investment-grade, interest-bearing instruments and government securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_004"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common
stock in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion
of our business. Any future determination to pay dividends will be at the discretion of our board of directors and will depend upon a
number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions
imposed by applicable law and other factors our board of directors deems relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="g_005"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our cash and capitalization as of June 30, 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 24px; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an actual basis;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&#9679;</TD>
    <TD STYLE="text-align: justify">on a pro forma basis to reflect (i) the conversion of $3,447,484 of principal amount and accrued interest
of outstanding convertible notes into an aggregate of 836,742 shares of common stock upon the closing of this offering based upon an assumed
initial public offering price of $5.50 per share, which is the midpoint of the price range listed on the cover page of this prospectus
and (ii) the conversion of convertible notes in the aggregate principal amount
of $335,000&nbsp;issued in July, August and September 2021 into an aggregate of 63,516 shares of common stock upon the closing of this
offering based upon an assumed initial public offering price of $5.50 per share, which is the midpoint of the price range listed on the
cover page of this prospectus and (iii) the conversion of rolled over convertible notes which expired in August 2021 into a new note in
the aggregate principal amount of $82,500&nbsp;into an aggregate of 18,839 shares of common stock upon the closing of this offering based
upon an assumed initial public offering price of $5.50 per share, which is the midpoint of the price range listed on the cover page of
this prospectus; and</TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on a pro forma as
adjusted basis to give further effect to our issuance and sale of 3,000,000 shares of our common stock in this offering at an
assumed initial public offering price of $5.50 per share, which is the midpoint of the price range listed on the cover page of
this prospectus, after deducting underwriting discounts and commissions and our estimated offering expenses.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this table is unaudited and is illustrative only and our capitalization following the completion of this offering will
be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read
this table in conjunction with the information contained in &ldquo;Use of Proceeds,&rdquo; &ldquo;Summary Financial Data&rdquo; and &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operation,&rdquo; as well as the financial statements and the notes included
elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30, 2021</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Actual</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Pro Forma (Unaudited)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pro Forma As</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Adjusted<SUP>(1)</SUP></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 14%; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">29,271</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 14%; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">364,271</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 14%; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">14,811,771</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Related party convertible notes, net, less short term portion</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,360,024</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Short-term portion of related party convertible notes, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">646,477</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Stockholders&rsquo; deficit:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and
    outstanding, actual; 10,000,000 shares authorized, no shares issued and outstanding, pro forma; 10,000,000 shares
    authorized, no shares issued and outstanding, pro forma as adjusted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Common stock, par value $0.0001 per share; 250,000,000 shares authorized, 6,357,314 shares
    issued and outstanding, actual; 250,000,000 shares authorized, 7,277,221 shares issued and outstanding, pro forma; 250,000,000
    shares authorized, 10,277,221 shares issued and outstanding, pro forma as adjusted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">636</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">728</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,028</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Additional paid-in capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,214,535</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7,741,313</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">21,940,347</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Accumulated deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(8,510,752</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(8,510,752</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(8,510,752</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Total stockholders&rsquo; deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(6,295,581</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(768,711</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">13,430,623</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total capitalization</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(4,289,080</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(768,711</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">13,430,623</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 97%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    $1.00 increase (decrease) in the assumed initial public offering price of $5.50 per share, which is the midpoint of the price
    range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of
    cash, total stockholders&rsquo; equity and total capitalization by $2.8 million, assuming that the number of shares offered
    by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions
    and estimated offering expenses payable by us. An increase (decrease) of 100,000 shares in the number of shares offered by us, as
    set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash,
    total stockholders&rsquo; equity and total capitalization by $0.5 million, assuming no change in the assumed initial public
    offering price per share and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock to be outstanding after this offering is based on 6,357,314 shares of our common stock outstanding
as of June 30, 2021, assumes no exercise by the underwriters of their over-allotment option and excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,480,998
    shares of common stock reserved for future issuance under our 2019 Stock Incentive plan;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">903,468
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issuable upon exercise
    of outstanding options with a weighted average exercise price of $4.269; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">150,000
    shares of common stock issuable upon exercise of warrants to be issued to the representative of the underwriters as part of this
    offering at an exercise price of $6.875 (assuming an initial public offering price of $5.50 per share (the midpoint of the price
    range set forth on the cover page of this prospectus)).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="o_003"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
you invest in our common stock, your ownership interest will be diluted to the extent of the difference between the initial public offering
price per share of our common stock and the as adjusted net tangible book value per share of our common stock immediately after this
offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2021, we had a historical net
tangible book (deficit) of $(6,544,383), or $(1.03) per share of common stock, based on 6,357,314 shares of common
stock outstanding at June 30, 2021. Our historical net tangible book value per share is the amount of our total tangible assets
less our total liabilities at June 30, 2021, divided by the number of shares of common stock outstanding at June 30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After giving effect to (i) the conversion of $3,447,484 of principal amount and accrued interest of outstanding notes into an aggregate
of 836,742 shares of common stock and (ii) the conversion of convertible notes in the aggregate principal amount of $335,000 issued in
July, August and September 2021, and the rolled over notes issued in August 2021, into an aggregate of 82,355 shares of common stock upon
the closing of this offering based upon an assumed initial public offering price of $5.50 per share which is the midpoint of the price
range listed on the cover page of this prospectus, our pro forma net tangible book value as of June 30, 2021 was $(1,016,877), or
$(0.14) per share of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After giving further effect to the sale of
3,000,000 shares of common stock in this offering at an assumed initial public offering price of $5.50 per share, the midpoint
of the offering price range set forth on the cover page of this prospectus, and after deducting underwriting discounts and commissions
and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value per share as of June 30, 2021 was
$13,430,623, or $1.31 per share of common stock. This represents an immediate increase in pro forma as adjusted net tangible book value
of $1.45 per share to existing stockholders and immediate dilution of $4.19 per share to new investors purchasing shares
of common stock in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table illustrates this dilution on a per share basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed
    initial public offering price per share</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">5.50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif">Historical net tangible book value per share as of June 30, 2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1.03</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
    forma increase</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> in net tangible book value per share attributable
    to the conversion of convertible promissory notes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.89</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Pro forma net tangible book value per share as of June
    30, 2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">(0.14)</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Pro forma increase in net tangible book value per share
    attributable to new investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.45</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
    forma as</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> adjusted net tangible book value per share immediately
    after this offering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.31</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution
    per share to new investors in this offering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">4.19</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
information discussed above is illustrative only, and the dilution information following this offering will be adjusted based on the
actual initial public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed
initial public offering price of $5.50 per share, which is the midpoint of the price range set forth on the cover page of this
prospectus, would increase (decrease) our pro forma as adjusted net tangible book value after this offering to $1.72 per
share and the dilution to new investors purchasing common stock in this offering to $4.92 per share, assuming that the number
of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts
and commissions and estimated offering expenses payable by us. An increase of 100,000 shares in the number of shares offered by us, as
set forth on the cover page of this prospectus, would increase our pro forma as adjusted net tangible book value after this offering
to $1.48 per share and decrease the dilution to new investors purchasing common stock in this offering to $4.16 per
share, assuming no change in the assumed initial public offering price per share and after deducting underwriting discounts and commissions
and estimated offering expenses payable by us. A decrease of 100,000 shares in the number of shares offered by us would decrease the
pro forma as adjusted net tangible book value after this offering to $1.41 per share and increase the dilution to new investors
purchasing common stock in this offering to $4.23 per share, assuming no change in the assumed initial public offering price per
share and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the underwriters exercise their option to purchase additional shares in full, the pro forma as adjusted net tangible book value
per share after giving effect to the offering would be $1.48 per share. This represents an increase in pro forma as adjusted
net tangible book value of $1.62 per share to existing stockholders and dilution in pro forma as adjusted net tangible
book value of $4.02 per share to new investors.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock to be outstanding after this offering is based on 6,357,314 shares of our common stock outstanding
as of June 30, 2021, assumes no exercise by the underwriters of their over-allotment option and excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,480,998
    </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">shares of common stock reserved for future issuance under our 2019
    Stock Incentive <FONT STYLE="background-color: white">P</FONT>lan;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">903,468 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issuable
upon exercise of outstanding options with a weighted average exercise price of $4.269; and</FONT></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock issuable
upon exercise of warrants to be issued to the representative of the underwriters as part of this offering at an exercise price of <B>$</B>6.875
(assuming an initial public offering price of <B>$</B>5.50 per share (the midpoint of the price range set forth on the cover page of this
prospectus).</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes, on the pro forma as adjusted basis described above, the total number of shares of common stock we
issued and sold, the total consideration we received and the average price per share (i) paid to us by existing stockholders or (ii)
to be paid by new investors purchasing our common stock in this offering at the assumed initial public offering price of $5.50
per share, the midpoint of the price range set forth on the cover page of this prospectus, before deducting underwriting discounts and
commissions and estimated offering expenses payable by us and (iii) the average price per share paid by existing stockholders and by
new investors who purchase shares of common stock in this offering:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares Purchased</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Consideration</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; text-align: left">Existing stockholders</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">7,277,211</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">70.8</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,820,997</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">18.8</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.53</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">New investors</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,000,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">29.2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">16,500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">81.2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.50</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,277,221</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">100.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,320,997</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">100.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.98</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
$1.00 increase (decrease) in the assumed initial public offering price of $5.50 per share, which is the midpoint of the price
range set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by new investors by $2.8
million and, in the case of an increase, would increase the percentage of total consideration paid by new investors to 83.6% and,
in the case of a decrease, would decrease the percentage of total consideration paid by new investors to 77.9%, assuming that
the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. An increase (decrease) of 100,000
shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the total
consideration paid by new investors by $0.5 million and, in the case of an increase, would increase the percentage of total consideration
paid by new investors to 81.7% and, in the case of a decrease of 100,000 shares, would decrease the percentage of total consideration
paid by new investors to 80.7%, assuming no change in the assumed initial public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table above assumes no exercise of the underwriters&rsquo; over-allotment option in this offering. If the underwriters&rsquo; over-allotment
option is exercised in full, the number of common shares held by new investors purchasing common stock in this offering would be increased
to 32.2% of the total number of shares of common stock outstanding after this offering, and the number of shares held by existing
stockholders would be reduced to 67.8% of the total number of shares of common stock outstanding after this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that stock options or warrants are exercised or convertible debt is converted, we issue new stock options under our equity
incentive plan, or we issue additional common stock in the future, there will be further dilution to investors participating in this
offering. In addition, if we raise additional capital through the sale of equity or convertible debt securities, the issuance of these
securities could result in further dilution to our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="g_006"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>You
should read the following discussion and analysis of our financial condition and results of operations together with our financial statements
and the related notes included elsewhere in this prospectus. In addition to historical information, this discussion and analysis contains
forward-looking statements that are based on our current expectations, estimates and projections about our business and operations and
that involve risks, uncertainties and assumptions. Our actual results may differ materially from those currently anticipated and expressed
in such forward-looking statements as a result of a number of factors, including those which we discuss under &ldquo;Risk Factors&rdquo;
and elsewhere in this prospectus. See &ldquo;Information Regarding Forward-Looking Statements.&rdquo; All amounts in this report are
in U.S. dollars, unless otherwise noted. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are a pre-clinical biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism
resulting in IMCD for treatment resistant cancers. Our most advanced product candidate is HSB-1216, an IMCD modulator, targeting a variety
of solid tumors. In a clinical pilot study conducted in Germany by the University of Heidelberg, the active drug in HSB-1216 was found
to reduce tumor burden in treatment resistant cancers, including TNBC and epithelial carcinomas. Our goal is to submit an IND
to the FDA in 2022 and start a clinical study with HSB-1216 in 2022; however, no assurance can be provided that our IND will be
accepted by the FDA in 2022, if at all. If our IND is accepted by the FDA, our HSB-1216 clinical study will focus on expanding upon the
clinical pilot study conducted in Germany. If we are able to start our clinical study with HSB-1216 in 2022, we anticipate that initial
data from such trial will be released either the end of 2022 or early 2023. We use Quatramer&trade;, our proprietary tumor targeting
platform, to enhance the uptake of HSB-1216 in the TME with an extended duration of action and minimal off-target toxicity. In addition,
Trident, our artificial intelligence precision medicine platform, is used to identify biomarkers in our clinical programs to target specific
patient segments.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discovery of regulated cell death processes, such as apoptosis and autophagy, has enabled novel target discovery for drug development.
Ferroptosis, a form of IMCD, is an emerging regulated cell death process which decreases intracellular iron or the LIP. Cancer cells
increase the LIP leading to unregulated cell growth and metabolism. Decreasing the LIP induces iron-led ROS production and lipid peroxidation,
two key hallmarks of ferroptosis/IMCD. HSB-1216 binds iron in the cytoplasm of cancer cells and decreases the LIP, thereby inducing ferroptosis/IMCD,
leading to regulated cell death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quatramer
is a tumor targeting platform which allows us to leverage and exploit key tumor targets and novel emerging pathways such as IMCD to facilitate
the delivery of potent drugs directly to the TME, while sparing healthy tissue. By efficiently extending the circulation half-life, as
well as targeting delivery to the tumor site, Quatramer traps drugs into the TME. This emerging orthogonal anti-cancer approach utilizes
a fundamental recognized mechanism of iron mediated tumor growth and metabolism. We are building a portfolio of long-acting, potent anti-cancer
drug candidates using the Quatramer platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Trident
uses an artificial intelligence precision medicine platform to identify novel biomarkers. Trident integrates diverse public datasets,
including TCGA to identify novel gene signatures to stratify patients prospectively in clinical trials. Quatramer tumor targeting also
allows us to segment patients by exploiting Trident&rsquo;s findings by (i) synthetic lethal sensitivities with novel combinations, (ii)
pursue undruggable targets such as <I>c-myc</I> and (iii) target tumors with a high degree of cell plasticity indicative of recurrent/drug
resistant phenotype.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical components of our business strategy to achieve our goals include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Developing
    our drug candidate, HSB-1216, in solid tumors.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0pt 0 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
from a clinical pilot use study in Germany led us to progress HSB-1216 into IND-enabling studies with the ultimate goal of submitting
an IND to the FDA in  2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Developing
    our combination drug candidate, HSB-888, for pediatric sarcomas.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888
is in IND-enabling trials with the ultimate goal of submitting an IND to the FDA in the first half of 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leveraging
    our Trident Artificial Intelligence Platform.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="margin: 0pt 0 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAI
is a computational intelligence platform that identifies synthetic lethal sensitivities associated with degree of cell plasticity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Developing
    and commercializing Quatramer in collaboration with leading pharmaceutical companies.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our internal development programs, we actively seek opportunities to collaborate with recognized biopharmaceutical companies
to develop Quatramer incorporating therapeutic payloads from their proprietary product portfolios.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leveraging
    our novel platform to develop a pipeline of high value Quatramer leads.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tunability of our technology allows us to efficiently expand our pipeline of Quatramer, both on our own and in collaboration with others,
through various combinations of targeted DNA encoded for anti-tumor cytokines and therapeutic payloads, which enables us to move into
other areas of oncology, including immuno-oncology whereby we could increase the effectiveness of ICIs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Commercializing
    proprietary Quatramer based products, including HSB-1216, directly in the United States and with collaborators outside the United
    States.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0pt 0 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
own </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">HSB-1216 and our other proprietary pipeline and expect to maintain
similar rights with respect to other proprietary Quatramer we develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Continuing
    to extend and protect our product technology and Quatramer through our intellectual property portfolio.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to protect our novel platform through U.S. and international patents as well as know-how and trade secrets relating to the design
and manufacturing of our technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trends
and Uncertainties&mdash;COVID-19</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global COVID-19 pandemic continues to evolve. The extent of the impact of the COVID-19 on our business, operations, pre-clinical and
clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread
of the outbreak, COVID-19 variants such as the Delta variant, and the future impact of COVID-19 on our clinical trial enrollment,
clinical trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as its impact on regulatory
authorities and our key scientific and management personnel. The ultimate impact of the COVID-19 pandemic or a similar health epidemic
is highly uncertain and subject to change. To the extent possible, we are conducting business as usual, with necessary or advisable modifications
to employee travel and with many of our employees and consultants working remotely. We will continue to actively monitor the evolving
situation related to COVID-19 and may take further actions that alter our operations, including those that may be required by federal,
state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business.
At this point, the extent to which the COVID-19 pandemic may affect our business, operations and clinical development timelines and plans,
including the resulting impact on our expenditures and capital needs, remains uncertain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Components
of Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revenue</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
did not recognize revenues for the six months ended June 30, 2021 and 2020 or the years ended December 31, 2020 and 2019.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include personnel costs associated with research and development activities, including third-party contractors
to perform research, conduct clinical trials, stock based compensation and manufacture drug supplies and materials. Research and development
expenses are charged to operations as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
accrue costs incurred by external service providers, including contract research organizations and clinical investigators, based on estimates
of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment
in clinical trials, administrative costs incurred by third parties, and other indicators of the services completed. Based on the timing
of amounts invoiced by service providers, we may also record payments made to those providers as prepaid expenses that will be recognized
as expense in future periods as the related services are rendered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred research and development expenses related to the development of HSB-1216. We expect that our research and development expenses
will increase as we plan for and commence our clinical trials of HSB-1216 and HSB-888.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot determine with certainty the duration and costs of future clinical trials of our product candidates, HSB-1216 and HSB-888, or
any other product candidates we may develop or if, when or to what extent we will generate revenue from the commercialization and sale
of any of our product candidates for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any
of our product candidates. The duration, costs and timing of clinical trials and development of our current and future product candidates
will depend on a variety of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, rate of progress, expense and results of clinical trials of our current product candidates, as well as of any future clinical
    trials of our future product candidates and other research and development activities that we may conduct;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainties
    in clinical trial design and patient enrollment rates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    actual probability of success for our product candidates, including their safety and efficacy, early clinical data, competition,
    manufacturing capability and commercial viability;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    and changing government regulations and regulatory guidance; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and receipt of any marketing approvals.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change
in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority
were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development
of a product candidate, or if we experience significant delays in our clinical trials due to slower than expected patient enrollment
or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of compensation and consulting related expenses, <FONT STYLE="background-color: white">including
stock&nbsp;based compensation</FONT>. General and administrative expenses also include professional fees and other corporate expenses,
including legal fees relating to corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance
costs; travel expenses and other operating costs that are not specifically attributable to research activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support our
continued research activities and development of our product candidates. Following this offering, we also expect to incur increased expenses
associated with being a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq,
additional director and officer insurance expenses, corporate governance expenses, investor relations activities and other administrative
and professional services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Acquired
In-process Research and Development Expense</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs incurred in obtaining technology licenses and asset purchases are charged to research and development expense if
the technology licensed has not reached technological feasibility which includes manufacturing, clinical, intellectual property and/or
regulatory success which has no alternative future use. The licenses purchased by us require substantial completion of research and development
and regulatory and marketing approval efforts in order to reach technological feasibility. As such, for the  years ended December 31, 2020 and 2019, the purchase price of licenses and assets acquired was classified as acquired
in-process research and development expenses in the consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Change
in Redemption Value</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for derivative instruments in accordance with Accounting Standards Codification (&ldquo;ASC&rdquo;) 815, <I>Derivative and Hedging,
</I>which establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded
in other financial instruments or contracts, and requires recognition of all derivatives on the balance sheet at fair value. Our derivative
financial instrument consists of an embedded option in our convertible debt that we call the &ldquo;redemption liability.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial fair value of the redemption feature relating to the convertible debt instruments is treated as a debt discount and amortized
over the term of the related debt using the straight-line method, which approximates the interest method. If a loan is paid in full,
any unamortized financing costs will be removed from the related accounts and charged to operations. Amortization of debt discount is
recorded as a component of interest expense. In accordance with ASU 2015-03, <I>Interest &mdash; Imputation of Interest</I>, the unamortized
debt discount is presented in the accompanying balance sheet as a direct deduction from the carrying amount of the related debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Split-Segment; Name: Split_001 -->
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The redemption liability includes provision that
provide the noteholder with certain conversion and put rights at various conversion or redemption values as well as certain call options
for us. The fair value of the redemption liability is calculated under Level 3 of the fair value hierarchy, determined based upon a Probability-Weighted
Expected Returns Method (&ldquo;PWERM&rdquo;). This PWERM was determined to be the most appropriate method of estimating the value of
possible redemption or conversion outcomes over time, since we have not entered into a priced equity round through June 30, 2021.
The significant assumptions utilized in these calculations are the possible exit scenarios (either a conversion of the principal
and accrued interest of the Notes in the event of a Next Equity Financing (as defined below), a repayment of the Notes and accrued interest
in the event of a Corporate Transaction (as defined below) or a repayment of the Notes and accrued interest at maturity), the pre-money
valuation of our common stock, the probabilities of such exit events occurring and discounts/premiums available to the noteholders at
such measurement dates. At June 30, 2021, we assumed a 65% probability of a Next Equity Financing event occurring at IPO
pricing, an increase from 40% at December 31, 2020. At June 30, 2021, we assumed a 25% probability of a Corporate Transaction,
an increase from 5% at December 31, 2020. At December 31, 2020, we assumed a 40% probability of a Next Equity Financing event occurring
at IPO pricing, an increase from 9% at December 31, 2019. At December 31, 2020, we assumed a 5% probability of a Corporate Transaction,
an increase from 1% at December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Comparison
of the Six Months Ended June 30, 2021 and 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth key components of our results of operations for the six months ended June 30, 2021 and 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Six
                                            </B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Months Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June
                                            30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Consolidated Statement of Operations Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 52%; text-align: left">Research and development</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,570,675</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">291,714</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,278,961</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">994,636</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">161,324</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">833,312</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,565,311</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">453,038</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,112,273</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">337,090</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79,132</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">257,958</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in redemption value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">903,744</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">175,222</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">728,522</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,240,834</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">254,354</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">986,480</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,806,145</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(707,392</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,098,753</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses increased by $1,278,961, or 438.4%, to $1,570,675 for the six months ended June
30, 2021 from $291,714 for the six months ended June 30, 2020. The increase was primarily the result of an increase
in stock based compensation expense of $510,434 related to research and development team members, expenses for pre-clinical activities
of $648,248 and consulting expenses of $121,407. These increases were offset by decreases of $1,128 in various other expenses.<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses increased by $833,312, or 516.5%, to $994,636 for the six months ended June
30, 2021 from $161,324 for the six months ended June 30, 2020. The increase in general and administrative expenses
was primarily due to an increase of $705,901 in stock based compensation expense and $154,853 in expenses associated
with accounting related fees. These increases were offset by decrease of $27,442 in various other expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interest
Expense</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense increased by $257,958, or 326.0%, to $337,090 for the six months ended June 30, 2021 from
$79,132 for the six months ended June 30, 2020. The increase in interest expense was primarily related to the additional
convertible promissory notes issued (See Note 4 of our condensed consolidated financial statements).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Change
in Redemption Value</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in redemption value increased by $728,522, or 415.8%, to $903,744 for the six months ended June
30, 2021 from $175,222 for the six months ended June 30, 2020 as the probability of conducting a larger priced financing
increased due to advancing manufacturing processes and pre-clinical data readouts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Comparison
of the Years Ended December 31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth key components of our results of operations for the years ended December 31, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated Statement of
    Operations Data:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating expenses:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 52%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and
    development</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">847,272</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">368,732</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">478,540</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Acquired in-process research
    and development</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">289,200</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">429,403</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(140,203</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">671,879</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">625,807</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">46,072</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    operating expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,808,351</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,423,942</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">384,409</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other Expense:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest expense</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">246,534</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">75,074</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">171,460</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in redemption value</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">362,486</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">26,458</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">336,028</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    other expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">609,020</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">101,532</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">507,488</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,417,371</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,525,474</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(891,897</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses increased by $478,540, or 129.8%, to $847,272 for the year ended December 31, 2020 from $368,732 for the year
ended December 31, 2019. The increase was primarily the result of an increase in pre-clinical related expense, license expenses, and
GMP manufacturing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Acquired
In-Process Research and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
in-process research and development expense was $289,200 for the year ended December 31, 2020 and $429,403 for the year ended December
31, 2019, a decrease of $140,203. The in-process research and development expenses represent expenses incurred with the acquisition of
Farrington that closed during the year ended December 31, 2020, and the acquisition of Nanoproteagen and small molecule analogues that
closed during the year ended December 31, 2019. The expense amounts represent acquisition related costs which were approximately $20,000
during the year ended December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses increased by $46,072, or 7.4%, to $671,879 for the year ended December 31, 2020 from $625,807 for the year
ended December 31, 2019. The increase in general and administrative expenses was primarily due to an increase of $134,746 in legal expenses;
$81,998 in expenses associated with accounting related fees; $61,439 in stock based compensation expense; and $7,187 in insurance expenses.
These increases were offset by decreases of $200,000 in payroll and related expenses; $25,298 of various other expenses; and $14,000
related to travel expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interest
Expense</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense increased by $171,460, or 228.4%, to $246,534 for the year ended December 31, 2020 from $75,074 for the year ended December 31,
2019. The increase in interest expense was primarily related to the convertible promissory notes which were exchanged on September 27,
2020 and had default interest rate of 20% and added an original issue discount of 37.5%. &nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Change
in Redemption Value</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in redemption value increased by $336,028, or 1,270.0%, to $362,486 for the year ended December 31, 2020 from $26,458 for the
year ended December 31, 2019 as the probability of conducting a larger priced financing has increased since 2019 due to advancing manufacturing
processes and pre-clinical data readouts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception in 2017, we have devoted most of our cash resources to research and development, in-process research and development and
general and administrative activities. We do not currently have any approved products and have never generated any revenue from product
sales. To date, we have financed our operations primarily with proceeds from the sale of our convertible promissory notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2020 and June 30, 2021,
we had cash of $191,852 and $29,271, respectively. We have determined that our current levels of cash will not be sufficient to
meet our anticipated cash needs for our ongoing operations. We have incurred significant operating losses since inception, and we expect
to incur significant expenses and operating losses for the foreseeable future as we advance the pre-clinical and clinical development
of our product candidates. We expect that our research and development and general and administrative costs will increase, including
in connection with conducting pre-clinical studies and clinical trials for our product candidates, engaging contract manufacturing organizations
and building out internal capacity to have products manufactured to support pre-clinical studies and clinical trials, expanding our intellectual
property portfolio and general and administrative support with respect to our operations. As a result, our independent registered
public accounting firm has included, in its opinion for the year ended December 31, 2020, an explanatory paragraph expressing substantial
doubt about our ability to continue as a going concern within one year from the date of the initial filing of the registration statement
on Form S-1 of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are seeking significant additional capital funding to advance our product candidates through pre-IND, manufacturing and clinical trials
as well as for general corporate and working capital purposes. However, there can be no assurance that such efforts will be successful
or that, in the event that they are successful, the terms and conditions of such financing will be favorable. In consideration of our
plans, substantial doubt cannot be alleviated with respect to our continued operations. Management&rsquo;s plans, of which the raising
additional capital is not within management&rsquo;s control and cannot be assured, do not alleviate such substantial doubt with respect
to our ongoing operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Cash
Flow Activities for the Six Months Ended June 30, 2021 and 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table sets forth a summary of our cash flows for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Six
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Months Ended June 30,</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(761,793</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(446,019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">599,212</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">417,068</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    decrease in cash</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(162,581</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(28,951</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Cash
Flows from Operating Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash used in operating activities for the six
months ended June 30, 2021 was $761,793 which consisted of net loss of $3,806,145, partially offset by $2,395,799
in non-cash charges and other adjustments to reconcile net loss to net cash used in operating activities and $648,553 in net
increase in operating accounts. The non-cash charges consist of stock compensation expenses of $1,228,092, change in fair value
of redemption liability of $903,744 and amortization of debt discount of $263,963. The net increase in operating activities
was primarily due to an increase of $477,596 in accounts payable and accrued expenses, a decrease of $97,893 in prepaid
expenses and other current assets and an increase in accrued interest of $73,064.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash used in operating activities for the six
months ended June 30, 2020 was $446,019 which consisted of net loss of $707,392, partially offset by $222,608
in non-cash charges and other adjustments to reconcile net loss to net cash used in operating activities and $38,765 in net
increase in operating accounts. The non-cash charges consist of change in fair value of redemption liability of $175,222, amortization
of debt discount of $35,629, and stock compensation expenses of $11,757. The net increase in operating activities was primarily
due to an increase in accrued interest of $50,447, an increase of $43,503 in accounts payable and accrued expenses offset
by a decrease of $55,068 in due to founder and an increase of $117 in prepaid expenses and other current assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Cash Flows from Financing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash provided by financing activities for the six
months ended June 30, 2021 was from net cash proceeds of $703,014 from the issuance of convertible promissory
notes offset by deferred offering costs of $103,802.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash provided by financing activities for the six
months ended June 30, 2020 was entirely from net cash proceeds of $417,068 from the issuance of convertible promissory
notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
Flow Activities for the Years Ended December 31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of our cash flows for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Years
    Ended December 31,</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash used in operating activities</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,078,432</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(706,113</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash provided by financing activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,232,003</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">708,385</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net increase in cash</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">153,571</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,272</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Flows from Operating Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
used in operating activities for the year ended December 31, 2020 was $1,078,432 which consisted of the net loss of $2,417,371, partially
offset by $1,031,622 in non-cash charges and other adjustments to reconcile net loss to net cash used in operating activities and $307,317
in net increase in operating accounts. The non-cash charges consists of change in fair value of redemption liability of $362,486, in-process
research and development expense of $289,200, stock compensation expense of $234,580 and amortization of debt discount of $145,356. The
net increase in operating activities was primarily due to an increase of $306,570 in accounts payable and accrued expenses and an increase
in accrued interest of $101,093, partially offset by an increase of $100,346 in prepaid expense and other current assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
used in operating activities for the year ended December 31, 2019 was $706,113 which consisted of the net loss of $1,525,474, partially
offset by $576,675 in non-cash charges and other adjustments to reconcile net loss to net cash used in operating activities and
$242,686 in net increase in operating accounts. The non-cash charges consist of in-process research and development expense of
$429,403, stock compensation expense of $92,012, amortization of debt discount of $28,802 and change in fair value of redemption
liability of $26,458. The net increase in operating activities was primarily due to an increase of $213,524 in due to founder, accrued
interest of $46,190, a decrease in prepaid expenses and other current assets of $13,400 offset by a decrease in accounts payable and
accrued expenses of $30,428.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Flows from Financing Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities for the year ended December 31, 2020 was entirely from net cash proceeds of $1,232,003 from the issuance
of convertible promissory notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities for the year ended December 31, 2019 was from net cash proceeds of $580,885 from the issuance of convertible
promissory notes and $127,500 from the exercise of stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
Promissory Notes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commencing
in May 2017, we issued convertible promissory notes (the &ldquo;Notes&rdquo;) to certain investors to help finance our operations. The
principal amount of such notes range from $1,000 to $300,000. Interest on the unpaid principal balance accrues at a rate of 5% per annum,
computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier converted into shares of our common
stock or preferred stock (&ldquo;Equity Securities&rdquo;), the principal and accrued interest shall be due and payable by us on demand
by the holders at any time after the earlier of (i) the maturity date of each Note and (ii) the closing of the Next Equity Financing.
&ldquo;Next Equity Financing&rdquo; means the next sale or series of related sales of our Equity Securities pursuant to which we receive
gross proceeds of not less than $5,000,000 for Notes issued in 2017 and through November 2020 and $7,500,000 for Notes issued after November
2020 (including the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of Notes). This
offering will qualify as a Next Equity Financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
general, the maturity date was two years from the date of issuance, except for the Notes issued in December 2020 and thereafter, in the
aggregate principal amount of approximately $1,450,000, which have a maturity date of three years from the date of issuance.
For Notes entered into in 2017 and through September 2018, the default interest rate of 20% was added to the Notes for the period after
the maturity date (&ldquo;default period&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares
of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued
interest due on the Note on the date of conversion by the lesser of (i) 80% of the price paid per share of Equity Securities by the investors
in the Next Equity Financing, or (ii) an equity valuation of $25 million ($50 million for notes issued after December 2020). No Next
Equity Financing has occurred through June 30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
prior to the closing of the Next Equity Financing or the maturity date of the Notes, there is a sale, merger, consolidation, liquidation,
dissolution or closure of our Company (&ldquo;Corporate Transaction&rdquo;), the holders of the Notes shall be entitled to receive 150%
of the principal amount of the Notes together with any interest accrued thereon. In the event that there are insufficient funds available
to pay the foregoing amount, the holders of the Notes will receive a pro rata share of available proceeds.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2020, we issued a related party note holder notes (&ldquo;Exchange Notes&rdquo;) in exchange for seven Notes which were
in default (&ldquo;Original Notes&rdquo;) at such time by more than 90 days. The Original Notes had a principal of approximately $265,000
and accrued interest of $37,000 at December 31, 2019. As of September 27, 2020, the aggregate outstanding principal of the Original Notes
was approximately $265,000 and accrued interest (which included the default interest rate of 20% as described above) was approximately
$71,000. The Exchange Notes took the then principal and accrued interest of the Original Notes and added an original issue discount of
37.5% to determine the new principal, which amounted to an aggregate of $537,968. The Company accounted for this transaction as a debt
extinguishment, and the incremental amount of the principal of the notes payable of $201,737 was recorded to accumulated deficit (analogous
to a &ldquo;deemed dividend&rdquo;), since the notes are with related parties, and included in the calculation of loss per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
September 27, 2020, we issued certain related party note holders Exchange Notes in exchange for five Notes payable which were in default.
As of such date, the aggregate outstanding principal and interest was approximately $26,000, which included the 20% default interest
rate. The new Exchange Note in the aggregate principal amount of approximately $26,000 had substantially the same terms as the original
Notes. There were no accounting entries required upon the re-issuance of such Exchange Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective October 1, 2020, all Notes which
matured, and were not repaid or converted, were rolled over on substantially the same terms as the Original Notes (&ldquo;Rolled Over&rdquo;).
Approximately $495,000 of such Original Notes were Rolled Over through June 30, 2021, of which approximately $166,000
occurred prior to December 31, 2020 and $328,000 occurred between January 1, 2021 and June 30, 2021. Since the terms of the new notes are
not substantially different from the Original Notes, this was not accounted for as a debt modification or debt extinguishment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
connection with the consummation of this offering and based upon <FONT STYLE="font-size: 10pt">$3,447,484 of principal amount and
accrued interest of outstanding convertible notes as of June 30, 2021, we will issue 836,742</FONT> shares of our common stock upon
the conversion of our outstanding convertible notes, assuming an initial public offering price of $5.50 per share, the midpoint
of the range set forth on the cover page of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
did not have any off-balance sheet arrangements for the six months ended June 30, 2021 and 2020 or the years ended December
31, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies and Use of Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and related disclosures in the financial statements and accompanying notes. Management bases its
estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often
may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls
within that range of reasonable estimates. Estimates are used in the following areas, among others: research and development expense
recognition, valuation of acquired technologies, valuation of common shares, allowances of deferred tax assets, valuation of debt related
instruments, accrued expenses and liabilities, and cash flow assumptions regarding going concern considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Critical
Accounting Policies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and
development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies
and materials. We accrue for costs incurred by external service providers, including contract research organizations and clinical investigators,
based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties,
patient enrollment in clinical trials, administrative costs incurred by third parties, and other indicators of the services completed.
Substantially all of the prepaid expenses at December 31, 2020 relate to the purchase of an active pharmaceutical ingredient and substantially
all of the prepaid expenses at June 30, 2021 relate to product candidate manufacturing expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acquired
in-process research and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acquired, and may in the future acquire, rights to develop and commercialize new product candidates and/or other in-process research
and development assets. In accordance with Financial Accounting Standards Board&rsquo;s (&ldquo;FASB&rsquo;s&rdquo;) ASC 730-10-25-1,
Research and Development, the up-front acquisition or licensing payments are expensed as acquired in-process research and development
provided that the drug has not achieved regulatory approval for marketing, and, absent obtaining such approval, have no alternative future
use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
based compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation represents the cost related to stock based awards granted to employees, directors and consultants of our company and
our affiliates. We measure stock based compensation costs at the grant date, based on the estimated fair value of the award and recognize
the cost over the requisite service period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize compensation costs resulting from the issuance of stock based awards to employees, non-employees and directors as an expense
in the condensed consolidated statements of operations over the requisite service period based on a measurement of fair value for each
stock based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model.
The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally
the vesting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. We are a private
company and lack company-specific historical and implied volatility information. Therefore, we estimate our expected stock volatility
based on the historical data regarding the volatility of a publicly traded set of peer companies. The expected term of stock options
granted to non-employees is between five and seven years. The risk-free interest rate is determined by reference to the U.S. Treasury
yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The fair
value of common stock is determined with the assistance of an independent third-party valuation expert when issuing stock options and
computing its estimated stock based compensation expense and value of shares issued in acquiring product candidates. The assumptions
underlying these valuations represented management&rsquo;s best estimates, which involved inherent uncertainties and the application
of significant levels of management judgment. In order to determine the fair value, we considered, among other things, contemporaneous
valuations of our common stock, our business, financial condition and results of operations, including related industry trends affecting
our operations; the likelihood of achieving various liquidity events; the lack of marketability of our common stock; the market performance
of comparable publicly traded companies; and U.S. and global economic and capital market conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
value measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
apply ASC 820, Fair Value Measurement (&ldquo;ASC 820&rdquo;), which establishes a framework for measuring fair value and clarifies the
definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received
for an asset or paid to transfer a liability in our principal or most advantageous market in an orderly transaction between market participants
on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable
inputs and minimize the use of unobservable inputs when measuring fair value. The fair value of the redemption liability is determined
based upon a PWERM. This PWERM was determined to be the most appropriate method of estimating the value of possible redemption or conversion
outcomes over time since we have not conducted a priced equity round from inception through June 30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Debt
discount and derivative instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial fair value of the redemption value relating to the convertible debt instruments is treated as a debt discount and amortized over
the term of the related debt using the straight-line method, which approximates the interest method. If a loan is paid in full, any unamortized
financing costs will be removed from the related accounts and charged to operations. Amortization of debt discount is recorded as a component
of interest expense. In accordance with ASU 2015-03, <I>Interest &mdash; Imputation of Interest</I>, the unamortized debt discount is
presented in the accompanying balance sheet as a direct deduction from the carrying amount of the related debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for derivative instruments in accordance with ASC 815, Derivative and Hedging, which establishes accounting and reporting standards
for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts and requires
recognition of all derivatives on the balance sheet at fair value. Our derivative financial instrument consists of an embedded feature
contained in our convertible debt that is bifurcated and accounted for separately. See Note 4 of our audited and unaudited consolidated
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
Issued and Adopted Accounting Standards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2 to our audited and unaudited consolidated financial statements included elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JOBS
Act</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company,&rdquo; as defined in the JOBS Act. Emerging growth companies can <FONT STYLE="background-color: white">take
advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting
standards. In other words, an &ldquo;emerging growth company&rdquo; can delay the adoption of certain accounting standards until those
standards would otherwise apply to private companies. We have chosen to take advantage of the extended transition periods available to
emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise
apply to private companies provided under the JOBS Act. As a result, our consolidated financial statements may not be comparable to those
of companies that comply with public company effective dates for complying with new or revised accounting standards.</FONT> For as long
as we continue to be an emerging growth company, we also intend to take advantage of certain other exemptions from various reporting
requirements that are applicable to other public companies including, but not limited to, reduced disclosure obligations regarding executive
compensation in our periodic reports and proxy statements, exemptions from the requirements of holding a nonbinding advisory stockholder
vote on executive compensation and any golden parachute payments not previously approved, exemption from the requirement of auditor attestation
in the assessment of our internal control over financial reporting and exemption from any requirement that may be adopted by the Public
Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing additional
information about the audit and the financial statements (auditor discussion and analysis). After we become a reporting company under
the Exchange Act, we will remain an emerging growth company until the earliest of (i) <FONT STYLE="background-color: white">the date
on which we are deemed to be a large accelerated filer under the rules of the SEC</FONT>, (ii) the end of the fiscal year in which we
have total annual gross revenues of $1.07 billion or more during such fiscal year, (iii) the date on which we issue more than $1 billion
in non-convertible debt in a three-year period or (iv) the end of the fiscal year following the fifth anniversary of the date of the
completion of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="hj_001"></A>BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Overview</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Hillstream
BioPharma is a pre-clinical biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer
mechanism resulting in IMCD for treatment resistant cancers. The most advanced product candidate which we own is HSB-1216, an IMCD inducer,
targeting a variety of solid tumors. In a clinical pilot study conducted in Germany by the University of Heidelberg, the active drug
in HSB-1216 was found to reduce tumor burden in treatment resistant cancers, including TNBC and epithelial carcinomas. Our goal is to
submit an IND to the FDA in 2022 and start a clinical study with HSB-1216 in 2022; however, no assurance can be provided
that our IND will be accepted by the FDA in 2022, if at all. If our IND is accepted by the FDA, our HSB-1216 clinical study will focus
on expanding upon the clinical pilot study conducted in Germany. If we are able to start our clinical study with HSB-1216 in 2022, we
anticipate that initial data from such trial will be released either the end of 2022 or early 2023. We use Quatramer&trade;, our proprietary
tumor targeting platform, to enhance the uptake of HSB-1216 in the TME with an extended duration of action and minimal off-target toxicity.
In addition, Trident, our artificial intelligence precision medicine platform, is used to identify biomarkers in our clinical programs
to target specific patient segments.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
discovery of regulated cell death processes, such as apoptosis and autophagy, has enabled novel target discovery for drug development.
Ferroptosis, a form of IMCD, is an emerging regulated cell death process which decreases intracellular iron or the LIP. Cancer cells
increase the LIP leading to unregulated cell growth and metabolism. Decreasing the LIP, induces iron-led ROS production and lipid peroxidation,
two key hallmarks of ferroptosis/IMCD. HSB-1216 binds iron in the cytoplasm of cancer cells and decreases the LIP, thereby inducing ferroptosis/IMCD,
leading to regulated cell death. Areas of interest for the development of HSB-1216 are as a treatment of solid tumors, including TNBC,
uveal melanoma, glioblastoma multiforme, head and neck squamous cell carcinoma and other treatment resistant cancers with high unmet
need.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Quatramer
is a tumor targeting platform which allows us to leverage and exploit key tumor targets and novel emerging pathways such as IMCD to facilitate
the delivery of potent drugs directly to the TME, while sparing healthy tissue. By efficiently extending the circulation half-life, as
well as targeting delivery to the tumor site, Quatramer traps drugs into the TME. This emerging orthogonal anti-cancer approach utilizes
a fundamental recognized mechanism of iron mediated tumor growth and metabolism. We are building a portfolio of long-acting, potent anti-cancer
drug candidates using our Quatramer platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Trident
uses an artificial intelligence precision medicine platform to identify novel biomarkers. Trident integrates diverse public datasets,
including TCGA to identify novel gene signatures to stratify patients prospectively in clinical trials. Quatramer tumor targeting also
allows us to segment patients by exploiting Trident&rsquo;s findings by (i) synthetic lethal sensitivities with novel combinations, (ii)
pursue undruggable targets such as <I>c-myc </I>and (iii) target tumors with a high degree of cell plasticity indicative of recurrent/drug
resistant phenotype.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our
Product Candidates and Research Programs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are leveraging our proprietary technologies and developing multiple product candidates with differentiated profiles designed to address
rare and treatment resistant cancers, as shown below.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
1: Pipeline Chart</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><IMG SRC="drsa_001.jpg" ALT="" STYLE="height: 273px; width: 670px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to submit an IND with the FDA for HSB-1216 in 2022, for HSB-888 in the first half of 2023, for HSB-510 in 2023
and for HSB-114 in 2024; however, no assurance can be provided that our INDs will be accepted by the FDA based on our anticipated timeline,
if at all.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
Lead Candidates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I><U>HSB-1216</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HSB-1216,
our most advanced product candidate which we intend to develop in the clinic in 2022 for multiple high unmet need solid tumors,
is an IMCD inducer delivered using our proprietary carrier, Quatramer. We intend to submit an IND application to the FDA and obtain clinical
data to support our strategy in 2022; however, no assurance can be provided that our IND will be accepted by the FDA in 2022, if at all.
HSB-1216 exploits a key feature of certain tumors that rely on an excessive LIP within the cell to modify the dysregulated iron microenvironment
of cancer. We have received ODD in small cell lung cancer (&ldquo;SCLC&rdquo;) for HSB-1216&rsquo;s active drug. In a clinical pilot
study conducted in Germany by the University of Heidelberg, HSB-1216&rsquo;s active drug was studied in 7 patients with positive results
in heavily pre-treated and therapy resistant cancers. By design, HSB-1216 circulates systemically after an intravenous injection and
concentrates in the TME of solid tumor masses. The localization of HSB-1216 has been demonstrated in multiple <I>in vivo</I> models with
pharmacodynamic signals showing significant decreases in tumor size after multiple weekly injections.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
2: HSB-1216 - IMCD Mechanism of Action: Shifting the Intracellular Redox Balance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="drsa_002.jpg" ALT="" STYLE="height: 468px; width: 600px">&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
                                            a tumor concentrating therapeutic, HSB-1216 has the potential to be used in cancer patients
                                            who have failed standard-of-care therapies for treatment resistant tumors without any approved
                                            therapies. We intend to submit an IND to the FDA for approval in 2022 and,
                                            if such IND is timely submitted and approved, we anticipate initial data either
                                            the end of 2022 or early 2023; however, no assurance can be provided that our IND will be
                                            accepted by the FDA in 2022, if at all.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-888</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemotherapy,
an important part of antitumor treatment, exerts anticancer effects by killing cancer cells, and anthracycline-based regimens have been
and continue to be the mainstay of treatment for a vast majority of tumors. The clinical applications of anthracycline regimens, above
certain dose ranges have limited use due to adverse events, including cumulative lifetime doses resulting in cardiotoxicity. The nonspecific
accumulation of anthracyclines, such as doxorubicin and similar agents in non-target tissues such as cardiac cells, continue to be a
problem.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
                                            second product candidate, HSB-888, is a dual-loaded IMCD inducer coupled with our
                                            ultra-low dose next generation anthracycline analogue for solid tumors. HSB-888 is in IND-enabling
                                            studies, and we intend to develop such product candidate in the clinic in 2023 for
                                            multiple sarcomas after we submit an IND to the FDA for HSB-888 in the first half of
                                            2023; however, no assurance can be provided that our IND will be accepted by the FDA in 2023,
                                            if at all. The FDA has granted one of the active drugs of HSB-888 a Rare Pediatric Disease
                                            Designation and ODD for pediatric osteosarcoma. In addition, one component compound in HSB-888
                                            is our next generation anthracycline analogue approved and marketed in China and Japan
                                            which has potent antitumor activity and indicated for multiple tumor types, with an improved
                                            therapeutic index compared to doxorubicin. We believe targeting the agent in our proprietary
                                            dual-loaded Quatramer with our novel IMCD inducer may confer key benefits for multiple reasons,
                                            including a synergistic ultra-low-dose approach as well as leveraging a key differentiating
                                            mechanism of iron-mediation to kill the tumor and reduce off target toxicities simultaneously.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
3: HSB-888 &ndash; Structure &amp; Mechanism</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="drsa_003.jpg" ALT="" STYLE="height: 304px; width: 650px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HSB-888
                                            has the potential to be used in solid tumors whereby a potent anthracycline may be effective
                                            but prohibitive in current available forms due to their off-target effects. We intend
                                            to include data from our own pre-clinical studies as well as the human data available
                                            from Japanese and Chinese studies in our IND which we intend to submit in the
                                            first half of 2023 and, if such IND is timely submitted and approved, we anticipate
                                            top-line clinical data in 2023; however, no assurance can be provided that our IND
                                            will be accepted by the FDA in 2023, if at all.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
Other Candidates</I></B></FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I><U>HSB-510</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
                                            own HSB-510 which is a novel highly targeted bifunctional inhibitory compound in Quatramer
                                            with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate
                                            <I>c-myc</I>, a highly pursued and yet undruggable cancer drug target. The Quatramer platform
                                            achieves optimal tumor targeting and bioavailability of the highly potent targeted small
                                            molecule. Through an ongoing Cooperative Research and Development Agreement with the National
                                            Center for Advancing Translational Sciences (&ldquo;NCATS&rdquo;), part of the NIH, we analyzed
                                            novel dual PI3K/HDAC inhibitors and a lead compound which showed good antiproliferative activity
                                            against multiple oncology cell lines. This compound obtained ideal pharmacokinetic properties
                                            in our proprietary Quatramer, while maintaining specific HDAC6-PI3K-delta specificity. We
                                            intend to continue our collaborative effort with NCATS through our collaboration. In addition,
                                            we intend to submit an IND to the FDA for HSB-510 in 2023; however, no assurance
                                            can be provided that our IND will be accepted by the FDA in 2023, if at all.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Figure
4: HSB-510 - Structure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="drsa_004.jpg" ALT=""></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-114</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
own HSB-114 which is a novel immunotherapeutic agent that uses our proprietary Quatramer platform to deliver the human TNF-alpha gene
into cancer cells. Finding ways to selectively increase intratumoral TNF-alpha levels in tumors while managing the toxicity associated
with such approaches remains a major unmet need. We believe we have developed a novel approach to include a peptide-DNA complex which
preferentially releases genetic material and localizes into the nucleus of the delivered cancer cell and has demonstrated highly effective
in achieving a desired tumor response in our pre-clinical oncology models using TNF-alpha. We believe this intratumoral expression of
secreted cytokines, such as TNF-alpha, represents a novel approach for inducing anti-tumor activity and potentially reprogramming the
tumor immune microenvironment, and we intend to develop this technology further to strengthen our pipeline. We intend to submit
an IND to the FDA for HSB-114 in 2024; however, no assurance can be provided that our IND will be accepted by the FDA in 2024,
if at all.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
5: HSB-114 - Structure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="drsa_005.jpg" ALT="" STYLE="height: 291px; width: 650px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
Programs</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Our
technology platform enables us to generate a pipeline of early-stage product candidates spanning multiple targets in oncology utilizing
diverse payloads to treat rare and treatment resistant tumors. While the payloads in our most advanced product candidates, HSB-1216 and
HSB-888, are novel, and have pilot and extensive human data in multiple solid tumors, any solid tumor or non-oncologic disease requiring
delivery of a peptide, protein or biologic is conceivably a candidate for our technology. Our early-stage product candidates are focused
on rare and treatment resistant diseases; however, we believe our technology could potentially deliver meaningful benefit across a wide
range of oncologic and viral diseases. We have tested several peptides, nucleic acids, proteins, small molecules and antibody constructs
against multiple targets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Platform Technologies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Quatramer
Technology</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
key aspect of oncology treatment is that effective anticancer agents do not penetrate the tumor bed in order to kill cancer cells due
to the limitation of the microenvironment of the tumor. The TME is protected by stromal tissue comprised of multiple layers of collagen,
proteoglycans, hyaluronans and laminin layers shielding the tumor from the deployment of traditional treatments, including chemotherapy
(novel small molecule and immunotherapies). Parts of the tumor create an environment to survive despite reduced nutrient sources whereby
hypoxic regions of the tumor continue to thrive by incorporating a shift in metabolism, including iron dysregulation. Any drug that reaches
the tumor is effluxed out of the cell by transporter pumps upregulated by the cancer cells rendering any such drug that reaches the tumor
ineffective. The TME continues to thrive by the inability of immune cells normally designed to infiltrate and kill the tumor made ineffective
by a reduction in their ability to activate their killing effect of the cancer.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
6: Tumor Vasculature</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="drsa_006.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proprietary Quatramer technology overcomes the limitations that have hampered development of nanoscale and liposome derived products
as cancer therapeutics. Limitations include, but are not limited to, drug efflux, toxicity, eluding phagocytosis, physiological barrier
penetrance and immune responses. Our Quatramer technology incorporates a therapeutic payload and is designed to be tunable while having
a prolonged circulation within the blood, allowing a targeting of diseased tissue or cells, while providing a controlled and timely release
of the therapeutic payload.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Characteristics
of our Quatramer technology include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prolonged
    circulation</B>: the stealth nature of Quatramer allows for a prolonged circulation time resulting in accumulation at the site of
    disease prior to being cleared.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Targeted</B>:
    the size, shape and surface of Quatramer allows it to escape via gaps in the blood vessels in the TME allowing for release of the
    payload directly into cancerous cells.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Blocks
    drug efflux</B>: Quatramer composition offers reversal of p-glycoprotein mediated drug resistance in cells via generation of poloxamers
    (breakdown products comprised of small co-polymers).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tunability</B>:
    Quatramer physicochemical characterization allows for optimizing size, shape and surface chemistry based on payload characteristics
    to render enhanced permeation and retention into the TME.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ease
    of manufacturing</B>: large scale production efficiency and analysis for uniform chemistry, manufacturing and control capability
    at lower costs.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Established
    regulatory path</B>:</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> chemical compositions listed in the FDA Inactive
    Ingredients Database with known profile</FONT>.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payload
    versatility and flexibility</B>: combined with the tunability of Quatramer, the technology allows for a variety of delivery payloads
    including peptides, small molecules, nucleic acids and antibodies with the added flexibility of dual-loaded payload therapeutics.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biodegradable</B>:
                                            Quatramers ultimately breakdown into known metabolites such as lactic acid and ethanol.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Trident
Artificial Intelligence</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Trident
uses an artificial intelligence precision medicine platform to identify novel biomarkers. Trident integrates diverse public datasets,
including TCGA to identify novel gene signatures to stratify patients prospectively in clinical trials. Quatramer tumor targeting also
allows us to segment patients by exploiting Trident&rsquo;s findings by (i) synthetic lethal sensitivities with novel combinations, (ii)
pursue undruggable targets such as <I>c-myc</I> and (iii) target tumors with a high degree of cell plasticity indicative of recurrent/drug
resistant phenotype.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Trident platform:</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has the ability to create
    a Ferroptomics Atlas which integrates diverse multi-omics datasets including not only genomics, epigenetics and transcriptomics but
    also emerging proteomics data which enable identification of dynamical re-wiring of intra-tumoral signaling circuitry designed to
    target IMCD;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has the ability to identify
    biomarkers that potentially differentiate between progression of cancer plasticity and correlate it to degree of sensitivity to a
    synthetically lethal target that is induced with standard-of-care treatment and development of resistance; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is designed to classify
    and select patients that are most likely to respond to treatment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Figure
7: Trident is designed to establish clinical development</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="drsa_007.jpg" ALT="">&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Key Programs: HSB-1216 and HSB-888</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
                                            have leveraged our proprietary technologies and are developing multiple product candidates
                                            with differentiated profiles designed to address rare and treatment resistant cancers. Our
                                            HSB-1216 product candidate is an IMCD inducer delivered by our proprietary Quatramer
                                            platform. We intend to submit an IND to the FDA for approval in 2022
                                            and, if such IND is timely submitted and approved, we anticipate initial data
                                            either the end of 2022 or early 2023; however, no assurance can be provided that our
                                            IND will be accepted by the FDA in 2022, if at all. Our HSB-888 product candidate
                                            is a dual-loaded IMCD inducer that is coupled with our ultra-low dose next
                                            generation anthracycline analogue for solid tumors. We intend to include data from our
                                            own pre-clinical studies as well as the human data available from Japanese and
                                            Chinese studies to submit an IND to the FDA in first half of
                                            2023 and, if such IND is timely submitted and approved, we anticipate top-line
                                            clinical data in 2023; however, no assurance can be provided that our IND will be accepted
                                            by the FDA in 2023, if at all.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-1216:
Our Novel Iron-Medicated Cell Death Inducer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iron,
an important factor of many organisms, satisfies an assortment of vital living processes including DNA replication, protein synthesis
and cellular respiration, essential for normal growth and propagation. However, iron also produces ROS via a chemical process in which
there is a catalytic decomposition of hydrogen peroxide by ferrous ions, known as the Fenton reaction. This process may cause damage
to the membrane lipid and DNA caused by ROS, known as lysosomal membrane permeabilization (&ldquo;LMP&rdquo;) rupturing and killing the
cell by spilling its contents into the surrounding microenvironment and causing degradation in the surrounding extracellular milieu.
Emerging evidence suggests iron may have a twofold role on cells, both stimulating cell growth and causing cell death, particularly a
new form named ferroptosis, first described by the accumulation of iron-dependent lipid peroxides.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
8: Role of Iron</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="drsa_008.jpg" ALT="" STYLE="height: 416px; width: 650px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
that has been published by us with respect to</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> the active drug of
HSB-1216 targeting chemotherapy resistant tumors suggests that it sequesters iron in the lysosomes of resistant tumor cells causing LMP
of hard-to-treat cancer cells known as persister cells causing them to rupture and stop replicating. We believe an area of high interest
for the development of HSB-1216 could be SCLC or TNBC or other rare cancers with high unmet need.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Figure
9: HSB-1216 Mechanism of Action</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: -4.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="drsa_009.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">One
of the standard limitations to achieving successful cancer therapies is the manifestation of multidrug resistance (&ldquo;MDR&rdquo;)
which is a cross-resistance to many commonly used drugs after repeat dosing. Extensive evidence to this point has shown that the mechanisms
related to tumor MDR are complex and there is an urgent need to decipher the nuances of this phenomenon and discover new agents capable
of evading resistance which can be applied to a clinical strategy in cancer. MDR can be developed by various ATP-binding cassette (&ldquo;ABC&rdquo;)
transporters, including the well characterized ABCB1, also known as p-glycoprotein, which has been shown to be an important protein of
the cell membrane and can transport a variety of molecules across extra- and intra-cellular membranes. The protein is an <FONT STYLE="background-color: white">adenosine
triphosphate (&ldquo;</FONT>ATP&rdquo;) dependent drug efflux pump that transports foreign substances out of the cell including drugs
and xenobiotics with broad substrate specificity. HSB-1216&rsquo;s active drug has been shown to block this ABC transporter in numerous
studies as evidenced by drug efflux assays in MDR cell lines overexpressing these proteins by inducing a conformational change on the
transporter protein itself rendering it ineffective. Furthermore, the byproduct of the Quatramer bio-degradable process results in formation
of poloxamers which blocks the p-glycoprotein transporter system. This evidence may also allow other traditional chemotherapies, such
as paclitaxel which is highly effected by these transporters, to stay in the cell and elicit anti-tumor effects in combination with HSB-1216.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-1216
in Oncology Indications</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
drug candidate, HSB-1216, has novel characteristics which may benefit patients with hard-to-treat recurrent tumors, such as TNBC in a
number of ways. HSB-1216&rsquo;s active drug, traditionally used as an anti-coccidial drug in livestock and poultry, has been shown to
possess anti-cancer effects in a chemical screen on the basis that it has more than 100-fold potency compared to paclitaxel, a commonly
used FDA-approved anti-cancer drug. The active compound is a monocarboxylic polyether compound first isolated from <I>Streptomyces albus
</I>strain (Strain No. 80614) shown to eliminate self-renewing cancer cells which may remain dormant or undetectable in the presence
of traditional chemotherapeutics, such as paclitaxel or other agents commonly used as first-line agents in a variety of tumors. Salinomycin
alone could not be advanced further after its discovery as an anti-cancer agent for a variety reasons, including a short half-life along
with a relatively narrow therapeutic index and potential toxicities. Subsequently, other groups have shown cytotoxicity of the compound
on human neuronal cells showing it had an increase on cytosolic Na<SUP>+ </SUP>concentrations consequently resulting in elevated cytosolic
Ca<SUP>2+</SUP>. In addition, overdose or accidental ingestion of similar compounds has shown undesirable effects in cats, dogs, pigs,
horses, as well as humans<FONT STYLE="background-color: white">. </FONT>These results and other data from third parties suggest
it may be prudent to develop tissue-specific strategies to deliver the drug and prevent neuro-specific adverse events and capitalize
on the specific mechanisms of HSB-1216&rsquo;s active drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Recent
data from third parties suggest that the specific mechanisms of HSB-1216&rsquo;s active drug are three-fold which include a novel
selective iron-induced cell death known as ferroptosis, an ability to reverse a phenomenon known as EMT, as well as an ability to evade
the ABC transporters, of which the latter two are linked to multidrug resistance to commonly used cancer chemotherapies.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Clinical
Data with HSB-1216&rsquo;s Active Drug</I></B></FONT></P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                            several reasons, HSB-1216&rsquo;s active drug was not established as a human drug due to
                                            several reports published by third parties in the past decades which reveal
                                            considerable toxicity in mammals such as horses, pigs, cats and alpacas after accidental
                                            oral ingestion or inhalation. It has been relegated to use in livestock as a coccidiostat
                                            and growth promoter. The European Food Safety Authority has declared an acceptable daily
                                            intake of 5 <FONT STYLE="background-color: white">&micro;g/kg</FONT>. Based on these findings,
                                            the compound was therapeutically used in a &ldquo;first-in-man&rdquo; clinical pilot study
                                            conducted in Germany by the University of Heidelberg with a cohort of 7
                                            patients with metastatic breast, ovarian and head and neck cancers in which tumor and metastatic
                                            regression were observed clinically in 4 patients with metastatic breast cancer, 1 patient
                                            with metastatic ovarian cancer, and 2 patients with squamous cell carcinoma (1 of the head
                                            and neck and the other of the vulva). Administration of 200&ndash; 250 <I>&mu;</I>g&middot;kg<SUP>&minus;1
                                            </SUP>of active drug intravenously every second day for three weeks in these patients resulted
                                            in partial regression of tumor metastasis. Intravenous active drug therapy resulted in tachycardia
                                            and mild tremor for 30&ndash;60 minutes after administration but lacked side effects observed
                                            with conventional chemotherapeutic drugs, such as myelodepression, neutropenia, alopecia,
                                            nausea and vomiting, or gastrointestinal, thromboembolic, and neurological side effects.
                                            Only 2 of the 7 cases are described in the publication relating to this trial, both of which
                                            are detailed below showing that these promising results inducing cancer regression of
                                            heavily pretreated and therapy-resistant tumor types may define HSB-1216&rsquo;s active drug
                                            to have novel effects as a clinically significant anticancer agent.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Thirty
months prior to&nbsp;treatment with the HSB-1216&rsquo;s active drug, a 40-year-old female patient was diagnosed with unilateral ductal
breast carcinoma (post-mastectomy and axillary lymph node dissection) and subsequently experienced a recurrence of the subcutaneous multifocal
thoracic tumor that was ER, PR, and HER2 negative (i.e., &ldquo;triple negative&rdquo;) with vertebral bone metastasis. After all therapeutic
options were exhausted, experimental treatment with HSB-1216&rsquo;s active drug was recommended. The patient received 12 systemic administrations
of intravenous (&ldquo;IV&rdquo;) treatment at a dose of 200 &micro;g&middot;kg<SUP>-1</SUP> given every other day. After 12 cycles,
there was a marked regression of the subcutaneous thoracic metastases (Figure 10). A biopsy of the metastatic tissue, as investigated
by molecular histopathology, demonstrated that approximately 85% of the cells had undergone apoptosis. Additionally, serum levels of
the tumor marker Ca 15-3 decreased from 14.3 U/mL before therapy to 7.2 U/mL after therapy. Similarly, serum levels of Carcinoembryonic
antigen, another tumor marker, declined from 50.8 ng/mL to 15.5 ng/mL posttreatment. These results demonstrate that the drug was not
only able to kill hard-to-treat cancers, but also more differentiated tumor cells and more importantly, highly indolent tumor cells displaying
efficient mechanisms of resistance to cytotoxic drugs, radiation, and induction of apoptosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Figure
10: Clinical Pilot Study</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drsa_010.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
a second case study, 18 months prior to treatment with HSB-1216&rsquo;s active drug, an 82-year-old female patient was diagnosed with
advanced and metastatic (pelvic lymphatic metastasis) squamous cell carcinoma of the vulva (after radical vulvectomy and bilateral lymph
node dissection). Given a poor therapeutic response to existing treatments at the time and exhaustion of therapeutic options, experimental
treatment of HSB-1216&rsquo;s active drug in combination with erlotinib was recommended for this patient. The patient received 14 IV
administrations of the drug at a dose of 200 &micro;g&middot;kg<SUP>-1</SUP> given every other day plus erlotinib 150 mg daily for 30
days. Significant tumor regression was observed 30 days after combination therapy, based on clinical inspection of the tumor, as well
as decreased serum level of squamous cell carcinoma (&ldquo;SCC&rdquo;) antigen from 11.3 ng/mL before combination therapy to 0.13 ng/mL
after therapy. Three months post-treatment, SCC levels increased to 3.2 ng/mL, and clinical inspection demonstrated significant tumor
progression.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">After
experiencing numerous marked adverse effects with erlotinib (including fatigue, anorexia, nausea, and inappetence), the patient refused
further treatment with erlotinib and was retreated with HSB-1216&rsquo;s active drug as monotherapy. The patient received 12 IV administrations
at a dose of 200 &micro;g&middot;kg<SUP>-1 </SUP>given every other day, which resulted in no progression and stable disease for 2 weeks,
4 weeks, and 4 months post-treatment, based on clinical inspection of the local tumor and no marked changes in SCC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
11: 2012 &ndash; Human Serum Levels of the Tumor Marker Squamous Cell Carcinoma <I>in vitro</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="drsa_011.jpg" ALT="" STYLE="height: 243px; width: 450px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
results demonstrate that the drug is able to induce partial clinical regression of heavily pretreated and therapy-resistant cancers,
particularly in combination with novel tumor-targeted drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>HSB-1216
Pre-Clinical Data</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-1216&rsquo;s
active drug has been shown to target elusive cancer cells in different types of human cancers, including gastric cancer, lung adenocarcinoma,
osteosarcoma, colorectal cancer, squamous cell carcinoma, and prostate, suggesting that the drug may be effective against side populations
of many types of human cancers. The drug is able to enhance the cytotoxic effects of conventional chemotherapeutics and novel tumor-targeted
drugs in regular cancer cells, potentially playing a central role for HSB-1216-based combination therapies in the future treatment of
cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
12: HSB-1216 Inhibits Tumor Growth in SCLC Mouse Model</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;<IMG SRC="drsa_012.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">According
to the National Cancer Institute&rsquo;s Surveillance, Epidemiology and End Results, there are anticipated to be more than 230,000 new
cases of lung cancer in the United States in 2021, and according to the American Cancer Society, SCLC comprises approximately</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">10-15% <FONT STYLE="background-color: white">of all lung cancers. Although SCLC
is responsive to chemotherapy, recurrence occurs rapidly, with less than 7% of patients surviving over five years. Recently, SCLC has
shown to be responsive to immunotherapy with approximately </FONT>one-third <FONT STYLE="background-color: white">of patients responding
to</FONT> PD-1/PD-L1 <FONT STYLE="background-color: white">therapy and achieving a median overall survival of approximately eight months.
The need to rapidly advance therapeutics is an urgent, unmet medical need in these recurrent cases. In one pre-clinical mouse model of
SCLC conducted by a third party in Asia, both HSB-1216&rsquo;s active drug as well as HSB-1216 showed no antitumor activity <I>in vivo</I>,
believed to be due to lab dilution errors of the test articles. The same articles showed marked antitumor activity in a tumor sphere
model owing to the potent effects of both compounds. Our previous studies with HSB-1216 has shown a profound inhibition of tumor growth
as a once-weekly injectable product in a nude mouse xenograft models utilizing an N-H69 SCLC cell line, with three 5 mg/kg doses administered
over three weeks when compared to placebo.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
13: HSB-1216 is 2x-4x more potent against chemo-resistant SCLC cell <I>in vitro</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="drsa_025.jpg" ALT="" STYLE="height: 336px; width: 670px"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-1216
is two to four times more potent in chemoresistant SCLC. Using chemoresistant cell lines for SCLC (NCI-H69AR), our approach demonstrates
an increased potency of our compound using our Quatramer formulation when compared to standard-of-care therapies for these resistant
tumor types.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-1216
Clinical Plan in Solid Tumors</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to submit an IND for our HSB-1216 product candidate for solid tumors to the FDA in 2022, and, if approved,
we plan to conduct a Phase 1 clinical trial to obtain human pharmacokinetic data and dose optimization data on our formulation thereafter;
however, no assurance can be provided that our IND will be accepted by the FDA in 2022, if at all. Based on the data obtained
from pre-clinical studies, we believe a Phase 1 basket trial can be conducted in the US with HSB-1216 where there are limited
therapies. Even with the advent of ICIs, there remains a large patient population which either does not benefit from allowing
HSB-1216 to potentially prolong survival in ICI failures as well as recurrent disease patients.</FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-888:
Our Dual-Loaded IMCD <B>inducer and</B> Ultra-Low Dose Next Generation Anthracycline</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">HSB-888 product candidate has a component selected in pre-clinical
screens for its similar cytotoxic activity to doxorubicin accompanied by its reduced cardiac toxicity. The component drug has been in
use in Japan for more than two decades, and our clinical studies support its claim of similar efficacy to doxorubicin but with reduced
toxicity. We intend to obtain approval of this product in the United States as a drug that can be used in the treatment protocol of recurrent
osteosarcoma. HSB-888 combination could be a more tolerable therapy which may improve response rates, overall survival, and quality of
life. We intend to submit an IND to the FDA in the first half of 2023 and, if approved, we plan to initiate a clinical
trial in recurrent pediatric osteosarcoma.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
active drugs of HSB-888 have been used clinically to treat tumors such as osteosarcoma, breast cancer, lymphoma and acute myeloid leukemia
in countries outside the US such as Germany, Japan, China and India. One component compound has shown lower cardiotoxicity and greater
antitumor effect than other anthracycline agents, commonly used in these tumors, due to the fact that it is taken up by tumor cells to
a higher degree than other drugs in its class. This rapid uptake into tumor cells causes targeted incorporation into the cell&rsquo;s
DNA and causes cell cycle arrest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
in multidrug-resistant cells, we believe HSB-888 can disrupt cell cycle kinetics. Currently, the most important impediment to improving
outcomes of patients with osteosarcoma is the clinical resistance to the primary chemotherapy, MAP, which is widely used. One of HSB-888&rsquo;s
active drugs has been shown to be taken up by tumor cells approximately 170 times faster than doxorubicin and distributes its DNA into
tumor nucleus and intercalates. In MDR osteosarcoma cell lines (MG63/DOX), the drug was shown to have a marked cell inhibitory effect
in both resistant and sensitive cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a retrospective Chinese study of relapsed and refractory osteosarcoma conducted by a third party, 3 of 23 evaluable patients who
received only one of the active drugs of HSB-888 with cisplatin, had partial responses, with 1 patient after 7 cycles achieving
disease free progression for more than 29 months. In another Chinese study, the <FONT STYLE="background-color: white">5-year disease-free
survival (&ldquo;DFS&rdquo;) rate of the patients treated with the drug was 70.2%, significantly higher than that of the DOX-based regimen-treated
group (53.1%). The drug decreased the lung metastatic rate significantly compared with the DOX-based regimen (19.1% vs. 36.7%, </FONT><I>p</I><FONT STYLE="background-color: white">=0.045),
as well as the relapse rate (31.9% vs. 49.0%, </FONT><I>p</I><FONT STYLE="background-color: white">=0.067). The compound also showed
lower rates of alopecia (63.8% vs. 85.7%, </FONT><I>P</I><FONT STYLE="background-color: white">=0.012), nausea and vomiting (51.1% vs.
79.6%, </FONT><I>p</I><FONT STYLE="background-color: white">=0.003), and mucositis (48.9% vs. 75.6%, </FONT><I>p</I><FONT STYLE="background-color: white">=0.003).
It also resulted in lower cardiac toxicity and demonstrated that it is better than the DOX-based regimen in terms of the 5-year DFS rate,
pulmonary metastasis rate, relapse rate and side effects</FONT>. These data suggest that an updated regimen utilizing HSB-888 delivering
two active drugs in refractory cases in a setting that would use high-dose methotrexate along with a platinum-drug may be warranted,
and we intend to study these patients in a clinical trial, due to the high unmet need in this population.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-888
Low Dose Strategy</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemotherapies
like anthracyclines, including doxorubicin and others in its class, have been used for decades as mainstay therapy in combination with
other drugs for multiple tumor types, including osteosarcoma as first-line therapy. The most important issue is that although the regimen
may benefit patients in this setting, there is a dose-limiting cumulative effect on the patient with these cytotoxic approaches whereby,
after a maximum accumulation of dose over multiple cycles, the class of drug can longer be used in the recurrent setting for patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The
components of our HSB-888 product candidate are two anticancer drugs with distinct and complementary mechanisms of actions
(ferroptosis and DNA intercalation) which together constitute an active combination for treating osteosarcoma. We investigated whether
the efficacy of this combination could be improved by controlling drug ratios following <I>in vitro and vivo </I>administration. The
combinations were evaluated systematically for drug ratio-dependent synergy <I>in vitro </I>using multiple tumor cell lines. <I>In vitro
</I>screening informatics on drug ratio-dependent cytotoxicity identified a consistently antagonistic region between active drugs at
various molar ratios, which also showed multiple synergistic ratios, dependent on the chemical characteristics of either DNA intercalating
active drugs combined with a ferroptosis inducer. Co-formulations of these two agents were developed that maintained a fixed drug ratio
for stability and release profiling over broad timelines. Drug ratio-dependent antitumor activity was demonstrated <I>in vitro </I>and
<I>in vivo </I>for these ratios and improved antitumor activity was observed for the Quatramer 1:3 molar ratio of DNA intercalator:ferroptosis
inducer (designated HSB-888) compared to drug cocktails in models tested. HS-888, is a fixed-ratio formulation of DNA intercalator and
ferroptosis inducer, and a near-clinical candidate for development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Furthermore,
our proprietary molar ratio as seen by its <I>in vitro</I> and <I>in vivo</I> efficacy profile enables a low dose to be administered
that is presumably 5-fold to 10-fold less than the traditional DNA intercalator therapy that is currently utilized in multiple high unmet
need tumor types. This low dose strategy may allow clinicians to treat a variety of tumor types requiring cytotoxic chemotherapy without
the burden of dose-limiting toxicities for traditional chemotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-888
Synergy and Combination Index</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Extensive
research suggests cancer drug combination may act in synergy, additively or antagonistic based on drug ratios of the separate compounds
combined. While this relationship can be evaluated readily</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>in
vitro</I> <FONT STYLE="background-color: white">where drug ratios can be controlled, the translation of such information</FONT> <I>in vivo
is </I><FONT STYLE="background-color: white">complex due to the fact that individual drugs administered separately may be distributed,
metabolized and eliminated differently. This prevents control of the drug ratio following administration and may result in exposure of
cancer cells to antagonistic drug ratios with a corresponding loss of therapeutic activity.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
approach with a combination of two drugs in HSB-888 as a dual drug-loaded formulation with our Quatramer strategy circumvents multiple
hurdles when compared with administering compounds separately. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
distinguishing feature of our technology is our proprietary Quatramer delivery platform which maintains drug combinations at the desired
ratio after <I>in-vivo </I>administration. Drug combinations used to treat cancer are often encompassed with drugs which are highly varied
in chemical and physical composition as well as properties. Subsequently, formulating such drug combinations with unrelated features
into a single pharmaceutical approach that discharges both agents at the same or pre-determined different rates in the body as well as
in the tumor tissue of choice presents a significant technical challenge. We have developed the Quatramer platform to provide versatility
in controlling drug loading to specified drug loading and release rates with the precise retention properties for therapeutic agents
from drug classes important for unmet need pharmaceutical development to benefit cancer patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have specifically identified cell-based screens and identified synergistic drug combinations of HSB-1216 and HSB-888 which have markedly
different chemical attributes. With respect to our combination approach, we have controlled the ratio of the compounds in the delivery
when prepared, maintained the ratio of the compounds within the carrier system while circulating in the blood and have ensured the release
at the proper synergistic ratios when delivered to the tumor. This approach allows for the combination product HSB-888 to have different
physicochemical properties of the original drugs and allows for the co-formulation and coordinated release of both drugs with widely
different properties from the same particle.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
14: HSB-888 is 5 times more potent in synergy with HSB -12-16 <I>in vitro</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drsa_014.jpg" ALT="" STYLE="height: 241px; width: 600px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-888
Combination Drug Clinical Development Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to submit an IND to the FDA for HSB-888 in the first half of 2023 and, if approved, thereafter progress our
program into a Phase 1 study to identify the dose of our formulation that would optimize the pharmacokinetic profile of the drug in line
with the known cellular and human kinetic profiles in Japanese and Chinese studies; however, no assurance can be provided that our
IND will be accepted by the FDA in 2023, if at all. We intend to work with the FDA to further progress a Phase 2 trial in
a refractory sarcoma setting in patients who would benefit due to the cumulative doses of anthracycline regimens these patients have
already received. We intend to develop our combination strategy that incorporates our Quatramer platform using HSB-888, a dual drug-loaded
formulation that may be synergistic in mechanism to explore improved outcomes in these patients.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recurrent
Sarcoma Market Potential</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarcomas
in a broad sense are tumors which are mesenchymal in nature capable of forming in connective tissue, blood, lymphatic and vessels, believed
to also effect bone and soft tissue. They are rare and account for 1% of cancers, yet encompass about 13% of cases under the age of 20.
Most common in bone are osteosarcoma and Ewing&rsquo;s sarcoma, while those arising from soft tissue are commonly rhabdomyosarcomas.
Other sarcomas, such as desmoplastic small round cell and synovial sarcoma are more common into adolescence and young adulthood. All
of these tumors are treated with combination strategies including surgery, radiotherapy and traditional chemotherapy of various kinds
with 5-year survival rates of 60-70% depending on histology and metastatic disease at diagnosis. Metastatic disease has a poor prognosis
at about 20-30% 5-year survival, while recurrent disease is even worse at less than 20%. Recurrent osteosarcoma, either initially non-respondent
to treatment or returning after an initial response, occurs in about 30-50% of patients with local disease and upwards of 80% in metastatic
disease. The most frequent site of metastasis as well as recurrence is the lungs, and often times these patients undergo surgical resection
of the tumor prior to continuing on therapy. Research has suggested that patients can benefit from multiple surgeries, but this does
not obviate the need for systemic treatments to mitigate or eradicate the disease in recurrent cases, a significant high unmet need.
Other than palliative approaches using bone-seeking radiopharmaceuticals, limited agents have been approved for this high unmet need
tumor, predominantly in children and young adults. <FONT STYLE="background-color: white">Vascular endothelial growth factor</FONT> inhibitors
as well as <FONT STYLE="background-color: white">mechanistic target of rapamycin</FONT> inhibitors and immunotherapy have been studied
but none have been conclusive in elucidating a regimen that could be FDA-approved for this disease. Ewing&rsquo;s sarcoma, the second
most common bone sarcoma when it recurs, has a dismal prognosis with a 5-year overall survival less than 10%. Frontline therapy consists
of vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide in alternating cycles of interval compressed treatment. While
chemotherapy regimens are used in frontline treatment, there remains no standard backbone therapy for recurrent or refractory cases.
Rhabdomyosarcoma, the most common soft tissue tumor in young adults, has been historically treated with vincristine, actinomycin D, and
cyclophosphamide as standard-of-care for the last 50 years. Desmoplastic round cell tumors as well synovial sarcomas are much more aggressive
sarcomas and have had no new interventions in recurrent and refractory disease. All of these sarcomas, effecting younger patients, share
the commonality of very poor prognoses when the cancer recurs or becomes refractory to standard-of-care treatment protocols, creating
a vital urgency for novel treatments in these tumor types.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>HSB-510:
Our Novel Bifunction HDAC6-PI3K-Delta Inhibitor Downregulates &not;c-myc</I></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">HSB-510 product candidate is a novel highly targeted bifunctional
inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate <I>c-myc</I>,
a highly pursued and yet undruggable cancer drug target. The Quatramer platform achieves optimal tumor targeting and bioavailability
of the highly potent targeted small molecule. In October 2020, we renewed our Cooperative Research and Development Agreement with NCATS.
The agreement enables NCATS to use our Quatramer drug delivery platform in formulations of HDAC-PI3K-delta dual inhibitors for the treatment
of rare cancers, including AML and acute lymphoid leukemia (&ldquo;ALL&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
series of compounds were rationally designed and synthesized as novel dual PI3K/HDAC inhibitors by incorporating a <FONT STYLE="background-color: white">histone
deacetylase</FONT> pharmacophore into a PI3K inhibitor (Idelalisib) via an optimized linker. Several of these dual inhibitors were highly
potent (IC50 &lt; 10 nM) and selective against PI3K&gamma;, -delta and HDAC6 enzymes and exhibited good antiproliferative activity against
multiple cancer cell lines. The lead compound induced necrosis in several mutant and FLT3-resistant AML cell lines and primary blasts
from AML patients, while showing no cytotoxicity against several select normal cells. Target engagement of PI3K-delta and HDAC6 by the
lead were demonstrated in specific cells using the cellular thermal shift assay. The compound also showed ideal pharmacokinetic properties
in mice via intraperitoneal administration which provides a means to examine the biological effects of inhibiting these two enzymes with
a single molecule, either <I>in vitro</I> or <I>in vivo</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Studies
conducted by NCATS have shown that by disrupting multiple compensatory cytoprotective pathways, HDAC6-PI3K-delta dual inhibitors
have therapeutic value. Our primary objective in conjunction with NCATS was encapsulation of NCATS&rsquo; developed HDAC6-PI3K-delta
dual inhibitors into our proprietary, tumor infiltrating Quatramer platform to enhance delivery to malignant cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to continue our collaborative effort with NCATS through our Cooperative Research and Development Agreement, and we intend to expand
such agreement and execute a license to this novel HDAC-PI3K-delta dual inhibitor to move the compound through further pre-clinical testing
and into IND-enabling work.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>HSB-510
HDAC6 &amp; PI3K-delta Inhibitor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Histone
deacetylases (&ldquo;HDACs&rdquo;) are an important class of epigenetic enzymes that regulate gene expression by removing acetyl
groups from &epsilon;-amino lysine residues on histones. HDACs play an important role in regulating expression of various proteins, including
tumor suppressors and transcription factors. Dysregulation of HDACs is involved in cancer initiation and proliferation. HDAC inhibition
has emerged as a therapeutic approach for cancer and several inhibitors, including Vorinostat (&ldquo;SAHA&rdquo;), Romidepsin,
Belinostat, Panobinostat, and Chidamide, have been approved in recent years Pan-HDAC inhibitors, such as Panobinostat and SAHA,
modulate the acetylation status of a wide range of protein targets leading to a therapeutic response; however, these molecules also have
undesirable side-effects, including hematological, gastrointestinal, and cardiac toxicity with less than disable efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Class
I phosphoinositide 3-kinases (&ldquo;PI3Ks&rdquo;) are lipid kinase enzymes that transduce signals from cell surface receptors
(RTK, GPCR, etc.) to downstream effectors (AKT, mTOR, etc.), leading to a variety of cellular processes, including cell proliferation,
survival, differentiation, metabolism, and angiogenesis. Specifically, class I PI3Ks phosphorylate phosphatidylinositol (4,5)-bisphosphate
(PI(4,5)P2 or PIP2) in vivo to form the secondary messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3 or PIP3). The PI3K&alpha;
and PI3K&beta; isoforms are ubiquitously expressed, whereas PI3K&gamma; and PI3K-delta expression is limited to leukocytes. Aberrant
regulation of class I PI3Ks has been implicated in several cancer types, and their inhibition continues to be an active cancer therapeutic
area with at least four approved PI3K inhibitor drugs (Idelalisib, Copanlisib, Duvelisib, and Alpelisib) and several others in ongoing
clinical trials. Despite tremendous progress in the discovery of PI3K inhibitors (&ldquo;PI3Ki&rdquo;) over the past decade, clinical
trials conducted by <FONT STYLE="font-size: 10pt">third parties</FONT> with PI3Ki as a monotherapy have shown poor efficacy prompting
their evaluation in combination therapies and/or developing PI3K-based multitarget drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although
both PI3K and HDAC inhibitor drugs are limited by insufficient efficacy and resistance mutations, there is strong evidence that simultaneous
inhibition of both PI3K and HDAC can synergistically inhibit tumor growth and address these limitations by improving efficacy, limiting
resistance, and providing a better therapeutic window than single inhibitors.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Figure
15: HSB-510 - Mechanism&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><IMG SRC="drsa_015.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-114
(TNF-alpha DNA) for Metastatic Soft Tissue Sarcoma</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">TNF-&alpha;,
identified in 1975, cloned in 1984 and named for its ability to induce necrosis of induced-sarcomas in mice, is a chemokine with potent
tumoricidal properties. However, severe systemic toxicity (capillary leakage, disseminated coagulopathy, acidosis and shock) limited
its use as an anticancer agent, until procedures were developed to use the cytokine in the clinic where high concentrations were infused
into isolated limbs of sarcoma and melanoma subjects. It has since been shown that direct intratumoral injection can augment ICIs by
slowing progression of tumors in various models, with unreliable efficacy due to the fact that levels of TNF produced must be sufficient
to attract specific T cells to the tumor via signaling, notwithstanding TNF&rsquo;s direct antitumor necrotic effects. Despite the potential
to activate tumor cell death, physiological intratumoral levels of sufficient TNF concentrations are unlikely to induce cancer regression
in patients utilizing the current strategies available to deliver this potent cytokine. Finding ways to selectively increase intratumoral
TNF levels in tumors while managing the toxicity associated with such approaches remains a major unmet need.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">HSB-114 product candidate is a novel immunotherapeutic agent
which uses our proprietary Quatramer technology to deliver the human TNF-&alpha; gene to cancer cells. Previous immunotherapeutic strategies,
including the payload of HSB-114, pHSB-114, used adenovector technology requiring replication deficient gene deletions and complex manufacturing
controls in order to deliver the gene to the desired cells, although posed a theoretical risk of systemic toxicity and adjacent tissue
damage due to overflow of TNF-&alpha; in blood from the tumor, had some dose-limited toxicities. <FONT STYLE="background-color: white">In
early phase trials of pHSB-114 in combination with radiotherapy conducted by GenVec Inc. (&ldquo;GenVec&rdquo;), significant clinical
activity was observed in patients with metastatic melanoma, soft tissue sarcoma and locally advanced esophageal cancer. Anti-tumor activity
was also observed in patients with pancreatic, rectal, and head and neck cancers. However, a Phase 3 trial conducted by GenVec
in patients with locally advanced pancreatic cancer failed to demonstrate a survival benefit prompting discontinuation of the development
of this agent.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our novel non-viral immunotherapeutic TNF-&alpha; gene therapy, HSB-114, builds on the pHSB-114 clinical development program
with improved scalability and tunability providing efficacy with an overall enhanced safety profile to potentially minimize dose-limited
toxicities. We <FONT STYLE="background-color: white">have developed HSB-114 via a modified Quatramer delivery system which includes a
peptide-DNA complex designed for maintaining the balance of DNA condensation and intracellular release and nuclear localization. For
delivery <I>in vivo</I>, the system circumvents the challenge of DNA-nanoparticle serum interactions that have limited this field from
progressing without use of a viral vector delivery scheme. Our results demonstrate that this approach is highly effective in conferring
TNF-induced anti-tumor activity in the absence of toxicity (</FONT>Figure 5<FONT STYLE="background-color: white">).</FONT><FONT STYLE="background-color: white">
Our findings further indicate that this system maybe broadly applicable for expression of intratumoral cytokines that promote immune
recognition and destruction.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
16: 2017 &ndash; Antitumor Activity of HSB-114 in Mouse Model</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drsa_016.jpg" ALT="" STYLE="height: 134px; width: 570px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinical
Data with pHSB-114</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
Phase 1 studies conducted by a third party evaluated TNF-&alpha; gene transfer therapy using a radiation-inducible polymer combined
with ionizing radiation therapy in patients with soft tissue sarcoma and solid tumors. This combination therapy optimizes the therapeutic
index of TNF-&alpha; by facilitating a synergistic supra-additive interaction between the two therapeutic modalities by selective destruction
of the tumor vasculature leading to tumor necrosis. Further, this strategy allows for direct cellular toxicity by locally targeted induction
of high concentrations of TNF-&alpha; within the tumor with minimal systemic toxicity. The studies, summarized below, provide preliminary
evidence that pHSB-114 + radiotherapy is feasible, well tolerated, and provides a potential alternative to isolated limb perfusion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase
I Study in Soft Tissue Sarcoma of the Extremities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Phase 1 dose-escalation study evaluated pHSB-114 and concomitant ionizing radiation therapy for up to 5 weeks in 14 adult patients with
soft tissue sarcoma of an extremity. pHSB-114 was administered by intratumoral injection, twice weekly during the first week and once
weekly during weeks 2-5 of radiation therapy. Three escalating dose levels of pHSB-114 were administered, with 3-6 patients treated per
dose level, starting with a dose of 4 &times; 10<SUP>9</SUP> particle units (&ldquo;pu&rdquo;) and escalating in 1-log increments to
a dose of 4 &times; 10<SUP>11 </SUP>pu or until the maximal tolerated dose (&ldquo;MTD&rdquo;) was reached. There was no intrapatient
dose escalation. Concomitant single-daily fractionated radiation was administered 5 days per week (total dose, 36-50.4 Gy). Surgery was
performed in 11 patients whose tumor was resectable 3&ndash;9 weeks after radiotherapy ended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
objective tumor response was observed in 11 patients, or 85%; of these, 2 were complete responses and 9 were partial responses. Of the
11 patients who had surgery, all were resected with negative margins. Pathological complete response was observed in 2 of the 11 patients.
Of the 8 patients who had partial response, 4 had &ge; 95% tumor necrosis, which prognostically carries an improved long-term survival.
Of the 2 patients who did not have surgery and received pHSB-114 for palliation, 1 had stable disease and the other had partial response.
Tumor response assessment was not consistent between results obtained via computed tomography (&ldquo;CT&rdquo;) and those obtained via
histological assessment after resection, whereby CT scans showed less response than pathological assessment in 9 of the 11 patients who
had surgery, suggesting that the magnitude of the true anti-tumor response rate of pHSB-114 with ionizing radiation may be underestimated
by CT scans, particularly if performed shortly after the end of treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HSB-1218:
Research in Treating COVID-19</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Coronaviruses
(&ldquo;CoVs&rdquo;) are important human and animal pathogens, and at the end of 2019, a novel coronavirus emerged as the cause of a
cluster of pneumonia cases in Wuhan, China. Since then the virus identified as severe acute respiratory syndrome coronavirus 2 (&ldquo;SARS-CoV-2&rdquo;)
has been identified to causes the designated as COVID-19. According to GlobalData Inc. global cases of COVID-19 have reached over 214
million confirmed cases and more than 4.4 million reported deaths as of August 26, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
there are no specific clinical features which can reliably distinguish COVID-19 from other viral respiratory infections, development
of dyspnea, anosmia and myalgias were strongly associated with a positive microbiologic test. There has been much research on finding
effective vaccines and therapeutics against SARS-COV-2, including remdesivir, chloroquine or hydroxychloroquine, convalescent plasma
and other antibody based therapies, as well as IL-6 inhibitors, direct and indirect acting antivirals, immunomodulatory agents as well
as antibiotics including azithromycin, and anti-helminthics such as ivermectin are all in various stages of testing and clinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
has been reported that CoVs present and adhere to host cells via Angiotensin-Converting Enzyme-2 (&ldquo;ACE-2&rdquo;) receptor-mediated
endocytosis, which is a pH-dependent process. In this process, Spike (S) protein plays a major role in receptor binding and membrane
fusion of SARS-CoV-2 for access into host cells. It is a large transmembrane protein on the surface of the virus consisting of two subunits,
including the S1 subunit necessary to fit with the ACE-2 receptor for viral entry. Subsequent to binding, SARS-CoV-2 enters the cytosol
of the host cell, by pH-dependent proteolytic cleavage of spike protein by transmembrane protease serine 2, a plasma membrane-anchored
protease that participates in proteolytic cascades of several human proteins, including those relevant to the normal function of the
human prostate. This host protein primes the S1 subunit and promotes viral uptake and host cell entry. Then, the combination of viral
and host cell membranes occurs in acidified endosomes, permitting viral genomes to affect host cells with the aid of the S2 subunit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">HSB-1218 product candidates uses our Quatramer tunable technology
to encapsulate a potent antiviral and deploy the agent either systemically or in an inhaled formulation to target SARS-CoV-2. Evidence
suggests the payload of HSB-1218&rsquo;s active drug inhibits replication of viral RNA in the cytoplasm by altering the pH. We believe
this product candidate has the potential to prevent the entry of SARS-CoV-2 into the cytosol and prevent membrane fusion (a pH-dependent
process). Further, it has been reported to interact with the S-protein, and impact ACE-2 attachment and impede the release of viral RNA
into the cytoplasm identifying the active component as a <FONT STYLE="background-color: white">potential antiviral agent against SARS-CoV-2.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
recent data supports the use of HSB-1218 with data generated in a BSL3 laboratory which grew SARS-CoV-2 virus in the commonly used Vero
E6 cell line. These cell lines were seeded into 96 well tissue culture plates and incubated overnight followed by the addition of HSB-1218
and a 6 h SARS-CoV-2 challenge at various multiplicity of infection concentrations to measure the 50% tissue culture infectious dose
(&ldquo;TCID<SUB>50</SUB>&rdquo;). At concentrations of 1 and higher &micro;M doses, HSB-1218 significantly reduced the production of
infectious SARS-CoV-2 TCID<SUB>50 </SUB>values at 24 hours. We are continuing further mechanistic studies in order to identify the antiviral
effect of HSB-1218 against SARS-CoV-2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
17: HSB-1218 - Dose dependent effect of HSB-1218 in an <I>in vitro</I> COVID-19 Model</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="drsa_017.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
believe HSB-1218, which utilizes our Quatramer delivery technology, may offer an approach for effective use of this agent as an antiviral
delivered to the site of infection in attacking SARS-CoV-2, and we intend to continue to develop this compound and seek government and
other funding to further develop this program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Iron
Mediated Cell Death Inducer Analogues Program</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
December 2019, we acquired intellectual property and data related to analogues of HSB-1216&rsquo;s active drug with varying molecular
constructs with increased efficacy against a subgroup of tumors consisting of breast, pancreatic and prostate cancers. Several lead analogues
have demonstrated increased potency when compared to HSB-1216&rsquo;s active drug, whereby the increased potency of these compounds is
expected to have ferroptotic effects greater than HSB-1216&rsquo;s active drug at micro-dosage levels, creating an increased therapeutic
index as novel small molecules. We expect to develop these advanced compounds as follow-on therapeutics to HSB-1216 to treat a variety
of high unmet needs, including orphan cancers, which are sensitive to the ferroptotic pathway.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Quatramer
Technology</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Our
proprietary Quatramer technology is based on know-how and permits manufacture of uniform size polymer aggregates that can be packaged
and tuned specifically to interact with pharmaceutical drugs, biological molecules and/or combinations of molecules to bypass delivery
problems. The system is biocompatible and can be tailored to form therapeutics which solubilize the drug in aqueous media such as human
plasma and blood which dramatically increases the amount of drug available at the disease site while administering a lower dose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Figure
18: Quatramer Platform - Disintegration</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drsa_018.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
studies</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> have shown that targeted delivery of drugs to a site of action,
including tumors, is directly related to the length of time of a circulating therapeutic in the bloodstream. This is an expected outcome
as most drug delivery formulations delivering payloads to sites of action are cleared extremely rapidly by the reticuloendothelial system
(&ldquo;RES&rdquo;) in the liver. The stealth nature of our technology allows for a prolonged circulation time whereby there is accumulation
at the site of disease prior to being cleared.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Figure
19: SEM of Quatramer </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drsa_019.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
size, shape and surface of our Quatramer allows it to escape via gaps in the blood vessels in the TME allowing for release of the payload
directly into cancerous cells. Furthermore, the system functions as a &ldquo;peeling onion&rdquo; in coordinated and precise acidic versus
basic conditions depending on the TME as well as inside cancerous cells. Certain portions of the technology release a payload due to
its own physicochemical characteristics while the core of the Quatramer system would release a different payload depending on its own
chemical and physical properties. This type of a profile for certain of our Quatramer therapeutics, particularly our combination products,
are specifically designed to cleave or disperse in response to external stimuli causing internal changes for delivery and is a designed
approach to our size tunable vehicles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
designed size tunable feature of certain of our Quatramer compositions offer further advantages, as certain cleaved materials create
a reversal of drug resistance in cells. <FONT STYLE="background-color: white">Drug resistance can be classified into two categories:
<I>de novo</I> resistance or acquired resistance. Cancer patients that exhibit <I>de novo</I> resistance do not respond to chemotherapy
from the start. However, in acquired resistance, the cancer cells initially respond to a drug but eventually acquire resistance to it
and the cells might also show cross-resistance to other structurally and mechanistically unrelated drugs, a phenomenon commonly known
as MDR whereby treatment regimens that combine multiple agents with different targets are no longer effective. Our Quatramer technology
circumvents this phenomenon upon cleavage of the payload from the system, whereby the remnants of the system, such as certain hydrophobic
chains flanked by hydrophilic chains which are not related to therapeutic efficacy, cause drug efflux pump blockage and allow the payload
to continue to be effective in MDR cellular systems both <I>in vitro</I> and <I>in vivo</I>.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Quatramer
physicochemical characterization allows for optimizing size, shape and surface chemistry based on payload characteristics to render enhanced
permeation and retention into the TME. Our scientific know-how and scientific expertise in developing Quatramer based therapeutics has
led to understanding the optimal conditions for encapsulating therapeutics of different physicochemical characteristics into our proprietary
delivery, and the combination of multiple materials used varies depending on the drug itself, causing a highly specific tunability platform
that can be scaled. The proprietary know-how behind our Quatramer structures with multiple layering allows for therapeutics of different
levels of hydrophilicity and hydrophobicity to interact within aqueous mediums of varied acid-base conditions, including human serum
and blood. The importance of the Quatramer structure extends the certain aspects of the core and thereby has the capacity to increase
drug uptake and sustain its release over long periods of time, including over many days and weeks in both <I>in vitro</I> and <I>in vivo
</I>systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Quatramer technology has been designed to be a scalable process with production efficiency whereby the analysis of the output of a designed
chemistry, manufacturing and controls system creates a predictable and uniform product with controllable capability and cost efficiency.
Chemical compositions listed in the FDA Inactive Ingredients Database with known profile. Combined with the tunability of Quatramer,
the technology allows for a variety of delivery payloads including peptides, small molecules, nucleic acids and antibodies with the added
flexibility of dual-loaded payload therapeutics. The payload diversity and flexibility of the system coupled with its numerous advantages
allows for a targeted system with prolonged circulation time, which takes advantage of an efficient EPR effect with numerous mechanistic
features deployed at various conditions with the TME as well as in intracellular environments, which makes the methodology of Quatramer
therapeutics, a highly advantageous platform to deliver low doses of therapeutics directly to tumors.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
Artificial Intelligence Platform</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Overview</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tumor
cells are constantly undergoing phenotypic switching that may or may not be dependent on the drug target and without additional secondary
genetic mutations but are now understood to engage three different mechanisms: EMT, Dedifferentiation/Trans differentiation and Treatment-induced
tolerance. These stepwise phenotypic transitions through a slow cycling state potentially induce a synthetic lethal sensitivity of key
driver functional pathways making them amenable to novel therapeutic strategies. These phenotypic transitions present novel opportunities
for targeting specific drug pathways and gene circuits which none of the conventional approaches are designed to do.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
recognize these dynamical aspects which make cancer a constantly evolving progressive disease and are taking a biomarker-guided approach
to drug development that will maximize treatment benefit for patients. We are developing TAI, a drug targeting technology platform, to
enable the development of rational therapeutic strategies to target the plasticity of cancer cells associated with drug resistance. TAI
aims to establish clinical development by applying state-of-the-art deep learning artificial intelligence technologies to patient-based
multi-modal datasets.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Trident platform:</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
    the ability to create a Ferroptomics Atlas which integrates diverse multi-omics datasets including not only genomics, epigenetics
    and transcriptomics but also emerging proteomics data which enable identification of dynamical re-wiring of intra-tumoral signaling
    circuitry designed to target IMCD;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
    the ability to identify biomarkers that potentially differentiate between progression of cancer plasticity and correlate it to degree
    of sensitivity to a synthetically lethal target that is induced with standard-of-care treatment and development of resistance; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
    designed to classify and select patients that are most likely to respond to treatment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
is based on a deep learning engine that identifies synthetic lethal sensitivities associated with degree of cell plasticity using biomarkers
that can be translated for patient selection. Trident is designed to maximize enrichment for patients who are most likely to respond
to treatment and thus de-risks clinical development.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cell
plasticity is a leading contributor to drug resistance</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tumor
cells are constantly undergoing phenotypic switching that may or may not be dependent on the drug target and without additional secondary
genetic mutations. Three critical mechanisms are understood to be involved which are engaged more or less simultaneously.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
are EMT, dedifferentiation and transdifferentiation, and transient drug-induced tolerance. EMT is characterized by both morphological
and molecular changes characterized by loss of apical-basal polarity and epithelial cell junctions leading to changes in cellular composition
of basement membrane, altering intra- and inter- cellular signaling, and eventually resulting in metastasis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">At
the same time, distinct compartments of the epithelium maintained by different pools of resident stem cells begin to transdifferentiate
or even reverse completely and dedifferentiate upon treatment. For instance, <FONT STYLE="background-color: white">epidermal growth factor
receptor</FONT> (&ldquo;EGFR&rdquo;)-driven non-SCLC are observed to convert towards a SCLC phenotype upon EGFR inhibition and melanoma
cells dedifferentiate progressively through transitory and neural crest-like states under <FONT STYLE="background-color: white">v-raf
murine sarcoma viral oncogene homolog B1 </FONT> inhibitor treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Figure
                                            20: Cell plasticity is a leading contributor to drug resistance</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drsa_020.jpg" ALT="" STYLE="height: 269px; width: 500px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Lastly,
tumor cells undergo a slow-proliferating drug-tolerant state, called drug-tolerant persisters, before further developing secondary mutational
drug-resistance. This phenomenon has been observed in glioblastomas, melanomas and non-SCLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collectively,
these stepwise transitions through a slow cycling state potentially induce a synthetic lethal sensitivity of key driver functional pathways
making them amenable to novel therapeutic strategies. This presents a novel opportunity for drug targeting to identifying treatment-induced,
state-specific, synthetically lethal drug-target pairs.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conventional
approaches to drug targeting are limiting</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conventional
approaches to drug targeting are not equipped to handle the challenges of identifying synthetic lethal drug-target pairs. Signature-reversion
principles or guilt-by-association strategies used to uncover drug-drug or drug-disease similarity have yielded few successes due to
large transcriptional differences between in vitro long-lived cell lines and in vivo tumor macroenvironment. Chemical similarity approaches
have their pitfalls - errors in chemical structures as well as physiological effects that exist beyond the structural relationship limit
the use for drug targeting. Structure-based molecular docking virtual screens, for predicting drug-target pairs, are limited by lack
of widespread availability of 3D protein structures for drug targets and poor predictability of target binding affinity. Pathway- or
network-based approaches to integrate gene expression patterns, protein interactions and genome-wide association study data help identify
enrichment of drug targets but do not yield biomarkers that can be translated for patient selection. None of these approaches are designed
to search for context-specific synthetic lethal targets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
21: Conventional approaches to drug repurposing are limiting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="drsa_021.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Trident
is a Deep Learning Engine that identifies synthetic lethal sensitivities associated with degree of cell plasticity</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
takes a multi-pronged approach to address each of the leading causes of tumor plasticity as the disease progresses namely EMT, dedifferentiation/transdifferentiation,
and transient drug-induced tolerance and sensitivity. The platform builds on a deep foundation of diverse multi-modal and multi-omic
private and public datasets which include not only genomic and transcriptomic data from patient derived blood or biopsy samples and sublines,
and pan-cancer epigenetic and transcriptional drug response data from TCGA, Cancer Cell Line Encyclopedia and Genomics of Drug Sensitivity
in Cancer, but also human cancer proteome datasets from emerging global efforts that include Human Cancer Proteome Project, The Cancer
Proteome Atlas and The National Cancer Institute&rsquo;s Clinical Proteomic Tumor Analysis Consortium. Inclusion of proteomics data is
very critical for identifying dynamical re-wiring of intra-tumoral signaling circuitry which is likely to be missed if one looks at the
genomic and transcriptomic level alone.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
is a deep learning engine that integrates <I>in vitro</I> and <I>in vivo</I> epigenetic, transcriptomic and proteomic data characterizing
genomic alterations, methylation states, cellular differentiation, and drug tolerance to identify:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomarker
                                            fingerprints that deconvolve a heterogenous tumor biopsy into a discrete phenotypic state
                                            along a gradient of progressive cellular plasticity;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Network
                                            of dis-regulated functional pathways that underscore a patient&rsquo;s pathology; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indication-specific
                                            synthetic-lethal sensitivities to drugs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
utilizes state-of-the-art convolutional neural networks to classify and select patients based on their tumor-derived multi-comic profiles
thus enabling a targeted synthetic-lethal approach to kill persistent tumor cell populations and treat patients in select indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
22: Trident identifies synthetic legal sensitivities associated with degree of cell plasticity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="drsa_022.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Trident
maps the phenotypic tumor transition from a high-dimensional landscape onto a quantitative, measurable one-dimensional scale</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
traces the complex high-dimensional landscape of tumor progression to identify biomarkers that mark milestones in this continuum and
enable quantification of degree of plasticity along the trajectory. Trident&rsquo;s deep learning engine trains a model that can reduce
this high-dimensional information into a one-dimensional quantitative and measurable scale which provides the degree of plasticity in
a biopsy sample or cell line dataset. Trident&rsquo;s unbiased search in the vast repository of multi-modal datasets enables identification
of synthetic lethal sensitivities that correlate linearly but contrast with degree of plasticity. This biomarker-guided, state-specific
approach enables to successfully deconvolve signals from a heterogenous tumor biopsy into a discrete phenotypic state along a gradient
of progressive and divergent cellular plasticity and complementary synthetic lethal sensitivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
23: Trident maps the phenotypic transition of tumor onto a quantitative, measurable one-dimensional scale</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="drsa_023.jpg" ALT="" STYLE="height: 194px; width: 511px"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Trident
is designed to establish clinical development and deliver on the promise of precision medicine</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trident
is designed to deliver on our ultimate goal, which is to identify and treat the right patients that are most likely to benefit from treatment.
Using Trident, biomarkers measured in patient blood/biopsy samples will assist in determining the degree of plasticity for a specific
patient, which will then directly inform about a patient&rsquo;s sensitivity to activation/inhibition of the synthetically lethal target
and probability of successful treatment. More than just de-risking clinical development, Trident aspires to deliver on the promise of
precision medicine by building a platform based on the robust foundation of patient-based biomarker research and deep learning artificial
intelligence technologies. Trident has successfully identified biomarkers correlating dedifferentiation in melanoma with sensitivity
to inhibitors of ferroptosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
24: Trident is designed to establish clinical development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="drsa_024.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
goal is to disrupt the biotechnology landscape by developing novel therapeutics by leveraging both our targeted-delivery Quatramer platform-based
therapeutics and our TAI platform to address significant unmet medical needs, with a focus on treatments for cancer. We believe that
our technology has the potential to generate differentiated products that hav<FONT STYLE="font-size: 10pt">e the potential to treat rare
and treatment resistant tumors.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business strategy includes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Developing
    drug candidate, HSB-1216, in solid tumors.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
from a clinical pilot study conducted in Germany by the University of Heidelberg led us to progress HSB-1216 into IND-enabling
studies with the goal of submitting an IND to the FDA in 2022. These IND-enabling trials are pre-clinical in
nature and include toxicology and pharmacokinetic profiling as well as bioanalytical assay development. We engaged in discussions with
the FDA in 2020 and expect to use the 505(b)(1) FDA approval pathway and conduct a Phase 1 trial to obtain initial pharmacokinetic and
dosing information in patients. We intend to evaluate the development of HSB-1216 in other high-unmet need oncology indications, including
certain brain, breast and prostate cancers, and in combination with other cancer therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Developing
    our combination drug candidate, HSB-888, for pediatric sarcomas.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888
is in IND-enabling trials with the goal of submitting an IND to the FDA in the first half of 2023. These trials
are pre-clinical in nature and include toxicology and pharmacokinetic profiling as well as bioanalytical assay development. Based on
this data we plan to initiate discussions with the FDA in 2021 and intend to use the 505(b)(1) FDA approval pathway and conduct a Phase
1 trial for obtaining initial pharmacokinetic data and determine the optimized dose in patients. We intend to demonstrate the safety
and efficacy in a Phase 2 program in a basket trial enrolling patients with recurrent cancers due to multiple sarcomas, including
Ewing&rsquo;s sarcoma, rhabdomyosarcoma and eligible osteosarcoma patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leveraging
    our Trident Artificial Intelligence Platform.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAI
is a computational intelligence platform that identifies synthetic lethal sensitivities associated with degree of cell plasticity. We
undertake a multi-pronged approach to address each of the leading causes of tumor plasticity as the disease progresses including epithelial
to EMT, dedifferentiation/transdifferentiation, and transient drug-induced tolerance and sensitivity. The platform builds on a deep foundation
of diverse multi-modal and multi-omic private and public datasets which include not only genomic and transcriptomic data from patient
derived blood or biopsy samples and sublines, and pan-cancer epigenetic and transcriptional drug response data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Developing
    and commercializing Quatramer in collaboration with leading pharmaceutical companies.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our internal development programs, we actively seek opportunities to collaborate with recognized biopharmaceutical companies
to develop Quatramer incorporating therapeutic payloads from their proprietary product portfolios. We intend to establish collaborations
with industry leaders and strategic pharmaceutical organizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leveraging
    our novel platform to develop a pipeline of high value Quatramer leads.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tunability of our technology allows us to efficiently expand our pipeline of Quatramer, both on our own and in collaboration with others,
through various combinations of targeted DNA encoded for anti-tumor cytokines and therapeutic payloads, which enables us to move into
other areas of oncology, including immuno-oncology whereby we could potentially increase the effectiveness of ICIs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Commercializing
    proprietary Quatramer based products, including HSB-1216, directly in the United States and with collaborators outside the United
    States.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
own</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> HSB-1216 and our other proprietary pipeline and expect to maintain
similar rights with respect to other proprietary Quatramer we develop. We intend to build a focused oncology sales organization to market
Quatramer in the United States following FDA approval. Outside the United States, we expect to rely on collaborators to commercialize
proprietary approved Quatramer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Continuing
    to extend and protect our product technology and Quatramer through our intellectual property portfolio.</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to protect our novel platform through U.S. and international patents as well as know-how and trade secrets relating to the design
and manufacturing of our technology. We expect to continue to file patent applications as we apply our technology to new targets and
therapeutic payloads. In addition, we believe the heightened regulatory requirements for generics of this technology may strengthen the
protection afforded by our intellectual property portfolio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Team</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Our
Chief Executive Officer and directors have</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">
extensive scientific, drug development, and commercialization experience across pertinent disciplines including oncology; small molecule,
peptide and antibody drug manufacturing and quality; clinical drug development, and commercialization. Our Chief Executive Officer
and directors have held various research, clinical development, artificial intelligence, strategy, corporate development and operational
positions at large biopharmaceutical companies</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">, <FONT STYLE="background-color: white">public
biotechnology companies, and universities having worked at companies such as DuPont Merck Pharmaceuticals, Amgen Inc.,
Exelixis, Inc., Salix Pharmaceuticals, Inc., Global Cancer Research Institute, Sanofi and UCLA School of Medicine.
Our Chief Executive Officer and directors have been involved in the discovery, development, manufacturing and commercialization
of multiple marketed products across various therapeutic areas, including, but not limited to, Cabometyx<SUP>&reg; </SUP>(cabozantinib),
Remicade<SUP>&reg;</SUP> (infliximab) and Clolar<SUP>&reg; </SUP>(clofarabine).</FONT></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis
on proprietary products and intellectual property. We face competition from m</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ajor
multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and start-up
companies, universities and other research institutions both in the United States and internationally. Any drug candidates that we successfully
develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical
testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions
in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number
of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel
and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary
to, or necessary for, our programs. Earlier stage companies, such as smaller discovery phase biotechnology companies, may also prove
to be significant competitors, particularly through collaborative arrangements with large and established companies. Some of our competitors
include BridgeBio Pharma, Inc. (Ferro Therapeutic, Inc.), Bayer AG and The Broad Institute of MIT and Harvard, Moderna Inc. and Takeda
Pharmaceutical Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective,
have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors
also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours. In addition, our
ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of generic products.
Generic products are currently on the market, including the therapeutics payload in HSB-1216 and HSB-888, for the indications that we
are pursuing, and additional products are expected to become available on a generic basis over the coming years. If our drug candidates
achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy and targeted drug
therapy. There are a variety of available drug therapies marketed for solid tumors. In many cases, these drugs are administered in combination
to enhance efficacy. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis, including
drugs in the same therapeutic class as the payloads contained in HSB-1216 and/or HSB-888. Many of these approved drugs are well established
therapies and are widely accepted by physicians, patients and third-party payers. In general, although there has been considerable progress
over the past few decades in the treatment of solid tumors and the currently marketed therapies provide benefits to many patients, these
therapies all are limited to some extent in their efficacy and frequency of adverse events, and none of them are successful in treating
all patients. As a result, the level of morbidity and mortality from solid tumor cancers remains high.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
are also a number of products in late-stage clinical development to treat solid tumors including, but not limited to, Merck &amp; Co
Inc. (Keytruda), Bristol-Myers Squibb Co. (Opdivo), AbbVie Inc. (Imbruvica), Roche Group (Tecentiq), Regeneron Pharmaceuticals, Inc.
(Libtayo) and Eli Lilly &amp; Co (sintilimab). These products in development may provide efficacy, safety, convenience and other benefits
that are not provided by currently marketed therapies. As a result, they may provide significant competition for our product candidates
for which we obtain marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
Property</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends on our intellectual property, and we strive to protect it, by, among other things, obtaining, maintaining,
defending, and enforcing our patents in the United States and internationally for our proprietary technology, improvements, platforms,
products and components thereof, novel biological discoveries, new therapeutic approaches and potential indications, and other inventions
that are important to our business. For our product candidates, generally we initially pursue patent protection covering compositions
of matter, methods of production, and methods of use. Throughout the development of our product candidates and technologies, we will
seek to identify additional means of obtaining patent protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 17, 2021, our utility patent portfolio includes six patent families, as set forth below. These families include issued
patents and pending applications related generally to our polymeric nanoparticle technologies, methods of making our polymeric nanoparticle
technologies, and methods of using our polymeric nanoparticles therapeutically (<I>e.g</I>., for delivery of therapeutic compounds).
We own all of the patents set forth below and currently do not out-license any of our patents to third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
Family #1 (HSB-1216; HSB-510; and HSB-114):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 21%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 21%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles and A Process of Preparation Thereof</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validated
    CH, DE, ES, FR, GB, IT, NL</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2033</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles and A Process of Preparation Thereof</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles and A Process of Preparation Thereof</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2033</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles and A Process of Preparation Thereof</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2033</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles and A Process of Preparation Thereof</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles and a Process of Preparation Thereof</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2034</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles and a Process of Preparation Thereof</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
Family #2 (HSB-1216):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 21%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 21%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Salinomycin</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Salinomycin</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Salinomycin</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Salinomycin</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Salinomycin</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
    Korea</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Salinomycin</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Salinomycin</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
Family #3 (HSB-114; HSB-888 and HSB-510):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 21%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 21%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
Family #4 (HSB-114):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 21%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 21%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
    Korea</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
Family #5 (HSB-407):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 21%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 21%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
    Korea</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
Family #6 (HSB-1216):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 21%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 21%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salinomycin
    Derivatives and Therapeutic Uses Thereof</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2036</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of individual patents depends on the legal term for patents in the countries in which they are obtained. In most countries, including
the U.S., the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the U.S., the term of
a patent may be lengthened by patent term adjustment (&ldquo;PTA&rdquo;), which compensates a patentee for administrative delays by the
USPTO in examining and granting a patent or the term of a patent may be shortened if a patent is terminally disclaimed over an earlier
filed patent. The term of a patent that covers a drug or biological product may also be eligible for patent term extension (&ldquo;PTE&rdquo;)
after FDA approval for a portion of the term effectively lost as a result of the FDA regulatory review period, subject to certain limitations
and provided statutory and regulatory requirements are met. PTE can be for no more than five years, typically only one patent per approved
product can be extended, the extension cannot extend the total patent term beyond 14 years from approval, and only those claims covering
the approved drug, a method for using it or a method for manufacturing it may be extended. In addition, the length of the adjustment
or extension granted could be less than that requested, and we may not receive the full PTA or PTE available if we fail to exercise due
diligence during the testing phase or regulatory review process, fails to apply within applicable deadlines, fails to apply prior to
expiration of relevant patents, or otherwise fails to satisfy applicable requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on trade secrets and know-how and continuing technological innovation to develop and maintain our competitive
position. However, trade secrets and know-how can be difficult to protect. We take measures to protect and maintain the confidentiality
of proprietary information in order to protect aspects of the business that are not amenable to, or that we do not consider appropriate
for, patent protection. We require employees, consultants, outside scientific partners, sponsored researchers and other advisors to execute
confidentiality agreements with us on or prior to the commencement of employment or consulting relationships with us. These agreements
also require such individuals to assign to us any inventions conceived in the course of employment or consulting relationships with us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also filed a trademark applications with the USPTO for &ldquo;HILLSTREAM BIOPHARMA&rdquo; for pharmaceutical preparations
for use in cancer treatment and therapies&rdquo; and for &ldquo;QUATRAMER&rdquo; for nano particle technologies and nanoparticle
technologies for cancer therapy and treatment, namely, drug delivery agents in the form of nanoparticles that provide controlled release
of active ingredients for a wide variety of pharmaceuticals for the treatment of cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate any facilities in which we can formulate or manufacture our product candidates. We intend to rely on contract manufacturers
to produce all materials required to conduct pre-clinical studies and clinical trials under cGMPs, with oversight of these activities
by our management team. We have identified alternate sources of supply and other contract manufacturers that can produce materials for
our pre-clinical and clinical trial requirements on a timely basis. However, if an existing or future contract manufacture fails to deliver
on schedule, or at all, it may delay or interrupt the development process for our product candidates which may have an adverse effect
on our operating results and estimated timelines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Government
Regulations</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
authorities in the U.S. and other countries extensively regulate the research, development, testing, manufacture, labeling, promotion,
advertising, distribution and marketing of pharmaceutical products such as those being developed by us. In the U.S., the FDA regulates
such products under the FDCA and implements related regulations. Failure to comply with applicable FDA requirements, both before and
after approval, may subject us to administrative and judicial sanctions, such as a delay in approving or refusal by the FDA to approve
pending applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions and/or criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
Food and Drug Administration Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>United
States Drug Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs, medical devices and combinations of drugs and devices, or combination products, under the
FDCA and its implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations. The process
of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations
requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any
time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial
sanctions. These sanctions could include, among other actions, the FDA&rsquo;s refusal to approve pending applications, withdrawal of
an approval, a clinical hold, untitled or warning letters, requests for voluntary product recalls or withdrawals from the market, product
seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution,
disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the United States generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
    of extensive pre-clinical laboratory tests, animal studies and formulation studies in accordance with applicable regulations, including
    the FDA&rsquo;s Good Laboratory Practice regulations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND, which must become effective before human clinical trials may begin;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with an applicable IND and other clinical study related regulations,
    sometimes referred to as GCPs, to establish the safety and efficacy of the proposed drug for its proposed indication;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an NDA;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the product, or components thereof,
    are produced to assess compliance with the FDA&rsquo;s cGMP requirements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    FDA audit of the clinical trial sites that generated the data in support of the NDA; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the NDA prior to any commercial marketing or sale.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a pharmaceutical product candidate is identified for development, it enters the pre-clinical testing stage. Pre-clinical tests include
laboratory evaluations of product chemistry, toxicity, formulation and stability, as well as animal studies. An IND sponsor must submit
the results of the pre-clinical tests, together with manufacturing information, analytical data and any available clinical data or literature,
to the FDA as part of the IND. The sponsor must also include a protocol detailing, among other things, the objectives of the initial
clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the initial clinical
trial lends itself to an efficacy evaluation. Some pre-clinical testing may continue even after the IND is submitted. The IND automatically
becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions related to a proposed clinical trial
and places the trial on a clinical hold within that 30-day period. In such a case, the IND sponsor and the FDA must resolve any outstanding
concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials
due to safety concerns or non-compliance, and may be imposed on all drug products within a certain class of drugs. The FDA also can impose
partial clinical holds, for example, prohibiting the initiation of clinical trials of a certain duration or for a certain dose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations. These
regulations include the requirement that all research subjects provide informed consent in writing before their participation in any
clinical trial. Further, an IRB must review and approve the plan for any clinical trial before it commences at any institution, and the
IRB must conduct continuing review and reapprove the study at least annually. An IRB considers, among other things, whether the risks
to individuals participating in the clinical trial are minimized and are reasonable in relation to anticipated benefits. The IRB also
approves the information regarding the clinical trial and the consent form that must be provided to each clinical trial subject or his
or her legal representative and must monitor the clinical trial until completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
new clinical protocol and any amendments to the protocol must be submitted for FDA review, and to the IRBs for approval. Protocols detail,
among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters
to be used to monitor subject safety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases that may overlap or be combined:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    1. The product is initially introduced into a small number of healthy human subjects or patients and tested for safety, dosage tolerance,
    absorption, metabolism, distribution and excretion and, if possible, to gain early evidence on effectiveness. In the case of some
    products for severe or life-threatening diseases, especially when the product is suspected or known to be unavoidably toxic, the
    initial human testing may be conducted in patients.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2. Involves clinical trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily
    evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage and schedule.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically
    dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit relationship of the product
    and provide an adequate basis for product labeling.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used to
gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate
the performance of Phase 4 trials. Companies that conduct certain clinical trials also are required to register them and post the results
of completed clinical trials on a government-sponsored database, www.clinicaltrials.gov, in the United States, within certain
timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progress
reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA, and written
IND safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events, findings from other
studies that suggest a significant risk to humans exposed to the product, findings from animal or in vitro testing that suggest a significant
risk to human subjects, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in
the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified
period, if at all. The FDA or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including
a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate
approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&rsquo;s requirements
or if the product has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an
independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee.
This group provides authorization for whether a trial may move forward at designated check points based on access to certain data from
the study. The clinical trial sponsor may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive
climate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry
and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance
with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate
and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product.
Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product
candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NDA
and FDA Review Process</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The results of product development, pre-clinical
studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the drug, proposed labeling
and other relevant information, are submitted to the FDA as part of an NDA, which request approval to market a new drug
product. The submission of an NDA is subject to the payment of a substantial user fee, and the sponsor of an approved NDA is also subject
to an annual program user fee; although a waiver of such fee may be obtained under certain limited circumstances. For example, the agency
will waive the application fee for the first human drug application that a small business or its affiliate submits for review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews all NDAs submitted before it accepts them for filing and may request additional information rather than accepting an NDA
for filing. The FDA typically makes a decision on accepting an NDA for filing within 60 days of receipt. The decision to accept the NDA
for filing means that the FDA has made a threshold determination that the application is sufficiently complete to permit a substantive
review. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act (&ldquo;PDUFA&rdquo;), the FDA&rsquo;s
goal to complete its substantive review of a standard NDA and respond to the applicant is ten months from the receipt of the NDA. The
FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional
information or clarification and may go through multiple review cycles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is
safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMPs to assure and preserve
the product&rsquo;s identity, strength, quality and purity. The FDA may refer applications for novel drug products or drug products that
present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other
experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The
FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
The FDA will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and us during the
review process. The review and evaluation of an NDA by the FDA is extensive and time consuming and may take longer than originally planned
to complete, and we may not receive a timely approval, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether
they comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are
in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition,
before approving an NDA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates
the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete
Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present
form. A Complete Response Letter  describes specific deficiencies in the NDA identified by the FDA. The Complete Response
Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming
requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant
may either resubmit the NDA, addressing all the deficiencies identified in the letter, or withdraw the application. Even if such data
and information are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from
clinical trials are not always conclusive, and the FDA may interpret data differently than we interpret the same data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
is no assurance that the FDA will ultimately approve a product for marketing in the United States, and we may encounter significant difficulties
or costs during the review process. If a product receives marketing approval, the approval may be significantly limited to specific diseases
and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the
FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval
of the NDA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct
post-market testing or clinical trials and surveillance to monitor the effects of approved products. For example, the FDA may require
Phase 4 clinical trials to further assess drug safety and effectiveness and may require testing and surveillance programs to monitor
the safety of approved products that have been commercialized. The FDA may also place other conditions on approvals, including the requirement
for a REMS to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS;
the FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication
plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.
Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of
products. Product approvals may be withdrawn for non-compliance with regulatory requirements or if problems occur following initial marketing.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Orange
Book Listing and Paragraph IV Certification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
NDA submissions, including those under Section 505(b)(2), applicants are required to list with the FDA certain patents with claims that
cover the applicant&rsquo;s product. Upon approval, each of the patents listed in the application is published in <I>Approved Drug Products
with Therapeutic Equivalence Evaluations</I>, commonly referred to as the Orange Book. Any applicant who subsequently files an ANDA or
505(b)(2) NDA that references a drug listed in the Orange Book must certify to the FDA that (1) no patent information on the drug product
that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent
expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the
application is submitted. This last certification is known as a Paragraph IV Certification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an applicant has provided a Paragraph IV Certification to the FDA, the applicant must also send notice of the Paragraph IV Certification
to the holder of the NDA for the approved drug and the patent owner once the application has been accepted for filing by the FDA. The
NDA holder or patent owner may then initiate a patent infringement lawsuit in response to notice of the Paragraph IV Certification. The
filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV Certification prevents the FDA from approving
the ANDA or 505(b)(2) application until the earlier of 30 months from the date of the lawsuit, the applicant&rsquo;s successful defense
of the suit, or expiration of the patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reimbursement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
sales of any of our product candidates, if approved, will depend, at least in part, on the extent to which such products will be covered
by third-party payors, such as government health care programs, commercial insurance and managed healthcare organizations. These third-party
payors are increasingly limiting coverage and/or reducing reimbursements for medical products and services. A third-party payor&rsquo;s
decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&rsquo;s
determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product.
In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including
price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment
measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our future
revenues and results of operations. Decreases in third-party reimbursement or a decision by a third-party payor to not cover a product
candidate, if approved, or any future approved products could reduce physician usage of our products, and have a material adverse effect
on our sales, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the Medicare Part D program provides a voluntary outpatient drug benefit to Medicare beneficiaries for certain products.
We do not know whether our product candidates, if approved, will be eligible for coverage under Medicare Part D, but individual Medicare
Part D plans offer coverage subject to various factors such as those described above. Furthermore, private payors often follow Medicare
coverage policies and payment limitations in setting their own coverage policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Healthcare
Laws and Regulations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our product candidates, if approved, or any other future product candidate will be subject to healthcare regulation and enforcement
by the federal government and the states and foreign governments in which we might conduct our business. The healthcare industry is
highly regulated under both state and federal laws and regulations. Our operations and relationships with healthcare plans and providers
are subject to extensive and increasing regulation by numerous federal, state, and local government agencies including the FDA, the Office
of Inspector General (&ldquo;OIG&rdquo;), the DOJ, the CMS, the Office of Civil Rights, and various state authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
healthcare laws and regulations that may affect our ability to operate include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>False
Claims Acts</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be subject to numerous federal and state laws that prohibit the presentation of false information, or the failure to disclose information,
in connection with the submission and payment of medical claims for reimbursement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal civil and criminal false claims laws and civil monetary penalties laws, such as the federal False Claims Act, 31 U.S.C. &sect;&sect;
3729&mdash;3733, impose civil liability on individuals or entities that submit false or fraudulent claims for payment to the federal
government. The False Claims Act provides, in part, that the federal government may bring a lawsuit against any person whom it believes
has knowingly or recklessly: presented, or caused to be presented, a false or fraudulent claim for payment or approval to the federal
government; made, used or caused to be made or used a false statement or a false record to get a claim for payment approved, including
a false or fraudulent claim; concealed, or knowingly and improperly avoided or decreased, an obligation to pay or transmit money or property
to the federal government; or conspired to commit any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal government has used the False Claims Act to prosecute a wide variety of alleged false claims and fraud allegedly perpetrated
against Medicare and state healthcare programs. The federal government, including as a result of the passage of the ACA, and a number
of courts have taken the position that claims presented in violation of certain other statutes, including the federal Anti-Kickback Statute
(&ldquo;AKS&rdquo;) or the federal physician referral law, 42 U.S.C. 1395nn (the &ldquo;Stark Law&rdquo;), can also be considered a violation
of the False Claims Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of states have enacted laws that are similar to the federal False Claims Act. Under Section&nbsp;6031 of the Deficit Reduction
Act of 2005, as amended, if a state enacts a false claims act that is at least as stringent as the federal statute and that also meets
certain other requirements, the state will be eligible to receive a greater share of any monetary recovery obtained pursuant to certain
actions brought under the state&rsquo;s false claims act. As a result, more states are expected to enact laws that are similar to the
federal False Claims Act in the future along with a corresponding increase in state false claims enforcement efforts. Violations of federal
and state fraud and abuse laws may be punishable by criminal and/or civil sanctions, including significant penalties, fines, disgorgement,
additional reporting requirements and oversight under a corporate integrity agreement or similar agreement to resolve allegations of
noncompliance with these laws, and/or exclusion or suspension from federal healthcare programs, such as Medicare, and debarment from
contracting with the U.S. government. Penalties for False Claims Act violations include fines ranging from $11,803 to $23,607 for each
false claim, plus up to three times the amount of damages sustained by the government. In addition to the provisions of the False Claims
Act, which provide for civil enforcement, the federal government also can use several criminal statutes to prosecute persons who are
alleged to have submitted false or fraudulent claims to the government for payments. Additionally, private parties may initiate <I>qui
tam</I> whistleblower lawsuits against any person or entity under the False Claims Act in the name of the federal government, as well
as under the false claims laws of several states, and may share in the proceeds of a successful suit. Generally, federal and state governments
have made investigating and prosecuting healthcare fraud and abuse a priority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Federal
and State Anti-Kickback Statutes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
AKS, set forth in Section&nbsp;1128B of the Social Security Act, prohibits the knowing and willful offer, payment, solicitation or receipt
of any form of remuneration in return for, or to induce, (i)&nbsp;the referral of a person for items or services reimbursable under federal
healthcare programs, (ii)&nbsp;the furnishing or arranging for the furnishing of items or services reimbursable under federal healthcare
programs or (iii)&nbsp;the purchase, lease or order or arranging or recommending purchasing, leasing or ordering of any item or service
reimbursable under federal healthcare programs. The core of a violation of the AKS is an &ldquo;inducement&rdquo; to refer patients for
services or items that are reimbursed under a federal healthcare program, such as Medicare, Medicaid, or Tricare (which covers military
personnel). The ACA amended the AKS to make it clear that a person need not have actual knowledge of the statute, or specific intent
to violate the statute, as a predicate for a violation. Court cases have resulted in the interpretation that a violation may occur where
even one purpose of the remuneration is to induce or reward referrals, and the OIG, which has the authority to impose administrative
sanctions for violation of the statute, has adopted a similar standard.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are certain AKS &ldquo;safe harbors&rdquo; which, if the respective requirements are met, would afford protection from the AKS. Failure
to meet all requirements of an AKS safe harbor does not necessarily mean the arrangement violates the AKS, but it may be subject to scrutiny
by legal authorities, in light of the parties&rsquo; intent and arrangements. In other words, if an arrangement does not fit within a
safe harbor, it does not necessarily mean that the arrangement is <I>per se</I> illegal&mdash;only that it is not shielded from regulatory
scrutiny. The federal AKS provides criminal penalties for individuals or entities that knowingly and willfully solicit or receive any
remuneration. A violation of the AKS is punishable by imprisonment of up to ten years, fines of up to $100,000 per offense, or both.
Violation can also give rise to federal healthcare program exclusion, liability under the False Claims Act and civil penalties, which
may include monetary penalties of up to $100,000 per offense, repayments of up to three times the total payments between the parties
to the arrangement and suspension from future participation in Medicare and Medicaid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
some states have enacted statutes and regulations similar to the AKS, but which may be applicable regardless of the payor source for
the patient. These state laws may contain exceptions and safe harbors that are different from and/or more limited than those of federal
law and that may vary from state to state.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Health
Care Fraud Statute</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Health Care Fraud Statute, 18 U.S.C. &sect; 1347, prohibits any person from knowingly and willfully executing, or attempting to execute,
a scheme to defraud any healthcare benefit program, which can be either a government or private payor plan. Violation of this statute,
even in the absence of actual knowledge of or specific intent to violate the statute, may be charged as a felony offense and may result
in fines, imprisonment or both. The Health Care False Statement Statute, 18 U.S.C. &sect; 1035, prohibits, in any matter involving a
federal healthcare program, anyone from knowingly and willfully falsifying, concealing or covering up, by any trick, scheme or device,
a material fact, or making any materially false, fictitious, or fraudulent statement or representation, or making or using any materially
false writing or document knowing that it contains a materially false or fraudulent statement. A violation of this statute may be charged
as a felony offense and may result in fines, imprisonment, or both.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Civil
Monetary Penalties Statute</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CMPL, 42 U.S.C. &sect; 1320a-7a, authorizes the imposition of civil monetary penalties, assessments, and exclusions against an individual
or entity based on a variety of prohibited conduct, including, but not limited to: (i)&nbsp;presenting, or causing to be presented, claims
for payment to Medicare, Medicaid, or other third-party payors that the individual or entity knows or should know are for an item or
service that was not provided as claimed or is false or fraudulent; (ii)&nbsp;offering remuneration to a federal healthcare program beneficiary
that the individual or entity knows or should know is likely to influence the beneficiary to order or receive healthcare items or services
from a particular provider; (iii)&nbsp;arranging contracts with an entity or individual excluded from participation in a federal healthcare
program; (iv)&nbsp;violating the federal AKS; (v)&nbsp;making, using, or causing to be made or used, a false record or statement material
to a false or fraudulent claim for payment for items and services furnished under a federal healthcare program; (vi)&nbsp;making, using,
or causing to be made any false statement, omission, or misrepresentation of a material fact in any application, bid, or contract to
participate or enroll as a provider of services or a supplier under a federal healthcare program; and (vii)&nbsp;failing to report and
return an overpayment owed to the federal government. We could be exposed to a wide range of allegations to which the federal CMPL would
apply. We cannot foreclose the possibility that we will face allegations subject to the CMPL with the potential for a material adverse
impact on our business, results of operations and financial condition. Substantial civil monetary penalties may be imposed under the
federal Civil Monetary Penalty Statute and may vary, depending on the underlying violation. In addition, an assessment of not more than
three&nbsp;times the total amount claimed for each item or service may also apply, and a violator may be subject to exclusion from federal
and state healthcare programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>






















































<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 17, 2021, we employed 1 full-time employee and 1 part-time employee. We are not a party to any collective bargaining
agreements, and we believe that we maintain good relations with our employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Facilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters are located at 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807 pursuant to a monthly rental agreement. We
believe this to be sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available
on commercially reasonable terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation
is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.
We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse
effect on our business, financial condition or operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our Corporate
History</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HBI
was incorporated on March 28, 2017, as a Delaware C-corporation. On July 16, 2019, Holdco was formed as a Delaware C-corporation. On
July 24, 2019, Holdco entered into a Contribution and Exchange Agreement with Nanoproteagen whereby the members of Nanoproteagen exchanged
100% of their membership interests in Nanoproteagen for shares of Holdco common stock. Also on July 24, 2019, the stockholders of HBI
exchanged 100% of their shares of common stock for shares of common stock of Holdco. HBI and Nanoproteagen became wholly-owned subsidiaries
of Holdco. On August 7, 2019, pursuant to a certificate of amendment, Holdco&rsquo;s name was changed to Hillstream BioPharma, Inc. and
HBI&rsquo;s name was changed to HB Pharma Corp. On November 12, 2020, Hillstream BioPharma, Inc. entered into a Share Exchange Agreement
with Farrington whereby the members of Farrington exchanged their membership interest in Farrington for shares of common stock of Hillstream
BioPharma, Inc., and Farrington became a wholly-owned subsidiary of Hillstream BioPharma, Inc. The estimated fair value of the common
stock issued in exchange for 100% of the members&rsquo; interest in Nanoproteagan and Farrington was $185,000 ($0.079 per share)
and $289,200 ($3.817 per share), respectively.&nbsp; Management estimated the fair value per share with the assistance of an independent
third-party valuation firm. The fair value per share was based upon the cost approach prior to September 2020 and comparative companies
thereafter, as the Company has not had a priced equity round to date. At June 30, 2020, Hillstream BioPharma, Inc. has two
wholly-owned subsidiaries: HB Pharma Corp. and Farrington.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_001"></A>MANAGEMENT</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors
and Executive Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the name, age and position of each of our executive officers, key employees and directors as of September
17, 2021.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 22%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
    Milby</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board of Directors</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Thomas
    Hess</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">57</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Leonard
    Mazur</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">76</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">Lynne
                                            A. Bui, MD</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">51</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sireesh
    Appajosyula</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">46</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Randy
Milby</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
Milby has served as our Chief Executive Officer and Chairman of our board of directors since inception in 2017. Mr. Milby is an experienced
biopharmaceutical executive and served as the Chief Executive Officer and member of the board of directors at CorMedix Inc., a biopharmaceutical
company focused on developing and commercializing therapeutic products for the prevention and treatment of inflammatory and infectious
diseases, from May 2012 to December 2012 and from January 2013 until September 2016, respectively. Mr. Milby has served in various other
positions including, but not limited to, Global Business Director &ndash; BioMedical and Global Business Director &ndash; Applied BioSciences
of DuPont de Nemours, Inc.; Global Marketing Director of DuPont Crop Protection; Securities Analyst, Investment Research, Biotechnology
of Goldman Sachs; and Senior Director of DuPont Merck Pharmaceuticals. Mr. Milby received his BS in pharmacy from The University of Kansas
and his MBA in finance/marketing from Washington University in St. Louis &ndash; Olin Business School. We believe Mr. Milby is qualified
to serve as a member of our board of directors because of his extensive experience in the biotechnology industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Thomas
Hess</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
Hess has served as our Chief Financial Officer since June 2021. From August 2014 until June 2021, Mr. Hess served as Chief Financial
Officer and Senior Vice President of Finance of Genomind, Inc., a mental health company that developed and sold a pharmacogenomic test
that analyzed how an individual&rsquo;s genes may affect medication outcomes. From September 2011 until its sale in April 2014, Mr. Hess served
as Chief Financial Officer and Executive Vice President of Finance of The Keane Organization, a comprehensive provider of unclaimed property
services. Mr. Hess also previously served in various other capacities including, but not limited to, Chief Financial Officer and Senior
Vice President of Yaupon Therapeutics, Inc.; Chief Financial Officer and Vice President, Finance of Adolor Corporation; Corporate Controller
of Vicuron Pharmaceuticals, Inc.; and Senior Manager &ndash; Accounting and Audit of KPMG. Mr. Hess was formerly an adjunct faculty member/lecturer
at Pennsylvania State University and DeSales University. Mr. Hess received his B.S. in accounting from The Pennsylvania State University
and his MBA from Katz Graduate School of Business, University of Pittsburgh. Mr. Hess is a Certified Public Accountant in the state of
Pennsylvania. He currently serves on the Alumni Council of Penn State and is the Chairman of the Nittany Lion Club Annual Fund.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leonard
Mazur</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leonard
Mazur has served as a member of our board of directors since July 2021. In addition, since September 2014, Mr. Mazur has served as Executive
Chairman of the board of directors and Secretary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) (&ldquo;Citius&rdquo;). Mr. Mazur also
serves as the Secretary of Citius&rsquo; majority-owned subsidiary, NoveCite, Inc. Mr. Mazur is the co-founder and Vice Chairman of Akrimax
Pharmaceuticals, LLC (&ldquo;Akrimax&rdquo;), a privately held pharmaceutical company specializing in producing cardiovascular and general
pharmaceutical products. Akrimax was founded in September 2008 and has successfully launched prescription drugs while acquiring drugs
from major pharmaceutical companies. From January 2005 to May 2012, Mr. Mazur co-founded and served as the Chief Operating Officer of
Triax Pharmaceuticals LLC (&ldquo;Triax&rdquo;), a specialty pharmaceutical company producing prescription dermatological drugs. Prior
to joining Triax, he was the founder and, from 1995 to 2005, Chief Executive Officer of Genesis Pharmaceutical, Inc. (&ldquo;Genesis&rdquo;),
a dermatological products company that marketed&nbsp;its products through dermatologists&rsquo; offices as well as co-promoting products
for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company. Mr.
Mazur has extensive sales, marketing and business development experience from his tenures at Medicis Pharmaceutical Corporation as Executive
Vice President, ICN Pharmaceuticals, Inc. as Vice President, Sales and Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories,
Inc. Mr. Mazur is a member of the Board of Trustees of Manor College, is a recipient of the Ellis Island Medal of Honor and was previously
the chairman of the board of directors of LMB, Citius&rsquo; wholly-owned subsidiary. Mr. Mazur received both his B.A. and M.B.A. from
Temple University and has served in the U.S. Marine Corps Reserves. We believe Mr. Mazur is qualified to serve as a member of our board
of directors because of his extensive experience in the biotechnology industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lynne A. Bui, MD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lynne
Bui has served as a member of our board of directors since July 2021. In addition, since June 2017, she has served as President, Chief
Executive Officer and a member of the board of directors of Khloris Biosciences, Inc., a biotechnology company dedicated to revolutionizing
medical treatment and prevention of cancer and other diseases. Dr. Bui is a board-certified hematologist oncologist, seasoned entrepreneur,
angel investor and drug developer, having unparalleled experience in basic, translational and clinical research spanning over 15 years
with direct patient care and leading clinical development programs from preclinical IND enabling studies to Phase 1 to 3 registration
studies for multiple approved drugs, including cabozantinib, carfilzomib and enzalutamide. In addition, she has held senior level positions
at Exelixis, Inc., Onyx Pharmaceuticals (acquired by Amgen Inc.) and Intellikine, Inc. (acquired by Millennium/Takeda in 2012) and has
served as Chief Medical Officer and clinical development lead for multiple biotechnology and pharmaceutical companies. She has experience
with small molecules, antibodies, dendritic cell vaccines, gene therapies, embryonic stem cells, and cell therapies. As a clinician,
Dr. Bui has previously been clinical attending at Stanford Hospital and UCLA Medical Center, and is the Founder and Chairman of Global
Cancer Research Institute (&ldquo;GCRI&rdquo;), a community-based hematology/oncology clinical practice and clinical trial site. She
is also the Founder and Chairman of GCRI Foundation, a non-profit organization dedicated to funding clinical research in cancer; and
a former Fellow of the Leukemia &amp; Lymphoma Society, Lymphoma Research Foundation and Howard Hughes Medical Institute. Dr. Bui received
her B.A. in molecular and cell biology, with an emphasis in neurobiology from University of California, Berkeley and her M.D. from the
David Geffen UCLA School of Medicine. We believe Dr. Bui is qualified to serve as a member of our board of directors because
of her extensive clinical and industry experience.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sireesh
Appajosyula</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sireesh
Appajosyula has served as a member of our board of directors since July 2021. Since April 2020, he has served as SVP, Corporate Development
and Operations of 9 Meters Biopharma, Inc. (Nasdaq: NMTR) (&ldquo;9 Meters&rdquo;), a company focused on rare and unmet needs in gastrointestinal
patient populations developing compounds with unique gastrointestinal biology, and since 2018 he has served as Managing Member of Highpoint
Pharmaceuticals, LLC, a pharmaceutical research and development company. In addition, since 2015, Mr. Appajosyula has served as Managing
Partner of Channel BioConsulting, LLC, a company that assists in enhancing search and evaluation efforts for complementary assets to
be added to existing portfolios of biopharmaceutical companies. Prior to joining 9 Meters, Mr. Appajosyula spent approximately 8 years
at Salix Pharmaceuticals, Inc. (&ldquo;Salix&rdquo;) (Nasdaq: SLXP) in various roles in medical affairs, product commercialization and
business development until its acquisition by Bausch Health (Nasdaq: BHC). Prior to Salix, he was involved in various roles at Amgen
Inc., Critical Therapeutics, Inc. and Sanofi (formerly Aventis). Mr. Appajosyula received his Bachelor of Science and Doctor of Pharmacy
from Rutgers University. <FONT STYLE="background-color: white">We believe Mr. </FONT>Appajosyula is qualified to serve as a member of
our board of directors because of his extensive experience in the biotechnology industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our executive officers or directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the consummation of this offering, our board of directors undertook a review of the independence of our directors and considered
whether any director has a relationship with us that could compromise that director&rsquo;s ability to exercise independent judgment
in carrying out that director&rsquo;s responsibilities. Our board of directors has affirmatively determined that Leonard Mazur,
Lynne Bui and Sireesh Appajosyula are each an &ldquo;independent director,&rdquo; as defined under  Nasdaq rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Committees
of Our Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors directs the management of our business and affairs, as provided by Delaware law, and conducts its business through
meetings of the board of directors and its standing committees. We will have a standing audit committee, compensation committee and nominating
and corporate governance committee. In addition, from time to time, special committees may be established under the direction of the
board of directors when necessary to address specific issues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Audit
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee will be responsible for, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
    and retaining the independent auditors to conduct the annual audit of our financial statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the proposed scope and results of the audit;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and pre-approving audit and non-audit fees and services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    accounting and financial controls with the independent auditors and our financial and accounting staff;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving transactions between us and our directors, officers and affiliates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    procedures for complaints received by us regarding accounting matters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    internal audit functions, if any; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the report of the audit committee that the rules of the SEC require to be included in our annual meeting proxy statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
the consummation of this offering, our audit committee will consist of Lynne Bui and Leonard Mazur with Lynne Bui serving as chair.
As permitted under the applicable rules and regulations of the SEC and Nasdaq, we intend to phase in compliance with the audit
committee composition requirements prior to the end of the one-year transition period. Our board of directors has affirmatively
determined that Lynne Bui and Leonard Mazur each meet the definition of &ldquo;independent director&rdquo; under  Nasdaq rules,
and that they meet the independence standards under Rule 10A-3. Each member of our audit committee meets the financial literacy
requirements of  Nasdaq. In addition, our board of directors has determined that Leonard Mazur will qualify as an
&ldquo;audit committee financial expert,&rdquo; as such term is defined in Item 407(d)(5) of Regulation S-K. Our board of directors
will adopt a written charter for the audit committee, which will be available on our principal corporate website at
www.hillstreambio.com concurrently with the consummation of this offering.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compensation
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee will be responsible for, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and recommending the compensation arrangements for management, including the compensation for our chief executive officer;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and reviewing general compensation policies with the objective to attract and retain superior talent, to reward individual performance
    and to achieve our financial goals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    our stock incentive plans; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the report of the compensation committee that the rules of the SEC require to be included in our annual meeting proxy statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the consummation of this offering, our compensation committee will consist of Lynne Bui and Leonard Mazur with Lynne Bui
serving as chair. Our board has determined that Lynne Bui and Leonard Mazur are each independent directors under Nasdaq rules.
Our board of directors will adopt a written charter for the compensation committee, which will be available on our principal corporate
website at www.hillstreambio.com concurrently with the consummation of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nominating
and Governance Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and governance committee will be responsible for, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">nominating
    members of the board of directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    a set of corporate governance principles applicable to our company; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    the evaluation of our board of directors.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the consummation of this offering, our nominating and corporate governance committee will consist of Lynne Bui and Sireesh Appajosyula
with Sireesh Appajosyula serving as chair. Our board has determined that Lynne Bui and Sireesh Appajosyula are each
independent directors under Nasdaq rules. Our board of directors will adopt a written charter for the nominating and governance committee,
which will be available on our principal corporate website at www.hillstreambio.com concurrently with the consummation of this offering.</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scientific
Advisory Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are supported by members of our Scientific Advisory Board who provide advice and guidance in their respective fields of expertise from
pre-clinical to clinical development.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> Our Scientific Advisory Board
is currently composed of the following members who receive compensation in a combination of cash and options to purchase shares
of our common stock:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Donald Kufe,
MD &ndash; Chair of the Scientific Advisory Board; Dana-Farber Cancer Institute/Harvard University</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Kwok-Kin
Wong, MD, PhD &ndash; New York University School of Medicine</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Paul
Richardson, MD &ndash; Dana-Farber Cancer Institute/Harvard University</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Surender
Kharbanda, PhD - Dana-Farber Cancer Institute</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Joseph
Paul Eder, MD &ndash; Yale University/Yale Cancer Center</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">David
Weaver, PhD &ndash; FemtoDx</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Richard
Stone, MD &ndash; Dana-Farber Cancer Institute</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jonathan
Rayner, PhD &ndash; University of South Alabama&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Scott
Dixon, PhD &ndash; Stanford University</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Harpal Singh, PhD &ndash; Indian Institute of
Technology Delhi</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Business Conduct and Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have adopted a written code of business
conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial
officer, principal accounting officer or controller, or persons performing similar functions. A copy of the code will be posted on our
website, www.hillstreambio.com concurrently with the consummation of this offering. In addition, we intend to post on our website
all disclosures that are required by law or Nasdaq rules concerning any amendments to, or waivers from, any provision of the code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations
on Liability and Indemnification Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws contain provisions that limit the liability of our current and former directors for monetary
damages to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally
liable for monetary damages for any breach of fiduciary duties as directors, except liability for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    breach of the director&rsquo;s duty of loyalty to the corporation or its stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unlawful
    payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    transaction from which the director derived an improper personal benefit.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of equitable
remedies such as injunctive relief or rescission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws provide that we are authorized to indemnify our directors and officers to the fullest extent
permitted by Delaware law. Our Bylaws also provide that we may advance expenses incurred by a director or executive officer in advance
of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee
or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted
to indemnify him or her under the provisions of Delaware law. Our Bylaws also provide our board of directors with discretion to indemnify
our employees when determined appropriate by our board of directors. We have entered into agreements to indemnify our directors
and executive officers and expect to enter into agreements to indemnify our other employees as well. These agreements
provide for indemnification for related expenses, including, among other things, attorneys&rsquo; fees, judgments, fines and settlement
amounts incurred by any of these individuals in any action or proceeding. We believe that these provisions and agreements are necessary
to attract and retain qualified persons as directors and officers. We also intend to maintain obtain customary directors&rsquo; and officers&rsquo;
liability insurance upon consummation of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
limitation of liability and indemnification provisions in our Certificate of Incorporation and Bylaws may discourage stockholders from
bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation
against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder&rsquo;s
investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers
as required by these indemnification provisions. At present, there is no pending litigation or proceeding involving any of our directors,
officers or employees for which indemnification is sought, and we are not aware of any threatened litigation that may result in claims
for indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_002"></A>EXECUTIVE
AND DIRECTOR COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Compensation Table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the compensation awarded to, earned by or paid to our principal executive officer, who we also refer to as our
&ldquo;named executive officer&rdquo;, for the year ended December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name and
    Principal Position</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Salary<BR>
    ($)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bonus<BR>
    ($)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Option<BR>
    awards<BR> ($)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total<BR>
    ($)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Randy Milby, President and</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">193,627</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">193,627</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer<SUP>(1)(2)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    fiscal year 2020, in lieu of base salary, Mr. Milby was compensated with stock options to purchase 200,000 shares of common stock
    per month.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    the aggregate grant date fair value of stock options granted during the fiscal year calculated in accordance with FASB ASC Topic
    718. For a discussion of the assumptions made by us in determining the grant date fair value of our equity awards see Note 6 to our
    audited consolidated financial statements for the year ended December 31, 2020 included elsewhere in this prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment
Agreements</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Employment
Agreement with Randy Milby</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 1, 2019, we entered into an employment
agreement with Randy Milby, to serve as our President and Chief Executive Officer. Pursuant to the employment agreement, Mr. Milby received
an annual base salary of $200,000; provided, however, instead of base salary, Mr. Milby was to receive 75,757 shares of
our common stock per year until funding met or exceeded $2,000,000 after which cash compensation would be paid. Mr. Milby was also eligible
to receive an annual target bonus of up to 100% of the base salary, subject to achievements to be mutually agreed upon by our board
of directors and Mr. Milby. Mr. Milby was also entitled to receive an annual grant of stock or stock options as determined by our
board of directors, in its sole discretion, among other bonus payments based upon our capitalization. In January 2020, we
amended the employment agreement pursuant to which Mr. Milby was to receive stock options to purchase 7,575 shares of common stock
per month (at an exercise price based upon the most recent 409A valuation) effective January 1, 2020 until funding met or exceeded $3,000,000,
after which time, cash compensation of $200,000 per year would be paid. In addition, if Mr. Milby raised more than $3,000,000,
he would receive a grant of options to purchase up to 757,575 shares of our common stock at an exercise price of $0.185.
Effective January 1, 2021, we further amended the employment agreement such that in lieu of base salary, Mr. Milby would receive stock
options to purchase 18,939 shares of our common stock per month at an exercise price of $7.822 per share effective January
1, 2021 until funding meets or exceeds $5,000,000, after which time, cash compensation of $300,000 per year would be paid. The amendment
also provided for a base salary of $435,000 after we received funding greater than $5,000,000, or we completed an initial public offering
or similar transaction as set forth in the employment agreement. In addition, if Mr. Milby raised more than $5,000,000, he would receive
a grant of stock options to acquire 757,575 shares of our common stock with an exercise price based upon the most recent 409A
valuation. Subsequently, on January 20, 2021, we entered into a further amendment to the employment agreement pursuant to which Mr. Milby
would receive a base salary of $200,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
June 1, 2021, we entered into an Amended and Restated Employment Agreement, as amended on September 24, 2021 (the &ldquo;Amended
and Restated Employment Agreement&rdquo;), with Randy Milby pursuant to which Mr. Milby will continue to serve as our President
and Chief Executive Officer. The term of the Amended and Restated Employment Agreement will commence upon the closing of this offering
and continue for a period of five years and automatically renews for successive one year periods at the end of each term unless either
party provides written notice of their intent not to review at least 60 days prior to the expiration of the then effective term. Pursuant
to the Amended and Restated Employment Agreement, Mr. Milby will receive an annual base salary of $485,000, which may be increased from
time to time, and shall be eligible to receive an annual cash bonus equal to 55% of his then base salary based upon the achievement of
Company and individual performance targets established by our board. In addition, in the first year in which our market capitalization
(as defined in the Amended and Restated Employment Agreement) equals or exceeds (i) $250 million, Mr. Milby shall receive a cash payment
of $150,000; (ii) $500 million, Mr. Milby shall receive a cash payment of $350,000; and (iii) $1 billion, Mr. Milby shall receive a cash
payment of $750,000. Furthermore, on or as soon as reasonably practicable following the date of the consummation this offering, Mr. Milby
shall be granted 757,575 shares of our common stock at the public offering price per share of common stock
sold in this offering which shall vest over a 48 month period commencing 12 months after the date of grant. This shall be in addition
to any additional equity-based compensation awards we may grant Mr. Milby from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Amended and Restated Employment Agreement, Mr. Milby&rsquo;s employment may be terminated (i) by us for Cause (as defined in the
Amended and Restated Employment Agreement); (ii) upon Mr. Milby&rsquo;s death; (iii) upon Mr. Milby&rsquo;s Disability (as defined in
the Amended and Restated Employment Agreement); (iv) or by Mr. Milby for Good Reason (as defined in the Amended and Restated Employment
Agreement). In the event Mr. Milby&rsquo;s employment is terminated, we shall pay Mr. Milby his then base salary through the last day
of his employment, the reimbursement of expenses incurred on or prior to the termination date and any earned but unpaid bonus (collectively,
the &ldquo;Accrued Compensation&rdquo;). In the event Mr. Milby&rsquo;s employment is terminated as a result of his death or Disability,
we shall pay Mr. Milby (i) the Accrued Compensation, (ii) his then base salary through the date which is 90 days after his death or Disability
and (iii) such other or additional benefits as may be provided under our employee benefit plans, programs and arrangements (collectively,
the &ldquo;Plans&rdquo;). In addition, all shares of our capital stock that are subject to vesting and all stock options that are scheduled
to vest on or before the next succeeding anniversary of the effective date of the Amended and Restated Employment Agreement shall be
accelerated and deemed to have vested as of the termination date. All shares and options that have not vested as of the date of termination
shall be forfeited. Any stock options that have vested as of the termination date shall remain exercisable until the earlier of (i) 60
months after the termination date and (ii) the expiration date of the option (all payments to be paid upon Mr. Milby&rsquo;s death or
Disability are hereinafter referred to as the &ldquo;Death and Disability Severance&rdquo;). Any payments that shall be made to Mr. Milby
as a result of his Disability shall be contingent upon Mr. Milby executing a general release within 21 days of separation from service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the event Mr. Milby&rsquo;s employment is terminated for Cause, Mr. Milby shall receive (i) the Accrued Compensation and (ii) such other
and additional benefits, if any, as may be required pursuant to the Plans, and all shares that have not vested as of the termination
date shall be forfeited while all stock options that are vested as of the termination date shall remain exercisable for 90 days after
such termination (all payments to be paid upon termination of Mr. Milby&rsquo;s termination for Cause are hereinafter referred to as
the &ldquo;Cause Severance&rdquo;). If Mr. Milby&rsquo;s employment is terminated other than for death, Disability or Cause, including
if Mr. Milby&rsquo;s employment is terminated for Good Reason, then, subject to the execution of a separation agreement within 60 days
from the separation of service, we shall pay Mr. Milby, (i) the Accrued Compensation, (ii) his then base salary and provide him with
health benefits for a period of 12 months following the effective date of his separation from service and (iii) provide such other or
additional benefits, if any, as may be provided under the Plans. Furthermore, all shares and stock options that have not vested as of
the termination date shall be forfeited, and any stock options that have vested as of the termination date shall remain exercisable until
the earlier of (i) 60 months following such termination and (ii) the termination date of such option (all payments to be paid upon Mr.
Milby&rsquo;s termination other than for death, Disability or Cause, including Good Reason, are hereinafter referred to as the &ldquo;Other
Severance&rdquo; and together with the Death and Disability Severance and the Cause Severance, &ldquo;Severance&rdquo;). In the event
Mr. Milby&rsquo;s employment is terminated either (i) by us without Cause at any time within 12 months prior to the consummation of a
Change of Control (as defined in the Amended and Restated Employment Agreement), (ii) by Mr. Milby for Good Reason at any time within
12 months after the consummation of a Change of Control or (iii) by us without Cause at any time upon or within 12 months after the consummation
of a Change of Control, then Mr. Milby shall (A) be entitled to the acceleration and vesting in full of any then outstanding and
unvested equity award, with options continuing to be exercisable for 60 months following termination (or, if earlier, their expiration
date) and (B) all Severance; provided, however, that such Severance amount shall equal two times the sum of Mr. Milby&rsquo;s
then base salary and target bonus and the Severance period shall be 24 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
Equity Awards at December 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning outstanding equity awards held by our named executive officer as of December
31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="16" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">OPTION AWARDS</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Securities<BR> Underlying Unexercised<BR> Options (#) Exercisable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Securities<BR> Underlying Unexercised<BR> Options (#) Unexercisable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity Incentive <BR> Plan Awards:<BR> Number of Securities<BR> Underlying Unexercised<BR> Unearned Options (#)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<BR> Exercise<BR> Price ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<BR> Expiration<BR> Date</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 13%; font-weight: bold; text-align: left"><B STYLE="font: 10pt Times New Roman, Times, Serif">Randy Milby</B></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: center"> 6/20/2018 </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">13,257</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">5,682</TD><TD STYLE="width: 1%; text-align: left">(1)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">13.200</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">6/20/2023</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9/20/2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,836</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,148</TD><TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13.200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9/20/2023</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7/31/2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,531</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,347</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0792</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7/31/2024</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8/30/2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">189,393</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0792</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8/30/2024</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9/17/2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">917</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">976</TD><TD STYLE="text-align: left">(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.6400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9/17/2024</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9/19/2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">917</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">976</TD><TD STYLE="text-align: left">(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.6400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9/19/2024</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/5/2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">443</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">503</TD><TD STYLE="text-align: left">(7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.6400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/05/2024</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/13/2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,774</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,801</TD><TD STYLE="text-align: left">(8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.6400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/13/2024</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/31/2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,867</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,011</TD><TD STYLE="text-align: left">(9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.6400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/31/2024</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1/31/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.3142</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1/31/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2/29/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.3142</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2/28/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3/31/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.3142</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3/31/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4/30/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.3142</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4/30/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5/31/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.3142</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5/31/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6/30/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.3142</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6/30/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7/31/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.3142</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7/31/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8/31/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.3142</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8/31/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9/30/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.3142</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9/30/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/31/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.8174</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/31/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/12/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.8174</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/12/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/12/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,878</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.8174</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/12/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/30/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.8174</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/30/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/31/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.8174</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/31/2030</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,787
                                            </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">of the options shall
                                            vest on the one year anniversary of the date of grant, or June 20, 2019, with the balance
                                            of the 15,152 options vesting over a period of 48 months thereafter.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,787
    </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">of the options shall vest on the one year anniversary of the vesting
    starting date (September 20, 2018), with the remaining 7,197 of the options vesting in equal installments over
    a period of 48 months.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    of the options shall vest on the one year anniversary of the vesting starting date (July 31, 2019), with the remaining 28,409
    of the options vesting in equal installments over a period of 48 months.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    of the options shall vest on the completion of this offering or a public listing via reverse merger with a public company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    of the options shall vest on the one year anniversary of the vesting starting date (September 17, 2019), with the remaining
    1,420 of the options vesting in equal installments over a period of 48 months.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    of the options shall vest on the one year anniversary of the vesting starting date (September 19, 2019), with the remaining
    1,420 of the options vesting over a period of 48 equal monthly installments.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    of the options shall vest on the one year anniversary of the vesting starting date (November 5, 2019), with the remaining
    710 of the options vesting in equal installments over a period of 48 months.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,787
    </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">of the options shall vest on the one year anniversary of the vesting
    starting date (December 13, 2019), with the remaining 3,788 of the options vesting in equal installments over
    a period of 48 months.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    of the options shall vest on the one year anniversary of the vesting starting date (December 31, 2019), with the remaining
    28,409 of the options vesting in equal installments over a period of 48 months.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017
Stock Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our board of directors and
our stockholders approved the 2017 Stock Incentive Plan (&ldquo;2017 Plan&rdquo;) on March 30, 2017, under which we may grant
equity incentive awards in order to attract, motivate and retain the talent who are expected to make important contributions to the Company.
The material terms of the 2017 Plan are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Administration of the 2017 Plan: </I></B>The
2017 Plan is administered by our board of directors. Our board of directors may delegate any or all of its powers
under the 2017 Plan to one or more committees or subcommittees of the board (a &ldquo;Committee&rdquo;). All references
in the 2017 Plan to the &ldquo;Board&rdquo; shall mean our board of directors or a Committee of our board of directors
to the extent that the board&rsquo;s powers or authority under the 2017 Plan have been delegated to such Committee.
The Board shall have authority to grant awards and to adopt, amend and repeal such administrative rules, guidelines and practices
relating to the 2017 Plan as it shall deem advisable. The Board may correct any defect, supply any omission or reconcile any inconsistency
in the 2017 Plan or any award in the manner and to the extent it shall deem expedient to carry the 2017 Plan into
effect and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made in the Board&rsquo;s sole
discretion and shall be final and binding on all persons having or claiming any interest in the 2017 Plan or in any award thereunder.
No director or person acting pursuant to the authority delegated by the Board shall be liable for any action or determination relating
to or under the 2017 Plan made in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Eligibility Participants: </I></B>The 2017
Plan authorizes the grant of stock options, restricted stock, restricted stock units and/or other stock based awards to employees, officers,
directors, individual consultants and advisors of the Company. The Board determines, in its sole discretion, who will receive awards
under the 2017 Plan. Notwithstanding anything in the 2017 Plan or any award documentation to the contrary, for so long as the Company
has elected Subchapter S status under Section 1362 of the Internal Revenue Code of 1986, as amended, no award shall be granted or exercised,
as the case may be, if the result of such grant or exercise would result in the termination of such Subchapter S status, unless such
grant or exercise, as the case may be, is consented to by all stockholders of the Company. Any such purported grant or exercise of an
award that does not comply with the foregoing shall be void and have no legal force or effect and shall not be recognized on the books
of the Company as effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Shares Available Under the 2017 Plan: </I></B>The
maximum number of shares of common stock that may be issued to participants under the 2017 Plan is 94,696, subject to adjustment for
certain corporate changes affecting the shares, such as stock splits. Shares subject to an award under the 2017 Plan for which the award
is canceled, forfeited or expires again become available for grants under the 2017 Plan. Shares subject to an award that is settled in
cash will not again be made available for grants under the 2017 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Stock Options:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>General: </I>The Board has the authority to
grant options to purchase shares of the Company&rsquo;s common stock and determine the number of shares of the Company&rsquo;s common
stock to be covered by each option, the exercise price of each option and the conditions and limitations applicable to the exercise of
each option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Exercise of Options:</I> An option may be exercised
only in accordance with the terms and conditions of the option agreement as established by the Board at the time of the grant. The option
must be exercised by notice to the Company, accompanied by payment of the exercise price. Payments may be made in cash or, at the option
of the Board, by actual or constructive delivery of shares of common stock to the holder of the option based upon the fair market value
of the shares on the date of exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Expiration or Termination</I>: Options, if
not previously exercised, will expire on the expiration date established by the Board at the time of grant; provided that such term cannot
exceed ten years and that such term of an incentive stock option granted to a holder of more than 10% of our voting stock cannot exceed
five years. Options will terminate before the expiration date to the extent the vested portion of the option is not exercised within
3 months of the termination date if the holder&rsquo;s service with us terminates before the expiration date. The option may remain exercisable
for specified periods after certain terminations of service, including terminations as a result of death, disability or retirement, with
the precise period during which the option may be exercised to be established by the Board and reflected in the agreement evidencing
the award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Restricted Shares and Restricted Stock Units</I>:
</B>Eligible participants may be awarded grants of restricted stock units, which represent the right to receive shares of the common
stock to be delivered when the common stock vests. The holders of restricted stock units will have none of the rights of a stockholder
of the Company until such time or times as shares of the common stock have been issued to participant in settlement of the award. The
Board shall determine the participants to whom and the time or times at which grants of restricted stock units shall be awarded, the
number of units to be awarded to any participant, the conditions for vesting, the time or times within which such awards may be subject
to forfeiture and restrictions on transfer and other terms and conditions of the awards. Each restricted stock unit shall at all times
be equal in value to the fair market value of one share of the common stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Other Stock Based Awards</I>:</B> The Board
may grant or sell other awards that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based
on or related to, common stock or factors that may influence the value of such shares. In addition, the Board may grant unrestricted
shares to eligible participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Other Material Provisions</I>:</B>
Awards will be evidenced by a written agreement, in such form as may be approved by the Board. In the event of various changes to
the capitalization of our Company, such as stock splits, stock dividends and similar re-capitalizations, an appropriate adjustment
will be made by the Board to the number of shares covered by outstanding awards or to the exercise price of such awards. The Board
is also permitted to include in the written agreement provisions that provide for certain changes in the award in the event of a
change of control of our Company, including acceleration of vesting. Except as otherwise determined by the Board at the date of
grant, awards will not be transferable, other than by will or the laws of descent and distribution. Prior to any award distribution,
we are permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements. The Board also has
the authority, at any time, to discontinue the granting of awards. The Board also has the authority to alter or amend the 2017 Plan
or any outstanding award or may terminate the 2017 Plan as to further grants, provided that no amendment will, without the approval
of our stockholders, increase the number of shares available under the 2017 Plan or change the persons eligible for awards under the
2017 Plan. No amendment that would adversely affect any outstanding award made under the 2017 Plan can be made without the consent
of the holder of such award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>2019 Stock Incentive
Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our board of directors
and our stockholders approved the 2019 Stock Incentive Plan (&ldquo;2019 Plan&rdquo;) on July 24, 2019, under which we may grant equity
incentive awards in order to attract, motivate and retain the talent who are expected to make important contributions to the Company.
The material terms of the 2019 Plan are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Administration of the 2019 Plan: </I></B>The
2019 Plan is administered by our board of directors. Our board of directors may delegate any or all of its powers under the 2019 Plan
to one or more committees or subcommittees of the board (a &ldquo;Committee&rdquo;). All references in the 2019 Plan to the &ldquo;Board&rdquo;
shall mean our board of directors or a Committee of our board of directors to the extent that the board&rsquo;s powers or authority under
the 2019 Plan have been delegated to such Committee. The Board shall have authority to grant awards and to adopt, amend and repeal such
administrative rules, guidelines and practices relating to the 2019 Plan as it shall deem advisable. The Board may correct any defect,
supply any omission or reconcile any inconsistency in the 2019 Plan or any award in the manner and to the extent it shall deem expedient
to carry the 2019 Plan into effect and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made
in the Board&rsquo;s sole discretion and shall be final and binding on all persons having or claiming any interest in the 2019 Plan or
in any Award. No director or person acting pursuant to the authority delegated by the Board shall be liable for any action or determination
relating to or under the 2019 Plan made in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Eligibility Participants:</I></B> The 2019
Plan authorizes the grant of stock options, restricted stock, restricted stock units and/or other stock based awards to employees, officers,
directors, individual consultants and advisors of the Company.&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board determines, in its sole discretion, who
will receive awards under the 2019 Plan. Notwithstanding anything in the 2019 Plan or any award documentation to
the contrary, for so long as the Company has elected Subchapter S status under Section 1362 of the Internal Revenue Code of 1986, as
amended, no award shall be granted or exercised, as the case may be, if the result of such grant or exercise would result in the
termination of such Subchapter S status, unless such grant or exercise, as the case may be, is consented to by all stockholders of the
Company. Any such purported grant or exercise of an award that does not comply with the foregoing shall be void and have no legal
force or effect and shall not be recognized on the books of the Company as effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Shares Available Under the 2019 Plan:
</I></B>The maximum number of shares of common stock that may be delivered to participants under the 2019 Plan is 3,901,512,
subject to adjustment for certain corporate changes affecting the shares, such as stock splits. Shares subject to an award under the
2019 Plan for which the award is canceled, forfeited or expires again become available for grants under the 2019 Plan.
Shares subject to an award that is settled in cash will not again be made available for grants under the 2019 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Stock Options:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>General: </I>The Board has the authority to grant
options to purchase shares of the Company&rsquo;s common stock and determine the number of shares of the Company&rsquo;s common
stock to be covered by each option, the exercise price of each option and the conditions and limitations applicable
to the exercise of each option, including conditions relating to applicable federal or state securities laws, as it considers
necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Exercise of Options:</I> An option may be exercised
only in accordance with the terms and conditions of the option agreement as established by the Board at the time of the
grant. The option must be exercised by notice to us, accompanied by payment of the exercise price. Payments may be made in cash
or, at the option of the Board, by actual or constructive delivery of shares of common stock to the holder of the option based
upon the fair market value of the shares on the date of exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Expiration or Termination</I>: Options, if not
previously exercised, will expire on the expiration date established by the Board at the time of grant; provided that such term
cannot exceed ten years and that such term of an incentive stock option granted to a holder of more than 10% of our voting stock cannot
exceed five years. Options will terminate before the expiration date to the extent the vested portion of the option is not exercised
within 3 months of the termination date if the holder&rsquo;s service with us terminates before the expiration date. The option may remain
exercisable for specified periods after certain terminations of service, including terminations as a result of death, disability or retirement,
with the precise period during which the option may be exercised to be established by the Board and reflected in the agreement
evidencing the award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Restricted Shares and Restricted Stock Units</I>:
</B>Eligible participants may be awarded grants of restricted stock units, which represent the right to receive shares of
the Company&rsquo;s common stock to be delivered when the common stock vests. The holders of restricted stock units
will have none of the rights of a stockholder of the Company until such time or times as shares of the common stock have been
issued to participant in settlement of the award. The Board shall determine the participants to whom and the time or times at which grants
of restricted stock units shall be awarded, the number of units to be awarded to any participant, the conditions for vesting,
the time or times within which such awards may be subject to forfeiture and restrictions on transfer and other terms and conditions of
the awards. Each restricted stock unit shall at all times be equal in value to the fair market value of one share of the common
stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Other Stock Based Awards</I>:</B> The Board
may grant or sell other awards that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based
on or related to, common stock or factors that may influence the value of such shares. In addition, the Board may grant unrestricted
shares to eligible participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Other Material Provisions</I>:</B> Awards will
be evidenced by a written agreement, in such form as may be approved by the Board. In the event of various changes to the capitalization
of our Company, such as stock splits, stock dividends and similar re-capitalizations, an appropriate adjustment will be made by
the Board to the number of shares covered by outstanding awards or to the exercise price of such awards. The Board is also
permitted to include in the written agreement provisions that provide for certain changes in the award in the event of a change of control
of our Company, including acceleration of vesting. Except as otherwise determined by the Board at the date of grant, awards
will not be transferable, other than by will or the laws of descent and distribution. Prior to any award distribution, we are permitted
to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements. The Board also has the authority,
at any time, to discontinue the granting of awards. The Board also has the authority to alter or amend the 2019 Plan or
any outstanding award or may terminate the 2019 Plan as to further grants, provided that no amendment will, without the approval
of our stockholders, increase the number of shares available under the 2019 Plan or change the persons eligible for awards under
the 2019 Plan. No amendment that would adversely affect any outstanding award made under the 2019 Plan can be made without
the consent of the holder of such award.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="aR_003"></A><B>CERTAIN
RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following includes a summary of transactions during our fiscal years ended December 31, 2020 and December 31, 2019 to which we have been
a party, including transactions in which the amount involved in the transaction exceeds the lesser of $120,000 or 1% of the average of
our total assets at year-end for the last two completed fiscal years, and in which any of our directors, executive officers or, to our
knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons
had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and
other arrangements, which are described elsewhere in this prospectus. We are not otherwise a party to a related party transaction, and
no transaction is currently proposed, in which the amount of the transaction exceeds the lesser of $120,000 or 1% of the average of our
total assets at year-end for the last two completed fiscal years and in which a related person had or will have a direct or indirect
material interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Convertible
Promissory Notes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commencing
                                            in May 2017, we entered into Subordinated Convertible Promissory Note Agreements with our
                                            Chief Executive Officer with respect to the issuance of convertible promissory notes in the
                                            aggregate principal amount of $2,031,236. The convertible promissory notes accrued
                                            interest at a rate of 5% per annum. Unless earlier converted into shares of Equity Securities
                                            (as defined herein), the principal and accrued interest shall be due and payable by the Company
                                            on demand by the holder thereof at any time after the earlier of (i) the Maturity Date (as
                                            defined in each note) and (ii) the closing of the Next Equity Financing (as defined herein).
                                            &ldquo;Equity Securities&rdquo; means, subject to certain exceptions, the Company&rsquo;s
                                            common stock, preferred stock and common stock and preferred stock equivalents. &ldquo;Next
                                            Equity Financing&rdquo; means the next sale (or series of related sales) by the Company of
                                            its Equity Securities from which the Company receives gross proceeds of not less than $5,000,000
                                            for notes issued from 2017 through November 2020 and $7,500,000 for notes issued in December
                                            2020 (including the aggregate amount of debt securities converted into Equity Securities
                                            upon conversion or cancellation of promissory notes). The principal amount of the notes together
                                            with interest accrued thereon will automatically be converted into the type of Equity Securities
                                            issued in the Next Equity Financing upon closing thereof. The number of Equity Securities
                                            to be issued upon such conversion shall be equal to the quotient obtained by dividing the
                                            outstanding principal amount together with interest accrued thereon by the lesser of (i)
                                            80% of the price paid per Equity Security in the Next Equity Financing or (ii) an equity
                                            valuation of $25 million for notes issued from 2017 through November 2020 and $50 million
                                            for notes issued in December 2020. This offering will qualify as a Next Equity Financing.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
September 27, 2020, we agreed to provide our Chief Executive Officer Exchange Notes in exchange for Original Notes which were
in default at such time by more than 90 days. The Original Notes had a principal of approximately $265,000 and accrued interest of $37,000
at December 31, 2019. As of September 27, 2020, the aggregate outstanding principal was approximately $265,000 and accrued interest (which
included the default interest rate of 20% as described above) was approximately $71,000. The Exchange Notes took the then principal
and accrued interest of the Original Notes and added an original issue discount of 37.5% to determine the new principal (which amounted
to an aggregate of $537,968) of the Exchange Notes outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective
October 1, 2020, all notes held by our Chief Executive Officer which matured, and were not repaid or converted, were rolled over on substantially
the same terms as the original notes with a new two year term. Effective December 1, 2020, all notes held by our Chief Executive Officer
which matured, and were not repaid or converted, were rolled over on substantially the same terms as the original notes with a new three
year term. The principal amount of the notes together with interest accrued thereon will automatically be converted into the type of
Equity Securities issued in the Next Equity Financing upon closing thereof. This offering will qualify as a Next Equity Financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 22, 2020, we issued Leonard Mazur a subordinated convertible promissory note in the principal amount of $300,000. The note accrues
interest at 5% per annum and, unless earlier converted, matures upon the earlier of December 31, 2023 and the closing of the Next Equity
Financing. The principal amount of the note together with any accrued interest thereon will automatically convert into the type of Equity
Securities issued in the Next Equity Financing upon the closing thereof. The number of Equity Securities to be issued upon such conversion
shall be equal to the quotient obtained by dividing the outstanding principal amount together with interest accrued thereon by the lesser
of (i) 80% of the price paid per Equity Security in the Next Equity Financing or (ii) an equity valuation of $50 million. This offering
will qualify as a Next Equity Financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Payments
to the Chief Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2020 and 2019, we owed our Chief Executive Officer $200,000 and $255,068, respectively. The expenses were comprised of
expenses paid by the Chief Executive Officer on behalf of our Company of $55,068 (which was converted into a convertible promissory note
in 2020) and $200,000 for accrued compensation at December 31, 2019. At December 31, 2020, the balance comprised $200,000 for accrued
compensation.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Related
Person Transaction Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, we have not had a formal policy regarding approval of transactions with related parties. Upon consummation of this
offering, we shall adopt a related person transaction policy that sets forth our procedures for the identification, review, consideration
and approval or ratification of related person transactions. The policy will become effective immediately upon the execution of the underwriting
agreement for this offering. For purposes of our policy only, a related person transaction is a transaction, arrangement or relationship,
or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants
in which the amount involved exceeds the lesser of $120,000 or 1% of the average of our total assets at year-end. Transactions involving
compensation for services provided to us as an employee or director are not covered by this policy. A related person is any executive
officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family
members and any entity owned or controlled by such persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person
transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to
consummation, our management must present information regarding the related person transaction to our audit committee, or, if audit committee
approval would be inappropriate, to another independent body of our board of directors, for review, consideration and approval or ratification.
The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related
persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to
or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information
that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable
us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our
code of business conduct and ethics, our employees and directors will have an affirmative responsibility to disclose any transaction
or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions,
our audit committee, or other independent body of our board of directors, will take into account the relevant available facts and circumstances
including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risks, costs and benefits to us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact on a director&rsquo;s independence in the event that the related person is a director, immediate family member of a director
    or an entity with which a director is affiliated;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of other sources for comparable services or products; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms available to or from, as the case may be, unrelated third parties or to or from employees generally.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
policy requires that, in determining whether to approve, ratify or reject a related person transaction, our audit committee, or other
independent body of our board of directors, must consider, in light of known circumstances, whether the transaction is in, or is not
inconsistent with, our best interests and those of our stockholders, as our audit committee, or other independent body of our board of
directors, determines in the good faith exercise of its discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="aR_004"></A><B>PRINCIPAL
STOCKHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information regarding the beneficial ownership of our common stock as of September 17, 2021
by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our named executive officers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of our current directors and named executive officers as a group; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    stockholder known by us to own beneficially more than 5% of our common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities.
Shares of common stock that may be acquired by an individual or group within 60 days of September 17, 2021, pursuant to the exercise
of options or warrants, vesting of common stock or conversion of convertible debt, are deemed to be outstanding for the purpose of computing
the percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage
ownership of any other person shown in the table. Percentage of ownership before the offering is based on 6,357,314 shares of
common stock issued and outstanding as of September 17, 2021 and excludes the conversion of all outstanding convertible notes.
Percentage of ownership after the offering is based on 10,277,221 shares of common stock issued and outstanding as of September
17, 2021 assuming the conversion of all outstanding convertible notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
noted otherwise, the address of all listed stockholders is c/o Hillstream BioPharma, Inc., 1200 Route 22 East, Suite 200, Bridgewater,
NJ 08807.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as indicated by the footnotes below, we believe, based on information furnished to us, that each of the stockholders listed has sole
voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community
property laws where applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of
    Shares<BR>
    Beneficially Owned</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage
    of Common<BR>
    Stock Beneficially Owned</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of
    Beneficial Owner</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prior
    to <BR>
    Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Before<BR>
    Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>After<BR>
    Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors and Named Executive Officers:</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy Milby</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; text-align: right">3,067,037<P STYLE="margin: 0"></P></TD>
    <TD STYLE="width: 1%; text-align: right"></TD>
    <TD STYLE="width: 2%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; text-align: right">40.08<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; text-align: right">28.23</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Leonard Mazur</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">73,850<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">*</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Lynne Bui</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,043</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">*</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">*</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Sireesh Appajosyula</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,373,103</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)(5)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21.46</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">13.31</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All current named executive officers and directors
    as a group (4 persons)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">4,534,033</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">58.23<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">41.48<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5% or Greater Stockholders:</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Highpoint Pharmaceuticals LLC (5)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">972,222</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.29</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">9.46</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kufe LLC (6)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0">833,240</P></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">(7)</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0">13.06</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">8.11<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald Kufe</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0">834,186</P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: right"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)(8)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0">13.07</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">8.12<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surender Kharbanda</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">722,186</FONT></TD>
    <TD STYLE="text-align: right"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.36</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">7.03<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Varinder Kaur</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">653,059</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.27</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">6.35<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bearing Circle Capital LLC (10)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0">659,030</P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">(11)</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0">10.33</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">6.41<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Escape Investment LLC (12)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0">509,197</P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">(13)</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0">7.91</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">4.52<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    (i) 1,772,725 shares of common stock, (ii) 589,040 shares of common stock issuable upon exercise of options and (iii)
    705,272 shares of common stock issuable upon conversion of $2,903,527 of outstanding convertible notes, including interest
    accrued thereon, assuming an initial public offering price of $5.50 per share, the midpoint of the range set forth on the
    cover page of this prospectus. Excludes 32,719 shares of common stock issuable upon exercise of options which are subject
    to vesting.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    (i) 3,156 shares of common stock issuable upon exercise of options and (ii) 70,694 shares of common stock issuable
    upon conversion of $311,056 of outstanding convertible notes, including interest accrued thereon, assuming an initial public
    offering price of $5.50 per share, the midpoint of the range set forth on the cover page of this prospectus. Excludes options
    to purchase up to 6,313 shares of common stock, which options vest in 10 equal monthly installments.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    options to purchase up to 20,043 shares of the Company&rsquo;s common stock. Excludes options to purchase up to 8,365
    shares of common stock, which options vest in 10 equal monthly installments.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    (i) 41,034 shares of common stock issuable upon exercise of options, (ii) 284,090 shares of common stock, (iii)
    972,222 shares of common stock held by Highpoint Pharmaceuticals LLC and (iv) 75,757 shares of common stock held by Mercer
    Lake Group LLC. Excludes options to purchase up to 6,313 shares of common stock, which options vest in 10 equal monthly
    installments.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sireesh
    Appajosyula is the Managing Member of each of Highpoint Pharmaceuticals LLC and Mercer Lake Group LLC and in such capacity
    has the right to vote and dispose of the securities held by such entities. The address of Highpoint Pharmaceuticals LLC is 16192 Coastal
Highway Lewes, DE 19958. The address of Mercer Lake Group LLC is 1200 Route 22 East,
    Suite 2000, Bridgewater, NJ 08807.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald
    Kufe is the Managing Director of Kufe LLC and in such capacity has the right to vote and dispose of the securities held by such entity.
    The address of Kufe LLC is 179 Grove Street, Wellesley, MA 02482.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    (i) 810,395, shares of common stock and (ii) 22,845 shares of common stock issuable upon conversion of
    $100,521 of outstanding convertible notes including interest accrued thereon, assuming an initial public offering price of $5.50
    per share, the midpoint of the range set forth on the cover page of this prospectus.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i)
    810,395 shares of common stock held by Kufe LLC, (ii) 946 shares of common stock issuable upon exercise of options held
    by Donald Kufe and (iii) 22,845 shares of common stock issuable upon conversion of $100,521 of outstanding convertible notes,
    including interest accrued thereon held by Kufe LLC, assuming an initial public offering price of $5.50 per share, the
    midpoint of the range set forth on the cover page of this prospectus.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(9)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Represents 721,240 shares of common stock and (ii)
    946 shares of common stock issuable upon exercise of options.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandeep
    Laumas is the Managing Member of Bearing Circle Capital LLC and in such capacity has the right to vote and dispose of the securities
    held by such entity.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(11)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Represents
                                            (i) 636,008 shares of common stock  and (ii) 23,022 shares
                                            of common stock issuable upon conversion of $101,302 of outstanding convertible notes, including
                                            interest accrued thereon, assuming an initial public offering price of $5.50 per share, the midpoint
                                            of the range set forth on the cover page of this prospectus.</P>
</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Veronica
    Todd is the Managing Member of Escape Investment LLC and in such capacity has the right to vote and dispose of the securities held
    by such entity. The address of Escape Investment LLC is 245 Main Street, Suite 204, Chester, NJ 07930.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(13)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Represents (i) 431,818 shares of common stock  and (ii) 77,379 shares of common stock issuable upon conversion of $316,881 of outstanding convertible notes, including interest accrued
thereon, assuming an initial public offering price of $5.50 per share, the midpoint of the range set forth on the cover page of this prospectus.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="aR_005"></A><B>DESCRIPTION
OF CAPITAL STOCK</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our authorized capital stock consists
of 250,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of September 17, 2021, there were 9 record holders of our securities. As of September 17, 2021 there were 6,357,314
shares of common stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following description of our capital stock and provisions of our Certificate of Incorporation and Bylaws is only a summary. You
should refer to our Certificate of Incorporation and Bylaws, copies of which are filed as exhibits to the registration statement
of which this prospectus is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are authorized to issue up to a total of 250,000,000 shares of common stock, par value $0.0001 per share. Holders of our common stock
are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. Holders of our common stock have
no cumulative voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
holders of our common stock have no preemptive or conversion rights or other subscription rights. Upon our liquidation, dissolution or
winding-up, holders of our common stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation
preferences of any of our outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares
of preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our
board of directors out of our assets which are legally available. Each outstanding share of our common stock is, and all shares of common
stock to be issued in this offering when they are paid for will be, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of a majority of the shares of our capital stock, represented in person or by proxy, are necessary to constitute a quorum for
the transaction of business at any meeting. If a quorum is present, an action by stockholders entitled to vote on a matter is approved
if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action, with the exception of
the election of directors, which requires a plurality of the votes cast.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors will have the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred
stock in one or more series and to fix the designations, powers, preferences, privileges, and relative participating, optional, or special
rights as well as the qualifications, limitations, or restrictions of the preferred stock, including dividend rights, conversion rights,
voting rights, terms of redemption, and liquidation preferences, any or all of which may be greater than the rights of the common stock.
Our board of directors, without stockholder approval, will be able to issue convertible preferred stock with voting, conversion, or other
rights that could adversely affect the voting power and other rights of the holders of common stock. Preferred stock could be issued
quickly with terms calculated to delay or prevent a change of control or make removal of management more difficult. Additionally, the
issuance of preferred stock may have the effect of decreasing the market price of our common stock, and may adversely affect the voting
and other rights of the holders of common stock. At present, we have no plans to issue any shares of preferred stock following this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
2017 Plan and 2019 Plan provide for us to sell or issue shares of common stock or restricted shares of common stock, or
to grant incentive stock options or nonqualified stock options, stock appreciation rights and restricted stock unit awards
for the purchase of shares of common stock to certain service providers. As of September 17, 2021, options to purchase 903,468
shares of our common stock were issued and outstanding. For additional information regarding the terms of our plans, see &ldquo;Executive
and Director Compensation&mdash;2017 Stock Incentive Plan and &ndash; 2019 Stock Incentive Plan.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exclusive
Forum</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Certificate of Incorporation provides that unless we consent in writing to the selection of an alternative forum, the State of Delaware
is the sole and exclusive forum for: (i) any derivative action or proceeding brought on behalf of us, (ii) any action asserting a claim
of breach of a fiduciary duty owed by any director, officer or other employee of our Company to us or our stockholders, (iii) any action
asserting arising pursuant to any provision of the DGCL or our Certificate of
Incorporation or our Bylaws or (iv) any action asserting a claim governed by
the internal affairs doctrine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the
exclusive forum for the resolution of any complaint asserting a cause of action arising under the Exchange Act or Securities Act. Any
person or entity purchasing or otherwise acquiring any interest in shares of our capital stock are deemed to have notice of and consented
to this provision</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover Provisions of Delaware Law, our Certificate of Incorporation
and our Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Delaware
Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are governed by the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly traded Delaware corporation from
engaging in a business combination with an interested stockholder for a period of three years after the date of the transaction in which
the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A business combination
includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder. An interested stockholder is
a person who, together with affiliates and associates, owns (or within three years, did own) 15% or more of the corporation&rsquo;s voting
stock, subject to certain exceptions. The statute could have the effect of delaying, deferring or preventing a change in control of our
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Board
of Directors Vacancies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Bylaws authorize our board of directors to fill vacant directorships. In addition, the number of directors constituting our board of
directors may be set by resolution of the incumbent directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Special
Meeting of Stockholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Bylaws provide that special meetings of our stockholders may be called by the board of directors, the Chief Executive Officer, or
the President (in the absence of a Chief Executive Officer), the chairman of the board of directors or stockholders entitled to
cast at least one-fifth of the votes which all stockholders are entitled to cast at the particular meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Advance
Notice Requirements for Stockholder Proposals and Director Nominations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Bylaws provide that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election
as directors at our annual meeting of stockholders, must provide timely notice of their intent in writing. To be timely, a stockholder&rsquo;s
notice must be delivered to the secretary at our principal executive offices not later than the close of business on the 60<SUP>th
</SUP>day nor earlier than the close of business on the 90<SUP>th</SUP> day prior to the first anniversary of the preceding
year&rsquo;s annual meeting; provided, however, that in the event the date of the annual meeting is more than 30 days before or more
than 60 days after such anniversary date, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely
must be so delivered not earlier than the close of business on the 90<SUP>th</SUP> day prior to such annual meeting and not later
than the close of business on the later of the 60<SUP>th</SUP> day prior to such annual meeting or the 10<SUP>th</SUP>
day following the day on which a public announcement of the date of such meeting is first made by us. These provisions may preclude our
stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting
of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Authorized
but Unissued Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval and
may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions
and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more
difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. If we issue
such shares without stockholder approval and in violation of limitations imposed by The Nasdaq Capital Market or any stock exchange on
which our stock may then be trading, our stock could be delisted.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transfer
Agent and Registrar</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is Philadelphia Stock Transfer, Inc. whose address is 2320 Haverford Road, Suite
230, Ardmore, PA 19003.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Market Listing</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have applied to have our shares of common stock listed for trading on The Nasdaq Capital Market under the symbol &ldquo;HILS.&rdquo;
No assurance can be given that such listing will be approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_006"></A>SHARES
ELIGIBLE FOR FUTURE SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has been no public market for our common stock, and a liquid trading market for our common stock may not develop
or be sustained after this offering. Future sales of substantial amounts of our common stock in the public market, or the anticipation
of these sales, could materially and adversely affect market prices prevailing from time to time, and could impair our ability to raise
capital through sales of equity or equity-related securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
a limited number of shares of our common stock will be available for sale in the public market for a period of several months after completion
of this offering due to contractual and legal restrictions on resale described below. Nevertheless, sales of a substantial number of
shares of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could materially
and adversely affect the prevailing market price of our common stock. Although we have applied to list our common stock on The Nasdaq
Capital Market, we cannot assure you that there will be an active market for our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Of
the shares to be outstanding immediately after the completion of this offering, we expect that the shares to be sold in this offering will be freely tradable without restriction under the Securities Act
unless purchased by our &ldquo;affiliates,&rdquo; as that term is defined in Rule 144 under the Securities Act. Certain of the remaining
shares of our common stock outstanding after this offering will be subject to a lock-up period under the lock-up agreements as described
below. These restricted securities may be sold in the public market only if registered or pursuant to an exemption from registration,
such as Rule 144 or Rule 701 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Affiliate
Resales of Restricted Securities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Affiliates
of ours must generally comply with Rule 144 if they wish to sell any shares of our common stock in the public market, whether or not
those shares are &ldquo;restricted securities.&rdquo; &ldquo;Restricted securities&rdquo; are any securities acquired from us or one
of our affiliates in a transaction not involving a public offering. All shares of our common stock issued prior to the closing of the
offering made hereby, are considered to be restricted securities. The shares of our common stock sold in this offering are not considered
to be restricted securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Non-Affiliate
Resales of Restricted Securities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
person or entity who is not an affiliate of ours and who has not been an affiliate of ours at any time during the three months preceding
a sale is only required to comply with Rule 144 in connection with sales of restricted shares of our common stock. Subject to the lock-up
agreements described below, those persons may sell shares of our common stock that they have beneficially owned for at least one year
without any restrictions under Rule 144 immediately following the effective date of the registration statement of which this prospectus
is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not an affiliate
of ours at the time such person sells shares of our common stock, and has not been an affiliate of ours at any time during the three
months preceding such sale, and who has beneficially owned such shares of our common stock for at least six months but less than a year,
is entitled to sell such shares so long as there is adequate current public information, as defined in Rule 144, available about us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resales
of restricted shares of our common stock by non-affiliates are not subject to the manner of sale, volume limitation or notice filing
provisions of Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
701</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
701 generally allows a stockholder who purchased shares of our common stock pursuant to a written compensatory plan or contract and who
is not deemed to have been an affiliate of ours during the immediately preceding 90 days to sell these shares in reliance upon Rule 144,
but without being required to comply with the public information, holding period, volume limitation, or notice provisions of Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Rule
701 also permits affiliates of ours to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements
of Rule 144. All holders of Rule 701 shares, however, are required to wait until 90 days after the date of this prospectus before selling
such shares pursuant to Rule 701 and until expiration of the lock-up period described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
Incentive Awards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to file a registration statement on Form S-8 under the Securities Act after the closing of this offering to register the shares
of common stock that are issuable pursuant to our 2019 Plan. The registration statement is expected to be filed and become
effective as soon as practicable after the completion of this offering. Accordingly, shares registered under the registration statement
will be available for sale in the open market following its effective date, subject to Rule 144 volume limitations and the lock-up arrangements
described below, if applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, each of our directors and executive officers, and our stockholders, have agreed, subject to certain limited exceptions, not
to offer, pledge, sell, contract to sell, grant any option to purchase, or otherwise dispose of our common stock or any securities convertible
into or exchangeable or exercisable for common stock, or to enter into any hedge or other arrangement or any transaction that transfers,
directly or indirectly, the economic consequence of ownership of the shares of our common stock, in the case of the Company and our stockholders
for a period of 180 days after the date of this prospectus, and in the case of our directors and executive officers for a period of 365
days after the date of this prospectus, without the prior written consent of <FONT STYLE="letter-spacing: 0.2pt">ThinkEquity as representative
of the underwriters. See &ldquo;Underwriting&mdash;Lock-up Agreements.&rdquo; The underwriters do not have any present intention or arrangement
to release any shares of our common stock subject to lock-up agreements prior to the expiration of the 180- or 365-day lock-up period.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_007"></A>MATERIAL
U.S. FEDERAL INCOME TAX CONSEQUENCES TO<BR>
NON-U.S. HOLDERS OF OUR COMMON STOCK</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the material U.S. federal income tax consequences to non-U.S. holders (as defined below) of the ownership and
disposition of our common stock but does not purport to be a complete analysis of all the potential tax considerations relating thereto.
This summary is based upon the provisions of the Internal Revenue Code Treasury regulations promulgated thereunder, administrative rulings
and judicial decisions, all as of the date hereof. These authorities may be changed, possibly retroactively, so as to result in U.S.
federal income tax consequences different from those set forth below. No ruling on the U.S. federal, state, or local tax considerations
relevant to our operations or to the purchase, ownership or disposition of our shares, has been requested from the IRS or other tax authority.
No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to any of the tax consequences
described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary also does not address the tax considerations arising under the laws of any non-U.S., state or local jurisdiction, or under U.S.
federal gift and estate tax laws. In addition, this discussion does not address tax considerations
applicable to an investor&rsquo;s particular circumstances or to investors that may be subject to special tax rules, including, without
limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks,
    insurance companies or other financial institutions, regulated investment companies or real estate investment trusts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    subject to the alternative minimum tax or Medicare contribution tax on net investment income;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt
    organizations or governmental organizations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">controlled
    foreign corporations, passive foreign investment companies and corporations that accumulate earnings to avoid U.S. federal income
    tax;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">brokers
    or dealers in securities or currencies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">traders
    in securities that elect to use a mark-to-market method of accounting for their securities holdings;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    that own, or are deemed to own, more than five percent of our capital stock (except to the extent specifically set forth below);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
    expatriates and certain former citizens or long-term residents of the U.S.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">partnerships
    or entities classified as partnerships for U.S. federal income tax purposes or other pass-through entities (and investors therein);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    who hold our common stock as a position in a hedging transaction, &ldquo;straddle,&rdquo; &ldquo;conversion transaction&rdquo; or
    other risk reduction transaction or integrated investment;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    who do not hold our common stock as a capital asset within the meaning of Section 1221 of the Internal Revenue Code; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    deemed to sell our common stock under the constructive sale provisions of the Internal Revenue Code.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-U.S.
holders</B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> are urged to consult their own tax advisors
with respect to the application of the U.S. federal income tax laws to their particular situation, as well as any tax consequences
of the purchase, ownership and disposition of our common stock arising under the U.S. federal estate or gift tax rules or under the laws
of any state, local, non-U.S., or other taxing jurisdiction or under any applicable tax treaty.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Non-U.S.
Holder Defined</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this discussion, a non-U.S. holder (other than a partnership) is any holder of our common stock other than:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    individual citizen or resident of the U.S. (for U.S. federal income tax purposes);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    corporation or other entity taxable as a corporation created or organized in the U.S. or under the laws of the U.S., any state thereof,
    or the District of Columbia, or other entity treated as such for U.S. federal income tax purposes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    estate whose income is subject to U.S. federal income tax regardless of its source; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    trust (x) whose administration is subject to the primary supervision of a U.S. court and which has one or more &ldquo;U.S. persons&rdquo;
    (within the meaning of Section 7701(a)(30) of the Internal Revenue Code) who have the authority to control all substantial decisions
    of the trust or (y) which has made a valid election to be treated as a U.S. person.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if a partnership or entity classified as a partnership for U.S. federal income tax purposes holds our common stock, the tax
treatment of a partner generally will depend on the status of the partner and upon the activities of the partnership. Accordingly, partnerships
that hold our common stock, and partners in such partnerships, should consult their tax advisors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Distributions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in &ldquo;Dividend Policy,&rdquo; we have never declared or paid cash dividends on our common stock and do not anticipate paying
any dividends on our common stock in the foreseeable future. However, if we do make distributions on our common stock, those payments
will constitute dividends for U.S. tax purposes to the extent paid from our current or accumulated earnings and profits, as determined
under U.S. federal income tax principles. To the extent those distributions exceed both our current and our accumulated earnings and
profits, they will constitute a non-taxable return of capital and will first reduce a non-U.S. holder&rsquo;s basis in
our common stock, but not below zero, and then will be treated as gain from the sale of stock as described below under &ldquo;Gain on Disposition of Common Stock.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below on effectively connected income, backup withholding and foreign accounts, any dividend paid to a non-U.S.
holder generally will be subject to U.S. withholding tax either at a rate of 30% of the gross amount of the dividend or at
such lower rate as may be specified by an applicable income tax treaty. In order to receive a reduced treaty rate, a non-U.S. holder
must provide us (or the applicable withholding agent) with an IRS Form W-8BEN, IRS Form W-8BEN-E or other appropriate version
of IRS Form W-8 certifying qualification for the reduced rate. A non-U.S. holder of shares of our common stock eligible for a reduced
rate of U.S. withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by timely filing an
appropriate claim for refund with the IRS. If the non-U.S. holder holds the stock through a financial institution or other agent acting
on the non-U.S. holder&rsquo;s behalf, the non-U.S. holder will be required to provide appropriate documentation to the agent, which
then will be required to provide certification to us or our paying agent, either directly or through other intermediaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dividends received by a non-U.S. holder that
are effectively connected with the non-U.S. holder&rsquo;s conduct of a U.S. trade or business (and, if required by an applicable
income tax treaty, attributable to a permanent establishment maintained by the non-U.S. holder in the U.S.) are generally exempt
from such withholding tax. In order to obtain this exemption, a non-U.S. holder must provide us with an IRS Form W-8ECI or other
applicable IRS Form W-8 properly certifying such exemption. Such effectively connected dividends, although not subject to withholding
tax, are taxed at the same graduated rates applicable to U.S. persons, net of certain deductions and credits. In addition, dividends
received by a non-U.S. holder that is a corporation that are effectively connected with such non-U.S. holder&rsquo;s
conduct of a U.S. trade or business may also be subject to a branch profits tax at a rate of 30% or at such lower rate as
may be specified by an applicable income tax treaty. Non-U.S. holders should consult their own tax advisors regarding
any applicable tax treaties that may provide for different rules.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Gain
on Disposition of Common Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below regarding backup withholding and foreign accounts, a non-U.S. holder generally will not be required to
pay U.S. federal income tax on any gain realized upon the sale or other disposition of our common stock unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    gain is effectively connected with the non-U.S. holder&rsquo;s conduct of a U.S. trade or business (and, if required by an
    applicable income tax treaty, the gain is attributable to a permanent establishment maintained by the non-U.S. holder in the
    U.S.);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    non-U.S. holder is</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> a non-resident alien individual who is present
    in the U.S. for a period or periods aggregating 183 days or more during the taxable year in which the sale or disposition occurs
    and certain other conditions are met; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    common stock constitutes a U.S. real property interest by reason of our status as a &ldquo;U.S. real property holding corporation,&rdquo;
    (&ldquo;USRPHC&rdquo;) for U.S. federal income tax purposes at any time within the shorter of (i) the five-year period preceding
    the non-U.S. holder&rsquo;s disposition of our common stock, or (ii) the non-U.S. holder&rsquo;s holding period for
    our common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Generally, a corporation is a USRPHC if the fair
market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property
interests and its other assets used or held for use in a trade or business. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we are not currently and will not become a USRPHC for U.S. federal income tax purposes, and the remainder of this discussion
so assumes. However, because the determination of whether we are a USRPHC depends on the fair market value of our U.S. real property
relative to the fair market value of our other business assets, there can be no assurance that we will not become a USRPHC in the future.
Even if we become a USRPHC, however, a non-U.S. holder would not be subject to U.S. federal income tax on a sale, exchange or other
taxable disposition of shares of our common stock by reason of our status as a USRPHC so long as (i) our common stock is regularly
traded on an established securities market during the calendar year in which such sale, exchange or other tax disposition of shares
of our common stock occurs and (ii) such non-U.S. holder does not own and is not deemed to own (directly, indirectly or constructively)
more than 5% of our common stock at any time during the relevant period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Non-U.S. holders described in the first bullet
above will be required to pay tax on the net gain derived from the sale under regular graduated U.S. federal income tax rates, and a
corporate non-U.S. holder described in the first bullet above also may be subject to the branch profits tax at a 30% rate, or such lower
rate as may be specified by an applicable income tax treaty. Non-U.S. holders described in the second bullet above will be required
to pay a flat 30% tax (or such lower rate specified by an applicable income tax treaty) on the gain derived from the sale, which gain
may generally be offset by U.S. source capital losses for the year (provided such non-U.S. holders have timely filed U.S.
federal income tax returns with respect to such losses). Non-U.S. holders should consult their own tax advisors with respect
to the application of the foregoing rules to their ownership and disposition of our common stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Backup
Withholding and Information Reporting</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
we must report annually to the IRS the amount of dividends paid to non-U.S. holders, their names and addresses and the
amount of tax withheld, if any. A similar report will be sent to non-U.S. holders. Pursuant to applicable income tax treaties
or other agreements, the IRS may make these reports available to tax authorities in a non-U.S. holder&rsquo;s country of residence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
of dividends or of proceeds on the disposition of stock made to non-U.S. holders may be subject to information reporting and backup
withholding at a current rate of 28% unless such non-U.S. holders establish an exemption, for example, by properly certifying
their non-U.S. status on an IRS Form W-8BEN, IRS Form W-8BEN-E or another appropriate version of IRS Form W-8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax; rather, the U.S. federal income tax liability of persons subject to backup withholding will be
reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained
from the IRS, provided that the required information is furnished to the IRS in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Foreign
Account Tax Compliance</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Foreign Account Tax Compliance Act (&ldquo;FATCA&rdquo;) imposes withholding tax at a rate of 30% on dividends on and gross proceeds
from the sale or other disposition of our common stock paid to &ldquo;foreign financial institutions&rdquo; (as specially defined under
these rules), unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect
and provide to the U.S. tax authorities substantial information regarding the U.S. account holders of such institution (which includes
certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or
otherwise establishes an exemption. FATCA also generally imposes a U.S. federal withholding tax of 30% on dividends on and gross proceeds
from the sale or other disposition of our common stock paid to a &ldquo;non-financial foreign entity&rdquo; (as specially defined for
purposes of these rules) unless such entity provides the withholding agent with a certification identifying certain substantial direct
and indirect U.S. owners of the entity, certifies that there are none or otherwise establishes an exemption. An intergovernmental agreement
between the U.S. and an applicable foreign country may modify the requirements described in this paragraph. Non-U.S. holders should consult
their tax advisors regarding the possible implications of this legislation on their investment in our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Each
prospective investor should consult its tax advisor regarding the particular U.S. federal, state and local and non-U.S. tax consequences
of purchasing, holding and disposing of our common stock, including the consequences of any proposed change in applicable laws.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_008"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an underwriting agreement, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021,
with <FONT STYLE="letter-spacing: 0.2pt">ThinkEquity acting as the sole book-running manager (sometimes referred to as the &ldquo;Representative&rdquo;).
Subject to the terms and conditions of the underwriting agreement, each of the underwriters named below have agreed to purchase, and
we have agreed to sell to it, the number of shares of common stock listed next to its name at the public offering price, less the underwriting
discounts and commissions, as set forth on the cover page of this prospectus and as indicated below:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriters</B></FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of<BR> Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 84%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: 0.2pt">ThinkEquity
                           LLC</FONT></P></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriting agreement provides that the obligations of the underwriters to pay for and accept delivery of the shares of common stock
offered by this prospectus are subject to various conditions and representations and warranties, including the approval of certain legal
matters by its counsel and other conditions specified in the underwriting agreement. The shares of common stock are offered by the underwriters,
subject to prior sale, when, as and if issued to and accepted by the underwriters. The underwriters reserve the right to withdraw, cancel
or modify the offer to the public and to reject orders in whole or in part. The underwriters are obligated to take and pay for all of
the shares of common stock offered by this prospectus if any such shares are taken.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the underwriters and certain of their affiliates and controlling persons (within the meaning of Section 15 of
the Securities Act or Section 20 of the Exchange Act), among others, against specified liabilities, including liabilities under the Securities
Act, and to contribute to payments the underwriters may be required to make in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discounts
and Commissions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters propose to offer the shares of common stock directly to the public at the public offering price set forth on the cover page
of this prospectus. After the offering to the public, the offering price and other selling terms may be changed by the underwriters without
changing the proceeds we will receive from the underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the public offering price, underwriting commissions and proceeds before expenses to us. The underwriting commissions
are 7.0% of the public offering price. We have also agreed to pay a non-accountable expense allowance to the Representative equal to
1.0% of the gross proceeds received at the closing of the offering. We have paid a $50,000 advance to the Representative,
which shall be applied against actual out-of-pocket-accountable expenses, which will be returned to us to the extent such out-of-pocket
accountable expenses are not actually incurred in accordance with FINRA Rule 5110(g)(4)(A).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per
    Share</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Without<BR> Over-Allotment<BR> Option</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    With Full<BR> Over-Allotment<BR> Option</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Public offering price</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriting discount (7%)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-accountable expense allowance (1%)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds, before expenses, to us</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>&nbsp;</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also agreed to pay certain of the Representative&rsquo;s expenses relating to the offering, including the fees and expenses of the
Representative&rsquo;s legal counsel, data services and communications expenses, road show expenses, market making and trading and clearing
firm settlement expenses, for the Representative&rsquo;s use of Ipreo&rsquo;s book-building and commemorative mementos and
lucite tombstones, prospectus tracking and compliance software for this offering, totaling $207,500.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
total estimated expenses of the offering, including registration, filing and listing fees, printing fees and legal and accounting expenses,
but excluding underwriting discounts and commissions, are approximately $575,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-Allotment
Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted a 45-day option to the Representative to purchase up to 450,000 additional shares of common stock from us solely
to cover over-allotments, if any, at the public offering price less underwriting discounts and commissions.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative&rsquo;s
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
closing of this offering, we have agreed to issue to the Representative, or its designees, as compensation warrants to purchase a number
of shares of common stock equal to 5% of the aggregate number of shares of common stock sold in this offering (the &ldquo;Representative&rsquo;s
Warrants&rdquo;). The Representative&rsquo;s Warrants will be exercisable at a per share exercise price equal to 125% of the public offering
price per share in this offering. The Representative&rsquo;s Warrants are exercisable at any time and from time to time, in whole or
in part, during the four and one-half year period commencing 180 days from the effective date of the registration statement of which
this prospectus is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Representative&rsquo;s Warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to FINRA
Rule 5110(e)(1). The Representative (or permitted assignees under Rule 5110(e)(2)) will not sell, transfer, assign, pledge, or hypothecate
these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call
transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180
days from the effective date of the registration statement. In addition, the warrants provide for registration rights upon request, in
certain cases. The one-time demand registration right provided will not be greater than five years from the effective date of the registration
statement in compliance with FINRA Rule 5110(g)(8)(C). The unlimited piggyback registration right provided will not be greater than seven
years from the effective date of the registration statement in compliance with FINRA Rule 5110(g)(8)(D). We will bear all fees and expenses
attendant to registering the securities issuable on exercise of the warrants other than underwriting commissions incurred and payable
by the holders. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances
including in the event of a stock dividend or our recapitalization, reorganization, merger or consolidation. However, the warrant exercise
price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discretionary
Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to &ldquo;lock-up&rdquo; agreements, we, our executive officers and directors, and our stockholders, have agreed, without the prior written
consent of the Representative, not to, directly or indirectly, offer to sell, sell, pledge or otherwise transfer or dispose of any of
shares of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition
by any person at any time in the future of) our common stock, enter into any swap or other derivatives transaction that transfers to
another, in whole or in part, any of the economic benefits or risks of ownership of shares of our common stock, make any demand for or
exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration
of any shares of common stock or securities convertible into or exercisable or exchangeable for shares of common stock or any other of
our securities or publicly disclose the intention to do any of the foregoing, subject to customary exceptions, for, with respect to the
Company and our stockholders, a period of 180 days from the date of this prospectus, and with respect to our executive officers and directors,
a period of 365 days from the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted the Representative a right of first refusal, for a period of 18 months from the closing of the offering, to act as sole
investment banker, sole book-runner, and/or placement agent, at the Representative&rsquo;s sole
and exclusive discretion, for each and every future public and private equity and debt offering, including all of our equity linked financings
(each, a &ldquo;Subject Transaction&rdquo;), or any successor (or any of our subsidiaries), on terms and conditions customary to the
Representative for such Subject Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
Capital Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have applied to have our shares of common stock listed on The Nasdaq Capital Market under the symbol &ldquo;HILS.&rdquo; Our application
might not be approved and the consummation of this offering is contingent upon such approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price
Stabilization, Short Positions and Penalty Bids</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to facilitate the offering of our securities, the underwriters may engage in transactions that stabilize, maintain or otherwise
affect the price of our securities. In connection with the offering, the underwriters may purchase and sell our securities in the open
market. These transactions may include short sales, purchases on the open market to cover positions created by short sales and stabilizing
transactions. Short sales involve the sale by the underwriters of a greater number of shares of securities than they are required to
purchase in the offering. &ldquo;Covered&rdquo; short sales are sales made in an amount not greater than the underwriters&rsquo; option
to purchase additional shares of securities in the offering. The underwriters may close out any covered short position by either exercising
the over-allotment option to purchase shares or purchasing shares in the open market. In determining the source of shares of securities
to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase
in the open market as compared to the price at which they may purchase shares through the over-allotment option to purchase shares. &ldquo;Naked&rdquo;
short sales are sales in excess of the over-allotment option to purchase shares. The underwriters must close out any naked short position
by purchasing securities in the open market. A naked short position is more likely to be created if the underwriters are concerned that
there may be downward pressure on the price of our securities in the open market after pricing that could adversely affect investors
who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of securities made by the underwriters
in the open market before the completion of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to other purchase transactions, the underwriters&rsquo; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our securities or preventing or retarding a decline in the market price of our securities. As result,
the price of our securities may be higher than the price that might otherwise exist in the open market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters make no representation or prediction as to the direction or magnitude of any effect that the transactions described above
may have on the price of our securities. In addition, neither we nor the underwriters make any representation that the underwriters will
engage in these transactions or that these transactions, once commenced, will not be discontinued without notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Offer, Sale and Distribution of Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on the websites maintained by the underwriters or selling group members, if any,
participating in the offering. The underwriters may agree to allocate a number of shares of securities to underwriters and selling group
members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriter and selling group
members that may make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format,
the information on any underwriter&rsquo;s website and any information contained in any other website maintained by an underwriter is
not part of this prospectus or the registration statement of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the underwriters and/or their affiliates may provide in the future, various advisory, investment and commercial banking
and other services to us in the ordinary course of business, for which they will receive customary fees and commissions. However, except
as disclosed in this prospectus, we have no present arrangements with the underwriters or any of their affiliates for any further services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pricing
of the Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price was determined by negotiations between us and the Representative. Among the factors considered in determining the
public offering price were our future prospects and those of our industry in general, our sales, earnings and certain other financial
and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities, and certain
financial and operating information of companies engaged in activities similar to ours. Neither we nor the underwriters can assure investors
that an active trading market for the shares will develop or that, after the offering, the shares will trade in the public market at
or above the public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offer
Restrictions Outside the United States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with
the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are
advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Canada</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted
clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale
of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements
of applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies
for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies
for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s
province or territory for particulars of these rights or consult with a legal advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>China</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in the People&rsquo;s
Republic of China (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau Special Administrative Region
and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to legal or natural persons other than directly
to &ldquo;qualified domestic institutional investors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>European
Economic Area&thinsp;&mdash;&thinsp;Belgium, Germany, Luxembourg and Netherlands</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this document has been prepared on the basis that all offers of securities will be made pursuant to an exemption under
the Directive 2003/71/EC (&ldquo;Prospectus Directive&rdquo;), as implemented in Member States of the European Economic Area (each, a
&ldquo;Relevant Member State&rdquo;), from the requirement to produce a prospectus for offers of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
offer to the public of securities has not been made, and may not be made, in a Relevant Member State except pursuant to one of the following
exemptions under the Prospectus Directive as implemented in that Relevant Member State:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose
    corporate purpose is solely to invest in securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    any legal entity that has two or more of (i) an average of at least 250 employees during its last fiscal year; (ii) a total balance
    sheet of more than &euro;43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii) an
    annual net turnover of more than &euro;50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive)
    subject to obtaining the prior consent of the Company or any underwriter for any such offer; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            any other circumstances falling within Article 3(2) of the Prospectus Directive, provided
                                            that no such offer of securities shall result in a requirement for the publication by the
                                            Company of a prospectus pursuant to Article 3 of the Prospectus Directive.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Hong
Kong</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the information in this document nor any other document relating to the offer has been delivered for registration to the Registrar of
Companies in Hong Kong, and its contents have not been reviewed or approved by any regulatory authority in Hong Kong, nor have we been
authorized by the Securities and Futures Commission in Hong Kong. This document does not constitute an offer or invitation to the public
in Hong Kong to acquire shares. Accordingly, unless permitted by the securities laws of Hong Kong, no person may issue or have in its
possession for the purpose of issue, this document or any advertisement, invitation or document relating to the shares, whether in Hong
Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong other
than in relation to shares which are intended to be disposed of only to persons outside Hong Kong or only to &ldquo;professional investors&rdquo;
(as such term is defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (&ldquo;SFO&rdquo;) and the subsidiary
legislation made thereunder) or in circumstances which do not result in this document being a &ldquo;prospectus&rdquo; as defined in
the Companies (Winding Up and Miscellaneous Provisions) Ordinance of Hong Kong (Cap. 32 of the Laws of Hong Kong) (the &ldquo;CO&rdquo;)
or which do not constitute an offer or an invitation to the public for the purposes of the SFO or the CO. The offer of the shares is
personal to the person to whom this document has been delivered by or on behalf of our company, and a subscription for shares will only
be accepted from such person. No person to whom a copy of this document is issued may issue, circulate or distribute this document in
Hong Kong or make or give a copy of this document to any other person. You are advised to exercise caution in relation to the offer.
If you are in any doubt about any of the contents of this document, you should obtain independent professional advice. No document may
be distributed, published or reproduced (in whole or in part), disclosed by or to any other person in Hong Kong or to any person to whom
the offer of sale of the shares would be a breach of the CO or SFO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Israel</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority (the &ldquo;ISA&rdquo;),
nor have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public
in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with the offering
or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered
an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities
offered by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities
laws and regulations.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>United
Kingdom</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Services
Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as
amended (&ldquo;FSMA&rdquo;)) has been published or is intended to be published in respect of the securities. This document is issued
on a confidential basis to &ldquo;qualified investors&rdquo; (within the meaning of section 86(7) of FSMA) in the United Kingdom, and
the securities may not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any other document,
except in circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not
be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in
the United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the
issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be
communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to our Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters
relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial
Promotions) Order 2005 (&ldquo;FPO&rdquo;), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high
net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together
&ldquo;relevant persons&rdquo;). The investments to which this document relates are available only to, and any invitation, offer or agreement
to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document
or any of its contents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_009"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the issuance of the common stock offered by us in this offering will be passed upon for us by Sheppard, Mullin, Richter &amp;
Hampton LLP, New York, New York. Certain legal matters in connection with this offering will be passed upon for the underwriters by Dentons
US LLP, New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_010"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of Hillstream BioPharma, Inc. as of and for the years ended December 31, 2020 and 2019, included in
this registration statement, of which this prospectus forms a part, have been audited by Mayer Hoffman McCann P.C., independent registered
public accounting firm, as set forth in their report (which includes an explanatory paragraph related to the existence of substantial
doubt about the Company&rsquo;s ability to continue as a going concern) appearing elsewhere herein, and are included in reliance upon
such report given on the authority of such firm as experts in auditing and accounting in giving said report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="aR_011"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the common stock offered by this
prospectus. This prospectus, which is part of the registration statement, omits certain information, exhibits, schedules and undertakings
set forth in the registration statement. For further information pertaining to us and our common stock, reference is made to the registration
statement and the exhibits and schedules to the registration statement. Statements contained in this prospectus as to the contents or
provisions of any documents referred to in this prospectus are not necessarily complete, and in each instance where a copy of the document
has been filed as an exhibit to the registration statement, reference is made to the exhibit for a more complete description of the matters
involved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may read and copy all or any portion of the registration statement without charge at the public reference room of the SEC at 100 F Street,
N.E., Washington, D.C. 20549. Copies of the registration statement may be obtained from the SEC at prescribed rates from the public reference
room of the SEC at such address. You may obtain information regarding the operation of the public reference room by calling 1-800-SEC-0330.
In addition, registration statements and certain other filings made with the SEC electronically are publicly available through the SEC&rsquo;s
website at http://www.sec.gov. The registration statement, including all exhibits and amendments to the registration statement, has been
filed electronically with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, we will become subject to the information and periodic reporting requirements of the Exchange Act, and,
accordingly, will be required to file annual reports containing financial statements audited by an independent public accounting firm,
quarterly reports containing unaudited financial data, current reports, proxy statements and other information with the SEC. You will
be able to inspect and copy such periodic reports, proxy statements and other information at the SEC&rsquo;s public reference room, and
the website of SEC referred to above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_007"></A>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEX
TO FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B>&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUDITED
    FINANCIAL STATEMENTS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_001">Report
    of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_002">Consolidated
    Balance Sheets as of December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_003">Consolidated
    Statements of Operations for the Years Ended December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_004">Consolidated
    Statements of Changes in Stockholders&rsquo; Deficit for the Years Ended December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_005">Consolidated
    Statements of Cash Flows for the Years Ended December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pri_006">Notes
    to Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">UNAUDITED FINANCIAL STATEMENTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#a_001">Condensed Consolidated Balance Sheets as of June 30, 2021 (Unaudited) and December 31, 2020</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 48px; text-align: center"><FONT STYLE="font-size: 10pt">F-23</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#a_002">Condensed Consolidated Statements of Operations for the Six Months Ended June 30, 2021 and 2020 (Unaudited)</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-24</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#a_003">Condensed Consolidated Statements of Changes in Stockholders&rsquo; Deficit for the Six Months Ended March June 30, 2021 and 2020 (Unaudited)</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-25</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#a_004">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2021 and 2020 (Unaudited)</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-26</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#a_005">Notes to Condensed Consolidated Financial Statements (Unaudited)</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-27</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 114; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="pri_001"></A><B>Report
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">To the Board
of Directors and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stockholders
of Hillstream BioPharma, Inc.:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Opinion on
the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have audited the accompanying consolidated balance sheets of Hillstream BioPharma, Inc. (&ldquo;Company&rdquo;) as of December 31, 2020
and 2019, and the related consolidated statements of operations, changes in stockholders&rsquo; deficit, and cash flows for each of the
two years in the period ended December 31, 2020, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020,
in conformity with accounting principles generally accepted in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Going
Concern Uncertainty</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
1 to the financial statements, the Company has incurred recurring negative cash flows from operations and is dependent on additional
financing to fund operations. These conditions raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.
Management&rsquo;s plans in regard to these matters are also described in Note 1 to the financial statements. The financial statements
do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts
and classification of liabilities that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Basis for
Opinion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ Mayer
Hoffman McCann P.C.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have served
as the Company&rsquo;s auditor since 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">San Diego, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">May 17, 2021 (except for the effects of the reverse stock split described
in Note 2 and Note 11D, as to which the date is September 27, 2021)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 115 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_002"></A>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
BALANCE SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    assets:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">191,852</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,281</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,946</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,600</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current assets</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">294,798</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,881</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">294,798</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,881</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
    and Stockholders&rsquo; Deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">514,828</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">241,409</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    interest</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73,066</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61,429</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
    to founder</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">255,068</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,777</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,626</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redemption
    liability</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,325,288</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">126,183</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
    portion of related party convertible notes, net</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">563,425</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">430,600</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,725,384</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,130,315</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    party convertible notes, net, less short term portion</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,286,942</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">532,766</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,012,326</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,663,081</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments
    and contingencies (See Note 10)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&rsquo;
    deficit:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2020 and 2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock, $0.0001 par value, 250,000,000 shares authorized, 6,357,314 and 6,281,557 shares issued and outstanding as of
    December 31, 2020 and 2019, respectively</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">628</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in capital</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">986,443</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">462,671</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,704,607</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,085,499</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholders&rsquo; deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,717,528</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,622,200</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities and stockholders&rsquo; deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">294,798</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,881</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying footnotes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 116 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_003"></A>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the years ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">847,272</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">368,732</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
    in-process research and development</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">289,200</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">429,403</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">671,879</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">625,807</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,808,351</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,423,942</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from operations</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,808,351</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,423,942</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Expense:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">246,534</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,074</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in redemption value</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">362,486</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,458</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other expenses</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">609,020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101,532</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,417,371</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,525,474</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per share:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.38</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.41</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average number of common shares outstanding:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,347,144</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,753,886</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 117 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_004"></A>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Paid-in</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Stockholders&rsquo;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Par Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; font-weight: bold">Balance at December 31, 2018</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,335,855</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">234</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">58,553</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(560,025</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(501,238</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance of shares for the acquisition of NanoProteagen LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,335,856</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">234</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">184,766</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">185,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,012</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercise of stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,609,846</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,525,474</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,525,474</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Balance at December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,281,557</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">628</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">462,671</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,085,499</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,622,200</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of shares for the acquisition of Farrington Therapeutics LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,757</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">289,192</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">289,200</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">234,580</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">234,580</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deemed dividend upon debt exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(201,737</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(201,737</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,417,371</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,417,371</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2020</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,357,134</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">636</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">986,443</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(4,704,607</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(3,717,528</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying footnotes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 118 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_005"></A>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Consolidated
Statement of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For the years
    ended</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash flows from operating activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD><TD STYLE="width: 2%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,417,371</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,525,474</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustments to reconcile
    net loss to net cash used in operating activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In-process R&amp;D expense</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">289,200</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">429,403</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization of debt discount</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">145,356</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">28,802</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock based compensation</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">234,580</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">92,012</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value of
    redemption liability</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">362,486</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">26,458</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes in operating accounts:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes in prepaid expenses
    and other current assets</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(100,346</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,400</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes in accounts payable
    and accrued expenses</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">306,570</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(30,428</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes in accrued interest</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">101,093</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">46,190</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes
    in due to founder</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">213,524</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash used in operating
    activities</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,078,432</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(706,113</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash flows from financing activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds from related party
    convertible notes</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,232,003</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">580,885</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from exercise of stock options</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">127,500</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,232,003</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">708,385</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net increase in cash</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">153,571</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,272</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash - beginning of
    year</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,281</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">36,009</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash - end of year</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">191,852</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,281</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Supplemental disclosure
    of non-cash investing and financing activities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Acquisition of in-process R&amp;D expense</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares issued upon acquisition</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">289,200</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">185,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assumed accounts payable upon acquisition</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">174,393</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deemed dividend</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">201,737</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued interest roll-over to new notes payable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">89,456</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Due to founder converted to note payable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">55,068</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying footnotes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 119 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pri_006"></A>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;1
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>- Description of Business and Liquidity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Hillstream
BioPharma Inc. (&ldquo;HBI&rdquo;) was incorporated on March 28, 2017, as a Delaware C-corporation. On July 16, 2019, Hillstream BioPharma
Holdings, Inc. (&ldquo;Holdco&rdquo;) was formed as a Delaware C-corporation. On July 24, 2019, Holdco entered into a Contribution and
Share Exchange Agreement with Nanoproteagen LLC (&ldquo;Nanoproteagen&rdquo;) pursuant to which the members of Nanoproteagen exchanged
100% of their membership interests in Nanoproteagen for shares of Holdco common stock. Also on July 24, 2019, the stockholders of HBI
exchanged 100% of their shares of common stock for shares of common stock of Holdco. HBI and Nanoproteagen became wholly-owned subsidiaries
of Holdco.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
August 7, 2019, Holdco&rsquo;s name was changed to Hillstream BioPharma, Inc. and HBI&rsquo;s name was changed to HB Pharma Corp. On
November 12, 2020, Hillstream BioPharma, Inc. entered into a Share Exchange Agreement with Farrington Therapeutics LLC (&ldquo;Farrington&rdquo;)
pursuant to which the members of Farrington exchanged their membership interest in Farrington for shares of common stock of Hillstream
BioPharma, Inc. Farrington became a wholly-owned subsidiary of Hillstream BioPharma, Inc. At December 31, 2020, Hillstream BioPharma,
Inc. has three wholly-owned subsidiaries: HB Pharma Corp., Nanoproteagen and Farrington.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a pre-clinical biotechnology company leveraging a tumor targeting proprietary platform, Quatramer, to develop a pipeline
of novel product candidates to treat rare and treatment resistant cancers. Quatramer are designed with specific physico-chemical parameters
to target specified cells or tissues and converge a therapeutic payload at the site of disease to boost efficacy while abating adverse
effects on healthy tissue. The Company is building a portfolio of long-acting product candidates based on Quatramer, initially in the
oncology space. The Company is advancing its product candidates, including novel small molecules and proprietary DNA expression vectors
which encode inflammatory cytokines directly into the tumor&rsquo;s genome. The first product candidate, HSB-1216, is in investigational
new drug enabling studies for solid tumors with an enhancement for small cell lung cancer (&ldquo;SCLC&rdquo;) and triple-negative breast
cancer. The Company has achieved orphan drug designation in SCLC for HSB-1216&rsquo;s payload. The Company&rsquo;s second product candidate,
HSB-888, is a dual-loaded Iron Medicated Cell Death modulator coupled with the Company&rsquo;s ultra-low dose next generation
anthracycline analogue for solid tumors which has a highly synergistic tumor killing capacity. HSB-888, can be developed in the clinic
for sarcomas, including pediatric osteosarcoma. The U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) has granted HSB-888 the Rare
Pediatric Disease Designation and Orphan Drug Designation for pediatric osteosarcoma. The Company plans to develop other Quatramer based
compounds with therapeutic cargoes from the product pipeline, which include DNA-based contents which the Company believes hijacks the
tumor&rsquo;s genetic code and kill the tumor from within by generating an array of cancer killing cytokines, such as tumor necrosis
factor alpha and interleukin-2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and going concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates,
among other things, the realization of assets and satisfaction of liabilities in the normal course of business. For the year ended December
31, 2020, the Company has incurred operating losses in the amount of approximately $2.4 million and has an accumulated deficit of approximately
$4.7 million at December 31, 2020. The Company has financed its working capital requirements to date primarily through the issuance of
promissory notes payable. Substantially all of the debt is with stockholders of the Company, who may extend the maturity date or convert
the debt into equity at some point, although there are no agreements in place to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
additional financing to support the successful development of the Company&rsquo;s contemplated plan of operations, and its transition,
ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. Such funding is necessary
to conduct the clinical trials and pre-clinical activities to support the development of the Company&rsquo;s product candidates. The
Company is applying for government program facilities and grants, although there is no assurance that such funds will be received. The
Company is pursuing additional capital funding or other strategic transactions, and the Company will continue to seek funds through debt
or equity financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements,
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 120 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;1
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B> - Description of Business and Liquidity (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and going concern (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
sources of financing. However, there can be no assurances that such financing or other strategic transactions will be available on acceptable
terms, or at all. If the Company is unable to obtain additional funding, the development of its product candidates will be impacted and
the Company would likely be forced to delay, reduce, or terminate some or all of its development programs. See Note 11 for funds raised
subsequent to December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2020, and with the funds raised through the date of issuance of these financial statements, the Company has not raised sufficient
funds to finance the operating requirements for at least the next 12 months from the issuance date of these financial statements. These
factors raise substantial doubt regarding the Company&rsquo;s ability to continue as a going concern. The consolidated financial statements
do not include any adjustments that may result from the outcome of these aforementioned uncertainties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
risks and uncertainties</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
there can be no assurance that the Company&rsquo;s products, if approved, will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or
that such products will be successfully marketed, if at all. The Company is subject to risks common to biopharmaceutical companies including,
but not limited to, the development of new technological innovations, dependence on key personnel, protection of proprietary technology,
compliance with government regulations, product liability, uncertainty of market acceptance of products and the need to obtain additional
financing. The Company is dependent on third party suppliers, in some cases single-source suppliers. The Company&rsquo;s products require
approval or clearance from the FDA prior to commencing commercial sales in the United States. Approvals or clearances are also required
in foreign jurisdictions in which the Company may license or sell its products. There can be no assurance that the Company&rsquo;s products
will receive all of the required approvals or clearances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, a novel strain of coronavirus (&ldquo;COVID-19&rdquo;) was reported globally. The World Health Organization has declared
COVID-19 to constitute a &ldquo;Public Health Emergency of International Concern&rdquo; on January 30, 2020 and a global pandemic on
March 11, 2020. In March 2020, individual states mandated &ldquo;stay at home orders&rdquo;, restricted access to hospitals, prohibited
elective surgeries and instituted other restrictions in connection with the COVID-19 outbreak. The extent of the impact of COVID-19 on
the Company&rsquo;s operational and financial performance will depend on future developments, including access to products, potential
disruption in global freight networks, domestic and foreign government actions and changes in demand based on the duration and severity
of the COVID-19 outbreak. To date, the Company&rsquo;s operations have not been materially affected by COVID-19.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;2
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>- Basis of Presentation and Summary of Significant
Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&ldquo;GAAP&rdquo;). The Company operates in one segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Reverse stock split</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">On
September 16, 2021, the Company effected a reverse stock split of shares of the Company&rsquo;s common stock at a ratio of 1-for-26.4
pursuant to an amendment to the Company&rsquo;s Certificate of Incorporation, as amended, approved by the Company&rsquo;s board of directors
and stockholders. The par value of the Company&rsquo;s common stock was not adjusted as a result of the reverse stock split. All issued
and outstanding common stock share and per share amounts contained in the financial statements have been retroactively adjusted to reflect
the reverse stock split for all periods presented.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principles
of consolidation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of Hillstream BioPharma, Inc. and its wholly-owned subsidiaries, HB Pharma Corp.,
Nanoproteagen and Farrington. All significant intercompany balances and transactions have been eliminated in consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 121 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;2
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>- Basis of Presentation and Summary of Significant
Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and related disclosures in the financial statements and accompanying notes. Management bases its estimates
on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield
a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that
range of reasonable estimates. Estimates are used in the following areas, among others: research and development expense recognition,
valuation of common shares and stock options, allowances of deferred tax assets, valuation of debt related instruments, accrued expenses
and liabilities, and cash flow assumptions regarding going concern considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company from time to time during the period covered by these financial statements may have had bank account balances in excess of federally
insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit
risk beyond the normal credit risk associated with commercial banking relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and
development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies
and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical
investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed
by third parties, patient enrollment in clinical trials, administrative costs incurred by third parties, and other indicators of the
services completed. Substantially all of the prepaid expenses at December 31, 2020 relate to the purchase of an active pharmaceutical
ingredient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acquired
in-process research and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has acquired, and may in the future acquire, rights to develop and commercialize new product candidates and/or other in-process
research and development assets. In accordance with Financial Accounting Standards Board&rsquo;s (&ldquo;FASB&rdquo;) Accounting Standards
Codification (&ldquo;ASC&rdquo;) 730-10-25-1, <I>Research and Development,</I> the up-front acquisition or licensing payments are expensed
as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing, and, absent
obtaining such approval, has no alternative future use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
based compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs resulting from the issuance of stock based awards to employees, non-employees and directors as
an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each
stock based award. The fair value of each option grant to employees, non-employees and directors is estimated as of the date of grant
using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line
basis over the requisite service period of the awards, which is generally the vesting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 122 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;2
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>- Basis of Presentation and Summary of Significant
Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
based compensation (Continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company is
a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock
volatility based on the historical data regarding the volatility of a publicly traded set of peer companies. The expected term of stock
options granted is between 5 and 7 years. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in
effect at the time of grant of the award for time periods approximately equal to the expected term of the award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
stock valuations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was required to periodically estimate the fair value of common stock with the assistance of an independent third-party valuation
expert when issuing stock options and computing its estimated stock based compensation expense and value of shares issued in acquiring
product candidates. The assumptions underlying these valuations represented management&rsquo;s best estimates, which involved inherent
uncertainties and the application of significant levels of management judgment. In order to determine the fair value, the Company considered,
among other things, contemporaneous valuations of the Company&rsquo;s common stock, the Company&rsquo;s business, financial condition
and results of operations, including related industry trends affecting its operations; the likelihood of achieving various liquidity
events; the lack of marketability of the Company&rsquo;s common stock; the market performance of comparable publicly traded companies;
and U.S. and global economic and capital market conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset-and-liability method in accordance with ASC 740, <I>Income Taxes</I> (&ldquo;ASC 740&rdquo;).
Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is
recognized in the period that includes the enactment date. A valuation allowance is recorded if it is &ldquo;more likely than not&rdquo;
that some portion or all of the deferred tax assets will not be realized in future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and
clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement.
The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical
merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely than-not threshold
are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the
taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that
the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties
related to tax positions in income tax expense. As of December 31, 2020 and 2019, the Company had no unrecognized uncertain income tax
positions, and therefore no amounts have been recognized in the consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 123 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>Note&ndash;2
- Basis of Presentation and Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Fair value measurements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company applies ASC
820, <I>Fair Value Measurement </I>(&ldquo;ASC 820&rdquo;), which establishes a framework for measuring fair value and clarifies the
definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received
for an asset or paid to transfer a liability in the Company&rsquo;s principal or most advantageous market in an orderly transaction between
market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize
the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions
that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent
of the reporting entity. Unobservable inputs reflect the entity&rsquo;s own assumptions based on market data and the entity&rsquo;s judgments
about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best
information available in the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The carrying value of
the Company&rsquo;s prepaid expenses, accounts payable and accrued expenses approximate fair value because of the short-term maturity
of these financial instruments. The redemption feature of the debt instruments is recorded at fair value (See Note 5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The valuation hierarchy is composed of three levels.
The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement.
The levels within the valuation hierarchy are described below:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 92.15pt; text-align: justify; text-indent: -41.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&ndash;1
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">- Assets and liabilities with unadjusted, quoted prices listed on active
market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets
or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 92.15pt; text-align: justify; text-indent: -41.75pt">Level&ndash;2
- Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying
terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted
intervals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: justify; text-indent: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&ndash;3
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">- Inputs to the fair value measurement are unobservable inputs, such
as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 124 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;2
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>- Basis of Presentation and Summary of Significant
Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Debt
discount and derivative instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial fair value of the redemption feature relating to the convertible debt instruments is treated as a debt discount and amortized
over the term of the related debt using the straight-line method, which approximates the interest method. If a loan is paid in full,
any unamortized financing costs will be removed from the related accounts and charged to operations. Amortization of debt discount is
recorded as a component of interest expense. In accordance with Accounting Standards Update (&ldquo;ASU&rdquo;) 2015-03, <I>Interest
&mdash; Imputation of Interest</I>, the unamortized debt discount is presented in the accompanying balance sheet as a direct deduction
from the carrying amount of the related debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for derivative instruments in accordance with ASC 815, Derivative and Hedging, which establishes accounting and reporting
standards for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts and
requires recognition of all derivatives on the balance sheet at fair value. The Company&rsquo;s derivative financial instrument consists
of an embedded feature contained in the Company&rsquo;s convertible debt that is bifurcated and accounted for separately. See Note&ndash;4
- Debt for further details.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
loss per share</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reports earnings (loss) per share in accordance with ASC 260-10, <I>Earnings Per Share</I>, which provides for calculation of
basic and diluted earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available
to common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential
dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives
effect to common stock equivalents; however, potential common shares are excluded if their effect is anti-dilutive. Management concluded
that the deemed dividend (see Note 4) is analogous to a return on equity classified preference shares, the deemed dividend is added to
the net loss for purposes of the basic and diluted loss per share calculation. Accordingly, the numerator of the loss per share calculation
(basic and diluted) is $2,619,108.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities not included in the computation of earnings (loss) per share at December 31, 2020 and 2019 included options to purchase
675,731 and 475,368 shares of common stock, respectively. The number of shares issuable upon the conversion of convertible
debt and accrued interest is not included in the denominator since their inclusion would be anti-dilutive. All common share amounts
and per share amounts have been adjusted to reflect a 1-for-26.4 reverse stock split of the Company&rsquo;s common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
accounting pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated all recent accounting pronouncements, and believes that none of them will have a material effect on the Company&rsquo;s
financial position, results of operations or cash flows except as discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 125 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;2
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>- Basis of Presentation and Summary of Significant
Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accounting
policies being evaluated</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the FASB issued ASU 2016-02, <I>Leases (Topic 842</I>), which replaces the existing guidance in ASC 840 -
Leases. This ASU requires a dual approach for lessee accounting under which a lessee would account for leases as finance leases or operating
leases. Both finance leases and operating leases will result in the lessee recognizing a right-of-use asset and a corresponding lease
liability. For finance leases, the lessee would recognize interest expense and amortization of the right-of-use asset, and for operating
leases, the lessee would recognize a straight-line total lease expense. This ASU is effective for fiscal years beginning after December
15, 2022 and for interim periods within those fiscal years. The Company is currently evaluating the impact of this adoption on its consolidated
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU 2019-12, &ldquo;<I>Income Taxes, (Topic 740): Simplifying the Accounting for Income Taxes</I>&rdquo;.
This standard removes certain exceptions to the general principles and improves consistent application of and simplify GAAP for other
areas of Topic 740 by clarifying and amending existing guidance. This standard is effective for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2021. The Company is currently evaluating the impact this standard will have on its
consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB recently issued ASU 2020-06, <I>Debt &ndash; Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging
&ndash; Contracts in Entity&rsquo;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&rsquo;s
Own Equity</I>, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity.
The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the
existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately
from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded
conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments
revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that
are both indexed to the issuer&rsquo;s own stock and classified in stockholders&rsquo; equity, by removing certain criteria required
for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification
(and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract.
The amendments in ASU 2020-06 further revise the guidance in ASC 260, <I>Earnings Per Share</I>, to require entities to calculate diluted
earnings per share (&ldquo;EPS&rdquo;) for convertible instruments by using the if-converted method. In addition, entities must presume
share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments are effective
for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December
15, 2020. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accounting
principles adopted</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB issued ASU 2018-13, <I>Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements
for Fair Value Measurement</I>. This amendment modifies the disclosure requirements for fair value measurements. The guidance is effective
for all entities for fiscal years ending after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted.
The guidance was adopted as of January 1, 2019. The impact on the Company&rsquo;s financial position, results of operations and cash
flows was immaterial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 126 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;3
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>- Acquisitions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Nanoproteagen</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 24, 2019, Holdco issued 2,335,856 shares of common stock to acquire 100% of the Membership Interests of Nanoproteagen, an
early stage biotech company. On the date of the transaction, Nanoproteagen had no assets on its books and accounts payable of $174,393
which were assumed by the Company. The transaction did not meet the definition of a business combination for financial reporting purposes,
since there were no business inputs, employees acquired, processes or outputs at the time of the transaction. The fair value of the common
stock issued was approximately $185,000, for which the single asset was recognized as a component of acquired in-process research and
development expense in the accompanying consolidated statements of operations, summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair value of shares issued</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">185,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liability assumed</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">174,393</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase price</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">359,393</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
fees and other costs of approximately $20,000, related to this transaction, were included as a component of acquired in-process research
and development expense in the accompanying consolidated statements of operations. The previous license in place between the Company
and Nanoproteagen was cancelled as a result of this transaction without further consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Farrington</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
November 12, 2020, the Company acquired 100% of the member interests of Farrington, an early stage biotech company which owned a next
generation anthracycline, HSB-888, for pediatric osteosarcoma. Pursuant to the Exchange Agreement, the Company issued 75,757 shares
of its common stock to the seller as consideration for the purchase. The transaction did not meet the definition of a business combination
for financial reporting purposes, since there were no business inputs, employees acquired, processes or outputs at the time of the transaction.
The fair value of the common stock issued was estimated to be $289,200, for which the single asset was recognized as a component of acquired
in-process research and development expense in the accompanying consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Note&ndash;4
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>- Convertible Notes - Related Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commencing
in May 2017, the Company entered into Subordinated Convertible Promissory Note Agreements (the &ldquo;Agreements&rdquo;) with certain
lenders (together, the &ldquo;Holders&rdquo; or individually, the &ldquo;Holder&rdquo;), pursuant to which the Company issued Subordinated
Convertible Promissory Notes (individually the &ldquo;Note&rdquo; or together the &ldquo;Notes&rdquo;) to the Holders, principally all
to the Chief Executive Officer and founder of the Company (See Note 9). Interest on the unpaid principal balance accrues at a rate of
5% per annum, computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier converted into shares
of the Company&rsquo;s common stock or preferred stock (collectively, the &ldquo;Equity Securities&rdquo;), the principal and accrued
interest shall be due and payable by the Company on demand by the Holders at any time after the earlier of (i) the Maturity Date (as
defined in each Agreement) and (ii) the closing of the Next Equity Financing. &ldquo;Next Equity Financing&rdquo; means the next sale,
or series of related sales, by the Company of its Equity Securities pursuant to which the Company receives gross proceeds of not less
than $5,000,000 for Notes issued in 2017 and through November 2020 and $7,500,000 for Notes issued in December 2020 (including the aggregate
amount of debt securities converted into Equity Securities upon conversion or cancellation of the Notes).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 127 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;4
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>- Convertible Notes - Related Parties (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, the stated Maturity Date was two years from the date of issuance, except for the notes entered into in December 2020 (in the
aggregate principal amount of $418,000) which have a stated maturity date of three years. For Notes entered into in 2017 and through
September 2018, the default interest rate of 20% was added to the Notes for the period after the Maturity Date (&ldquo;default period&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares
of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued
interest due on the Note on the date of conversion by the lesser of (i) 80% of the price paid per share for Equity Securities by the
investors in the Next Equity Financing, or (ii) an equity valuation of $25 million ($50 million for notes issued after December 2020).
No Next Equity Financing has occurred through December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
embedded features contained in the Notes in the aggregate are embedded derivative instruments, which were recorded as a debt discount
and derivative liability at the issuance date at their estimated fair value of $1.073 million. Accretion of debt discount for the Notes
was recorded as interest expense was approximately $175,000 for the year ended December 31, 2020. Accrued interest expense associated
with the Notes at December 31, 2020 and 2019 amounted to approximately $73,100 and $61,400, respectively. Interest expense, including
accretion of the debt discount, amounted to approximately $246,000 and $75,000 for the years ended December 31, 2020 and 2019, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, all convertible debt instruments which had matured had been rolled over into new notes as described below. The
convertible debt balance at December 31, 2020 and 2019 is summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Principal amount outstanding</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,598,340</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,020,076</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less: debt discount,
    net of accretion</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(747,973</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(56,710</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Carrying value</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,850,367</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">963,366</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current portion</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">563,425</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">430,600</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Long term portion</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,286,942</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">532,766</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total carrying value</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,850,367</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">963,366</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exchange
notes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
September 27, 2020, the Company agreed to issue a related party Note holder notes (&ldquo;Exchange Notes&rdquo;) in exchange for seven
Notes payable which were in default (&ldquo;Original Notes&rdquo;) at such time by more than 90 days. The Original Notes had a principal
amount of approximately $265,000 and accrued interest of $37,000 at December 31, 2019. As of September 27, 2020, the aggregate outstanding
principal was approximately $265,000 and accrued interest, which included the default interest rate of 20% as described above, was approximately
$71,000. The Exchange Notes took the then principal and accrued interest of the Original Notes and added an original issue discount of
37.5% to determine the new principal amount which amounted to an aggregate of $537,968. The Company accounted for this transaction as
a debt extinguishment, and the incremental amount of the principal of the Exchange Notes payable of $201,737 was recorded to accumulated
deficit (analogous to a &ldquo;deemed dividend&rdquo;), since the Exchange Notes are with related parties, and included in the calculation
of loss per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
September 27, 2020, the Company issued certain related party Note holders notes (&ldquo;September Exchange Notes&rdquo;) in exchange
for five Notes payable, which were in default. As of such date, the aggregate outstanding principal and interest was approximately $26,000,
which included the default interest rate of 20% as described above. The September Exchange Notes in the aggregate principal amount of
approximately $26,000 were issued with substantially the same terms as the Original Notes. There was no accounting entries required upon
the re-issuance of such Exchange Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Roll-over
notes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective
October 1, 2020, all notes which matured, and were not repaid or converted, were rolled over on substantially the same terms as the Original
Notes with a new two year term (&ldquo;Rolled Over&rdquo;). In the fourth quarter of 2020, approximately $166,000 of such Original Notes
were Rolled Over. Since the terms of the new notes are not substantially different from the Original Notes, this was not accounted for
as a debt modification or debt extinguishment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 128 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;5
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>- Redemption Liability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the redemption liability is calculated under Level 3 of the fair value hierarchy, determined based upon a Probability-Weighted
Expected Returns Method (&ldquo;PWERM&rdquo;).</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">This PWERM was determined
to be the most appropriate method of estimating the value of possible redemption or conversion outcomes over time, since the Company
has not entered into a priced equity round through December 31, 2020. The significant assumptions utilized in these calculations are
the possible exit scenarios (either a conversion of the principal and accrued interest of the Notes in the event of a Next Equity Financing,
a repayment of the Notes and accrued interest in the event of a Corporate Transaction (as defined in the Notes) or a repayment of the
Notes and accrued interest at maturity), the pre-money valuation of the Company&rsquo;s common stock, the probabilities of such exit
events occurring and discounts/premiums available to the noteholders at such measurement dates. At December 31, 2020 the Company assumed
a 40% probability of a Next Equity Financing event occurring at IPO pricing, an increase from 9% at December 31, 2019. At December 31,
2020, the Company assumed a 5% probability of a Corporate Transaction, an increase from 1% at December 31, 2019. The calculation of the
redemption liability also used the following assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 11pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assumed ranges pre-money valuation at time
    of Next Equity Financing</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
                                       &ndash; 50 million</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
                                       &ndash; 50 million</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Discount rate</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.86-
                                            11.13</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.29</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected coupon interest rate on Notes</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected term to exit event</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.0-3.0
                                            years</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.0
                                            years</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
fair value of the redemption liability is re-measured at each period and is summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Beginning balance</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">126,183</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,574</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initial embedded redemption value</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">836,619</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">61,151</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">362,486</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">26,458</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ending balance</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,325,288</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">126,183</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in fair value of $362,486 and $26,458 for the years ended December 31, 2020 and 2019, respectively, is recorded as a component
of other expense in the accompanying consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;6
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>- Stock Based Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Company&rsquo;s 2017 Stock Incentive Plan (the &ldquo;2017 Stock Incentive Plan&rdquo;) the Company may grant incentive stock options,
non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, restricted stock, performance
shares and performance units to employees, directors and consultants of the Company and its affiliates. Up to 94,696 shares of
the Company&rsquo;s common stock may be issued pursuant to the 2017 Stock Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2019, the Company authorized a new plan (the &ldquo;2019 Stock Incentive Plan&rdquo;). The 2019 Stock Incentive Plan reserved 284,090
shares of Company&rsquo;s common stock for issuance in the form of incentive stock options, non-statutory stock options, rights to
purchase common stock, stock appreciation rights, restricted stock, restricted stock, performance shares and performance units to employees,
directors and consultants of the Company and its affiliates. Pursuant to the written consent of HBI dated July 16, 2019, the 2017 Stock
Incentive Plan and all outstanding option agreements were assigned to Holdco. On August 30, 2019, the Company authorized an additional
2,575,757 shares of the Company&rsquo;s common stock which may be issued pursuant to the 2019 Stock Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 129 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;6
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>- Stock Based Compensation (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has granted options to acquire 92,801 shares of common stock at $13.20 per share under the 2017 Stock Incentive
Plan, and 1,895 remain available for issuance. At each of December 31, 2020, 2019, and 2018, there were options outstanding to
acquire 92,801 shares of common stock. As of December 31, 2020, all such options were fully vested, and the weighted average remaining
contractual life for such options is approximately 7.0 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has granted options to acquire 2,192,777 shares of common stock under the 2019 Stock Incentive Plan, and 667,070
remain available for issuance. The shares issued in 2020 and 2019 and the shares exercised under the 2019 Stock Incentive Plan are included
in the table below. At December 31, 2020, there are stock options outstanding to acquire 582,930 shares of common stock with a
weighted average exercise price of $0.2112 and a weighted average contractual term of 7.82 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes stock based activities under the 2017 Stock Incentive Plan and 2019 Stock Incentive Plan:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares Underlying Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
                                            Price</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Contractual Terms</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: justify">Outstanding at December 31, 2018</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">92,801</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">13.20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right">9.2 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,992,414</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,609,847</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.08</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Forfeited/cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Outstanding at December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">475,368</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3.22</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt">9.4 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,363</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Forfeited/cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Outstanding at December 31, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">675,731</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.09</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 2.5pt">8.8 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Exercisable options at December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">309,718</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.49</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8.8 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Vested and expected to vest at December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">430,493</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8.8 years</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 130 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;6
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>- Stock Based Compensation (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock option awards is estimated at the date of grant using the Black-Scholes option-pricing model. The estimated fair
value of each stock option is then expensed over the requisite service period, which is generally the vesting period (ranging between
immediate vesting and 4 years). The determination of fair value using the Black-Scholes model is affected by the Company&rsquo;s share
price as well as assumptions regarding a number of complex and subjective variables, including expected price volatility, risk-free interest
rate and forfeitures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options granted during the years ended December 31, 2020 and 2019 were valued using the Black-Scholes option-pricing model with the following
weighted average assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected volatility</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">83.0</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">92.4</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk-free interest rate</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.7</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.8</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected dividend yield</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected life of options in years</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Estimated fair value of common stock</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.455</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.079</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average grant date fair value of stock
options granted during 2020 and 2019 was approximately $1.531 and $0.053, respectively. The weighted average fair value
of stock options vested in 2020 and 2019 was approximately $1.373 and $0.055, respectively.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation expense was approximately $234,000 ($124,000 included in research and development expense and $110,000 included in
general and administrative expenses) and approximately $92,000 ($43,000 included in research and development expense and $49,000 included
in general and administrative expenses) for the years ended December 31, 2020 and 2019, respectively, and is included in the accompanying
consolidated statements of operations. The intrinsic value of stock options outstanding at December 31, 2020 was approximately $517,000
and was negligible at December 31, 2019. The intrinsic value of stock options exercised during 2019 was negligible. At December 31, 2020,
total unrecognized compensation cost related to non-vested options was approximately $92,000 and is expected to be recognized over the
remaining weighted average service period of approximately 2.0 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Included in the above table are stock options granted
in 2019 to purchase 231,058 shares of common stock at an exercise price of $0.079 per share and stock options granted in
2020 to purchase 14,204 shares of common stock at an exercise price of $5.280 per share, which vest upon a specified performance
condition. Since the occurrence of this condition was not considered probable as of December 31, 2020 or 2019, the Company has not recognized
any expense for such grants in December 31, 2020 or 2019.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;7
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>- Stockholders&rsquo; Deficit</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to an amendment to the Company&rsquo;s Certificate of Incorporation filed in April 2019, the Company increased the number of authorized
shares of common stock to 250 million shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2020 and 2019, the Company issued 75,757 shares of common stock and 2,335,856 shares of common
stock, respectively, for the Farrington and Nanoproteagen acquisition transactions described in Note 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2019, the founder and a consultant exercised stock options to purchase an aggregate of 1,609,847 shares of the Company&rsquo;s
common stock for total proceeds of $127,500 (See Note 6).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 131 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;8
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>- Income Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not have any significant current income taxes due because of the losses generated in each period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. The Company&rsquo;s deferred tax assets relate primarily to its net operating
loss carryforwards and other balance sheet basis differences. In accordance with ASC 740, the Company recorded a valuation allowance
to fully offset the gross deferred tax asset because it is not more likely than not that the Company will realize future benefits associated
with these deferred tax assets at December 31, 2020 and 2019. The valuation allowance increased by approximately $589,000 and $407,000
for the years ended December 31, 2020 and 2019, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
components of the Company&rsquo;s deferred tax assets at December 31, 2020 and 2019 are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred tax assets:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Federal
    net operating loss carryforward</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">424,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">149,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">State net operating
    loss carryforward</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">182,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">64,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Capitalized R&amp;D
    costs</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">199,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">106,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Acquired In-process
    R&amp;D</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">205,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">134,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">R&amp;D Credit</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">66,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">35,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    expenses and other</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">99,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">98,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total deferred tax assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,175,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">586,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Valuation allowance</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,175,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(586,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred tax asset,
    net of valuation allowance</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax benefit for the years ended December 31, 2020 and 2019 differ from the amounts computed by applying the U.S. Federal income
tax rate of 21% to loss before income tax benefit as a result of non-deductible expenses, tax credits generated and increases in the
Company&rsquo;s valuation allowance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Income tax benefit at the federal
    statutory rate</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(508,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(320,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Permanent differences
    and other</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">117,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">State income taxes</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(167,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(144,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">R&amp;D Credit</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(31,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(19,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in Valuation allowance</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">589,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">462,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective income
    tax expense</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 132 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Note&ndash;8
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>- Income taxes (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2020, the Company had available net operating loss carryforwards of approximately $2,020,000 for federal income tax purposes,
all of which was generated after 2017 and can be carried forward indefinitely under the Tax Cuts and Jobs Act. At December 31, 2020,
the Company had approximately $66,000 of federal research and development (&ldquo;R&amp;D&rdquo;) tax credit carry-forwards. If not utilized,
the federal R&amp;D credits will begin to expire in 2038.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2020, the Company had available net operating loss (&ldquo;NOL&rdquo;) carryforwards for state tax purposes of approximately
$2,020,000 generated from 2018 to 2020 with a 20 year life which will begin to expire in 2038, unless previously utilized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sections
382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state regulations, contain provisions that may limit the NOL
carryforwards available to be used to offset income in any given year upon the occurrence of certain events, including changes in the
ownership interests of significant stockholders. In the event of a cumulative change in ownership in excess of 50% over a three-year
period, the amount of the NOL carryforwards that the Company may utilize in any one year may be limited. Although the Company has not
undertaken a formal analysis, it is likely that such an ownership change occurred during 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (&ldquo;CARES Act&rdquo;). The CARES
Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund
a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19
pandemic, some of the more significant provisions which are expected to impact the Company&rsquo;s financial statements include removal
of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years,
and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and
Jobs Act. The Company has concluded that the CARES Act did not have a material impact on its financial position, results of operations,
or cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 27, 2020, the United States enacted the Consolidated Appropriations Act which extended many of the benefits of the CARES Act
that were scheduled to expire. The Company evaluated the impact of the Consolidated Appropriations Act on its consolidated financial
statements and related disclosures, and concluded that the impact is immaterial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note&ndash;9
</B></FONT><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>- Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 4, the Company entered into the Notes with the Holders commencing in May 2017. The Holders of substantially all of
the Notes are the Company&rsquo;s founder and Chief Executive Officer and third parties that are family members of the founder and Chief
Executive Officer. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the above Notes, the Company has amounts due to the founder and Chief Executive Officer that totaled $200,000 and $255,068
at December 31, 2020 and 2019, respectively. The balance comprised of expenses paid on behalf of the Company by the Chief Executive Officer
of $55,068 (which was converted into a convertible promissory note in 2020) and $200,000 for accrued compensation (See Note 10) at December
31, 2019. At December 31, 2020, the balance comprised $200,000 for accrued compensation (See Note 10). There are no established terms
for repayment of such amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 133 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
10 - Commitments And Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Small
molecule analogues</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2019, the Company acquired a series of small molecule analogues pursuant to an asset purchase agreement (&ldquo;APA&rdquo;).
Pursuant to the APA the Company is required to make a payment of $50,000 upon the raising of at least $2 million in funding, and up to
$1.75 million based upon successfully meeting clinical and sales milestones. As of December 31, 2020, such fund raising requirement was
not met, no payments were made under pursuant to the APA. The Company included, in accounts payable at December 31, 2019 and 2020, the
$50,000 required initial payment. Milestone based payments, if any, will be expensed as incurred. The $50,000 consideration is recognized
as a component of acquired in-process research and development expense in the accompanying consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment
agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2019, the Company entered into a three year employment agreement with its Chief Executive Officer which provides a specified
base salary and bonus annually. The employment agreement also provides the Chief Executive Officer with certain benefits while employed
and if employment cease. The Company has accrued $200,000 related to the Chief Executive Officer&rsquo;s base salary as per the employment
agreement which is included in due to founder in the accompanying consolidated balance sheet as of December 31, 2019, which remains outstanding
as of December 31, 2020. No bonus was approved by the Board of Directors of the Company for the years ended December 31, 2020 or 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
January 2020, the Company amended the employment agreement pursuant to which, in lieu of a cash base salary, the Chief Executive Officer
will be compensated with stock options to purchase 7,575 shares of common stock per month (at an exercise price based upon the
most recent fair value of the common stock) effective January 1, 2020 until the Company receives a minimum of $3,000,000 of gross proceeds
from the sale of the Company&rsquo;s securities, after which time, cash compensation, pursuant to the employment agreement, shall be
paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the Chief Executive Officer acts as the &ldquo;finder&rdquo; of an investor who purchases more than $3,000,000 of the Company&rsquo;s
equity, he will receive a grant of options to acquire 757,575 shares of common stock of the Company at an exercise price of $0.185
per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
11 - Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events through September 27, 2021, the date on which these financial statements were issued.
No significant subsequent events through this date would have had a material impact on the Company&rsquo;s consolidated financial statements
as of and for the years ended December 31, 2020 and 2019 other than described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.25in"><B>A.</B></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment agreement amendment</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2021, the Company amended the employment agreement with its Chief Executive Officer to provide a revised base salary pre-funding
(as defined in the employment agreement). In lieu of cash base salary, the Chief Executive Officer will be compensated with stock options
to purchase 18,939 shares of the Company&rsquo;s common stock per month (at an exercise price based upon the most recent fair
value of the common stock of the Company) effective January 1, 2021 until funding meets or exceeds $5,000,000, after which time, cash
compensation, pursuant to his employment agreement, shall be paid. &nbsp; The amended employment agreement also provides for a future
base salary for the Chief Executive Officer after the Company receives funding greater than $5,000,000, or completes an initial public
offering or similar transaction, as defined.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the Chief Executive Officer acts as the &ldquo;finder&rdquo; of an investor who purchases more than $5,000,000 of the Company&rsquo;s
equity, he will receive a grant of stock options to acquire 757,575 shares of common stock of the Company at an exercise price
equal to the most recent fair value of the Company&rsquo;s common stock. This clause replaces the previous &ldquo;finder&rdquo; fee agreement
mentioned in Note 10.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 134 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020 and 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
11 - Subsequent Events (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.25in"><B>B.</B></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible notes payable</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
January 1, 2021 to May 10, 2021, the Company entered into Subordinated Convertible Promissory Note Agreements with the Chief Executive
Officer pursuant to which the Company issued subordinated convertible promissory notes in the principal amount of for $360,000 and $153,025,
to its Chief Executive Officer and other investors, respectively. Interest on the unpaid principal balance accrues at a rate of 5% per
annum, computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier converted into shares of Equity
Securities (as defined in Note 4), the principal and accrued interest shall be due and payable by the Company on demand by the holders
at any time after the earlier of (i) three years or (ii) the closing of the Next Equity Financing (as defined in Note 4).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares
of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued
interest due on the note on the date of conversion by the lesser of (i) 80% of the price paid per share for Equity Securities by the
investors in the Next Equity Financing or (ii) an equity valuation of $50 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>C.</B></FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock option plan</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2021, the stockholders of the Company approved an increase in the number of shares authorized for issuance under the 2019 Stock
Incentive Plan by 574,494 shares. From January 1, 2021 to May 14, 2021, stock options to acquire an aggregate of 170,920
shares of common stock were granted at an exercise price of $7.822 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, the Company modified the stock option exercise price for stock options granted during 2020, increasing the exercise price
of such stock options from $0.179 or $2.598 to $0.050 or $3.025 per share. The increase in the stock option
exercise price will be accounted for as a modification in 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>D.</B></FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reverse stock split</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 16, 2021, the Company amended its Certificate of Incorporation, as amended, to effect a 1-for-26.4 reverse stock split of its
issued and outstanding shares of common stock. All common share amounts and per share amounts have been adjusted to reflect such reverse
stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 135 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_001"></A><B>CONDENSED
CONSOLIDATED BALANCE SHEETS</B> </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.4pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021 (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%">Cash</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 16%; font-weight: bold; text-align: right">29,271</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">191,852</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">5,053</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,946</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred offering costs</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">248,802</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total current assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">283,126</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">294,798</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">283,126</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">294,798</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Liabilities and Stockholders&rsquo; Deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Accounts payable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">1,038,891</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">514,828</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accrued interest</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">116,288</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,066</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Due to founder</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">200,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accrued expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">147,310</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,777</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Redemption liability</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,069,717</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,325,288</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Short-term portion of related-party convertible notes,
    net</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">646,477</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">563,425</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Total current liabilities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">5,218,683</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,725,384</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Related-party convertible notes, net, less short term
    portion</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,360,024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,286,942</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Total liabilities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">6,578,707</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,012,326</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Commitments and contingencies (See Note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stockholders&rsquo; deficit:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding
    as of June 30, 2021 (unaudited) and December 31, 2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Common stock, $0.0001 par value, 250,000,000 shares authorized;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">6,357,314 shares issued and outstanding as of June 30, 2021 (unaudited) and December 31, 2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">636</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">636</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Additional paid-in capital</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,214,535</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">986,443</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(8,510,752</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,704,607</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total stockholders&rsquo; deficit</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(6,295,581</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,717,528</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&rsquo; deficit</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">283,126</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">294,798</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these condensed consolidated financial statements.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 136 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_002"></A>CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; font-weight: bold">For the six months ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left">Research and development</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 16%; font-weight: bold; text-align: right">1,570,675</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">291,714</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">994,636</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">161,324</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,565,311</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">453,038</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Loss from operations</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,565,311</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(453,038</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">337,090</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79,132</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in redemption value</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">903,744</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">175,222</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,240,834</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">254,354</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(3,806,145</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(707,392</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Net loss per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Basic and diluted</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(0.60</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(0.11</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt">Weighted average number of common shares outstanding:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Basic and diluted</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">6,357,314</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,281,557</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these condensed consolidated financial statements. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 137 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B> </FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_003"></A>CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&rsquo; DEFICIT</B> </FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 (UNAUDITED)</B> </FONT></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
    Paid-in</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;Accumulated</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></P>
                    <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholders&rsquo;</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Par
    Value</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capital</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deficit</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deficit</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at
    December 31, 2020</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,357,314</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">986,443</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,704,607</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,717,528</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock based compensation</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,228,092</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,228,092</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,806,145</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,806,145</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at June 30, 2021</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,357,314</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,214,535</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,510,752</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,295,581</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
    Paid-in</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accumulated</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></P>
                    <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholders&rsquo;</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Par
    Value</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capital</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deficit</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>
                                                                                <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deficit</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at
    December 31, 2019</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,281,557</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">628</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">462,671</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,085,499</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,622,200</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock based compensation</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,757</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,757</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(707,392</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(707,392</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at June 30, 2020</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,281,557</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">628</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">474,428</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,792,891</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,317,835</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these condensed consolidated financial statements.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 138 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_004"></A><B>CONDENSED
CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)</B> </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; font-weight: bold">For the six months ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Cash flows from operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: justify">Net loss</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 16%; font-weight: bold; text-align: right">(3,806,145</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">(707,392</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: justify">Amortization of debt discount</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">263,963</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,629</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: justify">Stock based compensation</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,228,092</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,757</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: justify">Change in fair value of redemption liability</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">903,744</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">175,222</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify">Changes in operating accounts:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: justify">Changes in prepaid expenses and other current assets</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">97,893</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(117</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: justify">Changes in accounts payable and accrued expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">477,596</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,447</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: justify">Change in due to founder</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55,068</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: justify; padding-bottom: 1.5pt">Changes in accrued interest</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">73,064</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">43,503</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify">Net cash used in operating activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(761,793</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(446,019</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify">Proceeds from related party convertible notes</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">703,014</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">417,068</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Deferred offering costs</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(103,802</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">599,212</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">417,068</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Net decrease in cash</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(162,581</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,951</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">Cash - beginning of period</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">191,852</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">38,281</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Cash - end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">29,271</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,330</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Supplemental disclosure of non-cash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Unpaid deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">145,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Accrued interest roll-over to new notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">29,842</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these condensed consolidated financial statements. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 139 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_005"></A>Notes
to Condensed Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
1 - Description of Business and Liquidity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hillstream
BioPharma Inc. (&ldquo;HBI&rdquo;) was incorporated on March 28, 2017, as a Delaware C-corporation. At June 30, 2021, Hillstream
BioPharma, Inc. had two wholly-owned subsidiaries: HB Pharma Corp. and Farrington Therapeutics LLC (&ldquo;Farrington&rdquo;),
(collectively the &ldquo;Company&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a pre-clinical biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer
mechanism resulting in iron mediated cell death (&ldquo;IMCD&rdquo;) for treatment resistant cancers. Our most advanced product candidate
is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The active drug in HSB-1216 was found to reduce tumor burden in
a clinical pilot study in Germany in treatment resistant cancers, including triple negative breast cancer and epithelial carcinomas.
Our goal is to file investigational new drug application (&ldquo;IND&rdquo;) with the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;)
in 2022 and start a clinical study with HSB-1216 in 2022; however, no assurance can be provided that our IND will be accepted by the
FDA in 2022, if at all. If our IND is accepted by the FDA, our HSB-1216 clinical study will focus on expanding upon the clinical pilot
study conducted in Germany. If we are able to start our clinical study with HSB-1216 in 2022, we anticipate that initial data from such
trial will be released either the end of 2022 or early 2023. We use Quatramer&trade;, our proprietary tumor targeting platform,
to enhance the uptake of HSB-1216 in the tumor microenvironment with an extended duration of action and minimal off-target toxicity.
In addition, Trident Artificial Intelligence, our artificial intelligence precision medicine platform, is used to identify biomarkers
in our clinical programs to target specific patient segments. The discovery of regulated cell death processes, such as apoptosis and
autophagy, has enabled novel target discovery for drug development. Ferroptosis, a form of IMCD, is an emerging regulated cell death
process which decreases intracellular iron or the Labile Iron Pool (&ldquo;LIP&rdquo;). Cancer cells increase the LIP leading to unregulated
cell growth and metabolism. Decreasing the LIP, induces iron-led reactive oxygen species production and lipid peroxidation, two key hallmarks
of ferroptosis/IMCD. HSB-1216 binds iron in the cytoplasm of cancer cells and decreases the LIP, thereby inducing ferroptosis/IMCD, leading
to regulated cell death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and going concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates,
among other things, the realization of assets and satisfaction of liabilities in the normal course of business. For the six months ended
June 30, 2021, the Company has incurred operating losses in the amount of approximately $3.8 million and has an accumulated deficit
of approximately $8.5 million at June 30, 2021. The Company has financed its working capital requirements to date primarily through
the issuance of promissory notes payable. Substantially all of the debt is with stockholders of the Company, who may extend the maturity
date or convert the debt into equity at some point, although there are no agreements in place to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
additional financing to support the successful development of the Company&rsquo;s contemplated plan of operations, and its transition,
ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. Such funding is necessary
to conduct the clinical trials and pre-clinical activities to support the development of the Company&rsquo;s product candidates. The
Company is applying for government program facilities and grants, although there is no assurance that such funds will be received. The
Company is pursuing additional capital funding or other strategic transactions, and the Company will continue to seek funds through debt
or equity financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements,
or other sources of financing. However, there can be no assurances that such financing or other strategic transactions will be
available on acceptable terms, or at all. If the Company is unable to obtain additional funding, the development of its product candidates
will be impacted and the Company would likely be forced to delay, reduce, or terminate some or all of its development programs.
See Note 9 for funds raised subsequent to June 30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 140 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Condensed Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
1 - Description of Business and Liquidity (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and going concern (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2021, and with the funds raised through the date of issuance of these financial statements, the Company has not raised sufficient
funds to finance the operating requirements for at least the next 12 months from the issuance date of these financial statements. These
factors raise substantial doubt regarding the Company&rsquo;s ability to continue as a going concern. The condensed consolidated financial
statements do not include any adjustments that may result from the outcome of these aforementioned uncertainties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
risks and uncertainties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> can be no assurance that the Company&rsquo;s products, if approved,
will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable
cost and with appropriate performance characteristics, or that such products will be successfully marketed, if at all. The Company is
subject to risks common to biopharmaceutical companies including, but not limited to, the development of new technological innovations,
dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, uncertainty
of market acceptance of products and the need to obtain additional financing. The Company is dependent on third party suppliers. The
Company&rsquo;s products require approval or clearance from the FDA prior to commencing commercial sales in the United States. Approvals
or clearances are also required in foreign jurisdictions in which the Company may license or sell its products. There can be no assurance
that the Company&rsquo;s products will receive all of the required approvals or clearances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COVID-19</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, a novel strain of coronavirus (&ldquo;COVID-19&rdquo;) was reported globally. The World Health Organization has
declared COVID-19 to constitute a &ldquo;Public Health Emergency of International Concern&rdquo; on January 30, 2020 and a global pandemic
on March 11, 2020. In March 2020, individual states mandated &ldquo;stay at home orders&rdquo;, restricted access to hospitals, prohibited
elective surgeries and instituted other restrictions in connection with the COVID-19 outbreak. The extent of the impact of COVID-19 on
the Company&rsquo;s operational and financial performance will depend on future developments, including access to products, potential
disruption in global freight networks, domestic and foreign government actions and changes in demand based on the duration and severity
of the COVID-19 outbreak. To date, the Company&rsquo;s operations have not been materially affected by COVID-19.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
2 - Basis of Presentation and Summary of Significant Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;) for interim financial information. Accordingly, they do not include
all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements
include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited
condensed consolidated financial statements of the Company as of June 30, 2021 and for the six months ended June 30, 2021 and 2020. The
results of operations for the six months ended June 30, 2021 are not necessarily indicative of the operating results for the full year
ending December 31, 2021 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction
with the audited financial statements and related disclosures as of December 31, 2020 and for the year then ended which are included
elsewhere in this prospectus. The Company operates in one segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Reverse stock split</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">On
September 16, 2021, the Company effected a reverse split of shares of the Company&rsquo;s common stock at a ratio of 1-for-26.4 pursuant
to an amendment to the amended and restated certificate of incorporation approved by the Company&rsquo;s board of directors and stockholders.
The par value was not adjusted as a result of the reverse split. All issued and outstanding common stock share and per share amounts
contained in the financial statements have been retroactively adjusted to reflect this reverse split for all periods presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 141 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Condensed Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
2 - Basis of Presentation and Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principles
of consolidation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements include the accounts of Hillstream BioPharma, Inc. and its wholly-owned subsidiaries, HB Pharma Corp.,
Nanoproteagen and Farrington. All significant intercompany balances and transactions have been eliminated in
consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and related disclosures in the financial statements and accompanying notes. Management bases
its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often
may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls
within that range of reasonable estimates. Estimates are used in the following areas, among others: research and development expense
recognition, valuation of common shares and stock options, allowances of deferred tax assets, valuation of debt related instruments,
accrued expenses and liabilities, and cash flow assumptions regarding going concern considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company from time to time during the period covered by these financial statements may have had bank account balances in excess of federally
insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit
risk beyond the normal credit risk associated with commercial banking relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and
development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies
and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical
investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed
by third parties, patient enrolment in clinical trials, administrative costs incurred by third parties, and other indicators of the services
completed. Substantially all of the prepaid expenses at June 30, 2021 relate to the purchase of an active pharmaceutical ingredient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acquired
in-process research and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has acquired, and may in the future acquire, rights to develop and commercialize new product candidates and/or other in-process
research and development assets. In accordance with Financial Accounting Standards Board&rsquo;s (&ldquo;FASB&rdquo;)
Accounting Standards Codification (&ldquo;ASC&rdquo;) 730-10-25-1, <I>Research and Development,</I> the up-front acquisition or licensing
payments are expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for
marketing, and, absent obtaining such approval, has no alternative future use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 142 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Condensed Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
2 - Basis of Presentation and Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
based compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs resulting from the issuance of stock based awards to employees, non-employees and directors as
an expense in the condensed consolidated statements of operations over the requisite service period based on a measurement of fair value
for each stock based award. The fair value of each option grant to employees, non-employees and directors is estimated as of the date
of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on
a straight-line basis over the requisite service period of the awards, which is generally the vesting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company is
a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock
volatility based on the historical data regarding the volatility of a publicly traded set of peer companies. The expected term of stock
options granted is between five and seven years. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve
in effect at the time of grant of the award for time periods approximately equal to the expected term of the award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
stock valuations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was required to periodically estimate the fair value of common stock with the assistance of an independent third-party valuation
expert when issuing stock options and computing its estimated stock based compensation expense and value of shares issued in acquiring
product candidates. The assumptions underlying these valuations represented management&rsquo;s best estimates, which involved inherent
uncertainties and the application of significant levels of management judgment. In order to determine the fair value, the Company considered,
among other things, contemporaneous valuations of the Company&rsquo;s common stock, the Company&rsquo;s business, financial condition
and results of operations, including related industry trends affecting its operations; the likelihood of achieving various liquidity
events; the lack of marketability of the Company&rsquo;s common stock; the market performance of comparable publicly traded companies;
and U.S. and global economic and capital market conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Debt
discount and derivative instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial fair value of the redemption feature relating to the convertible debt instruments is treated as a debt discount and amortized
over the term of the related debt using the straight-line method, which approximates the interest method. If a loan is paid in full,
any unamortized financing costs will be removed from the related accounts and charged to operations. Amortization of debt discount is
recorded as a component of interest expense. In accordance with Accounting Standards Update (&ldquo;ASU&rdquo;) 2015-03, <I>Interest
&mdash; Imputation of Interest</I>, the unamortized debt discount is presented in the accompanying balance sheet as a direct deduction
from the carrying amount of the related debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for derivative instruments in accordance with ASC 815, Derivative and Hedging, which establishes accounting and reporting
standards for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts and
requires recognition of all derivatives on the balance sheet at fair value. The Company&rsquo;s derivative financial instrument consists
of an embedded feature contained in the Company&rsquo;s convertible debt that is bifurcated and accounted for separately. See Note 4
for further details.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 143 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Condensed Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
2 - Basis of Presentation and Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
value measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies ASC 820, <I>Fair Value Measurement </I>(&ldquo;ASC 820&rdquo;), which establishes a framework for measuring fair value
and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that
would be received for an asset or paid to transfer a liability in the Company&rsquo;s principal or most advantageous market in an orderly
transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an
entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs
reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained
from sources independent of the reporting entity. Unobservable inputs reflect the entity&rsquo;s own assumptions based on market data
and the entity&rsquo;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to
be developed based on the best information available in the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the Company&rsquo;s prepaid expenses, accounts payable and accrued expenses approximate fair value because of the short-term
maturity of these financial instruments. The redemption feature of the debt instruments is recorded at fair value (See Note 5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input
that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 -</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
    and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable
    inputs, such as quoted prices in active markets for identical assets or liabilities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 -</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms,
    as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 -</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no
    market data exists for the assets or liabilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.55in">&nbsp;</P>

<P STYLE="font: 10pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify; margin: 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred
Offering Costs:</B></FONT></P>

<P STYLE="font: 10pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify; margin: 0 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering consisted of legal, accounting, printing, and filing fees that the Company capitalized which will be offset against the proceeds
upon completion of the planned financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 144 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Condensed Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
2 - Basis of Presentation and Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset-and-liability method in accordance with ASC 740, <I>Income Taxes</I> (&ldquo;ASC 740&rdquo;).
Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry
forwards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is
recognized in the period that includes the enactment date. A valuation allowance has been recognized for all periods since it is &ldquo;more
likely than not&rdquo; that some portion or all of the deferred tax assets will not be realized in future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and
clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement.
The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical
merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely than-not threshold
are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the
taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that
the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties
related to tax positions in income tax expense. At June 30, 2021 and December 31, 2020, the Company had no unrecognized uncertain income
tax positions, and therefore no amounts have been recognized in the condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
loss per share</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reports loss per share in accordance with ASC 260-10, <I>Earnings Per Share</I>, which provides for calculation of basic and
diluted earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to
common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential
dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives
effect to common stock equivalents; however, potential common shares are excluded if their effect is anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities not included in the computation of earnings (loss) per share for the six months ended June 30, 2021 and 2020 included
options to purchase 903,468 and 521,386 shares of common stock, respectively. The number of shares issuable upon the conversion
of convertible debt and accrued interest is not included in the denominator since their inclusion would be anti-dilutive. </FONT>All
common share amounts and per share amounts have been adjusted to reflect a 1-for-26.4 reverse stock split of the Company&rsquo;s common
stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>


<!-- Field: Page; Sequence: 145 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Condensed Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
2 - Basis of Presentation and Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
accounting pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated all recent accounting pronouncements, and believes that none of them will have a material effect on the Company&rsquo;s
financial position, results of operations or cash flows except as discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accounting
policies being evaluated</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the FASB issued ASU 2016-02, <I>Leases (Topic 842</I>), which replaces the existing guidance in ASC 840, Leases. This
ASU requires a dual approach for lessee accounting under which a lessee would account for leases as finance leases or operating leases.
Both finance leases and operating leases will result in the lessee recognizing a right-of-use asset and a corresponding lease liability.
For finance leases, the lessee would recognize interest expense and amortization of the right-of-use asset, and for operating leases,
the lessee would recognize a straight-line total lease expense. This ASU is effective for fiscal years beginning after December 15, 2022
and for interim periods within those fiscal years. The Company is currently evaluating the impact of this adoption on its consolidated
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU 2019-12, <I>Income Taxes, (Topic 740): Simplifying the Accounting for Income Taxes</I>. This
standard removes certain exceptions to the general principles and improves consistent application of and simplify U.S. GAAP for other
areas of Topic 740 by clarifying and amending existing guidance. This standard is effective for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2021. The Company is currently evaluating the impact this standard will have on its
consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB recently issued ASU 2020-06, <I>Debt &ndash; Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging
&ndash; Contracts in Entity&rsquo;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&rsquo;s
Own Equity</I>, to reduce complexity in applying U.S. GAAP to certain financial instruments with characteristics of liabilities and equity.
The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the
existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately
from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded
conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments
revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that
are both indexed to the issuer&rsquo;s own stock and classified in stockholders&rsquo; equity, by removing certain criteria required
for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification
(and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract.
The amendments in ASU 2020-06 further revise the guidance in ASC 260, <I>Earnings Per Share</I>, to require entities to calculate diluted
earnings per share (&ldquo;EPS&rdquo;) for convertible instruments by using the if-converted method. In addition, entities must presume
share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments are effective
for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December
15, 2020. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 146 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Condensed Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Note
3 - Acquisition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Farrington</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 12, 2020, the Company acquired 100%
of the member interests of Farrington, an early stage biotech company which owned a next generation anthracycline, HSB-888, for pediatric
osteosarcoma. Pursuant to an Exchange Agreement, the Company issued 75,757 shares of its common stock to the seller as consideration
for the purchase. The transaction did not meet the definition of a business combination for financial reporting purposes, since there
were no business inputs, employees acquired, processes or outputs at the time of the transaction. The fair value of the common stock
issued was estimated to be approximately $289,000, for which the single asset was recognized as a component of acquired in-process research
and development expense in the accompanying consolidated statements of operations in the quarter ended December 31, 2020.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>Note 4
- Convertible Notes - Related Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Commencing in May 2017, the Company entered into
Subordinated Convertible Promissory Note Agreements (the &ldquo;Agreements&rdquo;) with certain lenders (together, the
&ldquo;Holders&rdquo; or individually, the &ldquo;Holder&rdquo;), pursuant to which the Company issued Subordinated Convertible
Promissory Notes (individually the &ldquo;Note&rdquo; or together the &ldquo;Notes&rdquo;) to the Holders, principally all to the
Chief Executive Officer and founder of the Company and third parties that are
family members of the founder and Chief Executive Officer (See Note 9). Interest on the unpaid principal balance accrues
at a rate of 5% per annum, computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier
converted into shares of the Company&rsquo;s common stock or preferred stock (collectively, the &ldquo;Equity Securities&rdquo;),
the principal and accrued interest shall be due and payable by the Company on demand by the Holders at any time after the earlier of
(i) the Maturity Date (as defined in each Agreement) and (ii) the closing of the Next Equity Financing. &ldquo;Next Equity
Financing&rdquo; means the next sale, or series of related sales, by the Company of its Equity Securities pursuant to which the
Company receives gross proceeds of not less than $5,000,000 for Notes issued in 2017 and through November 2020 and $7,500,000 for
Notes issued after November 2020 (including the aggregate amount of debt securities converted into Equity Securities upon conversion
or cancellation of the Notes).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In general, the stated Maturity Date was two years
from the date of issuance, except for the Notes entered into in December 2020 and thereafter (in the aggregate principal amount
of approximately $1,450,000) which have a stated maturity date of three years. For Notes entered into in 2017 and through September 2018,
the default interest rate of 20% was added to the Notes for the period after the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Notes will automatically convert into the type
of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities to be issued will
be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note on the date of conversion
by the lesser of (i) 80% of the price paid per share for Equity Securities by the investors in the Next Equity Financing, or (ii) an
equity valuation of $25 million ($50 million for Notes issued after December 2020). No Next Equity Financing has occurred through
June 30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
embedded features contained in the Notes in the aggregate are embedded derivative instruments, which were recorded as a debt discount
and derivative liability at the issuance date at their estimated fair value for all Notes of approximately $1,774,000. Accretion of debt
discount for the Notes was recorded as interest expense was approximately $263,000 and $36,000 for the six months ended June 30, 2021
and 2020, respectively. Accrued interest expense associated with the Notes at June 30, 2021 and December 31, 2020 amounted to approximately
$116,000 and $73,000, respectively. Interest expense, including accretion of the debt discount, amounted to approximately $337,000 and
$79,000 for the six months ended June 30, 2021 and 2020, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 147 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Condensed Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
4 - Convertible Notes - Related Parties (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2021 and December 31, 2020, all convertible debt instruments which had matured had been rolled over into new notes as described
below. The convertible debt balance at June 30, 2021 and December 31, 2020 is summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">June 30, 2021</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">(unaudited)</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">December 31,</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">2020</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Principal amount outstanding</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">3,331,196</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">2,598,340</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: debt discount, net of accretion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,324,695</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(747,973</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Carrying value</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,006,501</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,850,367</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">646,477</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">563,425</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Long term portion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,360,024</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,286,942</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total carrying value</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,006,501</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,850,367</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exchange
notes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2020, the Company agreed to issue a related party Note holder notes (&ldquo;Exchange Notes&rdquo;) in exchange for seven
Notes payable which were in default (&ldquo;Original Notes&rdquo;) at such time by more than 90 days. The Original Notes had a principal
amount of approximately $265,000 and accrued interest of $37,000 at December 31, 2019. As of September 27, 2020, the aggregate outstanding
principal was approximately $265,000 and accrued interest, which included the default interest rate of 20% as described above, was approximately
$71,000. The Exchange Notes took the then principal and accrued interest of the Original Notes and added an original issue discount of
37.5% to determine the new principal amount which amounted to an aggregate of $537,968. The Company accounted for this transaction as
a debt extinguishment, and the incremental amount of the principal of the Exchange Notes payable of $201,737 was recorded to accumulated
deficit (analogous to a &ldquo;deemed dividend&rdquo;) in the quarter ended September 30, 2020, since the Exchange Notes are
with related parties, and included in the calculation of loss per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2020, the Company issued certain related party Noteholders notes (&ldquo;September Exchange Notes&rdquo;) in exchange
for five Notes payable, which were in default. As of such date, the aggregate outstanding principal and interest was approximately $26,000,
which included the default interest rate of 20% as described above. The September Exchange Notes in the aggregate principal amount of
approximately $26,000 were issued with substantially the same terms as the Original Notes. There was no accounting entries required upon
the re-issuance of such Exchange Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Roll-over
notes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
October 1, 2020, all Notes which matured, and were not repaid or converted, were rolled over on substantially the same terms as the Original
Notes (&ldquo;Rolled Over&rdquo;). Approximately $495,000 of such Original Notes were Rolled Over through June 30, 2021, of which approximately
$166,000 occurred prior to December 31, 2020 and $328,000 occurred between January 1 and June 30, 2021. Since the terms
of the new notes are not substantially different from the Original Notes, this was not accounted for as a debt modification or debt extinguishment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 148 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Condensed Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
5 - Redemption Liability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the redemption liability is calculated under Level 3 of the fair value hierarchy, determined based upon a Probability-Weighted
Expected Returns Method (&ldquo;PWERM&rdquo;). This PWERM was determined to be the most appropriate method of estimating the value of
possible redemption or conversion outcomes over time, since the Company has not entered into a priced equity round through June 30, 2021.
The significant assumptions utilized in these calculations are the possible exit scenarios (either a conversion of the principal and
accrued interest of the Notes in the event of a Next Equity Financing, a repayment of the Notes and accrued interest in the event of
a Corporate Transaction (as defined in the Notes) or a repayment of the Notes and accrued interest at maturity), the pre-money valuation
of the Company&rsquo;s common stock, the probabilities of such exit events occurring and discounts/premiums available to the noteholders
at such measurement dates. At June 30, 2021, the Company assumed a 65% probability of a Next Equity Financing event occurring at IPO
pricing, an increase from 40% at December 31, 2020. At June 30, 2021, the Company assumed a 25% probability of a Corporate Transaction,
an increase from 5% at December 31, 2020. The calculation of the redemption liability also used the following assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><P STYLE="margin-top: 0; margin-bottom: 0">June 30, 2021</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">(unaudited)</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><P STYLE="margin-top: 0; margin-bottom: 0">December 31,</P>
                                                                  <P STYLE="margin-top: 0; margin-bottom: 0">2020</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Assumed ranges pre-money valuation at time of Next Equity Financing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 5 &ndash; 50 million</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 5 &ndash; 50 million</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Discount rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.49- 18.48</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.86-
11.13</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Expected coupon interest rate on Notes</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">5.0</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">5.0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected term to exit event</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.0-3.0 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.0- 3.0 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the redemption liability is re-measured at each period and is summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended June 30, 2021 (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; text-align: left">Beginning balance</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">1,325,288</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Initial embedded redemption value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">840,685</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in fair value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">903,744</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Ending balance</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,069,717</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in fair value of $903,744 and $175,222 for the six months ended June 30, 2021 and 2020, respectively, is recorded as a component
of other expense in the accompanying condensed consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 149 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Condensed Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
6 - Stock Based Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Company&rsquo;s 2017 Stock Incentive Plan (the &ldquo;2017 Stock Incentive Plan&rdquo;) the Company may grant incentive stock
options, non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, performance shares
and performance units to employees, directors and consultants of the Company and its affiliates. Up to 94,696 shares of the Company&rsquo;s
common stock may be issued pursuant to the 2017 Stock Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has granted options to acquire 92,801 shares of common stock at $13.20 per share under the 2017 Stock Incentive
Plan, and 1,893 remains available for issuance. At each of June 30, 2021 and December 31, 2020, there were options outstanding
to acquire 92,801 shares of common stock. As of June 30, 2021, all such options were fully vested, and the weighted average remaining
contractual life for such options is approximately 6.5 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In July 2019, the Company
authorized a new plan (the &ldquo;2019 Stock Incentive Plan&rdquo;). The Company initially reserved 284,090 shares of its
common stock for issuance pursuant to the 2019 Stock Incentive Plan in the form of incentive stock options, non-statutory
stock options, rights to purchase common stock, stock appreciation rights, restricted stock, restricted stock, performance shares and
performance units to employees, directors and consultants of the Company and its affiliates. On August 30, 2019, the Company approved
an increase in the number of shares authorized for issuance under the 2019 Stock Incentive Plan by 2,575,757 shares. In January
2021, the Company approved an increase in the number of shares reserved for issuance under the 2019 Stock Incentive
Plan by 574,494 shares. On May 31, 2021, the Company approved an increase in the number of shares reserved for issuance under
the 2019 Stock Incentive Plan by 467,171 shares. At June 30, 2021, a total of 3,901,512 shares are authorized for issuance
under the 2019 Stock Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has granted options to acquire 2,420,514 shares of common stock under the 2019 Stock Incentive Plan, and 1,480,998
remain available for issuance at June 30, 2021. The shares issued in 2021 and 2020 and the shares exercised under the 2019 Stock
Incentive Plan are included in the table below. At June 30, 2021, there are stock options outstanding to acquire 810,667 shares
of common stock with a weighted average exercise price of $3.2469 and a weighted average contractual term of 8.77 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 150 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Condensed Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
6 - Stock Based Compensation (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes stock based activities under the 2017 Stock Incentive Plan and 2019 Stock Incentive Plan:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares Underlying Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted Average</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise Price</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Contractual Terms</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 50%">Outstanding at December 31, 2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">675,731</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">3.09</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: center">9.4 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">227,737</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right">7.76</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited/cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Outstanding at June 30, 2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">903,468</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.27</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">8.6 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercisable options at June 30, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">556,443</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8.7 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Vested and expected to vest at June 30, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">672,409</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9.1 years</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock option awards is estimated at the date of grant using the Black-Scholes option-pricing model. The estimated fair
value of each stock option is then expensed over the requisite service period, which is generally the vesting period (ranging between
immediate vesting and 4 years). The determination of fair value using the Black-Scholes model is affected by the Company&rsquo;s share
price as well as assumptions regarding a number of complex and subjective variables, including expected price volatility, risk-free interest
rate and forfeitures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options granted during the six months ended June 30, 2021 and 2020 were valued using the Black-Scholes option-pricing model with the
following weighted average assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Expected volatility</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">111.3</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">94.5</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected life of options in years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Estimated fair value of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.32</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>


<!-- Field: Page; Sequence: 151 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Condensed Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
6 - Stock Based Compensation (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of stock options granted during the six months ended June 30, 2021 and 2020 was approximately
$5.465 and $0.238, respectively. The weighted average fair value of stock options vested in the six months ended June 30,
2021 and 2020 was approximately $5.201 and $0.238, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation expense was approximately $1,228,000 ($516,000 included in research and development expense and $712,000 included
in general and administrative expenses) and approximately $12,000 ($6,000 included in research and development expense and $6,000 included
in general and administrative expenses) for the six months ended June 30, 2021 and 2020, respectively, and is included in the accompanying
condensed consolidated statements of operations. The intrinsic value of outstanding and vested options at June 30, 2021 was approximately
$3,329,000, and $1,231,000, respectively. At June 30, 2021, the total unrecognized compensation expense related to non-vested options
was approximately $111,000, and is expected to be recognized over the remaining weighted average service period of approximately 1.7
years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in the above table are stock options granted in 2019 to purchase 231,058 shares of common stock at an exercise price of $0.079
per share and stock options granted in 2020 to purchase 14,204 shares of common stock at an exercise price of $5.28
per share, which vest upon a specified performance condition. Since the occurrence of this condition was not considered probable as of
June 30, 2021 and 2020 and December 31, 2020, the Company has not recognized any expense for such grants through June 30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2021, the Company modified the stock option
exercise price for stock options granted during 2020, increasing the exercise price of such stock options from $0.179 or $2.598
to $0.050 or $3.025 per share, respectively. The increase in the stock option exercise price was accounted
for as a modification of the stock grant in 2021, however the impact on the Company&rsquo;s condensed consolidated statement
of operations was immaterial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>Note 7
- Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As described in Note 4, the Company entered into
the Notes with the Holders commencing in May 2017. The Holders of substantially all of the Notes are the Company&rsquo;s founder
and Chief Executive Officer and third parties that are family members of the founder and Chief
Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the above Notes, the Company has amounts
due to the founder and Chief Executive Officer that totaled $200,000 at June 30, 2021 and December 31, 2020 for accrued compensation
(See Note 8). There are no established terms for repayment of such amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>Note 8
- Commitments And Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Small molecule analogues</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 30, 2019, the Company acquired a series
of small molecule analogues pursuant to an asset purchase agreement (&ldquo;APA&rdquo;). Pursuant to the APA the Company is required
to make a payment of $50,000 upon the raising of at least $2 million in funding, and up to $1.75 million based upon successfully meeting
clinical and sales milestones. As of June 30, 2021, such fund raising requirement was not met and no payments were made
under pursuant to the APA. The Company included, in accounts payable at June 30, 2021 and December 31, 2020, the $50,000 required initial
payment. Milestone based payments, if any, will be expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>


<!-- Field: Page; Sequence: 152 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Condensed Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
8 - Commitments And Contingencies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment
agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2019, the Company entered into a three year employment agreement with its Chief Executive Officer which provides a specified
base salary and bonus annually. The employment agreement also provides the Chief Executive Officer with certain benefits while employed
and if employment cease. The Company accrued $200,000 in 2019 related to the Chief Executive Officer&rsquo;s base salary as per the employment
agreement which is included in due to founder, which remains outstanding as of June 30, 2021. No bonus was approved by the Board of Directors
of the Company for any period through June 30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2020, the Company amended the employment
agreement pursuant to which, in lieu of a cash base salary, the Chief Executive Officer will be compensated with stock options to purchase
7,575 shares of common stock per month (at an exercise price based upon the most recent 409A valuation) effective January
1, 2020 until the Company receives a minimum of $3,000,000 of gross proceeds from the sale of the Company&rsquo;s securities, after which
time, cash compensation, pursuant to the employment agreement, shall be paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Effective January 1,
2021, the Company amended the employment agreement with its Chief Executive Officer to provide a revised base salary pre-funding
(as defined in the employment agreement). In lieu of cash base salary, the Chief Executive Officer will be compensated with
stock options to purchase 18,939 shares of the Company&rsquo;s common stock per month (an exercise price of $0.2963 per
share) effective January 1, 2021 until funding meets or exceeds $5,000,000, after which time, cash compensation, pursuant to his
employment agreement, shall be paid. The amended employment agreement also provides for a future base salary for the Chief Executive
Officer after the Company receives funding greater than $5,000,000, or completes an initial public offering or similar transaction
as set forth in the employment agreement. In addition, if the Chief Executive Officer acts as the &ldquo;finder&rdquo;
of an investor who purchases more than $5,000,000 of the Company&rsquo;s equity, he will receive a grant of stock options to acquire
757,575 shares of common stock of the Company at an exercise price equal to the most recent fair value of the Company&rsquo;s common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 1, 2021, the Company entered into an Amended
and Restated Employment Agreement, as amended on September 24, 2021 (the &ldquo;Amended and Restated Employment Agreement&rdquo;), with
Randy Milby pursuant to which Mr. Milby will continue to serve as the Company&rsquo;s President and Chief Executive Officer. The term
of the Amended and Restated Employment Agreement will commence upon the closing of the Company&rsquo;s initial public offering of its
securities and continue for a period of five years and automatically renews for successive one year periods at the end of each term unless
either party provides written notice of their intent not to review at least 60 days prior to the expiration of the then effective term.
Pursuant to the Amended and Restated Employment Agreement, Mr. Milby will receive an annual base salary of $485,000, which may be increased
from time to time, and shall be eligible to receive an annual cash bonus equal to 55% of his then base salary based upon the achievement
of Company and individual performance targets established by the Company&rsquo;s board. In addition, in the first year in which the Company&rsquo;s
market capitalization (as defined in the Amended and Restated Employment Agreement) equals or exceeds (i) $250 million, Mr. Milby shall
receive a cash payment of $150,000; (ii) $500 million, Mr. Milby shall receive a cash payment of $350,000; and (iii) $1 billion, Mr.
Milby shall receive a cash payment of $750,000. Furthermore, on or as soon as reasonably practicable following the date of the consummation
the Company&rsquo;s initial public offering of its securities, Mr. Milby shall be granted 757,575 shares of the Company&rsquo;s common
stock at the public offering price per share of common stock sold in the Company&rsquo;s initial public offering of its securities which
shall vest over a 48 month period commencing 12 months after the date of grant. This shall be in addition to any additional equity-based
compensation awards the Company may grant Mr. Milby from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 153 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Condensed Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note
9 - Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events through October 15, 2021, the date on which these financial statements were issued. No
significant subsequent events through this date would have had a material impact on the Company&rsquo;s condensed consolidated financial
statements as of and for the periods ended June 30, 2021 and 2020 other than described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A.</B></FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible notes payable</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
July 1, 2021 to September 6, 2021, the Company entered into Subordinated Convertible Promissory Note Agreements with the Chief
Executive Officer and other investors pursuant to which the Company issued subordinated convertible promissory notes in the aggregate
principal amounts of $262,500 and $155,000, to its Chief Executive Officer and other investors, respectively. Interest
on the unpaid principal balance accrues at a rate of 5% per annum, computed on the basis of the actual number of days elapsed and a year
of 365 days. Unless earlier converted into shares of Equity Securities (as defined in Note 4), the principal and accrued interest shall
be due and payable by the Company on demand by the holders at any time after the earlier of (i) three years or (ii) the closing of the
Next Equity Financing (as defined in Note 4).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares
of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued
interest due on the note on the date of conversion by the lesser of (i) 80% of the price paid per share for Equity Securities by the
investors in the Next Equity Financing or (ii) an equity valuation of $50 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>B.</B></FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock Split</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Effective September 16,
2021, the Company amended its Certificate of Incorporation, as amended, to effect a 1-for-26.4 reverse stock split of its issued and
outstanding common stock. All common share amounts and per share amounts have been adjusted to reflect such reverse stock split.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 154 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>3,000,000
</B></FONT><FONT STYLE="font: 14pt Times New Roman, Times, Serif"><B>Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="logo_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Hillstream
Biopharma, Inc.</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 30%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1.5pt solid; width: 100%; font: 12pt Times New Roman, Times, Serif; padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-bottom: 2.25pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRELIMINARY
    PROSPECTUS</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 12pt Times New Roman, Times, Serif; padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>ThinkEquity</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: center"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Through
and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (the 25<FONT STYLE="font-size: 6pt"><SUP>th
</SUP></FONT><FONT STYLE="font-size: 10pt">day after the date of this offering), all dealers effecting transactions in these securities,
whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&rsquo;s obligation
to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</FONT></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 155 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II&mdash;INFORMATION NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
13. Other Expenses of Issuance and Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth all expenses, other than the underwriting discounts and commissions, payable by the registrant in connection
with the sale of the securities being registered. All the amounts shown are estimates except the SEC registration fee, the FINRA
filing fee and The Nasdaq Capital Market initial listing fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount
                                            to</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">be
                                            paid</FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">SEC registration fee</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,200</FONT></TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">FINRA filing fee</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,524</FONT></TD><TD STYLE="text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Nasdaq Capital Market initial listing fee</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Transfer agent and registrar fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">20,000</P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounting fees and expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">150,000</P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal fees and expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">300,000</P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Printing and engraving expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">20,000</P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Miscellaneous</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,276</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">575,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
14. Indemnification of Directors and Officers</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 102 of the DGCL permits a corporation to eliminate the personal
liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as
a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or
knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or
obtained an improper personal benefit. Our Certificate of Incorporation provides that no director of the Company shall be personally liable
to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing
such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary
duty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or
a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in
related capacities against expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party
to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and
in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding,
had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation,
no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable
to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the
adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity
for such expenses which the Court of Chancery or such other court shall deem proper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 156; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws provide indemnification for our directors and officers to the fullest extent permitted by the
DGCL. We will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action,
suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become,
a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee
of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being
referred to as an &ldquo;Indemnitee&rdquo;), or by reason of any action alleged to have been taken or omitted in such capacity, against
all expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection
with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably
believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable
cause to believe his or her conduct was unlawful. Our Certificate of Incorporation and Bylaws provide that we will indemnify any Indemnitee
who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the
Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as
a director or officer of another corporation, partnership, joint venture, trust or other enterprise, or who was an employee or agent
of a predecessor corporation or another enterprise at the request of such predecessor corporation, against all expenses (including
attorneys&rsquo; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection
with such action, suit or proceeding, except that no indemnification shall be made with respect to any claim, issue or matter as to which
such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all
of the circumstances, he or she is entitled to indemnification of such expenses. Expenses must be advanced to an Indemnitee under certain
circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> into separate indemnification agreements with each of
our directors and executive officers. Each indemnification agreement provides, among other things, for indemnification to the
fullest extent permitted by law and our Certificate of Incorporation and Bylaws against any and all expenses, judgments, fines,
penalties and amounts paid in settlement of any claim. The indemnification agreements provide for the advancement or payment of all expenses
to the indemnitee and for the reimbursement to us if it is found that such indemnitee is not entitled to such indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we also intend to maintain obtain customary directors&rsquo; and officers&rsquo; liability insurance upon
consummation of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any underwriting agreement we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree
to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities
Act against certain liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
15. Recent Sales of Unregistered Securities</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is information regarding securities issued by us since during the prior three years that were not registered under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
May 2018 to December 2018, the Company issued convertible promissory notes in an aggregate principal amount of $274,316 to certain investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
May 2018 to December 2018, the Company granted stock options to purchase an aggregate of 48,862 shares of its common stock at
a weighted-average exercise price of $13.20 per share to employees, directors and&nbsp;non-employee&nbsp;service providers pursuant
to its 2017 Stock Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
August 2018, the Company issued an aggregate of 972,222 shares of its common stock in connection with the stock purchase agreement
to acquire HSB-1216.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
January 2019 to December 2019, the Company issued convertible promissory notes in an aggregate principal amount of $580,885 to certain
investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
January 2019 to December 2019, the Company granted stock options to purchase an aggregate of 1,992,414 shares of its common stock
at a weighted-average exercise price of $0.217 per share to employees, directors and&nbsp;non-employee&nbsp;service providers
pursuant to its 2019 Stock Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2019, the Company issued an aggregate of 2,335,856 shares of its common stock in connection with the Contribution and Exchange
Agreement pursuant to which the members&nbsp;of Nanoproteagen exchanged 100% of their membership interest in Nanoproteagen for shares
of the Company&rsquo;s common stock and Nanoproteagen became a wholly-owned subsidiary of the Company.</FONT></P>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
January 2020 to December 2020, the Company issued convertible promissory notes in an aggregate principal amount of $1,287,068 to certain
investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
January 2020 to December 2020, the Company granted stock options to purchase an aggregate of 200,363 shares of its common stock
at a weighted-average exercise price of $2.803 per share to employees, directors and&nbsp;non-employee service providers pursuant
to its 2019 Stock Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2020, the Company issued an aggregate of 75,757 shares of its common stock in connection with the stock exchange agreement
with Farrington pursuant to which Farrington became a wholly-owned subsidiary of the Company.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
January 2021 to September 6, 2021, the Company issued convertible promissory notes in an aggregate principal amount of $1,448,742
to certain investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
January 2021 to June 15, 2021, the Company granted stock options to purchase an aggregate of 227,737 shares of its common stock
at a weighted-average exercise price of $7.756 per share to employees, directors and non-employee&nbsp;service providers pursuant
to its 2019 Stock Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
foregoing offers, sales and issuances were exempt from registration under Section 4(a)(2) of the Securities Act or Rule 701 of the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
16. Exhibits and Financial Statement Schedules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1***</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate of Incorporation</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex3-2.htm" STYLE="-sec-extract: exhibit">Amendment
    to Certificate of Incorporation dated August 7, 2019 </A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> 3.3** </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex3-3.htm" STYLE="-sec-extract: exhibit">Amendment
    to Certificate of Incorporation dated September 16, 2021 </A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex3-4.htm" STYLE="-sec-extract: exhibit">Bylaws</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> 3.5* </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <A HREF="ex3-5.htm">Amendment to Certificate of Incorporation dated October 11, 2021</A> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex4-1.htm" STYLE="-sec-extract: exhibit">Specimen Stock Certificate evidencing the shares of common stock</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2***</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriter Warrant</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1***</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Sheppard, Mullin, Richter &amp; Hampton, LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">10.1**+</FONT> </P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex10-1.htm" STYLE="-sec-extract: exhibit">Amended and Restated Employment Agreement by and between the Company and Randy Milby dated June 1, 2021</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2**+</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex10-2.htm" STYLE="-sec-extract: exhibit">Hillstream BioPharma, Inc. 2017 Stock Incentive Plan</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3**+</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex10-3.htm" STYLE="-sec-extract: exhibit">Hillstream BioPharma, Inc. 2019 Stock Incentive Plan</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex10-4.htm" STYLE="-sec-extract: exhibit">Form of Subordinated Convertible Promissory Note</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">10.5**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex10-5.htm" STYLE="-sec-extract: exhibit">Form of Subordinated Convertible Promissory Note</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">10.6**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex10-6.htm" STYLE="-sec-extract: exhibit">Form of Indemnification Agreement for Officers and Directors</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> 10.7**+ </P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex10-7.htm" STYLE="-sec-extract: exhibit">First Amendment to Amended and Restated Employment Agreement by and between the Company and Randy Milby dated June 1, 2021</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex23-1.htm">Consent of Mayer Hoffman McCann P.C., independent registered public accounting firm</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2***</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Sheppard, Mullin, Richter &amp; Hampton, LLP (included in Exhibit 5.1)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> 24.1** </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/forms-1.htm#poa_001" STYLE="-sec-extract: exhibit">Power of Attorney</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Filed herewith. </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> ** </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Previously filed. </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be filed by amendment.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    a management contract or any compensatory plan, contract or arrangement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financial
Statement Schedules</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules
have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements
or notes thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
17. Undertakings</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates
in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">(<FONT STYLE="font-size: 10pt">b)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
of Hillstream BioPharma, Inc. pursuant to the foregoing provisions, or otherwise, Hillstream BioPharma, Inc. has been advised that in
the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by Hillstream BioPharma, Inc. of expenses
incurred or paid by a director, officer or controlling person of Hillstream BioPharma, Inc. in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, Hillstream
BioPharma, Inc. will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of
appropriate jurisdiction, the question whether such indemnification by it is against public policy as expressed in the Securities Act
and will be governed by the final adjudication of such issue.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The undersigned hereby further undertakes that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
For purposes of determining any liability under the Securities Act the information omitted from the form of prospectus filed as part
of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by Hillstream BioPharma, Inc. pursuant
to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time
it was declared effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
For the purpose of determining any liability under the Securities Act each post-effective amendment that contains a form of prospectus
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Amendment No. 1 to the Registration
Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Bridgewater, State of New
Jersey, on the 15th day of October, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
    BIOPHARMA, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Randy Milby&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
    Milby</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer <I>(Principal Executive Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-1 has been signed by the following
persons in the capacities and on the dates indicated below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; white-space: nowrap; width: 36%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; white-space: nowrap; width: 42%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; white-space: nowrap; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Randy Milby</I></FONT><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></I></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer&nbsp; and Chairman of the Board
    of Directors</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 15,</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">
    2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy Milby</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Executive Officer)</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; width: 36%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT> </TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 18%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 15,
    </FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas Hess</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Accounting and Financial Officer)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">October 15,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">
    <FONT STYLE="font-size: 10pt">2021</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lynne Bui</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; width: 36%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>*</I></FONT> </TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 18%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 15,
    </FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leonard Mazur</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; width: 36%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>*</I></FONT> </TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 18%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 15,
    </FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sireesh Appajosyula</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
    By:</FONT> </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Randy Milby&nbsp;</I></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
    Milby, Attorney-In-Fact</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 160; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>












































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.5
<SEQUENCE>2
<FILENAME>ex3-5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 3.5</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex3-5_001.jpg" ALT="" STYLE="height: 868px; width: 670px"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex3-5_002.jpg" ALT="" STYLE="height: 868px; width: 670px"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the inclusion in this Amendment No. 1 to the Registration Statement on Form S-1 of our report dated May 17, 2021 (except for
the effects of the reverse stock split described in Note 2 and Note 11 D, as to which the date is September 27, 2021), with respect
to the consolidated financial statements of Hillstream BioPharma, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2020 and 2019,
and for the years then ended (which includes an explanatory paragraph related to the existence of substantial doubt about the Company&rsquo;s
ability to continue as a going concern), and to the reference to us under the heading &ldquo;Experts&rdquo; included in this Amendment
No. 1 to the Registration Statement and accompanying prospectus on Form S-1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Mayer Hoffman McCann P.C.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San
Diego, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
15, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex3-5_001.jpg
<TEXT>
begin 644 ex3-5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ER!TH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI*,B@!:*3/N*,^XH 6BDS
M[BC/N* %HI,^XHS[B@!:*3/N*,^XH 6BDS[BC/N* %HI,^XHS[B@!:*3/N*,
M^XH 6BDS[BC/N* %HI,^XHS[B@!:*3/N*,^XH 6BDS[BC/N* %HI,^XHS[B@
M!:*3/N*,^XH 6BDS[BC/N* %HI,^XHS[B@!:*3/N*,^XH 6BDS[BC/N* %HI
M,^XHS[B@!:*3/N*,^XH 6BDS[BC/N* %HI,^XHS[B@!:*3/N*,^XH 6BDS[B
MC/N* %HI,^XHS[B@!:*3/N*7- !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !2$XI:C/)H ,YHHHI%!1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/_"_Y[I3F$Z)YNY1U&X'/Y5LV?Q4AN-6TJ&335CT_5+AK:VN1<DN'!P \>P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!WV?/RV+%\#^''-2^%O^2[>+O^N,/_H JDKM/U_ B_N7]/Q/4HD$42Q@DA0
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M[ZW]NGU&QB/EK L:B,?=/!]S_D5K-)2EY-D:V3[_ .9VXZ"EH'2BH+"BBB@
MHHHH **** "BBB@ HHHH **** "@=110.HH$R2BBBF(**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ)_$UYH]53Q=I$J:>\<UP4U'_CU/V2;#_P#CGR_\"Q7)>'-:L(_&GC+4)?$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M44 >S;A1FN M/'\VM?#)O$N@0VUU?6\0-S9MNPD@ WH,<_3VP:XG0OC%XO\
M%6FZO_9/AVS,]G#YSS[SY<2;6SG/5N 5'?:U 'NNX9QS^59NI^(-,T>YT^WO
MK@QRZA.+>V4(S;Y/3(!Q]37GGPA^)MYXV-WINK)&NH6L0D#QIM\U<X8GL""5
MX%>62ZYXKUKXTQ-<V,5]JMC=-';V1E*PPLAXP0>@ZD]^] 'U1D9Q2UEZ#+JM
MQH]O+KEK!:ZB=WFPP2;T7YCC!_W<'\:U* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR-F,$YXH XK]I65%M?#D1@C9V>Y83$MN0 194#.,'()R"?E&".<\E\3[.5/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH .U1U)VJ.D-!1110,**** "BBB@ HHHH 0UP?Q:GO
M=+\#7>JZ=J-W:7=J4V&&0J#N=0<COP:[VN ^-'_)+=5_[9_^C%I/^OP*@O>,
MS3--U75? NE7]OXEUE=7N;6.XVFX)60X!88QQFLNRGU:;XW7_AM_$&JG38(!
M,L8N2#DHC=?3+&M?X<:3J,$>@ZC/J$MQ9RZ0B10NJJ(3C.!M R/<\UE:>?\
MC)K5A_TY+_Z+BJ_^7EO4B/POY?F)X=NM6NOC7J^@S:]J<FG6,!GBB:<\L&CX
M)[CYCQ7K6H6OVRRD@^T3P;QCS('VNOT->2^%O^3CO$Q_Z<#_ .A0UZV]U#]J
M%KN F,9DVC^Z#C^M1+X%Z ])OU1XY\+KG4_%.A:E=:QXEU@30W7D1-'<D#E0
M1P!SR:Z?7X-9TSX5W$T^KWT>J6*R,MRDNUI,2$*6]?EQ^=>=_"K2]0OM'FN+
M:_D2WM]8C>6V"KMD  R2V-V?;.*];^(TB2?#W7%1PQ2+:V/X3P<?J/SIU7:-
MUV15E[2WFS@+:^\26GPJLO&UKKM]<7UNOFW%O<R[XID+;2-O; .?PKU7PMK\
M7B;PW9:O"-HN(PS(3RC=Q^%><:/(D7[-TSR8V_V?(O/J20/U(K<^"MM-;_#2
MQ\X']XSR+G^Z3D5;7Q>5C-/1,]#K-\07E_8:+<7.F6:WEVBYCB:0(#[DFM+M
M5?4/^0?<_P#7)OY5C)^ZV7'='$_"WQ)JOB3PS=ZAJC>9=+=2*(TP H'11VJC
MX.\6>(M:^(NKZ7K,$=G':0*4M(W#;23U+#J:;\#_ /D4;W_L(3?SJ'PP?^+Y
M^* /^?=*VM^\2\F2OA?J>E/J-I'?QV+W4*W<B&1("XWN@_B"]2/>O*M?3Q-X
ML\9WMKX<\:6NFBT_=&P^T'S&P 3)M4$X^8#/M7<7GA'3+SQS:>))9W6_MX/*
M2(,,,,GYL=>,FO+_ !K\(9;;[;XIT'69YKV"1KJ19",Y!W84KT('KZ5G%I-?
MUU'O%I'7^(=9O[/Q%X9\(+J$R->#-U>(^V5PO4!NQ)JW\/O$=[?7NM:#J,K3
M76DW;PI,_P!Z6+.%)]ZKW7AVY\6:;X;\36]VEGJUFB2AYE+(PX+!AUYK-^$,
M=QJ&K^)_$%P$9;R\9(Y(E(20 ]5SVJHJS:[7_P" *6J3]/UN>H7=REI93W,A
M 2&-G8GV&:X'X4>,)O%>G:JMW<F:XM[MMOM$WW<>W%=!XRU&"QTE([BX2".X
MG2(R/T SN/Z#'XUYAX-U*PTGXXZA8V%Q&^GZK"QB$8.W<!N[]\*WYTH[V?8<
MOA_$U/BGJ&O^%M5L]9TS5KT62.LEU:M+F,@N!@#L/:O0-;U1F\)M>:?,P>ZA
M!MY%/(W+N!_*LOQOH2^([/4M,(!>73F\LGLX;*G\ZY+X;:U_;W@6&SDW>=I%
MI+#*"..A"#ZA0/SJ?LM?,;>J9H?!._U36_#][JFJZK>WDZW36ZB:7*JH53T]
M>:Z3XA:[K/A[PM<W^C64<\L2LSR2.H$*@'YL$_,?8=:Y7X!<^"+[_L(O_P"@
M)75_$L?\6WU[_KSD_E557:WR_3_,:^)KU(-"\230_"ZU\0:C(99EL1/*_P#>
M.W-<[IWB;4M-'A35;V^FGBU_<+J.5_W<)/S)L!^[P<>])Y3S?LYJB*68Z2.!
M_NUS^L1R3^#?AI%']]I$P!UZ+5.W._5$+X;OS/7-3N;@:SI=E;LP),EQ*JG&
M]%7;M_[Z=/RKC?"WBSQ#JGQ.U'2-7MTLH+6VW1VR.'ZL,$L.IQ76Z</M7BG4
M;HC*6T26J'T)RS_^TZXK0O\ DONO#_IQ7^8HA\5O)ANF_0F\7^+?$6F^/=#T
MB*V2UTNZNE7S_,4O,.XP#E1]:[O7;M['1KF:-B)-H5".S,0H_4UYY\3?^2@^
M"?\ K[KN->'VB]TK3QR);@RR#U1!_BRU*U@OG^82=I/T/./B%-X_T[3O^$@L
M=4^RZ?IVP/;@D23<J"[ CD9.,>E=!KGC:Z_X0O0KBW8V]]K3Q1*P_P"6>[&X
MC\,UI>/XGUK3X/"UJ?\ 2-4D42G&?+@0AG8_D /<BN4^)5C%:3>"XK-1]FMM
M2CB^4<+CC%):I=FQO3Y)_P# .AT/7[NR\6ZUX:EFFO!:PI<6;S/OE<,H)4GJ
M<-G\*X[4=8\>>$?'VCW6L7Z7.G:Q,8Q:1$[(<[1MQCAAD<]\&MW3X7D^/VI2
M("8X[! ^.G*C&:UM4L8_$WCNQ>0#^SO#X:65B.&G<#:N?]D#)^HIQ=^5O^M6
M+77^NB*?Q9\6>(?"_A_[1H]HBPOA);UW&8B2  J]23Z]J[^Q=I+"W=FW,8U)
M/KQ7G7QR.[X:3D'(,\6#_P "%>B:=_R#;7_KDO\ *FOA?K^@WT+5%)2TD,**
M** "BBB@ HHHH *!U%% ZB@3)****8@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN<\=>*$\
M'^$+W6"@DDB4+"C E6D/"@X[9H Z.BO!='\;_$G6++2]=TN-=4M;JZE%S9PP
M($MU#8$9.-PXYW9Z$=P<^Z1.[11LZ;)"H+)NSM/<9[T 34444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 =JCJ3M4=(:"BBB@844E'<T">@M%(,]Z.XH 6BD_&@4#N!.*Y;QWX8O_
M !?X>ET>#4;>SMY\><SVQE<X8$;3O4#IW!KJ#[TN,]:7D%S!\)Z-?>'O#MOI
M-W?6]W]EC$4,D=NT9V 8&X%VR?IBN7M_A]KD'C^Y\8+K]@;R=/*:)M.<QA=J
MJ/\ EMG.%'.?7BO1L#K0 !0V[\_472QYM8_#W7].\;W_ (KM_$.FF]O(S%)%
M)IKF,*2IX F!S\H[UN6?AWQ#;ZA?ZE<:Y93WUQ$(H/\ 066&!<Y/R^9EL_[U
M=9@>GO2X%/HD#U9YMX/^'GB#P38W=KIOB/3I$N9/-=KC3'9@V,<8F [=P:T+
MKP5K%SX,NM"?7H'N;V9Y+N]DLR2^XC 5?,&W  '4\ 5W.!1@4/71A=WN>:VO
MPQU!O"]IX7U+Q!'+HD#AI([6S,4TP!R%9R[#;NP3A<\=:]#LK.WT^RAL[6)8
MK>% D:+T51TJ<"BAOJ%M0[52U:"]NM,EAL+B""=QM$D\)E4 ]?E#+S^-7J0]
M*35] 1Q7@/P;J7@RRNK)M7M;RWE=I5_T-HV61NY/F$%?; /O5?2/ VMZ9XWN
M_$LFNV$TE[A+B$:>ZC:/[I\TX/N<_2N] %+57UN%CD[_ ,&?;O'UEXH_M*>/
M[-;&W-J/NL22<Y[#GD8[5EZ-X!U/1;K5+>#Q%YFC:C*SRVDUL6D0-G<$D#@#
M.<?=/'OS7?X%&T>E3;0+'-:_X<OM9M8=,@U=].TGRREQ';1#SI%QC:)&R%'T
M7/O6QI>EV6BZ;!IVG0+!:P*$2,$G ^IY/UJ]@48%-.P/4YB_T36KGQ5::I%J
MMHEG;(R+:26C,3NQN;<)!\WR@#C YXK$\7_#W4?$?BG3M=L]:MM.GT\YA(LV
M=VYZ,?, (]@!U->@T8I)6MY <]!I>NKKXOKC5;![0P^2UNEDRMC.<AS(><^V
M/:LW3/ K:#I>M6VD7L,,^J7,D[230&01J_\ " &&<#OG\*[/%&*&DT!Q/P\\
M$7W@:PN-/?58+ZUEE,P M3&X<@ \[R,84<8_&M7QAH5_XE\/W&D6E_;V<=TA
MCF>6W,K;3_=PZ@'ZYKH.A^M+@$<TW[V_]6!;LYGPQX;N=&\+)H.HWEO?6\40
MAC:.W,1V8QALNV3[C'TJAI7@06=YI@N[T7=EHX<:;%Y.UX]Q_P"6C;CO(& ,
M!>.N:[7 HP,TWNV%C.T[3FTVVG43"2::5IFD*XY. ,C/8 #\*Y+3/ VN6/CN
MX\4OKMC+)<J(IH%T]E7R\CA3YIP<=SGZ5WV!1@>E*[3N!P7BKP/K'B/Q'IVJ
MIK=G:KITGF6T1L6<D_[9\T9_ "NJBTR4ZM#J-U/')+%:^3B.,JH8G+L,D\'"
M\<XQU-:9 HP*.E@ZGE_BCX8>(/$/B*?5H?&T^GB10B16T#KM0=B1(,\\UT<O
M@N.?P=9Z)<7TDEU:!'COB,MYR\ASDG.3UY_&NM(&*"H]*.G+T#?<YK2_#$UA
M<:GJDMW!+K>H +)<QP%(E"KM4*A8D  9Y8Y.>@XKA[/X0:_!JZWDWCN\D@:X
M\^:V2%T23YLD8\S'.,=*]=Q2]*!G%^/O!U_XRTA=)AU2VLK(E6?=:F1R5.1@
M[P /PKI-'M[VTTV&WU"Y@N)XQM\R"$Q*1V^4LW/XU?(!H Q1<0M%%)0,6BBD
M_&@!:*3GUHH%<6BDYQ2CI0,*!U%% ZB@3)****8@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJHR3\I^\?8,5Y=\! %^&D!\V%R;B7*I(&9/FZ,,#:>^"3P0<\X'J- !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ]>O>ICK<<NC/1.YH'44>U ZB@&24444Q!1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:P
MIU% $=%/Q1M'I2'<913]H]*-H]* N,HI^T>E&T>E 7&44_:/2C:/2@+C**?M
M'I1M'I0%QE%/VCTHVCTH"XRBG[1Z4;1Z4!<913]H]*-H]* N,HI^T>E&T>E
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MKZWOK&TU*T:UO;6"ZMWQNBGC#HV#D94\'D UD_\ "%>%?^A9T?\ \ 8O_B:
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M[-NN"ZO65HY)((P9&!"DH @VG."6(QTY.>,U[_%!'#"D,4:QQ1J%1$ "J ,
M #H/:N>N?A]X2N]3AU";P[I[7$.XJ1"%5BW4LH^5_P#@0..U 'C_ ,+-(_LW
MX4>*M9OXK>$7,,BQSS1"3Y%4@AD/49[=ZB_9N=4U?7PS*I:&$ $XR=S=*]_N
M]-LM0M3:7MG;W-L<9AFB#H<=/E/'%4;;PIX>L[B.YMO#^E03QG*216<:,I]0
M0,B@#G_C!_R2C7O^N<?_ *-2O-_@!XBT;2=)UBVO[JVLIV<2AI9<&5%1F8@'
MC"@$G'K7H_Q@*K\+-9CR-\JQI&O=V\Q> .YXZ>U>;_ [1]"UW0[ZRURP2YEB
MND>!+L@C(^8B-2 1RHWC)## (QP0#%^!6@7-]XQO-6%O+]E@ADC%QP(P[@C!
MSU.#VJU\(-.N?"GQ>U/0]0CCC>*WE4RR1A2P5AM9">0&!S[C%?06DZ/I^B:;
M#IVF6L=M:0C"1Q]/KD\D^YY-5M;\*:#XDB9-8TBUNRT?E^8\8$BKG.%<?,O)
M/0B@#P#PEII\2_M!W-VB"[L[6XEN)7E+$84;%(W<DAV3'TXX%5O$;O\ \-&V
M+RO/M_M6V*M.P.%\Q<;3_<]*^D],T?3]%LEL],L8+2W'_+.% H)P!DXZG ')
MYXJ@W@WPP[EF\-:.6;)+&QB))_[YH UI9EBMI)Q\ZJA<;3U &>*^9-.^(:>+
M?&MR?%T\C:,L4S6=BRCRQ*-QC#I]UF 9AEAR<5].06L-K!';V\,<,$:A4CC4
M*JJ.@ ' %48O#6AP7_V^'1=.CO-YD^T+:H)-QZG=C.3D\^] 'SE\"M5L++XC
M7[7-Q':K=6KPP+)A=SM+&0@ XS@=!Z4NI7,>B?M&-=WDIT:W6_$DDK%L2(3R
M2>RN/PYKZ+M_#6A6E\+ZUT73H+P%F$\5JBN"003N SSD_G2WOAK0M2NS<W^B
MZ==7! !EGM4D;CIR030!XK^T%J,&IZ!X=N;1F:%[B?:2,;QA<,/8C!![@@U@
M>+M&GUCX'^#]9L8,0:;Y\<\*;G*AW^^2>@S'S_OBOHN\T#2-29FU#2;&Z9GW
MDSVR.=V ,G(Y. !GT ]*DM-'TRPLY+.STVTM[64DO!#"J(^1@Y4#!R.* /"O
M&6LAOV=] MU*++?&*(Q6\: <$MR.WW.W?ZFN@\&Z%)I7P!O%ETY)+J]M)IC"
MAVM.&!V D<YQ@>HKT"S\ ^%+#4AJ%KX?L(KI6+HXB'R,2IRHZ*05&,#CG&,F
MMF]T^SU*U-M?V<%U Q!:*>,.A(Z?*<B@#YW^ +JEOXN!:)2;./'FD;?^6G7/
M;UIG[/MW.GQ$U:U,Z+#)92.T<1 C9UE0 @#@X#-C'8FO>XO"7AR 2"+P]I48
MD4HX2SC&Y3V.!R.!3[/POH%A>1W=GH6F6UQ'DI+#:1HZY&#A@,C@F@#8HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M',$Z^6_S#(&#W['WKPOQ+J-_KO[1NGVSLACL-4MXXDW[5"(ZLQ^8XW$9Z=<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'YUM?%WP5XN\:7VG/I^E-+]EA"R[;B$0ER,L4+,'/)*_,H^[GO7MV#2;3C%
M&+X3%Y'X:L;6_P!/EL+BUACMVCDD1]VU%&X%&(P3GKSQTKQ[XM^ _&'C+Q:+
MG2]#5K*WB$:2M<Q*TA[G!?./3@'K7OF#[48- 'B/Q9\)>+?&W]E1:7X>E5+:
M(&1I;R ?,1RN-W4="<X]/6CQ-X9\9Z[\)]$\-V_AA(;NU94N!]LAQB-0%=?F
MP=^23W!!Z\$^W!<&C#=>,^] 'D?A+PEXIM_A%K'A:]M&TS4"C_9I(I8W$P8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HH/ S7E_BGXJZEX3U2'3;[PM/)<W((M/L\ZR"X;! V@?-@
MN5'*@X)..,$ ]0HJG83W=Q9K->6OV65R3Y.\.4&> Q'&[&,X)&>A(YKBI/'V
MN)XP_P"$9'A28WIB-PA^V1;3!YCH),[NG$9Q][YFXX&X ]!HID1<Q(90HDP-
MP4Y /?'M3Z "BD)Q7G7C[X@ZSX5U#3K2T\.7,L5Y=+ MY(Z;&)9/E4!NI!8?
M/LY&1D X /1J*9&S.BLRE"0"5.,K['%/H **** "BH)[F&UMY+BXFCAAC4L\
MDC!50#J23P!7!6WCWQ'KT4^H>%_"JZCHPDV6]S+?) ]SABK,J-]T @_>*DC'
M':@#T2BN-\,>/X/$GB75=%.GW.G7.GHA:"]9%F=B6W85205 "'<"0=WT)[*@
M HHHH **1CBHHKB&;?Y4R2>6^Q]K [6]#Z'VH FHKD_#>O:_JGBC7K._T9K3
M2[.;RK2Y?(,V."0"!D'KD<<XKK* "BBB@ HHHH **P/%GBRQ\(:7'>WL5S.9
MITM[>WM8]\DTC=%4=,X!/)'3UP*\^L_C=<6=[&OBKPGJ6BV4SA(KIXW*@YZL
M&53@#GC)]J /8**A@GCN8(Y[>5)89%#QR(P974C(8$<$$<YKC_'OQ(TOP+;V
M\<SQS:C<L/*M]Q 5,X,CD E5'/8DG@ X. #MJ*R-3U^TT?PS/KMY(!;06WGM
MM8#=\N0J[L9).  <9) KS:Z^-UYI%Y#-KG@[4M/T>Y9Q;W$G$K ' S&<8/MG
MIR,T >P456L;Z#4;&WO;63S+:YC66)\$;D89!P>1D$'GFK- !1110 45QFM^
M+=3_ .$EF\.>'+"WO;^"R-U<33S%(H"3B.,E0WSG!.UMO&#GGAG@?QO=^(KO
M4-(U?2Y-.UG32HN8U/F1'(&")!\H.?X<_3.#@ [:BH9[B*W"---'$KN$4NP&
MYB< #/<GM7'_ !$\=W7@725OXM$EO8BRJ9C.B1J3GY3R7SQV4CWH [:BJ>DW
MQU/1K*_,?EFYMXYBF<[=R@XS^-7* "BBD/2@!:*X+QW\0KOP-;+?76A2S6+S
M^1',LZ#<WENPRN<@$@ =^') PNZ"R^(/B"_T>/6;;P1?3:;)'YZRQ74#.T61
MDB/?N)V[CMQDD =\@ ]$HKB/"WQ1T#Q/>SZ>&GTW4(9/+-GJ(6*5FZ849.3G
M(V]1CI7;T %%%><_$?XD:EX#N;4KX>^U6,Y\L74ETJ OC.U5&YN!W('XT >C
M44@).<TM !1110 4444 %%%% !1110 444R1UC0NS!5 R23@ 4 /HK@8/B#?
M>(K^[@\&Z)_:=M9/Y4][<SBW@9\J,1'!+X!8G@8"\9W+F+6_B#K7A:SN;G7_
M  PT%O&D@CO+:Y6:!Y0,Q*<#>BN<KN9!@E?7@ ]#HJ*%S(BL>XSBI: "BBB@
M HHHH **** "BBJ]]<36MG)-!9S7DJ#*P0LBN_/8NRK[\D=* +%%<%\-/'EW
MXW;7!=V26IL+D1HJON.TYX/;(V]1ZUWC' ZXH 6BN2\4_$#2O#4T-@N_4=8G
MD\N'3K,AYMQ&06&?E'(Z]CD9P:J)XE\;00K=:AX*46ZJ&FBL]026=1AR=JG"
ML057(#<[QC)!  .XHKD?!OCE/&,^J+%IEY8K82)$T=XNR7<02=R\XQBNNH *
M*** "BBB@ HHHH **** "BBB@ HJ&*YAN%9H)HY K,C%&!PRG!''<$$$=C7,
M>$]?U_6=3U]-5T9["QM+PPV4SY4SJ."<'!(X#!NAW8'W2: .MHH'2B@ HHHH
M **1C@5YAXL^+D_@W7%T[5/#EPHE8FWE2XC831A]H8#.1D<X.#GCWH ]0HK,
MT2\U.^L%GU731IT[8_T?SEE9>!G)7Y?O;L8)^7!."2!IT %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7BWQ5_Y*_P##P?\
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M2Q=V);)Z9)SVZ5=^!^NVVI_#BUM0T:SZ>SPS*L:H,9+*<#KE2,L>2<DY.30
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M7QG:>-?#<.I6[1BX "W4*$_N7[CGG'H>]<9\?O$$NE>#+?3X7FCDU"8J7C;
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MP]I\MB79E@\YC+Y()'F'''!'(^IZ5M7?B_6-;^&J^(O"%I!<7DD)9H';<T9
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "L;Q+X7TOQ9H\VF:K!YD$@X9>'C;LRGL1^
M7J#6S10!YW8_#;6M)L4T[3/'>I6^G1HZ1P-;12% 6)7YSS@*0,=\9&T<#I_#
M7A/3O"UE)!9-/-+,^^>[NI/,GF/0;W[X& !T 'U-;M% '%ZC\-;#4?&"^*3J
M^K0:I&I2)X7BVQKM*X ,9[,W7)YJ/Q%\,K'Q1J,-[J.O:[O@?? D,\:+"?\
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M"':5B66)5+  ;F CY)QDYXR3@"NHTW3_ .SM.@L_M,UP(5VB24(&([#"*JC
MX& .!5RB@#D?&/P^L/'"1PZKJ6I):QL)$MK=XU0. 1NY0G.&(ZXKFY/@/X<E
M;=)K/B%F(923>(>&^\/N=^_K7J5% &?HVC6F@Z+9:58J5MK2)8DR!E@!C+8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* 'TAZ4F??@5Y;JFK_\ "3?&2'PK+>/'IME:N\T,-V\9N)2N>L>"-O<%L<4
M>H1LKA65MRL,@@Y!%25P7@CP5J_A37]5=]:-QHTK;;.RD,CF"(<H%+.0N,E<
M8.0JG(Z5WM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% "'I7EOQ[F$7PV=?)CDWW<:?."=G#?,,=^/U->I$X'6O)?CWJ\=OX'
M.F0WB)?3SQLUNK_.\7S9..I7(_2@"UX/U;QK'X-TI;+PI:RP"V7RS<:AY4C#
M#GE?+&.54?\ ;1>2 Q'%:]-XDN/CMX9GU&WMK&8SQJL(E#+Y08;R)'50Q89P
M 2P/'!(KU#X6ZQI^I^!--ALYXVEM8%2>%=H:(DG[RCIG!/O7EGC76M%U'XY>
M'[N/48%L[.6%YKL &/*L#@LOTQST^E '0?&V#4(;_P .R:??:BTEW>^6+6&0
M[!@+]U5&23WY-=C\73CX6:_GC]RG_H:UPOQKUC2M4G\+16^K6^$NA-))&V_R
MXV52KD+S@CD&NM^*>KZ?>_"+5;FUO()H+I%C@DC<$2MO'"GN?E;\C0!M_#=6
M7X=Z&'BMXV^S#*V[AD')Z$$C]>N:X+]GZ??H>O1K#&&COOO*"&?()^8^U=5\
M+];TJ3X;Z?Y,T$*V%KFZC\W=]G^\3O)Y' )YKD?@/JMM%I.IZ?+JD9NI+IY(
M+1LAE4 DE0>H/7B@#,\/:OI.MZ]XETKQ_-<Z/K4MT\D1FO#$L$6 %C1\A3@#
M@XPP((SFMKQ?X9M4^!S?VG<7F_3?,DMYHIA*TB/,=FX[MKJRE#UXZ]L50GU;
MP3\1O!KMXDU'3K37X5:'[9M\J1MA.UU5L$JPP=O8G':IO#UIK5S^SGJ=J4@N
MBHE^P^8HP]NK@EB#WR)",\]/:@"7P[X2C/P6;5-,N-3AU*?1Y"$M9B?,8(^$
M"X/WCC.,$X&,5D>!/ E_XX\"V&HW/BC4+5XGDCB$6[*XE);<2WS9Z#ICWJ]X
M=\;:++\'#H+7,EM,FF36EQ<2QLB0NT;[0#_&Q/15R3^%;7P%U6RG\!II23 W
MMG+(TL9!!"LY(//4<T 8K:__ ,)'XPUJWOM-\0ZIINE$:;8Q6<9!:501-)(X
M(3=E01EAPRX7.:/AX_B#0?B!-:6NEZS+X8U5MD=QJ22>9 T<>[+;A\HRQ7D
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MXO:*^OEV\+V\/VB "$O&\NT[6&/O$,5QZ5@WGB.UNOC5HNN)HVH164R 6_\
MH/S3KT61%QE@1T/6@#:\:6.KV_QP\/6]EKUU&E] VQY95E\ELRY_=*0=H!&"
M>^>3@@5/&.B3?#WQ?X1O]/UG5)EN;T+>>;<^:TF64-MA'S$%2_0'&0.I&;7C
M+6]+'QY\*7<C);I;6@-U/,Q3RMPD*HZG[A 8'GGYQ[4SXSZUIEWKWA5;6^MY
MI+2]5YE@8"6-25.?-Z1C&.I'8_PT 6?CX;NRTW2+^UU._B$UT$\E92B ;#R
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MV_VAL10'E&90Q4.V<GDCGH.E033:1\5/%5UI3WEO<Z)I<9)@3[]Q(ZE=X/\
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MH;:[M/)AEDD&R64O%A8SWZ<#KP: #1[1_!7QUM-&AU>Y.E7=J<)=W@D9F*'
M()RIW8P"!GMFMGQ9XAEU7XECPT;'4[K3-,MQ/<P62$&>=E#(I<' 7:?XBO(/
M-<[KGB71A\?-*U2/5[3[%'$(Y;B&$. =N-KOT.>F?X:G^(US>_#OXI0>-+:W
M%Y!J-OY+Q.V K*JJ0 .?NA3SW)H K6B:]X;^(EGJGA[0]?ETBXCBAO;;4=[&
M!IG8_+C(PJJAR-P7.UB"<5[X.>HKS?2_B7-XUOX=/\(V,I"B*6]O;E-L=LA/
MS)@]7.,#'')/:O1P>3T% 'CW[0$H@L/#4IBCE":@3Y<H)5OEZ$#M76?$VP\0
M:IX=AL]".V.2X3[=(MRL+I"/O$%N,>O(/ QGFN.^.6JVQN/#MK#J<=O>6U^)
M9"A+/ I7ARHYQ4OQG\033^%=&ETF[:70+VY9+ZXM/F5D! V[A]'X[X]J .;\
M:WNDZ!XE\/7?@[4]3DG@N(HK@+YLEK(K9 )?!W,^''R!L[6Q@K@]7\:?#<UW
MX5?Q-I]U?6^H6B(98K9WVR1D@$D<8V@DYQT!SCMQOQ1U[3=5T/PU+I.D:A_8
M]G-&([Z6RVQRJ,C8"X!)^3IT/X5[C;)#XF\*R6UY9SV]I>6Y@:.3Y':-EQG
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MGRP>3@Y'U% '*^"O!,GB+X3:??7FMWL<5O:W!LK6UE%NL3"64DNV?FR0.3@
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M4[]]2CBT^YC;9.DB>1(2,C<P./IWSUH ]VT^TCT_3[:RB=WCMXDA5Y&W,P4
M L>YXZU;IJFG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 444A.* %HIN[KQ2Y]J %HI,\TM
M!144T\=O"\TSI'$BEG=V 50.I)/05)NH 6BBB@ HHHH **** "DVCTI:* $P
M*,4M% "  4;12TF[VH -HQC%!4$<T;J9+/'!$TLSK'$@W,[L %'J30!#+IME
M-<K<RVD$EPFW;*\:EQM)*X.,\%F(],GUJP5R.I_.E!S2T )CBC I:* (I[:"
MZB:&XACFB;&4D4,IP<C@^XI(+6"UB$5O#'%&"2$C4* 2220!ZDDU+NI V>W%
M $9M8&N1<F)#.$V"7:-P7.<9ZXR <>U2X%&[\J-W&:  J",4A4&@M@9IPY%
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MTM% #=H^GTI=HI:* $V^YHVC&*6B@"K::=8V"E;*SM[92%!$,80$*,*.!V'
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M&&*@E6(!(XY13]5!["K5% #=@&?0]J7;2T4 (!BEHHH **** "BBB@ HHHH
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M]7OD9U:&U=MT8!/3MGC\ZXGX 01Q?#=I8W+//?2R29<-AMJ+CCIPHX//?N*
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MOB%KMQ>^/]+\+'3;V_TN"!K^_L[9=QNL ^4I YVB15R#QR,]* /6\_6C=FO
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M[[+MO*E*6[;Q\V5QDCKW''(/2O9UB02O((U#L &8#E@.F3WZG\ZDQ['_ !H
M\?\ BKHNH37OA_QYX?,TSV 3S!&@8B$G<&5",D_,V<^W%6O%WBS3/'G@6XT7
M01<S:IJ;)%':O"RM%B3):3LJXC;G)_.O50,8Q_*HX;6"W9FA@CC9N&*( 2,D
M\_BS'\30!X/\4-*CTGX7:%X3"W-]JEB\;8MHFVJ-K99OE.1@D8!!R0?:NI^*
M.N6&I_#2>UL)I)9[E%\F-;%I2^TX(PR_+T^]U'45ZH>AR*3!YX./:@#DOAE>
MI>^ -(0273RVMNMO,+J(1NCJ,;<  8 P >XQG)S784T#D'OWIU !D5XQ\$K2
MZO\ 6O%7BBYEA9KV\:,BW5O*8[BQ9"W)7+8'?BNZ\6-K.K(WA[1('B:Z7R[O
M4I?E2TB8')4 @O(1G 7@'&2*U_#_ (?L/#&AVVD:9&R6MNN%WMEF)Y))]223
M0!<O;RWTZSDN[I_+@C&68*6QSCH!FO&_A!J%EI>M^+?.CN[2&[N1/;BXB<ET
M02,[9"@=.?R'->UXSVH(/84 >'^%-1B/QOUJZ\V]6RU)3#!*FGB*.0D\*QVY
M^C<$GK67X;\27?P9UK5-!U30[N31I[R2>VNQS)Y0.P.<<,,*IQQU^E?0F#WJ
M&YM+:[7;<VT4PP5 D0-P>HY[<"@#SJ#QAJ>N:/>ZY=)+HF@26LUM9((FDN;F
M9@2LWR@%0 ORJ,9+-D\"J?P)O53PQ<Z1/'>1WL-S).6N(&3S$8CYLGJ?4>]>
MJI&L:+&B!40 *%& !Z"GC/<4 >!>(KW5?A1\4M1UFRT\ZAIVL 3W!96)0;LN
M R@!><XSGBN^\.>+M2\<>(!<:7:WFG^'[$NLTTZH&O),+A-K*2H4[@<,.WTK
MO)(8YHWCEC62-QAD=<@CT(I$A2%2L481=Q;:H &2<D_B22?K0!XM:ZA:>$/C
MQK^I:];WEM!J$&RUO-F8=NU6;=@9_P"61P<\8.1SD:>J6K_$+XEZ'=:7;*NF
M:%)'<R:FX<>;R&\I5.!S@9.#]>Q]5FMX;A56XACE4$D!U# 9!!Z^Q(^AIZKM
M4 #"C@ #&!0!F^(-$LO$&B76FW]M'<0S(1LDZ;L<'(Y!SW%>3?!G0+RYN)+K
M5O+9/#;2Z39Q(VY!+YC22R8(X;YU4,N,J,$<5T7BCQCXU@\77GA_P]X6:Z06
MZ^3?2$I&KD EB2-I SC;G/'X5V/A70SX?\/VUC(PDNCNENYAC][.YW.V<#/S
M$XR.@ [4 ;8Y KQCXC6VJ^$OB78>.]*TFXU*$0>5=H.54?<PN.02#UY&:]H'
M2FD9/M0!YAH_Q#O_ !_=V%KX<T^^L(/W<U]?R!"(QSNB3>K!N>-W'0]*YGQZ
M^K?#CXI#QCI5A_:$&JVICN$<,WE["F_&T#;\JI@G/.[TKV^WM8+2%8;:".")
M<[8XD"J.<\ <5(Z"2-DD0,K @J1D$'M0!YMIOQ#U#Q?=C^P[";3M*LF2?4=0
MO(\D(OS/"B8^\P&-W. 20,XKGO ^KQ0_&CQ'/*^H3V^J'9:7,MJZH,-D)D]%
M X!_E7L\5O%"A6*)(U)W$(H&3Z_I4N#Z4 >3?'6WO!IF@ZC%$LEE97ZO<[8@
MT@R5*[3C('RMG!&>,YXI/B)XHC\1_"W4T@T^]@^W)']CCFA;S9RLJE_D .T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIRE(E5BH522^!G H V:*Q?"GB2V\6>&K'6[2.2**Z0G8_5&5BK#WP0>>];5
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M<X(!]C^= '344@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU;3/,$#,R%)=H="#CY@"<9ZCV-;9;':N \ _#S3O >J7B66L/<27-M%OM9,
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M^['U?H.!T_&I/C'8WLNG^$=>20S1:?=HT\!'E33LY0KLC;!+?(WR?>&>G!P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'YNV#ZUV%]X"UI?!$_A_3=80W%_EM0U"[:1I9'.P$J0>A"[<'M^->AT9&<4
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MF.!,[MB#H!GTKLJ* /+K3P7XK\*>+-7U/P[+IMW9ZI/)<2Q7:;9%=B#@N.2
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M(G,A? W8;^$9!Z<XQFL3XD:?J>M2>%/#MIJ0/B&";[4UO&S-"(U.!-)NY)!
M SU+/7L39[5Q/C'X:Z?XMU2VU@7]_INKVL)BANK.;8<<E<^P+-]W!.X@GI@
MY&>T^-L#@6UWI4RLN6(CB7!R>.1_G-=_X$U^\\3^$K35;Z*WBGF+92W?<H .
M!^/J*YO2OAWXG%VQUWQ[J5Y9D#,%JOV<O\R-@N"6 .S'RE3R<$9.?1+6VBLX
M([>WB2*"-0J1H %4#H !0!S/Q#\&GQQX4DTA;H6TOFK-'(5R-RYX(].:XO4O
MAKXPU_P)_9NJ^)6^TVZ&."R@54@D12NP2$<L?EX)Z9^M>P44 >9W_P .]=U/
MX<-X:NM;6:YFAB#W$^Y@C(ZD!0.V 03U)Q6A'X6\31^ (O#(N=&?R[86GFR0
MNZF,(%!*G@MQ]*[RB@#S'1OA?>#X>7'@W7[^TN;,/OM)[>'$D)+%B?FX)R3@
M]?F(]*S=#\!>/=,TV\\,/KEJV@3I) LDB;Y(XF9,[?0LID !X!R>XKV"B@#S
M?X7^ =9\%V+17FI0^4[ES:PPKDD@_?DQDD=L'%='XVT/5/$?ARZTC3I[2!;N
M-HYI)PQ*@XP5V]_K72T4 <?\//#&L^$O#JZ+J=]:7EO Q-JT,95E4DDJV>O)
MR#[GVKCO%/PHUN3QW_PE?A75(K&Y:6-V1BV=Q.UV/8KM)RO< CO7L-% '"^$
M?!VI6C/K?B:^:_\ $$JL%8ME+56ZI$.B_A65HOAWQ[HVB2:&LNG7=G<&1OM%
MV[&:$2EV<,5/SL"<D]]W' KT^B@#@M/^&%AI_P ,[OP>DK2"Z0O+,S$!IS@A
MN.@!5>/052\+^ =?C\&RZ#XBUH&U-F]I!;VBA?*5U9"6/\9 ;(!XSSU%>E44
M >1>'/AGXMT[0+GPY<^*3::7$<VS6$85W+?,VYCR%R2,5L?#CP+KGA?PY<:5
MJNKB:W=IDCM5C5T16. V2,\\MMZ?-SSFO1:* /+?!/@#Q5X8%[9-K5LFE"XD
MGM[>&+89'^4J69>53( *CJ!CH:L>&? 7B+0/'6J>(Y+[3)5U1\W$"I(-@+!C
MLYZ\=Z]*HH \Y?P3XF'Q-E\7)JFGR1^6;>&UE60B.+@>O7C/IDFH/$_P_P#$
M&L>/M+\5V6J:?;7-C%Y:Q/$S*V'D.?Q5P#[_ (5Z;2&@#QKQ1IVL^)OBE;?\
M(UJ\<=UIMKB\FD3?%9-D':F><OC:P'5<@\$U%>WWQ@\.6"ZM?RZ7<6=N&EN;
M=5C7Y5/0$#))'I73:]\*H[OQ#=>)- US4-%UJ=D9I(GW1.0P)WH>6!P/ESMX
M''7+M%^&U\#&/%?B:[U^&&19([610D!*C"EUY+D'GDX)Y()H [C3[A[NPM;F
M6WDMI)HDD:"7[T1(!*M[C.#5NFJ#W%.H **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<%2LG5>1T'4X/:O:[;=]EBWYW[!NSUSBN%\5_"G3/&MU#/K6M:S+]G!$*1O
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M%.U3X:6NK>*8/$<^OZTNHVV1;O&UN!"N6(508>0-Q^]D^YH YCXR[O\ A)_
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M"QNI!.TMC(__ %T =/\ #S03H/@RQCN!(=0ND%W?R3 >:]Q)\S[SU)!.,GG
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4'A?P;H?@^R^S:19+$6 $DK<O)CNQK?Q0  ,"@ H(!ZT44 &*3 I:* $P*7
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M?A]=]N%,LQ*NH\T\)]UL9"]<@$ DKG.!CKO@F?\ BV-CF#R?WC_PH-_3YOE
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MQGR_X!(F[YMP Y*\;3G'48PWTM0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP:EJ]A9RNN]4N;E(V*Y(R Q''!Y]JDO-8TW3K..\O=1M+:UE($<\TRHCDC(
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M0V-#8I_J81CJ#DY)]>.O?L =AWJA<:WI=I.T-QJ5G!*N,I+.JL,\C@D&O/\
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MQ8MG:><>F,= *U=!T.Z\2_"-O"VOVE];W@M1"\EX#S(&+(P(;+!2J''L!TH
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MD .P) "LBD<8VX[4 .^"DOE>-O%]E!8):64OE2?9@3((3EL+N'R@_,V0><C
MZ&IO"&A:?'\=?$]BVCQP6B6JS11.N59A+&RR*#T^89&/2H_!]EXHTOXO:[-=
M:"RRWYC)N6;SXH(CDY,C?.<A-H"L "!D$*H%B*UUOPK\;]6U"R\.W>H0ZM
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M:V'4@C(.001UKSOP;X?O+[QWK?C74K.;39)A]AM;)XD1O* 4F1R!\Q) P3R
M".0!CT5@,?6@#Q7P!HUJGQ?\7V4^E6T$%ML:VA$ 5559/D<#UQ@Y[TGQ&T^#
M4OCAX2M9+N51/;^6\<+,C*N9/F##IGD<<\>]/TRTUWPK\8_$$MEX;N;Z'5L.
MDOG*L:!GR7)V_=SVZCWJ3Q+;:U??%7PWK2^&KZ:+2X_+N[N&$CS&!?.Q2Y&S
M)R._S<DX% &;\3_"^B^%-:\%7>D:5);[-11)9+:+/F ,APQ'+.<' [_-6OXF
MU2_UCXTZ3HT-M;SV]C;?:H[:YEV*\K*=KLIZE#S@<X!J#XLV>K^(]5\/OI?A
M?4[D:=<>?-,I:)MIV'8C!N"<<MC(*C!ZY/B'X?\ $?\ :FB^-?!]E=1ZQY7D
M3PO&))$!4@%@Y*\#(Z<YS0!!J?@CQF_BNQ\3:+I6G:1?Q(INEMIEVW#.Q+]>
MN <'/7'%>VAN?:O*=%\2>-/'S0V8TU_#MDL,;WMZN1*Y(#8AS]T,".N2,]:]
M5)'7!H \#_X28^!/&7B:+QMI$]Y;ZU<($NA!B%H@"K8!Z@!QG'I6]?ZIIGA/
MX'7U]X-NVELYY&%O*6*M 97P1GJ&7/?GBKFF^)[R.TU#1O&GA?4+B&2Z)M8V
MM_M,<L)D55!#$DX=D^\3]X= *H>$_AEJ,GPNU?0];E:(ZBYFM;=BV+-ARIP#
MUW8) _'- $9\*>(=8^&]CH%KH>BBSELH2+HSAW\PC+2@KP<GY@?1_7-='X?T
MOQ!H_P (-1L/$DZ2WD5G<+&%8,8XA&0JDCJ1@_A@=JXOPGXH^)GAW2HM!O?"
MLUY)Y2Q::TB!!$J +A]N,J!CWYZFO0I[76M.\":FFIO>:OJVI"7=';(&6%GC
MVA$&1B-< ?4D]Z .5^$]\NA? ^_U2W9;E[1;JZ,9!4!E3=L/Y=1ZUG^!M.U7
M7/ L<UQH.EZQ#?RRW%Y/<3J\LSY)7G. P^[ANA%;_P *]+OH_ <WA;Q'HES:
M[UE23="(D>)P%QN4@EB">>O'7BN1T2\\=?":^FT:72'UC04\QK<P1A?5BP;&
M?J#GVH C^Q^+?A'\,M86ZEM9!>7$44"@[C&7C_>'/?& N/52>XKOY/ &F:]\
M)+#0(T2%GM8YH+AUWM'*1OSGKSEA]":S]2\&Z_XP\ :L^NJJZWJ+1SVUD+B0
M06910JJ%+$ GYF/');G.!6)X=\;?$6PM/^$;E\)K=ZC;XM[>Y8%(PJ%0S28Z
M@*Z8*X]3GF@#4^(_AI=.^$=Q]OGM]3U&PA$<5[?(H=$) 8*3_%C('<G'>NJ\
M!Z-ILWPXT=9+*%A>Z9;_ &D%!^]_=*/F]> *RO%/A#4;SX0WFB/)<ZEJAC$K
M-]H9FDE#!\ N6^7(^[^ QUJ?X?:CX@M?"T%IJOARXLH-+L8K=%)#S7$BJ 2J
M]-N,?CF@#C?A/%)HNL?$B^@M"MI;W#B#@A"8VE.P'V!7\Q6E\'+"S\2>']7\
M1:K;K=W^I74MO,TYW_NL*=@ST'.#ZX%1_#'0-3M?%7C0ZQHU[;V6M2EXGF3:
M&0O)D$@Y!Q(/UJOX8^V?![4-9L-8L]0N=!NI5DL;BU4RHC?-\FS.02O4_P"P
M/6@"OH3/X+^/5SX;TUI?['U!?-:TCBRD;,I(P!]T ]_3K57_ (170[G]H*^T
M2*":WLC8 S0PMY:D[$.!CDJ1C(/?-=GH6CWFO_$NY\8WUA<:=;VD7V>R@EA1
M7G#+@NQ')X/ /3UK%MEUYOC?/XFN-#UHZ.UJ+> 21Y,>54$!=WRC<&/'KF@"
MCJVG6?A+X^>&HO#UO';)=VA2XLK9?*#*2_S,3\IS@''7]W[BO<37C7C.SUC5
M_BEH&K6_A_5;C3=,W+*MQ )(<Y/S1QY'S=/FSSA/[O/L:/YB*VUE+ ':PY7V
M/O0!Y)XAO%\4_&_3_".I6Z2:58PFZ$>?];)Y>[YO4=L5'\<K!=)TO3/%FF/]
MCU2QN5B22)0I=6R<$^@(/'^T:L_$#PGJEGXWTOQUX?MIKJ:V9%OK6WE*R3(.
M..<8V\$8_.D\327/Q8T*QT2TTF_T^-IHKB]N;J/:L V!MJ_WR1(,'C^E %7X
MK7-MJ?P;M=:N;=EOYXX461OW+_,59QM."RDIG:/0-T%=QX#T2RT[PMID\=C;
M07C6H\QXK?R2V[!/RXR,D US7Q2TO4+SP"GA?1=.U*[FC2#;(B'8ZKQM8A@"
M> <,"/;.".F^'\MZ/"-A9:CIT]C=6L*Q2I) L2LWJH7C'Y4 ;^HV\UWIUS;P
M7'V>:6-D27:&V$CKBO#KJST32/A/?>&DT]=9O+2>1;N_AB9+=)\EM[3$8W*I
M1<9SG KV'Q?9W]_X0U:TTJ1HKZ:V=8&20H0Q'9AR*\A\.S^-1\-W\%6?A*:*
MXM(Y8Y[JYN&B4AB9-J["#NQ(N.<'G/6@"L(;'4OV:9+W45,\]BOEV\L>QGAS
M*F!D'@9(SGG&?:MK3O _AZX^"XU:]MUDO)='WB[N093;XC."@ZJ!Z"L[3]/\
M:Q_!?4/#!\/W]O=^7^XF2X8NX\Z(,FTGY049^ 0I ;CDYZ_2KC4['X30:.VB
M:['J,5C]DVVR!) ^P_,C9X'^UZT 2_ VY\_X6:<A67,4DR%G0@-^\8_*3U'.
M..^1VKM?$%C<:GH%_8VMS]FGN(&C68KNVY&.E<-\&+/4]$\('2-6TB_L;F"1
MGW3N620,21L&<+CN!U//4FNE\?V&IZMX$U>QT=F6_EAQ%L<H3\P+ $>J@C'?
M.* /(M>BT*T^#LNAVFFKJD]DSB;4XX6CMXYUR6<3$8+=% !RQ('>O2/AE=R7
M?PJTUY9A*R6I3=N4X &,?+Z>_/K7 :7!XMNOA+=>%]+\)"S>WC>"\DFG,3SL
M5))14QN8_*#DD'H<@UUW@"77]%^'D5GK'AZ\C:VC,4:1S&:5^<#Y&/RC'/!Q
MZ 4 <W\%+*PU'X1:U;2VC7@>ZE\Z"505=_+4@+CGIM]\YJ_\#M'L+KP;=2W>
MFQ">'4YT02+EHA^Z;;D\\,B_BHIWPATS6=)\&:AX=UG1+JTEE:5XY/)1%9&0
M##..2V<X+ \ #H *9\*+3Q1X9M+GPW+X<FMH3>27'V^YD!01_(NT 8+,0O!X
MZY[8H SO"%QK_BC4?$&KC0;+4X]1G-HSWCD);1!L%!G[R;<G"YY JYX9^'>K
MZ=JNMOJ=K:0>&;WSKC^R\J_E-EO+ QP"%QR.,8%9\FD^*?A9XYO+_P /Z4^J
M:#J<R VZ.Y\LLX&.OW^<!CGK76:)JGB/6+>X\5ZKIMW#;2P&'3]*MF=V*L21
M)*A8*QP0,D=!0!Q'P>\"^'O%_@S49-2BN;B&/4IHK=7E*^6I2$[@!P'( !(]
M,5/\3_"NB:/XL\"V^F1I9-+?)$R0 K(R^9&-^\="/7KELUT7P3M-=T/3]2TG
M6]!N;%Y[M[U)_+5(CN55*!5X7&W( XP>V*A^)UMK>L^,/##Z;H-[<6FDWRW%
MS,MLA) 9"-C]2,!LC@$@9Z"@#GOC3X/T'PUX7TRXTNVBM;I;H*90A:6?CG<_
M<]\FNV^(.G6>I3^'=?U2^2#2+"432Z?=0'S)BV-JA<9+]!M/I69\78=7\5>&
M[33M(T76WE,J3.H CCVXSMD&?F(].QYK'\7VFN_\)5X*\5VGAW4)8K2%+=[*
M67?<+(I;Y68Y)SG[QZ]30!3UN^B'QT\.ZAINBRZ?)*Y1_/B>.2Y^7&\Q ;@H
M!(#$<E3V6M'5],TN3]I+3+'^S(!%=6<S70(RMQN@D!RO3H/QJAXP'C'5_%WA
MGQ#>^%)A:PRNMO91R^;*"!G#JX,:DE20P4$@#G*KC<\2V'BRQ^)'A[Q?%I=S
MK$<-I(LEC;$HL#LC*<;B0"=XSZ[: +'QPT#3(?AU<7-O80I=+<1B-T3!&]\M
MCZDUU=IX<36?A9IVA:C 8W?28('5P5:-Q&O7N,$<_2N=^*=OKVO^ &TF/1IY
M]1N)4F"6J;HXE#YVLQ/+ =P,'T%=EX-CFA\%:);W5K+;7$%E%!+%,N&5T4*>
M/J,CVQ0!YY\(?$46E>$/$&ESP.9O#C2-*^_/G+\Y 4'I]P\=.1ZFGZA)JG@G
MX1ZYX@ECMX]<U*3S9)H/E:/S6"KR.Z!LC'&:J>,?AQJ6I_%2*>QM]FB:S L>
MJR@E@0CJ[ \Y3=Y<8!7'(/OGTKQ7X9M?$WA"\T!\(DT.R)B3B-E^XW!R<, <
M=\4 >:?\(=K6J?#>ST63PIIV]=/4QW,CA95G<<OAN0PZMGDG.*[WX<Z/KN@>
M%(],\07D=S/;R-' R<E8!P@)[]R/0$#M7E_AKQ=X[\$:?_PB=SX:>_GMW-K9
M3EG8%SRH)SR@4C&,8&*]B\,:=?Z?ITC:I=/->W4QN)4\YY(X&( ,<6\DA!C.
M,XR3C P  6/$%K:WN@7D=WY(B6,R!YFVK&R_,KD]1M(!R.1BO*?@7HME/X=O
MM0NK*UFE2[S#.8/F^1MP.\CYL, 1CI7JGB*[EMM'G6&UO+B296B46BL60E3A
MCM96 'J"#TQCK7F_P6T[6O#]I?Z7K6B7=KY\YDBG,"@%<'.]\[B?3.: (/@Z
ML'C*7Q#XLU:W%QJ%Q>O"HE8NL4153L7/0 ''T K,N((_ _QVMM&TM631M<ME
M-SI\4.Y,$.H 0>Z9SV#-5W0[*Y^#WBC6OM%E?7'A:^826KV@:1;<DG"E"<EL
M87=W"@UM6UA=^+?B-#XMGTZ\L=.T>S4V226Z++>LX<DYZ[0#@*3U.1C)R <E
MX>\(:'J/QL\4:3(N_38H!,UK%N2/*R1D1N/XER <=*3XM^"]'\)^%-%AT6".
MWB&HF23?(/,D)&.,\MC]!6SX;BUJR^-&J:X_A34(-,U-/L_GE>4)93YC@L>Z
MX(& !S6Y\9O#E]X@\*6[Z=9?:[JTN5E6) =^.AVX('3KD&@!GQUAAD^&UQ))
M#"SI/&59Y-A4\]/[Q_V:YKXMZ+93?"#1]5^Q.][%':)]HB0$JGEG[Y[)D_F5
MH\=ZYXI\<>!A;VOA&>RCN)H?+6X19GG#!B#&<#80!R>O(Y'.5\;V>N^)?A?I
M>B?\(GJL>I6[PR(B%60!$9,N3W//R]>0<]J -'QK\/O#T'PNU+4!9ROJ"VHN
MOMI0S3[@ V"W4+Q@]@,U'X)\%:!XD^%T.HZO817=[/:E3<-,97C"+M4*W\&
MHRHZ'(K4UVZU?4/A.VDMX?UR;5+FS-N4&(RC<#+LF!M[XQA@"#UJUX(6_P!!
M^%L-A>Z1??;($:)H8K-8V);)X4'#8S@MU)R3UH S/V>[NYN?AY<)<322)!J$
MD4(8Y")LC;:/;<S'\37K0Z5Y!\*X?$WA7X;ZO;:CI-V+ZSEDGM(;IL(8R@^5
M3SCY@YP.Y]ZZ/X;^-M7\61:E;ZWI2:??V+Q[E0, RR E>"2?X3W[T =CJ%G;
MZA936EW;I<02H4>*1=RN#V(KR7X#:>CZ3K-Q?Z?##?V^JRKM\H(8"43<JC^'
MIC'M7L3@,I&,\5XQ\,-/\4>#+F^T'_A&;A;*74'F-[-*"HA"A<+@#<QVC!X!
M]* *<>A:;X@_:)\06-U]I,#6"R3Q[]@D8>3\O'5,;>#U.:2XTO2_#/[1F@PZ
M3:I!#+;,'M;2!@%)C<!C@8(R<D]@N36IHL>O+\;=2\27FB:Q_95S:"UM6DCR
M8P?+XQN^5<ASQZY[U#XC3Q#<_%W1?$5CH?B!K"Q'ER\)C:<JVQ&S@$'GN>,8
M.#0 RRU+6M>^*?BFXM=.L;Z;3%:TM8+JX 6(*<%@IY&_ID<9-7O#/@3Q+HGQ
M)EUFPALM)T2X*QW%E P*.J1J-R@= S[R,\CG/6LCQAI7BOP-X^N_%'A&QDN+
M&_037\?E>8N0<L&))(R<GY<8S79>&[_Q)XSUA=2O]/FT+2["=A! )G$UPX^5
MUD (1D# ]5[<=R0#T.OGW0H6M/VGKY+JS</.\\D#/E<*8V.X#N" 17T$>E>4
M_$KP#K-[K4'C'PI=FWUNQBYC7.Z?'0#)QTR-I&&S@T >JX%4]3NS8:5>7:H&
M:WA>0*3@$JI./TKA]-^*PFG2TU/POK-C>R2F.*%(?.WD':>1@#Y@1^%;&F1Z
MMXBGN;W6;>33]/VS6]OI^]@\D;8!>;G&[Y3M ^Z&/)S0!QGP<L+/Q+H&K^(]
M5MUN]0U*ZEMYFG._]UA3L&>@Y /K@5EZ+N\%_'BX\-:>9?[&U)?-:SCBRB%D
M)& .@!ZGTSFK?A&"_P#A/J^J:3J5CJ%YHM_<(=.FM%,J*Y)'E[2>"1U.?X1G
MK6_X?T:]\2^/CX[NS>6ME#"8-.LYC\Q!4JSE3]T'K@=^M &'\+DMA\6/B$EL
M'\K[201( /F\U]V,=LYQ[8J70X88?VEM;$,4,8.E9;RY-V3F+EA_"<8X] #W
MJI;C6_ ?Q2\275GX4NM4M]8<20-:N54G[[G+9YR_/09S@ <4S01XJ/QKOM=F
M\.F2">!;-Y(D6%(=R1R?.V"791\I)SDX&0   "GK_AC1;G]H#3-'BAFMH+RR
MF^U+ WEA@T,N<$<\\AO:M/XG?#_0/#?PXUNXT:S@M9KB:*21I) . P.Q,]/9
M1UI-:/B1_C3I?B6#P]K%SI%E$8=A4#:65D=E4G'\0/;.*[3XI:/>^(?A]?V&
MGV*W=RX5TA=BIX.<C!&6'8'CUH L^!-)T^+PEH%]'90I>/IMNSRA &8F%%))
M^BJ/PJ;Q_P"(;GPOX'U76;-$>XMHU\L/T!9PF?PW9_"L[X>7>O2Z#I]CJ6AM
MI4&GVL=JWVA]TD[*BJ&4#[J\'KG/X<]!XGT"W\3>&M0T:Y_U=U$4!)/RL.5;
M@CHP!QWQ0!R7P\\/:3J/POT];^QBNTOT^UW"SJ'#R,<GKVR!7*?""ZN=.\5>
M)? \T\UYI=A+(D'F1[E7#E3D]%!QT]<U>\"ZSJ_@.Q'A7Q!HFJW'D.?L]Y /
M.612ZJJJ/X1EAW[UK^!O#%UH5WK_ (OU&WN5O=8D>?\ LZ,!WA0L6"]LOS["
M@#C_  3IVB77QO\ %%DUI%)#%"L<$,C^:%5-@(!&5P"JX!Y7 '8U[PH 48
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MN<X50 .>_2KE)C%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !113)IH[>%YIG6.)%+.[$!5
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MC<,U2O\ 6=+TIH%U'4;.S:=BL(N)UC,AXX7<1D\CIZT 7-OO1M]_TI0P-+0
M4FWKS2T4 )CWH*YI:* &A0!BEV\8I:0D"@ V^]&W Q6=<^(=%L]1CTZYU:PA
MOI2HCMI+E%E<L<* I.3D]*TLT )CU-&*6B@#A_B9X3U;Q9H-K;Z-?0VMW;72
MSJDZYBEQV;@C Z\J02/QK&@\0_%;SWL)O".FM-S&E^MUM@5MQQ(5R7*8QQP>
M_'0>H8YYI M &)X<T.73(KJ\U!K>75]1=9KV6"/:F\(J!4R2=H"CJ3DECQG
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\<T >E6_C3PS=ZJ-+M]<L9;XN8Q;I,"Y89R,>HP:T]1U2QTBS>\U"ZBMK9"
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MFG0WEPEFWGVCQ.$$RCHN#NQGH0V:G^#,$(^$VDS@)#.\4Z&X"KO"B>4C)(Y
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MMO*^SSE06CW31AMI[9'!K,NO"/B?Q#\/++P_;P^'(M)>S@,+K$[.K;23(K9
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M-DW-CCE0>1D#&:2?2(/$?P(T*.\U-]'M;:V@DE:>)664(!U'4@XR,$'GD=J
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MRXUVPCO@XC,#3 -N/08]>16S=WMK86<MY=SQPVT2%Y)7;"JHY))KQ;XU^$-
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M06QZX_$5M[A7C?C3X=>)_&.JP7AMM$TZYMY?/2\MUS))E8]J29'S%"K#=G!
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MD-E1@#KUXQCF/XV>$-!T3X>VSZ9IT5K-%>IB:*'?))D/D22D[L<YR2<D =^
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M:&"VGFM-ZIY;I@JQ.5+>7L.._MP #TWQQ!X0O+.R'BVYM8[:"Z6:%;B;8K2
M' (_B&,\'@UIZGXFT+0&C75-4M+(.F8Q,X7*^U>7?M!Z3;SZ!I$MO9P'49]1
M2 3;%$C H^%+<<9QP3BO1/&'AJ#Q5X+N])GPK20YC?D[' RK8!&<'M0!JZ=K
MVE:M8R7NGW\%S:QDAY8FRHP,GGZ$&F:3XDT;74G?2M2MKM8,"4PN&"9SC/IT
M->6?#?QG-;_!JX$FXZEI$KV2+//\S,S?N^&!P%WA0,'[GX!OC^"_\%?!JTTE
M;FV2]U*]6"_O$4Q M)OD=\K_ +H4G!RN1CI0!Z')\1/!T+8E\1Z<A_VI@*Z7
M(KR3Q!X&U[Q5X9ATE]/\/6]MM@2UN(8CYMI'N5G(;^(8&, +G/;'/<>!].U?
M2?"5E9:Y(LFH1!A+()WFW\G!+.2<D<D=!T  XH W+V_M--LY;N]N$@MXANDE
MD.%4>YKQ+P]XST+6?BEXGU#6+NQ_LM[06-O)=/L+Q%A\FP\,#SR?8=Z]PDC2
M6-XY$5XW!4JPR&!Z@CN*\2^&6GVDGQ:\7JT%I<0Q!51V64E<2(RA5<D8!4')
MY!5=N!0!W6C^'O#WP[EU/5%U(6EGJ$H<0R.$@AR> JCCVSUKH-(\3Z%KDTT.
ME:M:7DL7,B0R!BOUKS+PU*GBGX\>(9=5@CF.BIY=BI+%8BKA=P4DC<>OUY&#
M5+XOV)\*^*/#_BG04>SO9IVBN6M8U"R98,2PQ\S-N(.[K@4 >MW?BG0;#45T
M^ZU:TAO&C,@A>4!MH!)./3Y6_*LX?$CP802/$VFG'7$XXKRWQ9HNB7GQW\,V
M"Z;):+?6327<<3^1OW"7KY>"'R&#'<<@@=CG?^)/@CP[H/PR\27&CV%II\UP
MD)ED).&"R(0JYSC.!P, G&?6@#T2[\4Z%8Z;;:C=:K:Q65RNZ&=G 1QC.0?I
M5BUUO2[[2EU2VOX);!PQ6X5QL(4D'GV(/Y5P]BC2_ &W1;:.Z+:&H$$CE5?]
MWT)!!'X$53^&FG66J_ C3K>^LHKN+RKIA'(JGYA++@C<" ?0]J .T/CCPNNE
MKJ;:[8"Q:7R!.9AL,F,[<^N.:E7Q=X>;1FU==9LCIRML:Y\T; V<8S^->6?!
M3PEH6I>&+J\U'2X[J:"_GMXTO&\]8UQ&3A#\F[@98*"<=<5G_"_POH=]X\\3
M6]S:PW5I93EK>W._[."?EW>4^<D D L3C/ [@ ]FTCQ3H.OR2QZ1JUI>O$H:
M18) Q4'H3BM>O$?#VFV&A_M&ZKI^F[K&V>T$@M(0?+D9D#-D9PH!)(&,#/&*
M]N'2@#Q;XY^*]+.GV.@)J&96U",W\"%L"$ DJ^WGKM('4XXZ5TMQX:\)>.IK
M#6-.OHDN--F1Y;JQ8+(=HX1GZ@?CD5S7QYA@!\/%(42ZFU! 9\;\@ @!HS\D
MF"W&X\<CHS5/\;]2FT7P%:6-BD<*:I<A+EHU\LL,;F^[@?-CGKD&@#T"7QWX
M5M[IK:;7[!)Q(8BC3 $.#@K]<\5K:AJVGZ59/>W]Y#;6R#+2RN%4#..OXC\Z
MYOQ!X)\/W'@6;0TTZ"&SMK9Q;;(U+P<9RK,"=QQR>IZDYKR'0+O_ (2/X ZV
MVMV4^HRZ3(8K*X9$+Q(?+.U'()X/+<?=(&>F #V[_A./"WVBUM_[>L/.NPI@
M3SAF0,<*1ZY-;^X>M>1_#?X<>&M4\!:+J&J6/]H7<@2X$ES(S>7M)VH!G&P<
M_(<@YY!KUH+@8QP* ,_5?$6CZ&81JFI6UH9L^6)G"E\=<?G3=(\2Z)K[3+I.
MIVMZT./-$$@8IG.,_D:XGQ)::=H_Q2TSQ'?WLE]<SVWV2RTI+='E5LD[T/&
M.>6R<L<'' X_PM-+%^T;?*FF+I EM7#P1'B4$*VYLJ1DD G;M&5ZGD, >SGQ
M)HHU@:1_:EK_ &@5+BV\P;]H!)./H":JZ;XU\,ZQ>K9Z;KEC=7+ D113!F('
M7BO)-9\*Z/<_M"6>EM;6Z:?>6,GG6MHS0'_5/G=Y>W[WL>1G-2^.])TSP_\
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M(_>)IR2E6=@QY Q@9'&>O%;7PS%EXUN9O'&I7<=]JXD>WMX&51_9T(=BL>%
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M#D'!'X5?UKQ+I/A_2_[1U*\2&W89C/4R'&0%'<D=!WKS;4?!6N^)?!%MH_\
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MGEB^/.HJFDP:2+RS<R6B*25&0V3\P"L2H)V@CVZD:?Q#E2+XW>!C);QS!B%
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M&:ZWQ!:>(=$\'#P[X;T_4+^ZD0AM16:)5AWNS/CS)-Q(S\J\X! WY&:]"HH
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MV\GES13Q['0]LC)'.#W[55;X@V$FL:CI=AINJ:C+IYVW,EI"FR-AU7+,,D4
M=A4<\T=O;R3S,$BC4N['L ,DUQGAOXJ^%_%%Y#:V-Q.EQ-@*DT)'S$L A(R
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M8Y-:EC>VVI6D5Y9SI/:S*'CD0Y5@>XJOH.K6NN:#9:I8HZ6MS$'B5U"D+V!
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M'EOHKJ\L+JVOIO/D9-_F*<8 &1B@# ^.-IYMUX+M+=8HQ]M944NL:*!LXR2
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M-%96HB:9R[G:JY7(/SD  '].:V?B/:OX6^!UIIT FB!:&.[5F7?*6RTNX@L
MS-DG!(ST)%;^I?#--0^*EGXN:['D1!7DMAE29$^X01P1G!.:ZOQ+H</B7P[>
MZ//*8DNH]AD102F3U&: .'A\ 7^O^!(K%_%5\+._LH ()H5D6),[P!C;D@>6
MN?\ 9;CYN.J\$>';/PKH+Z39:@]Y!%.W+L"8S@90\\8]..M>;Z9\/?B7X;N&
ML='\41'2]AAB,S$K$C;R2$/1AA>1_?XZ&O6/#VAVOAW1HK"U7 7YI')),DA^
M\Q)ZDF@#F_BBOA=O#"GQ1),(4E#01V[[999.RJ.AS[\#U%><?%@ZV^EZ'+J.
MFVNFV\-VL5A;"<2W485B-S$$]5$9P@DQW(/!]&^)W@.?QUI%G#9W:6US9SF:
M,R+E6.,$'%<GXG^''C7QAH%E<:UK%C-JUG*)8;9(56,*P7<&;N01],"@!U_J
M$DGQ_P#"5I=F69$TLO I<KY<KQR;W.5!.0F,$+S@\8Q7H7B'0_#MSJ&G:_KA
M@B?2I-\%Q-*(T0D\9)./O8(]P*X[Q%\+-3\1:-I,CZZ(-?T[<\<\2D19)3&T
M=5"J@P!W)]:E\+^%/&M\MDGC;5TEL[&998[6+!>9T;*-(X^\,X;'J!F@#.^(
M8E_X7/X&)M1Y7F "YV').\_)NZ<#G'7FK/[0"/-\/;9(T9Y&U*)550222KX
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M7\0ZSI/B+0;R&+4]*YBBF7*N0=P_'/KQ65XA^&WC3Q!<Z1JD_BNU&JV)8C;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "D(S2TA.* #;1M%&ZC=[4 &
M!1@4F[G%+N]J #%&T4;N*-U !M%!7-&[VH+>U !M&<TAR"!VIOGQ><(?,3S=
MN[9GYMN<9QZ>]<MJ_B36+3Q_I&AV>B/<Z?<0-+=7NX@1<D#MCC&<9R=PZ8Y
M-!?"]K)XI/B"\GFN[F*/RK..8CR[0'[YC4#AFXRQR<#&<<5N  4@..U+NYH
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MDW4 &VC:*,U1U?5[70]'O-4O6*V]I$TLF",D =!D@9/0#/)(H N$8..?SIV
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MCMD4JD?GH0@V[<+E. !T Z=172^'_#%IH#7=PLLUYJ%[*9;N^N2#+,?X02
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M.!WXH <10 "N",5Y[K?Q'NK#XA:1X431)81>S -=W,BX9-S E%4G@XX)(/\
MLUZ$" #_ %H 7:",=J,49]J3=[4 *!BEI-V3BEH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%;F!+DQF%S\F\(I 5F"?>ZD<GDFK'C#3?"VC_#OQGI?ABWB2XBBM7O/)&>K
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M Y ')"_*">3^/% '2B_\8P>#V8:#IL,D4:B(7-Z<)&L)?S)-ZC!#!%P>^2<
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MQQG"$%>N&!^Z0>#FNJU+P)\.O#\-GJ5Y8PH()(S"2Q8RM@*HQ_'G&?<Y/4T
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MD8//6LC5_@CX>U*]TZ]2YU".\@E5[NY>[DDENPH &YF)VMD#E<8&>.F/3J*
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M='BU+S/MZ64*W!E;<_F!!NW'N<YS6A):P/=)<M!$T\8*I*4!90>H!ZBIATH
M",UR7BKP):>(KVUU>UN9M,UVRR;:_ML!LX.%=3PZ9Z@]1D9P37744 <3IW@.
M>:\LM2\5ZU<:[J-D^^V.Q;>&%@<AA''@%NV6+4_Q=\/8/&<BC4=9U&.")UDA
MA@2!?)8  E',9<9(R?FZ_08[.B@#FY_"]S<^&GT2?Q'JDBR91[ED@,K1%-IC
M),>,8YW8W9[UG^#_ (>1>"3Y6FZ[JTMDS%GM+EHGC)(QG[@8>O!&<<YKM**
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MMK%<Y*Y[ C(..<$X(/-<WX5\ V/A&[GFT[4=4=+AS)-%<3*ZR/C&X_*&S^-
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MW%>J44 - YSBG444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%7Q#7XG7WA6.>WW2VH>U>"V7RHCM4^9\V6*YW*<GJ?3% 'M5%>%^+?$WQ/\
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M2L9<1LQ W,/8$^V<"@#K**\9\6^)?&7@[POHNN?VS)>O-(AO+:XLHHU52.F
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M@ET\?9+>2W 6%OX,E<,PQP>: -OPO#XM77_$,^OR0_V9)=D:;"I!81 X!XZ
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MRBPNH;R^5+%AGKGH*Z%-8N]<^%-_>W]E<6ETVES"6.=-I9O*/S#M@YR/_K4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLZ+G9O(+M_>8J023DYH \\^#ULVK_!;5=/MH8(IY7NK96!8!W:)0&;)..H'
M P!QUS:^!&I6T'A>X\/3OY.I65W()(9"%9L\_*#R< '/%>B:%X8T7PS%-'HU
MA'9QS$,ZHS$$CH<$GUK)UOX>>&]>U$ZA<VCPWQ5E-Q:R&.0Y4KDD=QG/U'-
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MU&&^O-+1)HW#,83L$N/X6 ZCZ8- %'7K^;QSX4\6Z7I,,3VT*&V@N_-)6XD
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M.\#. <GW- 'G/P*U2QLO"]UI]S-;6MY/K,R1VB2;CGRT.%&2=HVMR2>G6F^
MUA/QY\;.9'$_EL!'LRI7<F3NSUSCC'.>O%>A6/@/PMIM_/?66BVT%U.KH\J
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M#D<=*YSQO>Z98:)"VLZ;%?Z?-<I!*LI3]T&!&\;NX/I@@$GM716UM#:6L5M
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M"*EU%.K>;$5;82G(VAB<C ;@?-S4'PIU3Q9;>(-8\+>([E;R'2XE\NXP&(Y
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M]X3TGPXUQ)80OYUP1YDLTA=R!T7)YQWQ[U4_X5UX3^V_;?['3[5_SV\Z3?\
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M2N;>%8_MC+LD+8 +<="?3D4RX^&WA*:#3H/[%MTBT^4RP(@QR220WJ,\\^E
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MV=Y!?P+<6L@EA9B X!PV"02/4<<'H>W%6:CB1(D2*- B(NU548  X&!Z5)0
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MGJR>9)G;,TA# ,0V,#</E(^7K5?P!+XBT[Q_J.CP:9K4?AW4(2T,U_)F6Q5
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M8#?.G'(QNYZ&G^-/ D^D^$)M8T77M6CU?28#=&66]<QSE"'=G0@@G:&P!@=
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M>ZDN9IRD$ES*TY61\D9+'.U57 ^@SGDFL?A[-K/@M)IO$.K2:]<P_:1>)=M
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MNWTQ1Y$8Z(OY4L]Q!;0F:XFCBB'5Y&"J/Q-,M[ZTO$9[:ZAF1>&:.0,!]<4
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MY_\ 'G<_5CZUSWC'P]=^)XI-+BL;...:'RY-2N%61DC+J7C1.H;Y%()XR!W
MKKZ* (;>W%O;Q0J<B- @)[@#%2;<CI3LBB@"A'H^G17AO$L;=;EBS&41C=DA
M0>?<1H/^ CTJXT8; 8 CWYI]% $8@13E44?08I!!'_SS3_OD5+4$][:VNS[1
M<PP^8<)YCA=Q]L]: '&%&/**>,<BG*@10%4 #L.*?10!1BTBPAU&74([*W2\
MF4++.(P'<#H":ME-P 901Z&GT4 4K/2-/TZ1Y+.R@MWD 5S%&%W %F ./=F/
MXFK'D(3ED0D]3M%$ES!"RK+-&C,,@,P!/('\R!^(J,ZC8@9-Y;XQG/FCI@G/
M7T!/X4 .N+2&ZMFMIXDE@<;7C<9!'IBJZ:/IT=X;Q+&W6Y)9C*(P&)(4$Y]P
MB#_@(]*OY%%  .E-(R:=45Q=6]I"9KF>.&)>KR,% _$T 51H^GK?&]6RMQ=$
MEC+Y8W$E0IY^BJ/H!5QHU?&Y0V/45%87]IJEA#?6,Z3VLZ!XY4.0P-6* &)&
M$8X55SZ"GFBB@""6VBGC:.:-)$92K!QG(/44Z""*V@2&"-8XT4*J(,  < "I
M:* (A H.=BYSGH*/(B_YYI^0J6B@"+R(SUC3_OD5XI\7+RRE\=^#I/.;&GZ@
MHG_='8J[XV8[^GR@#(_VA7N%-(.[- %*PCTZX3^T;%+=UNE5_/C4?O !A3GO
MQ5MHD?&Y02.Y&:>.E+0!&(E52%4 'J .M4(?#^DP7S7T6FVB7;2^<TRQ ,7V
ME=V>N=K$9]":NW%W;6<?F7-Q% F=NZ5PHSZ9-5].UK3-6C#Z??V]R"-W[N0$
MXSC..HYH Q_'7B:3P?X4N=7CM&NY4942(=V8X!/M7.^&)=2\=>)8?$NJZ/)I
M^F6$0_LN"X0%W>107E/X  $<8SWS7HY((II(0;F("J,DD\ 4 +M.<U3N-'T^
M[N$GN;*WEE3;M=XP2,,&&#[,H/U I]CJ=CJ23/9745PD,ABD:-L@. #C/T8?
MG5K(H 3:3P>15.31].FO5O)+&W:Y3;ME,8W#;NV\^V]\?[QJ]10!3N=,LKUF
M:ZM89BT+P'S$#9C?&Y>>QP,_2G6MA;6*NMK;Q0J[%V$:A<L>I/N:M44 -VU!
M-8V]S)%)/!%(\,GF1LZ@E&P1D>AP2/QJS1G% $9C!.X*-_J:001YSY:?]\BI
M<YHH C:)7^^JM]12>2F,>6F/I4M% %&STBPTXG[%906^0 ?*0+D#.!Q]3^=6
MFA1FW,BDXZD5)10 PQJV 54@= 1TII@3@>6F/3'2I:* ///BU:Z_-X8AAT&Q
M>\BDG"WUK!D/-">J?+S@G@X[5SEOXW\-RW%I9R_#VYAU'S&CM;9K5<[D BX.
M,#[A3V"5[(W7BDP>.<B@#C_ 'A(>'1JU_+I]MIUSJ=P'-I:MF.&)!M1>.,_>
M8D?WO:NIU&^@TZR>ZN"WEK@!57<SL3A54=R20 .Y-6%&,\]:JPZI87.H7&GP
M7<4EW;!6FA5OF0'ID4 >,?!BSTJ>#5]/U73H()[JX-Q:65RI9O)>/DKNY(QW
MKW )M7 P![<4HSG-.R* *4FDV,M\M[):0M=*5*S,@+ J&"\^P=\?[Q]:D6QM
MH[F:Y2WB6>; DD"C<^.!D]^":LT4 1B% 00B#'3@5%=6-O?1&*Z@CFC./ED4
M,#@Y'ZBK-% %:ULK>R@$%K!'#$,X6-0 ,G)_6B:QMKB>&>:WBDFA),;LH)0D
M8.#VXXJQD4M %:*QMH9I9H[>))9F#2.J %R%"@D_0 ?04-8VSW<=TUO&;B-&
M1)2H+*&() /OM7\A5FB@"LEC;1W,MPEO$)Y@%DD"C<X&<9/MD_G4@@C'(10?
M88J7I40NK<SO )XS*@W/'N&Y1ZD=J $$" @^6G_?(ID]E;W+PO/!'(T#^9$6
M4'RVP5W#T.&(_$TW3]4L=6MVGT^[BN8ED:(O&V0&4D,/S%6Z &[:0H&X8 CW
MYI]107,%U")K>:.6(YP\;!@?Q% #@@4 *H ]N*J-H^G/?+>M8V[7*L&$IC&X
M$*R@Y]<.X^C'UJ]10 @&!BD9<T[(HH K0V5O;-,T$$<;3OYDI10-[;0N3ZG"
M@?@*6VL;:SMEM[:WBBA3.U$4!1GKQ5BB@"(0(,_NTYZ\5G:]>RZ+H5[J5K8-
M=S6T1=8(A\SD?YS^%:U!Z4 >5>&=5UKXB^)]'UJYTJZTO1=+A>=!(?ENKEP8
M\@'JJKOP>HS[UZGM/6C;T-.H :TB(I9F 4#))[5X9I.IZ8G[1&J:I)<[+2\L
M@B//$8QO(B55!/WMP4,".H:O<MIS_P#7I<'TH @M;*WLX%AMK>*&(9PL:@ 9
M.3^M2&WC//EI_P!\BI >.:7- #-IXZ<>M9\/A[2(-5EU6+3+1-0F7;+<K$HD
M=>.">_0?D*L6NJ6%[=W5K;7<4MQ:.$GC1LF-B <'\#5N@!NW XI-@R#@9'0D
M4^B@!A3<H# $>]126D$T,L,D,;1RJ4=2H(92,$&K%% &>-$TU;I;H6%L)U((
MD$8W#"E1S]"1]#5UHPWWE!'N.E/HH 8L:KG:H7/H,54NM(T^\G2:YL;>:5 -
MKR1@D897'_CR*?JHJ]10 P1@+MVC;Z4@AC&<(O/7@5)10!$(44@JB@CI@#BG
M[3WYIU% %:[LK>^MWM[J".:"0;72100P[YI;:RM[.,QVT$<*%V<B-0,LS%F/
MU)))]S4^12Y% $1A1SET4GZ4Y8PF0H 'H*K/JMA%JD.F/=PK?31M+' 6^9E4
M@$@?B/\ (-7* &D5!;6-M9QF*VMXHHRS,410!EF+,<>I))/UJS10!$((P<^6
MGITH$*!@PC4'Z#BI:* *%_HVG:JI74+"VNAM9,31AN&QD<]C@?E5JVMXK2WC
MMX(UCAC4(B(,!5 P !4M% "$9J/R(\_ZM/\ OFI:* (A;QYSY: ^RBG%">]/
MIKR)&C.[!549+$X 'J:  KE2I (/8U2FT;3KBY2YFL;=YTV[9&C!(VG*X/L3
MFI;'4K+4XI);&YCN(XY#&SQG(##J,U:R* &*@3A0 /04%,C# ,/0TYG5%+,P
M50,DDX %5M/U*RU:T%U87,=Q 25#QMD9!P10!1M_"N@VM]%?0:/8QW<2>6DR
MPJ&5<8P#CIBM79QC P.U/HH B,$9&/+3KZ4?9XC_ ,LT_P"^14M% #57;P.
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M;3XATG=G&/ML><_G7%?'+Q!>:#\/G2R9HY-0N%M#*K$,BD,[8^H0K]&-:S^
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M/??88=4LI+SG_1TN$,G R?E!STKY]\>7MOXC^"&B>(M2CE.LO<I;&X\HKYA
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MR>1R*\A\1>!O#\/P;GU>:-6U%K"WF%]=;I7C.V,!%('"]@.V:T_#_AFR\>_
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MA.);>2.X4RQ'Y-P&W(P69F'.?W78D YWQET:\'PUT?4M92V&NQ3I'=3"0 R
M*X 49^;J#@<]3V- 'L%QXP\-VNH265QKNGQ7$:%G1[A05YP1G.,_[/6L'P/\
M1;#Q=/JN;NRA":@]O80^;B2:%57#[6P3N.X]..G:DM_AAX<2*+4+NW^U:@+-
MXKBXD'%P67YGD7NQKCO@#HFE2:!JET8(+J>#5"L-WY9!*JB[2,\C[S'!_O4
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M-J$<*P0W#!RQ<*"7ER3NX(8XQUKU[0K&[TW1[>UOK^2_NU#--<2=79F+' [
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MTO4O#^J6D\EY-<*JVY9%38"%W9Z_*0/P]:R/AEH.I0ZEXETK6_#NHV.DZT'
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M\U&SO4EU,E(M-BCWRI&67E@.^5!QV&:I?!G3;_PZ-7T^^T;5+)+J[,T#W,7
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M1QQJ6=W.%4#DDD]!7.>'O'WAKQ5?SV6B:F+JXMTWR*(9% 7(&<LH!Y/8UTK
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MU0/<1PQEY8@21\R#YAT)Z= 30!TU%<GX?^(F@^*(+V;2&O+B.SC\R8BT<?\
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MUI;Q6]O$-J10H$5!Z #@"O)OB9+>WOQ5\%Z3!J"6D0D^THY5<B0-C(R#DXX
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M]YLLFE33K!L^5;A06\P*200.@R#UZU2E\ >-O WBB\U+P+<V=QIM](9);.Y
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MD"AI/P^UA_A+J'@S68].CD*?Z-/8RMB1PP=3)N3CYE7)&<KZ8H M:/?W&E?
M&WO[.3R[JVT0RQ/@':P0D'!X-87PST;7KKX>V$>E^([6/3'AD/V8P+*RR,/F
M1W&#MW%FP,,,XW'%=1X(\,^)M.T2#2/$MSI;V%I#]GAM[.-G\Y-N/WK..?H
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MTMT@C,ARQ55"C/ YP/2KM !1110 4444 %%%% !1110 4444 %%%% !1110
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M;0K-'E!N$9^;^/('<*WI4OAKXAZ-XLUZ?2],6Z\RW@,TK31&/;\P7&#]?TH
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M   BEI,CUI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK)))<1D#S/EPJXSR,XYSSVH D3XF:U>>&YO%5EX7#:#!YG,EWB>=0P5710I
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M?UK4-!O;1M+UJR<A[.24/YB\?,K #/7ICH1[X\Q\5Z[K]W\9/"SW.BR6DL1
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MS3]G3_DG5W_V$Y/_ $7%0!Z!XPU:_P!"\*:AJ>F:>;^\MXM\< [^I(ZD 9;
MY.,"O/?@GKFM7GAJVAN=*FEM9;BX=]3DN=Q9RQ8DJ1D\G&2>M>B^+W2/P7KK
MR330(NGW!:6 9D0>6W*C(RP[<CGN*X[X&X/PLL3G(\^?D]_WAH Y'PEXBDTK
MXD_$#[/I^H:CJ4MPOD63R@RR!&<$[B  @!&..%*CG&:[?PI\3#XAU_5-!O=
MN].U/3[<W#6QD64N 5R.@ ;YEP.^>HQ7-_"Q8)_BI\0)E>2X9+I566= '7YY
M RCD\ C YY"@X'0,T2X6#]IC68XFL/WU@8Y )'1\YC;HPP\GRC(! V\YR""
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MUX]VTS3[;2M-M]/LXQ%;6\8CC0'.U1T% 'EVEZG+X3^.&J>'FCCMM)UP_;H
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M[N%.#T"GGU;H&L+\1/$/AN\MY)7L-(M#>7BRI&RO<NICC! 8E6'[UNG''J,
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MLI%O$5<9;8#D9)&."3GVH 9X_P#B-=^ 8[2XN?#IN[2XPOGQW84)+@G805]
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MGW2=PY(&.C&O0?!\NE>(?ASI MHA-ITMBD'E2_-@(-C*20,D%2,X&<9%>?\
MQAEL[CX0Q+I5C NGVVHI#$9,( JAU+Q#<"3NRN",XW'&/FH TM3^+%SHFC"]
MM_"E]>:/;)'&VH-,(5+\#A2I.,D#/>O2=)U*#6='L]3MMXM[N%)H@XP=K $9
M'8\UQ7Q+W?\ "FK_ &^=G[''GRH!*<?+G()&!ZMU49/.*U?AE*TWPUT!GE\S
M%G&@/DM%@!0 ,'KCIN'#=1P: &?$?7=5T+PK=2Z/ILMW<R1NIE#A4MUQR['(
M.>>,=_UQO@]JVK7G@_2[6[TB2*S%O(R:@\X?SF#CJN,C.XD')^Z:W?B8KO\
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M:C<QVUK",O(_0?XGV')KROQ]$!\;_ \GV:4,<+]H)_=M\S?*!C[PZ]>A''J
M:L7Q7G@\0Z5I^L>%[K2K/5)66UO+FX'S@ 8.P+D9W(,9XW5O>)O&G]A:[I6A
M6&FMJ6JZD[;(5F$8C0#+.QP<8'/3H#Z8KB/CMM^U^#P"GGG4#L"9^T=8_P#5
MD_)Z9W=]F. U;7B35; ^/O#^D:99P?\ "721EEO;U"1:0;"7+!"!(Y4, H.,
M]QW -/2_'[7/CN3P=J6D_8[]8/.5X[@3(PV[L9VKCBJ6O?%>VT#QE:Z!>:+>
MHLREC<N1T!895!DL#MXY'7I7$7&G:AI?QZT&#4M6;47,*XGDB$3,<<]T!YZ
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M&X8.#D8;&:Y[XM66O6H\.7&NZE:$/>JL=A90HL, 4GD2/(CL<%0>$7CDKQD
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M;F5#T?A.F>,5U]YX]2S\,:3J']DW9U/55 M-*8A97?&2,] ,<Y]"./3D/@1
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MJ* /'K7X(26-S>6]EXJU"UTBY"[K:/JP#$[#ST (Y'.<UO\ BKX7P>)-!LM
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$CH">*Z3P7XOLO&GAVWU.UDC$K*!<0(Q8P2=U.0#^.,&@#HFKE-+\3ZMJ'Q
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M)!<1B1&5@>#VR.,CI0!9;/;K7+Z[X[T[0]7MM&2&ZU#5[A"R6EHH9@,<%R2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH+Q3J-N)?(L=,EN;R,MMWA53*KC@@_+PW<$]A2?!O0]>O/#^N7<'B2_L+_\
MM)HID98YXV<!"SL'5OG.X@L#S@9SBO5-#\%V&D:;JMI-<7&H/JSNU[<W)'G2
MAEV[2R@' &<#MDXH X+0DG\9^!M4O=+<:/H#O)Y6F6<'SRA>7#LOS?/T(7L3
M4WP-W_\ "KI]V<&2;8)=P4]?[W&/7''KSFKVC_!NRTR2>U?Q!K<VB.&']EB\
M>.%MP(8.$(R.G]<U9\(?">S\)VNH1P:M=R27.](W94/D DC<@*D!RN Q[XH
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M9Z?!#]@O95AM)! %W[0!+*I]'?=D]3C)H ]&MH8K>WC@@C$<42A$0# 50,
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MMS$Y;*CDY([8JNO@&XU2[LI_%^M-K<=BPEAMY+:*.+?MP68*H+#/(!.,=<T
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M^\L'\VRNK955HF"D* <9"@[3@$?='I0!UH89QD9[@56U)]NF73>9Y9$3D/\
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M7H6H^%]*O_"EQX<-K%%ITMN8%C2-<1C'#*",!@<,#Z@&@#*\#$#X6Z(,Y/\
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M];BC2*)(XT5$0!551@*!T ':@#/\0:6NN>']1TJ1VC2\MGA+J,E0P(X%>3?
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M?:]-C!V$ROA0(1T/+%>/^>7M7N<MW!HNDK-J5^/+A0"6YGVJ6/\ >.  "?0
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M&9KD[MQ+L5.3G;SU^4#.* ,WPZR)\ X&D>)4&C2;FFC\Q -C<LH^\/;O7'>
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MW)NZ[64<$<XYKL? ]_KVH^&HIO$E@UGJJR21S(5"A]K$!E )PN.,GKC(X()
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ME\K[1M/E^:#LW=LXYQ5+PY)'-X>LI(M+&EQLF4LPH7RER<#   R.<>]:1ZT
M>&:1XT^)>O>)_$NB::-,G>PN7@\QE5%MP)&7<H/+_=[YZ5H>%O'?C'3OB8/!
M_C"..X:Z!-M-%&L8  8AQCJI"D>Q'UIOPNEM1\7/B#' 73==M\LC@LS"63>1
MP.,YP.P(R3UIWBBT76/VB/#MM!;!_L5CY]S-!,Z.JY? 8AN &*\ <[SG(Q@
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M>"0J8AOF(W,I!')7C/(/I4_A83C]HKQ/]H1%!TX^5Y:(NY-\7)VCDYSR>>*
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MN$ 12(Q&!R<DY)J7X>Z9+<?%[QIK*I-]C$LL<5PDA$;.6Z<'#<9Z@X^M6O@
MTC>'=>,]R+J4ZJ^^X#E_..Q<MN/)SUR?6@#3^$_C/6O$=[XDTO79H)[C2KE8
MTFC0)O!+J>!V!CS_ ,"KTW->)?">6&;XJ>-W62VD;S %;[&(Y,!V!"E>% (
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MJYZG^\:Z4XQS0!\_>(2VN_M-6NGWS6\EI8F%8HIL %?*$F/]IM[D^OY5[_Z
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M?3]*TD:AJIU*&6XQ&6@6-XI!R2-@ 8$<8->@>._%.I^&_!VFRZ;#/-J%Y)#
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MSC!);W]L#VKHZ* .';X5^&_M\MS"EY;I+.T\MK;W+1PR%E"E2H_AXS@=R>V
M.LMM/M+73TL(+:..T1/+$*K\NWIC%7** .$U'X0^#-4U(WTVDA)&8,ZPL41B
M&#<KVSC'&."?K72ZMX=TG6])&EZC813V*E2(.54;>F-I&,5K44 <CIOPX\/:
M9=0SI#<S^1@PQW-PTD<1!<@JI.,@/M'LJ]\D]:.@I:* &L,Y_*N9L?A]X8TN
M]:\LM+\FY=BSR+<2Y<G/+?-SU/6NHHH Y6W^'GA:TU(:E!I92]R#YXN)=YQ@
MC)W<C@<'-2^(? ^@^)[FWN]2L0UW;NC13QL4<;6#8R.QQCUP3C'6NEHH P-
M\(:/X<E>>P@D-W)&L4MS-*TDDH7IN)/]*@UOP)X>\2:S::KJVGBYN;6,QH&8
MA2N[<,@=<'./J<UTU% $:1B,*B*%11@*!@ ?2I*** .*U/X5>#=7OI+VZT93
M<RSF>619&!E8G)W<]"3SC%=78V-MIEC#965ND%M H2.-!@**M44 <3>_"[PU
M>:O=:FD-U:75T")&M)S%D[6';W8-]47W!W8_#.DQZ$FBQVGEZ>@ $4;LAX[Y
M4@YS[\ULT4 <OIWP_P##.D1S1Z?IIMHYE*R+%<2J"#CMNZ\#GK3+#X=>%=+O
MVO;+25@N65U:9)I-Q#<-D[N<Y_K75T4 <3)\+/"[IY4-M=VUNWW[>&[D6.3+
M!CN&3G(&T^H8]^1UAL;9K$V)MH_LI3R_)VC;MQC&.F*M44 <-I_PE\':7K4>
MJVNEA98G+QQERR(=JC@'TVDC)ZL?;&SK?@S0/$LJR:QIXNRH 57ED"C&<':&
M SR>>O-=!10!S-UX#\-WVGQ6-UIS36L6=L4ES*0,D'GYN>0.O2I[/P;H%AH=
MQHEMIR1Z;<@^;;^8Y5L]>IR/PQ6_10!BZ#X7T7PO;RV^BZ=%9QROO<)DECC&
M23D_A6R.E+10!C^(/"^C>*+>*WUJP2\BB;>BN2 K8QG@BIX-$TVVT5='BLH5
MTY8_*%OM^7;Z>_UK1HH XBT^%?A6QF+06<XMS(939FX?R=WR8.S/.#'D9_O-
MG/&.U10J@* % P !C%.HH 1LXXKG-7\"^&=>U1-1U31K>YO%"@2MN!XZ9P<'
M\?I7244 <QJ7@#PQJ]ZMY?:6LTZ$%&,T@V$8 V@-A>@Z =*34?A]X9U=(DU#
M33<K"H5!+<2D #IQNZ^_6NHHH QT\,Z1%X>.@+9#^RFC,9MR[$;3VR3G'XUS
M^F_";P?I.MQZK::9MFC<O&C.61254# /IM)&>[M[8[BB@!!TI&ZYIU-:@#PC
MP-H]CXB^*WCV26)K:>WNW2&>T<H\9,CJS#)(RV,G.1GL*]?T3POI.@18L+4"
M9O\ 67$AWRR' &6<\_PCCIQTK32VAA=GCB17;EF51EO<^M3+WH Y7Q%\._#'
MBJ\%YJVFB6Z'E@S"1@S*C9VGM@\@]\$\CK4^F^!]"TOPXNA6UHPLLAGQ(RO(
MW]YF4@D_I7244 <WH?@?PWX:O&NM&TM;.9UVNT<CG</<%B*;K?@70?$&HIJ5
M[:.-0C"JEU#*R2*JG.T$'H<D'V)KIJ* ,/0?"VE^' YL89&GE4++<SR&25P.
MF6/\A537O >@>(]0AO[ZS87L)7;<0N8Y,#H"1_\ KKIZ* ,71_"VE:'92VME
M X%P!]HFDD9I9B%"Y9R<DX'; '.,51M/A[X7L-3&I6VE^7>;@QF%Q*68@@C)
MW<C@<&NHHH Y-OASX5:_^WG3&^U_\]_M,N_Z9W9I;OX=^%[[Q(FOSZ3$;\,7
M<X^65B ,LO0D8_4YS75T4 <M;?#[PU9^)SXAM]+CCU#"A63Y5C(##<JC@$AL
M'Z#@<Y;)\.O"TVHF_DTLM=\_O_M,H<9]#NSCDUU=% $84*.^!Z\USVH^._#.
MD:\NB:EJB6E^V"J3QNBD$9!WD;,>^<9R.M=(>E5Y;.VN'#S6\4C8P"Z G'IS
M0!YM\'=,P?$^NJJ1Q:EJ3+%%&A"%(RV'5B3N#%S[9!Q[=)=_#;PI?>((];N-
M)C:^$_VAW+$B5\?Q G!YYQ[5U,<:0HL<:*B#HJC %2T <?!\-?#,.K7FIM8"
M6ZN6/SL=GE*1C:@0+M QP>OO5C3/A_X7T?55U33])6"^!)\Y99"QSUSEN<^]
M=110!SVN>"] \2RK)K&G"\90  \KA1C./E# 9Y/.*9>^!?#FHZ7;Z;>::+BT
MMW,L22S2-M8\9R6S^M=)10!R^E^ ]$TG55U*);J:X3=Y7VJX:41;F+94-T."
M%SZ*.^29O%'@K0_&$5O'K-GYYMR3$X8JR9*E@/8[0#[>E=%10!PH^$G@\V=O
M:R::TL<#[_WDI)?"LH#'K@;R0!@9 K4U3P%X9UIXVU#24G$8 C3S'5$ &!A0
MP X]!7344 4)])L+G3ETZXM(Y[1(P@CF&\8 P.3SG'?K7+Z'\*/"&@:FFHVF
MF;KJ/!C:9RPC;+?,!TS\V.<_='?D]O10!B:_X4T/Q/%%'K.F17BPG,>_(*^O
M((-1W/@W0+G1K?2)-.7^SK==L=NCNBX]#M(S^.:WZ* ,?0_#.D^&X'ATBT^R
MQ-@&,2NR\9/ 8G'4]*Q;SX9>&+K6)-46UGM;J7_6M:3M%YGSJQSCUVX/LQ[X
M([*B@#'7PUI*:(NCQV@BL%QB*)V3ISU4@]??FJ.E^ ?#6B"0:;IOV42##+'/
M( >G;=UX'-=-10!SMAX)\/:7JTFJ6&FBWO)9#+)(DKC>QSDE=V#]X]1WKH%!
MSDTZB@".X@BN;>2">-)8I%*NCC(8'L17%6_PH\,VM^9HX[W[&1A=.-TQM4/!
MR$ZYR,\DC)-=S10!E:AX>TO4],73;FS7[$IR(8F:)>A&/D(XY/'3FJ&B>!?#
MGAV[%SI&FBTD[E)9,'(QR"V#P>XKI** "LS7-#T_Q#I,^F:G;B>UF'S*>H/8
M@]B*TZ* .6M?A[X8M-#_ +'ATM4LF8/(BR.ID;:5RQ!!/!/'3GI3[/P%X;TZ
MREL[/3VM[:7 >..YE ZYX^;CGTKIJ* .:T7P'X9\.73W.DZ3';2R(4<I(Y#*
M>Q!)!K&UGX/^$-;U)[^>P:*61XV=;=O+0[,\;<8 8$ X_NC&.<]]10!!:6L-
ME;1VUM$D4$2A4C0851Z 5,>E+10!3OM.M-3MFMKZVBN(&&"DJAA]<'O[UQ:?
M![PQ;W(FL6U&P7SO,>*TNV1)!QA6'4J,'OGYFYZ8] HH RM*\/:5H0?^SK&.
M!G)+R<L[Y/.6))/XFJ?B;P7H?BZ%$U>R$LD?^JF0E9(_H?\ '-=#10!@:'X2
MTK0+B6XLX9&N905:XGE:639N+!<MT W$ #L!G-1^)_!.A>+UM_[9LO/>W8&)
MPY4J-REAZ8;;@^W3'6NCHH XN7X5>#9?LR2:.C6]LC)%;^8VQ=S;B>N<Y]ZF
MO/AKX1U"Y^TW>BQS2@Y5C+)A.<X4;L*,] , 5UU% $"6T26HM@@:%4$81_F!
M7&,'/7\:Y_0/ 'AOPUJ<^HZ9IL<5W*S'S222@;JJ^@_7D\UT]% #,'\>E0W5
MI#?6LMM=0I-#*I1XW&58>E6:* .)LOA7X5L9R8;.?[.7,GV1IV,&[*$$IG!P
M4XS_ 'CG/&.BU;0=.URQ%GJ-MYUN/^60D9 1C&#M(R,'H>*U** .=T/P1X>\
M-3F?1].%HYSGRY7*G/&2I;&??%=$.E%% #2,GIUZUR&O?#3PSXAU(ZE<V<D-
M^<YN;:0QN21@-QW'4'U'.:[&B@#E]'\!Z+HMU'=QI=75U$ (I;NX:4I\H4E<
M\ G;DG'4G&!Q3]6\!^&]<OQ?:GIOVFY!W*[3R?(>.5 ; Z#ICI72T4 <QJ/P
M_P##&K10Q:AIGVF.%0L:RW$K 8SC^+KR>>M1ZM\._#.M:3'IM[IQ>*'=Y,AE
M8R1D]<,Q)_ Y%=710!R3?#7P<UI:VQ\/VGE6C%H1@Y!)R<G.6Y]<T^]^'OA7
M4KE+BZT:-Y(SF/$KJ(SQRH# +T'0"NJHH Y?4OA_X8U=(DU#2S<K"H5%EN)2
M% Z<;NOOUJV?"&@MH2:(^EPR::BE4@DR^P'J%))(_ UNT4 <=X:^&7ACPI?R
MWVFV)-TSNZ33-O,0;'RITP!CCJ>3S6UKWAO2/$UE'9ZU8I>6\<@E5&8@!L$9
MX([$_G6O10!R7A?X<^'/"%W)=Z59,+ET"&25MS  <X],]ZGUGP%X8\0:C_:&
MJZ4EU=X $C2N" .F & 'X5TU% '/^(O$FD>"=#BO=4DDBM%DCMXPBEV)/3\@
M"3D]!W.!7*:%?V7Q"^($/B/3TE.EZ#%)!;W+97[3+*,$A2OW54'N#DCBO1IX
M8IU"31)(N<X=01FB"&*%=D4:(GHBX% #U![TX]*** *]S:Q7EK-;7,8DAF0Q
MR(>C*001^(-1Z=IMII6G0:?8P"&U@4)%&"2%4=N:N44 9VCZ+I^@:<FG:7:K
M;6D98I$I) ).2>23R367J_@7PYKU_P#;=3TW[3< AE=II!M( &5 ; Z#H*Z6
MB@#%U'POI>J>&9O#MQ#(=.ECV%/,8L.=P(8DG((!YSTJE'X \,1:*-(CTI$L
M-Q9HDD==Y(P=Q!!;Z'BNGHH YBU\!^&[+3Y;"VTYX;23&Z)+B4#@D\?-QU/3
MKWIFG?#SPKI"W"Z?I(MA<($F\J>1=P!R,_-ZCKUZUU5% '.:5X&\.Z)]K_LW
M31;?;(S%/LFD^=3UZMU]^OO45C\/_#.FWYO[/3##=EMS2BXEW,<YRWS?-^-=
M110!R2_#;PDNHIJ T@&]1@PG,\I?(Z'):NJ"X.?>GT4 8WB/PWIOBG1IM+U6
MW\V"4=1PR-V93V(I^D>'=)T+3#IVEV$5K:,3F-,\YZY)Y/YUK44 <*/A#X'C
MO8+J/0HT,.<1AV*,<@@L"><8X[<G.:W];\*Z-XBMHK?5;$7$,8VK%YCHF.."
MJD ]!UZ8XK;HH YG_A O#8TK^S!I[?82<F#[1+MZ8Q][ICMTJWH7A;1_#D3Q
M:19_98V&"BRNR]<\ D@=>U;=% #,8SQ61XA\,:5XITR:QU6T2:.1"HDP-\??
M*MC@Y /X5M44 <*OPD\'+8M9_P!FLT+2B3#2$X ;=L&>BY],$CO6Y?\ @W0-
M2\-Q>'[C3H_[,A \J!25"$ @$8[C)ZY]\UO44 <5)\*O!SZ#'I']D1K;I*DW
MF GS"ZXY+=<$<$=.3C!Y%;5?'_@WX>,OAZ=Y;8VEIYD5O#$SC'\,:D_Q'MDX
MXY(KOJK2V=K,^^:VAD?N70,: .1^&>BWEAX=FU74TV:IK5PVH740!58V?D+M
M(RI QD<\YYK2U[P1H_B6]CO-1CF,\**D$D<GEM#AB258<\YP<DC'3!R3TM%
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M99&<%LISAD900P'.*T/!_@_Q/XL\/>'M>G\9:A8-&!F."1W\Z)7RI.YL!_O
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M?ZA0,D#!.,XP 8OP/N-3GC\3'6+FYGO8KY8W>XD+/\JD8)/I7K*L&C5D8,I
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M^\ <<UH^'_ GB34Y-%\277C34;-I;6-YK2V<NA.S:I7S"5&5V$AE;YMQSR,
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M6IZ=X*C\4:E;V=I9W=[&;>UE+.[6CK\H8H& D;E_0 X)S7 ^.M \-&XT_7?
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MV[L9;)P5&2!G('6O:_"FI0ZQX5TS4( XCGMD8![<P'H,X3L/3!(QC!(P3.-
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MK\QRJCN#]W!XJEX?UK1O^&B[^=+W2Y(KJ-HH)XI'56D(& #C:[G&.H4YX);
M/NRV=LIRL$0/L@H6TME8,MO$".00@XH \!\.^*A\%]:UCP]X@L;^>TFG\^SN
M8E4ATZ9"EL 'J<'(/!%>G^'?&P\7:O<7.B^4WAJR0I/?391I9BH;"*0"%4'D
ML!DGC@9KJ[S3K+4%1;RUBG",'42*#@@Y!IUK8VMC:QVMK!'#!&@1(T7"A0,
M8^@H \8^"VJZ6?&/C..&X@A^V7D9MH7N%9IL&8L4Z;AWX!P#^->WX%1):V\;
M!D@C5AW50#4M 'GOQHLWO/ACJ02U:?RBLQ"RA-@4\OSUQZ#DU3\.^.O#]_\
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M-EP A;<3ST(Q[3!IME;3S3P6L,<LQ#2.B %B %Y_  ?A2VVG6=G:FVM[:**
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^E6[:[@O+=+BUFCGA?[LD3AE/T(X- $K9[#-9TVN:5:W4=K-J-K'<2$A4:4
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M8TW4BRV.H6MT4QN$$ROM^N"<4FI:WIFC0^;J5_;VB;68>=(%+!1D[0>3CVH
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M,@G/3F@#2JCJ&KV&E0//?WD%O$B-(S2N!A1U..]337UK;V9NY[B&*V #&9Y
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M+=V\$B1S3Q1O(<(KN 6/MZ]JG%>&?%JPM[7XG^!;F)9/-N=05I=TK,,B6(#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
ME'[0EO-/\.86BADD6+4(Y)2JDA%V2#<3V&2!D]R*]7K(\4:%#XE\,W^CSG"7
M410')&&ZJ>.P8 _A0!D_#06Z_#G0OLS2-#]D7:TBA6/)Z@$BNL)S7B?AK6/$
M?PK#^'O$&G7^J:8L@-K?6J[HXH@K,_N<*I;;V /K79CQO<>(&AMO#&EW<DDK
M+YMS>0/%%!&5W;L]22#D 4 <K\=K<S+X586TY U#;]IC)"P[BG!XQD]L_P!T
M]:R?C/X)T'P[X(@U&Q40ZF-03=>2EGGN"5<E=P'7^+)P,)US@'3^*NB:O??\
M(I!I]EJ>I_V3<;;F<0EFD 6([R>^>>?4$=JO_&!-3\4^ H;71M$OKB=KN*1X
MY+,[T3;+R,C@@J 2.0&'9J +'CC3(-=\,>'M6U'48+30+&2*ZOX;Z)XS-& ,
MKC&XL>@4CDD5Q?C;4@/B+X7UBQTG4=&19S DEU:I;QRJ'/S?,RX)_NOMXP>]
M3^,K;6-O@OQ/%H6JO:Z* U[;SY,RB-E<EL\D84_,>*9X_D\1ZYKGAGQ)%X/O
M[5H9A"J/,1,6W'"D+]S/8]30!H?&_2+%=?\ "E[%((+NYO\ 9(5+;Y!F,!@>
M5&W ].HZ\U3^,_@O0O#G@NUU#3U$.I"^3-U(S//<$AR06 ZC[V3@87UP#I_$
M[^WO$-]X;2W\,W^^PO?.O"EMYOEC*$!) ,$$ D@=P >E7OB\^H^)O!D>F:1H
M^NR7,LL<S)':LJE03Q)GZ9QUSM- %?X@:H-;U;P;X6DGFM=-U8I+<,X>-Y5R
M (BNW()/KCGKQ6_XZ^&R^([K2]0T:6WTZ^LY07=5*"6+(.TE?3GMSFN;\9>'
MM;UKP[X:\1Z#I5['K6C8+0WS$S!4&[&&^^=P_&IM,\;^,_'5G!I=KX>FTN28
M#[7J)9T2%&"NAC/7<48'\: )OB#J.I:A\3="\.VFGF_MK2W_ +2FL]Q"W1+[
M &.-J[,%@6(4DXSDC.1XC\!>*[[Q#::]H&A6.D7]I.TK^7=*4NRN'C) ([H$
M(.!EAVR1K_%+P;K#:CHOBSPPDUQJ>E!8I8ED8R3Q _+CUZN&[D-[4:3XR\8>
M/?+TBSTB70E:$&_U%L[HE)Q^YS_$0& ST//:@#$^)_AFQN?B7X4A-A<P+J,X
M6YO(9&4,Q;E0>@;OP?PKL9_@_P"%X=/U;['92-=7MIY(9Y<G<H'()Z%B 6/<
MYZ5SGQ#AU*[^(?AW5M-\/:W>C2)0)F2W(1PK9^4]_KTKV*"87%O%,$D02(K[
M9%VL,C.".Q]10!Y+\'-?_L[P[JWA[5+1+35M##/)"^R)Y(1DY)8C.#G+'"@.
MO/-=%\+=)$6B7'B&<0?;-<F-T_DXVJA/RJ/3WP2*X[QYX,@G^*NF6]C.8QXG
MCDCU-&^8>5"T<AQW4ML49'I[FO4O$FHW'AOPA?7^GV0N7L;9GCA+8!"CN>X
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M,2>I)_*O,/A^FJ:;\4O$E[<>&-4L]/UFX9H9VA?:/G9MS9Y&[=GT&<5[..*
M.'^*]M:_\*^U:^FC@^T6]O((99 F4+J4.TL0,D,0.^3P"<"N:\$1V?A?X,+X
ME@TU/[0@T^27>ZLK.,EL990<$G.0"/0D5U7Q,EN;CP=J.DV-E?W%W>6SK']F
MA=@#Z,R=,].>#WXS6%\.M,GO?AFWA37M)N[*7R9(I%DMC"K(Q(&&'5L<D]:
M&_"'1+#4_ 4.MZG"+[4-6:9KN:Z_>%L2NH S]T<$X'<FN?\ AY/+H?Q1\1^
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M"3:9J6DSV-VLC2,TELR%P6.,L>&./3H,5Z'JEN;O2;RV 8F:!XQM.#RI'!-
M'EWP(TNS_P"$0>_>P6.^BOKB%'=?WD:G9E<GZ#\JQM"\.P>(?C/XPM-7MYH;
M92)3;H#&MR@D!!<?Q*W7T-:/PH;Q%X9L)-!NO#%_%:17,]U-=S+UCV?*L8'W
MG+!>!U!-,\"P:IIWQ7\2ZM>:)J\-EJCE;:5[1L<N""W]T8]: *>AZ?IOAG]H
MRYT_2T\JTEL@/LMM%(1"Q1#\W&/5MW0;NH/%/\/ZIKGB/QOXHU6WT*SU:2"X
M%E;I=7D86SB02;AM/S#S&5,';@D'GY:FFEUJ3XVP>([?1?$/]E&!;=FDM#A
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M^(;E[1R=Q<8W.WS*N,DY/:@#VZO ?C+'<3?%SPG'/*;?3]D12:2-O+\SSF+
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MM4JJ@=_E- #H? /B:+X@6VM:7I-CHMI+$MOJ4"SAHYD?>TI&#G'"+T!W8(&
M365X;\&Z-JOQD\5:/,[2Z;$@E:WB9E5BLB$1ON&6 ('3\ZZ_1/$_B3QS?PS/
MI%YH^CZ:5N+ME=UFN91&2(D"_>4[D;'L >M9/A4:G9?&?6-7?POJMOINJCR5
MN&@?"DL#O<'H#C!]* /3/"WA+2_!^D_V;I,<BP%RY,C[F8GWKSS]H'2K:;PA
M;7HB07AO8;=9G?: I#G!R< 9[FO7\BO*OC_L/P^MO,#F,ZE#NV?>QM?./>@"
MS\2K2T'P0N3> %H;*W5)(55RK;XP,'.,$X!(/3/6G:7:6UU\ [5;F"&<?V,2
M%EE6(9V'_EHW"?[W:M7Q3I,^M?"2YL-.17FDTZ/RHYHA(6VA6VX_O$+@>C8/
M:N'TK6_$<_PXG\)P^"+V2YL=/6"Y%R_EJZE<$*!ABQ&< <T 5="T[3KO]F@3
MZBCD6T5TR/%RR'SFY R ?QJ[\.OAIX>\2_#_ $+5-42XGNMN5;S<;%264A%X
MX4EB2.]5?#Q\0:;\&+KPW<>$]2%Z$EB@#VWFK*S.7Y3'  ;J>,@^E=K\'_M]
MIX%MM(U/2;[3[JP+(?M,142AF9@RGOUP1VP/6@#BCI=GI'[3FC6MA (819.^
MT,3R89?7-7OB5?:IX8^(>E>*=1T]=0\-0QFWVHNXQ%N&+ \9ST_+-+>-JB_'
M2V\2Q^'=4DTI+,V\DQT]F=6"N,H,9') R.Q-=%J?B6_T+QW=QW^F:M<:#<PQ
M*DBV_FQ),0!A<#//0CUH @\(WWA2?4O$/B+PC+:-;_9%^T6\:-$YF4R.696
M^4A@ 1QE2.U9GPABC\7C6O&6L1Q3W=Y=&".%TW);HJJ2%SZY3/'\'O5;P1X3
MC?QSK>I:):ZCIGAJ_L %CN(C&DS2#[T8/\*Y. >F[CBLSPG?ZY\)];U'PU>:
M/>:AHK.\]K<00'<S_(H(]02T:'T)'O0!/X)TNVT;X_Z[:6=M/;6_D.R1O9G&
M"0?E89VIZ,>O3O4FC:1%IW[2E['I]HZ6<%B-Q4,RH6B7J3G&3GK5;PM'XA;X
MW7NL)X8O+>QNI&@N'\YMD9QDEF^ZV./EZ9Z<UHV%KJ<_Q]?Q#_8NJPZ5/;B!
M9Y;5D ;RU7D'H,@\T 6O!$L7C'XG>*]6U-Q+)IDGV"ULGRZPQ@D%^5V_,4SU
MR#N[8K?\/_#>W\->.M2URRG3^SM0MWCDL=F%C8LA&!R".'SGU^M<-K$7B?X6
M>.=<\0:1HOVSP_J<BR3@$N5(P68D<K\SOC/!S[5W/A2]U[Q9K@US5=).F:9:
MQNMA;3$^:[N%_>D=!A=Z@CM(?>@#@O!?AGP]??%OQEI#V"3:=&G$$J *C"0'
M"X)X!Z&K'QXT^UAU+PU?11!;FXO<2R9/S!=@'M^57+?^W_"_QJUJX_LF^UA=
M3A7R)(OE2*,N,;F;C"]/:I/BO%X@U*]\-KINEZC-?:9/YUS/9V[^6,JF=C=^
M] %OXT:S<VZ^&] @DDBAUB^V7$L,A5MBL@*@^^_/_ :O^/\ X?Z"WP]OFM;.
M*VN=*LWFM;F-?WB>7^\(SZMMP3[T?%?P?=^,?#-CJ&DK(FK:<_VFV5B4?:P!
M90.SY5"/]W'>J=SXX_X2/PG?>&+;2-5D\0S6)M9;:6!AY3N!&7=SP "P8F@#
MA]6OQXO^ 3:QK$V=4LY1 MU+%(!( _"@@88D<$] >I%;^H^!/#Y^# UF[&_4
MGTBWF6]NRTAA_=H J[1PHQ@#'>I/$OA&Z\/_  >3P;9Z=>ZS?.1+OMX7**Y?
M).1Z'D ]:W)KV\_X5!;Z3'I&NIJ TY++9!:,LBR)&@.">B]1GO@T :?P>N)I
M_A?HQGBD0HKJK2,&\P!S\PP3@<XP<'CIC%=UFO&_"NHZYX)^$.(?#,IU6UG0
M-!+ T7F>8^T-S]]N@^7U6N[\!>*Y/&7A:+5)K06EQYCPRQ Y 93@X]J -77M
M/M-3T6YM[R(2Q!&?:21R <=*\-^#/@;1_%W@J>?6&N98K?4I0ENLNV+)BC^8
MKCEN1S["O?KP2?8I_+)\SRVVD=<XXKP_X-^*I="\.:U'K&FZK(1JCO+=Q6[2
M@RLJ*R,1T8$#K_>% #_AO82^%/BAXB\#S+<S:5<V[21>9 _S 8PVX<*N&==W
M ) &<X%5/"_A'0=9^+OBW27%P=.@(=K8L%5V60':>264'Z&NT\&>#9I?'6J^
M.M3MWMIKMF6SLYU_>0K@*7/]UB 0!Z,?6L3PC_;5G\9-<U2Y\.:A%IVJ,8(K
ME;0HJC<"&<8[XY/XF@#/\2Z-8:#XJ\)?#W3EN8M'NYOM=R?.)>8EB &XZ#;^
MM=1\8O#UFO@A]<L4CLK_ $F1+B":",*W+!2N1CC)!_X#3?BSX-U/5+C2_$^@
M)*^JZ6PW)"Q$DD8;.$]^3]<U#KWB*;XA^$)_#^G:'J5OJ5\4287$)6.U42,"
M[/T(S$PP._% &9K]B?B+\"$UNZ 75;.W-VTSQ&/>8@2W498%-V,<9[\5K:#X
MHFO?@I8W5C:&?4;A5T^-)%0+)<$[-S#(&TMS7=^&="C\.^&+#15E,RVD(CWD
M?>[_ ,S7EOA'X>G3_B;J=C(9CHVEW*:C9A0=OG,/E4L>257''>@#5\8^$-/T
M/X'S6+6L!N-.L5)DBR%,QV[W[9R<GG]*B\.^()_"W[.EIK5K$DL]M;'8KGY=
MS3%03]-V<>U=-\3Q<77@34M,LK&\O+F^A*1+;0EP""#\V.E8VD^'+WQ#\#CX
M<O+.;3[\6YA\IH!#\Z/O7 Z8.%R?<]Z )?AGX7TVZ^'T%WJ<$5_/K$;37+S)
MDE6S\F3DX&2.W6O/?A-J<?AKP=XTU"TDM+N2R#/&R2,KR*!P=I&0GH2,YXQ6
M_P""?%_B3PA:_P#"):YX9OKJ:R!CMI+./<&PC.J<=<[>#]2>E4/AMHGB&6W\
M3Z#KNEW=Q;ZA<21W5V\BJF\$H[!S\SG(YP: +7AG2==UCX;QQIX;TO4WU1)I
M;J_N;U"\LC/PXV[N@(&,@@Q,"!QFUHC^,/A?\)=;GUA;>5K%E33HMX;:K.$+
M$C^'+ @=>#G&:P?#'B;QM\-TF\/:AX=NK_3;<2I8LD&S)$GWP?XE+./?D8KO
M[WPQXC\6^ -<AU^Y\J_U2%&@L8C^[M3&=ZID]V8#<?IZ4 ,^''A73)_AS;SZ
ME!%?3:M"9[F6=-Q(<?=SSP <5S7[/")#IVO117 GB2[PLB6S*KC ^8.P'7^Z
M<$=2.:=X*\8^)/"MG_PB>M^&;ZYN;%6AMI;./<' 0LJ\=<@?>].35;X2IXK\
M/?\ "4?;]'N;EA)+(;B2X(26="5<#/#$E3EAS^E 'NB]ZK:GIMGJ^GRV-_ L
M]K* )(F)PPSG!Q]*XOX9^/;_ ,9#5+;5-*&GWM@87**3@I*I*\'D'"Y^A%=\
MW2@#Q7X':7:3_P!O7-S9V)NK34CY+0;72+*X.Q@2,?0FJMUIEOXC_:-U?3;D
M/#;BP19&MFV-,/+B;#GN#G';@"K'PTM_$OA/5]2TA_"=S%#=ZAYK7!8F"*(<
M-M8\L<=/6IK&766^.5WXCN-&UHZ-):+;6SO9O\F53(V]AN#G]: ,W4=%T[PK
M^T#X:@T"UCC2:W;S;&VRI&1)EV+84C'.,D_)TSC/3:[8V'A_X@W?BGQ#=V=^
M);00:7IB)NNFD+!=L<7\1.=N1Z\XZUC^,8=2U7XK:!JL&@ZQ<Z;INY9O/LG:
M%6^;YD4<D]#GIPOH:J1R:YX+^+NM:Q)X9U'4[?5@5LQ;+G.</W[@(<CM0!-\
M-'G@^+?B2 6%U:6VH0K>-;7415X-_P X!"95?O8PQ![8SQ4.E:+HDO[16N:8
MNEPK9K8[Y(C\R/(?*<N!CY>3T]03WQ4>A6WB32_C3JEY<>'&6:_^:)DB5HH$
M=CAW=1V[E>2<YK:UBV\1Z!\;I?$,.CW^M6%U8+!"+<?+;Y*@J2>!RA8_[] '
MK%K:0V=LD%L@2%,[5!Z9.3_.O'/B;H]G'\5?!ERFE8:[OHEN+H+\DF'&$88P
M3CGKTKV2R-RUG$UXD:7!&76,DJOMGZ5Y3\7=.OX?%?A+Q'9Z;=WZV%X@>.WP
M<_."%QUR3@ ].: +?QDL(M.^$LUEI>G1FVMWC41)&2(4&?FXZ8]3ZUD:UX T
M-OA#+JTEG=7NJMIT$RW.#--'\B?*@XP@ _ 9-6/B8^O^*/AM#8CP[?KJ=S,M
MP+>&%G$409MJNPX#[=N1ZU?UZXN;SX/+H\?A_5[B^>RCM/LQM9%(=%CR21T'
M.0>AVD4 <S>>([J'X"^'++3+LM=ZG-'IDD\3M(\)))8;4!8G V[0,X;CG%6_
M$'@C6_$N@6UI;>"[/1[R#R8K>Z6[3="!@N3M.=O4#JWL*@M_"6I^(_@<VB7F
MFW]KK&D'S[6.XA*%V4$@)C[V06 SW(J30?B+X^%LN@7WA>6;6WF$44TL?DQJ
MI&?G QC"\YH ]0\$V>K:?X-TFSUQXFU"&W6.7RSD#'"@GNP7 )Z$@D9KH*S-
M T^XTO0K*RNKR6\N8HE$UQ*Y<RO_ !-EN<9S@=A@5IT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4AS2T4 -"XYI ",XZ4^C(]: &A?:C!IU% #<'THP:=1D>M #-IP/6@].>
M*?FL#Q5XLTCP=IT=_K$SQP2SI NQ"Y+-WP.P 9C[*<9. 0#=P2/>DVG SVI8
MW62-74Y5AD'U%.H :?>CDFL+Q%XOT?PS>Z59ZG.Z3:I,8+<+&6&1C)..@RRC
MURP[9(W5'- !@CI6'XL3Q&VB%?"QM!J1D4!KLG:$ZMCKST'3N:WLT4 <-X/\
M-:['XBU'Q1XK:S;5[B%;2".S+>7! #N*C/7+8/.2,=<'%=;J$=^]HPTZ:WBN
MLC:]Q$TB#GG(#*3Q[U<HH QM!\/1:$ET1=W5[<W<QGN+FZ<,\C=!P %4   !
M0  !6S110 TXSS]:.<< &L&?Q?H]OXRMO"TD[_VK<PM/&@0[< $X)]2 Q';Y
M3WP#OCI0 FW@#K1@_2G9HH 9@CM^M!! '>GYK%\1>+-"\+6OGZSJ4-J" 50G
M<[<XX49)Y[XQ0!K]3BEQCH.*J:3J$.K:59ZC;I(D-W D\8D&&"LH(!Y/.".]
M3WEW!8V4]W<R>7!!&TLCX)VJHR3@<] : '\XR?RI]8OAKQ)IWBW18]6TIW:V
MD8K\Z;6!'4$?X5M4 -P<^U&#3J* &\CO^=&*CN9XK6"2XN)$BAB4N\DC!54#
MJ23TIMA>V^HZ=;7UI)YEM<Q)-"^"-R, 5.#R,@CK0!*%/IWS1@Y/'7WI]&:
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M<4+3RM",QH%*#&_H2=XQC/0Y(XSTN10 P@YR/TI>13J*  =*:P)IV:3(]10
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MD^%X[>VM42VO D$>_P LHHV@*BCC& ![ "O8(9&EMXI60(SJ&*AMV"1TSWH
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M$40+O3"\G'4YSR>> .U '*>/++3_ /A?7A>(?9;=?.@+@(IW$.-JD+D\]!N
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M"*$VDA<NN&=V4 L %!.2!@9KV2O'_!<9C^/?B_-J+?=;;AAB?,!=?FY/?TH
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M $\D9Q7/F)I?V6U1;47/^A ^621C$X.[((^[C=^%=[\-@#\,_#PZ@V,?'X4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M'?%473?#+719NR3>0/F638=N]=W.1_#GZ].]=C7(_$70M8\3^%;C1-*%BJW:
M[9IKJ9T,>&5EVA4;=G!!SC''6@#DOA]JGB^W^'&CVEEH5E=22P-]DNC<E(8D
M 8J9A@MNW #"]<]5Q6AI?@"\\.?"Z\T71M@UO4(O])G:Z9%65AAF5@N0%[#
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M<F%.X#<AD #8'.#[GCGA/^%,Z%_T&/$7_@Q/^%'_  IG0O\ H,>(?_!B?\*
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MGT#;1GCV%>?_ !=\%ZWXXTNPT_2ELU6"<SO)<3%?X2NT *<]>N:])P/2C H
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M@-J"\ET6)<[F;@("^.%!)7J /F3XT:3::IX6L )_L^L#48(M+E!VDS.X7:6
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MTHP* .)^)7@B7QOHEM;V=W'9:A:7 N8+@QDMD*WRA@05!.TY']T<5Q.K:/\
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MP49.>.2* .QHHII;G% %#4];L-'ELDO[E(/MMP+: OT:0J6"Y[9VD#WP.]:
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MD;@N.,8R2N#S6Y\0_"OA#1/A=J=M_9UE:JD1:V;;B1[@#"'?]YF)XR2<YYH
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M6KV<L[2N$V%2H<83.[GI@#WJGX4^'U]8_#^?P=KYL9;)D<+-:2.7)9BQ.&4
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MJ4N[)&X=9(T& <@;2,X SQG)Q8\"?#+5M'\'ZYH6KW5JMKJ4,D:)''OD0L"
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M.TGY2*+RXHAGAP2,M[C'TS6KXS\ >)_$_P#PCACU&Q+:8WVBX:>60>=,6#,
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M0?Q';K0!ZL>E>7:9)%9>,?$UOX&M5U&^N%234;F^OBMO;3#<(T7",[DY<D9
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M2?'^I>(;DZ";75&87-O"9-RJ23E25Y///3/M5.W^&_B'P7XQGU'P1<V8TR_
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M,MX],"F!+AY"68')) 7 ZXZ]* /0[?3K*TD>2VM(('D55=HXPI8*,*"1U '
M]*H^*+J:P\*:S>6TACN+>QFEC< '#+&Q!Y]#BM2#S?L\7GA!-L'F",DJ&QS@
MG!(S2O&LB,CJK*PPRL,@CTH \P^ \2_\*Y6Y.XRSW4ID)8D$AO3.!^%<[I4+
MZ7^TWJMMIL2K;W$/G7$9F902R*[/T.X[F) XZ]16[IO@[Q9X U:\_P"$5%GJ
M6BW3M,;.YE\N1&VG"AN@!.![]\5TOASP6UKXCU#Q3K#6\VNWIV V^?*@B "J
MBY ).U1DD#)[4 <C\(W9_'GQ"+S0SG[7#\\*;5QF;C&!R.AXZ@\GK4'B&R@O
M/VCM BN["TEMI;.3.\!S+B*3[RDD #C' _''&IIOP[\4:-XUU>_TS6=.M=)U
M6YCFN%CA;SMJ$MA1T!)9@3GD$GVJ;5/ OB2?XL0>-+*323';0F&*WFFD4NI1
MERQ"'!^<],]* ,;XHEH_BAX&-K%9R70G78CNZ.?GX!;!4)[X)S[57N1?ZW^T
M)K%I;ZY/IUY9V$:6+);)(@0I&[J^2#C+$XZG/48YVO'7@/Q;XOUK2+^*YT>"
M/3PK^1))(RO)U/1 <=OIZ5)\1/AGJ/BI['7-*O(['Q!;PJDH21A')CG ;&<@
M\ D<C&<8H 74/A:;OQCIWBK5?%=TTUI*N?W2197C9&K _*-[-UW$A@O7DXFN
MZ=:7O[2NB"YLIB!;><))'.QWC1F0J !C:0,\G/M6]X=\->,]9N=-N/'EU9O:
M6:^;'8P.0YN 0$:4C*M@!B,'J11J/@GQ/+\5(O&%K-I3Q6\30PVT\\HRI0KD
MX0@'YLX&>E 'H-GIECIR,EC9V]JCG++!$J!CZG I;\A;"Y)7>!$WRAF&>#QE
M02/J 3Z5:JCJT5]+I-U'IKQ)>O&5A:5BJJQXR2 3QUZ4 >5? ,$Z?XB?=A6O
M_EAV@[/O?Q$[VZ_QJ.G'4XR?A1::OXF?7[^+Q'?:=.;\-=F*.)Q.Q.<C<GR_
M+D=^3GV/4_#SP5XP\$_:X;B[TF_@O+A996,LBNG)WD?N^2<]R.E9OB;X9>)[
M+Q/=:UX&UH6/]H.#=0,^S:2PRPXP5'7'7L,T :6C?#E/!^MWOB$>([BYU&Z@
MFDF21%03N4!9PH/9]S8P<!@.V3G?L^QI<^%=8UB8;M0O=29;B?."X"JPX' Y
MD<\#^*NI\'>&]<-Y)X@\8RV\^LR1B.**!CY=K$5&Y,=-Q.<D$@^M<K#X"\9>
M"_%E[J'A*\MKS3]1$DL]M<D1K'(7^7 ]@^01U"L#C*Y *GAZ**+]I'6R(50O
M;N^7O?F+8'S*BCYO]QN@RV> *K>'HM6\1?%SQFMKKMSIM[;N\8N(XHY%,:MM
MC0H1T! .<Y(XXZULZ/\ #WQ;;?%5O$UQJ&FQ0$#SY(82#<@J=PV=CD 9R.Q&
M>15CQ[\-];N_$#>*/!NI_8=5:/9/'OV"7 P-IQC)]_KF@"S:?#,VOCB#Q?J'
MB>675))AY@6$0QS?>'EA=Q.-@0 98_(3SGCG/A+HFFW?C?QY+<Z60R7"0K%=
M_O#L=W9L@@ @E$8<< #ZGJ?"_A?Q7/?PZEXSN[6[N-/C,>G0QN0H<%E,KX&"
MS *0>H!Y /%5O 7@;Q5X3\4ZKJ%[>Z7/9:JYDN$C>0R(06*;25&<;B,''!]J
M '>(9/#VG_$+1%TBQ^T^*;=##;6$++;PB)U.YY7V'Y57<1MR?:N1E.JG]H/2
MY-9-I'=.A(AM<,D:?PKOWHSG&,EE'/1",5U'C'P)XED\?VGC'PQ>67VM(UMV
MBNU.%!&PM[@*Q)[\< U2G^'/B^?QQI&O'7+?[5#%NN[IXPR!RYS'$G4J!C&<
M?6@ ^,BL_BCP(J0PSG[;+^[F;:IYBZG(Z=1SU_*O7QTKS'Q[X"\3>+]2T26*
MYTI8M)D$JR2O(KSL=A;*A2%Y0XP3P:](LC=FSC-\D*7./WBP.60'V) )_*@#
MSWXG^$]6UNYL=7\-ZA!;Z[I:&6"'!$LJYY ;=@#V*D$\$@5C>$OB-'K'BZQT
M?Q?83Z;XGLY9X(UB7]Q(7QP0<D' XP2#C.>:Z_Q3H'B"[\6:/K>A2Z8GV%'2
M5+LNK2ANJ J#QC\CS699^$M5\1^,K'Q+XDTVSTV73D0P1VLWF/*Y&3O?'1<E
M<=R#@XQ0!QO@"WU;Q/XU\;3V_B"]TVZBOE2>6*.)Q.@=EC&&7Y=JI(,Y.=ZG
MC;\W::-\.(=&\>_\)5=Z_+-J%RTJF%4$*3$K@ KN.["AB1W.#QMP</QC\//%
M5KXQNO%7@>]AMYIXD\^T,FUIW#<C! 7;@+U(Z-ZUTWA7PGK*:G_;WB[44OM6
M3=]FAA)$-H&&&VC^\1D?3.,YH YGX$W2:G8^(-2GC9]3EOR;FZ8KF0D9& %&
MT>V3SSQ7>:-X=\/>'_$6J3V&R+4]6?[3/&TV68=RJ]=N[<?JQ[8 \[U?X:>)
MO#/BA]6^'MXD%M<9DFLI'PFX<A<'JI/'M].:[[POX=U*RNKG6?$5]#>ZU<HL
M1:W7;##$I.U4!YYR6)]2?2@#A/@L8)/%GC]K>*2.+[=%A7DWD'=-GD =3GMW
M[]:L>$=W_"_?%FYI#FSXWP"+CS$Z8/S#_:/)I]IX-\9>%O&6JW7AAM-?3]69
M9)S<KY81\2X( ).%)4G^\7],D1Z!X"\9Z'X]OM;BU*RF6>$)++=,S-='[V
M/W8W  ]< Y&: *7@C1=.NOC7XV>YL4<H6*K+*LP^=SN.  ,-_=()'0\BK_QU
ML88/AI:V5E!#!'_:,2I'&HC0$A_H!R:O>#_ OB7PYXWUG7KB3298=7F,DT<<
MTFZ(%RQVY3YNO?%7_BAX.USQQH\6D:?)I\%LLB3-+<2.'WC<,!0I&,$<YH Y
M?XSP21_!O2D,$$ACDM@[._,6(R-R88;CGC^+AB<=QZW;8_LJ'!_Y8K_Z#7"^
M*? 6I>+?AQ#H-[)90:E:/&UM)%*YB^0!<ME0>5+\8ZXK4\/67C.'P\)]5N+&
M;5B@C2UW&."-<_Q%0Q+8[CCM0!Y/\-I[W2O@3XNO[;?!)YCM#*5ZC8JDC/![
MBNH^'OAG6M3\!:3)8^,KBUTEK5DCM(]-C!SYK%RY=GW?QKP ,;3CJ#K_  W\
M :YX0T>\T35IM.O-.NG9V:*5RZY4#:%9,8X)Z]ZYJ'X=?$/P;JGE>$=:AET;
MS6EBM[A^%SM&'4]>"3P?X.Q(! -VS^%UCIG@K7O#+^($F;4I49GN8ALMR7^3
M;$KC#$].0"0."!@\>WBOQ#X+LI/"?Q$LKBXT:X@>VAU&S(:5EZ @L<-QZ@'O
MS7?7'@'4)OA]J>G&ZM9O$.IE'NKV=G:,R*X(*X&1M'W>.#5?7_#GC/Q9X:ET
M#4K30!M"+]N::1O,( RR+LRI[<_K0!Z)8WEOJ%E;WMK()+>XC66*0 @,C#(.
M#SR,59JIIFGPZ5IEIIUON^SVD*01!CD[54*,GZ"K= !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %-:G5B^*=;F\/:#/J=OID^HO",^1"P7Y<9+%CT  /KVH U\9X&.*7%<I\._
M%\GC?PW)K#VJ6JFYDBCB5MQ"KC&3W//M76Y% " '.32T9HR* &X.>M.HR*3(
MH 0J3FG4F1ZTM !FDR#T-(W?->>7OQ"U26TU:_T+0DO=-TFZ:"::2X(>X"</
MY2A3GDX#9.<=* /1<YHK#\*>);3Q5H,.JVB2Q*Y*/%*I#1N/O*?7'K_^JMS-
M  1D4T*<Y)I<BER* "FA32Y'K2Y% !29%+D5E:]JYT/29[\65S>")2QBMP"<
M $Y.3P..3[]* -3<*,BN0^'?C&7QSX>FUA[5+5/M3PQQ!BQ"J%ZGN<GL!76]
M!0 IY Q2KTKDO"WB?4M>U_Q!9W.C/:66FWC6]M<MG]\%.T]1[9R.,,!SC)ZT
M=Z !NE(O4U6U"\-E9/<+:W%T4Q^ZMU#.V3C@$@?K7)?#?QX_CVUU*\-D+.*V
MG$4<>_>V-H)R>!U]J .W.<<4F#W'Y4ZB@ I-P]::TL:NB,ZAG.%!/+'&>/7B
MN$\<?$A/!5Y96\FB7=R+F41"?S!'&>!]T\DXSR,"@#OJ*3-&1ZT +2%<G-&1
M1D4  &*#DCBC(HR*  #!)H/2C(]:AO;C[+8W%P(S(8HF<(.K8&<4 28QQ5?4
M+!=1LVMGFN(5;'SV\S1.,'/#*0161X,\177BG05U6ZTB;2S(Y5(9GW,RC'S=
M!U.1R.U=%D4 4].TNRTFS6TT^TAM;922L4*!5!)R>![U<I,BC(H 0@YXI1P*
M,C.,TN10 UAD\'%*!BC(]:,B@ ;D8II&1@8(IS8(Q7.>,_$T_A+09=4BTF?4
MEBRTBQ.$$:#DLS'.!^!H Z(=:=7/^#/$J^+_  K9:ZEJ;5;K?B$OO*[79.N!
MG[N>E=!F@ HHR*,B@!IZ]?PIPZ5B>*]9G\/^%]0U6VM&NY[:/=' N<N20!TY
M[Y_"K'A[4+K5/#]C?W]F;*ZGB#R6[')0G_.?QH TZ0@FER/6DR,9H 3:: N.
ME+D>M+F@! ,<F@F@].:X_7_&4UEXD7PYHVGIJ&K-9O=LKW'EI&HX Z'))[<<
M8YYH Z[ )SWJOJ%BNHV;VSS7$*L0=]O,T3C!SPRD$5R?@GQS=>(]2O\ 2-5T
M672=4L8XWDB=MPD#9RPXP!G'<]?8UVV10!4T_2[+2;-;33K6&UMU)(CA0*H)
M.2<#U-6P1BC(KSO6OB3<Z?X\TKPS'H%Z%O)/FN)0 74;P?+ .#RJG)/3/'2@
M#T0@F@# H!XY-+D4 %%&11D4 (W2D  -*37%^/\ QU+X$L(KT:)<ZA;LP$LJ
MRB-(LG !.#R3VQ^- ':9%+6?HNHC6-$T[4Q'Y0O+:.X";L[=ZAL9[]:T* &E
M<]Z=1FC(H **3(]:6@ HHS29&,]J %I#TXHR*7- #0N#FG49I,B@!:;MI<CU
MHR/6@!,'/:G4F11D4 +7+>.? ]CXZTJ&RO)YK=X)1+#-"?F1NAXZ'BNIS29'
MK0!P<7P_UF*U> >/==97W?.[*SC( X)Y'3CTR?6NF\/>'K/PWI*V%D&(+&2:
M5SEYI#]YW/<G_"M;(HR* $V\YH52*=FC(H **,BF-+&A0.ZJ7;:H)QN."<#U
MX!/X4 /HHR*0LH!)( '4GM0 F#DFC%>=7?Q#UJYMKS4?#OAAM1TVQOGM99/M
M&V28(N79%QC;NP V3G!XYXZKPAXEA\6>&[;5XH&MS+D/ Q),; X(S@9H W%&
M%Q_*E)Q1D56O;@VMK).L$TYC7/E0@%V]@"0,T 3GG%"]>M<'X*^(5SXO\3:W
MICZ-/81::$4&3E@Q9P=Y[9 4@ 'HW)XKO1QF@!:*,TF1ZT +11D4F1ZT -([
M9Q3Z\]UCXD2Z9\1-'\+_ -CSK'?2&-[B<A=W)4,F"<KD9YZ^U>A#I0 A!I-M
M.R*,B@! ,#%+29'K2Y% #6&1UQ67I?A_3M)N)+J&-GNY!MDNIW,DSKV4NW)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2V\31Z)/=K-:QW+I'*BI#N"G#L2&_BP"JGIR!3[3Q9JFJ?#RV\3:9H]O--+
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MR(=O(YSG=QG[U;OQ3\16&D#1-/N-*BOM0O[@_P!GO.H,=O,K(H=N_'F9X]*
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MX/XH:-JEIXH\,75]J-QJ5Q-=HB%('18\?PHJ!@23SQEO:@#N_'WQ*F\#WUC
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MZ"Z>DT>4CD! \PGL%W ^IS7 _%K1M6M+SPS>:EJ<^HW$E[%&GE0.D<3=2%"
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MM&"H+:E"H+$ #*OU)Z#WH Z7Q%XZ30M*T25+%Y[[6988+:$LRQ*TF/OR;3M
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M3R0!G-3^*?A[%XGU'3=2;7=5L;[3XVCCFM)0I)8 %@.BDC.=N,YP>@KMZ,4
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M@GO@#/K],"H;#X;-I_C&?Q2GB._?4[E1'.S0P[9$^7Y<;,#A%Z5WV** //\
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M*4OY3 ,(SGYBV#@5T6B_%JQO/AG+XLU"%8I()6@EMHVQNDS\JH6ZDJ0?S]*
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M) P2>0?=3B@#TFHKEIUM93;)&]P$/EK(Q52V. 2 2!GN ?H:\WL/$WB/Q/\
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MH$#: ?\ OK..Z&NEN+SQ#/\ $:/3+#5P--AA^U7R-9@B-20$C5_5L.>>0%-
M%O\ XJ]OB0[;8$\+1VH +$%I)".P!)R#Z@#&:ZL5Y9:>,O$W_"ZX_"U_)9"Q
M-N93';H3_P LRP.X\]JT=6\5ZG<_$V'PAIUY%I\26C7$MR%29F. 0NT_=Z]^
M3],4 >AT5QGABZ\56>JZ_%XKN8)=/MEBELKQ(A&CQGS-Y)'<;5R.W!Z&N9M?
M&^J^(#J.HQ>)M+T&PCB8VEO<QJTC?,%25R?^6;,0./;% 'K.*,"O-/A-\2+G
MQQ;W=IJ,<2:A9A2S1*0LJ]-_H,GL*[[6+_\ LK1KR_\ *>4V\32!(T+%B!TP
M.: +M%>-6_BOQG>?"V]\8G6;>UG5F:&UELT2/;N QO?!8X)P1U( ZUNS_%*.
MP^%%MXMNK8"\GC"1VS9022GCY<]5[Y'8&@#TBBO,?%VI^/?"NA_V^M[9WZPS
MEKBPAM?D6(GC#XW<#J36OKWC]-%\%:7JC) =5U6*$V=D[$"21PI(SU &[K]/
M6@#MZ*\Q\5S_ ! T'P5-K<&LVTU];@2W%FEDK(J$\A6ZG:#DD]E-9^M>,_%4
M'P@L?%\%VEM>>5'YL)@1UF+,!O\ ]G@]* /7J1B>U<'J&LZ]-\*K'Q'9ZG!:
M7XTR.[F,L:>7*S1J3DMPHR3^=6O!&NZSXD^&NG:N[VTFJ7".<R*4C)$C+R%Z
M<#M0!/X(_P"$O*ZI)XK6!-]T39QQD%EC]\$C'3 SGKFNK/2O*_AGXS\4>*[7
MQ&MQ+8R7EC<I';AXRD8!+;L[>3PO%<[X<\;_ !/\3VFLVFF)IMQ=64RJMV%7
MR^N"JG[C<<YSTH ]*\7GQ<]]H<?AA8! ;DM?RS,H"1C& 03D@Y;H">!TKJ\F
MO'/&7C+QUX4C\+QWKZ9%-?2+%<"!"[%ALW9SP/O'[M;'Q@\7>)/!NAV^HZ/)
M91P27*0EGC+R;BKL1@_+CY1SUH ]-HKQSQ?XD^(^D>&9_$Z3Z?8648C LFB$
MTA#$#>6&1SG..U=5JOCXZ9\*X/%DT,:W%Q9Q2QPC)7S9%!"^N,GK0!W-%>1:
MOKGCK1_AM9^+!K%M=S%(KBXM_LJ(@B?G@]<X*C\375_#OQ!KOB/P[#J>L6]J
MD=Q&LEO) W+ LX8,.Q&%^N: .RIK'%<YXU\967@K03J5XIE+2+''"C -(Q/\
M.>N!R?85RNH6WQ$TOPH^O2:W'/K$,"O-IR6JM$0"257'\6#@D>E 'IPR>M+7
M :7X\N?%7PXN/$&@1P17ENL@N([H-MC=$W,%Q][JI';GFN'\.^,?BEXQ\+K?
M:&+4SP7#1S/-"B+*",C:3Q\N"#_O"@#W9B0I*@$XX!KS'2/%?BJX^,TOAS6(
M;>VLH;)IXX[;<R2Y5/F#L%+@'<. ,'(YQ7H]H;G['#]M\L7)0>;Y6=N['.,\
MXKQ&]N+^']HK6#H-L;G4CIRH4G=5CC8QQ?,.?N@8..N<T >[45Y%IGB[QEH_
MQ8TWPEXAO;#4(;ZW:3?;P>7L.'(Y[GY"/3YJV=5\7:IJ_P 0$\(^&[N&U:U4
M37UV8?.P,\H!T4^[8YP.] 'H.3VKR[XG>,_$OAK6M$L+,6<%EJ-T(A.K,TS
M-'NR" $^\1P6R#VJ+4/%VM?#?Q1INFZ_>2:IH-Y$L<5Z8,2QN.#N(^\>Y[XJ
MG\;7BC\1^!'FA$J?;I,IN*Y^:+'(]^: /917%?$OQ!XA\,^&;C5-%BTXI H:
M1[N;:PY'"J<!N.VX'T!IWQ"\;IX.TF%((FN-5U!VM[*WCP7\PJ=K;3U4-M!Q
M_>%<3\4[;Q5:?#"6YU+6+6]#"-;NV:R4!2Q RAZ@@D')]* .STS5/$.I?"6S
MU"PA=]=FTR-XA.4!ED*CY\AMH#?>&2.O(!XK?\+IK,?AJP3Q \3ZJ(A]H,73
M=V_'&,XXSG%>>:?J^IZ%\!=/U706TQ6MK /*PW, >,X'3?G.X'C.:V-!\3>(
M=5^$%OXAA:T;5&@FFE:5"J80R#@+W^5>.G6@#T*BO&_!OB;XC>./#$5Q93Z?
M9ND\@EOIX@0^,8C$8Y'4G)]*W/A+XXU7Q;H&HS:SY)N+&X,1DC3;O&,_=]J
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M()C!!X#'D*!Q].N: ./_ &?Y0/!FHV7F6LAM=1D0-"J_.-JG<2 "V23ACS@
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M1E^W  BY>&7&],@,#A5Z9?JIVX[UZ%??#WPQJ.JIJESII-ZBJD<J7$L9C4#
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MH \W^!;,1XJ,C6S,=1&6ME"QDX/W0H  ^@%0^ IIE^.7C..26^&]S\LS)(&
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MA<HEP< ?./PS\N"3US6S-X*\/W'AN#P[+8;M)@.Y+83.HZD\D-DC))P2?TH
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M0D<[2>O(/1?#2VM=9^$FG65V);BVFMC!*DSKRN,%04/ ],_-ZT 4+C5;"V^
MMBDM[;H\FCP0(#&L^9/*7Y?+/WC[&M'X-S1/\+-%C22-I$23>H8$KF5\9':K
M.G?"GPCIUM+#;Z?(-YD(8SOF/>>=G. 0, 'K@#)/.=+1O GA_0=$ETG3K(PV
MT^WSF25EDE(Q@EP0W;L0.3QR: //O@/*A;Q9&L"JZZ@"\@)R^2^ <G''/0=Z
MD^ ]Q#-;^)O+EBD#:CO!CA6$%=O41KPH]AP*[G3?AYX8TB6:33]/DMFF5ED\
MN[F&_<I4D_/R<,>>HSD<T_0_ 'ACPW?F]T?3!:7)4J76:0Y![$%B#0!Y_P#'
M$P#5_!1N5E,/VY\K&P5NL>,9!'7%7_V@"1\.%PUNN;V('S44LPVOPA()#=.1
M@XW<X)![+6O ?AOQ#?"\U:P>YG!#*6N90$( &54, O0= .E+JG@7P[K6G6EA
MJ=B]U:VI)ACDN93@GJ2=V6/N<XYQ0!S_ ,2#)_PIN_\ +-P&^QQAOL\H0[?E
MSD]UQG<.XR.]8'V;2+C]GBP37([K[&MG&^Z"X,KHV,JP)/ !_@Z+TQQ7>W?@
M#PW?Z='I]W933VD>=L4EY,5Y(//S\\@8ST[5P'Q(T_0O WA2'3K#26BTW4YA
M!=2[I)UMDSDLL;-@,<G!ROXT 5;%?$_B'X:6/AJ\N-$AM;FRBC:^>[!D2/)8
M?NQCD*(EQ[,3G/'K>AV5MIVB65E9^3Y$$*HI@4!"0,$@#CDY->,2>'?@BEH+
MPZMMA8!AB5R0&:4#Y=N?4=.D:9ZY;N_A=H3Z'IFH);ZA=W.BRW ;3([I?F6(
M+RV< X8GH0,;?>@# _:!TVZO?!=I>0(&CL+H2S?W@I&T$?B:[V'6X-9\"#65
MVPQ7>G^>59P=FZ/.TGU&<5N3017-O)!/&DD4BE'1U#*P/4$=Q7%1_"7PU#(Z
MQ-J*6)96&GB\?[.N.2 N>0QY.2>>F* ..^#>F7&F?"/6KVX-W9/<M-)%)O;Y
M8UB&)$7. <[N1@G:.>!C;^ Q\SX=NQE:7-_,=[=6^[R?K7H=YI-E?Z7)IMQ#
MFSD3RVB1C&-G]T;2"!QVJAH'@_0O"Y;^QK)K56!!03R,G)!/RLQ&>!SC- &T
M0%7_  KR"T+?\-.7X9K9@-+ 41( R_)'_K" "6SD@G)VE1T  ]@(R"*Y>7X=
M>&)M7GU9["4:A<$F2X2[F5VSVR'&!TXZ4 >?>.+A!\??",4YU Q)"2!',50,
M=X^3!&#D#?SRN 1V,?A]YO#G[1>KVU[$ NMQNUO(&PJCAQ]2=N,>I%>C:C\.
M_#&K745U?V$EQ/#CRG>[FS'@ 97Y^#\HY'I5KQ#X.T;Q/:10ZA;MYD'-O<Q2
M%9H&Q@,CCG(ZC.1D XH \X^.]G/JK>%M/LXWGNI+UBL49^?&!S[?6E^+T9M?
M$/P_AAEB41W<B!KP^:I \H?,7SN/N<G//7FO0- \$:5X>NFO('N[J\,2Q"XO
M)S,ZJ!@[2>F3DG'<GMQ1K'@+PWX@OQ?:I8/<W"D,C-<R@(< 94!L+]T= .E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"LS5M!TO6FMVU*S2Y^SMNC#YP#D'IT/*CKZ5IU5U*":YTRZ@MIO(GEA=(Y?[
MC$$!N/0\T 5](T+2]$25-,M$MEE.YU0G&?H3QU-:5<WX)\/77A7PQ!IE]J4F
MH3HS,TSDD#)Z+GG _J:Z/(H 6BDW#UI: "BDW"C(H ,C.*7K7CFN:EKVG?'S
MP]I;:Y>2Z==PF4P<)'@F;"E5X;&!R>>E>Q \4 +12;A1D4 +12!@1D49% "T
M4A=0P4D GH/6C(H 6BDW#UI: "BDW#UHR* &R1+*C(ZJRL,$,,@CN*S]*T+2
MM!@,&EV$%K%DL1&N,DG)YK2R*\X^('B&Z7Q?X9\+6=X]F-0N%DN9HY_*8Q!L
M%%8<ACVQUZ4 >C @#_&E!S7 Z/X3\1^'O&LDVGZL9_#=R6:6TNY7D>)S\S,"
MQSN9RQ_'FN^Z=: %JGJ>EV6LV36>H6Z7%NQ!:-\X..E6\BC</6@#'T[PIHFD
M7\U]IVG0VMS,S-(T>0&+').,XYJ]J&FVFJV,MC?0K/:S "2-LX89SVJUD4;A
M0!B6/A#0=,U-M1L=,@MKILEI(LC)(QR,XZ5N4@8&C<!WH -W.,&@L!UKF/"_
MA_5]&O\ 6+K5==GU%;RY+V\+L2EO'N)55![_ #8/T%:'_"06C>*E\/QN'NQ:
M/=R;6'[M0Z* 1UYW<?[IH V*0D XI PQS2;@ZAD((/((Z&@!VX#UH!S7C%\F
MMP?M":/I[ZO?W]BT1U!H';$<'RRQC"C@ <#/7+'UKV=: %HH)Q2;AZT +2!@
M:K7]_;Z;IUS?7+[+>WB:61L9PJC)JIX?U>+Q!X?LM6@1XXKN(2*KGD ],T :
MM%)D49% "TF1G%&15+58+FYL)$L[UK*8X*S*BN1[888YH O Y&:*\H^!-[?7
MV@Z[-J5\U]=#4RCW#2^9OVQHH(;N,#@^E>K;AZT +2$9%+D4FX4 )M/K1MYS
MFE) HS0 %@/6C<*\K@N6\??$7Q%HMY=W,>BZ?;_9OLT%V8C*Y(#,0A&Y2,CG
MI70?#W0?%>@V=[#XEUC^TB\Q,,CR,[J!P.2> 0 V.V: .UI"P!Q^?M06 !R<
M =:P-"\16_BW3;^?2WD@6*XEM$F903N4 ;P#QU/0^E %N30-'DU:75)--MWO
MI8Q&\SQAF91T'-:BC KR#X?W&J'XP>*K/4]6DU$VT.R)VD!"*9!QM'"G_9'2
MO7P1B@ (S6%>>#/#U_=3W-WI<$T\^/,=\DG#!ACGCE0>/2MW(HR* (;2TALK
M:.WMT"0Q*$102< =.M3T9IDLB0PO+(P2-%+,QZ #J: %WCUH# UY%9>)->^)
M_B/4]-T#4_[+\.6+!9+^V&)YB?N["?N\JW([?45T]QX-\06,4DFA>+[];ILJ
M%U)OM,6"0>C9P0 >1ZT =MO%.KC/AAJ&K:CX$LY-<:1M2B>6WF\T8?,;LF&_
MVN.?>NQWKN"Y&3T'K0 ZBC-)D4 +129%&X4 +129HS0 M%)D8SFC<* %I"P%
M&16'XI\36?A31CJ%YO<&18D1.KLQP![?6@#<W4;A5:_@FN-/N8()O)FDB9(Y
M1P48@@'CT-8G@?PY=^%O#,6F7VIR:C<!VD:5R< L<X7/.._U)H Z4<T4@(HR
M!0 M%&: <T !&163J_AG1M?-L=6TZ"[^S,7A\T9V$XR1^0_*M:DR* (XX(X(
MUCB18XUZ*@P!] *DW4=1BO'/B+-K%E\2?!T/]N2/I]WJ<.ZQ#*@&)4(RHY8#
M'4YP: /4=8\/Z7K]NL&JV:742DD(Y('/7H>:9HOAG2/#L;QZ18QVB/C<L9..
M,XX)XZFM7(HW"@!0,"DSBC<,XKQGXXC5K.71;RRU^YM4GNTA6#S1%%&5^8.6
M'<$ Y/2@#V;<* <UQ7Q2;4(/ .J7=AJ4MDT%NS.(T4F0<#&3RO?D4_X3W-Q=
M_##0YKJ6228PL"TA); D8+U]  !["@#LB<"@L!0QP.N*\7^-JZO;7&CR6VOW
M-O:ZA/\ 99+3S1% %QDECWS[T >T YI:;G!.:7- "T4F1ZT;A0 M(6 ZT;A2
M'F@!=PI0<CIBO%I[[7+7X[Z=HTNOW]_:21B62W#_ &=%PN1D#"L.Y Z]*]G!
M '/% "D9[U@:EX(\,ZNSM?Z+9SEV5F+1XR0" >/]X_G6_D4$@4 5-/TNRTJ.
M2.QM8;=))&D=8UV@L3DFKE)N&<49'K0 M%)D4@=3G# X..* '44F1FC(H "P
M'6D+8['\J#S7BEU>:E9?'W2=/O?$]Q/!Y9=8Y(@B*S(0$"@;<MG&1SSZT >V
MYI"<4+TH;ZT  8$XI:P]&\36>M:UK.G6@<MI<D<4SGH78$X'TQU]ZV]P]: %
MHI%96&5((SCBC- !N%(6 JKJ%K<W5F\5K>-9S,1B98U<KSSPW'3BO,/@7=:K
M>:5KSZU<7$U^FH>7*UPQ9P511@D^F,4 >MT4FX49% "T4F1G%&: %HI,C%(S
MJBEF( '4GM0 ZBD!S2T %%)N!HR* %HI,BD+JI + 9.!F@#-U30=+UF:WDU&
MRCN6MV#1"3) .0<XZ'D \^E)H_A_2O#\$D.DV45I%(V]TCS@MZ]:TF*@$G@
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MR@=^..A [<+XK\(ZIX.^'G@_6PB?:_#L_F7L-NX4,)7!)+\'/RHAP#][T'(
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M, 9SZCFG_%PW_A;Q?H7C#2D9II$:QFCC0*&S]W<_.,Y &1_#UH Z;P^C:_\
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M*XR%&%7IT4 >@%:&B75W\0O'6MO/>7</A[1C]B@MK:XDMFEF)^=V:-PQQMP
M>,$8 .<X?PIU72A\3?'"FXA$]WJ$C6\AN5VSH97*A%_B/?()R"..YS=*\16_
MPD^)?B:WUJTO9-.U>X22&]2': 02YP"<,H\X@D$D;1P<\ '=^#-+\7:%XVU7
M3+^\O+WPV(C+9374@E;>67@N?GR!NXSBN6L?&B^+=0U/4-6G\0)H]M(_V&#3
M,PHR#Y09&C(D,A;HI;;GMBNW\-^-7\9>(6;0HY?[ M$<7%W/;[1<2\;%B.X$
M 98G*]L<9S7F7@[Q99?"7Q1K7AKQ#9S6T5Q="6*>*03JBGH6X4E<<Y S_LB@
M#IOA3J?BU/$>I:+J\6J7&CQ>8UE<ZAM\R-5E=?G;&69B#WXV\<8KU^N-\+^,
M;CQEJC7.D6#Q^'8!)&U[=#8US+NP#$O]P <DX.3C (-=E0!P?Q7\9S^"O!KW
M=B0NH7+B"V<QA@C'DL0>.%!(R",XR*H:W\/M3/A>2XM_%6MMK\2/.URM\\<4
M\AYP8AE%0'H% X]:3XV>%K[Q+X&+:?&\UQ83"Y6"-,M*,%6 Y'(!)XR3C '-
M7='^(V@ZCX#M]4O]8T];Q[/-Q 'PPEVX91'G<?FR.,^V: ,CP;KLGQ5^&=S'
MJ;S0W]M(8I6LYVC:8JH(8JI7A@Q!7."0<8XQS/P6\-_VC'JDKWVL62V-^HB@
M@OF2 D.&(,63SA-IW%@0Y[C(Z3X::,_@_P"'5_<Z_'9:7/J=Q)/'&T@0QJR
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M*QH$CW#D [>O7)KMM-^(\?BW6+?3_"%K)=QI)')?7TZ&."&'.749^9I",@#
M&3G. :Y!==T=_P!HX7B:U#):_82AD>9/)1B@^5'W$'/X<Y^M #9;?5O GQA\
M.:;'XEU>\TG4(3YO]I78E!;+Y7!X'1,' /)&>U0_%[0[./XA^$+EKZ_,E_?Q
MHUJTSF-%$B!GC;=F,\J,+]1@CEOQ(U?2/^%S>%KDZGI(CME\NXE*M,T1#OQ(
M =H&3P,Y!R3QBM3XTRK:ZOX(UF6*'^S+;4D:6]^\4&Y6  !Y!56;@'[HY[$
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M4>,?PH>5'M6D>G-8?@_5;;6_"NG7]I)=R0R0+M:[CV2'CJV  3[C@]JW#TH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&,G!9A^K,?QJTUA9N[,]K SL<EC&"3^E)-J%I;W,%M-<Q)/</LAC+?,[;2V
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M,.0(A@_I3H[.V@;?%;11OTW)& ?TJU10!ES:#I-S?B_GT^VDNP5;S7C!.5#
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MNGW\C)9W]M<.HR5AF5R!ZD U%+KVDPS/%+JUC'(C%61KE 5(]037CGQ<T]/
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M;8S.[!GB+Y,0Q_>R?3/<UW6EZ5IWA[31:6$"V]K&-QW.6Z #+,Q).  .3P%
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M7MG#"65E#JK$(N2S$-D #.0, YQ0!W%U\2=.C\?V/ARWN[%K=X'EN;HS#$9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWB#Q1;ZK9F(JL$=BD)#Y!#;EYX&[CWKK1UZT .I#TI:#R* .%^*LMU-X&O\
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MXIX4&H?"+Q%JVE:CI^HW&@7TRS65S;1M+%" KE@0.=VU0#WPF>E>X$9I-HH
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MU%;EX,>9&8VC< ]]K ''OTH WY&55+,0% R2>@%<]9^./#.H:\=#L=6CN=1
MSY4",X QG.\#;CD<Y]NM2ZIXNT/3M173)KII[]@2;.TA>YF48!RT<89E&".2
M,'->2^%;ZQU;]H:\NM&!-I]A8,MM";<QE2JL)DD"DD'L!_=]#0!ZW)XOT>'Q
M?#X7>=AJDT+3(FP[< 9QGUP&/_ 3[9W<\UQ5MXC\#77C];>SN[.Y\230F(2P
M*9/D4%BN\94$!3D9S5^Y\?\ A>S\00:'+J\#:E-)Y:P19D*OG&URN0ASV;%
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M<J<#&3CBLB3XL^"HM%AU9]95;2:9H(R89 [,H!;";=V ".<8Y SDT =H3@T
MY&:YN#QUX?N_"LGB6WN9IM)CW!YDMI"5VG!)7;NP.YQ@=:Y3X>_%&V\4ZCJ
MN([V(W5\4L(/L\DBK&L:9RZJ54_Q$$\;O3% 'J%%<W?>.] L-<?17N+BXU*.
M,2O;6=I+<LBGNPC5L=N#ZCU%6_#_ (KT;Q1;S3Z1>"<02>7*C(R/&WHR, P_
M$=C0!LT5A:AXOTC3=3.F2/=3WRQB1X+.SEN7C4]"PC5MN>V<9K+M/BIX-N[]
M[%=96&Z286[0W43P,LA)&TAP.A!!]#C/44 =C16#K7C'1=!O%M+VXE:Y,#7+
M0VUO).\<2X!D<1J2JY/4X'7TI/#/C30?&$5Q+H=Z;E+=@LI,+Q[2>GW@,]*
M-^BFM(B@EF"@#))/2N4B^)O@Z?4+RRAUVVDDM(3/-(F6B"#'(D VG[P& >O'
M6@#K:*X[1?BIX+U^]>TL-;B,R1-,1,C0C:HRQ!< ' R3[ GH#3=)^*W@K6]7
MBTNQUI'NYFV1J\3H';T#, "3VYY[4 =G16-XA\5:-X6M8KC6+P6Z32>7$H5G
M>1O154%C^ K/TSX@:)J7B!M#8W=EJ)&^""_M9+=ITP/F0.!GG<,=?D8XP,T
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MW;=5_P !>$?%7A3Q-XBU&ZL+&2+69S, EZ<PX:1@/N?-DN!V]: ,KP^HT_\
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M12R>8DDDG,DX(8%C@X4L!G Z=*G^'.G^+;30-.MO$/V2T@L[9(8+6V4EW4(
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M1/%^B:?!8:_-IZ65G;"WMX;0%F<YSO=CW R,# YKMKB$SVLT.=OF(5SZ9&*
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M'QZ\)VMW:>>LUKB:.50T3KF7 QW.<D_A6MH>C>/O%DL%OXVG2STF"*,S6UJ
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M '<;<CFO$K?3-)U#]I;5K>ZLUF06*R%;A%*>:%BP4'L,>^<U[?7DS>$/%_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD*#@<=3P.YH TZ*Y?P'XP3QOH,FKPVK6T/VAXHT<Y;:N.3COS744 !Z5Q'Q
M\!S^+_[-OM/U673=6TMGDM9E&5)8#ANXY5>>>,\'-=O10!YE;>&OBE]L\BX\
M6Z8ECM*_:4MV>?[A ;80%SD@_>QD ^Q[G0]$M/#^DPZ;9"4PQ9.^5R[NQ.69
MB>I)))]S6I10 4444 %%%% !1110 4444 %%%% !1FBHII!%$\C!B$!;Y5+$
M_0#K]* ):*X7P]\1;?Q'XYO?#EKI]U"+*V>:66ZC,3$AD  0\@8<]0#P*[D<
MC- "T5QVN^.X-%\?:)X7>SDD?4T+><",)DD+^JG/X5UZG.: '4453U348]*L
M)+N6&YF1.J6T#2N?^ J": +E%<7\/OB#9^/;:_GM(?LXMIPBPR.#*4**=[ =
M 6W ?[M=I0 4444 %%<CJ7C/[%\1-,\)IIUQ<-=VK74D\8RL2[BJD^V5.3ZE
M:ZZ@ HHHH **** "BBB@ HHHH ,CUHJ">7R())2I(12Q ZG S7.> O%Y\;>'
M3K']G3V49GDBC$HXD13PRGN.<'_:5AVH ZJL[6QJITJX&BK:'4&7$1NW98U)
M[G:"3CT[^HK0'2EH \Z^&W@O7O!']I6-[-97UG=73W O%G?SVX &Y"F,G&2=
MYY/>O1%X%+10 4444 %%%% !1110 4444 %%%% !2$9I:* /(8OAGXQ\*_:$
M\%^*H5M;B1V-IJ$9"Q!AP590V6'T4=ZZ?0_"6NW%S;W_ (QU>*_N(-YCL[1&
M2W1F=FR2>9,#:!D#&.YY/;T4 ,4$#!I]%% !16'XH\26GA31)-4O5D>-65%C
MC&6=V. OH,^IXKEX?BE!:^,SX:\0Z5<:-<2E3:RSNICD4@8^8$C);>,CCC&<
M\4 >B44@Z4UNM #Z1JX7QO\ $FU\'7%M9OIU[<75S((XW,+)#D[?XR,-UYVY
MQ7=+TH \X\7^#O&?B#Q:)],\3)I>B/9FWD5,M*-V=V$P!R0O.X$#./0]MH.B
MVOA[1;32K-2(+:,(I;&YL=R0!DGO6E10 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5PO
MQC_Y)5K@_P"F<?\ Z-2NZKBOBU*L'POUUW@CG7R5&R3=MYD4 _*0>,Y^H&<C
MB@#A=$^+%MX:^'FB/!X9U":T2(PR21Y6*-UYP&;);C)S7H^A>.-%U[PNVNQW
M44=M%$)+I=^XVYVY*O[BJOPWM0WPMT2TNX,J]GLDAE3@J<Y!4]00>AKPFQ2>
MV^%OC,:7,QTY=5C4"!F:0ID9)D&T%=OJ@]?:@#V&^^)FHV7A^?7V\'7_ /94
M3X66294=XS@K)L(R%((KM-#UFTU_1[75+)UDAG0."K!MIQR,^HZ5PFB^ =)\
M3>$=.N+O7?$%]:75JCB&?4MX4'<S(Q15WX9^2V3\@' &*Z7P1HN@^']+NM/\
M/3M+:Q7;"4-)OV2[$#+G'H 3[D_0 '4UR>K>-([+Q1!X;T^R;4-5DB:9X_-$
M2QH!GEB#R?2NLKRGQIX8U;5_&,FN>#->@MM?L+=;>>UE&_ 8;LC=D+E2. N"
M>^<T =+HWC.ZO[G5[6_\.7]C<:>D<GE#$K3H[.H9 ,9&8VKF+7XXZ?>PZD(-
M$O7OK23;'9*P:250&+OT^4*J$G/L.])\-/'LNO\ B6[T?7=(>T\36]FL5S<
MD+,L3M@%.B$&7/&0VXG@ "J7P/MK>/5O&#-9/'J$=Z%DDDQG8S.0JC *CC)Y
M.>.F.0#I_ 7Q0T_QU>7=FEE/87=LN\Q3,&W+TS]<]JN2^.9[G7+S3=!T.XU5
M+$M'<W22K'%'*O6+)'+#(_&N!U+3F7]I&&32A(L@MA+=B)%C504Y);#;MPZ\
M*2>,CK5/X2:3!XD\.:A;WFMZSI^K">2&=8+Q(Y&YWL^TIG<2VTLVYOEX*CB@
M#T[P1X\M/&MM?;+9K*]LIS#-9RR!I$Q_$0.V=P_X":JKX]NK^ZOUT#P[=:K9
MV:ONO$E")(Z_>C3(^9OYUDKX'\->#Y]4ET:YNQK]QI-VRH\Y>21-L8+],Y#J
M"#U)=NH "Q? :_L[CP)):PM+]KM[IS=I*^Y@[=_NC .#QR>#S0!O>&_B-8>)
M/"LFM6UG<&2%RDUC#B66,@\$@=L<T_P/X]C\<>'+W5[739H3;3/"(&<,TA5%
M;@@=]P%6]/LO#6EW.K6&C6=K;7JQM)=+# 5(W@L,MC&.<A<\>@KB/V>5A7P#
M=M%,[.VH.95:/:$;8@ !R<C !SQUQVR0#FY/$NN/\>8[V?0[N*[33FCBT^"X
M ,R!2^)#C!'WN./F5:[SQA\1K?P7#9:EJ/ANZ-Y,HB+#;A PW%!+CGIR*Y]8
MY(?VFE,,;(LNGEI/.&W<,'E/*P&&0/\ 69Z-W"8=^T,T"^&]$:Z222W&H@R)
M&X1F78V0&((!QWP?H: /3_$&O67AO1Y=2U!RL*$*%'5V/11[FN-U7XG7^@V.
MGW^L^$KNQL[R;R3))<*3"<X^<8XXR?H*Q?CQ(RV?ASSC=?83?'[1]GDV<<;<
MDAE!!Z9!KH+[X:^&O$%JUQ>ZOJNH6KN9BSZD7B) 4%@!\HY5^F /,<<#:% .
MC\0^*=/\/^%IM?D8W%LBJT8A.3,6("A?J2/YUYS\3_%.L3_#2=KSP]?Z;;WJ
M*OFQW:[H\]%D7'"GH1WSBN?\?RZ3H5[\-XM,OW;0+6[,P=G++M29"6( YVY8
M XSCZUZ%\8VAD^%FIL_V9D(0KYY<#[PP5V_Q>F>,XSQ0!L_#5I'^&_A\R-,Q
M^PQ >;&$( 48  _AQC![C![UU5<G\,<?\*UT  */]#C^[<&8$XY.X]#_ +/1
M?NC@5U3'&* /%/C'=6EA\1_ M]?2O';VLK7#F.,NQV2(P4 =R1C\:T+CX[Z?
M9ZQ#:7F@:C;VDS+LN9,+NC;D/L(SR"#C-,^*(2;XG?#ZW=;>-OMRRBXE+!OE
MD0[!CCYCCJ.N.0,UL?&VTLKCX:WLEVJ%X75X7+!2KYX .UNO3'&?44 3>,?B
M7)X/U>VM)M!N+FUO"HMKQ+A1&Y. 03CC!/Y8-=7K&KR:1X:N=7^RB4VT'G-"
M)0N0!E@&/'3/U_&N"D\+W7BGX":?I<L8GU#[!%+:^9+P& RG*JH^X< $''0E
MC\QYC2==N?''A/PYX)OGDCNVU!K?4@%5P]M;+O(?;@IEC&@(_NGD]" >P^&-
M:D\1:!:ZM)9/9"Y7>D3ON.WL3CI]*VJBB188TB081 %49Z 5+0!XU\;)(XO$
M_@)Y85F3[=+\C,0#\T('(P>#S7<>*O&T7AS5M)TB&PEU#4M2D*0P1R!,*!RQ
M)X ''Z^E<9\8V=/%W@)DF@A;[;-\\Z!D',78@_0<=<=.M:WC.]T4^/=%L++1
M;+4?&+1R/9R73M'%;@1LP:3 ._[IP,=<D%3S0!IV'Q $OC?_ (175-+DT^_>
M'S8F\X2(_&<9 '.*K:Q\1;C1_&EEX8FT!VN;]LVTBW:[70L0&/''W2<5PE_9
MZE;?'K0/[8U#[==R?O,HFR&,=EC1D?:!Z[B3UW(>1U'QKT=FT&R\36<4OV_1
M[A9#)"P0^5GYLMUP.V#_ !&@#1\7?$N;PEXBL](N/#UQ,+YE2TN%N%5)22%(
MZ<$%AGZ@]ZV_%7B:]\-:?!=IHSWZR.D1CCN%5_,=E544$?,26[5Y5X^OKGXH
MZ(NH>'&06VA6JWTTB#+M<.1^Z1RH*^6J,S$'G*\=".B\*ZX/B/K?AV[A+?8M
M$MS<7D4L:R*;IE*1C<<'< 6;.,9 [\T >I6<DTUK%)<0^1,R O%NW;#Z9'6K
M%,SCK2C)/M0!%>SO;6%Q<10//)%$SK"GWI" 2%'N>E>(:/XY\07/Q<UV0^'[
MF[DMK)H!8PW'^H52&/)XW,0!QC)Q7NU>/^"F9OCUXQW302XM\#R4"[1O7AN!
MEAW//U- $'Q0O8M/^+/@NZNIK:.UB8.Y('FCYCU/7;Z#.,YK?/Q4:T\26.E:
MOX:O]*@OYFBM[N[<*K8Z'&,\Y7C_ &A6'\2K9+CXP>"$FLK:2%I K2/\S-\Y
M^0J3C;WSCJ>O:D^/"!9?"5T%820Z@=LQ8%(\F,\QCYGZ#H1C!]1@ ]*\3>([
M7PSI(O+A6EEED6"VMX_OW$S<)&ON3^F3VKF=:^);^%;FS'B70+FQM+K(6YCF
M690P&=I  YKE/C"[S^(_ Z7,SBPGG*32HSPI&[E%$HY^5U#,RY)QCG(R#TFM
M_"7PSJEA(=3U366MX\R!YM1+K%SG(WY XXR>WOS0!Z-&RN@96#*1D$'.12M5
M'0UL%T'3UTH@Z:+:,6F"2/)VC9C//W<=>:O-VH X9_'=_J/B'4='\.:&;Y].
M>-;FYEG$<0)8;D'JVW..V?I3O"OQ#A\7>%M0U;3=+N7N;)F1K+<"SL!D!6Z<
MBN<\,7X\0:MXBC\ P6>A09VWUY=6[2R/<'(4QQB0(H W'/()QE:S?@:SG6_%
M(9#&?M!)CW*<'/\ L%4_[YC ]#CB@#*\.>(]<7XU>)[M]$NI+YT5'T^WN $V
MH%168D$,=NTCZM72?&N[U"#P;?10Z)"D5Y!";R_:1<@)(,1<#+,&;([8WFJ?
M@W]W^T%XLCD_T>5HP5MX_P!RDBX4[S&-P8X(.[<.6)Q\V%W?CM&)/AC<MNC&
MRXB;YF4'KCY=RDD\]%*G&3G *D L>$=:NKWP1!#J?A_4+G3Q91KYDQ6XDNU?
M@@ICD8SG/05-X4^)UMXI\-WVM0Z1?(EI-Y1@BQ*[?*&SQCCFMWP0R2>"-&,<
M[SI]E3$KRF5FXZEBJY_(5YO\ WN#\.]5#A4C2X?R7:( $;!DDX^;G/7.,8]J
M +4/QWM)]#_M*W\.WL^VX,$T4<H)B^52C'CHWS@?[AK2G^,FF6GB.UTJ]TF_
MM%GM?M)EF7:5&QF "=6SMVCU)%4/V?HHSX3UJY;[/)</K$JO<0QA1( D9&,
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M%:1WC(8A%@\2R!0I! 4  \8],8Q0!G>"O$>N+\6?%ER=$NI[Z8*);""X"Q(
MZ(';(.Y@""#V!<U[S;00P(WEP1PM*QDD5 !ESU)QU/O7CWPQ_>?&/QI(,1C
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MA>YGTB1CMECN5+!=Q7<RXRHR/U%<7\(TTY_!OC!+R:VM+*2Z:-IK:[EV(I
M*H3N"9(PQ.6'!Z5!>R>,OA1IL5O?O!XB\%20O:^5$!%A7&<EE!9<DD Y88ST
M)& #WVVF%Q;0S8*B1 X'ID9J>LGPYJMKK?AW3]2LHWCMKB!7C1_O*N. :UJ
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M)/J<MC=721(S%8%R!@9RQ_A'O6]7-_$"WDNOA]K]O" 99+&55!8+D[3W/ H
MX7_A?%C+HD>HVOAS4I\,1<*O"P\D+\^,-G!Z=,5V_@CQG9>.= _M2RCDA*R&
M*6&0@LC  _B,$'/^%8?P559/A!HZ.H96^T @\@CSY.*\^^',$UMJ/Q,&D2S?
M98H)5C$8$9$O[S9M0 G(PX!##_=.1M /28_'5_K6HW%MX7T0ZC;VT@62^DG$
M<+88!U7N6QG!J?PQ\0+?Q1;7\-O8O!K5BS)+ID\H5PP..N,?CVKF?V?Y[1_
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M"X!W!<$@X;'!(KIY/A?HNN:,B7^OZ]J-O)$NQY;\,-H7"G"J%)'WLD$D]<T
M=SI>I6^KZ7::C9L6M[J)98R1C*L,C/H>>:NU@>#K'1=,\,6=AX?E\[3;<O%'
M)OW[F5V#G/<E]QXX].,5OT %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR1^Y/SYP?3-6O%_@75/&>@1:1J'B&%(@XDE>+3\%W!)!'[S@8(&.>F>]=V%
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M&"FU<D[02-XSS@!>I)QZ+M%&T4 4],TZUT?3;;3K*(16UN@CC0=@*NTFT4M
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M\XKN=HHV@9]Z .5M_!D4W@4^%M;NAJ5LT?E>:L0A.T$%3@$C<" 0?4#BO/\
M3O@OX@TN>6UM/&L\6F3+Y3H$;<8\?= S@<\<'IS[5[5CBC H K:?8VNF6,%E
M90)!;0($CC08"@5:I, 4M !1110 4444 %%%% !1110 4444 %%%% !1110
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MW6RBOV$2(0DA?S&3EB2%X0?PCH,UZ1XI\<?\(W;:9 FFM=ZWJ6%M=.$ZQAF
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M.<9STSC.1TS6!_PL#Q.?"-QXF'@N)+&*-IA%+JA2=HAR7V^3@<9."V>#UXR
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M-M!.U>2<>GO7 ^&/B5/XD\?7?AJ319-.-G;232_:'S(2'C"<#@ JY)Z]JT_
M/CJW\<:5/<?8GL+VUF:"YLY) S1L.AZ X(]5'(([9KC/!^__ (:'\8_Z(&0V
MJYN2K90_NL)G.T;N3R,_)QCF@#>\1?$VXT7QMIGAH:',OV^[A@CO)VPCJTBJ
MY51R< \'/7M7HE>/_$C[1_PN'P#]G\O?YIW^9MQL\Q=WWN,XSC'.>G.*]@H
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MB4MYHCQ$OS;E!W@=<@'-:>E?"&XL3)92^);XZ%^]$>EJY,(#.Y"D'@@!D/\
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M\%T_F3PRQ)AVP0.0,CKGBIO'GPXTKQY;1?:RUO>P<1740&X#^Z?49H S=2\
M>!-#GM]7U.,H\=Q&L+SS%MTA=RB =3R_0=D7T)K!\3>#[S5O$^L:]X!\01V>
MN0@6U_:+\A8XW<D]V(3!.%XZ\5O>#_AG<Z)=:??:YKUUK%S8PO%!#,=T,&<
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M9%)8^#KF76X-7\0ZJVJW-F6^QH8ECCARQP^U1@OC )_*@#C=*5A^TSJY9;<
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MKVWBO.].^%%OI?BV74[75+J/3))_M9TR,[(O.#90X'!"^AH Q;>(I^TW<O\
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M2NP'!'RX\Q>_(<8X%>RA2 *\U\7?!S3O$6N?V[8W]SINJM,LDDL;9#8*\^Q
M4XQWQF@#L0VF67B;R+>S4:C>Q&6>5% Q&O 9B>OS$# R>?3FO*_V>YTBM?$&
MF7BR)J\=WYD\<L;"11@+\Q(Z[@>#S7H?@_P:?#D<EU?W\^IZQ.NR:_N'+.4!
MX0$\A1Z5G:I\/;F'Q'<>(O"FJ_V1J-U@72&,/#-SRQ7^]_7F@#C/&L+G]I#P
MJ+5U@E>S1C)Y>[/S3YR.,\#&?I5[PQ'N_:+\2M)#:@KIY9#"RL?OQ#+8)PW)
M'.#C'K7=>'_"3:?JESK6K7AU/6I\Q"[= OE0 _+&BCA1W..K$^U9>F_#=M+\
M;7GBFWU^Z^V7IQ<(8(]KIN4E>G'W0,CF@"M\;8&N?A9J01HU*O$Y\R15! <$
M@$GD^@')[5K^'(X9?A-I"3@&(Z)#N& W'D+V[UC_ !NCC?X6ZD)IA$H>(@[2
MVY@X(''J>,U4\+^%O$%]\/-$L(O%$T&F76FQR2,(P;A Z*1&C=D4' [XXZ4
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M6\[_ +N)W!#,%'!)!(YIEO\ #2>W\9R>*QXENVU25!'(YMHMK* %QMQ@<**
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M=NM=#X/^&,?A@RP7.K7>IZ?&W^A6EPW[J$$98[.FXLS\^A]S6%)\$?L'B?\
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M!P,^E 'DOQKA-QK?@FWAM)9[I]09D,>254&,L-H'/KGM@UTGQD^S#X5ZT]Q
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MO4+N\@,)$CM\L.U<.8U]6(4Y//&>IKTG3+#^SM,M[,W$]R85VF:X<N[GU)-
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M- "Y'K2UR7@4^+I=/O9/%T=O%.]RQMXXB"R1^AP2,>G)..M=8.E "T49HS0
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M>F2%]30![+D>M&1ZU5L$O!91_P!H-";HY9_(!V+DY"@GDX&!NP,XS@9P//\
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M=V0OMY) VG'IFM[QMXSN-!U#2]$TFW@N];U1RL,4DH41K_?;OC.<=CM-<?\
M$26*/XV^!6D@68'"J"Q&UC)PW'IU]*K_ !4:;0OBOX0\32P>99(%M_E;!W!V
MSGTXD!_.@#:\6Z[XX\"6]GK=W=VFKZ2CQQWL,-KLD0L&RP(X"@[0">I('>K?
MCGQQJEE\.8_%7AEK4VDB1N)+E6W@,ZJ,+C!ZG.2*O_%IK<_"[6A.9'CDCC""
M(C<S&1=N,]><9]LUR.L64^A_LU&WGN+NQG^RQ^8'9F;+. 8^O"L#MQT 8\4
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MNH[F^"?OI8H]B,WL/0=/?%:%-!Y&.AIU !1110 4444 %%%% !1110 4444
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M"\'Y^1\BX!X&#C&36CH7AS3/#=J;72H988#C$37$DH7'90[':.>@Q6KFC/\
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MH[5+X>\2^ _"MX]UHG@WQ19S2IL<K;2L&'NK2$'\N*]IW4#GITH \3\4>(_
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M$_%]I#.")(X4N%!SCG'F\'Y1\PYP,5$^K_#]]034'\)>,6OD&U+D_:3(HY&
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MC>S@H<Y^3#X7GL,"MC6-$TW7]+DT[5K2.ZM9,;XWR.1W!!R#[@YK2P/2DP*
M.,T?X::+I-XMQ+=:GJ0AE66UAU"[:6*U8!@-B<#@-@%MQ&!C%;&O^%-&\40K
M#K%M+<P*,>4+F6-#R#RJL W(')Z5MX%-YSS0!S)\ ^'&T<:0;6Z.GCCR#J%Q
MMQC&W[_W< ?+TJ'_ (5IX2.BG1SIDC:>9%D%L]Y.R(R[L%07^7[S=,9SSFNO
MP*,"@#D-,^'>AZ;=V]P[ZA?-;%7MDOKQYDA8;@&5"=N<-C)'&T8P<D]<O2C
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M:%J0V1O=SM)M!. 3G."#Z8R* -?Q#<ZU'\=/#FERZV\M@Z?:Q;.5B0?-( H
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M]IO;RV&IP6CI>0S2@,SJN"Y'R\-PW' W8SQ4,^M_$>Z4+<?#>PE"G($FIPL
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M?#75WCU6UD$T1BB\J4.7;*@A0KJ3C<,\\ Y((X.8VH>/W=G?X7Z4S,26+:A
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MG#QF1 2I!R"*XOQI\3$\)>)[308M%O=2NKJT:>-+5=S%BQ"J!U/W&SZ#'7G
M!P?POTC6IO$L?AO45;^S_"UW-<R>;MD665UV0J!D[, NXP2,^AP:]\7IS7)>
M!-(U"UTVYU75PT6J:M+]JN+; "P'& HQWP!D_H*ZT# H Q/&&C/XA\):II,<
MAB>ZMVC5PN[![<9'IZUY_P#!SQ-;Z;X2F\.Z_=6NFZAI-R\/V>X<1-Y;?,"2
MQPWS%^G8#UR?6R,UDZEX6T/6+J*YU#2[:XGB#!)'3) 8;6^N0 * /-? FDFX
M^*'BCQNP@_L20.EK=2_+N/R[G7(X4!6!;CKW&:J_ "^T\VVOV\$BPF6^WP6\
MDZM(4"_0;L>H KV2*SMX;-;2.&-;=4V"(+\H7IC'I3(--LK:42PV=O'(. R1
M*I_,"@"SC!I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ***,XH *@O+RVT^UDNKN=(((QE
MY)#@*/<U7.N:0K%6U2R!'!!N$X_6LSQIX?TKQ1X;DTW6+QK6R>1':1)%0Y!R
M!E@1S0!T"NK %2"#T(IU4+1+'2]*MHK=XX=/MH%2)C)E5C  7YB>1C')-2G4
M[ +"QOK8"?B(^:O[SG'R\\\GM0!:HJ"YO;6S0/=7,,"L<!I7"@G\:;'J-C-!
M)/%>V[PQ_?D652J_4YP* )\>M*!Q5:#4K&Z61K>]MYEC&7,<JL%'O@\=#1;:
ME87DACM;VWG<#)6*56('KP: +5%5AJ-B6F47EON@!,H\T9C'JW/'XTEOJ5C=
MAS;7MO,$&7\N56VCU.#Q0!:HJE#J^F7$JQ0:C:2R-]U$F5B?H :FN;VULT#W
M5S# A. TKA03Z9- $U&0:IIJNFSI(T6H6LBQC<Y292%'J>>!7+:%\0[#6_&>
MMZ1'<6:V>G+"D=P90#/*V[>!GL" O'<'GD4 =M156XU/3[27R[F^MH9,9VR2
MJIQZX)J6"YM[J+S;>>.:/.-\;AAGZB@"6BJO]I6),P^VV^8/]:/-7]W_ +W/
M'XTMMJ%E>[OLMW!/LQN\J0-C/3.* +-%4]0U;3M)@:?4+V"VC5&<F5P/E49)
M ZG'M4EI?V=_&9+.ZAN$&,F)PV/RH L451U'6M,TB,OJ%_;VP W?O) #C.,X
MZ]:L6]Y;7D9DMKB*= <%HW##/ID4 2G@9I&954LS *.I/:E8\5X[XZ\76-]\
M2?#?AT:K#_9GF![T1G>DA)P(I>=I0CKG.* /7XYXI21'*CD==K T_%>?Z'\/
M-(T3Q:_B;P[JLMG8W(=KFS@=&MI.G3@X .\]>,X7:.*[6#5]-N9EA@U"TEE;
M[J),K$_0 T 6MIZ]Z=44]Q!:Q&6XFCAC'5Y&"@?B:A75=.:9(5O[4RN 403+
MN;(R,#/.10!;HI,BJMQJFGVDOE7-];0R8SMDE53CZ$T 6Z*B@NK>ZB$MO/'-
M&3@/&P8?F*B&I6!\[%[;_N/];^]7]WV^;GC\: +5%58-2L;I)'M[VWE6,9D,
M<JL$'O@\=#^51QZUI4LBQQZG9N[$*JK.I))Z #- %ZBJUQJ-E:.J7-Y;PNW*
MK+(%)^F35C(- "T5!/>VMM)''/<PQ/(<1K(X4N?8'KU%-M]0LKN1H[:\MYG4
M998Y0Q'U - %FBJ,FM:5%(T<FI6:2*2K*TZ@@CL1FK+W5O';?:7GB6#:&\UG
M 7!Z'/3% $M%9UEK^D:C.\%GJ5K/*CF,HDH+;@,D =^/2KD]S!;0F:XFCBB'
M!>1@H'XF@"6BJEOJFGW<OE6U];328SLCE5CCZ U+<W=M9QB2ZN(H$)VAI7"C
M/IDT 3457MKZTO0QM;J&<+]XQ2!L?7%+]NM/M)MOM4/V@#)B\P;\>N.M $]%
M5+?5-/NY/+MKZVF?&=L<JL<?0&K>10 454N-5TZTE\JYO[6&0#.R295./H32
M2ZMIL 0RZA:QB1=R%YE&X>HYY% %RH+N\MK"VDN;N>."&-2[R2-@* ,D_D*:
MFHV,EL]RE[;M;H</*LJE5/N<X'4?G7C?Q^M=/O?!]MJ]M?+(Z7J1X%V[1N-K
M\*@)3=SG. < \]J /;%974,I!4C(([TM9L.J:?:VT$-Q?VL,@B7Y))E5NGH3
M5^6:*")I99$CC499W. ![DT /HK.M]?T>[OVL;?4[26Z55<Q)*"<-NQCU^ZW
M3TK ^(?CNT\$^&KF]#V\VHX"6UJ[X+NW ) YP.6/3(&,B@#L <T54LK^VO8?
M-M[B"90/G:)PP!]#@U&NMZ2[!5U2R8DX %PIR?SH OT5'-<0VT32SRQQ1K]Y
MW8*!^)JO!JVFW4PAM]0M9I6Y"1S*Q/X T 7**9+-%!$TLLB1QJ,L[G  ]S5>
MWU33[N3R[:^MII,9VQRJQQZX!H MT52FUC3+>5HIM1M(Y%.&1YE!'U!-3/?6
MD=J+I[J%;<@$2M( ASTYZ4 3T576^M'M3=+=0FW )\X2#9QQUZ5%#J^F7$RQ
M0:C:2R-]U$F5B?H : +M%037MK;RQQ3W,,4DIQ&CN 7/3 !Z]:;;:A97CLEK
M>6\[*,L(I Q'UP: +-%%13W$%O"TL\L<42_>>1@JCZDT 2;A4#W]I'=Q6CW$
M8N)<E(BPW-@9.![5ROAKQ]I?B76=6MK6[MS;VDT<,#EMK3,0=V 3\PSC&!7!
M:7I]EI7[2<D%K/<.!IY,@N9'D9#Y:\;W9F;C!YZ=.U 'MI!)IU5+;5-/O)/+
MMKZVGD SMBE5CCUP#4MS>6UG&)+JXB@0G :5PH)],F@":BH+:]M+Q6:UN89U
M4X8Q2!@/KBG-=6Z3"%YXEE*EPA<!MH[X]/>@"6BJMMJ=A>2&.UOK:=P-Q6*5
M6./7 -6LB@ I">*#TKB_'GCVT\'VULL<EM-J%S<) L#R<H"1N=@.< $=QU%
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MH>@0S6DLM]*_VF1I>+=%!QGL"6!')XP>.174-K6E1A-^I6:[EW+NG49'J.:
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M#=0K-;S1RQ-T>-@P/;J*DH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@/C%XAN?#W@1FLY?L
M\U]<I9BYW%?(#!B7X!)X4C@9YR.17?UQ?Q4\*S>+_ USI]I#YU]'(D]JGF!
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M^W6:7]]:P2E4NF'#0\ [<,#]X@=B12^*? WB35-;M]7\-^&;?0K^WG+2R+>
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MRA<&/;W4'D_E7/6DEQ_PO:X\2#P]K<6F2V@@^TMI\_[Q]B@';LRH&,>G&>]
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M"&"[&QWYXY]ZZ+6H]1\2_"*^M=/AN;3439K&8Y[5XF+(%9U5&&2" 5!'!)H
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M:5F5>!P,E&X)!^5N*]&H \/^(VDZ/'\9O""C3D$]]<(]T^04F&_;ADQR??\
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M6  )#+P>?RK%236?@_\ $'5)O[-NM4T'5R;AY8(#E7'F/M#=-R@.2,_=Y[4
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M% !1110 445@^(?%ND>%ELVU:Y,(NYQ!%A2<GN3["@#>HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M40F1=NU,!=SL =PV@@B13D@T>/TDT/X[>&+_ $I)?M6H!!<1QR;?. ;;MYX
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M9);>6TEA9%! R0ZKW8<=>:99>/?#VH>(%T&"\G&J%2XMI[*>%BH&2?G0#I7
M>$1 O[17BWR?-S]A/F>8!][?%]W';&/UJ6[9#^TOIZHT1<6#[@L15A^Z/WF_
MB]O2@#T36?%6E:%<0VMW-,]Y-&TD5K:V\D\KJ.^U%) [9.![U3\.^.?#OC%Y
M[/3KL27<* W-G/"T<D>>""K ;L'@XR!QGJ*X?X=W$6K_ !;\<7UXIDU&UNFM
MH7V@+'"KLBA>^2$&?7%=Q;>"M*L/&\_BFVWQW]U \,Z;LJ^?+P0.V-G;KN-
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MQ+,S^8VX<2,,#/;C/UKF?"D;:-^T/XCT:PCD;3KB+SIH#(-H9EC?>0>N&=@
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MA<Y) [T >D6OBG0[O08]<AU6U_LQP,7,D@C49XP=V,'V/-8B_%;P6VC-J_\
M;B"Q6;[/O,$@8R8!P$V[CP1R!CFN5^!*,_@*\2=7:(7,@565MO?. W'Y?C6?
M\ -)TFXT;5K];-998M0>*">= 9!&47 /I[T >E:3X[\.Z[I5UJ6DZ@U[;VK!
M9E@MI6E4GI^ZV[R#ZA<<'T.'>'O&^@>*KBX@T:\EN9+;_79M98PG.,$NH&?;
M.>OI7FWPDECMOB9XZLXC9QQR3))Y23;V.UGY4]" 6.[T) IEIY_PV^-AMI!'
M'HGB:0K#'%G:DA("_*.^X@9Z8<T >HW/B[1[3Q%!H$UQ.-3G :.%;29@P]0X
M0K@=SG [XK;!)KS_ ,&VY\1^+]7\7W#1S6\<CV&EE7#J(D.&=3VW$'->@X%
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MC^(?&GAWPHB'6]6@M&< K'R\A!S@A%!;'!YQCBJD'Q)\'W.L6FE0Z_:R7ET
M843<5;(.!OQM#'&-I(.<#&2*Y?X\H#\-Y'5+7<+F,%IMN[&&^YG^+Z<XS6K_
M &#HVC>"$\06.D64>J:?HS2VUQY +(PA+?S)_,T ;&J^/?#NB:C<V%]>3K<V
ML0GN%CLYI1'&>=S,B$ ?4T^S\<^']0T ZY8WSW=@KE&>WMI971AUW1JI=?7D
M#C![UROP2M[*;X>)>1QEI[J:3[5)(HW2,#C&>ZCM6QX?\+:%X*T'5M'TZ=R)
M%ENY49\NJ,"%X] %P#WQF@#4TKQIH6N:#<:SI=Y->64$AB=X;29G##:2 FW<
M?O#H#^AJ/2?'OAG6[2\N[/5XA;V3JES)<(]NL3,< $R!>I&*XG]GWRO^$"OS
M#O,7]K2[-^-V-D>,]LXJ'X+J)-6\:I,EJV;],K!M,?\ 'TQQ_P#7H ZT?%;P
M6VCS:LNMH;*&40LWDR!BY&=JJ5RW'< BG:=\4?"&I>'9M;36(X;6W""=)E99
M(F89"E,98]1\N0<'!.#7 _ ?1])N(M<OA9+))#>F.WEN$!D5"O0]A[U%X4M-
M.F_:#\20&#36CC_>Q1Q0E@) !E@V/E8$G=ZL3Z4 >H^&_'GAKQ?-/!H6JI=3
M0*'>/RWC;:3C(#@$CU(Z9&>HJ?4O%NCZ3J/]GW-Q/)>^7YIM[6TEN'5,XW,(
ME;:/3.,UYCJ6F+!^TWH[V%IL7[ ;BZ\E,#E94W-CWV#/TI/%*^)_ 7CW6/%^
ME:(FJ:?>6P21E&/*Q\[,P7G V\L: ._MOB1X8O=$GU>SU"2XM(9A QCM)BQD
M(R%"[-QS[#%<Q\-?BE:^)IM1BU"ZE%W<:FRV4'V9\1P%!Y:EE!12=DAY;DAL
M5H^"->\)^(]/UBY\.P[+FY/VB]LR-K+*4P2![],C@G-8'P+AMH_ NNB\M4MH
MDU:<2Q2\^4HBCRI)YX&1S[T =C<_$SPU!=W%O%<W5V+-RE[+9V4TT=J K-N=
MU4C'RXXSS[ D;%KXIT.\T&/7(=5M?[,<#%S)((U&>,'=C!]CS7F>C.+#POKV
MD^#(+?4M,\R>6XU2]94M5W1L3&O]\#"C/0;N:F^!"/+X!O$G4M&+E]H8,4[Y
MVY^7\J .K7XK>"VT9M7_ +<06*S?9RY@D#&3 . FW<>".0,<UL>'/%^A>+;:
M:XT+44O(X6"281D9">F58 X/.#C!P?0UY;^S_H^ERZ-JUZ88+J>"_>&&[:/#
M-'L7IGD ]<&H/A]+/H?B7XG_ &6UFB\D?:%>?:#&X$K*"O<')(]@,]: /3=1
M^(/AG2]2N=/N-1=KJUB,UQ';VLT_DH.K.8T8*!WR1CO5_P /^)](\4V!OM$O
MDO+<,4+*K*5/H58 C\17%?! QW/P_:Z>6.>:XO)7F;9@JQP2ISU_E4LGA6R^
M&?@CQ-?:#/.)FMY;A5F<LBD9V_*>.!QGO0!N7OQ*\*:?=W]M-J<C2:?C[68+
M.:9(,_WW1"H].O7(Z@BMW1]9L=>TJWU/3;CS[.X!:*385W#)'1@#U!KRCX?Z
M'X@U+X8:9'I>NV4-C<0S))NM-[.6D8MN+#.03(O''RJ1U-=7\-? EWX$MKZR
MDU8WMK,R/%$?^63 ONP/<;/Q4T =Y5>ZO+>QM);J[G2&WA4O)*[850.Y-6*Y
MCQ[;Z7>>#KZUUC5#IEE,NQKD2;,9Z#GKGT[T 9Z?%?PHR1W#75Y'ITNU8=0E
ML)TMY'+,I0.4ZC;R3@<]>#C<UOQ;H/ARQ6]U;5;:V@=0T9+;FD&0,HJY9A\P
MZ X!R>*\;\?WVIW?PBMH[?2X+;P_;I EO<7S*+BXV[E#HG\.5"L.Y#''%='X
MMB2X_9U=KR0QNME 1+,CLV1*A Y&[D@#\?2@#J;_ .*O@K3(K22[UU$6[A$\
M(6"5V*'H2%4E<_[6#73V>HVNH:;!J-M.&M)X5GCD8%048;@3GD<'/->;^'O#
M^FGX%?N--S/>Z.6F-K$#-*WED<9ZMZ5PMCXEU'2OV;E>PO8DF6[:U+1,3(B,
M[$AL_=/ICL10!ZEXA\=^#[C1-36XN#?6L"LCRQ:?+<P!RG \Q5\O/S ??'7&
M17/_ +/SH_A"_,7"&]8JOV8I@'I\^2&^@/R_C73Z!HUI9_".WTZW@D:&32RV
MQ!N=F>,L<9ZG+''X5S7[/\+P^#+U3'<(@O75?-D!''4!?X3Z^OX4 >M4'I17
M,?$34;C2?A[K=]:,%GBMCM8C.,D _H30!#J/Q$T'3=2N;!WOIYK-P+TVUA-*
MMHI0N'D95(QQCC)Y] 2-2W\5:+>>&Y/$-MJ$<NEQQ-,\Z*QVJHRV5QN! '3&
M?:N:^#UM;Q_##294B3S+A7DG<#F1MS#+>IP *XGX9(^D?&+Q7X?LUE;2EWDQ
MM("L9###$'J><<>M $-EX^TRZ^-FIZG?321Z=9VS6T23V4S3)CARJ(I*@MDG
M> <'MTKUC1O#&AV.IW6NZ?9&*ZU *[,5,>$V* NSC;]W.",@EJ\U\,HMU^T1
MXBEC4/%'&5<R#SB#C& XR$&1]T_3M7M>T4 -R:\M^(/Q/A\/^(M%TN*6YM8S
M>HVH3R6DBKY"L-P0D9?/J@88[YKU3:*\;^*26Y^+'@'<LAE^U(,$#85\P?KF
M@"E\8+RPU?2O#NJZ;!;NDFI&*6XEB\F<,CA"NU]KG!4@\'&!TKOKSXJ^"=/U
MB32KG7HDNXY!$ZB&1E5O0N%*\=^>._2N0^/%LDNG>'O]!,D8U##3#.V/<5R"
M.GS<]?2I?C9H^F:9\+%M[*PM8(H;M#&H81["0^2H_B/)X]R>U 'I^I:Q8:1I
M,^JW]Y%!8PIYCSDY4+VQCJ3V R22 *P+;XF>$;FXMK?^U_(>ZC\R!KNVEMTD
M7^\KR*JD?CSVKSSQWJ5[/>?#O2F,-F+G;-&LXWJERH582VW.0&8''3UXK<\7
M_#7Q!XUB@CU'7K.)+=C)!%#;[1&Q3INQDKG]/>@#U,&G55TZ![73K6W>Y>Z>
M&)(VN).6E( !<^YQDU:H Y23XE>#HM9&DOXBLA=D9^_^[ P2<R?<!X/&<YXJ
M71O'_A?Q!97EYINL026]D-UPSAHO+']XAP#CWZ5YYK.E6LW[2.B"?2T$+6K2
MK(ZY25DC9@0.F5('2H_B[ING>'=&T;2-(@M-)LM2U ?:GB@X^7&TD#D_2@#N
M#\4_"\=Y:0SW%];QWBH;6>;3IXX[@L<80E,G'RDG&,.O)YQI^(O''AOPIM&M
M:O!;.Y $0#22<YP=B L!P><8KDO%/@#Q+XOTB#2M2U^S:VBE,XECM@CD[L(H
MP, !,GW8^@%<S\8=*&C?!_2+'4;J2\O;>]2*.Y !,A"R8WD\X"9Z=P.U 'H6
MJ?%7P9HNH/87^N1QW*8WHD$LFW/8E5(S[=1WQ4FL_$[P;H%S';ZCKT"R2Q+,
M@BC>8%&&5.8U8#(P1D\@@]ZP_'?AW2;?X.ZE!::5$L26OV@+"5CPX&[?GO@C
M)'>J_P /-*TR\^"T9EL[.;[3:2>>RV^W>R@J-V1R0% )[XS0!Z+9ZM8ZAI4>
MJ6EW#+821^:LX;"[>Y)[8YSG&,<URK?%CPH(WNA=7KZ;'D2:@FGSM;HX8+L+
MA,9.>W''7D9XWX.:9]J^#&JVVH3SV5I=W,Y%P&*%8O+0%@?3*L#VX(JEJ5^U
MW\&+W2?#NG&[T.RC>&34[E5;S%C^;<L0^;.[: V,+][M0!ZMK^N>&H_#4D^M
MZA9_V1=PG+-+E9T(R0H'+Y'9<FJN@ZUX1TWP5:ZAI-W;6?A\&3R)'W1)G>VX
M /@YW!N._:N*TY3+^S9.9U9F72I-AD#9 V\8W=L=,<>E:GPTAM1\#+)&D%Q#
M]EN2S*F""7D) ![@DC\* -EOBKX+31H]6?7$%E).;=&,$NYI  6 3;NP 1DX
MQR!G)K5T3QCX?\0Z7/J>EZK!-9V^?.E?,8BP,DL' *C&3DC'%><_ '1]+?PG
M=ZB+&-KD7TT"3RH#((ML9"G^=-^",)M-6\86'V.9(%O!DS[0RGYOE*^X)/I0
M!VOA;6?!5[K&LIX;GMI+T2&;4)(8WPS$G+;R-K#(/W21WJ:/XD>$9=0N[*+7
MK9Y;2$SS,@8QK&,9(D V'[P& 2<G'6N$^%MI(OQ4\?W"PL+;[9)$'"_)N$K'
M'IT(XJI:Z+I=_P#M*ZQ!<PV]W$+%9C"\7$4BK$!P>"<8.1_>H ]%T#XD^$O%
M&I?V=H^LI/>%"ZQ-#)&6 Z[=ZC<1UP.<9/8UJ:_XFTCPMIXOM:ODM;<L$4E2
MQ9CV55!)_ <5YAXDM_L/[1GA:YMK*4F:W=#]U(V CD!*GN5#$D?3'6K'Q>%[
M9^*_".M7 D.@6%XCW94;E1MXP2H]LC\<4 =FWQ(\+17@L[K4I+*X:(RA+ZTF
MM=RCJ0944'Z=^U=#INHVFKZ?#?V%PEQ:3KOBE0Y##_/&.H(Q7C_Q=TZ#Q5XC
M\+VVB)!>:FMQ()O*8%DB1P#N/90P<<]\U[1&JHNU%"J.@ Q0 X^U<W>>/?#%
MCKT&B3:S;C4IY/*2! TA#YQABH(0Y[,172-7BGQ1TE+KXM>"3/9B2RFE6&7*
M?(Y,F2I/KB@#MX/BQX(N=7&EQ:_"UVTIA ,4@0L#CB3;LQQP<X/8U>UGX@^%
M?#^H0V&IZW;074K[!$,N4/'W]H.SJ/O8K@/CAX5L(/!EIJVF:>(KS2Y(XHY;
M=-OE0C/!QV! QZ9K%\?/'X@T[X:WUQ8"=;JY2.XN2X=228U*,1PQ?:3SR-I'
MK0!ZWI/C[POK>MRZ/INM6]S?1@L8T# ,!UVL1M?U^4FH+GXC^%K87+?VF\\-
ML,S7%I:37$,?&>9(T9!P?7BN<^*.FZ=X8\ :]JVCZ;:6E_<Q+;2W$<0#,DCJ
MC#/T-;WP[T^TC^&>AP1V\:13V$;2A !N9D!8GW))S0!K2>*M'708==2Z>XTR
M9=R36L$D_'/)5%+#&#G(X(P<&H?#WC70_%9<Z)<SW4: DR?8YHX^,9 =T"D\
MCC.:\M^"R/;>)?&OAQ8Y)='M[ED2.23<L?SNF,'DEE4#/^SS3_AO=_\ ""^/
M_$7A+5!:6EHZ/?03N/+WJO.!GJH0N?;8?>@#T_\ X370?[<NM'>]>.]M$,DX
MFMY8TB0#)=I"NP+[YP>U4/".K^"[_5M9B\,2VTE[YQFOWAC?#NQ(+;V&&!(/
MW21W[U'\/89[_2;OQ!J,6+K6)FFP9-ZB'I&H]!M[5Q'PF 7XK_$-5  %[(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>IJ2>HP:7% 4#I0 'I7F7Q1^'FH>*;S2M:T*:UM]5TTED,D8S*=R% 6]%PQ
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M'^K4 8V]SZGFNPV]CR*3;SU- 'A&C^%OB?\ #R_CTS0YH-6TV:1?+:9V\J$
M%F&PG]V&9SDCDD5ZAX.T34-.M[C4M=F:;7-08&[82EHXU4MY<<8Z!0&)^K'.
M:Z<+BEVT +7&_$SPK=^,O!5SI5C)''<ETEC\SHQ4],]L^M=E2;: /%+WPO\
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M()C.),#&TR-E@K>F>" >V*HZ=;_%S6(TT;59H;&QBN##=WT&V.>:$]3&0,
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M40317-O'-#(LD3J&5U.0P/<5A>-_#<?BWPE?Z,[!7FCS$Q)PL@Y4G'4 XXH
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M%@2W]T A 2< >8N<8;$OP;\@_"C1/L_F;-LN?,QG=YK[NG;.<>V*X3X7N_\
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M,;1@$Y!/"X!K<\?Z/H7CJVMK$^/-$L=/MF#Q1*8Y'#!2O+>:,C!Z8_&@"O\
M'?+6?AR&:YN(+"2^/VEH@2 .,$C([].>.U;VJ_#+1/$VGRM?Z_K%Y:N6>-C?
M[HXP JKM'W?E"L-Q!)WL6+'D3:Q+X7\3^%9-%\0^*=%NFDY,UO<1P[6S\I"F
M1N1]37GVB^"K73_*TFZ^)VG3>&DN&F:TAO$C>3Y5P,[CM!)?(!(P!U+': >T
M>%K72K+PS86NB.'TV&/9"P<MN )R<GKSFM4C)K!M/$OA&QM(K6UUS1H8(E"I
M&EY$ H';[U3_ /"7^&?^ABTC_P #8_\ XJ@#QKQM)+\-/C-!XKBM(7T_54VR
M*$V!6("R<CJV1O)Q_%W/->@_#J.XU1M9\6W-R)?[8N0ELJ.3&EM"72/:#RI)
M+L1G'.<#FH?'L/A+QUH<>F3^*M(M@DZRB87$3L .JCYAC/K[5N:9KWA'2=,M
MM/M-?TE(+:,1(/MD70#J<'J>OUS0!G_%EU7X7:X6G>$&  ,DOEDDL %)P<AN
MA&.0<9&<BK\&&9OA?I6^6"0_. 8$"@#<< X RP[GDD]SUH\9W6E>*M%FTJV\
M<:'86MPFRXW&*9V&0?E)D 7IZ'KQBJ7@Z/3/!OAQ]'M_'V@W$2AC;NPC4QNQ
M))8>=\PYZ<?6@#F/ ,A;]H#Q5Y=['*A\S=YSB64D$#"N4!"J<J5&, */FP#5
MC]H2.<VWAN2W\MI!=E4C>"-PSD#;EFYQQRN-IS\W05+H_AW3M(\;W/BI/B1H
M,M[=;A,C0Q*A5B,@ 3<< #//ODU)\0/#FB?$&^MY;KX@Z+:06N_[/%&(V*AM
MN0S>;S]T= * /6K(.+"WW@!_*7(   .!G&.!7 _&\71^&5[]DD=/WL9EV/MS
M'GY@>1D>W>NH\,ZA;3V*62Z_INJW,*\M9%5P@P!E0[G\<U8\1Z%;^)- O=)N
MES%<Q%,\94]B"0<8]<4 97PW8GX<Z"223]E'WB2>I]68_KCT"]!P^J)"W[4.
MCF25D==.8Q*$W!V\N4$$YXXR<\],=\C?^$%W%;>%Y/"LPD35=!F>"[C9"H(:
M1V1T)'*L"<9P>.F""7R_#K4KCXC67C.?Q! UU:#RU@73R%,9#*03YIYVN>?7
M!QVH POB9&?^%I^ G^RQ[?MJ#[1O.[/F#Y<9QCOG&??M3/CZ8X].\/2'[,)5
MOLH\A<NOW<[5!PPZ9SSTQ72>*/AY>>(_%&DZ\NMQVMSI<A>!?L6]2-^Y0W[P
M9QC!]?:F^,OA_K'C."S@N?$D%M%;%)!Y.FY8R #+;C)TW D =,X).,T <QKF
MH2+\??"#796:VETW]S(Y=(DD82;GC4M@,0%&#G@C/(!'H_B?3_#,D$&I^)+*
MTFBLWQ')<1>8%+_(!C!W9+#@@\X/4 USWC'X:OXQ\/V$5_J\C:UIT;_9KV./
MRD=V*\LF21]Q>0>#D^U5/#/PQU:SU"RN?$WB:XU:+3F#6=HN5C# AE=SG+$,
M,@'N <]J ,KQU*(OCAX(VW4ML&CV@Q#[^7/R'D<'H>OT-+\<V;=X3420*IU(
M91D!D;E/NG&0!WP1G(ZXXWO$/PZU+Q!XST[Q&^OP0R:;)NM81IY8!0VX!CY@
MW'WXK3\>^!H?&VGV<(NOL5Y9SB:"Z$7F%/4 ;@.2%Z^E '+_ +0*,_PW4_98
MY@M_&Q=F(,(VN-R@$9/.W!R,,3CC(Q_CU<31_#G0HDE=8Y9XUD56(#@1D@$=
M^0#SZ5JZW\*-=\4>'+.QUWQ0UW?)?&5[EH_DBAV.,)& -S$E,EB,#.#Q\W5W
M7@*VUCP7'X;U[4+G40I5FN]J1R9!!^7@A1QC'/&>: )?&,=DGPXU6.".R%D+
M%EC1B4@"8X'R8(7&,;:Y#X8EV^ THD:X*BWNP@E50 OS<)MY*YSRV3G<.@%,
MTOX6>*;70[GP]>>+EET-XS&L"P_.5W-A0Q^Z"NW/WL=!TR=7PK\-]5\,^";K
M0H_$>^6[)\PR6WF10JR8=8UW*<DG.XGT^4'- '/?"ZU:/X#ZP+B"5XYH[QQ'
M"PWNABQA>#@G! R/P-;?P.Q_PJR *"!]HGP&Y/WCUJSX;^'&J>&?".H>';/Q
M)$;>[5]DO]GE9(G?:&;(EY^4$#I@D'/&#:\*>"-9\(^''T:R\0VTL88O%++I
MQ+*S-ELXE^;]/QH Y7X!RW+6GB2-AFW_ +19PYM!!ER!GY0<+P!\@ V^O85/
M!LZ^ _B7XOL+B*6_M[V>%S<VB$^1(WFND3KV+ L <XX'KQUW@7P#/\/C?W$N
MNB^MYRTUP9;5ED+ ==WF$=B?NY/K7"^'_#'B+Q'J.K^)?!WBEM/TZYO)! 9]
MLDLF5^<O@' WK&%#<A23@=& .J^'>B3S^-_%/BZ>SO;2._8):+<*J[XR06)7
MDY!0=^]>H*/TKR>T'CWPIXMT2UU/Q!;:]!JD[6[VAVQ21QA=QF7@9V@,2/8
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MNY0= .M '/?M"Q>=X2T:$RQQB34U4RR$A4S&XR>O [UM?&7S4^%%Z(;P6_\
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M%C5QEN!\Q8] ,=<V/A_X'O/ FGR:;_:\=]8LS2!/L?EN';'.[>01A>F!UZT
M87P%O(9_AV+990]Q;W,OGH<[E+-D9^M8%A;F']J/4DLE@@4VPDE'E\-NBC+D
M8(^8DYR<\YSFNFB^'.M^&=:N[_P5K5O:6EVS2RZ=>PEXO,VG:=P.[&<?0?WN
ME=#H_@XZ5=7^K2WD=WX@OFS+?R6^%51PJ*@;A0H ^\3QR: .%^#*0IXV^(0@
ME:2/[;$=S)M.=\^1C)Z'(]\9[U%X:'V/]HW7XXSY(N;9BZR_O#)]T_(5P$^Z
M#\V> 1W%=3X8^'=_X3UW6M1L=>B>/5IC-+#+8$E3ERNUA(.AD.>.<8XJMI'P
MSU72?'EQXK7Q.CSW;?Z7;KIVU)4.,K_K21T!!YP0.O2@#T< C@XZ=J\7^%E^
M1\7/'MK?3R&\FN284E)+-&DC@8SV"E,>V,5[20<YK@_$?@*\E\4CQ;X8OH;#
M71%Y<JW*%X+H8  ?'*X  R,YP..I(!R'QKTZ3_A+O ]_:10),;X0F=U!^;S(
MR@8 AF4'<<9XYY&:7XZB19O"Q6:4S_;1B.UE>&0M_>1R2BG/0D$C/7&<]EIO
M@S5K_P 0Z?X@\7W]A>W=E Z6]E:VS+#!(S#]XK,V6.%QR!^E4O&GPUU/QGJU
MI>R^)5M([)R]M MAO"G((+9DPQ&.NT4 >AC@5P/Q/U7PWIZ:-#K>D-J5Y-=9
MTY YCVRJ5ZR Y4?,I[@XY'%=MIT-[#9JFH745S< G=+% 8E//&%W-V]ZY'XC
M^ '\;VNG26E^;+4-.F\VWD8;DY*[LCU^4$?3'?( /-/BG9>(5?0KOQ)J@F>X
MU-/(TZW1/LULG.0258R-]W!96 !<8YP>A^/L9/@C2V%K'(JW:$R%B#%QU4 @
M'/3H>O058\2?![5_$>GV37OC&ZO-6M+@-%<S0+&B1$KN"JG(88R#GD@#C.1I
M>+/A9=>*=/L]/;Q$8K6UD\Y3+:&65Y",,S/Y@'/7 4 4 'QP$9^&5WYBV[$3
M)M,S,,'G!7;U;T!XZUHZ=IB^*O@[:Z;<&&Y-SIBQKM#Q+N"_)GG(PRC)Z'!X
MP<4OBKP;KGBSP^-(NO$-I%$X_?O'IG,AW$C&93MX('KQG(SBMGPUIMSX;T*S
MTO4]8COY(SY-O,T0A9U"_*F-QW$ 'IV'3C- 'B^C>)+J/P#+\-;FZEMO$DMZ
MNE*@MU<1V\C .>.JA"^3UY'/<>\Z;IMOI.F6VG6<?EVUM$L4:;BV% P.3D_G
MFO//#N@:7J/QDUKQ/I\<,UK:P"'SE+\W;9#E3T;"9!P>,CBO3L'WH YKQ[HU
MMXA\)W&D75\;+[652.;+;5?MN"D9'!X)Q7E+>)O&/PO%AHGBK3[?6?#ZON6[
M"-(ZQJPVC)X!4[6 8$] #TQZQXV\+3^+M"&FP:G)IKK.DPF2/S,[<G!&X<9Q
M^58-WX)\1^)K:UT_Q;K-E/I=O*DS164#QR7++O&V1BV N"A.!R<], D Y+6Y
M8;[X_6 O[V]M;.33LV\J7 B50T9+KDCY=P^4E"K D$$$"NCUSX;>%HC87_B+
M5-3NUM3%! ]W<,YW;LX+ ;F+MDGGC^':.*T/B#\,;/QY96$0N_[/GLSA)A#Y
MIV8^YC</8Y]JS_"GPWUJQU"VO?%'B*35'L(D6RA4MY<; ?>;IOPV<9Y(&3C.
M  9&D>0?VGM<$2R*XTX"4NP(9]L/W1C@8V\'/()SS@1>+9A;?M%>%I8WLXI3
M"49V$DCD%'7#*#@9R0I'<DMD"NIM?A_K<'CI_%LGB2UDO)(!;O$-+VIY>02!
M^]SGCJ2>OI@5#J_PZUS5O&-CXE_X2J&WN[$D6Z1Z8-H4Y!#'S,G(.#^.,4 8
MUX9#^TQIZM="2/[ ^R'>3Y7[HYX/ SUXZU7^)#[_ (R>$HKN[O+:R,'[N:*4
M(L4I=LM\P*YP #WZ<BND\5_#F^UCQAI_B/1M9&DWT<+0W%PD/F.PVX!4$X]L
M<<'.3TJQXV^&MMXM\+0:2+N2*YMY#+%=S@R.6/+YP0/F/H,#L.U &=KOPJ\*
MWUBM[K.L:M-:VQ\X2W.HO(J)EF8 L3@,"@..2$7!SDG#O(K5?VCO#)M(I1&V
MG.%D9LHZ""3;MXSP.N2>HZ5I>'?A/JD5W _BGQ'+JEE:D&'3XP5B8[(P"_3(
M!3 7'.T'@DBM&Z^'>M7/C>U\4_\ "36Z75I&T5O;_P!FDQ(K*RXQYO7#=1CH
M* .>^*S>7\3O!$D,EC#<"==LLQ<E?G_B7<%V9^ASWJ33=0'_  TUK5M<E7(L
M8TMWED;,0\J-BB#.,,6)(P>>G?.YXN^&VJ^+]8M+^;Q)!:K92%[:)-,5MO.1
MN)D^;]![4SQ]\+9/&#6&HVFHQ6.N6R!9;N.%D\\X SPV5Q\V/O'D#/&: .KU
MBW\.VVJZ9JNIV]NFH"X$-G<^6?,,C(X";EY(VE^#QW[ UY1H]G%K'QD\96&H
MZKJ=C-*AC@EBNA$2FX!50D;LAL,-I XP002*[7PE\/=0TO58=7\2:_/K-[;1
M^5:(04B@ W#=C/S,5.,D#&6'/!JE\1OA-_PF>IQ:SIVI#3]3@A*J3&Q$KCE,
MN#E,>H!/- %V3X?^%]-\5V6OZA>W<NI&Y5+0W-P22P4+&G&"^T#JQ)/\1-=\
M0#QV[UPWA3P#=Z;JLVL^)=7?6]4#D6TCKM2)!P"$Z!R ,GMTYZGN<$_2@#Q?
MX*WV[Q;XTM+VXD;4);E90DQ)<HC.I.3V&Y!^(JO\5+=D^,/@>2R2"*\FEC_>
MO'N#,)0%WX(+ ?6NQUOX=W9\6_\ "4>%M7&E:G-L2\26'S([A-ZDYYR#A>@Z
MD 97DUHZ3X0NI=<A\0^*+JVU#58(_+MT@@*0VOJ4!)+$^IQ["@#@_C.;=O&?
MA"*X@:9/.W,-TC@C=T\M2HZ]P0?7@5[4,D5YMXN^&&J>+O$-MJ\WBG[(;-O]
M%AALCB,;B1D^;RW8D 9KT.PCNXK.-+ZXCN+D9WRQQ>4K<]EW-CC'<T >5_M"
M^:OP_MPEV(4-ZGF1ER//&&PN!UP<-@_W<]J[7QHD<GP\UA)8IIHSI[AHX#AV
M&WHI(.#^!H\>^#+;QUX:?2IYOL\@D66&XV;S$P/)"Y&<KN'7O68O@?7!X:O-
M+/BV::ZOLK<WLUIDA-NU1&JNNP@=\G/I0!G?"7_DB%@<D'R;K^ /C][+_">O
MT[UG? &=I/#.KP--&RIJ+L$%OY3#(&21]T9QPH'RX/MCHO#W@C6O#?@__A'+
M/Q#;&% RPSMIQWH&9F;.)>3EN.F,=Z9X$\ :IX'M;ZU3Q(+ZWN=TB)+9;3',
M>-^=Y+#CD=\#D<Y .9^'UO+_ ,+S\<7(4&(;HRV1]XNI''7H#3?$7ACQ)IGC
M;4_&/@K4DNI5.+W3I6=@V%!*Y).[G.%&W;T&.E=%H'PYU/0O&M]XE7Q#;S3Z
M@1]JB.G%59=P)"GS3M/'4Y^AI8O"/B[1]8U:]T'6K&.#4;F6X:SO8WE2-BQ(
M96&TC=GD8P/]KK0 WX6^.++QBFL.NEOI^J)-'+?J7++(YC";AGE?]5C;VP.I
M)KT+KQ7.>%O",/AR34;R287>J:E-YMW<B(1*^,[55 2% !]22223S4OB_+:%
M+;C7K/1%N0T#7-TH/#(PPF73#=P<GITH X7R?$_B/QW?>)-'BTYH=*,EA8B]
M#,A(4[W4QLN=S?+ALXSD5R?Q0TSQ+H.N:1XXO7T];BWN?)>33[7: JL=COO9
MMS,O&.V,=LUZ#X#&@>"= .DOXUT>^B$K21OYL<3+NY(/[QL\_2G>.I-"\9:$
M=)A\:Z-80R-F9B\4S..P&7&WZ_RH ZBZU.VU'P9<ZG;R@6TUB\RN463"E">5
M/!([J>.,5PWP%B@_X0*>YC2/S)K^7?*(PA<#&,@=!R>.V:;X:M;7PUX7FT"'
MXDZ%/:F-U@:6*+="6(S_ ,ML,/O<$=6SG Q4_@"UTCP/;W-H_P 0-(U&RF8R
M+"6BB*2$\D$2'@]QCTZ4 9DB1K^TY"RPS([6#;W=OE<B+C;P, =#R>:O_'Q-
M_P .8T+*N;^$;FX X;DU7\3:+HFL^,4\2Z;\2+/2KM8?)(6:&8 8P=N7&W(]
MC4WC'3-"\5^';+P^GCW2;73K9(QF5XYYG9 0&+^:HY'7CKS0!A_$*=["Y^%X
MEVSV"2IYH,CB N!$$<D$<@%B,^_;(/J_B'3]"U#2&FU^VMI["S(NRTZ[E39\
MV[Z8'([C(.0<5Q&KZ5X7\2>"K?PYK?C72IOLKJ]O<6L\4.TK&47<I=MW4DX(
MS[5S6@^$K6-;>R\1_$W3[W1H6\PV$-\H$Q((96<MG9T&.<C/3K0!O_&=K,_"
M!6LXT2R,UOY21)L 3/  QQQVQQ7/?$>1!H'PT57OH=+81E@DJY3Y(O++$J4+
M+DGE?[W2NN\>)HOC33%TQ/'.B6-GN61@6CE<NIR"&\T #VP:+^V\-:_X+;P]
MXA\8:+>[0OD7-O+';F,JH"G;YC GKGH.<8% %C5?AIHGB"QC^WZYJMWIRW(O
M)%DOO,CD*@C&X@[%P7^X5^\?1<=9X6M=/LO"^FVVDSFXT^*!5MY2<ED'0]!7
MC.B^"K.R:WTO4OB9IMUX:AF>4V4-XD;2\ *I.[A3E]PR1@#'+97U^V\3^%+6
MVCMX->T:**-0J(EY$ H'8<T ;C9["O ?$T[_  M^-T>O_983I6MQ['(3RUC!
M*B3&/X@55R<<[SWYKV?_ (2_PS_T,6D?^!L?_P 57(?$*+PMXVTFRM#XDT)7
MMKV.X/FW<?SQ@X=-P.5R#V[@?4 %[X:Q75Y::EXGO;CS)=:G\R-5<LB0IE8P
MH/(ZDD9-,^,CHOPPU7=<O!D* 4E\O<<_=/!R#TV\9]16Y:^)/"5E:Q6UMKNC
M10Q+L2-+R(!0.P^:N;\;2Z3XNTJ32H/'6AV%G*N)0?*F=N>Q,@ _+/O0!:^#
MQS\*]$_T46PV2 (-W/[QOF^8D_-][TYX &!7"?"YIO\ A=GBX>;Y$1B?=9EU
M&]O,3#[44(<#/.,C?W))KJ?#;0>&/#,6BVOQ&T"=;?Y8)9T1F52S$@_O_FZ@
M#I@#O6+X=\-:-X;\9W/B2T^(/A_SKL%)X!&@0JS*S;?WY*DE>ISUZ4 4OC^T
MGVSPU':B![XSDPQR)&V3D8R'4Y7.,@MM]5/4>Y@_*/I7C'C;P[I_CHVXU/XD
MZ#'%;EC&D$,0//J3,2?T%>F^']3M[ZV\D:[IVJW<?,CV150 3Q\H=L>G7F@#
MBOCS+/!\.PT*NT9OHO/12P5X\,2'VD':2!W]*[738;#6/"EA%/:VMQ92VL1,
M#J)8C@ @8;.<$=^>*E\0Z':^)-"N]'O3*MM=*%D,1PV,@\$@^E>7:=\&O$.G
M7<^F0>-+F+PU*$9HHP1,2KYV#L@Q_$#UZK0!C>.-3TBQ\6_#V73+EH_#5G.N
M""_E)LD&3\W4@9Y]*]1^)MC;WWPYUJ*86X"VY='G'RQL.AZ'!]Q3?$WP\T?Q
M)X1A\/%7M8[50+.5<L8& P#@GYO<9Y]169_PBGC/6[2;1O$VN:=)HN50O9P,
M+F[C!Z2%CM0L "=H;G.* /,-7\\?LQ:-Y\$-RIO3Y3*K@P+NE^8X;!.=PR1C
M# 8SS7IGQ%6-O@A>>8MNR_8H,"X9E4'*8QM.=V<8'0G /&:M^,OAW-XGT&WT
M"QU:+2='@"$6\-F68E=W!;S -O(X(ZC.:EUCP?KNL^$?^$?E\0VD43Q>3-*F
MF99D&,8!D(!P#D\]>,8S0!P>KW$\W[,EH5OXHF6"&,L@>+<H(!C/7)(X]#["
MN[L[S2[#X-:;=:U!]HTU-&MS/$$#;E,:#&#4,/PYDD^',_@_5-7%]"$V6MQ]
MEV-!C[IVA_FVGIR*?I'PZDMO#<VC:WKD^L0FW^RVXDB$201;0  JGYC\H.2>
MP]\@'$7JW]]\(+R_TV>+2O"T=O*MEIL-H+J69#(H#2M+N(YWGY<%<@Y.W%=A
M\& H^&6F[0O\70!<_7"KS[G)]S6+IOP?U?\ X1T:)JWC*\?3XT<06MG$(UC<
MD[6+9RXPQRO')Z\9K>\%^ ]3\(^&!9)K?F:ETCEEB:6&%"P)54W*3TZD_3W
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MHD;<N#]UAZ!AAL=LXYQ6_0 4444 %%%% !1110 4444 %%%% !1110 4444
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MO@^.V&GZ=$(;J40K>.^[:2!T3L0?7(->DJ>_7WH Y3_A6'@C_H6-/_[]4?\
M"L/!'_0L:?\ ]^JZZB@#D?\ A6'@C_H6-/\ ^_5'_"L/!'_0L:?_ -^JZZB@
M#D?^%8>"/^A8T_\ []4?\*P\$?\ 0L:?_P!^JZZB@#D?^%8>"/\ H6-/_P"_
M5'_"L/!'_0L:?_WZKKJ* .1_X5AX(_Z%C3_^_5'_  K#P1_T+&G_ /?JNM;I
M7)ZUJ/BB+QOHECI.GQR:/(K/?W#CA1G&,]B!R!WH 3_A6'@C_H6-/_[]4?\
M"L/!'_0L:=_WZKK!VIU &'HWA'P_X>N7N-(TBVLYI%V.\*8++G.#6Y7(_P!H
M>*6^)'V!+%!X;2UW/<L,$R'IM/<YP,>A-==0!EW.C6MQK-KJ9,L5S;;P#$^T
M2!@,AQ_$/E&,]*U!110 444C"@!:*\S^('CO7O#.O:)IEKIT,=KJ5VL/VQW\
MPD!X\X7HO#,.<^HZ5Z6* %HHI#TH 6BO-/BOXV\1>"K&WN=+T^VDM;AOL_VB
M5RSK,RL5VH/0*3SD'BO0;.226RMY)/OO&K-VYP* +5%<]XMUC5M%T&XO=)TQ
M+^:*-F*O($"X'!QU;Z BJ'PV\27?BSP1::O?HR7,KRACLVJ0)&QM]0!A<^JF
M@#L**8<E<CK45G>VU]$\EK.DR)(T;,AR RG!'X&@"2:-98VC=0R.I5E/<'K7
MFES\$]#2>2?1M1U#2G=9.(925#/@9"^@7<N/]KVKT^B@#D_"O@73_#,SWGG7
M%]J<B!);RY;<Q_W1_"#@=/2M[3=*L-)B\JQM(K=.>$7DYY/-6;EY8[:5X(O.
ME5"4CW;=[8X&>V3WKSSP/X[UCQ+X^\0:/J%K#:0Z8I188SN.X.026[G'''%
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M7K1+W3KE (]1M[8H-X0$]\#GDYZ=J /2Z*8IR1V]J?0 4444 %%%% !1110
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M)3=G&?K@U8/2@!:*Y/4M0\4)\0-*L-/L(WT%K<R7MRXZ-DC /J, @=]QKK*
M"BBB@ HHHH **** "BJUU>VUK+;PSSI')<N8X58\NV"<#UX!/X5.O6@!U%<Y
MXYOM>T_PK<3>&K0W6J%E2- N[ )P6Q[#FMBQDNFTZWDU!(HKKR5:=(SE5? W
M 'TSF@"W15:SO+>_MDN;29)H7)"R(<@X.#^H(JS0 4444 %%>6^./'OB/P]X
MWT718K&TBL-3NX8H[DOOE91*@?CH,AL<C/)KTB]N[?3K*>]NI5BMX$,DDCG
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M?/M?M978[[0@.[^'Y?/'S$?GMH Z/1OB3J&F>.[?P=XCFL+W[3M^RZK:$H)
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M1@'/05E_%X7#>.?!7E+?L3=KM%M&BY;>,;9&. _H#QWKK?BQX9F\3^!+J&U
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M!@P(WM@G!/S'J1U!SP.E11BX/[35P0M^5&G \(D2[,+SDG,D>>X^;=D8PN:
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M:>")]RHV.0,]/ISCIDXR=.C ]** "BBB@ HHHH **** "BBB@ HHHH ****
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M]6CL[FP1[FTCO'$<A= 3Q_",DG KM=2\(:5JGA>+P[.)UTV.-(_+BE*%E48
M)'4=#]15K1- L?#U@+'3S<BV7 2.:YDF$8 P%7>QV@ =!@5J4 8/A;PAI?@Z
MQELM)^TK;R-O\N:9I I_V<],_P!*S?$7PZT;Q!K5OK!-Q9ZG"R-]IM9#&S!3
MG!QU/;/:NO)YHP#UH P?#WA2RT%I;GSI[W49U1;B^NGWRR[5 ')Z#C.!QS6M
M>V,&H6%Q97*;H+B-HY!GJ&&#5@G% .: *&BZ+9:!H]MI>GQF.UMEVQ@MDX]S
MWK U7X<:)K.N1:S>SZD]]"^^"07CCR><X3^Z,]A77$XI 23B@#EM8^'^E:SJ
M%GJ4USJ$>HV5N(+>ZBNF5U S\Q]6YY)ZT:%X(M-&UN369K^^U'47A-N)[N8N
M5B.TE0#_ +2YS[XKJSR*0#% '&R?#+0Y=>&N-=:M_:8!5;D7S[U7!& ?3!(K
M3\3^$M)\66D<&I0L7A??#-&VV2-AW##FN@I-HH X_1_ D5EJ-K?ZGK&H:U<V
ML96$WTFX1N22SJO8E=J_\!]S5CQ#X!T7Q/JMIJ6HM>&YL\&W,5RR"(@@[E Z
M'('/L*ZC:*6@#D-=^'&B^)888=6GU.YBA "(]Z^,@8W8]?4UT.D:5;Z)I5OI
MMJ\S06Z[(S-(78*.@R>< <#V%7J0G% ',>)/ .B^*]1L[[4_M9FL_P#CW\JX
M9!&<YW #OD#GV'I4.N?#K1O$EM#;:M<ZI<P0@;8WO7P2,_,?4\GFNM!S2T 8
M%YX/TG4?#;:%J"37MF>AN)2[CTPQY&.WI7+^'?@UX;\.:U!J4$EU*\#EX8WD
M.Q6W,02.^%95_P" YZDUZ,>E(/RH Y_Q9X*TCQI:V]MK(N7@@<R)'%,44MC&
M2!U(!./J?6K0\,:8^A_V/>QOJ%ED$I?.9LX((R3Z8&*V** /,['X+>'+/,#3
M7L]F'>1+624F-6)/)'?"X7GKMS71^#? .C^"+>6/2_M!>=$69Y92VXKGD#HN
M2QZ5U&T4M "%05*D9!X(-<7X:^&7A_PGKD^IV$4K22#$0E<L(<_>VY[FNUI,
M9H X[7OA]I^K:Q_;5E>7>DZJP"2W=D^PR(.H8=#GIGVK3\-^%K/P]]JF26:[
MO;M]\]Y<MOED ^ZI;T4<#\3WK>VC-  &?>@ *@]:Y#5/ASHMWK/]M6;W&E:D
M6+2W-C(8VE!.6W8ZD^M=A2-TH YWPOX.TWPND[VWFSWMT0US>7#[Y)F[DGL"
M<G'3)-1^,? >B>-[%(-4@/FP[C!/&</&2,=>XZ''0X%=("!T%+G- '&^#?AM
MHG@N[FN]/:XEGE4Q[Y9"P5,@[0.W3K79.@=&4DC(QD'!%+M'I2T <=:_#31+
M/7VUR&YU0:FX DN#?.6D QPQ[CY5&/:I-0^'6B:CXF_X2*674(]44;4GANW0
MQK@C"XZ#!/YFNMHH XS7?ACX?\27ZWFJR:C<2H28\WCXC]E'85UT%NL%M%!O
M>01H$WRMN9L#&6)ZGU-2TA.#0!DZ#X:TSPW#=Q:;"T:W=R]U+N;=F1L9QZ#C
MI6)XN^&?A_QA>PW]]'+%>Q;5\^!RK.@8$J<=<C(SVSQ78@D]:7K0!P;_  E\
M*3WNFS/:,T&GQ;(H"WRLV[<6<]6)[YK2\0?#S0/$KV!ODN533T"6L<$[1I%C
MH0!WX'/L/2NJQ10!RWB3P!HWBR"&#5Y+^:"$+MB%TP3<H(#D=VPQY]ZU)_#U
MC=>'GT2Y$L]H\!MV,CEG*E=I^;KG!ZUJT4 ><6GP9\+VJ20@WDMIYGFQ6LD[
M-'&VT*<K_%G&>:OZ;X%\*>#O"%]I\X5;"XC O9[F3[W &<G[HSR!V)-=N0#U
MH*@]10!YG\)/#<6A1ZQ<:>I.C7CQFQF:3<TRKO#,1_#U ]\9KTO 9>>X[4AP
M"21Q2@X '>@#F-"\ :+X=U&\U#3VO5NKV42W,DERS&5@2?FSUR6)/K44/PYT
M2W\2S^(89M234IVS+*MXXWC(.TC^[\JC'H!76BEH Y;Q#X T7Q-K%IJNHM>_
M:[,@V[17+((B"#E0.AR <^PJ3Q%X'T3Q/HD&F:M%+<I !Y4SR$R@COOZDGOZ
MUTM% '!^#OA7H?@S4/MUI)<SW(C\M&EDRJ JH;"],EE+>V[%<-XQE\)>+/BE
M=Z=XANH='&DVH1;EY/+>Y8NC8W=,!=P Z_.2.E>Z8%8>N^#?#OB21)M7T>TN
MYD!42O&-^-K+C<.<#>2!G@X(Y - 'CNM_#[PQI%@T^B^+;@:[%E[&%+D-)/.
M@.$5<Y)+%>G.<>M=]K/PMTGQ0UCJ.NECK4<4:7=S:,8A.5&&X[9[>@Q6[H'@
M3POX8*-I.C6L$T9)6=DWS#/!_>-EL8[9KHMON: ."?X0^$6UNQU%=/"_98?*
M,.?EF]&?U8<\]\CT%7]8^&V@Z[J5M?WSZ@TUHP:U"7;*MN1C&P?P_='3TKK]
MHI>E $-K;BTM8K<22RB-0H>9R[M[DGJ:S_$/A[3/$^E/INJVXFMWYZX*GU4]
MC[UK48H X2Q^&]O!/:_VAK6IZI:6<K2PV=W*6B3  CX[[ &QZ[O85K>*? ^C
M>,X+>#6!<O!;MO2**8HN[&,D#J<9'XUTFT4  =* *NG6":;9I;)/<3JI.'N)
M3(__ 'T:MGI110!P&L_"/PWKWB.XUF[^V++<@F=(IV0._P H5N.F ",=]WM3
MH?A/X;C\2W.N!;D74N"FV8KY3;<;EQWS@@]B!7=[0*3J.!^- ')Z3\-]$T35
M[C5+&?4H[RY<O</]L<^<22?G]>2359OA5X>;6QK33ZJ=3&/]*^WOYG3'7Z<5
MW%% '">,OA;H/C+RY;EIK?4(D5([V)LO@$'YO[QXZGIDUJ>'? >C^&--O+/3
M#=Q"\'[V4SL9,XQE6ZC\*Z5NO08]Z4<B@#D=*^'&BZ+JUQJ=E<:FEW=-NN'-
MZY\X\GYO7DDTVV^&FAVGB#^W8[C5/[3( >X:]<LX&.#ZC@<5V-% '$7_ ,*_
M#NIZS'J]W+J<M_$ZO%.UZ^Z,J<KM],'I6[K'AG3-;T2XTO4XWN;69BQ\QR60
MDY^4_P ..WI6U01D4 <+8_#2WBDMTO\ 6M3U*PMIC)#8W4I:)5  C4COLP<9
MZY]JU/$_@32/%Z)%JSWKVZ8(MX[EDCR,X;:.,\GFNE P<TM %+2],BTJQ2TB
MFN9D3[K7$ID8#TR>U<#J7P3\*WVK&]@CFL(V"A[>T?8AQUX'3(_QKTNDVB@"
MAI&BZ?H>DV^F:=;K#:0IM1%[^I/J3U)[UPFJ?!+PMJ'B :HOVFTC9G:XM[>0
MJDI8=B/NX//'6O2Z3 )SWH P)/!^BS^$5\,36OF:6L0B",V6 '0[O4>M<O9_
M!;PE:Z9>6DEO/<&XW*LDTA8PKN)79GH0"!GOBO1]HI H% ',:)X"\/:+X<;1
M8].BFMI45+GSEW&XVG(+^O))]JQ3\)=)$#Z?#J.JQ:,\@D;3DN6$1.#^7S;6
M_P" X[UZ"0!S0 -U &9)H5D^BII-L9K*T1%5%LY#$54=@1VK,\+^ M'\';QH
M[WL4+DLT#W+/&6.!NVGC. .:Z< "EH \]\5_"+P[XIUB/4W$UE>&16FDMFV^
M:HSE2.Q.?O=>*Z[0/#NF>&=*CTW2K<06Z<XSDL>Y8]S[UI@4M $<T$=Q#)#(
MNY)%*L/4&N5\-_#;PWX4EN)=*MYXY9HC%YCSLS(IZ["?NYXZ>@]*ZZB@#CM%
M^&NA^'KN2YTR?4X'FE668+>OMF8$GYQWZG\S26'PQ\/:;XD_X2"W:_&I&0RO
M*UVYWD]=P[@^E=E10!P&K?"'PMJOB)]8DAGBDF<R7,<,I1)6..2![Y)]234^
MG_"SPUIGBT^(;.!X91M,=O&^(D<!@6V]#D$<=B,]Z[<C-&T?6@#A[;X5^&K?
MQ>/$,5O()=S2& N3$9"1A]OMSQZG/:NXV@=* ,4M ''ZA\-M$U37DUNYN-3.
MH1$F*9;UP8@23A/0#<<#WJ36/A]I6KZI%JYNM0M]5@MOL\%W#<LK(,'GW/)S
MGK7644 <OH'@RST35Y]6:]O;^_FC\KS[N8N5CR"%&?IUKIG0.A4DC(QD'D4N
MT>E+0!R&C?#?1- U"YOM.GU*&>Z8M<,+Q_WI.>6]3EB?J:BM?A?X?M/$:>($
MEU)M31MWVA[UV9N,8/J"."/2NTHH Y3QCX!T;QG&AOD>*[A4B&ZA;:Z9'ZCO
M@U/HW@VRTS4CJD]U>:C?@,D5Q>RF1HHRQ(5<].#C/?%=&1F@#% '*^,_ &C^
M-DM#J/GI-:$^3+"Y4J&*[A[Y"X]LFN@TW3[72]/AL;.%8;:% D:+T JT1F@#
M'2@#G_$_@W3/%UN+;59+QK88S!%<,B,0<@D#J:LZ;X;LM+T)]'BDNIK(Q^4$
MN)C(43:%"J3T  X%;%'6@#S[3/A!X7T_3]3L5BN)(+_"DM*=T2 JVQ6Z@%ER
M3WZ=J=/\+-.N+-=-EUC6&T9=H_L\W;&/: >,Y]<-^%=]M%&!0!EZ[X<TKQ'H
M\FE:G:K-:.!\O0J1T*GL:X_PS\'O#WAO5$OXY;NYG@N&FMO-E.V($8"[>AQD
M\GGFO1:0B@#D]<^'6B>(M6@U/49=0>YMW\RW*W;J(&R#E!_#RH/'I5G6_!.F
M^(=,AT[4KG49;6- A07;CS,'(+_WC[FNDI"<'% &%X9\(:;X2M#::7)=BU ^
M2&:X:1$Y))4'IDDYK2U338=6TRXT^X>589T*.8G*-@]0".F>GXU;!R*"<8H
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M+--(6:'DE=F>F 0/?'->A6]I;V=O';VT,<,,2!(XXT"JBCH !P /2G]\?UH
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M(J*C#8A5%!;.[)8Y(QC'-;GP^^(/B77;W6_#NM6=I#XDL=LD,4JO$C)D!]V
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MR",G@8[G%9,?C_4=5\-SZ_!XFT+1?M(EETW3;X)YCQ(Q3+DL#EF1_N@CH,T
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MZTW=SBE;I7">(_%.I3^,;?PCX:GLH]3,'VJZN+D[TBC!'R;1SO((.#C@@]Z
M.ZW>W%<F9O%S_$E8DAMU\+1VF7D?&]Y#_=P<Y!QU &,]\5A6WB#QGIGQ5L_#
M>I1Q:CI-Y;O,EW!:-'Y84<ECR.&PI&<?O%YR0*AA\:^)4^-%MX2ODL$LI;=I
M2MN&<_ZMF!W$ ]0.,4 >H;O:C=[5Y/XW\9>-_#WCC2--L-.L9[._DV0@%OWQ
MW'"M(P 1L8) SBIQXN\9>&+;7M6\9V6G1Z9;\6"P3KOF<L=JKSSQ@\X.!TZX
M /4<T9KR[Q#J?C[2_ ?_  DMIJ%A<3K&EQ-9)8LVV)O[K Y.T$$D@# 8]J=X
MP\7>)-*^&=IXKMC'877E1-/8W%L6.YV ZD@C&>F* /3]U&X5PFH:UKTOPKL?
M$=C?6=O??V;'=RB>-?+D9D5B-S, @R36./&/BRZ^#-KXIL+>SN-0:&26?Y&R
M-LNT%$ .?E!SDC &: /4MU&[VKR.S\2?$K7O!T&NZ7;:=;I'9-.XE3S'O6 8
MXB1,[>F #@DFF^&?&'C_ ,=Z!#<:+8V&GRP K<WEZC&*X<<8C4<_4] >* /7
M\^M)N_&O-_AO\0+[Q!#K6G^(K9(-3T1V%W)$ 8V 9AT!/(*L.,YP#WJ/PWXC
M\3>.-#U;6M'U&UMXX;J:&RM&M WF[$4IEV9<;L]QQ0!Z9N%06-_;:E86]]9R
M>;;7$:RQ2 $!E(R#SSTKRGQYJ'C.;X00WYDM=.N&MP=4$K&"7DX*(#P"?3.3
MT )(J3P]J_B#PI\(X-;OY;:]M(M*B:SMX+=]R''RAV /&W;EN #GMS0!ZUNI
M-_.,5XYJGB_QOH_PUT[QA]KM[IIWC:>U7370)&V[DL3D#A1NQCY@02"">B\:
M>,=:T[X;CQ1HMO;1J8(Y9!=JZNA=T7 0J,_>/4CC!&: /0MPQ1N%>/2>*?B+
M?^!T\3VD>EV5I;6'VJ0W*[VNB%W%D52=HXP Q!K?T3XC*_PDB\8ZND:2A'5H
MD<#SI%8IA<]V*YQ_.@#T+=[?A2;@>E>9:MK7CRV\&GQ7;R:<Z;8[H:9# \A-
MN54G]Y@'?R2>,  G/%:C_$(6OP\A\1WVGFSOIBL4=C=-]GW3,0% :3;E>=Q;
MH%#'M0!W6X8HW5XIXG\=>)O#'AV#4#XM\,WU\SHSV-L%9FB?[K)\V6X.<XQ[
MFMR]^)O]KWGA2T\..D(UXEC<SA6:$*65E\K<"3N4C=]TXX)YH ]/W#.*6N+T
MJY\4V7CM=+UC4+&\TZYLII[9H(#'(#&\*G>.0/\ 6GH3TKM* &[O:J][)=)9
MR/9013W(&8XY93$K'W8*Q'Y&N$\1^*+ZY\=Q^#;74%T/S8-ZWLT)9KEB.%AS
MA>.A)/7( -:GAR^\0CQ?KNCZU/!<6]M!;3V<\4(C,B2;PQ(#'&&0C'MGO0!C
M_#'Q=KWBG6/$T6N116[Z?-%#';Q(5"9,F3D\DG"\\=!P*]'!XQ7@7@";Q$/$
MOC?3M!L?L>H2W22^?J0=HH55FX)"Y+L&RHXX!/;GM/AYXSUG5O$VO^'/$)MY
M=0TQ^);6/;&5!VD<G).3Z4 >E;JCF:00N8D5I0I*(S;0Q[ G!P/?!KS'2O$W
MB_Q=+XGN](O+'3[33;I[:U@N[5M[LG4R;L%,CL1D'(/2M;X6>,[[QCX?NI-3
MB1;ZSNF@DE@4F&48!!5AE3Z$*3Q@_P 0H S/"'C;7]<^*NM:#J<5I;6^GVS%
M8+9C(-^^,9+D M@$] O7I3/%GC;Q'I7Q)\/^'A;V5M8:A<IF6.1I99(_,QSE
M0$R.H^;ZU1\""[/QT\;A4D^P[?G;9\GF93:"<<'&[CZ^E'C[[8/CAX(^QK*S
M;?WFQ=V(_,^8GT&.I[4 >O#C _*GTT=?YBG4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R'Q
M2^T#X:ZX;2X$$WD##E]G&Y=PS[C(]\XKKZ@O+6*]M)K6X3?!-&T<BY(RK#!&
M1[&@#S;P[J5C9_ *!KJ\MH5_LF1"9E$B@L& !3^+DCY>_2L;P%<"+]G>]9;W
M[+(D5TWG("6B^9OFP.:ZS3?@[X*TJ>>6#2W9Y4EBR]S*=L<B%&0?-TVLPR>>
M>O2I-.^$OA#3M(;38["<QRKMN'%W*CW'&#O*,,C_ &?NY[4 9OPEW?\ "D=.
M">9O\F[QY7WL^=+C;[^E>>>&-+O=5^!_C6VACG:<W9D_?S@EO+9'?*_PMA3D
M_P 1P.U>S6?P_P##UAI+Z5:07T%@_6"/4[D*!DD@?O/E!W'(&,]\TW0/AWX9
M\+W?VK1+&>SD/+*E[.4?@@;D+E6QDXR#C/% ''?#'4/!7B70]-B:RTT:UIB+
M)(K6RQF.3(RZ<>H'([UIW=[INH?#+Q'%X5TB-=/MXY8[4);KY-R>K,BXP5W9
M&>^,U+J/P6\%:EKG]J2Z<\>XLTMO%,R12L>Y .5QV"D#U!KI+SP=HNH:';:+
M<6\_]FVT0ACMX[N:,%   K%'!<8 ^]F@#E?A=O\ ^%'Z?Y?F[S;7.WRN'SYD
MGW??TK-^ :RCPMJC2"XYU!QF:;=D]_D_A/J>_P"%=G;?#_P]9:0^DVL%]#8/
MC,$>IW(4#YN!^\^4'<V0.#GG.!2:'\/O#?AE;L:+836@NXC%.$O9_F!],OPP
M[,.1DX- 'GN@[1^T=JX#"V#0-^ZC/EB?CJRGESWR._-1WSR^'?VF(KV[A)@U
M>V2*W<,./W:H2?H4/%=Y#\*_"-OJ3:E#87D=\S%FN5U.Z$I)ZY;S,G-;'B+P
MII'BJQ2UU>S$RQ-OA<,R/$WJK @C^7 XH X']H"*2[\":?:P(99YM4B6.-1E
MF)CD' []:R/'D+V/B3X76#7D_P E[;9MI2S$D21C>6/<9QSSS7HFB> M/T74
M(-0EO-2U2]@B,<,VIW33F(DDLR \*S#:I( X08QELNU7X>>&];U1-3U&TNI[
MR)_,BD_M"X7R6R#E ) $Y /R@=* ,?XT:?<7_P ,M1%LJLT#)<ON/&Q#D_7C
MM5OP'XQT/6_!VGM!J%HLUM91BZA&(_((7:1M_A7*MCMBNK&G6W]FC3Y(?/M?
M+\IH[EC-O7IABY);\2<UPTOP4\$R:_\ VI_9C*I!+6:RL("Y;=OVYR.N-H(7
M':@#A?BIK#:G9>$_&#:3'+HUK>SV[Q3%)1.C%<';TPPC?&>AP?2O0)=6^'4'
MAI-3==(^P.AB5$1&+80@QJ!U.TLN/?%=A?Z18:EI,NEWEG#-8R1^6T!7"[>P
M '3'&,=.,=*XWP[\'/"GAO78=7M8)YIX% B6XDWJCC_EH!C[WZ#J #S0!@S^
M,-1\2?$>T\*2K/H=FMJEY-Y4ABN"3$K^4S#[N"Q!QCI7-Z6=&T?]H.V@TV]4
MVDEN\9E$Y<R2EF+AW4Y8[@WW\]!Z+7J?BCX9^%_%M_%?ZKIP>[3:&EBD:,R*
M/X6P1D=L]<#@BD?X8>$Y=4LKZ728I!8VJ6MM;ODPQJK.V=G1B3(<EL\@'KDD
M X_5!-;_ +3&A2^2A@N]/>-)'0'[L<K':>QZ#([''0T?'N(WVBZ+IUM:FYO9
M[X+"D9.]3M[*.N>G-=YK?@70M<N8;R:VDMM0MX6AM[VRF>WEA4C'!0C.,\ Y
M'7C!(IN@^ ]$T"^748H[B[U7RA$^H7MR\\S >[$A?^ @>E 'GOQKL]LO@FRC
MG("WA02W$W7 3EG/4\=3U-3?',W.F77A/Q*ELEQ::;=R+,KJ&R7V$<'VC;GL
M<5WFO> /#GB:]6\UBSN+F9"&0&^G5$. ,JJN%4\#D 9ZFM1]!T^;0WT:X@:Z
ML'0H\=S*\Q8$YY9R6)]#G([8Q0!RB:S\.[/P]'K2C2$M=Q9!$B,QE!$NQ0.K
M[D4X'=175Z(\9T"R>.P:PC\A2MF5 : 8^Y@=,=,5RN@_!_PAX=UQM6M;%Y+A
M9!);+/*76W.,?(#U]<MN((!!%;'C+7GT?1I(;*$W.K72F*SME4MO<\ M@C"^
MIR* ///@L/M'C3QWJ"X6*>_(6-^)%_>2-\R]1]X?B#Z5[0>E<A\-_!R^"/"%
MOICE'O'9IKN2,G:TC>F2> H5>,9VYQS77T >5Q^(Y/%_Q0U/P\UY<Z98:/&2
MQMIS"]P^0O+J0=HSD#VYKD_AP=.TCXV:[IEI<QBUC1X(%4,H(C.,'LQ&.6;.
M3D]Z]*UWX4^$/$>L#5-1TH-<L<S>5*\8FX(^8*1W.<C!)')(XJVGPU\&Q:S_
M &LGAVQ%W@+PA\L<8R(\[ >.N,T <5I6_P#X:9U<-]G(_LL8\D+NQB+[^/XL
MYZ\[=O;%0^,%G;]H/PD +QD\I]@$WEH/E;<4/Y;A_$,#O7>#X=^&TU^77$M+
MI-3E;=)<IJ%PK-R#@XD^[P/EZ8 &,57O/A=X2U#4QJ5YI]U/?*P9+A]2N2Z$
M'(VGS/EP>1CI0!YYX0OX_#_Q\\50ZELM?[0D(A:=PF[<^4V@_>S[59^)VH*/
MB[X/ACN[D-%B0B(+(J9=AD)_>XP?8"O0O$WP\\-^+?);5-/5IHG5O/C.R5@O
M\+..2"..?PP>:R&^#/@V6.!;JQFNG1GDGEEN',EU(P ,DC@[LY&< @98\4 =
M^A!&000>A'>O(OVBO*_X0.R\P2E_MR^7LQMSM;.[VQG\<5ZS:6L-E:0VMNFR
M&&-8XUR3M51@#)Y/ [U4US0M.\2:3+I6K6_VBRF*F2/>R9VD,.5(/4#O0!A^
M+;BWNO!.L6<*QWUQ_9SO]E1SN<8QU'(YKG_A2RK\"[ N551;W9)9=P \Z7J.
MX]JW++X9^&K+PRF@):3FR&3*%NI8FG)&"9#&R[OH>!V JQ8_#_P]IEA)864%
M]#9O$T1@74[G8%8Y.%\S"DGN,'D^IH \W^#]G-J7PR\56MJ-[74EQ% WF;8V
M9HR!MC_Y9]1D]^/[M1_!C4O"KV*:'J%K81>(8';<7MU0NL;AE^;'S,"N[UXS
M7J'AOP'X=\(W$TVA6$EF\Z[9!]JE=6 .1E68C/H<9&3ZFLGQ+\)/"GBC5DU.
M\LGBNO-5YVMY"@N /X7 XY[D8;WH O\ A76/#U_?7EKX;M(39VZ1A[RVC A=
M@H58U(ZE5"_3I707]T-/TZYO'4R+;Q/*5'4A1G'Z4W2M(L=#TR#3=,M4MK2!
M=D<:= /KU)]2>3WJS)$LL;1R(KQLI5E89!'H10!XQX?NO^%B>&=>\0Z_?&*Q
M#D6NG+<>7#&(AOS(I.Q\G:3N!''/%2_ :[LT\)7EOYT N9KJ0+&I3<V 3T'/
M3U[=.*ZRR^$'@JPUE]3CT2*21N5AF=I(4)#!B$8D'.[H00,# %:&C>!O"_@U
MKR^T>P6P>:(K-(;B1EV]>=[$ ?2@#A_V>H9;7PMK-K.ACGAU-HY8V^\K!$!!
M'U!J'1M,.I_M'ZWJ$-ILMM/MP)9PN]7E*(!R?NL5)''9#ZFLGX*>#[34O#FM
MR)J-W;7:WYM6O-.N63S8E53@9XP220V PSP17M.A>'=+\,V<UKI5NT,4TS7$
M@>9Y"\C  L6<DY.!0!Y?\"U@CO\ QC%#.LR"^3:X7;N'S\X/-,N--_M;]I,3
M0VG[NPMTDGG"^8"VP;<YX4]LCG\:R?A1X:T_7K_QC/:W&I:?<+<^1#<V]R1+
M'&^[>.FPYQU*Y'!&" :]FT/POI7AV.[338)(_M<GFW#R7$DKR/C!8L[$YH \
MTT6%F_:;\22^;&JI91@H7PS9ABZ#N!CGTS[TGQ?\C_A/_AZ+CS/*-Z_^KQG=
MOAV]>V<9]LUV\'PU\,6^L'5H[2]743C==?VG=&1@, !F\S+#@<'CBIM8^'_A
MS7]234-3M+JXNHVWQ.;^X41-QRBA\)T'W0.E ' _%ZXFT#QQX,\3/*\.GVMS
MY5Q)&?FVE@S# Y(*!J[^\\<^&K?28M0_M6UG@F8K;B.0,9F!P54=SFKU]X8T
M?5-&72=1L5O;-4**MTS2NN1C(D8EPV"?FSGWK"\/?"CPAX:U!=0L-+S>QNS1
M2S2O)Y>3D!021P. <9XZD\T <S=>)+WQ5\4;KP9?.VF:=9VWGS_9IMDDY:.,
M^6S@_='F-TZX%<QX?3P_H7[0-U%9&TMK*VM) 22 %98\M@MWV]=GOVS7J/B3
MX7^%/%6K1ZGJ>F[KM=HDDBD:/SE ("OM(SU'/WOE S@8IW_"K_!@U2TU--!@
MBN[0QM"T+O& 4.5)56 )SW(.>^: .,O;I?\ AI+3FDOM\*Z>Y6-P0L68ST)X
MYZ\5!\:[ZSN#X(O(PEY:2WAD0JYVR(0A!!'..0:]!\5?#[P]XRFM9]9M))9;
M8C8Z3,N5W9*$ XP>A[^A%-U;X=>%]<EADU#3I9/("B"-;V>..$* HV(KA4P%
M'0#I0!P?QZAGM)?"?B 0F2TTV];S@K8.6,;* /?RVY^E=[XMO(KSX9:]=*RA
M)=(N&Z@XW0MP?SK;N](LK_29-+O(!<V<D0B>.8E]R^Y)R3T.<YSSUKE-/^$W
MAG3_ -RBWTFGB7S1ITM[(UMNW*P)CW8;!7HV0<\YXP >71Z5?V'[,TK&TF:6
M:;SFCG7>$B+_ 'T5ON\<Y'UKTBZ\T? :#R/M/F?V'!C[,<2?ZM.G]?;-=)X@
M\':+XIC6+6;>>XA48$*W<L<9P<@E$8 GW(S5:7X?>'I]%71Y8+Y]/3@0-J=R
M5Q@#:?WG*@*,+T'8<F@#%^"P9?AAI>X2#)<C?+OR-QY4?PC_ &?J>]>A5A>&
M_"6C>$;>:VT.SDM8)F#/&;B21=P[@.Q /KC&<#/05NT >(_ :631KCQ%X6OH
MO*O;6ZWN=X*D_<P/7E>M2^+].FU3]HOPTL"SLEOIZ23/ Q4QJ'FY)'09('XU
MWOB#X=^'_$>K0:M=6\L&I0E2MW:S-%(0.@)4\_7KQUK2T#PQIWAR.86:2R7%
MP5:YN[B5I9KAE4*"[L2>@X P!DX R: /+?B#<_8_CAX+DEEDCCW;%.9 ,L=N
M!@XY) ./7YLBO:QTYKCK[X7>$]1U4:G>:?=3WJL&6=]2N2Z$'(VGS/EP>@'3
MM75VELEG:16T9D*1J%7S)6D;'NS$DGW)H H>);^#3/#U]>7<1EMHXCYJ X)4
M\'GMUKQ3Q7\//^$(TN7QMX(U^:UMH8UD,0D+AT9D "MW4GD@^U>[ZA8Q:E92
MV=QYGDS+LD$<C1L5/7#*01^!KCX_A/X;2!K(OJCZ4=P&FG4I_LX!V$#:'[%6
M(YZN<YPN #A?BYJC>)/@QHNL?8')GFBD<DD& D,"QQQR?E_X%73?&/4+-/AC
M/ ]W;+-<!1"CH)"Y')VCL1_>[5VFL^%M&\0Z,ND:K8)<V2;=D;,05*]"&!#
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M:=I^H 7#KR5RZ/T[\1M^GK7LU4]4TNSUG3;C3M1MTN+2X79)$_1A_0]P1R"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%8FD>([+6=6U?3[02%],F6&=F& 7()P/7%;= !17)ZAX<U>\^(FFZ[
M'K#0:3:6AB:R0G,LA8Y)'3!&SW^45U8Z4 +1110 4444 %%%% !1110 4444
M %%%% !1110 C E>.M1^4GF^:8U\S;MWXYQG.,^E2T4 -&0?:G4C=#7G_P 8
M)M3L_AWJ=[I^I/:"*-5E1(P3*&D1<;NJ\$].N: /0<T5RWP]N[F_^'VAW5U*
M\T\MHC/(QR6/O74T %%%% !1110 45@>-=?_ .$8\'ZGK 0NUM#E  #\Y(53
MSV!(-<!%X=\6:KX/T;Q'HGB&9O$'E^=*);OS()EY;RE ^7!8(.N.O- 'KU%>
M2:9>:C\0/%_B+2-1OIK.TTZ$6IM[.ZV;I@<.Q'WF3.<$@>E=9X$L?%NEV5S8
M^*;VWOS%+_HUVC$O(I )W9'0$D#//'I@D Z^BBB@ HHK%T'Q'9^(SJ1L1)Y=
MA?/8NS#&Z1%4MCVRV/P/;% &U44\*7$3PS1K)&XVLK $$=P0:E'2B@"O9V-I
M81M'9VL%NC'<5AC" GZ 5,W(ILP<HP1MK$<-C.#ZUXUH>I:R/C_<Z3>Z_/J$
M5O9MA$M6"1EA&2I X3HIW=,X&<G% 'L%I86=B9/LMK! 9#E_*C"[CZG YJS3
M5ZTZ@ HHHH ***@G222"18FV2,I"MZ''!H GHKE? 7A[5/#7APV.L:HVHW;3
MR3-*<X3<<[5SR1G+?5C75#I0 4444 %%%% !112'I0 N:*Y*Y\-ZO<_$BSU\
M:NT6E6UFT/V)2?WCL><CIM^Z?7*"NMH **** "BBN>\9V^K3^'+S^Q]2>PN$
MA=@\=N96;Y3@*!R#] 3[4 =#17G/P3U*?5/AY%<W>I"]N6N9C+D@O&Q<G#'K
MDYW<]F%=_>W45C93W=PQ6&"-I9"!G"J,DX^E $^:*PM/U1O%'A:WU+2;AK,7
M:"2*62(.57=W4\<@'\ZX3X(:AJ>HVGB&35K]KZZCOA&9O-$@(" ?*PX(^E '
MK%%%% !1110 5%+$DL;QRHKHX*LK#((/4$5+3"/F/3% #+6TM[* 0VL$4$0)
M(2) JC\!4U>-:;)KL/Q]&E7VORWUI! ]R(I66, O&>$3/.,]L\<U[(O2@!:*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ K!U[P?H7B:1'UBP^U[ %"M*X7@D@[00,\GGKS6]10!GZ7H]
MGH]F+2QB:* '<$:1GQQCJQ)[=*OKT%+10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,$,G)Q@@$ YQC!SS7DWPOM?$6J>)(=)U@1C2_"<DBQ120(S>:050$@]5!)!
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M=IXG^&.AZCKUYXKN-:3[.D45K>RDJ9B.6&[)ZYP!@D=<U@ZS>7-SX0CNM/\
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M)\N"P)XX(/TH T/@.TA^&%H&:8HLTH021A5 WG[A'WAG.2>^1VJS\9]*BO\
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MNS8'4L>2?<U8KE/$/Q T;POKVGZ/J(NOM%^,Q-%%O5?FV\X.>OH#74\YZ]Z
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M(R13\4 )@48%+10!C-X2\//??;6T:R-QG=O\H==I7ITZ$UL%5(((!!Z@TM%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B@G%(
M""<4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M4$XI 0>E "T444 %%%% !1110 444A('6@!:*,TA('6@!:* <T4 %%%% !11
M10 4444 %%%% !12$@#)I<YH **** "BBB@ HHHH ***0D#K0 M%&:* "BBB
M@ HHZ4F10 M%%% !1110 4444 %%%% !129&<=Z6@ HHHH **** "BBB@ HH
MS0#F@ HHHH **** "BBB@ HHHH ***0G% "T49!HH **** "BBB@ HI-PI:
M"BBB@ HHHH **** "BBB@ HHHH **3(I: "BBB@ HHH) H **,T4 %%%)D4
M+1110 4444 %%%% !1110 444FX9QWH 6BD# TM !1110 444A(!Q0 M% .:
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXNRA=8C&\98#KC<H!/L.>I[&M/5_$FE:%-;PW]RRSW)(AABA>:1\#)(1%+8
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M0'C*DIR/<<4 =ID4N:P?$'B_P_X6C1]:U2"TW8VH<LY!S@A%!;'!YQCBL_\
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MGV7Q(\'ZAI=YJ5MKMNUK9C,[LKH5';Y6 8Y]@?2@#K<BBN5\/_$/PIXGU/\
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MFB@N,"&62QN%23/]UC'@_@: .RR**:ISCU[TZ@ HHHH **** "BBB@ HHHH
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MQ%U/']H\X.<E-I^4C'!R*?X)\$^*HO .J>&=8MX8+0I-'"CS,PF<N>2,_(O
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MKX=TC3([B*UM+V^$<S%"0JKR/NC./7 J_P"*O 'B/Q;IIT^_U/35@,Z2QF*
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M@BM'/O0 ^BL+PQXHL_%=A<7EE%/%'!<O;,)@ 2R$9(P3P<UN#I0 N!Z4444
M%%%% !@>E%%% !BBN=\:^*8_!WA2]UR2W>X%N%"Q*<;G8A5R>PR1D^G8UKZ;
M>G4=-M;W[//;?:(ED\BX3;)'N&=K#L1G!'K0!;HHHH **** #%%%(<XXH 6B
MN'L?B7I^I^/8?"MG97HF,;2237,#0!0%W#"N Q_$ >F:[B@ HQ110 8%%<#J
M/Q0L[/QO9^%5TS4/M=Q<+"L\T)BA93PS*6Y8 @C(&#V-3>+?B9IWA74[/2WL
M[VXOKN=84_<,D*DE.?,8 -P_\.[!&#B@#N*,#TH'2N8\9>.--\$Z>;O4(+Z8
M8&%MK=F')QR_"+]"P/IF@#I\48'I6=X?U,ZUX<TS56B$1O;2*Y,8;.S>@;&>
M^,UHT %(>E+10!Q?CWP/)XQ73)K35YM+O].F:6">--X&< \9!_A'?UX.:PK7
M2_BZTCV-UK^BQ6S@(-02W+SH%+$.(\!=S9"D'@ #'.2?4" .:JWM[#I]G+=W
M"S-%'@D00O,_)QPJ L?P!H KZ1I4>CV7D++)/*[F6>>3&Z60_>8@  9]  *T
M\5Q_@CQ[:>.FU-[&TGM[>RD2(-. '<D$GY1G'3U_*NPH **** "BBB@ HHHH
M ,48'I10>G% !@>E%5+Z^BTZSDNIQ,8HP-PA@>5^3@81 6/7L*YKP3X^M/'+
MZFUC:3V\%E*D0,^ [D@D_+VZ>OY4 =A1110 444QVV@GL!DT /HKE_ GC*/Q
MQHDNIQ:?=6<2W#Q1^>/]8H/# C@\<'T8$<XS744 &*,444 )@>@I:** "BN9
M\2>+1HE[:Z396$VI:U?1R/:6<;+&&V*22SN0H7CU)]C6;X3^)%IXGU_4M#EL
MIM/U.PD='@FDC.X*Y& 58Y8 9(&0/4]: .XP/2BCM10 48'I110 8HHHH ,4
M444 %%%5-0O[?2]/N;^[E\JUMHFFE?:3M11DG Y/ ["@"W17G%Q\6[33QI5[
MJFB:E8:/JB*;6\D,4A)//,<;LP&T@],\XQ7H<$RW%O',@<)(@==Z%&P1GE2
M0?8C- $E%%% !1BBD8XH 6BN:\7^-=/\%Z4;_48+V90 0MM;.X^\%Y?&Q>O\
M3#/;-:'AO5SK_AS3M6,7D_;+=)O*#;MFX9QGO0!JX%%%% !28'I2T4 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:N?N$X/<&J>M?#GPC_8)\-Z-JPL[T:A(\ )$C"Y*JRQ[B"5PNT?*02 ,Y(H
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M&&XM;R2*1DW$(N,X9%X(&,?AQ0!WOAOXE)J_B"[\.:EI-UIVM64.^:%AN#D
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M. ?W:D8.2>]\)^!O"_@[Q-</IT\SZM=6S%EGG+OY>\%FQ[L4&3Z#U.0#N=V
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M;BZ6]+&+*@,1NVA2>F?4UZ9X<M] TM+O1M!BMX%LY<W$,"XV._S<^IQ^F!T
MKSSX#"X_LOQ 9(D6#^T"8G5%#/\ >SDCD_C^% '7>%OB#%XGUW6-&33+BUO-
M*.V99'5@6#%2H(..HZTS1?B&NJ>.+KPG<:1<V6H6L'G2&21'7&%. 5)[.*Y7
MX<B<?&3Q[]HBCC;S 5"1JH*>8VTG;U)&"2>3WYJ2P$G_  TMJ/F&Y*C2/D$T
MN]0,I]P?PKG/'][<>] '7_\ ":2WFNZEI6CZ-/J+Z:R)=2+-'$JLP) &\C/
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M;K3F/B&_A"PV4""2=^<[,CC&XGGIG-<7I1FB_:2U +!#;QO:G>%#1&0;3AL
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MVJW1:T<>2[%0_'0D$']: .-_X7II9@TJ>+1=1FBU#*AHMK^5('*F,XZL!L;
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MT_0]5M=&CBFO]9NP#!8VPR[#/+,>B@#)R>RGTJG#\0H(?%<'AW6],N-(N[E
MUL\\B-',?[JLIQG^O%<1X:U I^TEXB@O[B3=-9M!9I,2<@&-]JY[85SZ<&F?
MM%P0G0]$N?)C%S]L,?FE1NV[2<9ZXSSB@#M?&7Q-L/!=Y:V]YI]]+Y\FSS5C
MV1#@'(=N&QGG'2LW4/C'8V%Q%(=$U)M'EN!;Q:L5"6\A)()#'L"&_P"^36'\
M<D;^S?"9NT,EVMZ-TL(VQ!ODW<')P3TY_.M3X]K&WPV;>D!9;R,J978$-M;E
M<=6QG@\8R>H% 'I\<JRQK)&P9& 96!X(/>JFJ:O8Z+827NI74-K;I@&29PJY
M/09/<U5\+%V\*Z69&G=_LR9-PJJ_3N!Q7F?[0D]Q%X>T81RRI;M>_OPK':0!
MD;NQY]: -^?XI7-IH-KKEUX/UB/3+@;_ #_D;RDR!N< Y4'.1GJ.E=!J7BM_
M^$:@UCP]82:T+H'R5MR,#Y';<WH,KMQUR0.M6M8:QUCPA>R[8KJRN+%Y4W*&
M212FY3@_@:\P^!?GCX6:PTB6\MM]HFVQ/%NW'REW!QG#*?E&..^3SP 5?@?K
M^H>1>VJZ9?W0N-0_?2;U$5ID,2>3GH#GW '4U[;9V%II]I':V=O%!!&H1(XU
M   & *\H^ 7'AO5<R2;?MK8B+_)'U^ZF/ESWY.:]?H XZY\=EO%UYX<TG1KK
M4KJRB22YD1TCCB+<A2S$#.,'_P#4:=X3^(-CXLM=5>&TN;>YTMREQ;,N]^^-
MNW[V=IX']:YBP-A?_$37T\"V.EVM_#'MU/5)XF?$K$@+$@( .58L>A8<@XS6
M)\'XY8_B7XM6YN7N[I5 >XE96=SN&3NVAL9[ @< $' ( .FC^,^D2:KJ>F_V
M9J"WEH=D4#1XEN9"P4(J?>!)/<<5?\-_$ZWU_P 1W&@3:+J&F:I##YPMKM0K
M,,9Q[<$'GUKF/ :1K\<_&OEQS)E"6\P@Y;S!DC@?+Z57F^3]IL&'Y&:S7S?L
MWSLWR+_K0V0HZ?=QQ@]2: .QTGXCG4_',WA-]"NK:_MX_-G9YHRB+A3G(//W
MEZ>OM6EXL\8'PM-I<?\ 9<][_:5RMI$8I$7$K?=!W'H>>>G%<!\8]/N/#^N:
M'\0[*9S<6,J6DL 0$%/G;()''!=3GU&,5O:!+#XS^)<VO^8SVNB6JP6L97&R
M>5<R,&'WAMXYSU[4 >C!B5!Q@]Q7.>(O&=IH.IZ=I"0M>:MJ#8@LXG56V\Y8
MEN .._7\*Z,J%7@XKR'3[QE_:8U>"[4NOV!%M7FD;]VOEQDK&,XP6+$\=<X[
MT =/IOQ$?_A,;;PIKFDR:?JMS"TT6V198V&6P,J3@[58\^GN*T==\:1Z5K-M
MHUCIUUJNIS89[>UQ^Y0G =R>%7)')JSJECH5MKVGZW>6$<FK9^QVDPCW2Y?)
M('T56.>PWXZG/F/A&XA;]HGQ*NI.'N?+=+$SC+* 02(R>@V;NG;- '>6OQ!@
M7Q6OAS6=-N-(OI4#VYN'5DGSV5E."?Z\50UGXMZ/H7BV'0K^SO8-Z%VNIH_+
M10-PR W+ [>".#GBN1_:$MHMGAJY2&+[2;MHQ*4^;;P0,]<9.<59\8O+%\=/
M _VN:RW"V^?8@5]_[P$DGYMA/W02<$-W)) -D_&6QM-5L;;6-"U32;2]8B&]
MO(PD97LWKMY7GMGFG:K\8;;1+U%U+PWK-KI\DWE)?S0;8V']X \D8YQUK%^/
M_&F>'FYPNI)\Q;S%'!ZP'Y9/Q'MT8UK_ !JY^$-US_';\A<?QKV[4 ;GB_XC
M:;X2T:#5&M;J_MKA4>*6UCS$RMT/F?=Y'(&>0:YO5_CKHVF);RPZ5?WEM-&&
M\^(#8LFU6:/)ZLH9<XZ;JR_B):>9^SSHZ6;-<0PV]DXD*[-T8C'S$$\<8XKO
M[9/-^%446Y$WZ(%WL<*,P=3Z"@"+7-:M?$/PEUC5;(LUO=:/<NFX8(_=-VK'
M^"?DVWPJL62<2('E=V"D;3N)(YZXZ9KC/AJT_P#PHGQ=!(%,$4%X(Y%0X8F%
MMV&SST'88SWS74?"RXLU^"D4FN16ZZ>B3"<20*J-$">6 &&R.I/)ZT 7D^*O
MVGPY>^([3PY?RZ+:NZ_:FDC3S%5L;E5CDC/]1VKJ--\46>J^%;?Q!:17,UM,
M@<1Q0L\O7:1L R2#Z?6O+;='O/AG>R^%].L-(\)%)9,3 3W%YM=T8MO#!?NK
MC(8C  (P,=)\"PJ_#*UVJHS-(6VJHR>.N%&3[G)]\8  -#PG\1].\3:;J=W:
M:5?PQZ?,L3QI 9'<L3R$3)[<UDZ7\;--UK3WDT[1-1N;\2F--/A4/,Z@ E\#
MHHSWK+^ 9@-MXF""03"_'F,6&T_>Q@8X[YSFI/@)&T6D>(HVM5M2NIE3;HQ8
M1':/E!))('3))H ZSPC\1K3Q?;ZO]FTZ\M[W2R1/92J/,)P< 8XR2K#'7(K@
M;#Q_KEU\8]1+>']0G^RZ8\*Z=#(&:'E)"[<X!. N!W*CK5GX7RK%\6_'-M$U
MG'').&,4)=]Q#/R&)X.2=P/<X& *M>%RQ_:-\3;GMV TTA?)4 @;XN'P!EO<
MY.,<T >N1N6B5BI4D E3U'UKD[SQT5\7W'AK2]'N]2O+:)9;AHV6-(MPR 68
M@9P176C!^E>6PS:;=?$76X_!.D:>NMQE5U+5)\E(6)(;;&,9;(^8@C)SG- '
M4>#O'EEXPFU6UBMIK2]TR;R;B"8@X/(!!'!&5;\O<56F\<WMU=71T#0I]7LK
M!V6ZN(I%7>0K$K$"?G8$*./7UK@_A5"\/Q<\6)</#+<QQHLDL<4:;FR-[ *@
MQD\D CWW'!%?5M$\6^%=6U3QIX(U9-2TJZD,UW:LS2EE5AE3N)+'[W(PP&0*
M /3K+QY8/X0F\1:G;SZ7#!(\4D%R/WJNK;=N!_$3QCK69<_$#6=,AAN]2\&Z
MA'8W+IY4D4B.848+S, ?D.YCP?YYK$TC6/#7Q(^'VI6[J^CP7%]MN/-VRXGD
M;=E2X(&2>P&.V*Y*;6/%'PQ@CT#QE VL^&9%\JVDC<JR*KY7Y^O3!VDG P 0
M* /9O%'BVV\,PVZFVGOK^Z8K:V%JNZ:<@9;:/11R3]/6L&3XGII_BG3-!UK0
M;_39M1*K!-(R.A+< 94GN0#Z9YKBO%FI6]]\;_"\EU?WUII]QIRFTECDV!'E
MW XR#@LN%)7#9*G(P*ZCQ!\+_#=Q:)>^)=8U*YL["/.^\NRVQ=P9R7/S'<!M
MQG@'C!YH O:_\5M+\/>*;70[RPO4:<D?:)8_*C'S$9!;&Y>.HXKE=4^-TUSH
M^KIIOA;5XKFT0QS2R ;;9B2N7(Y7!!_$4[XEV<5U\6O Z7&GPS6\DJHTDGS!
MQN/R%2<8[]/QKN/B7,8?AQKDBW<MH?L_^NB!W#+ 8&".O3Z&@##^$/B'4-1\
M)Z9:76E7R1BWD<:A,04F82#.._.\XSUVMZ5HVGQ'TZ\^("^%DTN]ANWB,AGG
MB\K@*6Y#8;''':G_  FX^%N@?]<#_P"AM7(/#YG[4"R>:B^78 [&;#-F(CY?
M7U^E '3:Y\5])\.^*K;0KZRO8?-SFZFC\N-0"1D;L;E^7@C@U27XQVD6L:?9
MZAX?U:QMM1E\NTN[B+:DH.,,HZD'<OTW"L?Q^L8^./@=A'*)< %\CR\;FX Q
M][KWZ$4WX[ND5WX/FS:K+'?EDDE9BR#,9)"@X*\#=WX7&,F@#T/Q1XQL?"YL
M()U:?4-0N$M[2SC8!Y69@N<G@ 9&2?ZUR^M?%EO"=XEIXFT&XM)IU>2W\F5)
M0Z@X4':3AC^59/Q=L)SJ'@SQ/ \5S)97\*I9IE6NG9T8"//<[.A['/:CQFEK
M\4]1T+2-+%UY5I>-->S&,H(XA\N06')/;CF@#U+2-6M]:T]+VU$HB9WCVS1F
M-U9'*,"IY!#*:OTT 9Z"G4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !EP??/3/%;8&*6@#AM%\%:]HO@]_#</B2S-NMJ\$$RZ:ZR1EFY8GS\'@L
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MY2"<@C%>-7GP7UC2-<>^\%^*)=,M&D,R6<@8K$W''7#CK]X9  '/6O9Z0C-
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MR<G\:EUOX<:OK/CJQ\5?\)'9Q7%@"EK#_9C,H3<Q ?\ ? L?G/(QGT%>BT4
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MD"6YN)M.(G6/D$ ;RAVJ% )'/?ID^D9%)@/S0!R&J_#O2=6\"1>%)I9OLUN
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M%!Z4 >3Z#\*O$&G:1<:!=>-[D:&$>."WM+5(V(?#%F8Y(^<O\H)R,<C.!I>
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M!FL7VO>$=+U74K);.[NH!(\2/N7!^ZP] PPV.HW8.<5OU&BH@5$4*JC"@#
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M3,?/F/15VN-J=MQSSVJIX.^)FH:WK.J^'-1TZT37]/,BA(9RL5PZL00I()4
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M22"[E );#*Z[0#M'0]<\U'X+^(=QJWB"]\+>(;:"S\06KL%%N&\J91SE=W/
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M6=MYWVBVA>-G.V-APSM@?.?RI\GB_P 2Z?\ %?2O"M]%IDNGZA')(MQ#"Z2
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MJJZ?]L.GVK7ZQ+>F)/M"P_<$FT;@N>=N<XS5J@ HHHH **** "BBB@ HHHH
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MJ!E^RR!XV!,Q!!!8'(P3SU)Z=*Z)OA#X:?Q"VK8N@)IY+BXM3*?*E=SG[O8
MD\5+IGPE\,:-?SWNFK>VMQ+G#17)'EDG.5].,@>Q([T <W\$W,FJ^-&:YBN&
M-^F9H5*JWW^@('TZ54\*B=OC=XR %^5\I@<PI$N,G&X9RR_W6')ZD"NYT/X<
M:/X;DNGTJ[U. W6[S@+LX=B"-QXZC<2#V-,TWX9Z'I7B/^WK>YU,ZBSEI)9+
MLMYF>H;U!]* .(_9YU"UM]"U;1)I1%JD=\\K6L@*R!=B+G!]"I!';OU%+HTD
M2_M,ZJ%7369K$J?F9'5OD/&X?-+CLN!L).<@@]3KWPBT#6-;&K6[3Z;=G<TC
MVC;?,<ONWGWZ_G[40?!_PM'KZZM+#-<2*@&R60D,Q+[G<]6)W#Z;10!Y_P#"
MZT\.IK^M>&O$=A''J\5\)U-S.NR1@^%0 $9.2#M^8'KVKT[2$\'Z7XL73-&M
M(7U7RY/.EM\RF$!B2)7).UBQ/!Y_"JOB?X2^'/%&J+J=P+F"[!C!:&3 *H>@
M'J1D9ZCK6KX;\#Z=X7\./I-C),LDH_?WBMMFE<]6W=CZ>E '#_"AWE^(WQ#9
MKB*X/VN(;XE*KPTH P0.0.#QU!Y/4^PCI7%Z'\,]!\/:^^MV$NH"]E+&5GN2
MPE+')W#OSS79CI0!YW\;Q ?A=J7GO(@#Q%2B!LMO&T')& 3U/./0UK>%Y8E^
M&.@PL\)EDT2'RXI' WX@7/<<=,^F:Z#6-*M-<TJZTR^0O;7,1BD .#@C'![&
MN;TSX;:%HVESV.GO?P+/C?*MR?,VXQL#=E]J .:^ 2LO@C4MR1QD:O."D3;D
M7Y(^%.3D?B?K7,>!H+S4(_B;I5KO>:Y@F2*W9O.+R%'5?WXPG4XP?7_9->G:
M%\/-*\-6-Q9Z1>ZI;6\V246Z.%8[?F''!PH&?3--\-?#70O"NKOJ>EO?I<2!
MA('N2RR9_O#OSS]: .!^$$/@[Q#X>2&ZLHUUFT!@E$UP T@"XWHJD=%XSC(]
M3UKT3PE+X534=0L/#%M"$MTB^T7-LN87;;A4$F<,P55) _O#N37/ZW\$_#FK
MZK<:G%/>V5U</))(T4G!9O0=@#VKN]"T33_#NDV^F:9;K#:P#:JCJ3W)/<D]
M30!I'I7(>&]5TSQ_X/:.]^RWN\-!?6Z@@(^2",'D>Q_(UUYZ5YU#\)['3H)'
MT;5]0TK498PDMW:O@28;))3H2: /.-<\+?\ "O/B_HK^&;PJ=1D^6R$>]XT8
MX91N*JRG'&6!_F=+5$T?3?V@=6B\46F+76+6,6L[SJD:+L52S<@@$QLN<@\8
MP0W'INC> ]-TG79M<GGNM1U23*K<WC[VC3/"C/3 P,]\5+XP\"Z-XVLDM]5A
M;S(L^3.APZ9'KZ9[>U &1=Z?X!\/ZQI,B:;9R:J]P@LH;5?,ES)A?,V@_<"J
M6+'@!21SUXWX(WEKH5_XC\/ZI=0VFJF^&VWDD +?PX4]&.3T!S7?>#?AQHW@
MRYGNK4RW-W* @N+@[FCC 'RJ>P)&?_U5G^*OA#X<\4:B-1VR6%XV]I)K;@R.
MW1C[@\T =+;^(--N_%4VDV<?VB[AMP]S<0F-EA^=@(W.[<&R&XP<>U>>_")7
M3QU\0@\4$)^UP'9 P9<;IL'()Y/4\\$D8'2O0_#/A/2/"6GM9Z5 R*[F2621
MMTDC$]6;J:Y_5OA/X>U;Q$VMNUW%<2SK+<)'*528*N-I [=#^?K0!RW@QH7_
M &@_& @B:,BU8/N?=N;?'DC@8'MS]:E^'DD<GQK\=%)YY@#@F9<%2)#E1R?E
M'0'CCL.E=!9_"'PU9:Y/J\8NDN7D9X_*E*+%D8&T#NIY!]<>E6]+^&.A:1XC
M.OVL^H_VBSEY)6NB?-)/.[CD&@#"^/X0_#F,2,P3^T(=Q49(&&S@9&?SJ[X[
MBBD^!ETD=O<7<0TZW**GR2$ H0QP&QC&XCG@$9[UO^*?!.F>,HT@U::^:V7!
M\B*<HA89PQ'KSUJZ_ANPG\+GP[<^;/8F'R#YLA+E>WS>HP,?04 9'PSGBC^&
MWAF.25%DELU$:LP!<@$D =^ 3^%<)\ A'/\ #_68K>!Q.;AE<M("'8QC&!@;
M>,#J?6NT\/?#+1O#.F26UG<WRW$H -TLY$B@'.$/\(/<#K6AX2\#:1X*BN(M
M'-TL5P0TD<LQ==PXR!ZT >4?!Z#PK<Z?<>%_$%I9#7X+Z4"VE#$N%4*3G)0M
MEG7Y>H4<' -=];3^!M&NM>BTBP1WBTY[C49; ;E$:#'E[PV Y&<*"/NDG&!4
M?B7X/>'O$>MS:P\EW:W\SAI)(7P#A-O ['H<^WO72:%X1TSPYX<.BV"-'%(A
M668'$CLPP7)]: /)]4\%:KH6FR^+OAGK;P:?>HL[V<C*BK&>2P:3C _VL$#N
M:]2^'OB6?Q=X(T[6KF!(9YPRR+&25W*Q4D9Z9*YQVSC)ZUC0?"VSMK633(M;
MU=='D#![ 7!V,K*0RD^Y.?TKN+&SMM/LH;.S@2"VA0)%&@P%4#  % #=1O[3
M2[":^OIT@MH%W22.<!17F'A#PMJNOQS>+QXDGL9]7D\PBT16!A#C: 74E?E#
M# R,L#SC![WQ/X7LO%>G_8=0GO%M2")(K>8HLHR#\P[X*C'XU-X?T*T\-Z/#
MI=@\YM(01$)I-Y4>@/I0!XA\0M!U'P%XIT#QH;ZZU4I(B7LTIV%V7_<7"H1Q
M@D_C78_&8OK'PJCU/2L3VZ307JR8P/*P2&PW7[R\8SSTKJ_%G@;2?&:0)J[7
MC10\K%#,44GU([FETGP/I&DZ)+HJ&ZN]+D39]DO)C*BC). #TY- !X8\4Z+J
M/A&SU!-7LS'#;1"YD,BH(F(QAP<;,L#C.,]J\R^,>IP:Y\*M.U"QTY8+)[P&
M/[08T=5P0'C57(.3]3@DX'6NCC^!?A:+76O UT+%P";#S"(RX;<"3W7'&VNP
M\0^#M%\5:+'I6IVF;6)@8A&=K1D?W2.G''T- &\)XC/Y'FIYP0.8]PW;<XSC
MKC/>JFM027>A:C;P+OEEMI$1<XRQ4@#\ZI>'/"^F>%;#['IL<@4L6:2:0N[9
M]6/-;/)^E 'D/[/UXH\)ZIHSQR+=Z?>L9@V-OSC  ()YRAS^%5;FSGNOVGHW
MB:=$ALU>1XAP!Y9X8X. 3Q^-=EJWPSTR^U_^W=/N[O2=2;=OFLWVAR490V.F
M<L#[XQWK>T/PW8Z MP;;S9;BZ?S)[F9M\LK>I;^E 'EFL@M^TIIH$VPK;ID8
MC;/R]/FDX_ *WHI'S'VT5Q%U\+]%O-8M]7N+W5Y-0M\"*Y:\)=,=,''O7:01
M^3"D6]WV*%W.<L<#J3W- #VZ=,UXW=Q21?M+VDEM;1EY;(^8\ER#E?+P2%4$
MJ0.@/7KD"O9#7"S_  IT&YUT:W+=ZNVIJ5*W)O#O&!QSCM0!V5U:PWUK+:W<
M*302J5='&0P/;%>.^.O!?ASP=H5X=)EN(]0U8K::?I;W;"%I'958J@(.0N>6
M.WD9Z@5ZS>:?<3Z(UC;:A/;SB-42[^^XQCDYZDXY^M8^F^ ]%L=9;6IXY;[5
M78/]ING+E&P02@/"@CM[#TH S?AGX9;P1X!A@U-H[>X.ZYNV?:HB]59@2"%'
M?-='XATC3]7T2[@U"TAN8O)? D7.TX['J/PIWB'0+'Q-HD^DZB)?LLVW>(I-
MC'!! S^%<KHWPGTK2[0VUSJ6I7ML9$E>"6<B-W50"67N"03CWQ0!G? >TGT[
MX7I=7ERAM[FYEN(<N<11#"$'/ ^9'/''.?6O0M0T[3]<L#;WMO!=VDJYPZA@
M001D'MP>H]:KZAX=T[4?#<F@O$8=/>(1>7 ?+*J", 8Z=*Y/3/A'I6F/-"FI
MZI)ITSAY+)K@['VLI0-Z@8;Z[O:@#'^ >G7-GX4U*YDE4VD]ZP@C#D^6$)#<
M'@9/I7J.GZG8:G"TNGWMM=QJVUGMY5D /H2">:A32-/AT=M*AM8XK#RC'Y*C
M"A2,$5YM\)?"\6AZSK5YI$YNO#T\<4-K=^8#Y\L>4E8#/ WAL'H1C!(H ]9;
MFO*)-;N_&GQ$UOPC:>5I$=E"5NKZ) ]S<1ATRB/QY>0Q&?FQUKU7MS^-<1XE
M^%VA>)]>36+N2[@N H2;[/*4$J ' XZ<D'/MB@#@/"/V#3/C?XD$<VZSM875
MWEF>38%Z@N\?&.F"P [,].N? MZ+*X\;_#75KNQFO/,>?3[F-8B#YC>8GS85
M2C KM(P-I^;U[A?A)X9B\3KK5O%-;[57_1XI"L;.#]YAWSW%)9_"RSTR.2UT
MW7-9M-/E;=-:I<DAR<[R3_M K^7O0!8^%WBJ^\6^$/M>I1QK>VUP]I*\;!ED
M*@'=QQSGL2.,]ZZ3Q!J?]B>'-2U80^=]BM9+CR]VW?L4MC/;..M2:/I%CH>F
M0:=IUNL%K N%11^9/J:MNBR(4D4,I&"".#0!XW:)/XW^&UUK]Y<K8:5LF:#1
M[.)(X5*2-CS&+KOSWYC!K+\*W*6_[-.KROYK*K2@B*4(P)=>X9L=>X7(_AP=
MS=MI?P8\*:;<SL4NKFW<%4MIYBT: C!X[G.3GWI^G_!WPQ8:#<:2%NF2XE9Y
M95E*.RD@B,G^Z,+]2,T .^%\DLWP?TT+!=QNEK(L?E&/S).6PT>3MSDX&['(
MY&.:PO@#)YGAG5(_-C8QWIR@W;TSG[^?EY[;?QKK=/\ ASI.E:!-HEE>:K!8
MS-N>-+M@>05(![ YY'L/2K'A[P)IGA?3[BRTNYU&*WF1E*FX)V$]67CAO>@#
MSSX<K'/XZ^)MO%"S7;W<X#[_ )6!DD 7;C@YSSGO5'X-6OA>]T^Y\/ZM8)%K
MNGWCEEN+A?WKLI7]V 025"-QSMSD'YCCT_P_X!TCPQK=WJUC+?&[O,FY::X+
MB4DDY(QR<DG\:RO%/PC\.^)]6_M8F>QOF_UDELVW?\K $CUR0<^BXH @E/AB
MTL?$>F^$K>V_M&/2)F>YAVM$A"D(CRL2NXDDD'L#NZ5%\$L_\*GMO4RW'W1G
MG>>@[UOV_P /M'MO"@\.V[75O9LI$[02['N-RE6WMW!!-&D> -,T+2)-+TV^
MU6VM&Y"+=D;.<DKQQGO0!YS\&T:3PUXU3:6N'N)AB3]W<$[#]Z 95.<]"><K
M_"*O_L]ZC:#PI?Z,TRKJ<%X\TEJP*NJ%47=@^ZD'TXSC(KN?"O@+2?"$LKZ5
M)?(LQ+21RW!978X^8@]^*R=9^$6@ZCJR:IITEQI%XS'SWM&VB9&W;U([%MW+
M>U '+>&I?*_:+UZ-FG0RP,%47<<BMT/S \@<9"#)!QGC-8GPHT[PO>IJ'A3Q
M3ID*ZU9W!0_:)D&\AS\B%2#N#9Z$Y]<<#TC3?A%X3T_5I+W[$;C=$L2+,Q;;
MCJV>I8^M-\9?"?0O%^H#42TUAJ65W7-N<;P/4>N.,T ,N(_"<5]JFFZ'91S:
MQ_9MPTTMH#((LJL>R1P?OL8QA>22C$XSS@_L^:C:?\(A>:09U&HV]V\LMLP*
MNJD* <'W!''3OU%>B^&O"NE>$M,-CI,!CB9S)([G<\C'NS=3Z?A7+ZI\'_#]
MYK\>L6+W&EW"D,?L;; SB17W?4@,/Q![4 <KX0O8W_:%\21K<7#DJ\> L4:Y
M4\@C.7 [$<GJ0!7L=KJ>GWEQ/;VM]:SSV[8FBBF5FC.<88 Y'(/6N,TOX4>&
M=(\2+KL44KSQ!?*WOD!@,%C_ 'F)YS7.^$?">EV7Q4FUOPL]Q<:/-;R-+,O-
MJ'8_=CDS^\((;.,[>G6@#U\UXCX;E?1/VD]<MKR"17U:!S:E=I!7 ?)YX!$;
M#USCBO;>U<SXH\%Z;XH-O<W#2VNHVA+6M];G;)"V.#[@'!QTXH X3X_6PN=&
MT&&/SVNVO\6\446_>Q'(/((XZ8!S[5%XP8+\>/ T,X\R]6W7S9U.U'YDZ)SM
MYW'[QZ@=LGO-"\%1:7>0ZAJ>I7FLZG$K)'<WC9\L$Y^5>@/;-0>(/AIH7B;7
MDUK4'OS>1*JQ-'<E!&%Z!1VYR?J30!V=%10Q^5&D>YF"*%W.<L<=R>YJ6@#Q
M;X RV5KX8U^1+@BR34#MFG C.W8,%ADA3[9/UJ;X2Y_X6/\ $/==+='[8G[U
M2Q ^>7Y?F /R_=Z8^7C(P:Z6+X4:!#K^H:P'NUFNY6F")*56)FZE0.,YR0>W
M2KFB_#?1] U*ZO\ 3[O5(KB[8M<-]J)\YCGEN.3EB?K0!Q>C><?VE-7 %^5^
MP-G$,<:!?EZY.7CSC##YMV., UE:5;:'9_&KQ-9>+8;*%;F;[79O<R%0WS;E
MR=VW&!G#=_RKT2V^&&B6GB1/$*7.JMJ:/N\Y[PL6XQ@^H(XQ3O&OPVT3QRR3
MZAYT=U%$T<,T+8VD]R/XL4 5VTOP%H'B2PL[33+8ZQ+)%''%; O)"(UPKN,_
M(H!&2>N>]=T/3-<MX1\ Z3X-%T]B))KFYD+-<3G=)LR=J9] ,#WZUU7O0!S>
MC:O;>)+K7M+O([>=M/O?(DA:(D;, H6R,$Y!Z>E>-?%CP/IW@>^TOQ+X;N5T
M^;[0JI:A2V9!SN0G(^H8@>A[5ZE>_#'2IO$,^OVE[J5CJ<TPEDFM[@@'H& '
M097*Y[9S3[+X<62ZO:ZIK&HWVM75H +<WK[EC..2%Z9)Y]J //OB%)'IOQ*\
M'ZWXEMD739+!8;F652/+D!9GPL;L01N7@%A\Q&3UKL]0M/AOIVBP:Q-:6,MO
M+%NM(XCO:?,BMMBCS\S%]H.!GH#@5TOBCPGI7C'2QIVKQR/ L@E'EOM8,!C@
M^E<YX5^$>@^%=734HWGNY84*VXN#E822264>I!4?@?6@#EM8U!?#_P ?])U7
M4'2PTO4+ 0K),% SL( /79ABH)X'OC->DZOXFT?3O[/D)COKF[=$LXK9XFDD
M#G 9-S#Y?4YJ#QCX%T;QMISVVHP 7 0I!=J/GA)YROX@9'>J/A/X7Z!X3O3>
MVPFN+I=RQ27#[O)0DD*H/3 XSWQ0!RVFJR_M-ZJ7B@0-I65:-@6<8BY<9.&S
MD8XX ..<EFM2I+^TIX:\O[*RK;31EXI TFX0R$JX#';@$$9 ZGKVZWQ;\--$
M\7:DNI73W5O?+"L FMY2OR!BW('7.2,_3TJC<?![PQ/KUKJ)@,<5M&%$$(VF
M1\CYI'SEL@8Q[F@#!^)X(^*O@#_2U"_;(_\ 1\MD_O!\_3;[=<\]*]4U;_D#
MWWI]GD_]!-<MK_POT'Q)J"7VIS:E+-%GR0MT0(1UPH["NCOM&2^T<:=)>7J(
M$"F:.;;(X P=S=\]_6@#RKX,NMQ\&-9B^R!]DMS&R09#S_N5/7GYCG' [#CU
MT_@7+%;?#AC*1;I_:4D865@""Q554DXYR0/<UU_ACP/H_A+3+K3]-%R;2Z.9
M(9YBZY(P<>F1@'Z"L[PS\+]!\+ZK-J-HLTLS.[1+-(2D(/HOJ.>?>@#DHA ?
MVGIS+)(LPL!Y:J@*M^ZYR<@CCV.?:L3PU!X=C^)OBWPWXOT^+S[F]FN+>2YE
M01[)&#!<Y!#,"A')],*<Y]*_X5EH_P#PD']N_;M7.J;=OVG[8=^W&,=.F.*?
MXT^&V@^-I([B^CDBO8AM2YA.&QD'!]>^/3- $4-IX*T?Q5IFFV-C#)K.XA!;
MYDDME2-_GE.257$A49Y.]>#CCBM0\!RZE<7WC3X<ZO-::BTDO[@[ DYSR%QP
MG? <=<9V]:]$\'>!]*\&6L\=@'EN+A]TUS,=TCC)VKGT K)M/AG#IMQ)+IFN
M:EIXGD$EQ':OL21MX)(7^'*Y7CUS0 SX3^*]4\4>';I-82(W^G7!M99XY%<3
M$ '=E>,^X)!ZBO0NU96@Z!IWAO2(=,TN 0VT(P .K'N2>Y/K5^5/-B:,,R[E
M(W(<$9[@T >'Z?,)_P!J"Y$;S2>7$ZMET@"'R^F,DRCD>^3GHE>R:GI%IJT=
MM]K!S;7$=S&R@95T8,.O0<8/M7)I\*- CUXZZESJPU7<6^U"\._)7:3G'IQ4
MUQ\,-'NK46MQJ&M/ L8C"&_; 0'=C\QF@"SJ'BS2;WP0^KBSNKFSO"T%K;O;
M$O=$DJF$/\+8W G'RD'BO,/!:)\)?'ITW7K553Q!!"]O=0QG;;29.Z'OQN;!
MPQZ(3UX]/D^'NE2/I1^UZFJ:6L:V<:W1"Q;%"@@8ZX49/UJ?Q;X#T3QL;)M8
M2X/V(N83#*4P6VY_] % 'GWQG4V'C#P-KMR/+TRSOT%Q/U"?O$?H.3\J,>!V
MKT?5O%6@6.@MK,UY:W5HN7B$4L;F5UYQ'E@"WMG-5Y/ .A7/AA/#]Y#->V,9
M8QFYD+O$2I&58\@@$XK!\-?!KPYX=U"&\9[B]EMR&A6=OD1L8+;>F<\^U &%
M\;&EFM/"$S6B1[KY2XG=?.A)*?* &P>^[&X# Y]=+X^;O^%:OM\['VR+=Y<
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M_P"T;K0"1$>2RED:),8'7:"Q8^I!4]V Z5ZAI7AO3]%T>73K 2PI+N,DP?\
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M_F*\K^%7B/7-7\;>*K/6-;AU 6Q1(Q% RIA6;[AX"@9P006/')"\@'KE%%%
M!156]%VUI(MC-##=?\LWGB,B#ZJ&4G\Q7EWPH\2:WK'BGQ3:ZOJD&H_9W1$D
M1]BKM+#"1[1QSRW7@ YSD 'K=%1MN\MMIPV.#[UY9X.O_B!:^*-2T#Q'?VVH
MRFQ$\<T#(%M&)8*& 122V.^>!GO0!ZO17EGP_P!8\9VOC34O#7BV]AU.5;)+
MM)[;;LM_F*[&VHOS-G//0+[UZB#DT .HHHH **** *UY:6]_:R6MW!'/;RC;
M)%*H97'H0>M<?>?"3P/=W*S/H%M&RR^:!#F-2<*,%5P"OR#Y>F2Q_B.>YHH
M9%&D,*11HJ(BA551@ #H *?110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5>0[7[Y  )XZ8XH ZSQ=XI\377PCT[Q1I6K)8RO;PO<IY'E,SG[Y0R$9&>@
M.X<@FDU&S^(E_P""1XD@\3?9ITT^*6&QLT5A*NQ69Y'?&'.7) &. !FN0O\
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MZ-D=D&>U &WH_C(^+%GU.\\9WFC?:WE@L[2TMB\=L5Y$DC[2 -H+'=LX!.0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWC P,$^M;-% &/HGA?1_#CWK:19K:?;)?.F6,G:6]EZ*/88%;'2BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex3-5_002.jpg
<TEXT>
begin 644 ex3-5_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ER!TH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK&JVNAZ/=ZG>R*EO:Q&1
MRS!<XZ $D#). /<BKM<S\0]$N/$7@#6-+M#_ *1-#E!@G<58/@ =SMQ^- '/
M6GCSQ9XATM=7\,^##/I\C!8A?7:V\L@P<N <C:" ,YYS[&MKP9XV/C&/5GCT
MNYL6L)Q;^1=#;)OVY(8?P\\5YIX'^,<VA26?A?QE836<L!6W^V2D@K[R _@,
MCH*]8\/V^BWNH:AXETFZ@O/[1**9XL$ 1@+M##MD9^M '$CXLZR?%C>%AX.N
M7UJ-5,D$=PC!,QQMDN#M ^9N2?[G<D#5U7QMXMT;2[G4;OP+<"WMT+R&.\AD
M(7#\[58G /EYP. 7/\(SYUXFUBUTO]I=+O4+DSVULD>0Q8"T_<@X'KG.<=,O
MZUZ#JGQ>T-)=-M-(W7UW?WT5J$*$+&K%=S'\&P!Z@^AH [+3=:MKWPY!K4SQ
M6UM);B=W>9&2-<9)+@E<#USBN7B^(<NOZC>V/@[2'U86DHCEOWE6.TSWP^<L
M1_L@YZ].:P/CIJDGAOX<0Z9I<:VT%],+5A%\FR/!8@ =CC!'H376_#'3+?2O
MAMH,-O&T8DLXYY Q).]P&;K[D\4 8FK_ !"\1^%;*2Z\1^$66*1HX;1["[28
M23.I.QE)##!&,@'.#CMGL=0\16>A^&/[=UIFL[:..-Y\HS&,N57& ,_>8#I5
MG6-*M=;TBZTV\C5X+B,HP90<9Z'![@\CZ5X7\4?M.K_$?PGX$VRS:9"(#+&C
MD&52<,S =U16Y[9- 'H-AXT\5^(M/_M7P_X41M.D!,!O[H02S84G(7!&TG@'
M/?/3FKWA?XAV>NZS+X>O[*ZTOQ#; ^?8SH2. "S(X^4ID\'(R,$<&NQCC6*)
M(T&%4!0/85X;^T2D=DWAO58K=/M23N&E"X+*NU@I/IDG\S0!UOC;XF:CX&:"
M;4/#-PUC<.R1W"2JP!#* K8.%8KYC =QM[[MO::!K^G>)M'@U32KE9[:8<$'
ME3W5AV(]*X?XBNWB#X<:&\T=P(M1N[(W*6S879)C<'/79DCWSMK@K#6]3^"'
MC671K^.XF\*7<I>!F^8HI_C7W'<=Q[XH ].\6>.-7\-:W:Z?%X<:[2_F$%C,
MMRBB60J#M()ROS<9/&*@\6_$#5_!ND)JFI^'"+5IA%\ERC,I8%AD9]-JG'\2
MOVVEI/'\Y;5_!1CNV2.36(B8E!*S#@C)'''7FLOX_0&;X9N1)&GEWD3_ #N%
MW<-P/4\]* +>E_$'Q+K&A1:U8^";B>PEC,B/'=Q%V4%0<)NW$\2X&,DA/4XN
M>&/BMH'B+59])F6XT?4HG$8M-3"PR2,3C:HSRV2!MZ^U:?P[G6Y^'NARK(S@
MVP&YBV>"1_%SV_PXKS/]H33+?3[?1_$MC&UOJR78C^U0DJP 4LI)'<$#!H ]
MSHKA=2\7^(A\/=(U_1/#XU*^OH(9I+>,DB,.H8X Y(YKK],GN+K2;.XNX/(N
M98$>:'_GFY4%EY]#D4 87CCQ7=>$]/LI[+2+C5;BZN&MTMK92TA;RI'!  )(
MR@SZ#)[5S'B/XIZOX2AMKG6_"%Q:VUS-Y<;?:HG8\YZ*QP=N3SWX]Z]%NM/M
M[RZLKF929+*8S0$,1AC&T9)]?E=OSKQ;]HY8/L6@M]F;[1]H(\_R^-F/N[OK
MSB@#K-4^('BC0X;>34O UW%'*55I8ITFCC.$!+E"=J[BW)QD =\@%]\1-3A^
M*FD>#SHYLXKK,CS32([2(%EQM"D@ E >3G@Y%>A7-M!>6[V]S"DT+_>1QD'O
MR*\8^(6KKI?QY\)3RW$LR16S;;-0?E=_,0$'I\QV@^FS)H ]LHKRF?XD>*]"
M\9Z'HOB3P_8V\&KW AB:VN"[C+! 3SC@LN?QKL/&7BL^&[>SM[2W6ZU749A;
MV4#MM1I#W8]A0!TU%>5ZU\2M<\(ZQH<7B.VTA-.U#B:>TD9V@8#YE(SSC*\]
M.?:O489H[B".:%P\4BAT93D,",@B@"AX@URS\-Z#>ZO?.%M[6(R$;@"Y'15R
M0"Q/ '<D5Y]JGCGQYH]MINJ7'A."6PO8X5-O#,YGAE<_=9"H<MCC:%/3K65\
M?KO7D\+2VX^Q1:-)-$I);]],?O8 [ ,!TYKN/!,NLVGAF#^V;&SL+"VLX3;Q
MQN[2(HC!(?<>J_=]R* .MAE6>".95=5D4,!(A1@",\J<$'V/(I]>;Z/XU\5>
M+K"_U;PSINE2:;')Y=HMS,PEF(.&#8.$/1N>S"K'@[XE'Q587ULNGK_PD5@<
M3Z<LH0. P4LC-V&?Y>HH ] HKQ#2/C+XI\0:??'2/#-O=ZC:3#?;1[V_='C<
M.>3NQQZ<UUEUX\UO;HVDVVBP1^)KVT%W<6MU-MBMXP<$D]<_[/4=Z /0Z*\S
M@^)=[I?Q&C\+>)DTR"&X@#VMW:NQ61V.%4Y/RY(8<]P/6M7Q3XTU'3_%^C^%
MM%T^*;4-0+.TUV2L21J"6((Y) &<>V.] ';T5Y1JWQ,\2^'O&UMX:O\ 0K6Z
MFNVB%M+;,R+*&/S8+GJ.GUK:UWQ]>6^I:-H>DZ=%_;NHVZ736U])L6!#U5B.
MK@YX']TT =[7*>.M<\1:+9Z=_P (WHKZI=W-XD3H =J)U)8XPH.,;C@#.:Y[
M4OB-K'@_Q396'C&PL8-*OBR07]H[$!AMY8$\+\V/UZ U)\3OB/JG@6RM+NRT
MB"YMKB0(MQ+-\K94M@*.>W7I0!Z117$?$OQKJ?@?0O[2LM*BNH@Z*TLLN%4D
MD8VCD_6N=U;XD^,8/#7_  D=CX7MUTF&VBDFEO9&C=G95),:YR4RX /?!H ]
M9HKE+3QQ9R?#9/&5W']GM_LIG:)G RV<! ?5FP!]17+S>._&D7P]'C :1I3V
M[()A:H9&D$1/WR0<# Y- 'J=%<=X \:W7C733?R:/+9VTF]X)BX99%$CH%]F
M 49^O'%=%K6K6^A:+>:I=,!#:Q-(V3C..@^I.!^- %^BO)Y_B!XW7P OC"#0
M]*DLFS+Y D<R+#_?/./J.W6M'Q1\2=0TKX?V/BK3-%2X@NH8I6,LPQ%O_A('
M)/N* /1Z*\GU'XC^,E\-+XBT[PM!_9<5I%+/+=NR,[LBLQC7J4!; /?!-3VW
MQ#\6^(M#M]4\+^%$FA%OYEPUW(4#/S\L6/O_ '3^8% 'J-%<9\.O'T/CG0YK
MJ2W-I>6;^7=Q'[JMST)[<&LFT\=^(_$&GWNLZ!I^EC1T5S9M>S%9;G82K< _
M+R#C- 'I-%>;^&/B@_B;P'<ZQ96,-QJUD'-Y9)+L$0 8JV6ZJ0!^.?2LSPU\
M3/%_C#0([G1/"]O+>><XEDE=H[944+@!B>7);IZ T >MU!>32V]I++!:R74J
M#*PQLJLY] 6( _$BN+^&GQ!E\<:-?W5[9QV<]C-Y<HC;*'C.1GFJ^A>-]<\:
M3ZE=>%[;3CH]LRQP3WHD5YGV L-H/&"<9H =X$\>ZEXH\5^(=)U/2)=-;3A&
M(X6C9B,L^2[XV@D;,#/(!(R,X]!KP/X/7=\WC'QQ>1:43=AT\RTBO<1B3>X8
M?,?FY#$-VY'\5;OAOXJ^*/%,>I6VF>&(IM1M[D11_.P@1?F+&1^@/RX '4F@
M#U^BO(]&^*OB/4=0U?0)/#"/X@LY/*CCMW)A!SM)=CT4'G/I5[1/B5K47CR/
MPGXNT2'3[NY16M)+9BZ.2">IZC@C([@B@#TZBN,\1>,+ZW\3P>&O#]I;7.I^
M2+NZ>[DV106^X)G(ZMEAQZ ^HK(TKXE7</Q%D\)>)$TZW>1%^R3VKLRS.Q^4
M<GC(SQZX% 'I5%>43_%;7+?Q_=>&I/##-)%;^8D,#^;*S% P!*_+CGD]A4NG
M?$;Q-:?$/3?"?B?0[*UEOX?,B>TG+[?O8)YQCY&X^E 'ITEQ!#)#'+-&CS,4
MB5F ,C!2Q"CN<*QP.P)[5)7@NO:MXPF^.WAJT>VT_P"UP12M:P9/E*CI('9F
MZDA%W8'ICO7M^F/>R:9;/J4,4-ZR S1Q-N16[@'N* .2^)?CF^\#:)]OMM':
M[1F5//:5%C1FSP1G<3QG@8]ZZG0[N74/#^FWL^WSKBUBE?:,#<R G'XFN%^.
MDK1?#"[Q=M;[YHU.T$^:#GY#CL??CBL67Q]XIT?X?Z?KFD:%93Z#:V$*O<7,
MY61F&(VP@.<;N/UZ4 >QT5P6J_$NWTWX60>,#:@2W4*FWM7?[TC' &?0<D^P
M-9/B3Q]XQ\'6NEZCK.B:;+I]R4%RUK(^Z G^').#]>E 'J=%<AXU\<)X9T.P
MO;.#[8^HRQQ6K\^4-^,,Q';!X]:B;6_%^G>*M(L-3L-*?2[^4P?:K9W#+)Y4
MD@7:Q](^OO0!VE><:;\1-3U'XK#PE/HYTZ**W::3SI$>1OD##[A*CKV)_"O1
MZ\%U;5I-&_:,U.ZM=)O=4OOL<:0V]KCO$N2V>PXZ4 >]45Y'9_%77],\>VOA
MKQAH=IIJW( 2XBE)7)^Z0QX(R"O'>NI\0>,+^+Q1#X:\/6EK<:BL0NKN2[DV
M100%@N>.K98<>U '9T5YKH_Q*ND^(D_A+Q''IUM*RK]DGM79EG9ONCD\9';U
MXK3U3QCJ4_BZ7P]X=M;*62Q5&U"YO9"J0AQE0H!RQ]: .WHKS7PQ\3+J^\8Z
MOX5URWL8-4M@/L26TA*W1VEB Q. <;2![GTK/M/BKXAO/%VM^'8O# DO+1-M
MO%$Y?$A95!E<?*$&[)/M0!ZU17F?AGXB:]=?$-_!_B/1K2TN_(\Y6M9BX'R[
MN2?;TKTR@ KSWXH>/-9\%:0UQI^@RSQL=GV]V4Q1,P."5!+<''4 'IFM+QWX
MXC\*16EE:Q+<:WJ+B.PMW!V.V]%.YA]T8;/X5YC\=[GQ"OA?3X=;L],:"6<&
M.:UDD#12 $X()PP*[J />;:X6ZM8KA%D5)4#A98VC8 C/*L 5/L1D5+7EWC3
MQWKG@.UT,I96<]K>E(%6>9Y)D(5=VYP<.<GKWK9^)/BK7O!FC_VQIMC97EFA
M5)4EW[U)SEL@XV_='U- %SX@>+KOP7X;GU:WT=[](@N]_-1$CRZJ-V3N.=W&
MT'WQ6CX.U:XUWP=I.JW807%W;)+($&!DCM7(_%NY:]^!NI7;J%:>"UD*CH"T
MT1Q^M6]&OM7LOA'I%]X?TZV:6'3UD^Q2^8Q8!,A$P<YSZT =]17'?#7QC/XX
M\+?VM<K9QS&9HV@MF8F+'0-GN>OT(I/!OBC5O$^K:T7@LETBPNGLXIH]XDED
M7&<@]  0,]R>* .RHJ.XN(K2VEN;B18X8D,DCL<!5 R2?PKR^Q\?^,=<\)WW
MB;1M#TV2QBE<6]O)(YFE1203P<9&.G>@#U2LOQ!J5]I.CS7>GZ3/JEPBL1;P
M,H;A2<_,1D9 &%R>> :Y[P_\2-,U7X=+XNO?]&BB4B[B3YS&X." .O/! ]"*
MQ)?$WBS7_A[J>NQ:9I+:;+#.8[>1Y%EEMQD%L@_*=NXXZ\>] &[\-/&-UXU\
M/3ZC>6K6TZ73Q^4(V"JHZ ,0 Q'.<=.^*[.O)?V?CCP#<2E7CB-VY!:?<H'L
MI^[CN>]:6C^.?$GC"+4=0\+:?I<FF0,4MC=RL)9F'&" ?DSU&>Q% 'I%%>?>
M#_B4_B--2TR?3TC\3:<[I+IZ2A5E"MC<C-V'?_ZXKF=&^+WBO7GUBTT[P>+J
M[LW*HT3DQ)MW$B0_WB%(7'4T >SU&+B W)MA-&9U02&+<-P4D@-CKC((S[&O
M*_!WQ5UGQ'?:OH=[HUO8^(;:%GM;61R@E<#[C9Y'K]*YWP5JWC&[^*_C.6WM
MM/N;I)1#<F0M&BK&Y1 @^@/)].>M 'O5%<;XD\87UIXDMO#6@6EM=:JT/VNX
M:ZDV10P;@F<]VR>GH/<5C:=\2KNU^(Y\)>)$TVW\Z-?LES:NS+,['Y5.3QGD
M8]<#O0!Z77G'B'XAZOH_CW1M!D\/W-O87LVW[8R^:9E!8$(L>[_9/.& /( J
M_KGCFX7QE:^$_#T-O<:J3NNOM081PQ;=V[(ZGVKS;QE-K$OQP\+VVK65LMU&
M$,4]A<O'YL1+?WC\I#;_ *_E0!] URGB'6_$5EXO\/Z9I.BO=V%T[&^NL$)"
M@XY;& 1G< 3DXP.M=77G/BCXB:MX?\>Z#X?_ +'A%KJERL(N))MS,I=5W*%Z
M?>Z&@#T:BO./B5\1=5\#7%@L&C13VUU-Y8GDESNX!("KR",]^M9?BKXF^+O#
M5L-9F\+P0Z$]R(8C<RE;DCGDIGY<[6(SV(H ];HJ"RNEO;"VNU4JL\2R!3U
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M.+&21M)R?]X]N*Z"T^('C/5_!=SXLTK0M->Q663R+9Y',SQ*Q!8X.,C!X]J
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MPS_98\FX55?IW"@#Z>V*YKXM>+K?PGX:A-QH]MJGVV4PQQ70#1(X&Y692/F
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MJT3$8W+VS]0: )=9UG2;'1?[7NO+NK:%PT1BVR$OG:-F3C=DD<'UKROPV_\
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MDUT!PV V0HS[>U,\57_Q&\(>&[B^AO=.U>.)5DEGD@$<L( 0,%5<*P+;L<9
M/6@#U"BJFE7;W^CV5XZA7N((Y65>@+*#@?G5N@ HHHH IZII.GZW8/8ZG:17
M=JY!:*5<J2#D?J*XFP^"O@JPNA,+&>X0 CR+B<O$<_[/ZUZ%10!!9V=MI]E#
M9V<"06T*!(XHQA54< "IZ** "BBB@ HHJGJ>J6ND6BW-VY6-I8X5P,DL[A%&
M/JP_#- %RBJ.M#46T*_&D,BZD;=Q:L^-HEVG;G/&,XZU0\'66M:=X4L+7Q#>
MB\U../$TN<D^@)_B(& 6[XS0!NT444 %%%% !117DGC?Q7XM\._$_P -:=%J
M5L-)U:\BB^SI;*6">8BMEF!.2&[8Q0!ZW1110 4444 %%%% !1110 445P?B
MKQ-J1\>Z'X0T:X>UEN8WNKZY6%7:*$ A-N\%>6!SQG@>M '>45P?A=/&^D^*
MKG2=7)U+0F5GM=0E=?-3'9\ 9))Z>WH*[MF"*68X4#)/I0 M%9%AK4?B+P__
M &EX?GAD65I$@EF4F-BCE"< @D94X_"N'^$OB_7O$^J>*;;6[J*?^SKE(H1'
M$J!06D!Z#)^Z.N: /3Z*** "BBB@ HKA?'_C#4=(N+'P]X>MQ+K^J BW>0#R
MX5!P7.>#CTK-U^X^(?A#0+_5_P"UM/UJ.&!"T4MJ(GC./G9=F,_-T!SQCWH
M],HK&T#5S>^#[#5[XM"7LUFG:5-F,+EF([#J?I5S2-5M-<TJWU.Q<O:W"[HV
M(QD9QG]* +M%%,EE2"%Y96"1HI9F/0 <DT /HJCHVKV>O:5!J>GR&2UGW>6Y
M&-P#%<_3(-7J "BBB@ K(\2^&]/\6:)+I&J+(UI*RLPC?:<J<CGZBM>B@#'\
M.^%]&\*Z>++1[*.VCP-[*/FD( &YCW/%;%<QX_\ %/\ PB'A&ZU1-GVC(BM]
MXROF-TW>@ZUR5Y%\1--?1];TS6AK4-ZMM%=6;VRF--P<F4% ,(-PY&"<#)(
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M,7+%5 7)8[5 .<X8X/->IV<D\UE#)<P>1.Z R1;MVQL<C/>@">BBB@ HHHH
M***Q?%<NM0>'+R?06MQ>Q0NZ^>A?.$8@* <;LXQG(]: -JBN#^$.M:GX@\"K
MJ.KW+W%Y)=S;V;MAN@'0 >@XKO* "BBB@ HI#G:<8SVS7D/ASQ'XJD^.5[X:
MUO58[FVM+:258[>(1Q_.L;@8ZMM#8!8D]?6@#U^BBB@ HHHH **** "BBB@
MHHK@-9\1ZIJ7Q)M_"&D7DEE%%;-/?7,<*.ZDKE -X(P>.@S0!W]%<%X&C\<V
M6N:KI_B*0WFD6["&PNY"@D95Y#-@9<LI7)/\0-=[0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB-M8M+42^5"?[PP%!S_LXQWS4?@^>&']HKQ5')J$4KS6K+&A8@@AD)C 8#)
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MO-(T"RO8;._U:4*UW(N[[+%G!D"G@G.0,G\#6!^T."? -N=N<7:\_: F.#_
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MRUD)^;+M&0<GON(/]Y: /HVO)_B?XD\6^&_$OAQ=-UBQ6UO[T0K8K!LDE7*
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M<98)@8Z8##T)ZT >R6$-Q;Z=:PW=S]JN8X42:XV!/-< !FVC@9.3CMFK%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %4-7T33->M%M-6L8+VW5Q((YT#*& (!QZX)_.K]%
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MBM;6/.R*)=JKDY/%6J* .9\0?#_PQXHN?M.JZ5#+<[2AF VN05*\D>F[(]"
M>U:DGA_2)=&CTB33[=M.C"JEL4^0!>G%:5% '/6O@7PK9)*EKH-C"LR%) D0
M 93C(/Y#\JDT[P7X9TB]2]T[1+*UN4)*RQ1!6&00>?H3^=;M% ')ZU\-?".O
MW,MS?:-;FYE+F29!M=RRE221U/.1Z$ UJW?A70;[3K;3KK2;26SMEVPP-&"D
M8QC 'T%:]% &7HWAO1?#PF&CZ9;6(FQY@@C"[L9QG'U-4M6\#>&==U9=3U31
M[6[NA$8MTJ @C(/([D8X/N?6NAHH P)?!7AR;7XM;DTFV:_B15CD*#Y=IRI
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MDFU;2;6]D1=BM/&&P,DX_4UKT4 9">%]"CT671TTJU&FS-NDM?+'EL>.2/\
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MT@G:IP=S $#W(/;%/\+ZCJGCOP3]HL_'+VOBV=II5LDND"J [87ROO*N,<T
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M5KJ[M8!%;?Z2!(,0E!\V<], 9->;^ _"-P?A;XMNI-,^PG6(Y#:!4:1Q"5X
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MA_2H)XV#)+%91JRD=P0,@U-K/A[1_$-NL&KZ;;7L:'*><@)3D'Y3U&<#..M
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MAM?"AF28O"!N=E*1J#U!"L3SUKW.J5CI-AIDUW-9VL<,MY,9[AQ]Z1SW)/\
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MYS]ABSG_ +YJW_8.E?VV-:%A NIA#&;I%VNRD*"&(^]PJ@9SC'&* -&BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *CGMX;J%H;B*.:)^&210RGZ@U)10!6M
M-.L=/#BRL[>V#XW"&)4W8Z9P.:LT44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !5";0])N&#3:792L!@%[
M=&(&2>X]23^-7Z* $ "J%4  < #M2T44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K)\0Z5I^IZ/>"^L+:Z_T65!YT0?Y2 2!T."40\$<
MJ#G(!&M5'6@C:#J*R1F1#;2!D"%RPVG(V@@GZ C/J* /&/@!HUA<V&MR75M9
M7'DZA')!'(@=K=TW;7 ;.T\\$'/7FN?^(&CW_AOXFW^M>#XELETNVAN;B*UA
M$*HA #8 ^5P>K<?7-=1^SH;?^S?$21021R+=)O+-@$8;: F,KCG.6;].>OM(
M;6\^+WB&UF(N$?2H4F@DD+J 3TVE0%!'. 6SUXZ4 ;/A7Q3HOQ \.)>6RQRQ
MM@7%I, QB<<[6!Z\X(/?@US7@[P_I-O\4O&-PFD01S0O:RP2/%&3&760.T9
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MW5LL/[J9&3:!Y?W!ZGCFO&O&>G7_ (1^*FL:_P"$X1:VFE+:R74%K"(42-T
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M0SF";:D[XY* 9#  #&5RIQQ[5<^'=KI^L?$?4%\=WD]WXPL)S%!'<8%O(B@
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M, ,AE0$$D]0!R>,5Q/[1<<+Z;X=W7$L4_P!J<1A$!!R%R2Q88(XQZ^HK6O\
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MS*6C0Y+,!C)P 3CD5Y1\)(8K?XM_$"&&-(XH[EU1$4!5 F?  '05-)JS:/\
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M<7.8CN+9X;TX'US3?B9I]MJ'QF\&6]S:7#1SIY<DHE*HR[G^0;0"&[DANA'
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M<A#TS@BK_P "(EO_ (8/9WB>?:F>5/*D^9"I)R,%!QG/=OJ.@ .^T7QAX?\
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MDL,G&?>O5?#YC;PWI9B1DC-G$45FW$#8, G R?? KD/C9*L/PHU=F@CF!\I
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MK-<PP@P65HERZQ*GRGS,*00Y.0><$ <<5W=5M0U"TTG3Y[^_N$M[6!"\DKG
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MG3)SR<UOVGAWQ9K[M;^,[RPDT?Y2]A;PC]^ZLKJ6;J%! ! Z[?0FN]50JA5
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M!T_V#4(##+&=0MS*#\IW ;\=448STR<]J[?XC>'KOQ5X!U+3+-G2[DC#Q(I
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\/O$D_B[P+IFMW4*17%PKB14.5W([(2/3.W..V<<UTU !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML]BEM"FHI>RR07,D; I+A.<D\@J%!QA>!D$KD]C\(O%EW-!<^#M?Q#K>CXC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3T8[ERYW9V\ # '!?\+&^,__ $*]W_X)9O\ "C_A8WQG_P"A7N__  2S?X4
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M]W_X)9O\*/\ A8WQG_Z%>[_\$LW^% 'L.N^ [7Q#X;@T&]UC5?L$<:QNL;Q
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MBOG/_A8WQG_Z%>[_ /!+-_A1_P +&^,__0KW?_@EF_PH ^C**^<_^%C?&?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN1F4QX6;Y8U)=@0> JCN<>F* /5F\:>&4@EF;7; 11%Q(QF&%*LJMGZ%T'_
MA6I9:A9ZC&\EE<Q7"(Q1C&P8!AV-<_I'@WPK+HMC(?#6AL6MXV+)9(RG*CD%
MADCW//K5+PM:>'O#>EZCK]@JVNF:G*MQM6%@4.2NW:N0!GH% ]\T =M17.Z/
MX[\,>(+MK72=7ANYD0NR1JW"CJ3Q4^C^+]!\07,EMI6H+<RQYWA8W&TC&020
M ",CCK0!MT5SNL^.?#^@S2P7EZ3/#L,L<4;.8U8XW-@8  R3D] :T-%U_2O$
M5E]LTB^BO+<,5+QGH1V(/- &E17.7_CWPOIE[=6=WK$,<]KCST"LWE9_O$ @
M5./&'A]M"36TU.*3378H+B-689&<@@#(Z'K0!N45BVGBW0K[0WUJTU!)].1]
MC3QHS -D#& ,]2.U5H/'OABZTF?4[;5XIK."189)$5CAVZ+C&<F@#HZR;7Q+
MI%YXBO- M[V-]3M(EEF@!Y52<?IQGTW+ZUP_P]^*ECXHN=46_OXHI)-1:/3[
M<QE2+?8-F3SR<,3D]<XX %=!H<W@F3QMJSZ-+:2^(IXP]Z\;L[E%VC@G( Y3
M(7&>,]* .NHKEW^(OA..^-D^L(+H9_<^5)O_ "VYK4UOQ'I'ARWCN-7O4M(9
M6V([JQ!/IP#0!J45DZGXGT71M/MK[4=0BMK>Y*B%G!RY(R,+C/Z5#I'C'P_K
MVI2Z=IFI1W%Y"ADDA"LK*N0,D$#NP_.@#<I&944LS!5'4DX I:\/\6ZQ/\1O
MBE!X$LKF2'2+)G_M!X+AD:XQCS$(Z$*?EP0>03F@#TX^//"@N_LI\0:>)_,\
MK9YPSOSC'UR"/PKH5974,K!E/0@Y!K%;P?X<?2%TI]$L6LEB6(1-"#A5W;>>
MN1O<@YSEF.<DUY3H&J3_  U^+,7@<ZB;C0M0V- ;MG9[;<K^7&G.!E\#ISD?
M6@#VJ]O;73K.6[O)XX+>)2TDLC851ZDUC:3XW\.:YJDVFZ=JUO/=Q'F)6Y8;
M0V5]1\P&?7(KS+XS^-=->?3- 6=I($OU;4D-NS)M4Y"D@JV<\X5AD=ZU?&4G
MP_OXAXQ$DW]JV[M';W5D)8Y)98U/R$# )&1DGG"XS@8H [35/'_A;1[T6E]K
M5I%/YODNI<?NVVEOF]!@?F1ZU<TWQ5HNL:O>:58:A#/>6BJ\J(V< ]QZ]L_4
M5Y-\,9O"WB?P"=!\2"RN;J^O)KV2(>8&9A@M(S# 1AWVD#! _B.>S\ :7X!T
M&_O=+\*S03:E&G^EN)&DD*@]V/ &2.%P.E '?45AZKXPT#1=06PU#4XH;MD\
MP0A6=MOKA0<5-H7B;1?$UO+/HNHPWL<3[',9/RG&>0>>] &M16!J7C?PWI&H
M2V%]JL,5U%'YLD05F*)ZG:#@?6K>G>)-&U721JMEJ,$EAN*_:"VU<@X(R<=Z
M -2BN3/Q-\&"P6^/B"U^S-*81)AL%P 2.GH1^==+9WEMJ%G#>6<R36\RAXY$
M.0P/>@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** .%^,;72_"G7#:(SR>6@8+'OPG
MF+O.,'@+N.>W7C%>1267BC3?@IIVKZ1XCOVTTH4OK(!"41CR49=Q  ZY((]!
MTKU_XJ:9K?B#P;=Z'HFFR7,UV$S,)XXUCVR*Q!W,"<@$<9J+X8Z/K&C^#8O#
MVO:*EH858&1)(V24,3V5B=V.I(YH F^%EAX2M?"$5QX2+/;7#%II)B#/O[I)
MCH5Z8'&.1G.3EZ@FEZ5\6QK4=S=:WJ]Q9M:)I%I%%)):@$.9"[.HC7'&&Y)D
MX)S@8NB^#_&OPV\27D/A:TBU?PW=L)1!-<I&T3'@_>(RP QGH1BH[O0?&OAO
MXL7_ (KT?0(M2BU> 0"-K@)Y!*JQ#GMCRL9^[\P&<F@"CX"GN[?X[ZHD^G6^
ME27EJS2V<2YV_P 0!+,N6X!)C#@]N,D$_A[0K[]HZ?3'M UJUANFMEC\J,-Y
M:D8VM\P(P3D#DG@]:MZ9X)\?Z;\6I_$R0Z>T-XKM,6N3Y2[E/R=-_!QT&,^U
M:TNB>+$^-4OBG^Q9;C2HX#:P*MU"&QM W %AP2"<'GF@#(\8Z?:Z1\>O!MQ8
M:;*N^':8K:W2.-L&3E6W %ANRPXP O)S@7/%EX^L?'_PUX:OE$NDI;O.UODA
M97V.XWC.& :)" 11XV\.>)]<^(^C:_9^%3-;:9^[83W\2B<!F(*KNXZY&>3T
M/2KGQ*^'>J:[J>G>+O#AV>(+(Q'[-*X"N%;(&<XR"3GG!&?:@#/_ &B+&"3P
MGIMUY4GFP7057C@#* 1C#MD%1Z=<G ]ZU?B=X7AUWX:PZC;QJ=3TVWCN+::&
MS:-F  )58R<H#UVG.W&*YKQ_IWC[X@>&]/1_#7V%8GBD"&<&261OE(*C[BC.
M[+8P!7KWAEM5D\.6@URS%K?JI26+SQ-P"0"7_B) !/N: /-CXYNO&/PLTFUT
MR51K6L7 TJ?$@WQ%5W32 , '^0 D#@>8!G->I:-I5MH>C6FF6B!8+:(1H!GM
MWYSWYKROP!X,^R?%+Q-<3O--8Z5=%K$/%B,37"J\I4] RJ$7CLPKV*@#@_C$
MK-\.KO;#!+B6(D3.%"C</F'(RP[#GZ&N&^*\4O@KXFZ)X\M[1I+20".\$+L&
MD=>/F.-H!38 ,\[#QWKO?B;I^MZUH<>FZ/HRWSF>*<O++&L0V/G:P9@3D"KW
MBC0#XX\"W6G7]BUG<S(6CBD9':*12=IRI*\_7HU '-RW<?Q%^(.FVD(8Z)H4
M4>I7(<??NI%_<HPX(*J6;(+#L:YKX6^8/C?XR\T7(?RGR+DH9/\ 6+][9\N?
MI7<?#WPY>^"/A[% ^G23ZNS&6YMTG0L[D[0 Y.W 4 ]?6N4^'_A?Q?H/Q$U;
M7=5T.3R-4!0L+V*1HLNIW,=V2 !VYH C\<:;&/C[X--I!!$Q43S$;8]Y$C9)
MSC<WYDUK?'_<?A_:;(1,W]J0XB()WG:_RX')STXJ#Q?X<\3ZS\5-!\06F@R&
MQTEPCLUU"#* Y.Y1NR!@]#@UK_&/PYK?BOPK;:7H=B;B?[6L[.9DC$84$?Q$
M9)W=O2@!GQ-6(_ R_%VLELOV2VRD4>2C^9'M7#$8&[ /.0,GDC!I>"_AWX7U
M?X3V$5QI40DU&SCEGG3_ %GF8^\&.<'Z<>U;6N>'=6\7_"N?P]+;C3+^2.&+
M_29%D'[MT8ME"W!VGWK*TG6O&NC^'+708_ [-J5NH@22.9$M"H&<[L\<#\^*
M ,#X,VTVK>#_ !'X.U4I/8VMQ);J=DB@9^\ &1>-V6P2&YY4<4GPN\7_ /"+
M:7XF\*ZM)^^\/^;/:?:/W7FQ GY>1A1NVD9))\WC.*]"^'G@F/P+X<^P?:6N
M;N=_/NYB3AI2 #MSVX ]^M</\0_#$>M_&#P];P73G[?:-'J=O$@;;;Q.'5I!
M_==\+D_W10!V_P .M,O;+PT;[5,'4M4F:]N,JNY=WW4)7AL#'/OTKKJ@DC>&
MQ:.R2(2)&5A1R0@('R@XY Z=*\]^&_B?QCJ6L7VE^+].6VE6W2ZMW\KRR48X
MQC^?<'@T =[JT,ESH]]!$NZ22WD1%SC)*D 5XQ^SC"+6+Q1:2V[QWD$\*3L9
M 0<>8 H '!!#<Y.<CICGW.O&O$7P^\0^$_%DOC'P,PG::1GO-,X0-'C) &?F
MR03CKDC - 'LM<WX_C$O@#78VM9KH-9N/)A.'?CH#@_R-8">/O$VHV6-+\ :
MNEZ6" :AM@BSC))).0, X..N!WJ?7?#6L?\ "#>(+:V,M_K6L;F<+.%2)F&
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M%;.20>V*]0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
(B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logo_001.jpg
<TEXT>
begin 644 logo_001.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !B ,P# 2(  A$! Q$!_\0
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M51_PDFL_]!K4_P#P-E_^*K.HHY5V T?^$DUG_H-:G_X&R_\ Q5'_  DFL_\
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M\0VL&@K+##J=]).D;F7!90Q.#CC-?,S^L?V=JX\MEWOT^1V+E]KYGSC^Q_\
M"30_C=\<++PKXADO8M-EL;JY+Z?<>1,'0#&'P<##$$=\UVO['6C6WAS]NK3-
M(L]XL]/U'5[.#S#EO+CBN$7)[G"CFD_X)O\ _)U&F?\ 8*O_ .25?_98_P"4
M@W_<;UW_ -!N:]#$SDY5X7TY/\S*"7NOS/._BW_R>;XD_P"QZ_\ ;Q:^E_V@
M/^4B^A8Z_P!A1_\ HFYKYG^+3#_AL[Q*O\0\=#([C-XN*^F/V@L?\/&-!4\%
MM!C('J/)N1D5SXCX8_\ 7N7Y(:V?J?3^L^&_"_@F.RM=7CU#4-0N(O-=K=PB
M(,XXY'?/KTK!T%O#R^*6\Y;Z2P\Y/L>PJ) VX8W^WTK>\/>-K?Q-)8:#XCTR
M/4MS""*Z7B9"> 3W^I!'XU@Z]H,7AGQXNGPR&2&*YA9&;J%8JP!]QFOC/)F[
MMHUL=E\4'\,KX@F&HQ:BVI?9EV-;E1%_%MSDYZ]:YOP9X*M/$WAK5KN>X^RW
M5LZJDTC[8D7 +,P[X&:F^,_R^-CGC=;1XSWY:K7@O_DF/B_Z?^R"ET*=G-W,
M'7M-T*6?3K#PW/<7]Y))Y4LLP*K(QP%V\# SFMS4M!\'>$9TT[5I+_4-0"JT
M\EJ=J19YZ9';ZFN9\$W45GXPT>:8A8EN%!9N@SP#^9%=I\0/$%MH?BBZBN_"
MVGW7F;72ZG!S,"HYSCL>/PI^1*M9R.2\;>%5\+ZC"+><W5A=Q">VF;J5/8^X
MR/P(JY83>![>SMQ>0:M<W)1?.=&"JK8YVC(R,U#XA\42^-)-&M#8PZ;#"WD0
MF(DKM8JO?L,"NA\87NF?#_48=*LO#UA<XA61KG4$,C2$Y''Y?KTH\@TNVMC#
M\>^$;3P[_9UYIL[SZ;J$>^+S#EEX!Z]P01^M7[7P?H4?@?3=>U&ZNK?S)2LJ
MPC>9/F8!4&, \#D^AJ_\5+@W'A7PG*T"6K21LWD1KM5,HIV@=@*BUC_DB>C?
M]??_ +-)2Z#LE)C[3P9X7\6Z'=7>BW-UITMF<S_;,N N,DD#.> <8/45'X;T
M#P3XFN/[+M9=22^9"8[F8A0Y R2%''O@CI2_"O\ Y 'B_P#Z]!_Z!)6%\*_^
M1ZTK_@?_ *+:CN&FFFYS^J:?)I.I7=E*09+>5HF*]"0<9JM6WXW_ .1RUO\
MZ^Y/YUB59B]PHHHH$?E)1117ZF<H5?T#6KKPSKVF:Q8E%OM.NHKRW,B[E$D;
MATR.XRHX[U0HI/71@=C\6?BSXB^-GC*3Q1XIEMIM7DMX[9FM(/)38F=ORY//
MS'FK_P &_CIXL^ ^K:IJ7A&:SANM2M19W!O;83J8PV[ !(P<UY_16?LH.'LV
MO=[#YG>_4[#X3_%?Q#\%?&<7BGPO+;0ZO%!);J]W!YT>R3&[Y<CG@<U'X=^*
M/B/PG\2D\>Z3>)9^)4OI=0$ZQ Q^9*6,@*=-C;V!7T-<G13=.#;;6^C] NSU
M/XU_M(>+/CQK&C:GK\&DZ?>Z2S26\VCVAMW,C%#O=BS%F!C3&3Q@^M>X?#3]
MKKQ[\<OB-X0\.^*H]%FB@>29K^UL/*NY6C@D*Y?<0!DDD*H!KX\KUG]E7_DO
M'AO_ ';G_P!$25P8K#T8X:5HKW4[>6A<9ROON?ILGQ8UA,R?9=--WC'VK[-^
M\_/-<E>WUQJ-Y+=W,K2W,K;WD;J3Z^U045^?6.AR;W.RD^*VM7&G_9KB.SN7
MV&/[1+#F3!&#SG&?PK!TWQ)?:5HU]I=NT8M+P8F#)ECQC@]N*RZ*+(.9]PKK
M]/\ BEK5G91VLXM=2BC&$-Y%O8?CD9_&N0HH!-K8U?$/B:^\3744]ZT8,*[(
MDA38J#.>/QK=7XL:[]ECAE%G<R1C"7$T&Z0>_7&??%<;119!S/N=)J7Q U;6
M-$;3+YH+I"V[[1)%F4<YX/0>G3IQ5&X\3W]SX=M]$=H_L$#^8BA,-G)/)_X$
M:R:*+!S,UM%\47_A^UOK>S:-8[U/+FWIN)&"./3[QJMHNKW/A_4H+ZS*K<0Y
MV%UW#D$'CZ&J5%,5V6-1OYM4O[B\N"IGG<R.5&!D]<"J]%% !1110(_*2BOV
M5_X83^!'_1/++_P*N?\ X[1_PPG\"/\ HGEE_P"!5S_\=K[#^W</_++\/\Q_
M5I]S\:J*_97_ (83^!'_ $3RR_\  JY_^.T?\,)_ C_HGEE_X%7/_P =H_MW
M#_RR_#_,/JT^Y^-5%?LK_P ,)_ C_HGEE_X%7/\ \=H_X83^!'_1/++_ ,"K
MG_X[1_;N'_EE^'^8?5I]S\:J*_97_AA/X$?]$\LO_ JY_P#CM'_#"?P(_P"B
M>67_ (%7/_QVC^W</_++\/\ ,/JT^Y^-5>L_LJ_\EX\-_P"[<_\ HB2OT\_X
M83^!'_1/++_P*N?_ ([6IX8_8[^#O@S7+?6-%\#VEAJ5ON\JX2YN&*[E*G@R
M$<@D=*PKYS0JTI047=IKI_F-8::=[GF-%?17_"L/"_\ T"(_^^W_ /BJ/^%8
M>%_^@1'_ -]O_P#%5\GS(V]C(^=:*^BO^%8>%_\ H$1_]]O_ /%4?\*P\+_]
M B/_ +[?_P"*HYD'L9'SK17T5_PK#PO_ - B/_OM_P#XJC_A6'A?_H$1_P#?
M;_\ Q5',@]C(^=:*^BO^%8>%_P#H$1_]]O\ _%4?\*P\+_\ 0(C_ .^W_P#B
MJ.9![&1\ZT5]%?\ "L/"_P#T"(_^^W_^*H_X5AX7_P"@1'_WV_\ \51S(/8R
M/G6BOHK_ (5AX7_Z!$?_ 'V__P 51_PK#PO_ - B/_OM_P#XJCF0>QD?.M%?
M17_"L/"__0(C_P"^W_\ BJ/^%8>%_P#H$1_]]O\ _%4<R#V,CYUHKZ*_X5AX
M7_Z!$?\ WV__ ,51_P *P\+_ /0(C_[[?_XJCF0>QD?'_A3PE\//'WQ@^/-S
M\3/$UQI\FE^)#!ITDWB>XT_[+!Y",3$JS*,!L\X(KVS]BW6O$NM?"O4VUS4=
M2UO2+?7+RW\.:QK"L+N_TI6 @F<L S _-ASRP /3%>._#+0_A%K/Q=_:(?XF
MVWA&=X_%16&3Q(;<2)#]G3=L:4[@N<_=[UW_ .PSJEQJ&F_$:'2+R]U#X86G
MB&2'P?<WKO)FU"_O$A=_F:%7X3/O[U[>*]ZE+?3EWVV6WG_P1T_B7S/J"OFK
M_@GO?76H?L[I-=W4]Y-_;FIKYEQ*TC8%RX RQ)P*^E:^8O\ @G6P;]G!"#D?
MV]JG3_KZ>O,I_P"[5/6/_MQL_C7S_0]^\?\ C"T^'O@?7_$]\I>ST>PFOI44
MX++&A;:/<XQ^-?-?P?\ V?U_:$\"Z=\1?C#J>L:YKGB.'^T+32;;5+BSL=(M
MI/FAB@BA=?F"%27;))/MD_0/QD\#O\2_A/XO\*Q2"*?6-+N+.)V. LCQD(3[
M;L9KQS]E7]H3PQ)\)])\)^+=7L?"/C;PC:IH^L:-K-PEI+$T"^6)%#D;D95#
M;AD<UI1YXT)3H_%=7MNE_P /O\B96<DI;%3X.ZGKWP/_ &BKSX,:MKU_XE\*
M:KI!USPO>:M,9[NT"/LFM'E/+J/O*3R !ZU]05\I?#W5H/VAOVP)?B)X=W77
M@3P5H<NAVNM*I\C4;Z9]TODL?OHB<%AQG'J*^K:C&?'&_P 5E?U_SM:_F.GL
M[;'Q_:_"?0_C9^UQ\:+#Q9-K%W9:-;:.;""UUBZM8[=I;8ERJQ2*,DH#]<^M
M=9^RGJ^J:1\1_B]\.CXBOO%OA?PE?V<>E:CJ4YN+B#SH2\MH\QY?RV '/(Y!
MKB+#X.Z'\8/VQOCA!K-_KEDMC;:*571=7GL/,#VIW+)Y3+O'RC&>G..M?47P
MX^&'A?X1^&TT'PEH\&C:8KM*T<66:61OO22.Q+.Y[LQ)X%=>(JQC3]FVW>,=
M.BT3O_7<B$7>_FSJ:^5/V,?B;HVF^ _&<'B3Q=96]^OC/6 D>K:F@E6(3 (
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:C;I"AD8Y9RJ@#<3U/4T45G'^'+Y?J/JC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>drsa_001.jpg
<TEXT>
begin 644 drsa_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '%!%@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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METCZ-8Q&/5;6%I(X@C,K21!N1@C*L14_B?1=-M_"/B41Z#8VJP6K""6.! 7
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M#^,\;IX\R\WF![2-D7 'EC+#;[\@G\:\\K2G)R@FR9JTK(****LD*^M?!_\
MR).@_P#8.M__ $6M?)5?6O@__D2=!_[!UO\ ^BUKEQ?PHVH[LVJ***X3H"O&
M/C[_ ,R]_P!O/_M*O9Z\8^/O_,O?]O/_ +2K;#_Q$9U?A9XO1117I'*%%%%
M!1110 4444 %%%% !1110 4444 %;7BG_D+0?]@ZQ_\ 26*L6MKQ3_R%H/\
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M# /P9"=V[ZYYIJ^*=?2]N+Q-8O4N+G;YTB3,IDVXQG'7&,5D44<L>P79M_\
M"8^(Q=S70UF\$\T8BDD\SEE&< _3)_.JBZ[JZZ:NG+J=X+)6#+ )FV @Y&!G
MUY^O-9]%/E78+LVI/%_B*:WDMY=:O9(I""ZO,6SC&.OT%*/&'B(7SWPUB[^U
M/$(6EW_,4!)"_3)-8E%+DCV#F?<U+?Q)K=IIKZ=;ZK>16;#!A29@N#U'L#5B
MW\8^([2&WAM]9NXX[==D*K)@(N,8'X5AT4<L>P78^::2XGDGF=GED8N[L<EF
M)R2:9115""MJU_Y$G5/^PC9_^B[FL6MJU_Y$G5/^PC9_^B[FE(:,6KUGK6I:
M?97-E:7LT-M=#;/$C8608Q@_A5&BFU?<1=TO5]0T6Y:YTV\EM9F0QL\1P2I(
M./T%/TS7=5T:21]-U"YM6D^_Y4A7=]?6L^BDTGN%V23SRW,[SSRO+*YW/)(Q
M9F/J2>M7H?$.LV]E%9PZK>):Q.LB0B9MBLIW @9QP0#]>:S:*+(+FU+XM\03
MK=K+J]VXNTV7 +_ZQ<8P?;!Q4O\ PF_B?.?[<O<[/+_UG\/I6!12Y(]A\S[F
MI)XCUJ6&SB;5+K998%L%D*^3@8&TCIQQ3QXJ\0"YFN!K>H>=, )'^T-E@#D
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M_P#C=?0-%'UFH'LHGS]_PHOQ/_S_ &D?]_I/_C='_"B_$_\ S_:1_P!_I/\
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M_P!_I/\ XW1_PHOQ/_S_ &D?]_I/_C=?0-%'UFH'LHGS]_PHOQ/_ ,_VD?\
M?Z3_ .-T?\*+\3_\_P!I'_?Z3_XW7T#11]9J![*)\_?\*+\3_P#/]I'_ '^D
M_P#C=>XZ#8RZ7X=TS3YV1IK6TB@=D)*EE0*<9QQD5H45G.K*>DAQ@H[!1116
M984444 %%%% !1110 5#=74-G;O/.X5%!/N?8>IJ5F"J68X &2:YN-_[?NOM
M<J@V,+?Z*H/$C _?]01Z&JC&Y,G8D>]U#5X_]%)L;1AQ.>7=3T8#^'!X/UI(
MO#UJS&66)[B5LDM,V>67!]NHS6RD8!^;!?J >F:9/=1P1B25PNQ@&!Z_Y_\
MKU7/;2(N6^Y2.A6;8'V*W( Q]T<?+M_I56308X)/,M'FLY!@KY3?*Q"X7(Z'
MG)-:!U6S!G_?<< <'G/I5Q'#D*K*PQEL<CFDJC'R(R(]7N=-V1:I^]B_Y_(U
MP !U+CMSP,=:W$=9$5T8,C %2.A%5)H(YHFRBO$?O(XR#Z9]1WQ6983-I%^N
MGN7>UG),4C<F-NI5CT&>PIM*2NA7:=F=!1116984444 %%%% !1110 4444
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MIU%>;_!AVD\+:M(T;1LVLW3&-B,J<C@XXS]*QO [:?+INL_$K7VN+K5;2>Z
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M@T6PTO2H(KGPU+?W87=$D<>"FV%1G!'7!X/3(ZUZC\/_ /DG?AW_ +!T'_H
MJ.Z^'7A*]LK2SNM#MYH;.W:UMQ(S,8XSV#$YSZ'.1V(K>T^PMM*TZVT^RB\J
MUMHUBB3<6VJ!@#)))X]:MM6?F_\ /_,7;R+-%%%0,**** "BBB@ K,\0?\@>
M7ZK_ #%:=9?B#_D#3?5?YBLZW\.7H:T?XD?4XB0U6D-3N:EL+>*8W$TX+1V\
M1D* XW'H!G\:\51YG8]QRY5=F4YJM(:W8X;6\L+V<0) T2QA<.Q526P3W/3Z
MTV\\/R->.$>UMD,P@1#([9<J#@';WSWQ5>QDU=:D^UBG9Z'-.:K.:Z.XT&8V
M]JJK!&VR5YIC(Q "'!W#'&.G&<U3M?#MSJ4DL=G/!,4'#*LA5N,_>V8'_ L4
MG2G>UBE5A:]SGW-5I#6[K5C!9V6E/$A5Y[?S)223EMQ'X5O7_AO3P\\9L4LX
MU\C[/</)(%G=\;D.2<]3RHXIQH2DVET$Z\8I-]3SMS59S7<7?A9;FT>.SMXX
MKO\ M*6 DS,R1QHN3R>H'KC-4+?P<CZ9>7USJ5N(%M_.MYX]Y1_FVG/R;N.F
M,9Y%2Z$^WF-5X=SCG-1UT7A>QL-1N;N"Y$$EYY7^APW$K1Q2OGD%E(.<=!D<
MU;N?"48TK[29197LFH&T%I,68)Z+D)R><YSC'<FDJ$Y1YE_6MANM&,N5G(TA
MKI(O!.J32W$<<EL6@O#:/\Y #!2Q;)'W0 >>OM5V\\(1RZ!ITVF36]Q=&&XG
MF:-I/WX1P,(&4<@'I@9YZTU0J-7L#K03M<XZD-:M[H5U8ZW%I,KQ-=.8U(1B
M0C/C"GCJ,C-=#>Z)IFE6]]=+8F^,5ZNG6\#R. \@7+NVT@DD]%!'6B-&33?8
M)58JUNIQ!HKKH_ ^K:O/+<6^F/I<+2"..WN$F8AL ]0A(7W; YZU'_P@6HK-
M:6\U[80W5V2(H'=]Y(;:1PI'!]Z/85.PO;T^YRM)74?\(+J#*ACO;"1I!+Y2
MJTF9&CSO493&1CO@'L326?@75;^QMKR!X?*G=(\R)*FPOP"2R ,,\94M3]C4
MVL#K4UK<YBDKIAX(U"0Q_9[NRN/,,J)Y;N-TD8RT?S*/FZX[''6G)X4>*QOH
M;HHM_%8KJ,81SE$S\R.", D$'\!ZTE1G:]@]M#N<O2J[1NKHQ5E.0P."#24E
M9FA[;\/_ (@+K*1Z5JL@74%&(I3P)QZ?[W\Z]#KY05VC=71BK*<A@<$&O=/A
MOXRN?$5I)97T4C75JH)N0ORR+T&X]F_G7J87$\WN2W/*Q>%Y/?AL=W1117<>
M>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDUP=8L9!% ]P4CN8RS(A(8@9YP01]>*YA/B5;WFN>&?LDMI'HNJV=Q<SS7+
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M>Q+'&W]:23Q8)I_$-]+'(;W5$\B,<;8HR><GKG 4#BM'_A4WB;TL_P#O]_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'5=EL%%%%=!S!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=<_\$5[_ /&:Z"B@#G_^$RTO_GUUS_P17O\ \9H_X3+2_P#GUUS_ ,$5[_\
M&:Z"B@#G_P#A,M+_ .?77/\ P17O_P 9H_X3+2_^?77/_!%>_P#QFN@HH Y_
M_A,M+_Y]=<_\$5[_ /&:/^$RTO\ Y]=<_P#!%>__ !FN@HH Y_\ X3+2_P#G
MUUS_ ,$5[_\ &:/^$RTO_GUUS_P17O\ \9KH** .?_X3+2_^?77/_!%>_P#Q
MFC_A,M+_ .?77/\ P17O_P 9KH** .?_ .$RTO\ Y]=<_P#!%>__ !FC_A,M
M+_Y]=<_\$5[_ /&:Z"B@#G_^$RTO_GUUS_P17O\ \9H_X3+2_P#GUUS_ ,$5
M[_\ &:Z"B@#G_P#A,M+_ .?77/\ P17O_P 9H_X3+2_^?77/_!%>_P#QFN@H
MH Y__A,M+_Y]=<_\$5[_ /&:/^$RTO\ Y]=<_P#!%>__ !FN@HH Y_\ X3+2
M_P#GUUS_ ,$5[_\ &:/^$RTO_GUUS_P17O\ \9KH** .?_X3+2_^?77/_!%>
M_P#QFC_A,M+_ .?77/\ P17O_P 9KH** .?_ .$RTO\ Y]=<_P#!%>__ !FC
M_A,M+_Y]=<_\$5[_ /&:Z"B@#G_^$RTO_GUUS_P17O\ \9H_X3+2_P#GUUS_
M ,$5[_\ &:Z"B@#G_P#A,M+_ .?77/\ P17O_P 9H_X3+2_^?77/_!%>_P#Q
MFN@HH Y__A,M+_Y]=<_\$5[_ /&:/^$RTO\ Y]=<_P#!%>__ !FN@HH Y_\
MX3+2_P#GUUS_ ,$5[_\ &:/^$RTO_GUUS_P17O\ \9KH** .?_X3+2_^?77/
M_!%>_P#QFC_A,M+_ .?77/\ P17O_P 9KH** .?_ .$RTO\ Y]=<_P#!%>__
M !FC_A,M+_Y]=<_\$5[_ /&:Z"B@#G_^$RTO_GUUS_P17O\ \9H_X3+2_P#G
MUUS_ ,$5[_\ &:Z"B@#G_P#A,M+_ .?77/\ P17O_P 9H_X3+2_^?77/_!%>
M_P#QFN@HH Y__A,M+_Y]=<_\$5[_ /&:/^$RTO\ Y]=<_P#!%>__ !FN@HH
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M?_X3+2_^?77/_!%>_P#QFC_A,M+_ .?77/\ P17O_P 9KH** .?_ .$RTO\
MY]=<_P#!%>__ !FC_A,M+_Y]=<_\$5[_ /&:Z"B@#G_^$RTO_GUUS_P17O\
M\9H_X3+2_P#GUUS_ ,$5[_\ &:Z"B@#G_P#A,M+_ .?77/\ P17O_P 9H_X3
M+2_^?77/_!%>_P#QFN@HH Y__A,M+_Y]=<_\$5[_ /&:/^$RTO\ Y]=<_P#!
M%>__ !FN@HH Y_\ X3+2_P#GUUS_ ,$5[_\ &:/^$RTO_GUUS_P17O\ \9KH
M** .?_X3+2_^?77/_!%>_P#QFC_A,M+_ .?77/\ P17O_P 9KH** .?_ .$R
MTO\ Y]=<_P#!%>__ !FC_A,M+_Y]=<_\$5[_ /&:Z"B@#G_^$RTO_GUUS_P1
M7O\ \9H_X3+2_P#GUUS_ ,$5[_\ &:Z"B@#G_P#A,M+_ .?77/\ P17O_P 9
MH_X3+2_^?77/_!%>_P#QFN@HH Y__A,M+_Y]=<_\$5[_ /&:/^$RTO\ Y]=<
M_P#!%>__ !FN@HH Y_\ X3+2_P#GUUS_ ,$5[_\ &:/^$RTO_GUUS_P17O\
M\9KH** .?_X3+2_^?77/_!%>_P#QFC_A,M+_ .?77/\ P17O_P 9KH** .?_
M .$RTO\ Y]=<_P#!%>__ !FC_A,M+_Y]=<_\$5[_ /&:Z"B@#G_^$RTO_GUU
MS_P17O\ \9H_X3+2_P#GUUS_ ,$5[_\ &:Z"B@#G_P#A,M+_ .?77/\ P17O
M_P 9H_X3+2_^?77/_!%>_P#QFN@HH Y__A,M+_Y]=<_\$5[_ /&:/^$RTO\
MY]=<_P#!%>__ !FN@HH Y_\ X3+2_P#GUUS_ ,$5[_\ &:/^$RTO_GUUS_P1
M7O\ \9KH** .?_X3+2_^?77/_!%>_P#QFC_A,M+_ .?77/\ P17O_P 9KH**
M .?_ .$RTO\ Y]=<_P#!%>__ !FC_A,M+_Y]=<_\$5[_ /&:Z"B@#G_^$RTO
M_GUUS_P17O\ \9K8L;V+4+..ZA2=(WS@3P/"XP2.4<!AT[CGKTJQ10 4444
M%%%% !1110 4444 %%%(S!%+,< #)- "T5@R:[->,4TN#>HZSR@JGIQZX-1>
M1JDJ*]QJCJ>,K @49SS@]ZT5-]2.==#HZ*YH:;>1LICU:[' R7(8<'G@TZ*^
MUJQ/^D)'?1X'W/D<$GTZ$ 4>S[,.?N='15/3]4M-2B#V\H+8R8R1O7G'([5<
MJ&FM&6G<****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M89>X8#D@]N*P_'<&AS?$;QDVKWES;SI*6LEACW"23CAN.!CW%*^B:[/]/O\
M(=O>:]/U_IGT_P"$M?7Q3X5T_6U@,'VN+>8R<[2"0?PR*X+XD?$S7O#OB6#0
M/#FEV]S<FW^T2R7.<8R>%&X= ,DYK*T77/B7#\/_  RWAO0K.[5K9EF,RJI
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MJ3:-:G5UC6_V#SA'TS_CZXXSTK0KVD[JYX35G8****8@HHHH **** "BBB@
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M]"NH:@JR:HZ\#J( >P_VO4_@/?NJ[\-AN3WY[GGXK%<_N0V"BBBNTX HHHH
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MS9!'<>47&&/7YB1W;-;M%"T Q->\(>'_ !/)!)K6EP7KP*ZQ&3/RAA@]#_\
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M_P $TW_R56Q8I>1V<:W\\$]T,[Y((3$C<G&%+,1QC^(^O'2@"Q1110 4444
M%%%% !1110 4444 %%%% !1156ZU*QLO^/J\MX/^NL@7^=-)O8"U16))XLT5
M.$NS,>WD1/)G_OD&K>FZU::HTB0^8DL?6*9"C8['![53A)*[0&A1114 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB>]ELM'UB.XN8U+-$T4D;$#J0'4;L>V:D?Q[X8B\,IXCDU:--)=S&D[QN"S
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$N)/)7=,H& '.,L .,&JI\,Z T4L1T/33',B1R(;2/#HF-BD8Y"X&!VQQ7E
MU[79?CC/IL.M7)$%T#+!]I3[&EEL!(*=?-W$#/7GTKM?BOJ5WI/@9[RRFNHI
MDN[;FU<K(RF5<J,$9R.,=\T+X5+O_G;^OF#;3:[?Y?\  )O&O@BX\6_9XX=9
M&GP(C12Q_8(9F9&&&V.PW1D@XR#^%;L'AS2(8-.C;3[:9M-B6*UEFB5Y(@
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MC./?%=/=?#KPE>V5I9W6AV\T-G;M:VXD9F,<9[!B<Y]#G([$5J-X>TM_#?\
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M$G(-/\/Q7'V*2[NN)KN5IMG]Q3]U?KC%:U:SJ23LGL!CZ5J,WVAM*U$!;^)
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MGOFK<_@SP_<-J3/IR@ZG"D%WY<CH)$7HN%(V]>V,]Z-U\OQ:U?\ 6P]+_/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %9^IZ%H^M^5_:VE6-_Y.?+^UVZ2[,XSC<#C.!T]!6A10!S_ /P@G@__
M *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-=!10!S_ /P@G@__ *%30_\
MP70__$T?\()X/_Z%30__  70_P#Q-=!10!S_ /P@G@__ *%30_\ P70__$T?
M\()X/_Z%30__  70_P#Q-=!10!S_ /P@G@__ *%30_\ P70__$T?\()X/_Z%
M30__  70_P#Q-=!10!S_ /P@G@__ *%30_\ P70__$T?\()X/_Z%30__  70
M_P#Q-=!3)I4AB:21@J*,DGL* ,+_ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0
MJ:'_ ."Z'_XFK&D7]WJDLEUY:QV!XAS]Y_\ :]A6Q0!S_P#P@G@__H5-#_\
M!=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T
M?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\
M^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P7
M0_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!
M10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P
M@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-
M#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_
M /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()
MX/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T
M/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\
MQ-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S
M_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@_
M_H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\
M!=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T
M?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\
M^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P7
M0_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!
M10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P
M@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-
M#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_
M /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()
MX/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T
M/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\
MQ-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S
M_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@_
M_H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\
M!=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T
M?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\
M^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P7
M0_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!
M10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P
M@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-
M#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_
M /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()
MX/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T
M/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\
MQ-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S
M_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@_
M_H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\
M!=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T
M?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\
M^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P7
M0_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!
M10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P
M@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-
M#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_
M /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()
MX/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T
M/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\
MQ-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S
M_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@_
M_H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\
M!=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$U
ML6-A9Z99QV=A:06EK'G9#!&(T7)).%' R23^-6** "BBB@ HHHH **** "BB
MB@ HHHH *0L!U(K+UK4Y+&*.*V3S+RX;9"GOZGV%8T>EV\VJ&QU2>ZFNFC$@
M<RE4;GD*!Z4 =;NK \7O(=#:WB.)+F1(5_$U0:QET[5?L>FW]Q!(Z[XX[CYX
MI,=0">11=ZCYMQ9V^M1M93P3K(D@&8I<>_:@#8\/7OVG3Q#(H2XMCY4J#L1_
MB*UZYO4&&EZK!J\)!M;C$5QMY'^RU=&K!E!!R#R* %HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "N:^(&L76@> ]7U.QE\J[@A_<R; VUR0 <$$'D]Q72US7CSP
M]=^*?"D^D64D$<DTL+,TY(7:LBLW0'G I-7T_K=#32=V>6V_Q*\5'5O!]K-=
MX4RBWUK]S'AY&G>(?PY'W#]W%>KMXW\-)K\^A'5X/[3@C,DEOAL@ 9(SC!(
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M\2?#C4==OO%DR7EK"NJK9M:;BQVO!R1(,<*3Z$UWFD+J2Z3;+K!M#J 3]_\
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M[P2YV.,'!P?SH B;4[%'V/=P*W3!D&:LJZLNY2"#T(K'F\+:3):/ ME$A92
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MOF?=QSG ]?2KY_Y$7_N&_P#M*O./A#?W&F?!2^O;2WDN+F&:X:**-=S,V!@
M#KS4[<WE_F-:J/\ 70Z!OBE"_P 58_!=K8K,N2DMWYV-CA22NW;SC&.M>AU\
MJ^$[N73_ (I>&9;K2-7COG+FZ6XMRKR22%LNH/.P CD^AKZJIV]U?/\ ,'\3
M^04444@"BBB@#A['XG6-]XBO-$70/$$-Q9J[3R36:K'&JJ6!)WY 8+\I(YR*
MNVGQ"T6_TW0;^V%Q)#K=Q]F@"JN8I,$D2?-QC:0<9KG+3_DI?Q#_ .P;;?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXP_Z#NA_^":;_P"2J/L?C#_H.Z'_ .":;_Y*KH** .?^Q^,/^@[H?_@FF_\
MDJC['XP_Z#NA_P#@FF_^2JZ"B@#G_L?C#_H.Z'_X)IO_ )*H^Q^,/^@[H?\
MX)IO_DJN@HH Y_['XP_Z#NA_^":;_P"2J/L?C#_H.Z'_ .":;_Y*KH** .?^
MQ^,/^@[H?_@FF_\ DJC['XP_Z#NA_P#@FF_^2JZ"B@#G_L?C#_H.Z'_X)IO_
M )*H^Q^,/^@[H?\ X)IO_DJN@HH Y_['XP_Z#NA_^":;_P"2J/L?C#_H.Z'_
M .":;_Y*KH** .?^Q^,/^@[H?_@FF_\ DJC['XP_Z#NA_P#@FF_^2JZ"B@#G
M_L?C#_H.Z'_X)IO_ )*H^Q^,/^@[H?\ X)IO_DJN@HH Y_['XP_Z#NA_^":;
M_P"2J/L?C#_H.Z'_ .":;_Y*KH** .?^Q^,/^@[H?_@FF_\ DJC['XP_Z#NA
M_P#@FF_^2JZ"B@#G_L?C#_H.Z'_X)IO_ )*H^Q^,/^@[H?\ X)IO_DJN@HH
MY_['XP_Z#NA_^":;_P"2J/L?C#_H.Z'_ .":;_Y*KH** .?^Q^,/^@[H?_@F
MF_\ DJC['XP_Z#NA_P#@FF_^2JZ"B@#G_L?C#_H.Z'_X)IO_ )*H^Q^,/^@[
MH?\ X)IO_DJN@HH Y_['XP_Z#NA_^":;_P"2J/L?C#_H.Z'_ .":;_Y*KH**
M .?^Q^,/^@[H?_@FF_\ DJC['XP_Z#NA_P#@FF_^2JZ"B@#G_L?C#_H.Z'_X
M)IO_ )*H^Q^,/^@[H?\ X)IO_DJN@HH Y_['XP_Z#NA_^":;_P"2J/L?C#_H
M.Z'_ .":;_Y*KH** .?^Q^,/^@[H?_@FF_\ DJC['XP_Z#NA_P#@FF_^2JZ"
MB@#G_L?C#_H.Z'_X)IO_ )*H^Q^,/^@[H?\ X)IO_DJN@HH Y_['XP_Z#NA_
M^":;_P"2J/L?C#_H.Z'_ .":;_Y*KH** .?^Q^,/^@[H?_@FF_\ DJC['XP_
MZ#NA_P#@FF_^2JZ"B@#G_L?C#_H.Z'_X)IO_ )*H^Q^,/^@[H?\ X)IO_DJN
M@HH Y_['XP_Z#NA_^":;_P"2J/L?C#_H.Z'_ .":;_Y*KH** .?^Q^,/^@[H
M?_@FF_\ DJC['XP_Z#NA_P#@FF_^2JZ"B@#G_L?C#_H.Z'_X)IO_ )*H^Q^,
M/^@[H?\ X)IO_DJN@HH Y_['XP_Z#NA_^":;_P"2J/L?C#_H.Z'_ .":;_Y*
MKH** .?^Q^,/^@[H?_@FF_\ DJC['XP_Z#NA_P#@FF_^2JZ"B@#G_L?C#_H.
MZ'_X)IO_ )*H^Q^,/^@[H?\ X)IO_DJN@HH Y_['XP_Z#NA_^":;_P"2J/L?
MC#_H.Z'_ .":;_Y*KH** .?^Q^,/^@[H?_@FF_\ DJC['XP_Z#NA_P#@FF_^
M2JZ"B@#G_L?C#_H.Z'_X)IO_ )*H^Q^,/^@[H?\ X)IO_DJN@HH Y_['XP_Z
M#NA_^":;_P"2J/L?C#_H.Z'_ .":;_Y*KH** .?^Q^,/^@[H?_@FF_\ DJC[
M'XP_Z#NA_P#@FF_^2JZ"B@#G_L?C#_H.Z'_X)IO_ )*H^Q^,/^@[H?\ X)IO
M_DJN@HH Y_['XP_Z#NA_^":;_P"2J/L?C#_H.Z'_ .":;_Y*KH** .?^Q^,/
M^@[H?_@FF_\ DJC['XP_Z#NA_P#@FF_^2JZ"B@#G_L?C#_H.Z'_X)IO_ )*H
M^Q^,/^@[H?\ X)IO_DJN@HH Y_['XP_Z#NA_^":;_P"2J/L?C#_H.Z'_ .":
M;_Y*KH** .?^Q^,/^@[H?_@FF_\ DJC['XP_Z#NA_P#@FF_^2JZ"B@#G_L?C
M#_H.Z'_X)IO_ )*H^Q^,/^@[H?\ X)IO_DJN@HH Y_['XP_Z#NA_^":;_P"2
MJ/L?C#_H.Z'_ .":;_Y*KH** .?^Q^,/^@[H?_@FF_\ DJC['XP_Z#NA_P#@
MFF_^2JZ"B@#G_L?C#_H.Z'_X)IO_ )*H^Q^,/^@[H?\ X)IO_DJN@HH Y_['
MXP_Z#NA_^":;_P"2J/L?C#_H.Z'_ .":;_Y*KH** .?^Q^,/^@[H?_@FF_\
MDJC['XP_Z#NA_P#@FF_^2JZ"B@#G_L?C#_H.Z'_X)IO_ )*H^Q^,/^@[H?\
MX)IO_DJN@HH Y_['XP_Z#NA_^":;_P"2J/L?C#_H.Z'_ .":;_Y*KH** .?^
MQ^,/^@[H?_@FF_\ DJC['XP_Z#NA_P#@FF_^2JZ"B@#G_L?C#_H.Z'_X)IO_
M )*H^Q^,/^@[H?\ X)IO_DJN@HH Y_['XP_Z#NA_^":;_P"2J/L?C#_H.Z'_
M .":;_Y*KH** .?^Q^,/^@[H?_@FF_\ DJC['XP_Z#NA_P#@FF_^2JZ"B@#G
M_L?C#_H.Z'_X)IO_ )*H^Q^,/^@[H?\ X)IO_DJN@HH Y_['XP_Z#NA_^":;
M_P"2J/L?C#_H.Z'_ .":;_Y*KH** .?^Q^,/^@[H?_@FF_\ DJC['XP_Z#NA
M_P#@FF_^2JZ"B@#G_L?C#_H.Z'_X)IO_ )*H^Q^,/^@[H?\ X)IO_DJN@HH
MY_['XP_Z#NA_^":;_P"2J/L?C#_H.Z'_ .":;_Y*KH** .?^Q^,/^@[H?_@F
MF_\ DJC['XP_Z#NA_P#@FF_^2JZ"B@#G_L?C#_H.Z'_X)IO_ )*H^Q^,/^@[
MH?\ X)IO_DJN@HH Y_['XP_Z#NA_^":;_P"2JV+%+R.SC6_G@GNAG?)!"8D;
MDXPI9B.,?Q'UXZ58HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>drsa_03.jpg
<TEXT>
begin 644 drsa_03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &1 EH# 2(  A$! Q$!_\0
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M5A4IRJ5;;="XXB,:=TCE(;*:WNS()H=RY/S/U^M5O$%U=0*OV8I<[0!N3+*
M>3CUP3CVJ"TF,USL=%*L#VZ8KJ-1C>[CMII64DQ*P &W:,'@8]3S73&E'"^\
MW>Y,,2ZTN6UBKX=,UTR)(I4*HE9>,ITSC/3IVY^E=A=VL%U9M:WJB:%QM#GK
MST/U]ZXG3;R$3HL2M',!PX/WCWKL+69FL[=9BN9&#*1T !R<_0"E#$*I.R./
M,,/R_O/O,C3+F^>>WTZ\8RK:2;GF49;:N0@?ZD@@^BUUD%\D+!6($1W98_PD
M=:XBUNC&]QJH&Y?/-M*BGED &T^Q4Y/T.:Z(2+Q/<RIY2L'8*=J@$=?4\UO.
MTE<\R-X2Y>QU .0".AHJG#>!P$RQ])'78"/;/6K8((R#D5RG99BT444 %%%%
M !1110 4444 %%5+K5+"R!^TWD$6.SR '\JQ[GQSH<&0MQ).?2*,G]3@4 ='
M17#7'Q(@&1;:=*WH9) OZ#-9LWQ$U.0D0VMK']=S'^8H ]+HKR[_ (2;Q7=\
M0B;'3]U:_P#UC2[O&TY/_(2'X!/\* /4**\O&E^-)1RU]_P*Y _]FI4\.>+3
MR3<?C>?_ &5 'I]%>;IHOBR'H;H?2ZS_ %J9(O%D(R3??]][OZF@#T*BN#75
MO$=K_K1/@?\ /2#/ZXJW!XLO5.)H87_-30!V-%84'BBWDXF@DC]QAA6G!J-G
M<_ZJ="?0\']: +5%%% !1110 V3[AJ"IY/N&H*I %<3\2/#>C7OA37-8N=/A
MEU&WTZ4PW!SN3:I*XY[&NVK+\2:7)K?A?5=*AD2.6\M9($=\[5++C)QVH8'-
MZ=I5EX5\*6^J^']'L$U"XM8%GFGG\F-5(!9Y&)^Z.N!R:KV/C^Y:T\1)+)I-
M_<Z38?;HKG3I2T$HPWRL,DJP*\\G@UK:_P"%KO4_#&DV%M-:FZTR6WF$=RI:
MWN&B7&QP.=IZCT(%9A\':Y?3>(+J_GTJ&75M)-A'#:(X2!LM@DD98?-R<#Z4
M@)#XI\2Q:5ICS:?IAU+7)HTTVWCD<I"ACWNTS8R< 9^7UQ[T+XTU+2-1UJT\
M1VMD%TK3$OVFL68^=EF& &^[TQCGGO3_ !/8+IGA_P /7+:I:6-_H\L2V]Q<
MAOL\C^7Y;(Y'*JPS\W8XK!TJQF\;^)O%8U"YLIK2YTJ&P:XTQB\,3[F;:KM]
M]ER&)''(% &K8>.=3.IZ9;W\F@.-6+1VZ6-T9'M9MA9%EY^8'!!9<8-8T&I:
MFOPT\67>N0V6IV\%].H@=Y,,RSX*DDY"#C:!SQ74:%X>UFSOK(WUGX:CAM1\
M]S:6I\ZY(&%." (SW."WMBJ4W@O6)?#/B?P_]HL1:ZC<R7%I<$OO4R2!V61<
M8XQ@$$YH MS:_P")+[Q1J>A:'9Z6HL;>WF^TWCR8_> G;M7KTZYXQWJO'XXU
M'4]'\/KI=A;+K6LF9?+N)"8;<0DB5R1RPR!@=\UNZ7H4]AXOUC67FC:&^@MH
MDC4'<IB# D]N<\5R-WH4GA+1_#EPVL:;;:IIUU<+#)=[EMIUF+,T;/CY#C&"
M>X]Z .F\.:YJU]KFL:1J]K9Q3Z:L!\RT=F67S QS\W(' X^O6N4\6#PRWQ40
M>*A;M9_V*OE"<,5\SSCTV]\9K3\ W-UJ?B?Q5JL\]I<)*]M"L]EDP%D0[E1C
M]_;D MZFNA71)U\>/X@\Z/R&TP67E<[]PDW[O3&*8'F.IB(^#/&HT<7'_"+Y
MM/L/G!]GF^8OF^5OYV?=]LYQ7>>*?$>JZ3J!BMY="L+98@Z3ZM=;3<OSE$12
M" ,<L>YX!K3\8:)/XD\*WNDV\T<4MP$VR2Y*C:ZMSCGM61J/AO6E\6:AJVEM
MI$J:C!%#(VH1LTEKL!'[O'#*<YVDCGO2 Q=0\1ZYK<O@34]*-M:P:G,S>1*[
M\OY3EE?;PR#''OBIX[>^N?C+J$MY#I<T-GI\#JTJ,S0Q%W.4SP'R.3TX%68_
M!FKV'AKPK;6=S8S:EH$YD'FEEAF4AU(R 2#A@>G45OV^A2Q^,]1UN62)K>\L
M(;3R1G<"C,23['=0!SO_  FOB!M /BY=,L3X<&9/(WO]K-ONQYN?NYQ\VST[
MYK2B\0:WJ7CB\T73+;3AI]BMM-/=3N_F/'*,E54<;N#@G@5F#P;XB'AO_A#Q
M?Z?_ &!_JOM>'^U?9MV?*V_=W8^7?GIVS71Z3H$FF^+=:U;S8S;7T5M'%$N=
MR>4I!SVYSQ1J!R)\>^)AX6;Q5_9FE-I4%P\$MLLL@GD F\K<I(VKSC@Y^M;]
MEKGB"U\5V>CZ]:Z:$U&"6:V>R=R8C'M+(^[[W#?>&/I5$^!;W_A6=QX6^V6_
MVF6Y:838;8 ;CS<>O3CZUT&H:+->>+M&UE)8UAL(;B-XR#N8R!0,=N-M,#:H
MHHI@%%%% %FBBBH Y_Q?ILU]HDTMH";NW4NBC^,#JOX]O>OGRZ\0S7+AH7((
M.0U?4=?-?Q'T >'/&MRD*;;2\_TJ  <#<?G7\&S^!%9S6AZ&!FN9Q9!9ZK+I
M.IVVMVI8*YVSHO?^\/ZCWKV$W%Q;Z;_:,,JW^G3Q>:9 @\T*1P?<"O#]-*SK
M+9,?EF&4)[..E>E?#+6FGT>ZT&<XFMWW0[O[C'E?P;^=%"5I<I>94KT_:6O;
M?T.EO(8F\-QXG#1SR1NH0_*1N4GBJ%T+DW>8P^W^''2GW0\C3IX(?E1;B.6$
M#HI9,D#VS6K<3V8THZBT9!*C* X ;THK1E4G;J986U&BI='?]"NT,\\3010N
MQE&T-M!13ZL2#QS]?2N&NM%F_M=+AY6* [0%R0Q''RGTS73V7BEIY&@=$^SL
M"&55VD*>"0:NZB]I*(HH5 C@C\I"S<,./\*Z:<:E%<MKE4Z\92.?LK[[-*(2
M9#D[2QX*D]OZ5->V]SY CMR616Y4<$#V]JN+IL<DKW"P$L@WL<X'UQZU/;W-
MI]H$,J*[#E@C$-_]>O.J*7,^?0[E--7CJ)H%K+*8X;@,1\V\=<*1T-9%U9P6
M^HC;(BAF.TLI)_'M6EJ?B$:;<M;6(\J,'DJ,LQ]23V]J=IMO#K#,\S*'B7S%
M.WJ*ZXTZ]&GS09P.K1K5/?18WBWLLJ&V(.%)S45O=&XCE65 0!R!W]JDN72%
M 3PAXV]<TMI$EQ'A H7!*@#'(]:YHN\TVSI:2@[(RV.FVUT(I6"R,<D9[=@2
M/6M2_NXICO,:PI&NTX/8=*Q[_P .75Q?LZ''F'Y@RG(/MZU;N;56A:$,<A0I
M_P!K']:[,8TX+74QPT8J>A#:"SGN/-MP%9<*WRXP#WQ757:K8VXP1\D+A,\9
M<#/Z@&N/A%OIA69F:19!\W;CCCVZUL2ZU#K0M;41!=[X<;LJ5(V]?Q-<]"$U
M'VEM"\3RU)JE<@\-206VB237TFR)K87(PN5V-E6'NQ*@8^E:?AZWF9"FI*PG
MMB/)@8Y$<9&5/NV."3TQ@5RVA3K=3:#H\X<RZ?<31W: \;4;,>X=QO(Q]*[7
M4+B/3M4M[Z9]L,J- Y_VOO+]>A%=E-\\4O+\4>-BH^RJ/NV_N;T_S.GMVW0(
M3UQBG!0#D<>U5=+>66Q625-A8DA#U49XS[U<K*2LRXNZ0449&<9Z50O]:TW3
M ?M=Y%&W]S.6/X#FD,OT5P^H?$6!,KI]F\I[23':OY#G^58C:SXI\0,5MO/\
ML]K9-BCZM_\ 7H ])O-3L=/7==W<,/L[@'\JYV]^(&E096V2:Z8=U7:OYG_"
ML&S^'VI7+>9?7,4&>O/F/_A^M=%9> ]'ML&=9;IO^FC8'Y#% '.7/Q U6Y?R
M[.WAA)Z *9&_S^%5_L?B_6O]9]MV-S^\?RE_+C^5>EVMC:62;;6VBA'_ $S0
M"K% 'G%K\.KZ0AKJ\@ASU" N?Z5L6WP\TN/!GN+F<_[P4?H/ZUU]% &-;^%-
M#ML%-.B8CO)E_P"=:<-G:VXQ#;0QCI\B ?RJ:B@ HHHH **** "BBB@ J.2W
M@F'[V&-_]Y0:DHH S9=!T^3I#Y9]4.*I2^'"O,$X/LX_J*WZ* .<0:CIYYWA
M!_P):T+?5@^!,FT_WEY%:=59K""7D+L;U6@"PCK(NY&##U%.K,^SS6K;E/'J
MO]:MPW.\8<8/KVH FD^X:@J>3[AJ"J0!1113 **** &NB2QM'(BNC##*PR"/
M0BDA@AMHEB@BCBB7HD:A5'X"GT4 %%%% !3)8HYXFBFC22-AAD=0RGZ@T^B@
M!D44<$2Q0QI'&HPJ(H4 >P%/HHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP"B@C(P:BW,I\MNO8^M $M%0*[+O7N.1]*F1@ZAAWH%<6BBB@84444 %%%%
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M< MM8Z@S"TD,%PIP]O,""I],'D5R2IM/4]^AC(SA[I4N5.M:PRQJ 'X&_P!
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MHEK]F:616>'9.[N 0H ^5L<#&..E77T.:S\&:AI\%C'$ZW4DZ10 8F3SO,
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M>*ET3Q)I?B/[2VES//';L$>0QE5)(S@9ZUI2P138\V-7QTR.E2F49=M8PVD
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MTKHZJ;LN5$Q5WS,LT445@:!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %0W'_++_KH*FJ&X_P"67_704 3444UY%C7<[!1G&30 /(L94,<;C@9]
M::LT;2/&&&Y<9'UZ5%<26TI>TG8?,F2"<<>Q]1Q7/S6\QDV%_+D0>4\A.=Z.
M3L<8_P!H#)^M7&%S.<^4ZFBLW3=46YL=\V5FB?R)@!G$@.#C';H<].:O0SQW
M <QL2$<H<@CD'!ZU+33LRT[JZ)***\Y^(^O:SX>US0KBSO7BL+AFBGB"J06!
M!!R1GH3^51*7*KFU&DZTU".YZ-17'_VQ?'D7+8/(X'^%<MXV\4:]I%I:7]G?
MR)&DP\Y BD.N0<'(^M2ZB2N:T\).<E%-'K-%1V\Z7-M%<1',<J!U/J",BI*T
M.4**** "BBL?3M8N)+&[N]7M!IL<$A :5\ H/XO\]::5QV-BFO(L8!<X!(&3
M4<=U;RVJW4<R/ ZAED4Y4CUSZ4D\MN2+>8J5E4\-T8=Q^5%B6[#_ #X_.,18
M!PN[!]*DKF+B"2.51\P,)++,6SO@;@_4KD=?0>M:FCWKSPR6L[!KJU/ES,O0
M^A'U&#^=7*%E=$1J7=F:=%9FJWTMHR+')'$#&\F^09#%<80<CDY/Y5<M;D7,
M6[8R,.&5AC!P#C]:EQ:5RE)7L3T5P'Q1UC6- M-)U#3+QX(?M/DW*JJD,&&5
MSD'T/YU=BUN^FACE6Y;:ZAAP.X^E9.:3L=2PTG351/1W_ [*BO+/&OB'7['0
M3=Z=J,D,D;C<0BG(_$5Z+HNH+JVB6.H(01<P)+QZD D?G1&:;L*IAY4X*;V>
MA>J*W_U;?[[?^A&I:BM_]6W^^W_H1JS EHHHH ;)]PU!4\GW#4%4@"BBBF!F
M''_"76OF=/L4GE9_O;USCWQBN=^(-J+C4K#>MML%E=!7NK:295D)BV[0A!#]
M<'ZXKJ=1L3>QQM%+Y-U _F038SM;H01W!'!%0KK5[ !'>Z/<F7H'M<2(Y]N0
M1^(J6@(W_P"1!'VU9D?^S1YBW!S(&\OHQ[MGK[U=L%D6Q@,V?.:-2^?7 JA*
ME]K-Q"MY!]DL482?9RP:24@Y&_' 7...<UL4T(JZEI\.JZ?-97#2I'*N"T,A
M1U]P17S_ .+_  1J/A6Z,LFZYL';$=X!^C^C?H>U?151W%O#=6\EO<1)+#(N
MUXW&58>A%#0SYYT5/&NG:<MUHD6J1V4Y\P-;IN1R.,XY],?A6D/%_P 14^4O
MJ'_ K 9_] KW"PL;?2[""RLX_*MX%V1H#G:*L[F_O'\Z5@/']&UGQQJ;!;DZ
MD?7%OY8_0"O1-$L[^% ]T"A/4.V6-;A)/4FDI@%%%%, I&19%*NJLIZJPR#2
MT4 <]+H$]C,9](GV*7,LEM(<K*W89["J[:U<62$:G83Q,D1DDD1=REV. /\
M)KJ:#R,'D>AJU4[ZD.'8YT>(-,RRB["[6C3Y@1R>M(WB#3-ZI]I,A9WCPBD\
M@<5N/9VLA)>VA8LP8DQ@Y(Z'ZTZ.VMXCF.")#NW95 /F]?K3YX]A<LNYS:ZC
MJ6I1@:;I[QB6/(GG^4)(I_K_ %J]9^'T$YN]1D^U7#,) A^Y$_<J*VZ*3J/I
MH-074.M%%%066:***@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "H;C_EE_P!=!4U0W'_++_KH* )JCF,0@<S;?*VG?NZ8[U)7->*9YAY-OMQ"
M?GW9^\1V_#^M3*7*KFE*G[2:B4IM1MM_E1,5&[=;RN,MTYC/L1G!/]*CGGQ
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MFL[*UBV0L4:24$[B.N,=*Y9-)M(]N%*>(C"4>WY:&C92_P!B_&/3I^D6H1M
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN/\ EE_UT%35#<?\LO\
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MYB6)5"RNJXB.8\@'#;3TSFE;P[I9QBW="'D<&.>1"/,.7 (8':QY*],\XHU
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M8(&0001U!!'3TJE#X7T^VG@FMGNH7B4*Y2;)F 8O\Y())W,QR,'YB.G%;5%
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M %FBBBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&X_Y9?\
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M#T- &.=8G.%6!"Q5CN^;:<9Y''(XH35KJ)#YMJTO)(:,'[N6]O1"?R]:V:*
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MZU+82BVC$YS+CYC@?TJ6B@ HHHH *BM_]6W^^W_H1J6HK?\ U;?[[?\ H1H
MEHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "H;C_ )9?]=!4U-DC65=KC(!SP<4 .HJ+[-'_ +?_ '\;_&C[-'_M_P#?
MQO\ &@"6BHOLT?\ M_\ ?QO\:/LT?^W_ -_&_P : ):*B^S1_P"W_P!_&_QH
M^S1_[?\ W\;_ !H EHJ+[-'_ +?_ '\;_&C[-'_M_P#?QO\ &@"6BHOLT?\
MM_\ ?QO\:/LT?^W_ -_&_P : ):*B^S1_P"W_P!_&_QH^S1_[?\ W\;_ !H
MEHJ+[-'_ +?_ '\;_&C[-'_M_P#?QO\ &@"6BHOLT?\ M_\ ?QO\:/LT?^W_
M -_&_P : ):*B^S1_P"W_P!_&_QH^S1_[?\ W\;_ !H EHJ+[-'_ +?_ '\;
M_&C[-'_M_P#?QO\ &@"6BHOLT?\ M_\ ?QO\:/LT?^W_ -_&_P : ):*B^S1
M_P"W_P!_&_QH^S1_[?\ W\;_ !H EHJ+[-'_ +?_ '\;_&C[-'_M_P#?QO\
M&@"6HK?_ %;?[[?^A&C[-'_M_P#?QO\ &GHBQH%48'US0 ZBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
8* "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>drsa_002.jpg
<TEXT>
begin 644 drsa_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'G G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHHHH **** "BBB@ HHHH **** "BBL_6[R6PTQIX71'$D:[G7<%#. 3COP:
M-"BL@:O'9VL<EU.;A)2VR:.+:I(Z)C/4\X]:C.NR07-^;FTE6WMDC;(VD@L.
MF,\GG]* -NBLZ;5OLZ1O/9W$<;$!F;;\F6P,\\]NF<9I&UF%$N)FAF%K 6!G
MP-I93@@#.>O'2@#2HK$DULS/;QPJ8I/M4<<J-M;Y&#8P02.WZ4NGZUOL0UR&
M:9+=[ARJ@ J&88'OQ0!M45CVVJS2W-Z1$\L:"$Q1H &&Y,G)) _6I(=<AN)+
M>.&WGD>96;  ^0*VUMQSC@_GVH U**** "BBB@ HHHH **** "BBB@ HHHH
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MV%8[Z\DF";BN%"88_=;CNO./K1-HOGFX+W<F+B-%D&T<LN,-[=.E6?[5L/\
MG[B_[ZH_M6P_Y^XO^^J=F+0K7VB)>W;S-<.H=4!7:#C:<C:3T]\=:4Z*KQW%
MNUS*;.8LWDX'RLQR2#C/7D"K']JV'_/W%_WU1_:MA_S]Q?\ ?5%F%T0+I+%8
M?.NFD:*=9@1&J#@$8P![U!_PCRK"D<5W+'^Y:"0A5.]&)/<<')/-7O[5L/\
MG[B_[ZH_M6P_Y^XO^^J+,-"F_A^,AMMPX),1Y4,OR+M (/4'K]<5/8Z1'8S)
M(DKML1T ('\3[ST]ZE_M6P_Y^XO^^J/[5L/^?N+_ +ZHLPT+E%4_[5L/^?N+
M_OJC^U;#_G[B_P"^J+,+HN453_M6P_Y^XO\ OJC^U;#_ )^XO^^J+,+HN453
M_M6P_P"?N+_OJC^U;#_G[B_[ZHLPNBY15/\ M6P_Y^XO^^J/[5L/^?N+_OJB
MS"Z+E%4_[5L/^?N+_OJC^U;#_G[B_P"^J+,+HN453_M6P_Y^XO\ OJC^U;#_
M )^XO^^J+,+HN453_M6P_P"?N+_OJC^U;#_G[B_[ZHLPNBY15/\ M6P_Y^XO
M^^J/[5L/^?N+_OJBS"Z+E%4_[5L/^?N+_OJC^U;#_G[B_P"^J+,+HN453_M6
MP_Y^XO\ OJC^U;#_ )^XO^^J+,+HN453_M6P_P"?N+_OJC^U;#_G[B_[ZHLP
MNBY15/\ M6P_Y^XO^^J/[5L/^?N+_OJBS"Z+E%5!JE@?^7N'_OJC^T['_G[A
M_P"^Q19A=%NBJG]IV/\ S]P_]]BC^T['_G[A_P"^Q19A=%NBJG]IV/\ S]P_
M]]BC^T['_G[A_P"^Q19A=%NBJG]IV/\ S]P_]]BC^T['_G[A_P"^Q19A=%NB
MJG]IV/\ S]P_]]BC^T['_G[A_P"^Q19A=%NBJG]IV/\ S]P_]]BC^T['_G[A
M_P"^Q19A=%NBJG]IV/\ S]P_]]BC^T['_G[A_P"^Q19A=%NBJG]IV/\ S]P_
M]]BC^T['_G[A_P"^Q19A=%NBJZ7]I(<)<PD^SBK'6D,**** "BBB@ HHHH *
M**0D*"6( '<T +159M1LD.&NH0?]\4W^T['_ )^X?^^Q3LQ71*;2V8N6MXB7
M^\2@^;Z^M2)&D2!(T5%'15& *K?VG8_\_</_ 'V*/[3L?^?N'_OL468[E+PU
M_P @H_\ 7>3_ -"-;%<]X=U.T&G2B2[B!^T2XRP'&XUK?VG8_P#/W#_WV*<D
M[E5)J4FRW153^T['_G[A_P"^Q1_:=C_S]P_]]BE9D71;JDVG+]JDF2XFC64A
MI8E(VN0,9Y&1P!T/.*=_:=C_ ,_</_?8H_M.Q_Y^X?\ OL46871!'HEL(TCN
M'>Z2.,11K-C"KQT  YX'/M4;^&]+>V>$VXPY8[OXADYP#Z5;_M.Q_P"?N'_O
ML4?VG8_\_</_ 'V*+,-"TJA5"J, # %+53^T['_G[A_[[%']IV/_ #]P_P#?
M8HLPNBW153^T['_G[A_[[%']IV/_ #]P_P#?8HLPNBW144-U!<[O)F23;UVG
M.*EI#"N:>?1O,?<D>[<<_(>M=+4)M+8G)MXL_P"X*J,K$RC<Y[S]$_N1_P#?
M!H\_1/[D?_?!KH?LEM_S[Q?]\"C[);?\^\7_ 'P*KG)Y#GO/T3^Y'_WP://T
M3^Y'_P!\&NA^R6W_ #[Q?]\"C[);?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'
M_P!\&NA^R6W_ #[Q?]\"C[);?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\
M&NA^R6W_ #[Q?]\"C[);?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\&NA^
MR6W_ #[Q?]\"C[);?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\&NA^R6W_
M #[Q?]\"C[);?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\&NA^R6W_ #[Q
M?]\"C[);?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\&NA^R6W_ #[Q?]\"
MC[);?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\&NA^R6W_ #[Q?]\"C[);
M?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\&NA^R6W_ #[Q?]\"C[);?\^\
M7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\&NA^R6W_ #[Q?]\"C[);?\^\7_?
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M11Y$/_/*/_OD4<X<AS?GZ)_<C_[X-'GZ)_<C_P"^#72>1#_SRC_[Y%'D0_\
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MBCG#D,_1WLG$WV,*,8W8!'KBM2FK&B9V(JYZX&*=4-W=RTK*P4444AA1110
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M"*R=8BNK^2/38HV2WE&ZXG[! ?NCW-:P 4    < "EI)V=P&HBQQJB !5
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M:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0)R1RS?WCZU9HHK(U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[E:)FZ\AY3]6/ ^@K2CT33DY:V$K?WI27/ZU?+%;D\S(!XEB)Q]CG_!D)_\
M0JLQZ_8.0)'> GIYR%1^?3]:2YM=(MXM]U!90QDXW2*J#\S58:1IMW#YMC-L
M5NCV\NY#^'(HM$7,S<1UD4,C!E/0@Y!I:Y*2UO\ 1&,T+@1=2\:G9_P-.WU%
M;FF:M'?CRV41W"C)3.0P_O*>XI.-M44I7-&BBBH*"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI;Z?J1LHWR?G&R-AQW8ER,#TK:T[4[+5[,7=A<I<0$E=R'H0<$$=01Z&O/\
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MQ9S(82OR[RQ<L/0[B3D=S6G10!COX4T"33IM/;2;3[),ZR21", ,Z@ -_O#
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M*T:9#$D$$<,8PD:A5'H ,"GUQO<V"BBB@ IDO^I?_=-/IDO^J?\ W30".?\
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M:E5N&WY^85'//%;6\EQ/(L<,2%W=C@*H&23^%25R_P 1BX^'VL[,X,&),?\
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MMGZ8V+*T2QMS"C%E\R23)]6<L1_X]5BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YSQQX4@\8^%[
MG2Y&$<^/,MIO^><HZ'Z=C[$UT=% 'R/X+\"ZAXD\;G0[J.6W2TD)U$Y(,:J<
M%<^K'@?GVKZTMX(K6WBMX(UCAB0(B*,!5 P *AM]-LK6]N[R"VCCN;LJ;B11
MAI"HPN?H*M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDC@NKV%X'88$@%O&I(]>01^%=31D'H:* "BBB@ HHHH **** "BBB@ HHHH
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J=_>+;QD
M_-W/I5RJD]A'/(78GGMC-<F-5>5)QH;O\BHVOJ>?>)#JNH@VUG ?)/\ K'+@
M;O\ 9'/3UKGE\*:JP^Y"OL9*]A&F0#U_2GBP@'8_G7E4,)CJ4.2"BCT(8_V<
M>6*/(?\ A#M1V%O,@R!TR?YXK"G@EM9FAGC:.1>JM7OC64+(5"X/KFN7U[PU
M#>Q;98^1]QUZK]/\*J<\5AGS5TG'NNAT4<QYI6F>3T5K77AS4K:Z,*0-.O\
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MI80)V)_&K5%<D<OPL7=017/)]2-8(D^[&H_"I***ZHPC!6BK$W"J\]G%.#D
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MP *J-IT98E)9HP23M5^,GV-)6ZC=^A,MU;O]V>(_1Q4P(/0YK.?2MQ_U^?\
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M%% !1110 4444 126\$W^LAC?_>4&DAM(+=BT484D8)]JFHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>drsa_003.jpg
<TEXT>
begin 644 drsa_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $D G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?S/(63SUD7?'<$\%<=LT0JPF[0=PJ4*E-7G%HEU33([J$1.=K!M\4H&3&_\
M> [M3]"U&2[MWMKKY;VU.R52P+$=F./6KS*K1,@;<1S6$[&P\165POR170,$
M@RJ*6ZJ<=6/;FNE>]&QS/W7<Z6BBBLC0**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHJK+=X.V, ^YII-[";2+5%9_VF7^]^E'VF7^_P#I5<C)
MYT:%%9_VF7^_^E'VF7^_^E'(PYT:%%9_VF7^_P#I1]IE_O\ Z4<C#G1H45G_
M &F7^_\ I3TNW!^;#"CD8<Z+M%-1U=0RG(-.J"PHHHH **** "BBB@ HHHH
M**** "N;\8Z%>:[#HRV;1!K/5K:]D\QB/W<;$MC Z^E=)10!S'C;0+SQ#::1
M%9-$&M-6MKR3S&(S'&Q+8P#S56ZB\::;?Z@EI!I^N:==RF2!;NX,#VP( ,9
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M#@9R>,5NZ=:1E[:) 9+2T38LJ#;D]>G89[#H*4</3IN\0K8F55*+7Y'1)D,
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MKH],UFSU6S^TP/M4-L99."K>AK.5.4=T7&<7L:%%%%04%%%% !1110 4444
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MEP-A;^PDB/=X6#C\C@_SKI+'Q3HFH$"#4(@Y_@D.QOR.*0S8HH!! (.0>]%
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M,@B4-G[WE[<$\@$&JFGV&IK%>Q"RU :6SV,MQ EK+ 9$!<3JJLS,Q^YNP06
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MD(Q]YO05%+=%N$X'KWJO5J'<ER[$%S+-<G#MA?[HZ5EZD/L^F74HZK$V/KC
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MH)Z\#BIZJ?VKIW_/_:_]_E_QH_M73O\ G_M?^_R_XT 6Z*J?VIIW_/\ VO\
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M_P JN.J.!*%$A RO-9[+;VJA,K-*.?F^XI/?'K^9-6[:5AM20,&;E=_WCZG
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M5/S=]VX@>G7UH]FUU)G.FU[JL>L4445!F%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4$@#).!15>_4OIUTJ@LQB<  =>#0!.K!E#*05(R".AIL
MDL<04R2*@9@H+'&23@#ZDUYSI<6OV\%C)&^H)]F_L^WCM2I$6QH%$FY<<X8G
M)_A([<U6D.K7EA"MPVMRJK6<M\9(&WPW(G4R>2-O0+N)VY4 *1S0!ZE38Y$E
M0/&ZNIZ,IR#7!6<OB)GL(HI-1>SO;AX5FF3$D,$<N]9'R,@O'O3)&3\F><U4
M6XU]$A!_M.*XV(;"*" B*20SR>8)<+@#9L^]CY22.: /2J1F5%+,P50,DDX
M%>?3ZGK<JO9QOJD4\%O>B>5;-V ;SX_**G #_NRQ&TDX)/)&*NI'-JOP^N8;
M^#56#2D#Y?,E*"0%7"NJLZ=]K+N*@C!SR =C#/%<1++!*DL;='1@P/XBI*\P
M2;5K&V#:;#]G2_O#8"2&V:V64R1IMN1"_*%-C XX/)Q5JZ/BBW6YN+"?49KF
M7^T(TBE7<BA'_<E1C@XZ'^+WH ]%HKSJP'B*>.$I?WDB*+J: ;)(U+*D?EI(
MTJAF7>7/.,\CD"J,.N:G96MY>VEYJEV=/BLY9;:]4JTCR^:CJ 0/XBA&.,KQ
MQ0!Z=/<P6R![B:.)2<!I&"C/XT]Y$CC,CNJHHR68X 'KFN/URT%M%X575XI=
M22WG(NG^S-/N<V\B[BJJ>K$=N,BL9++6H-(NHXTU""&#3;F6SLPN5!>63RD9
M<'++&4&S/'''% 'I=%<#JLGBI#J\-FUSLLB##-L)\])I58[<#),48D7C)Y'4
MXJ@H\2RV;M_:&I,(;">XMFABD3=()1Y:-YB[G(&1R/F'8]: /2C-$)Q 9$\X
MJ7$>X;BH."<>F2/SI]<#XS2[3Q%!=V_]IQRKI,Z6\EC$S9N"\9C1B 1@D=#@
M<<U?T"XUJ?Q1=V-_,YAL$\QB"-LC3[65/^V>V0?0K0!U]%%% !1110 4444
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MPL7\TN'B1F;?GH3EPA/_ $RJCJ?C;58[2)X=/2WN8KBWDEA\P3>;;/&\C $
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M-S9S@<9Z_A7H6!Z"EHAE]I)RFVNP5,TYHM0@D^_](****](\D**** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>drsa_004.jpg
<TEXT>
begin 644 drsa_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $6 G # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJ&L:UI^@V#7NI7*0
M0@X!/)8^B@<D_2N9C^)^C2WBVJ6.JM.Q4!!;#=R>.-V??Z4G)+<ESC'1L[6B
MBH+B]M;62".XN8HGG?RX5=PID;T7/4TRB>BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ J&:ZM[=E6:>*-G^Z'< M],U1UW6X=#LEGDC:1W;:B XR?KV%<
M1=VE[XLN)-3MHU$8 C='?)B( SCU'.>*UIT^;5Z(SG.VBW+,GB?4-:O9-,1(
MXH;HF!< [DSW)_G^-3:)X7-KJ$L.K)&T<D?EA%.023D'/;H<>];L&FVGV1)X
M84%W"BB1U4;WP!SGN3C(-6Y6%Q"CN?WD> Y7NIZ,/QP?P-:\R2M%6,^7J]2'
M2K&WTN6:RBC"Q2,1ZDG&1D^X_D:D@4K:W%NQ^\C$?[R_*?Y _C5C[/+.P:3Y
M'V[68?WE.58?K5A8(@Y)Y<L7Z],C!_"LW/N:*)14[K<1$<"9& _V6.?ZD?A2
M2(\EK$I4EHX7!^JD#^E:,7EL@9%P,8''3%(9<-*N.4&1[U/./D*D@+7RR8.T
M2(H_[Y8_UID,@2>2X8<>6\GX$X'Z**T8VWQJQ'4 U&6A9'9E&$.TY'I2Y^@^
M4HP;K>&=^LS%8Q[L1G^;'\JK/8VG]DSAH4+78*;L8)7U)^@W5K/:JV2I*M\Q
M'H&(QFJTUL<H&QY2X0>BH.23]< ?2K4DR7%HX^\\.3:-I+W=E<SM=2X7:ORL
ML?4@8[\#/XU)HWB.XT2R,>KI=/YC9@5A\VWOU[9QC\:ZDC[5=>9-\L:+O(;^
M%>P/N2,GV K-U/1H_$ETKRL\*Q+@,HYP><'/<]?88]:TYE)6F1RM:Q-ZRO(=
M0LXKJW;=%(,J<8J>O,SJFI:+K LK*5S:PR;8HB 5D3/4G'?DYKT.TO[2_5C:
MW,4P4X;8P.*RJ4W'7H:0FI%FBBBLBPHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2I[-?UO_ )%M6C<[.W\<>&+JY^SQ:W9F7IM+[?U/%= "",@Y%><^%/AMIO\
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M,CYB3^@KLP1:[F$:^8!C)^Y$/3W/TY)K/U30K?4H3=:E)*CH#LVD!S[8Y'T
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M$6I3Z1HF@L-:2[+-*Z(HE$388G!RPZ]<<@=<8K2+3TL<E:-2-YJ7HOT]?/\
MR+&N_P!N^'O"T.OV7BFYU*1W0%8RKQ/N."5)R,#MQR<=*BL+9]3\+Z_XLU-_
MM>L^5-"(U0XM5 QM12>"5.<]L^N2>>T[QF-)CO-$\2V#'1;K(N(6!22T8G!8
M*?X<\D#D'!'6NR^%5G =$UFT$WVRS^U-"'DS^\0@D9!Z91ER*)P;3O\ (BE)
M3<;=;W79V_K_ (<I:5XCB\.7=W$D'GW-S GV:$':#M9@23V4!AS^ S2Z;X]U
M6UFN;[5+J"?3X9]EPHBV>2ORY*$<G;NY!SD#J#7)>+MVA>([ZRM+T1Q1%((
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MHX]B(&;<V!D]3C\ !]?$K-+?P]>>?!=7%O-:Q&[-R"[B60_>0'E0=A)&00>
M<9S79:-IVH^./$,Z:KJ<\EO' LZW$+;/E;(C55'"X(+$@<\>N!MB(5&GS2T2
M2?\ EZ7_ !(H."T2U;T_S]3U^:X@MP#/-'$"< NP7/YUCZMXRT'1@HNK]&=E
MW+' #*Q&<9PN<<\<]37EGAC1[37/%-K#JL[W5LT4B>6TC.&EB.-@8DE4^\V
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M"?7:<UR,Z"62%).2/F'1AP17)ZFLBZA,)<Y!^4D=1VK:U![FTLG>,LO09#9
MS]>16%:R,;V$L/-)< J_S9R?>@#:T*V1K0320H6#'8Y7G%;-86J>);73I#;P
MJ)IEX(!PJ>Q_PK(/C&[)XB@ ],$_UKDJ8VC3?*W?T1O##U)*Z.THKBO^$QN_
M^>=O^1_QH_X3&\_YYV__ 'R?\:S_ +1H^?W%?5*GE]YVM%<5_P )C=_\\[?\
MC_C1_P )C=_\\[?_ +Y/^-']HT?/[@^J5/+[SM" P((!!Z@US.NP"&ZCV1*D
M13C:N 3GG^E4E\970/S10$>@!']:U(?$-MJ=G-&(PMRJ%A&^"#CN/7%:TL92
MJ/E3U\T1/#S@KL;H$+2&;=N$/' XR:Z#Y8T[*H_ "N*BGEAD#Q.RL#Q@]:ZM
M8)7PS@ _[9+$?ATKJ,2996E8>6OR=W;C/TIMV@:'+!2J\D.Y5?Q]:=]GW?ZR
M1W]LX'Y"I&4>65&1@<8IIV8GL9XDO)5"P *O8JFT?FW^%<3?Z4VF>)X9[V_A
MC2283^9N)8#.>1C\,]*[<PW4N3YDB+ZR2<_DH_K7'^+]*AAGANI-04/(-C(5
M+' [CD^O>NFFU>U]S&:TN>@*P90RD$$9!'>EJGI+0-I-I]EE\V 1*J.>X Q_
M2KE<S5F;H****0!134D23=L=6VDJVTYP?0TZ@ HHHH S=:L-*O+%I=7@ADM[
M8&7?(/\ 5@#D@CD<>E>(:VNF@VMU)9P6RR7$DL43H2882N-N 02Q^3C/WC7O
M-_8V^IV$]E=IO@F0HZY(R/J.E>::OX4\'_:9X=0\0,=1MRODR3;7-N.I4J!M
M8G/.1NZ=.M95%*Z<78X,;1J5'%Q:26_?;1?U]QY[:,;*RMX(;6.UTX2317+2
M[O,D8X=!L!(5L9"D'G@$9 -66O\ Q%XN\'K>#5+N^DM;<7=W"63RE5"<Y&T'
M?\IZ>A[4^5$'AJ=K."*]W7;W,44 VATC.XL5/*_*I8@\C..M97AK6M9N=<O]
M1MOLMG+9VCE#!#A&P1^[D'\:D9Z],9&"*PBI.\WHD]?ZZGG4JCO*=32-[.UM
M;:?/5ZOR*^IM,VAV#Q"T:XL[-);4I"%#M,WSMNSDN",YSUSP*M:#<G0M4TG5
MM-@N&EM[D1WT,]T!.TARK0B,]#EB0 .<U0FTF^O9(M-MY[)I8?\ 2/LT3%'A
M5CED0L-K ;LA3@C(Q0=?ETOQK9W=U#]ICTR\+E65E>8C)+NQRQ<]>>,FG'FD
MEKL[_(VI2<I+WM4[_+II^73U/1-8T>71/!>ESZUI@_L][^2YU&S@D59-C9,<
M6206&<94'^5,O?&/A37XH["TT*.WMH8P_FA5CFB7D%HU *LJX)()^;!XXKAO
M$/BN[\6:I,[^:\=_,T,%L\K2-:950N(Q\IR>X&[DCGO$]\=%TZWT]Q/%J<3G
M[3;R*$$"[R4Y/5#N)P0"N3S@XHJRDKJ.W]?U^*.VK.5G&&WY_P!=>O5&SXB\
M,:?:R36UV(+.0NB/+$SO;/OY641J>.F2,<#/7K69'X<U3[=:Z1=Q+=2W&T6K
M6]YN22,;O+*,#M(&& ! QWZTYR]]I^GFXUNY;48GD,RM;Y6)8U*@A\X8A5
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M'IEJ+FPN;:WDC6W(+72;V+MN/KQDD]#]*K>)-8U#6]6B^W:G;QRLI\FPR51
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MB:BUC=1W+2JH8F- 1@_C5#_A9FA_\\KW_OT/\:L:[X&M-=U5[^6\GB=D5=J
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M(KR-L^4X #-DGKPH],C-:'@O1OMEW9Z3J-Q(^B74[R+#;*(WG=<LOGN/FD0
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M!B"%,DMP?E S@=6)-=9I$6DV]E':P64UUIT8C?RHSL-ZQP3NDS\H Y/J1C@
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M,YH 6BJEGJNG:A))'97]K<O$<2+#,KE/J >*MT %%%% !1110 4444 %%%%
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M 'AR?PKX/M--NW1[PL\]P8S\OF.Q8@>PSC\* .FHHHH **** "BBB@ HHHH
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M]* ,+P?INN:-%!!<A7OK^P@:#4)K1F6 (BAK5T##8%ZKR-Q+9Y',4MM<W/\
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MYKO** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3<
M-P7(W$9 I:X6]N&&KZI>2*KS)K-A81B3/R0DPM\N",9:1C[\9SB@#JM;TI-9
MTQK1IG@<.DL4Z %HI$8,C '@X(''?I7.-X2U>]N;^?4=6@DNG>UDM+J*WVB+
MR7+A6B).1N)).[)W8XP*YO5?$&L7WA*Y-[=6\D6HZ7J$BI'#L\DPNJKSN.<A
MN?<<8K6N=8U*/7(M)OIK>[,6IQ1K,L1C.V2UF?& V,@KP>>#TSS0!8N_A]->
M69CDUA'DDDN9)FELE="9\994+85EQA6.< GKFKL?@KRI1MU%O)Q8ED,(R7MF
M4@YST8+@C''7/:N0MO$%[9^$=.M3?66H0OI=E<*%0J8#YT,>UBK<Y#'!.#E#
MUZ5I0ZSKUM97*1ZK'<2MK%Y$=ZQ^<D:;B%C1W4-T!QD$+G% &O<^!&N==DU!
M]3!1IY)PK6JM*-\31[/-)SL ;(4 8QWJS-X+CFL);4WT@$FC#2=WEC@#/[SK
MUYZ4^Z\221>#=/U2WEMY;B_^SQ13%&2'?*RJ'*DY"C=G!.>V>]59?$.HZ1H]
M_>3/!J]M;K*RWUOLC5"B_<==V6;>"/E]1WS0 H\!VZ:U=7R2VNRX=Y6WV2M,
MDC)M.V4G('?&,]><5TNF60TW2K.Q$AD%M D(<C!;:H&?TK@[S7/%-DNI(VI6
M4DUC!:;E6S^]=3$CR1\_W>4.>OS5-<^,M5BFU.*-;8G3KYH)GD0J@\QU2W0G
M/^V'8^B]MW !W^Y2Q4$;@,D9Y%+7#P2W<?BO2II-5M+]I;F:R:6VCV$QB$R%
M' )!*R(,8Z!B.N:[B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JB-)M5U6;4 I\R9$65" 59D.4?&/O#IGZ>@HHH G-E:E
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..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>drsa_005.jpg
<TEXT>
begin 644 drsa_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $) E # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BB@D 9)
MP* "BJG]IV.Z-?M<),APN'!R:L1RQS F*1' ."5;.#3::W1*E%[,?1112*"B
MBB@ HHHH ***S?$&MVWAO0+S6+Q)7M[1/,=8@"Q&0. 2/6@#2HKF]+\576I7
M\5M)X6URRCDS_I%U'$(TP">=LA/.,=.]7O#&N+XE\-6.LK;FW6[CWB)FW%>2
M,9[]* -:BBJ>JZK9Z)I5QJ>H2^5:6R;Y9-I;:/H.30!<HI$8.BNIRK#(-+0
M4452N=6LK34['3IYMMU?>9]G3:3OV#<W/08![T 7:**HKJ]BVN/HPFS?I;BZ
M:+:>(RQ4'/3J#QUH O453TN^?4=.BNI+*YLG?=F"Y4"1<$CD D<XSUZ$5<H
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MHJ2PKC?BO_R2WQ#_ ->W_LPKLJ@O;*UU*SEL[VWCN+:5=LD4JAE8>A!H P-
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MOG*8RH!'?/0<>] &AUE*#O+D_0 &IW?:R*!DL?TJAIU[#>32%20P!.UO<_\
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M,1_M8;^5<YJ%^]W<8EC4)&Q  &#[\UT;7FT$[ <#LV:YN&Z$^J)-+!&P=QE
M..O7ZU!1KW=S#HFGHMNF9)/NACW[DUS<NHWLS[GN9<GT8@?D*U/$ZM]L@/\
M#Y9 ^N:\]U"[N;6_NH['[28IC^_;R6;[.W +IQSD=AWKJIJ,8IGE5_:5:K@G
M:VR[_P#![?<=5]NGY_TN3Y>O[T\?7FE^V7)Z7,W/_30UQPT3[6#=VEGLAAQY
M4,XPUW@Y8R9]>V::UU+ 'M;..\AT^4CS"86W6F?O*OKGMCI5\RWZ?U^!E]7E
MK#F]_M^E[[^7R3N=E]NGP3]LDP#@GS3Q^M:>FZY/!*L=TYEA8X);DK[Y[BN
M@T$74R7D=G'!;AU5+693^\CZ%W_VN<CZ5T<%M':VZP0@B-!A023C\Z'RR]/Q
M)?/1>DGS+?M]]_D_P9OZFD=CJ*FV3:0 _/(S["M>RN[F]M5DVX)R"5&,X]S6
M?K#;+*RC>(>88QER.1@#BK6DW[O:;&C7]V=H(X!'Y5Q'MIW5S1CBD7H53/7
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MK2(6+95@,DXZ$D_Q'UKIC"<4Y6NWT,7*+:5]$5+2VOYK>3[&6=),I*B/R/\
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M)E.) /7U^E:-9>A6*6=@&619'FP[,O3V ^E:E<=7EYWR['1"_*KG.>-/$_\
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MWUY)&&BAB;Y$4C(+$=![=?I7 :!X7USXD:U_;6NRR)I^>9"-N]0?N1#L/?\
MF:[,)AE32J2T2_$\[,\QJ8J;I[O:W2*_K^NAWWPCM9K;P%"TH($\\DL8/]W.
M/Z&NZJ.W@BM;>.W@C6.&)0B(HP%4#  J2LZDN>3EW)IPY(*/8****@L****
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M[C]*Z/PYHC:+I_DRR)),6+%E'"@XX'?'%;-J"N]^G^9E\3LB[IFG0Z5I\=G
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M(Y/4\5MT %%9&J^*-&T74].TW4+U(KS49/+M8=I9G.0.PX&2!DXK7H ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH @O;*VU&QGLKR%9K:>,QRQOT92,$5RMOX%>QU_2]1BUR^O(;'>J6
MNI,)EC5EVYC(P0X'&YMW!([UV-% ')Q?#_3H;^WG74-4^SVMX;VWLC.#!%(2
MQ.%VYP2S'!)QGC%);_#[3;6\M9H]0U3[/9W9N[6S-P#!"Y+$@+MR0=[=2<9X
MQ76T4 <U%X(TV&8NMS>^4-3&J1P&0%(YOF)V\9VDN21GKTQ5?5_A[IFL3Z@T
ME]J=O!J)#W5K;W&R*60  .1@G.%7O@X&0:ZVB@#G[OP=IM[9:]:RR7(CUMP]
MT5< @A%3Y...$'7-3:AX5TO5;Z:ZO8WF\^P;3Y(BWR-$6W'WW9'7-;5% '+R
M>![:ZTF]TV_UC6;Z&ZC6(FXN@QC56##;A0,Y RQ!)]:M:AIEUJGBG3)I4$>G
M:9NN%.X$S3LI11CL%5F//4L/0UO44 %%%% !1110 4444 %%%% !1110 444
84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>drsa_006.jpg
<TEXT>
begin 644 drsa_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &1 EH# 2(  A$! Q$!_\0
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M5A4IRJ5;;="XXB,:=TCE(;*:WNS()H=RY/S/U^M5O$%U=0*OV8I<[0!N3+*
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M!D44<$2Q0QI'&HPJ(H4 >P%/HHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP"B@C(P:BW,I\MNO8^M $M%0*[+O7N.1]*F1@ZAAWH%<6BBB@84444 %%%%
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M< MM8Z@S"TD,%PIP]O,""I],'D5R2IM/4]^AC(SA[I4N5.M:PRQJ 'X&_P!
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MHEK]F:616>'9.[N 0H ^5L<#&..E77T.:S\&:AI\%C'$ZW4DZ10 8F3SO,
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M>*ET3Q)I?B/[2VES//';L$>0QE5)(S@9ZUI2P138\V-7QTR.E2F49=M8PVD
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MTKHZJ;LN5$Q5WS,LT445@:!1110 4444 %%%% !1110 4444 %%%% !1110
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MT4 <]+H$]C,9](GV*7,LEM(<K*W89["J[:U<62$:G83Q,D1DDD1=REV. /\
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M?GW9^\1V_#^M3*7*KFE*G[2:B4IM1MM_E1,5&[=;RN,MTYC/L1G!/]*CGGQ
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MFL[*UBV0L4:24$[B.N,=*Y9-)M(]N%*>(C"4>WY:&C92_P!B_&/3I^D6H1M
MWN6''_CP%>S5\[ZOKC:A%HFN^5Y,UI>(L@'3((;C\#7T0"" 1T-52>Z.7,:;
MCR.6]K/Y!5>]G>WM3(FS=N11O. -S!<G\ZL52U&^L[-(TO,%9FVJFW=GUX]!
M6QYRU93A\01LF9867&X%U8%2R@GY><D$#(..]7-/U./4?,,<;H$P1N(Y!S@\
M'CIT/-9MMK%O>7$4$VF^5$6PC2+GY@<+@8]QSVJWI,NF--<"P!\R3$TQ(;)W
M?=)SZ\XIM%RBDMBSJ5BFH6C1,<,.4;T-<9J.F3Z:4:=$.XG8R\]/Y5K>(M5)
MD:SB<")1^]/?/I]*Y2/5%O91"6ERH.PLV?\ ]5<E646[=3T,+3J1C=O0RVO0
M]X7$0194,;,.>.H)K6L9$MI$ND>0W,;))&H;)=6^21!G(ST(J-[&+#R10 2]
M5.>_L*G=UM]/@%L8_*\X7"[Q@Q2J/G3Z$=!79@I.5D_^'.',XJ*;MIH_1F[X
M4N@FH-:;G=);</&6'& Q[]^N/PK1BM-0\/RLEC!]LTMF++;A@LMN3R0F>&7V
MX(]ZP= N99?[/N(PLCVJ",HI_P"6;[B1CU 7/X5T>KW,]U>VNCV4K1-<*9IY
MD^]'", X]V) ![<FNF:?/;H]_D>=3:Y+]5M\R>/7()93"(+E91U1DP1]>:\O
M\01?V+\8%F"[(=5MU?'^UC:?U /XUZ[:V=O90"&WB6-!Z=3[D]S7FGQCM_(;
MP_JR##071A9O9AD?^@FN*ORM7CT/6RUOVO))_$FC5KD-4E_L7XE>'M6!VI+*
M(9#[-\A_G4/B7QM=:7?BULK:-L*K/)("1D@'  ^M8FOZW)KWA=+UX!%=64ZE
MMF<<\@CTZ5S29ZM##5%[TEI)6^\^C:BM_P#5M_OM_P"A&FV-P+NPMKD=)HED
M_, TZW_U;?[[?^A&NL\!JSL2T444"&R?<-05/)]PU!5( HHHI@%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!9HHHJ "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN/\ EE_UT%35#<?\LO\
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MYB6)5"RNJXB.8\@'#;3TSFE;P[I9QBW="'D<&.>1"/,.7 (8':QY*],\XHU
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M8(&0001U!!'3TJE#X7T^VG@FMGNH7B4*Y2;)F 8O\Y())W,QR,'YB.G%;5%
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M %FBBBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&X_Y9?\
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M#T- &.=8G.%6!"Q5CN^;:<9Y''(XH35KJ)#YMJTO)(:,'[N6]O1"?R]:V:*
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MZU+82BVC$YS+CYC@?TJ6B@ HHHH *BM_]6W^^W_H1J6HK?\ U;?[[?\ H1H
MEHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "H;C_ )9?]=!4U-DC65=KC(!SP<4 .HJ+[-'_ +?_ '\;_&C[-'_M_P#?
MQO\ &@"6BHOLT?\ M_\ ?QO\:/LT?^W_ -_&_P : ):*B^S1_P"W_P!_&_QH
M^S1_[?\ W\;_ !H EHJ+[-'_ +?_ '\;_&C[-'_M_P#?QO\ &@"6BHOLT?\
MM_\ ?QO\:/LT?^W_ -_&_P : ):*B^S1_P"W_P!_&_QH^S1_[?\ W\;_ !H
MEHJ+[-'_ +?_ '\;_&C[-'_M_P#?QO\ &@"6BHOLT?\ M_\ ?QO\:/LT?^W_
M -_&_P : ):*B^S1_P"W_P!_&_QH^S1_[?\ W\;_ !H EHJ+[-'_ +?_ '\;
M_&C[-'_M_P#?QO\ &@"6BHOLT?\ M_\ ?QO\:/LT?^W_ -_&_P : ):*B^S1
M_P"W_P!_&_QH^S1_[?\ W\;_ !H EHJ+[-'_ +?_ '\;_&C[-'_M_P#?QO\
M&@"6HK?_ %;?[[?^A&C[-'_M_P#?QO\ &GHBQH%48'US0 ZBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
8* "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>drsa_007.jpg
<TEXT>
begin 644 drsa_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #  F$# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !61X@N3:064QE:.-;R+S&!( 7)SG':K&KZB=+LQ.(?,RX0EB51
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MQEXY9HQ'.[% I<GY1_#SD\=<FM;3],BT^.%H6:*[C&?M5NQBDW9R2&7GO6V
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MFMI),\*DVHV[%O\ M*Z_YZG\A_A1_:5U_P ]3^0_PJI17!S2[FEV6_[2NO\
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M4-2OYEU=7A.#>:N(6/\ TQC78?U7]:F\17-Q9:!=7-J2)X]C+CO\ZY'XC(I
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M0#SU%OY)3.>"0 <]JV/#>F3:1H-M:W,GFW6"]Q(3DO(QRQSWZX_"@#5HHHH
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MPMT\I!'\7RL.F?2NJ+,>I)_&DP<9QQ1S%?5UW-^&:TDF B5=_J$Q5NL/2_\
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M>/MRZD,IP !E6!!' I+>Q\5:%$(K/^RM1ME_@\K[+(?IMRM=+_:%G_S]0_\
M?8H_M"S_ .?J'_OL5K[65K/5$<D;W1@?\)G]CXUK1=1T['67R_.B'_ TS_*M
M:PU[2-77%EJ%M<9'W%<;OQ4\_I5G^T+/_GZA_P"^Q61J.C^%]5):\MK%W/\
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M1H-N';KYG5&XF/61C]3FF%V)R3S6R=)@)X9_TIC:0A^[)C_@/_UZZN5GA*M
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MN+W0M/NKM-ES-;I)*N,88J">.WTJ]7#>!O&%[K-W+IFI^7)<)$98KA5VEP"
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M'9*9=&U.Y@D4+TMY0ZDX_P!E@/\ .*F--,#I]0UZWTS[09X;HI;(LDTB1Y5
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MT3;]93C&/X?=<N_#VX>W\<::;DE4EN'@!]4<,J_^/8'X5]"MHX/W9<?\!_\
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MGD^]P2>=;Q2[77>@;:XPPR.A'8T?9X $ ACQ&<H-H^4^WI4E !1110 4444
M%%%% !7,W>A7<]W+*NW#.2.?>NFHH$U<Y/\ X1Z]QC*X^HH_X1Z]QCY?S%=9
M13N+E1R?_"/7OJOYBE_X1Z]SG*_F*ZNBBX<J.4_X1^]]1_WU2#P]>CH5_,5U
ME%%PY4<G_P (]>YSE?SH_P"$>O?]G\Q76447#E1R8\/7HZ;?S%'_  CUZ?[O
MYBNLHHN'*BIIMN]K81PR8W+G./K5NBBD4%%%% !1110 4444 0W5U!96SW-S
M((X4&6<]!VK.LK?0-11WM;2QE"-M<?9U!4^X(R*GURUGO=(F@ME5IB4959MH
M.U@V,]NE86IZ+JVJ2/=LD<!=HU>T24'S$0/]YBI&=S@XQC"^M1)N^USJHPBX
MZRY7Z_H;_P#8VE?] VS_ ._"_P"%']C:5_T#;/\ [\+_ (5QTNFZ@FJ6UF4G
MGNE\O%TTDG[M!$05SM"LN[G/')Z9 JXGA?4H;^U:&X*11QQA'67_ %)"_/P5
M);<23U&<\]!4\W]TU=*V]7\_\SI?[&TK_H&V?_?A?\*4_P!G:1&I$<%JLL@0
M"- N]CT& .3UK&\/Z)J.GVEY'/<,DLL2HK^:''F ',@ 4=21UR3CFJ]CX:NE
MN+.2X@AC2WFB<QB=I,NJ.&E!(ZL63C_9R:=WT1#A&[4JETOQ_$ZZBBBM#C"B
MBB@ HHHH *\0\9_\EBC_ .V'_H->WUY;XF\':[J/Q*CU>ULU>Q'E9E,RC&U<
M'@G/Z5E6BVE;NCORZK"G.;F[7A-?-K1%3X&?ZG6?]VV_E)7KM>=?"KPMK/AF
M+4QJ]JMN9Q"(P)5?.W?G[I./O"O1:*$7&FDQYK5A5QE2I3=TWO\ )!7S%+]_
MQ/\ 4_\ I9%7T[7A<GPY\4LVO$:<F+DDP_Z1'\_^DI)Z\?*I/.*C$0E*UEW_
M "9T91B*5%U/:2M?E_"<6_P5ST#X4?\ ).[#_KK<?^CGKM*YCX?Z1?:%X-L]
M/U&$0W4;RLR!PV TC,.1QT(KIZUIIJ"3['GXN49XBI*+NG)_FSF_B!_R(&N?
M]>CU\\:C_P BS:?]=KS_ - MZ^D?%VGW.J^$=4L+-!)<SV[)&I8+DGMD\"O&
MKSX:>+9M"M;=-,0S++<EE^TQ_*'6$*<YQU1JY\1"4GHNGZH]C)\51HTVJDDO
M?3^7)-?FTOF>^0_ZB/\ W1_*GTV)2L2*>H4 TZNL^?"BBB@ J.:".X0)*@90
MRN ?52"#^8%244#3:=T%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K@[:^ULZ$-26>\"-;LTLEPT10L2
M-IC"\CGUQQ7>4SRH_*\KRT\O&-FT8_*IE&_4WHUE33O&^QR;^,9OM=W!#;V\
MNQ&:(B0J#ME6,@[@,GYL\=QCGK2KXEN);B.3=$UNR0'RX\J^\R2*_49(^3&/
MIS73_8K3]Y_HL/[W/F?NQ\^>N?6E%I;J4(MX@8QM0A!\H]!Z5/++N:>VH6T@
M<K<>)KN32?M$368N&CDD3R9BZQ_N&D <8ZC'3\?:M?3M8FN]1:P>./S(8]\S
MHQ*[3M\LC_>RW_?)K36UMT4JEO$JDEB @')ZG\:CM=/@LY9I(E(:8KG)Z!1A
M5 [*.<#W--1E?<4JM)Q:4;=BU1115G*%%%% !1110 4444 %%%% !1110 44
I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>drsa_008.jpg
<TEXT>
begin 644 drsa_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &! EH# 2(  A$! Q$!_\0
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M &GKS[8G]Q?RKOIX-3@I7W.&IBW";C;8^KO[9TO_ *"5G_W_ %_QH_MG2_\
MH)6?_?\ 7_&OE'8G]Q?RHV)_<7\JOZ@OYB/KS_E/J[^V=+_Z"5G_ -_U_P :
M/[9TO_H)6?\ W_7_ !KY1V)_<7\J-B?W5_*CZ@OY@^O/^4^KO[9TO_H)6?\
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M)IEJFH:&UK)*UMJ/EN%N%4LF92A!QP1\N?QJ[=>'[+[)?SQ7$LEU"\[-#"J
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MSD<IYLO_ #UD_P"^S1YLO_/63_OLUUZ>'-'@BEN99;FXMWT^YGC$<L;%'B8
MDLORGJ./KG-(/!EJ9;:S_M6-+^0P;D,B$$2 $A4!W94$'GKSTI>U@'LI'(^;
M)_SUD_[[-'FR_P#/63_OLULZO%IR^'],FTY9MCSW*L\ZJ)#CR\9*]N?PR:V[
MCPKI\FM?9)+B>.:ZOY;2 01(L:%8T8,1Z9;&!3=2*W#V;>QQ?FR_\]9/^^S6
MYX-DD/C;1 9'(^V1\%CZU@CWK;\&_P#([Z'_ -?L?\Z=3X'Z,F'Q+U/IZBBB
MO /="BBB@ HHHH **** /!OC%_R.T?\ UY1_^A/7G]>@?&+_ )':/_KRC_\
M0GKS^O<P_P#"CZ'BU_XLO4W/#\%HZ3?:!;I=S%8[&2^B9K=GS\ZG'\6"N,Y
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M@>W-3W_ANV>-7,XMXM."6U\R1C(Q$)&?W8NQ0 ]\5S2:Q>K$T2W1\MH5@*$
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M3^IT;V_47UNK:_Z'N'_"X?"W_3__ . __P!>C_A</A;_ *?_ /P'_P#KUX,
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M37KJ.#RA'%M_L]M/R0<^6S%B>OWLFO3OB-X&U[Q%XG2]TVVBD@%LD99Y@IW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !14+3X/RC\
M34+W6.K#Z"@"VSJO4XJ(W"CH#6>\[-G' ]:K&YAW8,R9]"PH&DV;(N ?X32^
M>GH?RK)W;1NW8'KGBF#4H=VW[3&3[FE<:BWL;7G)Z_I2&=1TR:SUN&[@$>HI
MQN%Q]TTQ6+ZS(>^/K4E98N.>5X^M6X)AQSE3^E %FBBB@04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 444SS$\[RL_/MW8]J 'T56
MO+V.R$6])7:5]B+&NXDX)_D#3X[J.3RPQ\N2096*3 ?\J )J*:9$7.748X.3
MTJH-4M6A6:-C)$V '3D<L%_F: +M%0+=P,5!D5';HC, QYQTI)+^TB1G>YB"
MJXC8[APQ. #0!8HJ$74. 7=8\N47>0-Q![>M.$\32F(2H9 ,E PSCZ4 2444
M4 %%%% !1110 4444 %%%% !5>YDVC'8<FK%9MV^6QZG- $#R,YY/'I67=:P
MD,AB@3S7'4]A2:GJ<-O#+#')FX(P%':LZRB382_;K[FLISUM$[*-%6YYK0;/
M=W=XX21MBG^!*&L!L[9_WN:M2@;#M&/3%*2%7)XK*U]SI4K*T58SGMI\+'OE
MV9^[NXJ8V*^7@*N[VJX%+8.":38Y)VD#VQ1RH/:,SEBNF;R_-EVKT&<8J???
M6A!29\>C=*F0,DOS'.[H:L,P9,?I0D#G?=#[+6%F<17 $<AZ'L:V8&P^WUKE
M+JV4H2O _E6IH=X]Q:;9#F2$[2?6M83=^5G-7HQ4>>!U4;[U]QUI]4HI<X=?
MQ%7%8,H(K4XQ:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;<_,?I74>8RQ1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;@WE)D# .T<#.<?G0MO I8K#&"QRQ"CD^]244 %%%% !1110 4444 95PQ+
M?C7)77&M7.[KD8^E=E=Q?,2.W/X5ROB"!4DAN5.'8["OK[UE57NW.O"22G;N
M2CYF(&32/'T!SM'ZTEJ^+<9ZC@4\L3UK,W>C$5!_" *PKN1YKUPQ&V,X K:O
M)3!82.O7!KGHCB)6ZEN2?4U<%U,YOH/5F;.[\Z4-@X!(I5(S@]*1@#G'3M5D
M"9=7$D;8<?K6OIUR;V#)X<<-[5@M+T!/Y5JZ$"EO(_\ >8U,MBHW3L:+0*K9
M!(/KFJ-^'Q@XY&,BM$DL>:I7K@H .QK)['1!OF-?1[DW.G(3]Y/D-;]L>5]U
MKEO#@/V.4]C)Q73VIX2MX.\4<%=)5&D7:***LQ"BBB@ HHHH **** "BBB@
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M1D_6MNU'$?UK-M8/L]M%".=HQ^-:UNF&4?W175%621YM1WDV6J***9F%%%%
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M4=*JC4K-KS[(MPAG_N T7&DWL6J**8\T4:AGD15)V@LP SZ4"'T444 %%%%
M!116+KOB73=&7[/-=G[?,I$%M;QF:=SV*QCD_CQ[T ;59.O:4-4LMB\2J0R.
M.JD=#7!?#[6?B!KWB&[37)(K;3]/<QSJ;54>23&0@.3C@@DC/4#O7J=)JZLQ
MQDXNZ//9="UF!U4I'*&Y)!QCVP>M6M+\.WDUZDE_&D4<1W*O7<?4_2NXKFO$
M^IR0/%:V[XD<$EL_<'K_ $K)TXQU9UQKU:GN*VIO)-;Q 1K(O%8.OZ,=2GCG
MLG5;A003V(/4&N1N+B&%\3W$FYN02['/N:T]*OY;34+<"9WBD.TAF+8)'!!/
MK1SJ6C0U0E3]Z$M41MHFL1R-%Y*28X#!L;OPQQ6SX?\ #\L4[7EZJK+]T(O(
M4?7U-=3&V^-6]1FH[NX%K;/,5+;< */XB3@#\R*I4XQ=S.6)J37+W)NE%94V
MI75G(%N(8Y  SL83R$ YX)ZY(^N:<-<MFF:*-)9&#;5V@?,=V,=>/Q[ U7,C
M+V4MT:=%9L6LQ3;0MO.'< QH0N7SGIS_ +)Z]J>^K0I9P7 CD99CA5P <^A)
M..WKS3YD+V<MK%^BLP:Y;-,T4:2R,&V#:!\QW;<=>.?7T-']MP$*?*E&8S(<
M@< 9]^>AZ9[4N9![*?8TZ*REU<AL2PE KE6;CD#:">O #,/7I4D>M6TMVELB
MR%W.,XX'!(/T(&?Q%',@]G+L:-%%%40%%%% !3)4WIQU'2GT4 94\9#%@.._
MM5:2&*7_ %D:/_O#-;C(K=0*;Y$7]P4#3L8RPJBX2)57T"\5C7^A[Y#-9D(Q
M^]&>A^E=D85/3(JM+:$G('/J*F45)69I"K*#NF<2NCWIR9C'#$HR\C-PH'4U
MFZ9HESJ;/K<;!H908K**8<^1_?QZN>?IBNKUG39M5*:0,BWDP]XPR,Q@_<_X
M$>#[9K72Q8*% "J!@ #  ]*E4HHU>*FW<Y6/P_<O%NDN%23LH&0!2IX>G9P)
MKA-G?:.377?8#CK^M(+(@\@G\:/91#ZW4[E:SMHX8555PBC"BM.*( !F'/\
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M^Y&[@'K[T@U-;"5#;)$[QG@2+N4?XFDO,;>FAV/@*UEAT>:63>HEERJ,N,8
M&1]?Z5U58'AKQ(FN1O%)&([J)07 /#>I'IS6_77&UM#R:M^=\P44451F%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 50UI'
M?2I1'&[L&0[4&20'!.!^%7Z* ,*_N[N::![2*\101_RS8 G> 05QZ9.3QZ56
MM8;V)!%&EUM#YD21?E!\X$;>/[NXG\.]=-10!S=I'J45Q:Q_O8H5VX782#\S
M;PW8<8Z_A5N2WNCJ\IC\V.-YD+.O 8",\$^F[ K9HH YR(:G(8T+WJARGVAF
M !5\G=LX^[CTXZ>]3W%O=W.DV<4D?F2K<C=YR;OE#'!8<9XQ6Y10!STMI>V)
M$4#SD$%XA F(_,+'*D<X4#'7W[TR=-0F\Q&6X<EB959?D&)%V;/PS_7FNDHH
M PM81WGN5",[&U7RE49)P^7P/7[M1ZHDNHY>"VE*F IB6(CGS$/(/; /Y&N@
M*J6#%02O0D=*6@#$^PFRN+7:T?FRW6_9$FQ54(0V!D]@,^^*VZ3:NX-@;@,
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MU8[5+'L,T +3?,0G[Z_G7EWB_P"(LUC=R6&EF&6= 1+(Y)6)O[H ZMZUQ?\
MPG/B;;\NHC .<^0F2?0\=*AS2-HT9-7/H8.I. PS]:6O$-%^)>IQWMNFK&*>
MWE8*TD2;&B)..G0C]:]J@F$T8/<=:I23V(G!PW):**:[K&C.[!44$LS'  ]3
M3('451M]8L+IU2&X#,S[ NT@YVENA'3 SGH:NY'/(XZT +12;ASR..M+F@ H
MI,CU'7%-25'W8/W20<C'(Z]: 'T4R*:.>-)(I%='&Y64Y!'J*1IXEDCC:10\
MF=BD\MCDXH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]JZZ:PL+ET>:V@D8-O4L@)SZU9W*>C#KCK41I).[-JF*<E9:'.MX/M< +<S
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M5/5;22^TV6WB9 [;2-^=K88$@X['&/QJY6?K8G?1KE+8S"9U"*T/WUR0"1]
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M4K1Z;92W8!_UCMY:GZ#!/\J3DEN7&G*6R/1?M?\ LG\ZD2]_VF7\:\NM/BK
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M5[2.OMCB8#U%7:SK1LM&?45HUJ<@4444 %%%% !1110 4444 %%%% !1110
MQHHW.616.,9([>E<_-X+TLV]RENKPR3#"ON+;.<\ ]N*Z.BJC*4=F)Q3W.&N
M/ ]U'I8@MKU9)#+O=6RJ'C ]>14=[X4UTQV,<5T)1"FW/F%1$<YX]1TYZ\5W
MM%:*O,CV43BCX9UEO$BWC7@,>X$SAR&QCD8_R*+#P(T4MP+R\#12(47RLACS
MD$Y^G3FNUHI>VF'LXF#8>$M,L[22WEC^U;V#%I0,\=,8Z5MQ11P1+%$BI&@P
MJJ, "GT5#DY;LM12V"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%%
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MH"/?=Q_(T0=ICJJ])W/9;-L*A]&K6K&M3\A]FK9KH.!A1110(**** "BBB@
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M#G)[5##IE]&-.C6W,:P+$K%91@8;Y\\]"/3KGFB'2KR&V6)8"(D55:%90/,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:Q6\.R-)O/D?/4@$ 9ZDG(_ 5HT#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>drsa_009.jpg
<TEXT>
begin 644 drsa_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'G G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHHHH **** "BBB@ HHHH **** "BBL_6[R6PTQIX71'$D:[G7<%#. 3COP:
M-"BL@:O'9VL<EU.;A)2VR:.+:I(Z)C/4\X]:C.NR07-^;FTE6WMDC;(VD@L.
MF,\GG]* -NBLZ;5OLZ1O/9W$<;$!F;;\F6P,\\]NF<9I&UF%$N)FAF%K 6!G
MP-I93@@#.>O'2@#2HK$DULS/;QPJ8I/M4<<J-M;Y&#8P02.WZ4NGZUOL0UR&
M:9+=[ARJ@ J&88'OQ0!M45CVVJS2W-Z1$\L:"$Q1H &&Y,G)) _6I(=<AN)+
M>.&WGD>96;  ^0*VUMQSC@_GVH U**** "BBB@ HHHH **** "BBB@ HHHH
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MV%8[Z\DF";BN%"88_=;CNO./K1-HOGFX+W<F+B-%D&T<LN,-[=.E6?[5L/\
MG[B_[ZH_M6P_Y^XO^^J=F+0K7VB)>W;S-<.H=4!7:#C:<C:3T]\=:4Z*KQW%
MNUS*;.8LWDX'RLQR2#C/7D"K']JV'_/W%_WU1_:MA_S]Q?\ ?5%F%T0+I+%8
M?.NFD:*=9@1&J#@$8P![U!_PCRK"D<5W+'^Y:"0A5.]&)/<<')/-7O[5L/\
MG[B_[ZH_M6P_Y^XO^^J+,-"F_A^,AMMPX),1Y4,OR+M (/4'K]<5/8Z1'8S)
M(DKML1T ('\3[ST]ZE_M6P_Y^XO^^J/[5L/^?N+_ +ZHLPT+E%4_[5L/^?N+
M_OJC^U;#_G[B_P"^J+,+HN453_M6P_Y^XO\ OJC^U;#_ )^XO^^J+,+HN453
M_M6P_P"?N+_OJC^U;#_G[B_[ZHLPNBY15/\ M6P_Y^XO^^J/[5L/^?N+_OJB
MS"Z+E%4_[5L/^?N+_OJC^U;#_G[B_P"^J+,+HN453_M6P_Y^XO\ OJC^U;#_
M )^XO^^J+,+HN453_M6P_P"?N+_OJC^U;#_G[B_[ZHLPNBY15/\ M6P_Y^XO
M^^J/[5L/^?N+_OJBS"Z+E%4_[5L/^?N+_OJC^U;#_G[B_P"^J+,+HN453_M6
MP_Y^XO\ OJC^U;#_ )^XO^^J+,+HN453_M6P_P"?N+_OJC^U;#_G[B_[ZHLP
MNBY15/\ M6P_Y^XO^^J/[5L/^?N+_OJBS"Z+E%5!JE@?^7N'_OJC^T['_G[A
M_P"^Q19A=%NBJG]IV/\ S]P_]]BC^T['_G[A_P"^Q19A=%NBJG]IV/\ S]P_
M]]BC^T['_G[A_P"^Q19A=%NBJG]IV/\ S]P_]]BC^T['_G[A_P"^Q19A=%NB
MJG]IV/\ S]P_]]BC^T['_G[A_P"^Q19A=%NBJG]IV/\ S]P_]]BC^T['_G[A
M_P"^Q19A=%NBJG]IV/\ S]P_]]BC^T['_G[A_P"^Q19A=%NBJG]IV/\ S]P_
M]]BC^T['_G[A_P"^Q19A=%NBJZ7]I(<)<PD^SBK'6D,**** "BBB@ HHHH *
M**0D*"6( '<T +159M1LD.&NH0?]\4W^T['_ )^X?^^Q3LQ71*;2V8N6MXB7
M^\2@^;Z^M2)&D2!(T5%'15& *K?VG8_\_</_ 'V*/[3L?^?N'_OL468[E+PU
M_P @H_\ 7>3_ -"-;%<]X=U.T&G2B2[B!^T2XRP'&XUK?VG8_P#/W#_WV*<D
M[E5)J4FRW153^T['_G[A_P"^Q1_:=C_S]P_]]BE9D71;JDVG+]JDF2XFC64A
MI8E(VN0,9Y&1P!T/.*=_:=C_ ,_</_?8H_M.Q_Y^X?\ OL46871!'HEL(TCN
M'>Z2.,11K-C"KQT  YX'/M4;^&]+>V>$VXPY8[OXADYP#Z5;_M.Q_P"?N'_O
ML4?VG8_\_</_ 'V*+,-"TJA5"J, # %+53^T['_G[A_[[%']IV/_ #]P_P#?
M8HLPNBW153^T['_G[A_[[%']IV/_ #]P_P#?8HLPNBW144-U!<[O)F23;UVG
M.*EI#"N:>?1O,?<D>[<<_(>M=+4)M+8G)MXL_P"X*J,K$RC<Y[S]$_N1_P#?
M!H\_1/[D?_?!KH?LEM_S[Q?]\"C[);?\^\7_ 'P*KG)Y#GO/T3^Y'_WP://T
M3^Y'_P!\&NA^R6W_ #[Q?]\"C[);?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'
M_P!\&NA^R6W_ #[Q?]\"C[);?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\
M&NA^R6W_ #[Q?]\"C[);?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\&NA^
MR6W_ #[Q?]\"C[);?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\&NA^R6W_
M #[Q?]\"C[);?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\&NA^R6W_ #[Q
M?]\"C[);?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\&NA^R6W_ #[Q?]\"
MC[);?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\&NA^R6W_ #[Q?]\"C[);
M?\^\7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\&NA^R6W_ #[Q?]\"C[);?\^\
M7_? HYPY#GO/T3^Y'_WP://T3^Y'_P!\&NA^R6W_ #[Q?]\"C[);?\^\7_?
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M11Y$/_/*/_OD4<X<AS?GZ)_<C_[X-'GZ)_<C_P"^#72>1#_SRC_[Y%'D0_\
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MBCG#D,_1WLG$WV,*,8W8!'KBM2FK&B9V(JYZX&*=4-W=RTK*P4444AA1110
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M"*R=8BNK^2/38HV2WE&ZXG[! ?NCW-:P 4    < "EI)V=P&HBQQJB !5
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M:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M45A7-_-_;\EG]N-NBI$400;]Y8MG)[=!0!NT5AQ^((+QFBBCD(D5_*,3J7;;
M[=5SCC/Z5;LA?;H2[#R-C%A(#O#9X'/H.,T :-1RS+$!NR2>BCJ:66011LYZ
M =!WJH!(TF.#,XRS=D7T%-(!SSR9^>18@>BJ,L?\_2F9;.<W1^@(JOJ.HQZ/
MY:1P^;-*"WS/@L!C/./>M*UG6ZM8KA00LB!P#U&12YE>R&X22YGL4+B^-I"S
MK*9'R%2)U^9F/  IVD6ZVT3K(VZ\D;S+AR.78^GL.@]!45NBZM?M>.,VL&8[
M?G[S?Q/^F!^/K5IXV1E1V)YS')W!]#_GFKZ6"2<79EVBHX)3+'DC# X8>AJ2
MH$%%%% !1110 4444 %(RAT*GH1@TM% '-:>ADTNXM3]Y&=,5IZ%,)=)B'\4
M>4;\*IS+]AUYL\178R#_ +0_S^M):R_V9JSQ/Q;W1RI[*W^?Z5K+5&4=&;]%
M%%9&H5QVIZM+<W4%W91HKP.51RV25S@AAZ&NQK)7P]9+=^</,V;_ #/)W?)N
M]<?TI-R5N4TIN"OS$VGZG%J"/$Z^3=1_++ _53_4>]<_9:0EQ97L,2E-1M)'
M3[1$Y7S<\\G\<8[5H^*+>V^Q+</ #+O5/.7AD!Z\C\OQJ/PQ(T3SV:[6@0!U
M(ZJ2>A/<]ZIU(KW5U",'R\Z*VB6=R-4AE%M) (U*S938N,8 QW.<'\*V=>F\
MK2W0??E(116G7/O+_:FK!UYMK;A3V9J5.%M"*U3FU9'J,96QM;)?O.ZICZ5T
M:@*H Z 8K"M%^WZV91S#:C /8L:WJN;U,X+0****@L**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "H([2..\FNE+>9,JJP)XP
MN<8_,U/10!2M-.6S<"*XG\D$E8"1L7//'&?ISQ5B&Y@N"ZQ2*S1L5=>ZGW':
MI:JW6GPW+"3YHIU^[-&<./;/<>QXH =<?-+%'VY8_AT_G2V@S%YAZR'=^';]
M*SY+FYLYPMZ T94JMQ&O';[X_A^HX[\=M&T=9+.%E(*E!@@YS3Z"ZF%=:UI-
MY+Y-] H@!81S2 ,-PXQCJ#5+2;*WN/-L([UTD$2LTEK<$QW"'(R1U5O4#%/G
MM#=RW%SI^E!769EBN(I@'653C<5/ 4G.<=1VJSJD]BNG36;[+2[90\K) VU6
MZ_,5' ;!&>M5"+2L]V:S:^SL-N]4NM-O/LT?V>&* 1K';E#B52.2&[8QCIU'
MO6O;7::KIOG(C1MDC:W56!_QK&T:/2-1C>W.GM'(\:NRLY8 >B-GC!/08ZUT
M<,$-G;B*%%CB0<*.U*:DI6)YH2CIN0V[YG5ATECW?B/_ -?Z5;JC;YWVPXX0
MD^W2KU)D(***HZG!>SP[;.=8_48P3^/:D,NAE8D @X.#@]*6L'1[._BAFC:5
MK<B3.#&&W<=<UK)#< ?-=EC_ +@% %BBFHK+]Y]WX8IU !1110!3U.Q%_:&/
M.)%^:-O0UDQ,NI6SVET"ES'PP[@CN*Z*L[4M+%V1/ WE72?=<=_8U<96T(E&
M^I5L]4>S<6>HG!'"3]F'O6T"& (((/0BN=-VC?Z)JD CD]6'RM[@]J<EG=6G
MS:?=XC/(CD^9?PIN%]A*=MSH:*Q%U74HN)M/\S_:B:G?V[*>!IEQGT_R*GE9
M7,C7DC26-HY$5T88*L,@U%'%:V$!$:101#DX 45EMJ.JS\0V:0#^](V:@>Q:
M0^=J=V9 .=N=J"FH/J#GT1)=7\NJ,UK8Y6WZ23D=1Z"HYW^S1QZ=8KF=^!C^
M$=R:!=R7/^C:5#D#@RXPJUJ:=ID=@A8GS)W^_(>I_P#K53:BB$G)DMA9)86B
M0)R1RS?WCZU9HHK(U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[E:)FZ\AY3]6/ ^@K2CT33DY:V$K?WI27/ZU?+%;D\S(!XEB)Q]CG_!D)_\
M0JLQZ_8.0)'> GIYR%1^?3]:2YM=(MXM]U!90QDXW2*J#\S58:1IMW#YMC-L
M5NCV\NY#^'(HM$7,S<1UD4,C!E/0@Y!I:Y*2UO\ 1&,T+@1=2\:G9_P-.WU%
M;FF:M'?CRV41W"C)3.0P_O*>XI.-M44I7-&BBBH*"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI;Z?J1LHWR?G&R-AQW8ER,#TK:T[4[+5[,7=A<I<0$E=R'H0<$$=01Z&O/\
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MQ9S(82OR[RQ<L/0[B3D=S6G10!COX4T"33IM/;2;3[),ZR21", ,Z@ -_O#
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M*T:9#$D$$<,8PD:A5'H ,"GUQO<V"BBB@ IDO^I?_=-/IDO^J?\ W30".?\
M CF3PA9ECDY?_P!#-:NL:M:Z%I%SJE\SK;6R;Y"BEB![ =:QOA^<^$;<>DD@
M_P#'C2?$>&6X^'>N0P1/+*]L0J1J69CD= .M3#X4;8G^-/U9TV]>/F&2< 9[
M]:!(C;L.IVG#8/3ZUYO=:#=7GB#QUJ%K:R'5H88QI,[Y CD:T"EH\\!B>"1Z
M8[5E):Z?(;8>%M-N[<Q:3=1ZOFVDC+$P_(DNX#?+YG/<\-S@\T8GKH=68J&!
M(Z@'I6%JWB^QTC56TV2UU"YN4MQ=2"TM6E"1EF4,<>ZGCKQ7+>'M$32]2\$7
M5K8R037&ER+J$@1@9#Y49 E/<ALXW<CG%7=2TS6+WXG73Z=J#Z;&=&A1[C[*
M)=W[Z7Y5+<!AG/?J.* .QL]1L]0L;:]M+B.6VN4#PR \.",C%6&=4QN8#<<#
M)QD^E>47>A:'H-_J&FZUIUU=6,>GP6^B'R'F/"-O6,H/EF+\D\$Y7' X8MK'
M!+_Q7UC<WLKZ/:169,#SXF$;><JE0=LQ?!SP3Q@\4 >E1ZU#)XFN-#$4@FAM
M([LR<;2KNZ@>N<H?SJ_-YGD2>5CS-IV9]>U<%X+M-6@\26[ZQ',;P>&K*.XE
M<$YE$DNX%NA8 C-=W<Q>=;2Q@D%E(!!P::W!D@SM&3DXYKGO$_A9->$<\,H@
MO8EVJY&5=>NUA]>A[<UO02&6!)"K*64$JPP0?2I*<92A*ZW)<5)69YQ:?#W4
MI)PMY=P0V^?G,#,SL/;( 'UYKOXX[;3-/6- L-K;1X'HJJ/\*L5E^([2:^\.
M:A;6X)FD@8*!_$?3\>E:3JRJM*;)C3C33Y4<9>^/]2GG9M.MHHK4'Y6EC+LP
M]3@@+]*W?"_B_P#MF8V5[$D5X%+(8\[)0.N >A'I7!6M_ EA'!(CNIN-\@#%
M?DPH(X/)X(P:V-!2._\ &UI)81!(H%,DA48 &TC)X&,D@?@:[JM"FH/2UNIR
MTZLW):_(]/HHHKRSN([@2F!A"P63^$GI4E5VVW9>)ED5(W!+$8#$'.!ZBK%-
M[6$%%%%(84444 %-=$D&'56'H1FG44 0BSME.5MH0?4(*F P,"BB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** . \2>"E6>2^T^'=&Y+20J.5/<J/3VKDC8P@D%<$=0>U>V53N])T^
M^.ZYM(I&_O%>?SZUI&HUN2XGC_V*'^[1]BA_NUZF?"FBD_\ 'G_Y$;_&D_X1
M31?^?/\ \B-_C5>T0N4\M^Q0_P!VC[%#_=KU+_A%-%_Y\_\ R(W^-'_"*:+_
M ,^?_D1O\:/:(.4\M^Q0_P!VC[%#_=KU+_A%-%_Y\_\ R(W^-'_"*:+_ ,^?
M_D1O\:/:(.4\M^Q0_P!VC[%#_=KU+_A%-%_Y\_\ R(W^-'_"*:+_ ,^?_D1O
M\:/:(.4\M^Q0_P!VC[%#_=KU+_A%-%_Y\_\ R(W^-'_"*:+_ ,^?_D1O\:/:
M(.4\M^Q0_P!VC[%#_=KU+_A%-%_Y\_\ R(W^-.7PMHJG/V)3]78_UH]H@Y3R
M^WTDW<PAMX'ED/\ "HS_ /JKT7PQX6AT-&N) K7D@P6'1!Z#^IK=M[2WM(]E
MO!'$OHB@5-42FWH-1L%%%%04%%%% !7+^-K[5]+TV.^TR=4B1MLZF,-P>C<^
M_'XUU%0W=K%>VDUK.H:*5"C#V-*2NK(TI34)J4E='F_P^OM7N+Y-/AG":=;A
MI91Y8).3P,^Y_D:].K"\*^'AX=TQX&99)Y)"TD@[CHH_+]2:W:FG%J.IKBZL
M:E5N&WY^85'//%;6\EQ/(L<,2%W=C@*H&23^%25R_P 1BX^'VL[,X,&),?\
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MMGZ8V+*T2QMS"C%E\R23)]6<L1_X]5BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YSQQX4@\8^%[
MG2Y&$<^/,MIO^><HZ'Z=C[$UT=% 'R/X+\"ZAXD\;G0[J.6W2TD)U$Y(,:J<
M%<^K'@?GVKZTMX(K6WBMX(UCAB0(B*,!5 P *AM]-LK6]N[R"VCCN;LJ;B11
MAI"HPN?H*M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDC@NKV%X'88$@%O&I(]>01^%=31D'H:* "BBB@ HHHH **** "BBB@ HHHH
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J=_>+;QD
M_-W/I5RJD]A'/(78GGMC-<F-5>5)QH;O\BHVOJ>?>)#JNH@VUG ?)/\ K'+@
M;O\ 9'/3UKGE\*:JP^Y"OL9*]A&F0#U_2GBP@'8_G7E4,)CJ4.2"BCT(8_V<
M>6*/(?\ A#M1V%O,@R!TR?YXK"G@EM9FAGC:.1>JM7OC64+(5"X/KFN7U[PU
M#>Q;98^1]QUZK]/\*J<\5AGS5TG'NNAT4<QYI6F>3T5K77AS4K:Z,*0-.O\
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MI80)V)_&K5%<D<OPL7=017/)]2-8(D^[&H_"I***ZHPC!6BK$W"J\]G%.#D
M$]P.M6**FK1IU8\M170TVMCD]8\,V]Y&1/"&QT<<$?0]JX/4_"5[9OFV!GC)
MZ=&'^/X5[/Q52XT^&<' "GT[5Y,\!7P_O8:5U_*_T.VACIT]'L87AG24M+6&
M #(0?,?4]S^)KJ:@M+86T6W()]JGKKR[#2HTKS^*6K.6K4<Y-L****[S,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BF":(
MOL$B%_[NX9HEE2&)I)#A5ZF@!]%4FU)0,BWG/U 7^9J!M7QD!(0?]J8?R -5
MRL7,C4HK)_M"Z?/EJA]-D+M^O%:<3.T*-(NURH+*.QI-6!.X^BLI[:_>5\NQ
M&XX(F*+CMP!2?V9._P!\P_\  F=_YD4[+N*[[&FTL:??D1?JP%+')'*NZ-U<
M=,J<UFKI&/\ EI$O^[ O]<U<M;1+4/M8LSD%B<#]!2:0TV.FNH8&"NQW$9"J
MI8X_"H3J,?:&X/\ VS(_G4LUI!<.'D0E@,9#$<>G%,&FV8_Y8*?][)_G0K [
MD3:H!_R[N/\ ?=5_K20:F)KA(O+4;\CY9 Q'&>0.U65L[5?NV\0_X *E5$3[
MJJOT&*=T*S([J5X+9Y(TWL.W]:S_ +?=L/E"_P# ;>0_X5K44DQM&3]JOV[2
M?\!ML?S-)OU(YV^?GME(P/YUKT4^;R%R^8V/?Y:^9C?@;L=,UF/;:@9&)=FR
MQP5GVC';C%:M%).PVKF2+.]/5F_&Z;_"@Z?='J4_&>0UK44^9BY45;&VEMD<
M22!MQR%!)"_B>:9>V3W,J.LBX48V."1]>".:NT4KZW';2QD_V0YZFW_[]M_\
M51_8Y];?_OT?_BJUJ*?,Q<J,ZWTLPW"2F2,;><1Q[<_4Y/%6[J#[3;/#O*[N
MXJ:BDVV.R1D_V.W]^W_[\?\ UZ/['/\ >M_^_)_^*K6HI\S%RHR3HY((W6X]
MQ$?_ (JM2)/+B1"Q;:H&X]33J*3;>XTDC*DTR=I'821ON8G+E@?IP:;_ &;<
MCH8O^_L@_K6O13YF+E1D_8+L?Q#\+EQ_2KEE#<0J_GR;LGY5+EMOXFK5%)R;
M&E8I7J7C2(8"WEXY",%.?Q'2JW_$Q0?\O!_&-JUJ*$P:,CSM07KY_P",*G^1
MJ6WN;UKA$>,LA/S$PE,#'7.:TJ*=_(5O,BN9F@MGE5"Y4?=%9XU=AP5MR>_[
MXC^8K5H(!ZC-)-=1M,S5U8$_ZE3_ +LRG^M2#4EQDV\X]< '^1JRUM WWH8S
M]5%1G3[-NMM%^"@4[Q%:1.CK)&KH<JP!!]14#7]HKE&N(PP.#D]ZL !0   !
MP *J-IT98E)9HP23M5^,GV-)6ZC=^A,MU;O]V>(_1Q4P(/0YK.?2MQ_U^?\
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M%% !1110 4444 126\$W^LAC?_>4&DAM(+=BT484D8)]JFHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>drsa_010.jpg
<TEXT>
begin 644 drsa_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #9 BH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MIK,%4LQP!U- #J*I_P!IVF<?:(_SI?[3L_\ GXC_ #I<R*Y9=BW15/\ M2S'
M_+Q'^= U.S/_ "\1_G1S+N')+L7**J?VE:?\_$?YT?VE:?\ /PGYT<R[ARR[
M%NBJG]I6G_/=/SH_M*T_Y[I^=',NX<DNQ;HJI_:5I_SW3\Z/[2M/^>Z?G1S+
MN')+L6Z*J?VE:?\ /Q'^=']IV?\ S\1_G1S+N'++L6Z*I?VK99Q]IC_.C^U;
M+_GYC_.CF7<.278NT53_ +4L_P#GXC_[ZH_M2S_Y^(_^^J.9!R2[%RBJ7]JV
M7_/Q'^=']K67_/S'^=%T')+L7:*H'6=/'6[B_P"^J:==TP=;V'_OJBZ%RR[&
MC16;_;^E_P#/[#_WU2?V_I?_ #_0_P#?5.Z#EEV-.BLW^W]+_P"?Z'_OJD_M
M_2_^?Z'_ +ZI70<K[&G16;_;^E_\_P!#_P!]4?V_I?\ S^P_]]470<K[&E16
M;_;^E_\ /]#_ -]4A\0:5_S_ $/_ 'U1=!ROL:=%9HU[3#TO83_P*KL%Q'<Q
MB2)PZ'H13N#36Y+129JI+J=G Y26XC5AU!-*Z0EKL7**H?VSI_\ S]Q?]]4G
M]M:=_P _D7_?5',NX^5]C0HK/_MO3O\ G\B_[ZH_MO3O^?R+_OJCF7<.678T
M**S_ .VM//\ R]Q?]]4O]LZ?_P _<7_?5',NX<LNQ?HJC_;%A_S]1?\ ?5']
MKV'_ #]1?]]4N9=Q\LNQ>HJC_:]A_P _47_?5+_:UC_S]1?]]4<R[BY9=B[1
M5'^U['_GZB_[ZH_M>Q_Y^HO^^J.9=PY9=B]15'^U[#_GZB_[ZH_M>P_Y^HO^
M^J.9=PY9=B]15'^U[#_GZB_[ZH&K6)Z74?\ WU1S+N'++L7J*I?VK9?\_,?_
M 'U1_:ME_P _,?\ WU1S+N'++L7:*I?VK9?\_,?_ 'U1_:ME_P _,?\ WU1S
M+N'++L7:*I?VK9?\_,?YTO\ :EG_ ,_,?YT^9=PY9=BY15+^U+/_ )^8_P Z
M7^U+/_GYC_.CF7<.678N453_ +4L_P#GYC_.C^U+/_GXC_.ES+N'++L7**I_
MVK9#_EYC_.F_VO8#_EZB_P"^J?,NX<K[%ZBH+>\@N@3!*L@'7:<U/3N(****
M "BBB@ HHHH *J:CQ83'_8-6ZIZE_P @Z?\ W#2>Q4?B1Y6\OS,<GKZT>8=O
M#'\ZJM)^\;ZT[<2>*\^Y[:2LASL^?O''UIT;-C[Q_.H7)!'.:E3GG%(JR)!(
M=WWC^=3+(6Z&JF"6XJ1,J>:5PLBP6;N32;F[,:9NSWI-X%%PL2EB%^\::LA
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>drsa_011.jpg
<TEXT>
begin 644 drsa_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #6 8T# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFU;,S7.TCCGY=IZ?6M^$N+>WVJ""HW'.,#'ZUG^*_P#D4]5_Z]G_ )5IV_\
MQ[1?[@_E0 X%][ H HQM.>OKQVIFZ;RE;REWDC<N_IZ\XJ:B@!F7\W&T;,?>
MSW],4TF7RV/EC>"=J[NOISVJ6B@#G_$9:SN-+U<*-MI<;)VSTBD^1OK@E3^%
M;@+Y?*# ^Z=WWN/TJ'4;*/4=.N;*7_5SQ-&WMD8S53PY>R7VA6SW'_'S&##.
M/21#M;]1G\: -#,NQ#Y:[B1N&[[OKSCFG MYA&T;,##9[^F*?1B@"'=+Y1/E
MCS,_=W>_KCTIY+B10%!3!RV>A[<4^B@"+,F)/W8R"=@W?>_PI29,)A!D_?\
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MW[WK]*Q-/5M/\6:E9EL0WL:WL*XZ./DD_DA_&N@K \2?Z(^G:P./L5R!,?\
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M1?\ 03U;_P #I/\ &C_A'(O^@GJ__@=)_C6R>E9]GK%K=M= &2(VKA)?/78
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M/\:U!<0MOQ*A\OA\,/E^OI67?>)M-L;J*&2XB(>,3/)YJA4C+;0Q)//S<<4
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MA,&<'S_.&>>1VQ110!,?!0>5VFFMILWJW0>2 LY0.7,;$G!&3QQT]:ZY5"@
M  #@ 444 -DC$L;(2P# C*G!&?0URT?@PPZ=J=DM^TD=Y<Q3)YZE_+5-GR]>
M2=G7WHHH BE\#&1RR7D4)W3,/+@QDO.LP!YY4%=I'<$]*;/X$\XW#B[B5YUD
M)S#D1N\RR';SP!LQCU)-%% #KOP0UW%<1&[A"2_;-N;?)4SD-D\]5(K7T70Y
A-)O+V<W6]+DAO*5<*&YRW))!/<=.,]S110!M4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>drsa_012.jpg
<TEXT>
begin 644 drsa_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %K ;(# 2(  A$! Q$!_\0
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MDTW4+R*RCN4NQYOF.,Y\K;]T<Y.[MG%9:?%!5NDN+K26BT*>:Y@M[];@,SM
M&+%H\?*#L;')/'(&:OW_ (/U:Z\<)XCBU^!4B18X+6>P\T0)QOV-O&&;G+8S
MCCI5&+X7Q?:1!=:M)/HL,MS-;:>(%4Q/.&#9DSE@-[8&!C/.: *A^*US;BWA
MOO#QAO=1@@N-*A6[#BX65PBAVVCRV&03UXKK/"WB.7Q!#?QW5C]AO]/NFM+F
M 2^8H8 ,"K8&5(8'H*Y;_A5,L\4,E]XADGOK"&"#2[E;14%JL+AU++DB0D@
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M_NC^8K1H **** "BBB@ HHHH **** "BBB@ HHHH XCXO_\ )*-?_P"N*?\
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MY:A0"V>AKTOX>6,\":_?/83:?:ZCJCW-K;31^6XCV(NXI_#N*DX/- #/B_\
M\DHU_P#ZXI_Z,6NHT/\ Y%_3?^O6+_T 5Y[\;;#79O!FH7=GK$=OI,5NHNK(
MVZLTY\P8(<\KVZ>E>A:'_P B_IO_ %ZQ?^@"@"_1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% &=_P S*?\ KS_]GK"^(GBN7PQX?5-/3SM:U"06NG0 9+2M
MQNQZ+G/UP.];,T\5MKLL\\BQPQ6)=W8X"J&))/MBN%\$P2^.?%USX^OXV&GP
M;K30X7'2,$AYL>K'(_/T% '5>!?"D7@_PS#I^_SKR0F>]N#R9IFY9B>_H/85
MTM%% !1110 4444 %%%% !7!?%/1[C5=(TQX;*TO8K2]6>>WO;H00.FUAAB>
MO)&/?UZ5WM><_%R#[19^'D%C!>N=54+#>2!+9OD?B4GU[>^.O0@%SX:PQ0VF
MH>5H6C:4#(F5TN\6X$G!^\5Z$=OJ:[JN/\ V,EE;7PDT+0M)W.N%TB4.).#R
M^ .1V^IKL* "BBB@ HHHH XCXO\ _)*-?_ZXI_Z,6NHT/_D7]-_Z]8O_ $ 5
MR_Q?_P"24:__ -<4_P#1BUU&A_\ (OZ;_P!>L7_H H OT444 %%%% !1110
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M/<W(XX/'%=)0 4444 %%%% '$?%__DE&O_\ 7%/_ $8M=1H?_(OZ;_UZQ?\
MH KE_B__ ,DHU_\ ZXI_Z,6NHT/_ )%_3?\ KUB_] % %^BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/O\
M_D)Z7_UV?_T6U:%9]_\ \A/2_P#KL_\ Z+:@#0HHHH *:_\ JV^AHDD2*-I)
M'5$49+,< ?C7SG\;?'UY#XGLH?#/B>58%M<3K879VB3>WWMIQG&* /H'1O\
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M*$./F)S'\V21ST% 'L5%>*7'C/Q7IEQHVG/K2W4GB"SLYTN6M8Q]A::55;:
M,,N&XW9Y%=_X'U34KPZ[I^IW@O9=+U%K5+KRU1I4V*PW!<#<-V#@"@"I\7_^
M24:__P!<4_\ 1BUU&A_\B_IO_7K%_P"@"O/?C;KMQ9^#-0TE-%O[B&ZMU9[Z
M),PP8D'#GL>/U%>A:'_R+^F_]>L7_H H OT444 %%%% !1110 4444 %%%%
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MOP]TZ1E-Z1<ZK*AYAM5.<>Q8_P!.QKNM>UJT\.Z%>ZO?/MM[6(R-ZMZ*/<G
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MTW_KUB_] % %^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSX,\!:/X$@NX=(:Z*W3*TGVB0/RH(&, >M;6J6UW=P1QVLD"8D1V,J%L[6#
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MQ>)>(GS;+L%%%%=)RA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)(D]$4 5+117:DDK(X&VW=A1113$%%%% !1110 4444 %%%% !1110 4444
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MU0RML)))."HR">M=XZ)+&T<B*Z,,,K#((]Q4=O:6UIN^S6\,.[[WEH%S]<4
M349![]*KW][!IUA<7MRX2&"-I'/H ,UX_P#"+XE2>)/%>N:=?. ;J9KJT![
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M44 %%%% !1110 4444 %%%% !535;!-5T>]TZ1V1+NWD@9UZJ'4J2/?FK=%
M'#/\-8+R*V35-7NKS[/'#;J BQ#[/&P?R\+R-S*A9LY^4 8JU;_#W3[2[BDM
M[F=+>+55U2.!COVR>48V&YLL0V=QR<YKKZ* .=B\*@^+4\07=\]Q/!')%;H(
M4CV(^,AF49?& !GISWYKHJ** "BBB@ HHHH **** "BBB@ HHHH **** "BB
0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>drsa_025.jpg
<TEXT>
begin 644 drsa_025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" N %O4# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOYG]LP8KPZY'3Z?TSP.OIS2MRHVKP<_7MCI^!_//6OXG+/\ X/#HI;N WO\
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M #:+3QD(+ORQMIUUOOVU?W-G^U:548R2,_Y]Z=PH'/%?._[+'QKB_:,_9I^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ_STM2U*^UC4-0U75KZYU+6-4O-4O=9U;5KS^T=3O]4[ZUKGOZ_R.*SZ_O\
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MQG VM$PEY(*J4W$,K"M^O*/@C_R1GX3_ /9,/ O_ *B6B5ZO7^85?9_/]?\
M(_=0HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"OL7RR
M,=3CZX'Y#C\/Y5&%5!D)DC.23].?7_.?<SY^7D#D\<8''4^^<X].*_,+]OS_
M (*P?L<_\$Z;/3;;X_>--8N_'_B73)-3\,_"+X<::GB?XEZ[I2S/'/K<>D7.
ML>&_#F@:)"ZNK^(O%_BKPI9[@(X[EMKA-\LRC.,_Q=/*<ERJKGN;37N8>C2<
MIS=KOW80E+;5ZQC%6YI+F2ESXG$87"1>*Q4N1;<S=[6\M/O_  T/TZW?[<?_
M 'S1N_VX_P#OFOY;O^(MG_@G'_T13]M7_P -Y\"/_HCZ/^(MG_@G'_T13]M7
M_P -Y\"/_HCZ_0/^(,>+'_1N.,__  WU?_DSR_\ 63A[_H:TO_ O_M#^I'=_
MMQ_]\T;O]N/_ +YK^6[_ (BV?^"<?_1%/VU?_#>? C_Z(^C_ (BV?^"<?_1%
M/VU?_#>? C_Z(^C_ (@QXL?]&XXS_P##?5_^3#_63A[_ *&M+_P+_P"T/ZD=
MW^W'_P!\T;O]N/\ [YK^6[_B+9_X)Q_]$4_;5_\ #>? C_Z(^ND\+_\ !US_
M ,$TO$,\]OJW@O\ :O\  T5L,&^\4_#+X;ZE8760.8I/ 7QD\8[CUQE(QUR.
M *P_X@_XK_\ 1MN,O_"*7_R8?ZR</_\ 0VH_^!/_ .0/Z;-R< ''U! 'Y9I"
M">0$(/N,_CDBOQ2^%7_!P?\ \$F/BIJ=OH%G^U3I_@C6+E0J0?%7P-\1_AUI
M@ /);QEXB\+0^#@WT\4L0.AYK]7_ (7?&#X4_&WPQ;>,_A%\2O /Q5\)WH*V
MOB#X>>+M"\9>'6*C(\K6/#\]U 6('>8GJ17QN>\,\1Y$^7/,DXGR22=K5\-5
MI]%M*5*4'NM(SE=Z;Z'K87%87$J^$E&2MT_6S3^3L>L4445PFP4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3T8OZ-OBS@XN4\@A4:5U"'%&"<Y:I6BG5A&^M]:D59/6]D^:AQMP[+:IRO\
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MTOVO"XC#8K"K%X25X3M;3SC=;NUK_>BW1117*= 4444 %%%% !1110 4444
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M'@GQC\/=9N/#GC_P=XD\$^(+7'_%/^+/#>L^&]3R?^H'X@_3TJ<)FN1X^_\
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MES2=N:<K))RG*<FEK)V/Q+%8K&XS_;<<[V_X/^?](****]8Y@HHHH *_:/\
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MNX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>G>*?[+%EXVO/!^L^'/AK9Z9VU?6/BCKP/AO0]!8G"QQJTCL0J*20#_IY_\
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M6]DMV[7;>\I.RO*3E*3UE*3U/R/%8G&8S_;<=J_-_P!?T]K!1117JG.%%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-L=Q;3Q$QLC$X'R>8I5A(%/R'_%RK^@K_@@U_P %;O$7[!OQVTGX'_%SQ/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMF0207,:RP2B6&095AR"#Q@#'0^AZ#K[V?E&YNOK[<^GUK\HO^")>KZAJ_\
MP2J_8AN=6OIM0N;;X*Z5H\=U=DEY-)\/ZOK7A_12>  %T32K5?YG! 'ZJER
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M;'AOQ'XB\'Z]H_BKP?XBUKPGXHT*\^VZ1XA\/ZQK/ASQ+H6J'&=9T36_#_\
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MJRY?=TC"$5>=6K/:%."LDOBG)QA!2D_=\S,<QPF581XW&OEC&U]+MM[)+O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!G]T_[:?^@"O\FW_@LK_RE+_;G_[."\3_ ,A7^LEW3_MI
M_P"@"O\ )M_X+*_\I2_VY_\ LX+Q/_(5_4WT2/\ DL.,?^R,A_ZU>'/@./\
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MM(_BM_;<_P"#3WP_=VNJ^,/V!_C)<Z)J[8NQ\&/CU>+J&BZD^57;H'Q6\/\
MA^3Q'X>8N^U(O%GA3QG-(=QB\:^$8U:0?R"?M&?LJ?M#_LB>/[GX:?M'_"#Q
MI\'_ !>KR75I:^*;0'2M>TZ)WCDU?P3KWATMX8\?Z#'*C1R>)?"GB_QAL=&5
MBK!@/]DM0)% 9D<#H!P >.2< =1SCCUQTKRCXJ?!?X/_ !U\+IX+^-WPC^&_
MQ=\'O<+='PI\5/ OA3XA>&Q>Q@^7?G1/$FD:_HJW(!)2=XE9 Q^Z2<_T3P3]
M)SC7AM?4>)/^,GR7E4Y.4E3XIBFDN6EC)0?.DU?][2D]9?O$^5'R>9<%8#%K
M_89?V&[M-P2:Z6=N=._3=+2UK:'XS?\ !ME\/=3\$?\ !)_X+7>MZ//H]S\0
M?&/Q;^(EM:WI4WU]I>L^.]<TC0==D&<A]?T#0[6[7)4E'^7@L1^^RJ=S'_9.
M/RQ_/'^<UA:+HVD>'-+T[1M$TO3M(T?3;1;'3-,TJQBT_3[*PA4;+#3]+@VQ
M0JJ(!M2-5&<JO)4="P')!((QG\>/P/\ GO7X)Q#F[XBXBSCB6:C&>?XB>(:C
MJDYSE**O9)OELF[6YN;I8^JP&'^IX2&$Z037WV_56$[)]3_,5\]_M:_\FJ?M
M+_\ 9 /C+_ZKKQ%7T)V3ZG^8KY[_ &M?^35/VE_^R ?&7_U77B*O)P?^\9?_
M (Z?_I5$[%\7S?\ [<?XV%%%%?[1G\RA7^EY_P $?OV#OV'OB=_P3/\ V/\
MQU\2/V-?V4OB!XY\4?"PZCXD\;>,?V>/A%XG\3>(=27Q;XB_XF6N>(=?\)/K
MFKL[A'5KB8LV[&%#1E?\T.O]7;_@A\<?\$G_ -A['?X0'/\ X5_B88]O_K_2
MOY7^ECCL30X+X1CALUE.+XR6D93@].#X;2A.$EIVEJN9=6??< 4%B,9G#>EK
M+OJVOZ_I'M;_ /!,7_@G/)%-$?V _P!BM4G!#B+]E;X##=GC)/\ P@8Z>I#8
M->?^*_\ @C]_P3'\8Z7+I.L?L+_LXV5M.-TLOA'X9Z!X#U,GT&N>!$\-:\!T
MZ78(],YK]+MY_OC]?_BJ-Y_OC]?_ (JOX9I\4<34K^RXNXOI\UK\O&/%RO:Z
M5[\5S[OL?J/U+!/?+:#_ .W8K\M/P_)'\=O[?7_!JY\%O$7A77O'G[ GB?Q)
M\-/B%IEE+>VWP0^(7B(^-?AOXL:/++H_A[QEXA!\6>"-<E *QR^)_%GB_P '
M/*8HQ;^#'>7QA;_PT^-?!7BKX<>,?$_@'Q]X<U'PGXW\&^)-4\,^+_"GB&T_
MLW4M"\3Z%K7]@Z[HNN=B#[>W-?[4B[=J,#OYVACU'KGN3Q^?3I7^>3_P=;_L
MW:'\+OVTOA!\>?#MGI]A;?M'_"TP^+K:WM@\NI>.OA-K":%K>O3$ #?+\.=>
M\#^'!P"R:&K':6(7^M/HZ>,O%.:<2X?@GBC,JO$%.K2J/A%U:CJ5*%>'))4I
MO[4)1<XQE=VG!)-QFN7X#BWAW!87"SSC!+EG3:YET:=[2CI=;*Z:Z^1_+511
M17]M'Y>?T=?\&O\ ^T=>_"'_ (*1Z?\ !ZXO;FW\,?M._#?Q3X N]*!(TY/%
M'@;0W^*W@C75.#\RQ:-X[\,* .6U\*6 ;-?Z284Y QC*8_'/;MUZ_G7^3?\
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MD:O\6O@5\-?'&OVI WV/B7Q!X3TBXUZV !.$M]=;4XE)Y(C!]0/\=NO]2_\
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M(E9OD8^,?$'B))$$G@TD_P G5=A\0?'?BGXF^._&_P 3/&VJ7&M>+_B+XO\
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M;=6]]8WUSINHZ7>?;;*[M+S^S=3L-4]ORZXQBO\ 8<_8E^-EU^T?^R!^S/\
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MX>^'/PCCTJ[P/E\NV\1?&[PQXF8$_>SX8C Q\H/2L[_B+9_X)Q_]$4_;5_\
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M,A\":KXX\:>/TT7P7A@K'Q!X4\.Z'H@\:G&U_&/_  DSHS1LK'XIK^FW_@[
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MVQ6:4HI/52=K/M9*S^[38_J2!8@[E''<<?AP<?G3&.>L?Y9/Z\_I7\P7AO\
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M$GP;_;3N4MIPOVBT^'/P9DBN3@Y$3?\ #0T3LN<<NHS@?*!Q7LGP1_X.;?\
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M%+$-OMI+7H&'XKX=Q+]S.*;?FW%>K?)^/_ /ZF(\9XCQGUS^F/7I_2K0( Z
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MR7ZZ'GW_  <68?\ X(V_MARXPQD_9\# =!_QE#\#B.,Y'7Z>Y-?Y>-?WB?\
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M \\4T*IS@DX_S[4*,J1G&3_G^5?-7[0O[5/[.?[*OA=/%_[1?QO^''P?\/W
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M?NB!_GZ]/?\ #FIQCM@8_O'.?H,8_2O*_BK\7_A9\#O!&J_$7XR_$;P9\,/
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MT;I/C/5F/JVA:U\&?!EO]/\ BISTY)K],_XE\\7_ *I];_U*Q/)_-]8X7O\
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M"@JLJC 'S#(-?9/PK_X.Q/V!_&5];:7\4/A7^T+\'GN0<^(#H'A3Q_X8LVP
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M*M9T?PYX<TG4O$GB#7]9TK1?#?A[P_9_VEJFOZIKI_L'0M%T/0P,^(/$6>>
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M_!Q)_P $M/V=IK_2XOCE=_'CQ-IR*P\-_L[>'C\2K6\X/[O2_'7VCP[\+YV
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MMKFO3P06HV@D,[J3C!R^U: .VXXXC/Y@_H32%5/)C0_B?_K5^&7QW_X.*O\
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MT]#DG/Y5&Q<DX6)_\]^:_F$T+_@[#_X)N:UJEKIU[\,?VO?"UK<[?,\2:_\
M#KX2/I-EG.XSVWAWXW>)O$XVGA0OAB0,,'Y< 5^Y_P"R9^V-^SC^VS\+;?XM
M_LT_$K3OB-X*%V^C:GY%OJ.E^(/#&O(B&;0?%^A:VL/B+0M>MU<*T-[#"Q^=
MT>2-!)6_$G ?&O"F%6,XHX0XJR"$I*"^L86I2;DV[)-3<+M_#?EYGI&[LF87
M,\IQ>F#S2G-JVBDG]SE&+M_3L?6ZC'.0>W!X ZG/^?\ ZS#@DX![_C^';_\
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M]E/_ +-]\3?^K)URO-^C3_R>'(/^O/%7_J+(TXY_Y)O-_P#!#]#^1VBBBO\
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M3W_!-._M)+2Y_8._956WG7][]B^!_@;3KDDYZOI&A02\=BL@'8@U^BNY!RS
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_E$U_J[?\$/?^43W[$'_ &2$?^I?XGK^4/I;?\D7PC_V64/_ %D:9^@>'_\
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M  2"_;OO?^"?/[;?PY^+]]?W"_"OQ/\ \6U^.6F$;OM7PV\;ZWG5]? &,_\
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MK=?\$W_V0]*_80_8Q^"/[,UA=PZYK'@3P^]YX\\06K?+K_Q'\9:O/XB\=ZQ
MDD,,IT+_ (2;6=6@\+QRQE[;PEI.@VC.Y@!'\?7_  :T_P#!/9/BG\;O$_[>
M'Q&T>XN/!'[/U]?^#/@PETT;6&O?%W7M'9M>U@1R)*&7X7>&M6E1QM5CXL\=
MZ%)#(LW@L%?[]5D1H]R@C<H4#T //N../_U5_ OTI/$%YSGL.",MFEDO#4XN
MM!M*,^*I1<*KZN7L[Q2V2FVG>SM^M<$9+'"819N[IU$TO\*2;^7Z+[[U%%%?
MRX??!1110 4444 5CU7Z_P!#7^<Y_P '7_\ RDO\!_\ 9I/PO_\ 5G?%ZO\
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MT8J<(JHHQ<IQ7[9PYG4>(,'SJ-I;-+6[;6O=)ZK?K;I<[.BBBOS ]L_SDO\
M@Z^_Y27> O\ LTCX7?\ JSOB]7\RE?TU_P#!U]_RDN\!?]FD?"[_ -6=\7J_
MF4K_ %6\&?\ DU?AO_V1K_\ 2I'X#Q'_ ,E)G/S_ ""O]5'XS?\ !0OX)_\
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M:!X-UK6XF4'NTD,9&?X@I'S 5_C*S33S2W%Q<3_:;BZ_X_+N[]._Z^W7FO\
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M-94\6VW\4OQ1^*_Q*^-OC35?B%\7O'OBOXG>/=:NA=:IXH\:>(]8\1>([Q$
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M-S<K/XN:Z35E_0^2_P#(GRO_ *]?I_E;;38LT445\D>B%%%% !1110!^6O\
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M_P <;XR?%+Q3\</BQ\3_ (S^-I1<>+OBSX[\3^/_ !'=  !=2\<ZUK^NZX
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M?6UDVK]59)]&N]E8_H_HHHK^0S]'*Y8+M89P<$>W7]./KBE(R" ."?Q'7O\
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MZQ\,O@;HQ9/[3USXI>---FT3P_J**P\QK;PF)V\5>)&"E([#0G!,321B7_*
MK^U_HC9)C</#C?B"*M1]CAZ-/3XW3E6J5))WORQ=2%/9)RC*S:3M^8>(&)5L
MGP6S<G)^2M%+[U&X4445_9)^;']N_P#P9YZ1JEOI'_!03Q'<6@71]5U;]F71
M+&]/2^U;08_CXVNMG_936]&]1R:_M<.,#.<[5QC\<^E?S4?\&NOP!U'X1?\
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ME><H0C=NT5S3E!7;T2YKO9)O0\+#8;&8O_<KO_+_ ('H?$-%?L'/_P $"/\
M@KY903/<?L9>*/+@&5CM/B9\&-2=U R2J?\ "R=S#KR 0.2>@KX$^/'[)?[3
M_P"S)?FR_:$^ /Q:^#GVJ\-E9W?Q!\":SX;TO7M4)&!H>N'/AC7\>OA,G(^A
M->?EO%W!^:XU8')>,.#>(&[V3XRLW;>U[-VTO9.VFUSJQ.68W"?[[D[^::_0
M\0T'7M<\*ZSIWB/PYKFI>&]?T&\^VZ/XA\/7O]FZGH.J9_Y#6B:X#GG'^![U
M_H:?\&U?_!23XR_MJ_!CXR_!C]HOQ)?_ !$^(G[.M_X#O/#OQ'\1J'\2>*_
MOCU?$J:-I?C#5F#)X@\3>%-<\&W/VGQ/&@DN(/$7AQ<M(%5O\[*O[&?^#/\
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M_$;Q[\8_'_B[XH_$KQ1J'C3Q[XY\1ZGXE\7>*M4 34=<\3:V -<UA54 !5
M"C@  # Z?T+]'SPBP?B#CJ_$?$LV^'.'I0?L%)I\4U5[.4L/!P44J?)R2FE*
MZE/DNHRDG\7Q;Q,LJ2P6"USF23BK7M%WL]=6WTTV\[-^F_M(_M4?M ?M<_$/
M4/BA^T=\5_%7Q,\6W3,]G<Z[=!=+T+37)=](\$Z& /#'@'0'=B[^&/"A+.S%
MF)8DU\^445_H;@L%E^79?#+,LITZ-*G&,*=.E"%.G"$4E&%.G3C"$(Q2LHPB
MDE>RU;?XUBL4\9=MMMZMMW;OW>[OU=PHK]#?@/\ \$F_^"C?[37AV'QA\%_V
M1/BOXC\(:BHDTKQ7XBTG1/AMX:UM"6 US1=;^(7B7PE_;Z':X!\*C!",,\,*
M]QU+_@@C_P %=]&L)M5O_P!C#QG<VUOC8=*\??!KQ+J;9[+H>@?$D>)F]<#)
M /N*\;$<;\'87&/!8SC'@QI-IM<9IV:W3LVDUU3LU?5(]/\ LS./^A-^#_R/
MR!KN/A]\2/'WPF\6:/X^^%GCCQ;\./&^A7?VS2/%?@GQ)K/AOQ+H78C0]<T#
MKWX/Y8Z=/\7?@'\=?V?]<M?#'QT^#_Q/^#^NWHU-K#3/B5X%\8^"]1U)=#'!
MT)M?\.;?$((Y##([CBO(*]I/ 9U@4TX<29!.-TTXSA.$X]&G.$X2B^CE&47]
MJ,O>Y=<'Y/[FK?<TU;RVZ6/]0G_@@G^W]\1?V_?V'X_%WQFF@U/XQ_"'Q_J_
MP7\=>*K:R_LU/&\VC:)H6OZ'XR?3)2YBUVXT#7;>T\80*"!XTT3Q)' @C543
MZ3_X+%>,-0\#?\$O?VXM<TN>:WU"?]GSQ[X8AN;>Y^PR(_CJ!/ I*RDD(1%K
M[*Q)PRL5!.:_%+_@T1X_9*_:D;^[^T;IY^A_X5EX;P?_ -=?LU_P6@\.W7B[
M_@EC^W+IFF$"YLO@-XJ\4S^^E^!Y-*\;ZUU]=#T&YX]2/I7^97%/#^1Y'XZK
M(LOBHY!#C3A)J-THI5:G"%625]%'GJU6HWLG+I=)?MV78S%XSAV.,;]YTY._
M5I<RU?>Z^9_D[4445_J$?A(4444 %%%% !7[*_\ !OSXTUKP=_P5N_9*DTZ\
MGAM/%6J^/?!.MV5O@KJ6D:]\,/'P9'SD%3XB_L/Q.P((QH'0C%?C57["_P#!
M KPW>^)/^"NG[&-C90X_LSQ=X^\37AZXTS0_@OX^UT'/UT08]\9QQ7QWB5R_
MZA<8\UE'_4SC&]]K76][*VWX'I9%_P CC)[>7Z'^J@<9&[.X8Z=_T]?85EWU
M[8:9:3WM[<V]CI]G;&XNKN[N%L[.SLT!R[NQ$:;%4Y+[% XWK\JU<5RR(P[G
M'\S^F0>WX<U^2_\ P7*^*-[\'_\ @E)^VGXOTN?4;6^N_AMIG@"*YTD@ZBK?
M%GQMX/\ A,6CX!+&/QJ0VWG8<=":_P F,HP7]M9KE.3T+?\ "YB*.&C*VO-B
M*U"A!V[MU5?TW[_OV)K_ %7"RQ+WA&]O3F?_ +:?@;_P4M_X.CY/#FM>)?@K
M_P $Z] T36AI=U?Z-JW[3GC>R74M&GU-%&(?A-X%7*Z_&AR!XI\5Y)!:(>"?
ML_E^+D_D#^/G[37[0?[4WC(>/?VBOC!X^^,/B8?VF+*Y\;>(]8U$: -<P -"
MT(?\4QX>\.XQCPMX2 Z<=*\(HK_5;@CPMX/\/,&_[%R=N^KXR;?^N5[):*[4
M5I\,$HKHNI^%9EGF<YMIC=%K:*^%7[+;\PHHKW?P)^RS^T_\4M*M]=^&G[-W
MQ]^(VC7?^FV>K^"OA!\2O&NEWYQ_T'= \. >GX^IK[7%XO X&+GF$HP@E>4I
MRC""7=RG*,8K;5R2^9X7U9/:S]%<\(HKZFU']AC]MW2+&XU35/V-OVJ-/L+;
M_C\NM5_9\^,>G:;8#UQ_PCGL2?<?E\PWEG?:;=7%C?6-SINHZ7>?8KVTN[/^
MS=3L-4]_P]#BC!YME^/7-EV=TZB3M>G.$XWT=FX3FDTFKJZ=FG;5-]7U7&X/
M=-?UYI?>5Z]\_9M_:I_: _9&^(>G_%']GGXK^*OA3XMM65KRYT&Z#Z7KVFHV
M]-(\;:$?^*8U_P /HP#)X9\5 ,K@,I# &O Z*6-P67YCE\\MS.G3JTJD90J4
MZL(5*<X234H3A4C.$XR3LXSC*+6ZV:YL+BG@[--IK5-.S36S3W5NCN?Z9G_!
M&3_@MKX(_P""D/AO_A4GQ5MM&^&W[6?A+21=ZMX7T^5#X:^*'A[1Q%%JGCCP
M$T@W95L_\)CX5_>3>#[B9(]PB(\K^@/ 52I^Z._I@G'UZ_B<?2O\8?X$_&GX
MB?LX_&/X<?'3X3ZT/#GQ&^&/B_2_&7A'5"NX'4=$&&T/71QN\.>+03X6\;@D
M9!QQ7^O%^R7^T/X6_:O_ &:/@C^T=X0+6VA?&3X<>&?&D>FRR;CH.IZM;K_;
MWA&9B(LZMX6\0+JGABZ"JP-WI#H>"CM_G9X^>$F&\.,ZRK-LC;?#_$<'.BG=
MNE4@FW!-W_=M.,X*3;352";7+R?M7"G$/]KX18;%V52"MZK3?;5;:>6UW?Z?
MHHHK\ /KS\'/^#D;_E$%^TO_ -A_X$?^M _#BO\ ,*K_ $]O^#DC_E$)^TE_
MV,7P'_\ 5^_#BO\ ,)K_ $#^BC_R;/-O^RQ?_I?"1^.^('_(VI_]>X?J%?W;
M?\&AEZMG\ /VTIK^\%O8P?%7X970^TW0-C8(?!>NEPCLR[$RJ%^>2J<[@HK^
M$FOKCX<_MJ?';X/?LP_&7]DSX9>)!X+^'/[0/B[3/$WQ?N](+:=XE\5:5HVC
M#0O^$).N<(?A\PUD'QOC)\8@E"5\"F1/&/Z?XO<%9AXA<&KA?+7%3<N"M9W:
M4.9>T=EO)0;<$VHRGRJ34;GB<-9BLJQCQK5X\KNM.JMWO:^]D[)-Z+4_K@_X
M*U_\'+=MX#U/Q1^SI_P3NU#0_$?B32TU31/&'[3UW:C5_#.C:J=I.D_!C2)8
M_P#A'O$DB &)?BAXJ=?!#Q[Y/ T?C$21^++3^)_XD?$CQ_\ %_QEK_Q%^*?C
MCQ;\2/''B>\%[XC\6>-]7UGQ)XEOQ_V'/$&1P!Q[>]</171X>>&7#7AU@_J>
M390YU&DI\;R2YYM;[:0C?6-.GRTX](N2<Y&9YYC,VQB6,5DKV2V7_!\]6_P"
MBBBOT8\0*]>^!7Q[^,_[-/Q'T'XN_ 7XE^*OA3\0]$!%KXH\+W0T]"&*@Z+K
MJL#X7\0^'3@;O"WBL?\ "&$#H1FO(:*SQF#P&88"679C"%2G.,H3A.,9PG"2
M<90G"<9PE&46U*,HRC).TDTVFTVG=-I^3:?WKY?=WLU_IS?\$8O^"R/@K_@I
M7\.KGP#\0;?1_!7[6'PPT6*^\>^"[-FM/#_CKP\DHT6+XF^ Q,SE](EG,#>+
M?#85Y?!UWK%M%(9@\(7]ZE*[25Z=!]<@_CP.O_ZJ_P ;7]D_]IGXB_L?_M$_
M"K]I#X7WQMO%WPI\7Z;K%M:!F73M?TM@=!U[P9K;H0Z^'_%GAPZYX7#H5=3K
MVY6! -?Z\OP,^,/@W]H#X,?##XY?#N^&I>"/BMX&\,>/?#ER0-TND>(])BUF
M K$N0=3C6X,<V[A9(R ,HQ;_ #8\?/"O">'6>PQ63ISX>X@O5P\KN]&:TJ4K
M[N#A+GHN3;2]I3;?)3:_:^%,[>;X-?7&EG$6^>+5N:.EFNVNDDM-;]7?V67[
MC_\ ;3^0K_*3_P""Y/B_5?&O_!5[]M35=5EGF.E_%+2O!EJMQ=X1=-\#>"]
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MN$HWG&2_0.&^+<9A\7]1Q]W'7=W:YGW;VO9OT3L?ZE]%48+B"XBAGAE@G@N
M/LUQ;[2""#C!RP(X(RN.A!45>K^"C]8"BBB@ HHHH **** /P=_X.2/^40G[
M27_8Q? ?_P!7[\.*_P PFO\ 3V_X.2/^40G[27_8Q? ?_P!7[\.*_P PFO\
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M^,M%%%?V,?FQ]D?L ?L>>-OV\OVK_A%^S/X0.H6UOXZ\1_;_ ![XMM+,:@/
M?PNT$?V]XY\:%C@)CPX,>"RWR'QHWACP0Y_XJL-7^N)\-_AOX0^$'@'P7\*_
MAYHEIX:\#_#WPIHO@_PCX?LEV:?H_AWP[I4.C:)I"98_)#;P11IC+-Y9W$D
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MXIKX:^!M%94UKQGK?]YGD94C0<^-?&K*H!)Y_P!2W]A[]B#X#_L"? OP_P#
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M^#:3_@DKJ6C76F:9\$O'.A7US9K:)X@TWXZ_&*35K9N2U_'%XA\6^)?"ZW)
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M^*_BCXZ_&+XK?&WQI(LWBWXK_$;Q/X^\0HMVM^B:CXXUG^W55%4!555UL*H
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MJ/VY.,=%SM>WPUDG]K8UW?NK65KOJNW>^G8[3]BW_@@K_P $^?V/- TR>_\
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M2ER)1M&,4HPBKVC=N4OWW#87#83#1PF$2C!;)*_WNR3OY?IH[LG;KS^/^?\
M"OY+?^#@O_@B_P##_P",?PG^(7[;/[-_@ZQ\*_'WX:Z7JWC/XI>%?">E)86/
MQL\":$))O$6K2Z/%%;VX^(W@[P^)]?M-?C1[KQI:6#>$;F:XED\++:?UI9'R
M@],$G\<_7N.OY8K.OK*WU"UGL;V*&ZLKJ!K:YMKA0RW*N,;7SU4C=D8.2<C&
M,UZ?!W%V<<%<1Y5GV1U)4IX>JIR<=8SIJTI4JB=XRA4A*2OI*,^6<91<7?GS
M'+,)FV%E@\:DU+SUOJKKYK[MUN?XGM%?4O[;_P %[?\ 9T_;)_:<^!FGV/\
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M=4:2YFJ$)5J?V=>6U1*\K14G97;1^@>'^)_Y'&"[-27X7_"U_F?J'7,^+O\
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M! R"*_?NPL].TS3[?3M*M+6QT_3[9;>UM+6 6=G96B*-D<:*HB1450,)CN6
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M:A'(YT;Q;I2ZFVG3^1(1JVAZOO77O#WB %=B>(_#%U:^)(V='BFR%9?\P_\
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M77?@]XY(T/QNS+D;AX2\/A?%17@-XS\/^&5.:_/NBOTO/<KP6<9+G61XZ_\
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M@#/[I_VT_P#0!7^3;_P65_Y2E_MS_P#9P7B?^0K_ %DNZ?\ ;3_T 5_DV_\
M!97_ )2E_MS_ /9P7B?^0K^IOHD?\EAQC_V1D/\ UJ\.? <?_P#(HRS_ *_+
M_P!-(_,FBBBO[Z/R8_K5_P"#5_\ :1_9U_9S\2?MK7'Q[^/?P5^!T7BGP_\
M 4>&)_C%\4O"'PX3Q ^B:S\7UUO^R)/'FN>&GUF.-M=T*7S5CRCZXG.,J_\
M8O\ \/+_ /@G$"S1_M^?L3ASW;]J?X%C/?@GQ]@9_#Z=Z_R$Z*_FOQ$^C?E'
M'G%.;<5X[C'BK((Y_*,HQK8&C7E&2CRMJK.HIIO1I\J<4N5-H^WRSC?&91A(
MX/\ L9MQNU:;47?I**T:\OGY'^N)K'_!5K_@FCH,$\UU^WC^R//]G'[PZ3\>
M?AKK[C'4!=%\0W8)_$ ^IK\JOVJ_^#H3_@GQ\'-#U:P^ O\ PFW[5/CZU%]8
MVECX6\.Z[\._APNIQ1X!UKQ_X\\/QN-&+DEKKPGX3\9D@!0G):O\Y"BN+(?H
MG<!8'%0Q.<9SQCGL(+6G0ITZ$)/1_#",G%::QC))[.6QOB^/\VD[X.$+Z:\M
MWY:M[KO9?(^V_P!NW_@H!^T/_P %$OC"?B]^T#XCM[E=,MI=*\"_#[0GELO!
M'PV\.3,\C:-X)T=V>0DLQ'C/Q06_X3#Q>@2)?+@C\%(GQ)117]*95E6 R3 Q
MR+(<EC#A^$5&,(I1C&*O912T6[?5W;;;;DW\5BL5C,9C%C<:M;N[OO>WX*WX
MVVL &:^QOV"/V+_B;^WO^U%\.?V;_AE:W;W'B?5OMWCOQ2ED#IWPW^&&A_\
M(\>,]:W;5!\*DJ 7*KXQ\:>(/#'@AF4>+2PO?L3_ + '[47[?_Q*C^'/[.7P
M]F\0&"01^+/B#JW_ !+OAK\.-/;[NK>-/&HR=#8JI;_A%45_&A0,W@3P/M5M
MO^E3_P $M/\ @EG\$_\ @F-\&;CPCX+D_P"$V^+WCI-)O_C-\8=4L?[.U3QQ
MK&DIY,6DZ+I21.OASP!X6WS0^#/#-L[K;PN\LLC"967\6\9_&C*/#_*)99ED
MD^/VN5N/+46&YXR<*U:+DDE;WJ=.5I5I)*,>3VE2/TO#7#6+S7%_7<==Y(VN
M562YK*[BF];WLFU=)-W=[(_0OX4_#+P7\%_AM\/_ (2?#K2+;P]X#^&/A3PY
MX(\(:/:_<T[PSX?TB+1=&MU&!RD<(4DC#L)), L5'IKJ3@CZ4^BO\TJ\5B(Z
MO=MM^;U?XO\ '2VA^U)VU149 2SG S'M.3V'MU[9X]>?;_,"_P"#@W]NJ3]L
MW]OOQOX4\-ZEY_PA_9AN]4^!GP[LR2=-O_%6AZT?^%L>-68'!?Q9XET0^&9&
M&%D\(^ _#DQ4M*V?]"__ (* _M$R?LK?L5?M-_M 0S0V>K?#;X0^*M9\)O/*
M/*;QSJFGC0_ <<Q;("3^.]8T.W.0<JYV%<KC_((O;R>\N[B^O9[FYN+J\^VW
MMW=\?;^O7'<=^AK^M?HF\'PQN<YQQQBHITLAY>&:<FDW[;%PE*I**UY6J7)&
MZL_WLTGRMGYUX@YDXX-8'OJ]NETE\FGH^U[7*]%%=?\ #CP)XB^*?Q%^'_PS
M\'P6MQXF^(OB_P ,?#_PY:WF +[Q/XYUHZ#H1)Z #Q%KG/;&?P_NO%8I8-/'
MMJ,4FW)M)))-MMMI)))MMM))-MI)M?EA_55_P;X?\$3O!'[3ND1_MK?M=>$8
M_$7P;@UQ;'X%?"C5TD?2_B3J.@ZN\FN^,?&ZQJRZ[\/O"_B&)O"L?A>1D'C3
MQGH'BD^-H[CP0J6_C7^]O1],TC0]-L=!T.PT_2=+TRTCL]-T[3;:*PL;*QC3
M"1Z?# BQ1JJE<+%M3(W$ DLWG?P/^#_@KX _!SX7?!3P%;)I_@GX3> _#'P_
M\,V:@@QZ/X/TFWT6V)S_ !&*W4MS]\G;\H!KV 1H78@\L,'CM^A'0^QZ]:_R
M4\1?$#.?$/BC.,[QD^;*>?\ XQ>BZCE##X?]ZJ*C3ORPE**ISG*SE4E.=Y<L
M(Q7]$9/EF%RG!1P<4WI)O1*[NKN_5;WVM;34 H"XS@=!^7.?TZ=/2OA7]NC]
M@K]GW_@H%\'-7^$7QU\(PZHLMG=R^#_'VG1:=9_$+X<>)#@:-XK\%>(?G,+1
MS*EP_AVYCE\*^)HDDL?%=G<0-+$/NS@CN,'ZDD_EZ4UBH49Z#N<?7&.>G7KZ
MU\=@,?BLMQ4,9@YN&:PY*D94ING*,H.\6I+3E75.Z:O&491;1VUJ*Q/NRO:[
MZ7WWT[G^.5^V3^RS\0?V*OVD/BM^S7\39!>>)/AEXD:QL_$5I9_V;IOBKPWK
M+-K7@KQAHZ'E-$\3: NC^(I8G"R03+)&ZHZ,!\R5_9+_ ,'=_P #-/TSXB?L
M@?M*:1I2_;?&GAOQU\&_'.JKQM7P7K'A_P 1>!%;DDNW_"<^.9>BC;HJ#!QN
M/\;5?ZP^$_%\^.?#[)>)\Q<9587I5G%<L95J3]G5<5TC*<7**5TE-13:BK?@
MF=Y<LJS?-\(K\K2E&^MHR2DM]M&NVNK6K"O].3_@W6_:TO?VIO\ @F[\-M+\
M3ZD=6\??LY:UJ'[/_B.^NFC2]U32_!VDZ-K/PTU5E W@GX<Z_P"'] 8_*)[S
M0==8NQCD6O\ ,;K^PS_@T0^+R:;\</VN/@-=:G.Q\7_"[P-\6-'TGRR^GE/A
M7XND\":]JT3JP\MI'^*/A]<ME90OV<J3X7##\U^DQPPLW\-\QS))<_"]>G*+
M=KJ-1JA5BG9M<\*L;JZ3<(WTBFO4X'Q7U3.'@>C37?;5=ET?WG]X@/"^RX.?
M?/\ C7\X'_!T;\6[GX;?\$O=3\(V<LMM+\=_CM\+_AE<FS&Y_P"S=&_X2#XN
MNV1]TF7X7Z:I[X? XR#_ $?CD ^M?RU_\'9GA35-8_X)Y?"+Q%86S74'@W]K
M;P+>:RVU NGZ5K?PR^+FB)JI"]XO$,^AVX)YQJQW $ 5_%'@[AL'B_%CPYAC
M_P"'_K=A;*U[R]I-Q5K-6YH0U:T:3NFDU^H<1O\ X1<U:W=*S?E[M_U1_GAT
M445_J^?@)^QO_!"?]B?P-^W5_P % O!'P\^*EA%KGPL^&/A/Q#\<?B-X3E>1
M1XLT?P/K_AWP]I'@[6 D,[S:)XG\>^.=(D\6VNQ5N_"2>(;0S6XF,\?^I'HF
MBZ1X;TG3=$\/Z3I^C:'H]B+'3-+TBRBL-/L+& #RK#3M,M@D,2JL:X$<:*&)
MVJ22H_RE_P#@CQ^W?HG_  3N_;<\$_'+QCINJ7WPQUWP]?\ PG^*;:19_P!I
M:G8>!?&LWAZ7^U]'7(+P>&?$>@:)XBN8MRF6#1)8@Z[]P_U+?A#\8_A9\>OA
M]X;^*_P:\>>'/B+\.?%EJ-1\-^+/"VJMJ>D:E&RG+1S1RY1HS\LFDRHCQCEX
MQFO\_P#Z5V'XDCQODV,S&_\ 84^$<,L)I/E4U&K[1/7E51RO*[Y>:GRQ7-R2
M3_7. /JG]C>[\7,^:^]M+?C;YWV/8ZY7Q!X?\.>+-&OO#WBG1-'\3>']5M#;
M:MH&O:5IVIZ3?Z>R\+K&D:S&\<T(PW[N5&7(#,A(P.JHK^7S[P_FE_;L_P"#
M:7]B7]IFUU;Q=^S_ &9_9$^*\L<DUH/A[I$=]\(M=U)6FVKK7POED2WT >5&
MA#_"V?P0YWF2ZB\1@B*NS_X(:_\ !'KXE?\ !+JQ^/NO_&CQ]X \>?$3XQW'
M@72M.M?AR^MW_ASPSX)\"+KS0#^U]>\-^$==O=>\3/KA-YN\.Q0Q'P_ %:8R
M83^B #CEL]N <G^HZ_CSZ4T#G[X/7@]?QX/Z5]K5\3N/,7PNN#L=GM?.<@<X
MR]C6E&4H<C4E%56Y346TKQ=2HK>ZI15DO-62Y1];^N?V93]JMFE:_9J*ZKT3
MOTN6:***^*/2/Y/_ /@[C_Y,4_9\_P"SL-#_ /5*_&&O\^>O]!C_ (.X_P#D
MQ3]GS_L[#0__ %2OQAK_ #YZ_P!'_HQ_\FGR/_LK>+/_ $B!^)<;?\E)'_#'
M_P!(05^LO_!"[_E+5^Q7_P!E1U;_ -5?X_K\FJ_67_@A=_REJ_8K_P"RHZM_
MZJ_Q_7ZEQ]_R0G%__9'\8_\ K&Q/&R'_ )'.3?\ ;OYH_P!7.BBBO\CC^AC^
M-[_@[L^+MSI'P/\ V._@9!)<_8_B3\3OB3\3M5AM"H5G^%'@W1M TA-649*V
MY_X6GJ]PA+-O.D/SE2%_A(K^V#_@\!\+:HT/[!'C*"W:?2;<_M$^'+^Z."+#
M52GP?UG0""/^>B1:U.1C*C1AG.ZOXGZ_TN^CGA\)A?!O))8-)3G#BZ51I)7G
M+BVCS-V2YFG:/,[MJ*U=E;\3XU=^(<U\H4TNFBBK:>GEY]=2OZ5O^#9;]@SX
M7_M<?M4?%'XQ?&7P_IOC+P3^ROX<\*ZQI'@K7M'CU'P]KOQ.\=ZSKX\"ZWJX
MF!@\0:%X5;P/XV\2CPS/^Z7QJ_A>63</!^Q_YJ:_?3_@WY_X*4_#W_@GS^T]
MXPT'XV7)T/X)_M$^'/"O@_Q=XT-L]XO@CQ/X&U?Q"/ OC'7GC/F1>'L>(-;\
M.>+YD^:WNM;M[I0_D^6WU?C%AN(\7X8\9X+AE5)9URWG&ES>UE33BZD::@XS
M<W!224&I2O*,6I3B>?PS]4_MC*/KMNF^U]>6[U5K_P">MC_3?$8CC\N$!<=,
M^_4^Y_*I:XKPEXM\,^-_#>D^,?!?B+2/%WA'Q+I>GZOX?\4>'-4TO7O#'B#3
MM44M%JFA:SHQFAUB"50-L\;B.8%#&<N2.UK_ "F/WP\U^(GPU^'OQ;\*:GX$
M^*'@/PA\1_!>MVYM-6\+>./#>B^+_#-ZC*&_XFVAZ];3VUP  0JO$_4EMK;3
M7\Q?[=__  :V_LU_&UM:\<?L8>)O^&7_ (B7&Z\/@+5UU?Q#\$/$&JXC*;8$
M>?Q/\/@0SD_\(VWB?PC&55!X!D)+K_5THSG)W8Y')Z^^1_CWIK C^-5/M_4
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M/!OB"?PMHNJ2I+K9\&'P5\/?!,=E_P )&R1B]$HG$B%U @)*K^T)^08!CC
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M^)GA[0_BI^W_ .+/$OP@TW4&CN])_9^^';:(_P 2QITQ;RD\<>--;'C+P_\
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M  F']C"Z_B+_ &'9MZ1;OEK^:W_@KA_P;I>)/V,_A_XB_:7_ &3?%'BWXO?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH_X=H?\ !1O_ *,!_;4_\19^/?\ \[>O]?C:_P#?7_OTG^%&U_[Z_P#?I/\
M"O@O^)N>*/\ HB^#?OXK_P#FD]S_ % P7_0UJ_=#_P"2/\@?_AVA_P %&_\
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ME[ K@=!\H./ISR,C_P"L?\7'X3_$SQA\%?B?X ^,'P[U0:+XW^&/B_POX_\
M"&J$96Q\3:)K)UW0P5.001P<Y!'%?[$'[/'QGT#]H;X$?!CXY^&D-OH'QB^%
M_@7XGZ-"X5FL]-\;^'='\0Q6#GJ6C34O*WGDNNXX4+C_ #P^DWX>X#AKB7*^
M*,E2_L'B6,I5.9>[#BN$7+$Q32NN=2=2ST<W4:NW(_8N"LYEC<%]3Q6E2%[;
MZIZ6:?G9>GD>Z=D^I_F*^>_VM?\ DU3]I?\ [(!\9?\ U77B*OH3LGU/\Q7S
MW^UK_P FJ?M+_P#9 /C+_P"JZ\15_->#_P!XR_\ QT__ $JB?<+XOF__ &X_
MQL****_VC/YE"OU:^!__  1'_P""GG[1?PH\$_&[X,?LQ+XU^&/Q"T5=<\)>
M*C\:_@'X<_MW26#:&N="\0?$?PEXF\/C]V[ <C"'KBOREK_5N_X(AM_QJ<_8
MD4?]$@R>G./%OB3OUXK\*\<_$?B#PSX9R;.>')T83XBXRJ-RK4Y5()0I3E'W
M8U*3UJ<G,^?2/-97::^KX3R;!9]BIX;'*35.//:+2;2<;V;35]>UK_C_  A_
M\0Z?_!9'_HSUO_$@OV5/_GU5S.H_\&_7_!7S3A*9_P!C'Q"1$,W'V/XK_ #4
MC)P#F/\ X1_XD_/QR2N<#G/6O]4+S#_M?]])_P#%T>8?]K_OI/\ XNOYIC]+
M3CY7Y\HX-GVMAL5"WW<4SO\ A8^X?A_D_2,E\XO_ "/\>_XX?L#?MK_LUQ7]
M_P#'7]ECXZ?#G1M*(^V^+/$'PXU@^!B#DC_BN/#V[POS@XSXP..HKY!K_; N
M[>UN[>:WN(8)H)PUO<17$:%;E<8*L&R&XS@%2?8$5_+=_P %@_\ @WR^#/[1
M_@#Q1\>OV-/ .B_"C]I7P]I6L>(KGX<>";+2?#GPX^/!7.N:KH\_A^.T@\,^
M%OB-.D4@\*>*?#\-G'XIU-QIWC@W#2VWC/PA^F<#?2HPN:XJGDO'&3PR*4YQ
M@^,L-[2HH<VTIPF^>,$])2]Y0NI3BHWY?$S+@%83_;,E>NKY9:/[[6::V2?2
MQ_GH458O;.>SN[BQO8+FVN+6\^Q7MI=\_8.O7'<]^IJO7]?GYN?5?[&_[8GQ
MK_89^//A'X__  0\03V.NZ'>K:^)/#MU>E?#7Q(\#*1)K'@_QGH\;!]:T3Q.
MX62*:)TF@E1?'D;I(BL/]7G]C?\ :M^&'[:_[-GPL_:8^%MRR>&/B5H4=Y<Z
M7>/&NI^%?%,972_$?@S60JJ$U_POX@BN/#MT#Y9=X25#"1 ?\=NO[%?^#2[]
MKK7=%^+/QV_8IUN]N[KPOX[\(GXX_#NUN-WV#P]XV\%_\(_X>\>Z3%M/#^)_
M#VN^'Y2V&*Q_#Z3:,L:_F#Z3GA_@L^X;?&^!C_PN\/<O.HQC>?!ND(.=H\TO
M9.2<;R;C#G4=/=?W_!.=_5L8\D=[:M*[T?W[OKIU[G]VY7(4J.7*,?8]\_7W
M]AG%?R\?\'#O_!7'X^?\$_E^"'P9_98UWP[X1^*WQ2TGQ+\0/%7C_5O#VF>,
M]3\)>!="U.+0-"TK1_#WB'PQXF\*(_B_7&U=/[?\40""V/AZ01@&214_J(+"
M-B6^Z0B 8XY[@^N.^#@]>IK_ #N/^#M10G_!1SX.J#D?\,5_"W\_^%^?M+>H
M%?RE]'_AK(^+O$S),KX@RY5\IE3XGJ5*4KZRI8:4XU;)QNI3C[2SO&\8MI\J
M2^XXMQ.,PF3SG@M)74?EII=_RZ+S^\^*O^(BO_@LA_T>"?\ Q'S]E3_YRM'_
M !$5_P#!9#_H\$_^(^?LJ?\ SE:_$ZBO]#_^(8>&7_1&<%?^(=4_^6GXW_;^
M<_\ 0[?WO_,_;'_B(K_X+(?]'@G_ ,1\_94_^<K1_P 1%?\ P60_Z/!/_B/G
M[*G_ ,Y6OQ.HH_XAAX9?]$9P5_XAU3_Y:']OYS_T.W][_P S]L1_P<5_\%D0
M21^V%)R,?\F__LK8Q]/^%+8K]A?^")W_  7B_;,^/W[:7@']E_\ ; \:Z7\8
M_"_QM/B72?"/BAO!'PX\#Z[X"\4:'X1USQ+HTWD> /#7A2VU_1O$[:&WA^&9
MX&=+K6XV+;2Q;^,FOTV_X(U9_P"'I?[#&.O_  T%X9Q]<'%?%^(?A=X>4^"N
M-)4N"N"Z4H<&5JT)T8152G6]G-NK3NY+VKY;7:?/?DDI1DT>EDF>9Q+.,GC+
M..92LI1DVU*+T::ZIW^70_UHJ***_P T#]S"BBB@ HHHH _QW_V_/^3[_P!M
MG_L[3]HW_P!7-X]KY'KZX_;\_P"3[_VV?^SM/VC?_5S>/:^1Z_V-X:_Y)O*/
M^R-X._\ 6-X-/YNQ7^^YQ\OR85_??_P:(_\ )I/[4O\ V<;IW_JLO#E?P(5_
M??\ \&B/_)I/[4O_ &<;IW_JLO#E?C/TGO\ DTV>_P#96\)?^FYGTG!'_)2R
M_P +_P#23^NFBBBO\V#]M"BBB@ HHHH ***@FEA@C,TLHAAAY=CPH   !X)Q
MSV'- &1?WFG:792ZGJEW;6%AIULUS<W=S.+.RL[1 S-+*[L(T5%4G,A'( !7
M*J?\Y?\ X+\?\%EX_P!N3QY<?LO_ +.7B&?_ (9+^%_B,WNM>(])NQN^//CS
M127;6\YR/AWX5<F7P6H;#RD^/'WNW@]_!_T?_P %_/\ @N>?CQ=:_P#L0_L<
M>-IQ\$;<:EHOQX^+'AVY16^,^I+$$/PR\%:VK%#\'3A_^$W\4QD+XR4B%-W@
M)=_C;^1ZO[C^CYX(1RE91XA\9P2SR<U4X.X/E%*=5I)1JU%RQ<9M:PC;FA%Q
M;Y)/DA^7\7<2?6O^$; N[=TWT=NB7\JOVU?>VA1117]>GYN6(89YI;>WMX/M
M-Q=?\>=I:>G;]??KQ7^BQ_P;X_\ !(>Y_8D^%,O[3GQ]\+PV_P"U'\9] A.F
M:'JUO"NI?!7X7ZR8;@>#N4N&B\?^+) GB/QU.4BEMD30_"$;PRV_B:2Y_/#_
M (-X/^")9O9_ W_!0+]K;PEMM8!8>*?V8_A7X@M(P;M848Z+\:O&VAS*8I-L
MIC\1_!91N>/SE\=%0O\ PATB?V])L"94AEYYQ]YNWY?YQS7\*?2)\:(9W&7A
M[PI.V2-M<6SCRN,I1YD^$XM3_>4,/4BU5DO<E.#IMR4)H_4N">&W@K9SC?CD
MO<6JZZR;MIIMUN[]"[1117\E'Z,%%%% !1110 4444 ?PS?\'A?_ "-?[!7_
M &+W[1/_ *<O@W7\8%?V?_\ !X7_ ,C7^P5_V+W[1/\ Z<O@W7\8%?Z=^ 7_
M ":#A#^O^:R9^$<6?\E%F_I#_P!)@%?K+_P0N_Y2U?L5_P#94=6_]5?X_K\F
MJ_67_@A=_P I:OV*_P#LJ.K?^JO\?U]MQ]_R0G%__9'\8_\ K&Q.#(?^1SDW
M_;OYH_U<Z***_P CC^A@HHHH JOT7_MI_P"@BO\ *7_X+I_\I;/VU?\ LJ6E
M?^JP\ 5_JT/T7_MI_P"@BO\ *E_X+PZ;-IO_  5N_;4@F\C;_P )SX4O1]GS
MOQKGPO\  &O OW#@8W=\YZ9%?TY]$7_DO<__ .R2A_ZU% ^*X_\ ^1+_ -OO
M_P!)1^1=%%%?Z"'XX=[\+_A3\2OC;XXT+X;?"'P'XJ^)OCOQ)=-;:7X7\&:3
MJ_B+Q'>(B[F=]&T$A41%!+,Q"JH).!FOZF/V._\ @U _:#^(]GHOB[]L?XP>
M'?@-I%X=-O;OX8_#VUB^(GQ,.E(J.^CZQKL\D7PR\":^JNN9(!\9XU)*E@P8
M#V3_ (,^X;<^-_V])S;P&>U\/?LZ61NE )8#5/C$<>Q! /')( !Q7]RI4;F+
M'"8SSR3QQ^/IV]*_B[QP\=^-N'>*<UX)X8E'AJCD,HTU*"<Z\JDHMV2DG3IP
M35KVJ3>ZY4C]'X4X3RG%8%8[%Q<Y.]DVHI*]GJM;O[C^=OX=?\&QO_!*3P=H
MMOI?B?P'\8OBQJ+)F[\0^.OB_P",M)U.Z89 ,\7PJ?P'H8SC[HM,@<[FS@:_
MC;_@V:_X).^*-"O-(T3X4_$SX<:A=VNR#Q7X*^-WQ.OM8L6 ZPV_C[Q%XU\+
MD$G(!\+8"YRV37]!Q'HS?H/Y48]6;\<'^=?S._%7Q*^L_6UQMQ>JEG[W^M&)
M:^Z_3MS-'W_]BY-:_P#9=.WJK_?^.Q_F??\ !6;_ ((#?&'_ ()XZ#J/QS^%
MWBF_^/7[,GVV:RU;7;O2ET_XF_"E-5D$.C2^,]"T$)X>\0^&HY'2.7Q3X5B7
M9*0H\$>$8VBEE_GQK_:1^(/@#PA\5/ OB[X:^/=$TWQ3X$\?>&]:\)>+_#VJ
MVRWVG:UX;U[3)]&UK1YD;(,=Q%*Z2[E9P>BK)AX_\>W]K/X$7W[+_P"TS\?_
M -GS5)[FYN/@[\7O'GP_LKN\_P"0GKNEZ%K/]A:#K7_<V>&SHGB?KCD>U?V?
M]'+Q=SCQ"PF;9#Q14=;.^'Z4:U*L^6]6E*7)=\D8Q<H2<4Y1C%34X2Y8OF1^
M8<7<-8/*4L=@DTG?3LU?3[[Z?F> 4445_31\0?ZEO_! O]IRY_:D_P""8WP&
MU_7-737/''PAL]0^ /CZZ:\&HZJFL_"]H+?P\FM2!6(UN\^'6I^!O$DZ'=N?
M75(ZFOV@8 AU(X9<_3U/XX'YFOXY/^#0;XF/J7P5_;0^#I(">"_BG\,?B; &
M_N_%?P=K>@L<]OW7PJT@>Y(QQQ7]CAY#,>/W8_F!^@_.O\G?%O(J?#/B3QGE
M&$BHPH\58E))62A*:JNR[>]/563DW:*6C_?N',3]=R;*L6]Y0MYW7NJ_SM^N
MI:HHHKX$]H**** "BBB@#\'?^#DC_E$)^TE_V,7P'_\ 5^_#BO\ ,)K_ $]O
M^#DC_E$)^TE_V,7P'_\ 5^_#BO\ ,)K_ $#^BC_R;/-O^RP?_I?"1^.^('_(
MVI_]>X?J%?1_['7_ "=S^RQ_V<C\"/\ U9V@5\X5]'_L=?\ )W/[+'_9R/P(
M_P#5G:!7]$YY_P B;./^R-_1GR6%_P![^7^1_LDT445_CF?T>?@7_P '%G[(
M>J_M5_\ !-_QMJGA#39]:\??LZ^(--^/GAW2;-<7^J:!X>TG7-!\?Z5&2?E
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M\DAP?_V1O!W_ *QI_/&:?\CG.5VD_P Y!7^AU_P:3_\ *.SXU_\ 9ZGQ&_\
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M84?%HZ,F22%)\<97+' P"3UK\X:_>'_@Y0\+6?AW_@KE\?\ 6([B9CXT\)?
MOQ3=6Z'*V=^WP<\">!(7SDCYH? Z,V"1O)QQ7X/5_K=X>9F\W\/^#,:TT_\
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MZH_2C80$'89/TYZ?IC]:_.3_ (*P_LIW7[9W[ '[2?P"T.R2^\:Z[X);Q/\
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MU7DWHGU6NWH>PT445\8>L?"O_!33_E'%^W__ -F4_M4_^J)\=5_D(U_KW?\
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MO_OY,_".+/\ DHLW](?^DP"OZ1/^#5^ZEC_X*@W4$4HAM[C]G#XQ6UVO_/\
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M?Y9?_!P?I,.A_P#!8']L6RM2#%<ZO\&]8DV]/,UK]GWX1ZW(!CL'UIO;BO\
M4TCZCZK_ "6O\N'_ (.+O^4Q_P"V-]?V=?\ UF;X#5_1WT39-<?9M'I+@W%-
MZ:WAB>%&M>GQ._?3L?&>(*_X1Y/^\OQO_D?B=1117^B1^-']X7_!H'_R0O\
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MX1A^#>E?!N[\-GX/^(O"7AXZA_PGG_">C7!K4?COX;>,&=@?!&A$*J@G)RP
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M:[)&VDZ"KE7S\.?&.OH4DA.V/PMXPU]O%\LD<4WC6:/_ $.LCRR=YPQR&Y'
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M#'X$> _CSX3UWX=?%._^(.IW'Q@\._#WP_IUWIH\$^(=!E&BS^!_B=XQ:7Q
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MSS!9M=X-W2:=FVGJO)O1/JM=O0]AHHHKXP]8_D__ .#N/_DQ3]GS_L[#0_\
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M<1Y$FT[/:2M>,EHXR3M>,E&2NKQ2<7+X#%87&8/&?4L;_7GUN@HHHKUCF/\
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M3_#7O_Q0WC#P[KV,>_\ PFY.:_:OHV8CZKXLY'.Z_A<4_.^#E_F_Q/D^-?\
MDG*K[.'XV_R/X[Z***_TV/Q,*_VI_"VJKXA\->'M<$D$XUS0M-UC=:Y:U9-3
MTN.10A)8M$=QZG/(!QTK_%8K_7U_X)T_%-OC?^P3^QY\5)KFVOM3\9?LV?"&
M_P#$=S;8%E)XHA\&:)I/C58<85EB\2:9K$:9&1MP3\QS_'7TP\,EA>"L=;WG
M4XN@I:72E5IRY=7LVKZ)[7;[_H_AMK_:Z]'^:_4^XZ***_B0_40HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*G*,X-)2<??BI1]URB^9-+1IM'[KF.6X3-<*\%C;N+LY6:NFG:ZOH^_I^/\
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M;S[4**** "BBB@#_ !W_ -OS_D^_]MG_ +.T_:-_]7-X]KY'KZX_;\_Y/O\
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M++1_#7A[2Y]<UW5I#T9+>UMWE89W-M;;DD[O1&.4!]< _P"?J*_C5_X.HO\
M@H>/"'@KPQ_P3T^&>LX\4?$:QT?XD_'\6S,S:?\ #^/6&'@3P;(K<)/XK\2:
M/)XED 5&7_A'_#,#;D\5(Q^EX$X1QW&W%^3\+Y=%\^(J1C*72G32?M)MZ_#3
MBXP5GS5*D$]%(\[,LRCE>#EC9*]G>W=M72MY]?)/N?R9_P#!1']M#QA_P4 _
M:W^*W[3'BG^TM-T_Q-JXT7X;^%+N\ '@/X7Z%G0? W@S X&?^1I\;*O \::_
MXG &,5\0T45_K=E>5X')L#DN18!6R'AN*C%=HQ226M^BU;NV[MZMW_ ,5BOK
MF,>.QN[_ !"BOH3X+?LN?&S]H#P=\>_'OPH\%3^*O#/[-_PN/Q6^+>JVU[_9
MG]B^!_[7;1=BD]3LCU[Q45_Z$OP_XHY_XI("OGNEA,;E^.Q]3+LOJ4YSHN$:
MT(SC*=*52"JTU4C&3E3<Z=JD%.,7.'O1YHW:;PK5FXNSV=M'9V=O=UL]';KH
M%?T4?\&WW_!0M_V1_P!L2V^!7Q"\1&P^!7[6%[I7@V\2[O473?"OQB./^%6>
M,E+*P$GBH'_A6?C#!0&?6_"8>1(O"4E?SKU8AFGAEM[BWG^S7%K_ ,>=W:>G
M;]?;KS7B<8\,8+C#AC.>%<<[/B*SC*RDX3BU*G4BI77-3FHSC?2\;/1R.G+,
MS_LC&K'?U;;\>I_ME@KSQCC!QSQW/KW]^![4Q@@!R>#UX]^X[Y'<'ZBOQJ_X
M(E_\%!E_X*%?L2>"_&/BJ\%Y\<_A/*/A3\<[83,)[WQ-H.F1'1O&[!G):#XG
M^&Y=(\4R,SQ1Q^*IO$VGPJP\.,!^R)&\.I/3D=>N>G\^I^G05_DEG.38SA[.
M<SR3.:3IYOD5:I2K0:Y91:YXJ2L[.,^524EI*$XRTU2_?L/B8XS"K%81^[.S
M5]=FKZ^5U;YK< 21&V/;_/T'6OQG_P""ZO[%WCK]MW_@GQX_^&GPF\.VOBOX
MM^"?%OA?XO?#7PY>$6)UG6O!<]QI&O:;I,I*[?$M[\/]>\9P>$F(/FZA):Q*
M7+HS?L]E J\<$X'/3IWZ<C';'OFE<*0!CJ!]".WOGW_R#(\WQ>0YSE6>8&2_
MM?(ZU/$49)7M4C9WL]T[/JG:3:M)(,5AHXK"RPKNHR7+^+MMZO[C_('E_P""
M:?\ P49B>:(?L _MI[8?N-9_LM_'K:_&?E(^'&&_X"3G\\0?\.T/^"C?_1@/
M[:G_ (BS\>__ )V]?Z_&U_[Z_P#?I/\ "C:_]]?^_2?X5_47_$W/%'_1%\&_
M?Q7_ /-)\3_J!@O^AK5_\!A_\D?Y _\ P[0_X*-_]& _MJ?^(L_'O_YV]'_#
MM#_@HW_T8#^VI_XBS\>__G;U_K\;7_OK_P!^D_PHVO\ WU_[])_A1_Q-SQ1_
MT1?!OW\5_P#S2'^H&"_Z&M7[H?\ R1_D#_\ #M#_ (*-_P#1@/[:G_B+/Q[_
M /G;UZK\#O\ @D)_P4=^-GQ2\$_#5?V.OVE/AU:^)M?T>#6/B#\4_@K\2?AW
MX)\*://D:MKFLZWX\\.>%/#3?\(VP(A"Y\9S,"L6YL"O]:$(YS^\(]1Y:#/Y
M@TXH3]XJQ_ZYH./3TJ:_TN>*9824,+P7P;2;349\W%4N6332DX2Q7O<K<9<K
M24K.+:4FTUP#@E_S-:OFE&%[=K\R_P"']#F_"/AG2_!_A/PMX.TH :3X5T#2
M?#>EIW&G:#I5OI%N&P<;A#"H;!/)ZFO\[+_@ZRUB74O^"F_A6SD%P%\-?LK?
M"_2+3;]TL_C3XNZ^Q'U.NY]2>O?'^CJ>B_[S?^@U_G!?\'4NF7&F_P#!3O1+
MVX*F+7/V8?A=K%OMY']GCQIX^T&3GI]_0VR/6OF/HR6?BHV[-K@[B]QO:Z;H
M1YK=FTW>W2ZV/0XU?_&.3WWC^3_I'\UE%%%?Z.GXH%%%% !1110 4444 %%%
M% !7]_?_  :<?M3^+_BC^S5\?_V;/&&LZEK5K^S?XP\":Q\/'U6Y5ET+P'\5
MM$UP#P/HHW G0?#/B'P-KGB2)L-@^/0O4(#_  "5_:-_P9[VDLOB+]OZ_P#)
M"QVFC?LR6<Q)_P"6IU;X_1K@=SC1R,=!GCUK\)^DQEN"Q?A3FF/QK2GPYB,.
MZ;:3:E*M"#2;5XN<)U(-Q:DXMI7V/K>",0Y<2..KYHR37>\7^MC^Y*BBBO\
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MFTDN#>,FV]EJM^RU7WGBY9A?K><9/Y_\,?ZIE%%%?Y"G]#G^<E_P=??\I+O
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M(S_.Y_XA*?\ @HY_T6G]BG_PY?QY_P#H<Z/^(2G_ (*.?]%I_8I_\.7\>?\
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M^,-?U:M_'_US6OY2O^#N3_DQ#]GC_L['1_\ U2_QAK]-\$?^3M>'G_95X?\
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M-M>4903^32:[(ZL3PSG.%VR9OTU_(_$ZBOZ,?AS_ ,&MG_!4?QLMG<>)].^
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MX?EQ^V/_  ;H_P#*8_\ 8Y^O[17_ *S-\>:_U'IOO#ZG_P!%M7^7#_P;H_\
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M^S</AY_Z:7K_ "6J_P!:7_@CQ_RBY_81_P"S</AY_P"FEZ_E#Z6W_)%\(_\
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M0 4444 ?GM_P57_Y1I?M[_\ 9I7Q\_\ 59Z]7^1A7^N?_P %5_\ E&E^WO\
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M *ANM5_8EW7_ '5_]"%?QV_\&@?_ "0O]L[_ +*Y\-/_ %#=:K^Q+NO^ZO\
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M[7!S]NT]M)?0Y5R#_#+HCC!Y7&#@C _GEK^J#_@[3^&=_H?[=OP0^*7D6O\
MPCOQ!_9DTCP^K+C^T'\4> OB3XY.OLF.BCP_XY\%( >?D..,&OY7Z_U2\%\5
M'&^%'!KC\*X.G%737\.I5IO1ZVYH2MKJFGLS\!XDTXESG^MTG_D%?U5?\&D?
MBXZ=^W3\?_ L\%N/^$I_98U;63>CADU/P1\2?A,HT=<]PWCG6O3']@YS@8/\
MJM?MQ_P;P_'"+X*?\%5_V>OM=_#IN@?&&T\<_ _6+F<*9)5\:>#TF\$6ZAB
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M.GQCK^X^/K_P%/\ T*OX</\ @SR_Y&S]O;_L7OV=?_3I\8Z_N/CZ_P# 4_\
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MB)L_VV_+_P"RHV?[;?E_]E1_Q,QXN_\ 0UX6_P#$-P'^0?ZD\.?\^I?^!O\
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M_P FW_@C5_RE+_88_P"S@O#'\C7^LEW?_MG_ .@&OX%^EO\ \EAP=_V1D_\
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M24.>FZBBX*'.HN?M'R1^WR/@=9MA(XS'.W/\*2=VD]TK>7F^NVK_ ,N?2/\
M@@K_ ,%<-=L(+ZR_8H\>VUN.HU;QE\&O#>I@=>="\0?$CC/^>M=G#_P;O_\
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M_P"'@S\^+S\W\1_@R?\ Z^5/T"BBBO[8/R\_U</^"('_ "B@_8?_ .R2Q?\
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M>)?V>]8O+1?%/[,'Q'U.PL=.:Y5]0_X5K\6+C5_'?AC5Y!_K#GQ:WQ.\.(4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1Y>9<TT[V<DFHQM>ZO=.WAYEQ'E.58M83&U'"32::BW9-=%>]_5_<?Z(N_\
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M4>=M)M1]K3<K-)W:3Z<+QIDV+QJP49SYFTKR2LW?[2UZ];,_O"HHHK\(/JR
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MB+?L4_\ AM/CS_\ 1&5_GC_Q+/XN_P#0JX6_\3+ ?YG[)_KMPY_S]E_X _\
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M$;_H:<'_ /A96_3A%'Z1_P 1 R7^:7_@*_S/]1WR6]3^4?\ \31Y+>I_*/\
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M:S"Z9HWCO7-9!^*OA'Y4C3=X8\0%/%;*B^7'X/\ '_AR%=Q\'9'X+U_JJ_\
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MHA1110 4444 5CU7Z_T-?YSG_!U__P I+_ ?_9I/PO\ _5G?%ZO]&,]5^O\
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M[CO@[!\><,9SPMC7RRXA:G3G92]G5IOGI5$G9-TZBC*SLI+FBW:3:YLLS/\
MLC&K'?\  NO^#_5['^V,I!Z8S[<?SQ3V;;_=7'J WU_+].]?Y_/_  3K_P"#
MHGXH? KPGX>^%7[<?A#Q7^T)X8T&U2TT?XO>![_1F^-EAIJ<:)H_C?0/$(\)
M>%OB!YRA$?Q1)XN\)^,$V>;XTC\5W+R7#?T&:%_P<J_\$D]:T^'4;_XZ>/\
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M_P @K^QG_@S_ /\ DL?[:_\ V2SX.?\ J7_$&OXYJ_L9_P"#/_\ Y+'^VO\
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M"#SGJ?Z>/@)_P=I?M9^!O#%OH7[0'[/?PI^/^J6EH+2S\9>'?$^M?!'Q#J#
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M*,E:ZTE%QE%-^ED>=K*<8\:]4]&O7?\ "S_0_P!H *3_  H#TY']?2E^9?\
MGF/\_E7\;O[&?_!V1\*=6T31/#'[<GP>\7>"_&L7EV-U\4/@OIT7B7P#JP1
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MIJSBD]=#])X RO?.&G[R<;==79^CU:UV;U-VBBBOXN/T\_%;_@X,\,7WB?\
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MT.;*73/&>BVNNPNC,<D!9]K%R2,')P21ZNZ!DV8#+U'/<^G'I]/<9S7^</\
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M?^FEZ_E#Z6W_ "1?"/\ V6,?_60@?H' '^^YU_@_5'Z9T445_!Q^L%=OX_\
MKFM?RE?\'<G_ "8A^SQ_V=CH_P#ZI?XPU_5JW\?_ %S6OY2O^#N3_DQ#]GC_
M +.QT?\ ]4O\8:_3?!'_ ).UX>?]E7A__;SPN)?^2?S7_KT_S@?Y\E%%%?ZI
MGX(?K-_P0L_Y2V?L5?\ 94M5_P#58>/Z_P!6J+[B?]L_Y&O\I7_@A9_REL_8
MJ_[*EJO_ *K#Q_7^K5%]Q/\ MG_(U_G[]+G_ )+S(/\ LDY?^M/B#]=\/O\
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M-"\4>!=9&O:%K6>A_P"*BT0<>]?Z7O\ P3=_X+N?L@?MM^!?"^D>//BAX*^
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M+'P[^V_^UYX<T\'<+3P_^TW\8].TP'ID9\2=2/\ )KU;PW_P5N_X*>^%M/\
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M1^F=%%%?P<?K!_G)?\'7W_*2[P%_V:1\+O\ U9WQ>K^92OZ:_P#@Z^_Y27>
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M^#]4\&?L\_"KP-\ --\8Z.WC+PIK-[J_Q$^)OBWP/'K*C7VT3QQ!XA\%^&=
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M?EI],?S=_P#!T9_RBUU'_LOWP8_]#\0U_FUU_I*?\'1G_*+74?\ LOWP8_\
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M$A[2TN9K/]H?Q;?7%J,+96?P+^-<=_> <!535_AW;Y!(S]X'/?M7X[?MO?\
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M[<8K_%#K^M+_ ()M?\'.FL_LY_!WPE\ _P!K[X2>)_C!H7P]TO1_#7@CXL^
M-2T>3XDOX5T$I'I.C>-]"UZ2#PSK\WAJU3[-_P )<_C'PDBJ(A+;SQ(_BR7^
M6_I*^%/$_'-7)<]X7RF7$.;9#1JX?$4XZ3E"<E.G4A)M6=*7M$TM7"JVN9P4
M3] X)SS"93&6 QDG%NS4MU==&NJ=E]W1L_OZ4"-<;=HSZ@D]?H/Y]/K4H)(R
M  ",<XQZ]23S^/85_(CX^_X.Z/V5K?PY?7'PN_95_:"\6>*@NVUTKQ[K7PU\
M!^&Y., GQ%X:\2_%BY!!SA1X7 /&X$5QG_!*_P#X.(_VD/VUO^"@_A+]G/XT
M_#'X3^%/AA\7]*\>6W@2U^'NG>+X_$GA#Q-X(\(:[X]T>7Q#XA\2>*$36[/Q
M)X;T+7/#]V(_"0+^+8_#BK#X6\QK>?\ E2/@9XF9?DF;YWC^#ZN39)P^N>M.
MLX4^5;-0I0NN:S;<4TM-9RTM]O\ ZR9++&?5/[6BYO>^NKZ7TZ==_(_LA7A-
MO3"@D<=2P/\ (XK_ ",_^"L>I>)-1_X*9?MZ3>);+^S]2'[4OQALK6U-F!N\
M,:%XSU[0? VM\>OAW^Q,8P!GI7^N6Y*JQ']U1^8!_I7^6W_P<+_!O4_A#_P5
M@_:7WV/V71?BN? WQD\-7?\ S_:9XU\':%%KX'3I\1] \<CMTQD\5^E_1(Q6
M%PO'^<8.;LY<'XF,8Z[0J4G?:VD6G??6RNKV\3Q!O_8REWE+[]/U/Q3HHHK_
M $$/R,_TS/\ @V4G\.2_\$F?A2NB?9CJ,'Q.^.J^+Q;9V#Q-_P +0\0G=CNS
M>'CH(Z<C:>Q-?T!.RJI;&Y6_Q'Y'CH.E?YK'_!!G_@L9X;_X)S>+?''P2^/<
M>H+^S/\ &'Q$OB>Y\1Z#I$GB*^^%/Q..D)H<GC!]!\/!O$NO^'_%GAK0=%B\
M9S&&?QG;/H/AF1(IEW1R_P"A%\'OVI_V<OC_ .&?^$P^#'QN^%GQ.\+RD,NK
M^"?'>@^(H;4;26_M:.TN6DT=@0!Y=VL;$D$=\_Y=>-7 W$G#O'V=XO,<IJ1R
M?/L55Q>'J\DY4Y4ZS3]GS1BX\U-*<)TY\DN7EG#GBS]UX5S#"8K)LK<6E+V:
M@HZ?%&^JU>]TTTVMSZ'SN0#RP>N5YZ=,COT_STH&50[8B,_P\GZ<9S^/&.G'
M6OE_XY_MA_LK_LYZ"/$WQU_:(^$GPLTGRY#:MXL\=:%INH:ID*O_ !(]%:X?
M7=>89&%T&VN6('RHVQB/XO\ _@K'_P '*^K_ !GT'Q/^SW_P3\N?%/@/P!K=
ML^D^*OVCM5L=6\-?$KQ5IIC*2:9\+M$5(_$G@#1[@M-)+XK\20VOBT><8H[?
MP:PDGG^6X'\+^,/$/,%@LARBJZ;C&%3B25.,,-13MS2E5E22E.*U5*G*HY-I
M+DBW)=N9YY@LIBOKCLFVTKMM^5KVL^[2??4^%/\ @Y6^.WPN^.W_  4GO%^%
M/B[3_&=G\)/@IX'^"_C+5=!5-1TZS\?:%XX^(.O:]I?]LI),FMKX;.NZ)X>C
MA\QC!XQD\2PL R%1_/U117^I_!_#.%X1X8R7A;"SE5GPY%*522C&4Y)>]-Q@
ME"/,[OEC[L4U%-J-W^#9GBOKF->.VN[VUZ^H5_;)_P &>?7_ (**_P#=J'_H
M'[35?Q-U_;)_P9Y]?^"BO_=J'_H'[35?FOTC/^3.<8>O!G_K8U3V^$/^2DRC
MTJ?^D2/[=****_S(/W0_!W_@Y(_Y1"?M)?\ 8Q? ?_U?OPXK_,)K_3V_X.2/
M^40G[27_ &,7P'_]7[\.*_S":_T#^BC_ ,FSS;_LL'_Z7PD?COB!_P C:G_U
M[A^H5]'_ +'7_)W/[+'_ &<C\"/_ %9V@5\X5]'_ +'7_)W/[+'_ &<C\"/_
M %9V@5_1.>?\B;./^R-_1GR6%_WOY?Y'^R31117^.9_1X4444 ?YR7_!U]_R
MDN\!?]FD?"[_ -6=\7J_F4K^FO\ X.OO^4EW@+_LTCX7?^K.^+U?S*5_JMX,
M_P#)J_#?_LC7_P"E2/P'B/\ Y*3.?G^05_8S_P &?_\ R6/]M?\ [)9\'/\
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M]",\GZXXY_/K7^4C_P $J_\ @K-\9?\ @E]\2->USP?H>G_$_P"$7Q#.EO\
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M[7^NO#'_ $-8?^ O;[MS^YZ>:VMH#-/*L,$(RS-@# [<C/ P.,G'KV_SKO\
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M\2U;>4*<(P>UN:<6KWM^Q<!9=]3P7UK7FJ6222=UI^#8Y5PJCT&1[=1^G/\
M.OP9_P"#A']AZ]_;(_X)_>,]4\#Z(NO?&#]F_4)OCMX%MK.W236=:TG0M+9?
MBGX'TIP6>0>)_ 9O-?@\*QD1^+/%WAWPI"ZED+G][0<@9'7(_G_3/YU&2F.5
M_,\?Y_S]/YZR#.\;PMQ#E'$N7S4*^158XBE>[7-"<).,DMXSIJ=*?93NE>*/
MKL3AUBL++"RVDDG\[ZWZ:NZ]#_$MHK]_O^"_?_!+'4OV#?VDM3^,7PST=8/V
M5_VA/$6H:UX)_LBRV:9\./'4B_V]K7P?UE2<^3(Z^(/$W@=@61?",4T&]V\%
MN:_ &O\ 6_@[B?)>,.&<GXIR1K_C(6XR5TW"I&RG3GRMI3A+W9+NKJ\90E+^
M=\RRW&93C/J6-VW3Z-=UW3Z!7T+^RO\ M1?&;]C3XW^"OV@/@+XJ_P"$4\>>
M$;DHPN7:^\-^+=)88UWP7XVT=&237- \5GE7C=9$8!XV'CX!A\]45Z>-P67Y
MCE\\MS*$*M*K"=.I3J0C.G.G4C*$Z=2$U*,X3C*491DG&46TU9G-A<5]3LT[
M-6::;336S7H[69_J/_\ !,[_ (+8_LG?\%%?#6B^&K7Q'8_"+]I9+.,>(O@1
MXXUF'3M4OM421)6E^&&M2F.+X@^'F<$!(EM_&5M K+XO\'6#$*_[6,S&,;53
M/]UL;>@&0<\C]/8]*_Q/(9IX9;>XMY_LUQ:_\>=W:>G;]?;KS7ZM_LZ_\%R/
M^"H?[--CI6B>#_VH_%/B[PCIY4V_A7XQV&B?%G3I-,C!":,^N_$ ?\)1H6P#
MY?\ A%O&!VX&!@"OXTXZ^B?*>+GB_#[.W%35O]4N+FZ.)IZWM"M&,HM+HIPY
MEM>2LS]2RSC^*5LXBHR35I1_*U[._9?@?ZMF3Z']/\:,GT/Z?XU_G*P?\'77
M_!3"WM+:WE\&?LDSS@8%U<_"KXEJ+X#/W0/C8,'W'/'?!KS[XA_\'07_  54
M\;Z;/:>'/$GP,^$US<*5&J?#SX1Z5J-_8CU,/Q \3?%R$GT)CW \ @<5^>?\
M2M^*E_BX.]?]<*7_ ,CUW_/4]K_77AW_ )^2_P# 8G^CKXU\;^$/AWX<U3QA
MX^\4^'?!OA+0[22^UGQ5XLU?2_#WA[2-/C',NK:QK=S#!;H3DM+)(BEB$.&(
M+_RP_P#!1#_@Z$^"'P;M=8^&?[!VDZ3^T%\2HUO[&Y^*VO6^L67P1\*[8U7^
MU-$'V>+Q%\6-9@?<T<4)\)>"9)&$T?C;Q(H:V?\ B2_:'_;"_:E_:PUQ?$'[
M2'Q\^)WQ?F%X+RQL?&GB[6+_ ,+Z!J78:#X&4#PMX=QZ>%/" XP*^<:_9N"?
MHK91E<_K_&^=1S]<T6HT4Z?!\N395:]_;58MZ\B]E!V2ES+FYOE,SX_Q>+26
M217ES:O[ME;O;?HC[$U']OS]KCQ#^TYX(_:]\>_'/QYX^^-?@/Q?IGC'2/%/
MB'Q$-EDNB:T=>?P7HF@Z /\ A&- ^'3Y);POX5'_  AC%CNY)K_7XTR_M]2L
M+'4;<[H=0M%NH<]@\:./Q(;\0#UR<_XH=?[5/A(A?"GAA"0#)H&D$<=/^)7
M,_KSST].E?)?2TR?+,NAX:++\GAAH4J?%M"FJ4*=.$*4*M)PI0A"$8PA'E4(
M0BHP@IOEBKW?I< XO%XS^V.=[S35[MN3OK=N]TFW=ZNR\SI(^L?^XO\ ,5_
MI_P=W_\ )U/[*?\ V;[XF_\ 5DZY7]]<?6/_ '%_F*_@4_X.[_\ DZG]E/\
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MVTUO.*G\#Y5%2?Z#PSQ+@<HP7U+'.2=[^ZM++H]5\GK;71L_U'_);U/Y1_\
MQ-'DMZG\H_\ XFO\N+_B(L_X+(_]'A-_XC[^RI_\Y6C_ (B+/^"R/_1X3?\
MB/O[*G_SE:_&?^)3?$;_ *&G!_\ X65__H2/H_\ B(&3?S2_\!7^9_J.^2WJ
M?RC_ /B:/);U/Y1__$U_EQ?\1%G_  61_P"CPF_\1]_94_\ G*T?\1%G_!9'
M_H\)O_$??V5/_G*T?\2F^(W_ $-.#_\ PLK_ /T)!_Q$#)OYI?\ @*_S/]2
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M\_$T+P,K_P )A@]2*_(S4=3OM7U#4-6U6]N=3U#5+S[=>ZK=WAU+4]0U0?\
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MY7-1]Q>-PUF6-QG$JQF->Z:^5GHEM;LK)7:TN?W-T445_G@?L(4444 %%%%
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M*<ZDX4Z<8K>4YU)TX0BM+RG.,5=7:N"PSQCLDVWLDM;^BN_NN>!5]U_L"_\
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MN3@<$FBC:G6C):+FA+O\,XM_D:)V=_Z['^+'17V;^VW^P/\ M(_L$?%?Q/\
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M[_X9_"WXB?&GQUH/PU^$W@GQ%\1O'WB:Z:S\.^%?"ND:QXB\27NI*"69M%R
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M?V0OVBO+%M@N&_X5=XD!(SCYL,><DXW=B:_R*J_V;?CM\*M(^._P1^,?P/\
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M(YV8#/YU_C?_ !P^!_Q*_9R^*7C;X,_%_P ,:CX+\??#SQ#JGAKQ%I>IV?\
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M%O",L9;&Y.DIZWCJKM.UU=*]^V][K??^!&BOIW]I+]BO]JO]C[7/^$>_:6^
MGQ&^$$UW>"RL]8U[20W@77M4X.-#\<>'MWACQ >1D>%/%^1@>]?,5?VO@LVR
M_.\!',<MSR%6G-*4*E.<*E.:>SC.$IPDM]8S:WV::7YMBL*\'ICE9I[-?FG9
MK[OP"BBBNXY@HK9\-^&_$GC#6=/\.>%=#UOQ)X@U2\^Q:/X>\/:/K.I:G?\
M_8#T/P__ (^V,"OW_P#V&O\ @V\_;Q_:EO-)\3?&?PY_PR1\(+EEN[O7OBI:
MH?B=J.FMCY="^%;./$Q8+\Y3XKGP?(4!*1N2 ?EN)^,>%^#\&L9Q5G:X=E)2
M<87O4FH*\O9TTW4J-*UU"$K7C?EYDWZ6699C<W_W%?Y*_GLOO[]C\5OV=OV>
M/C!^U7\7O!_P+^!/@G4?'WQ&\87AM-)TO2]H33E SKNM:]KK?+X?\.>$^K>*
M#\HQSGFO]/[_ ()+?\$R/AM_P3+_ &>X_ >CO:>+_C#\0%TO7/CK\6;:R,+^
M+/$\#RG3-$T6$[;J+X?^#FUC5H/"4%Q&A$MUXC\5S1PW/BN[C7T_]@/_ ()J
M_LJ?\$[/A[-X-^ '@W;XBUVVLH_'?Q3\4M_:WQ(\>30^3*O]M^("NV'1HY K
MP>&?#ZVGA:!T.RT4[G'Z(JI1GW/D'^')^4>O8'!Y/O[<G_/SQF\<,5XC2619
M)!Y'P5"=-RIQDE/BJ34I4ZV)CSJRCI.G3M)MM2:;2Y/UGAOA3^R4L=C;2SB4
M97DK\L;NUEHT[]7=*VCUO>W1117X6?6A1110 4444 %%%% 'X.?\'(O_ "B!
M_:2_[&/X#?\ J_?AU7^857^I;_P7Y^%WQ$^,O_!*/]I?P;\+/!^M>/O%L(^%
MOB>'PIX:L7U3Q%J.F^"/C/X \2^(9](T7RP-8F\->'=*UGQ4+=F!?^P Z+)N
M)3_+2K_0'Z*&+B^ \ZP"DG)<90E**:YH\].,H\RW7,HMJZLTFTW9V_)./5;-
MH?X5^?\ P0KZ/_8Z_P"3N?V6/^SD?@1_ZL[0*^<*^S_^">OPN^(?Q;_;8_99
M\)?#;PAXB\9ZY8_'7X.:]J%OH&D:QJ*>'O"F@?$OP^WB#7=><G'A[PYX1&6;
MQ2V-@'//3^BN)<4L%PUG+Q[22X,<FVTDDDVVVVK))-MO1)-O9M?%857QF3_U
MO9'^P31117^.A_2!_![_ ,'>O@B]L/B[^QE\0A!<_P!D:Y\./B;X)^T_\PY=
M3\/^+?#>MIYF"?G*^-02>., # R?XZ:_UQ?^"B'_  3Z^"'_  4@^ UU\#/C
M4-;T273M:?Q;\//'WA.4KXD\"^-%TFZT2Q\0Z7!^]35-%F35IX/%?AV62UM;
MZ,JL\EO.MEXAM_X$?VSO^#>G_@HA^R=J.L:GX-^'MQ^U#\*K5]2NK+Q_\";+
M6?$7B@Z?AF6+7/A4W_%S/#\VQ&D>#PG_ ,)EX1CC*M+XT3<!7]U_1V\5^#(<
M'Y1P5GV=1X;SK(*DG2J2DHTJL:LY3AR5)-1YWSN+@Y1E=+E4U)'Y1Q?PUC98
MUX_!7:;N]+VZ.Z_KJG9GX445HZQH^N>&]5U#0_$>E:EHFOZ7>?8M8TG5K/\
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MM2C*/)*+6CA*+U4DW_0^6X7ZEE&68-W3C3C%JW1:_JT^S19HHHKYL]$****
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M%_6/_37-735SWB.UEO\ 0=?TN$XGU/2M4L;,?[<^EO$H]OG8].>:_G(^T/\
M%(HKM_B/\./'WP@\=^)_AG\4_!^M> ?'_@_5QHWB/PIXLM/[-U+0M3/((/3!
M'0C(/'//'$5_L[A<4L:EC\ U*,DI1E%J491DE*,HRBW&491<9*4924HN,E)I
MIO\ F<*_UI?^"/'/_!+G]A$?]6X_#P?^4E_\:_R:M-TR_P!8O[#2M)L+G4]8
MU.\TNST?2=)LSJ6IWVIY &BZ'T[D ?7KD5_K>?\ !+;P+XO^&7_!.[]C3P#\
M0?#U_P"$_&WA/]GOX9:7XE\+ZO8+I>K:%JL>A1-)I6JZ1O":5JT#R^3=1 #R
M[I'1VW+L'\D_2WQ<5PUPC@')*3XPYE&ZYG&/"--.2C?F:3E%-J+C%R2DTW%/
M] X _P!]SK1VY-_N\O(_0RBBBOX8/U@_SDO^#K__ )27^!#Z_LD_"\_^9.^+
MU?S*5_5!_P '8WPN^(5A^W#\)_C!=>#_ !'_ ,*O\2?LX>!/ VC^/O['(\-7
MGCSP]XW^,.M:[X)&N,$+:\GAW6-$\2IX:( E0"1 RDFOY7Z_U*\$,5#%^%7!
MZA)24>#Y0O%J24HSE&<79M*497C*-TXR33BGH?@7$B:XESF_G^2_3;R"O[&O
M^#/[_DL?[:__ &2OX._KXN^(0K^.6O[4/^#1;X7_ !#TW6_VO_BYJOA#Q%IO
MPV\5>&_A9X1\,>--4T;4K#0/%?B;P[KWCPZ_I/AW6)W0>()?"C%+?Q=)AEBN
M[BWW#&<>?](#%Q7@_P 7*4HQYI*,>:48\TGQDVHQNX\TGRRM&-Y/E=HOE=M^
M$TWQ%E/_ &]?RO&2N?W$4445_F*?NP5S/B[_ )%+Q3_V+^L?^FN:NFKGO$=K
M+?Z#K^EPG$^IZ5JEC9C_ &Y]+>)1[?.QZ<\T ?XI%%=O\1_AQX^^$'COQ/\
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M**?B\19-_;.!>"=]'I?9;JU_73S9_D(T5^JG_!07_@CS^V=_P3U\1Z_-\1?
M>H>/O@U;W3OX:_: ^&FD:SXC^&]_I495=%_X3A/O?#_Q"LA6-_"_BH;5<A?
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M4[;7O$@CUSQ#K]S;[/#1O!X8\("UA?Q2TI\42>*S+!_3.TH4.HY\M.PP.O\
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MSE)JZXSC=73:]R%DU=M72NKI76J36I^.\?\ _(WC_@B%?:G_  33_P"4BW[
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M/ARR3,.G:3I,*QQ!?ER^H-M>5Y26+S R#:J^6FE\)OA+\,O@;X \-_##X/\
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M=;T/Q!V(Y!Z8SZYKF*_H=--)IIII------)IIIM------IIIIM--_$A1110
M445]&_!#]CS]JS]I.YT^+X"_L[?&'XKVNJ7GV,ZQX+^'/C#4/# '4_VYXY)'
MACP_QU[CZ8KBQF:X# 8&68YCG<*<(*\IU)PA"*6[E.<X0BO[TIQ7=G1A<*\9
MHKOR6K=_35W]#YRK_76_X)60/!_P36_8*@FB$#K^Q_\ L[2LH).&D^%WAMRI
M!Q@A0IP.S ]:_C0_8E_X-9/VK_B7KWA;Q5^V5XF\)?L]_#BVU:QOO$7P\T;5
M=)^)GQ@\0:9;:V1-H2+X963X9^ I?%7AU7"^(D\7>,YO!YUN01^!"R/M_O[\
M,>&M#\'>&]#\'^'+&VTCPYX4T?3/#WA_2[4+'96&CZ/80Z1I6E1KDXB@MTBB
MB&"3Y:JQ9@"W\,?2:\1.&^+:60Y%PMF\N(:?#T:DYUK-4TW%0IPC-V4YS;G*
MT4THPUES/E/U+@K)<7@GFV,QSLYM**ZM:N4DNR76^KT6UUUNWY@><XP/?_/-
M?R1_\'<G@F]U#]D?]F'Q]!;7,UEX/_:#U7PWJMU;G_1;*+QW\-O$D@:0'G ?
MP8V%YV$\G+<?UO%B"GN"#]!GC\N*^5_VM?V4_@_^VI\!?'_[.?QOTRXU'X?^
M/[1%NY])O6T[Q!HNIZ+JUMK6A^*/#VL+&S:-K_AK7HTN;.XC1W25=KGRFF@;
M^?O#_B##\'<=\*<5XF/M/["Q<:[BM&Z<K4ZO+JKRBGSQ5TI.#6[BG]7G.%_M
M7*,SP3TYH<JM_,O>5_Z[-NR=O\=:BOZ-/VX/^#:C]NG]FO4-7\3? #3$_:U^
M$/V[[5:W7@&W33?B[X?T\!24USX6D@Z\QW I%\+5\5W!49:",@JO\^7C#P3X
MX^&_B/4/!WC_ ,'>+? /C#2P#J_A/QMX;UKPWXFL!_U'-#\0=C_6O]2^&..^
M%^+\(\7PMG<>(9J,92IMJ-6$9?"ZE)M5:=W=)SIQ3:DHRDTS\,S/+,;E'^_+
MK\FUTNM'\G^9S%%%%?5'FA117T;^SS^R'^T[^U?XA@\/_LX_ OXB_%^^%X;.
M\O?"_A[6-0\+Z!J8Y_XGGCEB/"WA[ Y_XJWQCGK7%C,;E^28"68YE.G2IP3E
M.I4G"G3A%6]Z<ZDZ<(QNTKRG%:ZRU1T87"O&:)-]DDVWZ6NW]Q\Y5_8E_P &
MT'_!);Q/XA^(&D_\%$/C]X5O-&\ >#[39^R[X?U_3Q87OCKQ.(SI+_&&YT=H
MY([?PSX;@1E\&2.H_P"$Q\82KXX5XY_#%GYGT#_P31_X-=]*\%:MX<^+W_!1
M'6-%\;ZS87NFZSHG[-/@R[_M'P-8ZF(U<R_%'QGD/XE$9$L4W@_PFT?A:.=$
M\SQCXMLYCX:@_L>TO3M+T/3K?2-*L[33M,TNUCL]/L=-LXK*PL;&.-4BT_3X
MHO*B1%6*,@($3"C"ICY?XR\;_I!Y#CLES3@CP^G&4<3>/%O%]U?%1Y'*4*-W
M&\90^*5FG3<DDXS<C]*X:X1QN%QCQN<:M6LM];V3=MM>E[MZ+RZ>BBBOXY/T
M8_D^_P"#N C_ (8/_9W [?M7:)^OP7^,1K_/HK_16_X.I?A?\0/B-_P3V^&_
MB#P-X0UOQ58_"G]H_P +?$#XASZ!:QZA_P (KX"@^&'Q=\/OXQUF-22=!L_$
M.O:!:7&,X.L(&"L"*_SJ:_T;^B_BH_\ $)J4%*+=/BSBN$TFFXR]A2:4DFW%
MN+4DI*+<6I)6=W^.<;?\E(NSC&S[[ZK^O+1W2*_6;_@A9_REL_8J_P"RI:K_
M .JP\?U^3-?M!_P0!^&/Q#\=_P#!4S]F/7_"/A+Q#K_A[X8^)-3\6_$/Q#IF
ME:GJ'AKP/X?F\&>/(8-5UG6YF2/09KB>2/PE!&Y'G3.D0+,W/ZKXDXJ.#X"X
MPYFHQ?!O&*;E)17O-16K:6KDDKM7;2W:3^<R)7SC)[>7YH_U.****_R//Z&/
MX/?^#O7P1>V'Q=_8R^(0@N?[(USX<?$WP3]I_P"8<NI^'_%OAO6T\S!/SE?&
MH)/'& !@9/\ '37^N+_P40_X)]?!#_@I!\!KKX&?&H:WHDNG:T_BWX>>/O"<
MI7Q)X%\:+I-UHECXATN#]ZFJ:+,FK3P>*_#LLEK:WT959Y+>=;+Q#;_P(_MG
M?\&]/_!1#]D[4=8U/P;\/;C]J'X56KZE=67C_P"!-EK/B+Q0=/PS+%KGPJ;_
M (N9X?FV(TCP>$_^$R\(QQE6E\:)N K^Z_H[>*_!D.#\HX*S[.H\-YUD%23I
M5)24:56-6<IPY*DFH\[YW%P<HRNERJ:DC\HXOX:QLL:\?@KM-W>E[='=?UU3
MLS\***T=8T?7/#>JZAH?B/2M2T37]+O/L6L:3JUG_9NIV&J?]1S0S^>"._.*
MSJ_K4_/@HHHH **^S?V6_P#@GK^V?^V=J>GV7[.'[/?Q'\>Z/=!B/&PT<^'/
MAM9X&2NL?%#7O^$2\-NQ .$C\7,[' 52<5_:I_P2X_X-J_A5^S#K'AKXX_MC
MZWH7Q\^-6DS66K^$?AUH5K<1_!/X7ZP% ;5'&KLFH?%7Q,02C2^)TA\(VS>8
MI\(>)[U(/&,GYAX@^+_!OAY@W'%YNZN?J2B^"J;4G&4E=*JTVJ2LTW*KR^ZU
M)0G=*7MY;PUG&;:M\J2^)WMOZ?EVM='&?\&U_P#P2:\4?LY>&]1_;C_:)\*W
MGA[XL_$WP]_8_P "_!.O64FG:I\/_AAJWERZWXSUG11'*-$\4_%1C$T5IR_A
M3P<OE*&3Q5<A/ZYMPY8#D*/PY_\ U'\.U,  "@G .3QV_GUQZ<?@:7/#^G!^
MG/\ G\J_S/XRXOSGC7B3-.)\]DG6Q4N;W;N$:<5I"G?7DA!**;LYU)5)M)SM
M']LR[+,)E>$6"P2LHMZMZW;M>7F]_)61, !P*\X^)_P[\*?&#X:_$+X3>-;!
M=<\&?$[P=XG^'OC'29BH&H^%_&VBS^']>MRSJV VB:O-'D+D;AC#@&O1%;/!
M^M/) Y-?-)QH1NKVO^1Z)_C:_M;_ +,OC[]CS]H[XN_LW_$NW(\4?"CQ=J?A
MH:J;$Z7IWBSPN>? GC/158 KH'BOPY_8?B=D(# Z]@@$5\X]*_T[?^"S?_!&
M/P1_P4U\&:=XZ\$ZCH_P]_:H^'FAS:-X&\>ZE93MH'CCPPD[:Y!\-?B9%I")
M<76@?VPDDGAKQ)&\EQX-EUOQ!-:6DK7CA_\ .Q_:F_8P_:@_8Q\;7'@']ICX
M+^-?A?K!O?L>CZOJUF=1\#>+,D$CP3XXT#'AK7R,\CPK@C'(S7^G'A!XOY1X
MB91E%.IF_)Q]"\7&5H^TY>6]:DD[3ISNI>[=TVW3J*#C%S_"^).&L7E6+NKO
M([[);>3[-?BM>NGS!1117[8?-A7ZS?\ !"PX_P""M?[%1]/BEJI_\QAX_K\F
M:_J3_P"#:+_@GW\9_'?[8W@K]M'QMX%\5>$?@7\%O"OBS6_!WB?Q#I&I>';#
MXF^.?'?@K7? &B:-X)6Y_<Z_X;\+:!X@UGQ%_P )7X;*P&;1_"D;$&15K\Y\
M6,^R_)_#3C#%YC4A3]MP;]7I\\XQ<ZM:,X4Z=-2DN>I)N3C""G.2A)J-HRE'
MV^&L-B\5G&4/![1]YNVBBM9-OI9+5NR/]#T@JR<?=_\ K'KSZ_C7\M__  <T
M_P#!.;6_VG/V?/#'[67P@\.-K7QA_9CM=4_X3'2],M3)J7BSX%2YUS6"RMQJ
MY^&'B%#XICAPL<?@[7_B:@/GS!6_J2 4GDG)_G[Y[_G]>>$(X)/0'&#SZGZ'
M&.W^%?Y?\)\5YAP1Q%D_$^2SC"OD-7VL8N_)+D23IRMJXNFY1E:[3Y9+6.O[
MEF.7X7-<++!XR+E&5GIHT]=5\_UN?XEU%?W7_P#!6[_@VK?XN>(/%'[2/_!/
MV'PQX:\<Z])J_B/QW^S1JMUI7ACPMXOU:-2TFK? _7I0/#/@+Q)XEPT3>&O%
MRP>#9Y=9GD'BWP+&F*_BW^./[.WQV_9J\8W'@'X^_"7Q_P#!WQ?:_P#,*^(/
MAO6?#8U#!Q_;6A$''B#P[GC_ (2GPGZ'H17^H7A]XI\'^(F"6-R;-W#/FG?@
MJ35TXVYK:VG%=)PO%IQE[O-RK\-S+(\9E.N-U71J]OD>,4445^B'B!117[-?
ML*?\$*/V]_VWM9TC5(OAK?\ P!^#-SLO+SXU?&W2=6\-V!TQSA!X&\"%AXI^
M(+O@B-%_XHV0J53QOX/;@_/Y]Q/DG!^"^O9[G4>'$W97>LFDWRQBKRG*R;48
M0G)I-J+2;73A<+C,9_L6!5_1?U][MN?DKX0^'WC?XAW7B"R\$>%M;\6W'A?P
M?XG^(7B3_A'[/^TO["\">!M&&O:[XTUP_P#, \/>%/#N/Q./2N/K_3*O?^"1
MWP(_82_X):_ML?!O]F/P9JGC[XU?$S]DWXS:'XN^(FI6G]J_$GXM^)S\--?M
M]'TF-(UD?1?#T$\T,'A+X:>%1&+9-L@?Q/XUENO%UW_F:U\-X9>*N'\4'QIC
M<HI>RR'AQQ]FI23J2@X-N<X1NJ=Y74(.4I<JYI-2?)#TL\R3_5[^QOKKNW>_
M:]]K]>EWIKWW97]LG_!GGU_X**_]VH?^@?M-5_$W7]Q7_!G]X$\7:;X*_;K^
M(VH:'J5MX&\7>(OV>/"7AOQ'=G_B6ZSXJ\"Z%\7]8\<Z-HZ_\\_"L7CSP<6)
M. =<&"6X'C_2,<5X.\7\S2O+@R,;M+FD^,:K45=J[:4G97=HR=FHNW1P5_R4
M64OM"I?TY)ZG]IU%%%?YH'[J?@Y_P<B_\H@?VDO^QC^ W_J_?AU7^857^I5_
MP7W^%_Q%^,/_  2I_:8\'_"[P?XC\?\ B_S/A3XEMO"GA321JWB:_P!(\$_&
M?X?^)/$$VCZ-M#:P_A_0-)UGQ(+=L[Q8[X]PX7_+5K_0'Z*&*B^ \YP*DG)<
M8PE**:YH\].+CS*]US*+<;I*23<6[.WY)QZK9M#_  K_ (/W7L%?1_['7_)W
M/[+'_9R/P(_]6=H%?.%?9_\ P3U^%WQ#^+?[;'[+/A+X;>$/$7C/7+'XZ_!S
M7M0M] TC6-13P]X4T#XE^'V\0:[KSDX\/>'/"(RS>*6QL YYZ?T5Q+BE@N&L
MY>/:27!CDVVDDDFVVVU9))MMZ))M[-KXK"J^,R?^M[(_V":***_QT/Z0"BBB
M@#_.2_X.O_\ E)?X$/K^R3\+S_YD[XO5_,I7]5'_  =C?"WXA:=^W#\)_C/=
M^#];_P"%3^)/V<? OP[T?Q^;'9X:O/'>@>./C!KNN^"5UD#Y-=3P[K6B>)8U
M/_+-4"[@":_E7K_4KP0Q4,7X4\'J$E*,>#Y0O%J24HSG&<7RMI2C*\9*Z<6K
M.*>A^!<2)KB7.;[Z_DK?UV"O[&O^#/[_ )+'^VO_ -DK^#OZ^+OB$*_CEK^U
M7_@T2^$_Q$T[5/VPOB_JGA'6M.^&OB?PU\+O"'AKQIJ>C:G8Z#XM\3^'];\?
M/KNC^'=9F(BU^7PG@CQDS;MLFN^&?EX->=](#%QCX/\ %RG*,>><81YI1CS3
MEQDW&$;N/-.7)*T8\TGRRM%J,G'?A--\193;M*_DG&2O^)_<'1117^8Q^[$
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M_P#P08_:[_8,\3Z]XK\$>%/$G[0O[-)N]3O?#OQ4^'^CG4?$_A'32@;9\5?
M_A\#^P"O!/BD8\& 8;@,O@ROPSK_ %*X9XGX9XOP7]M\+9S_ *P[73TE%N,9
M*,XOWH246KQDE)7U6C9^%8G+<9E&,^I8WN_^'OLUZ!1117OG.%?ZTW_!';!_
MX);_ +"F> /V<_AX/7KI (_7_&O\M?\ 9K_9:^/?[6WQ.T#X3?L^_#3Q%\1O
M%VN7FEV9;0-' TS0-+US_F->.-=('ACP]X=(/_(T>+#R0,C(&?\ 77_9B^"U
ME^SI^SG\"O@#9W[ZO;?!7X0?#;X8KJ]R &UK_A _!V@^&DU=^I#SC1_.3< R
M9V_P;C_&_P!+C/,#++>"LBYX_P!N4>>O6BFG*-)TITHRE'62C.<I<K:M)PER
M\UG;](X PV*6,SC&RVDU%>M[V7?;\5ZOZ#HHHK^)S]0"BBB@ HHHH _C)_X.
MW?V;O&_B?X?_ ++W[4GAW3+G4O"/PPU'Q]\-?B/<VENT@T!/'7_"/ZQX#UO6
M=P!'AT^(?#VM>&I^2/MGB+0<,QR3_"[7^TYXI\*>%_''AO7/!OC/P]I'BGPG
MXDTO4=&U[PYXATB+5?#VM:5K"F/5-+UG1M4\V#5K>XCWJZ20F*1)I(]BY97_
M )'?V^O^#5WX<_$*[UWXB?L$^.[7X/:_J%Q]LD^!_P 3[K6-3^&3.A*[O WC
M58O$OBOP,)0GF#P]X@M/&5A(SA;6;PB@^7^OO 7QUX<X:X<RO@?C2V0159^S
MXRI1<I4XU9<ZIU803<'"4I^^DXN$HN2BU(_..+>$L9C<;_;& UDEK'KIHFN^
MRT\G:Y_"+17W]^T__P $L_V^?V/)-7N?CI^S!\1]%\+Z6NI7UY\0O#NC_P#"
MQ_AK_96B@$:T?&W@#_A+O#7AW*D';XN7P81GZX^ :_LS*\]R3.<$L?D6=1XD
MB_M0E&47\XN2NNJ;NMFD]#\VQ.&QF$_WZZ?G_7KT"BBBO6.<***^K?V<OV$_
MVP/VMK^VLOV;_P!G;XG_ !7MKP[5\0Z#X<&F>!K)CT76O''B$CX8Z Q[#Q7X
MOW'/ KBS7-<!DN!>89CG4>&X15Y3G*,(Q7=RDXQ2N[:R5VTE=M)]&&PV,Q;_
M -AU?E_7Z'RE7ZR?\$KO^"2OQV_X*9_%*&TT/3]4\!?L[^%=6TP_%_X[7-D3
MIUEM!)\%>!0,GQ#\1>N% )\&$@>/ Q(4_P! O[!'_!J=%!=:-\1?^"AGQ"@U
M&"WQ>+^S_P#"'5)-M]N5B-)\>?$]1YT4*%")?#?PP%O& <Q^.Y20I_LB^&7P
MO^'7P:\$^'OAK\)_!/ASX=_#[PI8#2_#OA'PAI&G:!X<T+3D :.*VTNV$$<2
M)C.53>Y+,X.XL?Y9\4_I.91EF"GD?AVY9]GB?(^-Y0:4;IJ3I*<4JDEHHR<7
M2YFK^T2Y9?;Y'P3B\4_KN=M=^6^K5^O]7]-#C_@!\"/AG^S3\)/A]\#_ (1>
M%]/\'?#GX7^&M.\*>%-"LD2,6VF1;R9M4D1';5]>UZZEFUSQ3X@>7[1XH\42
MW5Y>W$]U-*X]Z8Y4'&,G_'_"@LIQD$X_S[4[A@..*_A*M6Q&)Q$L1B)7;YFV
MY<TI2D[RE)N[NVVWKN]M;'ZTW?<6BBB@1\X?M%?L[?"/]K#X.>._@/\ &KPA
MI_C3X;?$#19-$UC2KM(3-8Y>1]-UG193%*VB^(/#EVD&N^%]>MT%Q;WD4+KL
MPA;_ #.O^"K'_!'+]H/_ ()H?$'4=4FL=:^*'[,.NW9_X5Q\=])T<'3;!3C'
M@SXID$KX ^(71U*C_A#/&BLC> ]I/C+P5X-_U2SA?NOL^O4Y_//0<G%<;XQ\
M(^%/'/AK5?!WCGPYH'B[PIXEL)-(\0>&?%>C:9XC\.Z]ITJA9--US2-:CN8-
M6MWPS&*>.2.1U#.I*_-^G>%_BUG?A=F,IX&$<\R)RA+$\)UI-4:L8QY7*FE/
M]W6245SN,82C%1JJ7+"</$SOAW!Y_%*::EJDUJ]=>VO6]KOMU3_Q8J*_O!_;
M[_X-8/AC\2+W6/B1^P1X\L_@MKUX+_4+OX)_$B36=6^&]YJ$JGR_^$*\9VSW
M'BGP,,H=VA>(H_&5A(TB+;R>$41W'\G7[3__  2U_;X_8WEU"?XZ_LT?$;1?
M#.EC4[^\^)?A_2!\1OAN-*T159=:/C3P ?%GAOPX2K!BOBY?!K ') '3_0/@
MCQ@X XWC&64YS[#/9S5./!==QI2=26U.//-1J3E;W%2E4<[7A%ZJ/X[F/#6<
M94KXOWEKK'5676^NWG;?TO\  =%%%?IYX@4444 %%>[_  ._9@_:*_:9UT^'
M?V??@C\3_C#JYO197A^'_A#6/$6EV'/_ #'-=./#/A_()_Y&LCOZ5_2-^Q7_
M ,&K/[2_Q/N=&\5?MI>/]!_9T\!$I>7?P^\$WFD?$;XVZ@C&,G21KZ1R?#/P
M&@1RRR(OC2(NACE\'1?,Z_%<8>(W!7 LG3XHSN,JJCS^PIN-3$2C9M..'A)U
MGS6:BW"$&]JFC<?2R[(\XS5<V#RBRO9MJT5KUD[1\]V_)'X4?\$X_P!C#Q[^
MWE^UO\*/@%X0\.W.I>'=4\2Z7K7Q@U6T_P"07X3^#NB:V!XYUC6M;'.6\/$+
MX(P.?&NO^%Z_UXH(8K> 01((HH$VJHX4 #G'7C)R23]:^-?V-OV&?V8OV$?A
MP?A?^S9\,+#P/I<K17GB'7[F:;5?&OCC5[::56UGQEXTU@2^(=>E*R"2.)W'
MAWP\DWV7PE:6ELL<*?:9*A3C\>GUX]">.,]^_6O\ZO&'Q1J^*.=Y55PM/V&3
M9!">'PE.<HNHU)\\ZE3D<HQE.48<M-.;IPA>4W*;4?V3AS)(\/X)P;;<K-V6
MF]K7>NFMMM]%9!V ^O\ A^' _6OX#_\ @[MY_:K_ &51Z? #Q,O'/_-2-:^F
M>M?WY<9R.@&?Q[=.O)'?]*_D3_X.<_\ @G5\</VG/#?P1_:9_9]\$:Y\3-=^
M#.F^*?!GQ1\ >%=/U#7O&D_@;6M1M]>T/Q?X<T&W9CK9\(ZT-8;Q;;:"1J$E
MGK;.HEAMI'CT\!<TR_)?%/AW,<YG"G0A.I&4G)1AS5:;A23E)QC&]1\JYFDY
MRC"_-."DN+,/BL7PWFT,'K4Y$VNME).5M'V^[7I8_@8HJQ>6=]IMU<6-]8W.
MFZCI=Y]BO;2[L_[-U.PU3W_+IG&*KU_J,?A04444 %%%% !1110!_>I_P:'W
M5_<?LV?M=V4\?_$FL_CKX*O;*<V_E^9K#^"5BUOZA4T?1^0258@@$@5_7RXW
M>;_M(>ONPX_(5_-Q_P &Q7[,'Q$_9]_X)^>(/%WQ+\/ZKX3UG]H+XP:U\1O#
MOAS6['^S=7B\$:-X?\/>!]#UW6=*&UK>Z\5:SH?B#Q);$,I?PA<^%<_*,U_2
M0>$<D_P<\]>1W_E]:_RG\9<;A,V\4^-\;@I*5*7%6)::U2=)QA)76FDE-.ST
M::W3M^_<-X;ZKDV50V?(E][NG_7<>=H ;DCG(.,\8X^I_J*_EQ_X+?\ _!"6
MU_;<AUK]J#]EK3]&\.?M4:#I2?\ "4^!LZ;H>@_M!:7IDA9O/UMTV^'/B[_8
MLLL-GXIUX3:;XMM[7PWX*\:36]BL?BFP_J/X<=@H'N>I_P ^X/Z)@ #!XZ8Z
M=.>>>?U^M?)<+<4YOP5F]'/<BK2HYQ1DI*4;<LXVY94ZD9>[*$H][2C)1G"4
M913EW9CEV%S7"SP>,BY0EL];Q=]UY_UK<_Q5O&W@KQA\,?%FO> ?B+X5\2>"
MO''AC5_[&\1^$_%>D:SX<\2Z%J9)_P")-KFB:_Z^A[<\Y%<O7^LG_P % ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7PQ^%6F'2/AC\-_ 7P[TD6PMQI?@'PCH?@RP*J00##X>M+10 0,84LI^;<6
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M]%_K]QW_ -%GQCKO_P 97C?P_P!H5OD>9_9&3?\ 0KH_^ K\/^#<_.'X??\
M!)?_ ()K?#*ZL[SPE^Q%^SI!>Z?=F_L=4U_X7:!XTU>QU$@[M2@UKQQ%XEND
ME4<HXE:1'.[<2,#]"='T32O#VG6^DZ-IMAI.E6B;;33M,LH["RM5Y)"Q1*L?
M)Z[47@ D<9K23DY$F?S[>G4_EZ58.  "Q!]1G_\ 7C\OPKQ,9F&:YFF\YS.O
MG,FDN;$5*E1Z7MK5KUKO5O='5A\-A<+IA5&*UVV_])3'T445@= 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>>#_  3!<C ),D?AW0[42@G)!8$CMA:]XJ/(3@<D]?Z?Y_\ K4X-E23V]/\
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M#_L^_"+PAJPP>K:KX=\+03'C/\>1]*^LNG1#QZ@GZ<< 4[#_ -X?Y_"F$>K
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M5Z*[6WV]4<^(PV&Q6F*C&2_O+3_TEM'XA_\ $.?_ ,$;O^C07_\ $@OVJ?\
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M#P1T_K_G_P"O13KUZ-J^&E)2T:<)RIRTU5IPE%IZ;7Z#6CO^:NON/R0\>?\
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M &_\1OV//V6OB!K@'.K^,_V>/A'XGU;G_J*>(/"MS/\ ^1\]<"N4A_X)G_\
M!.R*6&>#]@G]BRVF@_X][BW_ &6/@:DB!AR4=? 8*<?W<#T.:^YQM/1@?;*@
M_P#H7'Y49 _A)_X$/Z8JO[6SZBO=SWB?Y<5<42OY:8W3\+WU,_8X;^6/W02_
M)?F<EX.\#>"?A]I1T+P)X-\*>!]*&;G^R?"'AO2/#>E[CD;UTG1(K>'/4?*G
M)^5222*[2BBI- HHHH **** /CWXW?L0?L<?M*WIU+X\_LO_  ,^*^JE %\2
M>,/AIX7U+Q,I4 !4\6/:#Q"B8  2.\4 '([BO@G5O^#>G_@D#KVI3:O?_L=Z
M?;WEXI:ZATKXV?M(>'=+8^AT+0?C'::#^"VW'7FOVJ4@CY9I,'U [^N6SS[U
M-G X&_I][&3^/^<UZV6\5\7Y+36%RCC#C#(Z:^&&%XIQM'33:$,1%=-K)))*
M*222YL3@,#BW_M66TIOKSJ,E\[J/]?>?CSX$_P"""O\ P25^&UU<:AX=_8N\
M#7UQ.!O'CKQ=\6OBM8D^O]E?$;X@^++4CU"Q+Z@CO^D?PJ^ 7P0^ NAIX9^!
MOPC^&/P=T% 0OA_X:>!_"O@C26]3):^'-$M(6^K(WMP!7L6U.H&1[DG/Y8_K
M2$L. 4'/' _J#^E<F:<1\0YDK9QG?$^>6_Z"<57KVNNGM<1*]OG^IIA<-A</
M=82,8WZ*ROZZ/[^JW+5%%%<AJ%%%% !1110 4444 %%%% 'P_P#&3_@GU^PU
M^T;?7VO_ !O_ &2?@+X]\5:M;-:W_BW6OA9X43QQ=(!G:WC?2K2#Q:JD@@*G
MB,!5&-R\N?A[4/\ @WD_X(]:I?:C>W/['ENMQJ=PES>+9?'+]I;2K$SE<EX-
M-TGXS6]II@."0(;>% >"3P*_;-,'@3R<]B%[^N#^')]JF!QG!#>[8/\ +_Z_
MO7L99QCQADU/ZIE7&'&&102]V.%XKQM%VNMH0Q2[=;=%\-HG-B<!@,6_]JRV
MG-_WE&7XN,5YW=_-'Y'?#C_@A9_P2<^&CF;P[^Q5\--2<7/VO=\1-5\?_%S]
MYC[Q'Q:\5^,<<\E,8'K7Z6_#OX;_  ^^$_A?3_!?PN\!^#?AOX/TJ,V^E>%/
MA]X5T7P5X9L4*EE72]"T"&VT*$GG BA0@@JY!!6O0D(/1\^G7].I_P *G;&
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MS(0/Y7^ESFV#CPCD>6IIU*G&-:48\R4G&E2<G)+JE*=.,GHHN4=6W8^_\/\
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M:RN=+;;O^EAU%%%,0U5V^YKR'XG? [X.?&_1CX=^,_PH^&_Q=\/L-RZ-\3_
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MYL/4J4)+F[RHUZ#5TE=<W32S.?$8;"XE6Q48R\GK]R<7HNFWF?B'_P 0Z/\
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M !.^$GP[^(9)YP5;Q/X=O&9SCACNSTR>!7T,6PH([^O^?:FY#\'@CI_7_/\
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M+G["W[%'Q]NFU;XS_LG_ +/GQ*UIEW#7_%OP?\':KXDZXPNO3:$VOK@]56[
MYX7K7Q#XO_X(!_\ !(CQM=QZCJO[&GA2QGMP1''X2^(OQS\"6D9/<Z5X$^)7
MAJU8]L&'L<@G-?LJA&,":0CW  .>Q(/'X]._I4ZGZ'COC\^WZ5[&6\5\89-!
M1RKB_C'(HINRPO%6-H[^4:\==M5/IHDCFQ. P.+_ -ZRVG/_ !*#_&R?S^^Y
M^'__ !#H_P#!&[_HSR?_ ,/_ /M4_P#S\:]K\%?\$5/^"5W@2.&'1?V'_@M?
MI;V_V1/^$UT+5OB5MBP/DS\0]=\6'\RSC(^?C-?JG@=MF?\ >7^F:7#>B_\
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M\.]2.N_#[]CC]EGX?ZP0<:MX._9X^$?AC5,>O]I:#X6MI@,>LH_"OK_ ]/\
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MPQJPQW.J:%X7@E"G@<M],5]90PQ6\:Q0PB**(85>=H&,]<],'O4VYCWQ^'^
MS1UZMG_OK_"IK8NO526(S!NVW/4G+6UKWJ5:KO;KHS3V:;U7R<?_ )&*)J**
M*H84444 >1?$;X,_!_XS:*WAWXP_#+X<_%KP^R970/B=X%\*^-=+'.<_V3XC
MT.\MU. >L>>H]Z_/WQU_P1'_ ."5?Q BFAUO]B#X,Z>EQ]__ (0>TUKX;Y'M
M_P *\UWPMSWXR/Z_JJ,DC.QO\^V.](T<9^]D8SR#Z^W&/SKJRO/,[RV[R?.>
M),E;M=X?%5Z3=KM?!6BM+O>W6][F6*PV$Q*MBXJ7E*SM^$7\S\0O^(='_@C8
M>!^R"_X_M!?M5?\ S[!77>#O^"!G_!(SP-<S7NB?L:>#[RXN/LF^3QCXZ^,?
MQ%8^6?DR/'_Q&\4*,=&. "!U.<U^R6!_>;_OE:3'/#-^>/Y5[%;CWCO$?%QG
MQB_^[MQS_P#2\14./^Q\G?\ S*Z/_@,5_D?'?PP_8 _89^"UVFH_"O\ 9$_9
MS\!:P(Q OB+PW\%?AOIGB-@01M.OQ^'5UYSR>&G(SA@-H!KZ[M[:"".&"&"&
M&" #[/!!A550#C:N  ,$D!?4DMUJX6/][/X8/^?H32%L#EB!]2?_ *Q^F<^U
M?.XC'8K$-XG%YE.HFW)RJ5)3NVK7<JDYMNUTM%IT/0]E%]%?9:6?W**7X^I/
M1110,**** &JNWW->0_$[X'?!SXWZ,?#OQG^%'PW^+OA]AN71OB?X#\+>-],
MSGC.E>)=&O(E/7[L>37KP*G@?EC%.K.A55!?[+NMN23376ZDFGT[V[W0[N]^
MOF?D#\0_^"%O_!)KXF2>;XD_8M^&FG.;D76[X=:M\1/A&?-(^]CX2^+?!N?4
M)C&>M>;_ /$.?_P1N[_L@2?^)!?M4C_WMIK]OMH'\3?DI_D:,?[<@^G'\C7T
MU#CWCK#?[KQGQBO\'%N/A\O<Q$?U^77S?['RA[9717_;L?U/S<^'7_!(_P#X
M)I_"^[LM0\)?L2?L])J6GW9O;35=?^'6C>--1L]1=2KZG!=>.AXDFBGR,I,C
MF1&^9<A1C]#M'T32O#VG6^DZ-IMAI.E6B;;33M,LH["RM5Y)"Q1*L?)Z[47@
M D<9K23DY$F?S[>G4_EZ58.  "Q!]1G_ /7C\OPKQ,9F&:YHG+.<SKYS)V][
M$5*M1Z-V5ZM>LM+MI75NYTX?#87"Z851BK/;_P#93U^?ZCZ***P.@**** *T
ML2S(8Y4)5A@X!'XXY!_R.E?)_CG]A3]B/XC:F->^(W['/[+7C_7% W:MXS_9
M[^$/BC5R3Z:IK_A6XGXX_P"6P^@S7UF!Z,!^)']!3\/_ 'A_G\*BC6Q-%6P^
M.FN_+)J[M;5TJM-W];E7:VT_KS3/AB'_ ()G?\$Z8I89X/V"?V+;::W'[BXM
MOV6O@2LJ@CDH_P#P@ \O/_3, <Y&.#7UCX.\"^"?A]I7]A>!?!OA7P3I:YN/
M[(\(>'-)\.:7N.0772M$AMX<]1E4Y/ ).0>S 8]"0._.!3690>N?Y_ER?SK>
MKB<PKKEKXZ<UV<ZLUO?5UZ]2^NJT>NJM8Y50PV'V27G_ /LQ5OZW+%%%%9G0
M%%%% 'S_ /%S]F+]G;]H&R%C\=/@7\'OC%;Q@_9D^)OPY\'^.!:_+A1$/$6A
M7+1(IYV@\G[W%?G;XV_X('?\$D?'U[#?ZU^QCX,T^XMU)1/!/CGXO?#6Q4XZ
MG3/AY\1/"UKC/(!BZ  DU^Q +'@E#SSP/Z ?K2[4ZD8'L2,?GG^E=F5\2<19
M:K9/G?$^2?\ 8/BJ]"^G54\1&WWK;2QEBL+A<1IBXQEZV=OO2OZZ'XBV?_!N
MW_P1XTVZM[ZV_8[MWE@G^UHM[\<OVE=2L1-G!=],UGXSSVP'?;]G*ANI/*GZ
MY^%__!,/_@G9\%]0L=7^'?[%G[.6@:[I"$Z/XEG^%GA;Q'XGL@5Y;2O$'B*U
MU_Q%!@<@17J-DY /%??P1ATD>GA'Z^;_ -]8)_'C/ZUW9CQCQAFD7#'\9<73
M@TTXSXKQLE);Z\^(J/>VJ=U;2QR8?+\!A?@RR":ZJ*=OT>FFWGN06=G;6=M#
M96D$%K;VBJEM;VX&VU #< 9QP6/ 49R1SG-:%%%>*>@%%%% !1110 5R/BSP
MAX4\;Z)>^%_&GAOP]XO\.:FG_$R\.^*M'T[Q!HU^"""L^DZRD]LX!)*"1&6,
MDE5#$FNNHH _)GXD?\$2/^"5/Q3$H\4?L2?"'3?. WGX:V/BGX,;OJ?A!XD\
M$$'\NE>/?\0Z/_!&[_HSR?\ \/\ _M4__/QK]O\ #>B_]]C_  I,#OLS_O+_
M %Q7TN'X^X^PL5'"<;<8TU%))?ZW\4QLELKQQ,7ILM7IU.#^S,J_Z%5/_P
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M^(''V%C]7PO&W&,(K11_UNXJBDK6WCB(Q?DW)GG/)\H>O]DTM>RBK^B3O?\
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M$\*Z58:%X<T;2M"T/3+7[-9:7HME'IFFV<8 Q'%I=LD<,:=QC+DDEOO%JZ(
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M>2O\3D^W_P"O_/-+$8O$U$HXC,).VJ3J2G;S_>U:NN]WN[].I&DJ/PW[Z?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '^5I_P<$?\I@?VS?\ L8_A=_ZS[\(J_'*OV-_X."/^4P/[9O\
MV,?PN_\ 6??A%7XY5_KCX;_\D)PA_P!D;P=^;/YXSW_D<9Q\_P V%?WW_P#!
MHC_R:3^U+_V<;IW_ *K+PY7\"%?WW_\ !HC_ ,FD_M2_]G&Z=_ZK+PY7YK])
M[_DTV>_]E;PE_P"FYGM<$?\ )2R_PO\ ])/ZZ:***_S8/VT**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?=I;ZI=?N7GKUTGHHHKX$]D**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /Y<O^"IW_!N=X?\ V\_CMXE_:D^$?QX/
MPB^+?CBRTJ+XC^%_&OA>7QGX%\7ZKX=T3P_X;T76-(GT77;/7_ <ZZ)X>TA'
M:)/%0?"N+6 .(Q^'T_\ P:6?\%#A<3&R^-7[&TU@UV3;W-YX]^.MCJ4^FC&Z
M*?2(/V=YK=91G!5)G'!.<%2?]$=2A!*DG'X#'3CKTI>H] #W.<G\!Z>WK7ZS
MP]X\>)G#>2K(,JXAE1R2"2A"=*A52A%)*-YI32BDHQ=WRQC%*]DU\WB>%,GQ
M6,^N3IRYV]4F[:WUNG^%C_/L\!?\&C7[;&IZH8?B=^T?^S!X1T0=;_P3>_%[
MXDW_ #GIHFO_  \^$I_\N_OCZ_UO_P#!+W_@FQ\._P#@F1\ ;KX+> _%NO?$
M#6/$OB.3QO\ $?X@>(;:"PG\5>+VT?P[H4MUHFBV[RKX8\.?8M$S9^&VO?%$
M\9GD,WBFX8PA?TRX()4\=,XY!^G^?U%(Q55RQP,'CVZ'Z>G^'%>9QIXO^(/'
M.7K)^*<]EBLG@U*-)0I8=.HM8\RA>ZC=M<TN6Z4N5M*W1EG#N495/ZS@J;BW
M?6_-IY*R_KJ6:***_.3W HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K@?'WP_\$?$KPIK'@GXF>#O"OQ!\$Z[9?8_$7A+QQX?TCQ1X8US3]N'
MBU?0]=AET*< Y8B6!P-H=4 157OJ* /YY/VC/^#:7_@F%\<KC4-<\(>!O'O[
M.7B'4;K[;>W?P3\8OI_AR5@.57P3XXM_%_AC0=(P'9K3P7:^$B3]QP, ?E!\
M0O\ @T!N%U._G^%/[<4*Z45SH^C^/O@D\M_8D#(&N>(_#_Q$2'7@QX4R^$8\
M]2%!S7]ML8_O87_@>X_D.<?F.@XI[OM&"^T?[Y4_AQ_*OT7(O&_Q4X?@J.6\
M88GE5_W.*:XEBU9*\OK5.<XI;K]YJVV[L\7$\-Y+BG:654WYJT7\M6F_DOD?
MYZGB7_@TD_;SLKXP^#OC_P#LDZWHZV63=^(O$/Q@\,:A_:.?OC2M#^"_BNV*
M@8;B<M@\+G@8W_$)3_P4<_Z+3^Q3_P"'+^//_P!#G7^B)L_VV_+_ .RHV?[;
M?E_]E7UW_$S'B[_T->%?_$-P'Z_\,>=_J3PY_P ^I?\ @;_R/X$_ 7_!HE^U
M1J<<'_"SOVK/@)X0G./M#>"O#WQ$^)(M\C=^Z_M[0?A(2!Q]\)DD<$<C]"/@
ME_P:0?LM^%FTN]^/7[3/Q?\ B]>6EX;RYTSP%X9\'_!7PO=@J0-.FMW;XH^*
MG@C<#>J>-5=P-JLN=P_KJW?[?YK@?B>U+@GG"'WP:\;,_'SQ7SB-I\:8C523
M=+V5.5I*VCA"<DX[QE&S3UUV-L/PGPYA?AR>%_[UY+[N9+?H? ?[+7_!,O\
M8=_8N@MY/V=/V=_ _@7Q%;V:VO\ PG]U93>,?B1<*ISF7Q[XVG\2^*&) (>/
M[>$88!1L'=][NN]03R>F/0\=>N?7C\Z1<@G#Y!XX/&?J34A?Y>>O?(&,?C_@
M*_)<;F&.S;$SQN:YI4SFK*[YZTG7J7;NVY2JU&TKOEBG&,>D59'T=+#PPRY<
M/%)+7KM]R_)_>2T444%!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 45YQ\1?B3X&^#WP]\:_%7XG>)M+
M\&_#GX<^%M7\8>./%6OW::=I?AWPQH.E2:QK>MZN[;4C6WMXI'E7:&.&"!I&
M$;_Y>W_!4+_@XE_;G_X*,?'67X"_L4>(OB/\#?@%KGC$?#WX7?#_ .#M[K6A
M_&[X[7^NZPFA^'=3\;:WX=D7Q5'K'C$RHL'PP\&SPVJ1>(IO!GB\>-[@JZ@'
M^JA17^69XB_X-E?^"X/P5\!:K^UYH'CWP3+\6['P^_B[Q%X0^%'Q^^):?M1+
M$R+K&M:6VJVWA/P]X9UOQ)!%"7N-$\,_%J[:X?2X4@:>\-NS_J7_ ,&Z'_!Q
M#X_\47GB#]CK_@H/\69_':>%/AAX^^('P4_:#\;WI?QG=:3\)/!^L>.O&_P\
M^*_C?6;E!XG5? >@Z[XH\&>+/%(/BEAX?\26OC+4KIKCPGY !_?117^-3;?\
M%,O^"N'[8_[6!\)_!C]MG]MGPUXV_:9^.]_:?#CX0> /VK/C[IOA7PGJ7Q5\
M8R#P_P""_#^DZ)XQ*Z%X7\*+K$.C6RI;JOA7PEHCAH_LUM$K?Z__ ,)/#WB3
MP1\+?AKX3\<^)+CQ/XS\->!/!/AOQ=XLN[O4K]O$GBS1M&TG2=?UG^T]7_TF
M63Q+KL;W($H$DQF=B#,6\L ]7HHHH \8^+_QZ^!_[//AA?''QZ^,_P */@CX
M+:Z&G#Q1\7_B-X0^&OAB74F(5=+M]>\<Z]X<T-KE@0D, FWR<':&Y/S'_P /
M8O\ @EI_TDL_8$_\3(_9P_\ GC5_GW?\'CGCCQ=K?_!4+P'X%U3Q'K%]X3\"
M?LN^ +[PCX7NK^1/#VA7_CGQ;XZE\0:IHNCW+I:?VUXE_L/18_%'B&UC6ZND
MT7P_9SR%/"U@M?R-T ?[Q?P:_:&^ _[0_AV\\6?L_?&GX0_'3PQ9W)L[OQ1\
M'/B/X.^(_AS^T58*T$FL^!M=\2VT,HZ&*64R* V<J#CVVO\ #?\ V(/VUOC[
M^P'^T/\ #W]HO]GGQGJGASQ7X,U6QN-4T""X,?AWXD>&089]:^&/CW1HW%MX
M@\,>++</:[[C=)822'Q5X6%MXSM+*YMO]H7]D?\ :6^'7[9'[-WP:_:@^%%X
M+WP'\:O VB>-=$C.V74-"DU?;_;O@_6@JK$OB#PCXBAU;PSXK2+:HO\ 0YV4
M,#'* #Z;HHK\_P#_ (*DZCJ&C?\ !,O_ (**:]HE]>Z-JVB_L+?M::WI&JZ9
M>/9:E8:KI'P"\>W6DZGINJQ,K02Q211ND@?S4."FUBX< VO%W_!2K_@G1\/?
M$6H^$/B#^W]^Q7X+\7Z%<O9:YX6\5?M4_ CPSXBT2X95W1ZQHNN_$"#6M)E
M9,QS)'(%:-R@#<?1OPO^+_PI^.'A.U^(/P3^*OPY^,/@;4E(L_%_PU\9:#\0
MO"U^ I+&'7?#&MW6@LQ .4248''T_P &"O\ 0%_X,>]3U&ZTW_@I=H<MY=S:
M1I=_^QSKEAI$ESBPLM5UJ#]IVWUG5HM*):!9IH]"T19)8XTFD71]&"JH560
M_OSHHHH *\M^*7Q>^%'P4\):AXY^,?Q*\!_"?P3IJ">_\7_$OQ=H/@GPSIXP
M"#)KOB2YM=%5@"#M$Y9<[BI8[J_E-_X+K_\ !S3X6_89UKQ7^RE^Q$OA7XG?
MM5Z3<2Z'\0_B%KBR:U\-OV?=1#GS-,CTF.>$?$'XF0JK*WAY9E\'^#+I8AXQ
M3Q5(9_!@_P ZK]I+]K']I']L#X@W?Q2_:C^-/C[XW>-[[Y8M6\=>(WU)=$@D
M9"-,\.Z,GE^'? ^@(T# >&/"UMX:LPQ+_9T.TD _UG?B7_P<5?\ !%CX3ZI!
MI7BS]O?X9:E-,;O,WPS\'_&+XV:29%V,5&O?!_X<^-?#ZL5OT?$TS&49&7,;
M,K/AO_P<:?\ !%7XJZI-H?A?]OOX<Z7?1( MS\2O!'QD^"VEY)'(U[XO_#3P
M9X>+#HP6?*G@I7^.-10!_O0?"SXS_"+X]^$;3QQ\#_BE\//B[X'U1-UIXN^&
MGC#0?&_A^Y&2,)K7AO6KJV=R!RHFW;<9&#7K%?X3/[-_[5'[17[)OQ%L?BK^
MS5\;?'?P0\?62PJ?$/P_\07^C-J,'G+NTC7](51X>\2Z)M8L_AWQ1:7?A>7#
M>9$1E:_UA_\ @WZ_X*A>-?\ @J9^P]+\3_BWH^CZ=\;_ (5?$G5OA#\4[K0H
M6L-!\5ZGI.C^'?$NB>.-%T)I3)H,'B;0?$,<$D 9(%\5Z%XB$"PVZ6\9 /V_
MUK6=(\.:3J6M^(=2T[1=)TNS:]U+5-5O(]-T^QL8AM:34M5G?R8T3+'>SJ,X
M!SN#-\2:A_P5+_X)DZ3>WVFZO_P47_82TC5--N?LNH:7JO[7?P TS4;"_57!
MT_589?B'YD<L3;DDC=#L:-E*R;#G\JO^#L1Y$_X(K?'G@?O?B?\ L]+[<?&/
MP]*/_0$_P]/\E>@#_>W^'WQ(^'GQ3\,:?XN^&/C[P;\2/".IJ_V#Q9X \2Z)
MXS\-Z@% 9VAUWPY/=:&[8(#;92.0H /%>@U_#Q_P9$R2-^S+^W'&9-T:_'?X
M8@1'MN^'6KE\<?\ +0JG_?L^O/\ </0 4444 %%%% '%>,?&WA#X?:#?>*?'
MOBOP[X)\-:4BF^\0>+=:TGPYX>L202/.UC6G@@C+;3M9GPQ!51D$#XSM/^"J
MW_!+^[G@M+3_ (*1?L#W4]Q.;>TMK/\ :^_9_EEN6"CY(XX_B*[._/&U6W$!
M5W,P%?S9?\'LLDO_  PY^R2G2/\ X:QOOJ2OP<\>[<_@\G/^%?YJM '^^?X>
M\0^'/&.C6'B'PMKND>)M UNT%SI'B#0-6T_4M)U#3W'+Z/K&CRNL\*G!\V*5
M@&#!7RN1U-?R[?\ !H9)++_P1S\*^;)Q#^T'\=$@R>0G]JZ$YR2>0)&(QZ,1
M7]1- !7%>,O&'A#X?:#?^*_'7BKPWX+\+:8F_5_$'BO6]'\.^'+- OR?VOK>
MNRPPQ!APDAD3=T/<UVM?Q:_\'L=W(O["W[)=J))5BN?VLOM-S;CTA^#OQ "
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MXT+6_B+::.S-XMUWQ'$+?P&ESH5I'!XD\;1^)1X*_P Z+X@?$'Q]\6O&FO\
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MY$?#'_!T]_P6\T#7=+U35?VNO#WCBPMKAWNO#/BO]G#]FRR\/:O%O,8BU=_
MGP=\)>*%C=6$A/A_Q5;3C8!YI7>&_:G_ (/C?^1Q_P"";/\ V+?[67_IW_9_
MK^"N@#_<;_X)W_M%^*_VM?V&_P!E;]I7QM8:!I7C/XT_ _P+X_\ %FG>'+'4
M]-\/6?B77M%CGUU-&@UB::Y321JI9HHC+<%%89FG3RW:_P#M[?'/QA^S%^Q#
M^UG^T9X%BT6_\<? 7]G7XP_%CPA9^*+'4]3T&[\3^!? VO>(M$@U_2-'F\/3
M3Z/)J^CQI-(EQ"[P;Y8IX<AC\\_\$._^40W_  3J_P"S5_A;_P"F-:ZO_@L?
M_P HGO\ @HY_V95^T;_ZJWQ'0!_FM^)_^#I[_@MYK^NZIJFE?M=>'O ]A<W"
M/:^&?"G[.'[-E[X>TB+>(S%I#^._@[XM\4-&BJ9,^(/%5S.=Y'FA=@7^MO\
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M/64\#^#=2331DL(O" ^)SO)YB^1,WAZ2-<2([??W_!\1YO\ PE'_  3BZ_\
M(J?M8]/3^V?V:M__ (]_2L__ (,>)(O^$U_X*.1 1";_ (1/]ETY7[S!=9^/
MF?J!N4GT!7I6])VA-]E_DOU _P!"6O\ &T_X+_?LZ6O[)W_!7/\ ;+\!>%-,
MNO#WA3Q1XZ7XM>$+:WBV6(\,_'3P9H?CS7ET8@D#08O$GC+QGX6"*J[6T26$
M@!*_V2Z_RA/^#MGXL>#?B/\ \%@_'/A[PDA74/@]\$O@_P#"CQW=QHY&I>-8
M]*\0_$-I@Q55_=>'/B=H/AN7 X?07^9@NXX ??O_  9M_L!V_P 5/CU\6O\
M@H5X\TK[?X>_9UC;X2_!=[B21@?C)X[T-I?'FN1[D94G\(?#;78;<Q!U#?\
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M&7[O_!4;_NR7^?[6]?P"U_?U_P &,OW?^"HW_=DO\_VMZ /[_J_GH_X.*?\
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MXEZGXBTB5"S+JJ6OQ(\1^-O"4I&U2T<WA653AP8\,Q7^E^B@#_+]_P""GO\
MP:8_M8?LHZ/XA^+_ .QAKVJ?M@_![28[J\U3P+:>'$L?VD_"^FQG(,/@W03+
MHOQ:C7+F1O!B6WB^8F,0^ F4,T?[S_\ !FG\+_''@7]@[]IC5?&/A?7?"EOX
MI_:Z\3V6D#7M'UO0-4OY/ WPS^'WA[Q!B'68+5/+\,^)CK/AF1<2&+Q7H_B:
MPFD:?PQ.L?\ 8W10!_-5_P '9O\ RA8^.'_95?V>O_5IZ!7^2Y7^M'_P=F_\
MH6/CA_V57]GK_P!6GH%?Y+E '^CC_P &0W_)LW[<W_9<?A;_ .H-K=?W#U_#
MQ_P9#?\ )LW[<W_9<?A;_P"H-K=?W#T %%%% !1110!_%G_P>S_\F/?LA?\
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M^CQXB\0Z9X6\/^(O%.MSK:Z1X6TC5-=UFY !^QZ7H^EMK&J2YSR%@@=V&02
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MC*>'],C,K(=8T;PK:6^O?$OQC##(DT_@WP1XE@MMUP84K_&@^*OQ6^(?QO\
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M_"W_ -,:UU?_  6/_P"43W_!1S_LRK]HW_U5OB.@#_$PK^Z7_@Q^_P"2U_\
M!0/_ +)9\!__ %,/B%7\+5?W2_\ !C]_R6O_ (*!_P#9+/@/_P"IA\0J /\
M13HHHH **** /\>7_@Y@_P"4X7[>7_8R?!C_ -9G^#U?FO\ L%?\GO\ ['7_
M &=1^SI_ZN3P-7Z4?\','_*<+]O+_L9/@Q_ZS/\ !ZOS7_8*_P"3W_V.O^SJ
M/V=/_5R>!J /]T*OGGX__LV? /\ :L^&UY\)?VCOA-X!^-7PZU6>&\O/"WQ$
M\-Z;XATU=1C);2=8TIYE9]"U^)Y=T'B'P]Y-U"QNUBFC5V"_0U?R\?\ !U)^
MVC^T_P#L4_L(?"/QA^RI\8/$?P5\9_$#]I_PY\/_ !5XN\*V^D)KU[X'N/A?
M\6_$<VA:3K&L:)=#0[N/Q!X?T.<7'AO[-XLBCTJ,K=?9S?+, ?2VB?\ !LW_
M ,$/?#FMZ7K-G^PCHUW?:=>-=P0Z]\=/VIO$VE@*K,HUC0_$'QL\1>&]<5M\
MC>3X@M);5\KB(>6@7]J/AA\+/AO\%/ GAWX8?"/P'X6^&'P[\&Z6NC^$_!'@
MC0-*\.>%]"TV$?+#HNAZ+''#;("5WK&J,[$R-ND9F;_%KTK_ (*V?\%3=,O]
M.U*#_@I#^W;/+8W:WEN-5_:T^/&K6+&*0D+J.DZ[X^GT34T8' AFC=&Y\S<0
MH7_4+_X-Y/VIOCM^V9_P2P^"?QL_:1\>7?Q,^*5]XQ^,7AO5?'&J:1HUCJ?B
M'3/!WQ,\0Z/HS:H-#@M="$RZ"$T5G6VB:18O,$DTBM*0#]TJ*\Z^)_B"^\+?
M#CQ_XGTK[.=8\,>"/%.NZ<MV-RF^T;0;G5XMP.<@M"FX8X."3MSC_&"\9?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.&T[0/CKX?T%8_$.A!1)%]FB^*GP]T6)DEE653XM\ >&[6%9)O%<CQ?W,_\
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MNM(T/X__  =UO6+?5C(=)_LS1?B1X;FG76",A=&:-3'<%CM:+S$/1 W^[50
M4444 %%%% '\U7_!V;_RA8^.'_95?V>O_5IZ!7^2Y7^M'_P=F_\ *%CXX?\
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M (AO^T?_ /.YKR;XV?L9_MA?LVZ)H_BG]HO]E7]I7X!>&M?U:30_#_B#XU?
MKXE_"O3=9U14;6'TO2-9\<^%O#$>N:U'"KR/#!YLJ1*60+%Y6P ^5:_T^/\
M@RP_Y19_'[_L_CXH?^L^?LO5_F#U_I\?\&6'_*+/X_?]G\?%#_UGS]EZ@#]Y
MO^"MOCG4?AY_P2\_X*!^--'U#^R]3TK]CG]HC^R-6@"E['5]5^&GB#1M"E0,
MK 2+<:M"R/M)215D7D*:_P 2&O\ :D_X+B?\HAO^"BO_ &:O\4O_ $QM7^*W
M0!^[W_!&7_@L':_\$@!^U;\0?#OP8@^,?Q@^-O@CX<>#OAO'K>L#P]X(\(2>
M']:\1ZYKVK^-=6BQXDUJVD,VASIX3\-Q6P\6!9,^,/",EO$;JU^T)_P<B?\
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MM'?LW>+[;QK\,/'%KFQG9TM-6T35(2B:WX2\7:*!))H/B3PQYXAOM GE,D;
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ML:SJ=Y8:3I6F:=:OJ-_J&HZN=NE:7I>F*&EE>:4^5''$&8NX5%W-&K_[4?\
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M0 5^5?\ P7$_Y1#?\%%?^S5_BE_Z8VK]5*_*O_@N)_RB&_X**_\ 9J_Q2_\
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MQ,FA^,(&7Q'X)\+>#YO#$TWA;_A'/&C^/'C\4W/@^#^(:PBLI[^UAU.:XM+
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MD2V>@?'7X5Z#JGB0:HVR0?V,/%GPWT'QGX>NRD<#W=YH?P[BDBE\I"WX&_\
M!63]JGX/_MQ_\%!OVE_VK/@5X6\:^"?A?\;/%?A7Q/X?\._$'1M&T#QEIU_'
M\._!F@>([C7M,\.>)O&/AJ.;Q-XET75_$D7V7Q3=HT-RTC2QM^[DL_\ !'CX
MBZK\*_\ @JK_ ,$\_%VF7%O9SM^U_P# 7PSJUW.NH,P\,>//B3H/@7QFS!3@
MY\,^(-;#,5958L61RICH _VQZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#_ "L?^#Q/_E+Q!_V:S\&/_3Q\0:_
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M5_K1_P#!V;_RA8^.'_95?V>O_5IZ!7^2Y0!_HX_\&0W_ ";-^W-_V7'X6_\
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MOX(^,]/USXC^.M6\-^(_VH[KPYJ\%Y%X&\$Z#J\7B#0?A9K$NAS;[?Q]XO\
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MR\66.D:_H"_\)%X.U'^R]:TI-%\2Z!X9\0JR,59))[4)+&\7E;HY%W_YO/\
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M4'P ^!?PR^#2^(2(XWUYO /@K0/#<^M&$!3&_B271FUUXE4"(R;-HP*^E:*
M/\]O_@^-_P"1Q_X)L_\ 8M_M9?\ IW_9_K^"NO[U/^#XW_D<?^";/_8M_M9?
M^G?]G^OX*Z /]J3_ ((=_P#*(;_@G5_V:O\ "W_TQK75_P#!8_\ Y1/?\%'/
M^S*OVC?_ %5OB.N4_P""'?\ RB&_X)U?]FK_  M_],:UU?\ P6/_ .43W_!1
MS_LRK]HW_P!5;XCH _Q,*_NE_P"#'[_DM?\ P4#_ .R6? ?_ -3#XA5_"U7]
MTO\ P8_?\EK_ ."@?_9+/@/_ .IA\0J /]%.BBB@ HHHH _QY?\ @Y@_Y3A?
MMY?]C)\&/_69_@]7YK_L%?\ )[_['7_9U'[.G_JY/ U?I1_P<P?\IPOV\O\
ML9/@Q_ZS/\'J_-?]@K_D]_\ 8Z_[.H_9T_\ 5R>!J /]T*OXX/\ @]:_Y1P?
MLT?]GL^&/_5!?'JO['Z_C@_X/6O^4<'[-'_9[/AC_P!4%\>J /\ ,FK_ %H_
M^#3+_E"Q\#_^RJ_M"_\ JT]?K_)<K_6C_P"#3+_E"Q\#_P#LJO[0O_JT]?H
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M%7C[QE(1XC\0Z/I'AR_;Q#)X8BM?#&M75U:3/+;&!?\ 3;HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1NOB4EJFG7VI?![]G>RU7PSX<N]10RG6M&UCXJ>)8H_%>N^'G$8BC;PSX/\
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MB1:1X0\!:G.OV:75/A9\,5G\3:'H&N0)$KV_BSQ+>>+/%]NZ"?3I_"IN)XF
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MI[NYN[EKFYN;@G=>,6R6;KDDEL\X ;'   _HV^&O_!J!_P %JO&^L/I_BO\
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M^RS\)M!^%/@>WFBU;5AIL;ZAXE\4^(A!%HX\4>,O$6M"7Q%XH\0>1:1(VO\
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MPI\0*P  0+9L&( /4FL_P)_P:H_\%LO&'B"'3/$?[,W@GX6Z;]G-RWBKQ_\
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M4$E99-.U*.7RI%(,+D[]C9!++$!\OZS?\$R?^"S_ .VM_P $L/$>H_\ #/\
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MO: +EO' UE-?2S\4K&='*O9E+A9T /\ '.K_ %H_^#3+_E"Q\#_^RJ_M"_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M45RWBFZO+#PSX@O]-DMH-2MM(U.\LS<\(NHQ:9(\.<$<@J,XW$G'\.:_C8_X
M*!_\%4/VFO@%^TC\2? _AR?P3<C['I=E_P BV-2Z?R.,'UP/PH _M0HK_/?_
M .'U7[7NG:-^XG\ ?:+N\_Z$_1CWZ_YZ?A5?_A]5^V7#_KSX ]?^1/T;_./\
M^] '^A117^>O_P /L?VP_7P#_P"$?HW^%6(?^"U7[7LW^O\ ^$ /&?\ D3]&
M_P ]>,8Q_.@#_0@HK_/>_P"'TG[7W_/?P!_X3FC_ .-'_#Z3]K[_ )[^ /\
MPG-'_P : /\ 0AHK_/7F_P""V'[8GKX ^O\ PA^C9_SVZ<_A1#_P6P_;$]?
M'U_X0_1L_P">W3C\: /]"BBO\][_ (?2?M??\]_ '_A.:/\ XT?\/I/VOO\
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M7^?/-_P6J_:]_P">_@#Z_P#"-Z-GG'?KV]/KQ5?_ (?8_MA^O@'_ ,(_1O\
M"@#_ $(**_SW_P#A]C^V'Z^ ?_"/T;_"C_A]C^V'Z^ ?_"/T;_"@#_0@HK_/
M?_X?8_MA^O@'_P (_1O\*/\ A]C^V'Z^ ?\ PC]&_P * /\ 0@HK_/7_ .'V
M/[8?KX!_\(_1O\*/^'V'[8DW3_A .N.?!^C?Y_\ U=.E '^A117^>O\ \/JO
MVO/^J?\ _A'Z+_\ $T?\/JOVO/\ JG__ (1^B_\ Q- '^A117^>_#_P6D_;$
MQG_B@/\ PC]&]?7^7XT3?\%I/VQ,9_XH#_PC]&]?7^?X4 ?Z$%%?YZ__  ^J
M_;$\W_F0/7'_  A^C=/\^^>W3FK$W_!;#]L3U\ ?7_A#]&S_ )[=.?PH _T(
M**_SSO\ A]9^V+_U('_A'Z/_ (U9A_X+2?MB8S_Q0'_A'Z-Z^O\ +\: /]"B
MBO\ />_X?6?MB_\ 4@?^$?H_^-+_ ,/L?VP_7P#_ .$?HW^% '^A!17^>_\
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M3T5_GOP_\%L/VQ9I?^9 [_\ ,GZ-[^W/<'U(]SF?_A])^U]_SW\ ?^$YH_\
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MP_7P#_X1^C?X4G_#ZS]L7_J0/_"/T?\ QH _T(:*_P ]_P#X?5?M>?\ 5/\
M_P (_1?_ (FC_A]5^UY_U3__ ,(_1?\ XF@#_0@HK_/?_P"'U7[7G_5/_P#P
MC]%_^)HF_P""U?[8G7_B@/7_ )$_1NY_SGG)]J /]""BO\]^'_@MA^V)Z^ /
MK_PA^C9_SVZ<?C1-_P %J_VQ.O\ Q0'K_P B?HW<_P"<\Y/M0!_H045_GOP_
M\%I/VQ,9_P"* _\ "/T;U]?Y?C1-_P %I/VQ,9_XH#_PC]&]?7^?X4 ?Z$%%
M?Y[W_#ZS]L7_ *D#_P (_1_\:7_A]5^UY_U3_P#\(_1?_B: /]""BO\ /?\
M^'U7[7G_ %3_ /\ "/T7_P")H_X?5?M>?]4__P#"/T7_ .)H _T(**_SWO\
MA]9^V+_U('_A'Z/_ (TO_#[']L/U\ _^$?HW^% '^A!17^>__P /L?VP_7P#
M_P"$?HW^%)_P^L_;%_ZD#_PC]'_QH _T(:*_SW_^'U7[7G_5/_\ PC]%_P#B
M:/\ A]5^UY_U3_\ \(_1?_B: /\ 0@HK_/?_ .'U7[7G_5/_ /PC]%_^)HF_
MX+5_MB=?^* ]?^1/T;N?\YYR?:@#_0@HK_/7_P"'V/[8?KX!_P#"/T;_  H_
MX?8_MA^O@'_PC]&_PH _T***_P ]_P#X?8_MA^O@'_PC]&_PH_X?8_MA^O@'
M_P (_1O\* /]""BO\];_ (?6?MB_]2!_X1^C_P"-?Z%- !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&@#0\_V_3_Z]5YIO\G_/Y#/J2://]OT_^O10!7_UO^<8Q^?K[]?R/(]_U_\
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MOT_^O5?S_;]/_KT 6)IO\G_/Y#/J2:K^?[?I_P#7HHH //\ ;]/_ *]6//\
M;]/_ *]5Z//]OT_^O0!8\_V_3_Z]5_/]OT_^O1Y_M^G_ ->CS_;]/_KT 6(9
MO\_Y_49]P:*/-F]?U'^-5_/]OT_^O0!8H\[ROQ]O\]<>_3\Z_G^WZ?\ UZ*
M+'VSW_\ ':/.\W\/;_/3/MU_*O10!8HJOY_M^G_UZ//]OT_^O0 9_P"F_P"G
M_P!>C/\ TW_3_P"O110!8HJO1Y_M^G_UZ "?M^']:KU8HH KU8S_ --_T_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=L_C^7/].OT[UCS6?^?Y<_S/X>U '/U8\CW_ %_^M5C['[?^/57\_P!OT_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC]1_.@"S!W_'^E6*KU8H //]OT_^O15>B@"Q11Y'O^O_ -:I_)N/^> _S^%
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M5B#O^/\ 2K$T,'7O_P#6_P /;/IU. "OY_M^G_UZK^?[?I_]>M"J\_;\/ZT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPSEKC5)-FX+\H\L*-C*O^M-_P;J_LB^%/V3?^"5?[-3:?I%M;^,OC[X+T?\
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M;D.E%O[,_P"&O?VCA:9'/D_\+;\8B+KC@1_=]@.U?Z4W_!J^MW:?\$5?A=<
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M\2^$/#6E^./V@_B;X&\-^,?B7^T)KWA6PA\=:CJ?C+28-7F\&>"#):";P'X
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M\+AKI\MV_)IM7\NOEVUT_P C3_@FI_P6J_;2_P"";'Q,\%ZAX*^+/C/Q_P#
M33+K2K7QE^S?XR\6ZOKWPSU?PAYL<^M:1X.T37Q=6OP\\0LIEBM?$WA.*TE2
MY\IKR+Q-:0F"3]R?^"S?_!U%\1/CI/\ \**_X)F^-?%_PB^#T_AZT?QQ^T(E
MCJ/@SXP>.-0US2U>_P##G@$F2T\0_"+P[X2DG-K>^*H5@\?>*O$]K')X2NO#
M?@ZW9O&G\TW_  5 _9V\._LD?\%!_P!K?]GCPG (/!OPV^.?CK2?!EJ6DS8^
M!]:N!XA\$Z:['(EE\/\ AO6=&MW<L6DEBR<9!']JW_!JC_P2'_9OE_9O\'?\
M%*?BUX>T3XM?&+XEZ]XYT7X.Z9XFT7^T?#/P5\-^"/&?B#X?ZYK6AZ/)#);:
MS\1O$^N^'=8=?%DZRCPMX7^S6_A.2TN)O%9OWA(QS[+8YABXJ65.%%W4(\TN
M=1J4H:Z-)/F]]N*LU9IJ+Z<0EDV8_5\+K>2Y7RKE;<>92=XZ.S3O927-U:;/
M\_R7XT_%Z3XC?\+BE^*'Q%?XN&]&JGXL'QSXM/Q(_M(:?_98U;_A.CK!\3F[
M\L;#.+W[1Y)-N)O(_<5_=S_P;%?\%U?CI\<_C'IW_!/;]L/XA:O\8Y?$/AW5
M-9_9T^+OCB_:_P#B2NN>"-#?Q#K?PS\::Y,)+SQ[;-X9T77?$/A7Q5XFFO/&
M$%SH,EM<SW%K>V*>%_UN_P"#I7]C'X3_ +0'_!,/XO\ QVU3PEX:C^-/[,0\
M+^//A[\0Y-,TI/$EGX=?QKH&@^//!LFOLHO7\/\ B3PYJTEQ'X=1U2?Q=HWA
MJ0QR>4KU_G<_\$<=?UCPI_P50_8"U31;G[-=/^UC\%]&:Y8 J=+\0>-]%\/:
M\I4@\'0=7NU*G/!VX/-;\/5?KN-J9(DFHN:M;X)^PJ582BTG;2+T2OHXVDFD
M^?.Z"H97/-,+IRPJ26B;4J<>>RZVEHM7:SO96NO]J\X49;H>YS^.,<>_?C!K
M^*/_ (.!?^#D;QM^R%\1/$O[#W["%UX:?X[:#;06GQL_:!UJTT7Q'IOPFU+5
M=.CG3P+X!T+6$G\+^(?B-:"2 ^+_ !/XGM[_ ,*>!"TG@MO!UYXV6ZNO!?\
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MQP3>(_AMXWU>8QS^/O$"^'2_BOPMXLU\R^+Y8O#WBN/QA>:A+]@N!_<?E%#
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M  0I_P""O6@?\%9_V>=:UOQ1H^B^!_VF/@O>>']'^-W@W1Y9GT+4%UNWNO\
MA'OB+X-23+V^@>+QI&L))H<DMU+X;\2Z-=6DLDUF-/NKG^;'_@Y7_P""H?\
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M_#3PWXN^$'BCP_)X=/AJ[T/34B\+I' (=#UCP;)]G/\ PC'B+P@LWG>"=?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** .1\;?\BAXQ_[%?Q%_P"F=Z_SK/\ @J[_ ,GK_$CZZ5_(5_HI
M^-O^10\8_P#8K^(O_3.]?YUG_!5W_D]?XD?72OY"@#\Z9O\ 4GZ#^533?ZX_
M4?SJ&;_4GZ#^533?ZX_4?SH @JO/V_#^M6*KS]OP_K0!8@[_ (_TJQ5>#O\
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M<?J/YU0G[?A_6K\W^N/U'\ZH3]OP_K0!7JQ!W_'^E5ZL0=_Q_I0!8JO5BJ]
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MWB/PU!X>\5H67:R>($92S(^W^,;_ (.D/^"1'C3]F']I7QC^W=\&?">H:O\
MLW_M$:\/$_Q/OM)M9+RQ^#OQR\03PP^(4\0@B;^R?#/Q7UR1/$_A/Q'*\40\
M;Z]XC\%[K?S/!UKJ/XO?\$SO^"M/[6/_  2M^(&N^+?V>-5\/:OX7\<G3K#X
MB_"+QY9ZIJ?PZ\:)I@?^S=5EM]&US0=>T?Q):12745MXDT"]L[M$N&CNC>P-
M':1XY/C7CLI^J8F;@^:$I*SE'_66"Y9TWK=1DI3C!_%%.$FY+FYN_/,$XX^&
M*P3O%3E*$9<LFN')\JE!RCM4BDE)-\KG!JT>>+C_ +2S1DJ%'8\>W ]_8_\
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M9_\ @W\N/$LG_!(#]AJ3Q;/JMUK,WPHU&Y\[5W+WUQI!\;^*3X<8,[-(8?\
MA&SHZPLY+LF"S%CNK]F!_%GT_J/ZUUX_"O+L7CL-S<SHU)J4FK<TH-TY2M>5
MM5M=VL_1<6!Q"S##+$6VE*&FUXS=[>KC=;Z-6ONV7:>=;NH[KD8//'Y],U_A
M_?\ !2'X+ZA^S;^WC^UG\$;ZQ_LR+X;_ +0?Q1T?1[16+C_A&)O%NKZOX+EW
M# 87'AC5-&G'95E !;;N/^X%NQY?HPY^A)SC\Z_A#_X.Q?\ @CUXT^)>H_\
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M"GA#Q%HBZS=>(9Y9-9UV-=<N8KC7XH/"]M=,(1%X4L4CS=?E3_P>MG_C!?\
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MO?@]X:T?P5X*^+?P7E\'^*/%7BKPOH4"Z/H6E^-/"'C[Q'X&C@UOPWX?72M
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M<MRW-,)A&H_VQQ"IJ*2TJU%&G!)*[:YG[1I67\1I)-I_Z6'P!^$7A/\ 9_\
M@Q\*O@CX(M8;'P=\(_AYX3^&GAFW3<!'I7@K0[;P_;*0Q)!:/2ED?^\Q=CT
M'LAVHN<9).<=LGO^.,^F.WK-@''''4=A^7_UL5&VP]0>GT'Z],#TKYVI6KXG
M$SQ&(?QN<Y6;DY3G)RE*7K*3_!)6'0PZPV&6&PVT=%=]_P#AN]]VW<FHHHI'
M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 <AXV_Y$WQG_ -BQXC_]
M,\U?YUG_  56_P"3TOB3_P!PO_V:O]%/QM_R)OC/_L6/$?\ Z9YJ_P ZS_@J
MM_R>E\2?^X7_ .S4 ?G#>=_^ UH5GWO_ +>-_6M"@ HHJQ!W_'^E %>B#O\
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M %OY_P A[ 'SO\3M-@\KS_\ #T_^L>W:OF^:'_)_S^1QZ@BOH#Q5>>=:_O\
M\NA_7KW^O?M7B\_;\/ZT >?ZQ9_NO4=N<?YS[=/2N/KTC6/]2/\ />O-IO\
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M^6O^?[U6/^67^?[M &?/V_#^M6*K_P#+7_/]ZM"@#/\ ^6O^?[U:%5_^6O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[B2>77->UV=X46Y\1>)9[OQ+/+$K7-S(0S-]"N>?<?\ Z_\ &E#C/W<>X_\
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M6EHOX;)6>-#_ &;#?5<-)I)V]=;W>E[ZOK?76YX3^SI^S_\ #K]ESX)?#/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!R'C;_D3?&?_8L>(_\ TSS5_G6?\%5O^3TOB3_W"_\ V:O]%3QM_P B
MAXQ_[%?Q%_Z9WK_.M_X*N?\ )Z'Q(_[A?\Z /S?G[_\ 7X]:%9\W^J_[?O\
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MBB#O^/\ 2B?M^']: +$'?\?Z5_K(5_DSP=_Q_I7^LQ0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '(^-O^10\8_P#8K^(O_3.]?YUO_!5S_D]#XD?]PO\ G7^BEXV_Y%#QC_V*
M_B+_ -,[U_G6_P#!5?\ Y/6^)'_<+_I0!^;\T/4_]/GI^?'\_P \]JL3?NO?
MI^OY?THG[_\ 7X]6;S_6CZG^1H SO/\ ;]/_ *]:%G#YWX?XG^=9_D>_Z_\
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MS3]5AC\J+4;.QO%!ZCS '*'UPNU0?0B@#8HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJGGP3W..?Y\^^/\ /6OL#X8_$.>:U_L/59_3BZ[_ .>WT/:OGZ&\\.:/H/\
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M/)\K\??_ #UQ[]/SKS0^;_G^?MT[T 9]6*L0V?\ G^?/\C^'M1_9G^U_G\Z
M*]9TW^N/U'\ZV?[,_P!K_/YT?V/_ )S_ /94 8\'?\?Z58JQ-9^3[_G_ $H_
MU7^<YS^7I[=/S *]03?ZD_0?RJ?S_;]/_KU7\CW_ %_^M0!7HJQ10 5_K(5_
MDWU_K(4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^:W_
M  6/_P"43W_!1S_LRK]HW_U5OB.OTIK\K_\ @MS+);_\$C?^"B4\,LL)3]DW
MXP0@P':09/#\T61C!!*ED8@C".^,=: /\5>O]\OP9_R)O@[_ +%[1O\ TSQU
M_@:5_O0_!*6:Z^#WPHN)IYKB>Z^&_@.\NKJX52;R23PAHIDD. ,&1F#,<'YP
MY)8DT >KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3PP>5_I'\\<>_P#GKZ=* //Z//\ ;]/_ *];%Y9_Y_+'/Y9_$XK'^Q^W_CU
M%>BM#['[?^/57FA_R?\ /Y''J"* *]?ZR%?Y-]?ZR% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!FWM[;6-K/>7\T-M9V]J;JYN[IE%E;)&
M!EF9BN5'+'YA@ $'+ '^-#_@IS_P=X? 3]GC6]?^#O\ P3_\%^&_VJ?B+IJ:
MC9ZO\;/%'B#6+#]G?0-85G!B\'#09K;Q1\8$0I,);OPUXI\%>#7C%N_@WQGX
MNBEC=?(O^#O#_@J?XD^#_@SPS_P31^"GB670?$7QG\+?\+"_:8UW1[R:UU2S
M^$,^JSZ+X+^$"/&L"1V_Q.NM$UOQ#XZB!BG?PAHWAOPO)%?>#/&]ZC_YTM '
M[Z?&+_@Y=_X+-_&+6-7U&?\ :\UGX7Z1J%XTECX1^#'@/X<>!=,T!28B-)T?
M6XO#%Q\1Y+2,J_/B7QEXIN#)*Y,KJL87QW1/^"_W_!9'1=4M]4L_^"@?QTDN
M86(9-6NO"/B/2EX.,:)K_AJZT @] &A.0>O8_#7[,G[&W[3W[9GC27X>?LM_
M CX@_'+Q/;BVN]7MO!'A]KW3O"UC=2S"'4_'/B-Q#X7\!:/.^F:G!;W'BSQ-
MX9M[B9HQ!<,-L<WU5^TU_P $7/\ @J5^R'X!U#XH_M"_L:_%+P1\-M%@DO/$
M/CCP^?"'Q*\-^%-,AD!?5O&NL?"3Q)XTB\-:(F\AO$/BAK6VWJ(EDWN@D /W
M1_8?_P"#R#]M'X2ZSH?AW]MKP#X-_:H^' )M-4\:^%=&T7X3?'*S4LF-8W>'
MUB^&'B'RUWD^'/\ A#?!KS'9CQ?" Q'^@'^Q+^W?^S-_P4'^"VG_ !V_9@^(
M5EXY\&74L>EZ]9RA=+\9>"_$<D44W_"*^-?#Q?[1H&O"*XCF6*60))#)&]O)
M*I\U?\-2OU8_X)*?\%,OBY_P2S_:R\*?'?P'?ZMJ'PSU&[TKPY\?_A-9W31:
M3\6_A<C$Z[I,NG7($:^/O"ZRR>(OA[XD,L?_  BOB]7CN';P5XF\5VE\ ?[4
M%%>>?#KX@>#?B[\/_ _Q5^'>O6/BWP#\1O"GASQ]X!\6:9.EWINO>%O&.D1Z
MWH6MZ1(I<-%=Z%JD<\3;=SPR(K( &4>AT 9-_?:?I%E=ZGJE[;V&GZ?;&YN[
MNYN/L5E962!BTDDA98T5%0Y9\$G"J5&U:_C;_P""E_\ P=W_ +.7[.FL>)/A
M'^P1X-TO]K/XD:,UY97?QJ\2:S<:?^SCHNIQB27[3H<FA.GB;XQBWUM8TN)/
M#EUX)\'W%K*I\'>/;V-F>+Y'_P"#NC_@K3XK\.ZO:_\ !+KX$>++G2[>]\-Z
M/XV_:[U[0M75=6NM/\0$ZSX$^ LJQQQS:-;MX;&C_$[QO$.?%'ACQ)\-(6N)
M+5O%=G+_ )_- ']!/QI_X.=_^"SWQDU34[RW_:IB^$.@WP @\)_!3X<?#GP9
MIFFXRF[1M>USPYXH^)"K(,!_-\9SM@ '9\V?G6+_ (+W?\%BK>6*2#_@H+^T
M*?)/GA;SQ'I&H@D\8;S= 8$,"5974@!N=M? WP&_9F_:"_:<\:Q?#O\ 9Q^"
MOQ+^.OC>ZA9E\._##PGK/C74K"PDU.VTD:OK9\/PSQ^'_#\4CQP2^(O$;6_A
MF)I'6>:*-9)(_P!!?'__  0(_P""Q7PP\)WGCCQ5^P)\:)_#^F0&^ND\(GP?
M\1_$R6*Y'_(E_#_Q-XL\6D !FX\,,RE69E 7;0!]Z_LT?\'9_P#P5C^!^JVB
M?%/QO\,_VJ/!UOJ$9N-#^*_PZT7PWXD73=NU]-T3QI\)(?!MP&)(D6?Q9#XO
M*E641MN4I_<5_P $EO\ @OS^Q]_P51L;3P+X<.H_!#]I_3M&.J>)/@%X^U&/
M4I-0D78-7U3X5>-XH[>W^('AZT:X )EMO"?B^%'$T_@N.VS,_P#D)ZKI>HZ'
MJ%WI&JV%WIVIZ;=R6>IZ=J=E+87]EJ"2LLFG:E'+Y4BD&%R=^QL@EEB ^7H?
M /Q"\:?"GQOX/^)GPX\1:SX-^('@+7])\4^#_%>@7CZ?JOA[Q/HNJ+K&C:SI
M$D>UTDMI8T:%"OEDD[U>-S$X!_O<T5^*O_!"O_@ITW_!4K]AKPK\7O%4.G67
MQX^'6K-\)_VA-#TEU_LD^/-$TNVUG1_&FA@$O#H/Q(\*ZMHOB9K4(D?A7QA)
MXI\$PM<KX6,[_M50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7XF_\'$_BS2_!7_!%S]OG6]4
MDFCM;GX7>&_"(^SC.-6\>?%#P#X%T+IRJ?V]K^DB1U(*1 Y(4M7[95_.=_P=
M6ZU_9/\ P1'_ &G[ >;_ ,5+XQ_9UT7]QWV_M _#[Q"1WRI_L/##N2@'6@#_
M ".*_P!SG]@KQ1I7C[]AO]C'QOX?68^'O&'[)_[.WBC1EN[=K*^_LO7?@[X(
MUG1]ZG!5Q;SJ95/RK(Q0;DBR?\,:O]L7_@C-K(UW_@D[_P $XKS$V;?]C']G
M?1OWWIX?^&?A[0/D_P!D?V/\@_A!7U- 'Z9T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?]?_ *U'D>_Z_P#UJ "BBB@ G[?A_6L__EK_ )_O5H>1[_K_ /6JOY'O^O\
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MS[=?RL0=_P ?Z4 >@:#,89;>X_GW[_\ ZR?YU][^#]2@O/"_D<<?Y]^?P_\
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MZ5Q_PK\5>3KMO//^'Y9Z?Y_'OY?\0O%7_"5:SY$'_'O[=_P]A^ [=ZK^&_\
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M]5_G.<_EZ>W3\R@ AA_S_G]3CV H\CW_ %_^M5BB@"OY'O\ K_\ 6HJQ5>@
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M=!GFEM_W']>>V/\ (Z=>M?0'AOP'//%Y_D=?SQGTY_SW]0#P;_A&KC_GB/\
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MWW^<^O7GZCV[T ?#WV.^O"8/L-R>GX#K6A!H,\,7^HN<^O\ G_(]^_Z<:/\
M '29O^6'^/X\9Y_.M#4O@;H<,7D>3T__ %\__7Z<],4 ?FOH^C^=^X\BY]^G
MIC\/_KY/K7K&@_!_[9S<'V_S_G^E?2^I?#'2O#<7GP67VG]/P^G^<5S$'B3R
M9?(@@Q_GC/\ /COSVH X";X)V,,77_/]#^?OZUYMKOPWGLY;CR(.>OX?S_GS
MCKR*^L(;S5;R+SX(/M6,_I_3^?O6/>33_:K>"^L?LQNL8Z']/;I_]>@#X'U+
M1[ZSE_U&>/Y'MTS6//V_#^M?<'C;X;_;/^05!]I-T?S_ /K?A[=J^3_%7AN^
MT&_N()X/^/7_ .M]>.?Y^HH Y?['YW'3]?P_'/7/MWQ6/>68\K]?3C]/_K\=
M>W46=Y!_GCZ_R]>OYU8AAMYO^6_;UQ[\XP/TH \GF\_G\?R__7]VB&'S?\_Y
MYZ]Z] U*RL9O]1US_G_/K[5R$]G/#U_D/7'U]?6@#.FA_>_C_/\ K^@ZU_K
M5_D_S]OP_K7^L!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?X_G_!;OX#_ /!0?XP?\%&?VR_VCOBA^Q]^U+H'@G7_ (Q>*;/P/XKU3X)?
M$M/ [_![P(R>!?A3JFF^,O\ A&D\.2P2_#OPWX?D4PS&.$R-EC,2J_B?\,?
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MXX\._#;X9^!]/O-9\5>,O%6IO8Z7I=A&I99&:7YW>1E*1Z+&KRN[*L:,Z88
M_P A;_@OW^QSX%_8<_X*H_M)_!CX3Z78^'/A-JE]X5^+/PW\,:4T*6/A+PY\
M5?!VB>(]:\(:;I4)CAT+0_"WBN;Q%X;\'>'BS&#P7#X:19!$8@/Q2K]-/^"M
M?[;4'_!1/_@H%^T7^UCI-GJMAX+\=^+['1_ASI.I7DTFH:=\-/ ?AW1/ _@@
MR07**-!E\2>&] B\3W_A^WW1P^*]=\1-^]=LO^?/AW0-<\5ZSH_ASPUIFH:_
MKVO:IIFBZ)H.CVCZKJ6LZKJ\D>D:/I6D:+!%YVK:S-/*(8(X%9Y9B(P3*XW
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M4Y'>1HX]^O?&K04MT2)7N-LQB9AH$KC_ #:: /[8O^#*/XSZQH_[8'[7/[/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R/C;_D
M4/&/_8K^(O\ TSO7^==_P51_Y/G^*'UTG^=?Z*/C;_D4/&/_ &*_B+_TSO7^
M=;_P51'D_MP_%"?_ +!?\CC_ #Z\4 ?G>/\ 77'^>QJO5@_\M_P_K5>?M^']
M: +$'?\ '^E6*KP=_P ?Z58G[?A_6@ \_P!OT_\ KT>?[?I_]>J]% %BBCS_
M &_3_P"O10!8AF_S_G]1GW!K8AF_S_G]1GW!KGZL>?[?I_\ 7H T+R;O]/\
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ME_G^[0 4444 %6(._P"/]*KU8H 2;_7'ZC^=+!W_ !_I1/V_#^M$'?\ '^E
M%BJ]:$,/F_Y_SSU[T>1[_K_]:@#/JQY'O^O_ -:K'[K_ #MHH K^1[_K_P#6
MJOY'O^O_ -:M"K$,/G1 ?3_]??\ ^M0!C^1[_K_]:K$,/^?\_J<>P%;'V/V_
M\>I/L=QZC\O_ *U &1/V_#^M5_(]_P!?_K5H3]OP_K5>@"OY'O\ K_\ 6H\C
MW_7_ .M5BB@"O111Y'O^O_UJ #R/?]?_ *U'D>_Z_P#UJL44 5ZL0=_Q_I5>
M?M^']://]OT_^O0 3]OP_K1!W_'^E5ZL0=_Q_I0 3]OP_K11/V_#^M% !111
M0 4444 %%%% !6A!W_'^E9]:$'?\?Z4 6(._X_TK0K/@[_C_ $K0\CW_ %_^
MM0!8A_Y>/PKL/#=GYUW^_'^?7C_/I7'64/\ I7[_ /I_GKU]\?A[CX;LX/\
M1_('OU_IG\OY=: /7_!_@G^TKO3X(,_IUS]?\:^N=!\'P6=K;P0?Z3<?G[?X
M]#Q7#_#'2/.L+>> ?Z1Q^F?U^GY]J_3CX _ &#7OL^N7W^D_9<GG^F/?\* /
MD?\ X0/Q'-:^=/I5S]FYZV?^>/\ /'2N U[PI/9R_OX,_P"?;O\ IZ\U^O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6W$5IX>M29I7<D^7&LEW'_DP_P#!8G_@LA\=_P#@K;\<W\2^(7O_  %^S?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX_THG[?A_6B#O^/]* +%'G^WZ?\ UZSZ* +%%%% !/V_#^M5ZL3]OP_K5>@
MHHHH **** "BBB@ HHHH L3]OP_K6?6A/V_#^M9] %BBBB@ HHHH **** "B
MBB@ HHHH )^WX?UH@[_C_2B?M^']:(._X_TH L43]OP_K110!8@[_C_2B:;_
M "?\_D,^I)JO6?/V_#^M &AYW[K_ #CI],].WZYJM#_KA]3_ #I?^67^?[M9
M\,W[W\?Y_P!?T'2@#H)^WX?UK/\ ^6O^?[U:'_++_/\ =K/H )^WX?UHJQ/V
M_#^M5Z "BBB@ HHHH **** "BBB#O^/]* "K'G^WZ?\ UZKS]OP_K1_RU_S_
M 'J -"BBB@#0AF_S_G]1GW!K0AO/\_SX_D/Q]ZY_S_;]/_KT>?[?I_\ 7H Z
MC[9[_P#CM5YKS_/\N/YC\?>L>&;_ #_G]1GW!HH V(;S][[_ .?S'X<>U:'G
M^WZ?_7KEH?\ 7#ZG^=6?/]OT_P#KT =!]L]__':K?VC<>HKF/MGO_P".U8\_
MV_3_ .O0!O\ ]HW'J*@FF\W_ #_/WZ=JQ_/]OT_^O1--_D_Y_(9]230 3]OP
M_K1_RR_S_=JO5B@#&F_UQ^H_G5G_ )9?Y_NU7G[?A_6K'_++_/\ =H (._X_
MTHG[?A_6B#O^/]*)^WX?UH L4444 6(._P"/]**(._X_THH GA_UP^I_G6C#
M9^=[?G_7_/6J]G#YTN1T_P C^G?M[]>XTVS]_KC_ #]1S[GWH Y^'1^_^?3/
M^//IGTK0_L?_ #G_ .RKJ/)@AZ<C_(_^OG_"K'^M_P XQC\_7WZ_D <O_8\/
MK_.C^S?^>'TQ^7;\OT&.]=!]CGE(_P#U_IQ^77J:T(;/]U[?Y_,_CQ[4 >?S
M6?D^_P"?]*/*F]/T'^%>@?V;YW'3MCZ]^WKT_3G%5_[&\GC./UQC_/3GICM0
M!YO-IG;/X_ES_3K].]6(=,[9_'\^?Z=?KVKN)K/_ #_+G^9_#VKEYIO)E)^O
M_P"KM_\ 7H SYM,[9_'\N?Z=?IWK/FTSMG\?RY_IU^G>N@^V>=ST_7\?QSTQ
M[]\T?ZW_ #C&/S]??K^0!Q_D>_Z__6HFA_R?\_D<>H(KL/[,_P!K_/YUGS6?
M^?Y<_P S^'M0!Q_G?O?\YZ_3'7M^N*L5L?V=^]_S^?3/7]>V:/L?D\=?T_#\
M,=<^W;% &/Y'O^O_ -:CR/?]?_K58F_=>_3]?R_I5?S_ &_3_P"O0 >1[_K_
M /6JO5BJ] !5>K%5Z "K$'?\?Z57JQ!W_'^E !1!W_'^E%$'?\?Z4 6****
M"&'_ #_G]3CV K0AA_S_ )_4X]@*(8?\_P"?U./8"MB&'_/^?U./8"@"O##_
M )_S^IQ[ 5L0P_Y_S^IQ[ 58AA_=?A_/^GZCK6A##_G_ #^IQ[ 4 5X;/_/\
M^?Y'\/:O:/!\/_'O^G_ZOSX^H]#7F\,/^?\ /ZG'L!7H&@WGD_9^O'Z?T_K[
MT ?HA\);,?V7_CZ?U_7/'6OUH^ /CNQTW0;BQ_Y>/L?Z#N!]!C\>:_(?X)ZQ
M!]EMA/\ \>_Z_P OZ=C[U]P>&_/LXOMUC_GM]?\ /7N #S_]JB'5IO$=Q?6,
M^;?/ _S]>W\S7QO%XUOM2E^P_P#/K_G/X=__ *X-?:'Q"AU7Q4?(_P!)QTZ?
MA_3'XG/>O#X?AQ9:#+]NG@/^<^H]Z ,_PWH^N:E+;S7T'^C]?;\\#'],CTQ7
M8>,-!L8;#SX/^?/_ "?TZ?6NXT'Q5H?V V,$%M]H_K_G]/QK U*#SM+N/;CK
M_G_/TH ^+O%6@_;/M'MGC^61_D^F>:^5_%7AN>&6X$/T]/P[<?Y%?:'BJ\_L
MV6X[^G^?;'3_ "/![RSG\27YA@XZ_P"?\_C0!X/X/\*SB_\ /G[<_P" _D.M
M?5&CZE_9L5O]G_Y=?\_YZUW$/P?GT[PY]N_K[]^G7C_(S7N'[,?P!'Q(\2:?
M8SX_TJ\^P_GR.W Y_P B@#G_  WX)\?^/+6WGTK2;JYM_3['[\?Y_GS7WA\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(/,DV@MEVQ7S#_Q"K_\ !$+_ *-.\2_^)(?M)?\ SSZ_HGHH _G8_P"(5?\
MX(A?]&G>)?\ Q)#]I+_YY]'_ !"K_P#!$+_HT[Q+_P")(?M)?_//K^B>B@#^
M=C_B%7_X(A?]&G>)?_$D/VDO_GGT?\0J_P#P1"_Z-.\2_P#B2'[27_SSZ_HG
MHH _G8_XA5_^"(7_ $:=XE_\20_:2_\ GGU_!9_P<>?L0?LT?\$_/^"A]K\
M_P!E+P-<?#7X8-\ OACXUD\/7/BOQCXUD'BCQ'J_CF+6]3&O>.?$/BGQ*$>/
M0](5(/M7DJD<JPK#EFG_ -?JO\K'_@\3_P"4O$'_ &:S\&/_ $\?$&@#^56O
M]E;_ (-Z])T_1/\ @C-^P'8Z>BPVUS\(=4UJ2,]1JNO_ !+\<Z]K9 Z#&N:M
M,P!QDMCMBO\ &IK_ &:O^#?G_E#5_P $]_\ LA*?^I?XDH _8ZBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH Y?6]=T'PEHNH^(O%.LZ3X=T#2;1KO4]<
MUZ^ATO3+#38^"VKZQK,BQQQY8[FFDC8,51MI<;OB:[_X*K?\$O[2>>TN_P#@
MI%^P/:SV\XM[NVO/VOOV?XI;9BI^22.3XBHR/QSN5=I)5MK*17^;A_P<:_\
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MZT3:W\/_  /KS:9XNE\6P07'A;Q3XMT/P_X,A;4#_P )B/"@!_2=_P %#_\
M@E!;:7_P;7P_L8^'/#^DWOQ+_8[^!7@/XX:'_8_AZ6_^V_&7X513>/OCMKF@
M:.)7F.N?%$>(/C<(26E?SO'CB:.="P?_ #)OV=_CCXJ_9H^//P9_: \ RA?%
MOP4^*7@+XF^'E%W)8I>ZIX%UW1O$2Z==/'@_V1KS:4MM*3"S>2[($&XB3_=H
MO;*VOK6>SOX8;FSN+4VMS:72J;*Y20#*LK!L*>5/RG(( &5!'^1S_P %YO\
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M3_Q,C]G#_P">-1_P]B_X):?])+/V!/\ Q,C]G#_YXU?XA5% '^WK_P /8O\
M@EI_TDL_8$_\3(_9P_\ GC4?\/8O^"6G_22S]@3_ ,3(_9P_^>-7^(510!_M
MZ_\ #V+_ ():?])+/V!/_$R/V</_ )XU'_#V+_@EI_TDL_8$_P#$R/V</_GC
M5_B%44 ?[>O_  ]B_P""6G_22S]@3_Q,C]G#_P">-1_P]B_X):?])+/V!/\
MQ,C]G#_YXU?XA5% '^WK_P /8O\ @EI_TDL_8$_\3(_9P_\ GC4?\/8O^"6G
M_22S]@3_ ,3(_9P_^>-7^(510!_MZ_\ #V+_ ():?])+/V!/_$R/V</_ )XU
M'_#V+_@EI_TDL_8$_P#$R/V</_GC5_B%44 ?[>O_  ]B_P""6G_22S]@3_Q,
MC]G#_P">-1_P]B_X):?])+/V!/\ Q,C]G#_YXU?XA5% '^WK_P /8O\ @EI_
MTDL_8$_\3(_9P_\ GC4?\/8O^"6G_22S]@3_ ,3(_9P_^>-7^(510!_MZ_\
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M7+?P1HLQED>+P'\67670SX9,C)!X];P^;2WA7Q1XNEK_ $GJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y'QS_P B
M9XS_ .Q5\1_^F>>O\ZW_ (*K_P#)ZWQ(_P"X7_2O]%+QM_R*'C'_ +%?Q%_Z
M9WK_ #M?^"J__)ZWQ(_[A?\ 2@#\X)O]2?H/Y5//V_#^M$T/^3_G\CCU!%)-
M_KC]1_.@""B#O^/]**(._P"/]* +%$'?\?Z44D/^N'U/\Z %FF_R?\_D,^I)
MJOY_M^G_ ->K$T/^3_G\CCU!%5_(]_U_^M0 0=_Q_I5BB&'_ #_G]3CV JQ0
M!C_\M?\ /]ZMF'_4CZ'^59W_ "U_S_>K1A_U(^A_E0!G3]OP_K5>M"J_D>_Z
M_P#UJ *]6*/(]_U_^M10 4444 %%%% %?_EK_G^]5BJ__+7_ #_>JQ0 4444
M %%%% %>K$'?\?Z57JQ!W_'^E !/V_#^M%$_;\/ZT4 %6*KU8H SZL0=_P ?
MZ57JQ!W_ !_I0 3]OP_K11/V_#^M% !1110!8@[_ (_THG[?A_6B#O\ C_2B
M?M^']: *\_;\/ZT0=_Q_I110 4444 6(._X_THG[?A_6J]6* *]%6)H?\G_/
MY''J"*KT %%%% !1110 4444 %%%% !/V_#^M$'?\?Z43]OP_K1!W_'^E %B
MBJ]5_/\ ;]/_ *] &A5?_EK_ )_O4?\ ++_/]VJ__+7_ #_>H T(._X_THH@
M[_C_ $HH **** "BBB@ HG[?A_6BJ\_;\/ZT %%%% %B#O\ C_2M"L^#O^/]
M*T* +%%%% !YW[K_ #CI],].WZYJQ9_OI<_R(QC\OPJOY/F_A[_YZ9]NOY=1
MH.C_ +W_ #GTX]ORZ_A0!V&CZ;_Q[_N?P(_F?_KUV%GIM]_:G]E00?Z/QS_+
M\SZ]A[58TVS\F+_KU^N1_GU[UW&FZQ!#%]N\C_2/;@^GT'/7\J .7_X0/R;[
MR(/])N3_ )QCM7<:;\!_%6I1?;H+&Y[?\N?]?S]NU?<'[.OP9@UB*X\8^*O^
M0?SG/3!_/K[]!7O&O?$+P/X;B_LJQ@MOIZ?X\G_/< _*^[^#/B/1XO/GL>I/
MY]N/\\\=:\GO--GANKB#R/\ Z_\ GGMGZG-?L!9Z]X<\8'[#/!;8NO;W]?IS
M^/2N7\8?LTZ5";?7/(_T>Z_TW_#'U_"@#\K[/0=6AS/!!<^_/?C]/R_2LZ\F
MU6'_ %]CTS[?G_GG-?K#IOPK\*V=AY$\-MC'_P"O]>HSFN?\8? WPYK%A_H,
M'^D?ET/K_DD]J /RGA_?2YXQT[_IQ_\ 6QQS5B]\$WUYB<0<_P!.GZ?A7UAJ
M?P'N-!O[B?R,V_\ ]? R>OZ=>G&:@_L&?S?(\@?3W],_Y..,4 ?'TW@.^AXS
MG]!_D?Y%8\MG?6?6#I^&>W?\<8]*^X)O#>8OW\!]/Q_PXS[9KC]2\*V,V?W'
M^??'7'?\<^X!\KP_NO?K^OY?TJQ_K?\ .,8_/U]^OY=AK'AO['+_ )]/\\_C
M@]:(=-_=?3]1^/IU[B@#CYH?WOX_S_K^@ZUCWD(\KM_+Z\_Y)^H%=A-9_P"?
MY<_S/X>U8\T/^3_G\CCU!% 'G\UG_G^7/\S^'M6/-#Y7^?Y^_3O7H%Y#V^G_
M -8D_P AC^M<O>0]OI_]8D_R&/ZT 8_G?NO\XZ?3/3M^N:S_ "/?]?\ ZU;'
MD>_Z_P#UJKS0_P"3_G\CCU!% &?5BJ\_;\/ZUH0P_P"?\_J<>P% %>BK'D>_
MZ_\ UJ/(]_U_^M0!7HJQY'O^O_UJL0P_Y_S^IQ[ 4 5X8?\ /^?U./8"K$,/
M^?\ /ZG'L!5CR/?]?_K5H0P_Y_S^IQ[ 4 6(._X_TK0AA_S_ )_4X]@*KP=_
MQ_I6A!W_ !_I0 ?ZK_.<Y_+T]NGY[%G^^Z=OZ^G7/?/Z9XK/\CW_ %_^M70:
M/9^=+CGGUY_SG\/3J30!H0PS]>W_ -?_ !]L>O48ZC0=-G^U6_GP777_ #T]
MO_K5U_AOPW!-_KX.G3_/Z5]0^ _A[!J4MO\ Z#]I^G^?Y?KS0!8^&-G!YNG^
M1;W)]_;\\?0_I7Z,?"6SGUZ+^RIH/]'_ !'^?Z5YOX#^%?\ I^GV/]E?9OM6
M/]+XSV_^M7Z ?#WP3X<T>UMS!_Q\6O?'H1_/^8[4 5]8^$EOIGA+SX+'[3_H
M9_\ K=/\^U?$_BKPW]LBN/W%SQT^G<^W^<=:_<"'XA?"NS\!_P!E:[!;?VA]
MC_3^7'\O:OS?^)WC'X?^;<0:5!;?\?F>G/\ +^1]^E 'Y/7G]N:;KWD6,%SS
MW^OX?GS7M.CZ!KFI1>???Z-;_8_Z?EQD_P#UZ^H/#?@GPKKUU]NG@MB?7_/0
M\@UZ1KWPW^V6'_$C@_T?DCH,=/3_ #_0 _*_QAX)_P"0A!_RW[=_\C/X9KG_
M (;^%8- O[B^OA;8/X^O_P"LG^=?H!K/[-/BJ\E$\'VG_2NG/OCW/T]_U^./
M%7PE^*F@_$&WT.>QN3I]UW_$_3_'B@"MX\\56\P^PZ'!<W-Q]/T/X\]_RKZ(
M_9%U[Q'X:\4:?JNJV/V;[+>?;?\ CSZC_#K^/US7T1\-_P!EWPYH]A;^(_$<
M'VF<?Z;_ *7_ )]!]>OUK8F_L2SUG[#I5C;6UOTZ=N@/Z_7OVH _=#X5_&RW
M^)&C6^B'%M<_YQSQQ[^I-?2'ANSOM,B^PSYN;<#C^G'I^'6OQ?\ A+XP_P"$
M5O[>>Q_7_/ !K]$9OVD(+/PY;SSC_2>_TYP/Z]NGK0![OX\UZQT?2[C[?]F^
MSVOM[?Y]^H["OB?QM\?M#L_#FH6]C/\ Z1T'V3^G7T]!Z]Z\?\;^//''Q(BU
MC[%-<_9KK_CS'7UYXX],^W3TKS?PK\$]=FBN)]5^TW7Z_P ASTH ^?[S7H/B
M%XCN)]<^TFWMKP?\?=Y_]?\ I[]*]'U.;PYH-K;P:'!_I/T'U]O\\8KZ9\'_
M  2\*7E_;V,]C;6UQ=8)'V/_ #[&NW\;?LHP:;]GGTJ#[3_+'M^?8'U% %#X
M&Z;#XDT;R-6[^O&?R_SZ]Z^T/"O@FQL^8+&V^S]?^//KCOW]\BO(/A+\']5T
MV*W$_P#HUOQ]>GX?X_F,_8UG:0:1:P09Y!ZCU'/3^OUZT 8\/A;2K/,_D6UM
MZ]<?CGV[#WK(U[QMI6C_ (?ACOGZ?G]:Z_4YH8;&>>>8VX(/.1G(/3'?(_#\
MZ^:)]!/B35/]?_HWVPGIS]/KU_KQ0!Q_CSQAX.\22^1?6.?7I^?\C@],U\W^
M)+/P!X;U3_A([&"V^T>W<=_YGI7USXP^&.AV=A^XM_\ 2/IGI^'^/'O7Y_?&
M;09[.6X_<?Z/_/']?U_ 4 >7_M%?'B?Q)X<_L.Q/V:WX/N/QZ>WI7S?^SWX)
MGO)?%%]<?\O5GUXYY]3GZ^_)KC_B=]NF_<6/MVZ=OU[=/SKZA_91\-WW^D_;
MI_\ CZL_KG_/?Z>QH _(_P"/T.JZ#\1KB""#_1_^)I],>O\ AGUR#Z8W@GS[
MRZN/MW_'O^G^?R/6OT8_:H^#-C_PF5Q?>G^<D<?X_P Z^#]2\-ZKH,VH>1!_
MH]KGM^7Y_B>.W8 X_P")UG8_V9<06-O_ )^G^?I7ROX5^&^JZQK($\_^C]^/
MZ9]/ZYYKZ0U+7A-^XOH![=_\_I^/2O/_ +9JMG+Y^E?_ %N._P"!Z^E 'B_B
MKX/V,%U<?OO](Z#_ #U^OXU_H\5_GCS0ZKJ5U<?;YP/\?\\^IZ5_H<4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^$#X2_\ E%1_PHSX,_\ 1'_A9_X0/A+_ .45>KT4 >4?\*,^#/\ T1_X6?\
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M"7_RBKU>B@#RC_A1GP9_Z(_\+/\ P@?"7_RBH_X49\&?^B/_  L_\('PE_\
M**O5Z* /*/\ A1GP9_Z(_P#"S_P@?"7_ ,HJ/^%&?!G_ *(_\+/_  @?"7_R
MBKU>B@#RC_A1GP9_Z(_\+/\ P@?"7_RBH_X49\&?^B/_  L_\('PE_\ **O5
MZ* /*/\ A1GP9_Z(_P#"S_P@?"7_ ,HJ/^%&?!G_ *(_\+/_  @?"7_RBKU>
MB@#RC_A1GP9_Z(_\+/\ P@?"7_RBH_X49\&?^B/_  L_\('PE_\ **O5Z* /
M*/\ A1GP9_Z(_P#"S_P@?"7_ ,HJ/^%&?!G_ *(_\+/_  @?"7_RBKU>B@#R
MC_A1GP9_Z(_\+/\ P@?"7_RBH_X49\&?^B/_  L_\('PE_\ **O5Z* /*/\
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MA>_&7X+7'A/PAX4T'Q._Q-^%&DRZ[H.C:-JJ0P&)O&.@C6_ABY+^2L7C9B3
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (_TK0_Y9?Y_NT 9]%$_;\/ZT0=_Q_I0 443]OP_K1!W_'^E !1110 4444
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M[XKX?\>:!I4U_<6,$!MK@^GIZ#G^?M0!\3WD,,,7].O7\?;TQUKC[R'M]/\
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M2?PKK'G:7^_L?LWIS_GI[U^5'PKFT/PK=:=/?7W^CVO^?\\8_*OU/^'OQ:\
M>*K6WL8(+:YN.N?L??IT_P .?TR =!X;AGO/%%O/!8W-S;\_\>GTX]_\]:^O
M].FAO8O)GLR,9XN@#GVY#?ABO&+SQ)H?A6Q\_2K*V%Q]DZ?3IT_SQ7S?X/\
MVBM5UCQ[<:5?3_9K?M_I@]C_ $/X4 ?H/%',//XM\D\<<=.^!_/_ /5!YW_3
MO^M>;P^-M#$MOY^N6WOF\_\ U\'\ZK^*OC!X.\'Z-<7T^N6US<=N3UYZ^O\
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M?OU110 4444 %%%% !1110 5_E8_\'B?_*7B#_LUGX,?^GCX@U_JG5_E8_\
M!XG_ ,I>(/\ LUGX,?\ IX^(- '\JM?[-7_!OS_RAJ_X)[_]D)3_ -2_Q)7^
M,K7^S5_P;\_\H:O^">__ &0E/_4O\24 ?L=1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ?Y/?_!V[\(K/X:?\%BO'GBFQ@F@'QU^!GP0^+=XF1DZI'HVM_"-
MB>F-P^$_0<@AP,U^XO\ P9%?%^:]^&/[>_P"F>-H/"/CSX+?%S1@MQM-W+X_
MT'QUX)\1;5)P%MO^%7>#5YX;^V21@?*?F#_@]O\ AUI^F?M"_L&_%:*PAAU3
MQI\%_C#\.[W5C$1=7^F_"WQCX>\1Z-I+N/WA2"X^+.LN@ "A]9<E,8%>$_\
M!EK\3M0\/_\ !0[]H;X3?:;==!^)O[)>K>)YX2I^V2>)_A;\4/A6-# X($*Z
M!XY\; J.6?D$>6P(!_IJ4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '(^-O^10\8_P#8K^(O_3.]?YWO_!5?_D];XD?]
MPO\ I7^B%XV_Y%#QC_V*_B+_ -,[U_G>_P#!5:8?\-I?$CI_S"^_^?\ /TY
M/SGG[_\ 7X]$T/\ D_Y_(X]015>?M^']:T)^WX?UH SZ/(]_U_\ K458H K^
M1[_K_P#6J>'_ %P^I_G2T4 $_;\/ZT0=_P ?Z57G[?A_6B#O^/\ 2@"QY_M^
MG_UZ//\ ;]/_ *]5Z* +%%5X._X_TJQ_RR_S_=H KS]OP_K5B&'_ #_G]3CV
M JO/V_#^M6* *\T/^3_G\CCU!%5ZL3]OP_K5>@ JOY'O^O\ ]:K%% !1Y_M^
MG_UZ*KS]OP_K0!8HH@[_ (_TJQ0!7HHHH **** "K'D>_P"O_P!:J]6//]OT
M_P#KT 'D>_Z__6JO6A6?/V_#^M !Y'O^O_UJ/(]_U_\ K58HH SY^WX?UJQ5
M>K% !1110 4444 %%%% !!W_ !_I5BJ]:$'?\?Z4 5_]5_G.<_EZ>W3\['VS
MW_\ ':SIO]<?J/YTM !1110 4457@[_C_2@"Q15BJ] !1110 58\_P!OT_\
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M_GVK\_\ Q5\5/L?BBXOM*OC;7'T_SZ?F*]PO(;'6+ S_ )G_ #Z^YKY7\2>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5_E8_P#!XG_REX@_[-9^#'_IX^(-?ZIU?Y6/
M_!XG_P I>(/^S6?@Q_Z>/B#0!_*K7^S5_P &_/\ RAJ_X)[_ /9"4_\ 4O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#^(+_@]H\ :;J7[*7[$GQ+DT^%]5\(_M!>.O 5GJ*VP)L-.\?\
MPW;7]9TLZC\R@7<WPKT=R@0-(VALS9,)1?YT?^#3_P"(\G@;_@M#\#/#RI.]
MM\6OAK\=_AF\RX LO*^&&O\ Q51W)RJAW^&'E9("EG)VU_67_P 'E?@F^\5?
M\$J_AQXEL!9$?#G]LCX7^)]9>YN&RFDZQ\+OCEX&,>G%B,S/X@\1:&XCPNY$
M=CCRRI_B7_X-V/$R^%?^"TO[ FJ2R>3]I^*/B3PT (1@CQE\+O'_ (809Z .
MVN@!MORJ5P"HH _V2**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIBOR_P#'GP8OM2\1W%O8V7VGU[?YY/'_ .O/[8>"?&VE>)->U#P=!C[/U_\
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M_%4'@/QEX7U6Q_Y_,?Y]/?O7])'P-TW_ (2KQ1I_B/S_ /CZT?\ Q^OIT_R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8,\_*3Z5^C% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJWP[237/['CD7PZFN>&O^$WR4&8VEM8B0<%TV>';Q3P<;.2T5]KIZZ]O/O\
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MB]QX?UF.+7XQPP,AB"C(4,-P4@'NE%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!_-E_P=AZ-_:O_  19^/&HBVAE
M/AKXG?L]ZQY\V,6QD^,?AGPZ7P.<?\3WR6P2"DS\$D9_S>_^"0?BG5O!_P#P
M54_X)R:YHMZFG3R_MN_LS>&;B\:WL0%T+QM\8/#/@O7T).0'N/#VMZO;LY21
M8S(LI)6*,G_2\_X.F].^V?\ !#G]L2[$F/['U7]G._\ J)?VGO@_HA4_CK&#
M]*_R]O\ @FU/#:_\%$/V")KB:&U@M/VTOV7[NXNIU.RVCB^-O@1W=_14"%NG
M#*&. IH _P!QZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML4 8]:$'?\?Z57G[?A_6K$'?\?Z4 %$_;\/ZT44 5X._X_TK0JO!W_'^E:%
M&/6A110 457HH L4444 %$'?\?Z444 $_;\/ZU7JQ5B@#/HHJQ0!G_\ +7_/
M]ZK'_++_ #_=JQ10 0=_Q_I6AY/[K_..GUST[_IFL^K$,W[W\?Y_U_0=* +$
M,/\ G_/ZG'L!706?;_@59\'?\?Z5H0=_Q_I0!H>1[_K_ /6K0AA_S_G]3CV
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MQ9^3+CGC\/\ ./Q].H%=19S7WE?OX!Q[?EZ9_P XJ_>0_;(?]1[^WM_GZ>M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?Y6/_!XG_P I>(/^S6?@Q_Z>/B#7^J=7^5C_ ,'B?_*7B#_LUGX,?^GC
MX@T ?RJU_LU?\&_/_*&K_@GO_P!D)3_U+_$E?XRM?[-7_!OS_P H:O\ @GO_
M -D)3_U+_$E '['4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >4_'/_DB_P 7
M_P#LEOC_ /\ 41URO\%VO]\OQ5X8L/%OA7Q1X4U*66"P\4:!JGAN\N+<_P"G
M+I^NZ6^D3LK;21*5ED93TW(N< -7\E__ !!8?\$LO^B^_M\_^'2_9P_^A2H
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M<#:JLP_G:_:F_;5\<?'V_O\ P[X=GU'P9\*0"+/0;2Z4:IKJEMQUCQO@<*.
MOA4D\*I9F;+'V[_@II\?;[Q+X\M_@;HEXR^&? XTF^\8+;XW:UXFUX F, #
M/A/P]EG ))?Q ?F(50OY:5@,**** "MG1]>USPWJFGZYX;U74M$UC2[P7MGJ
MVDWG]FZG8=NGH16-10!^]_[%/[<EO\5S8?"[XL7EK:_$<IL\.^( GV'3?':
M!5$:EMJZ\H&Z2%%_>=4 D^_^H-?QKV=Y?:;?V^JZ5?7.FZAI=Y]ML[NTO/\
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M 1@#^L>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH Y'QM_R*'C'_ +%?Q%_Z9WK_ #O?^"J/_)Z7Q(_W=+_K7^B%XV_Y
M%#QC_P!BOXB_],[U_G>_\%4?^3TOB1_NZ7_6@#\W[S]SU[_T]>F.W]<<UH>?
M[?I_]>L^\_?19_F3G/Y?A5C_ %7^<YS^7I[=/S "J]%% !1110 0P_Y_S^IQ
M[ 58\CW_ %_^M1#^Z]^OZ_E_2B@ \CW_ %_^M1Y'O^O_ -:B&;_/^?U&?<&K
M% %>BK%5Y^WX?UH KS]OP_K5B&'_ #_G]3CV HA_>^W7]/S_ *UH4 5YH?\
M)_S^1QZ@BJ_D>_Z__6K0JO0!7\CW_7_ZU'D>_P"O_P!:K%% %?R/?]?_ *U%
M6** ,^K%'D>_Z_\ UJL4 5Z*** *]%6/(]_U_P#K4>1[_K_]:@"O/V_#^M9_
M_+7_ #_>K0FA_P G_/Y''J"*K^3^]_SGK]<=>_Z8H **L>1[_K_]:CR/?]?_
M *U %>K$'?\ '^E'D>_Z_P#UJ* "?M^']:**KT 6*KS]OP_K1Y_M^G_UZL4
M5Z*L>1[_ *__ %J/(]_U_P#K4 5Z*L>1[_K_ /6H\CW_ %_^M0!7H\_V_3_Z
M]%5_(]_U_P#K4 :$'?\ '^E%5_\ 5?YSG/Y>GMT_.Q0 4444 %%6/(]_U_\
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M_$E?XRM?[-7_  ;\_P#*&K_@GO\ ]D)3_P!2_P 24 ?L=1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3_\ SX^"?_"O/_Q- 'Q1\0/%$OCKQWXV\;7@"S>,/%_BCQ,BJ %4:YK0UT*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** .1\;?\BAXQ_[%?Q%_P"F=Z_SO?\ @JC_ ,GI?$C_ '=+_K7^
MB%XV_P"10\8_]BOXB_\ 3.]?YVO_  56F_XS7^)&?^H7U'^';IZG^= 'YT7G
M^J_[?1_,5--_KC]1_.H)INH_Z?/7\^?Y_ECO1--^]_'^7]?T/2@ HHHH ***
M* +%%'D>_P"O_P!:K'D>_P"O_P!:@#.A_P!</J?YUHU7AA_S_G]3CV JQY'O
M^O\ ]:@ HH\CW_7_ .M6A##/U[?_ %_\?;'KU& "OY'O^O\ ]:CR/?\ 7_ZU
M;%G9_P"?SSS^?Z'%6/L?M_X]0!S_ )'O^O\ ]:C['[?^/5U']F?[7^?SH^Q^
MW_CU '+_ &/V_P#'JL>1[_K_ /6KH/L?M_X]5>:S_P _RY_F?P]J .?FA_R?
M\_D<>H(K/G[?A_6MB:'_ "?\_D<>H(JQ!9?\]_RQ_,?Y]1ZT <_!W_'^E6*T
M)O(Y_'\__P!7W:SY^WX?UH KT444 %%%% !/V_#^M9__ "U_S_>JQ/V_#^M'
MD>_Z_P#UJ "BBB@ HHHH */(]_U_^M11Y_M^G_UZ #R/?]?_ *U%6*KS]OP_
MK0 5/#_KA]3_ #J"C_5?YSG/Y>GMT_, T**S_/\ ;]/_ *]'G^WZ?_7H KT4
M>1[_ *__ %J/(]_U_P#K4 %6(._X_P!*K^1[_K_]:K$'?\?Z4 $_;\/ZU7_Y
M:_Y_O58HH LP_P"I'T/\JK3]OP_K5B#O^/\ 2J_D>_Z__6H (._X_P!*L3]O
MP_K5>&'_ #_G]3CV JQ0 0=_Q_I4\W^N/U'\Z@@[_C_2B?M^']: "BBB@ HH
MHH (._X_THG[?A_6B#O^/]*L>1[_ *__ %J ,?\ Y:_Y_O5H>1[_ *__ %JK
M^3Y,OY>O?K^'7IQ[5H4 5Z*** "BBB@ HHHH **** "BBB@"Q!W_ !_I5BL^
MK'G^WZ?_ %Z +$'?\?Z5T$'?\?Z5S\'?\?Z5T$'?\?Z4 =1_RR_S_=KH-'_U
MQ_SVKCX9O\_Y_49]P:Z#3;SR9>G;OU_KP* /<-!_<FWOH/\ G\^GX?Y[?C7]
M8'_!(7XA:'K'@C^P[X#[1]CTO'O_ )_/ZD5_)OX/UC_2O('_ !['/U[_ .3_
M )%?J?\ L0_M"3_!GQ;;3WT]S;Z/=7F<6G/_ .O/7TZ4 ?IS^UUX#@A\>:A?
M3P?\2^ZSU_'/?I],5^:_C#4M*\-7X\C5?M./^70_3O\ Y^OK7ZS_ !@^(7AS
MXP>$CJNE7UM]HNOP_P _7UZU^,'BKX&^,?\ A8)_?_:;>ZO./L=Y],?KGF@#
M]>/V+?B1I5G%;WPG_LS[+]?\/_K=,^@_5#Q)\<M#U[1K@6-_;?:,8_SV_P#K
M=Z_*?]EWX#ZK-:V\%]_HW&1^7TY['_Z_%?:'_"C=5L_$?_$JGN;G3S>'_/?_
M #TS0!\S_$+Q5/J^LW$$\&;?\Q_G'6OG_P"/'P4U:\\+^']<L;'[3;W5G]MZ
M_AU_S_C^T$/[.NA7FEV\\]C_ ,3#_P#7^&/Z<_7Y_P#&WP9\4Z1?7[:H1<^'
M],YL[7UXSD<_XYX ZT ?D_X5TV^\-Z7^YT*XMKBU_I^M9\/QL\8V>O\ D03W
M/^BW@'_UO?Z]J_3#PW-X.U+4+C2O[*MOI=V?_P!?G\/?/2O/_B1^SWI5Y?\
MV[2K"VMOM7.+3_'TH \7_P"%P:KXDTO[/KE]QT]/\3^?\ZX^SL[_ %B_\C2O
M])M[K//Z]AP..E;^@_L]^,=7\1V]CY'^C]??^G\J_0&S_9OM_ ?@W[=/!]IU
M#_ITS],?Y_&@#S?09IYO"7]E3V//V/\ #CZ>X_STKS?P?XPOO ?BWR9[XVVG
M_;,YY'Z]<?GQ^OT19^&X/"OARXOM4OK;[1==;3[8<\_A_3GZ\5\[>,-2L1HU
MQ??8>O\ R]_8_P"GY?3MQ0![%\?M!G\;:#]MTJ^_XE_V,_EVX_S^-? W@G4?
M$?@_5+C^P[&YN;>U_P"/SIQC_(Z^_P!:ZC_A;7BK6+7_ (0[0[#4KG//_'GV
M'K_]?^7-?6'P-T'0]'T'4(/%,%M_:%WT^U^W^?Z>N0#R?3?&'B/QA?\ D:3]
MIMO^G3]>_P#GWSQ7M'@F\\1^%M9MY]<@N?LY]/TQ[_E_CT/PQ\*Z'=^,KC^R
MH+8"U_TW'ID=?J.O3]<U[O\ %338(=&^W06/_'K_ ,?G^AC\O;IG\/6@#Y_\
M2?&#28?%MO;V/^C7'<_YY_3CL:]@\*Z]]KBN)X+[G_Z_\N..O6O@_7OL.L2W
M&JP077^B_P#3G_GO^')K'\!_$CQ%9ZS<6,$&I7$'VS_'\/QP: /V(T&;0IO#
MGGZK/;?Z+_GM[]_H.]>?WFFSZE=^?X<TK[3I_P#TZ#\_\_F>M?,\/Q4@L_#=
MS]N_M*V^R_\ 'YCC_/!]/IS7L'P3_:$\*ZE=6^AP3VW^E?\ /WTZ?3_/YT ?
M%_[7>G6,.EW$%]I?^D>GK[\?CW^O4U^%'B3X/CQ+JMQJNE#[-<&\[_T_K^F:
M_K8^/W@CP/XVT^XG\_3?M/V/_G\Z^GZ?_6K\-OCQ\-X/A[?F_P!"GMKFWNO^
M?3('U_I[]: /D#PWX)\5_P#"+W%C?07-U;VMGV_S],?Y%?*T/P?USQ7X\\@:
M5<_9[6\_PQGGG^OXU^A$/Q"_XE?V&QL;G[1C_GS_ "]/I]0:]P^ /@^"\UZW
MOM5@TW_2KS\.G&3C_P#5[]@#S;P'\&8/"OARW,^E?Z1^/Z_U'I7N/A7X,S^-
MS]A^P_\ $O/^?\^WM7Z$?&?P'X<\*Z7H]C/!;?:-4_Y]./KQV[?_ *JV/#=G
MI6C_  ^N)[&#_B86MYSQ^6 <<?\ UJ /R/\ CE^RO/H.C7%]! ?]$_ST[>Y^
MM?F/>>*I_"FJ7&E7T'Y?S'^<]>U?U$6>L>#OB%I=QI6JP&V^U#_E[[YZ<<<_
MC[5\O^//^">.E>)-4@UV"XT3[/=7GVWB\Z^F?I_+\J /S'^ /[.L_P"T)=6]
M]?3_ &;3^/Q_R/K^&,#]T/V>[SX2_ C[/X'TK0[:YU@_\O?^<=,_3-9_A7]C
M^?X8^$O[5\-SW./L7_+I>#^9_P _RKR?PKX5GT'QO;ZKKGVFZG^V<?ECV]AT
MQZ>E 'Z0>-?A[!KU_H_C&>Q^S?\ +[>?YZ?UQ^=?+_[8&C^#AX2M]<@^S?Z*
M=+]_Z?I_^JOO#PI=P:]X7MYY_P#CW^Q^W\O\^M>/_&;PKI6L>%[C_0+:YT_L
M+OZ<=\]OZ\]@#\E_V;]'TKQYXM\C0Y_LUOJEY_IG3CCOSP>O?\^WN'Q._97\
M<0ZI<?V&+FYM[JSY_P!#/X?Y_#UKS^ST&^T'XC>'['P=8_V9]EO!]L^R?@3Z
M\5^L'B2SURS^'-O?0?Z3J_V/Z?AU[>G- '\^_B3PMJOPENM7@\50?E^?/_UO
MS%>+Q0?\))?^?!/_ */^7\NWX^GMC[X^+7@G7/B%%K%]JOV:VN+;_G[_ ,\_
M7UZ=J^;_  39P:#K/V&_L;:YZ?\ 'IZ8[?G_ )% &/H_AOPYJ/\ H.J__K_S
MQZ<=J[#P?INE:/XB_P!1_H_/_P"OZ$C!YXK/^)/V[3+OS])L>A_Y\SW_ /U_
MG7@^FZ]JUY=W'_'R;CI[?E^G^>0#ZA^,.I66L77D:5]FMNXZ_KW_ /K_ (5\
M+>//!^N37Y@-P?L__'[_ )[<_CGTKN)M(\8WFO'C4N?\_0?YZ]3T&L?#?Q^)
M;;,'VG[5V_S]1^5 'D_PQT?2;R__ +#FYGQTS_\ KZ#K^0K[ TW^W/!-U;_8
M9[G[/=>F.F<_A_G-><>#_@;XKT+6;>^OH!;7%U]?S_I7M^I:Q_PBM_Y%_!;7
M-Q]C]N/\!_@* /6;SXA0:#X<-[?<W/UX.?\ /-?/T.I>./$FJ?;M*M[G[/<_
MX_XX]N_->7_%3XDWVOZ6;&Q^S6UQZ]?T/K[G_"E\!^,-<L]/T^"W_P"/C[9_
MI@_S_GK0!]3Z1\&?$>I75OKE\+GR/?O_ )]O6N7\>:]JN@ZKI^E6^/\ 13VZ
M?I[?SKZ \-_$F^U+PY;Z38V-R;CO_H?OFO6/AY^SW?>/-0M[[58/_ L8_7'^
M>/>@#YWTV'5?$FC6\'V>X_\ U_YQ].170:#\!_%6LVMQY$%SZ'\1_GZ^N37Z
MP>%?V?/"N@VMO!/ /M'^?\CWKUC0?!VAZ#_H\%C;?_K_ )?_ %^_- 'X'V?[
M,=]H/B.XOM<T.YN;C[;FSQQ_AW_/TKZ8TWX WVCW]OKECI7V86MG]MZ]#^5?
MJQK'AOPY/+^_L;?[1^O^/\Z^9_C9X\G\-RZA!8V-M;:?]C^Q?_6//Y_GWH _
M(?XS:!JVO>*+B^GA_P"/7\>/Z\?S[BOD?Q5INE0_N;Z#_2._]3]?_P!?H!]H
M?$+QY!-JEQ/Y/X_AVZ_Y_&N/\'^ ]*\>:]Y]]!_H_P"73_/U'O0!\W_#?1H-
M-NOW%E_Q]?\ U^?Y$>GIT%>L:Q^QGXQUC5+?Q5!8W-SI_P#Q^C(X]?K^G?O7
MW!#\,? &F_9[&Q^S?VC:_7U_G[?T%?0'P9^-GA73=9_X5SXC-M<W%U_H7'^?
MS].OT /SWT?P?_PC=K;P6,_]FZQ:GCGC/8<]?R_*O4-!^*GC_08O].U:ZN?L
MOIUY]O3_ #ZY](_; T?0_!-__:MC/_H]U_IO^B?X],=#Q^=?"\7Q"TK[+<03
MWW-UU_3V]_;U)]0#WC4OVHM#U*_N-*\1SVUSZ=N.W/\ GIZYKQ?QYK'@#7HO
M/TJ"V^T<^O8'GG_/-?+%Y9V.I>,O/MY_R_+Z\8[?TS2?&#6+'P?HUO\ 8KC_
M (^O^/S/K_G]?K0!7UCXDZ5H-U<0P3_C^/\ GWSZ\5\;_&#XS>=%<007'3],
M_3_/TZUX?\0OB1/-=7/D3]^O^?KCZG KYNUCQ)?:E+<>?<9'U_GSU_G]30!L
MZGXP^V71\^?].V/K]<],_2N/O-2@FE_R>_\ G_&N7_?>;_\ JS_G_P!FK0LH
M8/-\^X[\#&<COW[T ;$'?\?Z5_J,5_EKS7D&>_;C]1WZC]<_A7^I10 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5_E8_\'B?_*7B#_LUGX,?
M^GCX@U_JG5_E8_\ !XG_ ,I>(/\ LUGX,?\ IX^(- '\JM?[-7_!OS_RAJ_X
M)[_]D)3_ -2_Q)7^,K7^S5_P;\_\H:O^">__ &0E/_4O\24 ?L=1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_D>_Z_\ UJ ,?R/?]?\ ZU5ZV)H?\G_/Y''J"*SY^WX?UH KT444 5_^6O\
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M>?\ ZX)'UKW#QY^TKXX^*DITOR+G[/:CZ_ES^7OWH \_^'OPQGO-9N//L?\
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MKXO^&\VN:-?_ +__ #V_^N?4_G7UQH_D>*KK]_/;?:/^/+'\_P#.* .YT?\
MLGXJ:\-*T.QY_P ^O^&17'_$[]C^>'[1KFJYS]C//V/GM^'MW[],UC:#XJM_
MA+\4-/@@GMOL]U>=>>G^?KQT[U^C_C60>-/#FD3V]];_ &<VFF,?LA).2<G\
M">W  QC&: /YZ?&WP9_L>_N/)@-U;GT_IT_SCUKI_A+X#TK4KOR)X/\ /;CI
M_@<9YZ_K1XV^'OA6S\-W$\\'VFXX_P#U?YZYQZU\C_#W3=#FO]8\B#[-]E_M
M3U[?Y_4\4 >\?!/3OASH.LV^E7XMKKT'?Z]_\C\OT0T?3=*AEM_[#@_T?/\
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M]JY_7OV8]5AM?^)5!<X/_'Y_H?\ GU/?GVK]Z/#?CSX.ZCX2N-<OK#[3<?\
MZO8?Y''%6/ ?QL_9ZUZ[MO#E]H?V7[5_Q^7=W9Z,?;KZ\=?UH _EG\>?"O\
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M3_(]1S7YCS>%=5U**YUS5KZY_P!%O/\ G\_S]<GZ=J/!/Q.OM>UFX\*_;O\
MIRQ]>WKZ<]/SQ0!]X0_$B?0=&U#58+[_ (]>?Y#W_/./:OJ#]G7XA0?%GPOY
M%_?BYGNK//V7(P/4_AUXXR:_-?\ X0/QEJ6@ZA!!]I_+G\L>G;U_"OL#]A6R
MTKPW87&AWT]S_P )!:_\?@/?_']>OX4 >L>//A7?:#=7/_"*S_9OM7!^R?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?S9_\%%O^3K?&/\ V"_!
M/_J'Z#7])E?S9_\ !1;_ ).M\8_]@OP3_P"H?H- '[<?L>?\FQ?!3_L1=)_]
M!>OI2OFO]CS_ )-B^"G_ &(ND_\ H+U]*4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R/C;_D4/&/
M_8K^(O\ TSO7^=]_P57_ .3S/BC]=+_E7^B#XY_Y$SQG_P!BKXC_ /3//7^=
MM_P57_Y/,^*/UTO^5 'YS?\ ++_/]VM"?M^']:@A_P!2/H?Y5?G[?A_6@#/_
M 'O^=U;%GV_X%6?6A##_ )_S^IQ[ 4 :'G^WZ?\ UZ2'_7#ZG^=4/(]_U_\
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MVUQ:]3:>N<^OIT_,\&OH#X _&SQ_X5\1V%C/]IU+1_7']I>O]?PQQ0!_-/\
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M,?C5>\TW]UZ>_'_UNO\ 3ZUZQJ7@F^A_?^1SG/;U_P ].WY5S\VFSP_N)_\
M#\^V<_J* /-XH>OG_7&/Y_SY_.J\UG!GOVY_0=NI_3'XUW%YIOD\?Y/_ -?/
MX^@S7/S0S]>W_P!?_'VQZ=#D Y>:'_)_S^1QZ@BJ\_;\/ZUL30S]>W_U_P#'
MVQZ=#DFL_P!U[?Y_(_CS[T <O5BK$T/^3_G\CCU!%5Z "BBB@ HHHH ****
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MHPUS2K*V^SW7I9X)/OV/OCVXH ^8/"G@[^P9;BQU6#_1^>?SY_3Z8_.OS_\
MC!XP\5?L]_%K4?&/@Z>YN='U2\^VWEI:=NV,<>OO[\'-?H?\;/C98^&H1!]A
M-M/W)L\GN.2>YXS^%?E1XP\;7WC;Q'K'V&"UN?M5YG_2[/GW]OJ/_K4 ?<'A
MO]L"#XG6%O!Y' L\WEI^??'?^73IBOF_X\:EY.@^(/\ B5?\3#53_P 2>[_Y
M\/Z]>GYU[Q\/?@#I4/P^_P"$CTK_ )&#_GT[_AWYZ>G;%<_J6@ZMK&C7%CKF
ME?Z1:\?\>?X_3I[?UH ^'_@SX5GFB_M6XOA:ZA]L]/?_ /5[?E7WAIOAN^U[
M^S_L,_VFWM?^/PYX^GIS[_CTKXOF\*^(_#=_J,\'^C6Y]/3_ #R/SYXK[H_9
M*\56]Y:ZA8ZK_I/Z_P"//X_K0![3H_A6QO/"^L6-]/\ \>NC^V/_ *W3]>,U
M^3WQ:O/^$#UXSP:Y]FM^_P#7'0_Y_+]"/C;XJU71[7Q1_8=O<X^Q_P#UAT/^
M?RK^?_XP>,/%6O:S_P 37[3;<\?Y[8_S[@'VQKW[3D^L:-_94&J_Z1]C _/\
MN>?RK\__ !YX\OIM4N/MVJW/3C'./\_YZ5S^CZ]8_:O^7GUY^G^//'IZUR_C
M;PV->O[>>#ZC\_PSZ]\?C0 :E+/K'_+\>>_;'^?S]*L?#(?;/$=Q!/\ \NNL
M'\_ZU8A\$WVFQ6]];W'^CC\>G?Z>_H.M>X?!FST2SNM0GGL?](_MG//<8_EZ
M\T ?N1\ /$G@WP3\/M/_ +#T.VMO$%U_Q^7=IZ8_SC&>_2ON#1_B%/>>#;B>
M?_1KC\N@]NHX^G3GM7S?\!_^%9:/X-T_5=5M_P#2+K/'^)]<?2O>-8U[P=KU
M@;#0Y[:V]\>_^>O^!H _._XG0WVO>(_/\1_\3*W^V?\ +WS]?U].O3KFO-_&
MUYH?@_X5>,+[PI8VVFZA]L_X^[3W]OI_CV./L#XS?#'59K"W^PY_TKT_GQ_G
MKCKFO@?XA:#KGAO1M0\.:M_R]6?VW^G'X_YQU /R/A^)VJZOXMU"QGOO](^V
M8_'IU[>W7%>\#XS:'X#M=.GU72K;4M1_Y^^F/SZY]/RKY/O/A[KG_">:AJMC
M_P >_P!L^N>?TR?4?2O6/%7A3^V-+T^#/_$P_P >F>O^<4 ?IQ\&?B1!\2+#
M3YYY_LVG][0?_J]Q[<?G]<>-_#?@>S\.6^N>%;&VMM8M;/\ TS[)^77WSZ\?
MC7XO_"N\UWX>VMO]NG^S:?\ Y]Q@=CQ_,5^K'PK^+7PY\5:#;V/V[[3<_P#'
MD/\ 3./J!^6?\Y *_P  ?CSXXT?6;?2I[&YN?],(_J/Z_P!,U^R'V.Q\2>%]
M/U2^L1]HNK//_P!;_/;Z5\W^ _!_PYT:[T^?[#II_ISU/!YSWKZ(F^)'A6SE
M&E03VWV?[']#R/UX]?\ ]0!\'_$B#Q'H.O6\\$]S_9_VS_CT_K_]?J!^=>\:
MC\0O"I^&GG^(_LMM<6NC_P"'4?EQGOZCCE_BUX;GU*Z.N03VW]G_ %_,GFOE
M_P".6O:5K'A*WTJ"?/V7^R_MGV3/UZ_Y]>U '+_#'Q5?^*K_ ,87W@V#[-<6
MO%G]D_7Z_B?7@U\K_'/XV>./"MKJ$&J_:?[0^V'-W^?/''?\^GK7G%Y^V-I/
MP-U[4-#\*P?:?M7^A?\ 'G_:7/'_ -?/XXKY>^(7[0FN?%J__P!.L?LWVJ\^
MV_\ 'G_G'X>YH ^L/A+\6K[4I=/_ 'X_4\?E[\?D<\U]T7O]E0Z#;ZKJM_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#^"3_@]T\8^,='\.?\$Y_!NE^*?$NG>$/&5W^U
MG>^+/"MEK.M6?AWQ/J7AIOV:I?#T^MZ(K0Z'KK^&/[;UI?#;W(EFMWUB;R%
MWO<?Y\5?Z8?_  =:_P#!/_\ ;*_X* ^./^"<7@/]D7X$>*_C%J/AAOVN;KQC
MJ.EII>C^#O!5GKY_9:716\:>//$EQX;\*>&(_$:Z?K#64-YXFCN/$CZ7XA^P
MFYC\,W26?SI_P3>_X,X_"7A#4=!^*'_!2KXEZ7\1M2M;F"\C_9I^"FH:]8>
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M+_YK1^V'_P#0[4?\11?_  0N_P"CY?\ S6C]L/\ ^AVH _H"K_*Q_P"#Q/\
MY2\0?]FL_!C_ -/'Q!K^TS_B*+_X(7?]'R_^:T?MA_\ T.U?P+?\')'[:G[,
M7[?G_!1>T^.G[)?Q,'Q6^%K?L_\ PO\ !;>+#X2^(?@HKXFT#6/'<NN:0-!^
M(7AKPGXE7R8M:T@^:?#BPSF0>1(4BG,@!_/E7^S5_P &_/\ RAJ_X)[_ /9"
M4_\ 4O\ $E?XRM?[*_\ P;WZI9ZQ_P $9_\ @G_?:7()[:#X/ZCHTC<DC4?#
M_COQOH6N)N.<K_;ND7&&(SE: /VAHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OYL_^"BW_ "=;XQ_[!?@G_P!0_0:_I,K^
M;/\ X*+?\G6^,?\ L%^"?_4/T&@#]N/V//\ DV+X*?\ 8BZ3_P"@O7TI7S7^
MQY_R;%\%/^Q%TG_T%Z^E* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH Y'QS_R)GC/_ +%7Q'_Z9YZ_
MSM?^"J$/_&:7Q(@'0G2_7K_/@#\\]J_T2O&W_(H>,?\ L5_$7_IG>O\ .]_X
M*H_\GI?$C_=TO^M 'YS^=Y,7_;Y_+U[>G7WK0\_V_3_Z]9%Y_JO^WT?S%:__
M "R_S_=H KUL0_NO?K^OY?TK'@[_ (_TK8@[_C_2@"Q5B&',MOU]^W;OU_S]
M#1##_G_/ZG'L!4_$,WL/PZ_T_(<]A0!U.@P_\32W_P#U_P"?SP,YK[0\-?O]
M+MH/;/\ ^KV_R17Q?H_[G]_[_P!/Z>^!7TAX#U[K;S_Y[<_KU'J2.] ']('_
M  39^/VE:/HUQX<OI[>V_P"7+OW^OZ>_>OTXBA\'7GB/^W//MK;_ #^%?R/^
M _%6N>&[ZWOO#E]<C'I[?7W[_ABOTH^$OQR^(WBK[/!/<7//XG_]7'6@#^@C
MXA?$CPYJ7A+^RK[[-<_9;//UZ#V_PSGTK\Y]'LX+SQE<#0S_ &;_ *9_RZ#_
M #_+%:'@^'7/%5AY%]/<_:/\]_T_R:])\(?#>;1]9\_SO; Y_7^G- 'K_@/P
MKXJTV[_<>*M2N;BZ_IR/\.,=>]>?_M(?%2Q\*Z-<6.JZK_9NL:6,C_I_]?\
M/?KC@5Z!>>*H/ ?VC7+^?_1[6SZ8[>G^<_C7XO\ QR\>7'QA^+6L:Y//<VVC
MVMY_C_\ JSCJ* .H\%?MC:'X)\6_\)'#8VUS<6MY^'^?\/6OU ^&_P#P4X^'
M/C:ZT?0\6UMJ&I_\NG&>/;ZX_ U_/?XD\*V,.JV]]H<_VFWNKS[#>>_^?;\:
M^D/#?P?L=!B\/^*H(+JVN+K_ $T_0?CZ$C_.: /WP\2> _\ A-M>T_Q58S_:
M='_XEE[>?Y_IQ^&<5U'_  C?AR\EN+'PK8VVFW%U_P ?EW:=?QZ>O_ZZ^/\
MX&_$[5?!.F?8O%5]]IM[JS__ %8[=*--^-FJS>,M8L;&>VTW1[6\/V/[7_3N
M.3_+B@#[ F^ ^E:E8&QU6#^TKBZP?M=W^8&?\_TK8\%?LX>'/"NL6$\]C:W-
MOC_CU/0<=_;ZGUY]./\ #?[3GA709;>QUR>VN+CUM.H'^?;ZU]0>%?&VA^);
M7[=I4_VG[5_/O_+Z^] 'YK?\% ?"NB:QX6O]#L[<6Q^Q#[)CIGOC/09S[XQD
MU_*!KW@^_P##>O:QI5]!=?Z5>?Z'=C/KW_/)K^QC]I#38)O$=O<:K!_Q+_\
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MS[=L5GS]OP_K7H%YH_DR_AV[#GN/I6/-9P9[]N?T';J?TQ^- '+^3YOX>_\
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MQXCOK_[-<:7CKD_CC'YC^?% 'VQXD\-^ +/1M8N-5L;4?:K/TR??]2"3ST/
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M:QJOB35;G4]0NK/5#]DNP/KZ_G_*J_Q@\8:3\&?#EO\ 8;&YM;C['Z],'_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2/&<VN)I-N=8\;_#_P #Z_'KP?0I5N(1X7CB0[3'<GYI2 ?G?7^Q;_P;8_\
M*$G]@O\ [$;XF_\ J_OBS7^.E7^Q_P#\&Z.CW&@_\$5_V"=/N98)KBZ^''BS
M6HS!_%8Z_P#&3X@:]'N[,8X]8PY "Y;& <@ '[<T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#D?&W_(H>,?\ L5_$7_IG>O\ .]_X*H_\GI?$C_=T
MO^M?Z(7C;_D4/&/_ &*_B+_TSO7^=[_P51_Y/2^)'^[I?]: /S@O/]5_V^C^
M8K7K(O/]5_V^C^8J_P#\M?\ /]Z@ KH+/M_P*N?_ .6O^?[U=1IL(\KG^O\
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M:V%K9X^U_P#U^^?R)/;- 'S]H_PK@TW5/(US2K:Y^RV?^AV=W]>P'\J_*?\
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MY_M-Q]CQ_+_/7./RH S_ !O^SW!:7>(-*&/^O/\ S_3OVKR_4OA7?:;%Y_\
M95S]GZ?\>?\ ^KN1_G./V(^ _B3P/XDUG[=XCGTW[/\ ]/>?S_3!_7->P?&S
MQA\%M-M?L,$&B?3&C?D<?YS0!^1_P?\ #>APRV_VZ#[,/^O/W_3^G6ONC0?@
MGI6O2Z??PV-M<V_Z>O''KV/Y^GE'@G3O#GC?X@W%CI5]IO\ 9_V/[:.WIP,]
M3_D5]/Z/XJ@^&]U;P7W_ ![^Q_\ K?ATZCF@#N/$GP'\''PYY$&E6WVC[&,G
M^?I^G_UZ^3[.\OOA7]H_LJ?]Q:G/)'3^77_)YKZ9\>?'[0YM&N/L,Y_X\_\
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M:'_:6H?\_GV/^TN.W^>/QYKTCXY_$*?4O"5QI7B.^.FZA=7G?_B6G_/X]N*
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MT%C;7-Q:]_<=_P N?Z\UY=\>/&'@>;PY<>'+&XMM.U"U/_/X!U['U^O'4]J
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M=^U#\#M4GT^>X\-?:3.1P1R#QG\OIG^56?@SXVO?!,NG:5//]I^U?G^O7_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^=9_P
M? _\EK_X)^?]DL^/'_J8?#VO]%.O\ZS_ (/@?^2U_P#!/S_LEGQX_P#4P^'M
M '\+5%%% !1110 4444 %%%% !1110 4444 %?W ?\$:/^4>'P7_ .PQ\3__
M %9WCZOX?Z_N _X(T?\ */#X+_\ 88^)_P#ZL[Q]0!_,'_P5._Y/_P#VE_\
ML<M+_P#4.\/5^?=?H)_P5._Y/_\ VE_^QRTO_P!0[P]7Y]T %%%% !1110 4
M444 %%%% !1110 4444 ?[4G_!#O_E$-_P $ZO\ LU?X6_\ IC6OU4K\J_\
M@AW_ ,HAO^"=7_9J_P +?_3&M?JI0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHC]I;XA:'9^$=9@,_P#I'],?_6/T_2OE_P ;?'ZQUBPT^^T*QN;;[+_SY_\
MUL_G^'I7#^#]-U7XS7^H?VY]IMK>UO,_Z7_7Z>F: /!]2L_A_#H-Q]N_X^+K
M_IS_ )_CG(_KQ7@_@^'PYK'CS3]#TJ?_ (E]KG_1/K_G\.F*^B/VG/AC/X/T
MOS]*_P!)_P"7+V]/7TX[^M?,_P"S1X5OO#?Q!T^^UR"Y-OKW^FYY!Y_S^ Z\
MT ?T(?LZ:]!H/A;1])@&?\_ECKUZ5[OK&L:W#XCT\08^SFS[7GKW[=<D'Z_6
MODCPW-H?A72]'\C[3_Q^_;?^/SG(QGV.:ZBS\;7WB2ZUB>Q@N?\ B5_Z%9^G
MI[=O\^@!\C_MI:Q/K$OD6-]<BY],<=>F#^74>U?%_C;P3>V?PEM[Z>^N3<_\
M2OWX_P _R'2OT U[X>^,O%6O6^JWUC_I%S>=K,=/\C_#TKA_VD/!,_@_P1!!
M]HMO[0U2S_X]/T[?_7S^E 'Y#Z#H]Q>:]J'D0?:?LMG^/7WY/OTP/U^9_C;X
M#U;Q)JD]]]AS]E/8_3V_SFOTW\$^"?\ A7O@C4?$?B.^MOM&J?VI^A_S^9->
M40Z;X<\26&L7\$]M_I5YD?\ Z\?D/:@#\/\ XA6?V/3/(^P_Z1]?\_CP/ITJ
MQ\,=!UP6%QY$'_'U[^WTQVS7ZD6G[)>A_$C[3/8ZKIMS<6O^F_9+0_7CZ?X5
M?\*_!_PKINNV_@Z^N+:VN+7_ /5CM_\ JQ[T ?,'@/3?$?A:PN+C_CV^U#WX
M_P \'M]:^?\ XA?$B";7OL-]^7ITZ^U?J1\>/!-CX5\-^18P?Z3:V><].N?_
M *_TZ]\U^2_BK0?MFL^??3VWVCKC\?I],?C0!Z!X5UZ>SB^W6'^1_GMQ]:_4
MCR+'7OA+;WT__'Q_8_\ AT__ %D#Z5^:_P -_ =]K\L$%C/;9&<?_6';IQ[_
M $K] /$DW_"*_#G[#/-_I'V/IW]?\^G>@#\Q]8F_XG.L0?T]/_U9_P \?(_B
MJ'_B:7'M_4^O<_EBOHC6-2^VZSK$_?&/?_/OT^M?-_B3_C_N?\^E 'F^I_P_
MY]*QZV+R8^;W_E]>/\@_0"L^#O\ C_2@"O15B?M^']:(8?\ /^?U./8"@ @[
M_C_2M"&'_/\ G]3CV JO#9_O??\ S^0_'GWKT#1]'^V?3_/_ .OM_(4 <O#H
MXF_?_GWSC_/_ .KML0Z#W/U'Z>GXY_6O8-'\$^=%;]O\]?KQ^7/O78?\(?8V
M<77^6/3Z>WZ9YS0!\WS:#W'U/Z^OX8_2L^;3/)]3_+C\/KQ^'7BOI#^P8;RZ
M@MX/S]QZ?C_G-9^L?#R>']_!V]O3/Y_G[=^ #YO\GR9?R]>_7\.O3CVJO/V_
M#^M>L:QX;G@Q]H@[_E_+H./PKCYK/R??\_Z4 8]GV_X%786<T'FV_N!Z\9_P
M_J?>N7\CW_7_ .M70:#^^ES_ )_SW_/B@#ZH^$MG;S:I;_U_'KSSU_7GM7],
M'['.@V.F_"4ZKI4&-8NKS5++'M_AUQ^//05_,]\'_(L]9MY_YX[_ .<_UK^F
M']DO6+'4?A!]AQ_I%K>:I^7'O_G\* .H\7^#]<\5:7K$$\!^TW7_ "]X[YZ_
MCW_/TK\\+/0=6\$Z]K'AS_2;FX]/\_IZ=.>*_6?PMXDGO+K_ (1R?_CW_ ^G
M_P"K/UYKS?\ :*\">%?"NC:AKFE06W]L76CG[9QWQ_(_RXH _)_QAX/,UU_I
MT]M_I7^<?Y[=.>IH_P $]5-UIU]H>N?9K?[8>?MF.W^<_EV./D_XD?$+7/[5
MU"""^Y^V?0#KQ_D^V?3S_3?C!XXTVU_<:M^(Y_#T_P#U4 ?IQ#XJU7X,ZUYV
MJSVVI=_^/S_$?@/K7H/_  O[0_'DMO\ N+6VN,#_ "/_ -?4?6OQVT?XJ>,?
M&VO_ -AW\_VG^G^?:O0-8T;Q5X)NK>^G^TVVG\#^7^>O7M0!^^'ANS\&ZEX7
MM_L-_P#9M1NOSX_'W_STK'U>\\<>";_3[[0]4N?L_P!L/M_GWX!_&ORO\!_M
M%0:/%80?;N+7TO/;^OX#M7U!H_[76AWDMM8SSVW^3_GCF@#[X\-_M%?$V:*X
MAOO])_TS_E[O >.G;_Z_XBOJ#PWXE\+:QH/VZ^TNV_X2#KCT]NW;^5?%_P ,
M9M#^)T5O/8SVWVCK^77_ #Z_B:^T+/X8ZKIMK;ZK8YN1I?\ IO\ GCCMVH \
M/^(4W@[6+"X@\1P?Z3G-G_H?K]/P_'-?*^HZ]X<L[K["8+;[/Z79]OQ]/K7T
MQ\9M>_X3#2[B"WM[:VUC2_\ 0OID\^_8?A7YK_$C1_%7E7$'BJX^S:A_RYG'
M]F_TX_K0!H?$+PU!>2V]]H<'V;_KT]O_ -8'8Y_&O>/AOJ6AZEX7N(/%7V;[
M0;/C[7W].G3\\$>U>#_#&'58;7[#JM];?:,_\O?^<C/Z9K'^*DT_ANZM_P"P
MYQCIZ]NWKU_#W/4 ] \2>"8+S4+BXL<?V=C_ .M]1^!YQQ6/H7@.Q^U:A/\
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M\TW^3_G\AGU)-%$_;\/ZU7H L457\_V_3_Z]'G^WZ?\ UZ "BK$_;\/ZUGT
M6*_UB*_R9Z_UF* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *_PA/VHO\ DYG]HG_LNOQC_P#4YUZO]WNO\F+XW_\ !M%_P6S\<?'+
MXR>,O#'[%KZAH'BKXH^/?$WAW4V_:+_91TR:\TKQ'XNUS6]&U62";XX1RQL]
MK/'YD<L<4L;/&A6/Y6 !_-)7^^7X,_Y$WP=_V+VC?^F>.O\ (V_XA=/^"Z/_
M $8U_P";+_L>?_1$U_KG^%[6:Q\-^']/NX1;W%KI.FV5W;]0KPZ6BR(?4AU(
M8>JD'D4 =/1110!^+O\ P7"_X)@^'/\ @JI^Q+XH^#^D)IVG_'OX?7\WQ)_9
MQ\47UX-/TZS^)>BZ;)#/X.UZX 7;X9^)?AV:;PS>+(S1V<TOAWQBZ3GPO;QR
M?X]_Q'^&?C_X,?$#Q=\+?BIX1UOP%\1? ?B+4/#/C#P1XHL)-.\1^'O$6COL
MGT?6]'E^>*6.4B)E,95F<LDC1E2_^]E7X!?\%>O^"!G[+'_!6&P_X3V]FO?@
M1^U'H>B-IOA?X\>$M%TZZ7Q/;6ZW<.D>&/C;X:86\OCWPU X@DTZ:&\\,^-?
M"_R>5XKETY)_"=X ?Y%FA:]K'AG5])\0^&]3U'1M=T35M,U;2==TB\.E:EI.
MHZ/+'<Z/J>EZO!)]HTG5()H&FBD5P\4R),A+H@3]^_AS_P '0O\ P6=^&_@-
M_ %M^TWI/C/RK/[-H_C3XA?"7X<>,?B%H$"Z:T"R)K]SX9":^ZG.M&X\96_B
M^3>BB29XXQ".2_:X_P"#;+_@K5^R9J>J31_LTZM^T7X"TV6(V/Q _9C,GQ6L
M]2$CA&V^!M&2+XS01IN)<W?@F%8UVL)&&=GYE3?L!_MUPW7V";]BK]K.WU 7
M)MOLI_9R^,@OM^.0(G\* ENVT#G.0VWF@#E/VF_VJ/V@?VP/BYK'QL_:6^+7
MB?XQ?$O7X;.VNO%'BVXBF>TTW2O,BTK2-(T:.*/P[X=\/Q -/%X:\,6]KX7A
MFN9)HK=))))*\'TK2]1US4+32-*L+O4=3U*[CL],T[3+*6_O[W4'E58].TV.
M+S9&),R$;-[9(*K*#\W[+_LP?\&]O_!7']JS4]/C\+?L<?$7X4^%M0OVL[KQ
MM^T=:2_ 7P]HL3*Q_MB31O'QM?B+KMFOED/)X0\%^+)07'EQ.@8Q?W7_ /!'
M/_@V;_9Y_P""<VM^'?VA_CWKFF?M)_M;:4D-UX?U?^R)[#X1_!C5@JK)/\+_
M  [KD:S>(/%*O(57XE^*T@DCB13X,\'>#[DSW-P =_\ \&UG_!)C7?\ @FK^
MQYJ7C3XSZ&NB?M5?M1W.A^,?BEHMZ,ZG\-?!6A))_P *Q^%LQ*^3_;WAR'7-
M9\3^-D$)D@\7>(W\(3M+_P (I!</_2K110 4444 %%%% !1110 5_E8_\'B?
M_*7B#_LUGX,?^GCX@U_JG5_E8_\ !XG_ ,I>(/\ LUGX,?\ IX^(- '\JM?[
M-7_!OS_RAJ_X)[_]D)3_ -2_Q)7^,K7^S5_P;\_\H:O^">__ &0E/_4O\24
M?L=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNS2VUQ))*C/%(JKA_P#7&K_-\_X/=?\ D[+]BG_LW3QO_P"K-DH _B*HHHH
M_P!J3_@AW_RB&_X)U?\ 9J_PM_\ 3&M?JI7Y5_\ !#O_ )1#?\$ZO^S5_A;_
M .F-:_52@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y'QM_R*'C'_L5
M_$7_ *9WK_/$_P""J'_)['Q)^FE?S%?Z'?C;_D4/&/\ V*_B+_TSO7^>9_P5
M0_Y/8^)/TTK^8H _/#R?W7^<=/KGIW_3-:'G>5^/M_GKCWZ?G!-_J3]!_*K\
MT,'G?7_/;G^1H L0S?Y_S^HS[@U8@[_C_2L^K'_+K<3G_CXY_P X'3U.?UH
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M2^;/VS_G\!7SOX)\2:KK'B/3Y]<@N;K3K7MU]_\ /Z@4 ?IAX)^(7@;XM?\
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M_$FFXM?/_E]./Y^Y[?4 \?\ (]_U_P#K40GR9OW']/R_IC^=;$UGY,6/Y_\
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M5_HYO/MO_P"KU'MW[X-?2%Y-H=YHNGP7I.F_9;S2[+CTS^!SR?;M7O&I:GX
MT&PN(-5T.YMO$%S9_P"AW=W@=CV_7O[5\W_$[2(-8M;>Q@_TH_\ '[_H@_\
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M/H_GWE__ &5]AN?M';Z?X_ACU[FOMB'P=H>@_#ZXG\^V_M"UL_MN<_R]OZ4
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MQ10 >1[_ *__ %J_UB*_R;Z_UD* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "O\ *Q_X/$_^4O$'_9K/P8_]/'Q!K_5.K_*Q_P"#Q/\ Y2\0
M?]FL_!C_ -/'Q!H _E5K_9J_X-^?^4-7_!/?_LA*?^I?XDK_ !E:_P!FK_@W
MY_Y0U?\ !/?_ +(2G_J7^)* /V.HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/_U_Y[UX=>?!F^O->N((/])M\]>OM],_CWR*^T?ACH.A_#&P^W:K/;?\>?\
MQZ=?\]OQH ^'_P!I?PWI6F_$'4)X/^/C[9^G'O[_ (<]>M?-^O0_Z!^?;\#R
M/U_/VKZ ^/VO:5XP^(UQ?:5/G[5>8^R?_7Z_YXYYKQ_6/(-KY'^?\^WK]* /
M![S]SU[_ -/7ICM_7'-8]=AJ4,'7_/KW_IG_ !X>\F[_ $_^L"/Y'/\ 6@"Q
M!W_'^E=1H_VZ&6WG\_@>_K_GZ5R^CPSS''Y#_)QQ_/\ 7T'3='%Y_P L/M/X
M=ORQ[X]?>@#W?PK\2-5TV*W@@N/J">G0U]X? W]HKQ_H-_Y]C?7.;7I_/GZ8
MKYG^"?P!_P"$DNK>>^_T;(SQZ=R!V_SWK]%_#?P&\.:#%;^1]F^T?T^GMGMW
M/:@#].?V7?V]I_%6O:?X.\1_Z3_RY9_7_$?X]:^D/VS/AAX-\2>$O[<F@M[:
MXNK/_ET[?KQ_D=\U^4_P?^&.E:#\0=/U6"?_ )?.G^??\!Z]<?L1\9K.P\;?
M"^WL;&?[-J T?_0OY^O^??- '\]_BKX ^=%<7VE:YJ7V>U]_8\?7O^-?+^L?
M#?\ MFZN+&QOM2_M"U[]/S_S_A7VQ\0M8\5?"N74+'5=5MKG[5_RZ&S[].?\
M\_G7SOX/_P"$JO-9N-<L9[;_ $H?\^?^(P>O]>O% 'VQ^P3\3K#3=,\4?#+Q
MC/<W-Q:WGV+_ $O_ + I/].0?K6A\2/V,_ 'BK5-0OM*GMO[0NNGY_3]?Z5V
M'P!_9IOKR6X\?S6-S]HN_P#3;SG_ (__ //Z<\Y!KA_%7B7QCX;^(W[B"YM=
M/M;S_CTZ="?K^7_UZ /F_P"(7["O]@^$KB_\^Y_T7COCZ?\ U^O:OSOF^ .J
MWGBW[#.+GOWP/\X_"OZ\/@S\'[?XM>#?[5\90?Z/=?\ 'G^OJ.GI^1-5_&'[
M!_PRFNCJNAV5M;?9?U[\_P#ZQ0!_/O\ "7]GOQ'X/_XG<$%S<V]K>'C_  K]
M,/!_@_5?$FC6_P"XN;;[+QU'']/7VXZ<5]D>"?!_PS\*ZS_P@^J?9?M%T>G/
M7TX_"OL#PK\'_"N@Q?N(+:YM_P#IT)_7V[9Z],T ?E?J7P-UR'2_/G@^T\>G
MM_C^']?A_P",W[,?BK^P;_5A!_:=Q:G@?Y]\]?\ Z]?N!\9OB%H>@Q?V'8V7
MV;[+>_\ 'W]>_P!<\\_TKY/^(7QF\.:/HWVZ>Q^TZ?=?\NGKGU/^3QV% 'R_
M_P $W_BIKG@G6=0\'7\'V:X^V?\ 'IU&/_K>_K^-?M1_8^N>*M>N#JL'^C_\
MN6?\@?0].W2OR7\$_P#"N=-UFW\?Z3?:;HEQ=?Z;]D_#/MZ_RKZ@U+]JZ^\W
MP^-#\1Z;<DWG^F6EIVSG_)_^M0!X?^V;\$_'VL6NH>1_Q[^G^?7],_6ORG\*
M^&_'&I1:/X \BY^T?;/L7Z<#Z?2OZN-.ATKXG^"+>^U6#[3]JL_],XZ]/ZCU
M'3MR1XO9_L]_"NSU6WO;'P/<_P!H?;/^/O[9_P#K['_)H _._4OV2[[1OASI
M$%\/^)AJEGI?Y>OY_I70?"7]F_Q5\-Y;C7/L_P#I'/V/VZ]<_P"1UK]/_B=9
M^'(O#FGP:K/;:;<6O]EBS^U^OZ=,'CCD8-9'P]F@FS/?0?VEIY_Y>R<\GG\0
M?Z9SF@#XO_:6\83_ /"M+B#Q'!_RYX__ %<Y_#UX]J_)_P#9N\26,.I^*+>?
M/^E?\>?MG_/;/XU^H'[=6I:'>?9_"NE'[3<:I>:7_P >G7K_ )_SFOA_P1^R
M+XXA\1^'_L,'V:WNKS_3+O['S[8/_P"H_J" ?J3^SKXJ\*V>J6\\\'_+G_SY
M_AT_^MUQ7BW[5'QR\'>%?$>L3]NO_'E[?YQ_];%?8'@GX Z5X/\ "]O//_I.
MH?8Q]K^R#^61TS_AFOQ._P""AUYH<-_<0007(N+7_I\ZC/\ A^?4^M 'QQ_P
MGFE:EXM\0>(YYS_9_P!LU3M_GD=_Z5S^@Z;_ ,)OXMN)_#EC_P O??V]/KU^
MGL*Y?SO &I>%[>W\C[-J'VS_ (^_MG\R/KT_KBNH^%?BJ#X;^+='@TJ>VU+[
M5>?\>EI_GMCN!_6@#]</V=?'E]X;L+CPK??:?[0^Q]?7\^_UZ_J/3_\ A7L^
MO:7J!U7I<^N!U[_UQCKTK@/A]IM]XVU[3Y]*T.YMKC^Q_MMYUZ^Q'K]:[CXD
M?$Z#PK<_V'//]FN+7_/M[^U &/\ "7X2^%='U34/[5^S?9N^#G_.>>IY/Y'U
M#Q5X5\#Z;?Z??:5!_P"2?MS_ )XZXZ5\0#XY?VEXMT_2K'[2?M5Y_IG<#_/7
MUK['UB;2K/1K>^S]I^RX_P!$_KD?E0!Q_CSX5^!_&%A<7]C8VW]H?8S_ ,N9
M_7_ 9KX'O/V>_B-XD\1VUCI4%S;6WVS_ #G^N/PS7UAX#\87W_";_;KZ?[-H
M^,?9+OK_ )].>.]?3_CSQM!H/_"/Z[X5L?\ D*'[;[GC^?X<YH ])^#_ (5T
M/X2_#0^'/&,]M_:%U9\8[>O7^E?+]YH.E>%/B-_;D&A_VEI^J7GVW_CRX_SQ
MG\,UX?\ %K6/BWXV\9:?/!KGV;3_ /B5_P#+GCC&?Q'\J^N?ACX\@\*Z-<6/
MB/[-J5Q:]+ST]Q_G].@!Y-\3_&WANSNH-5TK2O[-U&U_Z<_SZ=<?R':NY\*_
M&#Q'KWPYUB^FU6X_T7_ET^V<\YZX_P#U<X]Z\NU+6-*^+7BC4-*@@^S6]K^'
MJ/\ /'I7#^&X8--\1ZQX<@_Y!]K>?8KS@?Z?ZY[Y_7W- 'S/\?OCE!>37%C!
MI7VK4/\ G[^QY_EVZ^WUYK\X->AOM8O[B?7/]&M^/Y^OL?K^M?KO\2?@_8Z/
M?W&JSZ5]I^U?_7[_ $^G^'Y_^*O!,_B3QY_87D?9K?[8?T_P_+/YT <Q\'_A
MC!XJU[[=!8_:=/M?\>O;(]N3^>:_5_X2_";P/>6MQ!Y_V;4/\_48_P ?2OF?
MPWX;F^&.F6^AZ%!]IN+K'^EVG/\ ]<=NOZ=1]L_#'X;ZK>:-_:L$%S;ZQ_DC
MG\O\YH \VU[PWJOANZN/!WD?Z-_Q^_:_\]^.N<_2OG?XJ>#Y]!M?[5@_X^+7
MV'7^?O\ X<5^I&@_ WQQXJBN-5F_TFX[W?V/_/X#GJ:^!_VD/"OB/X>W]Q_;
MG^DV_P#]<]/H>>: -C]F_P#:BOM2CU#X<^(_])T?[&+'%W_G!SZFL_XD? WX
M93>+;?7-#OAIMOJG^G7G^A^OZ^G.?:O%_!_@^>:Q_P"$Q\'?\?%U_P ?EI:<
M^XZ_Y]?6NX^(7A7QCH^C:/>WU]]F.J67VW_/U_\ KYS0!^D/@G7O@#\&?!'_
M !*H+;4O$%W9\?Z'_7/I_3TKAM2^,T_B/2]1OA!]FT__ (\C^?XYQS_^KBOG
MC]EWP38_$+6;>#Q'JO\ H]K_ *;>?:_;\^/7\:]^_:6L_ _@G2_[+T.>UM;?
M_P"MT]?P[_D2 ?#'Q.FL?[&UBQT3_CX^QB][=Q[_ .%?G/H_@_Q'XD\9_:/L
M/_'KZD?CZ?3VK[8UB'Q5>:-<7&E:5<ZEQ_Q]V9_^M]>>>]?0'[*_P]@U*Z^T
M7VA_:9\YO/7\_P"G/O0!\+ZEX5\1S:]I\$^E7/V>U_+/N/?MS7WQ\,?A+H?C
M#X?:Q?6,%M_:&E_Z%SCV_P YZ=/I7W1KWP?\#V>C7%]?6-M;:A=6?&??Z?Y[
M?7S?]G7X ^*IO%'B"^@OO^*7NKS5/]$^Q?T.>GX=/I0!^,^FWGBK1_B-K&AP
M6'_'KT_#W]P.>OY5](>#_&'B.SNKB>^_Y=<WOU_$_P#U^U?J!K'[(OAOPKXH
MUCQ'/I/]I?:O^?3V['IQ7S1X[^!L$W]H7UA_Q+;?[9_QZ G_ ".GUY_"@#Y6
ML_BIXC\>>*+?5?%4'V;3[2]_D.W_ -?M^->@>)/C9I7^C_\ ".:3_:7V7%E>
M?Z'WX_'G\_RK/F\'P:#K7A^"]LO^)/\ ;,WGO[_T]JX_4M8L=&UG4(/"MA]F
MM[J]_P"7O_/;OW- 'TQX/\'Z%X\M?/L83]FM?\_7K[=:\8^)W[,>E38OM#_Y
M"'X?Y_\ K5[_ /#'1]5T'P;<ZK!!]FM]4L_]"Z?RSV/^->@?"7P=XJ\>:S<6
M-]_Q+;?[9]M-W=^GI[]/ZT ?C/\ $+]EWXFV<NG3P?:>W_+YVZ]?QZY^N#7V
M!^QG\'[[PKK/]JZK/_I'K[ ?7TXSP:_6#QY\-['0=&UB?5=5TW_1;,?8_P#0
M_P#/'_ZZ_(_PK^T)8_#WXH:AI6N0?9M'NKS5/L=V>PZDX_/WH _<#XG>&]*U
M[X*_;O(_TBUL_7^OM_*OS7T+Q5X<T>ZN-*U72O\ 2.P^Q]_\@]N>M?6'AO\
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MC)KJ/&'Q.L=>TJXT/2M5U+^T/L?\_P#/K_05^O/P]_8;\*^)-5\^?2O^)/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^5C_P>)_\
M*7B#_LUGX,?^GCX@U_JG5_E8_P#!XG_REX@_[-9^#'_IX^(- '\JM?[-7_!O
MS_RAJ_X)[_\ 9"4_]2_Q)7^,K7^S5_P;\_\ *&K_ ()[_P#9"4_]2_Q)0!^Q
MU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7^=9_P? _\EK_X)^?]DL^/'_J8?#VO]%.O\ZS_
M (/@?^2U_P#!/S_LEGQX_P#4P^'M '\+5%%% '^S5_P;\_\ *&K_ ()[_P#9
M"4_]2_Q)7['5^./_  ;\_P#*&K_@GO\ ]D)3_P!2_P 25^QU !1110 4444
M%%%% !1110 5_-G_ ,%%O^3K?&/_ &"_!/\ ZA^@U_297\V?_!1;_DZWQC_V
M"_!/_J'Z#0!^W'['G_)L7P4_[$72?_07KZ4KYK_8\_Y-B^"G_8BZ3_Z"]?2E
M !1110 4444 %%%% !1110 5_F^?\'NO_)V7[%/_ &;IXW_]6;)7^D'7^;Y_
MP>Z_\G9?L4_]FZ>-_P#U9LE '\15%%% '^U)_P $._\ E$-_P3J_[-7^%O\
MZ8UK]5*_*O\ X(=_\HAO^"=7_9J_PM_],:U^JE !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!R/C;_D4/&/_ &*_B+_TSO7^=[_P50F'_#:_Q([?\@O/
M_P"KGV[_ -:_T0_&?_(F^,?^Q>UG_P!,\E?YYG_!5"$?\-K_ !([_P#(+S_^
MOCV[?UH _.__ )9?Y_NUH57FA_=?A_+^GZGK5^;_ %Q^H_G0!!5C39O)O[?/
M_'OTQ_G_ !JO5CSIX8AU./S_ ,/7KC_  ^L/A7J7_$TMX//_ ./6\^V_TQG_
M #W[8K^OC_@FI\<O#OBGX?6_PSUS5;8W(LC9 7?!)'89P,GW([9K^*_PKK/V
M.ZT^>"?'Z'\.H_#U_*OT ^ _QR\1_#?6?[5T/5<7'_+G_G\/IF@#^@C]JC_@
MGO\ \)MJFL>([&#[3;C_ $W_ $3\O\]/?J37X_\ C;]F/XJ:/%J'A70_#ES]
MG_X\OM?V/Z<CI[?S^O[$? W_ (*<:'-H&GZ'XX[_ /'Y=W=YWZ8.1SCC_)KV
MCQM^V]^SG>6'D6-]HGVC_G[_ ,.I]L=CF@#\C_V.?V:?$>@^+=/G\1V-S;7'
MVSC@?Y'?^=??'Q@^&/B.\\;ZQ<:58_:;>ZO,9Y]OY\D_C^/+WO[6FAZQK_G^
M%=*_T>U_Y>[3_/U_P%?6'P'^/'A3QYXC_LKQ']FMKFZ_Y^Q^G7]>* /G?0=2
M\?\ AN_T^QL9_LW'Z?IT]OUK]6/!_G^,/@U_96JS_P#$P^Q]O\]>?K]17F_C
MSX#^=?V^J^'/])-T/MO^B>AY!_\ UUZ!\-_!/B/3;74+&^^TVUM^?]?R]_6@
M#\Y[R'PYIFO:Q8SP6US<6O ]OS[?7\J^5_&WB0:#KU__ &5!;6W^F?Y[^W]*
M^V?'GP&\?V?BC6-<L;&Y_P!*O.I]O7KQU_+GFOE[QA\*]5M/[8OO$?\ HMS[
M>O;_  Z_I0!\[ZQ\5/%6FV'VZQURYMO],_Y_/7],]!7'P_M1>,8;^W%]/<G_
M #U]O\]C7F_C#S[,:A!_95R?],]#^7?Z9S]/?YW\2:S]CBMYY^OX_P N_;]>
ME '[D? W]HKPKJ6LZ?/KD'VG)_Y\^P..O7TS7ZP:QINA_$CPE;WWAS[-;3W5
MG_H?3]/Z#Z?4_P D_P //BI_8,MO?""Y%O:_\O?<^O\ A]?3M^G'P?\ VY-5
MO/[/TK0_M-S;VN1C_/U'I_6@#]@?A7X#\1Z;%J']N'[3IX[W=YG_ #WX_3KG
M\SOV_-8L=!M=1S?6MM]EZ?Z9Z<'\O\YZ5[!XV_;DOM,\+_8=*Q_:%U9G_P"M
M[=37X?\ [5'Q(\5?$B7]_JIS=<7EI_+V^G'U H Z#X;^)/!VL6%Q///_ *1S
MC_\ 5[GCV_"L_6/$GV/6;>>QG/V>U]._^>Q/]*^/]'O/^$;TOR+&?[3<>OZ?
MYY/?FNXTVSUR:P_MR^G_ -'_ ,^WTX/L/J ?4'_"26.O6MO/YXMI[7U[>_?J
M!U_+BONGX/\ BNQU+PE_8<]]_/O^/Y_45^3TTUQ#:V\&A'[3<77'^B=?;_/\
MJ^\/@_X/N/\ A$K>_P#MW_$P'_+I_G_/TH Y_P ;:=XJ\'^-[CQCY'VGP_\
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MZL0S?Y_S^HS[@UGU8@[_ (_TH.@V(9O\_P"?U&?<&M"&;_/^?U&?<&L>#O\
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MUGP1<6,_^O\ 3^O?_P"OZYKR?Q)X\OO[!_X1R?\ XEEO:\?:^?7_ .O_ )%
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MK/<W/VJSS_I??^77'?IQ7#_M=^/+>;_A'['2OM(^RZ/T_P /SZ_Y'N&C^*_
M'E6^DZ5]F^S_ &S_ )_.O\OR_7%<?\;/!_A76+"WU6"Q^T_9;/KQ[?3GZ_\
MZ@#X/\!_'Z^^&,MQ??;;G_2CS_3]?\\5],6?Q(L?CE86_P#:NJG_ .M_^O\
M7WS7Y_\ C#PWI>L6NH6/D?9M0_SU_+IZ#\*L> ]'US1[6W@L9[G[/:_Y]/\
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M;[/<V?V+/_Z_QQW_  H ]!UB&#3?A+X?\-V-C_Q,+7^U/MG^A]>_X_XYKO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?Y6/_!XG_P I>(/^
MS6?@Q_Z>/B#7^J=7^5C_ ,'B?_*7B#_LUGX,?^GCX@T ?RJU_LU?\&_/_*&K
M_@GO_P!D)3_U+_$E?XRM?[-7_!OS_P H:O\ @GO_ -D)3_U+_$E '['4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?YUG_!\#_R6O_@GY_V2SX\?^IA\/:_T4Z_SK/\ @^!_
MY+7_ ,$_/^R6?'C_ -3#X>T ?PM4444 ?[-7_!OS_P H:O\ @GO_ -D)3_U+
M_$E?L=7XX_\ !OS_ ,H:O^">_P#V0E/_ %+_ !)7['4 %%%% !1110 4444
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M40W_  3J_P"S5_A;_P"F-:_52ORK_P""'?\ RB&_X)U?]FK_  M_],:U^JE
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M U_#?H/Q@U6&P\B>?'7M]/\ Z]>D>&_B=H<.H6]]??:?M';_ $P?Y]O_ *]
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M5?!.JV_VZQ_T?UL_T_S^M?9'PK\26/BK2[<:5/J7VC_.>^?3Z?S_ %(\5?\
M!/'0_%6C?Z=]EN;C_KS]\^^/7G_"NH^!O["FA_#?[0)]*^TGI^G?CZ?_ %J
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M9U+5?&VO?V7/_HV/_K_S/KGGKUK[8B^&-CXDM;CQ'I7_ !,M0NO^/RTZ=/\
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MR[XZUL?"OQ58PS?\36#[-_CG^?;_ .M@5^F'PK^(7@#4M+_X1R">V-Q=#_\
M6._YY]J /YU_BU^R7?>&]&U"^L8?M/V6\Z_Y/;G^OM\/^-IO$9\+6_AP0?\
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MM 'TQX/^*ECJ7@.YGUR?_H*'MZGZ_P">M?G?\9M-FUZ6X\1^%;'/V7MZ]?\
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MU>9O/],_E_3U]L5Z1\5/AC;^%-!GN-#Z?K[?S]A7V1X)_91_X22_M]<\.?\
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MM_SC&/S]??K^0!7G[?A_6J]6)^WX?UJO0 4444 6*_UD*_R;Z_UD* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "O\K'_ (/$_P#E+Q!_V:S\
M&/\ T\?$&O\ 5.K_ "L?^#Q/_E+Q!_V:S\&/_3Q\0: /Y5:_V:O^#?G_ )0U
M?\$]_P#LA*?^I?XDK_&5K_9J_P"#?G_E#5_P3W_[(2G_ *E_B2@#]CJ*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "O\ZS_@^!_P"2U_\ !/S_ +)9\>/_ %,/A[7^BG7^=9_P
M? _\EK_X)^?]DL^/'_J8?#V@#^%JBBB@#_9J_P"#?G_E#5_P3W_[(2G_ *E_
MB2OV.K\<?^#?G_E#5_P3W_[(2G_J7^)*_8Z@ HHHH **** "BBB@ HHKX1_:
M=_;>^'_[/\MQX7TN$>./B8RAE\+V5ZR:=HQ8R$OKNKC"1R;3&RZ A%Q)EAB$
M*I8 ^[J_FS_X*+?\G6^,?^P7X)_]0_0:\X^*/[9'[1/Q6N9EUGXBZEHFC3@J
MGA[P5>GP[IJJ2"5#:"2WB!>% 7Q8<*%51A5 'S5--/--<3SSW-S<77_+W=^O
M;T]/Q[>M<X']1_['7_)L/P5_[$32_P#T U],U_'?X<\8>*O!-_\ VKX/\5>)
M/"6H=KKP]K&LZ;J>/3_BG_3_ /5VK]"O@;_P4E^+'@:]L-)^*MN/B9X1\O9<
M7@_XE_C;20JE5\K5V)BUP =5\4JH; W^.#@5T ?O^1C'N,_J:_S0O^"GG[:/
M[3O_  78_P""K/AK_@ES\ /B%J?@G]F2T^,VK?";P_H]C>ZG'X<\7/\ "IM>
M\0?%G]H+QUH)D\,1_$*/PKX>\'^(/B7X#\*7%Q,#X3T#PXG@Z7PSX[\4W7VC
M_1:\*?%'PK\7OAM?>-OAAK2ZY;76C:B+(6L8.IV6K+I:RKI.K:5YI:/6XY&1
M3;2)\C;!&60@R?Y<W_!I[?:%9?\ !8+X366MRZ7'K>H_#WXOP>$$U261KZ[U
M:W^#_C::4Z ISOOHO#$>L2(57">%EU]@S(%-:4,.JU:3>O)3E+_P%-OTT3_X
M/6:^F';Z\WW=O4_7O_@JO_P;8_"C_@G3^R(?VYO^">OQD_:"T;X]?LFR>%_&
MGC*_\3^.M+;5?%'AHZU'X=\0_$;0=7\/^'/"A\!>)?"<FLKXHFDBD7PD?!.A
M^(HYX6E033_BAX$\5_'C_@Y,_P""I?['_@_XV:<MA>:5\(OA?\)OC/XI\.;C
MY?P9^"P\0>//BE\3V6-3%X?\1^//$&N^.&ME6+_A%/"WC'Q[X5\'1KY,EN;C
M_1D_X+1?$SX?_"[_ ()0?M]:[\3[B"W\.:W^S!\4_AQ96K7<5H]WXQ^*_A:Z
M^%?@71]-U&4JC:K<>/?%NA06[%)2I8,T.V*4C^0O_@R8\._#J\^.G[?OBS4=
M!@_X6;HGPV^"VC> M6G&+_1? .O^+?'MU\4-)W-D^7=:YH7PI<LRJ3_8P&U=
MV%THOE<GVZ?-+]5_D.[^JWZ_\#\/^&/]!WPYX8T3P7X;\/\ A'PQI]KH_AKP
MKHVF>'?#NE6H$=A8:-HVG1:-I&D*"2WE01)''&,,W[M%9F?&>JHHKG&%%%%
M!7^;Y_P>Z_\ )V7[%/\ V;IXW_\ 5FR5_I!U_F^?\'NO_)V7[%/_ &;IXW_]
M6;)0!_$51110!_M2?\$._P#E$-_P3J_[-7^%O_IC6OU4K\J_^"'?_*(;_@G5
M_P!FK_"W_P!,:U^JE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]#VK!\$_!_SO%MQXCU6W_P"7S[;[=^/3I_G% 'P/XV_8_P#$>F:#_:NAP?\
M'UT_3^?Y#'Y<?X.^&-]X5BM]<\1WW]FW.E_]/A_GCI]1W'UK]K_$GBG0O"FC
MW)U2]M?]%M/]$M>YXQ^GJ>@SQQ7X@?M"Z]XC^*FO7]CH=]]FT_U]3G^I_P \
M"@#ZPA_;JT+38AH9FMO]%T?['GWZ9_7'Y^O'Y#_M3_M.>#O&'B/4//-S<W'7
M_0[//_Z_\>U?*_Q@T?Q5X/O[B^^W7/7^OK^/?\?2OE_PW]M\275Q?7T'VG/?
M\^W\CWZ4 ?4'@_QMX5ABUB?2OM-U<75GJG^B7=G_ ,2SH?\ #VK]R/\ @FGJ
M6JZE\.;?^U;&V_L_['_SY_YS_GVK\?\ X _LQ^./B==>?I7ARYMK?_G[Y_'G
MT_\ K?6OWP\*S>'/V7?V<Q!?3VUMK-KH_?VS_G\* /P'_;JF@T?Q=X@\B?IK
M.J#UY[#Z9'_ZJ_)_7M3[8_'^G'Y<&OKC]ISXM0>-_%'B">>?G^V-4_R./K_.
MOA?6+SSOY]1GO^.1QZ4 6(=3[X_#\^/Z]/KVKJ-'\8?8Y?KGG]/\C_(\_P#.
M_=?YQT^F>G;]<U7^V>3SU_3\?PQTQ[]LT ?5&F_$[R8L^=]1_P#7_P _UKH-
M'^,]]9W6?/N>OI_GZ?\ ZZ^-_P"W?\Y_^O6OINI>=_G_ #SZC^G0 _1GPW\9
MIYKJWGL;ZYMKC]?_ -6/\>M?4'P]^-GBO7O%NC^%?[5U*Y_M3!Z]O\_GU^GY
M/^"8;B&Y^T?YY]Q_GUP>:^V/V:?%0A^/O@>"^@_T?[9^7_ZO3L>_H ?TX?!G
M]EW^S9='\57T_P!FM[JSTO\ T3Z]^]?:]G\/?"L,MQY%AIO';MS^H_D:7PW,
M=2\!Z/Y'_0'TO_('YY!ST],50\*V>JZ9JFH^?_Q[_;.G^>._^3U /DW]IOX,
MPQ6FG7'ARPMQF[S@]1D=#Z'V]1Z<U[3\'_ ?G?#FVL=<L;;_ (\\?Y/X#_\
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M_I0!8I9O]2?H/Y4E% &?15CR/?\ 7_ZU'D>_Z_\ UJ *]?ZS%?Y-_D>_Z_\
MUJ_UD* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O\K'_@\3
M_P"4O$'_ &:S\&/_ $\?$&O]4ZO\K'_@\3_Y2\0?]FL_!C_T\?$&@#^56O\
M9J_X-^?^4-7_  3W_P"R$I_ZE_B2O\96O]FK_@WY_P"4-7_!/?\ [(2G_J7^
M)* /V.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM^V5\39OBG^T7\2-<$YN='T'6#X,\-Y).-+\#$Z$0#_='B0Z[XG'& -?"@
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MUK]5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C/&O_(H>+_\ L6/$
M/_IHFK_/*_X*H6<'_#9OQ0QT_P")7_+'K]0#7^AKXU_Y%#Q?_P!BQXA_]-$U
M?YZ7_!5";_C,WXH_]PO/T^I]\_J?:@VAL_E^1^<\T,'E?3\.OKCC]<58JO\
M\N7^?6B@H//]OT_^O5B&;_/^?U&?<&J]$'?\?Z4 $TT_3M_]?_'WQZ=3@AF,
M/[_U_#CC^7^<\U8FA_R?\_D<>H(K'\[][_G/7Z8Z]OUQ0<YT$-YYWM^7]?\
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MS_A%=9_M6&X_XF'^<_X<8SUQ7J'A74O^$J\1V^JS_P#(0^GY'I^'\N* ./\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MOC?XU_M^?L._LV7JZ3\>_P!L+]FWX0:VBGR/#OQ"^-OPX\-^)+T!=Q9= UWQ
M#'X@=5.1O6'&!EF&,4 ?9%%?B%X[_P"#C+_@BK\.1"OB']O;X<ZB)[BZM@?
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M_$E?XRM?[-7_  ;\_P#*&K_@GO\ ]D)3_P!2_P 24 ?L=1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR5_I!U_F^?\ ![K_ ,G9?L4_]FZ>-_\ U9LE '\15%%% '^U)_P0[_Y1#?\
M!.K_ +-7^%O_ *8UK]5*_*O_ ((=_P#*(;_@G5_V:O\ "W_TQK7ZJ4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% $/&,@'DXP3G/?C&#U IK
M ^H7ZG!_#)'^<T*QP#W(Z^@YZ?7U^N.M?%?[3W[<'P*_92M8(/B)X@N-3\7W
MMF;O2? 7AFU?4/$EZ B!96AA80Z)I6\-NNM?E@A^8%)&$:K7=D60Y]Q-FM')
M>&\IQ&?9W5:ITJ&%H3JUIR:3:4:4).$8IISJ3E2I4XW<ZL=$U6K*@G*6S;=V
M]DK=6[7Z+=OM;4^SRH/W@H^J1\_EUI0BCIL_[]H1_*OYS_$O_!=S4UU#R_"_
M[.^GC21<E5?Q!\1V.IWVG%<>9MT7PY*-%?<0P\\S $#J22?>_@E_P6Q^"WCJ
M^MM#^+O@;7?A%/<D6RZ_9ZF_C'P:IQR=9E?P[X6\3:(Q4D[9_"3(3QNV[4'[
M)F_T4_'O),FGG>-\.,;4A2INI6AAJG#>*Q-**;3YL/A\34KR:LWRT85YR2?+
M"35GP+.LM;2]JDFTDY1M%_?9;=VEYH_<$ #@4QESR/IS7-:!K^B^*='T[Q!X
M>UC3]:T'6;$7^EZMI5^FHZ;>Z?*,+J.G:K$7CD0I(#O1V4D$(006;J"0.37X
M4U&A&SO:_P!W]?ULST HHHJP"BBB@ HHHH **** "BBB@#^?C_@M!_P7=^"'
M_!)7PEH7A&ST:#XW_M5>/=,FU?P-\(X]5&D:1X>\.H[AO&?Q0UVWCDDT308]
MQ@\,>&[7S/%/C&Y1X+<6=LEWXF@_@T^)?_!;G_@NU_P4;\9:QX<^$GQ8_:%M
M1<!;U/A)^POX&\6^&9-!TIW9%D&J?"."Y^*L]N-C),?$_B^\C?80[IEHQ\U?
MMN^)O'O_  4=_P""T7Q/T+QCK]UINK_&S]M,? +PQ>7^'_X0CP2?BHGPC\!Z
M45*A/+\*^&$TF(K\RM)!*6QN*C_6E_8W_8X^ /["?P-\*? #]G'P)HO@CP/X
M7TW3[>XGM[&$^(?%>KHJ1:QXL\9:X ;CQ!XB\121^?=75R&D%S)+Y)6#RH+;
M'*\&I99#/,5%*>>PC+D3]Q)1HS2CIRI0C6I1M9MR;7PK77'U_JN9?V7AVG.*
M]Z5EI:_-JD].=24;6NH\S^)*/^4^?"__  <JZ!_Q.U\/?\%R=%:T8W3:M_9'
M[>^G?8E'1UU4QHR#&!N+ Y/4-FOIW]FG_@YG_P""P'[%WQ!E\(?M!>,-0_:%
M\/\ AZ^@TWQ;\'OVH?"!TOQUIP38\BQ^.[70?#GQ1T#Q"T;!C+XMD\76L8".
M?"<A!>O]8 D1XSR3_G_/Z]J_#3_@MM_P2>^#'_!2O]ESXB_;/!7A^P_:>^'W
MA'Q!XC^ OQ7M;.*R\3V7B;1=*N-57P-KNMQP1W.K^ O%[P1Z%<Z#>Q^1:7$T
M7BVR7[7$):FOCZV7X?ZS-)P37/HI.*>[2DKNRN[)IV6CO:Y0P>%S'$+"STYF
MHWWLY-15WI9-M)O6U[VMHOI/_@F-_P %0OV<O^"H_P  +3XR_!#4;G2=>T2>
MRT;XG?"SQ%J-K-XW^%_BF6$2'1]:^S(!J^CS L?#'B:.,6_BB*&23R[:YBO(
M8OTY^\"W&6&0/8'^N*_R1O\ @V4_:L\7?LQ?\%6_@QX(@O)H/!/[2UW<_ 'X
MA:$\[QVFH?\ "0P27'@75O)9C&^L:#\1=,T-89F0R"QU77H4:(3R*_\ K8&0
M@2?[$2]_]WI[G/M^/?T\QP^'IT<OQ.&M[/.*?.FM7%QE*%2-UHTN5.+ZJ6[M
M=^5"KB:>,S'"8M6_LKE<>C::E>ZM>\94YQ[.R=EJD]4P(CD_*>?SS_(#/''/
M/:OQU_X+H_MTS_\ !/C_ ()P?''XS^$M=/A[XP>)8-/^%/P-ND.F&_L_B;X]
M+Z3IVO:;;ZN/)E/A#0$\0>,9 \$X5- DS%AV)_8LOB3 X#*>/P/]3Q_2O\U[
M_@\:_;>/Q1_:I^$?[$WA?55N/"_[-OA/_A8'Q'M;.X5C_P +@^*VF1RZ/I.J
M*N=LOACX<#0KJ,F1<Q?$"[1CD&OG<<N:<,)07-'-WS56DVW3AR2GU5N=<L-T
M[SLFGM[>517.\4X\RRA<TKV<=+**::::;MHTTTFFFKI_EA\*_P#@XZ_X+">#
M/B1\-_%_CW]KOXD>/?!FA^,/#7B3Q%X)UGPY\--/TSQYX5T/6Q+X@\(R3V_P
M[WQP>([:*ZT&2ZMP7MY&#DJ(RT?^LK\&/B[X(^.OPJ^&WQJ^'FJ0ZWX#^*7@
M7PO\0/"&JQ'*W_AKQCHUKKFC3KP"&DMKR+<N  ZLO4&O\V;_ (*C_P#!)Z[^
M!'_!!W_@F%^T5IGA^YM_'WPYM-9N?CVTEMLU"UT?]JO5F^*?AQ]:!RRCP9XA
M;1O!R*P!CEU]5^[FOW[_ .#0_P#;G_X7Y^Q'XM_9%\7ZFT_CS]DK7_+\-+-=
M,U]J7P?^(%UK&M:"YC95)C\)^*$U_P /':SK!9R^&T^\25^LJ8;#SPO$N7KD
MCG&0<35*-2S3C.":C._:TJ:FK:*]9))71\_.+4.',UIM3RG.7)*4;.#NYPIR
M35XM>TC%*]KPJTVOB3/[ J***\H]4_RM;;_@N#_P58D_X*91? \_MJ?$(?"<
M_MSK\)AX0.@_#K^S_P#A ?\ A?4G@C^QAGPF-;%M_P (XD< 19O,R@*KM! _
MU/(3P<\;LL/3EEZ?7!K_ !7]/_Y3&P#_ *R1D_G^TI<M_,=_Z5_M/(<1H1WC
MC/XDK]..GY5.6PBN#>$\2HQ7/246TES-?ZJ<'NSE;FDE*I*23D[.3:2;;D\W
M4:?%>:X6,8Q4/;744E&T>*>)8I**2BN5>ZK16EELDHZ%%%%4(**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ]J_G^WZ?_7H T//]OT_^O5>?M^']:K^?[?I_P#7K0A_Y=O^!T =!:?\L/\
M@->\>"?]5!_S[XYZ=>?3\?Z\5X/#^Y^S_P#ZO^^?KD_TQ7M'@_6(+.6W@_Y^
ML?RS_GO[T ?LA^SW>P3>$O(@[<>OIQ]../\ &O-_BI]NANM0@L<_Z5W_ !_S
MWK/_ &>_&$&F_9["?K=?US^6 /\ ]7;WCXA>%9[R7_A)+&Q%S;X_X]._]?\
M)]* /CBSO+Z;]Q/8W/3U)_GSU]N.37W1\#?B%!H.C?V5?0?O_P#I[''K_P#6
MKCOAO\,?$?BK4/(@\*]<=/\ #Z?X_7H/C#\,?%7PQM?MT^A7-M[_ /U^O.*
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M_I0!XOXJU[^S?^7[_1[7\_\ ]7'3(^M<OIO[6FM^&[JWL?#D'VFXM<_\N?\
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ME?*_@_P%/XD\.:Q]N@^S:A:_VI^77\^OY^E?OAXP^#(UFUU"R@_X][OOW_\
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MI_\ 7JOY_M^G_P!>@"QY_M^G_P!>CS_;]/\ Z]5Z* -#S_;]/_KT>?[?I_\
M7K/\_P!OT_\ KT>?[?I_]>@"Q7^LA7^3?7^LA0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXA_;U_;C^"7_  3P_9H^(G[47QZUN?3?"7@RTM[#2=!TB$WWC'QYXRUF25M
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M9-#RBD'5X?#>O7,NCL.XEAC8\&,,,$?2E?X(/@?QWXU^&?B[0O'GPX\9>*?
M'C3PU??VAX?\;>"?$VK^&/$^@:E"Q5=5T;7=#DM-?T>4!L++!(DS+)( X+%1
M_>C_ ,$%O^#GCQSXX^(/@7]B[_@I)XLM=>U/QQJR>&_A%^U?JRZ7H&K2>)-7
MW/X:\$?&[REM_#]U'XAFEC\*^$/B-&MO(T[>'X_',3QRW?C2( _OMHHHH **
M** "BBB@ HHHH *_RL?^#Q/_ )2\0?\ 9K/P8_\ 3Q\0:_U3J_RL?^#Q/_E+
MQ!_V:S\&/_3Q\0: /Y5:_P!FK_@WY_Y0U?\ !/?_ +(2G_J7^)*_QE:_V:O^
M#?G_ )0U?\$]_P#LA*?^I?XDH _8ZBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K_ #K/^#X'
M_DM?_!/S_LEGQX_]3#X>U_HIU_G6?\'P/_):_P#@GY_V2SX\?^IA\/: /X6J
M*** /]FK_@WY_P"4-7_!/?\ [(2G_J7^)*_8ZOQQ_P"#?G_E#5_P3W_[(2G_
M *E_B2OV.H **** "BBB@ HHHH _#?\ X*<? 2^T[Q3I_P >_#MCY^CZ^NEZ
M1XX%K:#=8>)=!(31=8.9&=G\4>'BOAB0A$CC_L6.%2[^*V-?DO7]A/B;PQH?
MC#P]J_A7Q-I-OK.@ZY9R:3JVEWGS17^G/D,K@,I8$G>1N7D9!!&#_/1^U'^P
MIX_^"-[?^*O!%OJ/C7X5$&];5;*UW^(_")!*D:QHX 610P)_X2D . 5\Q(V8
MH #X-HHHKG ***Z#PMX5\1^-==L/#OA;1-2\1Z_J0)M-*TFS&HZE? #.3V Q
MW/\ +. "AH^CZKKVJ:?H>AV-SJ6L:K>:7HNCZ1:?\A._U37?;IGI[8]<BOZD
MOV8O@Y:_ [X,>$? )%J=9M;;^V/%MU;",_;_ !3K#"36)&'F/NV%5T&)OW8\
MG1X6";\FOEO]B_\ 8?M_@S+%\2OB6NGZC\3;FS"Z5I=L#?Z7X'5E1B(F=-LF
MO,K@23(2%!98R903'^F-= !1110 4444 %%%% !7^;Y_P>Z_\G9?L4_]FZ>-
M_P#U9LE?Z0=?YOG_  >Z_P#)V7[%/_9NGC?_ -6;)0!_$51110!_M2?\$._^
M40W_  3J_P"S5_A;_P"F-:_52ORK_P""'?\ RB&_X)U?]FK_  M_],:U^JE
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M#ZKX(FGB\6:.KL&3==>&T1MI(!QA?MKY#WP3^6?7O_.O\=?]I;_@W;_X*_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .1\;?\BAXQ_[
M%?Q%_P"F=Z_SM?\ @JO_ ,GK?$C_ +A?]*_T2_&?_(F^,?\ L7M9_P#3/)7^
M=G_P5=_Y/7^)'UTK^0H _/&;_4GZ#^5%Y_K1]3_(TV\_X]1]#_(TM %>#O\
MC_2K%%% !_JO\YSG\O3VZ?G8\_V_3_Z]5Z* -#S_ &_3_P"O15>B@#0\CW_7
M_P"M5>:'_)_S^1QZ@BBB@Z#0L^W_  *N@@[_ (_TKCZT(9O\_P"?U&?<&@#J
M(9OWOX_S_K^@Z5L0S?Y_S^HS[@UQ\,W^?\_J,^X-=!9WGDQ=_KZX],?I_P#K
MH.<]H\*WG[VW]/Y>GJ/\^W']"'_!*_[#_P +"T^?S[:YN/\ $_ET_ \_2OYK
M_#>I_P"E^O\ 7^?3_/)K]>/V _C9!\,?'FGWWGFV^U7G''Y?Y_\ UT ??_\
MP4R\23P_%"V\^?[-;BSTO\,Y^H/_ -:OQ0\>:QYUU<?8?^/?&.G?K_,']>U?
MTX?M(? 'PK^U%X2M_'-A]EN=9^Q^GX?7/)Z&OP7^)W[.NN>"=>N+&^TJY^SV
MO^>N<CUZXH ^9]'T&XU*U\_R/T[_ *?X5[A\)?A7_P )YK/D#2KFYN+7M:=?
MT[8Z>E=1IOPQ\8PRZ?!I6E7/]G77_'YSW^O\_?I7[(?LH_ WPIX)T$^.-<^S
M6UQ:_P"FWG\\>O?W_4T ?FO\2/V)]<ATNWOK'2M2^T?YSR>O_P"KKQ7E_@_]
MBWQ'K%U;WVN?:;:WM?7 _P ^W/0U^X'C;XV0:]K-S8Z'<?\ $OM<]/7ID_\
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MKU#X;S8E\B?H?IT^G'].F>:\_KN/!,WDW7^<>GI^7^- 'Z(?!F:"#7]/]/\
M/\Q^?6OZ8/V>_!^E>)/!MO!;P6WVC['^/;'UYK^7?X2:Q!9:II]Q_G'Z=/SX
M]*_H8_9+^.>E:/+I\%]/_HY_SW[^_P#*@#Y__;2\-^*M!NLP:5<_9_\ KS_7
MC\#S_P#6KS?X2ZE/J6@V^E3V/^D77^A<V>#Z#_/YGBOVH^.6F^#OB1H/V^">
MWNKC[&>OY9Z?SS[>M?G_ .#]!\':#XH,$\%MY_Y__7'\OTH [#X#^ _$>@ZI
MJ'V*?\O?M_G^M>?_ !@\5?$70=9U&";5;FV_[?/Q/?GM_2OIC1_$D_AO7O\
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MO[B>#_CXZ<#^I_R1^%>D:Q#?:Q;'SQC\/;]??_\ 6:\OFTTZ.+CZ?Y]OUZ4
M</KUY/VG_P _B/Z_T%>0:C_K3]?Z5V^O>?\ :KG'Z_K^&/\ Z]>;ZE-/T_SZ
M=_Z9_P 0#'O._P#P&L?S_;]/_KUH30P31#\/PQV_#'3\^,UCP=_Q_I0!8K8A
MF_X]_P#/UX'Z_EZ5GP=_Q_I1_P M?\_WJ .PFO/W7M_G\S^''M74:/J7E2V\
M_:U/N.G3\">O%>;0_P"N'U/\ZV;.;R?Q_P 3_*@#[P^&/Q"\G[//Y_\ I!]N
MG?T_SZU^G/P9_:$TJS^S_P!N06NI6^?^/0V>>W_ZLX_EQ7X3>%=8\BZ].?\
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MJ* /HGX8>//$?BKX.6\]]_Q\?\33]?\ Z_?]>U?#WC;Q5XQT?Q1<03P?Z/\
M;?\ GSSQ_+!],>G2OU0L_!/ASX>^'+>P_P!&^S_XXZ_Y_H:Y:;X5^!OB%%<3
MP06_VC]?\],?UQ0!\0> ]-_MB_MY[ZQM_P#2N.;,CMS^>.]>L>)/V2QXJM;B
M>#[-_P >?^>W7^?3/6NXAT'2OA[KWDS_ /(/M>OZ8_Q_GTKZ(\$_&#PKXDO_
M .RK&>V_T3C\_P ^WIG/TH _"?\ X8A_LWQ'XGU77(/LUOIEG]M_TOZC/_UN
MG%?5'['/@_PYX5\9$0?9N.OY?T^OYU](?M4:]8V<.H0:5/\ \?5G_P >G\O\
M\^Q%?DO9^-OBIX#UG^W-*L+G^S^_X^A_^O\ I0!^\'QL^)^A^&]+\C_1O^//
M'KU!/X?S_G7XG_M+:]X<U[1M0U6Q^S>>"/\ //7K_A7E'Q"_:6\<_%27^PYQ
M<_:/<X_S[_UKGM'^$OBKQK]GTJ^U6Y^SW5Y_QZ?UXZ>W8?K0!\[:9XDOKRPN
M(()\_93^/^>/\BO$/&WQ"U6\UFW@@_TFWM;/[%Z<XZ=*_<C_ (8A\#^"?#FG
MWVJWUM]HNO\ IS_#^8Y_GTK\_P#X\?LTZ5X)O[B^T.?_ $>ZL_MWX_SQ[GVH
M _/_ $V'^WM>MY[Z^'V?[9STQW_#CZ>OH*^^+/PWI6F^#;>X@Q]H_P !_G_'
M'%?#_AOP?/!XCMX)X#_Q^?3)SZ9Z^G;''T^V/%4T]EX<T?[/!_QZV?KZ_K^/
M;I] #A]>\'F&+[=]AN?LXZ=_R]N_TSU&:^Z?V79K&SBMY_(_X]>/\_Y_*OD;
M0?%4_BK[/X<GYMKK_0OY>W&<>AZ?B/U@^$OP9T/P?X.T_5?]&_TK^R_;]?PS
M^E %CXS?&&";3_L-C8VW]H#UL_TZ>GXGZ<U\;S?%K^P;JWOM5GN?7[):#^9[
M_@>M>D?&#3;'1_'G/_ZN_P#G'3MBOC_XG7ECJ=_Y$'_'P>O?C]>G\\\T ?;'
M@_\ ;&\<:#JAOO#G^D^'_P#ES^UV>3[<?6OTP^&/[6<&O:7;W'B.#[,>,_AW
M/?\ SGUK\!_!/B32O#>@:A8ZJ?\ 2+6T_P ]OY]?RKVCP3\2)]8BMX./L_VP
M?AU'Z?U';% ']"\/Q?\ "D]A<7L-Z#CH/M8)'T'3_#T%?''B2\L?B1XCN)X+
MZY/V7_I\/U_S[U\CP_$*";[/8P3_ &;KG/([8Z=_\^E8_P -_C98^%O%NH0:
MY_Q[W?\ :9Y_SSD?S- &/\>/&'CC3;^X_LF>Y^SZ#TY/I_+(_P ]O@_QM\5/
M&,-I^_G^S?:KSC'Y_P#ZR?K]/IGXV?&S0[SQ;J%CI5\?L^J7GY_Y_'KFO)M>
M^!OBKXG6'VZP^TW-OGGZ_P"?\]J ./T'QMKDUKI\YGMKG/3GGK^/./\  =Z]
MX^ /QROM2\77'@Z>?_1[JR_#]"?R_"O-_#?[.OCC[)_8=C8W)N/\1^!_S]:[
M#P'^R)\1O!%U<>(YX-2MKC[9]N]._P"@_,>WH ?1&O? '0]2UG6//@XNO^7O
M\_3_ !QTKY/^)'[%OB.;5+>#2H+FYM[K/_'I_GTYZXY%??'P]^)'AS38O[*^
M(VJ_9M0M?^?OGD=/?C_(]?:--^+7ARSO_P#D*_:<?\O?ISV]S_GK0!\3_!G]
M@\P?V??:K!<VUQS_ /K_ ,YSSBNX^,!\#_ W[/!Y]M]H_P"/+]>O7_#'I7M'
MQ@_;2\.?#?2[B>QOK6YU#/X>_P"/ZU^&_P 8/C-JOQFUZXUS79\:?_SZ?X]/
M<?GZ4 ?>%G\8/#FL6MSY'V;IS[?A[XKYG^(7CRQO/[0@L9S;7%USW_\ K?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY?'&+QG&NJD)+/<+H>@>"S-"DLK1(T++;0_VU))+_&A0!_HN_P#!MI_P;]_
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M@EXXU/P7JMU9H\>GZ]8QCS="\7Z."9&_L+Q7X=ET;Q':,[!_(UJ%7"N65/\
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M^4X:1_ZY* "BBB@ HHHH **** "O\K'_ (/$_P#E+Q!_V:S\&/\ T\?$&O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /R@_P""LG[/6L?&7]F:X\0^&+-M3\7?!W66
M\=V=I:86^N_##:5/I/C"%0 ,&&UD3Q"6 VM_8$2@EA@?R-G#91P#Z#U'J/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYZGKU_I7Y#Z]\2/$?@G0/(GOKGKZ>O7_ !Y/]:^?]!\>3^//%NGP?\O O/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_#I+J.WN_#DJG^M*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /X'_ /@\0_X)F^-_%-W\./\ @I9\)]!O/$.F^%?!^G_![]I+3M+LVO7\
M/:-H>I:[KG@3XF2(J%TT-9=<UOPGXOEP(86'A,S !II%_P ^>O\ >Z\<Q>!I
M/"/B:+XD#PU_P@']AZJ/&X\:#36\%'PR-+;_ (2 >-!K8;P\?#_]B[OM@\3
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?$*#09=0@@@%S<:I_,?_ %^W/UYKZHU_QY_PL+2_$&E3WW^C_;/MOVO\N_\
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M\\\/Q3OH;KR(-<U*VM[O_0OLOVWG_/Z?H*_<#_@GCKWA74HO(\1WWVFXNO\
MG[O/\G\?7BOROT?]F/0]8UG[=!?_ .C][3GMZ?Y/7TK]0/V=?V;_ !'X5O\
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M^SGTWQ';P3G^Q/U&"?\ (Q^M 'W!^TM\);'QM_PD%\?])T_''^?RX^M?E?\
M\(K?Z#JESH=C8W/OTZ?I_+J*_;C1YM*_L8V.JZK_ &E;W7_/WQ_CVP!6QX;_
M &;_ (<ZQ+_PE5]??9N@-K]C^AZ<D_I0!^9_P3^$OBK3;K[1]AN?L]U^'3'Z
M]0>U?2&F_ ;2O#?]H>-]5(MO]#_3WYSZ\5^C']L? _P3X<N//O\ 3;:XM?\
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M?I_]>O\ 68H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0+X,\1^)O"OBVX\8?OIX/"/_  AS>&/%7BG]]O&7_!E=_P $\+[PMJ\'P_\
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MG]JQ>$)(Y=)&N>'?#D]L9%9'1E$HF$C,K1QL)%C_ )R?^&$_VWO^C,OVJO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]?QK\Q_&VL7T,7VB _UQSGD'\/KWK[X_9%\;6.I:-<07]]]FN,=OP_7Z<^]
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MGUY]3^?^/I7I'AOX)WUYJG_$\@N/S]/\_F,U]\?!/X2^![.Z_?S_ &FXTO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#AK?V</_HK:/\ B-/_ ."67_1 OV^?_#6_LX?_ $5M?Y@E% '^O5_P3?\
M^#B[]B/_ (*@?M$/^S#\!?A9^U/X3\?_ /""^)_B0^K_ !@\"_"/PWX4_LSP
M<VB0:S$NI^!/C7XVU]M<EDUNW$"1>&A&ZB0^9"D6R7^@ZO\ *Q_X,[/^4O$_
M_9K/QG_]/'P^K_5.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MN&\>^&'\7^!/&_A:*40R^*?"/B;PV&;&$;6]&FT@.2>!@L"#VSUXKN:* /\
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M!#>G2_ACXQT+XX>(->=3O>70[-O 6B>'Y/+BRGB?Q+X98*8_-D'^517Z._\
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M/P8_]/'Q!H _E5K_ &:O^#?G_E#5_P $]_\ LA*?^I?XDK_&5K_9J_X-^?\
ME#5_P3W_ .R$I_ZE_B2@#]CJ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O\ .L_X/@?^2U_\
M$_/^R6?'C_U,/A[7^BG7^=9_P? _\EK_ ."?G_9+/CQ_ZF'P]H _A:HHHH _
MV:O^#?G_ )0U?\$]_P#LA*?^I?XDK]CJ_''_ (-^?^4-7_!/?_LA*?\ J7^)
M*_8Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M_P WS_@]U_Y.R_8I_P"S=/&__JS9*_T@Z_S?/^#W7_D[+]BG_LW3QO\ ^K-D
MH _B*HHHH _VI/\ @AW_ ,HAO^"=7_9J_P +?_3&M?JI7Y5_\$._^40W_!.K
M_LU?X6_^F-:_52@ HHHH **** "BBB@ HHHH **** "BBB@ HHKX!_X*B>/O
M%'PG_P"";W[>/Q(\"ZM-HOC#P5^R#^T7X@\+:YIZH-1T3Q%I7PQ\2OHNMP/L
M;8WAVZ"7!D;S#F(%@6X8 _D9_;;_ ."[O_!0']O[]OK1_P#@G/\ \$8=;TWP
M3HH\<:OX,C^-EC8:1J?B7XDRZ':ZY_PFWC0>,O&?AWQ5X4\!?!GP?%H^M^)X
MO$/A&%_&'B[PQX>AF\(>+6E\4_\ "#R8?[3'[2'_  7\_P""!'Q'^"?QL_:O
M_:>\-?MX_LK_ !*\52>#_%.B7%T;W2Y?$IT0:YJO@D:MXC^'WA3Q=X%\1Q^&
M]&\0^)/ ?B?PQ<3^#;I/#VOR^-K9GA_X1:?YE_X,N/!7AC6OVU?VI_B3>V=N
MWB?P]^SE?:1I&UF7^R=+\8?$_P !R:J$#$*,C08XE+*0(2_W2_']-W_!TGX?
M\)Z[_P $8OVC[CQ+J%AH][X;\7_ ;7/!6HWRZF?*\5GXT^ M#=M.CTK?)*[^
M =<\;0^68Y(SEA(A 9AT8C_9KK3YJZU5_G_2%A[8C%):6VV\]?Q_5NRV_G/^
M'_\ P4__ &^_^"N/_!<ZV^$G[!W[8'QI^&W[%VO>.?"'B@:!H=LOAO3O"?P+
M^%O@KPT/BAKVK:#K<4/B%)_&NMZ1K$"+),R_\)EX^\/Q[$=[9$_T62F3G.*_
MAG_X,J?V;/ &G? ?]K/]KNYVZG\3M?\ BSIO[.5B]U:*G_")>!O!?@OX?_%+
M6UT6X;RV)\:^)?'.@IXLB=F&_P"%/A:2)=S.6_N:)P,UGBDJ#:>T4OO:3_K?
M_)[BT445F 4444 %%%% !1110 4444 %%%% !1110 4444 %>??$#XA>#/A1
MX&\7_$SXC>)]$\%_#WP+X=U;QAXQ\6^(+Z/2_#_A/PUH.G2:OK>M:QJLC*B6
M\$"//(P;=(@S$DLF]7]!K^4?_@[V^/7C?X/_ /!+71O _@>_N],L_P!H/]HK
MP)\*/&][937ME?'P+H_A+Q_\6KC1_,C:)HC<^)_ ?@TSAMYE\,Q^(;?R568S
M( ?G)H/_  6Z_P""E/\ P5S_ ."IGPQ^#7_!*W3[?X9?LI_!7XC:1XT\8:EX
MZT@Z;I7Q%^&7A_6(-#\;^,OV@]<96\0Z!X5\70ZP/#W@KX8>#V@\8"77/#UR
MY'C6*.;PI_>D1D8/>OXZ_P#@S0^ NB>"?^"?WQI^/=QI>D'QK\;/VA=2\+G7
M;9TDU"3X:?"GP?X>'AS2-5,B[HS9^/O&/Q2D$0WMC6%<-M"QQ_@O_P ':_QE
M^,?P^_X*QVVB>!OBO\2?!>D-^RY\&KQ]+\)>/_%_AK2EU(ZY\0V?55TK0]=C
MCCD*X".8MRE"3O*LS]&(P_\ M;P6UKK;KI?SZAT/Z7?^#C']H[_@J_\ L66O
M[/7[9W[$OB+1+;]F3X&:Y';?'GP=;:7+XC?Q'XC\;:N?#VD'XR^$KBW_ .)]
M\&75M'\*6=QX2\3>$_%?A7QEXEGN&8W4OA#Q=X3_ $N_X)$?\%6_@]_P5B_9
MMM_B_P"#K2/P)\6/!UQ8>&_C?\'I]0@U'4? GB4J3;ZGI%\</KG@'Q@HNKGP
M;XH*#[0+?Q%X5;R_%?A7Q1'!][>-_A7X.^/?[.GB;X+_ !&TRWUCP1\7/A%J
MOP^\7Z;=P"^&H>&_''@UM!UR,(>&=H=6DPW3*@C;PZ?Y?7_!JO\ M >-/@__
M ,%A/A?\--,NKB;P;^U#X#^)WPS\>Z;97SP:0B>'OAKXA^-^@:TVCPL;9];\
M,^(O T5J[ *GA6#7O$<<3*DS+)S8?6WW_P#I/^8G;ZMYV_./_ _I'^L#1113
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!GS]OP_K5BJ\_;\/ZU8H //]OT_^O1Y_M^G_ ->CR/?]?_K4>1[_ *__ %J
M*]6(._X_TJO5B#O^/]* "?M^']:*L57H *L5GUH4 9\_;\/ZU8JO/V_#^M6*
M "J]6*KT %%%% %>?M^']:L57G[?A_6K% !1110!8\CW_7_ZU?ZR%?Y,_G^W
MZ?\ UZ_UF* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#^7S_@Z)_P"">O[8'_!1+]EO]G7X<?L>_"#_ (7%XR\!_M 7_C;Q7H__
M  G7PW^'2Z;X8_X5KXFT/^U!JOQ3\<^#]!G!UC5HT\JWFN+H@C:L:QJUY_$9
M_P 0NG_!='_HQK_S9?\ 8\_^B)K_ %]J* /\@G_B%T_X+H_]&-?^;+_L>?\
MT1-'_$+I_P %T?\ HQK_ ,V7_8\_^B)K_7VHH _QXO\ B&B_X+>?]&)>)?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ".OR/XB_P"$SC\,#Q5Y\KR^<)W,P_12@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OY\_P#@Y-_8'^(/[??_  38\4>&?@_X>N_%?Q;^ WC_
M $K]H;P3X+T^%Y]4\=+X;\*>./!WC3PCH6F);-=ZOXAE\*^,]8\3^#M M'@G
M\6>,_#WAW3(9IENWBE_H,HH _P Z?_@V)_X+0_LI_L7? WXQ_L6_MN_$N?X+
MP2_%+5?BY\,?&7B?1M:U#P4RZ[X4T30/&7PUU<^&_#?B&7PO-!<^!(_%5K>Z
M^8[?Q7/XD\11%H;_ ,@>*?QU_P""XW[4MM_P5@_;N_: _:I_92\!^.O'/[/7
MP!^%OPV\.:S\3M#\'^-!I]G\,M"*:,GQ%\=Z=<:"K> H/$/Q$\9:[X>M%\31
MQRS>&H_"\IMXC%XF2#_2]^.?_!)/_@FE^TYXRU7XB_'+]A_]G_QSX_URZ75/
M$'C.Z\!:3H'BKQ1J;(HDU/Q%K_AIO#OB#Q'<#8(YI/$D\S2[<KD ,WT;\#OV
M3/V9OV9_A[??"S]G_P" /PG^$7PVU/[=)KG@[P1X&T30M-UYWCD5Y=<18 FO
M2R":2)I?$3SL\4C<QQ$J>CZQ_M?UQ;O?YM7U%;2Q_/'9_P#!U-_P3:TO_@G[
M9?&NT^*%P?VI+3X5IHMM^RM+X/\ &1\:I\>8_!BLNBG6V\.?\(J/AVOB8>:/
MBBOBH^%?^$07:LA\= >!1_/%_P &C7_!//XF_%7]MR#]OSQ+X7U#3/@)^S;X
M>\=:+X&\;:C:FRM_''QH\<^#)? 7]@:,/W\?B*/PE\/O&OB#Q+XNNX[IX_"7
MBN3PF@<74TBC^V^\_P""''_!(2]\4?\ "7R?\$[OV7H]9(^U?9K;X:Z38^&<
M\Y5_ T(3PE@GJ!X8VYX(#96OTJ\&>"?!_P /O"^A>!_ /A;P[X)\&^%["/1?
M#OA;PGHFE>'/#.@Z:BD#2M#T?0UMX-&B4D2&.")(UD9G"EWXYQG<4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]:^D/@_H\\/CPSV-C;7.G^@].WT'^2*L?M(?!/58;O6?&,$&+>ZL^?LG^?\
MZ] 'YO\ [2WQ)OO&VE^0(/\ /7KU_P D5\H:/\8;'X>Z-]AZ7'0Y_H<]?7KV
MXI/C-\0K^SNKC1((,W'VSC\_7'3\L<]*X_PW\,9_&UK;WU] #<?G]/I^% 'K
M'@_X_0>*KJXAOH.G\OY_7KC!^E9^L?$G2M'U[TM_4_Y_SVJQX)^#,$VL_P!E
M6,'^D?YX_3->P:]\ =#FE^PWW_(0Z<<>W3/XCKWH \G\5:P/B=:FQ@^S?\>?
MOG].M?/_ (;^%>N:/+J'_'S]GZ]>?_U?U]!7T!H/P]U;^V=0@T,?:?LO]/\
M/:OICX8^"?[2BN+'7(/](_S]>^#G_&@#SC]F_P *_;/%UQ8S_P#+UHYSVX_R
M?\YK[7A^$FN:/%;V/V#.G_CU/7W_ ,\>E>T> OV;]#T&PT?Q5!/_ *1=:QI=
MD.V?_P!?K_\ K'W/XKT'2M'\$7)\BVN=0M;,8X]\_P"?S]* /P8^)'PKOM-U
MDZKI7VJVU"U_#_..PKH/"OQL\5:;+;^'/'$%S_9_-D?M>!ZX[=??IUJQ^T)\
M2)]&EN/L,/\ I%K><?7\O\FOGZS^)VE>,/"^H3>(X/[-U"ULP?;^O_US^H!]
ML_$+X;^#O&W@W4-5T."UN?\ B3]+3],#/Y#J<]/3^??XG?#WSM>.E06__'KG
M_/\ ];/7Z<_KQ^QS\<O^$DUGQ!X-U6#[3IUU_:EE9X_3]>.O7N:\P_:N^#]C
MX/\ $=_XCL<?9[J\_'C&/I[_ $_&@#\+_'GAN?[?;P3_ /+K_D'_ #SP3S4_
MA7P?!J7^H@X]?\_YZ5]4:QX/L=>NKGSR/Z=>WZ>M=Q\/?A7!9W]O8_\ UQ_7
M\_?\@#Y7L_@S/#=^?!;^_I_GW]3^-=!-\-[Z&+]_8]\].G_ZSS@>]?N!\*_V
M8X/$D5OY\';I_7\OS^G ^P=2_8#TJ\\+_;A8_P"D?8_\_P" '7I0!_)]J7AO
MR9>(/T[\_P#UQU]:X?7O"O\ HMQ/Y Y!_EZ__K[5^N'[0G[,<_@F^U#R(/\
MCU/TQ_/V]J^!]>TW['%<6,_K],]/?\J /A?6-'\F7CMV]/7\/>N/FA_R?\_D
M<>H(KWCQM9^3+U/Y>OX_7\\=J\7O._\ P&@#G_(]_P!?_K5H0=_Q_I5>?M^'
M]:(._P"/]* -":;_ "?\_D,^I)K8T>\]?\_3]>/TKG_/]OT_^O6Q9S'S>_\
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M[(^&_P"V-H?@/POI^AV..W7&.?\ ZQSW]>*_GO\ 'D-CH^OCQ'Y]U<_9>/\
M2\?3Z9KZP^%>I:5XPT;SYY_]([^O<=/Y_G0!^Y$/[6ECKVGV]O!-_P ?7M[?
M3G'X\?45R'Q^M-5^*GPYN/(_TG_0^_XCZ#_/:ORVFU*?P3%/?3WWI]C[_7O^
ME=!>?MO7'AOPY_96>_7_ #U__5F@#X?O/@R/!/BS49]5_P!&_P!,/3G^7M_7
MBOB?]HKQ)!K%UY$$_%K_ *%SQCV]>.<_XU[Q\?OV@]5\575Q?0'[-GG]??TR
M.N?SKX/UB\_MC[1//.,=NOU_#U/% 'F]Y-!#:]>_\^<?Y^F>E<_J5Y!+:G\_
M\^G4?3]38UB:#S/(^T<9_K]>G^>U<?J4WD_N/3ITSU_7'OWH YB\_P!:/J?Y
M&LZM"L^?M^']: ,^?M^']:L0=_Q_I5>?M^']:L0=_P ?Z4 6**** #R/?]?_
M *U%'G^WZ?\ UZ* #S_;]/\ Z]$_;\/ZU7_U7^<YS^7I[=/S* "BJT/^N'U/
M\ZLT %%%9] &A5>J_G^WZ?\ UZL4 %%%% !20_ZX?4_SI:* "\[_ / :+/M_
MP*BB@"QY'O\ K_\ 6K_60K_)O\_V_3_Z]?ZR% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 45\Q?M'?M=_LR_L@^'="\7_M/?&W
MX<_ SPUXHUP^%_#FO_$?Q%'X<TS7?$*Z:=8.E:1+-N\QTMHWGD R56)D8,QC
M#_)/_#\+_@D-_P!)%?V5O_#IZ%_\70!^J=%?E9_P_"_X)#?])%?V5O\ PZ>A
M?_%T?\/PO^"0W_217]E;_P .GH7_ ,70!^J=%?C[J/\ P7P_X([Z1<?8M1_X
M*$_L]2W17YAHWB35_$.GJ0> NK:%X>N;<D]V,GKP:Y#Q1_P<3?\ !%WP?I3Z
MYJO[?GPON;&,!&L_"WAWXG>.=1R2 '&B> _AYXG\0!22/F%KM!SD "@#]L:_
MQN/^#B:]\+:I_P %HOV_KGP8T3:.GQ2\,V=]Y!&!XKT;X7> =$\=AAU!/CZW
M\0!@222&/85_9#^WY_P=]_L5?#/X7>(--_8&3Q3^TA\=M;T?4+#PAXH\3_#[
MQ9\.?@[X%U(^28-<\:_\+!C\)>,?$4MM^_FC\*>$_"T<'BMM/EMY_'7A&1K2
M0_YL_CWQIXM^)WC7Q?\ $CQWK-YXC\:>.O$WB+Q=XT\1:BQ.IZWXI\2ZM+K>
MNZQJ[$D/+>:WJLDLC[0KL2HC0*% !^U/_!MQ^TG?_LY?\%A/V2+Y-8BL- ^-
MOB/5/V:O&%I<!G&LZ;\6M+'A_P %:4[D$1[OB8O@">(A2F[2%7!+@U_L*U_B
M:_\ !'KPQXC\8?\ !5C_ ()P:7H&GSZKJ-G^V_\ LS^);BRBY*>'? WQ=\.>
M.?&6KLS/'&(O#?AS0-9UZ?DND,$CJLF%C;_;*H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *_P K'_@\3_Y2\0?]FL_!C_T\?$&O]4ZO\K'_ (/$_P#E+Q!_V:S\&/\
MT\?$&@#^56O]FK_@WY_Y0U?\$]_^R$I_ZE_B2O\ &5K_ &:O^#?G_E#5_P $
M]_\ LA*?^I?XDH _8ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K_.L_X/@?^2U_\$_/^R6?
M'C_U,/A[7^BG7^=9_P 'P/\ R6O_ ()^?]DL^/'_ *F'P]H _A:HHHH _P!F
MK_@WY_Y0U?\ !/?_ +(2G_J7^)*_8ZOQQ_X-^?\ E#5_P3W_ .R$I_ZE_B2O
MV.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O\
MWS_@]U_Y.R_8I_[-T\;_ /JS9*_T@Z_S?/\ @]U_Y.R_8I_[-T\;_P#JS9*
M/XBJ*** /]J3_@AW_P HAO\ @G5_V:O\+?\ TQK7ZJ5^5?\ P0[_ .40W_!.
MK_LU?X6_^F-:_52@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *[,$"\98Y/)P
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M'Q-XJT.]^&D_@Q;'2X_#VKV^AR0:TOB;Q)X:+"6;5#(WE;UP5.]7C,H^U?\
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MU7O>%Q"U:5O\+?Y7.-UTMXM=KM6^^Q^D]%%%8FX4444 %%%% !1110 4444
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M_6JO5BCR/?\ 7_ZU!T!5?RH?3]#_ (58HH **** "BBB@ \CW_7_ .M1110
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M3_.#QWH _,?]L'P3!#XCU"^T.QN;:WNO[4^V?U^@QU&*_$^?P3XCO/&5Q/\
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MU^G-?HQX/UB>SBM]<OO^0/SS_GZGI_+D 'Y?^"?AC/\  V*X$&E7/]L=C_\
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M/QX^#/\ PE7A*W\8^%8/^/6S^VWG;H.>_P#GVK\YX9KZSU3S[Z#[/]E_G_\
M6Y'ZU^H'[+GQFTKQAI>G^ -5GMOL^O?Z%_I?K_\ 7_$]:Y_]J+]G2#PK+<7V
MAP?:K?\ Z=/ZX_\ U=* /S7A\5:KK'BVW@GU7[-;VOU[?YQZ]#T%?J1X)^)V
MA_\ "):?H<\_VFX^Q]KS\/U_+O7YWP_"N";_ $Z"?[+<>G_U^I[].U?4'PK_
M +#ANK"QOOM%S<6WKZ_KF@#UC_EZN)_/_P!'_GTS[?Y_&K$\,$T7]J_;OLUO
M:COCI]/7VK0^)UGH6FVMO?V-]]F_IW__ %=OZ?._C#XA0:G86^E:'/<Y_P"7
MSK^@R.A_3M0!S_Q"\;7VFWY_L.?]/RS_ )]17N'PKO/%6L:-]HG^T_I^8YQZ
M>GM7+_#'X2P>)+:WGU7_ ,F_K^A'^>HK]B/@_P# ?0],\!^?Y%M_3'^?\^@!
M^<^I>)-5\%?N#8W7V>Z]_P#(Q_/%=1X.TW5?&$OG:5!]F^U?EGT[9^GMZ5^E
M$WP3\&_$+2[B#R+;[1:__7/)Z?\ U^M<?K'P3G^'NGV\^AP?\OFEC_\ 5SZ\
M>] 'Q?XD^$NN:/K-O/KFE7/^E=,9Z<_3U[9KZH^&_P"S3X<\-Z7_ ,)SKD]M
M;6X_Y^^WKW_/\?3%<O\ 'CQ5/X;TO3S?3VUSJ';_ #^'3..W:O2-2\>:YXV^
M#=O8V%C<_:/L?_/G_G\<'_"@"Q-^T)\*_!/[B"#3;G[+G_2^G?C\#TQU'O7S
M_P#&RS^&7Q^\):A?>%9]-M=8M>/\X]S^/O7B^F_"O7-8^T6.K6-R/M7;Z$Y_
MR16/X)^&_BKX;>(]0^W3W/\ 8]S9ZI_^KOG_ !H _)_XM:#!H\NH>'-5N/M-
MQ;?\?G3'I[?RX[UXOX5^(4_@^_\ L-C??9K<]./7../\XKZ _:ZU*"\\>:Q_
M9,'_ !ZW>+S\\?Y__7G\K_&&O7T.M?N)^/?_ "?T]LT ?IAXJ^,$&LV%O]NO
MOM7V7\O\_7]>*^7_ !YX\L9HLP3_ /U_\X_#'?J?E^\\5:K#:_\ 'Q_G^F?J
M/3VKS?6/%5]-C]_ZX_#K_GV[T =QXD\83WG[CS_\CT_#^7/MYO>:Q^Z_<3Y_
MK_@>_O7,3WD\W7^8]<_7U]*SO]5_G.<_EZ>W3\P"O>0^=+]H_E_G_/.!7/WD
MT_F_GZ_X5H7FI>3S_D__ %L?AZ'%<_YWVS]_U[_U_''7]* *_P#JO\YSG\O3
MVZ?G7G[?A_6K$_;\/ZU7H K^1[_K_P#6JQY'O^O_ -:BB@ HHHH **** "J_
MD>_Z_P#UJL40^?Q^'Y?_ *_O4 5_)\K\??\ SUQ[]/SL0P_Y_P _J<>P%6)H
M9_)^G^>W'\Q1#9S^W?G]#VZ'],?C0!GS]OP_K6?7036<_MVY_0=N@_7/XUG_
M &/V_P#'J *]%'D>_P"O_P!:C_EE_G^[0 457_Y:_P"?[U:'_++_ #_=H KT
M57G[?A_6K% !1110!7K_ %H*_P F>O\ 68H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6L9&I:A>S%)-:U[Q%JX5[C7/%'B;7&GU[Q=XDD.^XNY'8P!"AB^G: "BBB@
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M_&CS4]?U'^-?R&?\1//BS_HSO0/_  ^E_P#_ #KZ/^(GGQ9_T9WH'_A]+_\
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M[XFW/P?^)7A:SU$I(L+:MH/AWX9?";Q'<:-O5$98O%\<P$AD$K.^V;^TNBH
M_P 7+7K#]LG_ ((4?\%&+C3[76W\(_'/]G;Q7I<_]J:+=:HO@?XN> =9,6K1
MHSSK ?$'PY^*'A:6)+BTDB\VW8-&5L_&'AHM8?Z\G[)?[0WA;]JW]F7X%?M&
M>"X5@\-?&WX9^'?'UI9S2+YFFOKNC&?5]%E#!7EN/#FMM-H-T^-C26\I7<NT
MG_-._P"#N#XH_#OXC?\ !5^70_ US8ZCK'PB_9_^&WPT^(UUI[[U_P"$W_X2
M3Q_XU&F3^60G]K:)X;\;Z!%,&<;780N0\31'^_/_ ((I?!WQ9\!O^"5'[$7P
MT\=VFHZ9XNTKX)Z9KNL:5JJQIJ.B3>.=3USQV-#G&2=^@0^(TM=I+;!'M4DD
M"JR_$XG-.%*./QM1PFJBC'$2:?LU-\3)I)MQ<:RIT^)4U[T?:PNU%I2Y\XH^
MQXA@\.N1NB[T];PBX<-3EVDW!RE'9[VW6GZST445)T" 8 'I2,X7K_A^M-<\
M*?7G^5?D?_P7#\0_'?PS_P $N_VL]4_9KO/B;9?'*?PAX2T?P%/\'GUY?B5_
M:6O_ !0\!:!=)X,_X19E\4#7'\.ZOJZQOX7(NP3<[&&*Y<;7^K89XFZWBKMV
M2YFE=OHE=-OHDV:X&@\5B8X1:.344[7U>EK7U\E?5]EJOG3_ (*Y?\%Z/V3_
M /@EWX1UWPBNL:5\9_VL)]#D/A'X >%]<&H2:+J+Q_\ $EUKXRZO#.[> /#J
MRS^<R2+)XO\ %$,")8V0AQ=P?Y8'[7_[87QU_;A^/GBW]HS]HOQ;<^,OB'XQ
MN6638\MKH/AK28@1HWA'PCI#O<)H7AOPX)A!9:)!(ZHH9Y3+<2SW<O\ 3S_P
M37_X-._VL/VG/$6F_&3_ (**^(M4_9T^%^I:Q_PD&L_#M[W_ (2+]I7XAQK>
M/+>1ZK)*;SPY\.?^$C$LLK^(_$[>+/&/G!A<>!HO-:ZKPC_@ZM_9B^ /[(_[
M2_[&WP)_9R^&OAKX8_#/P;^Q_86FF^&]!MXA<7LO_"X?B09]?U_72USXC\3>
M(M>E4F\\0^)YYIIV7;$[8=X^>K0HX#&9;3KSC4S?.G-24'I&4*;ERM;*2BU[
MMW*-[.TO=73A:\<=0S&AA&O[.45>IRI.2A*,E9IMN/,^9J+Y4^7632DO[JO^
M" 7_ "AY_8*_[(K_ .[?XFK]CO\ XW7XX_\ ! +_ )0\_L%?]D5_]V_Q-7['
M?_&Z^BSK_D99G_U]K_\ I4SYO*?^17@_\=3_ -/5S^!3_@[O_P""I/CCPQKO
MAC_@FC\&O$VH^'M$USP=8_$K]IS4-%U!["_\0V'B&60> OA>\\<J-#H'D:/+
MXP\8>'I6\CQ4FM>%;=E\D7(E\N_X(7?\&POPE_:/^!/@;]KW_@H1#XNO] ^*
M^BQ>+/A'\ ?"_B/4_!-MJG@/5#)_8GC7XF:UX=6S\5QQ^*[+['X@\(:#X2\5
M^&I#X<N+>_O)9GN&M(/T^_X*;_\ !J[9?\%"_P!KSXJ_M=Z=^W#K?PO\4_%K
M5-$O=6\(Z_\  N+XB:!I.G>'?!WAWP-HVE:)J\?Q1\%3JD6A>'84?S89A',X
M,<41!E/]7?P[\"Z5\-_ 7@[P!HD,4&C>!O"GASPCI5O;C:B:?X>TBWT2V10<
M8400*<GN-S88DUYV5/ZKE&.K58PAFN<Z5DTKJ/*]$G_>5*G#5\M.F]$YW/5S
M1RK8C*\+A/\ D6*-YN/NMRY8\UMK<TE*[6ZY5%I:'X??$K_@V*_X(M_$3PD/
M#=E^R/'\.;ZWTYK32/&7PT^*WQ>TKQ1I4V%<:FAU_P ?>*/#7B&88V@^,O#/
MBSY7R48_,/\ /[_X*J?\$W_VA/\ @A;^VIX%UOX:_%?Q#)X=U&XG^)G[+OQ]
MT2ZB\.>-I1X?U=+/5-!UJ/3)$"?$'P7%<:-'XP>WA'A+Q/::[;7<<$,7B6?P
MI:_[ I(+)P,.#G\<C/\ ]:OX./\ @]D^)7@.#X>?L1?!E%M+OXE7?CCXH?$H
M;=QU#0_!%OHFA>')%=3A5B\3^(-4C9 &):3PP^5 4,>*>)Q6 QN5XC"NWO<L
MKZI>[)N3771.]]&F[WO==F!I4,11S#"8F-X2C-MV^%I*46^G*[\K5FGS=UK_
M $W_ /!'+]O63_@H_P#L#?!S]I75K:PL/B)<QZGX&^+.F:<NS3[+XD^#;B#1
M_$4NF*S2E-+\11II/BJSB21EM[?7H;;<QBS7ZE86V01YQNWB/.>7(F<X^@91
MZU_)?_P9T^%?$VA?\$Q?B+K.J12V^C^,_P!K/QSK7A-I6S]JT?2O _PT\,ZE
M<(O)$?\ PD6@:W;HQZM$_.%)KZC_ .#F4_M7ZQ_P3Y\/>!_V.HOC;?\ Q1^(
MO[1/@#P#?Z)\!(O&DWC?Q)X*U;P]XYFUO19$\!,WB1_#LLNEZ.?%(9?L#6[(
MMX_V1Y5'J\3PI99C90PLE_$X8IN[24)\1KAA/FDVDE3>+G>[6CW6Z\;AW#+%
M4OJE?,X\T9\304Y*32APX^):D[I)/F4:/LY->[SQYFW%-R\@_P""T'_!R3^S
MI^P-X?\ %/P/_9HUWPO^T'^V7':2Z0MA87T.N_"_X+ZD8ESJ_P 4-<T.:.'7
M/$=O(-\'PQ\+W O1=(8?&EYX.@=$N_\ +^^,'Q?^)/[0'Q,\9?&+XO>*]9\<
M?$OX@:[?^(O%_B_7+IKW5-:U75/G>27HHP=RQK'M2.+;&JKY8#?VO?\ !+/_
M (-$_'7BW4_#OQ;_ ."G^MKX(\+E(=5A_9>^'NOPZCXYUQ'5Y%3XG_%#07ET
M'PI"C23?:?#/@JX\4^)[N%TC/C3P;=0R1'\3_P#@Y1^&'PY^#O\ P5A^,GPS
M^$?@OPS\.OASX(^&W[._A[PAX+\*Z/'X=\-Z!I.E_!/P&D6EZ1I42B)84(.,
M9W?.269=Q\N="E@<7@(59QGFV;1J.4HI*RI*#<;)M1TFFXJ[2LI2;7+'VL+6
MCF-#,XX/_D6Y.DV^5>_:48*\DKV3E%)7Y$Y/E6\G_JD_L:?\FF_LQ_\ 9O7P
M9_\ 5;Z'7U">LG_ O_0GKY>_8T_Y--_9C_[-Z^#/_JM]#KZA/63_ (%_Z$]>
MWG__ "46??\ 98<4_P#K5<4GQO!W_)+\*_\ 9+<+?^LOPR?Q8_\ !UO_ ,%@
M?&'[-'@[P]^P!^S=XOU#PO\ %'XU>$9?$WQW\9>'K^2QU_PE\'M8GN-'T?P5
MHVLP2>;X?U_XG-H^O+J;6P^TQ>"(< */%B2)^9__  02_P"#:'P=^V!\*?#W
M[8W[>D?BJ/X.>-[87OP;^!N@:AJ_@C4OB-X:^T"-/B/XP\:Z/)!XCTCPW>1J
M\WA+P]X:DM+GQ;$;?Q0?%T%A+%#=?D'^UU+J_P#P5#_X+\>._"&K375WHGQE
M_;@T/X Z7-8W;,;7X7^"_'&C?!^.\TIV(2/ROA]X=7Q"0%&)6<@EF.[_ %K=
M)L_ 'P;^'NCZ5:R^'/ ?P\\ >'=(T#2HKFZTWP]X9\+^'-#TRWT;1]+6XE:W
MM])MK>$00POP%C2.)6&4B/!D=!X/(*.=XA+^U\\O.<HI+EBH0T2MO[].E!/W
M(QC4<;R;9]-FJ<,[CD&&M&>41O4C%7=U+DDKI/FO4C4BFG*ZII:(_#3XW?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !15B#O^/]*/(]_P!?_K4 5Z*L30_Y/^?R./4$57H *L>1[_K_ /6JO10
M40P_Y_S^IQ[ 58JQ0!8JO##^]_'^7]?T/6K%.A_X^_\ /O0=!-##_G_/ZG'L
M!1-9_P"?Y<_S/X>U;%GV_P"!58\CW_7_ .M0 6</D_C_ ('^5;$,W^?\_J,^
MX-9_G^WZ?_7K0A_>^W7]/S_K0<YT&@P_Z5Y\_%O_ )'4_P!/85],>%828_/@
MX_/_ /5C_P"L>]>#Z#H\]Y%!Y'^>W_UO3Z"OHCP?H]]#_P L./Q]\?Y]>: /
M<?AOY_B3Q;HVASP?9K>ZO/\ C[_7''I_.OV'T'X ^!YO!OD3_9;FX^Q_;?Q_
M3K].HZU^0_ANSU6&Z@O]*@_TBU^@_P _GZ^E=Q-\8/CAH-K<>0;G[/\ 8^?\
MGOZ_C0!ZQJ5GH?@_Q;J%CI4'^D6M[^6/?K^/8_7-?2&@Z#XC\86%O_97^DW'
M]?Z?I].17Y?> ]8\<:QXMN-<US[5_P ?GX9^G^<'FOUA^"?Q"G^'MK_:M[8_
M:;;_ *\^W'&/7_/6@"QXJ^&_Q&AT'[#_ &'<_P#'G^6.?\_3U&*\/^&/@.#3
M-4N)[[_CX^V<6F>/3^GX^]?<%Y^U1_PE5U_H.A_Z/_UYX_'UYXSUQ7F%Y9V.
MF^+M/OIX/LUO=?Z;^O;Z?EQT] #[O_9[L['7[2WTJWA_LVX_Y^SZ]O\ /<>I
MKW#Q)\#=5T?Q1I]]/!_;?VK^R_\ 2\>_^.,^OI7R_K'B2Q\'^$K?Q5X;G_X]
M;/!^GO\ G7'^ _V\-<\57_V&>#[5_9=YV/O_ )'0?K0!^O'B0Z7X/^&A_M7[
M-;7 L_\ (Y__ %=0/2OS/^&\,_CSQOJ%]!!]IT_[9UQ_D>W3IP:^5_VKOVM/
M&.O?9]+L9_LMN/R^O7O_ )ZYKJ/V=?C98_#?PN=5UR?_ $B[_P \\=J /WN\
M%:.NA>';!(81D6:DKGGL1[\XR<5U?,,/N/PZ_P!?R.3V-?FMX/\ V\/#FL6M
MOI4$]M]IQC/&<'GMGCOZ5]00_&#59O!MQXD@L?M7V6S^V_\ 'GD#GTSCGZ?T
MH \7_:0T>QFU2WF,_P!F_'KCW[?H:\O\5:E\.?!_@CSY]5TTZA^/3_#/_P"N
MOA_]IS]JCQ5K&J>1/!_9O0>G^1_]? K\_P";XD>*OB%XDM]#^W:E<V_I:$?Y
M[_IF@#^C#]G7]HKP=-X<N+&^U6VMOLO]>^>N.3_/)(->X:]\8/"TT7[C5;;4
MK?ZY]_S'7C_ZQ_F_T?3?''PQ\1V\&JSZE;:/JG^FV?7Z?EV_ER*^V/#?Q4T/
MPKX#UC5=4GN;G_0_K_+]>.F: /0/C9\8-#UB_P!8@\.8\^TO/^/NT'^?Y\>U
M?)^I>,/B-XP\+W$&A:K<ZC]E_P"?0G_'^G%?/^F^//\ A9'BW4(/#D]R+>ZO
M#]L_GT[=L\U^@'[*_ANQ\-W5Q!JL']IV]UG^>1W_ /KT >?_  3\$^(_L OO
M&,%R+C/_ "^=<?C_ )X'M6A\6OC-9:;87/AS0KZV%QP?_K'^?(!%?LA_PBO@
M";PY]O\ L/V;_0_^?/\ '_'OZ\Y/'\^'[5WA6QT?QGJ$_AV>Y_X_.G/O_C^5
M 'DW]FW$VJ?VK//_ &W<75Y_QY\#_P"O^?KG'%?;'P9\.?#F'6?/\1Z5;#3_
M .73\?;ZXQ7Y_P#@.SU6&Z%[]NZ?\NGVS_)]N.P_/U#XG?'[^P=!^Q:38_Z1
M_P!.MG_(^_/I_*@#Z(^/'P?^!_BJ[U#_ (0>WTS^T.1_HGH/7KS^O:OB?0?@
M/JOAJ6X@OK?[-_TZ<8X_S[\$_2J_P-^.6JP^/-/^W6-S<_:KS./L>>_N/RZ5
M^R'Q.U'P=#H/@?5;[2OLMQJEY_I@^Q_T/\O3\!0!^5VI:"?#>E>1!?"VN;J\
MQV'3/\^:_1']DKX/_P!L:7]OG_TFX[W?^>?\2:^+_BIJ7AW4]>^P:5^6?\C\
MO\!7VS^S3\3Y_ ?P^MYY_P QZ_EU_#O0!Z/\8-'/E#0Y_P#CWM?0?A_G_'FO
M+_A[-X.T'0?$'V[[,3:V?'!_7^G3]<UX?XP^/%]XJ\>:A!Y%S]G_ "/Y#TQ1
MX;UZ#^V;C[=!<_V?C_3/]#[?X9YY_H< '06?Q.\.3>*;B#S[:VMR?^/3K^O^
M3UJQ\0OB=X<F_P!!TJQ_LW_I[S_G_P#5^ORO\3H=#A\1_;M*GN;;\?7UZ8_S
MUJQ_Q*IM&\^>?[3<#OD?Y_/CKZ\ &QK'C#5?!]A_Q-+X6UOJMY_HGZ<?S]_2
MNP^&^O7T.O:?/!XCM1;77IT_^O\ YSZU\WZE\0I]>M;C2Y[#[5<:5_QY_:[+
M^?7I[8S5?P'X;\5:]KUOKD]]_9MO:X'V7[9G_P#7US^?X 'WAX\O+Z&P^W3W
M'VG_ $S!N_Y\<?TX]*SX=-U7XG>'+?[#H=S<_9?^7L<>_P#G]17G_B3Q)XJU
M[0?^$.GL;;IG[7]/P^G3GZ9KL/A7\2+'X2V']E7T]S<W _SWZ^^>?PZ@!X5^
M&\&I:_;Z5JO^C?93]MY_7^7IU]*_3";_ (5SX;^"UQ8SWUM<Z@;/^7^>_'/Y
M?!^O^)+[XG:?]A\*V/\ 9NL?;/MOVO['_9O'ZYKZ)\!_!/59OASY_BK7/](^
MQ_\ 'I]L]O;./0'- 'R-X;\5>*M!UZXGT/[5_9]U>8_3GOCT]NI K] /!/G^
M/+73X()_^/K!^O'^?IGZD?-_C&STKPKHMMI6AV/VFXNKS[$+O['^/?\ ,^_J
M.OTA\!_"OB/PKI>CWU]!<_R/\STYQ]* /H?Q)\(+<Z"1860-T+/F['4>F1T!
M_+.??GR#_A5=]/HUO_R[?Y_K7T]X5^)EAXDU"?19@ ?LF<CJ<Y4YZ=1W/?![
M8KTO^S;'R_L_D<8Q^'\^O&/7O0!_/]\<O@G/XJU2XTK^RC<D_P#+V?K_ )_,
M&OD_1_V8[[0=9_X\<?K[]#C'_P!;TS7]-]Y\./#AEO[^:QMC<&SZBTS@<^GI
MC&!SSSWKXIUBSTJ\\>:A8P:5_P OF>+/\1^0 ^E 'YBZQ\-_[!TO_3H/^/KC
MGCKV]?;O[9KX ^+6@V.A2W'D9^T77U_7';M^=?T4?'CX5P?\(O;W\$'^>O3Z
MY_\ U9K\#_VD--M]-EN!^/X?Y^F<GZT ?F?\0IOMGVCKG^1S_GO^'-?'^O?N
M;JX//Y__ *O_ ->/K7UAXPF'FW'Z=>G?]/I7ROXDA_TJX_SG_'CO^F10!Y_/
MV_#^M9];&I_P_P"?2N7\[][_ )SU^F.O;]<4 =!##^Z_#^?]/U'6MB&;_/\
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M'[DS>,+[PW%;SZ5 /L_/;Z>O;ICI^5?:'P-_:Z_T6X\.:K_T!]4]>WIGO_\
MJ[U^5WPE^,WASQAHUO8WT]K]H_SZ\=/\\58U*;^Q]:^W:'?>_P#Q^?UX^@]/
M3U /VP^#/[0FAZ/KVH6.K:K;?Z5ZCZ__ %^/I[5]X3:[I/C7PY<"WO[8#[$+
MP7?88Z >F>/7@=NW\[_P9\$ZY\0O$>GSF^^S?Z9_S^<>O/Y\=*_=CP?\/;[0
M?!OV&"?[3<?8_P#G\Q_D=?:@#Y/LOA7_ ,+(\4:A!?3_ &JWTOC!/^?_ *^3
MBOHC3=8\.?"2PM]*OI[:YMS>?8NWY_7VZ>E=A\'_ (;WWAO^V)]5_P"/B[Z>
MOKT'K7+?&;X#ZKXWL/\ 0+XBX^V?;>;LC^>#^60?6@#S']I;QY!X$\.:?XJ\
M."VN;?\ X_L6GXCG/3/^<&OS>\;?'[QCXO\ L\\$%S:V^._X>G_UZ^H/VG-'
MU;0?A?X?\*WUQ]IN+3^U/Q)S]!]/_KU\7Z#IL$VE>1//;?:+6SZ^F>?\?:@#
M\Y_VEM>L=-U36)[[G4._K_GI_3K7Y;Z],=2O[B^@^GY?E]0"<<U]H?M@6>K3
M>(]8G\\?9^?3CO\ EGIV[^]?"\-X;.UZ^_M_^KK_ % S0!S_ (DO)_\ 1^/I
M_G/^/U[UY_>3?]-_7^N,C^7'T%;'BK4KB46_/^>GI^?^2?/[R;O]/_K C^1S
M_6@#0\_V_3_Z]8]YJ7G<_P"1_P#7S^/H<UG_ +W_ #NK/H )IO-_S_/WZ=JL
M0S?Y_P _J,^X-5Z* +'G^WZ?_7JO110 57JQ10!7\_V_3_Z]6*KU8H *L?8_
M;_QZBM"S_?=.W]?3KGOG],\4 5X;/_/\^?Y'\/:MB&S_ ,_SY_D?P]JT8=-G
MF[8_7_/I]?U[_1]'@LXO/G]\_P N/_U]^>E '+V?AN>\ZP>__P"OZ>OU]ZT(
M?#<^/]1Z<].O?^F?SK8O?$D%G^X@@]/T_KGKU^E9]YXV$,7^H_'^74?ATH @
MO?#?DQ?GV]?\C_(-<=>Z//#[YQ^?O^G_ .NNHL_&]O-*//QZ^W8=LYS]:["S
MAL=8B_7V_P#K_CGT[T >'WEGY/\ 4<\\_P _USWKGY^WX?UKU?7M'^QR_P"?
MP_Q[<$YP*X"\A/F]_P"?UY_R!]"* .7_ .6O^?[U:%5YH?\ )_S^1QZ@BB@"
MO/V_#^M6*KUHP_ZD?0_RH K443]OP_K1!W_'^E !Y'O^O_UJ_P!9BO\ )OK_
M %D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD:0T?]JZNGA_P+XI\3^((])B9XGFF:&1(E*J[##$?7E !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7^5C_P>)_\ *7B#_LUGX,?^GCX@U_JG5_E8_P#!XG_REX@_[-9^
M#'_IX^(- '\JM?[-7_!OS_RAJ_X)[_\ 9"4_]2_Q)7^,K7^S5_P;\_\ *&K_
M ()[_P#9"4_]2_Q)0!^QU%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#-37Z9];^CAWX9_P#"?B3_ .1/S+^R/I ?\_>,?_!O#/\ D?W4_P## O\
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M_@XL^/.H> _V6/AS\&] OUT^Z^-'Q!D;Q-$LP%[J'@3X:Z:NO:WI<!P0//\
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M/^S4-'_]6;X^KPLS_P"1GPI_V4-;_P!9?BD]K)/AXA_[)BK_ .M#PP?V9_\
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MXNO$]I8MVGQ7^+G_  4G_P"#C3]NC1](TG1+[QMX@NY[_3_A]\,/#UQJ>F?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME_G^[0!G^=Y7X^W^>N/?I^=CS_;]/_KUGWG?_@-$'?\ '^E &A^^\K_]6/\
M/_LM5ZT/^67^?[M9\_;\/ZT %6*KP=_Q_I5B@ H@[_C_ $HHH T*K_\ +7_/
M]ZBK%!T&A9S=_K_]<8_F<_TK8\_V_3_Z]<_9]O\ @5;$'?\ '^E &A##YO\
MG_//7O7?Z/H_G_7_ #^O;CI7(::?.E]/Y?3_ /6/:OJ#X>^#_P"TCUZ#_/UZ
MYZ?E0<YL> _#>);?]Q_H_(QD>WJ3^6:^^/AO\-]*U+[/!Y'^/IU^F./H:S_@
M/\'Y]>O[>#[#_H]K_4^_'X_RK](/ ?P9GL[K_CP'.1_GV_7^= 'G_@_X ^')
MH;BX\^VM?LO_ .O\?3ZGUS6?XWTSPY--;^'-#@M]2N/^G3_'G_/-?9'_  JO
M5;/[1_Q\_P#$TZ?8_P /\/7'X58\'_L?ZK-K/_"1SP7.?K_D>WI^E 'P?_PI
M/2M!^SWVN?9M,S],\?Y_EBO7_A[X;L?&UU_8<$'VFW_^O_GN,U^B.L? >W\2
M6O\ 97V&Y-QW_P!#Z?G^'7(%;'A7]F.?P?%]NTJ#_2/RXYYZ^@./SH ^?]'^
M -CH,MO!I6A_:;CV[>OZG_#-=!\9O@#XDFT:WU6#PY<VW^A_KZ_GZ_CZG[P^
M'OV'3;K[/JL'^D?_ %L?K_\ 7Q70?$[XD>#H;K_A%9[BVN=0^QY^R?C]>_?/
MMZ4 ?SS^/-2^(^@:7<:'/8:E_8_X?YY]?T[5Y_\ !_R/#=UJ$$_%Q=9[C/MQ
M^/Y^_3]0/B1>> /$FLZAX5\1V%SIMP.+/_0_TZC'T]??K\KP_ V>;QEYWAR"
MYN;>U[^GX=_\Y.1P ?+_ (PTWQ5KVO?O]*N?L_Z_3\._Z=J]'UCX8WWC#0+>
M#2IS]GM?;O\ S^F.E?JC\ ?@;H?B2ZU&#QC8_9KG^0_E[^O]>/\ B'\$_P#A
M&]:U"Q\-P?\ $OSV'X_7Z]!]: /RW^%?PK\8^%?&^G_N+FYM_MF,=OR_SW[5
M^Z%Y\6K'0? 6C^'+>Q_XF%U_H7/Y=N_7_/-?-_@GX27UE%<7U]_Q\?S_ ,]_
MIFL>;PKXCO->MK[_ )=]+O#_ )Z9_P#U9XYH \G^,'P-G^)%^9YY_L_''OCV
MX]NG\ZX?X2?#WP=\)?&^GWVJ^'/[;N+7^?\ AU_'O7W3H/@G5?&%^(+&?^G/
MZ_YZ=J]7T']CG_B:_P!JZK?9'?\ TSV__5F@#P_XJ>%?"OQLCT^>#2K;3?LO
M_'G:<?YZ?A^!R?+_ (P? VQTWP';Z'I5C_:7_/Y]DXS]<_3I]>:_5B'X*>'+
M.PL(+'C[):?GT.0!]?8Y!^E?)_[2'@_5?!^E^?I7VFY'M@C]?ZX[]: /QW^#
M_P #=5T'QE<00:3<VUO=7@]O?_\ 7W_"OV(^ /P?GL_W]]!_I&<>W;IQ_D<5
M^=_A7XD:YX;\;Z/_ &II7^C#ULO\\]/\YK]4/"OQFL=2M=/^PP?9OP[\9]OP
M]J /K";PYI4VEP:5/!]GQ:?7!_7H?7&,XZ\U^5_[5'[,?D_:-<T.#[3]J_KW
M_7O]:_2C1_B1I5Y:^1Y]M]OQ^?\ D]_SZ4>)/(\2>'+C[=!;?9[7T_ST_P#U
MT ?S7Q? ?5?#=U<7U]JOV>XNO^73 X)_S^6!GI@T'X,Z5XEFN+C7+ZVMH/\
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M_P -_A+X_P!8T&WG_P!)UO\ Y<O^/+.?\_B*^D/AQ^QIX.UW4_M_BJQMK;6
M,_9+H9)P.V,DGV .>*^L/AOX#_X0/PY;Z5!_I/\ IG3V_P#KY_'M78?$CQYH
M?@G3+F>"#_B8?XG_ /7QZYXH ^3]2^">E>#]>,&ASVUL;7_]7OQ[>GX57U[P
MWJMY=6\&E:Y]IT<_\??_ .O^OZ]Z\(F^+6N:]K.HSP?:?M'Y]>__ .KI^-=_
M\*]2\5:QK/V&>WN?L]U_GG^>/T[T 6+.;2K/Q'I^E3V/]I8O,_:_Y^G&>#@>
MG%?I!IL.AWFA6\,'V;M[?4^^<C_/-?-^O?#'0]!^SZK?3VUM<<Y_TP=<_3IV
M[=:X_P 5?$B#PW]H\_5?LUOTXO,=O_K_ (_A0!U&I36/P]\1W&J^>;;J1V_I
MUS_]?IBCP3^T3JFO^*+BWGL+@^'C=XM+O&01SP?4<XZ?SY^&/'GQ4.O77^@W
MWVFW[XO!@_J.U>;:Q^T)8^%=%^Q6/^C:A:__ %N_Z'\L4 ?LQXP^+7AOPUHU
MQJM]?6UM;?8^_7)Y]_\ ZWIFOD_X5_%3P/XV\4>*-5^W6US]EO,V?\C_ /7)
M_P#U_BOX]_:B\1^*C_8<]]FW^V'_ )?.O^?KGZ=O6/A7\5/"OP]TNWGOM5M?
MM%UC ^V?A_G\OH ?JQ^U%\9M*L_#GV&QZ_8_\_YX_3-?S7_M.?$*#4I;C]_Z
MGI^1_P \\<8KU#]J[]L"QU*7[#H=]]I]_P!/\]NE?E/XJ^)%]XE^T"^_SQ_3
M]1T- ''^*M2\Z:Y_?]_K]/\ #W_2OG?7KP?:NV?7('^?Y]Z] \2:Q[?E_+^O
MY_6O']1E\Z7\.H]QCC_/_P!8 Y^\F\[\/\1_.LZ'_7#ZG^=:,_;\/ZUG^?[?
MI_\ 7H.@L>=Y,7Y>G?K^/7IS[T0S?Y_S^HS[@U7G[?A_6J\'?\?Z4 =1!/T$
M'\_Q_P ,#'KSVJ>&;][^_P#\CVZ_X_SK(@[_ (_TJQY_M^G_ ->@YSN++4O)
MEMYL^O\ G^O7^M=QIOBJ^\WSX+[[-_\ 6Z'M^8^G>O'X9O\ /^?U&?<&M"&\
M_P _SX_D/Q]Z /I"S^)VN'_0?[5^S6YQ_I8)_P Y'_US1J7C>^O)<_VYS:_7
M_P#7W_E["OG^'4^^/P_/C^O3Z]J3[9<>@_/_ .O0![S_ ,)M/-%]GGG^T]^?
M\.<XX/6N?U*\^V?OX/Y_EWS["O+_ .T_]G_/Y5H66L=(,>@SGZ]A^AH ]@\-
M_$+5?"LH^PW_ /7M[]1W_EFOHCX>?'[Q'J7B/3[&>>YN?_K]_IQG/7T%?'\,
MUC^/IW]_ID#_  [UT'A74O['UFWU:#MGKZ?RX_3TH _H8^$OQ"UOPK::?JND
M_:?S_P XXZ\_CUK]\/V8_BI?>-M!M_MW^D7'?CI_3_ZU?S#_  '^+6AWFC:?
M!JT]MQS^OY''?\N]??'A7]JC_A XK>W\.7Q_#ZYZ^W]>HH _H8UC7K&RB OI
MSIWU]_P ^G'7],^'Q);WD>=*OA<P=CCG!]\>I[=^_K^1^@?M(3_$G1_[*U75
M?LVLCK_IO^./Z=NQK0\-_M%:IX)NO^$<OO\ 2;>Z_P"7O&/?CCG&/_UYH ]
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M'K0@[_C_ $H KS0_Y/\ G\CCU!%%:$_;\/ZUGT :%?ZQ%?Y-]?ZR% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M46E>SM_3W@!G6%659WDKEJY*I%:+W7",9+35^]&[[-^9TM%%%?S<?T4%%%%
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MK?\ @4/_ )4?@1_PWYXR_P"A!\-_^!NJ_P#QRC_AOSQE_P!"#X;_ / W5?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>>*/$%]_:OVFW^V?Y_ <=>]=Q-\ =5^(=U]O\.:5]FM_^G7'(_3_ #^OQ_\
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M?[?I_P#7JOYW[W_.>OTQU[?KBL?[9[_^.UH_;+?T/Y__ %Z )I[R>&7\^?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MC:GHFCZL(/[4TS3M2-N2;8ZC917X0D [E64-UQGD\]>IK9HH Y3_ (0SP?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K_*Q_P"#Q/\ Y2\0?]FL_!C_ -/'
MQ!K_ %3J_P K'_@\3_Y2\0?]FL_!C_T\?$&@#^56O]FK_@WY_P"4-7_!/?\
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M:I_:^L>'_@K\+?!?PJ\.ZWK"QC2X]8UO1_ /A[PU;:MK?DKY EEB9Q$(D20
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M<@N?[/\ ^GO\.0!Z=?KTKUCXM?MC>%?&,5O!_:MM;:?_ -?G^<>O\J /Q?\
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ML>1[_K_]:K'D>_Z__6H KT58\CW_ %_^M1Y'O^O_ -:@"O7^LA7^3/\ O?\
M.ZO]9B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* /XBJ*** /]J3_@AW_RB&_X)U?]FK_"W_TQK7ZJ5^5?_!#O_E$-_P $ZO\
MLU?X6_\ IC6OU4H **** "BBB@ HHHH **** "BBB@ HHHH _G\_X.B?^4%O
M[='T_9C_ /6R?@)7^057^OK_ ,'1/_*"W]NCZ?LQ_P#K9/P$K_(*H *_O4_X
M,<O^1Q_X*3?]BW^R;_Z=_P!H"OX*Z_O4_P"#'+_D<?\ @I-_V+?[)O\ Z=_V
M@* /]"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH _''_@X&_P"4-7_!0C_LA+_^I?X;K_&5K_9J_P"#@;_E#5_P4(_[(2__
M *E_ANO\96@ K^Z7_@Q^_P"2U_\ !0/_ +)9\!__ %,/B%7\+5?W2_\ !C]_
MR6O_ (*!_P#9+/@/_P"IA\0J /\ 13HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXD:7]HUR^MM-N-+ZY[>G7G_)%<_\5/CQ8WFEZ?\ #F>?[3IX'V*SN_\ Z_\
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M,6.<]>WZ\_\ U\\\4 5Y^WX?UK/K0JOY'O\ K_\ 6H (._X_THG[?A_6BB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&Z_QE: "O[I?^#'[_DM?_!0/_LEGP'_]3#XA5_"U7]TO_!C]_P EK_X*!_\
M9+/@/_ZF'Q"H _T4Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,-+_ ,^A/.?;C'K7]%'[(O\ P4X\.6>@V_@[Q_\ :=--K9_8OM=WSVS^/O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^5_0'_P:[?\ *=+]A?Z_M.?^L;?'N@#_ %]:*** "BBB@ HHHH **** "O\
M*Q_X/$_^4O$'_9K/P8_]/'Q!K_5.K_*Q_P"#Q/\ Y2\0?]FL_!C_ -/'Q!H
M_E5K_9J_X-^?^4-7_!/?_LA*?^I?XDK_ !E:_P!FK_@WY_Y0U?\ !/?_ +(2
MG_J7^)* /V.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** .1\;?\BAXQ_P"Q7\1?^F=Z_P \;_@JC_R>;\4OII?\S7^ASXV_Y%#Q
MC_V*_B+_ -,[U_GC?\%4?^3S?BE]-+_F: /SF_Y<O\^M'_+7_/\ >H_Y<O\
M/K1_RU_S_>H /^67^?[M5ZL?\LO\_P!VDA_UP^I_G0!!16A4$W^I/T'\J *T
M'?\ '^E:%9\'?\?Z5H4 5Z*** "L^?M^']:T*)^WX?UH SX._P"/]*L444 %
M%%% !115F'_4CZ'^5 "4444'05ZK_P#+7_/]ZK%5_P#EK_G^]0!8HHHH.<L4
M444 5Z*** #_ %O^<8Q^?K[]?RL0P_Y_S^IQ[ 57JQ#-_G_/ZC/N#0!L0P^5
M_G_/'7O5>\F[_3_ZP(_D<_UJQYW[K_..GTST[?KFN?FF_P G_/Y#/J2: "#O
M^/\ 2B?M^']:(._X_P!*)^WX?UH +.'M]?\ ZYS_ #&/Z5L0P_Y_S^IQ[ 57
MLX>WU_\ KG/\QC^E=A9V8\K]?7C]?_K<].X!CPV?^?Y\_P C^'M1]C]O_'JV
M)OW7OT_7\OZ5S\VI]\?A^7']>GT[T %Y9_Y_+'/Y9_$XKGYH?\G_ #^1QZ@B
MN@^V>=ST_7\?QSTQ[]\T>1[_ *__ %J .?A_=>_7]?R_I6A6?/V_#^M6+/M_
MP*@ _P"6O^?[U;$-Y_G^?'\A^/O6?/V_#^M9_P!L_>].?T^OY]O7MF@#L(9O
M-_S_ )XZ]JKWG?\ X#5?3)O._ ?K[?Y_3%6+SO\ \!H +/M_P*M"LZS_ -4?
MH/YBNATR'SOP/Z>W^?UQ0!8L[.>;'UP/\/\ /T]ZZBST?R9;?C/3M[\T0WL%
ME%]?\_Y[\^U:%G>SZC=>1!Z#\N>>A_SZ4 >@:/H\'DG-=19Z;H>?W^1<'\>G
M?],?KVHM/!.N3:7]H@_#I]?3CMQ_CQL>"?A!XJUZ7S_])_S_ /7'Z4 <O>>&
M[&\NAY';_/Y=/3VKE]2\$_8_M$\'O_7_ #U_#'7[@TW]G77+.+SYX/QS^7MS
M^?>N/\5?#V?1_/\ /^O3@_K^'OGUH ^#[S39_P#2.OM_/\/\.,5Y_P#8Q!+<
M?D?\.XS_ "Q7TQK&C_O;CW^G^<>G7GUKP_6+/R;K_'/UX[?A].: .'G[?A_6
MJ\,W^?\ /ZC/N#5B\_<]>_\ 3UZ8[?UQS7/S3?Y/^?R&?4DT =!]L]__ !VM
M"&\_S_/C^0_'WKEX._X_TK0@[_C_ $H ["SF@Z=\?Y]_R_$GFK$UY^]]_P#/
MY#\.?>N?AAG\GZ_Y[\?R%:%GV_X%0!Z1H/BJ^T>6WG@_X^/_ *_^<^V.*^@-
M-\>:'-:V\^J_\?'I]1P?\G/Y5\C?;!YWD=L?ICTQ^OX>]:-G>":7]_.?L_U[
M8]\_Y]NH!^J'PW^(6AZE%;P0>AY__7_C7]&'_!-GXD>%/$FESZ5!]F^T6MG[
M?7KC_P"MCU[_ ,>_@/Q)!9R^18S\XSQGO_GFOUP_8;_:6@^#WBC3Y[Z<6UO=
M7O3^GT[9H _9G_@H=\);[QM:S_8(/]']1_GTS^?XU_-]X\^&'B/0;JWL8/M.
M;J\_QZ_EZ_C7]F&@^,/ 'QX\$6\\\]M]HNK,'\3P?Q]L\5\K^-OV%? ^I:I;
MZK.+;_1;S[;W'IUYY/3K0!^7_P"Q#^SWJFL76G_VK!_H_%Z!_GCO[_6OJC]M
MCQ5X ^'OASP_X.@GMK;4+7\__K^O/?VZ_4'BKQM\.?V:?"=QY'V83VMG]B_S
M[<_YZ5_-?^T5\;+[XV_%LZKY]S<Z/:WG^3ZGT^O7F@#TCQ5KWVRU_M7PYJMS
M;7%J/_U^OY<_UKW#]F/]HKQCH]UJ&D^(_$=U_I7^A#[5>?YXZ8_F*_+?QA\0
MI]-BN(-#@N#]E]OYYS_@.*Y_1_BI/#%I]]_I-MJ!S_GN/KTQ^H /U \;:/JO
MC#X@W&N07W^CW5YU^A/^?T]JZ";P3H>FW5OJVN7W3ID?Y_S^5?F?#^T5XJLY
M?W$_\N>OX?A7#^-OC]XX\21&P^W7/\QCZ]?I^F* /H#]H3X_7'B6Z&AV,Y%O
MI?\ H77BOG>'XD3V5KS/_G_'I@'H,5XO->3S?O[X_P"D?S]>/3KV]37'ZEKT
M\W^H_P _Y_SUH ^@-1^(5]>?\MS^7\_?'X5YMK'B2^F_Y;]N/P/TZ\<]N]>8
M?VQ/Y7_'Q[_U^OOCT_.J_P#:/_3;]?\ Z] '4?VS?6<OG^?TQW [_CQ]..>.
M]=Q9^)()HOW_ /3'3Z9_I],5X_\ ;/W73C]?K^7;],5S_P#:4_F_Z/\ 7_/4
M?SH ^D/[8@\GI_\ KVXQ_GOQ7'ZE-!T_SZ=_Z8_P\X.L3PQ?X\'G^O\ ]>L;
M^V+Z;\^_OC_/^10!W$VI^3Z'^?'X_7G\>G-<OJ5YYTMQ/^G3VZ^_UZ5S\UY_
MG^7'\Q^/O6/->?Y_EQ_,?C[T %Y,?-[_ ,OKQ_D'Z 5CWDW?Z?\ U@1_(Y_K
M1--_D_Y_(9]236?--_D_Y_(9]230!8HK/HH L4444 %%%% !1110 57G[?A_
M6K%5Y^WX?UH KU8JO5B@ H\_V_3_ .O11-#_ )/^?R./4$4 'VSW_P#':SIO
M]<?J/YU9\CW_ %_^M1-#_D_Y_(X]010!8@[_ (_TJOY'O^O_ -:J];'D>_Z_
M_6H KP=_Q_I1-^]]NGZ?G_6B?M^']:* *\'?\?Z58HAA_P _Y_4X]@*L4 9_
MD_O?\YZ_7'7O^F*L0=_Q_I15B&'_ #_G]3CV H (._X_TJO/V_#^M6)OW7OT
M_7\OZ5GT 6*)^WX?UJQ_RR_S_=JO/V_#^M &?5BJ]6* "K,/^I'T/\JK59A_
MU(^A_E0 D_;\/ZU7JQ/V_#^M5Z "#O\ C_2BB#O^/]** "BBB@"O16A10!GU
M8JQ1!W_'^E !_P LO\_W:KUH>3^Z_P XZ?7/3O\ IFJ] !##_G_/ZG'L!6Q_
MRR_S_=JO!W_'^E$_;\/ZT $,/[W\?Y?U_0]:U[R\\[]Q_P#6X_E^?0^]0>3^
MZ_SCI]<]._Z9I--A,]__ )[?_KZG^= '0Z#H_P#R\?3D?AZ?K^5=Q#9_Y_GS
M_(_A[58TZ+R8OQZ'V.>?\_\ U_2/#?AO^V)>O^?R]N^<?E0!P]GH\_\ SP_'
M_P"O[_\ UP#Q6?K'VZSSG^??KQ@^O_Z^E?9&@_#<?9?]1GU[<_Y[^^:X?QAX
M$@A^T9@_SWSZG\P?:@#Y7T>:"\E^SS_7_#_/;IUXK0\2>%8/LOGP<=R.G?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "O\ .L_X/@?^2U_\$_/^R6?'C_U,/A[7^BG7^=9_P? _\EK_
M ."?G_9+/CQ_ZF'P]H _A:HHHH _V:O^#?G_ )0U?\$]_P#LA*?^I?XDK]CJ
M_''_ (-^?^4-7_!/?_LA*?\ J7^)*_8Z@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *_P WS_@]U_Y.R_8I_P"S=/&__JS9*_T@
MZ_S?/^#W7_D[+]BG_LW3QO\ ^K-DH _B*HHHH _VI/\ @AW_ ,HAO^"=7_9J
M_P +?_3&M?JI7Y5_\$._^40W_!.K_LU?X6_^F-:_52@ HHHH **** "BBB@
MHHHH **** "BBB@#^?S_ (.B?^4%O[='T_9C_P#6R?@)7^057^OK_P '1/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 <CXV_Y%#QC_V*_B+_ -,[U_G>_P#!5'_D]+XD?[NE_P!:
M_P!$+QM_R*'C'_L5_$7_ *9WK_.]_P""J/\ R>E\2/\ =TO^M 'YSS?ZK_M^
M_P */^6O^?[U07G^J_[?1_,5/_RU_P _WJ -"JTW^N/U'\ZLU6F_UQ^H_G0
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M7G^?Y<?S'X^] '87FL3S9S/^7UQ_GN.]<_YW[S_7\_\ UOKZ_K[US_VSW_\
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M_7? _B>Q5RQ3S]#\1Z+;:[%&P!V&6%%.UR6 0D>65_O'?&S]G[X&_M(>#Y?
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M1VJ^*3X7CUW2WMSJZ>'_ /A2WA;^VG!&Y('\56ZNJ,=S JL_\9%% !7Z#?\
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M-?[-7_!OS_RAJ_X)[_\ 9"4_]2_Q)0!^QU%%% !1110 4444 %%%% !1110
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M4 ?[4G_!#O\ Y1#?\$ZO^S5_A;_Z8UK]5*_*O_@AW_RB&_X)U?\ 9J_PM_\
M3&M?JI0 4444 %%%% !1110 4444 %%%% !1110!_/Y_P=$_\H+?VZ/I^S'_
M .MD_ 2O\@JO]?7_ (.B?^4%O[='T_9C_P#6R?@)7^050 5_>I_P8Y?\CC_P
M4F_[%O\ 9-_]._[0%?P5U_>I_P &.7_(X_\ !2;_ +%O]DW_ -._[0% '^A)
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?C
MC_P<#?\ *&K_ (*$?]D)?_U+_#=?XRM?[-7_  <#?\H:O^"A'_9"7_\ 4O\
M#=?XRM !7]TO_!C]_P EK_X*!_\ 9+/@/_ZF'Q"K^%JO[I?^#'[_ )+7_P %
M _\ LEGP'_\ 4P^(5 '^BG1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5\.?M'_MS?"WX W-UX5MXKCQW\0X$3[3X6T:[2PLM$R"-
M_B#7)%EAT%2N"@=)&(;)V$$'J_VROC?<_ 7X)ZMXJTF96\6ZU=IX7\'AXH\V
MFK:TSF76B>2J^&=#34[PE3EVC4.""17\Q]Y>7VI75Q?7T]SJ.H:I>?;+R[N\
M_P!IW^J?ECU_7M0!^D6L?\%2OCW>W]Q<:-X6^&.DV&P):V<FE:WJ>H.,8R^K
M+XE6WW'!Y6(#/( Q7L/PM_X*I3RWUO:?&;P!IUO9W"M]HU_P!/,L=DV.!)H>
MOF10"WWG/BR0KU56("G\=**YP/[ /!GC;PQ\0O#ND^,/!VLZ?X@\,:S:"\L-
M5LW#QR(1P>0"".58,JLI&061E8]A7\Z7_!/?]H#5OAI\7;#X<:G?X\ _$^\_
ML:[L[R\^30_%."=!U?1^K&)B%\+R*I7>HVL2OA)@?Z+:Z "BBB@ HHHH ***
M* "BBB@ HHHH _R%_P#@Y]_Y3;?M??\ 73X'?^L\_"&O].3_ ()>_P#*.#]@
M+_LS?]F[_P!5)X<K_,;_ .#GW_E-M^U]_P!=/@=_ZSS\(:_TY/\ @E[_ ,HX
M/V O^S-_V;O_ %4GARNC+/\ DAJ/_92+_P!0N(B^*O\ DLJ'_9-Q_P#37!Y_
M'-_P?!_\C5_P3K_[%[]I[_TZ_ >OU6_X,]_^44&J?]G/_%+_ -1WP)7Y4_\
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M )(OBGTA_P"HW%A_M1:%_P @C3?^O"Q_]%+6T_1_J?Y-6+H7_((TW_KPL?\
MT4M;3]'^I_DU*K_O$_5_^G&>/@/]TR__  P_])1/1116)V!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN/U'\Z +-%%% !111!W_ !_I0 40=_Q_I1/V_#^M$'?\?Z4 6**K^?[?I_\
M7H\_V_3_ .O0!8\CW_7_ .M1Y'O^O_UJK^?[?I_]>CS_ &_3_P"O0 4444 5
MZL>1[_K_ /6HHH /)\K\??\ SUQ[]/S*/];_ )QC'Y^OOU_*QY'O^O\ ]:@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *\C^,7P+^#?[0O@R]^'WQR^%/P\
M^,'@G4QF\\*_$WP;H?C;PW(PP"9-'\06UQ"2=H.516]QDBO7** /Y6/VO?\
M@TE_X)A_M$MK7B/X(Q?$?]CWQUJ&^ZMV^%>K-XT^&'V\[65]8^%OC_[0T<2D
M@_V!X1\7>"HU8D@*&93_ "R_M<?\&AW_  4S^ ;W>M_ >;X9?MA>#+>3-L/A
M]JX^'GQ/\H\AM6\ ?$*:#P\"H/$?A?QUXM9B")"A&*_U0:* /\(#XV_LX_'K
M]FSQ9)X&_: ^#?Q,^"_C&!;UW\/?%/P)KG@C4)RI1&;2QK]O;MK<8WKB6W,T
M8)*+(['(\&K_ &5_^"B/_!4+_@C?\$/".N_"K]N3XR_LZ_$^W:S:UUK]GZ\\
M-:'^T=XDO)B%C2WUWX6>'M!\7G0)"275_%L7A:#;$Q61,0Y_S/\ _@J=^TC_
M ,$H/C]XU:]_X)W?L*?$?]EY3K/V_4O&VN_%XQ>&?&416X6XTQ/V= GCCP[X
M C BTHQS>#_BYX<AMMY,G@H-E90#\:**** /[B/^#4#_ (**?MN?%C]O&_\
MV5/BQ^U#\5OBU\ +/X _%'QG9^ ?B5X@/Q"%GXA\/Z[X'M]!N-!\0^)U\3>*
MM!B@MM7U:0^'/#GBFT\,$32!K5V49_T<*_RL?^#.S_E+Q/\ ]FL_&?\ ]/'P
M^K_5.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OEK]J3]D/\
M9I_;7\ Z/\+OVHO@_P"$_C;\/O#GC/3_ !_I/A+Q8=3DTRT\;Z+HNOZ%HNN'
M^Q)[:1)HM \8^((5+R,BQ:S)NAD)4Q_4M% 'XZ?\0_W_  1I_P"D??P,_P#
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MK7;C)M;Z*Z=_6SWT-Z-'ZQBEA']J2C\W+E3^^VF^_8^V?^"4_P#P4/\ AO\
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M_P"R$I_ZE_B2OV.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]BW^R;_Z=_V@* /]"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP]U#2O&'B&YRHTY]6T,%M#T-5)!8KKZ/(P7)$<;M@A#C^ENN@ HHHH ****
M"BBB@ HHHH **** /\A?_@Y]_P"4VW[7W_73X'?^L\_"&O\ 3D_X)>_\HX/V
M O\ LS?]F[_U4GARO\QO_@Y]_P"4VW[7W_73X'?^L\_"&O\ 3D_X)>_\HX/V
M O\ LS?]F[_U4GARNC+/^2&H_P#92+_U"XB+XJ_Y+*A_V3<?_37!Y_')_P '
MP7_(X?\ !.8YZ>&_VH03]-3^ N?Y&OYSOV'O^"&__!0?_@H?\%G_ &@?V8_
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M[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#D?&W_(H>,?^Q7\1?\ IG>O\\;_
M (*K_P#)YGQ1^NE_RK_0Y\;?\BAXQ_[%?Q%_Z9WK_/%_X*H_\GI?$C_=TO\
MK0!^;_,,/N/PZ_U_(Y/8U8G[?A_6H+S_ %7_ &^C^8J>?M^']: *]6/)\K\?
M?_/7'OT_.O!W_'^E69O]2?H/Y4 )YL/K^I_QHK/G[?A_6K'_ "R_S_=H //]
MOT_^O5>CR/?]?_K4>1[_ *__ %J +%%%% !1#-_G_/ZC/N#15>@#8\_V_3_Z
M]5_/]OT_^O1_RR_S_=JO0!8\_P!OT_\ KU7\_P!OT_\ KT57\CW_ %_^M0 5
MH0P_Y_S^IQ[ 5G^1[_K_ /6K1A_U(^A_E0 D_;\/ZU7JQ5>:'_)_S^1QZ@B@
M"QYL/K^I_P :K^?[?I_]>J_D>_Z__6JQ0 4444 %%%% %B#O^/\ 2K'FP^OZ
MG_&J]%!T!_K?\XQC\_7WZ_EH0^1Q^'Y__J^]6?1Y_M^G_P!>@#0_=?YVUGS]
MOP_K1Y_M^G_UZ* "&;RO\_YYZ]J)IH.G?_ZW^'OGTZ')5>:'_)_S^1QZ@B@
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M_G_/ZC/N#15>#O\ C_2@#0G[?A_6J]6** *]%6)^WX?UJO0!7JQ11/V_#^M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME"P$O^BG110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ[\+-#31HXXO"TA?QO!H26UTG@XM/XR/^A-10!_E5_#?_@EU_P %L?V$M>^
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M_>I_P8Y?\CC_ ,%)O^Q;_9-_]._[0%?P5U_>I_P8Y?\ (X_\%)O^Q;_9-_\
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M$_PD\#?!CP=9>#? 6B)I&CVZ_:[D[$?4-8U)XX3-JVKS&)6GUF9XPTDAX9E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDK_&5K_9J_X-^?\ E#5_P3W_ .R$I_ZE_B2@#]CJ*** "BBB@ HHHH ****
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MUC$\&\7JK)XGVN'@H1PJIRIJ59_O8RI_T,?\/P?^"9?_ $<Q<?\ AG?CW_\
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M-@N(L1#BC#\,4\,N&$\+PEPE!4:6%J.=.G.C[1?6'*<J3JNE"*BBBOS(_O\
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MI6JSA&@H1=?V4JU?^AA?^"XW_!--N&_:39%]5^#7Q]63_@)_X5=( ?\ >_\
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MY''_ (*3?]BW^R;_ .G?]H"@#_0DHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /QQ_X.!O\ E#5_P4(_[(2__J7^&Z_QE:_V
M:O\ @X&_Y0U?\%"/^R$O_P"I?X;K_&5H *_NE_X,?O\ DM?_  4#_P"R6? ?
M_P!3#XA5_"U7]TO_  8_?\EK_P""@?\ V2SX#_\ J8?$*@#_ $4Z*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBB@"OY_M^G_UZ//]OT_^O5BB@ HHHH *_P!9BO\ )GK_ %F* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP>Z_\G9?L4_]FZ>-_P#U9LE '\15%%% '^U)_P $._\ E$-_P3J_[-7^%O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!R/C;_D4/&/\ V*_B+_TSO7^>+_P5
M1_Y/2^)'^[I?]:_T.O&W_(H>,?\ L5_$7_IG>O\ /%_X*H_\GI?$C_=TO^M
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M*** "K,/^I'T/\JK58\_V_3_ .O0 3]OP_K11Y_M^G_UZ*#H"BBJ\_;\/ZT
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M*L40P_Y_S^IQ[ 4 '_++_/\ =JO6A5>:'_)_S^1QZ@B@"O1_RU_S_>HI(?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#4X4U\4I5)N56>G1117J'PH4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7^=9_P? _\EK_X)^?]DL^/'_J8?#VO]%.O\ZS_
M (/@?^2U_P#!/S_LEGQX_P#4P^'M '\+5%%% '^S5_P;\_\ *&K_ ()[_P#9
M"4_]2_Q)7['5^./_  ;\_P#*&K_@GO\ ]D)3_P!2_P 25^QU !1110 4444
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M(5 '^BG1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]?J!X\_8Y^.$UU<&Q\ :E]GS_0<#_/X8->#:_P#L9_M"S?ZCX<ZCZ=^W^>:
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M_ABC]I3_ *)GJ-'_  Q1^TI_T3/4: /E:BOJG_ABC]I3_HF>HT?\,4?M*?\
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MH/[$_P 8_*Q/X U+C'&!_GFO2--_8S^,4W_,@:D/Q'U_3V_&@#\J?^$.O?\
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M_P"B<:C^5 'QM-9_Y_ES_,_A[5G_ &/V_P#'J^T)OV+?VC.G_"N=2ZC^7/\
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MG_UZ//\ ;]/_ *]?5'_#$7[37_1,]:_,T?\ #$7[37_1,]:_,T ?*]%?5_\
MPQ1^TW_T3/6Z/^&*/VF_^B9ZW0!\H5_K,5_F+?\ #%'[3?\ T3/6Z_TZ: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K_*Q_P"#Q/\ Y2\0?]FL_!C_ -/'
MQ!K_ %3J_P K'_@\3_Y2\0?]FL_!C_T\?$&@#^56O]FK_@WY_P"4-7_!/?\
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M_7U_X.B?^4%O[='T_9C_ /6R?@)7^050 5_>I_P8Y?\ (X_\%)O^Q;_9-_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#+"DR-
M%( 8R,$9P>/4UYUJOPE^%VO74]_K7PX\!ZO?W 'VJYU7PCH6I7S^F^66VD?)
M'.58D]>3G'I=% 'E/_"D/@S_ -$E^%__ (07A#_Y1TG_  HSX-?]$D^&'_A
M^#__ )0UZO10!Y1_PHSX-?\ 1)/AA_X0/@__ .4-+_PI#X,_]$E^%_\ X07A
M#_Y1UZM10!Y3_P *0^#/_1)?A?\ ^$%X0_\ E'1_PI#X,_\ 1)?A?_X07A#_
M .4=>K44 >4?\*,^#7_1)/AA_P"$#X/_ /E#1_PHSX-?]$D^&'_A ^#_ /Y0
MUZO10!Y1_P *,^#7_1)/AA_X0/@__P"4-'_"C/@U_P!$D^&'_A ^#_\ Y0UZ
MO10!Y3_PI#X,_P#1)?A?_P"$%X0_^4='_"D/@S_T27X7_P#A!>$/_E'7JU%
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M ,(+PA_\HZ]6HH \I_X4A\&?^B2_"_\ \(+PA_\ *.D_X49\&O\ HDGPP_\
M"!\'_P#RAKU>B@#RC_A1GP:_Z))\,/\ P@?!_P#\H:/^%&?!K_HDGPP_\('P
M?_\ *&O5Z* /*/\ A1GP:_Z))\,/_"!\'_\ RAH_X49\&O\ HDGPP_\ "!\'
M_P#RAKU>B@#RC_A1GP:_Z))\,/\ P@?!_P#\H:/^%&?!K_HDGPP_\('P?_\
M*&O5Z* /*/\ A1GP:_Z))\,/_"!\'_\ RAH_X49\&O\ HDGPP_\ "!\'_P#R
MAKU>B@#RC_A1GP:_Z))\,/\ P@?!_P#\H:/^%&?!K_HDGPP_\('P?_\ *&O5
MZ* /*/\ A1GP:_Z))\,/_"!\'_\ RAH_X49\&O\ HDGPP_\ "!\'_P#RAKU>
MB@#RC_A1GP:_Z))\,/\ P@?!_P#\H:/^%&?!K_HDGPP_\('P?_\ *&O5Z* /
M*/\ A1GP:_Z))\,/_"!\'_\ RAH_X49\&O\ HDGPP_\ "!\'_P#RAKU>B@#R
MC_A1GP:_Z))\,/\ P@?!_P#\H:/^%&?!K_HDGPP_\('P?_\ *&O5Z* /*/\
MA1GP:_Z))\,/_"!\'_\ RAH_X49\&O\ HDGPP_\ "!\'_P#RAKU>B@#RC_A1
MGP:_Z))\,/\ P@?!_P#\H:/^%&?!K_HDGPP_\('P?_\ *&O5Z* /*/\ A1GP
M:_Z))\,/_"!\'_\ RAH_X49\&O\ HDGPP_\ "!\'_P#RAKU>B@#RC_A1GP:_
MZ))\,/\ P@?!_P#\H:/^%&?!K_HDGPP_\('P?_\ *&O5Z* /*/\ A1GP:_Z)
M)\,/_"!\'_\ RAH_X49\&O\ HDGPP_\ "!\'_P#RAKU>B@#RC_A1GP:_Z))\
M,/\ P@?!_P#\H:/^%&?!K_HDGPP_\('P?_\ *&O5Z* /*/\ A1GP:_Z))\,/
M_"!\'_\ RAH_X49\&O\ HDGPP_\ "!\'_P#RAKU>B@#RC_A1GP:_Z))\,/\
MP@?!_P#\H:/^%&?!K_HDGPP_\('P?_\ *&O5Z* /*/\ A1GP:_Z))\,/_"!\
M'_\ RAH_X49\&O\ HDGPP_\ "!\'_P#RAKU>B@#RC_A1GP:_Z))\,/\ P@?!
M_P#\H:7_ (4A\&?^B2_"_P#\(+PA_P#*.O5J* /*?^%(?!G_ *)+\+__  @O
M"'_RCH_X4A\&?^B2_"__ ,(+PA_\HZ]6HH \I_X4A\&?^B2_"_\ \(+PA_\
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MW,3?YNG_  5K_P""8O[/G_!,/Q]IGP2T7]NO2/VH/VAK-M/N_'_PT\$? 9_
MFE?"O3-2,KZ>OC#QO+\8/&$0\0SC]Y:>%X[:7Q/% ZW?C9/"-I-X-G\9 'XG
M45K6-CJ&K7UOIFF6=SJ&H:A<BVM+2WM_MU]>WKE0L<:*K2,SL_1 >I9@V&8?
MN+^S3_P;;_\ !8#]IW3-*\0:'^RIK7PF\*:Q;+>6WBC]H'Q'H?PE C;D&3P5
MK\I^)R,PY7'@IE8?,'(XH _"2BOZS_\ B#<_X*S_ -G?;/\ A+?V-?M'F;_[
M)_X7!\2?[2VYSMW?\*2_L''_ &\_X5^?W[4__!N9_P %=/V3=(U3Q7XL_97U
M?XH>"-%@6[O/&WP#\2Z%\7]+2R:0)O\ ^$3T&8?$F.*-G5I)[KP=! B,)"RK
M\X /PQHHK]*_^">'_!,KXW_\%._'OB?X7?L__$;]G_0?BCH>GQ:]9> /B]\1
M]5\%>)O&^EE9&US6/!%NGA;Q.?$">&2B3>*D5X&M[=UDC68;&(!^:E%?U5?\
M0=?_  5Y_P">_P"RK_X>O7/_ )VU?GM^VU_P02_X*>?L&>$=<^)WQE_9WN=>
M^#_A^%[OQ%\6O@]XBT;XE>"=!TX2,7U?Q$GAZ8^+/"N@JKQA_$GBWPCX8\+Q
M2?)]HSM) /A7]D+]L[]I7]A?XOZ'\<OV8/BAXC^%WC[1KJW-VVCW<K>'?%FF
MI*6;PKXX\(M-_8/CCP^=SR'PYXDBFMC(PD2%9XH)(O\ 70_X([?\%3/AY_P5
M>_9-T/XYZ!8VWA7XH>%-47P#\>_A?9WTD[^ ?B7%I-OJLC:9M!EU?P'XKT:9
M?$?@GQ%*S+Y#7'A&YN+GQCX6\5);?XO%?U+?\&E7[7FI_L_?\%0=)^!-W?W(
M^'W[8_@/Q+\,M9TM#IPTQO'7@71M<^('PPUK5E<&5I8%T?QIX2A$19RWCL2L
MKHVX '^K%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?Y6/_!XG_P I>(/^S6?@Q_Z>/B#7^J=7
M^5C_ ,'B?_*7B#_LUGX,?^GCX@T ?RJU_LU?\&_/_*&K_@GO_P!D)3_U+_$E
M?XRM?[-7_!OS_P H:O\ @GO_ -D)3_U+_$E '['4444 %%%% !1110 4444
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M]DL^/'_J8?#V@#^%JBBB@#_9J_X-^?\ E#5_P3W_ .R$I_ZE_B2OV.K\<?\
M@WY_Y0U?\$]_^R$I_P"I?XDK]CJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K_ #?/^#W7_D[+]BG_ +-T\;_^K-DK_2#K_-\_
MX/=?^3LOV*?^S=/&_P#ZLV2@#^(JBBB@#_:D_P""'?\ RB&_X)U?]FK_  M_
M],:U^JE?E7_P0[_Y1#?\$ZO^S5_A;_Z8UK]5* "BBB@ HHHH **** "BBB@
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M$TJ^U/4YE@L=.MKVZNKIOE%K9Q R.Y*Y(VQQA\_[!XX%?X^__!0?]J[]I/\
MX+F_\%,[?2/ W]J>(;+QQ\2S\'OV4_AF^I./#GA3P-+K*:-HFHO#(JPZ#)XB
M"+XO\?\ B5H N7F:YN);;PU:"+"$,3C,RR_+<'9YC93E+11C&=TM96BU)PG+
M5J*C"I.5HP;3A'#T,+F&9XQVRJ"]Z7PQ;Y;R3D]$E%7D]6E9).4XQ?\ 5?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/'GQEU'36%\+#_BZWC<>!]%U0E5*M+&/@KKBC8S.BLS$2+*S-_#?0!_IL_\
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M:1:GHG@'X :'X^EM+5-.?4?%"_!OP)K\<VJY*_VZR>&-7\'6XNE1F1=*-HP
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M_E$-_P $ZO\ LU?X6_\ IC6OU4H **** "BBB@ HHHH **** "BBB@ HHHH
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M<GWYQZ_YZ\5^=O\ P5EUS4= _P""9/[?>N:9*+;4-,_9!_:*ELY^Z.?A;XE
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M^!W_ *T)\*:_D/\ ^#+_ /Y2,?'_ /[,W\6_^K@^#5:\'_\ (VXN_P"R;_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?YR'_  >U?"!=*_:5_8C^/L.G70A\=? S
MQ[\(;[5)%OSI[?\ "I_' \;:/I:L"B),P^->KOB,+(4;#>6D3*/X=J_V$O\
M@X7_ .";6K?\%(O^">'CCP;\/M.NM0^/WP/U=/CG\#-,M +C4?%WBCP]I&N6
M^M_#1%41!Y?&GA76M<\/^$(7;RQXS3PPSND:R.?\@.^L=0TF^N-,U.SN=/U#
M3[DVUW:7%O\ 8;ZRO4+!HY$95D5D9.C@= RA<JQ /] K_@VF_P"#@?X2>'/@
M_P##S_@G;^VKX]TSX7ZW\/<^&?V<_C7XXU%+'P+XF\)DE?#_ ,&?'/B*4JG@
M?Q#X4W7&A>!?$OB-[?P?=^$++PWX&DN+/Q=#X6/C'^\2RO;/5+2&]L9K?4-/
MN[;[1:7=K<K?65W&W0HZEED&<%2N03D9W*0/\!NOM'X!?\% _P!N+]EFPL=.
M_9U_:X_:%^#_ (>TE[ZYL?!G@?XL^,=*\!I+JW.I32>!$UW_ (1!KF1[YW,I
M\-2,TYDN0WFQR2@ _P!R>L34]3L-%LKG5=3O+33]-TZV:[O=2U&Y6PT^RL0<
MLSNQ$:A50?ZP#YMHW[BB5_CGR?\ !Q+_ ,%II4\IOV_?BD1U./#7PP#$>^/A
MZ#CWZ^]?#GQ]_;W_ &VOVIK2_LOVD?VM/V@OC/H^IS6%_<>%?'?Q3\7>(?!'
MFZ2V=.F7P0^O?\(II3QNV^+RO#<3),_VE?WDLDA /[,?^#E[_@X ^$/Q!^#_
M (O_ .">'[$'Q%L?B4_CBZ_L?]ICXU>$;XZEX)LO"KK%K)^&?PR\9JS0>*CX
MIE6*S\:^*_#4UUX-3P4/$'@6)[R3Q5=/X3_@$HHH _L!_P"#,KX;ZUXD_P""
MFGQD^(B:?=-X>^%O[)7C6SU#4S/B*R\1^.OB7\)]'T'2I%?#EY]!T?QC-#M!
M!&B2'<F(EK^QO_@KW_P7:_9M_P""1]YX6\"?$?X>?$[XL?&?XD> M2\:?#[P
M3X(M_#VE^'6TX:UJWA]=4\:>,O$.OHV@:+-K>DRQ#['X3\57"#;)';2Q%A#\
MI?\ !K3_ ,$U?$?["W[#&I?&+XN>'TT#XZ?MB7WAKXEZQH]YI-YIFO\ @SX/
MZ%IT\?PH\&Z['<(RG7IAKOB#XDSA8H);=?'-KX0NK)+OPG+<U_*C_P 'C_BV
M/Q)_P5L\,Z*)<+X _9!^#O@Y^^TS^-OB]X\ /U_X3?\ ,&@#^=G]K']I;XD_
MMC?M(?&3]J'XK7=O/X_^-?CS6?&7B.STX$Z=HB2K':Z#H.BH"'30?"WAV/1_
M#7A82S2/]BT>$.Y91))] ?\ !([X6ZA\9?\ @J'^P#X TN"&[75/VL?@9K>K
M)<L0A\-^"/&^A>.O&Q8C)PGAC0=:<+@[RBKD DU^<E?U]_\ !GY^QAK'QK_X
M*">(?VN-8T:Y/PX_9%\!:P='UR:0_P!FWWQS^*^AZOX"T+13"(8H]<:#X<ZS
M\4?$LK_O)?"MU'X7GE9O/M6< _T_:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /Y9O^#DK_@MEK7_  33^$_AW]G_ /9PUVPM_P!K_P"/WAW4=:TK
M6RMA>S_ WX/><^C2_$Q-,F::*?7_ !=KNGZQX5^'\1A6VMI/#WBSQD^^7PC;
MV7BC_+7\6>+_ !3X]\3:]XP\<>)_$'C7QCXEU:_UCQ%XL\5ZOJ/B/Q)KNK:P
M3_:^K:]KFM2OK>NZU*[1/-/<RR222(\\C,6D,GZ1_P#!9_\ :OU7]M#_ (*:
M?M<_'*\U1K_PXOQ<\4_#/X<JFKMJ6FV?PO\ A--)X#\"-I*2I(NC)XE\/:!#
MXJFMH4,0\5Z[XAD"&1IY!^4M !17^I)_P0J_X-[/V6_V8_V:OA'^T/\ M:?
M[P7\:OVLOBSX6\)_$JZM_B[X=T7QGX:^ UGX@&C:[X*\&^$_ ^NVLOAN/Q_X
M8AGTJX\6^,I8)O%D/B^*XM/!]W#!%'YW]*/C[]EK]FKXL^$;WP)\3?V??@KX
M]\$ZC9FQNO"/C#X6^"?$7AYK+YL!M(UC0'B7G^%8_D;#)R* /\(JOOS_ ()[
M?\%!?VD/^";7Q\T#X\_L[^*K_2-2M+S3;+QQX)N[_P CP3\5?!*:F+K5O!OC
M?17C>&:*X$;&S\1!OM?A6YC\RUD625DD_<#_ (.9?^"+?@#_ ()L_$[X;?M#
M?LO:+=:!^RY^T3K6N>&[GP%<WDNI67P4^,.C6\^LR^&]#U/6[F37I_ ?C7P^
MVM:[X.B?[2OA>;PQXCADO(+)O"<2_P H= '^XC_P3\_;;^$'_!0[]D[X5_M7
M?!>>XL_#'Q"TR4ZMX3U.[%UXB\!^.-$N%T7QOX(\0$I+G6O#?B&*98Y(H_L_
MB6U;0/%UF5L_$MM))]SU_GN_\&3/[36J6WC']LS]C75-3:XTG4_#OA7]ISP;
MH+! ;+4]%UK0/A3\4]:RV0/M$6O_  G@[,?[&!')6O\ 0BH **** "BBB@ H
MHHH *_RL?^#Q/_E+Q!_V:S\&/_3Q\0:_U3J_RL?^#Q/_ )2\0?\ 9K/P8_\
M3Q\0: /Y5:_V:O\ @WY_Y0U?\$]_^R$I_P"I?XDK_&5K_9J_X-^?^4-7_!/?
M_LA*?^I?XDH _8ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M25^QU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5_F^?\'NO_)V7[%/_9NGC?\ ]6;)7^D'7^;Y_P 'NO\ R=E^Q3_V;IXW_P#5
MFR4 ?Q%4444 ?[4G_!#O_E$-_P $ZO\ LU?X6_\ IC6OU4K\J_\ @AW_ ,HA
MO^"=7_9J_P +?_3&M?JI0 4444 %%%% !1110 4444 %%%% !1110!_/Y_P=
M$_\ *"W]NCZ?LQ_^MD_ 2O\ (*K_ %]?^#HG_E!;^W1]/V8__6R?@)7^050
M5_>I_P &.7_(X_\ !2;_ +%O]DW_ -._[0%?P5U_>I_P8Y?\CC_P4F_[%O\
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M_@L7^PYXC\17:66G:K\5=1^&<S3Y"C4OBKX+\4?"W0DQZOXE\5:."I  ( Y
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MKR2]T_X5>,='\2^,T2),.7A\(1^(;C*9(:$EHW7>!_%=_P &H'[?G@3]D?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?Q<_P#!>G_@V5LOVM_%'CS]M#]@O3]'\/?M(>(Q+K/Q9^ -U/IGAWP5\:=7
M40I-XU\!ZQ(]MX;\ ?%_Q"6,GB]O$LUOX'\=W$O_  F.H7'A'QN/%WBOQM_:
M-10!_@W?&/X&?%S]GSX@Z[\*?CE\-/&?PH^(_AVY%OK7@OQ]X<U3PSX@T_<S
MA"+;6_*7^QVV$P:TF^-P1(CO$6:O&*_W:OCU^RO^S?\ M2^'%\'_ +1WP(^%
M'QQ\+*P-KI7Q/\#Z)XU73F"JS3Z'+KD$L^A2_*"9?#TL4C'+!R2<_AG\7O\
M@U(_X(Y?$^76I-!^#/Q-^"E]K8O,WGPB^-7C0'0]0U>5W;5M$T;XA/\ $_PK
MI#P*TBP:(_A>7PE#&(HUL_(@2, '^3#17^GW_P 06'_!++_HOO[?/_ATOV</
M_H4J^A/@]_P:6_\ !';X7P:=_P )5\/OC?\ 'R[TVX:[EN?BY\;M:L?M8^WL
M3%JNE_!Z'X1:%+$%VQ2A;5!-'I49*R.DD<@!_EJ_"CX/?%3XY>-]'^&WP:^'
M/C7XK^/=?<VVC^"OA[X;UGQCXGU!L\"#1] BGN' .,X&U"5,F"P8_P!_'_!#
MO_@UEU+X.>)_"7[5_P#P4PT7P_KGC'0[C3O$OPV_9/MKO2/$?ASPOJ:PVTT'
MB3XWZQ L_A_Q)K5O<QYA^&/ANYO?!XAMX9?&OB?Q69I_!MK_ &$?L[?LA?LL
M_LD:'=>%?V9/V>OA%\"M"NS%_:UO\,_ FB>'=1UTK@^9K>LZ/$->U^17L%5I
M/$4MQ)*8TC+LT;1U]1T %?X]'_!RMXT'CG_@MG^W'?I>W$UOH7B3X7^"X"9=
MT=F?!?P ^%>@W&FQE1@!/$.D:NQ4DLT[M)G< :_V%Z^.=1_8,_8<UCXGW_QL
MUS]CG]E/5/C-J>K7>L:M\8M3_9^^$&H_$W5-<U%!I;:OJGCN?PH?%%QK5U&#
M'+<S7DF_<\/F*^30!_D=_P#!-C_@CW^VO_P4[\;:)I'P1^%VJZ+\'6U9[+QQ
M^TEXVTF32?A#X'T_;+%JMQ#KCBV/C_Q%:-I[*G@SP>WB+Q.+N6T>[3PU9--X
MGC_UB?\ @G)^P-\$/^":?[+W@?\ 9B^!VEG^R]*=M;\9^,[^RDM?%/Q4^)VK
MZ;HT'B7XD^,XE:;?K?B4Z1!' B#R?"WA+0_#G@RW<V?A>V*_=UE:66E6L%C8
M6MO8V%J@M[6TM+5;&SM44' 2-0B*I)PIC4*2>!N8L=.@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K#U>UGU'3+^S@O;C2KF[L[^UMM3MBA>Q9XV":BN
M2H5D;:RY/)/&%8L-RB@#^"SXB_\ !C]X)OKYKCX3_P#!0WQ5X;T\+F/2OB-^
MSAI/C74''.=^O>'/C+X+B7']U/"9)/5AC!^<H?\ @RO_ &C/#WCKP1>6_P"U
MI^SY\2O $/CSPK>^/="\2>&OB9\.]2O? 2ZQ&?&^EZ"WAP>+7D\02Z&ODVL&
M_P *+/(T>SQ=X4\EKD?Z,%% $$,$4$4<,,8BAAX1!P% !X'7(Y))S^-3T5S>
MJZMI>AZ7?ZWKEW9Z9I6EVE_>ZKJNIW4=GI]EI^DAVEU'4I93'&J1)'YCNV$5
M,G*A0  ?R%?\'JNN:5'_ ,$UOV<_#TLD1U[4?VXO!.KVMMU;^S="^ 7[0$.L
ML3D$*D_B#0L\982* <\'_,@K^C#_ (./_P#@JIX>_P""FO[:6E:?\(=1BU;]
MF#]F+2/$G@'X+ZO&%=O&VJ^(Y=%D^*/Q,:)MT6CZ1XJU[P_HWAGPC$LLBS>#
M_ _AOQD\=O=^*I[>'^<^@#^Q_P#X,L_!VLWW_!2+]H[QU!:3/X9\,_L4^)O"
MVIZJMP5BLO$?CCXU? G6/#^DL&RYEGT3P+XQ=!R,:'*6*$(!_ILU_'=_P9V_
ML2ZU\#_V)?BA^UYXVTB;2?$W[7WC;1[+P.MT':[/P:^$C:YH^BZTJ-#$T#^*
M/B#X@\=,8V#I-X<T'PU=B9TD4U_8C0 45_/'_P %$_\ @Y*_8<_X)H?M):O^
MRS\=?A=^U?XI^(>@>$O"_C"\U;X3>!_A%XB\$2:?XUTL:OHD::UXT^-G@SQ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?Y>O['/_ "=U^R]_V<=\#_\ U9OA^O\ 3]A^XG^XO]:_S OV.?\ D[K]E[_L
MX[X'_P#JS?#]?Z?L/W$_W%_K7\V?1U_Y$?%/_8:O_4>9_M?^VR_Y.MX&?]F[
MXL_];I%VBBBOZ3/\4 HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMXB22?XM_$29)?+W)<MX;ANECF\97\ 586_U5OV9/V:_A/\ L>_ [X:?L\?
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M^$B#C@'PM@<\9+$]7M\1B;O%1LWK+;5]=;)OO=W=]V[:Y>PPN'UPJMY62_\
M27;[DMKG^>9^VW_P7%_X*B?\%<'T_P#9[O[I]*\#^-M873])_9J_9;\'>)[6
MS\>:G()H].TO6H/M?B_XF^/YW$H*^'+CQ3/X3>9%O(O"-K,@*_UR?\&W'_!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 445\F?MA_M?? 3]AGX"^,?VCOVD?&=KX*^'7@^T!?]Y$_B#Q+J[%O[%\
M(>#M%<P3>(/$?B9HO)M/#L#>:\CDN$BCEF0 ^LZ*_A:_X)V_\'$7_!1S_@H[
M_P %6M%\ ? ;]F?0?$W[%-])J^A>)_A?;R:9I_B7X1_"S^V-!+?M#_%#XTW
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M?VA/^"I__!1?]J;6-1UKX[?MF_M!^-!K!0W_ (=M/B-JO@OP)F*0J?LWPQ\
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M'^M^&_$?B1?&'B31=:\66\/BGQ-<0Q6VMZ%#%:6ZP0E0#_6!HK_$*_X>Q?\
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M1_P]B_X*E_\ 22S]OO\ \3(_:/\ _GC4 ?[>M%?XA7_#V+_@J7_TDL_;[_\
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M\(/^R6^ /_41T.@#U:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?A?'JR)_8FF:Q\MO'\0/B7)$_AKP):ONE$A\0^,G@NM-\'^*C%XI_P $V?\
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M])0O_-*&_P#HLZ_EG_X+#?\ !-!/^"4'[7%O^RU_PNEOCV[?"WP5\3'\:?\
M"N3\*HU7QIJ>O0QZ%_PCX^('Q.+-9_V#.3>GQ.OV@/YJV\95O- /R=K_ &+?
M^#;'_E"3^P7_ -B-\3?_ %?WQ9K_ !TJ_P!DO_@W<T1?#W_!%S]@.P67SOM'
MPK\3:XLX@(^7Q#\4?'^OJ#GYAL_M@JK-RP##N: /VMHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\O7]CG_ ).Z
M_9>_[..^!_\ ZLWP_7^G[#]Q/]Q?ZU_F!?L<_P#)W7[+W_9QWP/_ /5F^'Z_
MT_8?N)_N+_6OYL^CK_R(^*?^PU?^H\S_ &O_ &V7_)UO S_LW?%G_K=(NT44
M5_29_B@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBG1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX'^'$K%Y!$OPI\,ZMI/AF>V6;[*_C0>+O%\"1IXK$2]I_P %1?\ @NY^R/\
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M?$+W'V?2-+\.11^:]KX9\+Z/X;\)>%;>U\+>&K."W /QG_X.S?\ E"Q\</\
MLJO[/7_JT] K_)<K_6C_ .#LW_E"Q\</^RJ_L]?^K3T"O\ER@#_1Q_X,AO\
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M%AX6U?7-#OM+L/'?AV7Q1X2O[^V*6/B#PW#XN\1^"7UK1)&5';2D\3>"]?\
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M_P!MBOYA?^#MOX0^#O'_ /P1[^)?C_7;2&?Q/\#OBY\%_'7@2_4XN[34=?\
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MA'_P=O?\%E?AQ*W_  F'Q,^"7Q[5KLW(7XN_ GPEI2[&'_(,C/P%'P><1M_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>,?%]I-_GH4 %?KI_P $FO\ @D9^T?\ \%7OC6/!?PQM)?!OP?\ !VH:5/\
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M!T%MX1MK:P@^[*_*S_A^%_P2&_Z2*_LK?^'3T+_XNC_A^%_P2&_Z2*_LK?\
MAT]"_P#BZ /U3HKX9_9V_P""C?["?[6_CJ]^&?[-'[5OP3^-?CVT\/:EXRNO
M"'P_\=Z-XC\1VGA;1-5T+0]7UDZ/$SR0:&D^NZ&K7 +,W]KJ\: G>/N:@ HH
MHH **** "BBB@ K_ "L?^#Q/_E+Q!_V:S\&/_3Q\0:_U3J_RL?\ @\3_ .4O
M$'_9K/P8_P#3Q\0: /Y5:_V:O^#?G_E#5_P3W_[(2G_J7^)*_P 96O\ 9J_X
M-^?^4-7_  3W_P"R$I_ZE_B2@#]CJ*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#_ "]?V.?^3NOV7O\ LX[X'_\
MJS?#]?Z?L/W$_P!Q?ZU_F!?L<_\ )W7[+W_9QWP/_P#5F^'Z_P!/V'[B?[B_
MUK^;/HZ_\B/BG_L-7_J/,_VO_;9?\G6\#/\ LW?%G_K=(NT445_29_B@%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?YUG_!\#_R6O_@GY_V2SX\?^IA\/:_T4Z_SK/\ @^!_Y+7_ ,$_/^R6?'C_
M -3#X>T ?PM4444 ?[-7_!OS_P H:O\ @GO_ -D)3_U+_$E?L=7XX_\ !OS_
M ,H:O^">_P#V0E/_ %+_ !)7['4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7^;Y_P>Z_\G9?L4_\ 9NGC?_U9LE?Z0=?YOG_!
M[K_R=E^Q3_V;IXW_ /5FR4 ?Q%4444 ?[4G_  0[_P"40W_!.K_LU?X6_P#I
MC6OU4K\J_P#@AW_RB&_X)U?]FK_"W_TQK7ZJ4 %%%% !1110 4444 %%%% !
M1110 4444 ?S^?\ !T3_ ,H+?VZ/I^S'_P"MD_ 2O\@JO]?7_@Z)_P"4%O[=
M'T_9C_\ 6R?@)7^050 5_>I_P8Y?\CC_ ,%)O^Q;_9-_]._[0%?P5U_>I_P8
MY?\ (X_\%)O^Q;_9-_\ 3O\ M 4 ?Z$E%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!^./_!P-_RAJ_X*$?\ 9"7_ /4O\-U_
MC*U_LU?\' W_ "AJ_P""A'_9"7_]2_PW7^,K0 5_=+_P8_?\EK_X*!_]DL^
M_P#ZF'Q"K^%JO[I?^#'[_DM?_!0/_LEGP'_]3#XA4 ?Z*=%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>M>#_'WAOP[XS\):U9D?8=9\->)=)M]<T/5(6 ) N=%FBE3<1M!4,%P@3_.
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M_P!8\.>'%PI,4EQN$;LQ0_YQ^L?L>?\ !9;_ (-O_P!KK6/B[\#/!?BCXC^
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M_:??1K>YO[GPCXH^!GC.[M(+1+O=I.F?&KP!HNJ%E&2([:'6FUXNRES%:R'
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M/B#7^J=7^5C_ ,'B?_*7B#_LUGX,?^GCX@T ?RJUZ?\ #WX<_$[XW_$/P_X
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M<^&_^"A?P]U3Q.D.^TT?7OV=]<\/>'KZ_()$;Z]!\9/%ETN0"N\>$@IR"(@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM2T#X.WGCKXY^+[DLZC3=*\!^"]<7P_JS>9PZCXCZWX'M\9!#ZNISQM/^O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOZ_X,9?N_P#!4;_NR7^?[6]?P"U_?U_P8R_=_P""HW_=DO\ /]K>@#^_ZO\
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MY^?\.G?^"6G_ $C3_8$_\0W_ &</_G<U_(W_ ,'=O[&O[(7[,_['G[+WBO\
M9S_95_9O^ GB7Q#^TM>:%XDUWX)_ WX<?"?5?$6C#X7>-M770]8UCP%X9\*S
MZYH*SQQ2+#.TJK/!',K>?O _OGK^+/\ X/9_^3'OV0O^SJ-2_P#5-^.Z /\
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M9;P_)KWAIK5OLLD8:3R6)G_TPZ_RC?\ @T<^.6B?"/\ X*\>'_"VO7BV+?M
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MJ /RG_X*3?\ !(3]C'_@J;X'LM'_ &COA_J.F?$+PQI^HV?P[^-7@&[B\/\
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M^#/3]DBX^#'_  3K\9_M(>(-'MM/\4_M<_%S4M7TF_-HUKJ5_P#!_P"$L+^
M_!".3(P")X^?XJZW"4'EM!K<3JI9\N ?USU_G,_\'HW[7_\ PE/QQ_9J_8=\
M-ZS<R:+\)O"&I?'OXG:5;S6#:7>>._B [Z%X TK65VQ:U;:_X0\ :)K_ (@5
M96:.>R^+T+JTKA/LO^B/K&KV&@Z;?ZUJMY;Z=I&EV=_JFJZG=-BSL-.TE3)*
M\AR NR(-(<'/[N7;N;8M?XBO_!2C]JR\_;@_;M_:F_:GF=I+'XO_ !8\0:SX
M2-S;26,UA\-=!1/!?PMTB:.0[O.M/AKHG@VUN"2 )HF9L;G:@#X0K^T?]A+_
M (.TO"'[!_[('[/7[)7@;_@FM;:[H_P4^'&D>#;_ ,6VW[5H\'_\)GXKD$VN
M^.O''_"/K^S#XL&BR>,/'^MZ_P"*I+%O%7B%K>76Y!)<2F573^2/X/? ;XU_
MM$>+1\/_ ( _![XG?'#QRVG7^LCP7\'_ (?^+OB5XK72]+4?VIJ[:#X&T'Q#
MX@DT. ,8Y;A84BC>13(T>^/?],?\.G?^"I?_ $C3_;[_ /$-_P!H_P#^=S0!
M_7O_ ,1S1_Z1>_\ FZ[?_0F5_/I_P6Z_X+.^$_\ @L7XD^ /C:/]D?\ X9I\
M>_!30_''A>]\0_\ "[C\6F\=^%O$NI^'M6T/2)$?X.?"IM"'A+7M*\07-M<1
M2W",/$FM*V)'!'PG_P .G?\ @J7_ -(T_P!OO_Q#?]H__P"=S3)?^"4?_!4:
M&.::?_@FU^WQ##!PS/\ L?\ [02!"2!\S'X=*I'<MC [T ?G_7^GE_P9T_MD
M)\9OV"/B+^RAKU_-<>,/V0OB8;C0X9DOI /A#\<I-:\;Z$5E=2&F@^(>F?%A
M9 C[8[>?P]N0-+$'_P PVOZ.?^#7W]LM?V3/^"KOPC\.>(-873_AO^U+I>H_
MLT>+S>ZJ]KI\'B+QDUOJ_P )M533@6BFUMOB7HV@>$X&G+_9X_&VO>1/&\SQ
MS '^M_7\6?\ P>S_ /)CW[(7_9U&I?\ JF_'=?VF5_%G_P 'L_\ R8]^R%_V
M=1J7_JF_'= '^:G7]LW_  0T_P"#<;]B7_@I[^P'I_[4'QQ^*O[4_@GXDZI\
M5?B9\/SIOPG\:?"33/!*Z3X+DT,:/(-(\=?!7QCXB:8J[><K>*E1@J*HM4WU
M_$S7^KC_ ,&AG_*'3PO_ -G%_'3_ -.WA^@#^>;_ (*I?\&E'B[]F;X0>+OV
MA/V$/BQXZ_:)\*_#_1Y_$'C_ .!?Q T#0C\7(?#?A^'5I-=\8^!=?\*-X:\.
M>.[O0[4Q[OAM+X*\+^*9H]'U]_"4OBV[EL_!S?Q3U_O\5_D!_P#!QE_P3WL_
MV /^"E7Q0T?P3X<70?@;\?[-?C[\%K2"QDT_PUH-CXQUF9/'/@C0)9$@T5(O
M"/Q#B\01P>&K5#%X5\%:WX/+1^7+"Y /TS_X-B/^"W?CG]G#XX_#[_@GS^TM
MXUOM7_9H^-.J6/@[X*Z[XJUR&<_ GXI:RV- TBWUK5U\N'X;>--:)\.?\(SY
MXC\)>+M;T&Z@,5JWBH-_IDU_@,6=[<65U#>V4T]I<VERMS;7-N3NLV#9#+TP
M00N.<$+CD$@_[.7_  13_;WL_P#@HS_P3H^ WQ]U'5;75?BKINC+\*OV@K*S
M99+[2OC-X#\O1->?65A9UTB?Q?H!\._%*&$HTL/A/Q[X?)D$I$0 /UUHHKGM
M<US1/#6C:EKOB34]/T'1-+LC?:KJVK7D>G:=86,8"M+J6J7#B&)4W'+O*.2%
M);<"X!T-%?#'A'_@I3_P3H^(7B;2O!7@#]O_ /8K\<>,O$UW'8>&O"_A+]JO
MX$>)O$>N:GM;R]+T30M ^($FNZU=,(Y6%O##+(X4D97=C[GH **** "ORK_X
M+=>$7\;?\$B_^"B6A1#/V;]D[XQ>,<#O_P (%H,GCX_^.: ^?>OU4KDO%GA/
M1O&_A3Q3X(\1VZWFA>,?#VL^&-:MLC-[I.N:4^C:K&1VW6T[H6Q\N0: /\#2
MOW2_X-OOC=8?!#_@LU^Q=K^O^($T'P_XW\7^+/@[JXFNA96.H7'Q:^&?C3P%
MX)TB=VP-DWQ%UKP6(1G<9PBDD,[G\P_VL?V<?&O[)/[2WQT_9H^(<4__  E_
MP2^)?BKX?ZM=2VWV)=9CT35I(=%\51Q,T\BZ'XIT#^Q_$]CYTRR?9M:M7;#-
MN/CG@SQGXE\ >+_"GC_PEJ]YH/B[P+K^D^+O"FOV/&HZ)XC\-ZM%K>AZM"Y&
MP2V^MPP2HSA@KQIO5@H60 _WQ:*_+?\ X).?\%(_AM_P5#_8^\!?M!^#KO2[
M7X@V-CI_A?XZ?#ZUN4;4?AO\8-,TJ)?$&B-A-ZZ#XCP_B7P;K)5OM?A'6;;+
MQW27$4'ZD4 %%%?,W[3/[6'[.7['/PTN?BY^TS\:/!/P5\ 03R6D>O\ C?6U
ML1JFJ,@:/2= T:,2^(O$.MDHI3P]X;MI[ID$A\H*#0!],U_E8_\ !XG_ ,I>
M(/\ LUGX,?\ IX^(-?Z>/PB^+'@#XZ_"KP!\9OA5XH@\:_#'XF^%-)\;^!?%
M=C;:C8V&O^%M=TY-8T/6/*UB./74CG@9)(U=(IE$@66!2"J_YAW_  >)_P#*
M7B#_ +-9^#'_ *>/B#0!_*K7^]%\#/\ DB_P@_[);X _]1'0Z_P7:_WHO@9_
MR1?X0?\ 9+? '_J(Z'0!ZM7^8%_P>G10P_\ !4OX$F),-/\ L#_"]KD#H2/V
MA/VG@"/0[47+=S7^G[7^8/\ \'I__*4SX _]F#_"_P#]:#_:AH _C_K_ ':_
MV0O^32OV8?\ LW3X*_\ JMO#E?X2E?[M?[(7_)I7[,/_ &;I\%?_ %6WAR@#
M_.2_X/.]<U6__P""HWP9T*ZFG33M%_8=^&G]GVS2,U@TFL?&?]H"35=4C1<$
M&0K#;N>PT5'92HQ7\@-?VW_\'M7PGDTG]KK]C+XYK-<%/B)^S?XJ^%(CS_H
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M0!^?E%?H'_PZ=_X*E_\ 2-/]OO\ \0W_ &C_ /YW-'_#IW_@J7_TC3_;[_\
M$-_VC_\ YW- 'Y^45^@?_#IW_@J7_P!(T_V^_P#Q#?\ :/\ _G<T?\.G?^"I
M?_2-/]OO_P 0W_:/_P#G<T ?GY17Z!_\.G?^"I?_ $C3_;[_ /$-_P!H_P#^
M=S1_PZ=_X*E_](T_V^__ !#?]H__ .=S0!^?E%?H'_PZ=_X*E_\ 2-/]OO\
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M?'C_ -3#X>T ?PM4444 ?[-7_!OS_P H:O\ @GO_ -D)3_U+_$E?L=7XX_\
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MDL^ _P#ZF'Q"K^%JO[I?^#'[_DM?_!0/_LEGP'_]3#XA4 ?Z*=%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ?Y6/_!XG_REX@_[-9^#'_IX^(-?@7^P5_R>_P#L=?\
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M%OBK-HMM%HT6D_&7P?!<6XUV5-#,'AZV^)?AV:+QCX1DAADFM?&UI:P^#Q_
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MPSK^F.;?5M!U[2-3TO6+"2)@0-6TC6(8Y8&&0PCD10A*ML!QD _K0_X+*_\
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M6-M/<R2-9Z3HVA(TK:-X3\(Z)&#!H/ASPY+<R)9>'[<B..,DDRS2W%U+YO\
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M/BW!:7(OPOQ=\>:Q<^.O'6FKJZ%8M5C\->(-;G\*V\\!,,L&B1")GC(Q^HM
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MXQT2*Z/P_<H66/PG+X6N/!Y+0O!<>#X8W@D /X4OV-OVWOVHOV"_BS;?&/\
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MK>NZ5X;^&N@W/B/Q2GB<Z3I1\FU\7V_@NV622/S[E\M&X!_JKU_'!_P>M?\
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MZIHVF>-/B7K^M:"VLC1)YH(;F71FBE,33$J9%4JD9B6, _=2OX ?^#YK[O\
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M_LW3QO\ ^K-DK_2#K^%'_@[@_P""<_[:O[57Q4_9?^-G[,G[/7Q+^/\ X/\
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M&B1E0L2K&N$P(>LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P EK_X*!_\ 9+/@/_ZF'Q"H _T4Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^?S_@Z)_Y06_M
MT?3]F/\ ];)^ E?Y!5?Z^O\ P=$_\H+?VZ/I^S'_ .MD_ 2O\@J@#^JK_@SL
M_P"4O$__ &:S\9__ $\?#ZO]4ZO\K'_@SL_Y2\3_ /9K/QG_ /3Q\/J_U3J
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "O\ *Q_X/$_^4O$'_9K/P8_]/'Q!K_5.K_*Q
M_P"#Q/\ Y2\0?]FL_!C_ -/'Q!H _E5K_9J_X-^?^4-7_!/?_LA*?^I?XDK_
M !E:_P!FK_@WY_Y0U?\ !/?_ +(2G_J7^)* /V.HHHH **** "BBB@ HHHH
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MK_LU?X6_^F-:_52ORK_X(=_\HAO^"=7_ &:O\+?_ $QK7ZJ4 %%%% !1110
M4444 %%%% !1110 4444 ?S^?\'1/_*"W]NCZ?LQ_P#K9/P$K_(*K_7U_P"#
MHG_E!;^W1]/V8_\ ULGX"5_D%4 %?WJ?\&.7_(X_\%)O^Q;_ &3?_3O^T!7\
M%=?WJ?\ !CE_R./_  4F_P"Q;_9-_P#3O^T!0!_H24444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XX_\' W_ "AJ_P""A'_9
M"7_]2_PW7^,K7^S5_P ' W_*&K_@H1_V0E__ %+_  W7^,K0 5_=+_P8_?\
M):_^"@?_ &2SX#_^IA\0J_A:K^Z7_@Q^_P"2U_\ !0/_ +)9\!__ %,/B%0!
M_HIT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_$E '['4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO_ZLV2@#^(JBBB@#_:D_X(=_\HAO^"=7_9J_PM_],:U^JE?E7_P0[_Y1#?\
M!.K_ +-7^%O_ *8UK]5* "BBB@ HHHH **** "BBB@ HHHH **** /Y_/^#H
MG_E!;^W1]/V8_P#ULGX"5_D%5_KZ_P#!T3_R@M_;H^G[,?\ ZV3\!*_R"J "
MO[U/^#'+_D<?^"DW_8M_LF_^G?\ : K^"NO[U/\ @QR_Y''_ (*3?]BW^R;_
M .G?]H"@#_0DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /QQ_X.!O\ E#5_P4(_[(2__J7^&Z_QE:_V:O\ @X&_Y0U?\%"/
M^R$O_P"I?X;K_&5H *_NE_X,?O\ DM?_  4#_P"R6? ?_P!3#XA5_"U7]TO_
M  8_?\EK_P""@?\ V2SX#_\ J8?$*@#_ $4Z*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***_D7_X/!/BY\5_@O^P!^SGXC^#WQ+\>
M_";7=6_:_P##6C7FN_#7Q?KO@C5;_29/@O\ &.X>PDU;PWKUE-%I$DNEZ3,T
M#.T)>*-FP))HV /ZZ**_PN_^&[/VWO\ H\W]JK_Q(;XP_P#S3T?\-V?MO?\
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M"=7_ &:O\+?_ $QK7ZJ5^5?_  0[_P"40W_!.K_LU?X6_P#IC6OU4H ****
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M7B+P5X+TOP9H&M2KX>_X2%M>\%^(?$M[<>*H/%T#)%X=A%H(KB;S?Y2_!O\
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MGA+0_$!T;69;>,0RZUX=?43H%S);R>5))#(Z&6,[E /HBBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _PA/VHO\
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M7_(X_P#!2;_L6_V3?_3O^T!0!_H24444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'XX_\ !P-_RAJ_X*$?]D)?_P!2_P -U_C*
MU_LU?\' W_*&K_@H1_V0E_\ U+_#=?XRM !7]TO_  8_?\EK_P""@?\ V2SX
M#_\ J8?$*OX6J_NE_P"#'[_DM?\ P4#_ .R6? ?_ -3#XA4 ?Z*=%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\1/ GQ6\!:Y:-<Z-XT^&WBW0_''A?4E"C8VD:[X=GNO#\H&?O1S@L3AT&'-
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M[<5L9[F=H();[]G7]K'2[%9'3"F34]7^!L,&E19"JTCRQ(O&.2IK]'_V>O\
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M6OC!X ^*$DVNNOA_^W)D\.'PQ9C^VGB6&1X[26'UC_@C%_P<?_\ !4GXZ_\
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M?>&-;\:^)K]HV! TK0-!M[C79@FY3LBB9L%6<<UY_7^P!_P;L_L(_!K]D/\
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M#X>T ?PM5_LU?\&_/_*&K_@GO_V0E/\ U+_$E?XRM?[-7_!OS_RAJ_X)[_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW_TQK7ZJ5^5?_!#O_E$-_P $ZO\ LU?X6_\ IC6OU4H **** "BBB@ HHHH
M**** "BBB@ HHHH _G\_X.B?^4%O[='T_9C_ /6R?@)7^057^OK_ ,'1/_*"
MW]NCZ?LQ_P#K9/P$K_(*H *_O4_X,<O^1Q_X*3?]BW^R;_Z=_P!H"OX*Z_O4
M_P"#'+_D<?\ @I-_V+?[)O\ Z=_V@* /]"2BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH _''_@X&_P"4-7_!0C_LA+_^I?X;
MK_&5K_9J_P"#@;_E#5_P4(_[(2__ *E_ANO\96@ K^Z7_@Q^_P"2U_\ !0/_
M +)9\!__ %,/B%7\+5?W2_\ !C]_R6O_ (*!_P#9+/@/_P"IA\0J /\ 13HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M_P MW_@\V_Y2Q?#O_LRGX0?^K5^/E?ZD5?Y;_P#P>9?\I8?AU_V93\'O_5I_
M'Z@#\;/^".'[3/PV_8X_X*3?LN_M*?&'Q%J7A;X8?![Q#X[\2^,-5TFPU'5M
M4;33\+?'>C/HVD:/;/&]SK'B:;5H_#<41D\H?VXK#R95W':_X*I_\%4_C_\
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ML-*^*J^(=!\>^'XHS))MT.W\3>'O#WB:&(8W>*/'GB)_(#R+@ _L7_:7^/\
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M%>D2.S)HW@'P.6>RM)/*D6"Z\3SF3Q?XK-NMSXNN;LL2GYX45_KV_P#!O/\
MLD_L3?#+_@F5^RE\6O@'X ^%GB'QO\;?@GX"\3?&GXQ:?HFB>(?&_B#XK,LD
MWC[P5K?C5K4:ZB_"KXBR>,?"D'AAKGR?!\FB21QI"\&Z0 _R$J_I^_X-,_CU
MXQ^''_!7CX5?!S3==UZV\%?M$_#GXR>#O$GAFPU6:#P]<ZMX+^%GB7XMZ)K6
ML:-Y@AU=X?\ A6$EO')&B2K_ &UE)5C!#?Z=/QA_91_9?_: \/R>%/CK^SI\
M%/B[X;F;,>D_$/X7>$?&5G#L"R*Z#6] N!H\R,%821O&R'.U]V17YJ_LK_\
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M\WK'_!)KX%?"G]IS_@I!^QW\ /C;X7/CCX3_ !6^,^C^&O'7A)M7UOPT=?\
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M\&_/_*&K_@GO_P!D)3_U+_$E?XRM?[-7_!OS_P H:O\ @GO_ -D)3_U+_$E
M'['4444 >)?M$?%[P]^SQ\ OC;\>_$\9'AGX)_"/XF_%KQ$([:6\?^R/ '@_
M7?&^LJJ1Y=B\&BN=HPK,0F%W*R?X5OCSQGXJ^)'C;QA\2O&NJW7B#QCX[\2^
M(O&/B_Q#=L1?:SXJ\2:O-K>N:O<'@>;<ZUJCRL8P Q+;50?*O^R-_P %V_$5
MYX?_ ."/G_!0_4]+(-S<?LX^+- E;^/^S/&,NC^&]<7&>@T/6I><9XR/2O\
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M8ZG<:#HNIZ(T154C\8:\-:^)$X"B03^)IQ(Y152, ^3_ -LW]O\ _:T_;_\
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MO1? S_DB_P (/^R6^ /_ %$=#H _ G_@["DGB_X(K_'N.*:6/[3\2/V>+.?
MP;J,_&'PVQC./5XUE8=&&T'KBO\ )3K_ %H_^#LW_E"Q\</^RJ_L]?\ JT]
MK_)<H _KQ^,W_!RO\0OA!_P3,_8R_8'_ &!]9UWP-\1/ G[,WPO\&?M"?M*7
M=I'8^)?"NKZ)X?CT36OAG\%]+UJ%LSVD:VZ7/Q.4QRI&7B\"Q131IXRB_D^\
M0>(-=\7Z]J_BOQ3K>H^(_$_B35-0US7_ !#KMVVJZIK>IZK*^K:SJFLZQK,A
MEU77+B:XWSO*QDGN&\U9&FES+]8_L*_L+?M!_P#!1#]H?PU^SO\ L\^%6UCQ
M1K\4%YXD\27:?\4=\-_!.85U?QKXSUF"-_[%T'01(D*J ]W=W+P^%X5EN+A(
M)?\ 1I_9J_X-%/\ @EM\*?A=HNC_ +0>@_$;]J3XJ&STV3Q;X]U;XA^,?A3X
M<_M- !JT/@OP1\-O$/A=M!\,R,%>-?$WB7QIXP2)"!XOWE54 _RM:_37_@FW
M_P %1/VEO^"7?QSTKXL? /QGJ-YX/FU'3_\ A:?P6U'6-1M_AE\9_#)D0:OH
MNO:,#<KIOB$1$)X/^)4,">+/!SHUQ$UQ;S7?A:[_ %^_X.(?^""'A+_@F&_@
MC]HW]F'Q!XIUS]EOXG>-;CP%JOA#QG=R:[XD^#'C]='USQ!H6C1^)C;PIX@\
M ^*/#^DZI!X6E\3-)XJLKG1#97%]XKD\00S+_*90!_NU_LO?M#_#;]K/]G[X
M-_M'_"#58M6^&WQC\"Z9X\\.3D8U"R_MG/G:)J\(DGACU_PSK<6K^'/%D#RO
M+!XKT:X1@IC(7Z-K^2+_ (,VOC)K?C__ ()<>./ACK=_'>0? 3]J/X@>%_"E
MF 0VF>"?&WA'P+\54A^8G>\GC[QCXZN2PQ\LP&,C)_H9_;V_:ET+]BG]C3]H
MS]JWQ#!:74'P1^%_B?QGH^E7179KWBL(NB^!]!$A8%#XI\5ZOH7AW>"#&VM*
M"R]" ?S2_P#!P_\ \'$&I_L.:AK?[&G[%VJ:1J?[55QI,*_%GXI//%JVE_LZ
MZ=KVF?:="TCP_I$MLFB:_P#&'Q/H&NQ^)#(X^R> H19M<6_BRZNTA\)_YNOQ
M5^+7Q1^./CC7?B7\9/B%XQ^*/Q \3W1O-?\ &WC[Q+JWB7Q-KDA8%GN-;UR2
M>XD Q\H=L*>$CVY0U?B5\2O&GQB^(?CCXJ_$GQ%J?C'XA_$CQ#J_C#QQXJU9
M_-U77/$^O:K+K>M:S*X51YD\K2,YPBKO;8B1[57^F_\ X-C_ /@C1\.?^"C/
MQB\??M%?M/Z-/XA_9I_9QUGPQHMA\/C<2VVF_&'XOZTC^(8= U]H%D+_  _\
M'^&XX/$7C/PV6M6\53^)?"MD9)?",GBVSH _E*HK_>6\%? SX,?#'PKH_@3X
M=?"'X9>!? V@V":1H'A'PGX&\)>&O#>@Z:B;/[-T31-#T2"TMX2JEI((X51W
M#/DDFOY$O^#G?_@BC^S_ .+/V2OB%^WW^SE\+_"OPN^.GP#32_%?Q;TSP!H.
MD^&_#_QC^%C:\=(\::OXDT/1!X>T!OB)X,CUVW\8'Q<[)?W7@S0?%7@V6+Q1
M,?!1\) '\XO_  1/_P"#B7X_?\$[_'7@CX,?'WQ5XA^,'[#E_<Z5X7U3PAK=
MPVO^*/@5HZR101^+?A1K!AE\1-HOAFW*M+\+6G_X1"YBAN/^$._X1.^D>2X_
MU5?!OC+PKX_\(^%O'W@W7=.\1>#O&F@:7XF\'>(-(N!>:7KWAS7=,CUC1-7T
MF0;@\=YHTRW$1$:ET=BRD#:?\#NO]5#_ (-'_P!K3Q'^T+_P3#;X5>-;I;_Q
M#^R7\7?$/P4\.:A/<+J&HW_POUC2-"\>>!$FFD9./#4NO^(/"-K#%OC@\)^"
M_#FP,<K$ ?U44444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM?[-7_!OS_RAJ_X)[_\ 9"4_]2_Q)0!^QU%%% !1110 4444 %%%% !1110
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MZU_-GT=?^1'Q3_V&K_U'F?[7_MLO^3K>!G_9N^+/_6Z1=HHHK^DS_% ****
M"BBB@ HHHH **** /\ >BBB@#]WO^#9__E.%^P;_ -C)\9__ %F?XPU_L-5_
MCR_\&S__ "G"_8-_[&3XS_\ K,_QAK_8:H **** "BBB@ HHHH **** "BBB
M@ HHHH *_P ZS_@^!_Y+7_P3\_[)9\>/_4P^'M?Z*=?YUG_!\#_R6O\ X)^?
M]DL^/'_J8?#V@#^%JBBB@#_9J_X-^?\ E#5_P3W_ .R$I_ZE_B2OV.K\<?\
M@WY_Y0U?\$]_^R$I_P"I?XDK]CJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K_ #?/^#W7_D[+]BG_ +-T\;_^K-DK_2#K_-\_
MX/=?^3LOV*?^S=/&_P#ZLV2@#^(JBBB@#_:D_P""'?\ RB&_X)U?]FK_  M_
M],:U^JE?E7_P0[_Y1#?\$ZO^S5_A;_Z8UK]5* "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K_+?_ .#S+_E+
M#\.O^S*?@]_ZM/X_5_J05_EO_P#!YE_REA^'7_9E/P>_]6G\?J /Y)Z_W)?V
M"OV>?A3^RI^R!^SK\#_@AX6M?"'PZ\)?"[PG<V.DP*OVZ^U;Q!I-MKOB#7M>
MG"LNL^(_%?B37-:\1>*O$)*O<7LSYC:-4DB_PVJ_WHO@9_R1?X0?]DM\ ?\
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M-+_X+)Z+^T7>6W[65U^SOKO[.^K?"ZTO]!_X9_?XMC7],^*</CZ;1-4CU?\
MX7+\+%T?R9O >L126[13M*%$BD J& /N3_B-/_X*F_\ 1 OV!O\ PUO[1_\
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M/&<ZS>)->T/PU_PEFLWGC&X,J^&_#PM++PW$UR\P!]>_\%M/V&-5_P""B?\
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M,?*W .0<@'\&/_!\;_R./_!-G_L6_P!K+_T[_L_U_!77]ZG_  ?&_P#(X_\
M!-G_ +%O]K+_ -._[/\ 7\%= '^U)_P0[_Y1#?\ !.K_ +-7^%O_ *8UKX&_
MX.=_^"?GC?\ ;K_X)YOXB^#6D7GB7XS_ ++'C4?'#PYX6TBS.K>)_&O@@>']
M<\/?%7P9X?T4+(^K:ZWAZ>/Q7;>'8H1<>*)O \?A.UCGO;FWB/WS_P $._\
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M:5I4!$4?BCX7^:?$,$\,9FF\,0^(/!LOEB^^U* ?[%5?Y@__  >G_P#*4SX
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M_4)7\O'_  :&?\H=/"__ &<7\=/_ $[>'Z_J'H _Q"_^"L?_ "E,_P""E/\
MV?Y^V/\ ^M!_$*O=/^""?_*8?_@GQ_V<9X6_]-FN5X7_ ,%8_P#E*9_P4I_[
M/\_;'_\ 6@_B%7NG_!!/_E,/_P $^/\ LXSPM_Z;-<H _P!H"BBB@ HHHH *
M*** /S(_X*$?\$GOV)O^"FO@L^&/VF_A/;:GXNT_3+ZQ\$_&SP68_#7QI^'2
M7$@E<>'O&R03"XBCE:-T\*>,;?Q7X*EE3S9_"+["T?\ "!_P4$_X-"?VU_V?
MGU;QK^QCXBTC]L/X8P$W:>"Q'I7PZ^/VB:>=TD@.@ZY,/"?CI8 CJLGACQ5'
MXKF)ACB\#.9%)_T]J* /\$'QQX$\:_#/Q=KO@/XC^#?%/@#QIX:OO[/\0>"?
M&WAG5_#'B?0-2A8,VE:SH6N1VFOZ/* V6BGC29EDC)0%@PX6O]CO_@LE_P $
M>_V?_P#@JK^SYXIT_4O#FD>'/VGO"'AW6=9^ _QNTK1?)\4V?BC1-+D73?!/
MC35H;=7\0?#?Q)+-;V]SX8E=O(:0^,O"+)>13^;_ (XE '^@1_P:&?\ !5[Q
M;XGU/7?^"7WQR\5:IXEL--\,:E\1/V4-;UR\EN-0\/Z?X9^SOX\^"<,@EEEE
MT%?#\C_$OP3$?+C\+P>'OB/#/.\,_A*V@_IH_P""^=C)J/\ P1S_ ."@EO9P
MRRRM^S]JMZ&M\Y%EHFMZ%K#O[+'%%)NP"2A8]J_S'O\ @@%K>K^'O^"R'_!/
MR^T>6:*YNOCII^CR^2 0=-\0>$O$/AW7=^0?E/AW7-75\ G$C<$$U_K5_MY?
M NX_:9_8K_:R_9XTZ=+;6_C5^SG\7_ACX?NFM&OA9>)?&W@C7=$T#4FTU&#3
M+#X@N-+N%",'+HVUXCOD(!_ABU_2U_P:>^.K'P5_P6?^"VAWUY/;M\3_ (7_
M !W\ VB;6$-[J"?#;6O'HTW5 RM\W_%"R/%\IS/'&21D;?YI:^Z/^":W[4-Q
M^Q;^WA^RE^T^9632?A'\9O#&M^+$6T>^9_AOK#/X<^*:1Q1#S'GF^'>M>(+>
M)4PZRS"0;-C;@#_<0HKEM UW1/%NB:3XH\.ZK;:WX?\ $&DZ?KFC:IIEP+[3
M=3TK5D74](UC3F =94G1TEA;8-R%3MVQJ#U- !1110 5_G6?\'P/_):_^"?G
M_9+/CQ_ZF'P]K_13K_.L_P"#X'_DM?\ P3\_[)9\>/\ U,/A[0!_"U7^S5_P
M;\_\H:O^">__ &0E/_4O\25_C*U_LU?\&_/_ "AJ_P"">_\ V0E/_4O\24 ?
ML=1110!^._\ P7SL9-1_X(Y_\%!+>SAEEE;]G[5;T-;YR++1-;T+6'?V6.**
M3=@$E"Q[5_C'U_N=?MY? NX_:9_8K_:R_9XTZ=+;6_C5^SG\7_ACX?NFM&OA
M9>)?&W@C7=$T#4FTU&#3+#X@N-+N%",'+HVUXCOD/^&+0!_2U_P:>^.K'P5_
MP6?^"VAWUY/;M\3_ (7_ !W\ VB;6$-[J"?#;6O'HTW5 RM\W_%"R/%\IS/'
M&21D;?\ 6>K_  [_ /@FM^U#<?L6_MX?LI?M/F5DTGX1_&;PQK?BQ%M'OF?X
M;ZPS^'/BFD<40\QYYOAWK7B"WB5,.LLPD&S8V[_;GT#7=$\6Z)I/BCP[JMMK
M?A_Q!I.GZYHVJ:9<"^TW4]*U9%U/2-8TY@'65)T=)86V#<A4[=L:@@'4T444
M %%%% !1110 5_BG_P#!:;XLZI\:/^"LG_!0OQO>DL;?]JCXO^ ;)@ -WAWX
M2Z]+\(O#[$=!_P 4YX&T@X[$XK_:PK_#P_X*?6<^G_\ !2K_ (*$:?>*1/IW
M[<7[6-I<_P"_#\??B KD<_Q,6(Z=1WH S_\ @G=\(M'^/'[>_P"Q=\%O$>AK
MXC\+?$[]J_\ 9U\!^+M N+5=0T_4O"7B+XJ>%M$\:+JBC(;21X;GUMKE5+?Z
M+YI7 4L?]Q^O\2C_ ()#>/KKX8?\%2/^">7C:"XALX+;]L?]GO0]:O+H9L;/
MPUXU^)>@>"O$3/R6!7PWKFMD%B0NT'!*N:_VUZ "BBB@#Y5_;=^*,WP-_8P_
M:Z^--N)VN?A!^S-\=?B;:BSP;_/@/X7^)?$H:/(^\9-&#!NX .05%?X6-?[=
M7_!5OPW>>*/^"8?_  42\.Z787^J:GJO[$/[3\.CZ;I=FU_J-]J;?!7QS_8V
MEZ;I*#=)+-<)% %B"S,7R@D=2$_Q%: /TZ_X)D?\%0OC?_P2D^./C#X^_L_^
M ?@GX[\?^,_ACJ7PDND^-?A_XA^)-*T3PIKGC'PKXVUA-'TGP-\1_A84UHZW
MX(T3RY9[BY@B0RI;+"9'EK]P_P#B-/\ ^"IO_1 OV!O_  UO[1__ -%;7Y0?
M\$6?^"4NB_\ !7_]HGXG?L\2?M'WG[._B#P%\%]7^,VD:NOP>/Q:TWQ1IFA^
M-/ 7@;6=)>%?B7\*3HCI+X\T=TD-S=>=%F,1#RSC^ES_ (@93_TE"_\ -*&_
M^BSH ^ O^(T__@J;_P!$"_8&_P##6_M'_P#T5M?RW?'/XP:Y\>_C7\6_COXR
MT[1]/\4_&7XF^//BMXGTSPU%J-GX>L/$GC[Q;K?C37M.T&WU>?Q \>B)KFMR
MO;6ES<W C5HX#*Z9N'_N._X@93_TE"_\TH;_ .BSH_X@93_TE"_\TH;_ .BS
MH _ ?_@V'\3WOAK_ (+>?L6&UDO([?7Y_CKX7U:TMKMK,7^FZK^S1\7]@U%2
M&,\,6M1Z+KWE^81YFC H"T<3I_K[5_*__P $B?\ @V+^$W_!+[]I:U_:Q\1?
MM+:_^TC\5_"GAWQ7H7POCG^#VE_"CPMX'?QOH$_AK7_$(T=_B)\5M?UCQ!)H
M6JZWX8AD7Q/X82&PUW78VMK@RI,W]4% '^'-_P %,/\ E(Y_P4"_[/7_ &K/
M_5^>/:^S/^#=7_E-1^P%_P!E3\2?^JM\?U\9_P#!3#_E(Y_P4"_[/7_:L_\
M5^>/:^S/^#=7_E-1^P%_V5/Q)_ZJWQ_0!_LFU_GM_P#!\;_R./\ P39_[%O]
MK+_T[_L_U_H25_GM_P#!\;_R./\ P39_[%O]K+_T[_L_T ?P5U_M2?\ !#O_
M )1#?\$ZO^S5_A;_ .F-:_Q6Z_VI/^"'?_*(;_@G5_V:O\+?_3&M 'ZJ4444
M %<EXS_Y$WQC_P!B]K/_ *9Y*ZVN2\9_\B;XQ_[%[6?_ $SR4 ?X&E?U5?\
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M'XCU#PMH/PRT'5=!T"XU0,'?0?#NM^(?$5S:Q$-%Y^N:](^&:,5_;?7\6?\
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M*_'C2%U;5IBBQZ4B>(6T;P_$SS(#/K?DKYLTBQ  _P PFOWT_P""9G_!P?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^TR2W_;*UWXBZ-I<D;W/A?XR^!?AW\2;+7E=GB,.LZ_KOAP?$2./!65W\/\
MBZUE4JFR14WJX!_L%T5_GW_L?_\ !Z=J?VO1O#'[>?[+=@;&29HM5^*G[+VJ
MZE91V2+JP2%7^#/Q#U^6::-='\P7-S!\7(6^T01R0>$I4G:!?[2?V.OVZ/V4
MOV\_AHGQ2_92^,_ACXL^&+9%M=:L]*NI+#Q9X3U*2..6/2_&G@S71;^)O#>M
M20-$R1>)+2!I<B5"ZNS, ?8]%%% !1110 4444 %%%% !1110 4444 %%%%
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MK_,[_P"(V+_@H/\ ]&N_L:_^";XV?_/HH_XC8O\ @H/_ -&N_L:_^";XV?\
MSZ* /],2BO\ ,[_XC8O^"@__ $:[^QK_ .";XV?_ #Z*/^(V+_@H/_T:[^QK
M_P"";XV?_/HH _TQ**_S._\ B-B_X*#_ /1KO[&O_@F^-G_SZ*/^(V+_ (*#
M_P#1KO[&O_@F^-G_ ,^B@#_3$HK_ #._^(V+_@H/_P!&N_L:_P#@F^-G_P ^
MBC_B-B_X*#_]&N_L:_\ @F^-G_SZ* /],2BO\SO_ (C8O^"@_P#T:[^QK_X)
MOC9_\^BC_B-B_P""@_\ T:[^QK_X)OC9_P#/HH _TQ**_P SO_B-B_X*#_\
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MWQL_^?11_P 1L7_!0?\ Z-=_8U_\$WQL_P#GT4 ?Z8E%?YG?_$;%_P %!_\
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M\^BOV(_S//\ 3$HK_,[_ .(V+_@H/_T:[^QK_P"";XV?_/HH_P"(V+_@H/\
M]&N_L:_^";XV?_/HH _TQ**_S._^(V+_ (*#_P#1KO[&O_@F^-G_ ,^BC_B-
MB_X*#_\ 1KO[&O\ X)OC9_\ /HH _P!,2BO\SO\ XC8O^"@__1KO[&O_ ()O
MC9_\^BC_ (C8O^"@_P#T:[^QK_X)OC9_\^B@#_3$HK_,[_XC8O\ @H/_ -&N
M_L:_^";XV?\ SZ*/^(V+_@H/_P!&N_L:_P#@F^-G_P ^B@#^,NBBB@#]WO\
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MKO[&O_@F^-G_ ,^BC_B-B_X*#_\ 1KO[&O\ X)OC9_\ /HH _P!,2BO\SO\
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M@#_3$HK_ #._^(V+_@H/_P!&N_L:_P#@F^-G_P ^BC_B-B_X*#_]&N_L:_\
M@F^-G_SZ* /],2BO\SO_ (C8O^"@_P#T:[^QK_X)OC9_\^BC_B-B_P""@_\
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MXV?_ #Z* /\ 3$HK_,[_ .(V+_@H/_T:[^QK_P"";XV?_/HH_P"(V+_@H/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-(FX\'DYKC_A3\8_A1\>/!&F?$?X)?%#X>_%SX<:[<ZG9:'X^^%_C/PQX_\
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M1)?_  6S^Q?V-_PWEXR^R^3]E\__ (57\ /[4V_]AO\ X4Y_;^<_]/'F[O\
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M&O!OA#0+<?Z#HWA;PYI$.AZ%I4  R8[71M+B@4.'VA%&7!RP!_ I_P 'QO\
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MOAG3;_6-<\1>(-6TW2_#6A:9I:AVU76]9U8QPZ5!'&-[3/*8X0)&D9RA8_Y
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M'Q&T)'B U[P'XT=8K3Q#HJDG[1',UKXG\,-/';>+K*RG\N, ']3W_!O_ /\
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M6W@]X+3P3X:M9+'^6']N_P#X)Z?M2?\ !.OXRWOP5_:C^&,W@K79AJ-_X/\
M%6EO+K/PX^(VA(\0&O> _&CK%:>(=%4D_:(YFM?$_AAIX[;Q=964_EQCX+H
M_P!WGX5?M1?LY?'KPM9>-O@?\>OA!\5_"VH FVU_P!\1/"/C'2@58HR/)H6N
MS*LB,&#1,?.&,E0N">5^.7[9?[)W[-/AB;Q5\??VDO@Q\&_#L4$CQ7?C;XB>
M$_#QU!3L1%T729=977]=G5G!6W\.PSSM\["-@DI7_"PHH _T"?\ @IW_ ,'B
M6GV0U#X6_P#!+?PT-5N6<V&J?M0?%_PC-8Z>(T&T2?"_X5>(/)UR1I%P_P#P
MD?Q2MX?)E#(? L@5;E_ZUO\ @E7^T1XW_:S_ ."=_P"QU^T=\4KN/4/B;\5/
M@QX>UOQWJ=OI.FZ;::UXH5IM'\0:W%I&@A=#T1/$FOZ7)X@BM[:&.*%;@VT4
M42(88?\ %:\&^"_%WQ!\4Z!X,\!^$O$?C?QMXFU$:-X<\)>$M"U?Q#XGUW59
M,,FDZ+H.@6TVN:UK3;BRP0Q.S!=@5HPK+_M3_P#!*+]GKQM^R?\ \$X_V,/V
M?/B7;_V=\0_AK\"O"VC^-]):[6\&B>*M9C;Q#X@T/?R9_P#A&=;UF7PX&4E%
M6WX<I@D _1>BBB@ K_(S_P"#I']F[6/V?_\ @L/\?O$$]O(GAK]H_1/ OQ^\
M$W"1#-U8^(/#Z^"O&JMAL"5/B-X*\:<A%#0F%BHW!S_KF5_.1_P<6_\ !(F\
M_P""GW[)]GXC^$EA'<?M7_LW-XD\8_!V*-[*VE^(GAC7-/1_''P;DOY#%&A\
M51Z3HEQX+>9XH+?Q=H<44DD5GXE\3W( /\F;0-=UWPIKFB>*?#NIW&C:]X;U
M?3M>T74K0E-1L=4T>0:OH^JQYSB2*1$DC?)0>6"Z.HP?]E__ ()&_P#!47X/
M?\%2/V7? _Q4\'>(-#M/C/X>\-Z'I?[0'PICO((_$'@CXFG2HTUV9-&5/M(\
M ^(M;AGU[P=XC*+'-;,EL76X2XAC_P ;#QAX.\4_#_Q3K_@OQSX4\0>"?&/A
MC5[[1O$GA'Q7I&I>&_$F@:KHY/\ :VDZ[H6MQ#6M#UF%UC2>"X2-XW9H64%7
M"7_AS\3_ (C?"/Q3:>-?A9\0/&GPN\6Z;(XT_P 6?#WQ=K?@KQ)IQ9@6\G6O
M#\]KKJ(6P#LE'.!C X /]Y^]O;:QM9[R_FAMK.WM3=7-W=,HLK9(P,LS,5RH
MY8_,,  @Y8 _S$?MW?\ !TW_ ,$_/V/?C%X3^"_PQ:?]JO7F\;Z5IWQ<\3_"
M;Q3IK?#'X4^&FUJ+1_$NKOXT@\/>)X_B#XI\,Z UQXBC\'^#5DMI9M$3PM?>
M-?"\KR!/\SWXC_MN?ME?&+PU>>"OBW^UU^TW\2_!NIMB_P#"/Q"^/'Q-\<>%
M[PANLGA_Q#XGN= 9,\',1&.,8KRCX/?"'Q_\=?BKX!^#'PO\/ZEXK\?_ !.\
M5Z3X/\(>'])M/M^HZGJWB#4TT>WB2- &)\QP7(PH4%P4ZT ?[NWBSPQI?C7P
MIXH\'Z["+G2/&6@:UX9UFW!&3I6NZ7)HNJQC)P1Y,T@/H3UK_"R_:4^!OBW]
MF;]H#XQ_L^>/8)(O%OP2^)WC3X7:PSV<MBEYJ'@C7)]&76$TRZDEDM](\0QQ
M1Z[9ABPDMM55XWF0@R_[M-E9PVEI!91>:8+:V%JGGG+,@ 4;B<;C@8) QC %
M?PN_\'1O_!"KXC?''Q5JG_!2;]C_ ,%ZCXN\:6WAO2]+_:A^$?A/2)M3\5^+
MM.T!5T70?C7X+T31())_$6NVOA[[/X=\?>';833GPCX>\/\ BX(D\'C&:0 _
ME*_X(6?\% ]-_P"";O\ P4<^#WQZ\<736WPA\3V.K?!OXV7,-M]NN[+X7^.?
M[$=]86-6C+CPGXGT3P;XKV*R^9'H$L6PL^T_[$?@'X@>!?BIX.\,?$CX:>+_
M  _X^\">--&TOQ/X0\:^"]9TOQ)X7\5>'-9B$NCZOH6MZ%-):ZQH;1R%HYHI
M61QN)D<(2W^"77Z$?LF_\%1/^"@/[#>DRZ1^RQ^U9\5/A/X=FNVOI/ MIJ>F
M^)_AR;XJGF:N/ GCN+Q1X.7679%,C#PN)7 61G)"J #_ &\*P]6UK2O#VG7N
MKZUJ-CI&D:;:F[O=2U*YBL-/L;!1DO)+*Z1H$"$ L4.XJH.2J'_'YN_^#E'_
M (+;W44L=S^WEXL>*88Q:?"?]GZQXYW!9(O@U&X4]"%9?3.*_.3]H']NO]LK
M]JM9Q^TG^U'\>/C;8W=Z+R/0?'_Q6\8^(?"^G2HWSOI'@ZXUU_"^A[@/E2T\
M-PJN!(HW%BP!_MH_"/X__ SX\:5X@U;X'?&+X5_&G3?!^O7OA/QCJ7PH^(OA
M'XB:?X4\9Z6L1U3PAKLG@O7_ !'_ &)XBMXF69_#=QMNHH=IDB(GB:7VROX:
M_P#@R1@\2)^SQ^W+>7+H/"<_QJ^$-KHUL=,,0C\21>!O$O\ PD3G6HU5;C=H
MDO@O9:.&6 EG+M+XA1C_ '*4 ?X<W_!3#_E(Y_P4"_[/7_:L_P#5^>/:^S/^
M#=7_ )34?L!?]E3\2?\ JK?']?&?_!3#_E(Y_P % O\ L]?]JS_U?GCVOLS_
M (-U?^4U'[ 7_94_$G_JK?'] '^R;7^>W_P?&_\ (X_\$V?^Q;_:R_\ 3O\
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M)/7^]%\#/^2+_"#_ +);X _]1'0Z_P %VO\ >B^!G_)%_A!_V2WP!_ZB.AT
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M+>+P5XA\&ZQJ^L7,DDNO?%/P_'X-3P46:!+CQ9X8_P"$/'FW'BSPO OY]_\
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M=5TSQ)\.]+9(F77O'_PPUE9;G1_#GG2S!_$OA;Q1XS\+6<4<#^,KGPJ<1O\
MS@4 ?[0W_!'G_@J3\./^"L'[)VB?';PS9VOA/XG>$KV+P+\>_A>I>9_ /Q,B
MTJWU6232R"TVL> O%R.WB/P/XF; >W,WA&YFD\9>&?%T5O\ KE7^43_P:=_M
M?Z_^SO\ \%5/"'P<N=6N+?X;_M@>#O$/PB\3Z;*S'3?^$U\/:%K?CWX5:Z02
MQ.MQ:_HFL>$;63<B)%X^UY2AW#;_ *NU !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7^$)^U%_R<S^T3_P!EU^,?_J<Z]7^[W7^$
M)^U%_P G,_M$_P#9=?C'_P"ISKU '@5?[Y?@S_D3?!W_ &+VC?\ IGCK_ TK
M_?+\&?\ (F^#O^Q>T;_TSQT =;1110!_F_?\'*W_  2U_P""A7[67_!4SQQ\
M8OV</V1_C)\8OAC>?"+X/Z-9>,_"&B+J?AN]U7P_H3QZUI:2><K%[>=U#QY"
M;B#N+$*OX ?\.$?^"Q/_ $CX_:&_\)[2?_EY7^T!10!_B_\ _#A'_@L3_P!(
M^/VAO_">TG_Y>4?\.$?^"Q/_ $CX_:&_\)[2?_EY7^T!10!_B_\ _#A'_@L3
M_P!(^/VAO_">TG_Y>4?\.$?^"Q/_ $CX_:&_\)[2?_EY7^T!10!_B_\ _#A'
M_@L3_P!(^/VAO_">TG_Y>5\)_M'_ ++WQ_\ V0_B!_PJ7]I3X2>+O@S\2Y/#
M^E^*/^$-\;6:Z?JZ^&M9\U=&U80I))F.X?2M502$@[XG4(<,M?[ME?Y6/_!X
MG_REX@_[-9^#'_IX^(- '\JM?M;^SU_P;^?\%;/VK/@WX"_:!^!/[*3^-_@]
M\4=).M^!O%<WQJ_9N\&IK.E#6)M&FU%="\>?%/PKXIT9&?2R8I)?#/G31*K+
MN\UHZ_%*O]FK_@WY_P"4-7_!/?\ [(2G_J7^)* /\Z+_ (A:/^"YG_1E=I_X
MDM^R=_\ /NH_XA:/^"YG_1E=I_XDM^R=_P#/NK_7KHH _P A3_B%H_X+F?\
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MDM^R=_\ /NH_XA:/^"YG_1E=I_XDM^R=_P#/NK_7KHH _P A3_B%H_X+F?\
M1E=I_P")+?LG?_/NH_XA:/\ @N9_T97:?^)+?LG?_/NK_7KHH _R%/\ B%H_
MX+F?]&5VG_B2W[)W_P ^ZC_B%H_X+F?]&5VG_B2W[)W_ ,^ZO]>NB@#_ "%/
M^(6C_@N9_P!&5VG_ (DM^R=_\^ZC_B%H_P""YG_1E=I_XDM^R=_\^ZO]>NB@
M#_(4_P"(6C_@N9_T97:?^)+?LG?_ #[J/^(6C_@N9_T97:?^)+?LG?\ S[J_
MUZZ* /\ (4_XA:/^"YG_ $97:?\ B2W[)W_S[J/^(6C_ (+F?]&5VG_B2W[)
MW_S[J_UZZ* /\A3_ (A:/^"YG_1E=I_XDM^R=_\ /NH_XA:/^"YG_1E=I_XD
MM^R=_P#/NK_7KHH _P A3_B%H_X+F?\ 1E=I_P")+?LG?_/NH_XA:/\ @N9_
MT97:?^)+?LG?_/NK_7KHH _R%/\ B%H_X+F?]&5VG_B2W[)W_P ^ZC_B%H_X
M+F?]&5VG_B2W[)W_ ,^ZO]>NB@#_  ^?"/[!O[3?Q!\8>%O GA'P-INI>*O&
M_B+2_"F@:0WBWPAI%G?^(M?U?^P=&T^WO-7UVVMD>?6&C3=/+#&P(8R*'21?
MTB_XA>_^"X+(7C_8PMB@C@*,W[2?[)PY5MXW ?''A6) POS8SP*^X/V-(Q)^
MU_\ LL1L1&)/VD_@4A=P,*'^)WAY2YSV7.3@]#@\5_IS13"59"4:/9##*8L
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M (A:/^"YG_1E=I_XDM^R=_\ /NH_XA:/^"YG_1E=I_XDM^R=_P#/NK_7KHH
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M(6C_ (+F?]&5VG_B2W[)W_S[J_UZZ* /\A3_ (A:/^"YG_1E=I_XDM^R=_\
M/NH_XA:/^"YG_1E=I_XDM^R=_P#/NK_7KHH _P A3_B%H_X+F?\ 1E=I_P")
M+?LG?_/NH_XA:/\ @N9_T97:?^)+?LG?_/NK_7KHH _R%/\ B%H_X+F?]&5V
MG_B2W[)W_P ^ZC_B%H_X+F?]&5VG_B2W[)W_ ,^ZO]>NB@#_ "%/^(6C_@N9
M_P!&5VG_ (DM^R=_\^ZC_B%H_P""YG_1E=I_XDM^R=_\^ZO]>NB@#_(4_P"(
M6C_@N9_T97:?^)+?LG?_ #[J/^(6C_@N9_T97:?^)+?LG?\ S[J_UZZ* /\
M(4_XA:/^"YG_ $97:?\ B2W[)W_S[J/^(6C_ (+F?]&5VG_B2W[)W_S[J_UZ
MZ* /\A3_ (A:/^"YG_1E=I_XDM^R=_\ /NH_XA:/^"YG_1E=I_XDM^R=_P#/
MNK_7KHH _P A3_B%H_X+F?\ 1E=I_P")+?LG?_/NH_XA:/\ @N9_T97:?^)+
M?LG?_/NK_7KHH _R%/\ B%H_X+F?]&5VG_B2W[)W_P ^ZC_B%H_X+F?]&5VG
M_B2W[)W_ ,^ZO]>NB@#_ "%/^(6C_@N9_P!&5VG_ (DM^R=_\^ZC_B%H_P""
MYG_1E=I_XDM^R=_\^ZO]>NB@#_(4_P"(6C_@N9_T97:?^)+?LG?_ #[J/^(6
MC_@N9_T97:?^)+?LG?\ S[J_UZZ* /\ (4_XA:/^"YG_ $97:?\ B2W[)W_S
M[J/^(6C_ (+F?]&5VG_B2W[)W_S[J_UZZ* /\A3_ (A:/^"YG_1E=I_XDM^R
M=_\ /NH_XA:/^"YG_1E=I_XDM^R=_P#/NK_7KHH _P A3_B%H_X+F?\ 1E=I
M_P")+?LG?_/NH_XA:/\ @N9_T97:?^)+?LG?_/NK_7KHH _R%/\ B%H_X+F?
M]&5VG_B2W[)W_P ^ZC_B%H_X+F?]&5VG_B2W[)W_ ,^ZO]>NB@#_ "%/^(6C
M_@N9_P!&5VG_ (DM^R=_\^ZC_B%H_P""YG_1E=I_XDM^R=_\^ZO]>NB@#_(4
M_P"(6C_@N9_T97:?^)+?LG?_ #[J/^(6C_@N9_T97:?^)+?LG?\ S[J_UZZ*
M /\ (4_XA:/^"YG_ $97:?\ B2W[)W_S[J/^(6C_ (+F?]&5VG_B2W[)W_S[
MJ_UZZ* /\A3_ (A:/^"YG_1E=I_XDM^R=_\ /NH_XA:/^"YG_1E=I_XDM^R=
M_P#/NK_7KHH _P A3_B%H_X+F?\ 1E=I_P")+?LG?_/NH_XA:/\ @N9_T97:
M?^)+?LG?_/NK_7KHH _R%/\ B%H_X+F?]&5VG_B2W[)W_P ^ZC_B%H_X+F?]
M&5VG_B2W[)W_ ,^ZO]>NB@#_ "%/^(6C_@N9_P!&5VG_ (DM^R=_\^ZC_B%H
M_P""YG_1E=I_XDM^R=_\^ZO]>NB@#_(4_P"(6C_@N9_T97:?^)+?LG?_ #[J
M/^(6C_@N9_T97:?^)+?LG?\ S[J_UZZ* /\ (4_XA:/^"YG_ $97:?\ B2W[
M)W_S[J/^(6C_ (+F?]&5VG_B2W[)W_S[J_UZZ* /\A3_ (A:/^"YG_1E=I_X
MDM^R=_\ /NH_XA:/^"YG_1E=I_XDM^R=_P#/NK_7KHH _P A3_B%H_X+F?\
M1E=I_P")+?LG?_/NH_XA:/\ @N9_T97:?^)+?LG?_/NK_7KHH ^+_P#@GY\,
MO&OP1_80_8H^"_Q/T$^%OB+\(?V2?V=_AC\0?#T=SI=^-!\;>!O@]X,\.>,M
M&35="N+W0M;%OX@T/58FO?#]Q<6DZQ++ YCF$M?:%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAA.U>TT4 %%%% !5"[LH+ZTGL[R(7%M<VWV:YMR 0ZL#N&<C&0Q[C^$U?HH
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M'OVO?^SJ--_]4WX$K_-3K_2L_P"#)C_DQ[]KW_LZC3?_ %3?@2@#^TRBBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI\)&1_ZE*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O\ %Z_:+_X)<_\ !3+7/V@_CMKN@?\ !.W]NS7=(UGXT_$[6-'U;2/V
M1OC_ '^F:CI6L>,];N-(U/2]6C^'1,L,J/%(CC:'41L"I$@3_:%HH _Q"O\
MAT[_ ,%2_P#I&G^WW_XAO^T?_P#.YK_;+\(P36_A3PQ;W$,UO-;:!I-I<VUP
M1N5H=+B5T;J,K(NTG((P591C ZJB@ HHHH **** "BBB@ HHHH *_P K'_@\
M3_Y2\0?]FL_!C_T\?$&O]4ZO\K'_ (/$_P#E+Q!_V:S\&/\ T\?$&@#^56O]
MFK_@WY_Y0U?\$]_^R$I_ZE_B2O\ &5K_ &:O^#?G_E#5_P $]_\ LA*?^I?X
MDH _8ZBBB@ HHHH **** "BBB@ HHHH **** /Y>/^#O/_E#IXH_[.+^!?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^/'QIT'0?[6U6#PV/7_0^O?CK^/.*^9YOVWOBI-JG^H\-_\ @&?RP<?Y[]*
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M]C_GB@#^D^BOYKX?V\/C%G_4>$OK]C_/]/;CCUJOJ7[?GQHL_P!_Y'A'_P
MQD_SS_+CM0!_2Q17\S^F_P#!0CXTZGF#R/"7_@&/\_YZ]*[#_AN3XQ>5CR/"
M7_@'^OI[_P!.] ']&%%?S;ZE^W5\8N\'A+/;_0_Q_'GT_J37/P_MX?&F&+_4
M>$L\?\N?^3^'J* /Z:**_FGTW]O#XTX/[CPEZ?\ 'G_^KU[Y_P =?_ANKXT_
M\\?"7_@(: /Z0:*_G'_X;J^,G_/#PC_X"?\ UZL?\-U?&3_GAX1_\!/_ *]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?&XE_MO_ ()S_LE6@SD'P?\ !?P=\.1^!^']OX4&!Z_)]>F/U/HH _ ?4/\
M@V3_ ."'FMZE?:K??L,:7;76H3W-[<QZ3\?/VJ?#^F*\I#LNEZ)H?QMM]!T>
M)"L86+08K>.)(P$C7<\:U?\ B%T_X(7?]&-?^;+_ +8?_P!$37TA_P %,_\
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M7_\ @ISX^UFZ\1^)O^"A'[9MS?2RY6.T_:2^,7A[3[8,P.W1]&T'Q39^']%
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M>_\ V0E/_4O\25_C*U_LU?\ !OS_ ,H:O^">_P#V0E/_ %+_ !)0!^QU%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '^7K^QS_P G=?LO?]G'? __ -6;X?K_ $_8?N)_N+_6O\P+]CG_ ).Z
M_9>_[..^!_\ ZLWP_7^G[#]Q/]Q?ZU_-GT=?^1'Q3_V&K_U'F?[7_MLO^3K>
M!G_9N^+/_6Z1=HHHK^DS_% **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,VG\^!VS]>_- &?\0OB3!K&C7&E&#\/\CV[^O-?"^L:;Y\MQ]AL3]HX_S_\
MJK'\4^-[[4M4_<3_ &:W_P /4?GTYKS_ $V;Q'_;/GP3_P"CY],?G_\ 7]_K
M0!]4> _[5T'3_P#4"V_SSQ]/\/4T?$B'^TK 7WGC[1GCV_IW^O3-<?--XBFB
MMSV_S^7X5]T?!/X S_$*UM_[5@_XE]UU_E]#Q_4<4 ?DOXJAU77XO[*L>?\
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MF%CG_4>@SW]?_P!?]:Y^:S@_YX?Y[?UQS]35B:6>$^N.GU]#_G\#5?[9[_\
MCM %?[)#_P ^_P#/_P"*JQ]DA_Y]_P"?_P 56A#-!T[_ /UO\/?/KU&+'[B'
MT''UP!_GWZ>U %G3?(AM1^X]<_B?T^N,=<'TK7D,&?\ 4?4]\=OZ=O7FK$,T
M'E>?]>N/K_DG_P#5CS:GWQ^'Y<?UZ?3O0!GS0P3=8,=N03_G_/XU_P"S8?\
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MS3!/_P +'[?\@?5!GC_.?;K7]3% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!/VD?@7JUM 7_MOP9\7QXE^W$@R(VLZ-\6M \;1F'<2K+9-X;D+Z8ARF9#*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!DGW&^E?SU?\ !3CX5^'/&'Q+\,:MKD%K
M]HM=8Z=O\YZ?@<5_0Q7X7_\ !2#]]XMT?UM;SMW]>H_Q]A0!^<%G>6.@V/\
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MN9^S:=:WG6[_  X]>N?P_"O<)K3_ (22_P!.TJQL+FVM\?YP>OU[_6@#S_\
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M+X5\536_GBVU*W_3/^3CVXK](-!^ _@";0;BQTK[-;7 L\=SU]\_Y/Z?C?\
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M,)M-OM2NO^F__/V/\XZ>E '?S7GVS]_!!_QZ]?;\^?<?UQ5BS\;0:;+Y$_\
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M6A->?NO;_/YG\./:J\T/D2C\B?Y]/\.WI1Y/[K_..GUST[_IF@ \[S?P]O\
M/3/MU_(^Q^W_ (]6A9P]OK_]<Y_F,?THO/W/7O\ T]>F.W]<<T 8_P#JO\YS
MG\O3VZ?F>?[?I_\ 7JQ-^]]NGZ?G_6J\,W[W\?Y_U_0=* +%5_(]_P!?_K58
M\GS?P]_\],^W7\J\WG\_C^7_ .O[M %BR$$,O^./Y>WTYR<5L?\ ++_/]VN/
M_?PR_7Z_Y_\ U]^^Q9WG^?SSQ^?Z#- !>0^=^'^ _G5>:S\GW_/^E;'G^WZ?
M_7HF_>^W3]/S_K0!GPWGD^_Y_P!?\]:L57\GROQ]_P#/7'OT_/0_Y9?Y_NT
M9\_;\/ZT>5-Z?H/\*L58L_(SGR/P[]S_ /6_P/0 K^1[_K_]:J\W[KWZ?K^7
M]*V)^WX?UK/FA_R?\_D<>H(H +.\_P _GGC\_P!!FM#^T_\ 9_S^59_^J_SG
M.?R]/;I^=?S_ &_3_P"O0!U%G-!-].OT].GY_GZ57U*'M;C]/KP>/KG'T K'
MA\^'/U]<XQCT[_7K^=:$,W^?\_J,^X- '+^3/YO^?7ZY]_\ Z_-:$,WE?Y_S
MSU[5L30P=>__ -;_  ]L^G4XQYH?\G_/Y''J"* -"&;S?\_YXZ]J/(]_U_\
MK5GPPS_\]_\ ]7USZ]>?3/I6AYWE?C[?YZX]^GY@%BL^:;RO\_S]NG:M#SOW
M7^<=/IGIV_7-8]Y#YWX?X#^= &A#-_G_ #^HS[@T3]OP_K5>&&?KV_\ K_X^
MV/7J,$TW^3_G\AGU)- %BS[?\"K0FA\W_/\ /VZ=ZQX9O\_Y_49]P:L37G[W
MW_S^0_#GWH T/L?M_P"/57O/]#_7'^1CK_GKQGPZGWQ^'Y\?UZ?7M5B],\T7
M^&?Y^_UXP,T ?0'[--X?^%@_]P?5/_K?G_\ 7]S_ %(5_*_^S3"?^%@_]P?5
M/\^G7_ ],U_5!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME\+]6M_$/P\^+'@GPQX_\'ZM;J1]O\,^(=(CUG1Y IP0X6?#*0-L@DC&0N2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5_E8_P#!XG_REX@_[-9^#'_IX^(-
M?ZIU?Y6/_!XG_P I>(/^S6?@Q_Z>/B#0!_*K7^S5_P &_/\ RAJ_X)[_ /9"
M4_\ 4O\ $E?XRM?[-7_!OS_RAJ_X)[_]D)3_ -2_Q)0!^QU%%% !1110 444
M4 %%%% !1110 4444 ?R\?\ !WG_ ,H=/%'_ &<7\"__ $[>(*_RCJ_U<?\
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M[_K_ /6H K^1[_K_ /6K0@[_ (_TJO/V_#^M5[.8^;W_ )_3C_('T)H T/\
M5?YSG/Y>GMT_.Q#-YO\ G_/'7M5C]Q-%]/I_G_\ 5V[5X8?\_P"?U./8"@"O
M-#_D_P"?R./4$5GS0_NOP_E_3]3UK8HFA_=?A_+^GZGK0!CPP_Y_S^IQ[ 5H
M0V?^?Y\_R/X>U6/(]_U_^M1Y_M^G_P!>@"OYT$/7D?Y/_P!;'^%:$-Y_G^?'
M\A^/O6/##YO^?\\]>]$T/E?Y_G[].] &A>=_^ UST/\ KA]3_.MF&;S?\_YX
MZ]JKWD/D_C_B/Y4 :$/[WVZ_I^?]:T/)_=?YQT^N>G?],UR\,T\/0Y_7_/\
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MYK^J"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&3'_ "8]^U[_ -G4:;_ZIOP)0!_:91110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?Q"TNV&E:'_I%U9C[9=_A_3IUZ_3%?I!J7@,?VS_ &'\1O\ 1?\ GSN[H?\
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MM_GDXH [B\U[SO\ 4?I]/Z#KTS7/S7GG>WY_TKGX9O\ /^?U&?<&M#[9[_\
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MH?\ )_S^1QZ@B@#8A\CC\/S_ /U?>H^QP2@__K_3C\NG0US_ )T\/3D_Y/\
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MS7]0% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^#O/_E#IXH_[.+^!?_IV\05_E'5_JX_\'>?_ "AT\4?]G%_ O_T[>(*_RCJ
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MFM_ [_A#?"5]JWB#P[KGAQOAOX!\4RMK*^(4+N\X\<RZ#)$JO"RPE6CVLRD
M^A_^"9'_  5O_9/_ ."J7PQN/&W[/^NWFE_$;PM;Z8GQ7^!/C1DTWXC?#+4;
MA2CO/;[(H/$OAG<ELMMXO\*?:?"TLD_D2_9O%HN_#$'ZO5_E4?\ !1KP9XG_
M .#>O_@N1I7Q0_8\N9M$\"3Z9H/[0W@#X:I>:KIGA?5?@S\4=;U[0O'/[/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7\O'[-_P US6-?T^>Q_T?_3.F?;Z>_&/6OZ7OASH,V@^&M(LKG GL[/[&?\
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M]4_T*\%WW^GIGI_]>@#WCQ)^U%\5--\9:C?W&N:E:V]K>?\ 'I]L^O&?T/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 445\Y?M0_M#_#;]DS]G[XR?M'_ !?U6+2?AM\'/ NI^//$<X&=
M0O?[&QY.B:1"9((9-?\ $VMRZ1X<\)P)*DL_BO6;=%#&0!@#X7_X*M?\%<_V
M:O\ @DU\&%\>?%JYNO&7Q3\:2ZG8_!;X%^'KPGQC\1M2TA8SJ^KRO)BS\.>
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MO-JVJS/R$CAC+2,S$#8%*G+#?I2^%85:\KYM+N^Z25O-_EW0J]=I?A]W]?\
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M[<?B6^GF7XU7'ARW^U!;73/"_A/PA8:?9A1M!9F\.MXH; SRQ)R>>YK(T/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ'K_ %_G^GUK0T?6/WOD3_3W//'^?2NPO)K&:U]#US[_ $./I^E 'F]5_/\
M;]/_ *]6+S]S+G^9&,?E^%9_G^WZ?_7H T*/(]_U_P#K57\_V_3_ .O5B#O^
M/]* *\_;\/ZT0S?Y_P _J,^X-:%$-G_G^?/\C^'M0!H0WG^?Y\?R'X^]9]Y_
MIDOOC_/7\,?X\T36?^?Y<_S/X>U5_MGD?N/P_P ^N.OZ4 9_D^5^/O\ YZX]
M^GY[$,T'3O\ _6_P]\^O48SYKR";L!^7\P?PQ_A5?_EK_G^]0!T$W[Z+/.>G
M;]>/_KYXYKG_ /5?YSG/Y>GMT_/0@[_C_2J\_;\/ZT 6(8?.B ^G_P"OO_\
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M ,E"/_8'U3^9K^GZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OXD?^#T7]K?4_A]^R[^S;^QKX;OKB&;]H'Q]K/Q4^(WD-$$NO GP131(] T
M/5X1M9X_$GQ!\;:/XEC\L*([CX?1L[ LJ2_VW5_EV?\ !Y3XRU'7_P#@J?\
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M_P ;_P#X-U_']Y\.?^"S_P"P7K<%S/!_;GQ1\1^ ;O,Q'VNQ^*'PR\=^ 2K
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M$8;$J^&:DD[/XEJMTT[6M==%HT34445\L;G\[G_!U/\ \H/OVL_^QC_9R_\
M6F?A)7^157^NK_P=3_\ *#[]K/\ [&/]G+_UIGX25_D54 %?W]?\&,OW?^"H
MW_=DO\_VMZ_@%K^_K_@QE^[_ ,%1O^[)?Y_M;T ?W_4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^7K
M^QS_ ,G=?LO?]G'? _\ ]6;X?K_3]A^XG^XO]:_S OV.?^3NOV7O^SCO@?\
M^K-\/U_I^P_<3_<7^M?S9]'7_D1\4_\ 8:O_ %'F?[7_ +;+_DZW@9_V;OBS
M_P!;I%VBBBOZ3/\ % **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ K\2/^"A$T__  F5O!_R[_;.WI]>/?\ D,U^
MVDGW&^E?@5_P4X\;7V@^,M'L8(/^/N\_7_/;F@#\5_B%^TAXJ\'^+;C0[&?_
M $?['UQSV/J/Q[]/2OHC]G7]H2P\26W]E:K_ ,ABZ_3]/K^7KBOE#X_?"6^_
MXE_C&Q_TFXNK,?Y_R:\&^#^L7VC>,O/G_P!&U"ZO/Y?SZ=Z /W0^)W@.Q_X5
M!J%]I7V;^V+J\-Z>Y_\ K8]NXZU^:_P-U[XFP_$'3['R-2N?]-'VSU_G_/@_
MK7TAH/C#XC7GV>QOOM-UH_V,=_?USZ^G?GZ]Q\,?$FEZ#XWU#_B56V?MF/M?
M?C\OSH _H(^"=GKFC_"6WGG_ ./C['GZ?G]>PSQZC-?)_P"TY\8/"LW@+^PY
M_M/_  E%K9XO!C_#V['TKTCP'\>-5_X1?^RK&#[38?8_T[]/;^H^GY7_ +5W
MBJ"\UZYG\_\ X^OY=_\ /X>N #R_X)^#Y_&WBVXOKZ?_ $?[9CKCW'^2*_8"
MS^)WPK_9[^&=Q?>*OLUS;BS/_P"KM_D9K\1_V:?B=8Z;XCN+&>?I>CKV]<_S
M[_ABOJC]JCP'>_$_X?W%CI6JY_T/CT_3T[_3- 'S/\<OVQO ]YXCUB?P=!_9
MMO=9^Q_Z'U_#'4>OX^M>L?LN_M^>*H;:X\ 6-C;7-Q=#-Y=_8_3M[\'UK\;]
M2^#_ (QFO[F"XL;G_1;S_P"M_GMZG'3[0_9I\*0> SJ.N:Y8_P"D6O?_ #QC
M _#\.0#Z ^/'BFQ^(5W<8^T_:/P%>3^%=!U71[6W\^^_T?&/^/ST[?I^1K/O
M/%7]L>([B^L8/^)?_C[<Y_\ K?GU&FS:KK%_;P0?\>_7\./\_P">0#]./V5]
M2U76-4\/Z5!!_HUK>>G\^W],YY[5^Y&FVGE6%AVVVF#]2 >F>A!%?C/^QS>6
M/A77O^)J/\]/\YZ=.G-?L<NNZ5+:P7WVCK:9'J.!^N<GZ8]Q0!LRPS>;YPQ@
M<8SG R/\^G2N0UCQ)_9M_;P?GSQ^7^/ ]>AKS:\^->GP^)(-*\X>0;O:<  D
M>F>X'H>_Z=#J4%OXDNK>^L3^/_ZNV<9% 'J\,WG6UN?^?G)_J>OT]/TJUS-#
M[G\>G]?S.1W-5H1Y,5O;CKT^O^<^O'?WL30^;_G^?MT[T >#_$CQ[_PA,5Q/
M?6]SY'_3I_/KQCOZU^8_Q_\ CE!XDU3.AWUU_9_V/_3+7_.?J>/Z5^K_ ,6=
M,LM8\+ZC8W'_ !\?9,CZ=?Q[FOQ ^)'PJ@T'Q'J,\_\ I-O==/P^OZ4 <?K&
MI?"2]\$?VK?6-S_;'V/_ )\_;'3]?S]*^-_C!K']O:9;V,'_ "#Q_P >7_Z^
MH[>_;GI7VAI'PKTKQY:G0X/RXZ^OT[=*\/\ B=\'[[1Y?[*@L?M/V7\?Y8YY
M/&3GZXH ^7_AAX*G\2:];Z'FY_T7/^E_KC/?_P"OZXK]T/V)_!^AZ/XCN((9
M[;[1:V><7?\ CG_]?\_RW^%?PQ^+>I1?;O#FAZD?IG]<<_USTXS7[(?L=?L]
M^*O#<)\1^,!=6US<@G_2NI(R0 .^>G..V: ,_P#;,U[QSKOBSPOH7@>XNK8_
M\32RO#:^W')]_7CG\:Y_0?V8_'^L> _^*JGMKG6.+W_C\_'@=O<_I7V_\6=.
MTO0M%O\ Q)9:%;3W.E@9NNX/7'U'?GMCTK9^$OC8^,/"7VB>#_2/MAL<#N3W
MR1GCTZ]SQ0!_,_\ M"?"6]\$^(]1@U6"Y%O=7@^Q\?RX]<_7V%9_PQ^#YU&U
M^W09N>/\_P"<>O2OW0_:6^"?@#QM+!!?P6WVC]1U['_/X]/EB\^$L_P@T:XG
MT+2_M/VKVQZ#GZT ?D-\2/%7BKPKXHT^Q@@'V>U_T+_)P/;'_P"JOUX_8;\;
M:Y>:II]C?=;KOZ=,=J\W^$O[/?\ PL[Q1J/BKXC>'/\ B7VM[_H?VO\ SU["
MOOCX Z;\%M!U34(-*M]-MM0TOUY_GZ?Y]@#[WFE\G[/G'GGC&?;'/^>E+YL/
MK^I_QK/_ +2LOL'V[[<?L_7/&/3IUQC\*^/_ -H3]KGPY\*K"X@@GMKFYQ@9
MSC&>P//% 'V1-Y$\0\^"VN?P[]>>/;GGM7FWB3X9>"->L;BWU73]-MI[H9+?
M9 "/08[Y^O'O7YX?#'_@H1;^)+K[//H?VGK_ ,OF.3GZ?UZXKV'QAXV^(WQ#
ML/[<\'?:;;3^WV3_ #^?7K[T 8WBK]AOPK>7=QK=C]F^SGUQ^?X9QGZ#Z</H
M/@__ (0G7O[#\BVN=._Y<\8_KC^?3Z5[AH/QEUS1_!MQ9>(Y_P#B86O3UP.<
M#/;TQ^5?FMX\_:HOO#?C+4)[ZQ_XE]M=Y^U_G_\ KZ\]* /V1\$S>%8=!N)M
M5_L2VN+7O[=?; _7Z@5\#_M%?M=:4+_0/ASX'GMKFXUZ\^Q=?S'U_P BO@_7
MOVWK'Q+]HTJQG^S?:LV>/MG;_/Y_C7E_P]\-SZEXHMO$8@^TZQ]L_P")/Q_G
MK^>/RH _:C08;?PK\*M0OIX+:Y\0:I9_\NG'7OZ]_?WK\W_AO#X_L_%'C"^\
M<3VO]CW5Y_H=I=_UQG^E>L:9\?I_#4MOH?C'_D(?8_\ 0S=_AZ#-<OXDEUSQ
MN;B""#_CZ_X]/;KZ]>/J: /F_P")VKWWAK7KCQEH=_;?Z+P/LG/UZ=\YX[^G
M'/Q/\0_BIXC\87]QJNJ06UU<77_/WSD8_'_Z_3T%?H!X5^ /B/QA_:%C?07-
MS_IFJ=?\?RY'?D5G^)/V)]5T>73_ /0?]'_Z\\_Y.??/OZ@'P/X)TW^V+KSY
M[$VUQQW_ /U^YQ7ZL?L]P_8K'3]#U7[3<_:>,\?C^/Z5U/A7]E&QL]+MYX/#
MF;CH?7_Z_3K^E?;_ ,$_@0++^S[^Y\.8%IWZ#KZGJ,]/2@#ZX^%GAS^QM L(
M?0$G&?J?I[<_SKUB?M^']:SK.&"SAMX!!]FP,X_R/3^N36C_ *W_ #C&/S]?
M?K^0!P_C'PW_ ,))H.L:5/\ 9O\ B:6?V*S'_P!?'M_G.:_-^;P2/ACXRMQ8
MZK<_Z+_Q^'[9^@X^O/X=C7ZC:O\ 8X;4W%QTMN1@]O0_S_,5\$ZEKW@?QAXH
M\06-]!;?:/M?V+^G\_\ /:@#L9OVNOAS9W5OH<Y_TC_E]X'U_P ^^?;-;Q)\
M2/ 'BJU_M72Y_LUQ:^O^?;IU^E?&_P <OV9)]-\)7'C_ ,*SC[1:_P"F_P"B
M=<=\9_SWK\E_A+^T5XXA^+__  @^JSW/^E7G/;I_+KS_ )P ?L!\5=9\1ZEX
M<UC5="U74K:X^Q_Z'_IG_P"L\?Y]_A_X/_M=>(_!_B/4/^$XU:Y^SZ7>?8AG
M_/K_ "K]$--TV>'1K>#7(/\ B7W5F><?X?IG\O3^??\ :BTW_A&_BKJ(L;[[
M3H]UK'_'I@=1W[T ?KQ\0O\ @H%-J4MO?:&;G^QQ_GO^'_ZZ_-_XJ?%3_A,-
M9N-5-C<VT]U9G_ES_P CZ?CQFM#P'>>!_$FEV]B(+:VN/\]/P'\Q7I'AO0?
M$VO?V5KD%MJ5O]C_ .7OI^O _'^N: *_[&7Q(L=-\4:?8ZX1_P ?OY=,G/\
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M4?$+XS:5X)UG]Q?7-M;]L?C_ #^M?6]YH\'E7%]/?_9O]#Z_C^O//^-?D/\
MM"0P7GB@P03?\OG/^>/PYH ](\2?M1ZY#^_TK5;G[/\ ]?OM^?\ ]>N?\$_M
M.:Y#XHT?59Y[FY_TS_3#T]OZ^G&1QWKP_P#L'PY#:V_V[[-W/'X9'L/_ *_8
MUYOJ7_$M\1^1H<_V;3_^7/W'KQ_C^- '[D>#_BU_PGEAY%QQ<75YT_G[_A_A
M7T1X.\53^%->T?R)[:V_TP]B?7_Z_P#DU^$_P]^*GB/1]8TZ""_N?\]??_\
M7^?Z$0_$+5=2L+>^_P"/FXM/7I[_ (?_ %^O< _<#XD?M"6.L^"-/L;&QUNY
MU#['_P ?=I9^G;/;@5\'ZQ_PD?BK%C!I6I?Z5C_ES^G/_P"O'?I7TQ^Q#\9_
MAEXVM;?PKXQL=-N=0_Z>\8[?J/R]J_5B'X)_#G_7V.AVO^E#\_?CG_\ 5^-
M'\F_Q.\-^*M-OKCSX+G_ #V_3^F:\FLYIYI1!/\ \?/Y_P#UOY]?6OZ,?VKO
MV:=#^P7%]I5C;'OZ^O7CCT/K7XW^)/@/?:;)<W$$ Z_AC^I_SUH \/TV&>&+
MSYY_S]<?7]"*[#0O&']@RW'[^Y'V7\/;/\^GXY%:$W@F>SM;B8?\NO\ ^O\
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MH?\ W!]4_I7]0%?S"_LT_P#)13_V!]4_D:_IZH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ HHHH **** "BBB@ HHHH **** /\R'_ (/._P!HZ;XA?M^_ O\
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MVZ9HGM%<R2,H=FVJ?NE-H&%))R.2.GY?ACCZ<TX]\L#Z]^/J1_45WY#G^?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M> ]5^P6\'_'SJ%U_SZ?C_GW)]1S]0:#\*_$>CVMO?0:'J5SGG_CS(_+M^O\
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M>]=C_P +:\8^)+K_ (1R>^N>_/KT_P#U4 <_H/Q.\5> ]9M[&QGTVY_TS/\
MQY]AR.__ .L_F/Z1_P!E?5Y_&OP,N)[&"VMKBZT?_C[Z_P"?;GW]C_+_ /\
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MY#']:Q[.\_X^/T_^N/R_4XK8\_V_3_Z] '/S0S^;]?QZ>N.?US1Y'O\ K_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".7_5/_
M +IKP/QO\6K'P?JGV&^GMO?T_P#U?IWKZ K\Y_VF[.";Q3;?]?G\S^7K[^W:
M@#V#QO\ !/P/\;-!.J^1;?:+KZ#\>Q-?D?\ '[]CCQ'H\NH0:'8G^Q[7'V/^
M@[>M?IQ\,?BI9>&["VTKK_GG\_K[=*]_&L:'XPM/[*G@MA]JQ_4?K]>H- '\
MQ'A7P3JWAO5/L,]CGG_GS[?3KD_UQ7UQX;TZ"\L+CSX/LUQ:^O/X<_XGVQS7
MW!\<OV:8+.7_ (2/2I_LW7_CT.>X_P __7YKY0AU*QL[6XL?(-U<6OI^/^>/
M0T ?1WP'@GLHKBQG@_T>Z_S[?_6YKUK7_A[8^&I;B^@@_P!(U3_CRS_G _&O
ME:;6/&.L'P_!X'@N=-N/MNE_;/LG'^?R']*_2CPK\/-5UWPYX7OO$=_<_P!H
M6MG_ *9T_KU_K[4 ?E?K&@WW]J:A/CO^77C]>G_ZJY?0?!/BK7K_ ,BQL?M/
M_;G^!_R >W;&/UXUCX#Z'/*9OL-MTX_KQT_#\Z[#PK\'_#GAN+-O8VUM<?GU
M_P ]?IVH ^+_ (;_ +,?]L?9[[7(/](_#';_ /7Z?3K7VAX4^%?AOPW:CS[&
MV-Q:^_XY [_ECTKU>+3H(!FW!M_]W\NY'^/]8+SR((CY\_\ G_\ 5UQS0!CV
M=Y;VEUY$$'Y9[CMV'(_"O-_BI>3PZ7<>1!^HZ>OZ]?\ )]0LYH+P^?!_GOST
MZ_YYJQK&CP:Q:^1/!_\ 6_SGG- 'X_\ C"\U6:ZU"#[/_P ?0Y__ %].O7_&
MO#]2\*WT$5P9_P#EZ[_YZ\9_KD=?UP\2? VPO(KB?R,Y'XX^G?T^M?)_C;PK
M!H_VB">#']?\GT_E0!\#V>F_V==>1/\ \O7^?Z?C7U!\'_%4&CW]O!/[>G?_
M #V[ UYOJ6FZ5/="?I_G^7_ZC6?H-G?_ -LV_D?:?L_0GIT_//>@#]L/A]>Z
M5J6GV\]E_KP,GCM_(?KT_/T#_EK_ )_O5\G_  'U.#[+;P3WWV?V/?\ 3CG\
MNIXKZ8O(9YH0()_Z_P! ._K[_4 L7NNP6?7\L#'7U]>E<=-XZ$VJ065N.IR?
M?US6C9Z#/>#_ $Z<7/KG'^>/<?7V(?"NE6G[_P BV^T?;/P_QZ#&.GXT =A#
M-^Z'[@]/P_S^/'6L;7IX(=&O[Z?_ $?[-9_;<\#& >3^( QW/T(K8F$HF@A&
M/(/4]^.!GZ=:Y_QK:"\\+Z_!_>T?5,?4@G^0- '\['[:7[15Q-KVH:%I6J_\
M>MYG_C\_7O\ X5\D?"7XM^,+R[^S^=<_9_;M[?7ZX_G7+?M=3?V/\0=8T/[#
M]FU#[8,WF,_K_G''<&OF?3?B=?>%9?\ 09\P<9S^/X]_4#OZ4 ?L1>?M+>*O
M"N@V^E:']J^T6O\ R]^ON/7VZ]^2*^R/V=?C9/\ '+1_^$'\<:';:E]JZW?V
M,C\?\CL 37\]_A7XS:KXDNKC2O\ 2<F\[?Y_SWS7]+'["OPK@A\!Z?XBOX/^
M)C_S^?U_G^- 'S?^TA_P3]T/1Y?[=\.6%S<^UIU_^L>1GOW^OUO^QGX/N-!T
M'[#??:;8VO;_ !('X9QS7WOJ]G97L'DWTVVW/4>_J<?SQV%8-GH^AV<MQ_9=
MC;>F!P/3Z=1U_2@#0^V?;+JX@_T;[/:_\?@N_P ^F>?Y=J_/_P#:Y_9+TKXJ
M1?;K'23]HR?^/3(__6?\^]=1\=_B%KG@GQEH^E6-]<VW]J?Z;]DM/US_ /JZ
MXKZ_\-WTVI>$].U.^G^S':6O/3 (!Y]LCC]>* /PX\-_LEZ'X)TNX@OH+G[1
MZ7?TX_S_ $%>#V7[$/C'7O'%QJNA0?Z/GW]OI_\ KZ"OZ"+S1_ _CRZN(+&#
M3;G[+_Q^'OT./_UUW_AOP5I7AN/_ $&"WML<_P"B @=?<=^W;\J /Q(\$_L-
M^*M2\1Z?!JV<6O\ ^OK_ )]?>O0/C!\'M)\$^*+?PY_I-S;@=KP_Y[>M?L!K
MWGPQ7$]E_P ?'V/I^>?_ -?^''Y/_&;XA>3XRN/[<MQ<7'VO_C[N^.G8>GI]
M.U 'Q/\ &;4M#^'OV>?2M*^TZA_^KG^N.W'&*Y?X>_MF?8_L\%]8_9M0M0/M
MA^Q^_P#D^A^E</\ 'CQY8S7]Q?>>/LW\OQXY_+VKYG\$_P#"*>*M8\0:W??Z
M-;W7_'GC]?3/_P!8&@#](/BU^VQX<\;>#?[*$%M]I_Z\Q]/K_7^GS?\ !/XJ
M6-YJGD7]C]I_Y\_]#QR?_K]_Y5\CZEX;T.;5+BQL;ZY_TJ\_T/-GCC'KZ?\
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MM_VI>?8O]+/-AVZ$?G],UY_^UUIOC_P'X#T_5;&?-OJEG]M^R?;/^/ ?7/\
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MQUS[=L58_P!5_G.<_EZ>W3\R"]_Y[_GG^9_SZ#THF_>^W3]/S_K0!7^V>_\
MX[5C[9[_ /CM5YK/_/\ +G^9_#VJOY4WI^@_PH L?;/?_P =K/FFGZ=O_K_X
M^^/3J<)]CN/4?E_]:M&&'S?\_P">>O>@"A!>3P]/YCUS]?3UJ_#/_P MS[=_
MYD?B"?TZU8FTSMG\?RY_IU^G>LB>SGAZ_P AZX^OKZT 7YKS_/\ +C^8_'WK
M'\[ROQ]O\]<>_3\TA_UP^I_G6S-9_NO;_/Y'\>?>@ LYN_U_^N,?S.?Z47G?
M_@-'D^5^/O\ YZX]^GYUZ #]_#ZCGZD$'_/KT]J*K_O?\[JT+2;_ )[GZ?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1/7J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZY^8AB0!7^-17^S5_P &_/\ RAJ_X)[_ /9"4_\ 4O\ $E '['4444 %%%%
M!1110 4444 %%%% !1110!_+Q_P=Y_\ *'3Q1_V<7\"__3MX@K_*.K_5Q_X.
M\_\ E#IXH_[.+^!?_IV\05_E'4 %?Z5G_!DQ_P F/?M>_P#9U&F_^J;\"5_F
MIU_I6?\ !DQ_R8]^U[_V=1IO_JF_ E ']IE%%% !1110 4444 %%%% !1110
M!^+/_!<G_DT[P%_V7[PI_P"JS^+-?,G_  0?_P"1F_:4_P"P1\,?_3WX]KZ;
M_P""Y/\ R:=X"_[+]X4_]5G\6:^9/^"#_P#R,W[2G_8(^&/_ *>_'M?WOPC_
M ,J_N-_^RXX@_P#6PX-/E\3_ ,E'3_Z]+_TVS^D&BBBOX(/J HHHH **** "
MBBB@ HHHH _G<_X.I_\ E!]^UG_V,?[.7_K3/PDK_(JK_75_X.I_^4'W[6?_
M &,?[.7_ *TS\)*_R*J "O[^O^#&7[O_  5&_P"[)?Y_M;U_ +7]_7_!C+]W
M_@J-_P!V2_S_ &MZ /[_ *BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH _P O7]CG_D[K]E[_ +..^!__
M *LWP_7^G[#]Q/\ <7^M?Y@7['/_ "=U^R]_V<=\#_\ U9OA^O\ 3]A^XG^X
MO]:_FSZ.O_(CXI_[#5_ZCS/]K_VV7_)UO S_ +-WQ9_ZW2+M%%%?TF?XH!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/;_/3/MU_*OY'O\ K_\ 6JQ##_G_ #^IQ[ 4>=_RP_';^N,?Y^G>@"OY'O\
MK_\ 6JO-#_D_Y_(X]016Q!W_ !_I1Y/F_A[_ .>F?;K^0!CV<WD_C_B?Y5T'
M_'W_ )SC/Y^OMNQ6?-IG;/X_ES_3K].];&FPS\G_ #Z\X_KG_$ R)[.>'K_(
M>N/KZ^M3PP_Y_P _J<>P%=Q]C\[CI^OX?CGKGV[XH_L>#R>O_P"O;G/^>_-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ'\._APTX0>*_$WB(6'B[Q3:E8? T2K=3>-;4 _43_@SW_X)AZ[\.? _C?\
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M.G_UZ7_IMG](-%%%?P0?4!1110 4444 %%%% !1110!_.Y_P=3_\H/OVL_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKG(K[ _91^,VJ?#'QOH^JV,]S_I7^A7F/I_GOS],5X/_ &E]LT;SY[$?9_\
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MW^PBVMK?_GTM.G(_SGK^- '\Y_PW\!^/YO%&GV-CH6I7-O\ ;/\ C[^Q]._
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M/C-X7_X2.>#[-<:7^GZ9ZX'Z9/2O']>\$Z5=V%P=*UNVMKC2_P#ETY]L=?\
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M:==&Z'6UO,9)^@QGZ >X-?GO\?O@_H>FS7$WD6W/U_$\C_/:@#\1[O1_L?\
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MF?PYKXG\-_;M2O[>"<_S_P _S]J_<#]E'X8ZY#X<^W7$'^C?8_Z'\,_U'UH
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MS\^1_GZ>O;^7>M^SO/)_U_\ ];G_ .MSZFN8\[IY'^>F.W^>!CI1YT\W^O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[*W_ (:S0O\ XBC_ (<>_P#!(;_I'5^RM_X:S0O_ (B@#_%:HK_:E_X<>_\
M!(;_ *1U?LK?^&LT+_XBC_AQ[_P2&_Z1U?LK?^&LT+_XB@#^ 3_@SL_Y2\3_
M /9K/QG_ /3Q\/J_U3J^$?@#_P $U_V!?V5/'Q^*/[-W[)?P+^"WQ&71=3\,
MKXV^'O@/2/#OB(>'M:DMWU?2!JT \YDG;2(C.N\+LB5&3:SLWW=0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!^5G[5/_  1=_P""7O[:.M:QXG_: _8U^%.N>,M9O4OM6^('
M@JTUGX3_ !%U[5&16:YU_P <_";7O!OB3Q#(1&J2#Q-<72$;=P(&X?!</_!J
M#_P14M[P7+?L_?$6=%)9=.N?V@?C&=.#'K\R>)TE(P<!?..,_2OZ1Z* /SP_
M91_X)1_\$[?V([W3=8_9A_9(^#WPU\4Z5:O9V'CPZ+)XT^)D=G+M+@?%/X@3
M>+/B1B3:@>/_ (2KRW"*KEE %?H?110 4444 ?,_QP_92_9?_:>;PN_[2G[-
MOP%_:$_X0=M8'@X?'/X1?#?XLIX2/B+^QO[?7P^GCWP[XF.@-XHDT;1#?#P\
M8FO%T70A/N$$<:>*?\.G?^"6G_2-/]@3_P 0W_9P_P#G<U^@=% 'S/\  _\
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MG_RAT\4?]G%_ O\ ].WB"O\ *.K_ %<?^#O/_E#IXH_[.+^!?_IV\05_E'4
M%?Z5G_!DQ_R8]^U[_P!G4:;_ .J;\"5_FIU_I6?\&3'_ "8]^U[_ -G4:;_Z
MIOP)0!_:91110 4444 %%%% !1110 4444 ?BS_P7)_Y-.\!?]E^\*?^JS^+
M-?,G_!!__D9OVE/^P1\,?_3WX]KZ;_X+D_\ )IW@+_LOWA3_ -5G\6:^9/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/8>G^/X=O>@#X_\ #?@F^^U>1/8_9OLO^>A_P'KCU^D/@GK&JV?CS3]*L/\
M/Y_CSBN@\-^#]5\577^@Z5<_7[&/Z?4?B?Q/V1\"/V:;[3?$=OXCOX>/4D>O
M/7T_Q- 'WQX)LYX=!M_MT'_'U9_GC/XGKQT[=:T+SP?X<O/W\\'X9_+TZX_/
MZ5T\)\F+R?)XMNG<=\$8_J>?3BEO)H(8CG'YG^I_G^M 'G\/@GPYILOV[_\
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M\]N./_U5] ?!/XM:Y>:6#JL]S]HNNO;C_/\ GL/SWO+R?_D%?\>WV7Z\]?\
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M0OC;\=_A+\1M0OM<T.UN;;[9JGV.Z_G_ )Y'Y4 ?JO>? BWU/0O#%]?0W/\
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MBU?Z?XQ_LFYMO],_Y\_\\CM_]>OUY^%?['.N0^$M/L?$<_\ H_V//V2\L_\
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MX>SZE?V\$$'Y?Y[Y_G7T!X)^%=QJ4MO^XQ^/^?\ #\:^M_ ?P9@TV43S^_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&,OW?^"HW_=DO\_VMZ_@%K^_K_@QE^[_ ,%1O^[)?Y_M;T ?W_4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM_[8X_TSGCI_0'_Z^:_?#_@FGXD_MCX:>?/_ ,>_V0?CSV_SU(_'\#]>\$^
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MX]<_E_+\_?GSCXD?#>^TRVN-<\'07/\ HN+W_1/?C]/I_@/K?41YT/;R._\
MC^'/'XUS^I7D%YI>H000?\N?TP#C]?Y<<4 ?D/J?[=?BKX;_ &BQUS[29[7K
MG&#VQC'(^GZUV'PK_P""BG@?QM+<3ZY/;&XM/^GSO^ _0U^8_P"W)INN67Q+
MUB>"Q^S:?=7@Y_'KU]?;/7WK\Y_#GB2_\'ZS<^>;D6]U_3].?KQ0!_81J7B3
MPK^TA\)?$$&ASVW_ !-+/_ETY_/_ #^E?RC_ +17P!\8?#'7O$$$WVG^S[J\
MU0XY^G?U_GCTK]</V%?C]I6FVOV&>>Y^S]^>>W7MW/;-?2'Q^U[X'_$*PN+&
M^@MO[0NL?\N>?Z_YXH _"?\ 9+^#_P#PE7CSPO!!JO\ HYYU>T]<>H'Z_P#Z
MZ]H_X*6>&]*L_%'A[0_#GARYN;C2K/2_]+M.F/[%_P#K=L\]Z^T/@;X)\ ?"
MO6=0US_2?M%U_P >?OR.O_U_Y<UX_P#'+QOI6I>-[C7-<@TVYT__ *>_\]__
M *WO0!^=_P"SK\3O&/A7^V-*GU7^Q+?[9_QZ7?..>>>O^>_%?8'PX\2_$WX\
M>(_L/A6_NM2N+7_GTXZ$UQ]Y\*O!WQ"NKB^T/[3;?:O^?3\<_P"?RK]0/^">
M_P  8/A7=7%]?0<_\_=W_D$>WU_( ^?_ !C^S3^TUIMK;W]]I6MZE;]O]#(X
M_F?T_D:\?O/V.?B-J0N-5_X1S4_^)I_Q^?3G.?R_/BOZ1S\0O!][J9T*]U?1
M+@D8%K]K!P?ZCG\N*X'XY>//#?PW\$:Q?^1IO_'G_H?_ -?L<]/3\Z /YUOA
MC^QS!IOQ&T^Q\8V/V;3_ +9]M_TL_H.O7'K_ /7_ *.+.S\*_"OX57$$,]M;
M:/:Z/_H?H>>OI_\ 7^IS^+_Q#^(7B3Q7%I^JZ']FMM0&L:7_ ,>G\R?IUK]4
M/ <W_";? ;4-#\1SG[1:Z/\ Z9=__7Z_SX/I0!^5_P 9O$GB.S\1W'CCP/JP
M^SF]_P"70_\ Z_QKR_XA:[!\9O#GV[Q%_P 3O6+7&?\ IPQ_GOS^%>'_ !L^
M)%]X/\>:AX TK[3<Z?=:R?7J/UYZ_P"17T1\&?A[I5G:ZA?7VJVUM<75IG[)
MJUY[9_\ U>OO0!\;^%?@/_:6O>?KFA_9M/\ MG_+WVX_^MQU[\]<_7$WAK0]
M \&ZAI6AFV_X\\X_E_(\<?D:^D->\-V/]@W%Q!/IN/\ IT _7I^/3->#V?B3
MPY#H.L:5C_B8]+/G^7X]ORH _/>\\'ZKJ5_<0?\ +O\ ;.,=_?W_ ,:^H/@/
M\)?[-U[1[^?_ )_#^/\ ];OS_05YOJ6I0:;+<3CK]L_SD_EGW].]C3?B1JL-
M_H_V&?\ IV[=_P#]= ']7_@2$0^#?#\,,_2RTSGN.F1U[XSSZ'VKX@_;+^'N
MN36EQXCTJW-S['_#(_+Z8]:^G_V=]?/B/X9^'[Z:;=/]BTW/(].!COGI_CS7
MI_BK0+#Q3I5Q87MO]H'IT _#_/3I0!_'3X\^)'BJ:_U#2I_M-MJ%K>?X_P"-
M>?ZE!<3:#Y\&?[8/\_Z>W^17VQ^W)\&8/!_Q!UG5=#_&T)_S]3U]:^%XKR^L
M_#=Q/_Q\ZC_SZ?Y_7MQ^- 'VQ^R7X#L?$D6=5G^S7%KF]_G_ #K0_:B_:$\*
M_!_7O#^AP6/_  DEQQ_HEI>?RYSS_+@'U^5O@_K_ (_O/L_]E9TW[5>?Z9_G
M\\_4UH_'[]GOQ5KU_H_B."^MKG4!9_\ ,6O/7I@8Q[__ %Z /UX_97_;D^%=
MG8?\3R"V\(ZA=6?^AVEW>?KSUK[@^'OQ@\'?'+QY;WVE3VUS_8)^Q>OK_@/3
M/2OY%]2L]<L]9M]"OOM/]L'_ (\SI/3ZY[^OU[>O]!'_  2U^#_CCPUI>H>(
M_$9N?]*O/MW^E]O_ *^>N>WO0!^E'[2OQ;@^"?@+4/$<_/\ H9]>W7]<=.A[
MBOXZ/VD/CQJOQ:\9ZQ/XCGN;G3[J\_T+_3/K^/Z8[9YK^D?_ (*<?$W28/AH
M?#D^/M!_M3/Y ?7..V.GI7\Q_P /?#>AZ]XR_P")Y/\ :;?ZGKZ_0]\4 >;^
M%? =]>77VZQ_T;3_ *^O/].OT],']H/^"5\T^I^+=0TKR/\ B7VMYJ8O/;^G
MMZ=/P^#_ (G:#I5G=6\'A6^_T?VO/Z\X_'\N1C]@/^"1>@Z5Y7B&?R/](^V:
MIR>OZY_.@#VC]M+PWX5\8:]]ATJ>V_M"U[9/X8'_ .O\:_'_ .*GA77='EM[
M[S_]'M;S[%>?ACIVS[>W>OW@^+7[+NNZQXWUCQ'8WUS]GN_^GO'7UST_SZU\
M3_$/]F^#6/#GBBQOM5^S:A:V>J?\OO.!]1^/?\LT ?D^/B%X U[7K?PK_HOV
MC_CR^UX_^MZ?Y[5Y?KUY?:;XCN(//_XD]K9_;/7OGC^G/7Z5XOXP\'ZY\-_$
M>L0&"Y_M#[8?L=W^'^'USG%>X>%?!^J^*O"5Q??\?.H>V#^/Y_EF@#]"/V2_
MBIH>L6%O!Y_^D>F/\^]?<&O0ZKY7VZQ_X]_7Z_Y_45_/OX)\5:K\)?$=N9_M
M-M;_ &S\/S_7_P"M7[D?"7XS:'XV\$6T$\]M]H^R?I^OX?IT&0#Q?XD:]?:E
M%<6-Q_Q\=>GZ].?Y5\3S?;O[>[XR/I_AUQTXZ=Z_0#Q5H,$UUJ$_3[5Z?Y]?
M7\>.N?X/^ _]O?:+[R.WYY_#_P"OZT ?+VI:/YUK;_:!CU_SZ=/0=JX#4K/R
M9>O;MU_KP*^H/B'X5N-'O_L/7[+U[_Y__77SQKUG/#+SWSU_S_/I_( Y:S/G
M2F#_ #UZ]/Q]?TQT$/[F+/.>G;]./_KYXXKE_.\K\?;_ #UQ[]/SZ"SO(/*_
M?_Y[^V>GK0!T&F0^=^!_3V_S^N*Z#RH?3]#_ (5Q\-YT\C\L_B,?_6/I6Q^^
M\W_]6?\ /_LU '4P_P"I'T/\J2#O^/\ 2M"S\CRN<=__ *WX=?PQ6A#9^=[?
MG_7_ #UH KV</;Z__7.?YC']*Z"STW[9R?\ /7';Z<UH6>F]?RS_ )_/C\3U
MKN='TV"(?C_7(Z'CV'^2 5M-TWR8N<_GZ?7_ #]*T/[-GA_?_KTZY/7V)_'F
MO0-'TV"\E]NGY_UKWCPK\-X-9NH(/(_X^N__ -?_ ",?A0!\_P#@^:^O+H0>
M1_B?QQV_&OOGX,^ X/$DMO!<0>OI^'?'H3C^E>G^ _V<-)L_L]_/!_GU_G[5
M](:/X/\ #G@F+[=_Q[_9>1VX/3\/;'KV- &OX<\+6.C8^PD?Z.<#W/X>H'I^
M7->8_%3X\>#OAE:ZA]OO;8:A:CH>W3OR..X!-?-WQG_;1T+P?+J&E:'_ *3<
M _8_Z<=<=<>N#BOQ_P#C-\3O$?Q(U34-5OI[G[/=?3'O^G<4 0?M.?M(?\+.
M\47$]C.?L^/L7_'Y_D#G_P"MZU\[?\('K<VC?VY!]I_E_3M_/V%>3^= /$?D
M7'_'O]L^AX]OIQ_7I7T!XKUCQ'>:%I^E>%K'[3;_ .>._?&/_KT >;SV>JZ;
MHUQJD$'^D6N<'C'^&/7_ !KYGU[XY>*O[4%C//\ 9OLH///Y^Q/XG\.OZ@>#
M_ <\W@.W_M6#.H70_P!,Z8_GZ>V>?IGP_5_V.=#\87]QK<%];6WI_IG.1^1_
M/Z<4 <_\'_$D_C#2[B?5?^77ZG_/ YYSUZ=*\H^,%G!#JGGV/_U_SY[]R.YY
MKTZ\TVQ^&,-QX<TJX^TW'_'E_G_/_P!;D-9\-WVI6MO<3^GN/\<'_/U .&\$
MV=]K&LZ?_G_#GCTZU_33^Q#XDGL_"5OH=]_Q[VMGZ=./U^M?SKZ/9S^%;^WN
M/)P??_/OU_IT^\/AO^TMJOA6UMX+&#_]7/I_6@#](?VEH;&:ZU"?_/;KTR<]
ML=\=J_';QY#_ ,32X]?U_P /P[CWKVCQC\?O$?BJ7]_]I_,_3^>?Y5\_^)-2
M^V2^?/P,_P!.WZ_TZ4 >73?ZX_4?SJO#_KA]3_.M'B:;V/X]/Z?F..XH\GR9
M?R]>_7\.O3CVH L0=_Q_I5BJ\'?\?Z58@[_C_2@#0L_W^//_  _7T]/P]^M$
M]E_SP_+'\A_GU/K1-^X_U'OC_P"MZYYZ]/RHL[S_ )^/S/Z'K^)(% &/Y,_F
M_P"?7ZY]_P#Z_-6*V+R:#IWQ_GW_ #_ CBL^&:#IW_\ K?X>^?7J, !Y'O\
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M/_BX/O\ V/JG_P!8_P#UO7/%?TX5_,_^S?#_ ,7!]_['U0^_^?;Z9.:_I@H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY0U?\$]_^R$I_P"I?XDK_&5K_9J_X-^?^4-7_!/?_LA*?^I?XDH _8ZBBB@
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M)_XA=/\ @NC_ -&-?^;+_L>?_1$T?\0NG_!='_HQK_S9?]CS_P"B)K_7VHH
M_P @G_B%T_X+H_\ 1C7_ )LO^QY_]$31_P 0NG_!='_HQK_S9?\ 8\_^B)K_
M %]J* /\J_\ 92_X(Z_\%'O^">GC_6?C+^V%^SFWPB^&_B7P1JWPQT?Q$?B]
M\"OB*-0\;ZWK?A[Q#I&C)H?PH^)WB[Q/MDT/P=KEUA+0(&TQB9EW"(>M_M>_
M\$V_VT_^"C'A3PQX=_8T^"__  N+5OAEXB?5?'5H/B+\(?AP="T[Q'HH@\/
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MZ:NS6:S*MUY/]A%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &;Y$91$7<(XLL<]2W7U/)P!ZXZG%(I>5BCQ8B'
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MYXN\3^"/$FG_ /'KKW@[7]7\.>(;92WW1K.@^5+@GJ$*]%#)C%?C'AKXH_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKVX_I7FT/[9?BJ[O[BQFL;@8_P"GP8'MW['Z#\J=^V9/_8.L^?!]FQ^F./\
MZW_UZ^-M&UC2KRPN+Z^GM;:X/K_GMU^G;H: /J#Q'\9K[QA=6]CKE]_Q]#_C
MS_R/SXST]*]9^"?PE_M+Q'_:L%]_Q+SZ?Y/?I_/%?CMJ7Q"GF\6^1!/UO,_6
MOU(_9U^)$^CZ,;Z>^_S_ /7_  QU/&* /U &CV,.GW%C!_I-Q]C]O4?U_P#K
M^@\?\2> _ WBJUN+'5;&UMKG/V+_ #C'X^E=_P##[7X/$GABVUN"?[3F[)]L
MC QU]S^7<UD?$C1[?^P;G51<?9B#]L/!XX_^OQZDX]* /!YO@;X<^%>@ZQJO
MVZVN;;['_H?&/;.3VZ#/'XFO@_6/VJ-<\":S<:5X<U0VUOCZ_C[]\>OXU](?
M&SXM_P#%H+B^GOOM-P?[4LO]$''T[_B:_(?Q+--XJL+B>QL;G^T/Q[^WY?\
MZZ /K#1_VY/&.CZ]Y\]]<ZE;_P#7YC(X_/\ 'KG\*]XU[]MCSM+T[S_"OVG4
M-4_Z?/I_GIC/I@U^1_@_X8^/[/61?7T!N;?\/\G\/KQ7U!J6L:5X/_L_^W(+
M8W'V,WO.>YZ'_/I0!]0>*O#?_";6MOKD'A7[-;W9_P!,_G_D?C5CX2WD'@^V
MUB^OH/[-^R?VI]CM,#_$C_.>M>H?LZ_%3PK\0M+M[&^^S6UO:\<]R?\ ]?\
M7-=_^T)X/\*Z#X2U#5=*F_X^K/U_ ?X?TH _'C]JCXY7VO?VAS]I-K^O\OS]
M/:OF_P '_'+PK_9=QI4^A6QUC_/ZY_+/O5CQA>0?VI<07WV:YM[GMCMD\$?Y
MZUR^L?\ "N='NO\ 0?\ D(75F?R_+\.WY4 6-8UZ#PY+I_B.QU7[-<77^?\
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MC/Y#TZ_F.@LX8(8OW!Q^7?V^E6/^6O\ G^]0!Y_X/\*SZ!HOV&^'Y^F??O\
M7]<"NXLX?L5KY&.<9Z=_T_K6A_K?\XQC\_7WZ_D3]OP_K0!7\GR<#CR.OO[?
MY./;FN AO+>\U74(()_]'^Q]O\GW_P#KUO\ B34H+/3+C]__ (8_S_GU\GL]
M8@\+:7K'B.^_X]_L>J?IT_\ KY__ %@'X+_M[>))O^%@^,()Y_\ B7VMY_H=
MIC\?\^AQ[5^-_P 0O&T&I:S;65CBV/\ CBOU0_; \26/Q5UGQQKEC_Q[_;./
MZ>O?^F.:_(>\_LJ\\4_83!_I/_ZL>W_ZLYYH ^L/@GXJUSP?%_H.J_:+B[QG
M_/\ D$>U>L>-?$GQ&^WZ??3V-S<_:;S_ (^^./S_ ,\GZT?LZ^ ]#\T7U]/_
M *1W^O;CH/\ /X_HQ\$]'TKXA>-H/#NNZ5;?9[7_ *<R.>_7K_GVH ]0^"?P
M9G^)'P@_X2/58,:Q:V1S[_CC\_\ "OA?X_?#WR?M&E:K!]IM^?;\>F?ZU_2Q
MX/\ !.E>"=+M]#TJQM3I_ICG_/3]/85\_P#Q^^$OA7Q)8?:/[*_TCO\ Z)^G
MX=?Z<8H _#?X/V?A7PKX;\^^GMK;[*/\?PXZ_P"<5W/Q._;VL?ACX<N-*TK5
M?M-QU_X_/7_ZW3\>!BOI_P ;?LEV,/PYUCQ'YXMK>U/_ "ZWGX9QQVQ7\V_Q
MFT?5?^%HW&ASP7/]GVM[_P O??DG].?\* /KCP3^TMXW\2>,O^$Q_P"$CN;:
MW%YS_G\NW4]>M??'QF_:*G^+7A+1_#ECJHU*XZ=QU_S_ "^E?E?IOANQTW1K
M>#_CVX]ORS]/J/;BOH#P%K'ASP%;?VY?3_:OL@Q_G)_S_, ]@T?7O%7@Z[\/
MP:K]I^SW7]E_YQ[]_H*_1C6/BIX_\$_#G^U=*T.YU+P_JEGT^G7'OU[8]#UK
M\K_%/[0GASXD6O\ Q(X+87&E_P P3U_K^E?>'[-/[0FE:QX#T?P=XQ_L[_GR
M_P!,_P __J'X4 ?%^LPS^,/&?_"5:YX<&F\_\O8Q^?'X\^O3%?)'[2'QLU73
M?'EO8^'/$=S]GM;S_3+2T_Y<,?U[U^]_CS0?#FFW^GWT&E6USH^J?\^EGC/K
M^?!/^17YS_M?_LQ^!]8EN/%7A6"YMM0NO^/PW8]/Z_AUH K_  9^(_BKQMX#
M\B#[1<_Z$#[_ ,O_ *]</>ZE8^%)=0G\1WWV:XS_ )[@^O8?@*]H_85^&^N6
M9U"QOH+8VY_M3_ZW_P!?CMTKY?\ ^"AO@_5=!\1ZA_97VG_MTZGG_/3ISS0!
MQ&O>,-#UZZN((-5ML]_\C/H.GKVK/TW4CIMU;_O_ +3]E_3M]/T_'-? WAN'
M7)K\?O[G_(Z9KZ8\-S:K%+;_ &X_YP.?7GVQSZ4 ?U\?L*Z]#KWP6T^<?\?
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MI_GV^O:N/O?%7B/1XO\ 47/^E?Y]O_U]>]>[Z;\#=#\*FWG,_P#:6H?\_?\
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M],XQGU[_ $Z_E6AILWI^/_UQ^?3Z#UH Z#R9_*_SZ?7'M_\ 6XJO##Y7^?\
M/'7O700WD'V7_/K_ )_7\<>::#IW_P#K?X>^?3H<@&A#-_G_ #^HS[@U8_=?
MYVUGPS?Y_P _J,^X-6//]OT_^O0 3?NO?I^OY?TK0AF_S_G]1GW!K'FF_P G
M_/Y#/J2:L6<W?Z__ %QC^9S_ $H T)H8.O?_ .M_A[9].IQG_8_)_P!1QS_D
M^O\ D'K1--_D_P"?R&?4DT>?[?I_]>@"O-Y_/X_E_P#K^[1##_G_ #^IQ[ 5
MH58_Y9?Y_NT 6(88.O?_ .M_A[9]>@SH6=X?-_3UY_7_ .MST[X_G^WZ?_7H
M\CW_ %_^M0!]8?LWWGG?$'_N#ZIG'3\.>O\ D\8K^EBOYA_V:?M'_"P1U_Y
M^J9]?_U9S7]/% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M^5C_ ,'B?_*7B#_LUGX,?^GCX@U_JG5_E8_\'B?_ "EX@_[-9^#'_IX^(- '
M\JM?[-7_  ;\_P#*&K_@GO\ ]D)3_P!2_P 25_C*U_LU?\&_/_*&K_@GO_V0
ME/\ U+_$E '['4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?BS_P7)_Y-.\!?]E^\*?\ JL_BS7S)_P $'_\
MD9OVE/\ L$?#'_T]^/:^F_\ @N3_ ,FG> O^R_>%/_59_%FOF3_@@_\ \C-^
MTI_V"/AC_P"GOQ[7][\(_P#*O[C?_LN.(/\ UL.#3Y?$_P#)1T_^O2_]-L_I
M!HHHK^"#Z@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R6G+&(/"IR\4@.
M"-N4!DDX/\!S_L@K@BOX6_\ @N!^W[?_ +1_QZO_ ( ?#S78S\#/@7JTFBS_
M -FSH=-\;?$G308O$FMZJQ9X]8T7PS-$?#?A+RUC9I4\0N))D\1P-#_6U^WS
M\=KO]FW]CK]H;XQZ7=V]EXD\+_#[6(_!=Y<@>79^./$Z?\(EX/=@2#A?%6I:
M4J)SN+E0"'(/^:K-/-,\MQ<SS7$]R3]KNKG.6QZGU)Z]L# QC _G?Z0'%..P
M>!RCAG+URKB&#G4<6[SIJHH**N[I2G+D:M:7+)/2Z?\ M'^QX^C]E7%?%7%O
MC_Q/EE.M2\/,52X1X,CB%1]E#C*OA9XGB/B:'M))2Q'#7"U2A3P]2,93PU3B
MFI4ARU.2<:-%%%?R.?\ 2*%%%% #FX^4=!U^M?T@?\$*/VX[;2?$>H_L _'1
M]/\ $/P7^-EIXFTKX<VFMB.^T[0_%/B&)HM=^',B%5CF\-_$ZWFUR18Y&53X
MQ.U%=O%05/YOP, D].1^/4>_^>:Z+POXIUSP;XF\-^+?"^JW&C^)/"6O:7XB
MT#5K-U34M%\0Z%K$6NZ'JHR-NY70$'##<JY#*N3]%PCQ'B^$^(LJSO!MV7*I
MQUU@W:4?7;EO;W^75/5?SG])GP0X:^D7X2<8>%G$L*?M,VPLI<)XGDI5*O"_
M&%&-2IPMQ/0=-RKQ5'$)*K&G",Y\-U^),/R5/;)Q_:C]H3_@SJUJ;X^:U\0/
MV)_VS(/@_P" M1ULZ]X=\)^/?"WBW4?&?PVE:1B^B:#\4/#^OI>>*+6.$2QV
MEQXAM;3Q4J>4GBRZ\77?F^*Y/UQ_8E_X-M_V0?V7?V1?VDO@A\1M;U_XV?&+
M]JWX;ZQ\.?C)^T/J^F0^'?%&CZ3JC:-K,.C?!;1W?Q1%X"T:U\?:'H'Q'221
M_%/B/Q=XPT;P[<>,[BY@\*^$_"OA;]WO@'\6;'XW?!CX7?&+3$\FS^(W@+P9
MXYMK8XS;VWC+0=-UV*-NQ*"XQG')W'!R*]O1,/(5/$BAA[ @'TZ]C[C'%?Z-
M4)O$85J2Y;;6UU:C+_TF<9=]T]4?\5>,P^*P&99AEN9*^:9/5J4I7T<9TJE:
ME.-M+\M6C4C?9V36DD?P=? +_@S CTCXR&7]IC]L>'QS^SIIOBC3]:N?AW\(
M_ >N>"?%'Q)BT5F72-/UW6M>\4^*++X?P"VUS58I39Q^*O%2V^LZ_;6WBN*Y
ME7Q=)_=?H.A:3X<T?2/#VC6B6VE:'I.E:/IMH+C<MIINB1"'1T_OD"-$4-SD
M*H8, 5KI**T.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 9)]QOI7\Z7_  5*T>#7OB#;_N/M/V6\/USCZ]#7]%LGW&^E?ST_
M\%/KR_T?QC_;EC8_:;?[9C_CSR,=^>IQ[_XT ?EA>S?\(W%;_O\ -Q]CS]D[
M_P#UAV-?&_Q@UC7)O$?GWT/V:WMOQ_SUXKJ/'GQ(GUW5+>?R+FV^R^QY_P#U
M]NU9^L7D'B6*W^W_ .D\?U_EG'\S[@'(>&[S^WK_ $_[/_I/^>G4G _+\*_6
M_P#97\!^=?\ VZ> VUQVX_Q_G7P?X;\5>!_!,5O;_P!AW/VC_KT/_P!?/H3V
MK]&/@/X\Q+I]]!8&VM[KC]/\XS^0H ^F-2\;:M#XCM]#GL/LUOC_ (^_K^G]
M!SZ<?3/@F'SI1]A@^TW &>/\_P">N#VQO^$5T/Q5%;ZK;\W'Z>GKC&?\\5[1
MX)^%>N0Q6\^E>O;KW.>O^>/Q .7F_:BG^#^J?8=5@^T6_ Z_G_\ K^E?2^@?
MM0:#XUT8WWAN87%P;3)M0!R2.I[YY_+VKY0^,W@G0]'M3<>*H+;[1^';VQ]>
M_P!*\O\ A+9SZ#-<7VAP?\2__P"O_GZ8R">: /!_VD/C9-XD\;_8;Z?-Q]L_
MX]/\]?Z#\Z^;_'MY]CL;>?/]F_:<=/3G]?UZU[Q\;/AC/_;W_"1_8;G^T/MG
MVWCT_'H/3I^6*X?_ (1N'Q)86_\ PD?^B_9?SZ_GVZ>M 'S_ .&YO#D)MX+Z
M^SK'VSG]>/KQGD#I7Z ?#?$W@C6/L%]Q:]?\C\N_YU\?Z[\$X)M4_P"$CL9_
M]'/^A<WA]^!V_6OM#X,^%9]!\)7'V[_CWNOQ'T_KQT]* /I#]D7]I;PYH]A<
M>%/%6J_V;]EO/\\=QZ_6NW_:/^-<_B_3Q\/_  !<&ZN-=NQ>?;+7DV(&>IP,
MG!S[G..M?(&C_![P=X/NM0\<>(_[2_L^US>V=I:7F/T_/ZBNYA\>> (?L_BK
M0]*UO_1+/C[7Q]/?U_PZ4 =?_P *?_XI?1_#GBK5?M-Q:_Z;>?:\]?\ /;_&
ML?Q5\/?AQX)\+W&J_P"C6WV7T]?QQ^O3WKQ?_A?'G?$&W@OO[2^SZI_H5ET&
M?\]/Y5X_^U=\>/.\+ZAX<L?M.>_7/^>!VH KS?M">%?[?M_#G]N_9K>ZO/L7
MVOG\NGY_6O2/BI\&?^$VM-'\56/_ !,M/_L?W^GZ^GO^?X/WFL:Y/XCT_P B
MQU+[0+P>G^>!UK]@/@G^U1JOA7X>_P#".>.;'_IRL_M=GCW_ ,\8% 'K'PKT
M>QLXO(L8/[-N/^G3CW]S^AZ9XK] /CQX#O\ 6/@9]NT+_2;BUT?@?4^^/T_*
MOSG^&/BK^TOB7H\\'_('NKS'_P!;],\<]*_5_P 2?$C0_P#A7MQI5C_I-O\
M8S^'_P"OKSZ' H _E@O/!/C_ %[Q1]AGGN.;S\?S[GGZ^G->+_%2:#0=9!G_
M -&U&UL_L7;\/R]\]?7-?KQ-Y&C_ !&N;[5K&UMM/^V?\^><YYXS_GCBOC_]
MIW]GN#Q?=?\ "5>'/^7K_GU_7IZ]_7Z4 ?"\/BJ?7O#GD&?[+!:_I_\ K!YZ
M_I7/Z/XDGTS5//TK_1N]Y_(^G'I_+D5[A9^ ['PKH-Q8ZK_Q\?3&?_U=>?J:
MX?['H<,5R((#W[]<9_G],=Z /UP_X)R_$C5=8\>:=H<&JW-SI]U>?\>G4_\
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M>>_U_EC^5:%GH.J^//%NH>,=6G_T>UO/^7OZX.#U]OIZBOU(_9%FT/Q5=?\
M".:KI5M<V_ _X\^G^'^>>U 'YS^#_A+_ ,)M_P (_P"#M#T/[-K/VS2_7_#O
M]/6OZ+_@%\(1\/?"6D65[@W*V8R >1G! ([ @Y]P16SH/P-\ >&]9_MS2;&V
MMM0X_P .?;\NE>GWNNZ'ITD$U]JEM;Y!'-YE3UZC/(]1WH T(CYOGCR/LWV;
MI[G!/7([ FO&->T'0_#=_<>,;\6WVCM:_P"?Z_RKP?\ :$_:0_X0_P#<>')S
M<^V?7GZ_Y/I7Q_H/QX\8_&";[#_I/V?\^2,\?6@#[HU+]I"QLY;C[#]FMO\
M('!Y^O'O7R_\2/VJ-<F^T6-C/UY_X_/7_#^OO7RO\;-'\1^";7^U3/<G_./Z
M]J_-?Q+\;-6L]4N+CS^?K]3^7U']#0!]X>)/VBO&.@W5Q?>?<Y_Z_!_GMVK0
MT#]H3Q_\2+74=*@\5:E]HNL\C_EP_3CZYXK\SX?B3JOBJ7R)SBW_ #/^ XX^
MO:O6/@U>#PIXG_M6>^!M_MA_^N>] '8?$+X#_%37O%%OJW]E7.I#[9_R%O\
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M?\]CTQ7W1-9YTOR)^UI@X[=#]>/PZX[5^!__  4"FT/3;JX@@OO](Q_S^?\
MZ\?C^G. #L/@G^V9/\5/%UQ\.?$=A_Q2]UR?],]N/\_7ZUY/^V-^Q//-=_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7^5C_P>)_\ *7B#_LUGX,?^
MGCX@U_JG5_E8_P#!XG_REX@_[-9^#'_IX^(- '\JM?[-7_!OS_RAJ_X)[_\
M9"4_]2_Q)7^,K7^S5_P;\_\ *&K_ ()[_P#9"4_]2_Q)0!^QU%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XL
M_P#!<G_DT[P%_P!E^\*?^JS^+-?,G_!!_P#Y&;]I3_L$?#'_ -/?CVOIO_@N
M3_R:=X"_[+]X4_\ 59_%FOF3_@@__P C-^TI_P!@CX8_^GOQ[7][\(_\J_N-
M_P#LN.(/_6PX-/E\3_R4=/\ Z]+_ --L_I!HHHK^"#Z@**** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?B_^W'KWPY/Q&T[P=XQG
MM[:WU2\%G@]?I[=>?\:_:"OR&_;=_9+F^,/Q T;Q(+_^SOLMX;T$$'/X].:
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M:KX\_L_PWH<]S;:O=?\ +I:9SQ_C_4 5_0/^RC^SM/X#\+Z?KFN7'V;6;KG
MZX/3\R.YSGTP:^,/^"?O[(L]G:_\)QXJL?\ 2/MGVVS-W^?Z],?KTK]4/B=K
ML^FZ9!I>E?Z/]FQU]N@'YG\2: .'^*GB35?#=UY\&JW/V?\ /K^GX?\ ZJ^)
M_%7Q"GUB6V@_X2.Y^T?;/3^G^?QQ5CXG>,-5^RW%C//]I^U7GV(C_/\ GCWS
M7@_C#X5ZYX)T'_A,?"OB33=2N;K_ )=,_P!I=?U]C]: .PUW09]>NK>X\_\
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M?_6Z5]L>-O@/8Z;:ZAKFE:K_ */]B'_+YGMV_P#K?6OS?\2>%?[2UJX\B?\
MTBUZ\=3V[=>O\_7 !L?!_P 57WBKQO;_ +C_ (];WW'^/T/X>E?TD>%?VD/#
MGPW^$&G0:K_HVL?8S^/_ .O';_ZQ_"?]FGX&ZK9^+=/U6>#_ (E_VS_3.XZ?
MYZ\?2OO#]KK^P]2L/#_@[PYJMM;:C]C^Q?\ 'X,_J!^GU- '<>*OVM#\2/%/
M]AV/B.YMM/M>A^O?O_A^=?:'P9^&&E>)-/M]<U7[-K=O=9^Q_:^X_'U_^O\
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M!^R'Q"TC_A)?!NL:5/"//NK+_CT_SG\L^W>OQ@_9U\'ZK\'_ (O_ ! _X3B
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M:1MYK_R/[5MO\^GI[=>* /TW\*^#_ &@Q6_V[5;:V_/\ ?\ ZWO]:]8F\>>
M/!^EW$\&JVWV>T_P[?\ UC_C7XWWGB6Q\56OG_VYJ1'3_1-8Z_Y_F>37S?\
M'+QC?Z!X7\C0_%5S_P!>?VP>G/3W_P ^@!]?_M!_MX:Y_;^H:'X5O@+;_ITO
M./IVX_#TK\B/B=\0M<\8>(]0OM5G^T_YS_GH,8KS?3?&PU+[1<7T_P!IU#J?
M\]#]>M9']L?VQ?W%C_R\=,8_/O\ YXH ]7TWQ)?0Z#<06,'VGO\ 7'ZCV_R*
M_._XD?\ "1_\);]N\BY^T?;?^/3GU_+]/PK]:/A7X)T/1XOMVN3VPM[H=>?\
M^Y-?0%Y\'_@1XDT;4/$?^C?:+;-[_P ?F?7]>G_UC0!P'[!^C^'+OPO<:KXQ
M@M[;M_/O^N./TX^UYOB=X T>Z^PP6.FW6GW7KZ_CU_\ K9]*_/>#Q)H?AJUN
M/#GAR^%M_IGY#TX[YYQGZ^^_H/PW\9>*K6"^L9[FY]?TY_\ K=<>U '4_$_4
MK&S\6W$_@?2K:X^U6?VW_1/R[@=*X_P3XDUR'6?/\1G[,+K_ (]/?OSUZ]?\
M:^F/!_PKM[/^SYYX+G^T/^7S[7Z?ACZ__7JM^TM\-_[-\&ZAKFE0<_8_]#%I
MT].WK[C\Z ,#6/&T&O16]Q#_ ,>__'ECJ,?TY]N?SKP?XG:Q?3?Z#//<V]QZ
M?_6QZ_KG/MXO\']>\5Z/?_V3Y_\ H_VS_CTN^<#V]:^F/$F@ZK\5/%'A?PY!
M!_Q,+G_C\^R6?O\ IQ^/Z8 /#_AO\/?$?Q)\1Z?8P07.I?Z9Q^')Q^/\Z_IO
M_9J^"6B?"OP;I_G6-M;:A=6GY#_/3_\ 57/_  '_ &7O!OPQM=(U6WL;8ZA<
MZ1I8.>N< XSZD$'CI^=?6,U[]C^T7%]/;6UO:Y]^V<\^F?Z&@#0_U7_+?/?I
MUSV_3T_+J./\2>._#GA6TGO=<N+>VP,')Y.!W."?UX[]Z_/_ /:$_:H_L'Q&
M=#T/5;;U'^1^?T]N3\/^,/C-XC\;77V&?5/TSSU/TZ=,_A0!]L?&S]O;0_"L
MMP/#GV:ZM[3U[^YZ=?R]ABO*--_;EUS7K"WG_P"?K_3L_;.ASTYZ_P"<8Q7Y
M_:QX5_M*Z\B?_2C]1S_GUKZ(\!_ C7/^$7N-<\C_ $>UQ]C&>/Y_EU[^E 'V
M1H_[;&E0Z-<6&JS_ /$P]_\ (],_S[U\_P#C;]J*^O/M$%C/<VWVKI^?'X>G
M/4]J_/\ ^,&FZ[X;E_MRW_X][7D?CT].>W7MT]?2/AO\6O ^O>#;C^U8+;^V
M+7Z=L=>O?\J *_C#XM?%33-4M[[2M<U+\;S&.H^AZ?6OL#]EW]LSQC>>,K?P
M=XYGN;:W_L;[;]K-YG\^G;^?6OR/\2?&S_BJ+FW@@^TV]K^)Z_\ U^_X=:+/
MXY0PW_V[R!IMQC[$;L#^M ']<_@KXD>$/B%;""POA<SX)(.03D=CDC\#QZXK
M(\;?"O0]?BN#Y%M]HQGL"._/T'Y<?C^(_P"S?^TMI/P]B_M6^U8W/<G[9^=?
MHA\/?VM/^%D:I;P:2/\ 1_T_S_\ J&#0!X/\7_@//IL5Q/\ 83]G_P C^N?\
MY'P_XE\!_P#'Q^X]?Z\?_6_#-?T43:;X<\5:6+&>"VN?\X'K]#UQG\_C?XG?
MLTP6?VB^L8/M-O\ KW]<'_.3TH _$^;PK/U\CU_3K_\ 6YX_2N'UBS@TW_7G
MVSC_ #P>GIG]?T0\;?#&?38KB?[#]FZ?A^?^>YK\O_C9XDGT>_\ ([=_R]C@
M_P O7M0!V.FS07G7_/\ 7^6?RK7FT']U]/Z]?;!Z^E>'^ _%/G2V^)QG';O_
M )[9]L\U]8:/#!J477\/I^7Y_2@#Y_U*SGAEZ_GVQZC/Y^_7TJO#-Y7^?\\]
M>U>L>,-'\G'D=/TZ_P"?Q_7R>\AGA^O3Z^O7\OR]: .HL[RW\K\NO/\ C5#[
M9;^A_/\ ^O7/0S3].W_U_P#'WQZ]!G0@[_C_ $H T//]OT_^O5B&;_/^?U&?
M<&L^K$'?\?Z4 =!9_ONG;^OIUSWS^F>*V(8?\_Y_4X]@*S],_B_SZUT'_++_
M #_=H ]P_9UA\_X@]>/[&U0?Y_\ U]N]?TL5_-/^SK,?^%@\]?['U3'_ -;'
M^?P%?TL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?Y6/\
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MX;BU#2=*GU*Y_KZ_EZ_EWK^P#QYH/ASXA:7<>')_LUS<?AP>._T_ET-?BO\
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M_P ,?B-XJEUB>QUS6[G1_P#GU^OOU_.N/F\83S:7<0WTX_TJ]^VY[=Q^G3C
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M\^).E:;XWM_#EC?6US<76L?8OLG7\>WK_GK7WS\/?AO8ZQX2.JZY!;?\>?\
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M?M5QX<TG7/\ 2/\ IT_/^OT_,"O0/VG/B1?> _"5Q#H=];6US_Q^WGVOJ/\
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M:#!%?W'09_'_ #WH \/JQ!W_ !_I6QJ5IY,O[@>H]O7Z_3/KFN7\F>'KR?\
M(_\ KY_PH Z"JT/^N'U/\ZH5L6</G1=3^6<__7H Z#3/XO\ /K74P_ZD?0_R
MK&T[3?3W&?\ ]7Y\G\>E;$T/V.+GCTZ8Z?AW]S^5 'K'[/<W_%QO^W/5/?'X
M=N^.W\Z_IHK^7_\ 9[F_XN-_W!]4S[CZC.1^'-?U 4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117
MYN?\%"/^"H/[(W_!,CX8+\2OVI_B2-#O]8LM<?X=?"CPW'I^O?%GXK:CHPEF
M_LOP)X0$T+.8WDT:"?Q#XHG\+^"?"\FKV?\ PEOC*TFN;>-P#](Z*_S9_P!I
MC_@]*_:]\6Z_=6/[)W[./P6^#'@>*74([/4_C'%XI^+7Q%O[7,C:-K#3Z#XC
M\$^$O#_F1O&;SPZWA7QHB/L%OXN>,/(_PY:_\'<O_!8Z.:"2Y\=_ 74(8)QF
MTF^!6@I]MY(VB2*X5T//RD-&ZDC"]J /]7NBO\[[]CG_ (/2?BM8:_9:%^WC
M^R_X,\6>%[N[%G=?$C]FR[U7P7XET"Q\Q!OU7X9>/O$7BOP[XGE"#4681>-/
M!.$V,D($;2M_<;^R3^V+^S5^W-\'-"^.O[,/Q2T7XJ?#O6T6UN+W39/L.JZ'
MJJJN_P +^,?#VLB/Q'X;\1H;G:^@>(X;>8;BV-CQ-( ?6E%%% !1110 4444
M %%9US=06=M->WTL-M;VUNUU<W%P5"V@"Y9B3@!%"MWSD8&<@5_*C_P4._X.
MQ/V%?V0-9U_X9?LWZ/J7[;'Q9T"]GT;5[GP7XFA\%? WP_?V\<3RB3XN3Z!X
MIE\53 &4PCX6>%?%W@^[?33;2>-O"]S(I(!_5_17^73\4_\ @\B_X*B^.-9O
M#\.O W[+'P:T$Z@W]EP:1\._&/C7Q'::6Q0"/5]:\<?$.;PYK4B@RG[1%X2\
M,;B\($,)#L?)+'_@[I_X+#V5[!+<>,/@#K20#:VF7?P+T:*QND/#*[:)K]LY
M;!)5HY5"\$'@"@#_ %<:*_SSOV5/^#V'XAZ=JFFZ3^VW^R5X5\3: 6V:IX^_
M9DUC4_#'B+3XB"5EA^%_Q'\1^)M!\23%CM*-\5O!J?*'7;DH?[7/V+OV^?V5
M/^"@GPQC^+7[*_Q8TCXF>&;4BUU_2;=6TOQIX'U1HA-%H_C?P=JQ7Q%X>UHP
MN'B%Q$([I6#PO*N'(!]JT444 %%%?P)?M ?\'FGQ.^$WQU^-OPI\+_L2?#7Q
M=X8^&GQA^)7@'PYXPNOC7XKTZY\6^&?!/C;6]$T37YM*/PW86[^)-$TF&5H\
MGR);@^9Y95$(!_?;17^=C_Q'"?&K_I'[\+?_  _7B_\ ^=Q1_P 1PGQJ_P"D
M?OPM_P##]>+_ /YW% '^B=17^=C_ ,1PGQJ_Z1^_"W_P_7B__P"=Q1_Q'"?&
MK_I'[\+?_#]>+_\ YW% '^B=17Y)_P#!&S_@H[X@_P""I7[&5A^U;XH^%>C?
M!^]O_B1XZ\"#P=X=\2ZIXITTKX+;1T75CK.LZ!X9EWR"8_NTC>*/8\?FETVK
M^ME !1110 4444 %%%% !7^5C_P>)_\ *7B#_LUGX,?^GCX@U_JG5_E8_P#!
MXG_REX@_[-9^#'_IX^(- '\JM?[-7_!OS_RAJ_X)[_\ 9"4_]2_Q)7^,K7^S
M5_P;\_\ *&K_ ()[_P#9"4_]2_Q)0!^QU%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XL_P#!<G_DT[P%_P!E
M^\*?^JS^+-?,G_!!_P#Y&;]I3_L$?#'_ -/?CVOIO_@N3_R:=X"_[+]X4_\
M59_%FOF3_@@__P C-^TI_P!@CX8_^GOQ[7][\(_\J_N-_P#LN.(/_6PX-/E\
M3_R4=/\ Z]+_ --L_I!HHHK^"#Z@**** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKZ@_3DU]D> _CEJO@/5+C5;&?[-H_I^O'IQ_]?M0!]$:1+?? WQ;K&E7U_\
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ML[JXT37(/M./Q_S^/;MGFO1X8?AE\6OA!;SG5=-TW4+JS_X].O3_ /7ZY[T
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M&$7[B#3;FWNO^70_3CCGZ_G7S?\ &W]G6#P'X<^W>"(#;?Z'[X_#CZ__ *J
M/Q_^&_PET/QM\?=/OKZ^N?\ 1/$GY<?IW[=L]*_?CQ)\*])T?X<_N+[[-_H?
MU'T].YQR:_(?PKX/_P"$#\>>%[[S_LVH7/B3_3+S\>O^?_U_KAXQ&N:EX#M_
MW%SJ7^AG-W:?G_GKS[T ?SS_ +2W@/Q5#XRN)]"@.I#[;GOW_#UKUCX)_&:>
MSM=/\*^/]"MKFW_X\O\ 2[//&#_G]*[#XG>,-5^'OC<P:KI0N;?[9_QZ?C_]
M?OVKG[/R/$FJ?VK?6(TVWNO]-L_M?Y^N?P[8[T >L?&;X ^&_&WA'_A(_!T%
MMIOVKO:=OSZ?YR>]>7_LWZ;KGP?\1V_[^YMOM5[]/\CZ?EZ^T3:EKD.EV^E6
M6JVUSI_I_+I^AQ5;R8/LEO/JM];6VH6MYI>.?\_E0!^@/B31_'^O:#;ZX=5N
M?[/NO^GS'?D<^OT_2O![SQO_ ,*WNK?[#!]I\077/IGZ'U_^OCM6A>?&;Q'9
M^%[?2H/])T\6?^AY']._\O?T^;_$GQ"L8?%&GZY<36US./\ 0KRTX_#C]<4
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M,/#EMH<Y_P!(^Q_8CS]/PYZ]?I7S?\5/V;_!W_"1ZAXD_P!&N;BZ/'Y?T/\
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MY_YSS[YH ^'_ /A5GQ-L[_[%Y%S]G[G].V.?\^U9_B3]F_Q'%%_:M]/<W/\
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M_3CM^7Y?EFOP_P#&&CWW]O?ZC']#V/\ D#KWK]\/C9XJL?&'@W3YX/\ 2?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+=^+XT.$^//BOXZ0P+KVL:_K\A?77\.MK1GD\(^$_.7POX,L@5LX5E6667]
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M&TUKXL-\,_@OI3JA??9^.?B+X??QG#M7!/G?#G1O&40;($9<2,"%(/\ D$T
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MV.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH _%G_@N3_R:=X"_P"R_>%/_59_%FOF3_@@_P#\C-^TI_V"/AC_
M .GOQ[7TW_P7)_Y-.\!?]E^\*?\ JL_BS7S)_P $'_\ D9OVE/\ L$?#'_T]
M^/:_O?A'_E7]QO\ ]EQQ!_ZV'!I\OB?^2CI_]>E_Z;9_2#1117\$'U 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M^+W_  4?\2>'--DGL=5L+:XR!P;/=V[G//U'7]:_9R6411F0\@8/YU^*G_!2
M#P'??$*7[#X<M_[2U"Z_Y]/\GZ^Y/XT ?S_ZEJ7AS7M:^PZ38VWV>ZYQ]C^A
M_P#U>M?3'@/X80:/+X?GT/\ X^+K_C\_S_+UZ]#BO)_!_P !_&6C^*+C2I])
MN?[0M/[4O?M?'\^<?Y/KG]8/V%? <&O>*!I7B/0[FYN+3KGCCO\ ECM[9[T
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M1?#?ASX)W5QK>N7]M;:A:_\ +K^.?\\4 ?H/XV\$ZY\*["WU6QUS[5]EL_\
MCTN[SG/)['_]?:N@\*_%K2OC!X2U'PI!.?\ A(+7_0O]+QGK^/8?3UK\A_BU
M^W5_PL+XM:=X<T/7/LVG_P!L?8M8M/\ J%\?Y'UX[5ZAXV\26/P-U#PO\1O
M^N6VMV^J6?VW6/LG\OJ>_/K0!]$>"?@/?7GCRX_X6-/_ &;;VMY]ML[O[9V]
M,_Y]Q7UA\2-2OO#?AS3]*\*W]MJ5O:VG_'W]LZ__ *\\D5\KZ;^TAX5_:$T&
MX@T.^MO^$@M;,?Z':<@_T'Y>]>7^%?&WBK[=X@\.:K/<Z)]ES_Q]]O\ '_\
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M_'_A76=.U6Q^SW/^F#_E]_SG\NV*_0CXA?L]_%/3=>MY]#@N=2M_^?2SL_\
M#O\ XYK[0_9[^&/B.\O]'@\5>'+FVMK7K]K_ ,_Y[G X /SOUCX&ZKH_AW^W
M/$>A_:;BZ_Z<_P#/X9P*X_P3\-[[1]9\/WUC/]FT^ZO,WEI]L]_U_2OZ*-7^
M'WAR>TN-+U2"V_L_['CGCN1TX/;N>G(K\A_VE]-\*_"N_P!0OK&>V^SZ6/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /\ (7_X.@OC'JOQ?_X+1?M26MQ>P7>B?".R^%OP;\)+""!9Z=X<
M^&OAS6M>@W9.YU^(7B3QK)(XZ&7;M. Q_GOK]%_^"L/B[4/'/_!4G_@HGXDU
M2^N[Z:X_;7_:@L;%[PLK+X>T'XQ>-] T'2P8<,B6WA_2='T*$#DQQ"-RQRQ_
M.B@#_7/_ .#7+X>-X&_X(H_LK7=QH[Z1JGQ#\3?&[XB:K!=6WV._U#^U/C5\
M0-#T/5V'DY8:WX8\/>'WMI\&-_##6QC?:HD?^BFOR5_X(6Z;9Z-_P2%_X)XV
M%@4,5S^S)X UMUP-PO=>BDU[6"W'7[5K,FWO@GG%?K50!_&K_P 'I_P_L]7_
M .">O[.'Q(BTH7&K>!/VOM%\,)=QVIW:?X7\?_!SXL'6W8AAMADU_P "^#HW
M9L1F;^Q N<$U_F8U_K&?\';VDPZK_P $9/BA=RS"!M ^-7P(UFW7(8W3/XS3
M00G'."NNL^>0-@)ZBO\ )SH _L<_X,MOB]JWA;_@H;^T%\&1<0+X;^+?[+&J
M^);JU8MND\4?"KXE^ SH3KD;2(_#WC?QONR3DR(>@)'^FY7^1C_P:R^,K_PG
M_P %N/V4M+MI8+;3_B)X;_:'\&ZU]JMLYTU?V??BMXXTHZ4&W,N[Q+X,T':Q
M&"Q>(!BX=/\ 7.H **** "O%OCU\%O O[1GP:^+'P%^)UMJ-_P##KXQ^!/%/
MPU\>V>C:J^E:K>>%?&FC3:+XAT^VU:-3)H[2Z).P,L94OYJN-S?ZWVFB@#^0
M[QY_P9C_ /!+SQ+?3ZAX0^+'[8?PX9HE,>D:=\1?AEXE\,Q 9Y\OQ'\&)O$,
MA;^+=XM.0 0J8):M^RM_P:1_L^_LF_MB_LX?M8^#OVJOB/XQTGX"?%/3/B8?
MA9\2/A7X1\1CQ1J?AY)9?!+1>,/#>N^%D\.ZSX?\3_V/XM_X2#_A#?$<:2Z-
M$$CMY5'B)OZ^J* "BBOES]K#]JCX(_L0? 'QY^T=^T-XQT_P1\+OAUI4MY?7
MESY1U+7-39)SH_@OP?HXF5]?\4>*[DIX?\)>'("+B6Z=-TGE+-+& ?PV_P#!
M[UX_\'ZE\2/^"=WPGLM4L[CQWX*\#_M,?$#Q)X>CN4-]IWAGXJZY\'] \$:U
M+IRE6C7Q-X@^%7CN.-Q'(S2^'Y Q3RR&_@\K]"_^"DW[>OQ%_P""D/[8OQA_
M:K^(<<NCCQKJ\>D?#GP8U\&L?AO\,-"9])\%>#HLN[">W\/@R^,);9X(/%'C
M#6?$OB]XHQ=O;+^>E '^A?\ \&/_ ,.]9L?A_P#\%$/BS=10G0?&7C']G/X>
M:)=L<7YU?P!H?Q?\1^-(UX)$:1?$_P $29;.6!/4*6_O)K\1/^#?;]A35/V
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M_&@#^R6BOXVO^(US_@G+_P!&S_MK_P#A-? ?_P"?C1_Q&N?\$Y?^C9_VU_\
MPFO@/_\ /QH _LEK_*Q_X/$_^4O$'_9K/P8_]/'Q!K^BG_B-<_X)R_\ 1L_[
M:_\ X37P'_\ GXU_&S_P73_X*,?"'_@J3^W':_M0?!3P5\2? W@U?@SX!^&B
M:%\5;/PGIWB'^U/!NJ>);B_U(KX7\2^,?#_]C3#746%UOE820RM+ HWB, _%
M*O\ 9J_X-^?^4-7_  3W_P"R$I_ZE_B2O\96O]E3_@WBUJ'7O^",/[ E[%'-
M%':_"+6-'7SR"2- ^)OCOP^QR, Y;2-X. -CI@8- '[24444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?BS_P %
MR?\ DT[P%_V7[PI_ZK/XLU\R?\$'_P#D9OVE/^P1\,?_ $]^/:^F_P#@N3_R
M:=X"_P"R_>%/_59_%FOF3_@@_P#\C-^TI_V"/AC_ .GOQ[7][\(_\J_N-_\
MLN.(/_6PX-/E\3_R4=/_ *]+_P!-L_I!HHHK^"#Z@**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/K^<^@^&]"_M3[#Y'V;M_DXX[9Z_AS7W!X)UZ^^'MK;_ &'_ $;K_I?8^O\
MD_KG- 'Z@^%/V8_AEX;M?^)KJOVFX_Z_.W'_ .H_U'3W?PKX4\ :/HUQ8V/]
MFBWR?3_/M^-?C?XJ^/&N65KY\\]S<^EWU[8'OS]1^'?R^]_:[\1V=K_Q*I[G
M[/\ \OG^F?CCU_R,T ?MAK&O0>&]+N(-*_LW[/:_K_GO_P#K!_+?]L#XS03:
M"+"""V^T<_\ 'I_^OCK_ /6KG_!/QRG\>:7K'_%1_9K@V?3'7OWS_GTXKY/^
M-FI:K-%^_@^T]<]OP_#OZ4 ?-_@/QA/J6O:Q!/\ Z-]JQ@].N>XX_P#K?I]
M0^)+B'2[B"?_ (]K7U]O\#^7?UKX7AO+ZS\4^?\ \>UOGC_/Y5]$0^,(/L'V
M&> _Z5^'Y^WZT >P?"OQY8?:KGS[X_:#U_0]SZGZ>OI7A_[0EY8^5<:KI,Y_
MM#C\./IV_F?I7C'B2\@\'^([>^TK_EZ^OKQ[?X<\U?FFG\22V_G_ /'O=?\
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MO$E]\3KK_B>:5_9MOC_ETLS[_P#U^,5_0!>^ [?QOHUQY]Q_I-K_ ,N?Y_\
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M '"-4_K7]1] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!_AS?\ !3#_ )2.?\% O^SU_P!JS_U?GCVO
MB"OT7_X*P^$=0\#?\%2?^"B?AO5+&[L9K?\ ;7_:@OK%+P,S-X>U[XQ>-]?T
M'5 (<LZ7/A_5M'UV$CD1RB1PIRH_.B@#_:D_X(=_\HAO^"=7_9J_PM_],:U^
MJE?DK_P0MU*SUG_@D+_P3QO[ ((K;]F3P!HCMD;C>Z#%)H.L!N>OVK1I-O?
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M-*2TO_"2_$'Q+!%;_P#"9^,9X&GN+DFVTV'PKX*AMO#5K^1% !7]>G_!KO\
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M"+9QM#W.[S5_,G_B!E/_ $E"_P#-*&_^BSH _@%HK^_K_B!E/_24+_S2AO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3_MG_'W]CS]/3TQ_G-?TH?#W3?\ A'/"^CZ'#_S"K3[%[#'OVP<?3T[5_/\
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MVZ?\>?\ GU'UZU]H>%?B=8:]+!!?3@'J/R]?T_EZ5Z?J^FZ7J5I<07$ \BZ
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M\CI619^,/.NO(^W>W]?R]<G\,<5Z!]L\Z+]Q_I//;U'OV_S]: )X9X!:^?\
M\>T'I^AYY_0?R-?,&L?!_P '0^*/^$QOM5MK:X'_ $^>W^/Z>E;_ ,??B'-\
M/O!MP;?_ $><V?5<$?A@GC_ZXSVK\*/C/^UUXJO(KBQ@U6YMK?[9_P _G/!_
M3K[?S- '[\0_&#P!#=>1;ZK;?^!A'^>G;T_&K'B3XJ>'--TO[;8SVUSC\,Y^
MOZ=#COS7\L]G^TA.=4,_]N' _P \]^?\]Z^H=-_:CGO-+\B>^-SGK_GGJ.O/
MUH _9_P?\>-"\;:IJ&A:Y!;6P_Y^[NSZ#\/7\,\=J]VF\+>"-2T?_3M)T74;
M:YY'^B+AL^V2W'N #[U_,3XJ_:6U71KK[1!??9OLOY_G[8_I7I&C_P#!2#Q5
M_8UOH<&JW%S;_P#7Y]>W7M_G' !^[&I?"OX+:#%]NG@\-Z;]J_Y^_P"QAZ'V
M^GMTZU\G_%31_P!F7PK?7&N7W]FW-Q_U"?[&Z8[@?Y[5^>_Q:_:NT/Q5\+[?
M^U=<_P")Q]C/Y]L?_7ZXKXOL]>@\2&W_ +5U7_1[KU_SW_E^. #]"+SQY^S9
MK]UK'V&QU*V_TS_ZV?7K_.N/A^-GP6\-_:(+?2OM/TL_Y8_^MW/-?(\VCZ'I
ML5Q_IUM_9]T>GXX_IW__ %>3^,/$GAS38O/TK2K:Y^RX[?AT_4?H* /MF\^)
MWASQM=>1!8W.FZ?S_P N9_(>OM_^JNW\*_#W2IK6XGGOC=7'_7Y_G ^GX5^0
M\W[5$$$O]AP:5]FN#_T^8_\ K_YX/6OJCP=^U%X<TVPM_/OO](Z8_7OCF@#[
M0O/!-]X;E_MR#/\ 9]K]?Q_Q^N*^)_C-^T5XCA\1W,%C/]FT_P#Y],CZ?7)]
M??I6AXV_;&U6\T&XL=*XM^,8O,_Y]N?QK\WO$GQ(U7Q)KUQY_P#D#IGZ<T ?
MU _L<Z]JOCSPO!Y$X^T?\(WU_P#K_P"??)Y'Y_\ [8,WC'PKKVL?VK/_ */<
MY[_U]?TK[ _X)FZE??8-/@M_^@/Z?7_/;K]*\_\ ^"BG@_5;S[1?3P#_ /7W
M]>O<=>#VH _"_6->@F^TB?\ X^.G^>G^';Z\_K&@WWB31KC[#/\ 7'^?QQT_
M6L?Q)H-]_I&.?],^O'X]_8=?>J_P]U+Q'INM:?!.;K^SQ>=>WI[_ -!S^0!K
M^&]9\?\ @/[/ ;ZZMK?_ *_,?X_Y/I7VC\,=?US7HH+Z^G^TX]LD]L_X_P!>
M16?J7A7PYXDTNW\_[,+CG^0_R*V/[-OOAOX7^WZ'FY_T/^8Z\]O;G/2@#8UW
M7A9ZI;S07'^D<?G^?(_SZ5^N'[$/BG5?#<5OK>JS_P"CW9_+_(_/^7XC_"7P
MKXC^+7Q!MX/])Q]L^V^_;V_SUZ5^F_C#XG#X Z7;^%;X?9KBU_T+O_,Y'^'/
MUH _H0\.>-M#UZ+S[&>V^S__ %N3^?\ GFNH^V:6?^6]O.?P],^XYK^2#4O^
M"C?C+PU?W$'AR^N?LW_7[^/\OIGKGI74?#W_ (*?>/Y]>M_[5OKG[/\ ]?F?
MY_IT/MB@#^E#XJ?#&Q\:Z5<06,%MSU^O?'MQC^M?B_\ '+]CG2O#>M?\)'/!
M<_\ 'Y_RZ?Y[_P">U?:'[.'[<FE?%K7K?PK/??Z1[WGY=@3_ #_.OT \8>"?
M#GC"UM]*U:QM;G[5DDY[]^?R_'CZ@'X/^)/V=?A7KW@>W_LJQU*Y\0?\N?''
M^>?:OA_7O@SXQT&_^P_V'<VUOVS9_CD?Y]J_IX\*_!/P;H5_<03^'+;_ $7_
M $VSZX'_ .H__KJ?XM?!GPYXD\+ZC]ATJU_M?U]<Y)Q]!C'7D^E '\J'C#X5
MP>&[ :K?7W^D9Q_Q^>GY=N]>3Z/X;U7Q)?V]C8V/VG_3/^72S]_S^O'T]_UH
MU[]A7XJ>//%MQ!?"Y_L?[9_GKV_R>>:[#6/@S\./V4;73[[5?LVI:Q:];3_/
M7V_GP, &/\,?V4?$EG\+_P#A*9[BYM?LMG]M_P!+O>N>/\^A%?/_ (J_:0\1
M_#&ZN-$_M7_1K7J;2\^G0?K7U1\2/VP/%7C#X??\(YX5TK^Q-/NK/[%]KM+S
MMG_]7^37Y@>-_AO/>1>??3?VE<ZIF]_^OC_ZW84 =?KWQ4TKXM75O_:NJW5S
M<?\ 7YCI_D#U_2OE_P"+7@G_ $JW^PSW/V?GK]._Y_X<5] ^ _V?+Z&6WOOL
M.;?O^' [?_JKV?QAX5TK3=+\C^RK8ZA^7/US_(B@#S_]DSXA>*?A+XMTZQ@F
MNO[/^V#[9QV^G?'^??\ 7C4O^"A'P_LK"X\.3P?\5!=:/G_CS_YBG7CZ^GIG
MUK\4-'\2:YX/UFXU6^TK_B7^W7_]?7^77FOG;QYKVN:EXH_X2/2M)Z_R_,\C
M'XT >\?'CX_?&GQ)K.H6,'VG^Q[K_/;KGU]^*](^"?P\U;7M&M[_ %6W_P"/
MJ\Q_CTSWY]?:O/\ X/ZQXI\>75QH>JZ5<_:#_P#J_P CCTSUK]@/ ?P-U70?
M!%O// ;;[3Q_G QS^'K0!^4_[2WP?\5376CP:'!_Q+^WZ_Y_$>E:'@GPW_8^
MC6\$\'_$P_,>F,_Y_I7Z4:Q#]BNH-#U6Q^T_9?7_ !X^O\J\_P!'^#\&L>(_
M/G@_<7.>OT_G_P#6YH Z#X;ZQKGAOX?6]]X<GN;:X^Q_Z9U_PY]J^%_C9\5/
M$>O:S<?VK/<FX.?R[?Y[U^\&C_ WPYX;^%=Q??Z-_P >?3U]>?;_ #R:_'?X
MS?!K^WM4U#5=*@_X]1[?TSUX_P#KT ?(\.L0:E:_\37_ (]_Y^_O^M?-_P 9
MO&$&G1>1!_Q[_7\__K_X\UV'C";7--O[C2O])^SVO'\^^3V/KVJO-\-X/&&E
M_P"G9QUY_P ._P#(_I0!\SZ/X\@O+7R/('VC]<9[_P OZ5]T?LT^-I[/5-/\
M^?/M@=L=>N?\X]1\3Z]X/TKP'=7'GC\OR_R?Y]_</@#-/>:I;^1V_K^/^.>A
MZT ?U\?LN^/+'6/"UO8_:/7';G^G?U_I6A\>/A[!K-K<7 @SW&.X]>O;TK\]
M_P!EWXA?\(W_ &?!<3]ORX^GTZ?_ %A^J$_C#PYXJ\.&>XGMN+0Y[_CUX_SS
MF@#\+_BIX#^QRW!__7QQ_P#6'J?SKY'U+3?[-EN#T[]Q_D\8Q]<9S7ZX?&;P
MMI5Y=7'D=/\ /Y?H *_._P 8>#_)NKC]/;OQQD?Y]"* #]FF8?\ "QO^X/JG
MK_/\^1QWK^IBOY=_V>]'$/Q+/_7GJG^0?K7]1% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_D(_P#!
MSW\)M3^$W_!:/]K.62R:TT;XH+\,/BQX;N"Q*ZEIOB?X6>"(]?G5,!8RGQ"T
M7QC&5&=QC#%N0%_GUK^^O_@]._8[U<ZM^RG^WOX:T*XN].BTG5OV9/BUK4,E
M[Y-@T&JZYX^^"K^2RM'OD?5_BQ:2Z\YC:>:+PU;F*4- H_@4H _UV_\ @UO^
M*"_$S_@BM^RQ9OK#:KK/PQUOXR_"_7&>4&33YM"^,_CG7M TC(Y\NW^'OB#P
M;Y:D@,DFYL8:OZ':_P T3_@TL_X*M?#/]E'XE_%#]B/]H7QII'P[^&O[1'BC
M3?'7PE\<^)[R/2/"NA_'6+2H?#>N^#?$.MSN+;2Y/BCX8TOPU'X3USQ!)%#%
MXD\"P^$(#+J'BZ C_2*\1>+/"_AKPYJ/C3Q#XCT/0/">DZ8VLZMXGU;5M*T[
MPY9Z5'"\BZIJNM7$\=O%I#*?EN&D2(@EF^0_* ?QV?\ !ZUX^TG3?V$OV4OA
M5<7D!UKQC^UROC^SLG8?;+G2OA=\%_B+X>UF5'125,,WQ7T-7)QDZO$"JKAF
M_P TNOZ2?^#E_P#X*>^ O^"CW[;FDZ)\#=?C\5_LZ_LM^&]<^''P]\96N#I?
MC_QOXBUE-8^)WCK1)I#;M_PC-V^C>'?"7A(J#'XGM? B>,K5Y8/%21C^;:@#
M^RS_ (,LO@[?^*OV_OVCOC603H'P:_9EE\(,1V\4?%WXD>&FT)CTX_X1WP%X
MX'<Y(Z#)'^F97\F7_!H7^QQ?_L_?\$Z-?_:,\3Z*FG^,OVSOB&OC+2Y;C37L
M=47X/_"IM9\#> K?6-T$3?O/$\GQ7\5^%I8\PR^%O''AZ>)I(+E&3^LV@ HK
M^<'_ (*Y?\'$'P?_ ."2/[2_@[]G#Q[^SG\1_B[J_C;X*^%OCC8>(O"7B[PE
MX<TO3M+U_P ;?$3P&-$9-=CF?S5D^&5Q<.Z! Z:NJIEE$<GY8?\ $;O^S5_T
M8S\=?_#H_#K_ .45 ']QM%?D]_P2+_X*D^"/^"MO[.'CO]I+X??"SQ;\']&\
M'_&WQ)\$;CPYXLU?1_$.IW>I^'/ _P /?'+ZS')H>V-+>XC^)UO#Y6Q9%;29
MI&<1R )^L- 'S!^UA^U%\&/V*?@!\1_VE?V@_%5GX3^&7PPT"76-7NS+C4];
MOGW)H7A#P[I3R";7/$_BO7)H?#OA/P[&&::\N55KB)/,>+_(6_X*W_\ !5;X
M\_\ !5G]HG4_BS\1=3O/#7PC\.7>IZ/\ _@I9:EO\/?#'P.1P+F.)!%K7Q"\
M3Q^1/XX\5-YLEQ.([.U:/P=;>&;:S_2O_@YZ_P""L6J_MT_M<Z]^R]\,O$-Q
M-^RU^R-XLU;PWI,%J[?V?\1OCOH1?P[\0/B7,/.CCUN#PO-<ZQ\./ DCI/&/
M"L6O^+K1@OC">)/Y9* "OZY?^" ?_!NIXI_;VOO"W[6G[7FFZIX*_8UT'6(;
M_P )>#;D+I?BK]I'^R)0RQZ260OX?^$*W V^+/%JNE[XR2:2Q\%,C&;Q79?A
M;_P3*A_8E'[7'P\US_@H;XVUOPG^R]X-0^+?&&C>'O ^M>.-2^*M_H=W;G0O
MA<T7A_S)M T'Q-*?/\8>(W!\SPGH6N^$8Y(;KQ+#<Q?Z.>@?\'4'_!#_ ,)Z
M'I/AWPU\6OB!X>\/:'I>F:-H6BZ3^SG\3--TW1]*T:.*/1],TC2;?PS$L.DQ
MP(4A6/:(D"Q*(U9/) /Z+O '@#P+\*O!?AKX<?#3PIX;^'_@3P-X?TOPUX0\
M$^$=)TSPWX8\+>&]%A6#1])T+1M$B6VT;0XXHBJ1)&%1$8;%R17HE?S7_P#$
M67_P15_Z+Q\3O_$??B]_\S='_$67_P $5?\ HO'Q._\ $??B]_\ ,W0!_2A7
M!>,O&7A7P#X1\5>/O&WB;0_!O@?P5H.H>+?%_BWQ1K>F:%X8\)>&= TN76=>
M\0:_K6L+'H.B>'O#&D1?V]?ZY<72VEO!:327,JQ0N)?S\_X)\?\ !6_]B7_@
MI_??%;3OV1O'7BSQG/\ !FU\)77CE/$7PZ\7^"DLHO'1\1Q>'2G_  D-O -8
MDF;P;K:R&(, L,:1EBS$_H7XY\&:%\1/!/B_P%XCB2\T+QQX3\3>#_$-MC_C
M\TGQ#I,N@ZP@!_B-M.T0.,#=QS@T ?E]X_\ ^"[/_!('X<Z=J5[KG_!0K]F_
M58M-M;^>=/ ?C<_%349< [/[*TGX<VOB^?6F)W)'';+.<@!1L:3;\[^!?^#E
MO_@D#\4?B[\+?@K\*OVB/%GQ!\=_&'XE>!OA1X133_@3\:/#6EOXA\?>+=$\
M%Z"VM:MX^^'WA&+1-%&N:Y"9IY@5@4R,YAR(Z_RC_P!J#X"^,_V7/VAOC?\
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M5_<10S>.O$7[.WA?18Y./M>K0_M+_"7QP%R ?N:!X*UN4@X.$[!*_P C*O[
M?^#H[_@LM\-?V]_'OP^_9#_98\267Q#_ &<?V?O%T_Q$\8_%329X;WPG\5OC
M=%HFN^&X6\!22/,-9\ _"SPSKVOVR>+(XE@\:ZCXU\2/8PGP9X:\(^+O%O\
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M"4_]2_Q)7^,K7^S5_P &_/\ RAJ_X)[_ /9"4_\ 4O\ $E '['4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
MBS_P7)_Y-.\!?]E^\*?^JS^+-?,G_!!__D9OVE/^P1\,?_3WX]KZ;_X+D_\
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M#A<$(^U'#I)XRR=[1L]5KI:W7KHNF_4/(^?/V3?^#C']IS]F']J#XD?L5_\
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MZL\^HQC_  /7UK^;?]I ^(]-^(WBC7-#GNOL]KK _#_]7UH \O\ &WCSQ_\
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MN?0=L<# Z8QQ7\__ ,3OB1?:E+<>1CT./\\CW/KSZGV#XD>-M5U*_N)]5O\
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M<?M3_8?BIK/V&QYN/\_E_@3Z5ZA\9O"NA_#?69['PY_I)YZ?UQU_+N:^=_\
MA*M#T&__ +<U6?\ TCC^?/X_X4 ?'_Q"^ /]@VOVV>"Z^T>HS^'?I_\ 6KYW
MG^'M]#%]NA^TVQQ^/7_#OQ^M?IAJ_P ;/"OCR/[%/!;?Z+_G_#K_ $KS?4M-
M\.:E_H-C!;#L/IZ_Y_G0!X_^S=XJ\8_#SQEI^N:5<#[1:]?M?MZ?Y^N.A_I
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M'Q\"?"Z\L3B_T[XD_%;6-(^%O@K7HL%=[^$/$'B]?%K(6PT6@LJ[F<*W _\
M!%W_ ()7/_P2(_9=\??LUCXXK\?U\=?M >)_CE_PF<?PP_X50VGOXA^&WPI\
M"#PG+X?'Q$^*1D, ^&/]N?\ "0CQ+;^<^L11+8PO ))[7_!9?_@F-XC_ ."M
M/[+GA7]E[2_VA_\ AFK1],^,'A?XJ>*/$R?"V3XK'Q78^'/#WCS2K?P8V@_\
M+&^%Y2*77O$&D>)9+N6[=HY_#UNB0S-<.8@#_&*HK^_K_B!E/_24+_S2AO\
MZ+.C_B!E/_24+_S2AO\ Z+.@#^ 6BO[^O^(&4_\ 24+_ ,TH;_Z+.C_B!E/_
M $E"_P#-*&_^BSH _@%HK^_K_B!E/_24+_S2AO\ Z+.C_B!E/_24+_S2AO\
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MSQ0B"2XUC7+CR(EUOQ'XFU^>X\2^+/$!C#W7BK6+FYDW-+-)%](T44 %%%%
M!1110 4444 %?Y6/_!XG_P I>(/^S6?@Q_Z>/B#7^J=7^5C_ ,'B?_*7B#_L
MUGX,?^GCX@T ?RJU_LU?\&_/_*&K_@GO_P!D)3_U+_$E?XRM?[-7_!OS_P H
M:O\ @GO_ -D)3_U+_$E '['4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !117/:QJ^E:%IM]K>O7EMIFD:99WVJZMJ=Y=?9+
M+3]/TE6FGU&5R2%1(E21VW ; #DD*K %#7-?T7PKHFH>(=?U/3=$T#2[(WVK
M:IJ=['ING6-A&OS:A?:I*P2.,*I&]G4#<,G'S+^)_P"T;_P6K\">$KW4?#'[
M._@YOB9J,!-JWCOQ;_:.@>"4U @A8]&T9$7Q'XA(',@=O#"AP0D\H"NWY?\
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MRK5*5I1E6E.E3DYMN3=.G)N\-?F?KF->.^O/7UD[=?M7OU?7J]=3^A_X ?\
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MV\*V]QXL4)_3!_P16_X.#_V!?!/[!W_!/_\ 91^-OQ6U?0OVE;74M)_96A\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4?LQ_M@>(_#?VCPX+'_B7_8^?]#X_+I78?&S]J*^U*Z^SV,]S;7'V/H/\_\
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M1?OY_P!?K^G49]?:O@^;QA/#?B#\?\#_ )_/O7U1\/=8^V:? .O^?3_/U[T
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M-T9YS;?Z+_SZ=?;\<G'45]<> _C9X<\5Q>>9_P#2#V__ %=O?H 3CCI_._\
M#'Q)XC\571_T?_E\_KGN/S_K7Z$>#]'\1^&]!_M7R+FV]?;_ !.#^% 'Z\66
MI6.I?O[*?^O'Y'KQ6=XJM/MNCW-CYVG">Y'_ "]XP?I@D\>N![>_YX>#_CE?
M:/\ :()Y_P!![=^?H./I6/XP_:B,-K<?\346WK^77KS[GZ_2@#W#PA^SK!#?
M^(+Z^OB;BZ.J?\>=Y^G\N<5XOXJ^#_Q \*_VQ?6-]<_V?U]O\.1QQCZ]JS_
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M*"#[.?\ CS_GU]OY]Z_7B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$]_^R$I_ZE_B2@#]CJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH A,8*8(P.3^>/0<>_?\ I&%$8^1<GCDY)_ ?Y[' J1F*X7)))]_Y_CD_
M@.@K\SOVXO\ @HSX0_8SUCP[X/7P+>?$7X@>)='3Q(=$M]?/AO3-/\/'5FT1
MM:UC6H_#_BF:- =+UID \-S,RZ--$KID-7L<(<*<1<=\04>&.$,HJY]GM=5'
M3PU-TXU)^RI>VJMSJ3I4XQI4TIU)3JTX13BN:\DC#$U\/A(_6L5+EBK*[NUJ
M[+1:N[>FC?EU/TNVCU?_ +Z'_P 31M'J_P#WT/\ XFOYV_\ A_5<?]&IC_P^
M7_XFJ/\ A_5<?]&IC_P^7_XFJ_;?^)2?I _]&WK_ /B4<(__ $5G!_;.5?\
M/U?^ ?\ VQ_1$K0JJ'&%8C82.,MD# P2.G/T^HK\4O\ @L]^T#<?#?X'>&_@
MSH-V+/Q!\:=7U-_$#6RQ[D\ ^$1')K<+A ")?$?B'5] A48(-LFO%G=ERO@J
M_P#!>F7SI(Q^RLA;:&<M\<Y",$#!4CX.@ CC^#CG'K7Y:?MO?M=:C^V9\3=
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M-S<V]U_9?VR[/^?\?4XXK\E_VM->_P"$#NK?PYH9%MC_ )>_P_'_ /7WXK]
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M?_\ 5P_@/4C#8#[#_P NOZGU_P \>U %CQ+^SKX.U+Q1;ZK;P&VMK;F\L_\
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MC_#K0!\#Z]#8S2_;KZ"YMM0'U[8_I_GM7Y?_ +2WP-^*GBKQ)<3P?:=2T?\
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M8!;"U!^4XSCH#@?=/.1^O:NRXA)FSDW/48]L]/<?3'KQ0!\[ZE^S)\,;V_\
M[4_L2X^T>G&>WKSS_B*]2TWPWX<\$Z7_ *#8VUM;GF\]_P#]74X]L5T]YJ,&
MF_O[Z>VMK?U_']./\GI7*^-;/_A*O".OV.B:J#<ZI98M#:78!/3\@>#@'''7
MI0 3Z[X(ATRXU;[1HA%J#_I7V,8[8[;O7G.,=LFOR"_:T_;DL=-EU#PKX<G^
MTV_-E]KTD=AZ?TS7RM^TAX\^/WPQNM8\-F?4O[/NA_Q]?;/?KGZ_3\J_)_\
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MYN?^WS^61^7\QQ7A'BKXP^#O <5O8^([X?9[;_/8^W/\QTKCM!^(6A^/+_\
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M?>OU8\$?"NQ_X1+_ +<NO^?IC\Z_._XV?!FQ\>>*+C0H)\'[9Q^'_P!?_.*
M/@^S\-ZY\>-9_MS2M*N?L]K_ ,O?;Z?C^7-5_BW#JNF^$AX<L8-2_M"UL_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7XW?\%#?A9JOB77--UVPM
M_M/V:[R 3T! /Y]/_K5^R->?^*O >A^,(O(U6#M_G_ZY'U!ZF@#^5^ST'Q'H
M_P!H^W3_ &;[->'B[]\?SQ_^NNPU/Q)YV@ZA/?3VV+6SQV/X?T_.OT'_ &G/
MV:?^$;NKC5;#FV.<<\8]>_MW_+M^3'B6?5=-\43^')[&Y_L_5/\ 0>G/'TH
MT+/QY/INC:A/!/\ Z1_3\>G]?3GCU'X)_ WQ'\;);?58(/LUQ<_G_GI^./7C
MQ[P?X#U7Q)XMT^Q@L/\ B7W5Y]BX&/\ .#C_ /7Q7]"'P]_X5S\ ?A_H]O\
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MSG/K7+_ >;7)O'&GPZK;W/\ Q^?\??X_Y_E5C]F/1Y_BIXGM]<\50#^Q^?\
MC[_SCG_(K]./&O@_X96=K;3Z'!;:;J'I]C_E_D_G0!]@?#?Q+H>CZ#;S_P#"
M8Z;<_9;/_3+08_3J!V_ST].E^+_@V7P[K&NV^NZ=]FTJQ^V7=UG"@#&,#UQW
M).*_)'4M8@AET_0O#FJ_Z1='_3/],_\ KYZ]*[#XG?"N^T?X+>*#I?B/4O[7
MU31_],M/MG_$L_+_ "* /F?]I;]NKQCK'BBXT/P=/<W.CVUY]B^V6G']/T_^
MM7I_[-_[2WC^SEN/[<OKG[/_ -/?^>N/Z5^?&O>&X/ ?@W[=JO\ 9ESJ%UK'
M_/YCV]O7].M>\? ?_B?6OGP3VW^EY_X^[S^?_P"OZYYH ^D?VHOC9X5\5:9Y
M&JV-M]HS_P ??Y8Y_7OW_'\!OC!KVA65U<?V5_I/_3W:=!^';K_];J*_7#]I
M#X)ZY#H/]N3SXT_'_+I>8Q[=A_\ 7'7O7A_P9_X)UP?M(Z7<:YI7B.Y_T7_I
M\Y[_ /UL_P ^: /C?X,Z]8ZE#J'^@_:;BULS_+V'/^3Z5Y?\2->OM8UG3[&#
M2KG_ !_SG^0]*_<#P?\ \$E]5^'MU;SP:Y<_9[K_ $*\S=\^GTQZ>O-?7$/_
M  3'^&5YI?[^^_XJ"USC_D#'Z?R_$]#S0!\?_P#!/?X3>'/M6GWU]I/^D70]
MOZ\_Y%?<'[2'[,?@[Q5KUO8P06W//V3^O7_/:OI'P?X)^%?P?B_X1R#_ $;4
M-+T?_C[^Q]N_Z#]?QKCM"\8>!_\ A-]0U7Q%XC%S;VMY_H=I]LR.?;(Z9Y_Q
MZ 'Y7^)/@/XCFNKGP/X<T.YN?LO4VEG[^GK_ )S7U1^Q%^RQXQ^'GBPZMXCM
M[K3K<7AR+H<G&> .Y/09(Z]N:_4'P?\ \*YUBZN)_#<%M<W'_/WQ^'?IVS7I
MUI 8I;CSH;89],<]_P"($<_Y]P"O-#^]\B:#[3;FT%F<?YZD=^O;FOD#]J*'
M0]!\&W%_!8^O;^9_S[ <5]D?\M?\_P!ZOG[X_?#A?%?@/4+$8/VK6-,O,>A4
MX;OQ@]<_7//(!^='PK^!FE?%2ZM_[<L?LUO=7G_+W^/Y?U[^E?4&F_ [X$>%
M=9MO"NJ^'+:ZN.W^<?EG_P#7[A\)?!\&@Q:?!Y!/V7T^O].?U'O6/\9M'\.:
M/XGT?7+Z^^S7&3@>GT[=,\T >T>#_AOX;\$Q8\.6/]FP#MG\,GOCM^0KP_\
M:S\>>*O 7@/^W/"MC<W5Q:WNF'_1..I)_)<C&<\8["O5])^*GA"'2Q-+JUM/
M]DM 3B[!)'H >F>QY/M7R1\3OVHO %YJG_"':Y/;7-OJG^A'Z8'Y_GUZ=<4
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MZ <# YS[U_/Q\$YI_&T7]ASSW-M<77YX[X_S]*_5CX/W=]\)8;?PH;X7-O\
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M]?\ /2@#C]>\-_O;CIS_ )_/GV]Z\OFT'-UF#]<5]LP^ [[4K6XGG@R>N/\
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M?6O</V:?B=?>%?B-H]]//S]L_ECT]_ZT ?W7V9M]2MH-4 _X^K0?B#W_ $/
M]L5LU\S?LX?%K2OB%X-T?R)LW'V/OGMSQ_\ K'OBOIF@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K_*Q_X/$_\ E+Q!_P!FL_!C_P!/'Q!K
M_5.K_*Q_X/$_^4O$'_9K/P8_]/'Q!H _E5K_ &:O^#?G_E#5_P $]_\ LA*?
M^I?XDK_&5K_9J_X-^?\ E#5_P3W_ .R$I_ZE_B2@#]CJ*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J":"*>*2&:,2PS<.AY
M# @<'I@< @Y_&IZ* /Y1/^"C7_!-OQ+\#=9UOXS?!+0[C6?@EJ=UJ&L>)?#N
ME6ZOJ7PJ;R\N%8X9OAX#N(8A1X0 W@%&R/QV^ZH(7  ^YCD=>G^<8K_0TN(4
MEB,;@2Q[<,C$89><DYZ8Y^ON*_)_]I7_ ())?LZ?&.ZU7Q=X$2]^!_CF_87M
MS=>$XHKOP/JFHMSNUKP3.8H(%&<*/"]SX69@,E]QP?\ 1+P+^G#A,@R;+N&/
M&6E7E2PU.-*AQGAJ;Q5>-.$(J*XKHI^UK.E&$8RXFI3J5IJE&6(I5:K]I5^6
MS'AQ3DL7@7%S;NXMVNVWMHWK?>VB=D[*R_DK*X_CD_0_G\I_6C;G^.3]!^7R
MC]*_93QA_P $2/VH=(NKC_A$/'/PG\8:<!FU:[U;6/#NHC'7&D?\(T8^G<^+
MQT/3BL[P[_P10_:UU6ZMQK?B7X/^%K''^E7%QX@UC4=3;@D!6T+PVB$G@#,@
M&2,D#FO[+C])GP"E@_KR\6.%/9<O->3Q$))63=Z4N%O;IIM1M[*_,GTBV?,?
MV+G"_P"91"__ &[^>Q^/K/M !Y<]  <$_P!/\_6OT+_86_8%\??M:>)M.U_7
M[&_\+_!'1M6<^*O&3;].O]="*S'PAX0D6-QJ^LIC$US(NSP62L:"2>6*&3]@
M_P!G[_@C/\$?AS<Z?XB^,^N:I\:=?M\7/]A+;1Z!X%B<Y+%M'B6Y\3:Y)"BL
MV+CQ2MF[&-3X47< W[':'HNE>&=*L=#T/3].T?2=+M!9Z;IFF6D>G6%C9PKN
M2*QTRW4QQJF54JJ+R21G<0W\G^-WTXLKK95F/#?@S#$2S&JJE-\9UZ?U>%&G
MRM.?"V%K?O95*CBU"OB(4X44U+ZM*4XN/OY;PURI_7;*2L]'=MWV36B2OJE=
MR[V16\)^$?#_ (&\-:%X0\+:=:Z-X8\-:5I^D:#I5HH6RT[3-(1([>*,#Y4"
M(JKDDDE0Q8DN1UI51DGZ\].OM0I(7)/OZ\<8I6;;CC.:_P S*M6-:/UG$[W<
MFY.[;D]9/JY-MMOJV?9:M_AI_6PZBBBMA!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML?!^QO/%'B#5I[[BUO-3_P!$^G'\O?Z5Y_-\8-*\'W]OH=O!C'].GH?;OWH
M^V/V&_CE?> _&5QX<GOO]&['\S[9_IS7]$_AO4CK&GV^JS?ZBZZ9/&><?AZ]
M3SQ[_P Y'[-/P\T/6-4_X3_59_[-MQ_IO0'Z^_3&37[0?#'XY>%=2^S^%?MW
M^C6O^A?:^G^1_6@#[(K/FA_R?\_D<>H(K'T?6-*U+'V&^^TYS[X[?R_/^=_@
M2SS3S6_V?G'^E$ 8'<] <=CC\Z (/.@AE/0X_P#K_CZ=,?X:$)M_+\_CIG^O
MZ_F/QKGXKS2M8E'V&>VN;BU].WI^/7T_"N7\>>*I_"MA<S_Z-]G_ ,_R_P Y
MXH \_P#C-\;-#\!:-J%P)Q]HMK/-H1Z\?CVZ\]*_%_QAK&J_'ZU\8WU]??9K
MBUO/L5I:8_\ K?S]OPS_ -ISQY<>*O%&H3V.N7-S;G_ETM+S^A]C_,UX/H6O
M:K#]GG@^TVUO_P OGM_GJ#C@T ? ^O\ ['/Q;_MG4-<_LO4O[/NNEW]CX'']
M?Q]^E?2'[.OA7Q'X5NO[#US2KG4^0++]._;_ #P*_2C6/CQX._X5+J&E9TT:
MQ]CS9]1TXZ^G^>G%?'_P]^,VAV>O8OH--MKC_(^G/3T^AS0!^H'[.WBK2O-_
MX0#Q'!_9MQ=9LK/[6>_X8'^<^M<?\3O@_!X#U[4/MT_^CZ]>&]L^/_K<X_F*
M^5_!_P 5+'_A;^G_ .G6Q/VSKV/X_I^E?M1J6F^!_C-X-T^X\^VN=0TNSXSZ
M?YY/;TH _%_XS> ['1_"]Q?0?\^8_'GI7Y+Z]>>(_'M_<0?VY]FT[2_]"^R?
MC^OY_@:_<CX\:#!Y5QX<@^TW-QWZ#G^?XD]>N.WD'@_]C^QU+P'K%]?0"VU#
M_B:7H_IUZ?IUH ^)O@GKVE>#XM/L9[ZVN;C'_P"KT[<?_JK[H,WA74M>\/SP
M6/\ I%U_9?J!WX_7\*^#]>T?0_"NJ7'A778-2T[4-+/^A_Z'C^T/8X_2O6/A
MO\5/MFLZ?!/!]F_LO_0?]+_ 9_D<<=NM '[<7GA7P?-\+K?R(+;^T/L?'/ ]
M/\^OYU\4>*O@#JMY]GU:>>V^P6MY]M^R?8QGO_\ JK[_ /@G9Z5\5/!&G^1/
M;$6MG_GC/]/<].?HC4OAC8WF@_V2(+;GKC_/'^>1Q0!^"\W[+E]\0_&7]N00
M?\2_[9^6?\\]^W:OKCPW^Q_!#]G^PV(R/\C\N?:OT_\ !_PW\.>#],^P_8?M
M-Q[_ )#'/MWSQ7H-G9V,,7[B#[+_ (_7/X^WK0!^;%G^Q;/#+<7UC_HUQ=#Z
M]?QZ_3..>M>C^#_V4?L<O_$\_P!)M_\ /^>>!V[5]\0Q>3&1W_EZ?TJO_JO\
MYSG\O3VZ?F >':#\!_ASX0%Q<0Z5;7%R1G!R"/K_ )XZ5\L?M(:QX5@\.:CI
M4]C;6W^A_K_^O_/-?H!>:E!]EN/W]MCH,?Y_S^%?D1^UI\/?%6OW]QJNE3W/
MV?\ Y]+3IQGK_P#J_/% 'YG:9IMC-KVL>1_R#^!G],?X]J\_T'X>S^,->N(-
M<_Y!^,67O^/T^G/'%>\1?#V"&U\_5;ZYTVXM;S_3?;\O;U_PKL-2\8>#M'^S
MPZ']FN;BUY_#G/\ ^J@#V?X8^"?^$#T:WG@@^S:?_3M_G_&M'XG:Q8PZS_;D
M]]]FT<Y^GU]/\^@%?GQJ7[>&K:!XW_X16^TK_B7_ /7G_3G/O^E>_P#Q4U*#
MXM? RXU30[ZYMM0^QZI_QZ?_ *S^GMSVH Y>#QYX<TWQ:;[2M<MKJ>Z_X\_\
M\=O_ *_I7T1K'Q4\?WGA*XT/5?M-U;_8\BT/IWSQ^'_UJ_)?X&^ _&,/C*WG
MUP7/V>UO3_Q]_P"<9'0Y[=NM?LAH.@ZYXDNM0L;'2O\ B76MG_Q]_8^V/Q_#
MM^IH _,_6/"L'CS7KC2K[[3IMQ]LS_IG;Z=^.G]1VY_XM>%OC5\*_#FCS^!_
M$?VFWX_X]+/W_P \#U^E?7$WP]_TK6//GMK;4+76/^?SV^GMU[_ABJ]IXJ^Q
MRZAX5\50:;<V_P#QY6=Y[_H* +'PK\;>/_B1\#-1L?'\]S<W%K9_\O>/KG\O
M3&236Q^P3^TA!\'_ !E<>!]<_P!&T>ZO/L5[=C]?\]/6NPO/[*T'PY<06,]M
M;6]U9_\ 'I_GC_.*_/>&'[9\0=0\B>VMO],_Y=+OIV[]: /W@_; _:NU7PWI
M>C_\(!_Q,N=+O1]DP>^.I_3IVKP?X8_MO3^*OL]CJD]S;>(-4_Z?.>O/_P"K
MIGKUKY?^,WPQ\8Z/X<T_7//N=2T__A&]+Z^I//;V_*OSGT?XD?\ "*^([>^G
MS;7%K]/K^GY_3L ?N!XP^-FJZE=:A?>([&YMKB[L_L5G]?Q__6*_*?QA\;/$
M>@_$;4+&^GN?L]U>?Z'C_/H.GH:](O/B%KGCS0=/OX?^77]#_GBOB_XV:E/_
M ,)1IYG_ ./CI]LX_/M0!^R'[(O[8UC]J^PWVJ_9M0_Y]+J\SC],'Z5^J'_#
M5W@>:U-O?:Y;6USU_7VS],<_AC _EP^%6@P31:?JL$_V:X^V?\??KZ^O^>E?
MIOH^@Z'KW@VW\B^%SJ'V/_G\_P#KC\/IR: /THTW]HK['+<:K8ZK_:6G]!_D
MY'8XKT?X>_M.?#KXD7Y\*WM]:BYQ_P _GMQGOC ]>OOFOQ _X3N?P'='0[Z>
MY-O=?Z%S_3.>M?0'P3\*^#O&WBW3_L.N:GINH?\ 3IZ]/?\ ^M0!^[^G"RB4
MBPB,\!Z$ ']#P<8XZ=Z_-C]LR:"\U[3[&?5?LY^QY_SQ[\^GK7W_ .%='@\'
MZ#;P&]U+4OLMG_R]_7OZ\\=:_%#]H2S\1^,/B#XHG^W:E]GM;S5/L?&>^#_G
MGID\XH \'^-?BKQ5X)\+ZA_PCFJW-S_H?_+KS^?^%?F/_P +4\5:GXCM[[Q'
M?7/VBUO/QX_/I^@]:]0^,W_"5:9]HL;[5=2%OG'-X?S_ ,?ZU\3WFO3PW7G_
M /'S]E_S_G]?8 _>CP?\2/''Q"^%_P#8?D7-SI_V/V_SV_\ KU\+ZQX/_L'6
M=0^WZK_9OVJ\_P"/3]??T_7I5C]F/]IR#38K?PYJMN+:W./SX_R,=^]?7'B3
MPKX5^)%K]N@GMOM%T?U/K_3C\0* ,?X,_!,:]+;^(Y]5MOL^,=?_ ->/\BOK
MCXA2ZYX;\!W$%C/]IT^U^F0/\GCT^G7J/V7?@GXCLY8(/])N='_Z>_8_AW_7
MO7O'QX\!ZK9V!L8-*MAI_P!CY_QZ^OY],T ?S#_&#1_%7C#Q1;S_ .D_9[J\
M_P /IT].GY58\!PG3;7R+_/^BWGT'MU[_C_C7Z4:]\$]5GEN+ZXTK[-;Y'^!
M_P ]>.:Y>S^#-C-%Y$$%M_I6/TQ_/MG^N: /D?Q)_:MYH-Q?Z'_GC^?!KP?P
MW\;-5T?5+BQUR"Y[_P"./I[_ /UJ_5B\^'MCX5L+C2OL'VD_Y]L5^:WQ:\$W
MVL>([BQTK0[:V^U?\O=I9^_T_EV^M 'US\'_ (P033?;K'2;FVQ_R]G Z=O3
MW_\ UU]8>*O%6N?\)'<:Y!JAMOLOAO2[WG/^?>O@#]GKX2^(O#<MS_PD?VG[
M/:_Y_P#U?6OJ?QMXD\.3:-<V,]]]FN./Y>O Q[\]_P 0#WC]G7]H35;WQO\
M8=6US_1_MGY>^?I^=?IAXD\;>!_B=:_8=*T/_A)-0M;/_3!:?YR?P_\ KU_/
MOX#\>:'H]U!Y'V;K_P ??3^8Y_IVK]6/V2_&/AS^U!?3WUK_ *5CG\/SY_\
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M0_E7Y#S:;?377V&#_1KBU_SS]/Y>O%>H>&]2OK,6]C?3_P#'KCMS]>_O^(H
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M \223EM*M<\9 M,C/U(!QT'0?2O@#XS?LNZ5H.M?\)'807/]G\?Z)9\@=?\
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M@_;O"L]M<ZA:\?9.W^>OXU]D?M40_#G6+K4+'PK>W/0_\>G'UZ?_ *_:N/\
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M7^#O@GX'\*Z-_94]A;7/V;CT(]^Q.?\ ]9KN-!\'Z'X;^T3Z58VUKZ'Z>O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^5C_P>)_\I>(/^S6?
M@Q_Z>/B#7^J=7^5C_P 'B?\ REX@_P"S6?@Q_P"GCX@T ?RJU_LU?\&_/_*&
MK_@GO_V0E/\ U+_$E?XRM?[-7_!OS_RAJ_X)[_\ 9"4_]2_Q)0!^QU%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'PW_ &J)_-N+'2K[GG\3UZ_GZ<&L_P ;?MO>*O#=U<6-]?7.?Y?U]?\ ]5?
M_P *]'\50VOVZ;2M2MM0_P"/+/V/G\O\XY]Z^R/@_P#LEP?&S5/[5\8SW-M_
MV^9^O7CZ_E0!T'[/?[8U]-XWU'[=/_H_V//_ !^'C_#UZ^E?5'QF_:$\'>)/
MA]K%C/KEM;:A=?\ UL\#\?Z>AZCPK^PW\./"L5Q]AG_TC['_ ,_G_P!;WZ^F
M.YKXW_:H_8F\8WGARXU3PKJO_;I]LXQ[_P"?0<\T ?G/X:\-ZY#XMN-<AOO[
M;T_5+S[%]1[<?Y^E>@>-M2\F6VTJ"#[-^OT]/\X[\US]G\-_&/@BZ_L.?[3_
M **/^/N[ZCK_ )^M5]>T>^T&UN-5N/M-SJ'Z<_GQ_*@#P?QYH^E0R^?!KG_$
MPM<?Z(>N>^/\]*^/]8O/&-YXC\^">ZMOLO;G'^/X5]D:#X/U7QYK-Q?7V+6X
M_P#U]>W/^->3^//AOKGAO5+C]_;?9[J\_P YQ_D'O0!CZ#J7CC1[JW\<?;KG
M[/I?^FY'L?K_ /J-?N!^P?\ M%:'>6%Q8^(]5_Y"G'^E\CGZ_P#Z_P"OXK^)
M;._T?X7ZA8V/^D_:K/C'^?\ /7Z\_P# 'QY?:/+;_P"D7-M<6O\ A_GV';TH
M _JP\8>"? ^I2_\ "1V'V:Z_I_GI_G-;^@PP:E89@@^S:/I?^F_Y^F?PKY _
M91^(7BKQMI=O8ZK!]IT_/3['^>/Q_P \D5],?$B\LK/2[B>">YTVXM?^/RT^
MO7^I_P#KT ?C1^W+>>'/$GQ+N-<TG2OLMOI=YW_'C _I^E>;?"7PK/\ $B*X
M^P_\2W[+[8S_ "_3\*^N?CE\-]#^)WA>X_LJ<?Z+_P ?MX/QYY]OZXKS7P'\
M'['3=&_M72M<N;:XM?\ 0O\ C\Z>GM_,T ?I3^R+X5USX8^#;BXOM5S_ *'Z
MGOQ_]?/]:W_^&T;?PYXR@T.^GS]JO/L7///^?U K\X(?C-XQ\-VMQX<%]FWZ
M<WO;'^?U]37+Z/X5/Q(UFWGN+ZY^T?;/^72\_#_]?\J /Z0-&^(^E:CHW]J"
M;[0!V& .>@XX].V!7G^C_&#^T_$?V'_EW]/7KSQU_D<5^;^@Z/XX\!^'+B"^
MU74O['M?^7N[O>G4^W^?K7Q_XD_:*U3P??ZA/!?7/V8<?YQV_P#U=\4 ?N1X
MU_:A\&^#M4N+&]GMLVPY_P!,&3^F#V[5\7?&O]O6PTNTQH-Z ,YP+P <>PP/
M3//ZU^/'Q(_:0U7QM]G@\\_:!_Q^7?7_ /5QU_#GO7D]YINN>)+ &>^'V?KD
M_3]3_GZ 'Z4:#^W5XC\2>(]/@_M6Y_L_'^F'_/ISGV[>GV!9_'C0]8M;>QGG
MMM2^U=^O3CZ_RZ<5_./_ ,(KXJT>7R+&>Y_TK/K[]/IU'KG\*^J/@_XPU7P1
M-;P:W/J5S<77^?\ /\_0 _0CX\_#&W\8>'+B?PY/]FN+K'U_,?YQ^%?F?_PK
MWQCX)\4>??3W/]G^^.^1_G\Z_6#X8WFK>-XK>WG^S6QNO^/.T''U_P _3K6C
M\;/V>]<O-!-Q8V/K_I><?YZ^F..GJ ?DM\2/@;I7B2UM_%6E0?Z1R;SZ^F/\
M]ZV/!/BH^&[3_A'(/^/?\ORX_P XYKZ0TWX,^./#>EZAY\%S<VYL^P_,?F.<
M?6OD>'_B0ZH+[5=*U*VN/MG_ "]V?;_/'^1@ ^E]!AU76;JW@L;'[+;?\_>?
MRQV[5]@ZE\6O$?@GP'X7\#^#K'[3X@N_]"^UVGISFOF?PK\6K&[\+W%C!!IM
MM/\ ].EF3T[?Y].V:Z#PKX)GUC_A#_$<^JW/^BW@O<_;,=/\]: //_&'@_Q_
MX/M;CQCXXGN;<:I>'_C[SZ<_Y_6O+]=FT/69;?7)]5ML?G^GO^AK]./C]9^%
M?$GPJ%C?0:E<W%K9YL_LG]>IZ=\?_6_#^'Q5JNCW^H6.N6(MK<_\>?\ H?\
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M(_Q)K'B/3=4_<?VE_P#J[]AS_C7U1^SKX]US[5]NG'^D6MX>_P"!Y/\ ]?\
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M>O?Z>^/\\UX]X]_9[G\!VG]JP?Z3_P OOTYX_/U]>]6-2_;2TJ&_N/[*L?\
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M:_ _P39^=JEO/!T_I_7]/>OZ0/V,[,P_"KP_SS_R^#J._7K_ /J[=* /QO\
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M_ WX,SSV%Q/JNJVW_'GFS'VSG';Z^W^<>SZ9\-X--^T3_8=2_M#/^AFUL_\
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MJ: /4/$DT_A7QE]BMYQ]GN^G;Z^A_ISZ5\G_ +2$/B/0=+N-5T.:YMM0NO\
MCS'X=/\ /N*Y?]HKQCXC^'OC+1X(/[;U+%Y_Q]C_ (F7/7KZ5[!9_&S2O$GA
M+3['Q'I-M<ZA_P N?^A_7@#I[XSP,T 9_P#P3?\ C9\8KSQEI_ASQ'?:D=/M
M;S_E[^OOV]O3KCK7Z@?'[]M[0_AC8ZAI7GC^V/LG_/YR#T/'T.,_KFN7_8A^
M$MO]JN/'\^E6UM_:G_3GZ_IGK^@KX'_X*3>#YYOBAI\$'V:VT^Z_Y>^G.>_Y
M]0,?T /#[S_@HWXQU+5-0@^WW/V?_ES_ -,_F3_0?TJO9_MO?$::7[0+ZY-L
M;SO_ /6]3Z]_>OE_Q[\,/#G@_1K?5;Z^M\_].EX3^'\NO-;'@^'P!KVE_O\
M5;:V^R\6?^F=?_U]_P"M '[H?LT_ML3^*K33['QQ/]F]KO@'_'GT]2,U]7ZQ
MK$'Q4UG3_P#A#M<_\ \_Y_Q]:_E@\2>,)_!TUQ/87VI6UOV^R=.G^?T^E>H?
M!_X_^(]"NO/TKQC<\=/M>L>W/;_Z_P"% ']=&@V=]H6EV]A/-]JU#\_\^GIZ
M^E7[S38-9TNXLM4L>,8QCKGW_P Y!XQ@$_A3\/?VY-5TVZ\/V-]JO]I?\_G_
M #$LX_/V]/7GBOL^;]O#0[/^SYYX+FZM^O\ HEGZC_ZQZ] : .X^/_[-.E>)
M/"]Q_P (YI7^D6MGTZ^_]<>XK\/_ (P>"I_A[=:Q8WT'_$PM;/V]?P_//?BO
MZ3_AO\3_  K\3-!L-=TK5;<_VI99^QW5V,XX_,GK@<Y''7%?FO\ MK_LB^)/
M'OBRV\2>!P;BXNP#>!N--&1GYL'J.<\GIQ0!\,?LWZEKEYX2G@^P_P"D6O7^
M1]O\#GFNQ\2?$B^F\1W&DV,'V86EG_IGK^G'^<8KZOT']G6^^&/P;N+B?%MK
M%I9_Z9^/_P!;Z]J_+?4M2GTWX@ZC]NG.?R/YC^0H ]0F^,L^@W6H0?;_ +-<
M?;/_ -7]<9_IBN?U+Q)?3?ZB_P#^/K'X9_'C\?I[5R_BJ'2KN+B#_CZ_Y>^W
M;/\ G\CFN/T&:PO=9_LKS\_K^G^1Z=: -@_%K_A&]4\B^U7\<_\ U_P[=?:O
M1X?B=_;/V?R+[[3;W7/KGC\/\]:^#_C-\-]<O-9N)[&>Y_SQGUZ'_/%4/@_-
MXXT&6XM]<S]GTO\ Y_.G^?\ /T /U)^ ^FV,/Q5T>>QO_LUQ=?RZ=_I^9/X_
MT;:0+T:9I\1Q<'&+PGCU/4]OI7\>'[-_C#7/%7[1NGP:5JO_ !Z7G4WG]/\
M/T/%?T\>,?B#KG@GP%]NG_Y"'V/')_SZ?XT >L^-O^%5>:/^$J_LW[1_T]Y]
M/?M^O3OBO'M>^*?P/\!Z-J$__$M_L^U'OV_S]*_!_P"/'[0GCC7O$=QG5;FV
M/VS_ )=+S_ZV/7TKC]!^(7]L'3]*US5=2N?M7_'X+N\_7KQR?7/K0!^L'B7P
MK\.OC!?P:YI4%M_9_?C^H'^>#WKJ-2^#_P .=2\.'2M#TJVMM0^N?\_S'K7+
M_LZZ#!INE6]]]NMKG3^O_'Y_]?UP?\XKZ8^)WC#P=X;\)?VKHD^F_P!L?8\?
M9/Q/'\OY4 ?$]Y\$[[3=?T^^TJ#_ $BU_P#K^G/Y?_J_4_X00ZA_PB5M!K0Y
M^Q@$'T)Y/'H,X_*OBCP?^T)I5Y8&^US2C;?Z9_SY<_Y/)ZU[1KW[0D,.CZ/?
M>%8+:Y-U_P ?G^>/\?3CB@#Q?]K2\GT*_N-5@_T:V^Q_S_S[<Y^E?B_XP^,U
M]!JGVB">Y'_UN*_HX^)'@+2OC9X-M_\ EVN+NS_TSOU_7U'OVYK\Y_'G[)?@
M?P'I=Q]N@^TW&/\ E[^A_(?J?3B@#\Y_&'Q:L=>\!VXX^T_C_CGC)^M? \/C
M#5?#?BC^U=*ON/MG3N/U_'^5?M!!\*_AQKUA<:5?_9K;[+_B/T_SZ5S$W['^
MDZQ%Y_AS^Q+GVN^/S'XX_P @4 >'?"O]JXWFE_8=5U7_ $C_ )<[3ITXS_/_
M #U7_0?$GBG^W-5OO]'^V'Z^^.1QV.><UC?&#]CG7/!]A_:MC!_Q,?\ ES^R
M8P/KGCO_ $Z\U\,:EIOQ-\-77[^WUOV_Y#/TY_Q]\4 ?K_KWQR^&6C^ [C0_
MMVFVUQ]C_$9[_P#ZZ_+CQ)\6M+U+6=0^PC[2?MG^A\?ET],_X]Z\_P!2UC7+
MS2_L)TK6_P"T/^O,XX_/ZY_#FN_^'O[/?BK6+#^W+[2KFV[?Z79=>?Y'_.<\
M@'H'@/Q5/-=6^J_\^O7U]/\ //2OU0^ /[;$_@^P_LK7.O\ U^=\X/\ +_\
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M@Q_Z>/B#0!_*K7^S5_P;\_\ *&K_ ()[_P#9"4_]2_Q)7^,K7^S5_P &_/\
MRAJ_X)[_ /9"4_\ 4O\ $E '['4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7+^))KZ;PYJ&J_;OM.H>]YUQGVYSGT- 'I'AO7['Q)J'V>^OOW_^(Z^OI_\
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M />/%7P]T/1[#6!!/;7.L:#>?8@?3/O^G?\ I7'Z/IO[W3[[7-*_T>TO._\
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M&6FRW'GZ'<Z:+7^GX<CDCU_&OJCPM\5+[3;"X@OH/^/7/^E_YZ9SUQFOW/\
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M9]#P?MTVBFW/_/SMSU_VCCK7E_BKQ)\*]'A^W:K/HF;7_GT_L;M_GCW_  -
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M1-_PBL/@W6//^S7/^A_\>G^>>XK[@U+]B;Q'INC7%]!8?:;?_ITSCOW/X_\
MUZ^3]2^$NJ^"=>\CQ5H>M_V.>+S_ $/\?YYH \G\'ZGX5U*Z^PV-C;6UQ_\
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M_&GQA:V]_!X5U+3+?2Q]M]L]<?UY_E74? [3-#\$^*+?58)[C4H+6\_Y>_\
MB9?YY]O>OZF/@;9^%?%7PYT_5;>QMK;_ )<O^//M@8Z]O7CU H _ ?3?@QX<
MA^'UQ_PG_A2VMM8^Q ?Z7S_,?_K^F:_*_7O"NJV7C>X@\.:5]FT_[9_RZ?7
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M_P#J_P >?_U8_A7]I#Q'9W5QX5GTJYMNUI_GZ^Y [5]L:]X;L?"GBVX@N/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;'A6;X.^%?&]OH?B.QTW3=0N_P#CS_KZYKS_ ,-P:K\)?"6CV-C_ *3<6O\
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M]AG@NKFXNO\ 0AU__6..3_\ 6KZ@U+]GO5? <MO_ ,)'8W.I?:N^/\"<^O\
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M\>X_PH _,[]JCX>ZK\-Y;C2M)_PS]/7_ .M7YCW?Q.U6&ZN-*G@)N/QQ^/\
M^K]*_HH_:B^%=]-XH_?C[3]J'/\ G/./>OQN^)W[--]#XMN+Z"W_ $_/'M0!
M\,6>I>(YM?U#'VG_ (_.?\.GT/TK[(\!_$+Q5>6NG^')X+G[.+S_ ",>IX_.
MN'T?X,:Y9ZS<WT\ Q]L]OZ=OU]J^^/@S\'_^$P_L^QL;'_B8?:_Y>GT[9_2@
M#]*/V#_AQ?"YT^^OO^/?I_D>Q^O-?M]9V=OI\4 @@%OV(S^A'^<YKY!_9C^#
M]]X)\+Z/]N_T:YM;/L?3^5?1'CS4KZSTNX\C\.W?^GI0!6^(7Q.TGP383SF>
MV^T#U]<8YP?\<>HZU^9'QL_;%G@TO4!8WV!P/^/P#ITZ>G3_ .M7G_[0GBKQ
M'-]H@-]^IXQW/_UA7X[_ !4U[Q'YMQ;C[2;?M^/Y_KZ?A0!ZAX\_:0\5>/)=
M0@%_<_\ 'Y[_ .?U].^*^?[R'^TK^WGN.+@G_)S_ )'ZFO-_#<\\-_\ O_T_
MGU/_ .O\:]HTVSQ=6\Y/^?R^N.N1Z8H Y_XA^#]5U+0;?]Q_3_./_P!?:M#]
MFG0;[PKXC^W3P>WT]S_@>^>IK[(ATW2KSPY^_@&?L?X_4]?Y_C7E_P#;VAV=
MA^X^S?:+4GT^GT_SZ4 ?6$.L07M_;S_3'I_DY[U^E'[*]GY-_I\__P"OVQ[>
MYZFOQ0L_&W[W3YX)\<_Y[>HK]/\ ]FGXJ6\-UH\'GVW;KZ?G],^_Y4 ?K_=R
MSBY A[8'\@>O';_.<U\D?&;09Y;JXU7S_LUO:_\ 'Y@Y]O;_ /7BOK?3;R&\
ML+>_'>S'/L/3ZX_7FOS _;V\>>,='\+ZA8^'-*U*YN+JS_Y=+/WZX_ST_( ^
MN?@_XJ\.:S8'2?MUMJ5P,_YZUPW[0GP\^$FO:+J&DZY/INFW%U_G\.]?F!_P
M3QUCQC-XMN/^$JGU.V^U7FJ9^U^_OSZ\_I7W-^V7^S)XJ^*NEW$_@[Q'=:9<
MW0Q: WFL9!/8D9'Z]^O- 'XD?M4?L?V-G+<>,?!H-SI]J>;NTL_P]SCJ.]</
M^S?\$_B!XPB_X3'PK<7/V?2_]-YZXX[]OS_2OZ&/@U^RP-&^"&H>#O'$XUO6
M+JTU0?;,XY)]?7^9Z9-? _@/0=5^ /C?6/AS8_9K:WU2\^Q'[7^?I_+ZCJ30
M!Y?X;\27^I6'B#S_ /D(Z59ZI9?3@?Y_/BJ'@/XV>/\ 6/[/\ 3Z5<_V/=#[
M%]L_'_\ 5VX[]*^__"O[(O\ ;TMQJL$_V8:I9_;>N.O^/^?6OIGPK\'_ (9?
M"71M'@URQTVYUC['Q_GT_#ZCB@#Y^^'O[&?@?Q)X<$^N6-M<_:C]M_X\^?7G
M_/I]*]8TW]CGP19Z%Y$%Z?L_&;7[&,#V/.<_ICOS@^P7GQ@\':#*-#@@_P!'
MN;/]>G0'I^O'K7B_BK]JC2M'EUC0_L-S;?\ /G=_IW[>E 'D_C;P3X<^$MUI
M^E>'/LW_ !-;W[%><<]_\_RKWC1_AO8Z;X(U#5=*U7_B8:I9F]__ %=N_3I[
MYK\+_CQ^TYKFI:]<3PWW^CVMX3^9/_Z^WX\5[Q^S3^TCKGB35/#^AZK?7-SI
M]UG^77_)X'MU /2/&&L7WAJP\3V/B2^QI_V,_P#'WG_#_'CBORWU+QM\,M-\
M6W$]C!;7-P,?YZ=>/_KXQ7ZL?MF?!GQ'XPB^W^#A<_9[JS'VS[)SVZ_R_G7X
M3P_ WQ5X)\>7&JZYC[/WM+OW]!^/Y#WQ0![ /$>AP^+;?7!8VW_7I[?E_GZ=
M?</#?QF_M+QOX?L;&Q^S6]U9_P"F?X?X_P LUY=H/@^^\2>([?\ T'[-;GI_
MG_('N<FOTYF_8A_X2KX<Z?XK\*P'3=8M;+2^G^>_.?SSUH Y?Q)X;^'-YK.C
MP?8;:YUB[_EWY_S].<5^N_P(AOM!\+:?!]@%O;VNC_Z'D9_'T[=^#WS7Y0?!
MGX&^,='\;^'SXJT/4KG[+>?\??3GIZ=NO?GCBOW0\-Z=Y.C6\!A_Y<^.Q]L<
M\GVY/>@#\Z/VM-=G\;:-J'AS[=]FG]/\^WMWSVK\%OC9\)?!_AO[//KFJ_9K
MC[9_SY?Y_I]!U'])/Q:^!L^I2W&JV,%S<W'7_1,]^_7Z_P"37PO\6OV%8/BI
M8"?^U;?3=0Y_T2[O.1^ !_ESF@#\]O@S_P *!L[""^\1ZY;?^ 73_/\ 3ZU^
MW'P]^,WPKT?X2^1X'U6VU/[+B]_T0^G\Z_+?Q)_P2O\ '&L>![>QT/7+;^T/
ML?\ RYWF>V>G;UKZP_9C^!NJ?LZVNG^'/B+?6US;ZI_H7^E\?Y]C[_4T ?3'
MPQ_:H^'.O:7<7WB.RMK?4;49_P!+&>/U_/\ *O@_]J[]M?X<^)8;_0]#^S6V
MH6I_KC\^GI_.OU \5_LT_#+6-!UF^TJWN=-/V/\ Y_/PQW^OK7\N_P 6OV:=
M<\2?%#Q1;^')[FYMK6\U3_E\SU[X[?K]/4 [#P?^T)XXO#J%C8SW5S;_ /7Y
M],?SZ?AS7G_BK4K[Q5%<3^(\VWMU_$=\^_'M7A]GJ7B/]GO6=8L=5L+FY^R7
MG:S'MV^I_P#KXKL+SQX/B=8 0?Z+<=3:?YST^OX"@"?X5^*K[3?$7_$CG^R_
M9>>?Y>G]?Z>\_$*'7/$EAYXOKG^T/4_Y'Z=.WI7S_P"#[.#P?]HGGYN !_G]
M<^I]>#7I%GX\@U*_MX(!SSC_ /7_ /6_^N ?J!_P33O+[P?KUO!KE_Q==KO^
MGO\ 7'-?L!\>?@;X5^+7ASFQMOM'_'[]K^O^&>X_I7X;_"34I_#=_H_B.#_1
MOLN./P_+_/OFOV8F^.5C#\+[>^\^V^T:I:?8O?N./_K=J /P/^,'PVG^ /C;
M4#8P&Y^U7G^A_7';]?\ ' Q7+^%;.#4HKC_A(['_ $BZ[GIZ9Q@=^/TZ5[Q\
M8/&T'C'QE<3ZY!_H]K>C[&,<8]_J/T_"J^CZEX<AO[C[=9?\N?\ H=V.?;UZ
M_P"'7- 'SO\ M(ZCXJ^&.C>'Y_#D M=/NM'SBT_R>?PR?R%<?\!_VP/B;X/E
M_LK1-*_M*XM>EY]LSGJ1Q^GXU[!^TM9ZK\0K71['2?LW]GVMGS_AV^O3@^U?
M._PK^&/]CW_V[R+G[1],YX].OU/3OUH ^X/A[^T)KGQ"NM0G\?V/V:X_MC/^
MEWGZGGV_Q]:^P/ACX\@U[QEI^ASZ5;_V/]LZ9_SUZ8Z_C7XG^-M-U71Y;B>Q
MGN>=8_Y=+P>_^'\J^Z/V2_%4_P!OM_/G_P!)Y/\ I?T_R?KQVH _2CXS?LZP
M:\;?5M#TH_\ 'F.+3KZ?7G'%?F/\0O@/KMGXC_T&#_CUQZ^O_P!?O7]"'PKU
M*?7M*-CJMA_H_P!C_P"/N[L\'/U/'KGT_$FN'\5? :QU+Q']H\C_ $>Z_D#^
M@]/IB@#\)_!_PFUS7H=0^W3W/^B_C_7W'X]JKZ#\']#O-9N((-5^S:Q:]?3H
M/_U=/?VK]6)OV;_^%>^([C5?])N=/NO^76T_7\.WI],U\;_&#X5GQ)XR_P"*
M.@U+1/\ 3/\ C[Z?Y^AY'7I0!\?_ !L\_1]+M_/U7^TK?2[W/V3C/Y_K^?TK
MS;PK^T)X5U*PM[&QL;73=8M?^7OCKV!_KVY^E:/[47P'\<>%;0WUCJMQ<V_V
M/_3!=WGKC/TKY/\ A[\*_%5Y8V_B/58/LUO:_P#/IC]/\_EUH ^J)OB1XQL_
M%!UR>WN=2N/L?_'W^?\ 3UYZ>U6/&VO>(_%]K_:M]!<GW^N!],?YXK]$/@/X
M)\&Z]X7T:^GL;;[/_P >7^EV?_$SQUY^G..?_K?;$/[*/PY\;:7_ *#8_P!F
MW'&/7/?G'X]_PZ4 ?S/PWGG7_P#R"OLWV7_C\N_P/&/ISC^?%?6'AN:#Q)H-
MO!I7_'QT_/O]/\/KG]"/BI^PW/H-KJ'D06USI_\ TZ<]O;M_*OBZS^">J^";
MK[#!??Z1=?\ +IVZ\^XZ^W'7W /2='\!WT.@B>"?_CU'KC SVZ#_  ^E;'AN
M\L?"MU]NOK'[5W^R#MQ_]:OG?QAXP\5?#W4-/G_M6VN;>UO/],M/7Z?_ %OY
M5]$?!_QAH?CRZ&N7T!^S\_Z)_D#K0!]P?"O4OAC"+?Q5?:5IOVCZ#'Z_7V]^
MM'Q@_;V\-^";6XTK2H+?_CS[?U__ %=/RKXW\8?%2QT'Q&;&Q@N?L_\ SZ?@
M?Q]3]*^9YOB%X'U+QEJ&J^,=#U+^S[6\_P"7K_/J* /4?ACX\U7XS>,M0OI_
MM-M;W1__ %]?7VS_ $K]3_!/A72O@_86_B35=6_T?['C_/OGTXQ^5?._[.OQ
M._9LU[2]0L=*@MM-UG['_H?VO^QOZ]_S]NE>+_M@?&""ST:XT.Q\1VUK_H?^
MAG[9GT]/KQ_3 H \_P#C-\?O"NL?&[3[[0[ZU%Q:ZQ]/3TZC].W%?MQ\&?'F
MA^,/A]IWGZY;?:/L9LC[=!^)Z#';WZ'^*?\ LS7-2\1W.JP:Y]IN/MG_ #^?
MUQZ>F:^P/@G\2/C3#XDT_2O[=U+^QS_T^?B/\_J>,@']8'AOX>^#M'O_ .U;
M&"VN=0N_^7HC_P"O^M?._P 2/@/KOCSQE<7T\]S;6_V,_8^/K^!YK/\ V=OC
MCX;N-%\/Z'J%[]JU\YR/M?!R,8(/'/?/!Z'/%?;$MY8?:K>>>;'VJS_S^/K_
M /KH _GO_:$\!^(_ACKUQJN+GK_3 Q[_ .>U?+]G^TY!H,OV?7)_;-W_ (9_
M^N:_>?\ ;%^'NE^*O"-Q?6-O]HN/L9_X]/0$@'CCGK@=">V#7\S'Q:^%?]L>
M(_[*L3_R^?Y[''O^G:@#WCQ5^U=H?_".7'_"*_9;;4+K_GT]O3KTQ_*OS7O/
MC-XJUCQ'J'VZ>X_TK/X_7TKVB;]GOQ'I$L\]C#<ZE;YS_CS^?^<57L_@//K%
MU_J/LUQGGG\CQCWZT >+Z;XP\1Z/XCM]5L9[G_C\/3OS_GU^G2OZ8?V"?B1>
MS>#;>?7+[_/3]/\ /.#7X;WG[/>JV?\ 9_[C\A_@._\ D=Z_0_X/^%?'^FW7
MA_0]+@N?[/\ ^)7V]#Z>_?GN: /V0^+7P]L?BUI?GP3_ &FXM;,_J/\ ]7!_
M#TK\3_%7Q"OO ?C?4/#GB/0_L^GVO'VO&?I^O7ZU^P&C^"?''A71O/\ [5_X
MF'7[)=]OT_R/3M\;_M.:;X<U+PYJ/]JV-M;:P,?Z7]C_ /U=OPS^H!^<_P 2
M/VD/#EY=?V'X<@MO7_13_GI^GYFOEB\T&>\UFWUS[=T_TWV'MG'^-<;KTT&C
M^(]0_P"74#_G[X_/KGIW_+M7D&I?$C5;.Z^PP3_G^?U[^@'MB@#](-,^+4\V
MC6^A0?Z3<>W'UQ_]8'\C7ZP?\$T[/59K_P 07U]8_P#'U9\D_B>_;K^?-?S7
M_#'7M<F\6Z?Y_P#Q[W7XYY.?0\=/U%?UO_L%0V,/P]M[[R2+FZM!C\Q^A QT
MZGU% 'WC>?Z':W\\\_N/\]0"/\?2ORW_ &BOBU?3:K<:5!./L]K[]>X_7CT]
MJ_1#XG:E/IGA'4+[S^G Q[?_ *A7XC?&S7O.NKB?_EXX]/;KQ[_RS0!!\$]?
MGO/B7_K_ /ESU0=/\Y__ %_4_P!#%?S/_L]ZE/-\2SW_ -#U3M^1Y_K]:_I@
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BDE6&
M,R2<!1DXY_S]:P-9US2/#FE:AKNM:G8Z/I&BV>HZOJVJZC<K8:?8Z9I"[]8U
M349<QPK%;HKRNTF(U7#LP&<?Y;?_  7=_P"#A[XO?M_^//'/[./[)WB_Q1\,
M_P!AK0Y]4\*7XTNY&E>(OVGQ'=2)KWC;QKJLCKKVC?#F8JB>"/A@FV.?PLS^
M*?'\'VRZM?"/@P _N6_::_X."?\ @D=^R?KEWX-^)7[8/@[Q7XXTRZU32M1\
M+_!G1_%_QIO-)U70Y_[)UK2=8U?X=>'O%7A?0/$%O=^9%)X?\6>*+.[:2W9C
MN\LR-\6VW_!W;_P1WGN(H'\7_M!V:3S;3/>_ O5EBM> #YLD>O3,J]<F.-P@
M)RF#7^4710!_M0_LA_\ !:'_ ()C_MQZO!X9_9Y_:V^&VO\ CV[N5LM.^&OC
M0ZO\)OB1J6HD'>F@^"OBSH?A+Q#XHD4[ S>$(_%,:!PN[<CJ/U7K_ 8L[VXL
MKJ&]LII[2YM+E;FVN;<G=9L&R&7I@@A<<X(7'()!_NC_ .#=C_@XR^*VG?$_
MX>?L'_M^_$&?QYX(\>7&D^"_V>_VA/&^L-J?C;X?^-)I3I&@_"_XH:Q-LN?$
M7AKQ8MM%X>\(>*_$;R^+_"?BN:W@OIO%7@OQ3"W@@ _T1**** "BBB@ HHHH
M **** "OQ%_;[_X+T_\ !//_ ()Q_'&']G3]I+Q;\2E^)O\ PA/AGX@W>D>
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M=WK/PG^(^JNWR^3H/@;XK:'X.\4^(MI7<3X:M;I"#N61F&1^HU?X ]?V5?\
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M_@D-_P!)%?V5O_#IZ%_\71_P_"_X)#?])%?V5O\ PZ>A?_%U_BM44 ?[4O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/AOX2?%27_A(X+&VN;BZZ?Y/Y?G^'D_Q:_9+TKQ5+Y^E?9K:WS]?IU_3!!H
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M]_\ /\LT >T:E^U%!J5_Y'G_ /'UZ\?T[8Z8]:^^/V/_ -HJQ\'W5O?3W_\
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M %?6OQ(F^ /B/^W]8MX?^/>UO!>_\>7X>_\ GD]* /%X?@SKDVC:/JL&A_\
M(4O../\ ./P'.>O7!XJF\5:;X-N-#\BYTVXM+S_ZPSU]?R'TK]0/@GHXUCPO
MHUC/]F_XE?\ TYY]._Y9[?2NH^)WP'\.:EX2U#[<;:VN+J]_S_,_I0!^,_PQ
M\2>/]?%QI7]JW-S]E_\ U=?ZD?2OUP_8)'Q3U[Q'<:'?:YJ=MI]K_:E[]D^V
M=?7_ /6?6OC_ ,$_!G_A5?B/4)[&?^TOM7J?KW]*_6#]BCX2S^&]8N?'_BDW
M-KI%T-4Q:6H_LX D=QD$@=^1D=Z /J#XA?!GQCKQ@U6>#[2/^?K@_P#U^?\
M/:OA?XG> Y_"LMQ/?>'--U+_ *>\YXQ]/ZYQ7W_\6OVHO!_VH_#G2H+FWN+H
M_8A=_:\8^G?\^<G\*^<-8FT.>*X@U6<7/VNS_P#U>F?TH ^#] \-^'/$FL_V
M7Y%MGK^'X=?R]?I7TQ\/?"MC\)==M]5\C_1QCO\ 3D?C^=5YOAC_ &/#_P )
MCH<'^CVO^F_RX^G/O^->?ZE\68-8_P!!OO\ EU'(Z?Y_#I0!^Z_PL\>:5XP\
M-VU]!/;_ /'IVX/Z^W8'M6C\0IH+/PCJ'V[_ )\^_P#GJ,>@Z5_//#^U=XQ^
M&-WY&E3W/]GVO_UL8_E_*OOCPK^UU!\;/AS_ &'!_P AC[&#^@Z_AQGI]* /
MB?XS>._^)SK%O/./(^V?Z'_G_)Z]*^#_ !Y>0:E%<>1/^@'^>U?8'QF^"?Q&
MABGU6^@N?L]U_P >6+/G_P#5W_K7YOZQH.N0W=Q8WUQGZ?G_ )(]<4 >?S6<
M_P!O_<7W^']>W''US7M'A6ROO-M_/G_T<#WXZ^WKUS^-<=H_@/SKHWWG_P"?
MKW_#'XU]$^%? <^LV%Q!!G[3TZ_3/I^- 'L$.L:'_P (Y]A^WYN/L8Z?Y]_Y
MU\KWEYI5G=:A!Q_+_P#7^'!%9^O>"?'&CZG<0>?<_9S_ )]\Y_,>E>;_ -FZ
MK_:NH?;O\\8S_P#6_'GB@#Z8\$Z#?:QHQ^P_\_GO^O7^5??'[/7@_7=-UK3_
M +=S]E'_ -<?3_#Z5^?_ ,*]>U6&*WL;(9_TS_ZW8X[8X'I7ZL?"N;6]-L-/
MGGA_TBZ_Z<\_K^)S^/M0!^N_P^UVQFT:VL>?M M,GW'3_P"OG/7\*Y?XM3?#
MFSTJXG\5?9KC[-C@D9'?G'I]<?SKXX_X3;Q'\*[7_A(]5XM[K]>N?_KU\S_$
MWXY3^//W\\_^CW1_T/MU]_\ /XT 'B3XP>#M&\47'_" 06VFW-I>?\?=GC_'
M)^GZ5]$?#C]L;28;K3]$\87WVJXNO^7N[]>^?\.E?G?J_@_SM+N=5@@N;;D_
MZ9^?_P"KTKXG\8ZQJNF_VA/!??Z1:_G^/U_ST- ']1'_  U%X'FB\^"^MOL_
M4?B<>]<O_P *K\'?&#Q1;_$:#[-<_P"F?;?\]>GOZC/%?S/^%/CEJMG87%C/
MJMS]H_Z_.O\ G./T[U^U_P#P3L^/T&LZ>?#=].;BXQR1U'&,\_A_]>@#]:-,
ML[*RL;"QL8!BUP!@$8P3GGN?Y8]2:_$#_@IQ^TYKGPJ\6Z-I.E?:?^8H!_3\
MN/P_&OW(U&[,-K!/98(-V,^GO^!';N#Z5\/_ +6G['/A7]H3^S]<OH,:A:]_
M\_IG'Z'(!^0_PW^)WQ&^(-A;^,9[ZYN;>UL_^/0__6_PK8^)UY\1O$G@S4/%
M4%C]FM[48^U_;,=NV.V.W3U]:Y_X\?$G2OV.;7_A67]E?\?6/]+Z?T_+Z<9[
M<?#\5/&/CSX+:A8:'/;?9[JS_P"?/MZ9./\ /Y4 ?E?XP\57T-_J$$VJW-S<
M?\^GZ\_Y)Z=S7L'P!^,^J^%=>T?R/\GI_GT^E>#ZQX;G^U:A//!<_P!L?;,7
MA/X]C^G?I7T!\$_AOJNO>)/#T$%CSC_/'IV&?;WH _IH^ 'BK5?B%H/[\'_2
MK/\ D?Z?GQU[5Y?\<OV/Y_'FO6\^E6(^T<G\?\],^]>\?LZ_#WQ'X5T;3_\
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M_7M_G^9%6/'GB37)O&6H7VN?Z3;VMX!9]O\ /7GW'Y>;^)/BI?:_Y&A^%O\
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M^>!_4A7\M_[-_P"^^(W?_D#ZI^O]./;KTK^I"@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_G_\
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MQ;;ZII6E7/V?[9_SYX'OQW]\]_8U^B'P9^T3_P!CZ5XCTK_1_P#E\_R!Z#%
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M_9IGFBM[Z""YN1G_ (]+NSZ?3_(]QTK]F/\ A _"L,OD0:'IMM;Y'_+H.O\
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MG/\ 0_6OS8\>_M@3ZE]H!G-M]E]?\D\XQ7+Z-^UI8V>BW$\]]_Y.Y[?Y.>E
M'ZP3>#_  L/(GTG3?L_:UYQ]/7].O0UX=\1_V;O@AJ]I/JI\'^&[<X^8_8L9
MX&3@?R[9QV-?G1IO[8%]K&J?88+C_1_\XSCT_P G'3Z8L_BI?>)-!N+#S_\
M2+JS[_Y_3L.,=: /!_AO\!_@1XJ^*NH>'/[*T3IJG^B&S_I_3^E;'Q^_8S\'
M>%;'[=X5^S6W_7I^7^>?YBO'_@;\,?'&C_M!7&N3W]R;"ZO-4YZCZ?\ UL5^
MI/Q4^'M]>>'?/\_[3_H8[=.O)X[]C0!^&UG\*[&;[38SV-M<_CR/3Z^_)X%<
M_KWP9_L>+3[ZQ@MK:X[#UQQTSZC_ .OCFOI#QMH][H^H7'D'_2/3I_\ 6_ST
MZ5Y_YWB/6+6WL9_P]?7_ #^O8  _._XM>#[ZSO[>>"]NK:X_/Z?X>PZ=ZX>'
M1_.M?L/_ !\\^O4?YZ#Z8/2OK#XM>%=5AU2W\^#_ $?@8]_\_P \CK7S_P")
M+NQT>ZT^"Q_X^+K_ (_.G/T__7VX]: ";09X=&MX/^7?_GT/M[?_ *_6O/\
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M]<<\]R*^#_V%?%-QXJ\9:?\ O[G[/]M]/?OV_"OUQ_;&\1S^%=!\+WVE6/\
MRY:7^OUZ\9_7\0#M_@;>?%4^#=0TJ?2K;4M/NK/FTN[SG_/]?H:^/_VG/"OB
M.SEMX-#TK^Q-0NN+S^R>?U^G_P!>OIC]EWXV_P#"5?9]*^W6UM<?7\NOY>GM
MG@_6'Q(\'Z5K%A_;E]!;?Z+_ )Z?7I@4 ?(_P&^%6E> _A?_ &YXJL;;^T/L
M?_+W_+G\/R_+YW^.6O:KXJL+B?0M*^S:?:WGV+_1./;\^GK_ (?2'Q(\57WB
M3018V,_]FZ?I8_S_ )'88'%?/_\ PUUX.^#^EW%EXC\.'6]'M?\ E[_XDW_(
M4Z^W0]>] 'SOX/\ ACXJ\22ZA?7\]SIMO:\V7\Z_2#X;WE]_PC=MX._X^;>U
M/VW[7Z#MZ9]_6OS?\2_MF>'/&%U;ZYH=C_9OA>ZS_HF.>XQ^78\YZXKTC1_V
MK?!L&@_VKX<OO](_X\KRT^V>G<GV_P YZT ?8'Q(^&/@Z\NO[5\^VMM8.3]K
M[]^OKU]?K7R_\0KS5?#=KY]E!_:1MO\ E[[_ )^W^<=:\XO/VBK'QM=>1]O_
M -(_Z_#Q]?Q_SBNOGUB^O-+N//\ ^/?[)Z?X^AZ]_P Z /*-!^/&N3?\2.>^
MN;;3^OV3\?;\,U6\2>%8-2S?:5]E^T77!Z?K_D8KYW^)$UCH]_Y]C/\ 9;C]
M1VYZ?ASTZ5G^"?BIKGVKR/\ CYM^W3/M^&?S]Z .H\2>%=<AB^SWT'VG[5UQ
M_P#7[\>OYYK8^!MY/\-_&5O?>?<_9\'_ $3V_7\L_7K7T!K%Y!_PCGA_59[?
M[3]IL_\ /3I]*X":ST/6+K[=9?Z-<6O^??D_S_"@#]/YOC9X<^)W@VXL=5L;
M:V_LJS-E9\#^?IT_'TK\?_CEX:L?[8N)['_1K<?J#U]L?3_"NHO/B%JNFW_V
M&#BWML__ %\_C^A[UR_BK6/[>BP/])N,^I]O\_\ ZJ /#]-TWR8O/\_[,>1_
M+M_G'3Z>L>&O$G]@Q9@GQZ#_ #W]_P#Z]5]-\!Z[>6N/L-S]GX_S^G_U_70T
MWX,^*M8E\BQL;D=_\]/Y^_'& #H)O%5CK _?P6US<=/7KG_/?^=>7^)/ ?\
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M[[!_/Z\\X_SQ7Q1XJTW['?\ G_\ +P21^8S]1_G-=/X4U_5=-^S^?!<VUO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#_%E_X+C?$>3XI?\ !7C_ (*&^*O)G@_LS]J3XG_#8"Y_
MB7X*ZLOPE5A][<KIX'C=.2"KJ<G<<?E#7V__ ,%,/^4CG_!0+_L]?]JS_P!7
MYX]KX@H _P!E?_@WW\!VOP[_ ."-?[ GAW2;8V=EJOP5;QNL;7(OBFH?%'QI
MXT^*FL:F@)^[-KWC29Q&QS$-J95$0G]H:_*O_@AW_P HAO\ @G5_V:O\+?\
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M$:SLDN4^&OPAT;RO^$AU]TE#Q+K=R#'X7\&B2.6.?QCKOAZWF"6Y:2, _O\
MO^#0G]EK5_@E_P $Q]7^,?BBREL=5_:P^,WB/XC>&[.X@D@D7X:>"]+T?X8>
M'I989[=&1O$/B;P]XV\1131AH;GPQK/AZ2)6"K/+_6#7FWPR^&7@?X-?#KX?
M?"/X;>']/\)^ ?A?X0\-?#_P)X<TR!1IV@>$_!>CPZ'H&CPJ@4JMOH4$<*;@
M&.'=F>1BTGI- '^;U_P>U?&.S\1?M6?L9? 6"1I9_A1\"O'OQ-NQ@E8'^-WC
MF#P\$W# 9Q#\$(9"H.Y%V*PR1G^(ROZ /^#G3XU7GQH_X+._M7?Z2;G1/A1_
MPK3X,^&UV./L5EX&^''AQO$,);HP_P"%AZWXTFW# 4R!>HK^?^@#]5/V;O\
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MAO7TAN8XI&AD>$!H06C:4M'NX#_A[%_P2T_Z26?L"?\ B9'[.'_SQJ_S>_\
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M/^DEG[ G_B9'[.'_ ,\:C_A[%_P2T_Z26?L"?^)D?LX?_/&K_$*HH _V]?\
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M/^DEG[ G_B9'[.'_ ,\:C_A[%_P2T_Z26?L"?^)D?LX?_/&K_$*HH _V]?\
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M/^DEG[ G_B9'[.'_ ,\:C_A[%_P2T_Z26?L"?^)D?LX?_/&K_$*HH _V]?\
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M/^DEG[ G_B9'[.'_ ,\:C_A[%_P2T_Z26?L"?^)D?LX?_/&K_$*HH _V]?\
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M/^DEG[ G_B9'[.'_ ,\:C_A[%_P2T_Z26?L"?^)D?LX?_/&K_$*HH _V]?\
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M/^DEG[ G_B9'[.'_ ,\:C_A[%_P2T_Z26?L"?^)D?LX?_/&K_$*HH _V]?\
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M/^DEG[ G_B9'[.'_ ,\:C_A[%_P2T_Z26?L"?^)D?LX?_/&K_$*HH _V]?\
MA[%_P2T_Z26?L"?^)D?LX?\ SQJ/^'L7_!+3_I)9^P)_XF1^SA_\\:O\0JB@
M#_;U_P"'L7_!+3_I)9^P)_XF1^SA_P#/&H_X>Q?\$M/^DEG[ G_B9'[.'_SQ
MJ_Q"J* /]O7_ (>Q?\$M/^DEG[ G_B9'[.'_ ,\:C_A[%_P2T_Z26?L"?^)D
M?LX?_/&K_$*HH _V]?\ A[%_P2T_Z26?L"?^)D?LX?\ SQJ/^'L7_!+3_I)9
M^P)_XF1^SA_\\:O\0JB@#_;U_P"'L7_!+3_I)9^P)_XF1^SA_P#/&H_X>Q?\
M$M/^DEG[ G_B9'[.'_SQJ_Q"J* /]O7_ (>Q?\$M/^DEG[ G_B9'[.'_ ,\:
MC_A[%_P2T_Z26?L"?^)D?LX?_/&K_$*HH _V]?\ A[%_P2T_Z26?L"?^)D?L
MX?\ SQJ/^'L7_!+3_I)9^P)_XF1^SA_\\:O\0JB@#_;U_P"'L7_!+3_I)9^P
M)_XF1^SA_P#/&H_X>Q?\$M/^DEG[ G_B9'[.'_SQJ_Q"J* /]O7_ (>Q?\$M
M/^DEG[ G_B9'[.'_ ,\:C_A[%_P2T_Z26?L"?^)D?LX?_/&K_$*HH _V]?\
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M/^DEG[ G_B9'[.'_ ,\:C_A[%_P2T_Z26?L"?^)D?LX?_/&K_$*HH _V]?\
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M/^DEG[ G_B9'[.'_ ,\:C_A[%_P2T_Z26?L"?^)D?LX?_/&K_$*HH _V]?\
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MW4%S%):R30S)Y?>5^??_  2<_P"46?\ P36_[,#_ &./_6?/A[7Z"4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#>J^%?L]A/?:E]HNO7Z=/\Y_G7R_X\UB^L[^W@\_/V7\_P"I_7'X8S^N&O>
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MH/\ A'/LNCYL[2[[=.W3UY.,5^,_C#]H3Q5K'C+[#8ZX+;2+H?8L ?Y_S[4
M?I1^SWX;\#^,/%&H7U]??VEK&E_\NEW_ ,@S\./QX';FOT?LX;&SMO(@^SV_
ML,#H>^<?H?PZ5^7'[-__  AW@F6V\1ZYKEM:_P!J?\O=W_G_ .O[^EG]J_\
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M;[9_AR<_J*]X^*GAO7? >BV__$J_T:Z]_?\ '_/Y  ^1_C!-_8^@7%]I5O\
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M^C^+;B>?[3_9]I>?\O?\N/?'L..M>L?%OXY0>%= N)_#D_VFXM/^73^0]_\
M]53Z#J^AZE:ZQ!JNE8N._P"!QG_/<\5\D:_H,$W_  D'GWPMM._XFF._3_/^
M/:@#Y_\ %7QLU7XA?Z=!]IM[C_GTM.?_ ->/KZYK[H_9OT'2M2TO[=JM]=?:
M!^9_E^N?<"O@_09O ^FW_P!A@^S77^3['\__ -5?;'P]U*#38K?[#_Q[CC_/
M8'\: /K"RO(+/Q&(-5G^TZ.?^/.T_IZ8_P ^]6+R\TJ;5;C^PX+G[/V_T/\
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M)\V_^>V/;TYH ^]]7T>RUB'R&QGVSS^?<=?3IGIQ8LK.#3;2"QYN,>P/3O\
M3K@?Y.!X0UG^V-+MY^?\GU^GKT^O7KY)0L@'I^GY^_3UZ4 8&I:1#>6&H6,T
M'VFWNL?R'X?T[U^,_P"U=\#O[,O[B>QL!]G_ .?OV_S^5?MQQ_K^.G7VZ?EV
MZ^_O7F_Q'\!:5X[T#4-)G@MS<7(')(R>V2>ASWQCI[T ?QH>-O =]#XM_<07
M/V;[8#_+Z?7M^N:W_$NFZ5_8%O!]G%M<?UYZ^^/SK]>/VA/V=;'P3_:%]!;B
MYS_GC_\ 57Y3ZC#JO]O7$$^E7(M_M@'^3^.<>_UH ](T?^U?A[X2N+[S[G_2
MM'/7\NWX_P"-?JO_ ,$J?B1/XU\.>,-*OOM(%K=Z7]D)X 'OZ =3GIZBORXT
MW6;&\L!8ZK_I/X@_7\S_ (U^F'_!/W4O"O@_69]*L?\ 1KC5><#CCO\ 7W_3
MV /N#]L;X-7WQ/\  _VC0Y[FV\0:#_IMG]D'_'^?0XSR.X&<^M?D1IO[5VK>
M&]9\/_"3XC:5IOVG2\65Y=]NO7\_QZ8K^@_QA>7UGX7U&>Q']I7'V,\<?_JY
M/4?I7\8_[5TWC&#]IO6+Z^TNYMCJFL:I>V?;WQ]/QY- ']1&L?%32O"OPYT?
M7-*G_P!'^Q_;;,]?49_SW_&OP?\ VNOC9??&;Q=86,\_V:WQ['/\_P"7/YU[
MA_POCQ)K'[,FCZ5/8W-MJ%K>:I]L'^?K7Y/_ !"UC5=2NK?59Y_TZ]\?X?RH
M ]X\5_"O2M!\):?KD&N?\?7_ !^?Z8>,_P">37[3_P#!,'3=*TWP;J$^E7W]
MI7%U>$ W?'^?Z_C7\R&O>,-5UCPGI\']J\VMYT_EG_#L>U?NQ_P2=F\1S:7<
M>???Z/\ ;.F1R/3]/2@#]X/&'AN^UC0=0TK_ )=_L9_K^9QR/S]Z_GW_ &NO
MV4=5A\1CQ5!8W.FW%K9\7>DG_C__ #_GW[=*_I&CBGD\Z">8G-J%P.V1C)^G
M?_'-<1XD^'NA^*I8(-<@MKGOCN<>GY<<9Z4 ?QH:E\/?B;XVO[?P=?:KXCN=
M/M;S_E[XYP1[CWKZ@T?X5^(_A7HVGZYI6E6US<6MYI?^EW8__7GZ<_3/-?T<
M2_LO?#B*^GN;#1+:WG(R#U!!'Y_S]O;S_P#X97TK6;^XL=5@MO[/Z^O?G@9_
M+% 'A_PQFU7XY?!;3]#GS_:%K9_YZ?AZ=?KGYW\$_LKZY\,?B-<>(]5TK[3I
M_K:?\3+O[?H/<5^J'@/X5Z'\'[6X@TJ ?9_\_H.OUK?M/&W@^T%U>WM_IUQ<
M&\Q]E&"1UY&0PXZC((Z9!% &#X4UCP=_PCFG_;M#_P!(M1T^Q]_3_P#7VQ7S
MM\0M'\*_\3"^@)MK>Z&?;O\ CU_.OH#QY\3O \.E^1!/;?Z5SS]>.OX?Y.1\
M;_&"SOM>\.7%]I7%OT]#^/.?\^M '4?!/QY\/_AAI?B#S]<^TW&O?\?EI=_7
MJ/\ /-?3&F^-O _B3P1J$]C<6UKC_GT]^_\ ];'OS7\V_C ZY9^,OL,]]<_9
M_MG/K_3U_+C%?:'@_P 8?V-X(N(?MUS_ ,>8/_'Y_G\/\X /U ^&_BKX90S?
MZBVN=8Y^V?Z&?Q]3U]?;TQ2?$/\ :S\*>!=8M["$ @]0?0YX.>OXY'YBOQPT
M'X_SZ/=ZA8P3_9OLO/VL?Y///T_"ODCXP?M":YJ6O&W_ -*N>O\ I?\ 7ZX]
M/TH _J7\-_&;PKXQ\+W&JV.J6WVC_GT]?Y=>/_K&OB[QM\8/L>O7$'V[_1^_
M^F?KGI_^KCCBOPHT?]I#Q_X5T:X\C5;G[/=?\NF?7GD8QQ_]>N'T?]J+7->U
MG_B:SW/],'U.?K].* /W U[XP7]Y^XL;ZY./7C\1_GT[UW'@/6(-8NK>'59_
MM(NO\?Y=NG/3TK\Q_"OQ@TKQ)%!8P3_\3 ?YX'Y^U?1'A76+Z&ZMYX+[_/;M
MUS_6@#ZX^.7P'TK5]!_M70^+C['SC]3VZ]/6OQ?\>:;XCT'6KBQOH/LT%K>$
M=>/\^GO7] 'PW\2?V]HWV&^G^TXLQW/^?;_]1K\Y_P!KKX>P6>J7%]!;^X_S
MGG/YG- 'P?IOB2_O+7^RA!:_9_\ /^?;\Z^;_&UGYVO:AI7V&V]?M?\ G\>^
M1TZBO:+.SG_TC[#/_I'/KZ<]/_UUXO>'7(=9N//@XZ<X_7_.* /)SX/OOM7[
MB#_1^?R[?T__ %YI89M=TW5+?^RH/^/7_C\SG_/T[=\>GK^F^)?L=UY$]CV_
M7WQ[_P"/>O2=!L]*TT:AKD\'^CY_TS([?GSC]/I0!Z/\-_B=X'AT:WT/5?\
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MK^7#]FF&?_A8)_[ ^J>OT_GS_+'6OZCZ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOCY\:[C25T_4OB-XGT<2+H^C:5N\TZ%\._!:ZQJUMX(\,M++-G6O$'BRX/\
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M\<W_ (-O4UA_^"U_[!/]CY%R/'GQ +#L=*'P4^*K:\&Z\?V NLGZCW%?[&5
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M(73_ (+H_P#1C7_FR_['G_T1-'_$+I_P71_Z,:_\V7_8\_\ HB:_U]J* /\
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M3J41D\/S3VDI.(+JX0(1Y)7Z"?\ !6/_ )2F?\%*?^S_ #]L?_UH/XA5^?=
M'[]VG_!L!_P7)O[6"]LOV(Q=VUS MQ:W2_M,_L>@.K88.O\ QD1@)@C+$%E.
M R @BI_^(73_ (+H_P#1C7_FR_['G_T1-?ZY/@S_ )$WP=_V+VC?^F>.NMH
M_P @G_B%T_X+H_\ 1C7_ )LO^QY_]$31_P 0NG_!='_HQK_S9?\ 8\_^B)K_
M %]J* /\@G_B%T_X+H_]&-?^;+_L>?\ T1-'_$+I_P %T?\ HQK_ ,V7_8\_
M^B)K_7VHH _R"?\ B%T_X+H_]&-?^;+_ +'G_P!$31_Q"Z?\%T?^C&O_ #9?
M]CS_ .B)K_7VHH _R"?^(73_ (+H_P#1C7_FR_['G_T1-'_$+I_P71_Z,:_\
MV7_8\_\ HB:_U]J* /\ ()_XA=/^"Z/_ $8U_P";+_L>?_1$T?\ $+I_P71_
MZ,:_\V7_ &//_HB:_P!?:B@#_()_XA=/^"Z/_1C7_FR_['G_ -$31_Q"Z?\
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M8U_YLO\ L>?_ $1-'_$+I_P71_Z,:_\ -E_V//\ Z(FO]?:B@#_()_XA=/\
M@NC_ -&-?^;+_L>?_1$T?\0NG_!='_HQK_S9?]CS_P"B)K_7VHH _P @G_B%
MT_X+H_\ 1C7_ )LO^QY_]$31_P 0NG_!='_HQK_S9?\ 8\_^B)K_ %]J* /\
M@G_B%T_X+H_]&-?^;+_L>?\ T1-'_$+I_P %T?\ HQK_ ,V7_8\_^B)K_7VH
MH _R"?\ B%T_X+H_]&-?^;+_ +'G_P!$31_Q"Z?\%T?^C&O_ #9?]CS_ .B)
MK_7VHH _R"?^(73_ (+H_P#1C7_FR_['G_T1-'_$+I_P71_Z,:_\V7_8\_\
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M$U_K[44 ?Y!/_$+I_P %T?\ HQK_ ,V7_8\_^B)H_P"(73_@NC_T8U_YLO\
ML>?_ $1-?Z^U% '^03_Q"Z?\%T?^C&O_ #9?]CS_ .B)H_XA=/\ @NC_ -&-
M?^;+_L>?_1$U_K[44 ?Y!/\ Q"Z?\%T?^C&O_-E_V//_ *(FC_B%T_X+H_\
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M/_"+:%)H\6LZN=;^(7B7PEX9 A?6-) C;Q%'>,9&"1R;SM_4G_B%T_X+H_\
M1C7_ )LO^QY_]$37U1_P9V?\I>)_^S6?C/\ ^GCX?5_JG4 ?Y!/_ !"Z?\%T
M?^C&O_-E_P!CS_Z(FC_B%T_X+H_]&-?^;+_L>?\ T1-?Z^U% '^03_Q"Z?\
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MZ?\ !='_ *,:_P#-E_V//_HB:_U]J* /\@G_ (A=/^"Z/_1C7_FR_P"QY_\
M1$T?\0NG_!='_HQK_P V7_8\_P#HB:_U]J* /\@G_B%T_P""Z/\ T8U_YLO^
MQY_]$31_Q"Z?\%T?^C&O_-E_V//_ *(FO]?:B@#_ ""?^(73_@NC_P!&-?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQCD?_7[^Y_$_IQ^TM-\%IK_[=?> +;Q)<77;[9_]?\?\C/R?_P +.\50VO\
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M2_M_D?Z1Q_GV_H/;IZQ\)=8\1V<MO^XN;FWM;WG\N_\ +I[]30!^N_@_P'X
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M8MT/0O%%Q/<>'#]GY_Y<_P#/7H,^E?N!X)@_LW2[?5?$<_V;_ITNQW^A_'_
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M_7'UKZX\$^//"NI>(]8@OI[;[.;/_0__ *_\CQ[]ZP/%7BK0QK/D0?\ 'O\
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M-'AMYK6#R;C[1;W-G^O^<#_ &OQ7_P""C7P4L3?CQQH6E:;;:A:]#=]^Y_\
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M>^%[>?Q5\,_$EMH]U9G['XAN^/M_^?K^'% '[4Z#\>(+R6W@OH+K_I\_T/\
MJ._^'UJO\>?VI_"GP:TO3[ZXG^TBZLOMF+7'TQCT/MU%?F/\)?C9KGCSP9<7
MUC/]IN+O_ET_Q_\ U_B374?M(_#?_A)/@C<:KKG^C:AV^U_Y&,]* ./^+7_!
M2S^WK7_BE?LWV?G_ (^_?_\ 4<]LFOE_7OCQXQ\>:7]NT/5=2MKCI_HGM^/]
M/7UK\G]8T'^S=>\C[=@F\XS_ $_3M@=*_3#X5Z;!_P ('Y$'^DW'V,8_^O\
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MZ5;"XNO\X'X>_7OTK\9_VBOV/]*T?7KB>"QYZ>F/_K=^F/RH _&?4H?._?\
MD?SSR/;'&?\ Z]5[S7M<O-+N-#LH+8?:L61_,]S_ (_RQ7O'CSX5SZ;JGV&
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MDWE_<?8;'_2+KC_1+/CU_G_G%?J!_P $]_V+9_&&J6'CCQ5!_P 4_P#\?O\
MI?IU[\9)^G^/QO\ L-_LT^*OCE\1M/\ $>JV-S<Z ;S&?Y]!Z]O_ *U?UH>
M_ FA?#?POI^E:59?9K>TLR/H>N#]>#Z_I0!OV=GI7AO0;?2X";:WM<=N!U__
M %?2ODCX\?&:"&P_LJQN._?]?;U/;KSFMCXS_&"QT:*X@@G_ -([X_+]/Y9[
M"ORO^)'Q4GO+JX%Q/_/_ #QT[_X &?\ $CXD3WDO^O\ S'Z\<5\WZ]XJGFB/
M[_IVSQTX_P #^'N:Y;Q5XDGFEZ?G].GY^O\ C7G%YK%Q-%^@Y/\ *@#8U+4I
M[R+U^F/\]^GI[5D07D\/3^8]<_7T]:SH?/FS]?3&<X]._P!>GYUL6</;Z_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?YBO_  >9_LX77PX_X*&_"+]HNPL8+?P[^TK\ -,L+R^!!NK[XE?
M_6)/#7B/S,?,A@^'VO\ PGCC/0@N& 8)G^/&O]@K_@X>_P"":^I_\%*/^">W
MBWPO\.]&_M7]H/X%ZS_PN+X$6L?EG4?%&IZ)I3V_C7X;!Q)$K?\ ";^&)-42
MT@,@:;QEH7A1?N*^/\A/5=+U'0]0N](U6PN].U/3;N2SU/3M3LI;"_LM025E
MDT[4HY?*D4@PN3OV-D$LL0'R@'^D;_P9F_MB:-X__9"^-G[%^MZM;_\ ">?L
M\?$:_P#B;X0TM,F^O/A#\5502F+"A=8/A?XD:9K[WLB92WA\=>&(5C&8]O\
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M@'X!^!Y)[';)CX?:1JGCOQW?_P!J.P+:/<MXZ\$0%4 "S:'+B1V\B-_[OJ^
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M2Y\-^!/!.C'S?%OQ!\9,IC^S^'_"VBR/.Y+1+-(VB^$K?SK_ ,2V<#_Z_/\
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M$MO^"\_[;G_!*[[1X.^&&H^%_BK^S]J6J2ZSJ_P ^*T6J7OAZSU"184U;5O
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M&83XIEC'[44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>/A]7^J=7^5C_P &=G_*7B?_ +-9^,__ *>/A]7^J=0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% '^-E_P<5?\IJ/V_?\ LJ?AO_U5O@"O
MQ4K]J_\ @XJ_Y34?M^_]E3\-_P#JK? %?BI0!_NU_LA?\FE?LP_]FZ?!7_U6
MWAROHVOG+]D+_DTK]F'_ +-T^"O_ *K;PY7T;0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M &C_ /YW-'_#IW_@J7_TC3_;[_\ $-_VC_\ YW-?[>M% '^(5_PZ=_X*E_\
M2-/]OO\ \0W_ &C_ /YW-'_#IW_@J7_TC3_;[_\ $-_VC_\ YW-?[>M% '^(
M5_PZ=_X*E_\ 2-/]OO\ \0W_ &C_ /YW-'_#IW_@J7_TC3_;[_\ $-_VC_\
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MSL_Y2\3_ /9K/QG_ /3Q\/J_U3J "BBB@ HHHH **** "BBB@ HHHH ****
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M]#[CK7O&F_LQWVCR_N-*[?3I^7'Z' QZ4 ?%_C6?R=&N+&?_ (][JS].V?\
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M..O[ ?"73?['\)06]OJOV;4/L?%W^7Y\#/\ ^N@#ZA\*^(Y]!L+@ZY/;=?\
MZ_3FOA?XY?M4>(]'EU"WT.>V_P!%O/\ 'C'IG..U<-\8/C!XCTV74-#GOKFY
M_P"GOW],_P"?S&*^3X=8L?&%KJ&E7UC;:CJ%W_:OV.[_ $^G^?>@ T?XY?\
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MH _7#]BV'2IO$>H_;H/^7S_0QV_+G_.37T!^T)-;PQ7$$$'MC^?3_.37SO\
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M\+W&E67C'4M-T_&;.T_Q]OSS0!^Y'[5W[9FE?"NPM]#\*P7.I>(;J\_Y=/\
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M0=2GT&U\^> 8_/MZXS[X],_C[1X5U[Q5-%<3V_VG^S[K_ETX_#^>3QZT ?T
M?LW_ +2W@?Q5X(_X17Q'8_Z1_P!>GOU/L?Q]^:K^-=-\.:=K-O<03_\ $ONO
MY]NWI_\ J-?C_P##?QM/H]_;_P#+M_G/?//TX_I]D_\ ";0:[]G\_5O7\/\
M/- 'T_\ $+P3I7Q"T&W@\*P6UM<6MG_Q]_EUQ_/'Y\4?!/X#Z3X5TO4/&/BK
M_B=SZ7_IOV2TSJ6.GX<>YKS_ ,!_$Z#1[_\ LK[=_P ?5GQQZ#'X>QQ_*OT
M^">@V,V@ZO//8_\ $ONO^/SOT'^>_P"% &QX#^+6E7O@W6-<T30_LO\ 97]I
MV?V06>,<^WN!P>HX/%?G?\5/VA/^$PNO$$_B.QN.W^B?8@..,<#TZ\^U?J1\
M*YO#FI0^(+&Q\*6WARWSJ=C>#.#?@D#N.P]\]AS7XS_MF?\ ".?#'X@^()[&
M>V_TJ\//^>/_ -7/; !R_P"ROXJL?^%M?;IY\?Z9G[)=_P!?Q_D*_=CQAX)\
M ?$ZUT__ (2."VN3]CZ\\]#_ )'';\/XS]>^.6N:#XC_ +<\'7USHFH?;#_Q
MZ<>O]/Z^I%?9'P?_ ."BGQ;FET_2O%7C'4KG[+_S]WGI^ ZT ?IA^UI^ROXJ
MO+6WTKP/_P @>ZO/^73'_P!? [?K7P1\3OV&_''ASX:?;OMW_$P_Z_,=/\,X
MY_\ U_K/\-_VV/#FI^%]/@U6>VNKBZXS]LSGG_/\J36/'FAZ]XMT>^U6^MKG
MPN?^/RTQ]._&/\_6@#\P/V>_@;\1KSP%J&E7W^BW'_$T[\'V_P ].]?._P ;
M/V4?'&FVFH7T\_\ R^]/MG/UYY)]Z_H8O/B%X TW_B1^#O"NF^?]C_Y<_P >
M@^O\N_?Y/^/'PQ\?^*?[/OH+ZYTW3[K_ (_-)'X_7/\ +]: /P7^&WA7Q'X5
MO]/%]_Q[_;/\YX/IW'2OUP^$L,^L>$K@:Y/;6UO]L_T/K_AU[GCOWKR?]H/X
M#ZKX)\+Z?XQ@^TVVGVO^FWEI]C[?_6_+\:^%X?VD/%7C#_BG/#D%S;:?I?3[
M)GK^?'/^>: /WX^ _P"RCX<N]9M_%5]_Q,K?[9[_ .'\O2OTH\ZQT?0;F#2H
M/LUOI?\ H0_#VZ^_'M[5_._^S3_P4E@^#^@W'ASQC/\ VGJ'V,?8OM?'3IC!
M]<?7O7Z<?#?]J^?XS:7<7VE6/V;3[K\<#IV_K^9H \'_ &H_B1-YVH0>?[?7
MZ?YP:_&_XA>))]2EN/\ K\/7KQSSV]OSYZU^D'[2'[Z_U"XGZ?YZX]/Y#WK\
MM_%4OG2W!\CUZ ]_\.?T]L@'G\UY^]]_\_D/PY]ZL6?VB8^O\_\ ZW_ULGTK
M O/]:/J?Y&NGT>'U_P _7'XG/U/I0!T$,/\ G_/ZG'L!746</;Z__7.?YC']
M*Q_(]_U_^M706?;_ (%0!T%G#V^O_P!<Y_F,?TKH+/M_P*L>SA[?7_ZYS_,8
M_I700_NO?K^OY?TH T*//]OT_P#KUG^?[?I_]>CS8?7]3_C0 33?Y/\ G\AG
MU)-5_/\ ;]/_ *]5_P#EK_G^]6A]C\[CI^OX?CGKGV[XH S_ #_;]/\ Z]$T
MW^3_ )_(9]231-9S^W;G]!VZ#]<_C6?--_D_Y_(9]230!H>=YOX>W^>F?;K^
M5C]U_G;7/^?[?I_]>M"&;_/^?U&?<&@#H(88.O?_ .M_A[9]>@R3100CUQT^
MGJ?\_B:KPS?Y_P _J,^X-$/[WVZ_I^?]: /H#]F_[/\ \+ _[@^J?]\_Y_2O
MZ:*_F(_9UAG_ .%@_P#<'U3U]O4D_EZ?2OZ=Z "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3=<UBT^SZYU_(>O^?_UT>*OA[XC^'MI_95C?7-R!_P O?^1_G\17VQ^Q_P#
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M7^C6T_.?\]>O;_) /A?]N3XS7WAO^T+#2K&Y^S_8_P#GSQTR/\D_B*_-_P"
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MMCK7]&'QX^ \&O?VA?:%_P" GUY[?_6P.M?D?\2/@;?:;=7'GP7/VCWY]O\
M.?K0!^>\UG^]X@_E_P#KX[]370:9_%_GUKUC4O!,\,MQ!-!Q_A^'U_P%<O\
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MY'CKW_2@#\YX9OL=UY$!/_ZQSC_]?T]_</ >@ZKKTL'[C]/\CZC]>*XCX>^
MM5\2:I_J3_Q^<?@?K_/_ /5^B_@GPWH?A"PM_MW-Q^/Z_K[_ )T 8_@KX/\
MG2_Z=QQVSW_'OQ]!BO4+SX8C0?L]Q!/_ /J([>W_ .L5S\WCSR;\P03_ &:W
MM?\ /3Z_R.?6L_7OB1/-%_K^G;^GMZ<_XT >D?\ "53Z;:^1//\ Y_ST_G7+
M_P#"8?Z5^XG_ /U>WT/Y<=J^?]8\53WDO[B?CKQ[^QY]/0_G6?9S>=_RWN<]
M/\].#T_"@#ZHL]>GO+GSQ/T_4'_ZY_K[5] ?#WQ5JMG=>?!?8^N/3T'L?Z=J
M^']-^W0Q9\_],<<9[=B?Y^]>T>"=2@TVZM_/U7_CY_\ U_X\>OTX /V \!^*
MM*\5:7]AU6QMKGM_QYC_ #U[=?6O'_C9^S'X<\5:-<7VAV-M;:A[<=?R]O8'
MM70?!^;2H=+M[Z>^MN?Q_#MW_']:Z#QY\>/"O@F&XGGON?L?_'F<?G[< C^>
M: /RGT#X5_V#K-QX<U6W_P!/Y_\ U8_K^G'&Q\0OV==#AT;[=_HUMJ';ZY],
M_P!<YKRCX\?'Z<>,AXJT/_G\_7I_];_(K7^'WQ9U7XJ7]O8:Y??9NG;G'M_]
M>@#R?PW\);&SU3]__P >^?T__7QUZ^X.>PU[3?#FC_N((!]H_P#U?Y_QSFOM
MC7O@_!H_A+^W(/\ 2?\ 0^!^G^<]!GBO@?7M8@TW5+F?58/]'M??C^9Z_P">
ME '46<VE6=A^_L;DW&?\]_4"N7UZ:>"PN-5@L;CR/Y?UZ<\].>M<OK'QLTK4
MHO(L=#MN_P#GWZ=N/PZ^L6?Q@\*ZEX(N+&?0]-_M#']/Y]>G:@#Y/FO-6U[5
M;>"QL/M-QJG_ $Y_UZ_ICC->T:/^Q/XXU*6W\1ZKI/\ H]U_TY_TYP>_8#^?
M8?LK^%8/'OQ0M_\ GWM;S_0[3'^<<8Y]J_H8AT&Q_L:WT/' LQS[8_G]<T ?
MS7Z]\&=<^&^H6^JV$'V;[*._X_B>/\^OJ'A7]I:?_1]#U7MW].G^1Q]/6OT0
M_:0^&/DV%P;&#[5;W0]>_P!/7V]*_&_QC\/9]'U2XOH+<_\ 'YWY]_\ /]:
M/U0\$^ Y_B%HQUR"#_1^_KC]/R_#M783? &^F_Y<>?3K^/\ 7^M>,?LK_M.>
M#O!/AO\ L/Q5??9KCZ<=/T_KQFOK^+]LSX+33>1!JO\ I'/_ "Y_Y]Q^7UH
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MP^^'NE:;:&?5-$MKFXZ BSS@X/;'T_'\:^3_  ?^U1X._LO_ $>>V'U[>O\
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M  ETS2O!-_<:'XKT+^S=8_Y^_L>/PZ_D3ZT <O#^S?/XJ\)>?/KG_$PM;/\
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M^?\ 81INH6O_ #Z ?0_S% ']W_@CXO\ PY^)MI;7VB:MIMU]JX^RF\&3Q[8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME?SX?#SXSP6=K]A^P_:;C_KS_P#KD_I@U^C_ ,$]>_MC2_/@M_P^OK_GU]:
M/V8G^(6J^,/"5Q8Z21_QYY_Q].O7\:_._P#X5[XQF\97%CJH_P!'NKS_ )>[
M,?7^G_Z^M?2'P!U+5/-_?VX^SY]3]1CV^O/;K7V1X;^&^A^*KK^W)Y_LUQ:W
MF/\ 1/\ /USW]NN #Y/\-_#W_A#OL]]?6/\ H_O_ )Z#Z]J^R/!^I:5XKTO^
MP_L-S]G^Q_\ +W_/H3^GO]/4+SPMH>HZ6-*\C[3Q^''4].F!_/ZU/HWARPT*
M$0VUE:V\Y'4$$'.>XQGZ_P Z /S@^/'P?_X1O4+BQ\*Z5_H^J?\ /IC)]O3V
M%?F/XQ\-^)/AOXCM[ZQ@N;:X^V?;>O\ 7Z=<_P#UZ_IHO--T34C!/?6-M<W'
MIZ'\^_7'J2#ZU\'?M:? VPO=!N?$>DV0R+/!]B!G';G&#TZ&@#Y8_9[_ &NH
M-'UG^RO&-Q]IT^ZX_P!+]_U__6>:^Z?^%2_ _P 8:I;_ !&M[&V_Y_?M>/\
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MWO\ GI]/\Y /!_A[X5T/1[#[=KD^,<]^/\^_KTX-5_'GQ(\*^ XL:5#;=/\
M(Y/'I[]ZZC6/!_\ Q(-0MYY[G[1:X]?\._UKXG_L&?Q)+K$%]?6WV>U_Y^[S
MJ>>.1Z?A^5 'D_Q:\83_ !.U0?V5?"V[_P ^ON?7K1\-]-U73=4MQ/??:1:]
M?T_SQ_7GY_U+3=5TW6=8_LJ^MLVO]J=+SCZ_KCU]ZK_#?XD:Y9ZR(+[_ $G-
MY^77ZC_/X4 ?UL_ ::?Q?\(-/L;B?T[9Z?\ UQ_^KI7XW?MH^ [[0?&^L&""
MY^S_ &SIP?U^O^>U?KQ^Q/K%C>?"_1O^?BY[X/O_ (\X/Y5V'QX^!'AOQO8:
MQJU["#<$<?CG'/:@#^?;X5V?]CV'V[R,?CT..G\_Q%=3KWC;S[_R//'^?RYX
MZ_XUZA\0M!L?#<NH6-C!_H]KGCT'T[_T_&OD_4_WUU<3^H/!_'VZ@<>] '<3
M:Q<>;Y_G_EC]>W_ZCT-$VI3^5[8_(#W]^WYUY?%J4]G+^_\ S[<\>_'^>*V/
M[8\Z+KZ9_KG]?I0!U$-Y_G^?'\A^/O706<W[W]QT_P ]^W^/(YKS_39CYO/]
M/_K?Y^E>T>&[."\BY_QZ_7_Z^* .PT&SGU+MV_K_ )_' KE_%6@^*M-NO/@G
MN1_3_'I_^HFOHGX>>&_.E&<^W^?3K^%=/\:]!_X1S0;>?R/^7/Z>X/3I_GWH
M ^/YOCQ\1O#=I]A@OKGTST^F.GX>F.U>?Z]\?O%6I6OD:K/<7/\ IF!U_#Z\
M_P N.*X_7=>^V7_V<?7_ /7C_P"MQQ[5P_C"SGAM;>^@_P"/?I[XS_\ J]/>
M@#V";4K'Q586_G^GZ_UX_P >U=!##_PKV/3];L;[_2/MGV+/Z]\\]C_]:OF?
M0/BII6FW5M8WWOP?Q_GS_/MBOH">\L?'EKI]C8S\6I^V_P"'^??(/(H _6CX
M,_%K2M9^&GV#Q'/_ *1]C]?_ -7^1]*^-_BUH_GW6H3P6/\ H]W_ ) QZ>G7
M/MS6/\/;*^^RV\$%]S:\_P#'Y_0\=^^/ZU]$>-M8\.6?A+_3X/\ 2+7]?R_S
M]* /R?\ %7GZ;?W!@@Z=?\/\_G5?3?%4']EW,'GG[1^1_E^6?;OTZCQY\0O!
MUYK-Q8P?9OM![\_KQ7@^I36,,MQ/!/\ _6XQ_A^E 'W1^R[XCOO#?C+1[ZQN
M/^/KCTX_S_A7]+'@^]GU+0=/U6XQS9_3/?\ QY!_I7\L_P"SK-/]JT>^SVZ?
MSSVZ#ZU_1QX$\>6__"M=/OK?_2?LOIS_ )Y__70![?J7AO2M=BN!JD'VJWN0
M.,XXZ=NW^>*_(C]KOP?X<T>_N+'2K?\ SS_];^N:_2B'XPZ'#HWGSC[-<?8\
M\?\ ZO\ 'KUK\U_C9K%CXPUZXN,<=O\ Z_I]?PH _,?7M!OK.TN/(G^S>WUY
M_P _F,YQ7'Z#>3_;_L/V[_2,8_S@>O\ DBOJ#XA:;80V%Q/_ ,N_'Z?Y^O7&
M17C_ (/\->'/[4^W7%_^?^?Q]: #4X?%6FQ6\]OXC^S?S]N?P_'%9&I?'+Q5
MH-W^_P!5^T_TZY[?E7'?M">*C9VGD:5??3K[CMW_ )>M?,^FZ]_PDG[^^G].
M3W/_ -;T_P * /L#_AI;Q_\ :K>>QU6ZMO\ /3.?\G KZ@^'G[=7CC0;6XL9
MY[FYN+3W_I]>O(Y^E?E^?$FE0Q>1!_Q\'@\=_P!,?A7<> ]7L9KJX@Y_M#\>
M>>?\X!^G- '] /PE_;DOO$DNGV.JV/\ Q]8_GT_E_7O7Z3Z;J4&L6%O?0?\
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M_P#6_P#U?KA\ =8\8Z;I?A?Q'/JMU;6]WK'^F_Z9U&<G\A]/;- 'S?\ M"_
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M6LHFU[XD>/\ 5C+"YTCP1X(@F.OZ[.J,1/<^7#X5\,K*+KQ7>VEJJ2#^)_\
M:K_X/5OCOK6N7NE_L8_LK_#/P'X3MKT+:>*OVB[W7?B!XRUG3MK?,W@_X?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH=?:EXC_ -.%M;9XS_/\?\.!CK]P>#_$G@#X\2V_]JWVF_\ @9VYY[GV/ZT
M?B?X)^ ]C9W-O?7T_P#R%?\ 3?LG'ID]/_K]*T/B1\);Z\\.:AI6AZ5]I[?:
M_P#ZW!R !^F:_8CXS?LKZ5H-K_PE/AS5?M-O:?\ +I:7GKWY_E^M?(_@GQA8
MWEKXATJ;2OM-Q_Q-+''V/^GZ\^G2@#\=_P#A6%]9Q6^E:Y_HQ/7V]?\ /7WZ
MUZ1\)?A[XCF\>6VD^#H/M5O=?V7S]C_S^M?=$_[+OC'XG:I<3P0?9K>ZO/\
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ME_7Z_P!,Y_'^LC]G7XJZ5\5/A]I&N6-]]I^U6?X_Y_KZ]P#\Q_C]X;N--O\
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M>4>)/%4^FZ#I]O?3_9K?5,?Z7_3I@YY^O)]*Z>\^(7A:\CU&RSNGM1J@ P,
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M/Q)/H.LZ?/CK_C^G;^=?KA\/?'FE:EJFCWT\_P#QZ_@1R?U_^O7XO_"O4O\
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MQS7#Z-H,]G_G\.,^_3/^-=A-^YBQSGKV_7G_ .OGGB@#'_Y:_P"?[U6*K_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 5W>-8P2#M/X'(XXXY]./YU^>W@+_@I?^Q#\3/VQOB+^PIX)^./A
MO7?VDOAAH9U7Q)X%M;PRZ=>,A8:[X5T/648Z%X@\4^#(4CD\9>&K2X.I>%/M
M!CGB$EOXF%I_-[_P<4_\'%5C^S1I_BO]AW]AKQA:7_[1VH6M]HGQJ^-.@WD-
M[8_ 6RF@D$OA#P5J\4P23XTOL=+N\B5XOA[&^Q&/CR8+X6_SK_!?Q7^(OPY^
M(^@_&+P)XS\0^$_B7X7\0Q^+_#OC_1=7U'3_ !1IWBRVU%M8CUN+6HW$HUWS
MSO></MG)!E,LA8R<^ J/$XB[=LJDE:2C[TD[^\D].5.UD]97=K1M)ZXS"O#8
M9W:6:M+DBU90TO>;W7-?X;)Q2N_>O&/^]$".@(^@Q2U_,!_P02_X+W>"/^"E
MW@BP^ _QXO-+\#_MN^"M)@_MO1XYGTOPY\=-$T4QQGQYX!B-P$C\11QJLWCK
MP;&X:(^=>V,<GA)WB\.?T_ \ GTR?RKMKT'A79^J:ZI=5Y?EU.&A7]MS)QLU
MHUYZ/HVG=---;WN+11161TA1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGA<0E=VMU=GIZ^7GMW[G(ZZ6\7]Z_.UOZ^1^J]%%%8FX4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?A_P#\%&KR"#QEIPFS@7F/\_XFOW K\5O^"@^C_P!I
M>+=.Z?\ 'X>_.?\ ZY[_ ,J /S(FF@O+JW^S_P#/H<=_QX'^1^==1ILT]G8=
M/](__5_/C^?2J_\ 8\%G?V__ %Y@_CS]/?/OUJO--_I=Q!T!_IT]_P"??\
MO9I_-\_CU],_U]/Z>V>=8[7WL?\ /\N![^M9^I33^;_+K_3/O_A1##YO^?\
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M;ZK-KUQ?3WQMM/\ ^?3I]?7^7I7\V]Y_P5O^,4/BW[=!;_\ $ONKS_ZX]_\
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M87VFYU^ZO/\ E[_S_A7P?H_[-/QI\86NCZYXCGN;:W^Q_P#/[[__ *_0=_H
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MN'C;7_ 'B31M8\.7%];7)NK/[%^F.GM_GB@#\[]-^(4_FZQK=]_HW]J79_7
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M^(7A7QMX2T_5M*U6VN?M=G_S^ \>G/\ AU&* /Q'U+X80> ]9N!_97^CVO\
MQ^?Y]?U^O?S_ /:*U[^Q]!T^^\.0?V;;W5G_ *9_^OU_#\*_6C]I;P'8VDNG
M^18_\AZ\^Q?:_;WY_P ^U?$_[17[*_BKQ)\,_P"U=*Q]GM;/G_/X_P#U\T ?
MA_IO[0NJP^([C2K&?J?\_P"?PSZZ$-GXQ^)'C+1X-)^TW/\ IFE]?\^GU[]:
MX>'P'/X#U[4(-<LKG[1_UY^^??/7D=_2OTX_X)U_#&?Q5\0?[5GL?M.G\^W^
M?3'Z4 =C\8;SQ5X/^"UMX(OO]&^U6?V+[(?3V]?Y^O2OYQ?%6FWUEXCU""^_
MY>M8^V^GT_P]O:O[0?VTOA7I0BT^^\C[-I^/\_S_ /U5_-?^U%\-_"NFZ_Y]
MCC_.?\]OZT >'?#W4O)M;>PL9_I^A_IQ^7I7TSINO:KH^G_Y^G^/MW^GP?\
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MM[>(_"NO_P"G3W.I6]K>>GIU/&?\GWH _6#PK\#?$=G:W&J^'?#ESIMQ:_\
M+W].P'T_7\:V-3\>:YX)L+B#QC87-SJ&/]"Q_GZ5\O\ @_\ X*K3ZOH.GZ'I
M6AVWVBZYO/\ B3_AW/Y]>@KZAGUB#XS:#;ZK?06UM<?X?X<=#^78 ^A_V:OV
MA;Z\BN-*U7_1K>Z_X\^V?Z=:_&?_ (+#:#JMYK.G^)+'2KD6]U>?\??KV/\
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M]Q/]FN/L?^?S_'\J^.->_:*_>_\ ']SC\Q[>AS[^]>3_ !^^*FJWEU<0"?\
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M^8!L36?G>WY?TK/\GR9O(_+\/?\ Q[X^M:$-Y_G^?'\A^/O5>;]]+CC'7O\
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MFA)Q?9ZM::=5?6Y)1117&=P4444 %%%% !1110 4444 %%%% !1110 4444
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MEJFJ2.L<$<,2F61W,8"0.S,-K,O^<E_P79_X.;O&7[0&M>)_V5/^"=_C'6?
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M_P!;GM^'T[\5]\?M%:/?7MKJ%]I4'^D6MY^OH3[?R'MBO@?4[R>&4P:K!_\
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M^,UCX5L/[#@G_P!(M?\ 31[<_ETZ<]^O>OPO\5_%.X^(5_I]C?6/^CVN._\
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MZ]/#+UY]?3C_ .OZ]/I703>,)X8OW&+G_#MS[GZ>_>N'AA^V?YZ]<<9_(?\
MZJT+/09_-/G_ $'\N>_^?44 ;,/C'7/-,\!N;;_//';_ "?:M^S\>:YJ4H@G
MGN>.G7//Z?X].M%GIL/E>1^G;G]/\^E+-H_V/]_CV[_Y_P#UT =/-IL$UM]H
MGG^T_CU_PQGO^=>7ZQ:8E_<<_EC/Y?K_ #[;$VO_ /+#\<_GSP/J.?;-9_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 444WA!WZ_B30 ZBO@/X)?\
M%-?V!_VC?BQXU^ 7P5_:R^"_CGXR>!?$.I^%]<^'NG>,=)M/$5_JFAXBU>7P
M=;:P+=?B!H,<J8N/$'@J3Q78J#,?M0"!X_OR@ HHHH *P=5TO3M<T^[TC5;"
MTU'3-2M)+/4].U.RBO["]T]XF633M2CE\V-@1,Y._>N"2RRD_-O44 ?YH_\
MP<3?\&[NH?LHW7BG]MW]B+PI=:C^S%J5PVL_&7X/:#:2WU_^SO>O,SS^,/!T
M2Q"=_@K))AKFV1S+\/9I"0&\"R ^$OXQW22*0<\\@$CTYYQ^A[_F*_WU=3TO
M3=;TZ[TS5;2VOM-O[9K2[L;R!;RQN[-PP:.2-D\MPZO@JVX 8.TD*X_S8O\
M@XE_X-W+S]E&^\4_MN_L0^%+J_\ V8M4N&UGXR_![0;2:^U#]G>]>5GF\7>#
M8EB%P_P5=\&YMD?S?A[))D;O LBGPEYL)_4+0E=Y<W!4YN=VGM&$F]'=:0FV
MND9-WC)>JG_:=D_^1KIU_B+\^;F]>;=>_P T9?Q_^!/'WC+X7>,?#?C[P%XC
MUKP?XX\(ZSIOB7PMXI\/7DNF:[H&O:(XGT?5M(U6 I-;O;W")+&\;J/D(PZ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'[2W[3=O\)?!&H:Y8_Z3J%U9_P#'I_GW^F<G&* .X\>> [#P?::AKFE7V?\
M0_\ /Z_YZU_/?^TMXP\1P^-[B>QGN;G_ $S^?KGKD_\ ZZ](\-_ML>,?B%KV
MHP:Y/<_V?=?\NG;].?\ '\Q7'_$'PW/XPNKC7/(N;:W]3]>2?TZ_US0!\[_#
M'XAZMKWCS3['7!_H_P!L'3Z?UZCGZ5^T&L:/Y/AS1Y]#N/LUO]C_ ./O_/\
M]<\YXK\=[/X;7VCZI;Z[;\_93W_^OSQ]/7VK]"/AOX\US6/"_P#94'^DW'V/
M_P"O^''% 'L!\83Z#:_Z=8_:;?\ Y^^?R_\ K9_PKXO^.7QX\-P?:+>X^S7/
M_P!?M_GO[&L>\_:0TK_A(]0\#^*H+G[1_P!.AXZ__7P..^>^*_/?X_7D^F^*
M+B^TJ"YN='NKS_E[]OP^OZXP: #XG?&:QUZ7^RM#_P");[_I_G'X<\UY?]L_
MLV_TZ>:^_M*XNO\ ET^N3C_]7!]JQ]2TV#4OL]]!@7&<=?;].WX]\&O6/AOX
M/_X236='@G_TGM]/Q^M 'Z4? 'PW/XVM='@@TG[/_P!.GK^/Z_7CI7[X? 'X
M/Z5X)T&WG@XU#G\/_K=_;GM7S/\ L9_ >QL]!T_7+ZQ^SXR<>A';_/X>WZ7P
M106?[B'CID<9Y]_YGUH ^2?VEO%5CH_A?_3I_P#CU_+@8SSCV%?S7?M$_$+0
M_$FO7&E>?]F_TSI]>,C\/:OZ(/VTM2T/3?"69Y[;[1=GV_S_ )]Z_FW^*DWA
M7[?<3G[,+@7GT_7M^GI0!Y_H_@+^S;7SX+C_ (^O^//]/R_.NHTWP'!J?VB"
M>?\ TC/KTY_/BC1]8\G2OMT__'O:]L>OMGV_'T..+/@F$>)+_4+ZWOOLUO\
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MY8K^L#XA?"70M>T^X,&E6IG/3%GD'_/-?._@GX&_V/XH\^]TJVN=/X_Y<_\
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M&R^\8>+=8OO$=A]FN+6\-EB[/TZ?Y/-?F_\ $W4M<_MG3[[2K'_B7XS]K/\
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M_P!8[]/;\*ZB'4O.BZ9Y_'K[_IZ<@]<5R_\ K?\ .,8_/U]^OY:$'?\ '^E
M'00S3PRG\?QSW_'/7\N<5U$TWVRP/;U]?\]2>OI[UR\'?\?Z5L>=Y-KY';\/
M\C_]9% 'E\T,\-U]?3C\S_G%=!!W_'^E<_KT_E2\?YZ'_.?>N0A\23PR^^..
MOX?GWH [>[FGL_UX]O;_ #]>M5]-_P!,E_SW]1^N._0CO61_PDECJ<1@^GKS
MV'M^7XCBJWVS['+^X[?Y_+_ZV#Q0!U$W^A_ZCG/7_P"OZ]\?IG-;%GK$_P#/
MCZ?_ %N/:L^&:";H<?I_G^=;$.FP?Z_CIZ_B!G\/Q[F@""\F@FE_ET_SCO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.O3Z\#'Y$U\<_MM_L0? 3_@H'\ /%O[.G[17A*+Q#X/\26TEUI.JVT42>)/
M_B<)+!HWC#P;J\JO_9&O: TCOE$,=Q&Q@G5X9'1^2K3Q.&Q?UK"IN+:<HIVD
MG;>/]Y:V;T:]V6EG'LP^(?U;ZMB=8_BGU:\M%=?]O*S3O_AJ>H!X_G7Z9?\
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M/K/U;_:]]?ST^[3YW=E>R=11169U!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% $*MCC&1WK.@U#3[]KR*SN[>>?3[@
MVEZD$P9K.\V F*4 _(X#CY3WRI4D,!_,S_P7P_X+X>"_^":_@O4OV>OV?M4T
M7QI^V_XYT:22PLIFBO\ PQ\"-#U59$'C?QRBO%!+XHN(29O /@J5]\\_V;Q?
MXTA'A+[+:>,?X<?^"7?_  74_:P_X)^_M:>,_C;XZ\9^+/CU\._CWXK/B/\
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M_:$V(MQ\9O@3\,/B3>*JB,0ZCXT\%Z+KNK0H@^55AU:ZFB &,!%.!T'U'_\
M&Z_//_@E'X)USX<?\$T?V$_!'BFV>RU_0/V5/@98:O:W++NLM1_X0'PZ[Z;C
M'2*240 9/S+GYBP%?H:V!O\ ]F(8^OR_SS_6N_B##X7"Y[G&&P33I4^),3"+
M5K.,*]2,+-:-*G345;3W$EL>/E%GE>7)-M<K46U9N*TC)[7;C9NUE=ENBBBN
M,[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^V/Y(-!\;64U_K%]!??^3G^??/T^E?K1^Q1\8)\6UC!./^/S&??H?\3P/;-
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M_7_9?]D3Q5!-+IVJP3_Z/==L^^?Y^Y]^U?S+S0SZ]XRT^"^!MM/^V9[G_/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"NRC85SAMI&.O7@>PXK_(S_ .#E+]@BX_89_P""E'Q
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M]V[^5_07MGA[_65]R;M\DK_AIW/PB_X.'/\ @W+U+X :GXN_;@_8,\$W5_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %?A]_P4.A$WC''_ $]X
M_$<?3M^7;-?N#7XG_P#!0>#'BP3=_M@Q[<<?KCC],<T ?F__ *F*W//^?P_I
M[58FO/\ /\N/YC\?>K$UGYUK;_T_R>,\=.?3I1#9_P"?Y\_R/X>U &?_ *W_
M #C&/S]??K^4_P!CN/4?E_\ 6KH88;'\?7O[_7 /^'>C4IH(8OW!_#Z=Q_3V
MH SX=-_=?3]1^/IU[BL^;3?WOT_4_AZ=>YJQ::E?"7_/?\:V)HIYCZ9Z?7U/
M^?Q% &?#Y$,73_)/K[]>]6+(P32_XX_G[_7C!Q5>:S_S_+G^9_#VHL_W/3O_
M $].F.^?TQQ0!L3]OP_K7/WEY_G\L<?EG\1FM":;_)_S^0SZDFB:SL9HO;GM
MZ?\ ZO?M0!7L]8G\WR.?L_O]>G'TZ>M=QIL-C-_GTY_'//I^=>;_ .IE_<?\
M>_OCZ^W3.?P[9JQ_:7D\]>^?IV[^G7]>,T >P0WD&FR^?[_USV^IY]NQKC_&
M'Q)GO(?L$''\L^W].W\Z\_FU+5;R6W@L9S_T^>O3/Y_RP/J-";3?)S./^/C_
M #@$?I_];- 'E&O>)+Z&;R+[_EZ[_A_G^7UQM'\23Z;=6_:WS[<GTP>A]??M
MTSZ!XD\*P:E%Y\__ !\?S[_I_P#KQQ7G\WAR>&+UM^/_ *_8=.<>E 'J&I>*
MM*FTLS_9_P#2/7MZ?7M]1T]*X_3=>G\[N ?I_3_/Z5R_]G7TT7D0>O\ G/'^
M?:N@M+.^A_Y=^G^1T_KGOTZ4 =A9ZQ/_ #X^G_UN/:J^I:E?0_N(.OZ?XY[=
M/Y4?V/YT7G\>_3\.O^/UYQ5>:SOA+Z=??MU'U_'% '+Z/#?3:];^?SUZGZ^_
M^%?M1\&=3L='\&V_GSC_ (\_K_7^7&:_&>"&>'5+>?\ P_#\>W;TP:^Z/!/C
M"?\ L$P?;^O'Z]_Y>_)YH [#XPZO_:<MSY'_ .OT_P ,5\/ZG>7T%U<=?3T]
MC^/U_KQ] :[KWVRZN((/KVZ]^W//]<]*\_O-!@'^O_Y>O8?YZX_SQ0!YO90S
MWDOOSG\O\^WY5Z1IL(\KG^O_ -;_ #]*S[30)[/_ %'Y#\*]0T'PW/-_RP]/
M7\^N1_GIF@ TVS_T6W__ %_RZ_YZ@5ZQX5TS_3[?G_/^?4_T%6-'\!3S16Y\
M_IC_ /7_ ")_6O>/ ?PEOKV_M_\ 0;FY_K^?XX]/RH ^R/@/IO\ HOI_3'Z?
MGZ]#7F_[:7B3^S?#?V'_ /5Z<CL/?^=?2_PW\-_V#:_\>_V:X/&/?WZX_4^V
M*_/C]OSQ(/LOV'[?;6UQ]?\ //\ ASS0!^6^I7GAR\TO4/MT%M<W'VS/)Y_S
MTZ]/SKP_QAK%CXDM?[*@@_X]>!_G_(^O-%Y-_9MU_IU];7/VKU_R/8#V]\XQ
MYM8L;.PN)H)[;[3_ )/_ .KG'6@#S?3?!^E32W$&JP>N,_KWS^?Z5H3>%=5O
M-&MX(+$6UMI?U]NOMSFO0/"LVE:]^_\ $=Q;?9^/^/3&F_F/USZ^_3V#0?\
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M >O>(]'\47&A_P!E?:?],-D<<@>F?\\\]J]!UZS\57FJ>1!8W5MCO]/\X_\
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M^XX_ECT_QSSFNX^$OB2>SBMYS?6_V?\ R?RS_7& ,U[1J6O:'K$7D7W^O_\
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MPY_^H_0_7^?J<?@/X\O/%4/B/4)X!<_:#]?\_KQ7]+&F7HAT'4-#FGMO[/\
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M$,WL/PZ_T_(<]A5>:;_)_P _D,^I)K0FL_.]OR_I4'V.W]3^7_UJ )[.;O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !14,LT-O
M$99F$48 R6X"YZ#"YP?I4,4\,\ FAF$\+ XGMR#G'7E2<^I('3D^M %RBBB@
M!BKCD_2L/6-(T_7M,O\ 1M6LX-0TC5;._P!+U2QN@#9WVG:LACFC;@AP\9\H
MX&1YC[2"5:M\$'D4QFQP/KS67NUH];7 _P 5K_@L9^Q!?_\ !//_ (*"_'G]
MGF.SNH/ D&O'QO\ !Z[N#O\ M_PC\<&;6/!@\T,[2/X=3SO"UVS@227V@73.
MJ!@#^7!?Y%!SD=>.,].G0_U XS7^E1_P>%_L##XM_LN?#K]M_P $:)'<^-/V
M9-6'@OXFW-I!B[N_@OX_U9%AU:X90JL/!WQ&DTD6ZJ!Y=OX[\1SLPVE7_P U
M41C"9YR3G\\8]^<'Z5CE.(E/"1PSDW+)Y<DKZR;M"TI-Z^\N1WU;:D];N_JY
MDW4K_7$TWFR;G962J1E%5%964?>]Y*UE&<;:))?[ O\ P;Q_M^P?\% ?^"='
MPRUGQ3K":O\ &SX"-IOP.^-!NIDEU34M5\#Z4B>"O&FJLR&21O&GA,Z/KUU<
M#=N\71^)2A"PL:_87XW?&;X8?LZ_"[QG\9?C-XST?P!\-O >DWNO>*_%.NW/
MV/3M-TZ,G#.1EI)7=EBCC1&E>9D"J SNG^57_P &W?\ P5&\,?\ !.#]M'7+
M?XW>*SX6_9H^/?@N]\(?%?5;Q-5O]*\+>(O#K/XB\">-SI&C)++-+:7"ZQX1
M!CLK@Q0>-YY\".V&,#_@N5_P7+^)W_!5+XH2^"_ LNN?#W]CGX?ZU<2_#'X:
MO>26=_XWU*)A&GQ(^)J12>3<:U,B.?"GALB6T\(6LS!&>\:XDD]//)/$8N6*
MP<4HYPW-Z? W+5<O=SG*RO9\\M;)W\/)\+&@Y83$IPIY0VXKJH3<O<3M:\=:
M=[-QC&+2NHI,_P""Y/\ P7+^)O\ P51^*$W@CP--KGP]_8Z^'NLSR?#/X;/>
M/9ZAXXU.)Q&GQ)^)RQ2>3/K<J1R'PGX:;SK7PA:S,$9[Q[B63^><@N<CITY_
MS_CUH!+G!Z=>/\_X]:_L#_X-YO\ @WGUG]M35_#'[8W[8_AC4-*_9&T6[M[_
M .'GP_U6)K#4_P!HS4])=7BEDAD1)XO@_%/&\5S=QE#XY>*:VM)DTZ.>XFRR
MW+:=.#U4*4$FV]WTN[6<I2>B2W>UHKW>C&XU))M66JC%=?O^>[\W=N[_ "]_
M95_X-]?^"G?[8O[*^J?M<_ [X.:/J?@'[9_Q0GA'Q5XPTOP;\2_B[I4;)'J_
MBSX8:%XE%KX<U?PY:1JV)_%'BOPF_B[Y$\!0>+]KHOY,_&#X(_%W]G[QWJGP
MW^.'PP\>?"'QYHS*=6\&?$3PIK'@_P 26>\!@SZ/KT-O.8R&!20 QL,A6.&
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MUI>5EZ+WNN_O==;-_P"S&ZX5<#H,GCD\GH/?&?Z^O^:S_P '<W[5G[;OBO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^+O_
M  4"_P"1G'_7Y_2OVBK\5_\ @H%#YWBCJ?\ C\_/OZ4 ?G__ ,NUM_P'^1JO
M-#Y\0_(G^?3_  [^M5YIO)M;?]?KUQCOC\OQK/\ [3G^U=\^G/\ +/\ 3WH
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M8G].WOU(^G_UZ /K?PKJ_ASQ58P>1]E_M#^7I6@/!-]#+Y\__'OGG^?7^?\
M^K/Q^=2@\*G[=8:K;?\ 7I[<8]<GK_\ JKWCP'^T)8S?9[?7(/M/3UQG^8Z\
M'\/2@#Z TWP3YT7[\?3C\?\ .:[#3=-^QR^1Y&.O0=><@8Z?Y-'AOQYI.L?N
M(._\LXZ?3_(&,>T:;_PBNFQ?;M5OK;].?Y]QG_)- %CP3-!-=6\%QI/M]?\
MZWT_+BONCP?J7@[0;#SY[ZVM;G_'W_#UZ=J_,?Q7^T5X<\*75Q;Z5#]IM_\
MES^R>]?&_P 6OVE]5U+[1Y%_<Z;_ -OG/T_^O[],T ?OOXP^/W@[0;6X^P7U
MMJ6L=+/_ /5VQ[9ZFOR(_:<G\2?$*_\ [=U:#[-;C_/;^5?GOX)^-GBJ;7OM
MT&K7-S]FO/\ E[&>I^F?7_/%?H1\*_BI??&:_MO#?B.Q/V>UZ?Y[<_\ ULT
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M*]0\'^&X-2BM[ZQL?[-''VS[9]1@\8^G7GFM#XJ:SX.T?0?(L;#_ (G'V/\
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M5:;=7%Q_:OVFX^G\L=1_GI7UAX5_;8N)M!T_2O(N;;4/^?O_ .OGC\><_B:
M/JCQY^SW!9_N-*@S]J_/U_#'U']*^9]>^%=]H_\ RP_X]>/\_P!>N:]PT']H
M2^UZUMYYY_U_ET_'\2:]XL]8\.>,-+@'V?[-<7?\_P N/RZC% 'B_P"SWX;G
MAO[;S[?_ #_GCO\ D*^Y]=TR'5]&-CGCC [C'X>I].M<?\/O#<&@@B"#&01G
MI[$C)Q^/2O3WM86&2,=/\]/\_K0!\ _$CX)SV<5S?0?Z2>W3K[=/_P!=?"_B
MJ&^L_P#0>+;_ $O'Y>Q_K7[4>/)K&ST&X\_U^G^>2/Q_.OPO^/VI>(_[9N/[
M*L;FYM_MHP;3M^?;IG^G< \W^(6CZK>:-<6,$_/XY[^W7K7YOZQIL%GK-Q8W
MT ^T#I_3ZG/I^!]?O#SO&.I77GSXMK?OGG_/?IG@^]>/Z;\)=5\;^-_W%OG_
M #GK^H _E0!Y/\)?AOYWBW3]<GL?]'^VCZ_U^F/YU^M'AOP?H<-UH]]!!_I-
MK_9>?RX]NN>.3Z>R?#WX ZKX5M;>"?PY<W/?OVS_ )Y_QKZA\$_LZ^*M2U2W
MUP7UM;:?:_\ +I=V>?P__5Z?C0!]O_"71Q9^%]'ON]U9C\/P[=,>O!->,?M-
MR^9I4XGYMA@#^GZ']1SUKVC7IY_!_@.W^P\_V79_X_X<<8]:_'_X\?M%7VO3
M:AI7VX_:+7IU_EZ']* /E?XJ:#!]KN9[&?[2.?MG^?\ ([G%?(^L7ECIDF9X
M,>O?Z9_R.M=#KWQ.U6"^U"">"YMK?[9S]K'_ !_],?X=:GO-'L?$FC?;Y\?:
M/PZ?X_U[XH V? ?Q(@L^D_0'Z_E_G_'Z'TW7H+RU^V_;N/8XY'3_  Q^O''Y
M_P!YH,^@W6(8;G(_+]?\CFMF'QAJNFQ<WW3MU]OK_6@#[O\ MG]I2_Z_GC\L
M<^WTK'O+.QU*7ZYZ?Y_IW]:^8/!/Q"GU*7R/MWV;_#^6>_MQ7?\ ]O7WE>?!
M/CGT_P ^O7^>* /HBSAL='M?]?\ YZ_G^5<OK'D:E$;B#C_$>N?\]^U?/^O>
M)-<LXO\ EY].O([X_P ]>G%9^F^,-<A_Z]_\^O?/7.>N.] 'N%GIN8OW_P#7
M@_XG_/6N?O+/R9;GG_'C_/(_+W\WA\5^(YKK]Q_A_3T]?K6Q]C\1WDOGSSCO
MGU_^M^>?RS0!Z!H-G!>2_O\ _P#7G&>O^?Z]1K'AN"&UN)X(,_S _'Z]_?\
M#.\'^%;Z&6WGGN/Q^OMTY_H>O6OJGPKH.E316\%]!]IZ<_\ UN??^7:@#XGF
ML[[_ *>?Y#CK^74^OX5H6?[GIW_IZ=,=\_ICBOLCXJ?![['H/]JZ5;]/\GZ?
MY&1V^((?/LYKC[= /\\C_P#5@XQ^8!?O+R";]Q??X=A_];VKR_Q)X<@O/^/'
MZ^OUQZ?3_P"L*ZC6.U]//]FMQVZ].>W(]/:O/]>\80"+_B5?Z3<<=#_GM_\
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M "./K^5>D>%9_P"TC]HL?]&'_P"KV&?\_2@#[@\>:#I-GX7^VV-]_D8'^?\
M"O'_  KX#_M+5/\ A)+'K:\8]_;'3T/OQQ5?^WO[8TK^P[Z?_2!Z\X]/T_R:
MZCPKXPL?!_\ Q*M5OK;3;?\ Z>_SY_/'OTYH XC]H3X;^'/B1HWD3P9U"U__
M %].?7WZ?E^9TWP?_L&ZU"">?[+]E]/7GI^@R/T%?LQK,WAR\M?MUC.+FWZ_
MK[<<=_UK\_\ X\7FE0RZA/8CWZ_K_GZ4 ?#^L67V.ZMX//\ ^7P\_P"?K_3Z
M?I1^S=H]C9VOA^XGGQ_GV[_S^O3\OX;.^\27]Q;P9^T?;.A_E_3^9]/KCX;Z
MGXJ\'_V/!??:;:WM>_?G_//'3% ']6/@.'2IOAI^X^S?\>?7_(],=\<_2OR^
M^-D/G7^L>_\ +\.]?5'[-_C:?7OA]Y'G_P#+G_C^O'O^%?*_QFAGAO\ 6/M'
MO]/?G/?_  Z4 ?%^I'R9?7^7T_\ U#VKS_XA6<]YI8YSQ]>OY_C7H&O30>:?
MW_\ ]88R/Q[GKWKS?QAXJL?L'D8]?;\>GKZ^G'L ?(_DSPZS];SV';/^.,C(
M.*^T/A[#YMK;X^O^>G;U/<U\CZ#9SZ]K/^H%M_IF,X_/_'^@[_:&@V?]F6%O
M .GY@?IZD<<^OU .PUB;R9?(@Y_SC_/(]NYKS>\_?2X_F!C'Y_C5_6-8_>^1
MQ_/)_P#K^_I^?,SWD\W7^8]<_7U]* )YH?\ )_S^1QZ@BL__ %7^<YS^7I[=
M/SL0WGD?Z^#./Z_S_P ]>:/.\W\/;_/3/MU_( T+.8^;W_G]./\ ('T)K0G[
M?A_6N7A\_P W_.?;VSC-=!!W_'^E %B#O^/]**)^WX?UH_Y8_P"O]_\ ZWY=
MO3O0!8\V'U_4_P"-5[V\A\W_ #U/IUZX/\JSYH9_^>__ .KZY]>G/KCTK'_>
M_P"=U &A-^]]NGZ?G_6JT/\ KA]3_.E^U_\ 3']/_K4?]/'Z_I_];K[^] !/
MV_#^M9TW^N/U'\ZT9^WX?UK/_P"6O^?[U %B&'RO\_YXZ]ZT(?(X_#\__P!7
MWJQYO/Y_'\O_ -?W:(?/X_#\O_U_>H V+R&#KWQ_GW_/\ >*KP^?Q^'Y?_K^
M]5#SO.E\COG_ /5G'OT].M;$/^I'T/\ *@#&O.__  &BS[?\"HO/WW7M_7UZ
MY[?USS5BSA\G\?\  _RH V*QYII_-^GX=?7'/Z9K8HF\CG\?S_\ U?=H S[.
M\_Y^/S/Z'K^)(%6//]OT_P#KUCS]OP_K6?#J7_3#UQ_7C^F?4^E &A>=_P#@
M-%GY_E<8[_\ U_PZ?ABC_6_YQC'Y^OOU_(AF\B4_F!_+K_CV]* -#R/?]?\
MZU5_^6O^?[U:'VR#RO\ 4?X9Q^77C'].*QIO]<?J/YT ?3/[,<)_X6#[_P!C
MZI^?TX_GZ]\5_417\M_[,<Q_X6#[_P!CZI^?UY_EZ]\5_4A0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0 !5P#
MDDY/X?E_+M^;N0A]S_D_TY[X(YHPO R<G\N?R_Q]1VKY@_:J_:E^#'[&/P*\
M?_M%_M!>,+/P7\,?AQI3:QK>JW#LVIZE>RLR:)X?\/Z06-QK?B?Q+K;VVA>%
M/#R O=WLT<:SH@;R^6KB'AL/]8Q,;R3C[J3NY2=HQ22;NW9))-MM)*Y="A]8
ME]7PV[M%):ZMO;\>MDKMM'5_'7X_?!_]FKX7^*_C3\<OB#X=^&?PS\%60O?$
M'BOQ/J']G:;8*RSI%&BK&TNKZO<NJQV^AVT<D\SCY(SM#U_ !_P4T_X/ /C5
M\1M7U_X7_P#!-KPY!\&/AU;R7VGR_M!?$#1M-\1?%SQ5&':--5\$^"]>BN?"
M7P]T::,/-&?$EGXS\52HZ2@^#YX6MJ_"/_@KO_P6+_:)_P""KGQFG\1^+KF\
M\ _L\^"]3U-?@Q\!M.OT/AOPCILL6!XM\8K%,4\3?$7Q);2(]WXDG"16O_(.
M\'6\%NCQ3_B_DL21U'(''4GD^G3\L\5GAXXG$17UIZO[*VBO/;WMM%HMKO<Z
M?]FPMOJR4G>^WNIVZ76MM=;;ZJU]?I#XY?M;?M,?M,:E+J?[0?[0'QH^,]Y+
M?3:G&/B5\2O&/CBRLK]V($FE:7X@UNXMM'5$)B'V6),* R)CKD_!_P#::_:)
M_9XU-=:^ ?QS^+_P5U!;E;E+OX4_$?QAX&;[<H&URWAO7K7SG"C DE+LPP#\
MN / FW9^;_/Y?6A=V?E_S^?TKT:'^S/_ &733HK+MLO+U\[ZG)7?UG_>+3[I
MI-+Y-6]-O*Q_;9_P2R_X.X?CQ\,->T+X5?\ !1^U'QV^%%]-I^E1_'GPYHFE
M:/\ %_P(DMQ+&VI^,=!T&&V\.?$C0;>$1><T%OX9\8PHDUU]J\6R$6R_Z*?A
M#Q;H?CSPIX9\9>&;I=1\,^,=&TKQ+H.I+"T*7^CZYI4&MZ1J05PK;9;:6%U#
M*I_>@LO +_Y]/_!M-_P;]_\ "RKOP/\ \%#?VV?!3?\ "N+*XL/$?[,_P5\3
MZ<<_$"^BE2ZT7XS?$#1=6B;SOAS&R";P%X<GM]GCBX%KXRD8^!1IZ>,_]$)(
MU2,HI//WOR/'4=CZ#KQC%=V8Q6%IQPE9*.:Q<U5]Y))JR47%*SG%N\Y>[R_#
M).7P^/A&J^)E]3M_92<MFG"4[OX6NB::;3<9/6-DKNY1117G'KGCWQL^$'@C
M]H/X,_$_X'?$G3K?6_ 7Q;\#^)? 7C#2VR!J&B>(M+FT75HSCH4BN,)UVR*H
M;@8/^(Y^VC^S5XU_8V_:D^./[,/Q"CD_X2;X*?$?Q%X.ENF38NNZ5"_F>'O%
MD(#R!;7Q5X:ET3Q);*&/[C5H1B/:4'^YXI^4#U'(/0Y Q_+\/TK_ #WO^#RS
M]@I=*\4?!7_@H9X$T0+:>)HX_@+\=;JQMY!CQ%I,5QK/PJ\5ZNR95FO/#\6N
M^$IIBJ 1>'?"\7S!B&\VI5>$S/ U_LU59K32=.7-"2N]W>4&]-)K70]+"S^L
M8?,,)MS)2C;^:-FU?IS16G6\=.Q_!JY!'4>H]^M(B%CC!/./_K8Q^9R.M*H
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MB'^S?\9/!7AFQTXLH74YM<\1>%+.SCAW$.[F01QH,Y(&%^@/^"2'_!._QO\
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M26'_ "-?^"D'_!-O]HG_ ()F_M$:[\!?COHC.K'5M:^&_P 1]%TZ6/P/\5_
MJNB0>+_!LSR8'RL(O%?AN0/?>#+PR6MVA0P2RQA\3&CB/JF*MS+9K:<=[I;7
M75:=6M+I=-6DL4GB<,EM>4+[/17BW:\=K]5I?HWZO_P23_X*W?'3_@E-\>H?
MB!X"FO/%OP;\8ZAI=G\</@=>7LL'A_QWX=@E7.KZ06F:/0?B!X:C>5O"7B7;
M(-TLEE?J^GSS1G_7%_8T_;+^ _[>'P"\&?M%_LZ^,H/%GP_\86@&W=&FO>%O
M$**'UKPCXOT906T/Q#X=D,=O<VT\I;<=Z%X'BENO\,L$YP<=,\5^N'_!)'_@
MK9\=/^"4WQZA\?\ @&>\\7?!OQAJ&EV?QP^!]Y>RP^'_ !WX>@E4G5](+3M'
MH/Q \-1/*WA+Q+MEYEDLK]9+">:-OH*=3"XO"K#8EJ%2":C)J\91>\9>3T::
M=XOO%M+PZ]!T6\3A5[_;^;2UG_>T5GM):-[-_P"SYC"\YR3P/IW_ %I"%9<'
MC'UYY_'U/;_ZWR5^QK^V7\"_V\O@/X-_:(_9X\90>*_ /B^U5<%T77O"_B%5
M#ZSX2\7:,H9M$\0^'9&C@N;6>5F#$2(9+:2&:Z^MCM'')YY/ _+K^M>?5I8C
M"XB6&Q,6I)RNN7EE&2W36M[WNFKIIJ46TTS6C6CB8_6,/>][---/1V::=FFF
MFK-)IIII-$U%%%0=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?C!_P4"_Y
M&@?1?ZU^S]?B=_P4-O(8/$ZYZ_:QGOD_YS0!^?,P\Z&W'3/]/QK.F_<RYXQT
M[_KQ_P#6QQQ5>";_ (]X/\^@R?RSBM":&#ROI^'7UQQ^N* "'4^^/P_/C^O3
MZ]JL37GG?9_(_K_^OU_05R_DS^;_ )]?KGW_ /K\T3:E_9OV? _X^N_Z_P!.
MG3WXX -C4M2\Z(V_;_/X8]/ITK'LX9X?W_O_ $_#M^';(JQ9S03?Z_\ 7_/4
M= >]6/MGG2_8>EN/S]OR_KGB@"O^_F]3S]"23_GTZ^]'G>1_K_\ /\B?_P!0
M[U8F_<?ZCWQ_];USSUZ?E1#Y$W^OZ_G^'Z=_TS0!8FF@Z=__ *W^'OGTZ')#
MY_'X?E_^O[U8\_;\/ZUH6=Y!#],_K[^W^?6@#H?[8GLXO(_#O_/K^?\ ]>JT
M,T%Y]#^G3]<YX]?QK/U*\@FBQ_R\8_/T]>?YXSFN7A^W>;W]\=/U[?IZ<4 =
M!J5GY7[^#&3['VQ_G]:H0ZE/#WS^G^?7Z_I?A_<?Z_VS_P#7]<\=.GYU7FO(
M,]^W'ZCOU'ZY_"@#0_M+SK6X]O\ //Z^Q^E<O-J?D^A_GQ^/UY_'IS6QYT$W
M[CWYX_SG]>E<_>0]OI_]8D_R&/ZT :%GK';_ #]?\>/6NPAU+]U_K_SZ<^WH
M:\GAA_S_ )_4X]@*ZF"&?_EOUZ_R[Y_E[]* .GO-2@F_UWY=#CZ<_P"/YUGV
M<T$/IZ>W_P!?CUX'TJ":S@F_U$^>??GZ<]NA_P#KYJM9V<\,H]/3Z_Y]_P"5
M '4:;"+RZZ'\/\_7O_\ 6K^*OAO/J=I_H'_'QW_+U[>X[<?CT&@P^3+]HSU]
MO;/MUZ\]1TKL!J4\TOD0?7_]>.W3^M 'P/>:#JNCZ]Y&JBYN;?V_QSS7T!#_
M ,(K#86T$%C<_:/^O/W]/\?RKH-7T&>\U3SY['[3;^WL,\Y_R/QKTBST?0S%
M;P?V'<_:./P_3MTQZG':@#0\!V<]G:^?!Q<9_GSCGT/K^'3%<?XP\;>(_P"U
M/L/VBYMK?G\_SQ].V*^@/ >F_8[_ .PV]C]I_P _3IG/;MZUG_$+P'/-?_;O
M[*N+8<_S_/O_ $- 'RO--/#=6]QJI_T?_P#7C)]OISVS7@_Q.O/MFJ_Z#!U]
M>N>WU]\__6KUCXP0ZKIOV:"WG^S6_P#RY?\ UP/3T KR?PW9WUYJEO\ ;K[\
M2?RQSSV_3I0!YOH]X=&\4:?!/!<VWVK_ #[G';]>*_1#X&PS0Z];WVE7US;=
M>OX^G_ZNIZUX?>>&_ \-U;S^([ZV_M#_ )<\>G7_ #^O85Z!\//%6AZ/=3_8
M>;;_ #^7/X>F: /Z$/@GXPL;S0;>QU6^^TW'MZ<X_P FO8-8\!>#M?L+B"?2
MM-N<CVP/\]1W_.OY]]-_:<_X16Z\_2M<']H6MY_QZ=OIS^GX5^H_[)?QXOOB
M?=7'GWWVFW^Q]P>/_P!6/SZ4 >X^&OA[H>CZS<3P:';6WV3_ *<^<_F#7R-\
M9[R";Q'<6]]]F]^G3_/TK],/)$45_#_R\77H,\X(STZ<_P">_P"?/QF^#^N:
MQKUQ?3_Z-;]>GU^N?Y>E 'YW>/-'OM-NKB^T/TY/_P"OM_,>G%5_ACX\GT>7
M^U?',]S_ &?_ ,^9'U^GT[5[!KWANXT&6X@GG^TV_P"/K[?S/]*\G\23>#O[
M+^PSP?VEJ(X^R6G0_P!/P_G0!](?\-@:'>Q?V5X.L1_X!_KZ=_;K7S_\3M8\
M1_%N6W\B>YT3^P/^?3I?\$?I_G-8_P /OAC!J4OGZ'8W.F^]Y_G_ #[FOM#X
M8_ >^U+2O%$_B/2;FY^RV?\ H?IZ=!_2@#\Y_"MG/>>*+?2K[5;FZ@M>W\OR
M]._K7M'Q;\-^'!_9]C8P?Z1GGV)Q_/C(_6NHA^$O_"+>*-8U7^P[FVM[7^U/
M\Y/8]NO;WKX_^,/Q.\5:/XHN)X-#U*YT^USC_/Y<^] 'K/BKX@Z5X6\.6^E6
M/^C:AZ_ET_IC->#7FFWVO6']JWVJ_P#'T/\ G\&>W^>1]*^-_%7Q@G\;:R8/
M/^S7'_/GC_/^>2#6?XV\8>(]-T:WL?[5_LP@]?;W_+O_ $H _5#3?AO\'9M!
MM[Z^L=-N;CO_ *'WZ9_^MVQ[5Y/XJU+P/X;^SV/@?2?](_Z\^V?P_K[U\/\
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M_K6QX;^(6E>/)=/@T2_MKG[5TQ]>W/7/'M]*^\/ACX/_ .$;M?MQ_P"7KO\
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M\XK] -2TW2=-TO\ <3VV ?K]/H.,?Y-?+^L:Q!-K]P9_^/?V/7US_/\ IG-
M'@^FZ#Y),\\'KQV_3^7./RKH+.\@\WB _K^/XC\^?7%=QJ4VE>5BWGMNY]@.
M?Y_CS7#FSG\WSX(/S/\ DG]?RH ](T?4H.?KC_Z_UZ\\?3FO</"MY^]M_3^7
MIZC_ #[<?-^F^?\ \\/J/P!_^MWXKWCPKY\WV>#G/K^O^/3VH ^\(--@U[P'
M<0>1]I_T/C\/R_7\>]?A_P#&#[=X;\;ZA8W\'V:W^V?Y_P _A[U^_'P!\B:Q
M^PSVX^SW7Y<\]?\ ]7\J^/\ ]N3]G6"\^T:[H6E#[1V_S_@,'G)'2@#\7_$G
MC:#4M&N(!BV_S^G^<^M>3Z#-Y-U;S^?]I';O_GTQ]!TK0^)W@_5?"MI<>?!<
MVO\ IG0=?T_EU%</X/O)X;6WG_X^21_CW_S^1H [C]H2&^F\.6^JV-O^X^Q^
MGY>Y_#C%?G/-XJUSRO(@^TVUQ_('I]?Q]L=Z_7"'6/#FO:/_ &%XCGMK;'_/
MW^>/Z9Z?6O!_$GP!TJ;5+>^T.#[3;_\ 3I^>3^?\OQ ._P#V:?\ A(_[!\^^
MGN?]+&/\#G_/K7J.L:/-K'C+1['_ $87&J<?Z7>?7\3TQ_C7I'A#P?\ \(W\
M.;B>Q_T6XM+//X?X^W\Z\7_LW5?&&J:./])_M"US_I?^>/QS_P#6 /T@L_AC
MX_\ #1\+^'/[#\)7.GZ\/L/VNTUC^TM4L/S_ ,]J_6_X$?#;2OA!X2N9]5-N
M-0NO]--W=>_8'\CD8(KXP_8_\$^3=&^\<?\ $[M[6STO^Q[O_GP_S^?Z"O2/
MVX_B1!H'A*WF\*^([>VN+6S-G]DM<=SGMZ#@ =AUH \?_:__ &BO ^I7X\-S
M_9OM%K> 7>?\3G/X]_4]/E?P3\9OA7\/8OMWA6#[3K%W_P ?F;/_ #R1_.OB
M?7O"&J^/-9M_%4^N?VE<75Y_I@_$_3U_QS7'^)/&WPY^&/[F?5;;^T/^OSIT
MQSSZ8_PH _0#4OVP+[QAK/\ PCD]C;6UO=#[%V_G^?'<>]>D3_!G7)M&N/%7
MA6^^TV]U9?;;S_3.O7_Z_;/6OR(\$?$+2O'FO6\^E7]M]H_R.W'UK]-_ ?Q:
M\1^&O"5QH=O?BYM[K_.>W_ZNWJ =A^R[\9O&/A7XE_V'XCN"+?[81_G_ #S7
M[8:/\2-"U[]Q8?\ 'Q]CSV_+L?U[8Z5^!_@0S_\ "47&JWW&H')[_E_7V_2O
M:/\ AI:#PK=>1]O_ +-N+4_\?=W_ )Y[?SS0!^D'C;Q5KGAO5/[6^SVWV?\
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M^F??_P"OS706<T$WTZ_3TZ?G^?I7/BS\Z7_ZPZ>I_KG'MZUL6</D_C_@?Y4
M6)H?-_S_ #]NG>B#O^/]*L33>1$/S(_GT_Q[>M+YUO\ \]S_ )_&@!)^WX?U
MI8+.":+\N/\ //\ G\JTTW^3_G\AGU)-5X9O*_S_ )YZ]J *]Y9^3_4<\\_S
M_7/>J]:$TWF_Y_G[].U9_DS^;_GU^N??_P"OS0 4>1[_ *__ %JL4?NO\[:
M*]G#YWX?XG^=6+R'R?Q_Q'\JKPS?Y_S^HS[@T>=YOX>W^>F?;K^0!GPPS^;]
M/PZ^F>?US6Q_RR_S_=JQ##_G_/ZG'L!5>\[_ / : ,^;R.?Q_/\ _5]VB&;_
M #_G]1GW!JOY,\W^O_Q_S_/''-'D>_Z__6H V/.\W\/;_/3/MU_*OY'O^O\
M]:J\,/\ G_/ZG'L!6A]L]_\ QV@#'FL_\_RY_F?P]JQX8?\ /^?U./8"NP_U
MO^<8Q^?K[]?RY_R/?]?_ *U %B#O^/\ 2C_EK_G^]1#-!T[_ /UO\/?/KU&+
M'_+7_/\ >H /(]_U_P#K45H5GWG?_@- 'TE^S3_R4(_]@?5/YFOZAJ_E?_9C
MF/\ PL'W_L?5/S^O/\O7OBOZH* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@"N4"!"2 %4CZ]2,=N^3S^/2O\J[_
M (.>_P#@JUJW[;/[6NO?LL_#7Q',/V8OV4O%.J^'K2UTVY/V'XD?&;2 ^B>-
MO&NJ;IDAGB\*R-K7@WP6)(VDMH1XBN;?>/%DRQ_Z)'_!4G]I"^_9/_X)Z?M=
M_M :)=P6?B;X>_ KQW=^$+JXW>7'X\UK2&\.>!F<#YGQXHUG1<@'Y@ O4DU_
MB67<T][///-++//+(TUS/.268@DERV69BQ(&XGDD*  *\FFHXG,)45&\<FY4
MF^LY0YDVNKC33:OIS236JNO1PMJ&72Q:6N:WI0UV7+3=1I[7?-"%T]N;NTZZ
MNP+>K#'^?;'?_P#77]S7_!!/_@V=T7XT>$?#/[:7_!1CPY?M\.-873/$WP;_
M &:KH:IIE]XQTPKOTCQM\59(W&MP^&908)_"GPR@4R^+;<PGQTRV!?PG=?B/
M_P &[W[!?A+_ (*!?\%*?AUX(^)6F1ZU\'_@YX=U+]H#XG^'[V/=IWBS2O N
MI^';?0?!>J!$6-]$\4^/]?\ #L.H6P_>7'A./Q G[QAE?]?"S2VL[9(88HH+
M>W58+>"$ (HX 4#@  *3C''+$G-?7U*L\MPL:Z<GFF;Q<KNR4(2G)J*[RJ.+
ME)VM&$>DFDOFW+ZQB?JD4TTDYN+=]M$GHU9>:O>W=G$?#CX3?#/X1>"]/^'7
MPN^'W@_X=> M$LO[)TCP5X+\-Z/X;\,Z?IVP*L=OHNB006JC:"O"(S[F=U#,
MS5^7_P"TU_P0T_X)E?M6?&OP+\=_B?\ LO\ @_3OB+X,\5Z=XPU>]^']C;>"
MM.^*AT=U0Z)\9=#T.#^P/'&B2BVTAW>: >*IHMULU^EH\UNW[%Q@\9[#GZ_G
M_GVK\K_^"B__  5__8F_X)B>$FU/]HGXF6M_\2M3LIK[PC\!_ C+XC^+GBP)
M$) T>@K/''X=T.1T<0^)_%\_A;PO*S+##<O.ZQ-X5:O['$_6:TI2?PIJ\I7W
M>GO2;U>UW?6ZMIZ^&H-6PN%B[_RJWX[12\WI^OZ>V6GZ=I=K;V-E;06=A:6_
MV>VM;6W6SL[.S4 "-(T58HU55'RHJX ^Z@W,?D']H?\ X*'_ +#7[)=__9?[
M1W[6/P%^#^NSQ>9;^%/&?Q*\*Z=XTNE"KEQX+%R?$[1KO4"3[$8SD*S(<@?Y
ML?\ P4<_X.E/V_\ ]LZ\\0^ O@9XAE_8Q^ ]TTMC9Z'\*=9D;XNZ]IBD;)/&
M7QJ5(?$B3E@P\GX8KX'MV20QW \2%5E/\S6JZKJ6N:A=ZMJM]=ZCJ>I7<EWJ
M>H:G>2W]_>W[RLTNH:C)*99'+&5P3(7?)(+29^:%4Q-?R;UT5V[ZWUZZ]V[W
MN4L/AL-:_P!RUM\[>733IKN?['WAK_@X%_X(U>*-7.A:=_P4#^#%M>VTXMFN
M/$O_  F?@O2Y#R=_]N>)_"_AOPZRC!7>MV5&TXW8)'ZB?#'XM?"_XT>#-'^(
M/P@^(O@;XK^ M=M?M.C>-OAYXLT+QMX8U- H"/I6N^'9[K0YPF?O12YW8#QC
MDU_@O D'/>OMG]C3]OK]K#_@G_\ $RU^*G[+7Q:\3?#G61=6-UX@T"VNY+OP
M/XWL+=TF72?&W@UW'A_Q+HK2+L$=W$SQ!D,$EO)L,?;2CAVG]8E:6MFXW5_-
M;VONT[K>S>CX:ZQ-O]E=G_+_ ,%;.VVENFBU/]QMC@9QSV]B??OC'/X5\0?\
M%#?V/O"O[=_['7Q[_97\6QVB0?%CP/JEAX?U:Y2,KX>\=Z/Y>N^ O%?J#X;\
M6Z5H5XSX)98C&WR-7Y\?\$7?^"VWP>_X*N?"Z;1;G3-,^&?[4WPPTW2[CXO_
M  ?EU&/[%=:8X$:_$GX923W'F^(? ,]T4BN89)#?^#;Z2*VU&-XKKPK>>)OW
MD)RH&?; /4#N?RXKDS7 2A1EAL4Y0?NR4D[-.,DXRBT]-4I)IIIQU5TS? XR
MTEB</I*,D]5JI+;3JFGYJ2>[3N?X*7Q'\">,?A9X]\:?#'QUI=SH?C/X>^+?
M$W@OQ?H-P/WFC>*/#6KSZ'KNERJ,9:VUG2Y+>3;Q^[^4M]XP>!_&OB3X=>+/
M#/COP?JMYH'B[PAK^D^)O#>OZ:YCU#1O$>AZI%K.CZO$<8,MM<PQ20_>4F(%
MT=5*-_53_P '<G[ TO[/'[;_ (;_ &M/!NC-:?#/]KW16O?$=U;V[I8:9\<_
M!$<6E>,X' DD"OXI\.#P]XJ0#8TU\_B:0@_)C^1Y9&#EMO.,'I_AC_&M,IQ]
M=X>&,5X9FU'F:=^6:_B6_P"WE>/:,HK7EUZLRPF%=?ZND_[,FE:+]Y\LHI3C
M*^DFDW"5U[UF[)2LO]MC_@E]^V=X:_X*#?L1_ C]J/07LTU;QWX6@L?B)HEH
M0R^%?BAX<)T3Q_H4<:Q[TBB\0PRW%EO=2WARXT6=U'FJS?HD4^^QZ-C'KGOZ
M\CG-?Y\W_!ES\;/V@(?$?[5/P%;P/XN\0_LS7=GHWQ,7Q^LI3P7\,_C$A_X1
MQM$C#L2VM?%+PO$C&+0<N(OA['+/&R8D7_0564[W']T<^OX=NV<?TKOS;#PA
MBZF)PJBH9DHUHM->Y"2E9<JUC[.THQBTO<Y&KQLSQ,MY88=8-7_X2)>S3<N9
MM6<HWE=WDHNTKV?,FY)-ENBBBN$](**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *0D="1]#B@G@D>F1^5?SW?\%O/^
M"WGPJ_X)1?"R;PGX9DTGXE?MA?$RP:;X7?"87_F:7X/TY@$;XE_$YU_?Z'X9
MAD$9L_#+2)>^-+Q1;68@LAXE\3V_-7K^QLE&[>B2WOKIY>;V23;=D:T*'UE\
MJW_J[OV7XW26I_0<  ,D]\Y'0YX(Z?F.H]J>""..G2O\VC_@BQ_P=$_&+X;?
M&.^^#7_!2OXF:G\4?@Q\9/'5]KFC?'7Q WE^)_@3XGU_68I'BUU=%20O\&)9
M(W3_ (1Z.#S/ Z,KVK1^"6EMX/\ 1K\/>(M%\4:+I/B+P_JNGZSX>UJPL-7T
MG5M.N$U'3=6TS6%1])U+3=2B<Q30W$3+)$\1<&.52I ,3MV5L.XX98FS<>5N
M,DE\XO6Z=M?-;7UMQ.O;%+#-6NM'9J]M-.FZMY?=?IP/DP!T;],5^*?_  7@
M_P""<]Q_P4H_8$^)/PG\(V=K<?&KX<74?QD^!"R1[9;WQ]X0TR>*7PDS*'*'
MQKX<N=:\+1RF+9#<:QHEP[;(F8?M>" H.#R?J<_IZ4/C'(S^/T]B/SKCQ=&6
M(H*C!M24XSBUNG!II[]TM]&FT]&V=F'KO"XCZRK75M'MU33\FFUWUTU2/\,#
M]G?]C;]I#]K'X^:)^S#\"_A5XJ\9?&G5-7O=$OO"D6G&QD\(C1M7AT37]:\>
M;HXH_ ?A_P +2$?\)?X@\2O%'9.GE3M]H93)_I]_\$6/^#??X _\$O\ PSI?
MQ4^) T3XW_MCZIINS6_BO?V"GPS\+AJC)&_A+X*Z'J^)=%MT::2WN_&][%'X
MQ\79G<P^$-/NO^$07]LOAE^RY\ /@S\0?BS\5/A9\(_ W@3XA?'GQ.GC+XN^
M,-!T..S\1>/?$\6GO&EWK^L0R^=*P/F7"(8S;0SW&N7(@^T>(9I#]%*B!"B]
M">>QXZ>I]<Y]>#WKT88F6'PTHX>,5CW3:J5.9IMO3ET:M!IN[^)WY6U%OFX<
M31>)Q5H_\BIIM0>\O)O71/333KJ[)6Z***YSJ/\ &U_X.$;XZC_P64_;PN?*
M\I8OBIH&GA>W_$H^&?@;1\@\##&U#<>H'6OQNTR-IKZSB7^.ZC!/U9EZ^P8U
M^M'_  7FU&;5/^"OO[?D\O\ K(_CYJ6GMCGG1=&T72$P1CJMJ/I@5^9?PKTT
M:O\ $/P)IOG>3_:7C/PU8_:3P$\_6K"/?_P R;A[XR2*[_#Q^W7AZ]^:7"*:
M?_3S/\*OP]HO^&VTX@J>QQ.85_\ IVV^J]VA&3\VFJ=UW36M[L_W8_AY9_V?
MX$\'64>0+;PMX<M5\W[V(-)@C .,?/\ * WN#UKO7/R'Z@?CMP1R.W?^G6L[
M3H!!8V4/4PP*OY(J=>3U!/U]:_FZ_P""\W_!>?X>?\$R/A_J/P5^"][I?CS]
MMKQWH1N/#/AJ4C4]!^#.E:N76W^)?Q.@+#<Q3;<>!/"$JJ/%3>7<W$2^$DED
MF\W&8G_:?;)<RG.;MLWSR<M]ENK]O.]GSY1AO]ERW"JT7R0C=W=M$^CULEMI
M\EJNO_X+._\ !P#\&/\ @E&WAGX7^&=!TCX[_M/>)K_PSKE_\(8?$']E:?X
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MZ22LDM%%%<9WA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!_C%_\ !<_]H?4?VF?^"K'[9OCFZO+F71?"?Q:U
M3X+^%HI_G2R\-_ V*/X61#2Q&%7R+RZT#5?$P#N3YFM2RMM8BORN\.Z-J'B/
M6=)\,Z7"]WJFNZQI>FZ=:K\SW-[J;1Q1)R1@O,Z)Z9=#CJ:]\_;*2[?]KO\
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M@>'DTE-<T,2^(/%D,<_ASPG<3F2"R\57-K->V\UL)-O+B,0L-AGBFEHE??\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M >H?#WXOZK\/;76+Z">Y_P!%Q]CY[#\.<U^Y_P"R;^TY9?$Z&PTJ]OAG[$2
M>F<<9(YQQ[GT!K^<"]UC29M!UB">?_D%_P#'Y_3CT/TQ_*OKC]A7QM!H/BVW
M@^W?\OGVTX[?K[4 ?TT:]XDL=!M;B>?_ /7Z\\ \>W3FOR'_ &D/&VE:QK-Q
M]A_X^.W&?Q&?Y>WO7W!\0_BIH<WARX\^?_2/?\>O_P"H?TK\B/B1-_;&J7$]
MC^A_J.W;T]* /G;XD7F;"XN/^7C^?\\_KTQWKYOO+RQEL!]N/^?Y?YR:^H-2
MT">]CN//QZ?YXZUX?XJ^&_\ H'GCWR/S/^?YT 8_@GPW!K,5Q/8\6]KG_/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9W>>7X/33R/+<VL88^!GDFN;6%].DGMXOX^:4$] 3]!FO=HUE24HRC=/=/\
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M5[KVEFG=W2DHJ5G%-)MI2ETBKM%%%>:>N%%%% !1110 4444 %%%% !1110
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MU HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\1_\ @H=J7V/Q
ME;=?^/S&?\_3BOVXK\3O^"@-I!/XR'G?\_F?TR/;_/;B@#\T-2U'SHK?]P?_
M -?]?6K$,,'7O_\ 6_P]L^O09T-2TV#R;?R/H/\ 'WZ?ITJO]C_==>/U^GY=
M_P!<4 $UG!-$/R]?3CGW[=@,BL>:'['_ ,M_7'_Z\GVR?<U8F\_G\?R__7]V
MJ\T,_7M_]?\ Q]L>G0Y +'D^=%^7IVZ_CUZ<^U9\\$\/^H/_ -;_ .L3U_QX
MH\Z>'IR?\G_ZV/\ "M"&;_/^?U&?<&@"O9PSS?Z_]?\ /0=0.]:!T>";V^OM
M^>?R_EFJ\VI]\?A^7']>GT[T0PSS=!C]/\_RH +R'R?Q_P 1_*L^&;_/^?U&
M?<&NX@TWSHLS_7_/^?K6/K.F_8XOW'?/X'_/7'O^ !G_ /++_/\ =JQ9S#RN
MW\OIQ_DGZ@UGZ;9&\/[_ /0_Y]Q_DUU'V+['^/M^/IS_ /6Z4 <Q>0WTTO7I
M]#_GK2?V;?31?EG\_P#//Y5L:E>?NK?R.<?J?Z_US6?!J=]#Z^_Y^^.U %<Z
M/?0RCO;C_)(_E_\ JK0AA_S_ )_4X]@*L_VE?31&#\\8[8Q^7X?@1BD\F>'K
MR?\ (_\ KY_PH L0V?\ G^?/\C^'M6/>6?D_U'///\_USWJQ]L\GGK^GX_AC
MICW[9K0O)AY7;^?UX_R1]2* ,^'SX8O\^O3.<G_ZU)YUQ_SW'^?QJU#_ *D?
M0_RI(8?\_P"?U./8"@"M-_KC]1_.NQTV'T_'_P"N?SZ?4>E<OY/[W_.>OUQU
M[_IBNPT?]SG';'X9_P ^W7M0!U%G9_8X?M'GG/)_SZ]L?6O2- _TSKSTS[?X
M9[]/?W\OAFGFE_Z=_P OR&1[9Z<_7CN-'F\F6V$'^?\ /'/U&0* />/!,T]G
M?\>W\^_?&/T[#FOU)^&^L6__  @=QYX_Y<^>O3]?7_.*_)[PW>S_ &_SY_U_
MR3Z_X]J^D+/XS?V/X<N+&"?I_+KGZ?YR: /A_P#:7F_MCX@>((()_P#CUO/4
M?YZ_3MWS7R/\0M-MY["W_P"?CGGT_#^7'M7N'Q"UB?4O$>L:K<?\O5YC'/\
MG]>F:\GATW^WI?/G_P"/<?Y_KT]O7H ?,_B2[U7PW86\$$__ !]9_3O]?7\<
M5W'PQU*Q_MFWOIY\_P"'X=?\C/->@>,/!_@W6+"X^W7]M]HTO_/K_G&.U?-V
MF^?H/VB^LO\ 2;>U_IU_Q_\ UT ?5/B3QAH<,6H3P6-S<W'_ #]W=F!C^?\
M];\*^=]'L]5U*_M_/GN?]*O../R_K[?6MB\\;?;-!MX)['/VK_/3M^==S\/M
M-GUCQ1I]CY'_ "^>_K_GZ4 ?K?\ L<_LZP7<NCZ[<< 67?ICU_R/KWK]AQ$-
M/TKR9B+?ME2#TY/(]>/RKYX_9IT&#3?A[I\\&?M/Y?CW_"N?_:B^.6E?"OPE
M<?;K[[-<=/Z8'Z\?KZ@'<>-OC]X.\!RV]C?7V+C\/;WZ]/\ .*SS^TK\/XK7
M[:=4!G(Z$#!'N/3_ !'UK^>?XA?M%P?$*_N)_MWVG_3,9^O^?Q]:L>"=8U;6
M)OW\]R;?W_/VS^7% ']!$W[2&AW=A<3V..,X/?O^7H>?2OS/_:0_; GUZZM]
M"@G^R_9><6G^?3WQQ7A__"SH/#>EW%CY_P#RY^O^>F/_ *_8?FO\3OB%/K'B
M/6+CS_\ CU'Z?CT_SUYP >X>,/$E]J0N+[S_ +3[\<?G_P#K_6N/T?7]5^P7
M$%C/<XZ?9![^G/8<?7K[>'Z/XVOM2B$$\_Y<>O'^?J.:[C1M>GT>ZMY_^/G'
MMSQ_G]?2@#]6/V2_V;X/B1:_VMKD%M=7'_/I=]_KGTK]F/A+X5@\%6G]AP6-
MM;6]KWZ$>_?IVXQG]?C[]@70K^7PM;Z[/FW@N@2 .I..!GWZ9QUY^OZ0WDUC
M9Q3SS],GMSGM_7KCCB@ O+R"S_U\_P!ER.2#G^73\/3OFN?F\1Z%J,9L9I[:
MYSCW&1WQV_#'N*^4/BU\8((?/@L9^/Z]/\\]_K7R]-\9K^SB\_[?_3_ ?YX]
MP#V#]J+]FCP/XDM;CQ58P:;;:A_TZ#K[U^<\/PJU6"+^RM*LO\^_\OU[XKV#
MQ5^TY?&+R-5OO]''Y?3C\_\ ]8KZ _9U\>^#O$DOGWT%MSWX';IZ\_F/6@#P
M?PK\!YX;"W^W6.;CW_G_ /JQVS7L&I? '0YM&M_/^S8&?3\#[GI_^NOOCQ)>
M>!_[&\^#[+GW/IQ^N*_._P 5?&""'Q'<:5!/_H_M]>!^7'ISF@#P?XJ>"/#D
M.L^%_"NE:'IOVC5;S[$3:66/SYK[P^%?[&7@Z'1M/U;5=*MK;4..O^?\\UY?
M\*_#>A^-O%&G^*I_LUS<:#>_;1Z?U_ES^5?IQ9ZO8S:7;S^?]FM^.?7GV_\
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MST^GK0!^5'C;X;P:=]H\B'[-<6O;K_G\>_Y5\;>-O"M]YMQY%E_V]_8^O?\
M^O[CZU^O'[14&A6>J6\]C]F_TOOZ\]/\_P#UJ^1[R;2IHKC]QTX[9_\ K=3_
M (]J /B?PK\/;Z:7SY_\GC]?\]:^B/"O@^?3;JWG$%M^'3OGI^'Z5H30SPYG
M@@__ %C]<_X9]JZ"RU*^,7I^/X^G3GDYH ^^/@GKWV.VM[?_ #]/\_7'K[!\
M2/B%YUAY'7\.OMC QUZU\/\ PW\8?V/%B>?MUZ_F.OZ9X%6/&/Q(\ZZ^S^?C
MI_G/M0!P_P 0M2GO);CG_P#7W_SU_'-?.]Y#/U[9_P ^WY_@!Q7<>)/%0FNN
MGT]_ZYSSZYKEYIOMG^>O3/./S/\ ^N@"QH/[Z7/^?\]_SXKWC0?"IUB6W_<<
M?K_G^=>+Z#9_O>^?QY'].?; Z5],^ _^/K]Q/TX[_P">.G?'\P#EOBI\'_&.
MF^'+C5=*GN?L_/-IU/\ GKS[9[FOROU[XG>/]!O[B#[=J5M]E_S@'ZFOZD-'
M\*P>*OA_<V,\'VG_ $/C'^><_P ^!7X3_M$_ V^\-^+=0G@L?]&^V?YZ\^O]
M/8 \/^'OCSQ_XJE\^>^UO_/4]\_Y]:[CQA\2/&,,7]ABXU*Y&#_Q]]>GX<?G
M7M'@G3?"OAOPQY_D6UM<?U'X=1]?\*^=_B1\3M#L[NX^PP6US<<=?;_/7]*
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M%;^\\+G^PM5TVYN+JS_X]/MG^?\ (]*X#P3IDW@_7K>?5?\ CXSF\]/\]_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+?Q3;0-XID_HU*!NA'TZ'Z<YX_SGJ:_P%"YS\PQZG_\ 4._O7ZJ? ;_@M?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?Y_SSU[58@[_ (_THAF@FZ''Z?Y_G5B&'$O[CW_EW_SGZT :$-GYWM^?]?\
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M:6X$^/([#_/I_P#K]P#^9?\ :$\$WT'BG4+'R+G[/I?^A#[7^OM[8^M?'_\
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MJ>UA\3]8_P!EQ3T6VNW_  .ZO=:M+='^+\0=V>_(/?)STZ_R_K7]7W_! O\
MX.#O%_\ P3\\5>&/V5_VKO$.J^-?V*_$-W!:>'M7D9]3\1_LVZKJ\H(UC0V$
M<5UK'PUDED9O&7A(HS6<LK>,/!*/,E]IWC#\ OVT_P!BSX]_L"_'OQ9^SO\
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MDHHHK4H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOJVWJVU;YO\ KR[)%%%%9G0%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7XF_P#!0R>'_A*U@;J;L9^N.?U.?Z&OVRK\/?\ @HE#YWC
M>UV/IP/U]_K0!^>)A@\JW_<>F/\ Z^>*SYH889?(\C_//IU]_KGO5CSOL<5O
M^O.?P[9 XS5C[9!-*9\]/\G_ .OCZ4 9_P#9G^U_G\ZL>3Y7X^_^>N/?I^=B
M:;S?\_S]^G:L>;SX<?7TSC&?7O\ 3K^5 !-^]]NGZ?G_ %JQ#IG;/X_GS_3K
M]>U9T/\ KA]3_.NIAA_=?A_/^GZCK0!GP^1#GZ>F<8QZ=OKU_.K$UY!GOVX_
M4=^H_7/X5GWG?_@-$,/F_P"?\\]>] %>\F@_YX<_T]_Z#'I]*SX?/X_#\O\
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M_P#5WH \/_:0^)'V.U^PV,_V;[+_ ,?G_P"K/USZXXK\;_BIXP_M+6?/\_\
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MSS_;[FVN+7_I\_#OZ?K^>?B_389X>>?P_//_ -;^637H&@:]/H]U;Y_QX_\
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M??\ \C^?\O:OMCP3XVL89;>"<]/\_P!??\Z /2->\2> /AC+;_;O])^O?O\
MK]>F:\WUC]K.QFO[?2O"MC<_9OZY[?Y]N*X_XY?#>^\2:7_:MC?7)Q_G^?U^
MM>+_  -\!V,.L_\ $\N.+7]/Z=?Q/KF@#],/!.L:5XJL-'OKZ"VMM0NKSWR?
MRZ?S'IV/VQXEA@A\$:?!I7^DW'V/CZ>V.<8_GZ5\7^&]!TJ&73I]*_TG[*>#
MS[?_ *^V>?K7V1\//#?B/Q5J&GP?8;G^S[3/^?Y_E^0!\/Z#_P +-U?XEV_A
MPV/^CW72Z^Q_EZD=_P#ZU?MA\*_V;O#FFZ#;S^*8+:YU"ZLS_I=I_7_Z^,_3
M@>C^&_@#X5AM=/US[#;?VSQT_P ^W/X5YA^T)\3M5^&^EW$%CS^/_P!?@_Y/
M.: /@_\ ; O?!O@F_P!0TJQG_P# 2\_K@^_X=*^!_"OAOX26=KJ&N>*K'7-2
MN-4_X\OLEY_G_P#6?7KZ1XVAOOB1KUQKFN3W/IR._P#GBL_P?\*_[>UZWTK_
M )=Q_G/7_/IQ0!ZA^R7X;U6:Y_XE4_V;3Q>?\O?^>G'^%?L!X)A_X167[?JO
M-OU^GU_R#R>]>?\ [.O[.NE>%;6WG\CCVZ>OZ?3\:]P^,W@G[%X-U"^&J?9K
M>U_P_P _E], 'S-\5-8\ 3ZR=<\1S_:='_Y]/MGX8]\^I[?C7S!XJ\2?L=ZG
M]G@\_4M-UBZO,_\ (8]^>>Q]^M?F?^T)^T)JL.O7'@^#7;GB\^Q<]/\ .?US
M7R_XDT>>'^S]5GU6YN=0_P"/W[7_ $]_;_.0#]F/'G[.OA7QMI?B"#P=?7-S
M;ZG9YL_MEY_G\?Y#H?</ ?\ P33\#ZEIFCSZY!<_:/['Q_HEYV[=?_UD5^/_
M ,,?VBO''AO[/Y'BJYN;?G_1/MGZCZ?G^N?TP\"?\%,M5TVPM]*GTJVN;BUL
M\?:_MG^?KQVZB@#ZIL_V.?"OPFL/[<T.#'V3/_'U_P#J_P ]>E:^O?M4>#O!
M/AS[#H?A4VVL6O\ H1N_L>C>W'ISQW]N>#7S/X<_X*0>%?%6LZAH7BJ"VMK?
M5?\ CS^UG^?Y?YYQX/\ $C]I#X+:EXH_T&#3/L_'/Y>W;T)R: -#XM_MI:YK
M$MO!?67^C_\ 7GC_ "?\^M>3ZE\<M5FBMY[&QQ;>OV/^77\^I[CTZC0O#?@[
MXJ7]Q/!I=K;6_KU]N_.>N,=:KZQX;\':;%<6,]]]F^R]<]?\_P#ZR,8H ] T
M']IR^\$Q>']4@O?^OVTX]\=,?SK]D/@G\>/#GQ@\+Z??>?\ 9K@]>G^?;K^8
MK^5_QM-I4-UJ/_$U^TV]IWQS_GIV%>D?!G]KJ?X;W6GV,%]_H_VP?4^_3IUZ
M<^] ']4'BKP3I7CO2[B"^@-SQFS)[?YYS^%?G/\ %3]EWSXM0_LJ#KQ_/\?P
M]*^@/V=?VKO"OQ.T;1X/MUM]H^Q<?X?3MBOL\V>EZE%/Q;W-O=6GL<@]_IG!
MX[Y]: /X\/C!X#U7PKXRN+'_ *?,8^GIZ8^O],]_\/=!U6\BMX(/M/VC_'Z_
M3\/4BOTQ_:B^ \&I?$&XU6Q@/V?[9US_ )]#Z^QJOX5^&/@[P'%I^JZJ;:V[
M?E_GC\Z /+_!_P )?%7V7S]5L?M-OV/V/^9]_P!/4UT$WP3U74K_ ,C^RO\
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MW7D=_P#'_P#7_D&M?]U_G;7/V<Q\WO\ S^G'^0/H37030^?$/R)_GT_P[^M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *_#;_ (*)_N?%@G@QG[8,_P#UOQ_R#7[DU^'O_!1'
M_D<%_P"OP?TH _-F:\\Z*W\_W_7Z9_S]#2S0^=-^X[_U]QCWJM>0GRK?_/\
M+V_'O@8K8TV:QA_U^>/;/T_^OZ_A0 0PS]>W_P!?_'VQZ]1BQ-#!U[__ %O\
M/;/IU..H\F":(>OZC_/;/IC%<QJ6F^3_ )_SQZ'^O4 K>3^]_P YZ_7'7O\
MIBM#B&U[Y_S]?7WS]*Y>>\GAE_/G_/'^?S/[2G\G]/\ /MCV]\4 =!Y/F_A[
M_P">F?;K^5B']U[]?U_+^E9]G-/Y6!SQ[?B3STX^GU&*SY[R>&7\^?\ /'^?
MS -B&&>;I!CMT!_S_G\;'[B'T''UP!_GWZ>U9^FWE]^7Y=.F.?KT_P *+W/F
MGS_Z=>_Z]>V?>@"Q]C^V?O\ \/ICOC/X]\=>.VA#9_NO;_/YG\>/:L^S\_\
MY88S_P#KQ_\ 6_2N@F\_G\?R_P#U_=H QY[+_GA^6/Y#_/J?6J_[^&7Z_7_/
M_P"OOWZB&\\F+/\ +_ZWTXSUS]*SYIO\G_/Y#/J2: "&*"8>F>OT]?\ /YBM
MB+_0_?IUX_+T[]?P[5S_ )_M^G_UZ//]OT_^O0!T$VI]\?A^7']>GT[U/#J4
M$W?'Z_Y]?I^N!#^]]NOZ?G_6B:&>'J,_K_G^5 &Q>6<$W^H]??\ +^N>?7K6
M?##]C_<<>G;V'^>_Y8HLYI^G;/\ GV_+\2.:V)H?/B'Y$_SZ?X=_6@"S!9P3
M1?EQ_GG_ #^2<0S>P_#K_3\ASV%%G-Y/X_XG^56+R'SOP_P'\Z +%G#YWX?X
MG^=:'[B&+]__ )Q^/)Z\_P"%<O#J7V/\L?C_ )_7\<)-J7VR+'^?K[?Y]* -
M&;4H/-]\_F3[^W;\ZL><9HO^/C_]?OZ_CCVXKR_4YI_-_<=_Q&/Q..?\XK0L
MYK[GS_TZ]O;_ !_'F@#H(=2GANKB#_EWZ\#_ #CMV^O:MB:\_=>W^?S/X<>U
M<OY_M^G_ ->CS_;]/_KT :'VR?SL_AC_ .OZ9X_K706<WG18'7_)_IW[^W7C
M_P"TH(?W'Z=.N1T]@?QYK8AUB"S/Y=?;V[=Z -CSIX93Z?S_ ,]\>N<T7EYY
M,O;Z^N/7/Z__ *JSQK$$WM]/;/US^?KZ8HFO+$1>G7W[]!]?QQ0!LS:[!]EM
M_P!__I'7_P"M7N_PR\83PV'GSS?9?\_Y]NO2OA?7KR^\T^1[^OX']/U-=AX;
M\8?8_P#7WUS]._Z9_F3^- 'ZL>%?&UAKT7]E7T]J/\_Y_&N/\>?"NQU+[1/8
MP?:?RZ#_ "1VZU\7:-\6K'1YO/\ ])X^O]/;/?M7M/AO]H2?4O\ KW_SV]._
M;VP* /G?QM\)9]-O[B?[!<Y]_P##U^OUZ5P^F^ _[2UG3X/)Q_I?I@_S';WK
M[HU[Q)H>O6'GS^O3_.2?U_P\/T>&Q_MG[1!/G[+^O\L\?D>E 'V1\/=2@^'O
MARW@@GMOM'V/_P#5G]/QK'\8>-I_L&H:K//CV_KGCT]:^-_&'Q(OX=4MX()S
MW'?I[X]>O/7GK6O>>)+[4M+/GS_RSV^N/Q- '$>*O& U*_N?M$_]/3Z^^?IB
MO%_$DT$TO^CYN?TY]>H_7Z5H>,?L_F_S]/?^GZ9KS_[9Y//7]/Q_#'3'OVS0
M 30_Y/\ G\CCU!%5X;/_ #_/G^1_#VK0AO/.]OR_K_GK6Q#9^=[?G_7_ #UH
M QX;/_/\^?Y'\/:M""R_Y[_EC^8_SZCUK8AA^Q_YZ=<<9_(?_JK/O/WW7M_7
MUZY[?USS0 36<$T0_+U]..??MV R*SX;.WAE_P ].W_U^M6/._=?YQT^F>G;
M]<U7A_?2YXQT[_IQ_P#6QQS0!/-_KC]1_.J$TW[W\?Y?U_0]*V)H?\G_ #^1
MQZ@BL^\A[?3_ .L2?Y#']: #SOW7^<=/IGIV_7-;%G-!Y7Y>G^%<O^]_SNJQ
M#Y_'X?E_^O[U '<0ZC!".W'X?Y'M6?J6I7'F^N/\_P!?YUQ_[[S?_P!6?\_^
MS58O;R>&[M[?_/\ G/3Z<T =!#-/,/W\_P#GI_D_SZ5H368\JX_^L/\ /_ZO
M3C/LYH/*_+T_PJQY_M^G_P!>@#P?4M-GBUGS^WY?Y_QKU#3=2G^RV_\ GI_]
M8^W/Z[$VFV,TOGS_ (?3Z_ET]>:S[R&"'_4?X=??J/3Z=?< L3:EYT7]?_U_
MR_/ S7+_ /+7_/\ >JQ-Y_/X_E_^O[M$/G\?A^7_ .O[U !-9_Y_ES_,_A[5
M8L[/_/YYY_/]#BB\FG\K!XX]OP/7IS]/H,U8TV:?D?Y].<?UQ_@ :'V.>(G_
M /5^G/Y=>AK/FF_R?\_D,^I)KJ/.^V1=N@_+/Y'_ /7]*Y?4K/K.1ZG_ #S]
M<<^O% &/]LO_ #OPSC_/M_\ J[5T%G9_;/\ 7\>OY_\ UL_YQ7/PZE/#+Y Z
M>Y]O\_XUT%GJ77\\?Y_+C\1UH L3:9Y/J?Y<?A]>/PZ\5H6<QA_<09/TX]?P
M'U&.U4)[R>;K_,>N?KZ^E)9S3BZZ=?T_G0!T'D^?_K_\_P R/_U'M7H'A6'_
M %'Z_P#U\_CD#\Z\_FAGFNK?/I_G\/Z 5Z!IL-]9V'GP?7CUS_GG_) /H#3=
M>@T:U\_S_P#2!_ASSC_/X5XO\5/C#/KUA<:5]H_SGU[=L_YQP]Y#XRUB6X@@
M@N3[]?J,_P!/_P!5>;ZEX/\ $>@W7V[58+K[/==<?IZ8]SQU]* /)SIOG7-Q
M//!<]OJ/\]/TKG]2\'_;+6X@@LO](NL]<?\ Z_K_ (U],^%?!^J^-KK[#HEC
M_I/Y?YX_'BOJ?PK^Q;XWF^SSWPN;:W__ %?YST.?PH _*?3?A[JL-UY$_P#Q
M\9]>G\OY_J:Z"'PW?:/=?\@NY[\]S]!^8]Z_6"]_9=L;._\ /GOLW%K9]?I^
MGZU] ? ?]FCP/J<VH3^,9[:Y_P"OK_#^G]* /QOLH?%6I6O]E3V-S_I7\^QX
MZ@^W]*KZ/\$]5AU[R(/]&U"Y_P"73OZ8QWX_SBOZ,-8^#_P/^&.@_P!JWVE:
M'<W'VS_0_K^.._8^]?+^O:;\.=8\1V_C?2K'3;;[+GO_ )SZXZ_K0!Y/^R[\
M*_['N[>Q\<6-S;6^/^/NZ_K_ )R*_3B\\5?"OX>Z-Y&E7VF_:/3]?U/'U_3X
MGU+XD:5Y0@OH+:V[=.^/?GM_GOX!\3OB1X<^R_Z#_P ?-KZ8X^G?^?3F@#]A
M_!^L:KXJT'^UH)_]'^G_ -;'O_\ 6S7E_P >-!\.:EX(N)_$5];6VH6O_/W^
M&/8X'XU^/_@G]LSQQH\O_".6-]<VVGVOI>=/TSQZ]/SKU#QY^T5JOC#PV8+Z
M 7-P+/\ 3W'7_/- 'D^I:G8WFLV^E:3!_P OGX]?Z_2OT8_9U^#^A^5;:W??
M9K;'_/WQ_P#7[?\ UJ_!_6/&VJZ;XHMYX)_[-_TS_/;OCWK]"/A-^T5JMG86
M]C?:YD'_ *?/7IT_$=* /W0TTZ'IH\B"^MORS_3^O?/I7S_^U3-_;'PYUB#2
MK[_ESS_HEY[GZ_\ UL5\[V?Q"GO-&^W_ &[.??\ S_D5\'_M1?M(>*K/0=0L
M=#U6Y[?_ *_?'^>M 'YO^*OA7I7_  ENH7VJP7-S<?;#_P OGU]/\].O:QK.
MI>%8=&N-*\^VXL\_Z9_]?![>M>8:;\9IYHM8G\1S_:;CV_PZ\C\O6OE[7M2\
M5>*M9N)]#_X]_MAR,^OU/O\ G]<T >P>"?!^JWFJ6\\$&I7-N;S_ #D=<8YY
M_"OT0_9[\!ZKK%U<V/B/2OLUO=?\O=W9_P">1_3Z5^?_ ,/=>\8^&Y;>"X^T
MG_.?T[G\*_3CX;S>,;S1K?59Y[D6_4_X$_T_QH \G_:6_9I\1^&]&N/%7A3_
M (^-+_TW_1/\._\ GTK\E_MGC'3=5_TZ>Z_M'[9_GG_]7;'I7]%$/Q"'B2+_
M (1R_P#](_Y<L\9SP/TQUS7PO\0OA7X<&O:AY%C;?:;G_//^>] 'E_PE_:*\
M5>%?L\'V?[3;W6,#['VZ?F1^E>\>/+R#QAI7]N6-]<W-Q=?\?@M+SK@_GG)_
M6OE_3/ ?C'PK%<6,'AS^V^?\]^WY=L=*/!/C#QCH^J7%C/H?V;C_ (]/_K_K
MZ>O>@#R?QY#XCLY;B#R=2^S_ ,OZ^WZ5R]GIMQ-I?G_Z3]H_,_I]/IT Q7WQ
M#H/_  E5K_IUC;6UQ=>_'_ZNOO\ 3->3S?#'5='UFX\^"V^S\_\ UAC'X_3I
MUH S_@;\<O$?P]O[?R+ZYM?LO_+I]?\ .>_]*_:#X5_\%"-5AT'R-5_Y\_SS
M^?XXX^G6OPGF\*WTWC(06,'VG[5>?Y_0X_\ K5^E'PK_ &2_'_C#PY;SV^E=
M/UZ?Y_#IB@#Z0O/VM+'QMJEQ]NGML_A^I'\_Y5\S_M"?'*?6-+^PV&NVUM^G
M\^1[=>_O7D_Q5^ _CCX;W5QY]C]F^RC/Y=_Z>PSVYK\__B%KVJPW_DSS_P"D
M<9__ %X_SZ'K0![A_P +4\8V<7D3ZY<W5OS_ ,OGZ?E_6N?A^*FJWNJ>1_:M
MR>W_ !^?U_SSVKS_ $?1]5U+2_/Z@^H]OP_3OZ58T'X>WWVKSY_3/X?AQV'^
M<4 ?H1\$_BWKFFZI;6_VZY^S\]_\_P">E?O1^SK>:%XVTNW^W?9KG[5_];]?
M;/M7\R_A47V@W5O_ ,^_Y]_7M[_CZ8K]P/V&_'D ET^QOI\?Y]>G^>F* /T
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MY_G^?'\A^/O6A]L]_P#QVN?AA_S_ )_4X]@*T* /I#]FF\/_  L'_N#ZI_\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_$?\
MX*&_\C@O_7TO_LM?MQ7XK_\ !0'R/^$L'G]/M8QTZ8./\G^= 'YCS0CRK?\
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M_P!8]?4_USGV]:]8O-'GASF#\OKG_/<]ZY>\TWOY'^??/X8'TH X?R/?]?\
MZU'D^;^'O_GIGVZ_EH36<_F\>^<>H_S[=:(;.?V[\_H>W0_IC\: /:?V:;.;
M_A8W';1]4_,?C[_K7]2]?S#_ +--G<?\+!_[@^J?Y_SWY]S_ $\4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !2$CH2/H<4$\$CTR/RK^9?_@O'_P %[/AS_P $ROA[
MJ7P6^!^I:'\0?VXO&6F3?V'X<EVZGI7P.TW58'2'XE?$Z".8QIJJQR1S>"?!
MTVT>* T=Y<P1^$<FYYZU9TG&,8W;T2V_-I*W5O;YI/6A0>)=E_G:_=]OS_*;
M_@O1_P %ZOAS_P $Q_AUJ'P8^"]YI7CS]M?QUH7G>&/#,Y&IZ!\&=*U@M';_
M !+^)\!;E@A6X\#>$)E7_A*G\JYNHD\*)(\W^5O\3OB;X^^,_P 0?%GQ5^)_
MBW6?'?Q$\=:_J/B3Q?XT\47;W_B'Q%J^KLCW&K:Q.YD:2>5@'W+E5W".,>6L
M0!\4/B9X_P#C/\0/%WQ1^*7BS6?'?Q$\=Z_J/B3Q?XS\4WCZAXA\1ZOJI5[C
M5M8N&,C23RM\Y*Y1"PCC'EK$*]C_ &1_V2?CK^V[\=O!W[/'[.?@Z^\9_$;Q
MO=E;2W$;II6B:9$5&L^+?%NL@/!H/AKPTDK37_B*YB6&*,;5/VB:*UEO 8#$
M5<1=V_M2WOS=HI**YI)2E90A!*^MDTN::T5KQN-PV%PS5U'*HZRD[1;<?M2M
MK>^B6MKVC=M\V)^S1^S%\;/VO?C5X-^ ?[//@;5_B'\3_'%ZMKHF@Z5;CR[2
M!%A?5M;UO4VE>WT+P]X>1FN;WQ#=E+>&%/F9GECMF_O0_9A_X,K/V<H_A?I<
M_P"V'^U!\<]=^,.H01WFL:9^SI=?#GP'X$\+WNS,FAPZO\0_AE\6]?\ %*J1
MD>)S%X.CD)5AX14DJ/WN_P""/'_!'?X(?\$I/@NVAZ +#X@?M"^.K/3Y?C3\
M<9](@LM0\17Z.#%X3\'JY^T>'_A]X;DBF:R\.1S2O<2;[Z_EFO)"D?[1@J%R
M!@"O3Q,\-0D\-A6VM;S=[R?=7Z6V>\MU:-K^31GB<2WB<1>,7LG:[M?5V2TV
MLNE]?>V_RH_^"VO_  ;?_$3_ ()E>%)?VB?@;X\U[X[_ +*R75K:>);W7M)T
MNQ^)OP<NM1DCM=$;QHNBR0^'O$7A_7];N8;5/%GAJU\,K8WEW':S>$$B,=VW
M\M@/*9['^6<_K^%?[A7_  4D;X=?\,#?MF'XM1:?-\.?^&8?CDWBU-4_X\_[
M+'PS\0^9NQ\P8'R_+9"&$H!7G@_X><@V2,.P.1VZ]?IZ5XN&Q+EB,QPSVA**
M3_Q7DD_-6NMGRM775^U4A?"X'$I-6;@WTE90FFO12M)=';O9?Z(7_!DQ\1M>
MU3X._MR?"F[DSX<\'?$'X0>/-%7/_'KJOCW0?'NB:^H!X_>0_#[0']/E)/#<
M?W/Q<B+C^"7] _\ A7^3;_P1_P#^"X'A;_@C_P#LS?'_ ,/?#SX"77QD_:4^
M.WQ(T>_CUCQ9XD3PA\)_"'@;P?X<GTOP[-JT.B/<^*/$FLC7];\1/+X>@B\(
M0K;SI.OC,&9(9/2O%?\ P=X?\%=M=UDZKI&J_LV^!;%+E2/#7A7X)MJ&B!'P
M"N_QWXK\7^)">I5O^$G#@<!ACGW\[E1K8_"2P\6E/A[AF";=^:<:$(U$];Q:
ME=M-7M\K^'@,++#T<S?+9/B.IRQLE[LW#WTNL+TYN_5W:W/]5HD#K7YY?\%&
M_P#@G=^SS_P4M_9]USX"_'[1%5"EQK/P]^(6D62-XY^%7C@1_9=*\8^#-6)^
M4J\AAU#PY.OV'Q=9,]C>1;-LL'\6'['/_!Z)\==!\2:?H/[=/[.'@3X@^"KF
M]C2]\??L]G5O!'C;P]I@3RY=1?P5XIU_Q5X8\<R*ZC,47BOP4I .)W9,R?W6
M?LE_M=?L[_MO_!SPS\>OV9?B3H?Q/^'?B4*WV_2I)-/U#0]3A8C4]$\6^'Y
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M6G>3YKM.RM%MOGQU%XK$)/E_LMI-Q3WE9-ZO514E=?)MW2M:HHHJ#J"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *_$7_@H;,(?&"_]?0/XD9_K^7>OVZK\_/VFOV6-5^,NNKJEE!<W,&T#
M%K?:1IYX [N [_[S#)^\>30!^%7^M^S8[Y_'_/X_C6Q+^YB\_P#S]/R_ ]\5
M^DO_  [[\0^7 /[)U4;>I_M3PCW]#_PD1!_X#FK7_#O[Q%_SX:C_ .#G1_\
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M2SU_Y#&CC_W9/KT_.@#XH\*ZEYUU;P ?Y]NWX=:^C[/P3JFL6OVZQ'^CG_\
M5ZCKG_'M7N&A?L'ZYIMUY]Q8:E^&KZ,3^GB3..!T_P :^H/"W[/>JZ-I?V&X
M@NOPN]&_7^G3^= 'Y;Z]_P 4W=>1??7GG_Z_^<\U8_XE6L:7Y]C;G[1_G@Y
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M;</_  3W\1P@?Z#J6>O_ "&-''_NR?7I^= 'Y7WEG_G\L<_EG\3BMC3/XO\
M/K7Z@3?\$]M<F_Y<=2_\'.B]/P\2?3_&JT/_  3R\1Q?\N.I'_N,:+_7Q)^G
M]#0!\$:;9^=TX_S^?7CTSUYKUCP?I$_VJW@Y^O\ G], #VK[.TG]A?Q#8@9L
M=3Q_V%]'.?R\2'\Z]9\-_LIZIHTOG'2[C/I]MT;./3'^?K0!\_S>,+'P?H/D
M3_\ /GS^6<^OX]17P!\0M>G\2:I<^1/_ */=?U/?O[?K7Z[_ !"_9.UKQ3:>
M1#97"Y(_X]KW15Z<<AL?X_E7@\__  3]\1S1?N;'4OQUC1NW_<R8_#_]5 'Q
MQX/U[P=H/]G_ -N&V^S]+P9S]/I_3D]*\7_:_P#$G@?QY=:-!X'OK;[/_P O
M@M+SG\?Z?G7W_P"*?^"<_C#6-*GL;>QUSGGG5_!XS^?B/CCUY/TXKRWP?_P2
ML\;:#)<F]LO$EV+G_GY\2>#G/Y+XC)SCG@?I0!^07@^ST/0?[0_T?[3J YSC
M_#\ORX[UT UC7/[+N9]5@_T?O_7///T[U^OUW_P2W\0S3>=!H>IVW; U;P?G
MVZ>(\5KZ;_P30\4P1?9[[0]3NK?.?])U?P>W'N%\1G':@#\"O^&J?$>CR_N(
M+DW%K>'CZ]._7UQ7N'PW^,&N?&S5-'@UR#[-]E]NO3M_^O\ (5]^^(_^"+.M
M:IK%SJ%O9>)<7.<Y\1>#UQ]0?$8/^?6O5_@K_P $K?$_PUUS^T)]#UQK;OY_
MB'PA*?\ OF/Q&[?ICC- 'OGP]^(0A^'UOX/L=)N=2%K9_;?M?/\ AC^?-?F?
M\<M-\8ZEXI\06,&AW-M;ZI><$^OYY]C^=?T*_"7]G_2/ =G/%?61:9LX-P-(
MD!S[H&X]R,?RKSCXL_LJ6WC'6?[7TFQNAGC_ $>ZTA#^3JI_E^M '\F/C;X2
M^([36+B^G@^R_P"A]_?C&.W^%;'@_P"'NMZQ87$\$'%M],=?\_UZU^\WBK_@
MFYXH\1R7),&N@7(YSJOA#CIR!_PD7;_/:NG^&_\ P3IU/P?I5Q9SV.I-/=9R
M;C5](D!/7I'XC8]/09_#- 'X)>%?AOXYU+6?^7G[/:X%YBS_ !%>H>)/!VN6
M<5O!]?S_ ,_K^5?MOH/[ NMZ/+J\_P!AU+_2\XQJ^C^G.2/$@ _''3O6A_PP
MAK=W_P ?VDW1^FKZ.?\ T'Q'S_6@#\2?!/@+Q5KVLV]C8SW/^?T_/OZ9K];_
M  ?\!O&4.C>'_/@N<_8^?]"]?Z_S_GZMX+_82U/PSXBMM5-CJGV>VZ :MI#'
MUZ+XC)^G'N:_2G0?"UOIVEV%C/"/]$L\<>O'!YZC\/PQP ?#%G\#8+SPY<?V
MK;_Z1]C]O?Z8]?RKY_\ ^%&^3K-S]AL?]'SZ=#_^K)'ZFOU_D\.V+0^2!@'U
MX_J?_KUS$/P]TJ&Z-P.OY]?3![?Y]P#YG^!NI3^'+^WTF^@^S9]<$X^GZ<^]
M?7$VI:5#=>?]NM>1CM[<?@?Y8KGIOAOI0NC?09%Q[C_'->3^*OAEXPU*_$UB
M=1\CT-YHP/Y'D<>V3B@#UGQ5J>E0Z-J&JV4]M<W%J,\8QGG(^O7_ .MW_,_Q
MM\5/!WBJ7Q#9:Y?6WVBUL]4-G:?;#Z<_Y_\ U5]S^&_A_P"*;/1;C2]5AN;H
M76?^/J\T<G/IA<DGUP#[U\'^-?V!/$.M>+9]=TK^V_L]W=[KL'6-'!]SM;Q&
M&&.X.,=P#0!\ _#W6-#U[QEJ$%]8XM[6\'?V_P _YZ?:^L:#H?C;PY;Z'X<\
M.#T^U_8^G3]>?Y^M=OIG_!/^]TZ_N=4MX=1M[FYZ_P"F:-QZ?\S'CGT]:^Q_
MAQ\$%\$Z*+&>Q)G/0W-UI+C\"H;\J /D'P'\$X-'\+W&E7$%M;:A^GT[\?X^
MM?._Q"UCQ'\,=,U"Q_X^?],]OU_GT_"OTW\:_"#Q5K$.=*@N;6?_ *=;S1U_
MF ?Z?AFOG?Q+^R7XW\51_P#$VTO4;DX_Z#&B@Y_\*3Z^OIUH _)C6/CQ/H]A
M;P3WWV:YNCQ_IO\ B1_]?^6AH/QLOKS2KBW_ .$B_P"/KV _/\^WYU]N^*/^
M":^IZW^_70M5^T8/)U3PB@_-O$0&?T]:Y&R_X)A^*(IOWVEZU;V_?;K/@T_C
MQXD/\NW:@#X0U[P%?>-HKG5;>?\ M(=^/ZY]/Y_C7S?XD\'ZKH-U_P >-S_G
M]?QXZU_1]\-OV+Y?"%@;&]LKB[@Y&+F]T9L?@,G\>_M4'C;]@_0_$F9X+&Z^
MT<?\O>CCVYSV]?\ (H _E@\2?VY-*?(L;G\>/P/^/;-?0'PE^&/C_P 2W^GP
M'2KG[/\ \_?V/O\ C_GITQ7[7WG_  3/MA,)X=+U&X]C>:,.V._B0<?A^-?9
M_P -_P!EO0/"WA/^R;[1!;ZC_P _:_V.V![[0<9]\>E 'Y]>&_BI_P *!T'3
M])G_ -*N./\ )QQST]?3)KV>\_;8L9O!O]E03YU#'7OZ=?\ /3%5/B=^PQXO
M\5WU_<6-EJ5Q;FZW68;5]'5@.Y96\1JRX[@@$=#CI7 Z1_P3L\8029O[#7/^
M ZOX.8_DOB,D\_S[4 ?*'Q4^.7BK4OW\$]R+?[9_GCJ>,<=/6OJ?]GK]H7PY
M_P (Y;CQ5/;"XM>W\A_G/\A6AJ__  3Y\;WMK]A@TK5/L_<G5O!X^G7Q'D>W
M'K7/:/\ \$Y_'VF/!";#7?LPZ_\ %1>#\G)&< >(LG\ 10!]]?$_XG:'J7PO
M^W>'+[[-V_S^?\O:OR'\>?&S7(=+U#2I]5_Y"G;/^'7O7Z7:[^RQXPO/ 9\'
M6,&I]^NK:0O;U/B,?X].>*^3KS_@F[XVU*+R;ZVU[_P?^$?IV\0D_7CVSVH
M_*+QMX\G\57]O!8SC_1?7U_^OZ^GOUX_1X=5U[QYI]C!<?\ +W_Q]\__ *_Q
MS7ZK3?\ !+'QAY4YM]*US[0>!_Q47@_OZ_\ %1\'ZD=/ST/!?_!,/QOH$HOK
MBPUZVN3Z>(?![_F5\1D D_RQ0![5\,?C9!\/?@9K&E7U_P#Z1]CU3'^>O0_T
MS7\[_P 9OB=?:SX\UC59Y\6_VS]>?\XY^G>OZ(->_8#\8ZEH/]E0?VW^&L:+
MV S_ ,S(.N3_ $KX^UW_ ((]^+]9NI[B?2_$9R./^*D\&#/^[_Q4F/KQ]<4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% #=B^GZG_&C8OI^I_P :-Z^O
MZ'_"OS?_ &RO^"JG[ /[ -NL?[5?[37@+X;^)Y;875C\.H&U7QG\3+RWFC @
MQ\+OA]#XK\6QP22$,?$UQX9A\+HQ+->*5S4>V7\S^_\ X)*H)_9?W?\  /T>
M4+G@Y/TQ^7_Z_6E;;GD\_C_^JOY&/%__  >5?\$K_#?B"72]'^&?[:?Q TVQ
M=?\ BJ_#'PL^$FG:-J*&-5>72(/'/QR\(>)G5F&-EWX:\.2 C> =QQ^A/[+7
M_!QW_P $DOVL?$FG>#_"_P"TG#\+?&VMK:'3/"WQ^\/ZO\)#=WTC!4TI?&VN
M;_AE)K3,T<::%!XUDEED*B!9_-?95'#RKW^K*5UO:+O_ . W;]='L]!XA_5_
MB5_P_P S]X"."!Z8'Y5^#?\ P6K_ ."*OPH_X*L_"674+"+2/AU^UE\/-)U2
M?X.?&6"S017T:Q,1\,_B<5!GUSP3XB?=Y<ICEG\(SS&ZLP\!O;'Q%^ZUO/!>
MQ07$$T-Q;W %S:7$&"K# (8'+!L@XSGD95@"*O$#J0/J<5SUZ'MK-.S6S_K>
M^S3T:;31M0KO#.ZW^[;=>GETT['^$=^T1^SI\7OV4_C#XT^ WQV\$:U\/OB=
MX U>?1_$/AO5[1HW&P2K#JFE2/:&/6]%UZ*2.Z\,>(+61[>:V>)U?!25?GU7
M8,2!G/\ D ]O\^M?[!W_  6L_P""*?PF_P""K'PCENK6/2?AU^UA\.])U2X^
M#?QFM[)/)O(A$S#X9_$PH//USP3XBDW-%((YKCPC<3F[M-\#7EEXC_R?OVEO
MV:/C1^R+\:_&GP"^/G@O5/A[\4OAWK$^E>(- U&%A&Z*K2:5K6A:LD#P:YX>
M\16[1W7ACQ#;R36TEI(C%T"%JG#8F]L/B7RR6Z_]NCY=UJXMV=TTWT5J-T\3
MAEVO%.[BWU75INZ3MJET=T?4/P?_ ."JO[=?P#_9#^*W["GPM^./B#P]^S]\
M5=0CN=;\,"1I/%'AJQN(YI?&6C>!-?#F;P5X;\:H /'6@66V*Y7<(FC:X\3S
M7OYK,VX_3M^6?Z?YZP$D'/?J?Q^OM@5[9\!]&^$.N_&/X9Z1\??%'BCP7\$=
M3\:>'[/XI>+O!N@IXB\7Z!X&EU';KVK^']#WQQZW>6]N)'@A+M(\J(D<;LL<
M,GJ4,/\ 6L5;2SW\[;>OZG$ZWL,/)7T6K^Z[M]WY;7/T^_X([?\ !';XZ_\
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M ?\ !(;P)K.LPR6W_"VOC3\8_B7H\-R22?#XU;1/A]%(@(&4=O EPZ;@.74
M8K^F=5!SDXQ7BG[/_P $O O[.7P5^%OP(^&NG#2? 7P?\%>&_ GA*TW%FCTO
MP_I<>CVID)9G:61$$TK%B3)(V#M KVM?N,1WQ_3_ !KNS2IA\9FE7%4-%*I-
M0C>[5*32C?LVH\S6ZYK7=E;R<MINC@')Z.<IU&K67-*3D^^W,E?K9OJ34445
MRG>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7B6Z\+>%=.GO]%\<?M;V2(OB7Q<(W:&YTKX';_-/A?0&"R*GQ0>"+QG.V)_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\*>#]9^/_B>P#("\/C0#Q3\*/"VAZPDAQGPQXO\ &431;23$S3(G]Y7[%?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOK9M)VZ72NUOJEH]C^9^7_@[O_X)))\9)?A<LG[2EUX:77AHK?':W^$FC?\
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M<KI.-.5[ZN_-=:+1:K73C>(7UEX:VJBWZW;=OPM^'=%NBBBH-PHHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4,;L>!;O2-7\0?$^3.57R+C0-%'A6X.[*#Q,@&6/'\P7_!G;^S5;_%/_ (*
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M7%+*Y.+GL^5MI6WMMHGHF][-I6U7]"'["'_!;G_@G#_P48UM? W[._QWMO\
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M_'GBGX'>+)[6$,;GPSXZT)O&?A]]4==VV/P]K7@S7HX%;Y#/XE</RL;+S_\
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MS:ZIK'@CP3#XDU_P[H5Q%;W1M?$OBB#PUX3NF0V]I=33)#"_XRZ%_P 'CO\
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MV(6%E:][67?1M)7;:6S;T;VUW_K7_9>_X.BO^"1/[3FO:#X4F^,_BO\ 9O\
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M^)FB:%H&B>-_#K1VOB;X>:YXFA-I:-;78N/!WB6XUY_!=EXV\63336Z_ZO\
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MV34KFZ-O-!/^RM\:+$1D,7;S?.^'T<6C;%&7>60( 3AL##?M%^Q?_P &E?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHQ?V?AKQGX(\?3>(-$WQ*"=*N9]!T*Y=&5@9]%MRH+M(S?B!_P &7FK7]O\
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M3C*.FKLDU[W'4P2S/+7B)76:*R;5FUS)I.%U?W7%7[QT\E_MV/J]O)H_]LV
M^W6GV'[;;FV(8W:M$TRF//!\Q-A48'+'(^7%?Y8GQU_X*@?\%T/^"R_QS\9?
M#C]EJ+]H31/ 6D>+=1M](^"'[)]AXS\$^'? VEOJ>IQ^&W^.?Q8T!O"MY+Y]
MLQ$]S\6?&%EX//BG0!/:>$O##E;<?Z'7_!)?XC:E\6_^"9O["?Q \07DM_KN
MO_LM?!H:W>W.U'U#5]'\%Z)H>KZF^ ,R3W>ERS;^ 6D;.3(6/A_[3/\ P4Y_
MX).?\$H8+OX4_$WXI_!_X)>)]0U?5/&]]\#O@K\/IM5\9S>(O'.I#6-=\8^)
MO _PA\+WB>'=;\83R:GXBF\2^-(_"Y\6M(]R+J[N)(V?#,,#A<MS[,\'BKMP
MJ5*35N9R=&K.BWLU)KD2:M9MM/L9Y?CL7B,D<L-!/-WRZW32<$^:/E[RYE)-
M-NR;22/\X#XJ?\$$/^"WGP/T;Q!^T5X[_9,^)<$GA"[OOB'K_CKP7\:O@U\3
M/B'IVJQR2:_=>,UT?X3?%_Q?\2Y]?M)$D\2W6O06LT\5RGGS3"11Y_UM_P $
M5/\ @OU^V3^R[^TM\*?@]^T3\<_B!\=/V6OBKXST;P3XPT'XN^)M3\:>)/AP
M?&6OV/AZ+QQX%\<>)[J?Q;H8\,L!>W/A)?%9\%S6<_B&YATZ+Q3*ERG].GBK
M_@\?_P""6.G:OK>AZ=\*/VV/&ND:?<WMG!XC\._";X.QZ#KUFF8O[5TF+Q5^
MT/X3\2+H\R8*)XA\,^'KSRP_G0QR1.H_S5_'_B32_$7QC\:>+?"-I<Z3H?B#
MX@^)/$GARPN(EM;S3]'U3Q'/J^BPEHRRB2WMYH8E 9EC\H[20PKV<AK8RMGF
M6937I.&4YY4HTW5;6G/Q*J<XP;4^6I&G+GC4CRSWBTXMQ=8W!+$99*]UFMM&
MFI.[B[-)Z^[-15KOFB[[L_W@F(9HU'(66(=,\)/&,]!@'/?L:_R?/^"B?_!5
M']OWX1_\%<OVG-,\._MN_M3>!OAG\+_VO_$VAZ5X!\-_&CXC:=\,='\%^"?'
M,VD0Z0?A/I?B2'X=:SH9T/0XS>:++X::/Q6&E>^25[R57_U6/!EQ+<>&/#<D
MO^NGT:P+ Y_U@M;20_J&/7T]S7^,)_P65W?\/4O^"@14X*_M9?&3&/\ 9\9:
MVV.O R?6OEZ5:OE_%6 TBTJ7$TDII2C?VW#,4W&2<6URU+.UU=V:N[ZX%0S/
MA'-Y26F<+AI727/&%27$7,HR:<E>,U>S2;A!M/EC;[R_X*4_\%'/V^/^"Z7[
M2/CKP1^SGX)_:'^(W[//@N_U.7X6_LS_  -\&?$;Q<7\!Z+J^^V^)7Q0\">
M8/$EUX@\4^()X-,UV2[\4K=6G@N::+P;X.FB2W>?4/[(_P#@U#\+?M->!/\
M@GE\5_!/[37A/XR^"-9\(?M/^*M*^'?A#XT:+XN\,^(_"W@9/AI\)=NBZ'H'
MC:*#7= \*Q^)9O$+00QVR6R7+:\8$C95S]G?\$ /V)_@W^Q?_P $WOV?M0\
M:9%=^-_VBOAKX ^/WQ;\>7EJJ:[XH\3>/_".F>(=(TE&2+S!X=\'Z#KW_"-^
M$HWE$(A$U[$AN?$EV7_<&XV_9IF7@R0<#H-H!/\ ,8]>.^:]S-)5.'<'Q+DN
M C%^]*.O+&_$M&513JJ,8OVCE6O3C*;;E%N3=N6*\[#5X9W'+,T@DZ=TX/EM
M[NO*TMX\T6I26CLTGJF?XV7B#_@KQ_P5-M?VH-6\36W_  4)_:WMKJ'XPZC>
MVWAN#XZ?$ ?#0 >*),:1'\*AXC/PQ_X1P1JL*^%CX57PJUN/*-N8@H/^O1\7
M_B_X3^ _P-^(WQX^(-Y]F\(?"+X:>)OB9XLNXP2T6D>#/#UWKFLM&H'+B'3)
M!&NTYD(7!R!7^'SXL;/[06M,/^BHWZGCKGQ3<#]./_K]_P#:@_;:^ .J_M0_
ML,_M*_LYZ)>6>G^(OC/^SUX\^'WAN]O #IVG^*-?\'W>FZ"9R2N((]=>V9B&
M# !LC@"N=QK+PVR7&8116;2C%<ZIP=3E_P!5^$6GM%S?+/$349.2=1V>LVW[
M69T,+_Q$G,<'B;+)_:5XRBWRQ4(\7S@K-64>6FK)V2C'2*2BDO\ +D_:T_X*
MO_\ !4G_ (+%_M-0?"GX8>-/C!I?A[XI>(-6\%_"']C_ /9^\2ZUH'AI?#6O
M^?'_ &#XU'A^;PJOQ*UA-%69O&/C+XEL]I;6I\2RQ+X.\$N-.ATX_P#@AS_P
M< ?L;Z;J'QI\ _LR_M!?#/4;/362]U_]FWX[?#;Q)\2FTT2'652#0/V>?C)X
MG^)NJQ%M.+M!:^')HQ/&J.OFI"M?GE^S7\=?VBO^"4'[<?AGXKV?@S_A%?CU
M^S;XU\1Z!XE^'GQ&TJZAV-=Z%KG@/Q[X+\1:63%-$FM^'M?UBQ>:&59(3+%=
MVLLP$8F_T*_V$O\ @[8_X)^_M,W&A>"/VE=,\3?L8?$N_P#L=HFJ^-[]/%GP
M/U'5)F\E8K?XJZ%!#=^'DR7GEN?B;X-\'^$[6(HTWC&:0L$WI4</'+\K63<L
MLSM)M\TW-SC+W$HI6E%P]Y-2<N9M<JW.+&U<5',>7,H*,8I)**M&*[)1NHKK
MI%I_%S7>OZ)?\$ ?CI^T/^T#_P $PO@E\1?VK=8\3>)?C5'XE^,?@[7_ !%X
MYTY]+\9ZM'X%^+/BKP5I9\80W(CG&OVZZ5_8,TLT*SSC2<SYG$F?S@_X.&/^
M"_.M?\$YOLG[*7[*UWH5_P#M<^-/#LGB7Q-XWUJS36M"_9X\-:W',F@ZP?#]
MQ'-H/B7XA>)K5S/X1\/>(;>7PGX9$5KXJ\8VWBA-1LK=_P"J31/$.B>)/#^D
M^(/#FIZ?K.@ZW8:=JNE:[I=W'J.EZQIFJQK)I6HZ;JT;2VVI17$7E2Q2)+('
MBEB<,0\7F?XJ?_!5SXU>(/VAO^"D'[:WQ.\0WDUY>:W^T?\ %31]),V\R6/A
M7P3XNUCP1X+T@*<@?9O"V@Z' <%4#Q.V#\YKS<RJ_P!J9Y+#*FHVO4E3TY8N
MI*,5'1125TWHHK1II-V>N44,+A\N>*LN5)22764G+NK6BE;=[K7EB?2?PW_9
MR_X+0?\ !;"Z\7^,?"5I^TI^V5I/AWQ4;[7]9^)/Q>L-'^%F@^*9K2,KIV@:
MQ\7OB#X2^&6D>(8-&N %\*^$9(I?#'A2:V1+>.RDC Y;XB?#[_@K_P#\$3OB
M'X1T;QC??M*?L8^(M:O!XK\.CP9\3Q)\-/'-_HPM/[46/7/AQXD\4?!3XAR6
MZ+H0\9>%KF?Q</(EM+3QG:1K*ELW^JY_P2P_9X\+?LJ_\$]?V2O@IX;TS3--
M_P"$:^"W@+6/$@TR!435?'GC/1(/$WCW7F#$EY/$?BO6-;NBSX;$P3>510OP
M]_P<H_ #PI\>_P#@D1^TY=:[9Z7+XA^"]CX;^-W@+6+RU5KS0=7\$^(=&.LM
MI+\RK+XA\):EXA\*R$';MU\APYCCV]>;SIY%CL?#+%:EE%=4;V3;I^V>&E-0
M:46M)2Y9)J4%:3=VS'(I1SQY9]8NHYVURW6RFFZ:DK-)N+@FDM'/E2T5_EO_
M (-W?^"Y&O?\%0O!_BGX(?M$6_AS3/VLO@IX>T3Q!=ZUX<CCTS2?C-\/I;[^
MPKGQN?#>TKX>\5^']=32H?'=OX>@7PBY\3^%;W3#9-?2^%_#G7_\'27[0OQR
M_9F_X)EZ+XT_9^^+7Q!^"GC37?VC?ASX.U?QE\+_ !7JO@CQFOA:\T#Q[KL^
MEZ3XNT*YM/$6AB>ZT+2I))- N(G91/%*Q@FN5E_A9_X-O?B=JGPH_P""R/[(
M-U9W\MA9>./$OB;X7>((F4$7VG^.O!WB'1K?3&##[K>)6T*9?NLKPQG@@Y_M
M&_X/$5S_ ,$JO"<8Z#]JSX78]/\ DG_Q<8'MZ_Y'%7Q;25'+<JS3#KECG4Z3
ME!62IQ_UI5.4(J,8I0Y)0<8IV6J7NV1KPI%_ZQ8_+7&+2IRE&]I:_P"K/%-G
M[R=G&I1;3MS*RE%IJZ_E?_8N_P"#EK]LG]DC]D?]HSX;>(?BI\7?VD?VCOB?
MXW\'S?!3XA_M#^.]7^*VD_ OPHNCZW;^._$"ZMXZN/$_B/Q-KUQ,N@_\(=X*
MF<>"8+AY_%MZ6:UN?"'C/\H?VJ/#_P#P5$^._AVR_:W_ &P/ W[:_CCX?:P6
MUG0?CY\:OAW\7/\ A4BVGCB42Q+X+\::]X<@^&WA[P_XF=-.BL="\*3P>&[H
M"&WM8HXXTCC_ %B_X-3?V3_@C^U#_P %)M;E^/'@K3OB'IWP1^!VK_&OP)X<
MUE$OO#O_  GVC^-_A_H>@:[K>B3P"/74\,#7=5NH(I(WM5\5#3YYXIS&N?\
M48^)?P[\'_%?X<^-?AIX]T'3O%?@?Q[X3\1>#_%_AS4[9;[3];\-:_I<^CZW
MHTT39!2Z@E>)QM+ACE%650\6N=4J>7X>&;1I1EF<N&HN22492A'VTK<]G;VD
M8*,]-Y*<G-Q37)EF(?UN66.+_LNZ<VN5<SE*+2BDMH\SDTW9RNE&%W(_S'O^
M" G_  76_::_9Q_:N^$O[.O[0WQB\9?&+]E_XY>/?"WPSOK;XI^,-:\8ZO\
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MZ2XB?Q->?(G_  66#/\ \%3OV_R.O_#5OQG/3/+>/M<S^F?7Z&O]0[_@A_\
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M^);/3Q<-Y<?BOXJ>,?$TFO:@$^XIG\/>"/ R@G+#R&R0&<G=_P""#'_!>O\
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MX:?#[2DTCPWX7T*U:*QLX\0R22RR.?-U?5II%>2?6IS-/+(SF1R<QK_D^?\
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MP1H^G:OXG^.7@SQ'Y7AG0-(DFECE\,PQV^HZ[X@DA-PLJE/JW_@JC_P<Z?\
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MG_!']J'_ (*3:W+\>/!6G?$/3O@C\#M7^-?@3PYK*)?>'?\ A/M'\;_#_0]
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M *U4C^\3_@V9"C_@B?\ L71OT_LSXQX]1Y7[0GQ7<]?7IZ_3&:_DP_X.#/\
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MG)^=D^UOU"_8R_X.2O\ @EA^VIXL\+?#[PW\5O%?P.^)_C*[_L_PSX _:/\
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M@5_!%X$_X3]OB%X-7X5GQ4/BJWC3PU_PK@^ CK \<?\ "<KJMNO@\^"CH/\
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M<7_\IG_V\O\ L?O G_JE/ 5?Z0/_  ;L_P#*&7]A[_L0O&/_ *M3QY71D/\
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ME;W8<.X9QTUUM-N3OJ];*Q\IE]_J\L1)IRC6XAOKLE444K]E&E%+R-6BBBN
M]@I; OEQCG'OGJ?7]>V*_&O_ (+3_P#!5KP-_P $HOV4[SXJ7NE:9XX^,7Q$
MU:X\#_ KX8W%XT-GXC\6II\EQJFOZ^8@+J+P%X*@V7/BRXAE5GN;KPWX5"V\
MWBJWE7]EBP&UA][!QZ __6S^>?;'^8C_ ,'DOQF\0>,/^"C?PI^#\US-_P (
MK\'/V:/#E]I6G'(C'BKXG>+_ !1K7B34@0>/M>A:'X&MF4C ;00"2"<>?B<1
M[>6 P2BG_:L9N2NU>$(4ZD]M=?:06FMG?9,Z\!07-C\1B'[J@Y*UM4FHP_\
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MP],)="O IQ]K@F.Y\[J_FI_X.+/^"]>N_P#!/EM*_92_9*U'39?VLO&7AO\
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MW80$_P"IU?Q)I'Q$T/6Y<$$_O+?P9H*!!P1%@CJ:^$?^#T D_P#!0#]G-O\
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M^#B'X_:_^T%\.OV%_P!NKXBZE\5_"/Q5U&P\'?!7XV>-+Z&_^)WA/QU.B_\
M"/\ @GQYXOE,DGC_ ,-^,)[4:!;^)?%+3>.K3QAJ]E#/J%Y:7<I\-_VF?\%"
MOVQ?"'[ 7['OQS_:P\7Z8NMV/PI\)&\T;PRUX+%O%7C76=17P]X)\+><%=X?
M^$A\2:]I=M)(%WQP222D J#7^,C_ ,)_H?@[]I:7XM_!>VUK0/#7A?XT?\+
M^%5MJS(WB+0_#^D>-KC7/!4>K2:.%#ZW:VL.F)/+;EE-]&R12RQF-C_K6_\
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M6WD>-?!'PA^&^G>'M1;YMWEV_P 0_C5\,O%493!#+<>%K="N63S5RB?YYO\
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M[H7C31]*#R/H^A^+="UJV3RV<PV_BFU\2VEL$@MH4?\ S6?^"A0_X*\F1/\
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M ,)Q_P (U_;/]MCP?_PF7E?V]_PB_P#;0\T^&?-%E]L)E^S^<=U?Y-G_  =
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M0G_(*_X**?\ 81_9?_\ 1/QWK:_X/=?^1"_X)^?]CC^T%_Z9_A16+_P9"?\
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MV>KU5GTNDVG_ $C?\&J_[27[0'[3_P#P3M\9>,/VC/C#X^^-OB_PC^TMXX\
MZ%XQ^)'B35?&'C/_ (1/2/!GPZU^TT[6?%VNSS^(]<,&K^(M9\J;Q'/)/' \
M<"S21K&%_%S_ (.W_P!N#]L?]G']L?\ 9V^'W[.W[5'[0'P \&:M^SS#XPUG
M1_@G\7_&WPI36_$>K?$KQYHD^IZZ? /B+PW-K'EZ-H6D1VT6O2R16X67RB!+
M-M_3/_@S4X_X)B_%4?\ 5XOQ)_\ 59_!ROPJ_P"#T[_D_G]F[_LU/3?_ %;7
MQ'K+BN*H<18&*BE^\X==DHQC=<(4ZCTBHJ[E)R;:NY-R=Y-R>W"*3P'$R:34
M9<7.-TGRVXGM&UT[<L=$U9I:)QC=/P#XC_\ !R-^WM\3?V./V6/V&/V8_%GQ
M9O/CK)X#B\'_ !S_ &AHYM5UW]I+XM^.=;USQ#%X:\'_  PU>S>Y\71W$7AZ
M7PS'>_$2VD?XD>,/%(=(9+9(I;SQ=^%7QL\'?MZ?LV?%;2?BA^T'X,_:W^ 7
MQN\3"]U?P]\2?C;X<^,?PJ^*FN)#I2:!<ZSHOC/QU:^&?%FN2KHR2>'YKNWN
MW"VK/8@YD\H_W+_\&;7[)_P,/[,/Q?\ VPK_ ,!V.H_M"R?'3Q-\&M&\>ZM'
M%?W_ (6^'6C^"/A[KKZ/X.=XI7T0>)]=\2ZL_BV5&6XNX[.QA\V.RC,1_67_
M (.=OA;X+^(W_!'3]IC5O$^AV&JZO\)KGX9?$GP)K%W!F]\*>)HOB=X8\-RZ
MGIL@96CFO?#'B?Q%X7D4'$MMKLN_!7GHS[$KARM6QZIQ_M"<Z,ISIQA&I?B7
M_5I15.\/<C>M2E*,)0IS2C[MX*2G)/\ ;YK*9>[E49.-GRM<Z<M].5Q3BXI-
MR:3:^%N+_*O_ (-=/^"TGQL_:\UWQE^PG^UMXSO/B=X^\#>"1\0O@O\ &'Q-
M?OJ7C?Q5X0T?4M"T/Q%X&\=:M/O?Q5KOAHZYH.O^%/$<[2^+;B"+Q5)XPN[B
M>TM9S_7#^T9\=_AO^R[\&/B3\?OC!XAB\,_#CX5^&-2\7>*]5*K*T>FZ%;2'
M[-IT.T23:QKSRPZ)9PJX:2[N((HWBR93_EC?\&N%[?6'_!:3]ERWM)9(8=6T
M/XV6=R1G%WIT?P2^(]P\9 S\OG:8AW=0T1"D8!/];/\ P>+?&C5_ 7_!-;X<
M_"[0+V:SB^._[1GA7PUXDCAG(6]\,>#/"WB7QW)I\B DLC^*=$\&7!7)7]TQ
M96!(K;B5U,+@\HJ8+EEFF?04FDD^5QXHGPW.KT5XPA)K7WYQ:LG)I\^38;GS
M?,<'B9*.5Y2J=2-HQ5HRX:E*5."MRI-PA!+1)5+V:BDOY._VVO\ @N-_P4Y_
MX*S?M%6'PP_9O\3_ !I^%G@#Q5XRC\.?!#]F?]G;Q#K?A[Q3KB3RAM&7QIK'
M@&6T\1?$+Q-<)#)=WGVN3_A$O"S".2WMX88)[Z3PGX@?\$5?^"V_[$W@O4OV
MJ-9_9F^+OPGT;P3I6H>)=5^(_P *OBY\+M?\;^#M$?2YSK6NZOI7P=^)7B;X
MB^']"'A^:\C\93W-C%;6]N)F\83PQ (>M_X("?\ !1K]C?\ X)<_M._$G]HS
M]JKX>_'3XA:S>?"]_ /PA@^"OA;X?>(9O#VH>(=8@D\8Z_K*^/\ XD?"V&%W
MT+2(/#=E-:S7Y>'6/$7F0P,\4Y_KJU/_ (/-?^"4^JZ==:3J7[/?[>]Y8W]L
M]M>6US\*_P!G(QW5K(C(\3J?VK!O#!VX7IS@ \UQUZ%'*\.EE%.+S**3YFW&
M]2_PWBD[**UDVY*_NQ23YNBCB,57Q-L5"^4)K2/6]N:R>B>NE[W:U>MU^:W_
M  ;Q_P#!Q)^T#X@^/_PY_86_;I^)&J_%GP?\5K_3/!_P7^-_C:_AU#XH^%?'
M,\(3PYX+\?>,9B\OQ!\-^,)8U\/P^)_%#3^.;7QCK%G'/J%Y:7+GPU_H5B*)
MH2%;Y'(/T( &#^?OGOSU_P *P?$30?!_[2\_Q6^#%MK7A_PUX7^-"_$#X4VV
MK,C^(M#\/Z)XW;Q!X(CU=]'P#K=M;QZ3'+);%D-Y&5AEDB:)F_W.O#U_'JF@
M:5JG\.H:=87@]O-C$I'KC+G&/QQ7K8FFYY-E>:N#A*KS1J15DW4I1C*\E;^(
MHRE&7G#7WDV^*I36%S/'Y9#WLKY9N+M9)JHX/EL_AJ1Y9)=-;:-(Z>BBBO*.
MX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ^F#T^E<)\0/B#X,^%W@SQ+\0OB'XET7P;X%\'Z-J7B7Q5XH\07L>FZ!X?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!6E_UB?4_^@&O(_C1_P DA^*'_9.O'/\ ZC>JUZY+_K$^I_\
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M (OUKQ_ZJIJ(_/Q;/C]?\\5_NIZ+_P @G2O:PL6/T^S ?TK_ !PM<_X)'_\
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MT<C,UM& VTM&/\C']JC_ ()Q?\%'/^"0OQK'C;7/ ?Q.\%2_!_Q/8^(_AO\
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M:M]$U(*P&X2>,]=\%V1ZG?JJG[K U_8[_P 'B0S_ ,$IO"G3YOVJ_A>?^^/
M'Q= _P ]C7U'_P $&?\ @BIH/_!*/X/:_P")/B)K&B>-_P!K7XT1:)'\5_$V
MB1B;PYX'\+Z/--/H'PR\#S/:VSSZ9#*SW_C/Q*5\SQCXHBA!5+3PKIS-P_\
MP=(?LY_'7]IW_@FAI'@G]GWX0^/OC;XU\.?M#_#SQKJG@SX;^%]5\9>-9/#&
ME>'/'^B:MJ>B^$-"MYO$&NB&Y\0:2LUMX>@DN!%+--A(TE</BRM[;+LJRR@U
M*.2U:251-2]K'_6E5ISBXWO!Q=-0:T:3EM),TX5NN(\PQ.*:BO9SBDVHV?\
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M_@;PQXB\/.TT-W&LT27 GMGW17*1RYBC_P!.C_@GYX#\6?"K]AK]C?X;>/\
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M=<2 QIIND^"_!6M0Z)J8#_?5_&.N>#+)>A+:HK#Y7R?].O\ ;7_X)P?L8_\
M!13P_P"#/#O[8GP6M?C+H7PTU>_UWP7%_P )S\2OA[?:3?ZOID>EZPHUCX4>
M*?!NOW"7$$<:RZ'=7<MG)/;0.;?>&5?S:_X('?\ !%'P]_P2D^$'B3Q#\1=7
MT7QK^UK\9[31XOBKXFT.$7'AOP+X8T66:XT/X9>")9+:W:72HY#)>>,_$Q7S
M?&/BA(!M2S\*Z<Y_H>SL4YZ+P,CC/Z=OYYKJS>>'J4<MH-IQR6-U)--RE*<I
M3DFMT^9<MG_-T:.+"RQ$L5F&,;LLU@H0:NO=BIMM[/WG.5TU\*BG>UU^ O\
MQ"[?\$,/^C&__-E_VPO_ *(BOT&_8F_X)P_L5_\ !.OPYXV\-_L<_!*Q^#&A
M_$K5K#6O&J#QC\3/B#?ZOJ&DQ-I6CJVN_%?Q3XQU^!8(Y9E308+J.T6YN)F6
M(2B)Y/OC>OK^A_PHWKZ_H?\ "N+ZQ_>?W_\ VQV>R3W4G\O^ ?#WQV_9V_8I
M_P""C?PJUCP!\;/!GP4_:D^%^E>)O%'A>67[7I7BH^"?'.C"X\-^-X_#_CCP
MQKR^*/AQ\0_#DDFL>'[J[\*>)O#/C+PE*]Q9N8S$NW^&C_@M_P#\&Q'P8_8Q
M_9V^*/[:/['?Q<\8V?@7X:7FEZWXY^!?Q7NM'\2M8>&O$OC;2_#<#_"_XF[/
M#-UY7A6;54\WPKXNM?%WBW4+50J>-);Y1'XB^#OVL?@A_P %N_\ @C;^VA^U
M#\;/@#;?M%?#?X9^-?BY\6?BA#\6/@MHVJ?$+]GOQSX(U75]9\<QZUX[\/R>
M'/%GPX#^%O#&LR33K\5?#,,OA.;2O$$T">3;&XKXA^,/_!2[_@M!_P %6_#H
M_9U\8_$_XZ?M1>%S=Z1J]Y\(_@U\$_"-C'JLK:S"-$N?&/A_]GSX9^%W\1K#
MKWE&S/BB"\BC\1&!K9%NXX&B\V'M,PPV6XC*JZ>83=-RBN:TE:,I)QNU*:7-
MRNT)1E%\TDKGH1?U;%+#YG)/*+W33W2OL[I*]UJG[MW>-_=/TD_X-$OVD_B+
M\./^"D__  S_ *=K%])\+?VBOAQX\'BSPPUT!HT/BGP#X>?QMX.\8B)G9?[;
MMX-%UGPM"R>6QM?$T\4@<A%3HO\ @\>^&/B+PK_P4R^&_P 2YK.<^%_BC^S1
MX+.C7XW-'/J_@CQAXZT/Q#IBA?F5K:WU3P_</V*ZU%C(R*_;'_@V<_X(7_&K
M]B;Q?XD_;<_;'\,2^ OC+XB\(7'P_P#@_P#!BZO=(U7Q%X#\-Z[+8-XE\>>,
MO[(,L6B^(?%,>EQZ#X4\,0S+-X4\)S>)T\7+'=W4-K9?L!_P7'_X)%:)_P %
M8OV8H/"?AS6M&\&?M&?"34-2\6_ [QUK.GEK!KG7(E3Q'\,_%DR*\D?AKQI;
M6^DXN8 UUX;\4:'X;\4>7-%#<6=S[/$4XPJ\.58.+>4TGAZDDDTXM2CO%>\X
M1<4I7EHN5-Q/+R248X[B25=<L<XC!-VM><8INI9WWJ12=TFU[VC7,?S9_P#!
MMQ_P2R_X)!?\%&OV(=>\0_M%_L\0?$S]ISX5_%[Q'X8^)5ZOQQ^._@?4IO#6
MM"+7?AYJ[>$?A_\ &#PGX9AT"?09M7\.QRKX:AEO;OPYXAW-<.7<_P!#G_$+
MK_P0O(!'[#?T/_#2W[8/;I_S</@?@,U_G07_ ,&?^"PW_!%SXS^*/B3IG@7]
MI#]E+Q/X,=M(U;XN>$_#6J:C\$/$^E$#1X;6;QM;6/B7X&?$?P],FOP):Q>(
M9?%<=MXLDMU"6WC2-5B^E?#/_!P?_P '!G[0%U+X!^&W[4GQ5^(VOFUDUJ;0
MO@_^RS\!+_QDNFZ0J/)J(;X>_ J+Q,ND1&=)+F7S%MU<J9AA@KU7KX?,G+&8
M25U*SLG=;=+.UM+V:33;36@4J.)P\GA\0])/F7DF[VO=II+1-/5)/1G^BS^R
M7_P15_X)A?L+_%6'XT_LM?LK:-\.?B7;:/JNC6/BW5?B/\9_B1J&D6&H1^7J
MK:&GQ<^(WC2UT*66!A;OK/AZ*WNGBN)HS*R%UD_)S_@\9_Y17>$,#_FZOX6N
M1[CP3\5C_3\>^:^8?^#8K]DS_@J5X6_:._:+_;"_X*#:)^T7H^F?%'X*Z?\
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M63X@^'RS^.] LH-4>[\+^&?&EOXT\$Q2W$4EOX7=HRY_SD_^"\W_  0\L_\
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M=KN^ENY_99_P9K_M(?$GXH?L;_M!_ ;QMK>I>(/#?[./Q'\+?\*T;5;QKQ=
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M:0>G7_AHGXMG_/2OYC/^#VF+'Q__ &%)?7X1?%U/Q'C7PVW)YQT Q_6OZO\
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MG,G_ &DIYVYQ7LJ'#,5'W;3<(KAI<LDTVT\/S.RG=-NT4G(\Y)9?BHX5M?\
M"Q4;BF]4Y1E-NUMDG9WLKRBD[NS_ ,U+_@LEQ_P53_;_  !PO[5OQFSCV\9^
M(#QTZ8'X&O\ 6M_X)=C_ (UN_L#>G_#'O[.?Z_!KPL:_S0_^"MW_  3$_P""
MBGB__@IA^VCXT\"?L*?M;_$7P1X__:(^)7C?PEXR^&O[/?Q1^(7@O6_#7C'Q
M!>:UHNHZ9XO\#>&/$7AYVFANXUFB2X$]L^Z*Y2.7,4?^G1_P3\\!^+/A5^PU
M^QO\-O'^CR>%_'/P\_9I^!O@GQIX?N61[O1O%GA[X:^'/#_B'2)'&Y?,MM?M
MYX2">&3:^&7 \;()17AWDF$NN;DX7M'FCS-?ZK9_"3Y4W-6<HQ^!KFDE*2NK
M^MQ*K\94,6G=>QXFB[-22=N%?M1;334;IIZV;5TG;^(S_@\__9(/A;XN?LT_
MML^'M,E6R^)OAG5/@%\0KN$?NK7Q1X'8^)/ ;L <FY\3>&=:\96T8 ?]WX$8
MN067=^7O['W_  5PM_@/_P $'?VZ_P!AF?7TM/BUX_\ B;X6\._"&UNYF^U7
M_P +?C?I!MOCBFDQ I_HWAC1/ 6KVUW,S82Y^+N@!"Y38W^@=_P6T_8KU#]O
M?_@FW^T1\!/".C'Q+\5O[ T[XE?!G2HWTZSO[[XE_#V^MM>T71[*?5Q'%;S>
M*X(=8\)M)+-!F/Q(XCG4L,_Y5^I_\$F?^"HFEWU[83_\$X_VY)YK&Z-K(^E_
MLH_'35K!_(D5=^GZOH?@.?1=3B*QLS3V\SQ-\_E%@DI3#*Y0>$XEX?<8U*>:
MSHMRJ25G"%6/$].G'VDHM<LHU(*,6]*C45RS:EZ]2I=<-9FI6EDTDG'F<>6=
M-24)M)]:=2"35U?AR/-+F2M^V?\ P:-?LA)^T#_P46U_]HOQ-I#7O@S]D?X?
M7'BC2;AMS0I\6/'\LOA+P/',H9#M3P]'X]\00L0P2XT&W^5N"/[ /^#G;X3>
M(_BK_P $</VF9/"UA=W^I?#[4?AI\3;BSM<;QX=\*?$SPU-XDU1G#(QBT#PS
M)K'B"<9 2*T8D.<+7,_\&T7_  3W\=_\$_?^"?LD?QU\#:E\/?CW\=?B/XJ^
M(?C_ ,*:^-/_ .$@\)Z#HA_X1CP1H&LO"SQ^;_8>D2>)'B#R&"7Q1*I6)XRJ
M_O?\1/ O@OXO> /''PK^(.AV'BGP'\0_"VM^#?%OAS4H_-T_6?"_B72)=*UK
M29ER2L4\,TD4A'S)YK&-@X#KW\5QABX?V7A9JLLAC0E&,9Z/B*C4AQ-+EJ1O
M'WJ[<.92DDU!W:A8^<X>Q:P^/>;8R2:E6:2^)_ZN*,N'&[.2CK"=>K%>ZM4U
M9OF7^0;_ ,$(_@O^Q;^T3_P4<^$7P&_;J\#P^-_@S\6]"\<>#]$TO4?&WC+X
M=Z6/BA)HLNL^!))?$'P_\1>$_$B"[DT>;PO:68\2I%/XEU^R\T7#DD_Z(B?\
M&O?_  0P95?_ (8=X/W3_P -+?M@$CV _P"&A0..G(/7'>OX:_\ @IW_ ,&Z
M7[>/[!OQ7U?QG^S]\.?B/^TK^S5)XAFU7X>_$GX,>%M8\8?$;P+I46-3T2P^
M*G@7PS!)XKT#Q!X91%2;QI:6TG@N]\B'4(KKPO<7D?A>V\1\-?\ !PY_P7*^
M NC6WP?C_;.^(6A7/@%SX;GT?XJ_!GX%^.O'6CW6E(-*DT?Q%KOQ=^#7BSXB
MS:W;& I<'Q1XCEN895GBF$;,0=WCJ&:8?+)0G+^TW'DE!I:^]S0D[-/F5^22
M:<6TG&2?Q=CP.*H8G,9QDY95WUT:T33OUBT[.THO=65U_H#6O_!L)_P0VM7B
MGMOV(8?-@G^T$3_M&_M970( X5DF^.CJR!L,L;J5SUSV_<?PEX1\/> ?"OA[
MP7X.T73/#G@[PCH^G>'O#GAS1;06&FZ#X>T73$TK1]&TC3H@T:06T,<4-NN
M/+14)<K'7^6!\._!7_!Q7_P5=^.'PGL?BNG[<?B_P%I_CKP#XIU+6?'^D>+?
M@+^SOX6T_1_'GAS6/^$P?1AI?PD^&.K>(?"$X;Q%:1^%H9/'MPNBI)X)C_XI
MRW,'^K9:-N7/M_7_   HG2Q4<#3CBY7<E+W+IV2L^9J]US7M=Q3:32;5SS?;
M8;^TK8>2DU'5IZ=FK7ER]'9/S:OM(>HP> "!^.#_ #S^=?Y]?_![9\.M9D\7
M_L"_%:&"YN?#;>'OCO\ #R_NMN+*QU^/4_ 7B#2(&=<G[1>VLVL2;#G]WHF&
MSN)/^@@)=B(>I8\GV!&!VXZYZ'IFOR__ ."L_P#P3@\"?\%1OV._''[.7B?4
MK/PKXNBO-.\;?!GXBSZ<-7D\"?%#0DE31-7>!8Y)3H?B&TU+6/"7C!;-_M(\
M*:[=RP(+J*V9/#Q])1]ECJ3M_8[FVDM5&4%&:BGIS1@U)6U]W35GO8&MA5BU
MA\5?EDFMKWUTD[:Z2WMT;?0_DK_X,O\ ]K+P'X?U3]J7]C;Q3KFEZ+XY\>ZQ
MX2^,7PNL=3NHK;4O%<.A:1KFB>/]"TA)@CZKJGA^UM_#^OI;1PLZ6CZ]<+%Y
M4+R+_?;KOB30/"6A:KXC\5:WI'AWPQH5BVJ:IKVO7\6EZ9HVF0QEGU+5-5U:
M2."%(PIS).T:HQ6-V)8&O\7C]I[_ ()R?\%#_P#@FMX\N=4^,'P5^,7PIF\!
MZU;:UX;^//@&TUZ[^'01=832-&\6^#_C/X'B?PYI$TMY# +>WF\4^&O%]M-K
M?A\WFG64T\*&QX?\5_\ !77_ (*7VL?PJTKQ[_P4#_;;T!==TN#4?"NI^/?C
M_P#'?P%H>M-()]'F\01Z[K_BCPKX="1?\35-<\1&UBAV+.)(HH9)Y/;Q6(_M
M1X&>&DI9C)*$W)+DORN-[N4;*=-)24W%1<+O3F:\JCAUEV*S%XB25VI6O%I.
M.]FFERO=/5ZO?K_KV^ ?C)\$_P!N;]FGQ+X[_9V^(ND_$WX7_$?1/B9X!TCQ
MQX>74!IM]J6FMK?@;6_[).L1PEUM]:@OXDN @BEC6,AG4;Z_Q4?#/A[1_A?^
MT!H?A7X\>'+F7PSX%^+5EX9^,7A5[S4M-U :3X<\6KH_CS1&FT@1Z]I5[';:
M=K%N#;(E]#,(Y(H1)Y?F?Z[7_!#/]CWXO_L'?\$TO@7^SA\>K+2-,^+?AV^\
M>>(_%/A[2M7BUVS\-OXZ^(/B/QG#H!UC1IK[0M7US1=(U98;F7PY/+9R2P!;
M>>6(&X;^7G_@X0_X-P_CCXV^-_Q(_;C_ &"?!'_"S]&^)D^I>-OC7^SQX2L;
M>'X@:'X]98CKGCOX6Z/'Y9^(4'C21)=?\6^%=#C_ .$UB\9BZN=/M/&:>+)%
M\*Y8B67Y%Q95K81_VSDZE[*,I6C%PIN$^22CJZ=2_$T8R7NQE",I-**OW85_
MVODTL.I).7O*5^5WY94VU*ZY96:FG>+5KH_>[P5_P;8_\$"OB'X4\,>.O!'[
M&VG>)/!WC#0=*\3>&?$.E?M0_M@WMAKWAS7-,CU?1M5TJ:/]H8AH+N&:&6$X
MW-&7(V-G'4/_ ,&O7_!"Q#C_ (8:S_W<Q^V(/_?AZ_SN_A%_P5(_X+0?\$M=
M"A^ 'A+XT_'S]FC1+2RGU?1?@]\:?A'H.O?\(_IDTHCBF\(>"_VF/AYXK;PS
MH#:WID\8/A.UT^V$\.O3-'+(;@-]#G]O#_@Y(_X*:Z)HWA3PCX\_;?\ C#X/
M\97SZ=;7OP ^$7_"J/!&M+(9/#MW'KWC;X ?#OX8>%XO#,']NM#XM?Q7XFC\
M(1L\=SXO*);1%+JQE7O_ &9+F5[I_#:._O:VTUO)-)^6J7/14\-IF4E%WW<;
MNWE%RCJ]-+Z:J^S?^H9^RE^Q_P#LW_L/?"2P^!G[*WPLTKX3_"W3M3O]7_X1
MK3-4U[7VNM5U9$?4=3U;Q'XWUSQ-XIUS5)/+6%KCQ#X@N9!$HA5S!!%%'_F!
M?\'49*?\%HOVD@&V^7X0^!<J]MS_ /"E_ ?RC/KW'?(P/3_1J_X(]_LZ_%O]
ME;_@FW^R?^S]\>+&72/BO\/?AE%9^,M FU.RUQO#>H:QKWB'7X/"L6KZ#-<:
M"S^%]%U>V\-,=!N;FV0V8-O/,@$EQ_"]_P '*O\ P3Q_;P^,O_!5SXR?%;X/
M?L:?M-?&KX<>,_!_PAG\->-/@[\#_B5\5/#5Z-!^&GACP]KEK)JG@#P]XCCT
M36(O$.C:O&-!UUDO$B(NPC6TD#+PYM34>+\F<IK-U&7%<55E*R?_ !CM.,)J
M4YOK!2@I3N^6,5>347V\/UU_8F:N7_"0W'X6TG?_ %H3ELU)W_B7C%]7+2S?
M]>7_  ;,_P#*%']BW_L&_%W_ -:%^+5?PA?\'4?_ "FA_:2_[%#X%_\ JEO
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MUW;ZCH^K6=CJFF:C;$/9W]AJBK+!-"W\8EB<2#< ?WD88 [E'^</_P '!?\
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M2PV*LDWJW9:6;O=Z+5)7MUOYK]>_!'CSP1\3/"/A[QU\-_&/A?Q_X*\3Z?\
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MX9TZPN(5:'5=)D\501Z]\1$M="2.T\+>#/A98W=MX=MY_#ML%\&^!E@O(O\
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MTS0_#.A"3S+J:1+2R265X;0?YQ/_  3"^#'_  79_;I_X*0_LE?M'_M4Z?\
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MV\1 LFH7&E_"+X@_"_PA;[Y7E;;9^$K8@8C1SY<C2?YL_P#P5)^%GP3^!?\
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M\U#2M"\4^/;?7-2&[<2EC+XAT&-L$@?VLA4XP:_T/8B(D"9&[8TAXYP>F?\
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M?2IECG@D@N8Y8F61 ,ID,Z [N%969@"><?X>Y]1WK_5/_P""^_\ P;_^"O\
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M6'P^SE%+97N]+[:_\"_E9_KM_P $$?\ @@EXX_X*7>.]/^/OQ\L=:\"_L-^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1110 4444 %%%% !1110 4444 ?F[_P57_8ZM?V]_P!@/]HW]F.-(%\1>./
M4FH?#V>X+ 6?Q-\'S6_C+P%)+L9"L1\2:'I,%R-P4VT\V_*C%?Y?'_!"G]I[
M5OV"/^"MGP)U3XARW'@WP_XB\;ZO^S9\:]+U_P#T Z+IGC^67P7*-?+X?2T\
M'?$/^P/$M[O("#P[*DN(]['_ &'<1&+GA2GIR%V=_?'X#KZ5^-_Q9_X(,_\
M!)+XX?&_6_VC_BC^QOX2\1?&3Q/XK7Q_XA\0P^//C+X9\-:]XL6<:Q+K&O\
MPU\.?$CPO\--?%]<+$_BF&Y\)S0^,)FFD\707LEQ=LW/DU59;G<LPJ./]F5*
M,?;.E)*:UE3JNGS/D4?]6G-1;5E4ITVVXJ<68]/,,DGE4DW&3?*VM5)QUU=_
MAG&,_7FM9-(_9RBJ4$$$,<,$, @AM\+; 8V@8(PHY(')."<MUJ[70 4444 %
M%%% !1110 4444 %%%% !1110!_F,?\ !X3^V/I/QH_;B^''[+/A6Y@N=%_9
M,^'<Y\63VUUDM\4/BPVB^(-:T>10/+;_ (1[PEH/@8Q?*TT5UJ^OQAHE5M_]
M1O\ P:]_L-7'['G_  3.\(^./&6EFR^)7[5^JM\?=>@NE_TS3_!6J:9'IOPJ
MT<G(RC^!HAXM0!<QS>.;J%VRK*/L7XS_ /!"K_@E!^T1\=O$'[3GQD_9%T+Q
MM\8_%WB6S\8^+O$-S\1_COINE>)?$.F/"C7^M^ ] ^(ME\.M9:2%L7%O<>#Y
M8_$KN_VQ9E=WD_6W3-.TC2M+M=/TRTALM,L+5[:TM+6!;6TM+.)9E\J*% 4C
M"*CB-4 X ) &YJ66N> R#&8%7CF6;2BZS=E=_O*DDGI).=><)2TTITXQO?0C
M.9_VEF.65XR2RO)Z<E!3E>5Z<'&G=I\KA&53B64D[>])>=_XD_\ @\2_;@UG
M1_AK\ _^"=GPSC\0WGB'X\:IIOQ7^)MII6ESWK:]X4\-ZX=#^%_@C1E:TEEU
MR7Q1\18)O$LUMX?V7-M?>!?#4+&1/$S0M]T?\&S?_!'+_A@?X +^TQ^T#X2L
M+;]KO]H'P[87?]GZC8*/$'P0^#^J(FJZ+\.CNCWZ+XG\4RQQ>)?B %6W>*9/
M#O@VY5+GPM</=?U1*(PI5?0ECWQT''Y<\G\*8C0F-PH(4=3W))/IQWSV/J#P
M*SP4YY?A,PIPY5F&;RE*I.ZNWH^1*VB]V',^;2,.1)*4KK'S>/CEE--0RS*+
MOE4OCE?F?,TE=<W+*2:]YP@FWRHNT445J:!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% "$<$#TP/RK^7__ (+Z_P#! OP1_P %*/!5_P#'[]GW
M3=*\'?MO>!M'_P!"U&=%L/#_ ,<_"VCF9T\"^.9Q %C\26T+&/P%XOE66:$1
M6_@^]D/A$VEWX4_J!I"!U('U.*YZU'VW*U*S6S6__!OLT]]O36A7>&=U]SV=
MNZ_%;6=GY/\ P3_B'\.O&_PE\;^*OAM\2/"NM^"?B!X'UO4O#/BWPEXBLGTW
MQ!X<\0Z+(8M5TC6-,E_>PRV\P:,[P 0NY2Z Y\_!??D8)P.YYZ^WY_SK_5M_
MX+[?\$"_ _\ P4H\$W_Q]_9^TW2O!W[;O@;1_P#0-2G1;#P]\<_"VCF61/ O
MCF<0;8_$EM 3'X"\82K+-"L5OX/OY#X1-I=^%?\ +2^(?PZ\;_"7QOXJ^&WQ
M(\*ZWX)^('@?7-2\,^+?"7B*R?3=?\.>(=%D,6K:1K&FR_O89;>8/&WF  A=
MP9T!SGAL2IIX;$I+,TH.I34[JSLKQ;?,X.6BD[N-U&3O9RZ:]!:XG"[=4_BB
M^E[;=>EI+5:72_KC_P"#>'_@XBU+]D'5/"_[%'[:_BG4-4_9:U:[CT?X6_%7
M5;J6^U']F_4'DVP:'K4Y\QYO@Q+.9 R>7))X!9UGA7_A"Q<067^E%H/B+0_$
M^BZ3XC\/:GI^M>'=:L+#5M*U;3;E=1TW5]-UA$DTG4M-U*)Q%-#<Q%9(WB+@
MQR+M.#&[?X'B/()"R@!@,$'O['T _P#K'V_L"_X-Y/\ @X7U[]BW6/#7['/[
M8OB74=7_ &1];NX-/^'OC_5)7U#4_P!G35-6=4BBDF=GGF^#\T\LDMS:1AV\
M#O+/=6D#Z=)<6\'T3C_:=W%?\*SO=6LJFU^J]_3O[UTI/FM)^))?4+R2;RUN
M3G%1NXMMOFBDFVFW=Q2=G=I-MH_T[:*YC0?$.B>*-'TCQ%X>U33]:\.ZW8:?
MJ^DZOIMTNI:;J^F:RJ-I&IZ;J<;^7+%/$5D1HR_R2+M(!C=NGKR3M"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MP6D>"/!FA>)?%/C'0O#'A[2/&/CDZ6/%_B;2M$TFR\0^)SH<1TC2/[>U9%,^
ML/X=@=XHA</*MNI2.! ',,W>T4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>(?$T.BS.@$PBFD5EC#3+A0&8 ]^HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>[_+YZ,_2K(QG(QZ]J,C&<C'KVJ ,?*S[G]!_4\U^//Q1_X+K_\ !*'X/_M
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M$_&'X7Z#HZR+KK0KH \/S3PG39#-?3'<(?WB_P""(G_!('Q=_P $AM!_:O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** (S_RS_#^E? W_!4#XBW_
M ,)_^"<W[;_Q&T>X%MK'@_\ 93^/>LZ+<  FUU>/X9^(5T=PO8K=O"1R.5_V
MA7WR?^6?X?TK\IO^"X4#W/\ P21_X*!1QR>6Z?LQ?$ZX('\20Z,9'4GT949
M?4^U>/G45/*<?3EK&=2G"2O:\9XBC"2OTO&<E=:J^FQUY5_R-,LTO[\=+-IM
M2BU==?>459Z:ZZ'^4O\ \$?O!D/Q#_X*A_L&>%+A3-;77[5'P?OKW@_-I^@^
M-] UV8=<@>1I4@ _AR*_VM8O]:/^!_\ I7+7^--_P00EMK;_ (+ ?L(O=6QD
M1OC79VBD\A+Z71=8CADSTRDK*<<GC/0FO]EF+_6C_@?_ *5RU]3F#?\ 8^31
M3O'GXEG;1^^ZW#L6[_X4E;9+HKGS46WG^8)W2C0X<Y4]DI2XEE)I7=KRBDWI
M=Q6]KG^>7_P>Z\?%G_@G^<=? ?[0A].OB7X4?7FOY^?^"6O_  6X_:F_X)*^
M&_BYX;_9S\!? #QE:?&C6O"NK>+9?C3X4^(OB2^L+OPA8:YI6CQ:&? OQ=^&
M(MXC;Z[="X>X%VX8K(F#$$;^@G_@]TPWQ:_X)^+Z_#_]H/\ 3Q'\*,_YQ7SS
M_P &MW_!++]A#_@HQX#_ &N=9_;+^!A^,FJ?#/Q?\(M)\"7)^)WQ>^'*Z!8>
M(-%\?RZY"D?PG^(G@\:OYLFAZ+)NUZ"8QX*12;9')\;A2E7_ +'S#ZNTM>)9
M2?11?%+79KXVE>WNM7ZGM9S7PD:N5/&1YHO_ %=BDE?]XW-Q?Q1U3;LM;NRL
M<:/^#TK_ (*E9)'P#_8&^4$?\DN_:,P?4'_C*KC\,$CZ8K\7O^"H'_!6?]HC
M_@K/\0_A?\2OVC/ WP9\'ZY\*?"6H^!_#]K\$_#OC;PYI6HZ1K&LR:Y,^M)X
M\^(_Q1F;6/M#%87@NK=(XHRLD+NJNG^DM_Q"\?\ !#%2/^,'?O D_P#&2W[8
M/.>,C_C(4XS[%?QK^*C_ (.@?^"=W['G_!._]H;]FGP1^QW\(A\'O#'Q#^#W
MB3Q3XLTQ_'/Q.\?C5O$FD^-;G2(K]M7^*_Q!\87<*"U;RFAMI+= R%V1F*"/
M/%5\(L7EL,1"\YJ3@XKWDE%NH]U:\.:ZL[^1OAW7;Q_U56:3OYJ\;V>O3E3M
MVMYG[Z?\&5'_ "9M^UW_ -G)^'/_ % /#5?E'_P>@^.]0U;]O']G'X;F4'1O
M!/[+,'BFTB7^'5O'GQ(\>6^L%O4R6_@71,Y_N]L5^KG_  94?\F;?M=_]G)^
M'/\ U /#5?CA_P 'ENCSVG_!2_X1ZM)O\C6OV.O (MSY6 #I7Q+^,4<@!/WQ
MN8%B1E-V",=/3XO47GF0<S^QD'*N\UPG'E7W.;UT]WO8CA=1^I\6MVYHT^)7
M&^ZOQ+PM&4DNK47JNVNRN?&'_!/?_@X.^.'_  2__8KU']F+]ESX(_"J^^(7
MC/XT>*OBOXU^-/Q4?6?$FFFTUKPYX9\/:/H6C>!_#^M^$BFN6:^#4G;Q'XC\
M4W=O]E;[)'X1E.R]2UH?_!U+_P %J-(\:+XFO_VFO!GBS08[N\O?^%<Z]^SO
M\"%\&RQ2N&72I-1\/?#_ ,,?$4:5&K#8T/C:WNQM"R7$OE@I_1W_ ,&>G[+G
M[,OBC]D'XH?M*^(?@_\ #WQ9^T3HW[1WB?X?V?Q(\0Z'%XD\3^%O!FE> _AQ
MK>CZ7H3ZW%)#X=:2YUS629_#02>YC6W^U2LT31']N_\ @OE^R+\'?VIO^"9'
M[6%SX_\ !GA[5_&7P5^"/Q$^-/PN\:W%C"_B#P1XK^%.B:QX[1=$UG:);1?$
MUOH>J^%O$D22F*:QUZY^TPNZ0S(^):L\LJU*V.I<\J5*A.;37-&%2GPU&FG=
M*[V;Z<L96UG)G)DU)9C-Y7AFDY5?9^]UJ3J*+5[JR<W:R=K-)+2*/C'_ ((5
M_P#!P=H?_!5/4=5^ 7QM\ ^&?@_^U?X=\,R>([33_"6J:G)\./C)X9TN2"/7
MO$'@BUU]KSQ)X5UWPP\8>X\(7_B3Q>)K4G5(?%[A[FV\._BU_P 'KOP7\3I\
M4/V*_P!HF#2C-X4U7P;\1O@UJVN0*,V6OZ%K=IXYT'1[HJS#_2M'UOQ!);D#
M:_\ 8NN%MKK@_P UO_!$;XE:]\(O^"M'[!7B+PY=7-M<:C^T=X%\ 7XMPV;S
M2/B=K@^'.NZ<23M9+C0O$DZL#D!L'&<&O];?]M[]BSX#?M__ +/_ (N_9K_:
M%\/SZSX$\426%_;ZAI-RNG^(_"GB?3%E;1?%_A'4W$ZZ1KNA.LH4O;RPSPRS
MVTT,D4TR21GN!@L)E6:X5:N;G)76LZ<G2J1CU2Y>(M/=:7(U'1J,=,MQ\<'F
MN9Y9BKJ+A%M)-6C5O"T5HK1EPTFKOX6VWS6/X6/^#3;_ (*F_LP?LF^'?V@_
MV5?VI_C!X,^!EM\1O&WA[XJ_"_QW\1-8A\+^![_5_P"PO^$:\::!X@\<:WY7
MAOPT!%HGAF>RFU^YM+>3S/$(2ZW1MY7]+'_!3?\ X+8?\$J/!'[(WQX\&3_M
MB?!OXV:]\6/@Y\2/AQX9\#_LX^.]#^-WB'6M4\:^#M<T+3X)V^'?B*YT'P[&
M#<DRZ]XF\6>%HH0JM!<B66%%_FE^._\ P95_M2:1XA=_V8OVO/@'XX\%W.I7
MUQ'!\>-)^(_PK\3Z+IS,D>F0K<?#_P *_%S0_$6L;6(EE>+PE"7PZVRI)Y4-
MO0_^#1*7]GG]GCXT?M&?MW_M<Z,^C_!;X-_$WXH7?P]_9MTJ6&QN]1\%^'M<
MU[2(G^,WQ9\/H(=$N8=*C%U$_P '%N<ZFB1W$1B9KGDSRKALRP&9?VA*?LY\
M.J-94T_:SIJ*ISY8VDW4=-.$8QUYE%Q3ER\W5E6'JX+-,L>$EK+B:G.*LWS3
M=2E*-K1BXQ<X0G?75-7U=OY0OV"=3N-(_;D_9"U:SA,]S8?M/? Z[M[?_GH\
M'Q5\,.J]_09//7K@#'^XY+C(/8PS'GICYOP^OX?C_BB?\$D/AKJGQ:_X*;_L
M*^!M'B%S<7O[4?P@URZC)VJ-'\%>.=&\;^(G+$<%/#WA_5B,XX]*_P!EK]H+
MXP^%?@!\$OBU\;_&UR++PE\(OAMXT^(OB.Z(),6D>#-$N->O-H )+/# Z(,?
M-(0O0D5[.;8F&&X8R.OB'_#Q7%-5QUO[*/\ JU23VO[S44EUDK+?7S,/0EB\
MY6$PRYJDJ?#ZM?>52M4C!7>GQ.2?\JYG+2Q_FH?\'=W[7K_'?_@HOX<_9VT;
M4/M/A']DKX<:=X9FM(&+I_PLOXJ0Z1XZ\<7 ;:/G3PV/A_X?=54[9M!=3N+9
M/]@/_!N=^Q3H_P"SC_P2"^$7A/QKX=MCK_[4.B^(?CE\5-/N[; U/2_C!ID<
M'A?3-7!);!^#L'@VWE5S&0TLJ_=(#?Y;OB;XSZ=\>_VJ=<_: _:4D\3ZEH_Q
M1^-DOQ,^,?\ PB!AOO$Q\,^(?&,OB#QII?A$>(=<T&.?6UT26:R\(QW/BBSA
M0):0RWT*[WB_T*O#O_!X[_P2F\+:'HOAG0/V=_V]M.T31-'TS1M&L(?A;^SH
M(K#2M&B73M.@C(_:I)46\2PQKE2V%5LE<NWG8##5,-PI#!8B$YYMF\;U5>\J
M4(J563A)6A.E[><8KHX\,P=_M+NS6H\3G5.MA)-Y7DR24];SDHJG"25]'*3J
MU+/:4HI[:_P._ME_ /QA^P1^W?\ '?X)VNH:EI>O?L]?''6[?P-K'G[-3.F:
M+KPUOX9>+HY54C[3>>&I?#?B:-MO[N2Z4$#/'^PM^P%^U1X=_;4_8S_9U_:?
M\-S6TMO\6/A5H6N^(;2RF1HM'\;V]F=&\=^'F93E)/#'C#2-?\.X!W2FT9L#
M(8_Y9/\ P7?_ &\?V1O^"E?[8>E?M4?LJ^"OC9\/7USX8^%O"'Q8TCXT^$_A
M[X<O=?\ &'@^\U?1-&\7:1-X$^)7Q-@U2*3PFOA[PY*UV]K/$GAJVV (P8?U
M._\ !FG^U];>,OV>_P!H/]B+Q)K&=?\ @YXOA^,7P\TZZE OI_A_\2X7T?QG
M'I:E"/LOA?Q]I$=W.Q=66X^(<>5;S#C?):>,Q7!^899BU*&=9(J52<W[E:<8
MM<,5^2'OPDI+V7$ONSBY3<K\LTT\,_>&HYW3S?#QCR9JW&3DM%[7WN13NDHQ
MXF@X14D^523^RD_Z+/\ @M0R_P##IS_@H8Z\[/V5?B]C_MGX1O%';G(-?Y(G
M_!/O]H+P/^RE^VY^S!^TE\2+'Q'K7@?X+_&3P/\ $CQ=IO@[3])U3Q3J.D>&
M]5L=:U"WT#2M<U[POHDVN30VXBM([KQ)IUJDNQFE7:RK_K=_\%J%7_ATY_P4
M,1>-_P"RK\7L?]M/"-XP[\8 K_)$_P""??[/O@?]JW]MS]F#]FWXD7WB/1?
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M&UN='_X61KLGQ \$MX)UZ=9 )O#UMX7\7-!M,,UT9TFB3^=[_@E=HFB^(O\
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M_9'TKP?%%^TO^UA^TCXX\>;2US=_ FU^&'PL\'69B?>J+I/C[X=_%_7M8!&
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MOG5_+6P;P^?MYNRJVP,V0?\ :\_X*+\?L ?ML$=_V3_V@O\ Q[X0^*/Y"O\
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M^SIX-N+@?V-,\)CNY[B%%<[(@0KU_3#_ ,&A/[%_[7G[+6@?MJ^*OVD_@/\
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M8>'/CW^TAX.7[!X]\8>.=;NQ\$?AOK&H:9!=+X7N]'\,ZW#XK\=^(K>5M/\
M^$G\-1^(O!<7AII&M6\3W-Z9X+7S:BHT\9EV(K1<IQ4UHN;113<GT222N[J^
MW6S]/#?6GALRH81:R@E)VV7-S+6Z^WTUO?9VTXC1/^#+#_@G?!X:BL_$W[2_
M[:>L^+8;5S=>(- \1? KP]X9>^ROE[?"-U\%/%&MQ*H+%HF\7W#,-A6Y&6!_
MAC_X*D_L)Z__ ,$R?VW/B9^R[<>-+GQM:> Y_"_B3P+X^CM1H.H:SX5\9Z+!
MX@T'5-5TN&>=-!\1()/L]S;P73QQS:2TT#F-XS#^X>F?\%U/^#G/]KVVA^)G
M[+/@#XNR?#^"#^SY;C]EC]@-?B_\/[[44U/5E9O^$@\;?![X]7=OK*'S?#[1
MP^*E@SH11DDN%NII?P(_X*(_%3]NSXU_M)ZYXY_X*,:/\2M#_:<N?#GA6Q\1
MVGQ7^#.C_ ?QI_PC&F:0D?@QY_AMI'@/X8000+H@2.VU ^%HI+N!EGGG8ME>
MRH\9_:67XKG7*TFX.UW+FBXM=G'K;[,M8V?,30]@L-F6&=FK*S>NJ>UK?"TW
M?FUT6^I_J]_\$0?VFO%_[77_  2T_8]^./CW4[C6_'NM_#IO!OC/7=0NDFU3
M7?$WPG\6Z_\ "?6?$&LN-I_MKQ/+X+D\27"A-KRZ@7)C5P#_ )X7_!U)_P I
MHOVD?^Q0^!?_ *ICP'7]R?\ P:W_ /*$_P#90_[#7QR_]:!^)E?PV?\ !U)_
MRFB_:1_[%#X%_P#JF/ =<O%U*-'Q"RNE!)1BN+9)**BE[3AWAJLTE'1)2K22
MM;35ZMF?#/\ R369=7[ROY+BFR^Y([W]@+_@DS_P4'_X+Z^(K7XR?%'XM7?P
MZ_9Y^%_AGP[\'-"^-7Q"TK6?$FF6OAKX?Z7%H/A_X:_ OX9Q:QX<C\01^$X-
M)MU\5'_A*?"/A.*XDO#<>++CQB\UI-Y+_P %D?\ @@W\9O\ @C[9?#+QM<?%
M?1?VA/@-\2]<D\'V?Q/T[P'+\.=1\,^/H]*E\1KX/\9>#9/$?C<1?\)!HUMK
MDO@SQ!:^++Q;T>'/$!N[3PU+%:QW']\?_!LLW_&E;]C!"<E-+^,2C_@7[0OQ
M<8GOUV]<_3W^*/\ @\8&?^"5O@]1U'[6?PP;Z'_A!/BN5/7!(+^W3WKKXKQ4
MLHQTL-@.54Y<5QH3M",>9\28F5%M<J5FZG$4)N2]Z4G*4FW.3)X8J/-9Q=96
MOSQA#1N%/AI5(PIIM:^[PQR:WM%I+;7\MO\ @R]_:R\::AXM_:L_8O\ $.LW
M^H^"+/PUHOQ_^'&E75Q^Y\+:G%KUOX'^(7]E!@,'Q,NO>!9I=I&Q]!+#AC7]
M/7_!<[]NK4_^">G_  3B^.?QU\&:G#IGQ9UB'3OA;\&+G:KM:?$GQ[<2:/;Z
MW"K.JF;PCH$>O^+HT9AE_#RQ]6./XL/^#,!B/^"CWQZ)/+?L@>*<\?WOC'\%
MR:_:#_@]1U?5H?V'/V4=$MS(-'U3]J1]0U$@GG4]&^%WCRUT8'U;[/K>M$8]
M.O')QOAH1H\*\B4)9T^%W4:C;FG5S_B64I22?O2G3PT8MZ:I-W:N^?AYQK9O
MF\*FL<GJN45T;7#$*T4]/AYI1;5K-)WT9_"?^P_^QI\?_P#@IS^UCX8^ /PO
MOO[:^)/Q9UK6/$OB_P ?^-;[5=2TW0M/CCN=<\;_ !)\=:V8[G7YGB:9IY2Z
MW$WBCQ3<6]K]J:2>-E_I:_:G_P"#-+]HWX/? [6_B3^SE^U-X9_:B^(WAC2I
M-=O?@S+\&)_A-K'B--.C#ZEI'@GQ%/\ $GQQ:Z[KKL&6ST+Q%;^#HYWB>W:[
M-VR1C8_X,H_#^@7G[5G[8_BB[AB;Q-H/P \$Z3H[$$/:Z9K_ ,1O-U[;R<,\
MWA_0 3DY&<\\U_I!  X<]-B]/H./S_\ UBN['P^KTLNAA=.6$)MOJYN3LNB2
M45OU=MDC#"XEU\7F2Q%FDX^3]Z*E*3?>[LK:65^I_@M>,/\ A*E\3^(+;QH-
M='C:W\1:A%XK7Q,=1/B;^WUOW_M@:_\ VR6U?^WQJV\7XN +L7 F%P/-$]?[
M:W[ !S^PE^QOWS^RK\ 5_ ?"W0C_ /6K_'Q_X*I,6_X*9?M[DGAOVQ/VAY#^
M/Q4\3J2/_P!?],_[!G_!/T_\8(?L<GN/V6_@$OX?\*MT'C]<_6KRS%_7N$L/
MF'+&G[>?#];V<4U&"GPLI\D=%[L+.,?=7N1@K:$<0T?J'',,+TAA^+(W>K:C
MQ'PQ;\)+OJY.^NGV@K[P%[9 /'..G],_YQ7Q_P#MS?M5>%?V)?V2?V@/VJ/%
MT%K>Z?\ !;X;^)/&-II-Q<BP'B'Q.JII?@;P?YBE663Q7XJN-#\-12*V1)<H
MX#%1CZ_!7'RCCIS_ (8&#7\UO_!U]K%]I?\ P1L^,\-G/+%;Z_\ %#X#Z+J2
M*,&ZLA\3-"UP+G@%!/H<#D<?=((QU\+,9JEA(TTK.K.C13>EG.<8M]=D_P $
M>UE=&,L5'ZS\+EJUHFDI/ETV4K<NCNDVW8_SF_!V@_M7?\%FO^"A6@>&]<\7
M2^,OV@?VI/B"ME>>)M>&J_\ ".^%-*$%UK^LN+(+,^C?#_X7^%M)U2>UT"S#
M1P6FB&&V:YF=93_;C!_P92?L*GX:P:9<_M6?M:'XP-H1MY_'%O\ \*?7X:GQ
M4V2-:'PL;X9OXHC\/D8)\,?\+B:Y09QXRX!;^>#_ (-'=.T35O\ @KUX5EU6
M*SFO](^ GQPU+PZTX^>VU?\ LO1=%D;3F);]Z?#NLZ]$0<_Z,9><@,?]6?[D
M:G R% 'MGM_3_P"MFO:Q6%PV&P&6X/")1C&ESMJR2]Z45&*6BC&$=%KZWNWY
M,,=BL1FF8XC$NZY82T6CE.+<NBT5E&*LE9722:2_E>_X-[?^"._[5'_!)OXJ
M_MR>'_C/XG\(^,/A3\0H?@Y:?![QKX.UF-;?QR/#DWQ#DU[5=6\$S&;Q#X'U
MF.QU_P /6[Q2W3J9C+'!=>)T@BN;?^.O_@ZG/_&Z#]H\CI_PBOP./Y_!CP#G
M\LGZ=Z_UJ+?HI_O+#DXYXA.0.?7GW]:_R5?^#J7_ )3/?M(CT\)? \_G\&/
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MR\\8TJEDDDDU6XE4Y-WNZ<=-+'XL?\$1O^".WBG_ (+*_'?XJW7CWXG:_P"
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M^NX=^H:1J(^*7P>T25M(9MV#/H6KW,%P^"?)8*H&-Q_TZ@X1=@Z)'N_'H/\
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M6=_Y%OVW_P#@DA_P4A_X)/\ Q#G\<^*_ 7Q$T_P5X*\0?;? G[6OP-NM<N?
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MP>C_ /)_G[-__9JEA_ZM/XA5^[G_  9I?\HO_BK_ -G?_$S_ -5A\&:_"/\
MX/1_^3_/V;_^S5+#_P!6G\0J_=S_ (,TO^47_P 5?^SO_B9_ZK#X,UYG"_\
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M:EJFKI]>'I8?$Y=F6$Q2NG'F3:3N^9)QDGHTXRO9:[ZK2W^D!_P3B_:WTO\
M;M_8@_9Z_:DTRW@L+GXK_#VTO_$VEV[HZ:+XXTHW'AWQQHD1"C,5MXJTG68X
ML#*P)$"6;#5_DP?\%9]8N_"O_!73]NC7[':M[H/[8OQ+UFT>4#'V_2_B3)J2
MD@\86>$ @YRN1SQ7^A-_P:;7NMR_\$=?AG#JI_T.P^,/QPM/#N>G]C1^+&N)
M,]<_\3^771C'7%?YX'_!9L>5_P %6/\ @H&H'7]K+XTKP>R^/-;48YSU45UY
MK3C@N.LMHX1M1_?UJ4G\2DZO"U5*_7EE4:3=]$KW=V<_#ZAB.%LWHXM*2IN.
M%G%WM*G[;BGAZ4):I^]2]V;5M7)W3LU^LG_!.G_@AQ^V5_P7=UCXP?MT_'OX
MYQ?!7P9\0?'WBR[3XM^*? FK?$KQ/\5?&[G.K)X)\%/XH\%QOX \*7#IX77Q
M _BU-/LIM$/@OPG!-_PC-ZFG_P!N/_!('_@F[:?\$2?V,?CEX$^)GQUT_P"+
M>BR?$GQY^T3XC\=:9X-U#P7IV@^%]&^''AC1+F*31'\3>+Y','A_P*-<F,4\
MF'G:,B9X(F3Z\_X)3:/HWAO_ ()K?L&6.B:;I^F6C_LD? 2_>TTV#['8PZIK
M7PT\.:QKK1Q EE\W6Y[N61B2[2.SDG=7"_\ !:WQ!J/A[_@D]_P4!U+2)I+;
M4%_9B^*6G9@_UGV#7]"ET'5]N!P/L6KW D.<E3GNU='$4YY'3XFR+)6J,<FJ
M+A3E5-1C#_5C%?5J=H7;A&,XJ;C&[Y(TX)WO*?%D;>=XC*\7F=K9W*G+7WG&
M,Y1=W9*\O9NVEHW=TE%12_RW?VTOVK_VD/\ @M=_P4+TN_:XU'4M8^+_ ,3=
M#^#_ .S;\,;VZOO^$=^''A7Q+XR.@^!O"2/'!*+12+R/Q%XU\2;=TUW)XAU*
M4!$BMK;^Q_X;_P#!E9^Q8GPQT:T^+'[4/[4>I_&LZ0K>(/$7P]O?A'X9^&/]
MO$;I#I'@GQ#\+?%WBA=&C=MB13>.6N'C =YXC^['\"7[''C?]ISX9?M)_"?Q
M[^QE9>+=3_:=\,>(FO?@[8> /AWI7Q9\;7WBAM(UC<OA[X8:MX:\7Q^)[@>'
M7U>22"3PEXE6-%+^6K/&T7]*G_#R?_@\94\?#O\ ;\0$<Y_X)0^"AGV);]C'
M^H/3'6BEA\)A,KRO!X2,5%*5[NUI)I).]M+)N4GJY-M]SIKU\3B,Q^M)J,59
M*"6B25HI*R22BDDEIN?BI^UM^SM^T-_P1F_X**:]\.- ^)-WI7Q8_9W\8^'_
M !I\*?B_X5@E\/0^(/"VMZ,GB'P;XJBTQIF\G_A)/#ERNB>-_"\LVH6JW'_"
M2^#KIO%%J9GN_P#6X_X)]?M0V_[:7[%'[./[4$%C;Z;<_&OX7>&_%.NZ7 5E
ML])\4@2Z1XTTB$G!,%EXGTK7+2$%6*I&JN2<,W^5%^UQ^SS_ ,%U_P!NSXM3
M?'G]J?\ 8A_;X^*GQ5ET'1O"$GBL_L'?$OP8#X<\/BX&B:8NB?#[X+>$?#:B
M :Q<8D7P]'<2F0.\TH)*?Z2/_! 'X"?&?]F;_@D]^RU\'_C_ .$M4\!_$[P_
M:?$C6-:\&>(89[#Q)X8L/&OQ6\>>-] TC7='EB270]:M] \1Z3]KT!U66S<L
MDR)/YL:;1G77".8X?,JM"6,R>I3C2LUR2C.7$DJS@VTY-TX<.5)Z<JJ0FX-1
MJ1YN;'+"O/,LQ.'7Q*2=KZ-T^W922M>UKZ:WY?VD7HG^Y!_*.OB?_@HU_P F
M&?MJ?]FF?M$_^J7\65]L+T3_ '(/Y1U\3_\ !1K_ ),,_;4_[-,_:)_]4OXL
MKY+B'_DGL]_[)K%_^FJA[_"__)2<*?\ 97\)?^M9PH?XO/P!_:(^*O[-/B_6
M/'OP:\22>$/'6L?#OQ_\,SXAM4"ZA9^&?BIX,N/ WB7^PY@L4NB:X_AS6=4C
MA\012B2,S%HL,&,_]4O[&_\ P9Y_M(?M$?LY>%_C1\:_VG?#G[,/C_QOI&G>
M)O"GP5U3X+ZW\0]6L_#^M0VMSH__  LC79/B!X);P3KTZR 3>'K;POXN:#:8
M9KHSI-$G\[W_  2NT31?$7_!2S]@C1/$.F:?K&@:G^U[^SQ9ZMI.JVWVS3+[
M3I?BGX=2:/5(P2'B:/*R)C!7)/RKAO\ ;6AD)B8YZ _H&]_5?RQ7W&/4J&6Y
M;B7*46TZ4FDK-4G)\NJ:U_UA;>MU9-;W/FO;+^T5A4KZ<SO?JY)+?1)1;MUN
MNA_*U_P6!_:R\9?\$0?^"-/[/?[./P>\:?;/VB]9^&7@3]DWX>_%"QM6T^30
M;'P/\-8H/B7\7]%B>XC71M=72=)2'P:D4LUU8>+/$GA_4(H;V/P[-&W\8W_!
M$;_@CWXF_P""R_QW^*MYX[^)GB#P#\&_A+!IGB7XP^/K&%]?^(WB7Q/XZ.OG
MP_H/AZ;7OM>AR:_XIGT+5O$'BKQ3XGEG%O%;,T=G>W-\#'^U7_![1X@U.X^+
M7[ _A</*^FV'PZ^.FM0QX^0ZGK?BGX?Z9*2<<L(M B"Y/*-CTK\%_P#@E]^U
M%_P6Z_9^^&WQ'T/_ ()6^%/VC-=^&FN^.--U#XHWOP4_8_T']H_35\9KHGV;
M28M:UO5?@E\5Y?#]V-!$4O\ 8D=Y:[X5%R86:X1SY.38ZOF&-XFSS,ITLUS;
M%U.)ZBJ5$HTTYXN492E;[<93Q,E&\E[>HZG+*:2?JYE05#!Y9EV$5GRJ3?VF
MK2C;7?EBDDM+)R^&-VOZ+?\ @I/_ ,&B/[/_ ,#?V5OBO\;_ -C'XZ_M$^(_
MB%\'O!'B?XE:I\/_ (XZA\-/&FF^.O#?@O0)M;UK1= U?P+\.?A?+H'B$:+;
M2R>'4NHO$45Y.K6D:0/.'MOR3_X-;OV_?'?[+7_!0CP+^S7J.O7;_ ?]KS5$
M\ ^*/"]U?J=,L/B@-*N3\*_&>E6^UBNMR>((8O!TQB:+S;/Q#OF8S:#"5]>\
M1?\ !03_ (.]?%^B:YX:\3?"?]O;5] \2:1J7A[6-.F_X)5^$K--2TO6=,;2
M-6MI'M?V289E26"1XB\,T; NS*]N0$7X@_X)>?\ !*__ (*:Z;_P4,_8X\6Z
MY^PS^UI\+/#W@;]I#X-_$#Q?XY^*W[/WQ1^%W@OPKX2\"^.]"\2^(=3U+Q7X
MZ\+>'=!5TT/2-3$5L;AKB[F=(H([F:5MO;PY]9_MFK3QM6"RK.;P4IN+C"\*
MCYYR5[*%50JW?O*TN1V<$<6=+#/(IK#M+-.6<H6YD[J#<4[Z7<X\L>5/25G=
MG^CU_P %K_V_KG_@G#_P3[^-'[0?ADZ8_P 5+E-/^''P7L]48,C?$OQP6TK1
M-7;2VDC&M1>$[:/5_%\UJ?W4L&@%&$D3,6_RZ/\ @G9^Q5\>O^"R?[=H^%=Q
M\0-0_P"$F\;IXC^+WQP^-'C%M3\1ZCH_AJTU2U7Q%XPNUENB^M:]?:YKVE>&
M_#D#W$4+WVO6REH8('$?]FO_  >J:Q>P?L8?LDZ)!-*MAJ_[2FK7]Y;*<I<R
MZ)\,?$D.G%AR6\L:U<=.K-ZK@_G7_P &4>BZ-/\ M)_MGZK<0V;>(+'X$?#F
MRTNZ*@WEOI.L>.;B375B9@<(T^D:$S$ $N@!)#D5P\.X>A5Q>:X^NE*>4JJH
M)_:E2=.$5/M!5*JG)+XE!*][<O3G-:6'RC 4<([?VM:3?K55.+6CNHK57M=R
MNT[/G_1?XD?\&5O[$MY\.;^R^#W[4_[5'A?XLR6+/IOBCXEO\(O'7PZBU)!G
M_B:>"/#OPS^&7B272'DC"LD?C@2QH=Z^=GRV_3+_ (-VO^"<O[3G_!,;]F+X
M[_ 7]IN;PW)J>H_M-^+O%WPZ?P7XE3Q3X;UGP"?!7PZT"U\6:;(L<$N@'Q/K
M6DZN1X=\06UIXHBBMO,N(8%V@_T+DX,7KCI]2?\  G_(H)"&4_W<\]^^?P/\
MO>M:.)Q=%9K!U%)9O*+<9*_+R3<XJ+M[OO\ ONU[*Z5KZ\E>B\1_9Z>T&GZV
M3^75KT?8_@"^+O\ P:X_ML?MU?\ !2G]KOXY_M-?'+PS\&?V?O&7Q\\6Z_\
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M,GL[>ZH-I7Z)RE:]VD]7KK_D^_\ !9KG_@JA^WZ?^KL/C5^OCW6_\*_UI/\
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MA-:>&K#1-;_MZ74W9?C!\4Y->ENI!I\*)_Q(!:11.5:3[0L:?R+?\&=?R?\
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M^'?&_A<2SL1KOA>\FEM8VME\8VGA:>Y@@D_FN_X*E_\ !H1X%T_P?XS^-O\
MP3-\4^)+#6M"TK5O$ES^RK\2=6?Q)I?B!=,@21=)^%/Q3UUQX@T36H85F-MX
M6^*#^+$\87TI1_B!X2CC2)OXBOV=/VA/BK^Q_P#'OX;?'OX2ZM?^#_BA\)/&
M&F^)]&E_?6F+W19!'JNA:S$PBDFT/Q-;G5O#WBK09!%'/9W-S:N74^2ON8'%
MX3-,1+"YDU"<KI3<5I4Z.I%6<HN6C=^9KFM+GM?S<1@,10PKQ65VTWLE:^]F
MM4KK6Z22;3:<4T?ZJO\ P<R?$+4/AK_P1C_:SN-%N)(+OQ79_"[P LT8X;3O
M%OQC^'VDZW ^"#^_\-W6K1;0<%G ) 8D?YKW_!''X5Z7\:/^"J'["_PXUZ&&
M?1;S]H?P)K6JVEPS>5?V'@;4&\=3:8P)&X7 T8Q,O\22,#D+BO\ 13_X. S<
M?M3_ /! CXP_%3PA:!;?Q'\.OV?/CW869)+6'AZ;QM\-O&FIL&()/D^&[^<'
MD\1@MR>?\YS_ ()"?&&P^!O_  5#_8C^*GB&\AL-#T7]H?P+8>(M2NBS6>FZ
M1XRU ^"=;U20X!CCMK75IIFD( 18R3@#CGX7PU7"\5YOA*D:D<VCQ-D=*G&C
MS^TC5A@ZE*C&FH_\O5Q)32H\KYG/D:M+D#.,12Q' N!Q>%N\LGPYQ14;A:SI
MN"G+3XO?X:O?9^SYDM.9K_:WHHHK$W*%S]X_[B_^CZ_QW/\ @XR_Y30?MW?]
ME&\#?^J8^'=?[$=S]X_[B_\ H^O\=S_@XR_Y30?MW?\ 91O W_JF/AW7A1_Y
M'>!_[!N)/_2N&ST</_R+\P_P0_\ 3I_HX?\ !NK_ ,H9_P!A[_L0?%/_ *M+
MQU7[5KT_'^EQ7XJ?\&ZO_*&?]A[_ +$'Q3_ZM+QU7[5KT_'^EQ7VN<?\CO-_
M^O\ 5_\ 2V?&</\ _(FR[_'B/_4KB8_S)?\ @\L\?ZIX@_X*.?!SP"TKG1O
M/[*?AK4+2#^YJOC/XB_$!M988ZB6WT'0E[[O)Z  5^F/_!DU\*=%M?AE^V]\
M<YH8)=<U/QM\,OA-83EL-::7H6D:]XVUI?G& +N?Q%H4CYZ/HJ[3R&K\SO\
M@\M\!ZGH7_!1[X.^/FAVZ-X\_93\,Z=9SC^/5?!?Q&^(":P!SSY5OKVA]AS*
M>O%?I'_P9-?&#1Y? _[;W[/]U<PQ:Y9^)?AE\8=)L7&'O-,UC3->\$>()%WD
MEOL<^A>&@X&01K*D @$5Y?"G+_8F?^Q_Z!L]]I:]^?\ UJ?MU[WI#FMI9>[I
MJ?1\5<OM<IY%[B7"K7)LE_JXE)SY=-*KG?FTYW_-9']YU%%%9B"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRN^J_J&_X+1!7_X)*?\ !1)P2?M'[*7Q=E/?AO!]P"._0DCGKCJ>_P#E;?\
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M *[@"L<BKBOV(4C[N.BC/]0?SK%L;&RTVSM;*S@AM[*WM1;VUM JQV=O9QJ
MBJ@"H%"(!@<;1@' 9CJJ29F&>!G]./\ '_.*Z<=B5C\SS'%6M[6K.5GNG4E*
M=G;2Z37-;3F;/(P-%X#+LOP\OB;;E;;FG*=225];*51J-W>R7FS\-?\ @XT.
M/^"+?[<"C_EGX-^&X_\ ,P_#;^H/OUK_ #\_^#7@'_A]=^R:>I_L[XY$?C\
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M@:]KOB32=21A\3_A7<:)K%M<:YJL<ISXA1XWC15B\D,_W9_P1_\ ^"8NC?\
M!)O]EG5OV:](^+^I_&ZZU_XJ^(_BCXA\<:IX2B^']A-J_B'P_P"'?#_]G:)X
M1C\1^+Y-#T>#0_!>B12)/XH\022W8N;G(B9(X\^'*;RW(>(\IQ*LLTJJI>][
M<O%-3B9+MI%QN]M-.QMGLHYA7X8Q&&>L7%RNFK)<,5HM^G/525M[::7/)/\
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M!7@_XB^"=$T70K*$>#HO@A;RCXCOK'AE2;5/#WAWPA)*71VM(9X&64_YI?\
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M+(XU\J4N)8-_%[TH\4\JT_F]K!7U26KTO;^('_@S#!;_ (*1_'SV_9"\6?\
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MI^R^0P'^S\4/AZ#^I_PK^N/_ (*3?\%L_P!G?_@EO^T9^SS\)_VF/"?CO_A
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MQS?9&MH+>W\1$^)?*>W2[07"$+_4!XR_X,K/^"@D'BVXM? G[3G[&_B+P/\
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MN\+)VU:@HO:UXQ>G,[?YG'_!K_\ \%B/@7_P3\^(7QG_ &??VI_$:> ?@O\
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M\=?B5\=V_:KU#]H?Q)XY^&,WPNL=-3X,1?"'2O#>E:KXB\.>)-:U*9Y/B?\
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MWA2'Q$WA:;PSXG\2#[;:>'QXRM7, NK?PO\ U,?MP_L$_LU_\%"_@K>? O\
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M&1^?:O\ =?F421RJWW;E7+?0V\;CCC/+\#^G7^'O4?\ @RR\"W_QIO?B,/\
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M_9\\=^&+B[O'=/CII/Q(^$OB#1M-5\:6@/@+PS\9K77[EXU*S2[?#,*2QC9
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M[J4*D8J6BO*-GHPR6;PN:9IB<3&ZE5A)1O9\LN&XT[^JYFU%[\MG9,_R5/\
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M^;1-<L'=IV333UM?Z!_X.K/V1/$W[3W_  2V\1^+O &FWVK^+/V7/B1X=_:
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M4BU#P!HGCKP]JGCS2=2T%DWZS]H\.6^JP3Z 2LEPQ^ROP[HW^NOXM_X+<?\
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M)ZIZ)D8^EA<7F2S3#I)^]:VRYK<T;/>',KQ>CZM)\R/WT^#W_!S?\&_VP?\
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M$3?^")>A?\$=_#GQ[TZU_:$U/]H#Q!\>M7\"WFL:Q-\+S\*=,T#3O <'B?\
ML32-,\/CXC?$Z2YD#>--<-SKA\2H=SK%Y),+./V#^.?P5^''[1GPD^(7P/\
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MH\43?#KQPGAHVW%V?$C^%=5711%Q@3"[\@1YYWA?K7^(7^S#XF^'OPZ_:H^
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M3=]:O',7]:C9.3<K)6NV[MI6MNVWW;;6AQ4,/'+T[;/IT^5K:7Z=%9'],O\
MP0T_X+)>-O\ @K\O[6_BOQ#\'?#7P9\%_!3QW\/M$^&FD:5K.L>(_$5[X;\:
M:1XDNI7\::_</!H.J^(X)_#Z;CX<\,^&[6*'4UA2"=S]H?\ SW_^#C/C_@M-
M^WAW*_$;P'^8^#/PZK_3E_X)C_\ !+#]F_\ X)3?"/Q+\)_V?+SQCXBN?'/B
M.+Q9\0?B#X_OM+U'Q1XQU]8AHVFQS)HFC^&?#6C:)X>MA)':^'O#]I;R1,\\
MEQ-=74Q:Y_$G_@I3_P &IWAO_@H!^V5\5OVO?#W[;FM? Z[^,,GAS6/$O@/5
M/V?H?BV+3Q+H?A_1?#L^HZ7XA;XV?# C1)X=%TDPZ%-X9G:T*/&MY.[Q-'Y>
M(IX3^V,O>#5HQX:Y-5:ZBZ#D^NDJE[/>VZ3LETX*6(6&S)8IM<TKPOJ^5)/I
M=+2[TTL_))_GO_P2K_X.C_\ @G]^PQ^P)^SE^RG\4OA!^V!XD^(GPB\)ZUHO
MB;5?AWX$^#NI^#K_ %#6_&GB3Q*KZ+JWB/\ :"\)>(9(577E5V?PO!(I4[(<
M!FK],O"?_!XW_P $O?%WB7P[X9B^$'[;GAR/Q+KVF:1_PD7B3X:? M/#VCQ:
MEJ":7-JNL_V'^T7XDUU=)MS,'D6V\-7=T53*6[%U,?YPC_@QIR./^"H(!]/^
M&*3_ "'[6?\ 6NF\%?\ !DOI&@^*?#>J:_\ \%(;O7]"T;Q#IFJZOHVF?LDG
MPQJ.M:9IFKPMJ^EZ3KK?M2^)'T25EC,"ZR?#=V;5YH)Q'(K28]S#U<#F&:/%
M9KS*+DY2Y$T[R:<GLWTOMN]#B^KQP&7O#Y=H_P!Y*Z;;YI^TFK7Z<\ODG:Z2
M/TL_X.H?^"<?BC]MK]B+PM\>?@WX=G\3?&+]D?6=;\7KH.G6S7OB#Q5\'_$&
MFI'\4-%TJ&$SS3:OX:ET/0/%XMU260V?ASQ'"L?GR0X_SR?^":'_  4%^*__
M  34_:N\&?M,_"Z"'7UTNSN_"_CSX?:E?OI>B_$OX<:\]O'K_A'6M4A FTC]
M[#::_P"&O$$,5[+X=\6:%X?O9;6[M8)K2X_VSH;.&"UALUP88;=;8+T^0*BC
M/OA?7J1UYK^4[_@I+_P:C_L;?MF^-/$/QG_9Z\<:S^QU\9/%NH7FL^([+0?"
M.E>.?@EXGUV>[>YUC51\+SK_ (-N?"^O^(Y&;SI_#'BVU\)QIYEQ-X*EN'F>
M;RLOGB,GQSJX9*I2ESV3U7+4CRU:<XOXH35KJZ:\[GIUFLQRSZGBULK6ULKI
MNV]U9W<=-';565O7_@S_ ,'8'_!&SXC>!M(\1?$+XZ>.OV?O%5U:B/5?A]\0
M/@7\:/&.KZ/?*"H:/6OA!\/_ (G^%]50D!DE7Q*KF,C= ) Q/QC^W#_P>,?L
M;?#'PYK'A[]A;P-XP_:@^)US"4T+QMX_\-:Y\*/@AHS.Q5-2UB'Q$?#?Q4\1
MO&IBSX<B\(^"H9B6QXSA+1HWXR>*/^#+/_@HQ9>(]7A\$_M*?L3^(_"D%Q(-
M$UOQ5XK^.W@GQ!J%B0K^;KGA[2/@?XVM-"D(\Q6AMO%WB94"(5GPSX_1;]E;
M_@RS^&WA;Q?I'B3]L;]KG6?BMX<T[^RI[SX8?!;P&_PZL=7N+>>UEFTO6?B=
MXF\1^*/$$WAF18KG0YK?PYX0\)>+9;-W>R\5>&93;R1=,:%'$2;C)95!:M1<
MK.^J6BY[+HM'96YK>\<[K?5_B6NFC_X?KZZ]C^M;1/VHKFW_ & -)_;)\1>'
MK2+4/^&0K/\ :;UOPMI;E[%=03X.'XL:SHFF.Y\UX]PEMH'<NSJ YD>3>]?Y
MO/A[_@Z^_P""O]I\?=+\?>)?B;\.-8^%R>*+.XU3]GFU^#'PTTOP)>^'GG^S
MR:%8>,/^$>D^-D.8U<QZU-\5Y[R.Y<.\K1$0M_I_WWP1^'NH?!:Z^ 5SH%F_
MPNO_ (:W/PED\+8SIP\"7'A'_A"CH2=3]G3P\/LRCEA&,@Y4D?QV^&?^#+']
MG[1/CI9^,]?_ &U?B7XH^!=GX@.L'X/GX/Z#IOCO4=-BECN(]'U#XUP^/_[!
M1EG5A)=0_""!Y(-JF ;G9KPCH/BRMBZU.7]CN<)4XN"G:@N)Z\ITY04U>H^&
MI44E=N\7&-1.S,L'R+A>.%Q\7/./<YW!N+FEPO34^6HT^63XF55)N.\H3::3
M2_M*\+>(+7Q/X;\/>(K> VT7B'1],UJV@FVE[9=7TR/5E24D EE$V'((Y!/
M %=:5&T\^^>O\NH_QS6+IFE:?HEC::;80):V5A:I:6EO;Y"VMI&@1% .3A1&
M ,9SMXS@D[18;3Q[8Z?RZ#_#%17:=:^'^%MOWM-+OEOYI66_??=QA_K/U9?7
M/B\OQ_';ON/HHHJ3J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>drsa_014.jpg
<TEXT>
begin 644 drsa_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #I D0# 2(  A$! Q$!_\0
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MD3!EVX'S$-NSCI6WH&G7#>/= O=$TOQ4D< ECOIO$",8XXF7I&9"2&)'\/\
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M%P<C'/!XI/"?@75]/NDCU2:&&VLM)ETJVFLIV\V57DW^;T'EL %  SSDYZ4
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M\JQ+MYY)9U_"G:?XHLKV\GLYH;K3[J&(3M%?1B,F/.-X.2",\'GCCU%<-?\
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M&TO/SD#&>>:@LIX[6PU&XE)$<-S<2.0,G 8D_P JKECI="YGW+_D+_SUN?\
MP*E_^*H\A?\ GK<_^!4O_P 56'=^(+NV\,?VX+&)H3;BX$9E.X D;03CJ0>W
M3%:=]JMII@@^VRF/SF"*0I(R2!^')%%J?8=Y=RSY"_\ /6Y_\"I?_BJ/(7_G
MK<_^!4O_ ,561<^(1'X;U#6+>V9A9M(OERG;OV-M/(SCD&I5U^VB%O\ :W5/
MM,OEP%%8ACD+SD<?,<?K2M3[(/>-+R%_YZW/_@5+_P#%4>0O_/6Y_P# J7_X
MJLNZU]+;7$TXPE@9(8F?/(:4.5P.X^3GZ^U+'K3OXFDTEH$CC5"RO)O5Y2 "
M=@*[6 SR0V?:BU/L'O$&JW5U:7OEV]Y=QH5!P+F0\_B:*BUW_D(_\ %%>=62
M51V.JG\*/>J***R+"BBB@ HHHH \]NM$_P"$B\;>*+1K@P/##8M#+L#F/(EW
M  ],X&?I5B3PMXNBA\JV\4B6/;MV3VZ%2/3!4U>T3_DI/BS_ *]K#_T&6NLK
M"6'A*7,KI^3L.$I0OR.U_*/ZQ9Y$O@CQ-I6H&^L)GLYB<NVFI&J2?[T655OR
MJ]-X[\4:3?16M_ID$D#8'VJ2&6'!_P!H?-CZ@$5Z?3719$*.H93U!&0:U;JR
M?OS<O5_KO]]Q^VK+;E?K!?G'E9S4'B;5/)6:?PY-- PR)M.NH[A3]!E3^E3P
M^--#>40W-S)83G_EG?1- ?S8 ?K61K_@^]M[C^U?"UR]K=*=TMD)-D4X]%/\
M#?\ COJ.]+I/B*XU2QE6YM!J44+>7=V[PA+JW;TDB/#>Q7KVI2I5H4_:WO'K
M;6WJM&O)V:\[Z!]<I7M7HV\X-M?<TSM(Y$FC62)U=&&0RG(/XU2UC1=-U_3W
ML=5LXKJV?^"0=#Z@]5/N,&L&TT#1;U&O/#E[-IDV?F^QOM4-Z/"WR_A@58_M
M+7]$'_$ULUU*T'6[L$(D4>KQ?U4GZ5*JZ7>W=:HZ(T*59<V'FI7Z/1_+7E?R
M:]#(-WK'P_.-1FGU?PN.!>$%[JP'_37',D8_O?>'?-=O;7,%Y;17-M-'-!*H
M>.2-@RLIZ$$=14-AJ-CK%F+BRN([B!N"5.?P(['V-<7=V<_PXN9=3TN*2;PM
M*Y>^T^,;C8D\F:$?W.[(.G4=Q6B::NCGE&4&XR5FCOZ*BM;J"]M(KJUF2:WF
M0/'(ARKJ1D$'TJ6F2%%%% !1110 4444 %%<OXE\27VEZ?<O;:9<H\3A5N)%
M4Q'Y@,_>SSVX[UE^%_&>J:G]J^TZ?-=[-NW[*BC;G/7+#T_0URRQE*-14G>_
MH_Z_ XI9A1C65%WN_)_U^!WE%-C8O$CE&0L 2K=1[&N5U9M0A^(/AX_VC)]A
MG-PGV-%VIE8B=S'JQST[#TSS74=IUE%<=X[.L6_A*2YBU7[,\,R-)]ECV&53
M*H5=Q)*C!^;'7V'%6/'XNW\/006-_-87$^H6D*W,)^:/=,HS[CGD=QQ0!U-%
M>/Z[XDU&_FNK>9KFWO[6S@@OK*UG:/$OVV)24.1@.C95LCY6Z]:V=WB'0I;J
M_P!+TN_@L7CBA6RU"[^UR&0N2TJ()6)PG\ <%O3CD ]'HK'\-:NVM:.+F26%
MYDE>*7RHGBVLK$;61_F1AQE3G![GK6Q0 4444 %%%% !1110 5X_I_\ R#H/
M]W^IKV"O,]&\,:Q>:/:W$,E@(G3*[V?.,GK@=:Z,-4C!MR,JL7):%2BMG_A#
M]<_YZ:;_ -]R?X4?\(?KG_/33?\ ON3_  KL^LT^YA[*?8QJ*V?^$/US_GII
MO_?<G^%'_"'ZY_STTW_ON3_"CZS3[A[*?8QJ*V?^$/US_GIIO_?<G^%'_"'Z
MY_STTW_ON3_"CZS3[A[*?8QJ*V?^$/US_GIIO_?<G^%'_"'ZY_STTW_ON3_"
MCZS3[A[*?8Y?6O\ D%2?]=(O_1BUH-]X_6IM>\*:S#I#M))IVWS81PTG>5 .
MU:9\(:X23YFF_P#?<G^%+ZQ3ON/V4[;'+W.CZ=>&0W%G'(TCK(S'()91M!R#
MD'''':F'0=)/G9L(F\Y0C[LG*Y!P,GCD \8Y -=5_P (?KG_ #TTW_ON3_"C
M_A#]<_YZ:;_WW)_A2]O1_I![.9QESX6TVY"H%:& +&AAC.%8))YBY[YR3DYS
MR:L1>'](A55BT^!55U=0 < JQ92.>Q8G\:ZO_A#]<_YZ:;_WW)_A1_PA^N?\
M]--_[[D_PH]M1_I![.H<Q:Z5:V=XUS I3,(A6,?=1=S.<?5F)/T%6YO^/>7_
M '&_E6Y_PA^N?\]--_[[D_PJ.?PCK:VTI,NFX"-GYI/3Z4_K%);,/93.?TK_
M ) UA_U[1_\ H(K)\4WFIVD<1T_>,PS,"BY+2@+Y:GV.6X[XKK=&\)ZU+H6G
M2))IVUK6(C+29QL'M5W_ (1#71_RUTW_ +[D_P *3KTW&UP]G*]['!:C>W5Q
MK%A]BN6:WC8"XMX)#&['?M8X*D.JD<@$'&34E[K=Q9W]YE 8H+JVME0YQMD&
M6DXZXS@=OE-=U_PB.N_\]=-_[[D_PJ"3P+JLL\<[C2VEC(*/NDR",X[>Y_,T
MO;PZ2'[.78\_BUG4KF;1]2B5_+G58KRQ&2(V<L%?!Y&U@,^QI= U.^:+3!<7
M$ER]S=W4$OF=0J;F1AZ<*![AJ]&_X1'73_RUTW_ON3_"F'P7K)F$Q;3#(%VA
MBTF0/3I2]M"]^8?LY=C(JAI8!AO 0"#>3@@]_G-=1_PA^N?\]--_[[D_PK.T
M;PKK,T-X4DT[ O9P<M)U#G/:K^L4[[D^RGV,>31-/DTYM.: FS9=GD^8VT+G
M.!SP,@4^^TBPU(PF\@\TP_ZLEV&.0>Q]5'Y5TW_"'ZY_STTW_ON3_"C_ (0_
M7/\ GIIO_?<G^%'MZ(>SF<P^CV$FGW-BT'^BW+L\L8=@&+'+=^,GG HNM'L+
MV:WFN8/,DM\>4Q=LKA@PZ'GE0>?2NG_X0_7/^>FF_P#?<G^%'_"'ZY_STTW_
M +[D_P */;T0]G,YN?3+.YN1<30*TV,;\D'@$ \=P&;!ZC)IT&GVULX:-&R.
M5WR,^TX"Y&2<9  ..M=%_P (?KG_ #TTW_ON3_"C_A#]<_YZ:;_WW)_A1]8I
M=P]E,X/7?^0C_P  %%6/%.G7>G:QY%TUN9/*5OW)8C'/J.M%<%62E-M'3!6B
MDSW*LK7M1U+3;..73-%EU:9I-K0Q3QQ%5P?FRY [ 8]ZU:S?$,45QX:U6&>>
M2WBDM)4>:-2S1J4(+ #DD=<"LRC%T#Q=J.KZLME=^'Q8(49O-.IVTYR.VR-B
MWZ5UE>3_  [\+V$7B.+6M%O_  _<6"6Q5SI\9$QD=(PRL#]U R%AGYOG(KUB
M@ HHHH Y/1/^2D^+/^O:P_\ 09:ZRN3T3_DI/BS_ *]K#_T&6NLH **** "N
M<\0^&Y;RYCUG1IDL]=MUQ',1\DZ?\\I0/O*?7JIY%='16E*K.E+FA_P_D^Z8
MFKG'65]I^OVMQJ)9M$UJP)2]#, T##G#]G0XR#T(Z5H:'XH@U I;SRP-*Q*Q
MSP-NAG(Z[3V;U4\UB?$KPQ;ZAI$^K1&2&\@BVRR1G EA!W$2#N%(W#TQ6/\
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MOJ/SH 6BDW+ZC\Z-R^H_.@#'\4_\@%_^N]O_ .CDK9K%\4L/[!?D?Z^W[_\
M39*V=R^H_.@!:QK/Q"EWJYL?LLD<;-,L,Y8$2-$P608ZC!/&>N#^.QN7U'YU
MDIX?T^*^ENXVG25V9AB=L1EF#/M&>-Q49]>?4T 5V\3,3+#%ID[7:WK6<<#2
M(ID(C$I;.2 -OKSTJ;3/$4.JWT=O#;3I'+91WD<LFT!E8], D@COFF-X8L6:
MX<W-[YDUQ]I\P7)#1R;=F4(^[E/EQZ5/:Z#8V6I1WMO),ACMUMDB$I\M8UZ
M+_6@#5J&[_X\I_\ KFW\JEW+ZC\ZANV'V.?D?ZMN_M0!4\._\BQI/_7G#_Z
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MEMG$<Z)"A,;$ @'C@X(/XU0B\/:HD6EV[/9FUMYC<7*%W+33;]PD+8YY);&
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MSV;WY[UUQ?*^1_+^O(]VO%58?6(?]O+L^_I+\'==COJ***T.,**** "BBB@
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M4+ W,32QOB-PJ';NR!)]YN!@@#- &G]OUO\ Z <?_@:O_P 31]OUO_H!Q_\
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M_?#?X5MT4 8G_"7Z#_T$$_[X;_"C_A+]!_Z""?\ ?#?X5MT4 8G_  E^@_\
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MIVU]>F]U*\TVYMC&EO>6!0"8-&"Y7<#@;B5Y':O0]!\/W>C33/<^(=4U42*
M$O3&0F.XVJ*RH>UY?WNYZ.+IX>G4Y<--SC9:R23O;7;^O7<W****V.8****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>drsa_015.jpg
<TEXT>
begin 644 drsa_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $J G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC@C^E6=0O PC-O"\_EN&;8.,?6I=5NK6&S=)W7]XI"KUS4NFM"=/A$17:%'
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MH **XS7_ !G+H'B(6DD(EM2BL<<,,UTNFZO9:M );2='R,E0>1^% %ZBBB@
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M6"D. #GI2U7GS)(D/\+<M]*@HCW(3BWC8G/)!P*F@69=QF<-D\ =JE "@ #
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MYR6(^8+V%>EV\(BC]S6D%9'/6E>5NQ-1115F(4444 9FN:I#IED&EBEE\T[
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M4 %%%% !11535;MK#2KN\50S01-(%/? S0!;HK&\,:U)KOABSU62)8WGBWE
M>!7,P?$9O^$*EUR:R!G^VO9PPHW#,&VC)[4 =_17#)XG\2Z5?62Z_I5N+2\D
M$:RVCEC$QZ;AZ>]0KXK\4:EXCUG3M&TVQDBTV81,TTI4MD9H [^BL'PIXB;Q
M%ITLDUO]GNK>5H)XLY"N/0^E5?&7B/4-#.F6^EVL5Q>:A<>1&LK;5'&<YH Z
MBBN<TK4/$D=O=SZ]I]M&L2;HUM)#(S^V*S_#WC6]UGQ7/I%SH\NGHEL)T\YO
MG8$XY Z4 =G17&:CXFUJ[\276C>';.VE>RC#W$MRQ"@GHHQWK4\)>(SXCTN2
M::#[/=V\K07$6<A7'I[4 ;]%%% !1110 4444 (1D$5SNMZ%!JD#6]U;B:)N
MWI]*Z.B@:=MCS.3X8Z&87 M)59APQ<Y7Z5RUK\.-9T[68YK2^A6.-LK(PR0/
MI7NA (P1436L+')05#A$T5::ZGCQ\$:^P-I_:D'V59?/5O+Y+UJ^'O#5W%KU
MS)JFIQW,LF&>!$P#Z$BO35MXE& @KC]3T:ZB\50ZE]H$$#NL8*]?QJ9+EU2-
M:4O:7C)VT.LMK2.) =O-6:0?=%+6IRA1110 4444 8GBBREOM)9([E(%4[G+
M]"/>O%]7T9;+[6OVP7QV;U,(YZ\X'TKWG4;"'4["6TGW>7(,':<&O'O$?AS5
M;#5X+"SX$I?_ $J28+OB[J2>E93I\TD<&+P[J24DOGU]+;'&"\^U:)!.EHJ,
MC.BRNP#,G0 TFCZM:Z)J\(U2V=DB1I-B\@N1D#Z59DC2.'5K1K8?9;./;"QD
M^XV>QZ-6?9:1>:IJ$:VA=B;3>[3,%PJC/Y4*BD[_ ->1A2I24TW;^MB[-XGO
M+N_N;YI7MH&;<((B0A?N,59CGFU_5+5%2U(N1M* ;O+)[_7O2:Z5FT&PO+30
MEA0YMVF\WY7;N6JSX!TO4-0%VMC;Q)>(3LG27:1G@]>HK&I3]Y:G<L/)_O%J
M4->:TM-0N["QN&"(B*)4CSN*]>OO5Z#PYK,?AJ?4+ZTQ;N^[:O#,<?>P>U;.
MHZ9IWA#4;2XU[R;R2+!-O&Q;<3_&V>GL*=XV\:QZSI=F+.VEC<9<$?,H3IS5
MT)4Z=1>UMZ6O_7^92HR:<F3^"]=TW2='U(H$74#&(EC(YD?%<Y>M;65C!<6M
M\7DN,&YB=L;7W<J1Z=ZAU'PQ>:#HFGZK*7E:[0G"=%).>3VXK3\+7FF:;>R?
M;8!<O=0D*"N\"3^$<UZ5*4%"4X].GET^9C4YG-0>W?\ ,N1W%GI4^H;_ "KU
MC%B,L,1IN';Z5;\+^(4\/36Y@43K>D+,F_[K9X(]>*P[71-06ZU+36TV1KR=
M@5S\P0=37KNB^$-,M=-L?M.GP&[A4$L!T:KE5IRI*ZW\^R+A3E&3.D4[E!QU
M%+117$=(4444 %%%% !1110 4444 %%%% !1110 5RWCV_NM.T!9K2=X9/-
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MQ"MI[KPZL=O$\K^:IVJ,FNMHH I:0C)H]FC@JPB4$'MQ5VBB@ HHHH ****
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M8#I5GY<2A%C!0=<<>M7Z]FC3E"-G*YP3DI.Z5@HHHK4@**** "BBB@ HHHH
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M/I7'-X=U*[3S[F*Y^T&> 9$A'R;?G[U!J&@ZZ#Y$ N!9)/+Y:KEF4'&T]>E
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M/BB"D$'((Q[TFGZ!<1:PFIZA>"XGB@\B((FT =R?<T ;]%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>drsa_016.jpg
<TEXT>
begin 644 drsa_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "3 G # 2(  A$! Q$!_\0
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M]9%1L!P?>MVN)^&<$5KI6N6]O$D,,6N7B)&B[510_  ["NVH **** "BBB@
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M.R\7Z+H$0AEDO_.\W$HWPA$W@E??WQ0!T%%%% !1110 4444 %%%% !1110
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MM=%XDE6'POJTKQQR(EG*S)(Y56&P\$CD ^U<;\+(MD5XP9\-'$0C6MW$%X/
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M^- '#^+O"?AU-6\(Q+H>GK&VHB!E6W4 QB&0[3QR,@&O0T18XU1%"HH 55&
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MA'2A9^1]G^SKL\AG*8]B_P W_?7/K6U63HD<>F^%[-3I[Z>D%L"UIO\ -:+
MR5W#.X^_<USS_$W3HT='TK55O4.39-$HE\ORS+YA&[ &P$X)W9XQF@#MZX3Q
M''9CXL^#9$6#[<4NUD(QYGE^4=N>^W.['OFM33/'>E:OK<>G6L=R4FW+!=E
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M:/3+F6VACFNHHF>!)/NF0 E<\C'/N*Q/!WBUO%5M,YL!;M!M61DNHID,F/F
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M.8_Z!T'_ * *N^*+E;/PKJL[1RR*EI)E(4+L?E(X ZU2^'_'P[\.?]@Z#_T
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MROL\GG[/)VGS-^-NW'.<]L4 >!_#?XAK>>,/$,&A^%X))]3G-S;HLT=N1&H
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M\%Z9HEOILNDV-[Y(.;BZB1I7).<EL4 >=?$^[\,6GC_15-QHMN;!4D,)T]Y
MV2>'*$+M'! [?0U[U&Z21(\;*T; %64Y!';%?/?C;X%SWGBL7'AA+6#2I0AE
MC:8+Y1Z-L!ZC SSW->CV_@W7M#M(H/#_ (XN1%"@2.VU*".X3 & ,C:P'XT
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M]#-8?]]G_"M;PY+X=O;%K_PXM@UM,VUI;.-5#$=C@#D9[^M &S1110 4444
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M_*IO^%3>!O\ H7X?^_LG_P 579T4 >?77P@\%SWUI)#8);I;,SSP)(Q$ZE2
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M6*.YO+Z>\>&)]RQ>8Y8(&P,X'?'7- &I=Z3IU];M;W5C;S0L02CQ@@D'(_4
MU-]DMO\ GWB_[X%344 <]?OX5:Z:]O9+#SM%/F.[.!]F,@*_-CN1D8-:ED^F
M:E917EE]FN+:5=T<L8!5A[&N-U?P5>RZAKUYI\-FGVJXL+N"'.P3/ Y=P^!Q
MN]>?>NA\'Z1=:+H/V>]\L7,MQ/<R1Q-N2,R2,^P' SC=C.* -(Z3IQO5O38V
MYNEC,0E\L;@A.2N?3(%-OI-,TRREO+W[-;VT0W/+( JJ/<U>K'\4VVHW?AZX
MBTBWLI]0)4P"]YB5@P(<C!R5QD>X% %"SO\ P;;WJ36MWIJW&MN)$(D!-PP
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M(T**I8<E<=0<^Q% '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>drsa_017.jpg
<TEXT>
begin 644 drsa_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "3 G # 2(  A$! Q$!_\0
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M;$%Y)%)8[B> "O3!Z]:[^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 3 ]*,#C@<=*6B@!,#&,"EP/SHHH ,#&,4F!Z
M"EHH 0*HZ*!]!2X'''2BB@!  .@ I:** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#*\2ZE=:/X;U#4;*VCN9[:!I5CDDV*=HR2
M3[ $X[]*P%\6ZA=ZE?6,%LH*02&$HI9S*D4,AX/!!\\ ?[OOQV%Q;PW=M+;W
M$:RPRH4D1QD,I&""/3%00Z98V]XUY#:0I<M&(VE50&*CH,_@/R'I0!4EUJVT
MJ"VBU:=EG811O*MO)Y9D<A1\P!498XP3W%:U<UX\_P"197_L(6/_ *515TM
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45XI#\
M8-3E#F74?#MJZRNGDRQR%E"L0,_/W S7??#WQ3=>+=$O+VZ-HS07KVZ/:!@C
MJJJ0W))YW5K.C."YF-IHZVBN)F\3ZA8SK:2#S[BSF,=UA N\2.$@SC[H(;<<
M?W"*AD\::A;B_GNK,+;K*D*(LH\R-S%O/;!!VGGKR.*R$=Y17%7?C&[M[W3F
M^SPM%>QMY4,<N]MQ= I?C*X!;@9R3CM75Z;=O?:=!=20- \BY:)F#;3]1UH
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MAGTXJ1W6Q+1110 4444 %%%% !17!:A\4;2RU>^TZ/0=8NVLIC#)+;QH4+
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M*:">9IU8!5\J-I"N.I)"GV]ZZ&J&H:-8:K+!)>P"4P"14!8@8="C @=<J2*
M,6R\7O=W]C;R67D"5ITG8L7"-& <!@,8P<Y.*K:'J^FZS\1-5N=+U"UO8$TJ
MU1I+:59%#>;.<$@]<$?G73:;IEKI5F+6T0K'N+'>Q=F)ZDD\D_6L*SBCA^).
MJ+%&B+_9%J<*H'_+6>@#"N/BGHR^)(HHO$FD#22A:1FBD,BL"!MSG&3DD<?P
MU/\ $*Z@O='\/W=M()()KZ.2-UZ,IC<@_E7GUO&G_"& [$S]A;G:/[IKJ]:_
MY)UX'^MM_P"B#7KX:BJ>)IM?UHSFS%6PM3T8>&_^1RTGZS?^BS6CXLUW4;C6
M[K1[?3M/GAM&@E\RX8[LG#XQCOC'TK.\-?\ (Y:3]9O_ $6:GU?_ )'O6_\
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M61X7_P"2@:7_ ->UQ_):]>A_R+_^W9?FSY;$?\CB'R_)CF_Y&+Q!_P!A!O\
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MV%^^FK!YI.H0-/%E,;5&,AO0\XQ['TK7K!TWPO%IM[%<K=22&/A591@#RPI
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MR-]_R*DW_7F/_0177> ?^11\7_\ 80NO_125R-]_R*DW_7F/_017MY7\<_\
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M],^EK_Z,6JZ_\A;2O^PA#_,UYU3XZGK+\V:U_P"+3](_H>HT445YQ[84444
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MJ_\ R/>M_P"Y;_\ H%0>&O\ D<M)^LW_ *+-3ZO_ ,CWK?\ N6__ *!2Q_\
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M/SKG-+_X]9/^OB;_ -&-77_#O_D8=>_Z][7^<M<AI?\ QZO_ -?$W_HQJ]K
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MO(!ZCWJ70YQ:^)XYVCED$=C.Q2)"[M\T? 4<DU+XQ_U_A3_=E_\ 10H\-?\
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M5]/:6$VWFH+I"R8@(.1GC!XKVZ4E]8IZ]7^3.?,5?"S2[,T/#7_(Y:3]9O\
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MBN_#K?Y')G,DU3L_YOT+M%%%=)X04444 %%%% !1110 4444 %%%% !1110
M4444 4=;@CN=!U""9=T4MM(CKDC(*D'D5CZ7I=G#XIN)TAQ(+2,@[B1E@%8X
MSC)$48)_V1110!M7&DZ;>2^;<Z?:SR8V[Y858X],D5%_PC^B@8&D6&/^O9/\
M***  ^']%/72+#_P&3_"C^P-&_Z!%A_X#)_A110 ?\(_HN<_V189_P"O9/\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6'KNF6>HZCIHNX?-"B=
M"Q P\3*PX/<$BBB@!?"UI!#X=M]B9,NZ20L2Q9B>22>35G_A'M%QC^Q]/Q_U
M[)_A110 O]@:-_T"+#_P&3_"C_A']%SG^R+#G_IV3_"BB@ _X1_1?^@18?\
M@,G^%9NM:%H\=G!LTFP7-Y;CBV3H9DSVHHH TO\ A']%/71]/_\  9/\*/\
MA']%_P"@18?^ R?X444  \/Z*.FCZ?\ ^ R?X4?\(_HN,?V18?\ @,G^%%%
M"?\ "/:)_P! ?3__  &3_"E_X1_1<8_LBPQ_U[)_A110 'P_HIZZ18?^ R?X
M4?V!HW_0(L/_  &3_"BB@ _X1_11TTBP_P# 9/\ "N;\ :)I,_P_T*272[&1
MVLXRS-;H23CJ>*** .D_X1_1?^@1I_\ X#)_A1_PC^BYS_9%AG_KV3_"BB@
M_P"$?T7_ *!%A_X#)_A4]IIMC8%C9V5M;E^&,,2IGZX%%% %JBBB@ HHHH *
6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>drsa_018.jpg
<TEXT>
begin 644 drsa_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (H EH# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  >@I:B4^;3H7&-M0HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M((.0:!BT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %(S*B,[$!5&23V%*2 "2< =ZYKQ'K<?V%[*UR\ER
MP@WCH ?O?7C-%@-72 6LVO).'NF,QSV4_='X*!^M-NM>T^UR#-YCC^&,;O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIKR+&NYS@4 .JO<WL-L/
MF.7[*.M5+B]D?*Q?(OKWJ@8\DD\FK4.Y+EV([R\GO,ACMC_N+T_'UK$E3S=:
M@BQ\L$+2GZL=H_3=6Z8JRK!/.U?59L?<D2 '_=7)_5JJQ)(8J:8JOF*FF*F!
M0,7M33%5\Q4TQ4 4#%33%5\Q4TQ4@*!BIIBJ^8J:8J *!B]J:8O:KYBIIBH
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M/!^AKF3%[4GEX.1P12:N-.QW5%4-)NVN[,>8<R(=K'U]ZOUF6%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!FWK[I\=E&*KYI9&WRLWJ33<UJB&+FES3<T9IB'9HS3<TN: %S2YIN:,T
M *1N4KZ@BN?\$N3X9CC)YBFD3GV;_P"O70 X(-<UX2)AFUFQ8\P7K,![-_\
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M+FVAOKFVOB)&4I'CY2P)!Y/TKJ@F=SI(I9U..WWCP?R'Z4UXG6!D"G:&9OP
MX_I^5-286.19M<T?28F8>9YDO&1YA48X'T/]*NKX@6*[AM+NVDBF94\P]E8C
M/3TYKH67=/"G\,9"_B!D_P A4)M[:>XFO)8(W<)A25YP> ,_YZT^85BM:WUK
M>@FVG23'4 \C\*L5BS^&((],Q:2/'<2R AF8D8&>..W_ -:G?9M;LKZWM('2
M[B\L;WD['OD]?I3NA:FQ1FL>V\002+(;B&6V\MMKLPRH).,9K4BFBG0/#(LB
MGH5.: ),TN:;FC- #J*3-% "T4E% "T<>E)FES0 FT4;!2T4 7+,8A(_VJL5
M7M/]6WUJQ6,MS1;!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %5-0.+7ZL*MU2U,X@0>K?TIK<&9E%)15D"Y
MI<TW-+F@!<T9I,T4 +FES2 %CA02?05:BT^5^7.P?K1<96]JPO'&FS2^%Y+H
M#:UK(LJYZ]<'^==K#;10_=7GU/6N!\<^*M0LWN-'.FI'!.A43R,6\Q3U*XP
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M)26]M<-IEQ(9I6&5=MOR9R5R/?'Y5UM%4I-":3.)74-0TN[@T^]3?:6R;I9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$#K-V@WYY^SH>?+'OZGUX[5Z+10 4444 %%%% !1110 4444 %%%% !1110
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M3/!,DT,ACEC8,CJ<%2.AKVSPCXFB\1Z9ERJWL("SQC]&'L:T!X?T8=-*LO\
MOPO^%6+?3K&TD+VUG;PN1@M'$%./3@4 6:*** "BBB@ HHHH **** "BBB@
MHHHH 0@$8(R*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** *T]A:W-W;7<L*M/;$F)^ZY&#5FBLZ_P!9M[%C&,RS 9*(1\O^\>@II-[
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MZZ0?UJ)_%GAR,9?7]+4>]Y'_ (T ;%%<U?>.O#4-A</!XBTEIUB9HU^UH<L
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M<MW.2>G'% '44444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <UH7R:U<HWWML@_*0Y_F*V=4!^PLV,A&5V'L&!/
MZ5AZANTK7EN@I,;GS,#N,8<?7HU=*K1S1!E*O&ZY!'((-:2W4B5LT<YXGL+_
M %"P$>G:BU@[[09U)'R@Y*Y'*@\<^U9OA[0]7L=8\VXUF6[M=G,+3O, W8[F
MZ'M@5U M[FT.R +-;]D9L,@] >XHQ?3 HD*6R_WV8,?P _QI#YGL.M/GU"[=
M?N@(A(]1D_U'YU6\1,!90 GDSKC\ 2:TK>!+:$1IG'4D]23U)KG-8F.IZG'9
MP'(4F($?WC]X_P# 5S^)IQUE<3T1M:,"NBV8(P?)7^57J:B+'&J(,*H  ]A3
MJS904444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 (5### $>]1&TMF.3;Q'ZH*FHH JG3;!CEK*V)]3$O\ A44F
MAZ1+_K-*L7_WK=#_ $J_10!AWWA/1+C3[F&+1=,662)E1C:H,,00#TKB?"?P
M1T71UBN-;D_M6\4 [&&V!3_N]6_'\J]2HH 9##%;PK%#&D<:#"HB@!1Z "GT
M44 %%%% '!>+['78O'?A[7])T235(;&WN8IHX[B.(@R!0/OD>AJ;3-'UW7O%
M]GXD\164.FPZ=%)'8:>DPF</( 'DD8?+G:, #/U]>WHH XCPIX:U"U\#ZQH]
M_&+:>\N;TIE@V%E9MK<$]CG%<E<Z;XSO_ 6E^$O^$3:)]/>U2:[:]B\N1(G7
MYHQG)R%SSC'/>O9** //9H=;\,>/-:U#2M&.M6>L+!)+%!<QQRVTR*4&X.1\
MC 9SVP:;\'S/)H.NW%S&D<D^NW<A$;[TR2N=K?Q#((SWQ72:WX)T#Q!>"\O[
M-_M6SRVF@GDA=T_NL48;A[&M;3=-LM'TZ'3].MH[:T@7;'%&,!1_GO0!:HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHKF-7\>Z#I&KVND-=?:=2N9TA6VM\.RECC+GHH^O/M0!NW]C'?VQB<E6!W
M(XZHW8BN?M[N\T*?[//$&B8\)G /O&3Q_P !-=53)88YXS'+&LB'JK#(-4I6
MT>PFNI1BUS3Y1\UPL+=UF^0C\ZDDUC3HAEKV$^RMN/Y"JTGAVS;_ %3SPC^Z
MCY7\FS3(_#ELOW[BX8>@8*/_ !T"G[@O>*E]KDUTWV:QCE3?QG'[QO\ ='\/
MU-7]'TD6*>;*%^T,NW"\B-?[H]?<]ZNVMC;62E;>%8\]2!R?J>IJQ0Y:60)=
M6%%%%04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHU8Q#*NCA3R"6&".0: ))OB-&F@P72Z:R:C)J)TI[.>=8T@N!DD/+R-N!D$
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MO)*<1I-*J%S[ GFO"M?U#3I]%U"\@?0]-N1K0*VA1I-1\U;@ R-(6RA(&>A
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M[SG'M69I>DW^JZEX L[_ %'4M/N_[!G9I;:3RYL Q[5)(/\ #C/':@#U.7Q
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M&P0PY!!Z@5>KG_&FM7&A>%[FZLMOVZ5H[:TWC(\Z1PBD^P+9_"@#?50JA0,
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MP/-B')C&/NAC@$^F1WS6RJJBA5 50,  8 %+10 4444 %%%% !1110 4444
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M#*P!R<C''.>* -^BN;M?'.B7<=X=]U!+:6QNY(+BTDBE,('WU1E!8?3-7O\
MA)=)-[I-F+M3/JT3362@']ZBJ&)SVX(/- &M17-W/COP_:8\V[DRUW+9($MW
M8O-&/F10!\Q[<=3Q6AH?B'3_ !#!/)8/+NMY3#/#-$T4D3@9PRL 1P0: -2B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /*M;T;3)/B1K5[X@\*7NK6DMK;+:216#7"AE#[
MP".G5:9INAZTFG>%UDTZZBM8/$;W%M:R?,]E9&.01J_7&,^IQD#M7K%% 'EN
MNZ7>:;X^U?4IY?$L=EJ44!@ET-!)AHU*F.1=K$>H/ ^8U&]C>:#;>'K&"S\1
M6F@I92;OL4:S7JSM)N6.5D!*K@G[N!G&3Q7JU% 'BUIX2U;5/"^DZ;-!J^G%
M_$=U--*?^/B*%TF^=FY'.X MZMQ6I-I^M0>'-%LYM%D>;PKJL$KI:0X2]MU5
ME$D(Z%L,&*]00?45ZK10!Y/J^GZGXUUCQ)+8Z9?V<%YX>6SMI;Z PB602LV,
M'D YQSCN>E:<UQ>>*]0\+VMOH6I:>=+O$O+R6[MS$D(2-E\M&/#EBP'RY&!F
MO1:* /(W\%:K?:GXATUK=XK'3A/<:+-C"M/<,LP*_P"XRE?^!FICHNL77A;2
M+Z?3;A=3O_$T&IWEOLRT">9@;O0*BI7JU% '*6UC=K\5M0OVMY!9OH\$2S[?
MD+B60E<^H!!_&L7QAI.HW?B?6Y[:QGFBE\)7%K&Z)D/,7)$8_P!HCM7HM% '
M!7&EWYM_AV%LYLV4L9N@$_U(%JZG=Z<D"L*?2-5N-*\4:;'I=VUU#XA_M:.-
MXRL=W")4<*CGY22%/'J.:]:HH X6">X\4^.]&U2WTJ_LK+2H+CSIKZW,#2/*
M%41JIY.-I)/3@8-4?B'X0O?%WBG2+:&:ZM;7[!=I+<PKE Q,95']5)'([@$5
MZ.S!5+,0 !DD]JCMKF"\MH[FVFCF@E4/')&P974]"".HH \^"ZQJVI^"9[K1
M)K.?3;V>*]1(SY4>(&4.AZ>6Q(VGWQVJMK^@:M=ZCXLN+;3Y)P-0TV]AA;Y1
M>)"J%T4G@GY2/J *]/HH X)&F\7>.-)U&+2;^ST[3+6Y2XDO[<PF9I0JB(*W
M) VDD].G-<M8^%M>M=(O+^73GDU'PU+%;:,FT[KB""1F)7_KHC[./[HKV:B@
M#S6Q\-W^G2?#Y#:RN]M/<W&H2!<B.26%V8L>WSN16[X:L;NV\;>,KF>VEC@N
MKBV:"1EPLH6!5)4]\$8KK:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+FSRH(C9LG>.<ALG@]3BNNK,T30-/T"WEBL8Y-T\GFSS32M++,^,;F=B23@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% $,EK;RW,-Q)!&T\.[RI"H+)N&#@]L]ZFHHH **** "BBB@"M?:=
M9:I;?9M0M(+N#<&\J>,.N0<@X/'%6    !@#H!110 M%%% !1110 4444 %%
M%% !1110 4444 %16UK;V5LEM:PQP01C"1QJ%51[ 444 2T444 %%%% !111
D0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>drsa_019.jpg
<TEXT>
begin 644 drsa_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "" '$# 2(  A$! Q$!_\0
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MKV/&C7W&3]FE)]OD-/M<[5& 1[5/J1!T2_.1_P >LG'OL- 'D]%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>drsa_020.jpg
<TEXT>
begin 644 drsa_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $_ E(# 2(  A$! Q$!_\0
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MC\N/ X/W6)"Y )J.R\'W5Q96$=_H<"BV\.R6'E2^4X6XW*,C!(^;!.[WYP:
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M-?(YEB/K-3V<=EHOU?Z'L8>CR0YWN374[75];ZL"1:VER(X1V96^1Y/S.![
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M#4;0GRI1RK##(P.&5AV((((]J^OP6)5>GK\2T?\ G\SRJ]+V<M-F7Z***[3
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M<%\2-0N+B"V\.6%P89[UE,\BC)6('D#T)P?P!]:[BYN(K2UEN9FVQ1(7=O0
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MRH4B:1?,['<J'./NG YZT2>--7T_3K:?4+*R,U_I_P!HL4MW;#SDJ%A.>O\
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M,$=:JZ<TE[#!>W(^<)MCC(_U>.&S_M''/ITJ"R+WD4<4F?)M&,;Y_P"6DBG
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M. ENXXGZ%8XN1(I]23W%/@VVUW<0G:D9 G3L%'1OIR ?QJO#=RF^E2SC4Q7
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MF:Q5M%_7RZ?*Z\AX,DT;+$_VV$8S#*7<H/J=J_G4<#(DGE6<WE/O.Z%QRWL
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M%/,1%)MFWG=%-(TOF'O\B#!^H-(93%,I<'3[PJ0I6..)&'U8G=ZX.#2[IID
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MN!S7HDFI6,-O%<27MND$I CD:50KD],'.#3I+^SAN%MY;N!)W(58VD 9B>@
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M4*9*G!(SU'H>AH GHJLVH6BZBFGM.@NY(FF6+/S% 0"?S8?G5@$'."#@X.*
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M\4861PI8*V6& <X/)H Y?2/!-]]DLH]4TNWD\C2+NU"2M'($D>;<@';[O<
M=..E8/B"S.E:5=V>I6-G>7UQIMC"C/<1&6V=%"% K'<<MD@H#DD].M>H#Q9H
M1TL:D-2B-JTIA# ,6,@ZILQNW8YQC..>E07WB+PO#'8ZE>7EDPD4R6MP5WD+
MW8$ E5'<G '>@#F8O".J+XPFNKB.XDC.I/?0W4;P*@4KPC$KYW ^0J#MQW[5
M;\$^']0T?59&FTI+.T2T$(:1XI)-P;.U70 O'C)S(-V2/>NGE\1Z/#JL6F/J
M$(O)=NR/.<EAE1GH"1T!.3VJ@/'OA<[@NL0L0"0 K$M@X.T8^8@]0,X[T <U
MIG@J[Q:KJ.F6TJQ:=?PXD*.%DEN-Z8^J]^W2M6[T+47\)>&H)+);V;33 ]W8
MO(N)ML10C)^4D,0PR<$KUK:N/%F@6L=G)+JMN([Q!) X;(9#P&)'1>>IP*/^
M$KT+^U3IG]I0_;1*83%SQ(!G;G&-V.0.I[4 <I)X>O(KB"^/A*UN;9[>>(:4
M)XR+9WDW;_F^7YAPVWICC(JG)X!OWT/5K:YL[:\O7TZQMK>=F4EGB!WX8\J!
MD<G&:[+2_%^DZIHMYJZ2M!9V<LL<TDZ%-H0D%N>W&?YX/%1KX[\+L<?VQ #Y
M@C((8;2<8)R.%.1ACP?6@#E/$NA_V;JXEBTBWDLKK5K$PVJ;%65ECD#?*> ?
MN]<9P*DM_#.I6LT&HR^'H;JV^TW4@T82Q_Z.)=FUAN/ED_(^0#QYIQGG/9S:
M_HAUA=*EO(&OE;<L3#.U@,XSC ;'.,YQ5 ?$#PJT32+K,#*JA^%8EE/=1CYA
MZD9QWQ0!R%WX,UF+3+"*/2H;J[2S, )FCD@CS*SB)UD&=BAE >,AOE^E:EYX
M9U$S3W7]FQW++XBCOTCWIN>'R41B"QP#D'@D'Y?I6RWCG28-=GL+R[MX8?*M
MY;>?>2LHEW8.0,*O P2<'-7W\4Z''/?0/J4*R6(S<@Y_==."<8R=PP.ISQ0!
MR?\ PC6I6MZM[-HL6IP)J%_+]B,D>2)G!CE&\[<@*1@D$!S]*K0^!+XV5Q%>
M:?:SO_8,MI "RN(I6ED=8U+<@*&10W XKLG\7Z FGQ7S:G$+>65H$)#9,@!)
M3;C.[ )QC-+-XNT"WTZUOY-4A%K= F%QD[@/O' &0!W)Z=\4 :&FQ30Z79Q7
M'^N2!%DR<_,%&>>_-6J:CI+&LD;*Z, RLIR"#T(-.H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *\=^+6@OI>H0>*;*W9XI6$-ZL8Y!Z
M!\=\X ^H'K7L55=1T^VU73KBPNXQ);SH4=?8_P!:VP]:5&HJD>A,X*<>5GS'
M;.!=Q2L"MH^?LP/\#-USZ9[>G([U)>JT;I%""R3-NEB']T<DCT)X'OFI]5TM
M_#FLWFB:@P,:L=KMP&4\AA[$<^Q!%4;*<F;-PS;G 6!W&-R#IG_:/7WK[.E*
M%2"Y7H];]O\ A]E]QYLJ5GZ%VYN([JU5(GW>=((SV([L".W -%Z!((8" ?,D
M&0?[J\G^0JI+&)M1:1&:-H5"[T."6///K@8_.F":\-\QW0R>4NP,RD<GD]/P
MK9\VMU>^GW"C2ML6Y$5K^!%11L!E.!CGH/YFJLU\L$]W(B^9*@"*N> !R23V
MY-0K-<.;FYDE$:#Y?W0Y(7W/OFH8[:YN7L](TZ/S=0N9%)0<G).<D^N?7TSV
MK.I4Y8N>RU?Z+]6;1I7W.J^'/A(>(_$\(GS)I^E,)[UFY$LYY2/Z#DD>F!WK
MZ+K \'>&+?PEX;M]+APT@S)<2CK+*W+-_3Z 5OU\9BJ[KU7/IT]#MC'E5@K@
M-0BU6/5/%MC;:+=W#:N$2VN/D$ !MUC+.Q.0 0>,$G''6N_KG7\765GJ>JV^
MIR16D%E/#;QRLQ/FM)&' QCKU '?%<Y1R#>%-6B\6H)1<NB3VS6E]#:QN8XH
MT0%3(SAHP2K[E"G(8]<U!:^';Y+BT3_A'KF/4H(KY;[4"4(N7>-@K!MV6W$C
M&1\O3BNV;QMHIN](@@G><:K(\4$D<;%590<AN.#D8QU!ZX%2KXR\//:2W2:G
M$T,<ODLRJQR_/RJ ,L>#P,XP: .5A\)R213/<:-&\S^&(;7<\:EC.%<%,^N-
MH_*LS5O"6J$:; MC*+/^RH;>%+:TCE:TGY,C#<ZB-B2IWC/*\^_H5WK]N--L
M;O3VCO!?SQPVQ5OE?<>3G_94,Q_W36)H?C"\U4M<SG1H;)'G\R)+MWN42-F7
M)C"]?ESCT- &-?>%-2?3=?G@M#]NGU9'=RBL]U:*(]R@%@""58["0#@CO2:3
MX0>>]T=;_3I9M-$UY*]O<VR11P;DC"J(E9@%)#$#U).!Q74ZIXYT+2XHG:Z-
MQYDD"XMT+[1,?D8X'3'/KCH.15Q_%6AI->POJ4*O8C-R#G]UTX)QU.X8'4YH
M X?3/#E_;'2)[G1Y'NO[#N;(S;59X9,C8&;.1\@*@\]<=ZHZUH>NR:9I\$>A
MS/=0:3:)!/&B2.DJ8+C>SCRBN/X02WJ<8KTJS\1Z1J!MQ:WT<C7#2+$O()9!
MEU((R" 0<'!Q4#>,/#Z?9=VJ0 72AXCS@J3M#$X^4$\ G /:@#E+_P /7*:G
MXB%IH[ W>HZ?=)-$BA9(U>(R#.<Y!5V(/UYS26VAWRZ_;G^R)TU6/5)+FYU@
MLNR:U+.0F[=N.4*)LQ@$9[9KLSXCT<:R-(-_"+XG:(N>6QG;GINQSMSG'.*J
M2>--!6VOYH;])S90M-(D0)+*IP2O'S#/&1D#O0!SGA#PS<:+<^&IUTTVLO\
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>drsa_021.jpg
<TEXT>
begin 644 drsa_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "S EX# 2(  A$! Q$!_\0
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MHHH ***JW5[%;DQ&3;,R$H/+9_Q(';-1.<8+FF[(:BY.R+5%>?Z1+XZAEO\
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M1113 **** "BBB@ HHHH **** "BD) !). .I-<=JWC0[Y(-*5&"\&X?D?\
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MH)9(I5LAM>-BK#]ZO0BNTKB_B%!-<Z%JD,$4DLK60VI&I9C^]7H!6%;XJ?\
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MW#I;.RM(2",<BK>F6-U#%*)(&4E@1GZ5PVN?$77M/U_4+.#[)Y,$[QINB).
M>,\U;TCQ[K=[8333?9=Z3!!MB(&"I/K6D:KJOV2*EAW2C[5[?YG;7=I.]G,B
MQ,69" !WKFO[&U+_ )\Y?TIL?C+5FD53]GP3C_5G_&KO_"3ZC_TQ_P"^/_KU
MG6I.DTI%T*CJ)N)Q?B;PKKUYJZRV^ESR1^1&NY<=1G(ZUK^ /#VKZ9>:@]]I
M\T"R0HJ%\<D-GUKISX@O@D1_=99 Q^3O^=+_ &_>_9)Y/W6Y-N/E]3CUH5!Q
M7M!RQ+FO8V\C1^RS_P#/)JX=O#VKEV/]GS=3Z?XUO1^)M0:5%/DX+ 'Y/_KU
MYA<_&+Q7%>3Q+_9^U)709MST!(_O5<<;[+IN0L!*KMT+WBSPAXAO9+ VVDW$
MHCA=7VXX)<GU]*@\)^#O$=CKZ3W6CW,40AD7<VW&2..]=]X"\7:IXC\.O?7_
M )'G"X>,>5'M& !CC)]:Z.XU.XBMI)%V;E&1E?>M?:RJQT6YDX>QGRO=',G1
MM2Q_QYR_I5M]*ORY(M9/TJ<^(K_'_++_ +X_^O6VM],44G;D@'I41C+#Z]RI
M3]OIV/*/B#X5U[5(-.6QTN><QO(7"8^7(7'?VK!\'^"?$]AXRTB[NM%NH;>&
MY5Y)&VX4<\GFO1/B#XSU;PU#IKZ?]GS<-('\V,M]T+C'(]37-^&OB=XBU7Q-
MINGW/V/R+B<1OLA(.#Z'=6<L.ZLO:_UH=%/%RI4_8I?TSV>BBBD<X4444 %%
M%% !445Q',[HI^9&((-2U%-;Q3@"1>0<JP."I]B.E U;J+)-%#CS)%4M]T$\
MM]/6B&99X5E3.UO6L?3=)CED>\NYI+F43.J>8>@5R!G'7I]/:MR@-+$-Q:P7
M2%)XD<$8Y'./K3XHHX4"1(J(.BJ,"B26.( R.J@_WCBG AE!4@@]"*!"T444
M %%%% !1110 4444 %%%% ')62_V1\0+V$X6#4XA*GIYB]?Q^]6OI)\[4=6N
ME V-.(@?78H!/YY'X5D>/K?_ (EEM>+(T3PS!?,4X*AN^?J!4&IZO>>$]*AC
M TWRF4K$L1<..,[\'.?4^M<:FJ<I1ELM?O\ ^#<X(U%2G*,MHN_W_P#!N<'>
M^$-1N?%U_8:9"EW!%-O9R^U$#?-M9O7J..:]$\:W,=GX22S>-8VN2D"QJ>$Q
MR0/88Q6KH=A;Z-HJEI 2X,\\[?QL>2Q->>ZC+J'CGQ2L%LC):P'"%AQ&G=S[
MGT^E*2Y*=OM2Z"FN2ER_:ET_KL<Q'I.I3^%-4N;:V=HMJP[QW^8%@/P&/QK*
M\/ZHD"K%+\DD?]\5Z'J&KS:-X9;PZ=D=W%<-"V%!$L)!8-^.1^-;FA:!H.NZ
M9;27NF6\MY:*L98Y^88RI.#\P((Z^]=F'Q7+2=&U^OH]GZE4H4ZO[N;>U]._
M8YG^QS>^')->-W%9VT +!F4MYH[].G. /6N<@_MC7)3#8VS#;%\RJ,OM]?UK
M5\1ZO>P1R^&U2(""Y\Z608(SC(4#I@<']*R+87RW*745S)#.OW98^"/RKFK8
MRVC=CG=2C0DK=.^OX;'1^$M)N;W58K9Y%2*-=\F<AC@C@"O7J\]^'L%RMY/)
M-<&7;&=[-]YBS9_QIS>.[Z7772SMXY;/S/*2,@[GYQD'U-.E5?)S3=[_ )&^
M&E&%/GEU?_#'H%%(,D D8/I2UTG>%%%% !1110 4444 %%%% !1110 4UW6-
M&=V"JHR2>PJMJFH0Z5I=S?7$L4<<,;.6E<*N0. 2:Y34]6U:)]$CFNK39J5P
ML9(MR/+/EEP>6.[[N,'U!]J 'V]MJ%Y=3:3_ */':+.+CS&W>9@R"7;MZ9Y'
M?O79UQEM>:C8ZGJ 46]^+<"XDE9_*8[U.5P 1QL&.G6NNMIUNK6&X4$+*BN
M>H!&: ):*** "BBB@ HHHH 9)#%*Z/)$CM&<H64$J?4>E/HHH **** *.M0W
M5SH=]!9!3<RP.D6]MHW$$#)[5S'_  C&H37\-TD,%E%%:_9DMTF)R$4["Y4#
M/S$''8+WS7:T4 >:ZK9:^-EI<B6:2XMU@MX4N)3Y;A443&15 + F1L$CL?IT
M>L:-=:EJMM!):1OIB1+')*)!YKC<"5.0<+\JDXY/J,<]/10!\\^*O^1NU?\
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MB/MC4D-MSC)QV.%_6NIDL+66W:!H4,;#!&*E<S5B5>2L<RB6\Q6=$C?<=P<
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M;XX@LO#VAF:'=+JMXWD+=3L7D"XRQ!/W>..,=:Y#3?">KW.GO>)I\QA1-P&
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MO"AMELHS"3(2?-PC[F1A@AU8!>"1@C//%;'V>^_Y_P!?^_ _QH^SWW_/^O\
MWX'^-:^VG_S[?X?YD<B_F7X_Y'@GBIE_X2[5^1_Q]R=_>L'6&7_A'XOF'_'Y
MZ_\ 3.OHR30(I9&DD6R=V.69K)"2?4FFMX;MG38\.GLN<[38(1GUK!\[O[C_
M  _S.^&)A&WE_78^8]!=?^$BTWYA_P ?*=_>O:B1GJ*[!/#%I&ZNEOIRNIR&
M6PC!!JU_93_\];?_ ,!5HCSQ^P_P_P Q5<1"HT_Z_(XNX(_<<C_4K_6M'02-
M]US_  K_ #KHSI<AQF:W.!@?Z*O^-.33IX\[+B%<]=MLHS^M:1J33OR/\/\
M,YYN,HN-U^/^12'4?6I3U-6OL5U_S]Q_^ X_QH^QW?\ S^1_^ X_QK2=><O^
M7;_#_,RA!1^TOQ_R.?U@CS8.?X#_ #K,F(^QW7/_ "Q:NQ;3YW(+W,+8Z9ME
M/]:0Z9*009H,$8(^RKS^M;PQDHI+V;_\E_S,IT%)M\R_'_(\LR/45O0$?9HN
M?X!78_V-_M6O_@&M/&ER 8$UN!_UZK_C6LLQ<O\ EU+_ ,E_S,XX6WVU^/\
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MYRNTNRF-(P!E2.0G)Z@]*>W@>Q,9@6[NDMD#_9H5*XMV8@EE.,GD=&R.3ZT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>drsa_022.jpg
<TEXT>
begin 644 drsa_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $] ET# 2(  A$! Q$!_\0
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M,T>;)_?;\S32I!Q@YKG_ /A,=)CU+7;.ZD:U71!"UU<3#$>)1E<8R?;IWHT
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M^?G2VF9IHU]>1AR/3BM:=.K43<%=(RJ5:5-I3=FSUK[&/7]?_K4?8QZ_K_\
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M?[S,N>>W0<=AFHM:/C3QMXPT+PG-IEEX?DLD^TVMO'RL"@9#-@GIMX&!U]Z
M/IA9!L&[(..?E/6E\U/4_D:^99X/&-]XXCT+P_XXU+5M0B)-]=([1VUMSSSD
M@X[\=>!DUZ1X*\7ZTGB.X\&>,$C&M0Q^;;7<8 6[C]>.,XR<CK@Y (H ]45@
MW3^5+5>UZ&K% !1110 445S2^/O#3:!=ZV-2!L+28P32>4^5DR!C;C<>HZ"@
M#I:*@AO+:X$7ES(3+&)47.&*'H<=<4AO[,0B8W<'E%M@?S!@MZ9]?:@"Q14
MO;4G'VF+//!<=NOY=Z<+JW+1J)XBTF=@#C+8ZX]<4 2T5&\\,<JQ/+&LC E4
M+ $@=2!5#0]>LO$5E)>:>7>V69XED9<"0J<$K[9SS0!IU2UDXT/4#Z6TG_H)
MJ[5'6_\ D ZC_P!>LO\ Z":<=T)[%#PK(T>DKI\KEI;(+&">K1E0R'_ODX^J
MFIM4/VS5+#31R@;[7./]A"-H/U<@_P# 34 'V#4-+O!Q%=0K:3?[V-T9_/<O
M_ A4NCG[4U]JQY%RY2$_],DR%_,[F_X%6CW<OZN2MK'->%\V6G6&HC[@NI+:
M<_[$C J3]'V_]]&N[ED2&)Y9&"HBEF8] !U-<GX3LX]0\(75G+PDS,I([913
MD>XSFK,EY)JVD6.G2<75U*8+L#^$1G][^!QC_@8JJBYIOU)@[1$\*F62_P!5
MNI\B6[,-P5/\ 93M7\%"C\ZZ>LBP&/$6K@=-L'_H+5KUG4=Y7+CH@HHKD_&F
MI7-I=Z#9+>MI]E?WIAN[Q"%**(V94#$84LP SU].M04=917EMWXOG\/ZGKJ0
M:L+U4^RQV?VHF97/DR.V-I4 G9R<CIW/!LK\1M2ERRV5BK7&F)=V,+39\YS&
MC,K/D!-I?&U@-W!!YQ0!Z317B&L^,=3UN&1]/OO),T-BKR*TJ*-]TT3!4W?(
M?EP2#DC(!Z&M31?%][;ZHVF1RVL*I<7;R3WUP[!UCF$>R,DYW<YP<@<<&@#U
MNBO(S\2-8U:S:33KBPMUBU&P3[4\+;'AG9AAE9LJ/EZY!(/135B?Q_?:5_:D
M<"VI:WEU&Y9[ZX=EE6"15\F+)X9MW Y"\8!S0!ZI17":7XWU&]\3P64UG:QV
M5Q?SV* %O.1HX!-ENW0E2/Q]J[N@ HHHH *XSXJ7OV/X>:E&IP]WLM%QW\QP
MK?\ CNZNSKRKXTWW[O0M,#?ZR>2Z<>T:[1^LGZ5K0ASU8Q[M&5>?LZ4I]DSR
MWC.!CZ>U%9L'F/X@NG*D1B%8T/J0<G]36E7UE.:FFUW:^X^0J0<&D^R?WD-T
M7^RRM"P\V,;T([,OS#]0*[V\O/[1\3ZO?-]ZY%M-%G_G@T"%,>V2_P".:\OM
M[V&TUC4DN9HXTDD5EW-WV@'Z=J[.TU)];\*Z9;VFE,E_IB-9IJ@OA%E%8X7:
M%;>N-O##Z5\WGO)5I*5TM6ON9[.!@X1E3EHG9KYHZ/2=_P#PFGASR,_:/M;]
M/^>7E/YF?;&/QQ3OC)X@NI=7@\-P7#QV0MA/=I&<>:68A48_W0%)QWR,U#X1
MUD^%;I[O4M!GOKF1?+DOX+P3RJF<X6(J@"YY(7D^]<5XO\06^N>*=;UJWD+V
MQ<+$64J=D: <@\CD,<'UKP.94\-RPE=^7F?8<-8:E6QD54LXQ3D^VB,Y55%"
MHH51T & *22-)4*2(KJ>H89%,M93/:0S, #(@8@=LBH[^Y-G8RW"J&* '!^M
M>:HOFMU/U656FJ#J/X;7VZ6OMZ=#V'X/>)9S%J.BZC>EX+1(YK5YWY1&)5DW
M'L"%QGINQZ5ZTK*ZAE8,I&00<@U\GZ=#:3^(=/\ M4$4\4H>(+(H89*[E.#_
M +OZUZMX NGT3Q3#I-LQ73-0BD(MLDK#*@#;D'\(*Y! XR :];#XE2482W/R
MC/:,,-F4Z,%9.S7:S5_\SUNBBBNX\P**** ,GQ3_ ,BGJ_\ UYR_^@FOGZ7_
M )#%A_O0_P#H-?2%U]FEB>UN6C*3*4*.P&X'@BO-$^%6FW.LSQ)XCE=;7;FV
MC"&:#(R@9OIR,CD"DU>QZ67XNGAXU%._O+3[SS/5_P#C\?\ Z[UZ%\+/^1A/
M_8,/_HT5=?X/)<>=)<:],TY;=$R6ZJJGU89Y_,5T?ACPG9>"[2YO;K4/.E$6
M);F8"-(HER< =AU))-)1LSMS#-*.(HRA!.[<?P1UE%,BECGA26)U>-U#(ZG(
M8'D$'TI]4> 5[K[H^M<#J$T=I\5();Z6&+S=':/29;DXC6X\PF0#_:*[.F"0
M,"N_N5+*, GGM6;?:7:ZI:FVU"PAN[<G)BGB#KGUP1UH \ZU3Q7KG]DZS TM
M@+NVU:TL);[3V,2F.0*6;>Y;:1NV;CG;FC49/$6D^%]=+7TEK'YUG]B/]H"[
MGMRTJK)ER =I&" V?XNU>A6^B:?::>^GVVEVL-DX(>W2W41MGKE<8/XU';>'
M-*L[22TM='M(;>1@[Q1VZA78'()&.2#T]* .%UG4-4\)W7BJTL=2O;M;?1XK
MZ%KV3SFAD:1T=QD=,#=MZ9'2K$LTFBZY;VFF:]>ZE!>:1=7-P)[KSS&453'.
MI_@W$D8'![#BN]-E&;E[@VJ&>2/RGD,?S,F2=I/<9)X]ZK66@:;IB3)8:3:V
MJS\2B"W5!(/0X'(Y/% 'GNF6NHW$O@Q)?$NLL-<L'DO_ /2/O[8DD79Q^[ZX
M)7!([YYJQH>KZDUSX<LY=0N)U76]0LI&=\M/%$LFP.?XB,#GVS7H*:=!&;8I
M9QJ;52D&(P/*4C!"^@P .*:FEVL;HZ6$*M'(TJ%8@"KMG<PXX)R<GOF@#A_#
M,LNJ>'DUR;Q//!K-Y'<J89KH>1#(-X"^2>!Y> >.>,G.:T?!-S(CW^E7K7W]
MJVBPO=">]^U1OO!Q)&_8-M)*D#''%="/#VEB\GO!H]G]JN%*33?9EWR \$,<
M<Y[^M2:?H]EI,#0Z=IT%G$S;F2"$("?4X'- %FBG>6_]QORH\M_[C?E0 VBG
M>6_]QORH\M_[C?E0 VBG>6_]QORH\M_[C?E0 VBG>6_]QORH\M_[C?E0 VO
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MSG\Z4-Y]N(#EHX^,;7[\C[S<&MWP=H+>&O#<&FR"W\U))7<P+A3ND9AV'\)
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MS(!@*>.1TXKR[3? /BBVTV:/R3'.+,VP+W:G/^DK*!$5&47:&W9/)QZ5=O\
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M:!;>SYOIR[J$E 0[<Q;"5^7&XG(Q7O%% &9X;4KX7TA2I4BRA!![?(*TZ**
M$(!Z@&C8O]T?E2T4 )L7^Z/RHV+_ '1^5+10 FQ?[H_*C8O]T?E2T4 )L7^Z
M/RHV+_='Y4M% ";%_NC\J-B_W1^5+10 FQ?[H_*C8O\ ='Y4M% ";%_NC\J-
MB_W1^5+10 FQ?[H_*C8O]T?E2T4 )L7^Z/RHV+_='Y4M% ";%_NC\J-B_P!T
M?E2T4 )M7^Z/RKYL\(>!5UOXGZYX>\07<JV6GWCWW]G@$"Z+-A7)]-I7WPV!
MWKZ4J);:!+F2X6&-9Y%"O(% 9@,X!/4@9/YT .AABMX4AAC2.)%"HB* % Z
M =!3Z** "BBB@ JIJ&F6>J) EY#YJP3QW,8W$;9$.5;CT-6Z* ,C4_"^CZQ=
M&ZO;4R7!2-!(LKHRB-RZ$%2,$,2<CGFLS_A M%@:U-M:D): B")YG9$SN!.T
MD@MAF&3SSUKJJ* ..B^'>BB!+=[0F%(5@3=.Y9$5]ZA3G(VMR"#D?2M/_A#=
M#V$&UD+&:*?S#<2;_,C7:C[MV<X)'ODYK>HH P]&\,VVC:UKFJQN'N-6G263
M"!0@5 H7W[DGN6K<HHH *SM?CDE\/:C'#&TLC6T@6-!DL=IP![FM&J-UJMO:
M3&*0.6'H!_C33L[B>QS.@ZY.UH+:*"&&^E=I9S?S>4WF,<D"/EB!P!TX JSK
MNF7IMH]1O]0>1;9LR16J>4OE-Q(,Y+=.>O\ #6C<:II=Y'Y=S;><G]V2-6'Z
MFLR2+2/+9+26^M%<$%(9,H0>OR,2OZ5LIJ]UH9VTL/NM&BGU^"WTZXFM5@C6
MYEV-O3< $B^5LC.%/_?(JY=:CJ.D)NOGT^YAZ;O-^SN?^ L2I_,5D6-I9VH=
M9=5U.;<%#!"L60JA5!*X;H/7U]:TK6;0;-_,@L0LG7S&0,Y_X$23^M)R6SU!
M?<4_!+R33ZG(+>XCM5,<5LTR;=\:[L8]< @9'H*Z^LL:]9D@8DY]A_C6FI#*
M&'0C-9SES.Y<=%86BBBI*"BBB@ HHHH **** "BBB@ HHHH *Y7QXMA_9$%Q
M<ZO9Z7>6DPN+.>Z<!"X!!4C.65E8J0.><]JTO%.KR:'X:O=0@5'N$4) K]&D
M=@B ^VYA7)V6@6UK<M>W;'4-5?\ UM]<@,Y/HO9%]%7 H X#Q!\3+EK*33[>
MTBLY)HRCZ@)FDB0'@F/Y1D^F<8K@; &>SA1YFFM;:246<;-E(E+')4>I(R3]
M*^DF)92K?,IZ@\BO./'W@_3[32KC7M+@6TN+<J]Q%$,1S(6 8E>@89SD>G-9
M8E2G1Y(:/?U\CU,DQ%'"XZ-;$+FCLMM&VO>\_P!-T<%4<T$<ZA9%S@Y5AP5/
MJ#V-25GZE>/;/!$A"^?N3>?X3C@UX-.,I22CN?J>,JT:-"4ZZO'KI<WV\2VK
M>#;N&]OHVU"..2(HQ^:0J?E)]R,52>&6_CQ>R.;<NTD5FKXBB#,6"\8WXSU/
MI7O&F:%IND:1'I=K:0_943:RL@;S?5FS]XGJ<UXKJUO:Z1XNU;0[7/DVT@DA
M7J(T=5;9GV+$#VQ7N\.U\-6Q$J4X:[J^WW'X;G&'G1I.I1=HWV[)[:^6Q0_L
MNPP +* 8Z80 C\:S]1LVTZS>>V9F@C8.\#G. &!)4]1]#6W55WBOH[VS&=R#
MRW!]67(_G7U^)PE"M#DE%7Z>IX.#Q^)PT^>G-I;/7=/1I_>=C%J5QJ$BQ:7I
MLU[<&))955U1(0PR SMQG'8<]ZKWVOC3;:X-[936UU;M'YMM*1G8[!0ZL,AE
MYZCTQQ6I\++B*X\&C:1]I6X?[2.^XXVD^VW;CZ52^)-E%JVHZ'I:'_2)Y/+E
MV]1$\D:C/L7QCZ&OSU48^T]FT?6RP%-8=5+ZG3^#+G['\0+=/X+ZRE@/NZ,'
M7]"]>M5X'I%\]O)X;U67*R6]W )O]G?^YD_]#/Y5[Y7?@W^ZY7TNCFHOW;=@
MJEJFJ6^DVAN;@.4R!A!DDFKM<5X_=A]@4?=^=O;/R_XUV15W8[,-256JH/8U
M8?&&ERSE"[HO&URO!]L=15EO%&C(6#7R J<'(/\ A7ERN,[L9QR>>M.E"";>
MJ94D%LG QCI6OLT>E/+Z:>C9Z8WBS1%0L;Y>"!C:<_RJG+X[T6/;M>>0DXPL
M1X^N:\]O(&!7S!(H?D(WWO85%Y'(G_>!!P2W7']<^M/V42%@J75L],'C+3C(
M(PDV\G&,#TR.]=#7B]LRJMN"2H7+ C&2V>!C_/6O:*SJ14=CDQ5&-*W*%%-9
M@O7^=)YJ>H_,5F<@^BF>:GJ/S%'FIZC\Q0 ^BF>:GJ/S%'FIZC\Q0 ^BF>:G
MJ/S%'FIZC\Q0 ^BF>:GJ/S%'FIZC\Q0 ^BF>:GJ/S%'FIZC\Q0 ^BF>:GJ/S
M%)YR 9+  =26% $E%<O/XYTO[:;2Q9;V9<[ECE4=/3-:ND:[9ZRLBP%X[B+_
M %MO*-LD?U'I[]*MTY)7:)4DW9&G15'5=6MM'M1<77F%2VT+$A=B?H/:KD<B
M31)+&<HZAE/J#4#NKV'4451U?4DTG3)KQT,A0?)&" 9&[*,^M -I*[+U%0VE
MU%>VD5S"<QRJ&7\:S;/73=:Y>:>UHT<=NI/G%P<XZY';KQZT Y+3S-BBL/1;
M&ZCU&\U"2^:>WN3F.,R%@.>#@\+@<8%:5UJ5E9,%N;J*)V&0K, 3]!UH=D$;
MOH6J*XGQ-8ZGXOB>WT34X+=+5E/S@E92RYR2.1MR,#USFNMT^U-EI]O:F0R-
M%&JM(>KD#EC[D\T%-:%FBBB@04444 %%%% !1110 5POC>U>[2[CBC9YO*;R
M@K8._9@<Y]Z[JHGMX)&W/#&S>K*#3B[.XI*Z/'=4TF^D2Q^PP2+Y<+&4"3:=
MV4. <\-PV#R!GWJ6^L+Z:;47CMI2LUQ:O&-X&57&_OQWX[UZW]CM?^?>+_O@
M4?8[7_GWB_[X%:>U9'(>0RZ9J#)!^XE\H7DT@BW!C'"4(53E@#SSC/&?:II-
M/U#^UO/B1_LLEQ$987?[H51AUY]<J1WX->KK:VK@D6T?4CF,=CBE^QVO_/O%
M_P!\"CVK#D/,M-TYK?6+V4P.D1>/[.Q;(QM ;C/KZUZC%_J4_P!T4S[';?\
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M0J)2<MS"K6=6URO=?='UKGM5\2Z=H]_#8W"WDMU-$TR16MJ\[; 0I8A0<#)
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M32/ UQ#&DPS*@!.0>@'RGD^A]*BTOX:)IT-BAOT=[.>U=)?*?<\<!;:C;I&
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M%G%:VZ[8HQA03G\:GKL5[:G$[7T"BBBF(**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Q]4\.6>JZE;7T[R++!M"A<8(#!AU'J*V***!**3
MN@HHHH&%%%% !1110 4444 %%%% !1110 4444 %9^N220Z)=R1.R.L9PRG!
M'T-:%87B>\:&P-H+65_M0\M905"*WH22,>WK4S=HL4G9%.R,D6LV2K<W3*\C
MJRR3NX(",>A)[@5U-<=-=_8;NUO/)DF2*5LI'C<=RE0 "1DY(XKKHG:2)':-
MHV8 E&QE?8XK*@]&B*;T'T445N:!1110 4444 %%%% !1110 4444 %%%% !
M7-:SX/35M:_M6+6=3T^X-NMNXM&C"LJLS#.Y&YRQKI:* .,_X5U;1VVGQVVN
M:M;RV:3H)XWCWRB:3S'W90C[WH!6YX=\/Q>';.>WCO+J[>XN&N))KDJ79V !
M^Z /X1VK7HH *Y+QQ_Q]>&/^PN/_ $1-76UR7C<$W7AC'_07'_HB:L<3_!GZ
M/\BH?$CDM:_Y#.K?]=M$_P#2F6NETW_DI"?]@>3_ -')7-ZT#_;6K#!SYVB?
M^E,M=+IP(^)$>01_Q)Y/_1R5Y6'_ (M#_"_U.F?PS]3M*S]?_P"1<U/_ *])
M?_0#6A6?KH+>'M3 !)-I* !W^0U[9R'FMC_J?!?_ %]6W_HEJS;3_D1= _Z_
M++_TI2GZ-K%A?7'A"RMIFDN8KFW,D?E.-NV)@<DC'!K/L-7L9?#>AZ6DKF^2
M]M T/DN""MPI/.,<"O/C"7+'3[1Z,IQYI:_9/>:***] \X*R=5M=&@9M3U1(
M@ %C+S$E.ORC;TZGT[UK57OC:K83M>A#:K&3+Y@RNT#G(HNUL)JYYKI]UJ$.
MKR#2KV&6TFNI6AL9)5VOAB65>Z#'*]N#TXS?CBDLK[5+K4+&>:>Y198[<$NJ
M'<P .T\@+MS[Y ]Y[.\L+Q+JVBU".*"Y7RK)GD5KE"P(/(Y Z;0QW=O2JEII
MU]HKE[GR[>W"[8S'<%E,W&'7=_JQC.[/!'K7%BJDG"ZMIKW_ *\@P\G":M?4
MV-,T^_%I:JC+';.A,A=,31'/.WTR/RR:L16=A"NV<WX:"9G54,C*H#$J1V'!
M'ZU%=-%J=V@M+R&YN(8\20QS%"I_OKZ?C5EVD,4$-P'FNK=5>5/*9XW)Z;L#
MVZXZCI7G4Y<KLEMLWJOP[;V_X!Z#DWK<WX)X[F!)HB3&XRI((R/QJ2J]E=K>
MVXE5'3G!5Q@@U8KW(2YHIIW.%JSL,>01C)IGVE/0TVZ^Z/K7)Z[XNB\/W4<-
MQHVKSI+)'#%/;0HT<DC_ '4!+ YSQTJA'7?:4]#1]I3T-9-C>_;;..XDM;BR
M9R1Y%V%613G R 2.<9'-60RL6"LI*\, 0<?7TH N_:4]#1]I3T-4@RDX#*3C
M. >WK0&4L5#*67JH.2/J* +OVE/0T?:4]#5(,ISAU.#M.".#Z?6JYO,7\5JL
M$KH\;2&X7:8D*D#:3G.XY].QH U?M*>AH^TIZ&J0*LVT,I( )&1P#WJKINIV
M>KVIN;"=9HA(\9(XPR,588/N#0!K_:4]#1]I3T-4@Z,F]74K_># C\Z"R@,2
MZ@*<,2P^7Z^E %W[2GH:/M*>AK+-TPU(6?V6?:83+]HP/+!W8V9SG=WZ8QWJ
M<,IW893M.&P>GU]* +OVE/0T?:4]#5)65U#*P93T*G(-+0!=6X5F  /-49+Y
MHU=W*JB@LQ.> .IZU)#_ *U:Q];NFLM&O+A+5KLJA'D+G,@)P1QST-)NRN73
M@YS4%U:1%_PG6@_]!FS_ .^VK:^UR>WZ_P"->0Z<FE7FI6UK)X$G@2614:5I
M9<(">IXKU?IQZ5C0J2J)MV_']3TLTP5+"2C&GS7=]W%_=RM_B3_:Y/;]?\:J
M:IK3Z7I=S?&$S"!-WEH3EN0,#\ZDHK9WMH>9!I23DKKMW.1L?BA]NO[>T&BW
MD9FD6/>S<+DXR>*[8W<@/;]?\:X+7-#\1_:;[4(_%+6EB"THCR_[M!SC ]/:
MI=#\7Z-;Z=:V5WKPO+S)4S>5)\Y+''4>X%<U.K*+<:K^^R_4]K%X*E6IQJX&
M-^ZCSRMI?5M)*VVGJ>D(=R*WJ,TM-C&(U!]!3JZCPPHHHH **** "BBL7Q.2
M-+3,[PQF9=[@-LV\\.5(95/ R.AQGC--*[L)NRN;5%<=9ZI?0V=FEL',5S.U
MK$SDRJ'W AE9@"4V"3&?[O4U5?5-8ECM6N+\Q1O)%,62#;M4M(NP^H.%Y]35
M^S9'M$=W17!?VUK=CIEM ;B/)C@8W4R%1$&C)VDX.3E<9//..I%2-JVJ0W%S
M*9/-N,^8(/+8K"#;J<J."5SNX//RGOFCV;#VB.YJ.>"*Z@>">-9(G&&5NA%8
MKW<D_A"_G2\^U.L$VRXCC,>[ ."!Z^XX..*S]7\2RK:6;:1=VS(=PFG<DJKJ
MH*H< \MD^YQQS24&]!N:6YL6&A1V=SY\L[W+)D0>8/\ 5K_5NV[T_'.M7"->
MZM'?WLR7S^9;BXF:%XBR@ 0E4[<')P>O7WI6U^_N]8:T,A\G[0F%5-K1[;A%
MP<=BI.03SUP!1&C961*FEI8[JBN9\4R!9[,2S^5#M<D2O)'$[<8R\9R&'. 0
M0<GN*S?^$@U=+F*)%\J-;566*Z!,TF8RQ?A>2",=AQR!FA0;5T4YI.QW%%<-
M/KVLV=NIFN8W*.C.RP!7D#1JVQ%)P>21C()XQT-/:]O?[8.;ATC>3:D!C."?
MM04MZY"D'_ZU/V;%[1';45Q5WJNJWEC*%+0R0^9;,R1G=YR0R%W7VSM K3TG
M4KV?4X;%IA-$L"W)G\O'F1LH"?CN#_@H]:3@TKC4TV=%1114%A1110 4444
M%%%8WBS7E\,>%=2UIHO-^R0EUCSC<W11GTR10!LT5Y]HL?Q&WZ1JEUJFEW]I
M>%'O+ 6WD_9HV&<QR DL1Z'K^M:-S\1=.L]=BTZYTS5X89;T6$=_):[8&G/
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M*\V7XL:?%JUU8ZC97$'V>X>+S87WJP5B,D'!'3MFNJTWQ-H^KE/L.JP.S?\
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M/][V)':O1:* /+/$_P .=?\ $ZVTEY)X?DN1:+"TIMY4>VD&?GBD4AF'?:_
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MR3:J60(%ARI(&0S'T^@K!/W59F5&3=.FHR6ZT2UZ^?;?0]GT?G1+#_KWC_\
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M/.*I4H=#*6.Q%[2_(X)/ NH+UN+;_OIO_B:L)X,OEZS6_P#WT?\ "NU62-B
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ML[2?#7BW3X8H'\6Q>1$@1(UT]" H& ,Y%7$\-ZK%XAMM536_1;N,0!%G4=.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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5"(P#P:=L7^Z/RI<8Z4 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>drsa_023.jpg
<TEXT>
begin 644 drsa_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #B E,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN.Q!]"#Q4]?3IWU1RA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]/G$USCM!'\S?F<"F^% -#\3:SX;(VP%_MUD.WEO]Y1]&K1)^QM\_E_6I/\
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M-V>U&SVJM_:L?_/O/_X[_C0-4BS_ ,>\_P#X[_C77[6/<Y_9LZO24%GHD\Y
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M5CZSJ6HZ]JD<$SK+O.]RN<%1TX[9. !SU^IK6@1KF.:U!6-UP9)$/''W0A]
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M;P]_T =+_P# ./\ PK6HKG.DR?\ A%O#W_0!TO\ \ X_\*/^$6\/?] '2_\
MP#C_ ,*UJ* ,G_A%O#W_ $ =+_\  ./_  H_X1;P]_T =+_\ X_\*UJ* ,G_
M (1;P]_T =+_ / ./_"C_A%O#W_0!TO_ , X_P#"M:B@#)_X1;P]_P! '2__
M  #C_P */^$6\/?] '2__ ./_"M:B@#)_P"$6\/?] '2_P#P#C_PH_X1;P]_
MT =+_P# ./\ PK6HH R?^$6\/?\ 0!TO_P  X_\ "C_A%O#W_0!TO_P#C_PK
M6HH S;?P]HMI.D]MH^GPS(<K)';(K+]"!D5I444 8OB?PU;>*M+6QNIIHD60
M2AHB,Y ([_6N.M/A]JGAR<W&EC2-4QR!J%N1+] XSBO2Z*UA6G%<JV(E3BW?
MJ<:/&>H:8-NN>%[^U1>#-: 7$7_CO(%:NF^,O#VK';::K;F3_GE(WEN/P;!K
M=K+U+PUHNL C4-,M9R?XFC ;_OH<T<U-[JWI_P $+26S-,A74@X96'X$5QW@
MHG2=1UCPQ(2!9S>?:Y[P2<C'T.13CX"%B=VA:YJ>F'J(A+YL7_?+?XUE3:)X
MUL_$EKK.ZPU*2&%[=FB_<O(C=-P/'#8/'O5QC%II2W^1+;NG8T]._P")]\1;
M_4#\UKH\?V. ]C,W,A_ <5U\LT4$9DFD2-!U9V  _$UY]H/A+Q?::8+.37+;
M3HG=I93:P^9*[L<DEFXS]*UHOAWH\D@EU6:^U:;NU[<,RY_W1@45%"_Q:+L$
M7*VQ8OO'_ANRD,*Z@+N<<>59H9F/_?/'ZUG7.N:WK\1BL?!I> ])-7943'KL
MY-=98Z78:;&([&RM[91QB*,+_*K=1SPC\*^__@%<LGNSRQ/A++?W7VC4;NTL
ME)S]GTV$A!^+'^E>I(H1%4= ,4M%*I5E4^(<81CL0W5I;7UNUO=V\5Q"V-T<
MJ!U..1D'BL__ (1;P]_T =+_ / ./_"M:BLRC)_X1;P]_P! '2__  #C_P *
M/^$6\/?] '2__ ./_"M:B@#)_P"$6\/?] '2_P#P#C_PH_X1;P]_T =+_P#
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MH+V4=WOZ?\$];!8:SYY%RBBBO#/4"BBB@ HHHH **** "BBB@ HHHH ****
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M5BT);6U@/E>3)=-<;@%)Y(4#.<5Z9_PB\G_/TO\ WQ_]>C_A%Y/^?I?^^/\
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M6?\ H*V/_?+_ .%>=[&KV/LO[1P7_/U?C_D>?^;[T>;[UZ!_PI76?^@K8_\
M?+_X4?\ "E=9_P"@K8_]\O\ X4>QJ]@_M#!?\_%^/^1!\)WW>,\?].[_ -*]
MTKS;P1\.-1\+^(!J-S?VTT?E-'LC#9R<>HKTFNW#QE&%I(^9S>M2JXCFI2NK
M+]0HHHK<\L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#*\1:!9^)=%FTV]!"2<HX',;#HP_SR,BOG#Q)X=U3PI=R66J0/(K
M']W>(A*.O3.>W';K_.OJ2FO&DL;)(BNC#!5AD$5VX3'5,,VEJGT$XIGR[X:\
M,:CXQU 6NGQS?90-KW<JMY,2]SD_>/8 >G8<U]'>'?#UAX9TF/3["/"+R[M]
MZ1L<LQ]>/PK51%1 B*%51@ #  I:6*QM3$OWM%V!)(****XQA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5@7.K:M_:.HQV5I:2PV(4LLDK+))E
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K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>drsa_024.jpg
<TEXT>
begin 644 drsa_024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "_ ET# 2(  A$! Q$!_\0
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M.!_KSR#G\EQZUW-7.#A:_4F,E*]@HHHJ"@HHHH **** "BBB@ HHHH ****
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M48P021U(QSUKQB"&4V,=P GDJ8XCR=VYD=AQC&,(>_>O>RZM!04+_P##MO\
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M<8T[-_S?^DV..O3E*I=+^7_TJY[2?O'ZTE*>II*XSM/)_BI_R,^E_P#7H/\
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M8Z5W);22?WH\*FWRV[%O^T;G^_\ J:/[1N?[_P"IJI17!S/N:79;_M&Y_O\
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M>5_48_&I=&GDUC2+34(XF(F0%@%/#=&'X$&LIIR@I=M/\O\ +Y#2:=CC9/\
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M\BEMKSQ/<ZL8H?M\=[#';?N9'1[:/*$R>:< ECP>.^,=Z]'I H!)  )ZGUH
MX.QM/$=X]M!-<:Q;VC2)]IDE>-9?,$4OF;2,XCW^5CWSCBH%/C4.&C6ZDNY-
M.  EV)%%-Y(YX)5B9!T.T@GNHKT2B@#GO"*ZJMA/_:<EP^9?W/VB/:X7:,Y^
M9B1NSU_EBNAHHH **** "BBB@ HHHH Q?&'_ ").O_\ 8.N/_1;5Y;J/W+G_
M + 5Q_Z-MJ]2\8?\B3K_ /V#KC_T6U>6ZC]RX_[ =Q_Z-MJ -&3[_B;_ +%R
MX_FU>:Z!-MU![7 )O[3[)@]PTT);_P =5J]*EX;Q-_V+ES_-J\PT2-)+F[OX
MI56YTO3)KV!N& =7B&&'<$,P/UKEJ_Q:?S_(]W+]<OQ:[\G_ *4=/=WOG_%S
M3[0?=MK"0_1G!)_0+78CJ*\L\,W,M[\2H+NXF26XG@F:1D&!]W  '8  "N^M
M;B^;5T$L\36LLETB1"'#)Y)B );/.?,/8=*WA-3CS(\O$X>>&JNE/=6O]USF
MO#:?;H?%VCL3^^N)Y$_X&77_ -"05Q32>5I6ER/U1<M]1$V:ZG0([R3QFL-C
M=BUEO+^>U>1HA(-ID=L[<CD$<<]Z/ &FVFJ^*?#5K?P+<0,[RLC]&80NX)]?
MF&<=*]-4&J56/24$_OM_P3RJ>+Y,50K+>$W^%_\ @&5>Z6-%U2[T[&&@:-7_
M -[RD+?J326=I'J&J:?92@&.YO((6!]&D53_ #K5\;HLGC[78VSM>_53@X."
MJ \BHDM(=/\ B!'96P98+?Q D42LQ8JJW0 &3R< 5\O*G^^Y_P"]8_4J6,7]
MFK#-:NBY7^]%[X<W,NE_$#1TDSO,DEE,!Z[6!_\ 'T'Y5](5A6_@WP_:^(I-
M>@TV--2D+,9=S8#-]Y@N=H8Y.2!DY/J:W:].C3]G'E\V?$9CC5C*JJVL^6*?
MFTK7^84445J< 4444 %%%% !1110!Y];ZG)I?AGQ+/!DW4VL7$%NHZF1RJKC
M^?X5V6B:8FC:+9Z?'@B",*2/XFZL?Q.37F>DZG8CQ1<Q:E=16UGINHW5X_FL
M ))6;:@ ZD@ GBNS/C%[[C0]%O\ 4<])63R(3_P-_P#"NJK"6R7F8PDMV=17
M):-/%H'B'6-(N94AM7/V^U:1MJA7.'&3P &_G4OV/Q=J?_'SJ-GI4)_Y9VD?
MFR8]"S< _05A^)/"ECI$5GK=PUSJ?V6X7[6;Z0R[X6^4\=."01Q4PC'X6]^P
MY-[I;%!KB!O#UU>B9#;GQ1YPEW?+LWCYL^F.<UTOBJ>#6UTS1+26*==1G!F>
M-@P$"?,_(]>!73):6AM!;I;P?9B.(P@V$?3I7!Z3X6T[6=;U?4K/S=-@AF^R
MVCV#^4<H/G;C@@GCTXJE.,O>>EOZ0G%K3N=P^F6SC 4IQCY3TK,U7PS'J6FW
M5F7&R>,ISQCT/YX-5OL/BW3.;34[75(1_P L[V/RY,>@=>"?J*/^$OEL>-<T
M._L,?>FC7SXO^^EY_2N?V"O>.OH4^7JK'&WCW-WX+LFG7-U:ZA#;7 [B1) #
M^F#^-=E)&ZN05(/7%<7K^KZ<=;*Z;=Q7-IJMQ;7 $;9\N9' ;(ZC*D'GTKUM
MD5QAE##T(S1B*"LK:;O[[&<(W;U.4HKHY+"VDZICZ54DT=3]R3'L17&Z,D4X
M,QZ*O2:7<)T ;Z&JKP21G#(1]16;BUN2TT1T4$8ZT4A!1110!>OAFUMOHW\Z
MHK'N8#!K1NAFTM_HW\ZCM559?,DXCC&]CZ <_P!*]*F[01JE<Y;Q;>#^TDM%
M(Q;QA3_O'DG]?TKG_.]ZKW]^UY?SW+YS(Y;'ID]*K^=7#*=W<^FI4.2"CV-#
MSO>O6=#.="L3_P!,5_E7BWG5[-X?.?#VGGU@3^5:47=LX\PARPCZFE12%U'5
M@/J:C-S O6:,?\"%;GE69+14!O(%ZR#\ 349U*V[.3^&/YTKH?)+L6Z*H-JL
M Z*Y_+_&F-J\8^['GZG_ .M1=%>RGV':[92ZEH&H6,!037%N\2%R0NXJ0,XS
MQ7"7/@KQ#/%<,$TT2SB92ANGPH>.)0<^7R<QGC ZCFNU.L'M$!^.:8VK3$\*
M@_#_ .O2YD4J,S5MXS%;11L02B!3CV%25AMJEP>C8_ ?X5&=0N3UD/\ *CF0
M_J\AOBK2+_55L'T];=GMY6=EGE,8(*%>"%;GGTK$T;PCK&G:QI\TYL3;6[I(
M[I,Q<D6PB("E,?>YSGI6R;J=CS*__?1IC2.WWCFCF*^KON=*9(UZNH^IIANH
M <><GX'-<WO8# 8C\:"2>II<P_JZ[F;KFBWMYXC>[@EM/LDCP.6>1PZ[.H"A
M"#GZBI?!]E<Z,;EM1%L"\$$*""4OGR]^2=RKC.X<5<HHYF5[")TL$B2Q!T7"
MGM4M5-._X\UJW5HY9JTFD%%%%!(4444 %%%% !1110 4444 %%%% !1110!B
M^,/^1(U__L'7'_HMJ\BN-3T^\CO3:WUM.(M"N#)Y4JML_>V_7!XKW8@,I5@"
M",$'O42V=L@8+;PKN&#A ,CTH \Y\&W>GZMXRO$M[BUO(3IA201NLBX,O0XS
MU':NYA\.:';B00:-IT0E0QR!+5%WH>JG Y' XJ_%;P0DF*&.,G@E5 S4E 'G
M?C#1M+TS5=">PTVSM'>2<,T$"QEAY1X) KF[;_D(V?\ U\:G_P"A6U=CX]_Y
M"7A__KK/_P"BC7'6W_(1L_\ KXU/_P!"MJ!FYX"\#Z)<6\'B*2.X.H)?W4@/
MVA]FX32*#LSCI6[HGPT\-^']4MM1L(;I;BVW>5YEU(ZKE2I^4G'0FIOAW_R)
M\?\ U]W?_I1)74U7/+N1R1['S1XS_P"2AZU_V$$_E'1=?\E.E_[&4?\ I6*/
M&?\ R4/6O^P@G\HZ+K_DITO_ &,H_P#2L5Y3^)_XT?=4_P"%#_L'E^9]+T44
M5Z9\.%%%% !1110 4444 %%!X&:I?VO8_P#/<?\ ?)_PH P[WP!HES?-?VZS
MV5Z7,GGV\I!W$DDX.1W]*7[#XOT[_CUU2SU.('_5WL/E/CT#)P3[D5M_VO8_
M\]Q_WR?\*/[7L?\ GN/^^3_A6GM);/7U(Y8]-#$_X2N^L>-9\.W]L!UFML7$
M?U)7D?E5E->\/>)+*>QCU&WD6XC:-XF;8^",'Y6P<UI?VO8_\]Q_WR?\*SM0
M@\-ZJ"+ZVMIR?XGA.[\\9IIP[6]/^"&O<Q+37[C3? 5U#*2VJ:>YTY5'5Y<[
M8R/7(*G\#6I8W^A^$-#M-.N]3M8G@CPZ[P69NK':.>2360?!WA(R,!/=K;LZ
MR-;B9]A900IZ;L@$]ZVM/LO"^E8-E:6T3#^/RB6_[Z(S^M7.5-K2_?\ K\2(
MJ1#_ ,)B]YQHVA:E?Y^[(T?D1'_@3_X4>5XRU'[\^G:1&>T:&XE'YX6MO^U[
M'_GN/^^3_A1_:]C_ ,]Q_P!\G_"L^=+X8_J7:^[.>@^'NEG4%U'4I[G4+U6#
M>9(P1<CD?*H%==5+^U['_GN/^^3_ (4#5K$G G_\=/\ A2E.4OB&E%;%VBD!
M! (Z&EJ"@I" 1@@$>]+10!7>RMY!S$!].*JR:/&WW'(^HK2HJ'"+W0G%,PY-
M)G7)7#?0U4DMI8L[T( [D8KIZ*AT5T(=-'D^IZMJ:7L\:W]PB)*ZJ@884 ].
ME9>I:]J5OI$['49SYG[H*6'.>HZ>@KU'4]'TZ297;3[9I')+,8AECQUKSOXB
MFQLKFQL+2V@B98S+(8XP"=QPH/T _6IJ*48WN>U@94ZDXT_9IM=?0X'^TKG_
M )Z?I1_:5S_ST_2I_-'M^5'FCV_*N6[[GT')'^1?>R#^TKG_ )Z?I7JGA#4+
MNYTP)-</(B0Q;%;!"_>Z?D*\R\T>@_*O=?"^FV1\,Z?*MM&CRV\;.R#:6..I
MQUZUM0NV]3S<SE&%.+<4M?T*^YAT)'TH+$]23^-;ITRW/0$?3%1G28>SM^-=
M'*SR%7@8M%:[:.#]V7'_  '_ .O49T=OX7!^I_\ K4<K'[:'<S**OG29QW7\
M#3&TVY'1,_B/\:5F5[2/<J#&X9Z9YKP;4[O51XMN9VDF&LI=LL0!.X-N^1%'
M]W&..A'UKU?Q]K%]X9T:%K556ZNI?*1W7(C !);'0G@ =N:\??4-0EU!=0DU
M&\:^486X\Y@X'H".@]NE<F)JQBU%MI[Z'T.2X*O6C.K3A&46G'WN_EH]OEZG
MT#S@;@ >X'3-%<?X \1WFNVMU:Z@ZRW5IL(E"@&1&S@L!QD%3R.N178E&'53
M^5=,9*24EL>+6HSH5'2J*S6C,OQ%)>0^&]2DT_=]L6W8Q;!E@<=1[@9(]Z\L
M^'L]R/&%NME([Q3*YNP&+!DVGYF]]VW!///N:Z'Q]XKU&RU0:1IMP;54B62:
M:/\ UA+9PH/\(P >.>>HKA;#5-1TJY>YL+^X@FD;=(=Y82'_ &@<AOQKEK5H
M1J)-O0][+LLQ-7!U'"$6I[-O71]-'^+1[_163X9UAM=\/6NH2(B3/N254^Z'
M5BIQ[<9_&M<#) ]:ZT[ZH^>E%Q;B]T<)\49KN/0[-(V=;.2<K<E3@'CY%8_W
M2<_4@5%\+)KI]-U")F=K".11 2<A7P=ZK[?=..Q-<IXB\6:GKMU<Q"Z>'3=[
M1I;PMM#H#@%R.6)Z^GM4.A>*M3\.R0B*Y>73T($EK*VY F>=N>5/?CCU%<;K
MT_;;OMY'T<<KQ3RWX([\U_M6MMM;;I?\3Z/T[_CS6K=5-.Q]C4@Y'8^M6Z]%
M;'Q=3XF%%0+=QM?R68#>8D2RDXXPQ8#\?E-,BU*QF9EBO('96VL%D!P<$X_(
M'\C1=![.?8M457%_:- 9Q=0F$1B4R;QM"'HV?0XZU&NJZ>ZQLM];D2%@A$@^
M;;]['T[T77</9S_E?W/_ "+E%9KZ_I:/!F]@\N??LE\Q=F5QD9SU^84Z[UK3
M[-;C?<QL\"[I(D<%U''.,^XI<T>Y7L*MTN5Z^3]#0HJ@^LV2Q)+'*LT;D -$
MRMSO5/7U89]*2VUFQNKE[9)T$Z*K%"PZ$$C!!P>%)XHYH]P]A4M?E9H44U'2
M6-9(V#(P!5@<@@]Z=5&04444 %%%4M5U?3]#T^2_U2\AM+6/&Z65L#)Z#W/M
M0!=HK,T3Q#I'B.T:ZT>_AO(4;8YC/*-Z,#R#]:TZ "BBB@#E/&FC:KJ<FESZ
M5!;SO:R2%TGG,0(9"O!"M_*N8'A#Q/$MG<I96#W"37CRPF\(51*8BN&V<_ZL
MYX'45ZE7.:IX]\+:+JCZ;J6MVMK>1[=\<A(VY&1DXP."* )?!NEWFC^&H;/4
M%B2Z\Z>5UB?>HWRNX .!GAAVK>IJ.DD:R1LK(P!5E.00>X-4)->TJ.2%#?P%
MI[DVD>UMV9@"2G'0C!Z^E '%ZQ\)+/6/$5UJ[ZQ>1&XG69H4C0J",< D9_AH
MD^$EG)XH;6SK%X"VH?;_ "/+3;N\SS-N<9QFO1:BN;JWLK:2YNIHX((E+222
M,%50.Y)Z5'LX=O,Z%BZZ5E-[<N_3MZ>1+12*P90P.01D&EJSG"BBB@ HHHH
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M?@2/X=-KX>U*PM'\Q[@,(@P $:]%0>RCUI[>&A.UU)<W1>6ZCDCD9(PH&X(
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M:S-?,7Q)B-FC*$C SG*KWSV'X]:UJT4(R5[')/$UZ53E<D[?<-1%C1410JJ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
